temozolomide has been researched along with Astrocytoma, Grade IV in 2773 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with tumors harboring an unmethylated MGMT promoter derive minimal benefit." | 9.69 | Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. ( Baehring, J; Bähr, O; Brandes, AA; Butowski, N; Carpentier, AF; Chalamandaris, AG; Cloughesy, T; Di Giacomo, AM; Fu, AZ; Idbaih, A; Khasraw, M; Lassen, U; Lim, M; Liu, Y; Lombardi, G; Mulholland, P; Muragaki, Y; Omuro, A; Potter, V; Qian, X; Reardon, DA; Roth, P; Sepulveda, JM; Sumrall, A; Tabatabai, G; Tatsuoka, K; van den Bent, M; Vauleon, E; Weller, M, 2023) |
| "Despite intensive treatment with surgery, radiation therapy, temozolomide (TMZ) chemotherapy, and tumor-treating fields, mortality of newly diagnosed glioblastoma (nGBM) remains very high." | 9.69 | Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. ( Abad, AP; Ahluwalia, MS; Belal, AN; Birkemeier, MT; Casucci, DM; Ciesielski, MJ; Curry, WT; Dharma, SS; Dhawan, A; Fenstermaker, RA; Figel, SA; Hutson, AD; Liu, S; Mechtler, LL; Mogensen, KM; Peereboom, DM; Qiu, J; Reardon, DA; Withers, HG; Wong, ET, 2023) |
| "Despite standard treatments including chemoradiotherapy with temozolomide (TMZ) (STUPP protocol), the prognosis of glioblastoma patients remains poor." | 9.69 | Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol). ( Biau, J; Casile, M; De Beaumont, O; Dufort, S; Durando, X; Le Duc, G; Loeffler, M; Molnar, I; Moreau, J; Seddik, K; Thivat, E, 2023) |
| "In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular features of glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase-wildtype (IDH-wt) in the 2021 World Health Organization (WHO) classification of central nervous system tumors]." | 9.51 | Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. ( Aldape, K; Atmodimedjo, PN; Baumert, BG; Baurain, JF; Brandes, AA; Brouwer, RWW; Cheung, KJ; Chinot, OL; Clement, PM; de Heer, I; Dubbink, HJ; Erridge, SC; French, PJ; Gill, S; Golfinopoulos, V; Gorlia, T; Griffin, M; Hoogstrate, Y; Jenkins, RB; Kros, JM; Mason, WP; McBain, C; Nowak, AK; Rogers, L; Rudà, R; Sanson, M; Taal, W; Tesileanu, CMS; van den Bent, MJ; van IJcken, WFJ; van Linde, ME; Vogelbaum, MA; von Deimling, A; Weller, M; Wesseling, P; Wheeler, H; Wick, W, 2022) |
| "Temozolomide is applied as the standard chemotherapy agent in patients with glioblastoma (GBM) after surgery." | 9.51 | The efficacy of temozolomide combined with levetiracetam for glioblastoma (GBM) after surgery: a study protocol for a double-blinded and randomized controlled trial. ( Cheng, Y; Huang, N; Liu, G; Mao, J; Sun, M; Tao, Y; Wen, R; Xie, Z; Zhang, X; Zhao, G, 2022) |
| "Nearly all patients with newly diagnosed glioblastoma experience recurrence following standard-of-care radiotherapy (RT) + temozolomide (TMZ)." | 9.51 | Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. ( Ansstas, G; Baehring, J; De Vos, F; Finocchiaro, G; Honnorat, J; Idbaih, A; Kinoshita, M; Lee, M; Leung, D; Lim, M; Mellinghoff, IK; Omuro, A; Petrecca, K; Raval, RR; Reardon, DA; Roberts, M; Sahebjam, S; Slepetis, R; Steinbach, J; Sumrall, A; Taylor, JW; Warad, D; Weller, M; Wick, A, 2022) |
| " We performed a phase I study to determine the maximum tolerated dose and preliminary efficacy of pegylated nanoliposomal irinotecan (nal-IRI)+metronomic temozolomide (TMZ) in patients with recurrent glioblastoma." | 9.41 | Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial. ( Baekey, J; Carcieri, A; Cielo, D; Disano, D; Donnelly, J; Elinzano, H; MacKinnon, K; Mohler, A; Robison, J; Safran, H; Sturtevant, A; Toms, S; Vatketich, J; Wood, R, 2021) |
| "Temozolomide offers minimal benefit in patients with glioblastoma with unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promoter status, hence, the need for novel therapies." | 9.41 | A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. ( Ashley, DM; Back, M; Barnes, EH; Buckland, ME; Fisher, L; Foote, MC; Hall, M; Khasraw, M; Koh, ES; Leonard, R; Lwin, Z; McDonald, KL; Rosenthal, M; Sim, HW; Simes, J; Sulman, EP; Wheeler, H; Yip, S, 2021) |
| " We investigated Depatux-M in combination with temozolomide or as a single agent in a randomized controlled phase II trial in recurrent EGFR amplified glioblastoma." | 9.34 | INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. ( Ansell, P; Brilhante, J; Chinot, O; Clement, PM; Coens, C; De Vos, F; Dey, J; Dubbink, HJ; Eoli, M; Franceschi, E; French, P; Frenel, JS; Golfinopoulos, V; Gorlia, T; Krause, S; Looman, J; Nuyens, S; Sanghera, P; Sepulveda, JM; Smits, M; Spruyt, M; Van Den Bent, M; Walenkamp, A; Weller, M; Whenham, N, 2020) |
| "We sought to determine the maximum tolerated dose (MTD) of 5-fraction stereotactic radiosurgery (SRS) with 5-mm margins delivered with concurrent temozolomide in newly diagnosed glioblastoma (GBM)." | 9.34 | A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes. ( Adler, JR; Azoulay, M; Chang, SD; Choi, CYH; Fujimoto, D; Gibbs, IC; Hancock, SL; Harraher, C; Harsh, GR; Hayden Gephart, M; Jacobs, LR; Li, G; Modlin, LA; Nagpal, S; Pollom, EL; Recht, LD; Seiger, K; Soltys, SG; Thomas, RP; Usoz, M; von Eyben, R; Wynne, J, 2020) |
| " TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 trial." | 9.34 | Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial. ( Chang, JH; Hong, YK; Kim, CY; Kim, JH; Kim, OL; Kim, SH; Nam, DH; Paek, SH, 2020) |
| "Ipi-Glio is a phase II, open label, randomised study of ipilimumab with temozolomide (Arm A) versus temozolomide alone (Arm B) after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma." | 9.34 | A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol. ( Blagden, S; Brooks, C; Brown, NF; Coutts, T; Elhussein, L; Holmes, J; Hoskin, P; Maughan, T; Mulholland, P; Ng, SM; Roberts, C, 2020) |
| "Standard of care for glioblastoma includes concurrent chemoradiation and maintenance temozolomide with tumor treatment fields (TTFields)." | 9.34 | Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma. ( Andrews, DW; Bar-Ad, V; Chervoneva, I; Evans, JJ; Farrell, CJ; Glass, J; Judy, K; Liu, H; Ly, M; Martinez, N; Palmer, JD; Shi, W; Song, A; Werner-Wasik, M, 2020) |
| "Temozolomide (TMZ) has been the standard-of-care chemotherapy for glioblastoma (GBM) patients for more than a decade." | 9.34 | Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma. ( Bendok, BR; Doyle, T; Hawkins-Daarud, A; Hu, LS; Jackson, PR; Johnston, SK; Massey, SC; Mrugala, MM; Porter, AB; Sarkaria, JN; Singleton, KW; Swanson, KR; Vora, S; White, H; Whitmire, P, 2020) |
| "Standard treatment for glioblastoma is radiation with concomitant and adjuvant temozolomide for 6 cycles, although the optimal number of cycles of adjuvant temozolomide has long been a subject of debate." | 9.34 | A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). ( Alonso, M; Balana, C; Berrocal, A; Carrato, C; Covela, M; de Las Peñas, R; Del Barco, S; Domenech, M; Esteve, A; Estival, A; Fuster, J; Gallego, O; Gil-Gil, M; Gironés, R; Herrero, A; Luque, R; Manuel Sepúlveda, J; Martinez-García, M; Mesia, C; Munne, N; Muñoz-Langa, J; Navarro, LM; Olier, C; Peralta, S; Perez-Martín, FJ; Perez-Segura, P; Pineda, E; Sanz, C; Vaz, MA; Villa, S, 2020) |
| "The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib potentiated radiation and temozolomide (TMZ) chemotherapy in preclinical glioblastoma models but brain penetration was poor." | 9.34 | Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. ( Carruthers, R; Chalmers, AJ; Cruickshank, G; Dunn, L; Erridge, S; Godfrey, L; Halford, S; Hanna, C; Jackson, A; Jefferies, S; Kurian, KM; McBain, C; McCormick, A; Pittman, M; Sleigh, R; Strathdee, K; Watts, C; Williams, K, 2020) |
| "This study aimed to explore the genetic alterations and to identify good responders in the experimental arm in the tumor samples from newly diagnosed glioblastoma (GBM) patients enrolled in JCOG0911; a randomized phase II trial was conducted to compare the efficacy of interferonβ (IFNβ) plus temozolomide (TMZ) with that of TMZ alone." | 9.34 | Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone. ( Abe, T; Adilijiang, A; Aoki, K; Aoki, T; Arakawa, Y; Asai, A; Asano, K; Beppu, T; Hashimoto, N; Hirano, H; Hirano, M; Ishikawa, E; Ito, T; Iwadate, Y; Kayama, T; Kobayashi, H; Kumabe, T; Kurisu, K; Maeda, S; Maruyama, T; Matsumura, A; Matsuo, T; Mishima, K; Motomura, K; Mukasa, A; Muragaki, Y; Nagane, M; Nakamura, H; Nakasu, Y; Narita, Y; Natsume, A; Nishikawa, R; Ohka, F; Okuno, Y; Onishi, T; Sasaki, H; Sato, S; Shibui, S; Shinoura, N; Sugiyama, K; Sumi, M; Terasaki, M; Wakabayashi, T; Yamasaki, F; Yoshimoto, K; Yoshino, A, 2020) |
| " In a previously-published multi-centre randomized clinical trial of 562 elderly glioblastoma patients, temozolomide plus short-course radiotherapy conferred a survival benefit over radiotherapy alone." | 9.34 | Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. ( Brandes, AA; Cairncross, JG; Climans, SA; Ding, K; Fay, M; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Perry, JR; Phillips, C; Roa, W; Wick, W; Winch, C, 2020) |
| "This was a phase I, two-stage, multicentre, open-label, dose-escalation study of buparlisib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma." | 9.34 | Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. ( Beck, JT; DeGroot, J; Donnet, V; El-Hashimy, M; Mason, W; Mills, D; Rodon, JA; Rosenthal, M; Wen, PY, 2020) |
| "To determine the efficacy of the thrombopoietin receptor agonist romiplostim for the prevention of temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma." | 9.30 | Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial. ( Cartalat, S; Chinot, O; Devos, P; Di Stefano, AL; Dubois, F; Houillier, C; Le Rhun, E; Lepage, C; Reyns, N; Weller, M, 2019) |
| " The present standard treatment for newly diagnosed glioblastoma is maximal resection followed by chemoradiotherapy with temozolomide." | 9.30 | A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703 ( Ichimura, K; Igaki, H; Kadota, T; Katayama, H; Kinoshita, M; Komori, T; Kumabe, T; Mizusawa, J; Narita, Y; Nishikawa, R; Saito, R; Sumi, M, 2019) |
| " We assessed the efficacy and safety of iniparib with standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma (GBM)." | 9.30 | Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. ( Ahluwalia, MS; Blakeley, JO; Chi, AS; Desideri, S; Eichler, A; Grossman, SA; Mikkelsen, T; Nabors, LB; Ribas, IG; Rosenfeld, MR; Ye, X, 2019) |
| "Memantine, mefloquine, and metformin can be combined safely with TMZ in patients with newly diagnosed glioblastoma." | 9.30 | Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. ( Aldape, KD; Alfred Yung, WK; Conrad, CA; de Groot, JF; Gilbert, MR; Groves, MD; Hess, KR; Loghin, ME; Mammoser, AG; Maraka, S; Melguizo-Gavilanes, I; O'Brien, BJ; Penas-Prado, M; Puduvalli, VK; Sulman, EP; Tremont-Lukats, IW, 2019) |
| "To evaluate the toxicity and efficacy of adjuvant temozolomide (TMZ) and irinotecan (CPT-11) for 12 months after concurrent chemoradiation in patients with newly diagnosed glioblastoma (GBM)." | 9.30 | Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. ( Curran, WJ; Hartford, AC; Lieberman, FS; Mehta, MP; Robins, HI; Schultz, C; Smith, RP; Tsien, CI; Wang, M; Werner-Wasik, M; Zhang, P, 2019) |
| "Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ)." | 9.30 | A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. ( Boockvar, J; Campian, JL; Chaudhary, R; Chinnaiyan, P; Cohen, AL; Fink, K; Goldlust, S; Huang, J; Marcus, S; Wan, L, 2019) |
| "In RPA V-VI glioblastoma patients both hypofractionated radiotherapy and exclusive temozolomide can be used; the purpose of this trial is to compare these treatment regimens in terms of survival and quality of life." | 9.30 | Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial. ( Borghetti, P; Bruni, A; Buglione, M; Fusco, V; Gatta, R; Krengli, M; Magrini, SM; Masini, L; Meduri, B; Pedretti, S; Pegurri, L; Pirtoli, L; Ricardi, U; Riva, N; Santoni, R; Scoccianti, S; Triggiani, L; Turco, E, 2019) |
| "A multicenter phase II study for assessing the efficacy and the toxicity of hypofractionated radiotherapy with SIB plus temozolomide in patients with glioblastoma was carried out by the Brain Study Group of the Italian Association of Radiation Oncology." | 9.27 | Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO). ( Buglione, M; Detti, B; Doino, D; Fiorentino, A; Fusco, V; Greto, D; Krengli, M; Livi, L; Lonardi, F; Magrini, SM; Marrazzo, L; Marzano, S; Masini, L; Migliaccio, F; Pirtoli, L; Ricardi, U; Rubino, G; Santoni, R; Scoccianti, S, 2018) |
| "Vorinostat combined with standard chemoradiation had acceptable tolerability in newly diagnosed glioblastoma." | 9.27 | Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. ( Ahluwalia, MS; Anderson, SK; Ballman, KV; Buckner, JC; Cerhan, J; Galanis, E; Gerstner, ER; Giannini, C; Grossman, SA; Jaeckle, K; Lee, EQ; Lesser, GJ; Ligon, KL; Loboda, A; Miller, CR; Moore, DF; Nebozhyn, M; Prados, M; Sarkaria, JN; Schiff, D; Wen, PY, 2018) |
| "We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly called ABT-414, plus radiation and temozolomide in newly diagnosed glioblastoma (arm A)." | 9.27 | Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. ( Ansell, PJ; Butowski, N; Fichtel, L; Fischer, J; Gan, HK; Gomez, EJ; Holen, KD; Kumthekar, P; Lassman, AB; Lee, HJ; Lwin, Z; Mandich, H; Merrell, R; Munasinghe, WP; Reardon, DA; Roberts-Rapp, LA; Scott, AM; van den Bent, M; Wheeler, H; Xiong, H, 2018) |
| "The GLARIUS trial, which investigated the efficacy of bevacizumab (BEV)/irinotecan (IRI) compared with standard temozolomide in the first-line therapy of O6-methylguanine-DNA methyltransferase (MGMT)-nonmethylated glioblastoma, showed that progression-free survival was significantly prolonged by BEV/IRI, while overall survival was similar in both arms." | 9.27 | Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. ( Belka, C; Friedrich, F; Glas, M; Goldbrunner, R; Grau, S; Grauer, O; Hänel, M; Hau, P; Herrlinger, U; Kebir, S; Krex, D; Leutgeb, B; Mack, F; Nießen, M; Proescholdt, M; Ringel, F; Rohde, V; Ronellenfitsch, MW; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schnell, O; Steinbach, JP; Stummer, W; Tabatabai, G; Tzaridis, T; Uhl, M; Urbach, H; Vajkoczy, P; Weyerbrock, A, 2018) |
| "This phase II study was designed to determine the efficacy of the mammalian target of rapamycin (mTOR) inhibitor everolimus administered daily with conventional radiation therapy and chemotherapy in patients with newly diagnosed glioblastoma." | 9.27 | A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. ( Ahluwalia, MS; Ashby, LS; Chinnaiyan, P; Fiveash, JB; Kee, AY; Malone, SC; Mehta, MP; Michael Yu, HH; Mohile, NA; Rojiani, AM; Shih, HA; Stella, PJ; Stieber, VW; Wen, PY; Wendland, MM; Werner-Wasik, M; Won, M, 2018) |
| "Disulfiram has shown promising activity including proteasome inhibitory properties and synergy with temozolomide in preclinical glioblastoma (GBM) models." | 9.27 | Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. ( Ansstas, G; Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, C, 2018) |
| "Concomitant radiochemotherapy followed by six cycles of temozolomide (= short term) is considered as standard therapy for adults with newly diagnosed glioblastoma." | 9.27 | Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany. ( Arefian, H; Hartmann, M; Kalff, R; Maschmann, J; Walter, J; Waschke, A, 2018) |
| "Results suggest that the combination of bevacizumab plus temozolomide is active in terms of response rate, survival, performance, quality of life, and cognition in elderly patients with glioblastoma multiforme with poor performance status." | 9.27 | Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG). ( Barrie, M; Barrière, J; Beauchesne, P; Benouaich-Amiel, A; Campello, C; Cartalat-Carel, S; Catry-Thomas, I; Chinot, OL; Delattre, JY; Fabbro, M; Frappaz, D; Ghiringhelli, F; Guillamo, JS; Honnorat, J; Le Rhun, E; Mokhtari, K; Reyes-Botero, G; Taillandier, L; Tanguy, ML; Tennevet, I, 2018) |
| "In this phase II study, we investigate clinical outcomes and tolerability of hypofractionated radiotherapy (HRT) combined with temozolomide (TMZ) to treat elderly patients with glioblastoma (GBM)." | 9.27 | Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma. ( Amsbaugh, M; Boakye, M; Burton, E; Hattab, EM; Nelson, M; Ugiliweneza, B; Williams, B; Woo, S; Yusuf, M, 2018) |
| "In total, 111 newly, histologically diagnosed glioblastoma patients treated at our oncology center with radiotherapy and temozolomide were prospectively enrolled." | 9.27 | Quality of Life Perception, Cognitive Function, and Psychological Status in a Real-world Population of Glioblastoma Patients Treated With Radiotherapy and Temozolomide: A Single-center Prospective Study. ( Bellu, L; Bergo, E; Caccese, M; Del Bianco, P; Lombardi, G; Pambuku, A; Trentin, L; Zagonel, V, 2018) |
| "We report a longitudinal assessment of health-related quality of life (HRQOL) in patients with glioblastoma (GBM) treated on a prospective dose escalation trial of 5-fraction stereotactic radiosurgery (25-40 Gy in 5 fractions) with concurrent and adjuvant temozolomide." | 9.24 | Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results. ( Adler, JR; Azoulay, M; Chang, SD; Choi, CYH; Fujimoto, D; Gibbs, IC; Hancock, SL; Harraher, C; Harsh, GR; Jacobs, LR; Li, G; Modlin, LA; Nagpal, S; Pollom, EL; Recht, LD; Seiger, K; Soltys, SG; Thomas, RP; Tupper, L; von Eyben, R; Wynne, J, 2017) |
| "Bevacizumab plus bi-weekly temozolomide was well tolerated and may be a salvage regimen to be considered in a subset of patients with recurrent glioblastoma." | 9.24 | Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma. ( Ahmadi, MM; Badruddoja, MA; Kuzma, K; Mahadevan, D; Norton, T; Pazzi, M; Sanan, A; Schroeder, K; Scully, T, 2017) |
| "We characterized health-related quality of life (HRQoL), cognitive, and functional status in newly diagnosed glioblastoma (GBM) patients receiving Tumor treating fields (TTFields) with temozolomide (TMZ) versus TMZ alone in a planned interim analysis of a randomized phase III trial [NCT00916409], which showed significant improvement in progression-free and overall survival with TTFields/TMZ." | 9.24 | Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. ( Avgeropoulos, N; Benouaich-Amiel, A; David, C; Demireva, P; Goldlust, S; Kanner, AA; Mehdorn, M; Pannullo, S; Salmaggi, A; Silvani, A; Zhu, JJ, 2017) |
| "In the final analysis of this randomized clinical trial of patients with glioblastoma who had received standard radiochemotherapy, the addition of TTFields to maintenance temozolomide chemotherapy vs maintenance temozolomide alone, resulted in statistically significant improvement in progression-free survival and overall survival." | 9.24 | Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. ( Ahluwalia, MS; Brem, S; Bruna, J; Di Meco, F; Fink, K; Hegi, ME; Hirte, H; Hottinger, A; Idbaih, A; Kanner, A; Kim, CY; Kirson, ED; Lavy-Shahaf, G; Lhermitte, B; Lieberman, F; Nicholas, G; Paek, SH; Palti, Y; Ram, Z; Read, W; Steinberg, D; Stragliotto, G; Stupp, R; Taillibert, S; Toms, S; Tran, D; Weinberg, U; Weller, M; Zhu, JJ, 2017) |
| "We performed a phase 2 trial of neoadjuvant temozolomide (TMZ), followed by hypofractionated accelerated radiation therapy (HART) with concurrent TMZ, and adjuvant TMZ in patients with newly diagnosed glioblastoma to determine whether neoadjuvant TMZ would safely improve outcomes in this group of patients prior to subsequent cytotoxic therapy." | 9.24 | A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma. ( Abdulkarim, B; Corredor, AG; Guiot, MC; Owen, S; Panet-Raymond, V; Petrecca, K; Shenouda, G; Souhami, L, 2017) |
| "The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II dose (RPTD), safety, and pharmacokinetics of ABT-414 plus radiation and temozolomide in newly diagnosed glioblastoma." | 9.24 | Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. ( Ansell, P; Fichtel, L; Fischer, J; Gan, HK; Gomez, E; Holen, KD; Kumthekar, P; Lassman, AB; Lee, HJ; Mandich, H; Merrell, R; Munasinghe, W; Reardon, DA; Roberts-Rapp, L; Scott, AM; Sulman, EP; van den Bent, M; Xiong, H, 2017) |
| "There is a need for a more refined, molecularly based classification model for glioblastoma (GBM) in the temozolomide era." | 9.24 | Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525. ( Aldape, K; Barnholtz-Sloan, JS; Becker, AP; Bell, EH; Blumenthal, DT; Brachman, D; Bredel, M; Brown, PD; Chakravarti, A; Curran, W; Flickinger, J; Gilbert, MR; Glass, J; Grosu, AL; Klimowicz, AC; Lee, RJ; Magliocco, A; McElroy, JP; Mehta, M; Pugh, SL; Robe, P; Salavaggione, AL; Souhami, L; Stupp, R; Won, M, 2017) |
| "In glioblastoma multiforme (GBM), both temozolomide (TMZ) and cisplatin are very active at various toxic levels." | 9.24 | Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients. ( Guo, Y; Kong, X; Ma, W; Wang, R; Wang, Y, 2017) |
| "In elderly patients with glioblastoma, the addition of temozolomide to short-course radiotherapy resulted in longer survival than short-course radiotherapy alone." | 9.24 | Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. ( Back, M; Baumert, BG; Brandes, AA; Cairncross, JG; Chinot, O; Ding, K; Fariselli, L; Fay, M; Feuvret, L; Franceschi, E; Golfinopoulos, V; Hirte, H; Laigle-Donadey, F; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Osoba, D; Perry, JR; Phillips, C; Roa, W; Rossiter, JP; Sahgal, A; Tills, M; Wick, A; Wick, W; Winch, C, 2017) |
| "Temozolomide (TMZ), an imidazotetrazine, is a second-generation DNA alkylating agent used as a first-line treatment of glioblastoma multiforme (GBM)." | 9.22 | Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme. ( Chitkara, D; Jatyan, R; Karthik, YG; Mittal, A; Sahel, DK; Singh, P, 2022) |
| "To evaluate the safety and efficacy of nimotuzumab, a humanized monoclonal antibody specific for the epidermal growth factor receptor (EGFR), in combination with temozolomide (TMZ) and radiation therapy (RT) in the treatment of newly diagnosed glioblastoma (GBM) in Chinese patients." | 9.22 | Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients. ( Chen, S; Dai, JZ; Pan, L; Sheng, XF; Wang, Y, 2016) |
| "We report on a phase II clinical trial to determine the effect of a concurrent ultra-fractionated radiotherapy and temozolomide treatment in inoperable glioblastoma patients." | 9.22 | A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma. ( Beauchesne, P; Bernier, V; Carnin, C; Faure, G; Gorlia, T; Noel, G; Pedeux, R; Quetin, P; Quillien, V, 2016) |
| "This study tested the hypothesis that ABT-888 (velparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, can modulate temozolomide (TMZ) resistance in recurrent TMZ refractory glioblastoma patients." | 9.22 | A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. ( Cavaliere, R; Chakravarti, A; Chmura, SJ; Colman, H; de Groot, JF; Gilbert, MR; Grimm, SA; Kee, AY; Kesari, S; Krauze, A; Lieberman, FS; Mehta, M; Mohile, N; Robins, HI; Trotti, AM; Wang, F; Zhang, P, 2016) |
| "This phase II study was conducted to determine the efficacy and safety of metronomic temozolomide (TMZ) in combination with irinotecan in glioblastoma (GB) at first relapse." | 9.22 | Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Benavides, M; Fleitas, T; Gallego, O; Gil-Gil, M; Martínez-Sales, V; Palomero, I; Pérez-Segura, P; Reche, E; Reynés, G; Vaz, MA; Vila, V, 2016) |
| "The proposed use of bevacizumab with radiotherapy/temozolomide for newly diagnosed glioblastoma raised potential safety concerns." | 9.22 | Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. ( Chinot, OL; Cloughesy, T; Dhar, S; Garcia, J; Henriksson, R; Mason, W; Nishikawa, R; Pozzi, E; Saran, F; Wick, W, 2016) |
| "Disulfiram, a generic alcohol aversion drug, has promising preclinical activity against glioblastoma (GBM)." | 9.22 | A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy. ( Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, CI, 2016) |
| "In patients with newly diagnosed glioblastoma that harbors a nonmethylated O(6)-methylguanine-DNA methyltransferase promotor, standard temozolomide (TMZ) has, at best, limited efficacy." | 9.22 | Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. ( Belka, C; Brehmer, S; Dunkl, E; Fietkau, R; Friedrich, F; Gerlach, R; Glas, M; Goldbrunner, R; Grau, S; Hänel, M; Hau, P; Herrlinger, U; Kebir, S; Kohnen, R; Kortmann, RD; Krex, D; Leutgeb, B; Maciaczyk, J; Mack, F; Mayer-Steinacker, R; Mehdorn, M; Pietsch, T; Proescholdt, M; Ringel, F; Rohde, V; Ronellenfitsch, MW; Sabel, M; Schäfer, N; Schlegel, U; Schnell, O; Steinbach, JP; Stummer, W; Stuplich, M; Tüttenberg, J; Uhl, M; Urbach, H; Vajkoczy, P; Weyerbrock, A, 2016) |
| "To evaluate the maximum tolerated dose of simultaneous integrated-boost intensity-modulated radiotherapy (SIB-IMRT) associated with temozolomide in patients with glioblastoma." | 9.22 | A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma. ( Bernier, V; Blanchard, N; Bonnetain, F; Dalban, C; Lagneau, É; Maingon, P; Mazoyer, F; Mirjolet, C; Noël, G; Truc, G, 2016) |
| " Patients with MGMT unmethylated glioblastoma (n = 111) were randomized 1:1 between standard chemo-radiotherapy with temozolomide or radiotherapy plus weekly temsirolimus (25 mg)." | 9.22 | Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). ( Bady, P; Brandes, AA; Campone, M; Frenel, JS; Golfinopoulos, V; Gorlia, T; Hamou, MF; Hegi, ME; Homicsko, K; Hopkins, K; Kosch, M; Lhermitte, B; Marosi, C; Pesce, G; Platten, M; Ricard, D; Roth, P; Steuve, J; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Villa, S; Weller, M; Weyerbrock, A; Wick, A; Wick, W, 2016) |
| "This trial was designed to evaluate the safety and clinical responses to a combination of temozolomide (TMZ) chemotherapy and immunotherapy with fusions of DCs and glioma cells in patients with glioblastoma (GBM)." | 9.22 | Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma. ( Akasaki, Y; Arai, T; Hayashi, K; Homma, S; Joki, T; Kikuchi, T; Koido, S; Komita, H; Mori, R; Murayama, Y; Ohkusa, T; Suzuki, Y; Tanaka, T; Tasaki, T; Watanabe, N; Yamamoto, Y; Yanagisawa, T, 2016) |
| "Temozolomide (TMZ) administered daily with radiation therapy (RT) for 6 weeks, followed by adjuvant TMZ for 6 cycles, is the standard therapy for newly diagnosed glioblastoma (GBM) patients." | 9.20 | Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study. ( Amadori, A; Berti, F; Bertorelle, R; Della Puppa, A; Farina, P; Lombardi, G; Marcato, R; Rumiato, E; Sacchetto, V; Saggioro, D; Zagonel, V; Zustovich, F, 2015) |
| "This phase I/II trial evaluated the maximum tolerated dose (MTD) and pharmacokinetics of afatinib plus temozolomide as well as the efficacy and safety of afatinib as monotherapy (A) or with temozolomide (AT) vs temozolomide monotherapy (T) in patients with recurrent glioblastoma (GBM)." | 9.20 | Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. ( Cong, J; Cseh, A; Eisenstat, DD; Fu, Y; Kavan, P; Mason, WP; Mathieu, D; Nabors, LB; Perry, JR; Phuphanich, S; Reardon, DA; Shapiro, W; Wind, S, 2015) |
| "Chemoradiation, followed by adjuvant temozolomide, is the standard treatment for newly diagnosed glioblastoma." | 9.20 | Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. ( Aldape, KD; Chang, EL; Colman, H; Conrad, CA; De Groot, JF; Fisch, MJ; Floyd, JD; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, KR; Hsu, SH; Lagrone, LW; Levin, VA; Loghin, ME; Mahajan, A; Penas-Prado, M; Puduvalli, VK; Salacz, ME; Volas-Redd, G; Woo, SY; Yung, WK, 2015) |
| " We evaluated the efficacy and toxicity of hypofractionated intensity-modulated radiation therapy with concurrent and adjuvant temozolomide and bevacizumab in patients with newly diagnosed glioblastoma." | 9.20 | Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. ( Carlson, JA; Chen, C; Damek, DM; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, KO; Ney, DE; Reddy, K; Waziri, AE, 2015) |
| "Patients with a newly diagnosed glioblastoma multiforme (GBM) have a high risk of recurrent disease with a dismal outcome despite intensive treatment of sequential surgery and chemoradiotherapy with temozolomide (TMZ), followed by TMZ as a single agent." | 9.20 | Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme. ( Reijneveld, JC; Richel, DJ; Stalpers, LJ; van Furth, WR; van Linde, ME; Verheul, HM; Verhoeff, JJ, 2015) |
| "Rechallenge with temozolomide (TMZ) at first progression of glioblastoma after temozolomide chemoradiotherapy (TMZ/RT→TMZ) has been studied in retrospective and single-arm prospective studies, applying temozolomide continuously or using 7/14 or 21/28 days schedules." | 9.20 | MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. ( Bähr, O; Felsberg, J; Goldbrunner, R; Hau, P; Herrlinger, U; Homicsko, K; Hüsing, J; Kästner, B; Ketter, R; Kollias, S; Marosi, C; Meixensberger, J; Nikkhah, G; Pichler, J; Platten, M; Reifenberger, G; Sabel, MC; Schlegel, U; Schnell, O; Steinbach, JP; Stupp, R; Tabatabai, G; Tonn, JC; Vajkoczy, P; Weller, M; Wick, A; Wick, W; Wirsching, HG, 2015) |
| "To investigate the safety of combined Wilms tumor 1 peptide vaccination and temozolomide treatment of glioblastoma, a phase I clinical trial was designed." | 9.20 | Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response. ( Arita, N; Chiba, Y; Hashimoto, N; Hosen, N; Izumoto, S; Kagawa, N; Kijima, N; Kinoshita, M; Morimoto, S; Morita, S; Nakajima, H; Nishida, S; Oji, Y; Oka, Y; Sakamoto, J; Sugiyama, H; Tsuboi, A; Yoshimine, T, 2015) |
| "The purpose of phase 1 was to determine the maximum tolerated dose (MTD) of motexafin gadolinium (MGd) given concurrently with temozolomide (TMZ) and radiation therapy (RT) in patients with newly diagnosed supratentorial glioblastoma multiforme (GBM)." | 9.20 | Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513. ( Ashby, LS; Bovi, JA; Brachman, DG; Curran, WP; Dunbar, EM; Narayan, S; Pugh, SL; Robins, HI; Rockhill, JK; Thomas, TA; Won, M, 2015) |
| " We conducted a randomized, noncomparative, phase II study of radiation (RT) and temozolomide with or without vandetanib in patients with newly diagnosed glioblastoma (GBM)." | 9.20 | A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. ( Alexander, BM; Ancukiewicz, M; Batchelor, TT; Beroukhim, R; Drappatz, J; Duda, DG; Gerard, M; Huse, JT; Jain, RK; Kaley, TJ; Lassman, AB; Lee, EQ; Ligon, KL; McCluskey, CS; Mikkelsen, T; Muzikansky, A; Norden, AD; Purow, BW; Ramkissoon, S; Schiff, D; Smith, KH; Weiss, SE; Wen, PY; Wong, ET, 2015) |
| "The aim of this prospective and multicentric phase II study was to evaluate the efficacy and safety of temozolomide (TMZ) and bevacizumab (BV) in patients (pts) with recurrent glioblastoma (GB), previously treated with chemoradiotherapy and at least three cycles of adjuvant TMZ." | 9.20 | A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Belda-Iniesta, C; Berrocal, A; Capellades, J; Gallego, O; Gil-Gil, M; La Orden, B; Ordoñez, JM; Pérez-Segura, P; Reynés, G; Sepúlveda, JM, 2015) |
| "Valproic acid (VPA) is an antiepileptic agent with histone deacetylase inhibitor (HDACi) activity shown to sensitize glioblastoma (GBM) cells to radiation in preclinical models." | 9.20 | A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. ( Camphausen, K; Chang, MG; Fine, HA; Holdford, DJ; Krauze, AV; Myrehaug, SD; Shih, J; Smith, S; Tofilon, PJ, 2015) |
| "The radiochemotherapy regimen concomitantly employing temozolomide (TMZ) chemotherapy and radiotherapy (RT) 4 weeks after surgery, followed by 6 cycles of TMZ is a common treatment for glioblastoma (GBM)." | 9.20 | Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial. ( Chen, JX; Chen, ZP; Li, ZY; Lu, YC; Ma, WB; Mao, Y; Qi, ST; Shen, H; Wang, JS; Wang, RZ; Wang, X; Yang, QY; Yang, SY; Yang, XJ; Yao, Y; You, C; Zhang, JM; Zhang, LW; Zhang, X; Zhen, HN; Zhou, LF, 2015) |
| "To evaluate the efficacy and safety of TTFields used in combination with temozolomide maintenance treatment after chemoradiation therapy for patients with glioblastoma." | 9.20 | Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. ( Barnett, GH; Caroli, M; Chen, TC; Desai, R; Engelhard, HH; Fink, KL; Hegi, ME; Henson, JW; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kesari, S; Kew, Y; Kirson, ED; Landolfi, J; Lieberman, F; Palti, Y; Ram, Z; Silvani, A; Sroubek, J; Steinberg, DM; Stupp, R; Taillibert, S; Taylor, LP; Toms, SA; Tran, DD; Tran, ND; Weinberg, U; Zhu, JJ, 2015) |
| "To evaluate the efficacy of limited margins intensity-modulated radiotherapy (IMRT) with temozolomide chemotherapy in patients with malignant glioma, and explore the prognostic factors of malignant glioma." | 9.20 | [Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma]. ( Cao, Y; Sun, J; Yang, X; Zhang, W, 2015) |
| "We conducted a phase I trial to examine the maximally tolerated dose (MTD) of the oral protease inhibitor nelfinavir (NFV) in combination with temozolomide and concurrent radiotherapy in patients with glioblastoma and to gather preliminary data for response." | 9.19 | A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme. ( Alonso-Basanta, M; Dorsey, JF; Fang, P; Hahn, SM; Lustig, RA; Maity, A, 2014) |
| "Adult patients with newly surgical diagnosed glioblastoma were randomly assigned to receive either temozolomide or semustine after radiation treatment." | 9.19 | Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide. ( Chen, JX; Liu, JP; Liu, YH; Mao, Q; Wang, X; You, C, 2014) |
| " We sought to determine whether the addition of a vascular endothelial growth factor (VEGF) signaling inhibitor (cediranib) to conventional CRT had an impact on the frequency of PsP, by comparing two groups of patients with newly diagnosed glioblastoma before, during, and after CRT." | 9.19 | Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. ( Batchelor, TT; Emblem, KE; Gerstner, ER; Jain, RK; Jennings, D; Kalpathy-Cramer, J; Pinho, MC; Polaskova, P; Rosen, BR; Sorensen, AG; Wen, PY, 2014) |
| "To determine the maximum tolerated dose of irinotecan administered every 2 weeks, in combination with a fixed and continuous administration of temozolomide, in patients with glioblastoma at first relapse." | 9.19 | A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Gallego, O; García, JL; Iglesias, L; Pérez, P; Reynés, G, 2014) |
| "We conducted a phase I study to determine (a) the maximum tolerated dose of peri-radiation therapy temozolomide (TMZ) and (b) the safety of a selected hypofractionated intensity modulated radiation therapy (HIMRT) regimen in glioblastoma multiforme (GBM) patients." | 9.19 | Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme. ( Ammirati, M; Chotai, S; Grecula, J; Lamki, T; Newton, H; Wei, L, 2014) |
| "The integrin antagonist cilengitide has been explored as an adjunct with anti-angiogenic properties to standard of care temozolomide chemoradiotherapy (TMZ/RT → TMZ) in newly diagnosed glioblastoma." | 9.19 | Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. ( Clément, PM; Eisele, AC; Eisele, G; Krex, D; Neyns, B; Nikkhah, G; Ochsenbein, A; Picard, M; Schlegel, U; Simon, M; Stupp, R; Tabatabai, G; Tonn, J; Weller, M; Wick, A; Wick, W, 2014) |
| "Surgery followed by radiotherapy and concomitant and adjuvant temozolomide is standard therapy in newly diagnosed glioblastoma multiforme (GBM)." | 9.19 | Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study. ( Ask, A; Costa, JC; Engelholm, S; Grunnet, K; Hansen, S; Hofland, KF; Kristiansen, C; Lassen, U; Muhic, A; Poulsen, HS; Schultz, HP; Sorensen, M; Thomsen, C, 2014) |
| "To assess the effect and toxicity of hypofractionated high-dose intensity modulated radiation therapy (IMRT) with concurrent and adjuvant temozolomide (TMZ) in 46 patients with newly diagnosed glioblastoma multiforme (GBM)." | 9.19 | Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. ( Hara, R; Hasegawa, Y; Hatano, K; Iuchi, T; Kawasaki, K; Kodama, T; Sakaida, T; Yokoi, S, 2014) |
| "Standard therapy for newly diagnosed glioblastoma is radiotherapy plus temozolomide." | 9.19 | Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. ( Abrey, L; Brandes, AA; Carpentier, AF; Cernea, D; Chinot, OL; Cloughesy, T; Henriksson, R; Hilton, M; Hoang-Xuan, K; Kavan, P; Mason, W; Nishikawa, R; Saran, F; Wick, W, 2014) |
| "Prognosis of unresectable glioblastoma (GB) remains poor, despite temozolomide (TMZ)-based chemoradiation." | 9.19 | Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†. ( Bonnetain, F; Campello, C; Castera, D; Chauffert, B; Chinot, O; Dalban, C; Durando, X; Fabbro, M; Feuvret, L; Frappaz, D; Frenay, M; Ghiringhelli, F; Guillamo, JS; Honnorat, J; Schott, R; Skrzypski, J; Taillandier, L; Taillia, H; Tennevet, I, 2014) |
| "The objective of this study was to report the patterns of failure in patients with glioblastoma multiforme (GBM) treated on a phase II trial of hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concurrent and adjuvant temozolomide (TMZ)." | 9.19 | Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme. ( Chen, C; Gaspar, LE; Kavanagh, BD; Reddy, K, 2014) |
| " The primary objective of this trial was to determine the maximum tolerated dose (MTD) and efficacy of HCQ in combination with radiation therapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma (GB)." | 9.19 | A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. ( Amaravadi, RK; Brem, S; Chang, YC; Davis, LE; Desideri, S; Fisher, J; Grossman, SA; Heitjan, DF; Hu, J; McAfee, Q; Mikkelson, T; O'Dwyer, PJ; Piao, S; Pontiggia, L; Rosenfeld, MR; Supko, JG; Tan, KS; Troxel, AB; Wang, D; Ye, X, 2014) |
| "Temozolomide (TMZ) may enhance antitumor immunity in patients with glioblastoma multiforme (GBM)." | 9.19 | Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. ( Abe, T; Hashimoto, K; Ikuta, S; Ishihara, T; Ishikawa, E; Karasawa, K; Maruyama, T; Matsuda, M; Matsumura, A; Matsutani, M; Muragaki, Y; Nakazato, Y; Ohno, T; Tsuboi, K; Uemae, Y; Yamamoto, T, 2014) |
| " We conducted a phase II trial in newly diagnosed glioblastoma utilizing a novel hypofractionated stereotactic radiotherapy (HFSRT) schedule combined with temozolomide and bevacizumab." | 9.19 | Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. ( Abrey, LE; Barradas-Panchal, R; Baser, RE; Beal, K; Brennan, CW; Chan, TA; Correa, DD; DeAngelis, LM; Faivre, G; Gavrilovic, IT; Grommes, C; Gutin, P; Hormigo, A; Huse, JT; Kaley, TJ; Karimi, S; Lassman, AB; Mellinghoff, I; Nolan, C; Omuro, A; Panageas, KS; Pentsova, E; Reiner, AS; Sanchez, J; Tabar, V; Zhang, J, 2014) |
| " Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in combination with standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly in tumours with methylated MGMT promoter)." | 9.19 | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. ( Adamska, K; Aldape, KD; Brandes, AA; Erridge, SC; Gorlia, T; Grujicic, D; Gupta, T; Hau, P; Hegi, ME; Herrlinger, U; Hicking, C; Hong, YK; Kim, CY; Kortmann, RD; Lhermitte, B; Markivskyy, A; McBain, C; Nabors, LB; Nam, DH; Perry, J; Picard, M; Pietsch, T; Rao, N; Reardon, DA; Schnell, O; Shen, CC; Steinbach, JP; Stupp, R; Taphoorn, MJ; Tarnawski, R; Thurzo, L; Tonn, JC; van den Bent, MJ; Weller, M; Weyerbrock, A; Wick, W; Wiegel, T, 2014) |
| "To determine the safety and efficacy of hypofractionated intensity modulated radiation therapy (Hypo-IMRT) using helical tomotherapy (HT) with concurrent low dose temozolomide (TMZ) followed by adjuvant TMZ in patients with glioblastoma multiforme (GBM)." | 9.17 | Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. ( Abdulkarim, B; Fallone, G; Field, C; Fulton, D; Ghosh, S; Jastaniyah, N; Le, D; Mackenzie, M; Murtha, A; Patel, S; Pervez, N; Roa, W, 2013) |
| "Among patients with glioblastoma (GBM) who progress on standard temozolomide, the optimal therapy is unknown." | 9.17 | Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. ( Batchelor, TT; Beroukhim, R; Doherty, L; Drappatz, J; Fadul, CE; Hammond, SN; Lafrankie, D; Lee, EQ; Lesser, GJ; Ligon, KL; Lis, R; Muzikansky, A; Norden, AD; Plotkin, SR; Reardon, DR; Rosenfeld, MR; Smith, K; Stack, EC; Tafoya, V; Wen, PY; Zhu, JJ, 2013) |
| "To evaluate the efficacy and safety of temozolomide (TMZ) versus semustine (Me-CCNU) in the treatment of recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA)." | 9.17 | [Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma]. ( Sun, J; Yang, SY; Yang, XJ, 2013) |
| " Temozolomide (TMZ) is an alkylating agent that is the first-line chemotherapy for glioblastoma." | 9.17 | Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. ( Colman, H; Conrad, C; Gilbert, MR; Groves, M; Hsu, S; Kang, S; Levin, V; Liu, D; Liu, V; Puduvalli, V; Yuan, Y; Yung, WK; Yust-Katz, S, 2013) |
| "To describe the quality of life (QOL) in elderly patients with glioblastoma (GBM) treated with an abbreviated course of radiation therapy (RT; 40 Gy in 15 fractions) plus concomitant and adjuvant temozolomide (TMZ)." | 9.17 | Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. ( Baldoni, A; De Sanctis, V; Enrici, RM; Esposito, V; Lanzetta, G; Minniti, G; Scaringi, C, 2013) |
| "The prognostic role of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients treated with carmustine (BCNU) wafer implantation is unclear." | 9.17 | MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers. ( Bock, HC; Brück, W; Doerner, L; Felsberg, J; Giese, A; Gutenberg, A; Mehdorn, HM; Reifenberger, G; Roggendorf, W; Westphal, M, 2013) |
| "To determine the safety of the mammalian target of rapamycin inhibitor everolimus (RAD001) administered daily with concurrent radiation and temozolomide in newly diagnosed glioblastoma patients." | 9.17 | RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. ( Chinnaiyan, P; Corn, BW; Dipetrillo, TA; Mehta, MP; Rojiani, AM; Wen, PY; Wendland, M; Won, M, 2013) |
| "To report health-related quality of life (HRQOL) in glioblastoma (GBM) patients treated on a phase II trial of hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with temozolomide (TMZ)." | 9.17 | Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide. ( Chen, C; Damek, DM; Gaspar, LE; Kavanagh, BD; Lillehei, KO; Ney, D; Reddy, K; Waziri, A, 2013) |
| "The current standard-of-care for glioblastoma (GBM) is represented by concomitant radiotherapy (RT) and temozolomide (TMZ), according to Stupp's protocol." | 9.17 | Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. ( Caroli, M; Carrabba, G; DI Cristofori, A; Lanfranchi, G; Menghetti, C; Rampini, P, 2013) |
| "To investigate the impact of nonstandard concomitant temozolomide (TMZ) administration in two prospective phase II studies for glioblastoma (GBM)." | 9.17 | Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials. ( Alitto, AR; Anile, C; Balducci, M; Chiesa, S; Colosimo, C; D'Agostino, GR; De Bonis, P; Fiorentino, A; Frascino, V; Mangiola, A; Mantini, G; Mattiucci, GC; Valentini, V, 2013) |
| "Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM)." | 9.17 | Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. ( Aldape, KD; Armstrong, TS; Baumert, B; Blumenthal, DT; Brown, PD; Chakravarti, A; Curran, WJ; Erridge, S; Gilbert, MR; Hegi, ME; Hopkins, KI; Jaeckle, KA; Mahajan, A; Mehta, MP; Schultz, CJ; Stupp, R; Tzuk-Shina, T; Wang, M; Wefel, JS; Won, M, 2013) |
| "Radiation Therapy Oncology Group trial 0525 tested whether dose-intensifying temozolomide versus standard chemoradiotherapy improves overall survival (OS) or progression-free survival (PFS) in newly diagnosed glioblastoma." | 9.17 | Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. ( Armstrong, TS; Bottomley, A; Brachman, DG; Choucair, AK; Coens, C; Gilbert, MR; Mehta, M; Mendoza, TR; Wang, M; Wefel, JS; Werner-Wasik, M; Won, M, 2013) |
| "We performed a dose-escalation trial to determine the maximum tolerated dose (MTD) of intensity-modulated radiotherapy (IMRT) with standard concurrent and sequential-dose temozolomide (TMZ) in patients with glioblastoma multiforme." | 9.17 | Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1). ( Balducci, M; Cilla, S; Deodato, F; Ferro, M; Macchia, G; Massaccesi, M; Morganti, AG; Valentini, V, 2013) |
| "Locoregional chemotherapy with carmustine wafers, positioned at surgery and followed by radiation therapy, has been shown to prolong survival in patients with newly diagnosed glioblastoma, as has concomitant radiochemotherapy with temozolomide." | 9.17 | Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. ( Casali, C; Ciusani, E; Dimeco, F; Fariselli, L; Gaviani, P; Guzzetti, S; Maccagnano, C; Marchetti, M; Milanesi, I; Pollo, B; Salmaggi, A; Silvani, A; Solero, CL, 2013) |
| "To determine the safety of the addition of bevacizumab to standard radiation therapy and daily temozolomide for newly diagnosed glioblastoma multiforme (GBM)." | 9.16 | Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. ( Bailey, L; Desjardins, A; Friedman, A; Friedman, HS; Herndon, JE; Kirkpatrick, JP; Marcello, J; Peters, KB; Reardon, DA; Sampson, J; Threatt, S; Vredenburgh, JJ, 2012) |
| "The new standard treatment of glioblastoma multiforme is concurrent radiotherapy (RT) and temozolomide." | 9.16 | Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma. ( Amin, P; Cheston, S; Dhople, A; DiBiase, S; Flannery, T; Meisenberg, B; Patel, A; Patel, S, 2012) |
| "The authors performed a phase 2 trial of combined protracted daily temozolomide and biweekly bevacizumab for patients with recurrent glioblastoma who had previously received radiation therapy and temozolomide." | 9.16 | Bevacizumab and daily temozolomide for recurrent glioblastoma. ( Bailey, L; Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; Marcello, J; Peters, KB; Reardon, DA; Vredenburgh, JJ, 2012) |
| "Radiotherapy with concomitant and adjuvant temozolomide has been the standard of care for newly diagnosed glioblastoma in adults since the pivotal trial by Roger Stupp and colleagues." | 9.16 | Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation. ( Chambers, CR; Lam, N, 2012) |
| "This phase I trial was designed to determine the recommended phase II dose(s) of everolimus (RAD001) with temozolomide (TMZ) in patients with glioblastoma (GBM)." | 9.16 | A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study. ( Easaw, J; Eisenhauer, E; Kavan, P; Lwin, Z; Macdonald, D; Macneil, M; Mason, WP; McIntosh, L; Thiessen, B; Urva, S, 2012) |
| "To report toxicity and overall survival (OS) in patients with newly diagnosed glioblastoma multiforme (GBM) treated with hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concurrent and adjuvant temozolomide (TMZ)." | 9.16 | Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. ( Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Lillehei, K; Ney, D; Reddy, K; Stuhr, K; Waziri, A, 2012) |
| " The primary objectives of this randomized phase 2 trial were to determine the safety and efficacy of cilengitide when combined with radiation and temozolomide for patients with newly diagnosed glioblastoma multiforme and to select a dose for comparative clinical testing." | 9.16 | A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). ( Batchelor, T; Brem, S; Fisher, JD; Grossman, SA; Hegi, ME; Lesser, G; Mikkelsen, T; Nabors, LB; Olsen, J; Peereboom, D; Rosenfeld, MR; Ye, X, 2012) |
| "To evaluate the efficacy of adding bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, and everolimus, a mammalian target of rapamycin (mTOR inhibitor), to standard radiation therapy/temozolomide in the first-line treatment of patients with glioblastoma." | 9.16 | Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. ( Brinker, BT; Hainsworth, JD; Shepard, GC; Shih, KC; Spigel, DR; Tillinghast, GW, 2012) |
| " Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma." | 9.16 | Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. ( Abacioglu, U; Frappaz, D; Grønberg, BH; Hegi, ME; Henriksson, R; Lhermitte, B; Malmström, A; Marosi, C; Rosell, J; Schultz, H; Stupp, R; Tavelin, B, 2012) |
| "To determine whether the pattern of progressive disease (PD) for glioblastoma multiforme (GBM) patients has changed with the introduction of the current standard of care protocol - postoperative conformal radiotherapy to a dose of 60 Gray in 30 fractions with concurrent low-dose (75-100 mg/m(2) ) temozolomide, followed by six cycles of adjuvant high-dose (150-200 mg/m(2) ) temozolomide - as compared with radiotherapy alone." | 9.16 | The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy. ( Bressel, M; Gunjur, A; Ryan, G, 2012) |
| "Chemotherapy-induced nausea and vomiting (CINV) is a side effect related to administration of the adjuvant temozolomide (TMZ) in patients affected by glioblastoma." | 9.15 | Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. ( Bria, E; Corona, M; Fabi, A; Lanzetta, G; Minniti, G; Nardoni, C; Restuccia, MR; Rozzi, A, 2011) |
| "In the present study we investigated the feasibility and effectiveness of a new biweekly schedule of fotemustine (FTM) in patients with recurrent glioblastoma, after at least one previous treatment." | 9.15 | A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. ( Abbruzzese, A; Addeo, R; Caraglia, M; Carraturo, M; Cennamo, G; De Santi, MS; Del Prete, S; Faiola, V; Genovese, M; Montella, L; Parlato, C; Vincenzi, B, 2011) |
| "To determine the maximal tolerated biologic dose intensification of radiotherapy using fractional dose escalation with temozolomide (TMZ) chemotherapy in patients with newly diagnosed glioblastoma multiforme." | 9.15 | Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. ( Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, K; Robischon, M; Rusthoven, KE; Stuhr, K; Waziri, A, 2011) |
| "To determine the maximum tolerated dose (MTD) of tipifarnib in combination with conventional radiotherapy for patients with newly diagnosed glioblastoma." | 9.15 | A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. ( Abrey, L; Chang, SM; Cloughesy, TF; DeAngelis, LM; Demopoulos, A; Drappatz, J; Fine, HA; Fink, K; Kesari, S; Lamborn, KR; Lassman, AB; Lieberman, FS; Malkin, MG; Mehta, MP; Nghiemphu, PL; Prados, MD; Robins, HI; Torres-Trejo, A; Wen, PY, 2011) |
| "A prospective randomized controlled multicenter phase III trial was conducted to evaluate the effects of neoadjuvant chemotherapy with nimustine (ACNU)-cisplatin (CDDP) when used in conjunction with radiotherapy plus adjuvant temozolomide in patients with newly diagnosed glioblastoma." | 9.15 | Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. ( Han, JH; Heo, DS; Jung, HW; Kim, CY; Kim, DG; Kim, DW; Kim, IA; Kim, IH; Kim, JE; Kim, JH; Kim, TM; Kim, YJ; Lee, SH; Nam, DH; Paek, SH; Park, BJ; Park, CK; Rhee, CH, 2011) |
| "This open-label, prospective, multicenter single-arm phase II study combined bevacizumab (BV) with radiation therapy (RT) and temozolomide (TMZ) for the treatment of newly diagnosed glioblastoma (GBM)." | 9.15 | Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. ( Black, K; Cloughesy, T; Elashoff, R; Fehrenbacher, L; Filka, E; Green, RM; Kolevska, T; Lai, A; Liau, LM; Mischel, PS; Nghiemphu, PL; Peak, S; Phuphanich, S; Polikoff, J; Pope, WB; Selch, M; Solis, OE; Spier, CE; Tran, A; Yong, WH, 2011) |
| "To analyse patterns of failure in patients with glioblastoma multiforme treated with concurrent radiation and temozolomide." | 9.15 | Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. ( Burnett Iii, OL; Dobelbower, MC; Fiveash, JB; Hyatt, MD; Markert, JM; Nabors, LB; Nordal, RA, 2011) |
| "To determine if the addition of bevacizumab to radiation therapy and temozolomide, followed by bevacizumab, temozolomide, and irinotecan, for newly diagnosed glioblastoma patients is safe and effective." | 9.15 | The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. ( Bailey, L; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Kirkpatrick, JP; Marcello, J; Peters, KB; Reardon, DA; Sampson, JH; Threatt, S; Vredenburgh, JJ, 2011) |
| "Concurrent and post-radiotherapy temozolomide (T) significantly improves survival in patient with newly diagnosed glioblastoma multiforme." | 9.15 | Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. ( Ananda, S; Brown, C; Cher, L; Dowling, A; Nowak, AK; Rosenthal, MA; Simes, J, 2011) |
| "This analysis was performed to assess whether antiepileptic drugs (AEDs) modulate the effectiveness of temozolomide radiochemotherapy in patients with newly diagnosed glioblastoma." | 9.15 | Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. ( Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Forsyth, P; Gorlia, T; Lacombe, D; Macdonald, DR; Mason, W; Mirimanoff, RO; Rossetti, AO; Stupp, R; van den Bent, MJ; Vecht, CJ; Weller, M, 2011) |
| "This open-label, single-arm, phase II study combined enzastaurin with temozolomide plus radiation therapy (RT) to treat glioblastoma multiforme (GBM) and gliosarcoma." | 9.15 | Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. ( Butowski, N; Chang, SM; Clarke, J; Costa, BM; Costello, JF; Hristova-Kazmierski, M; Hsieh, E; Lamborn, KR; Nicol, SJ; Nicole, A; Parvataneni, R; Pieper, R; Polley, MY; Prados, MD; Reis, RM; Sneed, PK; Thornton, DE; Vandenberg, S, 2011) |
| "To determine whether increased uptake on 11C-methionine-PET (MET-PET) imaging obtained before radiation therapy and temozolomide is associated with the site of subsequent failure in newly diagnosed glioblastoma multiforme (GBM)." | 9.14 | Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. ( Cao, Y; Gomez-Hassan, D; Hayman, J; Junck, L; Lawrence, TS; Lee, IH; Piert, M; Rogers, L; Ten Haken, RK; Tsien, C, 2009) |
| "This open-label, prospective, single-arm, phase II study combined erlotinib with radiation therapy (XRT) and temozolomide to treat glioblastoma multiforme (GBM) and gliosarcoma." | 9.14 | Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. ( Ayers-Ringler, J; Berger, MS; Butowski, N; Carliner, H; Chang, SM; DeBoer, R; Fedoroff, A; Haas-Kogan, DA; James, CD; Kabuubi, P; Lamborn, KR; McDermott, MW; Page, M; Parsa, AT; Parvataneni, R; Prados, MD; Rabbitt, J; Sneed, PK; Stokoe, D; Vandenberg, S, 2009) |
| "Standardized salvage treatment has not yet proved effective in glioblastoma multiforme (GBM) patients who receive prior standard radiotherapy plus concomitant and adjuvant temozolomide." | 9.14 | Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). ( Amistà, P; Bianchini, C; Blatt, V; Brandes, AA; Ermani, M; Faedi, M; Franceschi, E; Gardiman, M; Labianca, R; Reni, M; Santoro, A; Tosoni, A, 2009) |
| "In 2004, a randomised phase III trial by the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NCIC) reported improved median and 2-year survival for patients with glioblastoma treated with concomitant and adjuvant temozolomide and radiotherapy." | 9.14 | Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. ( Allgeier, A; Belanger, K; Brandes, AA; Cairncross, JG; Eisenhauer, E; Fisher, B; Gijtenbeek, J; Gorlia, T; Hau, P; Hegi, ME; Janzer, RC; Lacombe, D; Ludwin, SK; Marosi, C; Mason, WP; Mirimanoff, RO; Mokhtari, K; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Vecht, CJ; Villa, S; Weller, M; Wesseling, P, 2009) |
| "Alternative dosing schedules of temozolomide may improve survival in patients with newly diagnosed glioblastoma (GBM) by increasing the therapeutic index, overcoming common mechanisms of temozolomide resistance, or both." | 9.14 | Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. ( Abrey, LE; Clarke, JL; DeAngelis, LM; Gavrilovic, I; Hormigo, A; Iwamoto, FM; Karimi, S; Lassman, AB; Nolan, CP; Panageas, K; Sul, J, 2009) |
| "This phase II trial evaluated efficacy and safety of temozolomide (TMZ) in combination with irinotecan (CPT-11) before radiotherapy in patients with newly diagnosed glioblastoma multiforme (GBM)." | 9.14 | Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. ( Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2009) |
| "Temozolomide has been used as a standard therapy for the treatment of newly diagnosed glioblastoma multiforme since 2005." | 9.14 | Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. ( Baumert, BG; Leffers, P; Tjon-A-Fat, H; Twijnstra, A; van Genugten, JA, 2010) |
| "This trial was designed to estimate overall survival in adults with newly diagnosed glioblastoma treated with talampanel in addition to standard radiation (RT) and temozolomide (TMZ)." | 9.14 | Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. ( Batchelor, T; Chamberlain, M; Desideri, S; Fine, HA; Fisher, J; Grossman, SA; Mikkelsen, T; Piantadosi, S; Ye, X, 2009) |
| "Because of the poor outcomes for patients with recurrent glioblastoma multiforme (GBM), and some laboratory and clinical evidence of efficacy using interferon in GBM, we assessed the toxicity and efficacy of temozolomide (TMZ) combined with either short-acting (IFN) or long-acting (pegylated) interferon alpha2b (PEG) in two single-arm phase II studies, and compared the results to 6-month progression-free survival (PFS-6) data from historical controls." | 9.14 | Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. ( Alfred Yung, WK; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Hunter, K; Levin, VA; Liu, VH; Meyers, C; Puduvalli, VK, 2009) |
| "To determine the maximum tolerated dose (MTD) of fractionated intensity-modulated radiotherapy (IMRT) with temozolomide (TMZ) in patients with glioblastoma." | 9.14 | A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma. ( Balducci, M; Calista, F; Cantore, GP; Cellini, N; Cilla, S; Deodato, F; Digesù, C; Esposito, V; Ferro, M; Ianiri, M; Macchia, G; Morganti, AG; Piermattei, A; Romanelli, P; Salvati, M; Valentini, V, 2010) |
| "Although Temozolomide is effective against glioblastoma, the prognosis remains dismal and new regimens with synergistic activity are sought for." | 9.14 | RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study. ( Beier, CP; Beier, D; Bogdahn, U; Brawanski, A; Dietmaier, C; Gorlia, T; Grauer, O; Hau, P; Hegi, M; Hirschmann, B; Jauch-Worley, T; Kleinletzenberger, C; Kölbl, O; Muigg, A; Pietsch, T; Proescholdt, M; Rümmele, P; Schmid, C; Steinbrecher, A; Stockhammer, G, 2009) |
| "To evaluate the toxicity and efficacy of chemoradiotherapy with temozolomide (TMZ) administered in an intensified 1-week on/1-week off schedule plus indomethacin in patients with newly diagnosed glioblastoma." | 9.14 | Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. ( Bähr, O; Bamberg, M; Gorlia, T; Hartmann, C; Herrlinger, U; Meyermann, R; Tatagiba, M; von Deimling, A; Weiler, M; Weller, M; Wick, W; Wiewrodt, D, 2010) |
| "We conducted a phase I study to determine the safety and recommended phase II dose of enzastaurin (oral inhibitor of the protein kinase C-beta [PKCbeta] and the PI3K/AKT pathways) when given in combination with radiation therapy (RT) plus temozolomide to patients with newly diagnosed glioblastoma multiforme or gliosarcoma." | 9.14 | Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. ( Butowski, N; Chang, SM; Hristova-Kazmierski, M; Lamborn, KR; Musib, L; Nicol, SJ; Parvataneni, R; Polley, MY; Prados, MD; Thornton, DE, 2010) |
| "We assessed six-month progression-free survival (PFS) as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma multiforme (GBM) patients receiving temozolomide (TMZ)." | 9.14 | Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. ( Butowski, N; Chang, SM; Clarke, JL; Lamborn, KR; Polley, MY; Prados, M, 2010) |
| "To determine the maximum tolerated dose of ABT-510, a thrombospondin-1 mimetic drug with antiangiogenic properties, when used concurrently with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma." | 9.14 | A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. ( Fathallah-Shaykh, HM; Fiveash, JB; Gillespie, GY; Gladson, CL; Huang, Z; Johnson, MJ; Kekan, MS; Kuo, H; Markert, JM; Meleth, S; Nabors, LB, 2010) |
| "PURPOSE Concomitant temozolomide (TMZ)/radiotherapy followed by adjuvant TMZ has increased survival in patients with glioblastoma multiforme (GBM)." | 9.14 | Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. ( Bélanger, K; Easaw, J; Eisenstat, DD; Forsyth, P; Fulton, D; Kavan, P; Kirby, S; Macdonald, DR; Mason, WP; Perry, JR; Pouliot, JF; Shields, C; Thiessen, B, 2010) |
| "The aim of this clinical trial was to investigate safety and efficacy when combining cetuximab with bevacizumab and irinotecan in patients with recurrent primary glioblastoma multiforme (GBM)." | 9.14 | Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. ( Broholm, H; Hansen, S; Hasselbalch, B; Holmberg, M; Kosteljanetz, M; Lassen, U; Poulsen, HS; Stockhausen, MT; Sørensen, M, 2010) |
| "Compared with historical controls, the addition of concomitant and adjuvant cilengitide to standard chemoradiotherapy demonstrated promising activity in patients with glioblastoma with MGMT promoter methylation." | 9.14 | Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. ( Clement, PM; Dietrich, PY; Diserens, AC; Goldbrunner, R; Grabenbauer, GG; Hegi, ME; Hermisson, M; Hicking, C; Krueger, S; Neyns, B; Ochsenbein, AF; Pica, A; Picard, M; Pietsch, T; Schlegel, U; Simon, M; Stupp, R; Tonn, JC; Weller, M, 2010) |
| "The current study was conducted to evaluate the efficacy of sorafenib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, when added to standard radiotherapy and temozolomide in the first-line treatment of patients with glioblastoma multiforme." | 9.14 | Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. ( Clark, BL; Ervin, T; Friedman, E; Hainsworth, JD; Lamar, RE; Murphy, PB; Priego, V, 2010) |
| "The objectives of this study were to determine the safety and efficacy of polyinosinic-polycytidylic acid stabilized with poly-l-lysine and carboxymethylcellulose (poly-ICLC) when added to radiation and temozolomide (TMZ) in adults with newly diagnosed glioblastoma (GB)." | 9.14 | A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. ( Batchelor, TT; Chamberlain, MC; Desideri, S; Grossman, SA; Lesser, GJ; Peereboom, DM; Rosenfeld, MR; Salazar, AM; Ye, X, 2010) |
| "External beam radiation therapy (XRT) with concomitant temozolomide and 6 cycles of adjuvant temozolomide (5/28-day schedule) improves survival in patients with newly diagnosed glioblastoma compared with XRT alone." | 9.14 | A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. ( Chang, E; Colman, H; Conrad, C; de Groot, J; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, K; Hunter, K; Levin, V; Mahajan, A; Puduvalli, V; Woo, S; Yung, WK, 2010) |
| "Treatment standard for patients with primary glioblastoma (GBM) is combined radiochemotherapy with temozolomide (TMZ)." | 9.14 | Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. ( Combs, SE; Debus, J; Haberer, T; Habermehl, D; Haselmann, R; Jäkel, O; Kieser, M; Nikoghosyan, A; Rieken, S; Unterberg, A; Wick, W, 2010) |
| "To evaluate efficacy and safety of fotemustine chemotherapy in temozolomide (TMZ) pretreated adults with recurrent glioblastoma multiforme (GBM)." | 9.13 | Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. ( Ammannati, F; Biti, G; Bordi, L; Borghesi, S; Detti, B; Iannalfi, A; Leonulli, BG; Martinelli, F; Meattini, I; Sardaro, A; Scoccianti, S, 2008) |
| "This study was designed to assess the clinical outcomes of MGMT low expression glioblastomas with different p53 statuses to the treatment of temozolomide capsule chemotherapy." | 9.13 | Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results. ( Jiang, T; Li, G; Li, S; Wang, Z, 2008) |
| "To evaluate the efficacy of simultaneous postoperative temozolomide radiochemotherapy in glioblastoma patients." | 9.13 | Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. ( Becker, G; Borberg, SK; Fischedick, AR; Frommolt, P; Grauthoff, H; Herfarth, K; Kocher, M; Müller, RP; Niewald, M; Rühl, U; Staar, S; Steingräber, M; Stuschke, M, 2008) |
| "This is a phase-I study of gefitinib in combination with temozolomide in patients with gliomas." | 9.13 | Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. ( Chang, S; Cloughesy, T; Dancey, J; Fink, K; Junck, L; Kuhn, J; Prados, MD; Robins, HI; Wen, PY; Yung, WK, 2008) |
| "The study aimed to compare the cost-effectiveness of concomitant and adjuvant temozolomide (TMZ) for the treatment of newly diagnosed glioblastoma multiforme versus initial radiotherapy alone from a public health care perspective." | 9.13 | Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. ( Al, MJ; Crott, R; Gorlia, T; Jin Seung, S; Lamers, LM; Mittmann, N; Stupp, R; Uyl-de Groot, CA; van den Bent, MJ; Wasserfallen, JB, 2008) |
| "To evaluate toxicity and outcomes in patients with primary glioblastoma (GB) treated with postoperative radiochemotherapy (RCHT) with temozolomide (TMZ) comparing two dose regimens." | 9.13 | Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. ( Bischof, M; Combs, SE; Debus, J; Edler, L; Rausch, R; Schulz-Ertner, D; Wagner, F; Wagner, J; Welzel, T; Zabel-du Bois, A, 2008) |
| "To assess interim safety and tolerability of a 10-patient, Phase II pilot study using bevacizumab (BV) in combination with temozolomide (TMZ) and regional radiation therapy (RT) in the up-front treatment of patients with newly diagnosed glioblastoma." | 9.13 | Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. ( Bergsneider, M; Cloughesy, T; Filka, E; Graham, C; Lai, A; Liau, LM; McGibbon, B; Mischel, P; Nghiemphu, PL; Pope, W; Selch, M; Yong, WH, 2008) |
| "We conducted a phase II study of the combination of temozolomide and angiogenesis inhibitors for treating adult patients with newly diagnosed glioblastoma." | 9.13 | Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. ( Batchelor, TT; Black, PM; Ciampa, A; Doherty, L; Drappatz, J; Folkman, J; Gigas, DC; Henson, JW; Kesari, S; Kieran, M; Laforme, A; Ligon, KL; Longtine, JA; Muzikansky, A; Ramakrishna, N; Schiff, D; Weaver, S; Wen, PY, 2008) |
| "We performed a Cochrane Review to examine studies using different techniques to measure MGMT and predict survival in glioblastoma patients treated with temozolomide." | 9.12 | MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. ( Brandner, S; Cheng, HY; Dawson, S; Faulkner, CL; Higgins, JPT; Jefferies, S; Kelly, C; Kurian, KM; McAleenan, A; Schmidt, L; Spiga, F; Wragg, C, 2021) |
| "To determine which method for assessing MGMT methylation status best predicts overall survival in people diagnosed with glioblastoma who are treated with temozolomide." | 9.12 | Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. ( Brandner, S; Cheng, HY; Dawson, S; Faulkner, CL; Higgins, JPT; Howell, A; Jefferies, S; Kelly, C; Kernohan, A; Kurian, KM; McAleenan, A; Robinson, T; Schmidt, L; Spiga, F; Vale, L; Wragg, C, 2021) |
| "(1) Background: Studies in elderly patients over the age of 65 with glioblastoma have shown survival benefits of short-course radiation therapy with concurrent and adjuvant temozolomide, making it the standard of care adopted at Juravinski Cancer Center." | 9.12 | Outcomes in Elderly Patients with Glioblastoma Multiforme Treated with Short-Course Radiation Alone Compared to Short-Course Radiation and Concurrent and Adjuvant Temozolomide Based on Performance Status and Extent of Resection. ( Greenspoon, JN; Mir, T; Pond, G, 2021) |
| "Temozolomide (TMZ) is a first-choice alkylating agent inducted as a gold standard therapy for glioblastoma multiforme (GBM) and astrocytoma." | 9.12 | Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. ( Kumar, A; Shrivastava, A; Srivastava, C; Tomar, MS, 2021) |
| "Temozolomide (TMZ) a recent, oral, second generation alkylating agent is a chemotherapeutic with demonstrated efficacy for the treatment of high-grade gliomas." | 9.12 | Surgery, radiotherapy and temozolomide in treating high-grade gliomas. ( Barbarisi, M; Moraci, A; Moraci, M; Parlato, C, 2006) |
| "The implementation of combined radiochemotherapy (RCHT) with temozolomide (TMZ) has lead to a significant increase in overall survival times in patients with Glioblastoma multiforme (GBM), however, outcome still remains unsatisfactory." | 9.12 | Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol. ( Combs, SE; Debus, J; Edler, L; Haselmann, R; Heeger, S; Schulz-Ertner, D, 2006) |
| "The European Organisation for Research and Treatment of Cancer and National Cancer Institute of Canada trial on temozolomide (TMZ) and radiotherapy (RT) in glioblastoma (GBM) has demonstrated that the combination of TMZ and RT conferred a significant and meaningful survival advantage compared with RT alone." | 9.12 | Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. ( Allgeier, A; Brandes, AA; Cairncross, G; Curschmann, J; Fisher, B; Gorlia, T; Kortmann, RD; Lacombe, D; Mason, W; Mirimanoff, RO; Reni, M; Stupp, R; Van den Bent, MJ; Villa, S, 2006) |
| "To evaluate toxicity and efficacy of the combination of lomustine, temozolomide (TMZ) and involved-field radiotherapy in patients with newly diagnosed glioblastoma (GBM)." | 9.12 | Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. ( Bamberg, M; Blaschke, B; Herrlinger, U; Hundsberger, T; Koch, D; Kortmann, RD; Loeser, S; Meyermann, R; Reifenberger, G; Rieger, J; Sommer, C; Steinbach, JP; Tan, TC; Weller, M; Wick, W, 2006) |
| " The aim of this pilot study was to evaluate the efficacy and safety of metronomic temozolomide (TMZ) treatment in twelve consecutive patients with recurrent TMZ-refractory glioblastoma." | 9.12 | A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. ( Eoh, W; Kim, JH; Kim, ST; Kim, WS; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Park, K; Son, MJ, 2006) |
| "Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)." | 9.12 | A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. ( Abrey, LE; Chang, SM; Cloughesy, TF; Conrad, CA; DeAngelis, LM; Gilbert, MR; Greenberg, H; Groves, MD; Hess, KR; Lamborn, KR; Liu, TJ; Peterson, P; Prados, MD; Puduvalli, VK; Schiff, D; Tremont-Lukats, IW; Wen, PY; Yung, WK, 2007) |
| "To evaluate if timing of chemotherapy with Temozolomide (TMZ) was able to modify the outcome of glioblastoma (GBM), we analyzed two comparable series of supratentorial GBM patients, treated with surgery and radiotherapy, in which the administration of TMZ has been performed in the first group at first relapse and in the second group in newly diagnosed cases." | 9.12 | Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol? ( Borsa, S; Campanella, R; Caroli, M; Gaini, SM; Locatelli, M; Martinelli-Boneschi, F; Mora, A; Motta, F; Prada, F; Saladino, A, 2007) |
| "This phase II study evaluated the efficacy and safety of a 7-day on/7-day off regimen of temozolomide before radiotherapy (RT) in patients with inoperable newly diagnosed glioblastoma." | 9.12 | Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. ( Barrié, M; Braguer, D; Chinot, OL; Dufour, H; Eudes, N; Figarella-Branger, D; Fuentes, S; Lancelot, S; Martin, PM; Metellus, P; Muracciole, X; Ouafik, L, 2007) |
| "The purpose of this study was to evaluate the activity, measured in terms of progression-free survival (PFS) and response rates, of 1,3-bis(chloro-ethyl)-1-nitrosourea (BCNU) plus temozolomide in adult patients with recurrent glioblastoma multiforme." | 9.11 | Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. ( Chang, SM; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schold, SC; Yung, WK, 2004) |
| "Temozolomide has established activity in the treatment of recurrent glioblastoma multiforme (GBM)." | 9.11 | Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. ( Ashley, DM; Cher, LM; Chua, SL; Dowling, A; Rosenthal, MA; Wong, SS; Woods, AM, 2004) |
| "The primary objective of the current prospective Phase II study of cyclophosphamide (CYC) in adult patients with recurrent, temozolomide-refractory glioblastoma multiforme was to evaluate 6-month progression-free survival (PFS)." | 9.11 | Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. ( Chamberlain, MC; Tsao-Wei, DD, 2004) |
| "In the setting of a prospective clinical trial, we determined the predictive value of the methylation status of the O-6-methylguanine-DNA methyltransferase (MGMT) promoter for outcome in glioblastoma patients treated with the alkylating agent temozolomide." | 9.11 | Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. ( de Tribolet, N; Dietrich, PY; Diserens, AC; Godard, S; Hegi, ME; Ostermann, S; Otten, P; Regli, L; Stupp, R; Van Melle, G, 2004) |
| "Cisplatin and temozolomide (TMZ) are active in glioblastoma multiforme (GBM), with different profiles of toxicity." | 9.11 | First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. ( Basso, U; Brandes, AA; Cavallo, G; Ermani, M; Ferreri, AJ; Monfardini, S; Panucci, MG; Reni, M; Scopece, L; Tosoni, A; Vastola, F, 2004) |
| "Twenty-one patients with recurrent or progressive glioblastoma were enrolled in a prospective phase II trial to determine the safety and efficacy of a 1-week on/1-week off regimen of temozolomide administered at 150 mg/m2 on days 1 to 7 and days 15 to 21 of 28-day treatment cycles." | 9.11 | One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. ( Bamberg, M; Dichgans, J; Küker, WM; Steinbach, JP; Weller, M; Wick, W, 2004) |
| "An analysis of 73 patients with hystologically confirmed glioblastoma multiforme (GBM), treated with the ''3 step'' (90)Y-biotin based LR-RIT, is herein reported." | 9.11 | Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. ( Bartolomei, M; Bodei, L; Grana, C; Handkiewicz-Junak, D; Maira, G; Mazzetta, C; Paganelli, G; Rocca, P; Sturiale, C; Villa, G, 2004) |
| "Seventy-five consecutive patients with recurrent malignant astrocytomas and glioblastomas had been treated at our institute with per os temozolomide for five days every month." | 9.11 | Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas. ( Afra, D; Sipos, L; Vitanovics, D, 2004) |
| "This phase II study evaluates the activity of temozolomide and cisplatin administered before radiation therapy in newly diagnosed glioblastoma multiforme patients, in terms of response, time to progression and survival." | 9.11 | Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM). ( Balaña, C; Balart, J; Ballester, R; Benavides, M; Berrocal, A; Capellades, J; Cerdá-Nicolás, M; García, JL; Herrero, A; López-Pousa, A; Martín-Broto, J; Yaya-Tur, R, 2004) |
| "Patients with newly diagnosed, histologically confirmed glioblastoma were randomly assigned to receive radiotherapy alone (fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy) or radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle)." | 9.11 | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. ( Allgeier, A; Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Curschmann, J; Eisenhauer, E; Fisher, B; Gorlia, T; Janzer, RC; Lacombe, D; Ludwin, SK; Marosi, C; Mason, WP; Mirimanoff, RO; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Weller, M, 2005) |
| "This Phase II study was designed to determine the median survival time of adults with supratentorial glioblastoma treated with a combination of temozolomide (TMZ) and 13-cis-retinoic acid (cRA) given daily with conventional radiation therapy (XRT)." | 9.11 | A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. ( Butowski, N; Chang, SM; Lamborn, KR; Larson, DA; Malec, M; Page, M; Prados, MD; Rabbitt, J; Sneed, PK; Wara, WM, 2005) |
| " Food and Drug Administration approved temozolomide (Temodar capsules, Schering-Plough Research Institute) for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment." | 9.11 | Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. ( Cohen, MH; Johnson, JR; Pazdur, R, 2005) |
| "To investigate the efficacy of temozolomide (TMZ) in relationship to progression free survival at 6 months (PFS-6), median time to progression (TTP), response rate and toxicity, a phase II study was conducted in patients with recurrent glioblastoma multiforme (GBM) following surgery plus radiotherapy and a first-line regimen based on nitrosourea, procarbazine and vincristine." | 9.10 | Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. ( Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Iuzzolino, P; Lumachi, F; Monfardini, S; Paris, MK; Turazzi, S, 2002) |
| "Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma." | 9.10 | Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003) |
| "Temozolomide is a novel oral alkylating agent with demonstrated efficacy as second-line therapy for patients with recurrent anaplastic astrocytoma and glioblastoma multiforme (GBM)." | 9.10 | Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. ( de Tribolet, N; Dietrich, PY; Janzer, R; Leyvraz, S; Maeder, P; Maillard, I; Meuli, R; Miralbell, R; Mirimanoff, RO; Ostermann Kraljevic, S; Pica, A; Pizzolato, G; Porchet, F; Regli, L; Stupp, R, 2002) |
| "To determine whether chemotherapy with temozolomide (TMZ) versus procarbazine (PCB) for recurrent glioblastoma multiforme (GBM) was associated with improvement in health-related quality of life (HRQOL)." | 9.09 | Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. ( Brada, M; Osoba, D; Prados, M; Yung, WK, 2000) |
| "A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse." | 9.09 | A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. ( Albright, RE; Brada, M; Bruner, J; Fink, K; Fredericks, R; Friedman, H; Glantz, M; Greenberg, H; Hohl, RJ; Levin, VA; Olson, J; Osoba, D; Phillips, P; Prados, MD; Rampling, R; Selker, RG; Shapiro, W; Spence, A; Vick, NA; Yue, N; Yung, WK; Zaknoen, S, 2000) |
| "We report an open-label, uncontrolled, multicenter phase II trial of temozolomide in 138 patients (intent-to-treat [ITT] population) with glioblastoma multiforme at first relapse and a Karnofsky performance status (KPS) > or = 70." | 9.09 | Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. ( Brada, M; Bravo-Marques, JM; Bruner, J; Dietrich, PY; Dirix, LY; Dugan, M; Heimans, JJ; Henriksson, R; Hoang-Xuan, K; Macdonald, D; Rampling, R; Rao, S; Stupp, R; Yue, N; Zaknoen, S; Zonnenberg, BA, 2001) |
| "The efficacy of radiotherapy with adjuvant temozolomide for glioblastoma remains controversial." | 9.05 | The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies. ( Feng, Y; Wang, Y, 2020) |
| "Glioblastoma (GB) is one of the most common malignancies with limited standard therapies such as surgery, radiotherapy (RT) plus temozolomide (TMZ)." | 9.01 | Prognosis of patients with newly diagnosed glioblastoma treated with molecularly targeted drugs combined with radiotherapy vs temozolomide monotherapy: A meta-analysis. ( Aru, N; Ding, YM; Jin, WY; Liu, Z; Qin, HH; Shen, X; Wang, WL; Wu, SJ, 2019) |
| "Temozolomide is a first-line treatment for newly diagnosed glioblastoma." | 9.01 | Evidence-Based Practice: Temozolomide Beyond Glioblastoma. ( Chua, J; Leung, D; Nafziger, E, 2019) |
| "Here we review tumoricidal efficacy of Vitamin D analogues in glioblastoma multiforme (GBM) and potential synergisms with retinoic acid and temozolomide based on epidemiological and cellular studies." | 9.01 | From epidemiology and neurometabolism to treatment: Vitamin D in pathogenesis of glioblastoma Multiforme (GBM) and a proposal for Vitamin D + all-trans retinoic acid + Temozolomide combination in treatment of GBM. ( Altinoz, MA; Elmaci, I; Ozpinar, A; Perez, JL, 2019) |
| "Although reoperation likely confers survival benefit for glioblastoma, whether the extent of resection (EOR) of the reoperation affects survival outcome has yet to be thoroughly evaluated in the current temozolomide (TMZ) era." | 9.01 | Survival Benefit of Maximal Resection for Glioblastoma Reoperation in the Temozolomide Era: A Meta-Analysis. ( Burns, TC; Chaichana, KL; Goyal, A; Graffeo, CS; Lu, VM; Parney, IF; Perry, A; Quinones-Hinojosa, A, 2019) |
| "Temozolomide is the most widely used chemotherapy for patients with glioblastoma (GBM) despite the fact that approximately half of treated patients have temozolomide resistance and all patients eventually fail therapy." | 8.98 | Temozolomide for immunomodulation in the treatment of glioblastoma. ( Dastmalchi, F; Karachi, A; Mitchell, DA; Rahman, M, 2018) |
| "Resistance of malignant glioma, including glioblastoma (GBM), to the chemotherapeutic temozolomide (TMZ) remains a key obstacle in treatment strategies." | 8.98 | Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics. ( Ghatnekar, GG; Gourdie, RG; Grek, CL; Naus, CC; Sheng, Z; Sin, WC, 2018) |
| "The current meta-analysis evaluated the survival outcomes of newly diagnosed glioblastoma patients treated with radiotherapy (RT) alone and with RT + temozolomide (TMZ)." | 8.95 | Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis. ( Feng, E; Sui, C; Sun, G; Wang, T, 2017) |
| "Long-term temozolomide might be an optimal choice for patients with multifocal glioblastoma, especially with deep-seated structure involvement." | 8.91 | Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature review. ( Gao, Z; Hao, S; Liu, Y; Yu, L, 2015) |
| "Since virtually no trials have evaluated the effectiveness of temozolomide (TMZ) in the treatment of spinal cord (SC) glioblastoma multiforme (GBM), we conducted a systematic review to evaluate its efficacy." | 8.91 | Primary spinal cord glioblastoma multiforme treated with temozolomide. ( Bregy, A; Hanft, S; Hernández-Durán, S; Komotar, RJ; Manzano, GR; Shah, AH, 2015) |
| "Temozolomide (TMZ) alone has been proposed as a promising alternative to radiotherapy (RT) in elderly glioblastoma (GBM) patients." | 8.90 | A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. ( Cai, S; Cheng, JX; Dong, Y; Liu, BL; Yin, AA; Zhang, LH; Zhang, X, 2014) |
| "The efficacy of temozolomide (TMZ) in recurrent glioblastoma multiforme (GBM) has been evaluated by several clinical trials." | 8.89 | The efficacy of temozolomide for recurrent glioblastoma multiforme. ( Chen, C; Chen, J; Lu, Y; Wu, S; Xu, T, 2013) |
| "The landmark Stupp study demonstrated a survival advantage with concomitant and adjuvant temozolomide (TMZ) with standard radiotherapy (RT) in glioblastoma multiforme (GBM) patients but excluded those older than 70 years." | 8.88 | Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience. ( Bauman, GS; Cao, JQ; Fisher, BJ; Macdonald, DR; Megyesi, JF; Watling, CJ, 2012) |
| "This article provides historical and recent perspectives related to the use of temozolomide for the treatment of glioblastoma multiforme." | 8.88 | Temozolomide and other potential agents for the treatment of glioblastoma multiforme. ( Chow, F; Cremer, N; Kim, W; Nagasawa, DT; Yang, I; Yew, A, 2012) |
| "Temozolomide-based chemotherapy represents an incremental improvement in the treatment of patients with high-grade gliomas." | 8.86 | Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. ( Chamberlain, MC, 2010) |
| " In this paper we address different clinical outcomes measures separately and we illustrate the value of multiple outcome measures using the results of a recent clinical trial comparing temozolomide with procarbazine in the treatment of Glioblastoma Multiforme." | 8.82 | Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. ( Kiebert, G; Macdonald, DR; Olson, J; Prados, M; Yung, A, 2005) |
| "Temozolomide (TMZ) has been used as standard-of-care for glioblastoma multiforme (GBM), but the resistance to TMZ develops quickly and frequently." | 8.31 | Involvement of cell shape and lipid metabolism in glioblastoma resistance to temozolomide. ( An, YJ; Choo, M; Kim, DH; Kim, HS; Ku, JL; Lee, SK; Mai, VH; Park, CK; Park, S, 2023) |
| "The present study will investigate whether guggulsterone potentiates the anti-glioblastoma efficacy of temozolomide by down-regulating EGFR/PI3K/Akt signaling and NF-κB activation." | 8.31 | Guggulsterone from Commiphora mukul potentiates anti-glioblastoma efficacy of temozolomide in vitro and in vivo via down-regulating EGFR/PI3K/Akt signaling and NF-κB activation. ( Chen, XZ; Xu, HB; Xue, F; Yu, ZL, 2023) |
| "Temozolomide (TMZ) is the recommended drug for glioblastoma (GBM) treatment, but its clinical effect is restricted due to drug resistance." | 8.31 | Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma. ( Dong, J; Jiang, Z; Peng, Y; Wang, K; Wu, Y; Xie, Z; Zhong, M, 2023) |
| "Temozolomide (TMZ) has been determined to be the chemotherapeutic drug with efficacy for glioblastoma (GBM)." | 8.31 | Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma. ( Song, S; Tong, X; Wang, F; Wang, Y; Wen, B; Wu, H; Wu, Q; Xu, L; Yan, H; Zhou, Y, 2023) |
| "Complete resection of glioblastoma via a supraorbital transciliary approach with 5-Aminolevulinic Acid use was performed without any complications, as demonstrated on postoperative MRI." | 8.31 | Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note. ( Aboukaïs, R; Bourgeois, P; Devalckeneer, A; Lejeune, JP; Reyns, N, 2023) |
| " Even with aggressive treatment, tumor recurrence is almost universal and patient prognosis is poor because many GBM cell subpopulations, especially the mesenchymal and glioma stem cell populations, are resistant to temozolomide (TMZ), the most commonly used chemotherapeutic in GBM." | 8.31 | αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform. ( Che, J; DePalma, TJ; Mezache, LS; Sivakumar, H; Skardal, A; Swindle-Reilly, K; Tallman, MM; Veeraraghavan, R; Venere, M, 2023) |
| " In this study, we investigated the role of KDM1A/LSD1 in DNA double-strand break (DSB) repair and a combination of KDM1A inhibitor and temozolomide (TMZ) in vitro and in vivo using patient-derived glioma stem cells (GSCs)." | 8.31 | Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma. ( Alejo, S; Brenner, AJ; Chen, Y; Clarke, K; Gilbert, AR; He, Y; Jayamohan, S; Johnson, JD; Lai, Z; Li, W; Lv, Y; Palacios, BE; Pratap, UP; Sareddy, GR; Suzuki, T; Tekmal, RR; Vadlamudi, RK; Venkata, PP; Viswanadhapalli, S; Weldon, K; Ye, Z; Zhao, W; Zheng, S; Zou, Y, 2023) |
| "Although temozolomide (TMZ) provides significant clinical benefit for glioblastoma (GBM), responses are limited by the emergence of acquired resistance." | 8.31 | Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustaining ErbB downstream signaling. ( Cao, Z; Gao, G; Gu, J; Guan, Z; Guo, Q; Hao, Q; Jia, B; Li, M; Li, W; Liu, X; Wang, S; Wang, W; Zhang, K; Zhang, W; Zhang, Y, 2023) |
| "The development of resistance to temozolomide (TMZ), a standard chemotherapeutic, limits the effective treatment of glioblastoma (GBM)." | 8.31 | The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model. ( Kucheryavykh, L; Kucheryavykh, Y; Nuñez, R; Ortiz-Rivera, J, 2023) |
| "Temozolomide (TMZ) is one of the best choices for treating glioblastoma." | 8.31 | Exploring temozolomide encapsulated PEGylated liposomes and lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies. ( Laxmi Swetha, K; Narayan Saha, R; Roy, A; Singhvi, G; Waghule, T, 2023) |
| " Protein disulfide isomerase (PDI) is a molecular chaperone known to be highly expressed in glioblastomas with acquired resistance to temozolomide (TMZ)." | 8.31 | Targeting unfolded protein response using albumin-encapsulated nanoparticles attenuates temozolomide resistance in glioblastoma. ( Kiang, KM; Lam, TL; Leung, GK; Li, N; Liu, J; Shum, HC; Song, Q; Tang, W; Zhu, Z, 2023) |
| "Temozolomide is extensively applied in chemotherapy for glioblastoma with unclear exact action mechanisms." | 8.31 | Temozolomide protects against the progression of glioblastoma via SOX4 downregulation by inhibiting the LINC00470-mediated transcription factor EGR2. ( Cui, Y; He, J; Li, W; Liu, P; Ma, W; Wang, M; Zhang, M, 2023) |
| " TTFields therapy is approved for treatment of newly-diagnosed glioblastoma (GBM) concurrent with maintenance temozolomide (TMZ)." | 8.31 | Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines. ( Dor-On, E; Fishman, H; Giladi, M; Haber, A; Kinzel, A; Monin, R; Palti, Y; Weinberg, U, 2023) |
| "Glioblastoma (GBM) is a malignant brain tumor, commonly treated with temozolomide (TMZ)." | 8.31 | ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression. ( Chen, JC; Chong, ZY; Huang, C; Huang, HC; Lee, IN; Wu, YP; Yang, JT, 2023) |
| "Patients with glioblastoma (GBM) have poor prognosis and limited therapeutic options, largely because of chemoresistance to temozolomide (TMZ) treatment." | 8.31 | UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway. ( Gao, G; Wang, Y; Wei, X; Yu, J; Zhang, Y, 2023) |
| "Resistance to temozolomide (TMZ) remains an important cause of treatment failure in patients with glioblastoma multiforme (GBM)." | 8.31 | TRIM25 promotes temozolomide resistance in glioma by regulating oxidative stress and ferroptotic cell death via the ubiquitination of keap1. ( Hu, Z; Liu, X; Ma, L; Sun, T; Wan, J; Wang, L; Wei, J; Zhang, C; Zhang, Y; Zhou, L, 2023) |
| " In this study, we showed that after continuous oral consumption of high-fat (HF) diets containing M4N, the M4N concentration in most of the organs in mice reached ~1 μM (the M4N concentration in intestines and fat pads was as high as 20-40 μM) and treatment with the combination of M4N with temozolomide (TMZ) suppressed glycolysis and the tricarboxylic acid cycle in LN229 human glioblastoma implanted in xenograft mice." | 8.31 | Tetra-O-methyl-nordihydroguaiaretic acid inhibits energy metabolism and synergistically induces anticancer effects with temozolomide on LN229 glioblastoma tumors implanted in mice while preventing obesity in normal mice that consume high-fat diets. ( Chun, JH; Huang, RCC; Jackson, TLB; Kimura, K; Liang, YC; Lin, YL, 2023) |
| "Temozolomide resistance remains a major obstacle in the treatment of glioblastoma (GBM)." | 8.31 | The DRD2 Antagonist Haloperidol Mediates Autophagy-Induced Ferroptosis to Increase Temozolomide Sensitivity by Promoting Endoplasmic Reticulum Stress in Glioblastoma. ( Chen, H; Chen, K; Chen, L; Huang, A; Huang, Y; Li, C; Li, H; Lu, Y; Qi, S; Shi, L; Song, C; Wang, T; Zhong, C, 2023) |
| "Temozolomide (TMZ) treatment efficacy in glioblastoma (GBM) has been limited by resistance." | 8.31 | EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT. ( Cui, X; Fang, C; Hong, B; Kang, C; Tan, Y; Tian, S; Wang, C; Wang, Q; Xiao, M; Xin, L; Xu, C; Xu, J; Yuan, X; Zhao, J; Zhu, Y, 2023) |
| "Chemoresistance blunts the efficacy of temozolomide (TMZ) in the treatment of glioblastoma (GBM)." | 8.31 | Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation. ( Ahmad, N; Cheng, X; Deng, S; Li, H; Shu, X; Song, D; Wang, Q; Wu, M; Xu, H; Yang, X, 2023) |
| "Glioblastoma multiforme (GBM) is the deadliest glioma and its resistance to temozolomide (TMZ) remains intractable." | 8.31 | HOXD-AS2-STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma. ( Cao, YY; Chen, JX; Chen, QZ; Huang, GH; Li, Y; Liu, GL; Lv, SQ; Pei, YC; Ren, P; Wang, TT; Xiang, Y; Yang, L; Yang, W; Zhang, ZX; Zhou, S, 2023) |
| "Temozolomide (TMZ) therapy offers minimal clinical benefits in patients with glioblastoma multiforme (GBM) with high EGFR activity, underscoring the need for effective combination therapy." | 8.31 | Lysine methylation promotes NFAT5 activation and determines temozolomide efficacy in glioblastoma. ( Gao, Z; Hu, R; Li, M; Li, Y; Liu, C; Mei, M; Pang, B; Ren, Y; Wang, Y; Yang, J; Zhang, B; Zhang, X; Zhou, X, 2023) |
| " Glioblastoma is the most frequent and practically incurable neoplasm of the central nervous system; thus, new treatment modalities have been investigated to find a solution more effective than the currently applied standards based on temozolomide." | 8.31 | Autophagy Inhibition with Chloroquine Increased Pro-Apoptotic Potential of New Aziridine-Hydrazide Hydrazone Derivatives against Glioblastoma Cells. ( Głowacka, P; Jaskólski, DJ; Pieczonka, AM; Pudlarz, A; Rachwalski, M; Świderska, E; Szemraj, J; Szymańska, J; Witusik-Perkowska, M; Zakrzewska, M, 2023) |
| "To explore the role of forkhead box protein O1 (FOXO1) in the progression of glioblastoma multiforme (GBM) and related drug resistance, we deciphered the roles of FOXO1 and miR-506 in proliferation, apoptosis, migration, invasion, autophagy, and temozolomide (TMZ) sensitivity in the U251 cell line using in vitro and in vivo experiments." | 8.31 | FOXO1-miR-506 axis promotes chemosensitivity to temozolomide and suppresses invasiveness in glioblastoma through a feedback loop of FOXO1/miR-506/ETS1/FOXO1. ( Chen, C; Chen, J; Liu, Y; Shi, Y; Wang, H; Zhang, X, 2023) |
| "The cytotoxic effects of shikonin against murine glioblastoma cells, SB28 and CT-2A, were reported resistance to temozolomide, were evaluated using an allophycocyanin-conjugated annexin V and propidium iodide assay with flow cytometry." | 8.31 | Local administration of shikonin improved the overall survival in orthotopic murine glioblastoma models with temozolomide resistance. ( Maeoka, R; Matsuda, R; Morimoto, T; Nakagawa, I; Nakase, H; Nakazawa, T; Nishimura, F; Ouji, Y; Park, YS; Yamada, S; Yokoyama, S; Yoshikawa, M, 2023) |
| "Glioblastoma patients commonly develop resistance to temozolomide chemotherapy." | 8.31 | Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion. ( Bindila, L; Geiß, C; Kim, E; Lieberwirth, I; Régnier-Vigouroux, A; Sousa, N, 2023) |
| "To study the effect of cordycepin combined with temozolomide on glioblastoma, we explored the effect of the combination based on network pharmacology and biological verification." | 8.31 | Cordycepin improves sensitivity to temozolomide in glioblastoma cells by down-regulating MYC. ( Chen, J; Shi, SS; Zhang, GL; Zhang, Q; Zheng, SX; Zhuang, BB, 2023) |
| "In our previous study, we found for the first time that temozolomide (TMZ), the first-line chemotherapeutic agent for glioblastoma (GBM), can generate a large amount of reactive oxygen species (ROS) under ultrasound irradiation." | 8.31 | Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma. ( Jiao, J; Tong, X; Wen, B; Wu, Q; Xu, L; Yan, H; Yang, R; Zhou, Y, 2023) |
| "Temozolomide (TMZ) is a common alkylating chemotherapeutic agent used to treat brain tumors such as glioblastoma multiforme (GBM) and anaplastic astrocytoma." | 8.31 | LncRNA-associated competing endogenous RNA network analysis uncovered key lncRNAs involved in temozolomide resistance and tumor recurrence of glioblastoma. ( Mallick, B; Nayak, R, 2023) |
| "The purpose of this study was to explore the role of coixendide (Coix) combine with temozolomide (TMZ) in the treatment of Glioblastoma (GBM) and explore its possible mechanism." | 8.31 | Coixendide efficacy in combination with temozolomide in glioblastoma and transcriptome analysis of the mechanism. ( Ban, X; Jin, P; Li, Y; Liu, S; Yue, Y; Zhang, L; Zhang, X; Zhao, C; Zhao, Z, 2023) |
| "Temozolomide (TMZ) is a standard treatment for glioblastoma (GBM) patients." | 8.31 | Hypoxanthine phosphoribosyl transferase 1 metabolizes temozolomide to activate AMPK for driving chemoresistance of glioblastomas. ( Agnihotri, S; Cao, Y; Chen, D; Ding, F; Ge, X; Ge, Z; Huang, G; Ji, J; Lin, F; Lu, Z; Qian, X; Shi, Z; Wang, Q; Wang, X; Yin, J; You, Y; Zhang, J; Zhao, N; Zhou, Q, 2023) |
| "Altogether, our results indicate that using nanoemulsion containing temozolomide in combination with ferrocene is an effective approach to improve glioblastoma therapy outcomes." | 8.31 | Development and characterization of a temozolomide-loaded nanoemulsion and the effect of ferrocene pre and co-treatments in glioblastoma cell models. ( Bernardes Ferro, M; da Rosa, RG; da Silva, LF; de Oliveira, JVR; de Souza, BM; Henn, JG; Lopes Alves, GA; Morás, AM; Moura, DJ; Nugent, M; Pires Peña, F; Rapack Jacinto Silva, V; Silva Pinheiro, AC; Silveira Aguirre, TA; Steffens Reinhardt, L, 2023) |
| "Temozolomide (TMZ) treatment efficacy in glioblastoma (GBM) patients has been limited by resistance in the clinic." | 8.31 | Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis. ( Huang, G; Li, Z; Qi, S; Qu, S; Wang, K; Ye, R; Yi, GZ; Zhang, H; Zhang, W; Zhu, T, 2023) |
| "Chemotherapy using temozolomide is the standard treatment for patients with glioblastoma." | 8.31 | Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells. ( Arijs, I; Beerens, C; Biswas, A; Byrne, AT; Chien, MP; Connor, K; Dilcan, G; Fabro, F; Feller, KJ; Idbaih, A; Kers, TV; Kremer, A; Lambrechts, D; Lamfers, MLM; Leenstra, S; Lodi, F; Ntafoulis, I; O'Farrell, AC; Prehn, JHM; Salvucci, M; Tching Chi Yen, R; Verreault, M, 2023) |
| "The standard treatment of glioblastoma patients consists of surgery followed by normofractionated radiotherapy (NFRT) with concomitant and adjuvant temozolomide chemotherapy." | 8.12 | Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis. ( Ehret, F; Grosu, AL; Kaul, D; Klement, RJ; Lewitzki, V; Polat, B; Popp, I; Sweeney, RA, 2022) |
| "Resistance to temozolomide (TMZ) chemotherapy is the main reason for treatment failure in patients with glioblastoma (GBM)." | 8.12 | Biochanin A Sensitizes Glioblastoma to Temozolomide by Inhibiting Autophagy. ( Dong, Q; Duan, L; Li, L; Li, Q; Liu, Y; Pan, Y; Wang, D; Wang, J; Wang, X; Yin, H; Yuan, G, 2022) |
| " The current study evaluated the role and molecular mechanisms of anlotinib in glioblastoma, and the effects of anlotinib in combination with temozolomide (TMZ)." | 8.12 | Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway. ( Chen, J; Deng, C; Pan, H; Wang, H; Xu, P, 2022) |
| "Although temozolomide (TMZ) is recommended for glioblastoma (GBM) treatment, patients treated with TMZ usually develop TMZ resistance." | 8.12 | Oncogenic Forkhead box D3 antisense RNA 1 promotes cell survival and confers temozolomide resistance in glioblastoma cells through the miR-128-3p/WEE1 G2 checkpoint kinase axis. ( Ling, Z; Liu, Q; Zhang, J, 2022) |
| "It is necessary to elucidate the individual effects of temozolomide (TMZ) on carcinogenesis and tumor resistance to chemotherapy mechanisms." | 8.12 | The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro. ( Alonso, MM; Balnytė, I; Damanskienė, E; Preikšaitis, A; Stakišaitis, D; Valančiūtė, A, 2022) |
| "Temozolomide (TMZ) is a standard-of-care chemotherapeutic drug for the treatment of glioblastoma (GBM), but TMZ-acquired resistance limits its therapeutic effect." | 8.12 | Efficacy of Temozolomide-Conjugated Gold Nanoparticle Photothermal Therapy of Drug-Resistant Glioblastoma and Its Mechanism Study. ( Chu, L; Liu, X; Sha, C; Sun, K; Sun, Y; Wang, A; Wang, S; Xu, L; Yang, X; Yu, Y; Zhou, L, 2022) |
| "Temozolomide (TMZ) monotherapy is known to be insufficient for resistant/relapsed glioblastoma (GBM), thus seeking a sensitization agent for TMZ is necessary." | 8.12 | Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma. ( Ali, AAA; Chiang, IT; Chou, SY; Hsu, FT; Hsu, TI; Liu, HS; Liu, YC, 2022) |
| "This retrospective study enrolled 65 patients with IDH wild-type recurrent glioblastoma who received standard therapy and then received either bevacizumab (46 patients) or temozolomide (19 patients) as a secondary treatment." | 8.12 | Contrast enhancing pattern on pre-treatment MRI predicts response to anti-angiogenic treatment in recurrent glioblastoma: comparison of bevacizumab and temozolomide treatment. ( Kim, HS; Kim, JH; Kim, YH; Moon, HH; Park, JE, 2022) |
| "Sp1 is involved in the recurrence of glioblastoma (GBM) due to the acquirement of resistance to temozolomide (TMZ)." | 8.12 | Reprogramming of arachidonate metabolism confers temozolomide resistance to glioblastoma through enhancing mitochondrial activity in fatty acid oxidation. ( Chang, KY; Chang, WC; Chen, PY; Chuang, JY; Hsu, TI; Hung, CY; Kao, TJ; Kikkawa, U; Ko, CY; Lo, WL; Tsai, YT; Yang, WB, 2022) |
| " Temozolomide is widely used first-line chemotherapy drug to treat glioma patients, but development of temozolomide resistance is almost inevitable." | 8.12 | Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain. ( Bian, XW; Cai, XW; Cao, MF; Gai, QJ; He, J; He, MM; Leng, P; Lu, HM; Mao, M; Qin, Y; Wang, C; Wang, Y; Wang, YX; Wen, XM; Yang, FC; Yao, XH; Yao, XX; Zhu, J, 2022) |
| " We herein investigate the therapeutic potential of bioinformatically identified HOTAIR transferred by serum-derived EVs (serum-EVs) in temozolomide (TMZ) resistance of glioblastoma (GBM) and the downstream mechanisms." | 8.12 | Serum-derived extracellular vesicles facilitate temozolomide resistance in glioblastoma through a HOTAIR-dependent mechanism. ( Han, J; Wang, S; Wang, X; Wang, Y; Wei, K; Xu, H; Yu, X, 2022) |
| "Gliosarcoma is an uncommon glioblastoma subtype, for which MGMT promoter methylation's relationship with response to temozolomide chemotherapy is unclear." | 8.12 | Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients. ( Iorgulescu, JB; Kavouridis, VK; Ligon, KL; Wen, PY, 2022) |
| "To investigate the function of primary cilia in regulating the cellular response to temozolomide (TMZ) and ionizing radiation (IR) in glioblastoma (GBM)." | 8.12 | Inhibition of Ciliogenesis Enhances the Cellular Sensitivity to Temozolomide and Ionizing Radiation in Human Glioblastoma Cells. ( Cai, H; Gao, L; He, JP; Ma, W; Peng, SP; Tian, HB; Wang, JF; Wei, L, 2022) |
| "Glioblastoma multiforme (GBM) is an aggressive brain tumor, often occurring with seizures managed with antiepileptic drugs, such as levetiracetam (LEV)." | 8.12 | Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients. ( Banchi, M; Bocci, G; Cucchiara, F; Danesi, R; Di Paolo, A; Giannini, N; Giorgi, FS; Luci, G; Orlandi, P; Pasqualetti, F, 2022) |
| "Temozolomide (TMZ) is the primary chemotherapeutic drug for treating glioblastoma (GBM); however, the final clinical outcome is considerably limited by the poor response and resistance to TMZ." | 8.12 | SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy. ( Han, L; Hu, L; Yang, F; Yu, J; Zhao, M; Zhou, H, 2022) |
| "Glioblastoma patients have a poor prognosis mainly due to temozolomide (TMZ) resistance." | 8.12 | High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1/MRP1 upregulation. ( Andrade-Tomaz, M; Contieri, B; de Souza, I; Gomes, LR; Guedes, CB; Latancia, MT; Lazarini, M; Mendes, D; Monteiro, LKS; Porchia, BFMM; Rocha, CRR; Silva, MM, 2022) |
| "Temozolomide (TMZ) is the first-line drug for the clinical treatment of glioblastoma (GBM), but drug resistance limits its treatment benefits." | 8.12 | Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression. ( Yun, K; Zhao, W, 2022) |
| "The mechanism by which glioblastoma evades temozolomide (TMZ)-induced cytotoxicity is largely unknown." | 8.12 | SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against temozolomide in glioblastoma. ( Chang, KY; Chen, PY; Chen, SH; Cheng, SM; Chi, PI; Chien, CH; Chu, JM; Chuang, JY; Huang, CY; Hwang, DY; Lai, CC; Lee, JS; Liao, WA; Liu, CC; Wu, AC; Yang, ST; Yang, WB, 2022) |
| "Resistance to temozolomide (TMZ) is a major obstacle to preventing glioblastoma (GBM) recurrence after surgery." | 8.12 | PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition. ( Deng, L; Fan, Y; Gao, Z; Guo, X; Li, G; Qi, Y; Sun, C; Wang, S; Xu, J; Xue, H; Zhang, P; Zhao, R; Zhao, S, 2022) |
| "Temozolomide (TMZ) resistance remains the main therapy challenge in patients with glioblastoma multiforme (GBM)." | 8.12 | TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma. ( Gao, G; Wang, Y; Wei, X; Yu, J, 2022) |
| "We included 41 patients with isocitrate dehydrogenase 1/2-wildtype glioblastoma, who received 12 or more cycles of temozolomide therapy between June 2006 and December 2019." | 8.12 | Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma. ( Miyakita, Y; Narita, Y; Ohno, M; Takahashi, M; Tamura, Y; Yanagisawa, S, 2022) |
| " Optical microscopy and flow cytometry were employed to assess the differences in glioblastoma cells morphology, proliferation, and cytotoxicity of anticancer drug temozolomide (TMZ) due to increased substrate viscosity." | 8.12 | Substrate viscosity impairs temozolomide-mediated inhibition of glioblastoma cells' growth. ( Bucki, R; Cieśluk, M; Kochanowicz, J; Kułakowska, A; Piktel, E; Pogoda, K; Skłodowski, K; Wnorowska, U, 2022) |
| "A first-line therapeutic for high-grade glioma, notably glioblastoma (GBM), is the DNA methylating drug temozolomide (TMZ)." | 8.12 | Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics. ( Beltzig, L; Christmann, M; Kaina, B, 2022) |
| "The DNA alkylating agent temozolomide (TMZ), is the first-line therapeutic for the treatment of glioblastoma (GBM)." | 8.12 | Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole. ( DasGupta, B; Dave, N; Desai, JM; Desai, PB; Gudelsky, GA; Karve, AS; Phoenix, TN; Plas, DR; Sengupta, S; Wise-Draper, TM, 2022) |
| "A MEX3A/CCR4-NOT/MSH2 axis plays a crucial role in promoting temozolomide resistance, providing new insights into the function of MEX3A and suggesting MEX3A as a potential therapeutic target in therapy-resistant glioblastoma." | 8.12 | MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma. ( Gan, T; Miao, F; Nie, E; Qian, X; Shen, Z; Shi, Q; Wang, P; Wang, Q; Wang, Y; Xie, M; Zhao, S, 2022) |
| "Systemic chemotherapy including monotherapy with temozolomide (TMZ) or bevacizumab (BEV); two-drug combinations, such as irinotecan (IRI) and BEV, TMZ and BEV and a three-drug combination with TMZ, IRI and BEV (TIB) have been used in treating patients with progressive high-grade gliomas including glioblastoma (GBM)." | 8.12 | Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab. ( Ballester, LY; Bhattacharjee, MB; Brown, RE; Buja, LM; Chen, L; Glass, WF; Hergenroeder, GW; Hunter, RL; Linendoll, N; Lu, G; Pilichowska, M; Pillai, AK; Rao, M; Tian, X; Wu, JK; Zhang, R; Zhu, JJ; Zhu, P, 2022) |
| " The status of PTEN remains therapeutic effectiveness for chemoresistance of the DNA alkylating agent temozolomide (TMZ) in glioblastoma (GB)." | 8.12 | Smurf1 Suppression Enhances Temozolomide Chemosensitivity in Glioblastoma by Facilitating PTEN Nuclear Translocation. ( Dong, L; Han, D; Li, S; Li, Y; Liu, L; Meng, X; Xia, Q; Xiao, Z, 2022) |
| "Temozolomide (TMZ) resistance limits its use in glioblastoma (GBM)." | 8.12 | Hsa_circ_0043949 reinforces temozolomide resistance via upregulating oncogene ITGA1 axis in glioblastoma. ( Leng, H; Li, X; Wang, N; Xu, L; Yuan, H, 2022) |
| "The alkylating agent temozolomide (TMZ) has a significant impact on the prognosis of glioblastoma (GBM) patients." | 8.12 | NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells. ( Hara, H; Iwama, T; Nakamura, S; Nakayama, N; Shimazawa, M; Shoda, K; Tsuji, S; Yamada, T, 2022) |
| "Brain radiotherapy combined with concomitant and six cycles of adjuvant temozolomide (TMZ) is the standard treatment for newly diagnosed high-grade gliomas (HGGs)." | 8.12 | Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis. ( Ai, P; Chen, J; He, L; Huang, Y; Li, R; Liu, Z; Pei, Y; Peng, X; Wang, J; Wei, Z; Zhao, F, 2022) |
| "Although temozolomide is the primary chemotherapeutic agent in glioblastoma, current studies have focused on its combinational applications to overcome resistance by targeting multiple pathways." | 8.12 | Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes. ( Biray Avci, C; Goker Bagca, B; Ozates, NP, 2022) |
| "Radiotherapy combined with temozolomide chemotherapy (STUPP regimen) is the standard treatment regimen for newly diagnosed glioblastoma (GBM)." | 8.12 | The efficacy and safety of low-dose temozolomide maintenance therapy in elderly patients with glioblastoma: a retrospective cohort study. ( Ge, X; Gong, S; Guo, J; Tao, Q; Zhu, T, 2022) |
| "The purpose of this study was to determine the predictive significance of pretreatment pan-immune-inflammation value (PIV) in patients with newly diagnosed glioblastoma multiforme (GBM) who received postsurgical radiation (RT) and concurrent plus adjuvant temozolomide (TMZ)." | 8.12 | Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide. ( Kucuk, A; Selek, U; Topkan, E, 2022) |
| " The main cause is the presence of glioma stem cells (GSCs), exceptionally resistant to temozolomide (TMZ) treatment." | 8.12 | TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients. ( Amantini, C; Maggi, F; Morelli, MB; Nabissi, M; Pallini, R; Ricci-Vitiani, L; Santoni, G, 2022) |
| "It was found that radiotherapy combined with temozolomide administration often increased the size of the original lesion or produced a new glioblastoma lesion." | 8.12 | Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report. ( Cheng, P; Han, Q; Ma, H; Yang, H; Zhao, M; Zhao, Y, 2022) |
| " Therefore, we aimed to examine the Synergistic effects of Gefitinib (GFI) in combination with Temozolomide on VEGF and MMPs in glioma cell line (U87MG)." | 8.12 | Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis. ( Hossienpour, M; Karami, A; Kiani, A; Mohammadi Noori, E; Najafi, K; Rahpyma, M, 2022) |
| "Glioblastomas (GBM) often acquire resistance against temozolomide (TMZ) after continuous treatment and recur as TMZ-resistant GBM (TMZ-R-GBM)." | 8.02 | Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. ( Fujii, T; Ichimura, K; Kawauchi, D; Kobayashi, T; Kondo, A; Nakano, T; Narita, Y; Sasaki, N; Satomi, K; Takahashi, M; Tomiyama, A; Uchida, E; Wada, K; Yamamuro, S; Yoshino, A, 2021) |
| "Bortezomib and temozolomide effectively destroy cells of a radioresistant recurrent human glioblastoma; proteome mapping of the recurrent GBM cancer cells allows to identify new targets for therapy to improve the treatment results." | 8.02 | Effectiveness of bortezomib and temozolomide for eradication of recurrent human glioblastoma cells, resistant to radiation. ( Bryukhovetskiy, I; Pak, O; Sharma, A; Sharma, HS; Shevchenko, V; Zaitsev, S, 2021) |
| " Here, we show that NSUN6 methylates both large and small RNA in glioblastoma and controls glioblastoma response to temozolomide with or without influence of the MGMT promoter status, with high NSUN6 expression conferring survival benefit to glioblastoma patients and in other cancers." | 8.02 | NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to temozolomide (TMZ) via NELFB and RPS6KB2 interaction. ( Awah, CU; Mazdoom, CM; Ogunwobi, OO; Winter, J, 2021) |
| " CDC20 expression is increased in a variety of tumors and associated with temozolomide (TMZ) resistance in glioma cells." | 8.02 | Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. ( Ding, Y; He, L; Pan, Y; Song, X; Yu, S; Zhang, C; Zheng, C, 2021) |
| "Temozolomide (TMZ) is a prodrug of 5-(3-methyltriazene-1-yl)imidazole-4-carboxamide (MTIC, short-lived) and used as a first-line therapy drug for glioblastoma multiforme (GBM)." | 8.02 | Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy. ( Du, K; Feng, F; Sun, J; Xia, Q, 2021) |
| "Mesenchymal glioblastoma stem cells (GSCs), a subpopulation in glioblastoma that are responsible for therapy resistance and tumor spreading in the brain, reportedly upregulate aldehyde dehydrogenase isoform-1A3 (ALDH1A3) which can be inhibited by disulfiram (DSF), an FDA-approved drug formerly prescribed in alcohol use disorder." | 8.02 | Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study. ( Eckert, F; Ganser, K; Handgretinger, R; Huber, SM; Klumpp, L; Prause, L; Schleicher, S; Stransky, N; Zips, D; Zirjacks, L, 2021) |
| "We describe a pharmacological strategy for selectively targeting glioblastoma using a redox-active combination drug menadione/ascorbate (M/A), compared to the chemotherapeutic standard-of-care temozolomide (TMZ)." | 8.02 | Pharmacological Strategy for Selective Targeting of Glioblastoma by Redox-active Combination Drug - Comparison With the Chemotherapeutic Standard-of-care Temozolomide. ( Aoki, I; Bakalova, R; Lazarova, D; Miller, T; Shibata, S; Sumiyoshi, A; Zhelev, Z; Zlateva, G, 2021) |
| "The combination treatment is a way to improve the therapeutic strategy of temozolomide (TMZ) -resistant glioblastoma (GBM)." | 8.02 | Synergistic Effects of Taurine and Temozolomide Via Cell Proliferation Inhibition and Apoptotic Induction on U-251 MG Human Glioblastoma Cells. ( Chantree, P; Sangpairoj, K; Surarak, T, 2021) |
| "The short half-life of temozolomide (TMZ) limits its therapeutic effect on highly aggressive glioblastoma (GBM)." | 8.02 | Biomimetic Polymer-Templated Copper Nanoparticles Stabilize a Temozolomide Intermediate for Chemotherapy against Glioblastoma Multiforme. ( Du, K; Feng, F; Hu, A; Wang, X, 2021) |
| "About 95% of Glioblastoma (GBM) patients experience tumor relapse as a consequence of resistance to the first-line standard chemotherapy using temozolomide (TMZ)." | 8.02 | Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells. ( Bartsch, JW; Culmsee, C; Elsässer, K; Nimsky, C; Pagenstecher, A; Schäfer, A; Zhang, Z; Zhao, K; Zhong, L, 2021) |
| "To explore whether or not aberrant expression of miR-29b in glioblastoma multiforme (GBM) cells was associated with temozolomide (TMZ) resistance and to elucidate potential underlying mechanisms." | 8.02 | Micro-RNA29b enhances the sensitivity of glioblastoma multiforme cells to temozolomide by promoting autophagy. ( Luan, XP; Xu, JX; Yang, Y; Zhang, X, 2021) |
| "The study includes 132 IDH-wildtype glioblastoma patients treated between 2013 and 2017 with open resection followed by radiotherapy with concomitant and maintenance temozolomide." | 8.02 | Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide. ( Berger, K; Budach, W; Felsberg, J; Hänggi, D; Haussmann, J; Kamp, MA; Knipps, J; Malzkorn, B; Mijderwijk, HJ; Rapp, M; Reifenberger, G; Sabel, M; Steiger, HJ; Turowski, B, 2021) |
| "Overexpression of TGF-β1 contributed to temozolomide resistance in MGMT promoter hypomethylated glioblastoma cells in vitro and in vivo." | 8.02 | TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT. ( Jin, X; Miao, F; Nie, E; Shi, Z; Wang, Y; Xie, M; You, Y; Yu, T; Zhang, J; Zhi, T, 2021) |
| "We report a case of acute interstitial nephritis with associated nephrogenic diabetes insipidus in a patient treated with temozolomide and sulfamethoxazole-trimethoprim for glioblastoma multiforme." | 8.02 | Acute interstitial nephritis and nephrogenic diabetes insipidus following treatment with sulfamethoxazole-trimethoprim and temozolomide. ( Athavale, A; Gallagher, M; Jardine, M; Morris, J; Ritchie, A; Sen, S; Wang, AY, 2021) |
| " Temozolomide is an oral DNA-alkylating agent capable of crossing the blood-brain barrier and used as chemotherapy primarily to treat glioblastoma and other brain cancers." | 8.02 | Central diabetes insipidus induced by temozolomide: A report of two cases. ( Capes, A; Duck, L; Duprez, T; Labriola, L; Mahiat, C; Whenham, N, 2021) |
| "8% of actual body weight calculated body surface area dosing was determined for concurrent phase temozolomide." | 8.02 | Actual body weight dosing of temozolomide and overall survival in patients with glioblastoma. ( Chambers, C; Coppens, R; de Robles, P; Dersch-Mills, D; Folkman, F; Ghosh, S; Hsu, PYH; Leckie, C, 2021) |
| "Limited therapeutic efficacy of temozolomide (TMZ) against glioblastomas highlights the importance of exploring new drugs for clinical therapy." | 8.02 | Guanabenz Sensitizes Glioblastoma Cells to Sunitinib by Inhibiting GADD34-Mediated Autophagic Signaling. ( Chen, KC; Chen, PH; Cheng, CH; Ho, KH; Lee, YT; Shih, CM, 2021) |
| "Temozolomide (TMZ) resistance in glioblastoma multiforme (GBM) is mediated by the DNA repair protein O6-methylguanine DNA methyltransferase (MGMT)." | 8.02 | PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. ( de Groot, JF; Gao, F; Koul, D; Li, X; Wu, S; Yung, WKA, 2021) |
| " Temozolomide (TMZ) is widely used in the treatment of glioblastoma and is considered as the primary treatment modality." | 8.02 | Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line. ( Abbaszade, Z; Avci, CB; Bagca, BG, 2021) |
| " Treatment of patients suffering from relapsed/refractory glioblastoma (GBM) with a combination of depatux-m and temozolomide (TMZ) tended to increase overall survival." | 8.02 | Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR. ( Alvey, C; Anderson, M; Ansell, P; Boghaert, ER; Falls, HD; Mishra, S; Mitten, MJ; Oleksijew, A; Palma, J; Phillips, AC; Reilly, EB; Vaidya, KS; Zelaya-Lazo, AL, 2021) |
| "Temozolomide (TMZ), an alkylating agent with a broad-spectrum antitumor activity, ability to cross blood-brain barrier (BBB), shown to be effective against malignant glioma." | 8.02 | Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population. ( Baburaj, G; Jose, A; Kumar, JP; Munisamy, M; Munisamy, S; Subbiah, V; Thomas, L, 2021) |
| "To assess the recurrence interval and predictive significance of TP53 expression and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastomas treated with radiotherapy and combined chemotherapies, including temozolomide, lomustine, procarbazine and bevacizumab." | 8.02 | Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies. ( Alghamdi, B; Alkhayyat, S; Baeesa, S; Bardeesi, A; Bari, MO; Butt, NS; Dallol, A; Kurdi, M; Lary, AI; Maghrabi, Y; Mohamed, F; Saeedi, R; Samkari, A, 2021) |
| "The alkylating agent, temozolomide (TMZ), is the most commonly used chemotherapeutic for the treatment of glioblastoma (GBM)." | 8.02 | CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma. ( Arina, A; Bernal, GM; Cahill, KE; Campbell, PS; Crawley, CD; Mansour, N; Voce, DJ; Weichselbaum, RR; Wu, L; Yamini, B, 2021) |
| "Treatment for the lethal primary adult brain tumor glioblastoma (GBM) includes the chemotherapy temozolomide (TMZ), but TMZ resistance is common and correlates with promoter methylation of the DNA repair enzyme O-6-methylguanine-DNA methyltransferase (MGMT)." | 8.02 | Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells. ( Ananthan, S; Ayokanmbi, A; Cooper, SJ; Gordillo, JJ; Gordon, ER; Griguer, C; Hjelmeland, AB; Li, Y; Libby, CJ; Napierala, M; Otamias, A; Redmann, M; Williford, SE; Zhang, J, 2021) |
| "Glioblastoma multiforme (GBM) is a lethal disease with a high rate of chemoresistance to temozolomide (TMZ)." | 8.02 | Establishment of a Novel Temozolomide Resistant Subline of Glioblastoma Multiforme Cells and Comparative Transcriptome Analysis With Parental Cells. ( Cheng, YD; Chiu, YJ; Ha, HA; Hour, MJ; Li, CW; Li, J; Tsai, FJ; Yang, JS, 2021) |
| "Although histone deacetylase 8 (HDAC8) plays a role in glioblastoma multiforme (GBM), whether its inhibition facilitates the treatment of temozolomide (TMZ)-resistant GBM (GBM-R) remains unclear." | 8.02 | NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition. ( Cheng, TS; Chiou, SJ; Chuang, JY; Chuang, TH; Hong, YR; Hou, CC; Hsu, TI; Huang, CF; Huang, ZY; Javaria, T; Ko, HJ; Kwan, AL; Lai, YL; Loh, JK; Tsai, CY, 2021) |
| "To clarify whether differential compartmentalization of Survivin impacts temozolomide (TMZ)-triggered end points, we established a well-defined glioblastoma cell model in vitro (LN229 and A172) and in vivo, distinguishing between its nuclear and cytoplasmic localization." | 8.02 | Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination. ( Baymaz, HI; Beli, P; Christmann, M; Mühlhäusler, F; Nikolova, T; Poplawski, A; Reich, TR; Schwarzenbach, C; Tomicic, MT; Unger, S; Vilar, JB, 2021) |
| "Glioblastoma multiforme (GBM) is the most fatal cancer among brain tumors, and the standard treatment of GBM patients is surgical tumor resection followed by radiotherapy and temozolomide (TMZ) chemotherapy." | 8.02 | 17β-estradiol induces temozolomide resistance through NRF2-mediated redox homeostasis in glioblastoma. ( Chen, GY; Hsu, SP; Hsu, TI; Hung, CY; Ko, CY; Liao, KH; Lin, HY, 2021) |
| "Intrinsic or acquired resistance to temozolomide (TMZ) is a frequent occurrence in patients with glioblastoma (GBM)." | 8.02 | Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7. ( Li, T; Wang, B; Wang, J, 2021) |
| "To evaluate the predictive significance of the duration of temozolomide (TMZ) in patients with glioblastoma multiforme (GBM) who were treated with bevacizumab (Beva) as second-line setting." | 8.02 | Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting? ( Besiroglu, M; Demir, T; Shbair, ATM; Topcu, A; Turk, HM; Yasin, AI, 2021) |
| "Temozolomide (TMZ) is the first-line chemotherapy drug for glioblastoma (GBM) but acquired TMZ resistance is frequently observed." | 8.02 | LINC00511 facilitates Temozolomide resistance of glioblastoma cells via sponging miR-126-5p and activating Wnt/β-catenin signaling. ( Liu, J; Lu, Y; Tian, M; Wang, K, 2021) |
| "This is the first study to demonstrate that PDL1-SPIO can specifically target temozolomide-resistant glioblastoma with PD-L1 expression in the brain and can be quantified through MRI analysis, thus making it suitable for the diagnosis of PD-L1 expression in temozolomide-resistant glioblastoma in vivo." | 8.02 | Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid‑Coated Superparamagnetic Iron Oxide. ( Chang, YW; Chen, CY; Chen, YC; Hsu, JB; Huang, SW; Kuo, DP; Lee, GA; Li, YT; Lin, WL, 2021) |
| " We investigated the effects of dopamine in combination with platinum on human glioblastoma U-251MG cells upon X-ray irradiation, comparing with L-DOPA, 2-phenylethylamine and temozolomide." | 8.02 | Effects of platinum-coexisting dopamine with X-ray irradiation upon human glioblastoma cell proliferation. ( Kato, S, 2021) |
| "Improving the chemotherapy resistance of temozolomide (TMZ) is of great significance in the treatment of glioblastoma multiforme (GBM)." | 8.02 | Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic glycolysis and temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multiforme cells. ( Jiang, XB; Li, XD; Wang, MJ; Wang, X; Wu, YH; Zheng, JL, 2021) |
| "Temozolomide is used in first-line treatment for glioblastoma." | 8.02 | Temozolomide Drives Ferroptosis via a DMT1-Dependent Pathway in Glioblastoma Cells. ( Heng, X; Peng, S; Song, Q; Sun, Z; Zhu, X, 2021) |
| "Standard treatment for glioblastoma (GBM) patients is surgery and radiochemotherapy (RCT) with temozolomide (TMZ)." | 7.96 | ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide. ( Åkesson, L; Bratthäll, C; Broholm, H; Fomichov, V; Green, H; Grunnet, K; Hallbeck, M; Jakobsen, I; Malmström, A; Milos, P; Mudaisi, M; Papagiannopoulou, A; Poulsen, HS; Söderkvist, P; Stenmark-Askmalm, M; Strandeus, M; Łysiak, M, 2020) |
| "Temozolomide (TMZ) is one of the most commonly used clinical drugs for glioblastoma (GBM) treatment, but its drug sensitivity needs to be improved." | 7.96 | Gamabufotalin induces a negative feedback loop connecting ATP1A3 expression and the AQP4 pathway to promote temozolomide sensitivity in glioblastoma cells by targeting the amino acid Thr794. ( Chen, C; Hu, JL; Lan, YL; Lou, JC; Lyu, W; Wang, X; Xing, JS; Zhang, B; Zou, S, 2020) |
| "Current treatment against glioblastoma consists of surgical resection followed by temozolomide, with or without combined radiotherapy." | 7.96 | The synergistic effect of DZ‑NEP, panobinostat and temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells. ( Castresana, JS; De La Rosa, J; Idoate, MA; Meléndez, B; Rey, JA; Urdiciain, A; Zazpe, I; Zelaya, MV, 2020) |
| "Temozolomide is a first line anti-tumor drug used for the treatment of patients with Glioblastoma multiforme (GBM)." | 7.96 | Microarray expression profiles and bioinformatics analysis of mRNAs, lncRNAs, and circRNAs in the secondary temozolomide-resistant glioblastoma. ( Gao, Y; Guo, R; Li, H; Yang, B; Zhao, C, 2020) |
| "In the EF-14 trial for newly diagnosed glioblastoma (ndGBM) patients addition of Tumour Treating Fields (TTFields) to temozolomide treatment resulted in a significantly improved overall survival (OS)." | 7.96 | Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. ( Blau, T; Deuschl, C; Glas, M; Herrlinger, U; Kebir, S; Keyvani, K; Kleinschnitz, C; Lazaridis, L; Oster, C; Pierscianek, D; Schäfer, N; Scheffler, B; Schmidt, T; Stuschke, M; Sure, U; Teuber-Hanselmann, S; Tzaridis, T; Weller, J, 2020) |
| "Temozolomide is an alkylating agent which is used in glioblastoma treatment." | 7.96 | Effects of temozolomide on U87MG glioblastoma cell expression of CXCR4, MMP2, MMP9, VEGF, anti-proliferatory cytotoxic and apoptotic properties. ( Elieh Ali Komi, D; Kiani, A; Mirabdaly, S; Moini, A; Shakiba, Y, 2020) |
| "This analysis aimed to investigate whether the long-term administration of temozolomide (TMZ) claimed a survival advantage for patients with glioblastoma in China." | 7.96 | Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide. ( Li, X; Li, Z; Quan, R; Zhang, H, 2020) |
| "Chemo-induced thrombocytopenia is a limiting toxicity among patients receiving temozolomide (TMZ) as first-line treatment for glioblastoma." | 7.96 | Deleterious impact of a generic temozolomide formulation compared with brand-name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma. ( Alexandru, C; Basuyau, F; Clatot, F; Di Fiore, F; Fontanilles, A; Fontanilles, M; Hanzen, C; Joannidès, R; Lamoureux, F; Langlois, O; Massy, N; Pereira, T; Rouvet, J; Tennevet, I, 2020) |
| "The isocitrate dehydrogenase (IDH) 1 wild-type glioblastoma (GBM) is a major population of GBM that should be of concern in terms of the efficacy of using Temozolomide (TMZ) in adjuvant treatment." | 7.96 | Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching. ( Sangkhathat, S; Tunthanathip, T, 2020) |
| " In this report, we present the case of a 3-year-old girl with glioblastoma who continues to experience an exceptional and durable response (>2 years) to the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib." | 7.96 | Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. ( Britt, N; Chudnovsky, Y; Duncan, D; Edgerly, C; Elvin, J; Erlich, RL; Gay, L; Gorelyshev, S; Hemmerich, A; Huang, RSP; Konovalov, A; Kram, DE; McCorkle, J; Miller, V; Ramkissoon, SH; Rankin, A; Ross, JS; Savateev, A; Severson, E; Trunin, Y; Valiakhmetova, A, 2020) |
| "This is the long-term update of NOA-08 (NCT01502241), which compared efficacy and safety of radiotherapy (RT, n = 176) and temozolomide (TMZ, n = 193) at 7/14 days in patients >65 years old with anaplastic astrocytoma or glioblastoma." | 7.96 | Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. ( Bamberg, M; Bölting, H; Debus, J; Felsberg, J; Herrlinger, U; Hertler, C; Kessler, T; Ketter, R; Mayer-Steinacker, R; Meisner, C; Meixensberger, J; Papsdorf, K; Platten, M; Reifenberger, G; Reuss, D; Sabel, M; Sahm, F; Steinbach, JP; Vesper, J; von Deimling, A; Weisang, S; Weller, M; Weyerbrock, A; Wick, A; Wick, W, 2020) |
| "Temozolomide (TMZ) is a drug of choice in glioblastoma treatment." | 7.96 | Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions. ( Barciszewska, AM; Barciszewski, J; Belter, A, 2020) |
| "Temozolomide (TMZ)-induced chemoresistance to human glioblastomas is a critical challenge now." | 7.96 | Major Contribution of Caspase-9 to Honokiol-Induced Apoptotic Insults to Human Drug-Resistant Glioblastoma Cells. ( Chen, RM; Wu, GJ; Yang, ST, 2020) |
| "Glioblastoma multiforme (GBM) is the most frequent primary brain tumor in adults and Temozolomide (TMZ) is an effective chemotherapeutic agent for its treatment." | 7.96 | Reinforcement learning for optimal scheduling of Glioblastoma treatment with Temozolomide. ( Ebrahimi Zade, A; Shahabi Haghighi, S; Soltani, M, 2020) |
| "Temozolomide (TMZ) resistance is a major cause of recurrence and poor prognosis in glioblastoma (GBM)." | 7.96 | LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma. ( Chi, Y; Fu, Z; Guo, H; Huang, Q; Lian, C; Liao, C; Liu, B; Wang, C; Wei, Q; Xu, N; Yang, Z; Zeng, H; Zhou, J, 2020) |
| "Temozolomide (TMZ) chemotherapy is a current standard of care for glioblastoma (GBM), however it has only extended overall survival by a few months." | 7.96 | Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma. ( Martuza, RL; Rabkin, SD; Saha, D, 2020) |
| "Temozolomide is a first line anti-tumor drug used for the treatment of patients with Glioblastoma multiforme (GBM)." | 7.96 | MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT. ( Guan, F; Guo, R; Li, H; Li, M; Liu, X; Ma, S; Wu, J; Yang, B; Zhao, C, 2020) |
| "Temozolomide (TMZ) is a DNA-alkylating agent used for chemo-radiotherapy of glioblastoma, which is also a target cancer for boron neutron capture therapy (BNCT)." | 7.96 | The combined effect of neutron irradiation and temozolomide on glioblastoma cell lines with different MGMT and P53 status. ( Ikawa, T; Kinashi, Y; Takahashi, S, 2020) |
| "To evaluate the potential prognostic utility of pretreatment systemic immune-inflammation index (SII) in newly diagnosed glioblastoma multiforme (GBM) patients who underwent postneurosurgical radiotherapy and concurrent plus adjuvant temozolomide." | 7.96 | Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide. ( Besen, AA; Kucuk, A; Mertsoylu, H; Ozdemir, Y; Pehlivan, B; Selek, U; Topkan, E, 2020) |
| "To analyze retrospectively the efficacy of temozolomide (TMZ) in various treatment regimens in glioblastoma patients accounting for varying parameters of their treatment." | 7.96 | Temozolomide in glioblastoma treatment: 15-year clinical experience and analysis of its efficacy. ( Glavatskyi, OY; Kardash, KA; Khmelnytskyi, HV; Shuba, IM; Stuley, VA; Zemskova, OV, 2020) |
| "5, 1 g/kg) or temozolomide (10 mg/kg) treatment alone inhibited tumor growth in glioblastoma U87 and U251 xenografts." | 7.96 | Xihuang pill potentiates the anti-tumor effects of temozolomide in glioblastoma xenografts through the Akt/mTOR-dependent pathway. ( Fu, J; Kong, PS; Wang, J; Wang, X; Xu, HB; Xu, YQ; Zhu, SH, 2020) |
| "Temozolomide (TMZ) is a chemotherapeutic used for the treatment of glioblastoma." | 7.96 | A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status. ( Bello-Rivero, I; Leenstra, S; van der Kaaij, M; Vázquez-Blomquist, D; Villarreal, A, 2020) |
| "This study was conducted to assess whether levetiracetam (LEV) affects the survival of patients with glioblastoma (GBM) treated with concurrent temozolomide (TMZ) chemotherapy." | 7.96 | Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy. ( Chang, JH; Hong, CK; Kang, SG; Kim, EH; Kim, SH; Moon, JH; Park, HH; Roh, TH, 2020) |
| "Glioblastoma is an extremely aggressive glioma, resistant to radio and chemotherapy usually performed with temozolomide." | 7.96 | Cyclopamine sensitizes glioblastoma cells to temozolomide treatment through Sonic hedgehog pathway. ( Arrais-Neto, AM; Carballo, GB; Matias, D; Pessoa, LS; Ribeiro, JH; Spohr, TCLSE, 2020) |
| "We designed a conjugated compound by coupling temozolomide (TMZ) with doxorubicin (DOX) via an acylhydrazone linkage as a potential prodrug used for glioblastoma multiforme (GBM) treatment." | 7.96 | Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy. ( Du, K; Feng, F; Heng, H; Xia, Q, 2020) |
| "Surgical resection and systemic chemotherapy with temozolomide remain the mainstay for treatment of glioblastoma." | 7.96 | Injectable diblock copolypeptide hydrogel provides platform to deliver effective concentrations of paclitaxel to an intracranial xenograft model of glioblastoma. ( Bernstein, AM; Deming, TJ; Garrett, MC; Hung, D; Kornblum, HI; O'Shea, TM; Sofroniew, MV; Soto, H; Staarman, B; Wollenberg, AL, 2020) |
| "Resistance of glioblastoma to the chemotherapeutic compound temozolomide is associated with the presence of glioblastoma stem cells in glioblastoma and is a key obstacle for the poor prognosis of glioblastoma." | 7.96 | Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity. ( Hwang, WC; Kang, DW; Min, DS; Noh, YN; Park, KS, 2020) |
| "Temozolomide (TMZ) therapy is the standard of care for patients with glioblastoma (GBM)." | 7.96 | Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment. ( Alshareef, M; Cachia, D; Das, A; Infinger, LK; Lindhorst, SM; Patel, SJ; Porto, GBF; Vandergrift, WA; Varma, AK, 2020) |
| " In glioblastoma (GBM), predictive biomarkers of cellular responses to temozolomide (TMZ) combined with poly‑ADP‑ribose polymerase inhibitor (PARPi) remain largely unidentified." | 7.96 | PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency. ( Godoy, PRDV; Lima, SCG; Montaldi, AP; Sakamoto-Hojo, ET; Xavier, DJ, 2020) |
| " The transfection efficiency was determined with flow cytometry, and the therapeutic efficacy of CD::UPRT::GFP expressing MSCs was evaluated in cocultures with temozolomide (TMZ)-sensitive or TMZ-resistant human glioblastoma cell lines." | 7.96 | A facile and scalable in production non-viral gene engineered mesenchymal stem cells for effective suppression of temozolomide-resistant (TMZR) glioblastoma growth. ( Ho, YK; Ng, ZX; Teo, KJ; Too, HP; Tu, GXE; Yeo, TT, 2020) |
| "To assess the patterns of failure and prognostic factors in Brazilian patients with glioblastoma multiforme (GBM) treated with radiotherapy (RT) and concurrent and adjuvant temozolomide (TMZ)." | 7.96 | Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide. ( Faustino, AC; Hamamura, AC; Viani, GA, 2020) |
| "Temozolomide (TMZ) is widely used for treating glioblastoma multiforme (GBM), however, the treatment of such brain tumors remains a challenge due to the development of resistance." | 7.96 | Wnt/β-catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma. ( Baek, ST; Hsieh, JT; Kim, S; Yun, EJ, 2020) |
| " In this study, we explore whether CAP, an ionized gas produced in laboratory settings and that operates at near room temperature, can enhance Temozolomide (TMZ) cytotoxicity on a glioblastoma cell line (U87MG)." | 7.96 | Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells. ( Gjika, E; Keidar, M; Kirschner, ME; Lin, L; Pal-Ghosh, S; Sherman, JH; Stepp, MA, 2020) |
| "Despite aggressive treatment with temozolomide and radiotherapy and extensive research into alternative therapies there has been little improvement in Glioblastoma patient survival." | 7.96 | Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma. ( Areeb, Z; Gomez, J; Jones, J; Kaye, AH; Luwor, RB; Morokoff, AP; Nguyen, HPT; Paradiso, L; Stuart, SF; West, AJ; Zulkifli, A, 2020) |
| "Glioblastoma (GBM) is a malignant brain tumour with a dismal prognosis, despite best treatment by surgical resection, radiation therapy (RT) and chemotherapy with temozolomide (TMZ)." | 7.96 | Cytotoxic lanthanum oxide nanoparticles sensitize glioblastoma cells to radiation therapy and temozolomide: an in vitro rationale for translational studies. ( Jue, TR; Lu, VM; McDonald, KL, 2020) |
| "Objective To investigate the expression of cathepsin S (CTSS) in temozolomide-resistant glioblastoma T98G (T98G-R) cells." | 7.96 | [Cathepsin S (CTSS) is highly expressed in temozolomide-resistant glioblastoma T98G cells and associated with poor prognosis]. ( Guo, Q; Jia, B; Liu, W; Lyu, W, 2020) |
| " In this study, we investigated whether selective add-on BEV for patients with newly diagnosed glioblastoma (GBM) and anaplastic astrocytoma (AA) improves prognosis, in cases where tumors were continuously growing during radiotherapy concomitant with temozolomide (TMZ)." | 7.96 | The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma. ( Hirata, K; Houkin, K; Ishi, Y; Kobayashi, H; Motegi, H; Oda, Y; Okamoto, M; Tanaka, S; Terasaka, S; Yamaguchi, S, 2020) |
| "The natural product primary sulfonamide, psammaplin C (1), when used in combination with clinically used chemotherapeutic drugs, including temozolomide, reverses multidrug resistance and increases survival in glioblastoma, a highly aggressive primary brain tumor." | 7.91 | Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma. ( Bua, S; Kopecka, J; Mujumdar, P; Poulsen, SA; Riganti, C; Supuran, CT, 2019) |
| " These new molecules displayed cytotoxic activities towards human glioblastoma cell lines, including the U251-MG cells that are highly resistant to the conventional chemotherapeutic agent Temozolomide." | 7.91 | Chemical modifications of imidazole-containing alkoxyamines increase C-ON bond homolysis rate: Effects on their cytotoxic properties in glioblastoma cells. ( Audran, G; Braguer, D; Brémond, P; Buric, D; Carré, M; Chacon, C; Marque, SRA; Yamasaki, T, 2019) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic agent used against glioblastoma multiforme (GBM), but this disease exhibits recurrence and high lethality." | 7.91 | miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme. ( Chen, KC; Chen, PH; Cheng, CH; Chou, CM; Ho, KH; Lin, CW; Liu, AJ; Shih, CM, 2019) |
| " In this study, we investigate the underlying mechanism by which glioblastoma (GBM) cells acquire resistance to Temozolomide (TMZ) through Aurora kinase B (AURKB) thus to identify novel therapeutic targets and prognostic biomarkers for GBM." | 7.91 | Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide. ( Alafate, W; Liu, C; Sun, L; Wang, J; Wang, M; Wu, W; Xie, W; Zuo, J, 2019) |
| "To investigate the underlying mechanism by which glioblastoma (GBM) cells gain temozolomide (TMZ) resistance and to clarify novel therapeutic targets and new prognostic biomarkers for GBM." | 7.91 | Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. ( Li, R; Mao, P; Wahafu, A; Wang, J; Wang, M; Wu, W; Xie, W; Yu, X; Zuo, J, 2019) |
| "Current treatment of recurrent glioblastoma multiforme (GBM) demands dose-intense temozolomide (TMZ), a prodrug of 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide (MTIC), based on the spontaneous hydrolysis of TMZ at basic pH." | 7.91 | Enhanced Copper-Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme. ( Du, K; Feng, F; Li, X; Shao, F; Sun, J; Sun, Y, 2019) |
| "Temozolomide is the current first-line treatment for glioblastoma patients but, because many patients are resistant to it, there is an urgent need to develop antitumor agents to treat temozolomide-resistant glioblastoma." | 7.91 | Gossypol Suppresses Growth of Temozolomide-Resistant Glioblastoma Tumor Spheres. ( Jang, H; Jeon, JH; Kang, SG; Kang, SW; Kim, DK; Kim, HY; Kim, SY; Lee, BI; Shim, JK, 2019) |
| "Drug resistance to temozolomide (TMZ) contributes to the majority of tumor recurrence and treatment failure in patients with glioblastoma multiforme (GBM)." | 7.91 | Lovastatin Enhances Cytotoxicity of Temozolomide via Impairing Autophagic Flux in Glioblastoma Cells. ( Cheng, SY; Kiang, KMY; Leung, GK; Li, N; Wong, VK; Zhang, P; Zhu, Z, 2019) |
| "The purpose of this study was to evaluate the outcomes of elderly patients (aged ≥75 years) with newly diagnosed glioblastoma (GBM), who were treated with hypofractionated radiotherapy comprising 45 Gy in 15 fractions combined with temozolomide (TMZ) or TMZ and bevacizumab (TMZ/Bev)." | 7.91 | Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years. ( Ichimura, K; Igaki, H; Matsushita, Y; Miyakita, Y; Narita, Y; Ohno, M; Takahashi, M, 2019) |
| "Temozolomide (TMZ) is the most commonly used chemotherapeutic agent used to treat glioblastoma (GBM), which causes significant DNA damage to highly proliferative cells." | 7.91 | Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells. ( Harder, BG; Kitange, GJ; Loftus, JC; Peng, S; Sarkaria, JN; Sereduk, CP; Sodoma, AM; Tran, NL, 2019) |
| "In the management of patients with newly diagnosed glioblastoma, there is no standard duration for adjuvant temozolomide treatment." | 7.91 | Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma. ( Hasegawa, Y; Hatano, K; Hirono, S; Iuchi, T; Sakaida, T; Uchino, Y, 2019) |
| "Current standard of treatment for newly diagnosed patients with glioblastoma (GBM) is surgical resection with adjuvant normofractionated radiotherapy (NFRT) combined with temozolomide (TMZ) chemotherapy." | 7.91 | Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma. ( Flentje, M; Klement, RJ; Kosmala, R; Lewitzki, V; Lisowski, D; Polat, B, 2019) |
| "Temozolomide (TMZ) is known to induce thrombocytopenia but no early predictive test has yet been clearly established." | 7.91 | Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients. ( Alexandru, C; Clatot, F; David, M; Di Fiore, F; Fontanilles, M; Gilard, V; Hanzen, C; Langlois, O; Laquerriere, A; Marguet, F; Tennevet, I; Veresezan, O, 2019) |
| "Glioblastoma multiforme (GBM) has a poor prognosis with an overall survival of 14-15 months after surgery, radiation and chemotherapy using temozolomide (TMZ)." | 7.91 | Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide. ( Bjerkvig, R; Denisova, O; Grudic, A; Hasan-Olive, MM; Janji, B; Johannessen, TC; Latif, MA; Lund-Johansen, M; Nordal, A; Prestegarden, L; Røsland, GV; Saed, H; Simonsen, A; Sundstrøm, T; Tronstad, KJ; Varughese, JK; Wang, J; Westermarck, J; Yang, N; Zhu, H, 2019) |
| "To describe oncological patterns of care, prognostic factors, and survival for all patients in France with newly-diagnosed and histologically confirmed glioblastoma, and evaluate the impact of extended temozolomide use at the population level." | 7.91 | Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. ( Amelot, A; Bauchet, F; Bauchet, L; Bessaoud, F; Charissoux, M; Darlix, A; Duffau, H; Fabbro, M; Fabbro-Peray, P; Figarella-Branger, D; Mandonnet, E; Mathieu-Daude, H; Pallud, J; Rigau, V; Riondel, A; Sorbets, E; Taillandier, L; Tretarre, B; Zouaoui, S, 2019) |
| "Despite the clinical success of temozolomide (TMZ), its sensitivity remains a major challenge in glioblastoma (GBM)." | 7.91 | PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma. ( Han, L; Huang, K; Liang, H; Liu, Y; Wang, G; Wang, Q; Wang, Z; Wei, C; Zhang, A; Zhang, W; Zhang, Z; Zhen, Y; Zhou, J, 2019) |
| "Temozolomide was recognized as the first-line therapy for glioblastoma to prolong the survival of patients noticeably, while recent clinical studies found that some patients were not sensitive to temozolomide treatment." | 7.91 | Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma. ( Jin, X; Liu, N; Miao, F; Nie, E; Shi, Z; Wang, Y; Wu, W; You, Y; Yu, T; Zeng, A; Zhang, J; Zhi, T; Zhou, X, 2019) |
| "Glioblastoma multiforme (GBM) is the most malignant tumor of the central nervous system, and chemoresistance blunts the effect of temozolomide (TMZ) in the treatment of GBM." | 7.91 | MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1. ( Gu, J; Guo, Q; Hao, Q; Jia, B; Liu, W; Lv, W; Mu, N; Pang, Z; Wang, J; Zhang, W, 2019) |
| " We investigated the anticancer potential of combination of biochanin A and temozolomide against U-87 MG and T98 G [glioblastoma multiforme (GBM)] cells." | 7.91 | Combination of Biochanin A and Temozolomide Impairs Tumor Growth by Modulating Cell Metabolism in Glioblastoma Multiforme. ( Bhushan, A; Desai, V; Jain, A; Lai, JCK; Shaghaghi, H; Summer, R, 2019) |
| "For our studies, we have particularly chosen C6 rat glioma cell line due to several reasons: i) We previously showed that MPA reduced growth and induced procarbazine-sensitization in C6 cells; ii) temozolomide has a triazene-type molecular structure like procarbazine; iii) other groups previously showed that C6 glioma cell line is more resistant to temozolomide than human glioma cells; hence it may provide a native model of chemoresistance." | 7.91 | Medroxyprogesterone effects on colony growth, autophagy and mitochondria of C6 glioma cells are augmented with tibolone and temozolomide: Cell kinetic and electron microscopical studies with a broad review of the literature. ( Altinoz, MA; Bilir, A; Elmaci, İ; Ozpinar, A, 2019) |
| "Chemotherapy with temozolomide (TMZ) is the traditional treatment for glioblastoma (GBM)." | 7.91 | MCCK1 enhances the anticancer effect of temozolomide in attenuating the invasion, migration and epithelial-mesenchymal transition of glioblastoma cells in vitro and in vivo. ( Li, A; Liu, T; Xin, Y; Xu, Y, 2019) |
| "Temozolomide (TMZ) is an alkylating agent commonly used as a first‑line treatment for high‑grade glioblastoma." | 7.91 | Synergistic anticancer effect of acteoside and temozolomide-based glioblastoma chemotherapy. ( Choi, DE; Hwang, TW; Jang, TW; Kim, DB; Kim, DH; Kim, GH; Kim, JJ; Moon, M; Park, JH; Yoon, KA, 2019) |
| "Temozolomide (TMZ) is a widely used chemotherapeutic agent for glioblastoma multiforme (GBM)." | 7.91 | Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition. ( Li, A; Liu, T; Xin, Y; Xu, Y, 2019) |
| "Temozolomide (TMZ) is the first-line treatment for Glioblastoma Multiforme (GBM)." | 7.91 | Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy. ( Andrade, S; Coelho, MÁN; Loureiro, JA; Pereira, MC; Ramalho, MJ, 2019) |
| "Despite advances in cancer therapies, glioblastoma multiforme treatment remains inefficient due to the brain-blood barrier (BBB) inhibitory activity and to the low temozolomide (TMZ) chemotherapeutic selectivity." | 7.91 | Targeted and Synergic Glioblastoma Treatment: Multifunctional Nanoparticles Delivering Verteporfin as Adjuvant Therapy for Temozolomide Chemotherapy. ( de Melo, MT; Paula, LB; Pellosi, DS; Tedesco, AC, 2019) |
| "Standard-of-care treatment of glioblastomas involves maximal safe resection and adjuvant temozolomide chemo-radiotherapy." | 7.91 | Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study. ( Chan, DTM; Chan, KY; Ho, JMK; Lam, SW; Lee, MWY; Mak, CHK; Poon, WS; Tse, TPK; Wong, ST; Woo, PYM, 2019) |
| "The aims of the present study were to compare the longitudinal changes of glioblastoma multiforme after radiotherapy (RT) between 11C-methionine positron emission tomography (MET-PET) and gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) and to clarify whether these changes were predictive of survival." | 7.91 | Dissociation Between 11C-Methionine-Positron Emission Tomography and Gadolinium-Enhanced Magnetic Resonance Imaging in Longitudinal Features of Glioblastoma After Postoperative Radiotherapy. ( Asano, Y; Ikegame, Y; Iwama, T; Kawasaki, T; Miwa, K; Shinoda, J; Takei, H; Yano, H; Yokoyama, K, 2019) |
| "When only treated with D,L-methadone, 1 µM of the opioid was sufficient to reduce viability of fibroblasts, whereas 10 µM was needed to significantly reduce glioblastoma cell viability." | 7.91 | D,L-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro. ( Baran-Schmidt, R; Dietterle, J; Gaunitz, F; Glasow, A; Matusova, M; Meixensberger, J; Neumann, K; Oppermann, H, 2019) |
| "Although temozolomide (TMZ) resistance is a significant clinical problem in glioblastoma (GBM), its underlying molecular mechanisms are poorly understood." | 7.91 | Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma. ( Shi, Z; Yan, W; Yin, J; You, Y; Zeng, A; Zhang, Z, 2019) |
| "Temozolomide (TMZ) is an alkylating agent used in the treatment of high-grade malignant glioma, notably glioblastoma multiforme, the most aggressive form of brain cancer." | 7.91 | Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide? ( He, Y; Kaina, B, 2019) |
| " In this preliminary study, the purpose was to evaluate the feasibility of APT imaging in monitoring the early therapeutic response to nitroxoline (NTX) in a temozolomide (TMZ)-resistant glioblastoma multiforme (GBM) mouse model, which was compared with diffusion-weighted imaging (DWI)." | 7.91 | Assessment of Early Therapeutic Response to Nitroxoline in Temozolomide-Resistant Glioblastoma by Amide Proton Transfer Imaging: A Preliminary Comparative Study with Diffusion-weighted Imaging. ( Cho, HR; Choi, SH; Kumari, N; Thakur, N, 2019) |
| "The acquired drug resistance has been regarded as a main barrier for the effective treatment of temozolomide (TMZ) in glioblastoma (GBM)." | 7.91 | miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2. ( Li, X; Liu, X; Luo, W; Song, Z; Yan, D; Zhao, S; Zhu, X, 2019) |
| "To identify novel epigenetic signatures that could provide predictive information that is complementary to promoter methylation status of the O-6-methylguanine-DNA methyltransferase (MGMT) gene for predicting temozolomide (TMZ) response, among glioblastomas (GBMs) without glioma-CpGs island methylator phenotype (G-CIMP) METHODS: Different cohorts of primary non-G-CIMP GBMs with genome-wide DNA methylation microarray data were included for discovery and validation of a multimarker signature, combined using a RISK score model." | 7.91 | Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. ( Aubry, M; Barnholtz-Sloan, J; Etcheverry, A; He, YL; Liu, BL; Liu, YH; Lu, ZF; Mosser, J; Yin, AA; Zhang, X, 2019) |
| " In the present study, we examined the anticancer effects of papaverine in human glioblastoma (GBM) temozolomide (TMZ; as a first-line anticancer medicine)-sensitive U87MG and TMZ-resistant T98G cells." | 7.91 | Anticancer effects of a non-narcotic opium alkaloid medicine, papaverine, in human glioblastoma cells. ( Akasaki, Y; Ichimura, K; Inada, M; Kobayashi, K; Sato, A; Shindo, M; Tanuma, SI; Yamamoto, Y, 2019) |
| "A first cost-effectiveness analysis has raised a strong concern regarding the cost of tumor treatment fields (TTF) added to maintenance temozolomide for patients with glioblastoma." | 7.91 | Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model. ( Armoiry, X; Auguste, P; Connock, M; Dussart, C; Guyotat, J, 2019) |
| "Despite the increased understanding of the oncological mechanisms underlying Glioblastoma multiforme (GBM) pathophysiology, and recent advances in therapeutic strategies such as maximal surgical resection and post-operative radiotherapy with concomitant and adjuvant temozolomide chemotherapy, the prognosis for patients with brain tumors remains limited." | 7.91 | microRNA-181d associated with the methylation status of the MGMT gene in Glioblastoma multiforme cancer stem cells submitted to treatments with ionizing radiation and temozolomide. ( Carlotti, CG; de Assis Cirino, ML; Lizarte Neto, FS; Matias, CCMS; Pereira-da-Silva, G; Peria, FM; Rodrigues, AR; Tirapelli, DPDC; Trevisan, FA, 2019) |
| "The acquisition of temozolomide resistance is a major clinical challenge for glioblastoma treatment." | 7.91 | Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2. ( Chen, Z; Deng, S; Guo, M; Huang, G; Lei, B; Li, Y; Li, Z; Liu, Y; Pan, J; Qi, S; Wang, H; Xiang, W; Yi, GZ; Yu, L; Zhang, X, 2019) |
| "Glioblastoma (GBM) is an aggressive brain tumor with temozolomide (TMZ)-based chemotherapy as the main therapeutic strategy." | 7.88 | Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells. ( Kipper, FC; Lenz, G; Lopez, PLDC; Silva, AO; Villodre, ES, 2018) |
| "Standard treatment for patients with primary glioblastoma (GBM) includes surgery, radiotherapy, and concomitant and adjuvant temozolomide (TMZ)." | 7.88 | Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients. ( Hama, S; Kawamata, T; Kurisu, K; Muragaki, Y; Nosaka, R; Saito, T; Sugiyama, K; Takayasu, T; Yamasaki, F, 2018) |
| " Having established that CUX1 is expressed at high levels in most glioblastomas, we next show that the resistance of glioblastoma cells to temozolomide and to a combined treatment of temozolomide and ionizing radiation is reduced following CUX1 knockdown, but increased by overexpression of CUX1 or a short protein containing only 2 CUT domains, which is active in DNA repair but devoid of transcriptional activity." | 7.88 | CUX1 stimulates APE1 enzymatic activity and increases the resistance of glioblastoma cells to the mono-alkylating agent temozolomide. ( Abdulkarim, B; Guiot, MC; Kaur, S; Leduy, L; Li, L; Nepveu, A; Ramdzan, ZM; Ramotar, D; Sabri, S, 2018) |
| "Our study tested the diagnostic accuracy of increased signal intensity (SI) within FLAIR MR images of resection cavities in differentiating early progressive disease (ePD) from pseudoprogression (PsP) in patients with glioblastoma treated with radiotherapy with concomitant temozolomide therapy." | 7.88 | Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy. ( Agrawal, JP; Erickson, BJ; Korfiatis, P; Perry, LA, 2018) |
| " By manipulation of Cx43 expression or gap junction function, we found that there were gap junction-dependent and independent effect of Cx43 on temozolomide (TMZ) sensitivity in U87 glioblastoma cells." | 7.88 | Tramadol attenuates the sensitivity of glioblastoma to temozolomide through the suppression of Cx43‑mediated gap junction intercellular communication. ( Huang, H; Ma, L; Peng, J; Peng, Y; Shao, M; Wang, L; Xia, Z; Zhong, G; Zhu, Z, 2018) |
| "Development of resistance against temozolomide (TMZ) in glioblastoma (GBM) after continuous treatment with TMZ is one of the critical problems in clinical GBM therapy." | 7.88 | Intracellular cholesterol level regulates sensitivity of glioblastoma cells against temozolomide-induced cell death by modulation of caspase-8 activation via death receptor 5-accumulation and activation in the plasma membrane lipid raft. ( Ichimura, K; Kumagai, K; Mori, K; Nakashima, K; Namba, H; Narita, Y; Otani, N; Sakai, R; Sasaki, N; Shirakihara, T; Takeuchi, S; Tomiyama, A; Toyooka, T; Wada, K; Yamaguchi, H; Yamamoto, Y, 2018) |
| "The purpose of the study is to investigate the efficacy of combined treatment with temozolomide (TMZ) and metformin for glioblastoma (GBM) in vitro and in vivo." | 7.88 | High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy. ( Hong, YK; Lee, JE; Lim, JH; Yang, SH, 2018) |
| "The impact of DNA mismatch repair (MMR) on resistance to temozolomide (TMZ) therapy in patients with glioblastoma (GBM) is recently reported but the mechanisms are not understood." | 7.88 | Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma. ( Dong, T; Dong, Y; Gao, Y; Gong, Y; Li, Q; Pei, C; Ren, H; Su, J; Sun, Q; Xiao, Y; Xing, W; Zhen, Z; Zhou, P, 2018) |
| " In this study we aimed to evaluate the relationship of FBW7 with glioma pathology and prognosis, and examine its effect in glioma malignancies and temozolomide (TMZ)-based therapy." | 7.88 | FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells. ( Cui, Y; Feng, H; He, H; Ji, A; Li, J; Li, S; Lin, J; Lu, Y; Qiu, G; Song, C; Zou, Y, 2018) |
| "To retrospectively determine the safety and efficacy of combined chemotherapy with carmustine (BCNU) wafer, bevacizumab, and temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma (GBM)." | 7.88 | Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. ( Akiyama, Y; Enatsu, R; Kimura, Y; Mikami, T; Mikuni, N; Wanibuchi, M, 2018) |
| " This phenomenon, which has deleterious outcomes for the patient, has long been observed in patients with glioblastoma receiving temozolomide (TMZ)-based radiochemotherapy." | 7.88 | Characterizing the molecular mechanisms of acquired temozolomide resistance in the U251 glioblastoma cell line by protein microarray. ( Cui, Y; Feng, H; He, H; Li, J; Li, S; Lin, J; Qiu, G; Song, C; Wei, W; Wu, X; Xu, Q; Zuo, J, 2018) |
| "Glioblastoma is a malignant brain tumor that inevitably develops resistance to standard of care drug temozolomide (TMZ) due to a population of cells called cancer stem cells (CSCs)." | 7.88 | Outlining involvement of stem cell program in regulation of O6-methylguanine DNA methyltransferase and development of temozolomide resistance in glioblastoma: An Editorial Highlight for 'Transcriptional control of O ( Chumakova, A; Lathia, JD, 2018) |
| "Multi-institutional data from 159 patients with newly diagnosed glioblastoma who received adjuvant temozolomide concomitant chemoradiotherapy (CCRT) were collected." | 7.88 | A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location. ( Chan, D; Chan, KY; Ho, J; Lam, S; Lee, M; Ma, E; Mak, C; Poon, WS; Wong, ST; Wong, WK; Woo, P, 2018) |
| "To evaluate the prognostic value of the Glasgow Prognostic Score (GPS), the combination of C-reactive protein (CRP) and albumin, in glioblastoma multiforme (GBM) patients treated with radiotherapy (RT) and concurrent plus adjuvant temozolomide (GPS)." | 7.88 | Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide. ( Ciner, F; Guler, OC; Mertsoylu, H; Ozdemir, Y; Selek, U; Topkan, E; Tufan, K; Yildirim, BA, 2018) |
| "To identify patients with recurrent glioblastoma after temozolomide (TMZ) concurrent with and adjuvant to radiotherapy who could benefit from TMZ rechallenge at the time of disease progression." | 7.88 | Temozolomide rechallenge in recurrent glioblastoma: when is it useful? ( Bartolini, S; Brandes, AA; Cubeddu, A; De Biase, D; Di Battista, M; Franceschi, E; Lamberti, G; Minichillo, S; Mura, A; Paccapelo, A; Pession, A; Tallini, G; Tosoni, A; Visani, M, 2018) |
| "Human glioblastoma U251 and T98 cells and normal astrocytes C8D1A were loaded with coenzyme Q10 (CoQ)." | 7.88 | Regulation of the oxidative balance with coenzyme Q10 sensitizes human glioblastoma cells to radiation and temozolomide. ( Alcaín, FJ; Ariza, J; Arjona-Gutiérrez, J; De la Mata, M; Durán-Prado, M; Ferrín, G; Frontiñán-Rubio, J; Gil-Agudo, A; Gómez, MV; Lozano, E; Martínez-González, A; Moreno, M; Nieva-Velasco, CM; Peinado, JR; Pérez-García, VM; Pérez-Romasanta, L; Pesic, M; Santiago-Mora, RM; Villalba, JM, 2018) |
| "We retrospectively analyzed the safety and efficacy of hypofractionated radiotherapy (45 Gy/15 fr) combined with temozolomide (TMZ) followed by bevacizumab (BEV) salvage treatment in 18 glioblastoma patients aged > 75 years." | 7.88 | Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged > 75 years. ( Kayama, T; Matsuda, KI; Nemoto, K; Sakurada, K; Sonoda, Y, 2018) |
| "Temozolomide (TMZ) is the preferred chemotherapeutic drug approved for the Glioblastoma multiforme (GBM) treatment." | 7.88 | miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma. ( Deng, S; Guo, M; Li, Y; Liu, Y; Peng, Y; Qi, S; Ren, J; Shu, S; Yi, G; Zhao, L, 2018) |
| "To investigate the anti-glioblastoma effects of myricetin, GBM cells were treated with myricetin alone or in combination with temozolomide." | 7.88 | A Multi-targeted Natural Flavonoid Myricetin Suppresses Lamellipodia and Focal Adhesions Formation and Impedes Glioblastoma Cell Invasiveness and Abnormal Motility. ( Chen, ZP; Li, WP; To, ST; Wang, G; Wang, J; Wu, CP; Zhao, HF; Zhou, XM, 2018) |
| "Recently, D,L-methadone has been put forward as adjuvant treatment in glioblastoma (GBM)." | 7.88 | Efficacy of D,L-methadone in the treatment of glioblastoma in vitro. ( Brawanski, A; Brawanski, K; Brockhoff, G; Freyschlag, C; Hau, P; Lohmeier, A; Proescholdt, MA; Riemenschneider, MJ; Thomé, C; Vollmann-Zwerenz, A, 2018) |
| " In temozolomide resistance glioblastoma, nZn-CuO NPs disturb cell growth and sphere formation by inhibiting AKT and ERK1/2 activation." | 7.88 | Zinc-doped copper oxide nanocomposites reverse temozolomide resistance in glioblastoma by inhibiting AKT and ERK1/2. ( Gedanken, A; Lin, X; Shi, D; Song, L; Wang, C; Wu, N; Yao, W; Zhang, C, 2018) |
| "Temozolomide (TMZ) is the current first-line chemotherapy for treatment of glioblastoma multiforme (GBM)." | 7.88 | Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells. ( Arcella, A; Capriotti, AL; Caracciolo, G; Digiacomo, L; Frati, L; Mahmoudi, M; Oliva, MA; Palchetti, S; Pozzi, D; Rota, R; Screpanti, I; Tsaouli, G, 2018) |
| "Temozolomide (TMZ) is the first-line chemotherapeutic agent in the treatment of glioblastoma multiforme (GBM)." | 7.88 | Caffeine Sensitizes U87-MG Human Glioblastoma Cells to Temozolomide through Mitotic Catastrophe by Impeding G2 Arrest. ( Cheng, YS; Kiang, KMY; Leung, GKK; Li, N; Zhang, P, 2018) |
| "Temozolomide (TMZ) was used for the treatment of glioblastoma (GBM) for over a decade, but its treatment benefits are limited by acquired resistance, a process that remains incompletely understood." | 7.88 | A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. ( Chen, X; Fang, D; Gan, H; Giannini, C; He, L; Hu, Z; Kitange, GJ; Lee, JH; Meyer, FB; Parney, IF; Sarkaria, JN; Wang, H; Zhang, M; Zhang, Z, 2018) |
| " Multidrug resistance, particularly resistance to temozolomide (TMZ), is a challenge in combating glioma, and more effective therapies are needed." | 7.88 | Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo. ( Bai, Y; Chen, Y; Dong, X; Hong, X; Li, S; Li, Y; Liu, X; Su, X; Zhao, G, 2018) |
| " For example, temozolomide (TMZ), of use for glioblastoma (GBM) treatment, appears as capable of inducing autophagy partially inhibiting cancer cell proliferation." | 7.88 | Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis. ( Ascione, B; Buccarelli, M; D'Alessandris, QG; De Pascalis, I; Larocca, LM; Malorni, W; Marconi, M; Martini, M; Matarrese, P; Pacioni, S; Pallini, R; Ricci-Vitiani, L, 2018) |
| "Chemoresistance blunts the effect of Temozolomide (TMZ) in the treatment of glioblastoma multiforme (GBM)." | 7.88 | Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. ( Huang, X; Li, R; Shen, F; Wang, X; Wei, Z; Wu, W; Yan, W; Yin, J; You, Y; Zeng, A; Zhou, X, 2018) |
| "In this study, we aimed to evaluate the expression and functions of MAPK8 in temozolomide (TMZ) -resistant glioblastoma cells as well as to explore the mechanism of TMZ resistance in glioblastoma cells." | 7.88 | MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway. ( Hou, S; Sha, LG; Xu, P; Zhang, G, 2018) |
| "To estimate the mean lifetime survival benefit, an essential component of health economic evaluations in oncology, of adding tumor treating fields (TTFields) to maintenance temozolomide (TMZ) for newly diagnosed glioblastoma patients." | 7.88 | Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients. ( Guzauskas, GF; Salzberg, M; Wang, BC, 2018) |
| "Discriminating between tumor recurrence and treatment effects in glioblastoma patients undergoing radiation-temozolomide (RT/TMZ) therapy remains a major clinical challenge." | 7.88 | Diagnostic utility of restriction spectrum imaging (RSI) in glioblastoma patients after concurrent radiation-temozolomide treatment: A pilot study. ( Bartsch, H; Chen, CC; Dale, AM; Farid, N; Khan, UA; Rennert, RC; White, NS, 2018) |
| "To investigate the efficacy of lactoferrin nanoparticles (LfNPs) in delivering siRNA across the blood-brain barrier to treat glioblastoma multiforme (GBM) and with an additional objective of potentiation of conventional temozolomide (TMZ) chemotherapy." | 7.88 | Aurora kinase B siRNA-loaded lactoferrin nanoparticles potentiate the efficacy of temozolomide in treating glioblastoma. ( Bhattacharya, D; Chakarvarty, S; Kondapi, AK; Kumari, S; Rangaraj, N; Rao, NM, 2018) |
| "A series of polymer-drug conjugates based on 2-methacryloyloxyethyl phosphorylcholine (MPC) was prepared with the glioblastoma drug temozolomide (TMZ) as pendent groups." | 7.88 | Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma. ( Emrick, T; Saha, B; Skinner, M; Ward, SM, 2018) |
| "Temozolomide (TMZ) and radiation therapy combination for glioblastoma (GB) patients has been considered as the most effective therapy after surgical procedure." | 7.88 | Long noncoding RNA AC003092.1 promotes temozolomide chemosensitivity through miR-195/TFPI-2 signaling modulation in glioblastoma. ( Doycheva, DM; Fu, Z; Guo, H; He, Z; Huang, Q; Lian, C; Liu, B; Liu, Y; Xu, N; Yang, Z; Zeng, H; Zhou, J, 2018) |
| "To explore the effects of pulsed, focused, and microbubble contrast agent-enhanced ultrasonography (mCEUS) on blood-brain barrier (BBB) permeability and the efficacy temozolomide for glioblastoma." | 7.88 | Opening the Blood-Brain Barrier and Improving the Efficacy of Temozolomide Treatments of Glioblastoma Using Pulsed, Focused Ultrasound with a Microbubble Contrast Agent. ( Chen, L; Deng, Q; Dong, Q; He, L, 2018) |
| "The efficacy of temozolomide (TMZ) chemotherapy for treating newly diagnosed glioblastoma (GBM), a primary brain tumor with short survival, was demonstrated in a clinical trial in 2005, and since then, the standard-of-care for newly diagnosed GBM has been maximal safe surgery followed by 60 Gray of radiation with concomitant and adjuvant TMZ (standard radiotherapy and TMZ)." | 7.88 | Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice. ( Carter, TC; Lawler, BE; Medina-Flores, R, 2018) |
| "The impact of prolonging temozolomide (TMZ) maintenance beyond six cycles in newly diagnosed glioblastoma (GBM) remains a topic of discussion." | 7.85 | Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma. ( Behling, F; Bisdas, S; Borchers, C; Dangel, E; Gohde, J; Koch, M; Lepski, G; Naumann, A; Noell, S; Paulsen, F; Ritz, R; Schittenhelm, J; Skardelly, M; Tabatabai, G; Tatagiba, MS; von Hehn, U; Zips, D, 2017) |
| "Radiation with concurrent and adjuvant (6 cycles) temozolomide (TMZ) is the established standard of postsurgical care for newly diagnosed glioblastoma (GBM)." | 7.85 | Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. ( Baumert, BG; Blumenthal, DT; Brown, PD; Burt Nabors, L; Corn, BW; Erridge, SC; Gilbert, MR; Golfinopoulos, V; Gorlia, T; Hegi, ME; Hyun Nam, D; Kim, MM; Mason, WP; Mehta, MP; Mirimanoff, RO; Perry, JR; Reardon, DA; Stupp, R; van den Bent, MJ; Weller, M; Zhang, P, 2017) |
| "To determine if there is an association between the incidental radiation dose to the subventricular zone and survival in patients with glioblastoma multiforme treated with surgery, radiotherapy and temozolomide." | 7.85 | Influence of incidental radiation dose in the subventricular zone on survival in patients with glioblastoma multiforme treated with surgery, radiotherapy, and temozolomide. ( Algara, M; Foro Arnalot, P; Granados, R; Membrive, I; Ortiz, A; Pera, O; Reig, A; Rodriguez, N; Sanz, X, 2017) |
| "In glioblastoma several histone demethylase genes (KDM) are overexpressed compared to normal brain tissue and the development of Temozolomide (TMZ) resistance is accompanied by the transient further increased expression of KDM5A and other KDMs following a mechanism that we defined as "epigenetic resilience"." | 7.85 | Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells. ( Allemanni, G; Banelli, B; Daga, A; Forlani, A; Marubbi, D; Pistillo, MP; Profumo, A; Romani, M, 2017) |
| "Few population-based analyses have investigated survival change in glioblastoma multiforme (GBM) patients treated with concomitant radiotherapy-temozolomide (RT-TMZ) and adjuvant temozolomide (TMZ) and then bevacizumab (BEV) after Food and Drug Administration (FDA) approval, respectively." | 7.85 | Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study. ( Du, XL; Lu, G; Zhu, JJ; Zhu, P, 2017) |
| " This study aimed to improve the treatment of glioblastoma (GBM), the most common brain cancer, by testing whether the efficacy of the DNA alkylator temozolomide (TMZ) varies with the time of its administration." | 7.85 | Cell-intrinsic, Bmal1-dependent Circadian Regulation of Temozolomide Sensitivity in Glioblastoma. ( Binz, A; Herzog, ED; Kfoury, N; Kim, A; Marpegan, L; Rubin, JB; Simon, T; Slat, EA; Sponagel, J, 2017) |
| "Glioblastoma multiforme (GBM) exhibits high resistance to the standard treatment of temozolomide (TMZ) combined with radiotherapy, due to its remarkable cell heterogeneity." | 7.85 | Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines. ( Abdollahi, A; Dokic, I; Klein, C; Oancea-Castillo, LR; Régnier-Vigouroux, A; Weber, KJ, 2017) |
| "Temozolomide (TMZ) is a promising chemotherapeutic agent to treat Glioblastoma multiforme (GBM)." | 7.85 | MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor. ( Chen, Y; Li, R; Liu, N; Pan, M; Shi, Z; Wang, X; Yan, W; You, Y; Zhang, J, 2017) |
| " For these reasons, the anti-glioblastoma drug temozolomide was tested in vitro for activity against bloodstream forms of T." | 7.85 | Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine. ( Rushworth, SA; Steverding, D, 2017) |
| "Limited benefits and clinical utility of temozolomide (TMZ) for glioblastoma (GB) are frequently compromised by the development of acquired drug resistance." | 7.85 | Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling. ( Fu, Z; Guo, H; Lian, C; Liu, B; Xu, N; Yang, Z; Zeng, H, 2017) |
| " In the present study, whether MALAT1 contributes to the resistance of glioblastoma cell lines to temozolomide (TMZ) was investigated." | 7.85 | Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide. ( Dong, Y; Guan, F; Li, D; Li, H; Liu, X; Wang, H; Yan, D; Yang, B; Yuan, X, 2017) |
| "The present study analyzed outcomes of surgery followed by concomitant chemoradiotherapy (CCRT) with temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) at a single institution." | 7.85 | Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis. ( Ahn, SS; Chang, JH; Cho, J; Choi, HJ; Hong, CK; Kang, SG; Kim, DS; Kim, EH; Kim, SH; Lee, KS; Lee, SK; Moon, JH; Park, HH; Roh, TH; Suh, CO, 2017) |
| "Recent experimental data showed that the PI3K pathway contributes to resistance to temozolomide (TMZ) in paediatric glioblastoma and that this effect is reversed by combination treatment of TMZ with a PI3K inhibitor." | 7.85 | In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells. ( Agliano, A; Al-Saffar, NMS; Balarajah, G; Clarke, PA; Jackson, LE; Jones, C; Leach, MO; Marshall, LV; Pearson, ADJ; Sidhu, J; Workman, P, 2017) |
| " In the current study we examined the hypothesis that LDHA and anaerobic glycolysis, may contribute to the resistance of glioblastoma to radiotherapy and to temozolomide." | 7.85 | Blocking LDHA glycolytic pathway sensitizes glioblastoma cells to radiation and temozolomide. ( Ananiadou, D; Giatromanolaki, A; Ilemosoglou, M; Kostoglou, G; Koukourakis, M; Lamprou, I; Papadopoulou, M; Pouliliou, S; Sivridis, E; Tsolou, A, 2017) |
| "Temozolomide is the first chemotherapeutic agent proven effective for patients with newly diagnosed glioblastoma." | 7.85 | Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma. ( Chan, DT; Hsieh, SY; Kam, MK; Loong, HH; Ng, SC; Poon, DM; Poon, WS; Tsang, WK, 2017) |
| "Acquisition of temozolomide (TMZ) resistance is a major factor leading to the failure of glioblastoma (GBM) treatment." | 7.85 | Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O ( Chang, KY; Chang, WC; Chen, KY; Chou, SW; Chuang, CK; Chuang, JY; Hsu, CC; Hsu, TI; Hung, JJ; Kao, TJ; Ko, CY; Liou, JP; Liu, JJ; Liu, MS; Tsai, SY, 2017) |
| "Temozolomide (TMZ) is commonly used in glioblastoma (GBM) chemotherapy." | 7.85 | PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma. ( Chen, H; Chen, Q; Han, C; Lan, J; Liu, Q; Lou, M; Que, S; Wang, L; Xue, Y; Zhang, X, 2017) |
| "Temozolomide (TMZ), as a kind of alkylating agent, is widely utilized for the treatment of glioblastoma (GBM)." | 7.85 | miR‑146b‑5p suppresses glioblastoma cell resistance to temozolomide through targeting TRAF6. ( Lan, J; Lin, Y; Qian, Z; Qiu, Y; Que, S; Yang, X; Zhou, S; Zhou, Z, 2017) |
| "To assess the efficacy and cost-effectiveness of modulated electrohyperthermia (mEHT) concurrent to dose-dense temozolomide (ddTMZ) 21/28 days regimen versus ddTMZ 21/28 days alone in patients with recurrent glioblastoma (GBM)." | 7.85 | Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison ( Roussakow, SV, 2017) |
| " Standard of care for glioblastoma (GBM) includes temozolomide chemotherapy, which is not curative, due, in part, to residual therapy-resistant brain tumor-initiating cells (BTICs)." | 7.85 | Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. ( Audia, A; Bar, EE; Benavides, GA; Bevensee, MO; Bhat, KP; Boyd, NH; Cooper, SJ; Darley-Usmar, V; Dedhar, S; Fried, J; Gillespie, GY; Gordon, E; Griguer, C; Hackney, JR; Hjelmeland, AB; Landis, CJ; McDonald, PC; Nabors, B; Nozell, S; Scott, SE; Spina, R; Tran, AN; Walker, K; Xu, B, 2017) |
| "It is controversial whether concurrent chemoradiotherapy (CRT) with temozolomide is feasible and beneficial in elderly patients with glioblastoma." | 7.85 | A Model to Predict the Feasibility of Concurrent Chemoradiotherapy With Temozolomide in Glioblastoma Multiforme Patients Over Age 65. ( Fietkau, R; Knippen, S; Lahmer, G; Putz, F; Semrau, S, 2017) |
| "The current standard treatment protocol for patients with newly diagnosed glioblastoma (GBM) includes surgery, radiotherapy, and concomitant and adjuvant temozolomide (TMZ)." | 7.85 | Permeability Surface Area Product Using Perfusion Computed Tomography Is a Valuable Prognostic Factor in Glioblastomas Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide. ( Ikawa, F; Ishifuro, M; Kawamata, T; Kurisu, K; Muragaki, Y; Nishibuchi, I; Nosaka, R; Saito, T; Sugiyama, K; Takayasu, T; Yamasaki, F, 2017) |
| "It is unknown whether the addition of temozolomide (TMZ) to radiotherapy (RT) is associated with improved overall survival (OS) among older glioblastoma patients." | 7.85 | Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma. ( Arvold, ND; Cefalu, M; Dominici, F; Schrag, D; Wang, Y; Zigler, C, 2017) |
| "A recent Phase 3 study of newly diagnosed glioblastoma (GBM) demonstrated the addition of tumor treating fields (TTFields) to temozolomide (TMZ) after combined radiation/TMZ significantly increased survival and progression free survival." | 7.85 | The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells. ( Clark, PA; Deming, DA; Gaal, JT; Kuo, JS; Pasch, CA; Robins, HI; Strebe, JK, 2017) |
| "Temozolomide-resistant (TMZ-R) glioblastoma is very difficult to treat, and a novel approach to overcome resistance is needed." | 7.85 | Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line. ( Akiyama, Y; Asai, A; Ashizawa, T; Hayashi, N; Iizuka, A; Kondou, R; Mitsuya, K; Miyata, H; Nakasu, Y; Nonomura, C; Sugino, T; Urakami, K; Yamaguchi, K, 2017) |
| "Temozolomide-(TMZ)-based chemoradiotherapy defines the current gold standard for the treatment of newly diagnosed glioblastoma." | 7.85 | Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival. ( Ballhausen, H; Belka, C; Nachbichler, SB; Niyazi, M; Schupp, G, 2017) |
| "Glioblastoma multiforme (GBM), the most common malignant brain tumor, is currently treated with temozolomide (TMZ), but GBM often exhibits resistance to TMZ." | 7.85 | FoxO3a induces temozolomide resistance in glioblastoma cells via the regulation of β-catenin nuclear accumulation. ( Li, L; Pei, H; Wang, H; Xia, Q; Xu, K; Zhang, Z, 2017) |
| "The chemotherapeutic agent temozolomide (TMZ) is widely used in the treatment of glioblastoma multiforme (GBM)." | 7.85 | Rutin increases the cytotoxicity of temozolomide in glioblastoma via autophagy inhibition. ( Cheng, YS; Ho, ASW; Kiang, KMY; Lee, D; Leung, GKK; Li, N; Poon, MW; Pu, JKS; Sun, S; Zhang, P; Zhang, X, 2017) |
| "To explore an association with survival of modifying the current standard of care for patients with newly diagnosed glioblastoma of surgery followed by radiotherapy plus concurrent and 6 cycles of maintenance temozolomide chemotherapy (TMZ/RT → TMZ) by extending TMZ beyond 6 cycles." | 7.85 | Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. ( Bendszus, M; Felsberg, J; Gramatzki, D; Hentschel, B; Herrlinger, U; Kickingereder, P; Loeffler, M; Pietsch, T; Reifenberger, G; Sabel, M; Schackert, G; Schlegel, U; Tonn, JC; Weller, M; Westphal, M; Wick, W, 2017) |
| "Arginine-glycine-aspartic acid peptide (RGD)-modified nanostructured lipid carriers (NLCs) were used for the delivery of temozolomide (TMZ) into the GBM to provide a new paradigm in gliomatosis cerebri treatment." | 7.83 | Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. ( Du, J; Mao, G; Song, S; Zhu, X, 2016) |
| "Resistance of glioblastoma (GBM) to the front-line chemotherapeutic agent temozolomide (TMZ) continues to challenge GBM treatment efforts." | 7.83 | Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide. ( Gourdie, RG; Guo, S; Jourdan, J; Kanabur, P; Lamouille, S; Murphy, SF; Osimani, AM; Pridham, KJ; Rodgers, CM; Sharma, S; Sheng, Z; Simonds, GR; Varghese, RT, 2016) |
| " In this study, in vivo efficacy of veliparib combined with temozolomide (TMZ) was evaluated in a large panel of glioblastoma multiforme (GBM) patient-derived xenografts (PDX) and potential biomarkers were analyzed." | 7.83 | Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. ( Bakken, KK; Ballman, KV; Boakye-Agyeman, F; Carlson, BL; Cen, L; Decker, PA; Eckel-Passow, JE; Gupta, SK; Jenkins, RB; Kitange, GJ; Kizilbash, SH; Mladek, AC; Pokorny, JL; Reid, JM; Sarkar, G; Sarkaria, JN; Schroeder, MA; Sulman, EP; Verhaak, RG, 2016) |
| "The survival benefits of patients with glioblastoma (GBM) remain unsatisfactory due to the intrinsic or acquired resistance to temozolomide (TMZ)." | 7.83 | Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression. ( Han, J; Lan, F; Wu, Q; Yang, Y; Yu, H; Yue, X, 2016) |
| "Resistance to temozolomide (TMZ) greatly limits chemotherapeutic effectiveness in glioblastoma (GBM)." | 7.83 | Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant. ( Boyd, AW; Byrne, AT; Day, BW; Flanagan, L; Kögel, D; Murray, DW; O'Brien, DF; Prehn, JH; Rehm, M; Salvucci, M; Stringer, BW; Tivnan, A; Zakaria, Z, 2016) |
| "O6-methylguanine-DNA methyltransferase (MGMT) protein expression using immunohistochemical analysis was proposed as a prognostic marker for patients with newly diagnosed glioblastoma (GBM) treated with radiation therapy with concurrent and adjuvant Temozolomide (TMZ)." | 7.83 | Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide. ( El-Shorbagy, SH; Khedr, RA; Younis, SG, 2016) |
| "To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741)." | 7.83 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. ( Chinot, O; Cloughesy, T; Gilbert, MR; Gorlia, T; Happold, C; Hegi, M; Mehta, MP; Nabors, LB; Perry, JR; Pugh, SL; Reardon, DA; Roth, P; Stupp, R; Weller, M; Wick, W, 2016) |
| " Triple-mutant astrocytes formed serially transplantable glioblastoma allografts that were sensitive to radiation but expressed MGMT and were resistant to temozolomide." | 7.83 | Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide. ( Bash, RE; Ewend, MG; Huey, L; McNeill, RS; Miller, CR; Schmid, RS; Simon, JM; Vitucci, M; Werneke, AM; White, KK; Wu, J, 2016) |
| "The current standard of care for glioblastoma (GBM) is surgical resection, radiotherapy, and treatment with temozolomide (TMZ)." | 7.83 | MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival. ( Chaumeil, MM; Eriksson, P; Phillips, JJ; Radoul, M; Ronen, SM; Wang, AS, 2016) |
| "Despite the use of ionizing radiation (IR) and temozolomide (TMZ), outcome for glioblastoma (GBM) patients remains dismal." | 7.83 | Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model. ( Chenevert, TL; Galbán, CJ; Galbán, S; Heist, KA; Holland, EC; Lemasson, B; Li, Y; Rehemtulla, A; Ross, BD; Tsein, C; Wang, H; Zhu, Y, 2016) |
| "The role of temozolomide concurrent with and adjuvant to radiotherapy (RT/TMZ) in elderly patients with glioblastoma (GBM) remains unclear." | 7.83 | Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. ( Baruzzi, A; Bertolini, F; Biasini, C; Brandes, AA; Cavallo, MA; Crisi, G; Dazzi, C; Depenni, R; Ermani, M; Faedi, M; Franceschi, E; Michiara, M; Mucciarini, C; Paccapelo, A; Pasini, G; Pavesi, G; Pisanello, A; Servadei, F; Sturiale, C; Urbini, B, 2016) |
| "To get better chemotherapy efficacy, the optimal synergic effect of Paclitaxel (PTX) and Temozolomide (TMZ) on glioblastoma cells lines was investigated." | 7.83 | The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells. ( Duan, Y; Li, Y; Shen, M; Sun, Y; Teng, Y; Wang, Y; Xu, Y, 2016) |
| "The combination of radiotherapy, temozolomide and valproic acid (VPA) has shown some promise in retrospective analyses of patients with glioblastoma, although their mechanisms of action remain unknown." | 7.83 | Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma. ( Bumes, E; Eyüpoglu, IY; Hau, P; Hutterer, M; Proske, J; Savaskan, NE; Seliger, C; Uhl, M; Vollmann-Zwerenz, A; Walter, L, 2016) |
| "Temozolomide (TMZ) is an alkylating agent used to treat glioblastoma." | 7.83 | Sulfasalazine intensifies temozolomide cytotoxicity in human glioblastoma cells. ( Castilho, RF; De Melo, DR; Facchini, G; Ignarro, RS; Lopes-Cendes, I; Rogerio, F; Vieira, AS, 2016) |
| "Temozolomide (TMZ) improves Glioblastoma Multiforme (GBM) patient survival." | 7.83 | Temozolomide induces the expression of the glioma Big Potassium (gBK) ion channel, while inhibiting fascin-1 expression: possible targets for glioma therapy. ( Ahluwalia, A; Chau, V; Ge, L; Hoa, NT; Jadus, MR; Kruse, CA; Martini, F, 2016) |
| "Temozolomide (TMZ) is the main chemotherapeutic drug utilized for the treatment of glioblastoma multiforme (GMB), however, drug resistance often leads to tumor recurrence and poor outcomes." | 7.83 | Expression of dynein, cytoplasmic 2, heavy chain 1 (DHC2) associated with glioblastoma cell resistance to temozolomide. ( Chen, Z; Feng, W; He, M; Lei, B; Li, H; Liu, Y; Lu, Y; Qi, S; Sun, X; Wang, H; Xiang, W; Zhao, L, 2016) |
| "Glioblastoma (GB) recurrences are rarely removed, therefore, tissue modifications induced by radiotherapy, and temozolomide chemotherapy are scarcely known." | 7.83 | Cyclin D1 Co-localizes with Beclin-1 in Glioblastoma Recurrences: A Clue to a Therapy-induced, Autophagy-mediated Degradative Mechanism? ( Belmonte, G; Miracco, C; Pirtoli, L; Tini, P; Toscano, M, 2016) |
| "Genotoxic chemotherapy with temozolomide (TMZ) is a mainstay of treatment for glioblastoma (GBM); however, at best, TMZ provides only modest survival benefit to a subset of patients." | 7.83 | Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide. ( Johnston, G; Lincoln, FA; Murphy, BM; Noonan, J; Rehm, M; Weyhenmeyer, BC; Würstle, ML, 2016) |
| "Glioblastoma remains an aggressive brain malignancy with poor prognosis despite advances in multimodal therapy that include standard use of Temozolomide." | 7.83 | Tailored Nanoparticle Codelivery of antimiR-21 and antimiR-10b Augments Glioblastoma Cell Kill by Temozolomide: Toward a "Personalized" Anti-microRNA Therapy. ( Ananta, JS; Massoud, TF; Paulmurugan, R, 2016) |
| "Even with aggressive treatment involving radiation therapy plus temozolomide (TMZ), the prognosis for glioblastoma remains poor." | 7.83 | Inhibition of STAT3 enhances the radiosensitizing effect of temozolomide in glioblastoma cells in vitro and in vivo. ( Cho, BJ; Choi, EJ; Han, TJ; Kim, DH; Kim, IA; Paek, SH; Song, SH, 2016) |
| "To evaluate the safety and efficacy of postoperative proton beam therapy (PBT) combined with nimustine hydrochloride (ACNU) or temozolomide (TMZ) for glioblastoma multiforme (GBM)." | 7.83 | Proton beam therapy with concurrent chemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride and temozolomide. ( Ishikawa, E; Ishikawa, H; Matsuda, M; Matsumura, A; Mizumoto, M; Okumura, T; Sakurai, H; Takano, S; Tsuboi, K; Yamamoto, T, 2016) |
| " 1) VPA treatment clearly sensitized glioma cells to temozolomide: A protruding VPA-induced molecular feature in this context was the transcriptional upregulation/reexpression of numerous solute carrier (SLC) transporters that was also reflected by euchromatinization on the histone level and a reexpression of SLC transporters in human biopsy samples after VPA treatment." | 7.83 | Molecular dissection of the valproic acid effects on glioma cells. ( Hau, P; Herold-Mende, C; Hoja, S; Proescholdt, M; Rehli, M; Riemenschneider, MJ; Schulze, M, 2016) |
| "Temozolomide (TMZ) is an alkylating agent that has become the mainstay treatment of the most malignant brain cancer, glioblastoma multiforme (GBM)." | 7.83 | Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems. ( Assoulin, M; Constantini, S; Daniels, D; Fisher, T; Freedman, S; Guez, D; Last, D; Mardor, Y; Mehrian-Shai, R; Moshe, I; Pismenyuk, T; Reichardt, JK; Simon, AJ; Toren, A; Yalon, M, 2016) |
| " The purpose of this study was determining the effects of HL156A, a newly designed biguanide with improved pharmacokinetics, on glioblastoma TSs (GMB TSs) and assess the feasibility of this drug as a new line of therapy against glioblastoma, alone or combined with a conventional therapeutic agent, temozolomide(TMZ)." | 7.83 | Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). ( Chang, JH; Cheong, JH; Choi, J; Huh, YM; Jeon, JY; Kang, SG; Kim, EH; Kim, P; Kim, SH; Koh, I; Lee, JH; Lee, SJ; Park, J; Pollak, M; Shim, JK; Yook, JI; Yun, M, 2016) |
| "Twenty patients with recurrent glioblastoma were treated with biweekly BEV plus temozolomide." | 7.83 | MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma. ( Beppu, T; Kato, K; Ogasawara, K; Sasaki, M; Sasaki, T; Sato, Y; Terasaki, K; Tomabechi, M, 2016) |
| " Here we investigated the in vitro short- and long-term responses of six glioblastoma cell lines to clinically relevant doses of temozolomide for 5 days followed by 23 days of recovery, mimicking the standard schedule used in glioblastoma patient for this drug." | 7.83 | The regrowth kinetic of the surviving population is independent of acute and chronic responses to temozolomide in glioblastoma cell lines. ( Dalsin, E; Filippi-Chiela, EC; Lenz, G; Onzi, GR; Silva, AO, 2016) |
| "To observe the effect of RITA, a small molecule that targets p53, combined with temozolomide (TMZ) on proliferation, colony formation and apoptosis of human glioblastoma U87 cells and explore the underlying mechanism." | 7.83 | [RITA combined with temozolomide inhibits the proliferation of human glioblastoma U87 cells]. ( Cao, ZX; Feng, XL; He, XY; Song, XP; Wu, QH; Xiao, WW; Zeng, HC; Zhang, B, 2016) |
| "It has been reported that metformin acts synergistically with temozolomide (TMZ) to inhibit proliferation of glioma cells including glioblastoma multiforme (GBM)." | 7.83 | Metformin treatment reduces temozolomide resistance of glioblastoma cells. ( Kim, DH; Li, S; Liu, Y; Lu, G; Xue, H; Yang, SH; Zhu, JJ, 2016) |
| "Overcoming temozolomide (TMZ) resistance is a great challenge in glioblastoma (GBM) treatment." | 7.83 | Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway. ( Feng, J; Feng, M; Yan, PF; Zhang, FC; Zhao, HY; Zhao, WH, 2016) |
| "Herein, we report new quinazoline-urea based compounds with potent cytotoxic activities against TMZ-resistant glioblastoma multiforme (GBM) cells." | 7.81 | Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). ( Cho, H; Elkamhawy, A; Heo, JC; Kim, HY; Kim, KH; Lee, CO; Nam, DH; Pae, AN; Park, WK; Roh, EJ; Seol, HJ; Viswanath, AN; Yang, H, 2015) |
| "Concurrent chemoradiotherapy with temozolomide, the current standard treatment after surgery for glioblastoma, could be shortened without increasing side effects for patients with poor prognostic features." | 7.81 | Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features. ( Choi, SH; Han, TJ; Kim, IH; Kim, TM; Lee, SH; Lim, YJ; Paek, SH; Park, CK; Park, SH, 2015) |
| "Development of temozolomide (TMZ) resistance contributes to the poor prognosis for glioblastoma multiforme (GBM) patients." | 7.81 | A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. ( Chang, EH; Kim, E; Kim, SS; Pirollo, KF; Rait, A, 2015) |
| "To explore the role of dynamic contrast material-enhanced magnetic resonance (MR) imaging in the differentiation of true progression from pseudoprogression in patients with glioblastoma on the basis of findings in entirely newly developed or enlarged enhancing lesions after concurrent radiation therapy and chemotherapy with temozolomide and to evaluate the diagnostic performance of the quantitative pharmacokinetic parameters obtained at dynamic contrast-enhanced MR imaging, such as the volume transfer constant (K(trans)), the extravascular extracellular space per unit volume of tissue(ve), and the blood plasma volume per unit volume of tissue(vp)." | 7.81 | Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yun, TJ, 2015) |
| "The cellular responses to two new temozolomide (TMZ) analogues, DP68 and DP86, acting against glioblastoma multiforme (GBM) cell lines and primary culture models are reported." | 7.81 | Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth. ( Gynther, M; Mladek, AC; Phillips, RM; Ramirez, YP; Rautio, J; Ross, AH; Sakaria, JN; Wheelhouse, RT, 2015) |
| "The present in vitro study aimed to assess the effects of combining the mTOR inhibitor RAD001 and temozolomide (TMZ) together with irradiation by either low-linear energy transfer (LET) radiation (γ-rays) or high-LET radiation (fast neutrons) on the growth and cell survival of the human glioblastoma cell line U-87." | 7.81 | Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture. ( Bischoff, P; Burckel, H; Denis, JM; Gueulette, J; Josset, E; Noël, G; Slabbert, J, 2015) |
| " In this report, we describe the induction of a severe (grade 3) immunologic reaction in a patient with newly diagnosed glioblastoma (GBM) receiving autologous RNA-pulsed dendritic cell (DC) vaccines admixed with GM-CSF and administered coordinately with cycles of dose-intensified temozolomide." | 7.81 | Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide. ( Archer, G; DeLeon, G; Desjardins, A; Friedman, AH; Friedman, HS; Mitchell, DA; Norberg, P; Reap, E; Sampson, JH; Sayour, EJ; Schmittling, R, 2015) |
| "To evaluate 2 specific radiation schedules, each combined with temozolomide (TMZ), assessing their efficacy and safety in patients aged ≥65 years with newly diagnosed glioblastoma (GBM)." | 7.81 | Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. ( Arcella, A; Bozzao, A; Enrici, RM; Esposito, V; Giangaspero, F; Lanzetta, G; Minniti, G; Pace, A; Scaringi, C; Terrenato, I, 2015) |
| "Glioblastoma Multiforme (GBM), the most common and lethal adult primary tumor of the brain, showed a link between Sonic Hedgehog (SHH) pathway in the resistance to temozolomide (TMZ)." | 7.81 | Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level. ( Greco, SJ; Ligon, KL; Munoz, JL; Rameshwar, P; Ramkissoon, SH; Rodriguez-Cruz, V, 2015) |
| "Wee1 regulates key DNA damage checkpoints, and in this study, the efficacy of the Wee1 inhibitor MK-1775 was evaluated in glioblastoma multiforme (GBM) xenograft models alone and in combination with radiation and/or temozolomide." | 7.81 | The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. ( Agar, NY; Bakken, KK; Calligaris, D; Carlson, BL; Decker, PA; Eckel-Passow, JE; Elmquist, WF; Evans, DL; Gupta, SK; Iyekegbe, DO; Lou, Z; Ma, B; Mueller, D; Pokorny, JL; Pucci, V; Sarkaria, JN; Schroeder, MA; Shumway, SD, 2015) |
| " Chemotherapy has been observed to prolong overall survival rate and temozolomide (TMZ), a promising chemotherapeutic agent for treating glioblastoma (GBM), possesses the most effective clinical activity at present, although drug resistance limits its clinical outcome." | 7.81 | p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis. ( Fan, Y; Guo, G; Li, Q; Lian, S; Liu, X; Miao, W; Wang, H; Wang, S; Wang, X; Yang, X, 2015) |
| "Lack of robust predictive biomarkers, other than MGMT promoter methylation, makes temozolomide responsiveness in newly diagnosed glioblastoma (GBM) patients difficult to predict." | 7.81 | EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide. ( Bonetti, MF; Branca, C; Buglione, M; Buttolo, L; Cominelli, M; Dalerba, P; Facchetti, F; Finocchiaro, G; Furlan, D; Galli, R; Grisanti, S; Liserre, B; Liserre, R; Mazzoleni, S; Medicina, D; Pellegatta, S; Pellegrini, V; Pizzi, M; Poliani, PL, 2015) |
| "In this study, we developed and characterized a delivery system for the epigenetic demethylating drug, decitabine, to sensitize temozolomide-resistant human glioblastoma multiforme (GBM) cells to alkylating chemotherapy." | 7.81 | Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide. ( Cui, Y; Irudayaraj, J; Naz, A; Thompson, DH, 2015) |
| "Despite multimodal treatment, glioblastoma (GBM) therapy with temozolomide (TMZ) remains inefficient due to chemoresistance." | 7.81 | The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells. ( Bartsch, JW; Biniossek, ML; Carl, B; Conrad, C; Culmsee, C; Dolga, AM; Dong, F; Eibach, M; Koller, G; Nimsky, C; Schieber, S; Schilling, O; Schlomann, U; Strik, H, 2015) |
| "High-grade gliomas, glioblastomas (GB), are refractory to conventional treatment combining surgery, chemotherapy, mainly temozolomide, and radiotherapy." | 7.81 | Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response. ( Brem, H; Cohen-Jonathan Moyal, E; Dahan, P; Dang, VT; Lemarié, A; Saland, E; Sarry, JE; Scotland, SJ; Sesen, J; Skuli, N; Toulas, C; Tyler, BM, 2015) |
| "Temozolomide (TMZ) is widely used for treating glioblastoma (GBM), which can effectively inhibit the GBM growth for some months; however, it still could not prevent the invariable recurrence of GBM." | 7.81 | Demethoxycurcumin was prior to temozolomide on inhibiting proliferation and induced apoptosis of glioblastoma stem cells. ( Fei, X; Shi, L; Wang, Z, 2015) |
| "Currently, O6-methylguanine-DNA methyltransferase(MGMT) promoter methylation is the most convincing predictive biomarker for temozolomide (TMZ) response in patients with glioblastoma multiforme (GBM)." | 7.81 | miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase. ( Chen, H; Li, W; Li, X; Zheng, H, 2015) |
| "We examined whether the amino acid PET tracers, trans-1-amino-3-(18)F-fluorocyclobutanecarboxylic acid (anti-(18)F-FACBC) and (11)C-methyl-l-methionine ((11)C-Met), are suitable for detecting early responses to combination therapies including temozolomide (TMZ), interferon-β (IFN), and bevacizumab (Bev) in glioblastoma." | 7.81 | Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma. ( Baden, A; Doi, Y; Kanagawa, M; Mizoi, K; Oka, S; Ono, M; Ono, T; Sasajima, T; Shimizu, H, 2015) |
| "Two independent temozolomide-treated glioblastoma cohorts-one Australian (Australian Genomics and Clinical Outcomes of Glioma, n = 163) and the other American (University of California Los Angeles/Kaiser Permanente Los Angeles, n = 159)-were studied." | 7.81 | The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. ( Cloughesy, TF; Ha, W; Hitchins, MP; Lai, A; McDonald, KL; Nguyen, HN; Nowak, AK; Rapkins, RW; Wang, F, 2015) |
| "Resistance to temozolomide (TMZ) is a major obstacle in the treatment of glioblastoma multiforme (GBM)." | 7.81 | miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression. ( Mo, L; Qi, X; Wan, Y; Wang, Y; Wei, J; Xie, D; Xie, J; Yan, Q; Yang, S; Zhan, Q; Zhou, D, 2015) |
| " The objective of this study was to assess the survival benefit of LEV compared with other antiepileptic drugs as a chemosensitizer to temozolomide for patients with glioblastoma." | 7.81 | Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. ( Han, JH; Joo, JD; Kim, CY; Kim, IA; Kim, T; Kim, YH; Kim, YJ; Yun, CH, 2015) |
| "Temozolomide (TMZ) has been widely used in the treatment of glioblastoma (GBM), although inherent or acquired resistance restricts the application." | 7.81 | Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma. ( Lan, F; Pan, Q; Yu, H; Yue, X, 2015) |
| "Glioblastoma (GBM) is often treated with the cytotoxic drug temozolomide, but the disease inevitably recurs in a drug-resistant form after initial treatment." | 7.81 | Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide. ( Barford, K; Braun, CJ; Cerniauskas, E; Chen, Y; Hemann, MT; Lees, JA; Mazzucato, P; McFaline-Figueroa, JL; Nagel, ZD; Samson, LD; Sangaraju, D; Stanciu, M; Tretyakova, N; Vargas, A; White, FM, 2015) |
| "The objective of the study was to determine whether astrocytes and brain endothelial cells protect glioma cells from temozolomide through an endothelin-dependent signaling mechanism and to examine the therapeutic efficacy of the dual endothelin receptor antagonist, macitentan, in orthotopic models of human glioblastoma." | 7.81 | Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice. ( Aldape, K; Choi, HJ; Conrad, CA; Fidler, IJ; He, J; Kim, MS; Kim, SJ; Langley, RR; Lee, HJ; Lehembre, F; Regenass, U; Weinberg, JS; Wu, Q; Yung, WK, 2015) |
| "The AVAglio (Avastin in Glioblastoma) and RTOG-0825 randomized, placebo-controlled phase III trials in newly diagnosed glioblastoma reported prolonged progression-free survival (PFS), but not overall survival (OS), with the addition of bevacizumab to radiotherapy plus temozolomide." | 7.81 | Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. ( Abrey, LE; Bais, C; Bourgon, R; Chinot, OL; Cloughesy, T; Garcia, J; Hegde, P; Henriksson, R; Kharbanda, S; Lai, A; Li, C; Mason, W; Moore, N; Nishikawa, R; Peale, F; Phillips, HS; Sandmann, T; Saran, F; Wick, W, 2015) |
| " We investigated whether the widely used chemotherapeutic agent temozolomide (TMZ) can sensitize glioma stem-like cells (GSCs) from human glioblastoma multiforme (GBM) to TRAIL-induced apoptosis." | 7.81 | Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein. ( Anhua, W; Jia, L; Long, L; Yunchao, B; Zhitao, J, 2015) |
| " The aim of this study was to investigate the effects of HLF alone and in combination with temozolomide (TMZ), a conventional chemotherapeutic, on human glioblastoma (GBM) cells." | 7.81 | In vitro and in vivo effect of human lactoferrin on glioblastoma growth. ( Aalberti, S; Arcella, A; Bartolo, M; Cantore, G; Frati, A; Giangaspero, F; Grillea, G; Madonna, M; Oliva, MA; Pavone, L; Staffieri, S, 2015) |
| " Glioblastoma (GBM) has poor survival rate and uniformly acquired chemoresistance to its frontline agent, Temozolomide (TMZ)." | 7.81 | Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells. ( Munoz, JL; Rameshwar, P; Scotto, KW; Walker, ND, 2015) |
| " The present study was undertaken to determine whether the cytotoxicity of curcumin (diferuloylmethane), a natural polyphenolic compound isolated from turmeric (Curcuma longa Linn), in glioblastoma cells is mediated through upregulation of miR‑146a." | 7.81 | Induction of microRNA-146a is involved in curcumin-mediated enhancement of temozolomide cytotoxicity against human glioblastoma. ( Cai, T; Chen, YD; Liu, Q; Wang, ZF; Wu, H, 2015) |
| " Our aim was to determine whether the subependymal enhancement pattern and ADC can differentiate true progression from pseudoprogression in patients with glioblastoma multiforme treated with concurrent chemoradiotherapy by using temozolomide." | 7.81 | Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yoo, RE; Yun, TJ, 2015) |
| "Although temozolomide (TMZ) is the current first-line chemotherapy for glioblastoma multiforme (GBM), most patients either do not respond or ultimately fail TMZ treatment." | 7.81 | Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. ( Chang, EH; DeMarco, J; Kim, E; Kim, SS; Pirollo, KF; Rait, A, 2015) |
| " Interestingly, our findings showed an association of metformin therapy and prolonged progression-free survival in glioblastoma patients with diabetes and therefore serve as a foundation for further preclinical and clinical investigations." | 7.81 | Metformin influences progression in diabetic glioblastoma patients. ( Adeberg, S; Ben Harrabi, S; Bernhardt, D; Bostel, T; Debus, J; Diehl, C; Koelsche, C; Mohr, A; Rieken, S, 2015) |
| " We previously reported that the Smac (second mitochondria-derived activator of caspases) mimetic BV6, which antagonizes IAP proteins, sensitizes glioblastoma cells to temozolomide (TMZ)-induced cell death in a nuclear factor-κB (NF-κB)-dependent manner." | 7.81 | Smac mimetic-induced upregulation of interferon-β sensitizes glioblastoma to temozolomide-induced cell death. ( Fulda, S; Marschall, V, 2015) |
| "The efficacy of temozolomide (TMZ) plus radiation therapy (RT) in elderly patients with glioblastoma is unclear." | 7.81 | Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). ( Anghileri, E; Bazzoli, E; Bellu, L; Berti, F; D'Avella, D; Dall'Agata, M; Della Puppa, A; Eoli, M; Fabi, A; Faedi, M; Ferrazza, P; Gurrieri, L; Lombardi, G; Nicolotto, E; Pace, A; Pambuku, A; Pasqualetti, F; Rizzato, S; Rudà, R; Villani, V; Zagonel, V, 2015) |
| "PARP inhibition can enhance the efficacy of temozolomide and prolong survival in orthotopic glioblastoma (GBM) xenografts." | 7.81 | Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. ( Agar, NY; Boddy, AV; Calligaris, D; Carlson, BL; Cen, L; Curtin, NJ; Elmquist, WF; Kizilbash, S; Mittapalli, RK; Murray, J; Parrish, KE; Sarkaria, JN; Schroeder, MA; Sludden, J, 2015) |
| "The use of temozolomide (TMZ) has improved the prognosis for glioblastoma multiforme patients." | 7.81 | Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. ( Berdasco, M; Caba, O; Cabeza, L; Gónzalez, B; Melguizo, C; Ortiz, R; Perazzoli, G; Prados, J, 2015) |
| "Resistance to temozolomide poses a major clinical challenge in glioblastoma multiforme treatment, and the mechanisms underlying the development of temozolomide resistance remain poorly understood." | 7.81 | c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma. ( Chen, D; Chen, W; Chen, Y; Chen, Z; Cheng, G; Jiang, T; Liu, N; Lu, D; Luo, H; Peng, C; Qiu, W; Wang, H; Wang, HW; Wang, S; Wu, W; Xu, R; Yang, J; You, Y; Zhang, R; Zhang, S; Zhang, X; Zhao, C; Zhao, L, 2015) |
| "Temozolomide (TMZ) is widely used for patients with glioblastoma (GBM); however, tumor cells frequently exhibit drug-resistance." | 7.81 | APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line. ( Godoy, PR; Montaldi, AP; Sakamoto-Hojo, ET, 2015) |
| "Our laboratory reported that Irinophore C™ (IrC™; a lipid-based nanoparticulate formulation of irinotecan) is effective against an orthotopic model of glioblastoma (GBM) and that treatment with IrC™ was associated with vascular normalization within the tumor." | 7.81 | Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma. ( Anantha, M; Backstrom, I; Bally, MB; Chu, F; Kalra, J; Masin, D; Strutt, D; Verreault, M; Walker, D; Waterhouse, D; Wehbe, M; Yapp, DT, 2015) |
| "This study was performed to validate the effectiveness and safety of concurrent chemoradiotherapy and adjuvant therapy with temozolomide for newly diagnosed glioblastoma multiforme as a standard treatment protocol." | 7.81 | Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution. ( Han, JH; Joo, JD; Kim, CY; Kim, H; Kim, YH, 2015) |
| "Temozolomide (TMZ) is an oral DNA-alkylating agent used for treating patients with glioblastoma." | 7.81 | Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. ( Bui, Y; Cloughesy, TF; Hong, I; Lai, A; Liau, LM; McBride, WH; Menjivar, JC; Nelson, SF; Stream, A; Tso, CL; Tso, JL; Yamada, K; Yang, S; Yong, WH; Zhang, Y, 2015) |
| "Glioblastoma (GBM) generally exhibits high IC50 values for its standard drug treatment, temozolomide (TMZ)." | 7.81 | Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells. ( Ananta, JS; Massoud, TF; Paulmurugan, R, 2015) |
| "Notwithstanding current multimodal treatment, including surgery, radiotherapy and chemotherapy with temozolomide (TMZ), median survival of glioblastoma (GBM) patients is about 14 months, due to the rapid emergence of cell clones resistant to treatment." | 7.81 | The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. ( Allemanni, G; Banelli, B; Barbieri, F; Carosio, R; Carra, E; Daga, A; Florio, T; Forlani, A; Marubbi, D; Parodi, F; Pattarozzi, A; Romani, M; Würth, R, 2015) |
| "Glioma stem cells are associated for temozolomide-resistance in glioblastoma." | 7.81 | Co-expression of Cytoskeletal Protein Adducin 3 and CD133 in Neurospheres and a Temozolomide-resistant Subclone of Glioblastoma. ( Leung, GK; Poon, MW; Sun, S; Wong, ST; Zhang, XQ; Zhuang, JT, 2015) |
| "In this work, we have reported the preparation and optimization of paclitaxel (PTX) and temozolomide (TMZ) loaded monomethoxy (polyethylene glycol)-poly(D, L-lactide-co-glycolide) (mPEG-PLGA) nanocomposite which is a thermo-sensitive gel delivery system to glioblastoma." | 7.81 | Polymer Nanocomposites Based Thermo-Sensitive Gel for Paclitaxel and Temozolomide Co-Delivery to Glioblastoma Cells. ( Duan, Y; Gao, P; Shen, M; Sun, Y; Xu, Y, 2015) |
| "The current standard treatment of glioblastoma includes maximal safe surgical resection, radiation, and temozolomide." | 7.80 | Isotretinoin maintenance therapy for glioblastoma: a retrospective review. ( Chen, SE; Choi, SS; De Groot, JF; Lei, X; Rogers, JE, 2014) |
| "The standard adjuvant treatment for glioblastoma is temozolomide concomitant with radiotherapy, followed by a further six cycles of temozolomide." | 7.80 | Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain. ( Arranz, JL; Balañá, C; Benavides, M; Bugés, C; Cano, JM; de la Peñas, R; García-Bueno, JM; Gil, M; Lopez, D; Martin, JM; Molina-Garrido, MJ; Perez-Segura, P; Rodriguez, A; Sanz, SM; Sepúlveda, JM; Vaz, MA, 2014) |
| "Temozolomide, an alkylating agent, is a promising chemotherapeutic agent for treating glioblastoma." | 7.80 | miR-125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3. ( Shi, L; Sun, G; Wan, Y; Wang, Z; Zeng, Y; Zhang, S, 2014) |
| "Although temozolomide (TMZ) replaced nitrosoureas as the standard initial chemotherapy for glioblastoma (GBM), no studies have compared TMZ with nimustine (ACNU), a nitrosourea agent widely used in central Europe and most Asian regions." | 7.80 | Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma. ( Chen, B; Chen, L; Chen, X; Jiang, T; Li, S; Wang, J; Wang, L; Wang, Y; Wu, C; Zhang, X; Zhang, Z, 2014) |
| "Radiation therapy with concomitant and adjuvant temozolomide (TMZ) is the standard therapy for nonelderly patients with glioblastoma." | 7.80 | Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study. ( Mukasa, A; Narita, Y; Saito, K; Saito, N; Shibui, S; Shinoura, N; Tabei, Y, 2014) |
| " O6-methylguanine DNA methyltransferase (MGMT), which is frequently expressed in cancer stem cells of glioblastoma, has been implicated in their resistance to temozolomide, the first-line chemotherapeutic agent against newly diagnosed glioblastoma." | 7.80 | JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression. ( Kayama, T; Kitanaka, C; Narita, Y; Okada, M; Sato, A; Seino, M; Seino, S; Shibui, S; Shibuya, K; Suzuki, S; Watanabe, E, 2014) |
| "With standard treatment for glioblastoma (GBM) consisting of surgery followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ), median survival is ~14." | 7.80 | Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era. ( Chung, C; Jiang, H; Laperriere, N; Lwin, Z; Mason, WP; McNamara, MG; Millar, BA; Sahgal, A, 2014) |
| "As chemotherapy with temozolomide is far from providing satisfactory clinical outcomes for patients with glioblastoma, more efficient drugs and drug combinations are urgently needed." | 7.80 | Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. ( Debatin, KM; Dwucet, A; Halatsch, ME; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Westhoff, MA; Wirtz, CR, 2014) |
| "Ependymoma SC lines were highly sensitive to temozolomide and etoposide in vitro, but only temozolomide impaired tumor-initiation properties." | 7.80 | Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models. ( Arena, V; Binda, E; Lamorte, G; Meco, D; Riccardi, R; Servidei, T, 2014) |
| "Temozolomide (TMZ) is a promising chemotherapeutic agent for treating glioblastomas." | 7.80 | miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. ( Chen, J; Fu, X; Jiang, D; Shi, L; Wan, Y; Wang, Z, 2014) |
| "Little is known about the optimal clinical use of ABT-888 (veliparib) for treatment of glioblastoma." | 7.80 | ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. ( Beijnen, JH; Beumer, JH; Buil, LC; Christner, SM; de Gooijer, MC; Lin, F; Roig, EM; van Tellingen, O; Würdinger, T, 2014) |
| "Temozolomide (TMZ) has remained the chemotherapy of choice in patients with glioblastoma multiforme (GBM) primarily due to the lack of more effective drugs." | 7.80 | Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation. ( Cohen, MS; Grogan, PT; Sarkaria, JN; Timmermann, BN, 2014) |
| "Glioblastoma multiforme (GBM) represents the most common and deadly primary brain malignancy, particularly due to temozolomide (TMZ) and radiation (RT) resistance." | 7.80 | Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines. ( Anderson, JC; Bonner, JA; Bredel, M; Choradia, NV; Duarte, CW; Rohrbach, TD; Thottassery, JV; Welaya, K; Willey, CD; Yancey Gillespie, G; Yang, ES, 2014) |
| "Effective sensitizing strategies potentially can extend the benefit of temozolomide (TMZ) therapy in patients with glioblastoma (GBM)." | 7.80 | Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. ( Bakken, KK; Boakye-Agyeman, F; Carlson, BL; Gupta, SK; Kizilbash, SH; Mladek, AC; Reid, J; Sarkaria, JN; Schroeder, MA, 2014) |
| "The frequent recurrence of glioblastoma multiforme (GBM) after standard treatment with temozolomide (TMZ) is a crucial issue to be solved in the clinical field." | 7.80 | YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line. ( Akiyama, Y; Ashizawa, T; Hayashi, N; Iizuka, A; Komiyama, M; Kume, A; Mitsuya, K; Miyata, H; Nakasu, Y; Omiya, M; Oshita, C; Sugino, T; Yamaguchi, K, 2014) |
| " Temozolomide (TMZ) in combination with radiotherapy is currently used for the treatment of glioblastoma (GBM) patients, but less than half of the patients respond to therapy and chemoresistance develops rapidly." | 7.80 | miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas. ( Baumgartner, U; Glück, A; Haemmig, S; Kappeler, A; Mariani, L; Tschan, MP; Vajtai, I; Vassella, E; Zbinden, S, 2014) |
| " The aim of this study was to investigate whether quercetin could sensitize human glioblastoma cells to temozolomide (TMZ) in vitro." | 7.80 | Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27. ( Lan, Q; Li, RJ; Sang, DP, 2014) |
| "To analyze patterns of failure in patients with glioblastoma multiforme (GBM) treated with limited-margin radiation therapy and concurrent temozolomide." | 7.80 | Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. ( Bag, AK; Dobelbower, MC; Ennis, WH; Fiveash, JB; Gebhardt, BJ; Markert, JM, 2014) |
| "We examined changes to key UPR modulators in temozolomide-sensitive and -resistant human GBM cells (D54 and U87) treated with/without temozolomide at different oxygen concentrations using western blotting, and cytotoxic benefits of overexpressing key chaperone, P4HB, in GBM cells (U87 and U251) under normoxia and hyperoxia." | 7.80 | Hyperoxia resensitizes chemoresistant glioblastoma cells to temozolomide through unfolded protein response. ( Ho, AS; Kiang, KM; Lee, D; Leung, GK; Sun, S; Xu, FF; Zhang, XQ, 2014) |
| "Temozolomide (TMZ), a DNA alkylating agent, represents the most important chemotherapeutic option for the treatment of glioblastoma in the clinic." | 7.80 | Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling. ( Hu, X; Shao, J; Wang, L; Wen, C; Yin, H; You, C; Zhang, W; Zhou, C; Zhou, Y, 2014) |
| "Glioblastoma multiforme (GBM) commonly resists the frontline chemotherapy treatment temozolomide." | 7.80 | Temozolomide induces the production of epidermal growth factor to regulate MDR1 expression in glioblastoma cells. ( Greco, SJ; Munoz, JL; Nagula, V; Rameshwar, P; Rodriguez-Cruz, V; Scotto, KW, 2014) |
| "The aim of the present study was to evaluate the toxicity and clinical outcome of radio-chemotherapy with temozolomide in patients with glioblastoma aged more than 65 years." | 7.80 | Radio-chemotherapy with temozolomide in elderly patients with glioblastoma. A mono-institutional experience. ( Cocuzza, P; Fabbrini, MG; Fatigante, L; Ferrazza, P; Monzani, F; Pasqualetti, F; Pasqualetti, G, 2014) |
| "The current standard of care for glioblastoma (GBM) involves a combination of surgery, radiotherapy, and temozolomide chemotherapy, but this regimen fails to achieve long-term tumor control." | 7.80 | Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. ( Cairncross, JG; Luchman, HA; Lun, XQ; Nguyen, SA; Robbins, SM; Senger, DL; Stechishin, OD; Weiss, S, 2014) |
| " honey (ESH), beebread (EBB), and royal jelly (ERJ) with and without temozolomide (TMZ) on cell lines derived from a patient with diffuse astrocytoma (DASC), human glioblastoma multiforme (U87MG), and normal human astroglia (SVGp12)." | 7.80 | The interaction of bee products with temozolomide in human diffuse astrocytoma, glioblastoma multiforme and astroglia cell lines. ( Bartosiuk, E; Borawska, MH; Kochanowicz, J; Mariak, Z; Markiewicz-Żukowska, R; Moskwa, J; Naliwajko, SK; Socha, K; Surażyński, A, 2014) |
| "To review clinical outcomes of moderate dose escalation using high-dose radiation therapy (HDRT) in the setting of concurrent temozolomide (TMZ) in patients with newly diagnosed glioblastoma multiforme (GBM), compared with standard-dose radiation therapy (SDRT)." | 7.80 | Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide. ( Badiyan, SN; Chicoine, MR; Dacey, R; DeWees, T; Dowling, JL; Huang, J; Jalalizadeh, R; Kim, AH; Leuthardt, EC; Linette, G; Markovina, S; Rich, KM; Robinson, CG; Simpson, JR; Tran, DD; Zipfel, GJ, 2014) |
| "Standard treatment for glioblastoma comprises surgical resection, chemotherapy with temozolomide, and radiotherapy." | 7.80 | KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis. ( Ham, Y; Jin, J; Joo, KM; Kang, W; Kim, S; Nam, DH; Woo, SR; Yang, H, 2014) |
| "Recent findings show that exposure to temozolomide (TMZ), a DNA-damaging drug used to treat glioblastoma (GBM), can suppress the conversion of pyruvate to lactate." | 7.80 | Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells. ( Chaumeil, MM; Gaensler, K; Ito, M; Jalbert, LE; Mukherjee, J; Nelson, SJ; Park, I; Pieper, RO; Ronen, SM, 2014) |
| "To assess the prognosis predictability of a measurable enhancing lesion using histogram parameters produced by the normalized cerebral blood volume (nCBV) and normalized apparent diffusion coefficient (nADC) after completion of standard concomitant chemoradiotherapy (CCRT) and adjuvant temozolomide (TMZ) medication in glioblastoma multiforme (GBM) patients." | 7.80 | Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Ryoo, I; Sohn, CH; Yun, TJ, 2014) |
| "Temozolomide, an oral alkylating agent, is used in the treatment of glioblastoma." | 7.80 | Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma. ( Adeyi, O; Fung, S; Mason, M; Millar, BA, 2014) |
| "The objective of this study was to report the authors' experience with the long-term administration of temozolomide (TMZ; > 6 cycles, up to 101) in patients with newly diagnosed glioblastoma and to analyze its feasibility and safety as well as its impact on survival." | 7.80 | Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. ( Albanese, V; Barbagallo, GM; Caltabiano, R; Certo, F; Lanzafame, S; Longo, A; Motta, F; Palmucci, S; Paratore, S; Parra, HS; Privitera, G; Scaglione, G, 2014) |
| "The benefit of the introduction of alkylating chemotherapy in the treatment of glioblastoma multiforme (GBM) patients has been demonstrated by comparing radiotherapy with concomitant plus intermittent temozolomide (iTMZ) to radiation therapy." | 7.79 | The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study. ( Felsberg, J; Goeppert, M; Rapp, M; Sabel, M; Steiger, HJ, 2013) |
| " The current study investigates the trimodal combination of ABT-888, a potent inhibitor of PARP1-2, ionizing radiation and temozolomide(TMZ)-based chemotherapy in glioblastoma (GBM) cells." | 7.79 | Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. ( Barazzuol, L; Burnet, NG; Jena, R; Jeynes, JC; Kirkby, KJ; Kirkby, NF; Meira, LB, 2013) |
| " In this study, we investigated the predictive value of SLC22A18 promoter methylation and protein expression in glioblastoma multiforme (GBM) patients receiving temozolomide (TMZ) therapy." | 7.79 | Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy. ( Chu, SH; Feng, DF; Jiang, PC; Li, ZQ; Ma, YB, 2013) |
| "Temozolomide (TMZ) is commonly used in the treatment of glioblastoma (GBM)." | 7.79 | Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells. ( Canpinar, H; Castresana, JS; Ilgaz, S; Ozdemir, M; Ozkan, T; Oztuna, D; Rey, JA; Sunguroğlu, A; Taspinar, M; Ugur, HC, 2013) |
| "Valproic acid (VA) is an antiepileptic drug (AED) and histone deacetylase (HDAC) inhibitor taken by patients with glioblastoma (GB) to manage seizures, and it can modulate the biologic effects of radiation therapy (RT)." | 7.79 | Valproic acid use during radiation therapy for glioblastoma associated with improved survival. ( Barker, CA; Beal, K; Bishop, AJ; Chan, TA; Chang, M, 2013) |
| "The purpose of this study is to assess the preclinical therapeutic efficacy of magnetic resonance imaging (MRI)-monitored focused ultrasound (FUS)-induced blood-brain barrier (BBB) disruption to enhance Temozolomide (TMZ) delivery for improving Glioblastoma Multiforme (GBM) treatment." | 7.79 | Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study. ( Chen, PY; Chu, PC; Feng, LY; Hsu, PW; Huang, CY; Lee, PY; Liu, HL; Lu, YJ; Tsai, HC; Tseng, IC; Wang, HY; Wei, KC; Yen, TC, 2013) |
| "We investigated the pattern of failure in glioblastoma multiforma (GBM) patients treated with concurrent radiation, bevacizumab (BEV), and temozolomide (TMZ)." | 7.79 | Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme. ( Kadner, R; Shields, LB; Spalding, AC; Vitaz, TW, 2013) |
| "We have studied the consequences of the combination of the mammalian target of rapamycin (mTOR) inhibitor RAD001 and temozolomide on the growth and cell death of the glioblastoma cell line U-87 in vitro." | 7.79 | The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line. ( Bischoff, P; Burckel, H; Josset, E; Noël, G, 2013) |
| "To determine whether immediate post-operative brachytherapy can be safely applied to newly diagnosed glioblastomas to retard tumor progression prior to initiation of external beam radiation therapy (EBRT) and temozolomide." | 7.79 | Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma. ( Alksne, JF; Carter, BS; Chen, CC; Gonda, DD; Lawson, J; Murphy, K; Rose, B; Russell, M; Scanderbeg, DJ; Waters, JD, 2013) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 7.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| "Global gene expressions and drug sensitivities to three chemotherapeutic drugs (imatinib, camptothecin and temozolomide) were measured in six human glioblastoma-derived cell lines." | 7.79 | Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines. ( Andersson, C; Bergqvist, M; Blomquist, E; Ekman, S; Gullbo, J; Isaksson, A; Johansson, F; Kultima, HG; Lennartsson, J; Sooman, L, 2013) |
| "In glioblastoma multiforme (GBM), a tumor still characterized by dismal prognosis, recent research focuses on novel-targeted compounds, in addition to standard temozolomide (TMZ) chemotherapy." | 7.79 | Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers. ( Classen, CF; Linnebacher, M; Mullins, CS; Schneider, B; Schubert, J, 2013) |
| "To explore the role of histogram analysis of apparent diffusion coefficient (ADC) maps obtained at standard- and high-b-value (1000 and 3000 sec/mm(2), respectively) diffusion-weighted (DW) imaging in the differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide." | 7.79 | Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. ( Choi, SH; Chu, HH; Jung, SC; Kim, IH; Kim, JH; Kim, SC; Kim, TM; Lee, AL; Lee, SH; Park, CK; Park, SH; Ryoo, I; Shin, H; Sohn, CH; Yeom, JA; Yoon, TJ, 2013) |
| "Glioblastomas are the most frequent and aggressive intracranial neoplasms in humans, and despite advances and the introduction of the alkylating agent temozolomide in therapy have improved patient survival, resistance mechanisms limit benefits." | 7.79 | Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival. ( Caroli, M; Condomitti, G; Di Vito, C; Galli, R; Giussani, P; Riboni, L; Riccitelli, E; Tringali, C; Viani, P, 2013) |
| "To evaluate the efficacy of pulsed low-dose radiation therapy (PLRT) combined with temozolomide (TMZ) as a novel treatment approach for radioresistant glioblastoma multiforme (GBM) in a murine model." | 7.79 | Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme. ( Chunta, JL; Grills, IS; Huang, J; Krueger, SA; Lee, DY; Marples, B; Martinez, AA; Park, SS; Wilson, GD, 2013) |
| "Addition of temozolomide (TMZ) to radiation therapy is the standard treatment for patients with glioblastoma (GBM)." | 7.79 | Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging. ( Faber, C; Jacobs, AH; Kopka, K; Kuhlmann, M; Schäfers, M; Schelhaas, S; Schwegmann, K; Viel, T; Wachsmuth, L; Wagner, S, 2013) |
| " Such chemoresistance was overcome by apparently noncytotoxic doses of temozolomide, which chemosensitized glioblastoma cells to doxorubicin, vinblastine, and etoposide." | 7.79 | Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway. ( Annovazzi, L; Bosia, A; Caldera, V; Campia, I; Ghigo, D; Kopecka, J; Mellai, M; Riganti, C; Salaroglio, IC; Schiffer, D, 2013) |
| "Radiotherapy with concomitant and adjuvant temozolomide (six cycles) is the standard treatment after surgery in glioblastoma patients." | 7.79 | Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. ( Baumann, C; Beauchesne, P; Blonski, M; Chauffert, B; Darlix, A; Ghiringhelli, F; Lorgis, V; Pinelli, C; Rech, F; Taillandier, L; Zouaoui, S, 2013) |
| "The objective of this work was to determine the cost-effectiveness of temozolomide compared with that of radiotherapy alone in the adjuvant treatment of newly diagnosed glioblastoma." | 7.79 | The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. ( Hay, JW; Messali, A; Villacorta, R, 2013) |
| "The major cytotoxic DNA adduct induced by temozolomide and other methylating agents used in malignant glioma and metastasized melanoma therapy is O(6)-methylguanine (O(6)-MeG)." | 7.79 | Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide. ( Eich, M; Kaina, B; Nikolova, T; Roos, WP, 2013) |
| " Temozolomide (TMZ) with radiation is the most frequently used first-line treatment for patients with glioblastoma, the most common and aggressive form of primary brain cancer in adults." | 7.79 | Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. ( Espinoza, FL; Gruber, HE; Gunzburg, W; Hlavaty, J; Huang, TT; Ibañez, CE; Jolly, DJ; Kasahara, N; Martin, B; Ostertag, D; Pertschuk, D; Petznek, H; Robbins, JM; Rodriguez-Aguirre, M, 2013) |
| "Temozolomide (TMZ) during and after radiotherapy (RT) is recommended for patients with newly diagnosed glioblastoma (GBM)." | 7.79 | Glioblastoma management in the temozolomide era: have we improved outcome? ( Al-Zahrani, A; Atenafu, E; Laperriere, N; Lwin, Z; MacFadden, D; Mason, WP; Menard, C; Miller, BA; Sahgal, A, 2013) |
| "The effect of concomitant and adjuvant temozolomide in glioblastoma patients above the age of 65 years lacks evidence." | 7.79 | Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients. ( Behm, T; Bock, HC; Horowski, A; Mielke, D; Rohde, V; Schneider, S; Stockhammer, F, 2013) |
| "The goal of the present study was to compare the efficacy of treatment with irradiation (IR), temozolomide, and quercetin, alone, or in combinations, on 2 glioblastoma cell lines, DBTRG-05 and U-251." | 7.79 | Quercetin increases the efficacy of glioblastoma treatment compared to standard chemoradiotherapy by the suppression of PI-3-kinase-Akt pathway. ( Bellyei, S; Boronkai, A; Cseh, A; Hocsak, E; Pozsgai, E; Racz, B; Sumegi, B; Szabo, A, 2013) |
| "In 2005, maximum safe surgical resection, followed by radiotherapy with concomitant temozolomide (TMZ), followed by adjuvant TMZ became the standard of care for glioblastoma (GBM)." | 7.79 | Time trends in glioblastoma multiforme survival: the role of temozolomide. ( Darefsky, AS; Dubrow, R; Jacobs, DI; King, JT; Laurans, MS; Park, LS; Rose, MG, 2013) |
| "Bortezomib induced caspase-3 activation and apoptotic cell death in stable glioma cell lines and in glioma stem-like cells (GSCs) derived from malignant tumor specimens Furthermore, TMZ-resistant glioma cell lines retained susceptibility to the proteasome inhibition." | 7.79 | Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. ( Alexandru, D; Bigner, D; Bota, DA; Friedman, HS; Keir, ST; Vredenburgh, J, 2013) |
| "To examine whether adjuvant temozolomide treatment improved glioblastoma patients` survival in a large Canadian cohort." | 7.79 | Effectiveness of adjuvant temozolomide treatment in patients with glioblastoma. ( Al-Nuaimi, SK; Alnaami, IM; Gourishankar, S; Mehta, V; Murtha, AD; Senthilselvan, A; Walling, S, 2013) |
| "Although there is a relationship between DNA repair deficiency and temozolomide (TMZ) resistance in glioblastoma (GBM), it remains unclear which molecule is associated with GBM recurrence." | 7.79 | Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma. ( Arita, K; Furukawa, T; Hirano, H; Ikeda, R; Kawahara, K; Minami, K; Nishizawa, Y; Shinsato, Y; Tokimura, H; Yamamoto, M; Yonezawa, H; Yunoue, S, 2013) |
| "This study was conducted to investigate the feasibility and survival benefits of combined treatment with radiotherapy and temozolomide (TMZ), which has been covered by the national health insurance in Japanese patients with glioblastoma since September 2006." | 7.79 | Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results. ( Nagaishi, M; Nakano, T; Nakazato, Y; Noda, SE; Oike, T; Shirai, K; Sugawara, K; Suzuki, Y; Tamaki, T; Yokoo, H, 2013) |
| "To analyze initial recurrence patterns in patients with newly diagnosed glioblastoma after radiotherapy plus concurrent and adjuvant temozolomide, and to investigate cumulative recurrence patterns after salvage treatment, including surgery, stereotactic radiotherapy, and chemotherapy." | 7.79 | Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution. ( Arakawa, Y; Hiraoka, M; Miyamoto, S; Mizowaki, T; Ogura, K; Ogura, M; Sakanaka, K, 2013) |
| " Here, we report for the first time that the second mitochondria-derived activator of caspases (Smac) mimetic BV6 sensitizes glioblastoma cells toward Temozolomide (TMZ), the first-line chemotherapeutic agent in the treatment of glioblastoma." | 7.79 | Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner. ( Cristofanon, S; Debatin, KM; Deshayes, K; Fulda, S; Karl, S; Marschall, V; Vucic, D; Wagner, L; Zobel, K, 2013) |
| " We retrospectively surveyed 32 patients with GBM or GBM with oligodendroglioma component (GBMO) who underwent biopsy or maximal tumor resection followed by concurrent radiotherapy and temozolomide (TMZ)." | 7.79 | IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy. ( Houkin, K; Kamoshima, Y; Kobayashi, H; Motegi, H; Murata, J; Tanino, M; Terasaka, S; Yamaguchi, S, 2013) |
| " The aim of this study was to evaluate the cellular responses to temozolomide treatment associated with methoxyamine (blocker of base excision repair) in glioblastoma cell lines, in order to test the hypothesis that the blockage of base excision repair pathway might sensitize glioblastoma cells to temozolomide." | 7.79 | Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide. ( Montaldi, AP; Sakamoto-Hojo, ET, 2013) |
| "We investigated whether high levels of activated mitogen-activated protein kinase (p-MAPK) were associated with poor survival among patients with newly diagnosed glioblastoma during the temozolomide era." | 7.79 | High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era. ( Bannykh, SI; Black, KL; Carico, C; Dantis, J; Elramsisy, A; Fan, X; Hu, J; Mukherjee, D; Nuño, M; Patil, CG; Yu, JS, 2013) |
| " This study aimed to investigate the possible mechanism of mutant TP53 inducing temozolomide resistance in glioblastoma cells." | 7.79 | Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase. ( Chen, JX; Liu, YH; Mao, Q; Wang, X; You, C, 2013) |
| "To compare survival and hematological toxicity rates between two postoperative therapy regimens in patients with primary glioblastoma (GBM), namely temozolomide (TMZ) concomitant to radiation, followed by adjuvant TMZ, versus adjuvant TMZ after radiation only." | 7.79 | Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis. ( Bock, HC; Brück, W; Giese, A; Gutenberg, A; Reifenberger, G, 2013) |
| "For elderly patients with glioblastoma multiforme (GBM), radiotherapy plus concomitant and adjuvant temozolomide has resulted in longer survival." | 7.79 | Performance status during and after radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme. ( Jang, WY; Jeong, EH; Jung, S; Jung, TY; Kim, IY; Lee, JH; Moon, KS, 2013) |
| "To evaluate pathologically confirmed incidence of pseudoprogression and its impact on survival in glioblastoma multiforme (GBM) patients treated with radiotherapy and concurrent temozolomide (TMZ), followed by 6 months of TMZ maintenance therapy." | 7.78 | Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide. ( Oymak, E; Parlak, C; Pehlivan, B; Topkan, E; Topuk, S, 2012) |
| "We report retrospective data on the feasibility and efficacy of prolonging adjuvant temozolomide (TMZ) more than 6 months after chemoradiotherapy completion in patients with glioblastoma (GBM)." | 7.78 | Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. ( Auberdiac, P; Cartier, L; Chargari, C; Forest, F; Fotso, MJ; Magné, N; Malkoun, N; Nuti, C; Pacaut, C; Peoc'h, M; Schmitt, T; Thorin, J, 2012) |
| " Temozolomide (TMZ) is a promising chemotherapeutic agent for treating glioblastomas." | 7.78 | MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. ( Feng, K; Fu, Z; Shi, L; Wan, Y; Wang, Y; Wang, Z; Wu, F; Yan, W; You, Y; Zhang, J; Zhang, S, 2012) |
| "The standard-of-care treatment for newly diagnosed glioblastoma changed in 2005, when radiation therapy plus temozolomide chemotherapy replaced radiation therapy alone." | 7.78 | Glioblastoma survival in the United States before and during the temozolomide era. ( Johnson, DR; O'Neill, BP, 2012) |
| "To determine the maximum-tolerated dose (MTD) of radiation (RT) with concurrent temozolomide in patients with newly diagnosed glioblastoma (GBM), to estimate their progression-free (PFS) and overall survival (OS), and to assess the role of (11)C methionine PET (MET-PET) imaging in predicting recurrence." | 7.78 | Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. ( Brown, D; Cao, Y; Chenevert, T; Gomez-Hassan, D; Heth, J; Junck, L; Lawrence, T; Normolle, D; Piert, M; Schipper, M; Ten Haken, RK; Tsien, CI, 2012) |
| "Two glioblastoma multiforme patients underwent (18)F-FMISO (fluoromisonidazole) positron emission tomography study to access the tumor oxygenation status before and immediately after fractionated radiotherapy concomitant with temozolomide chemotherapy." | 7.78 | Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: changes defined by 18F-fluoromisonidazole positron emission tomography: two case reports. ( Aoyama, H; Hirata, K; Houkin, K; Kobayashi, H; Murata, J; Narita, T; Onodera, S; Shiga, T; Tanaka, S; Terasaka, S, 2012) |
| "The standard of care for newly diagnosed glioblastoma multiforme (GBM) is temozolomide (TMZ) chemotherapy given concurrently with radiation for 6 weeks followed by 6 months of adjuvant TMZ." | 7.78 | Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. ( Easaw, JC; Roldán Urgoiti, GB; Singh, AD, 2012) |
| "Alkylating agents, such as temozolomide (TMZ) and fotemustine (FTM) are widely used in recurrent glioblastoma (GBM) regimes." | 7.78 | Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma. ( Burattini, L; Cascinu, S; Onofri, A; Paccapelo, A; Santoni, M, 2012) |
| " The present study was to investigate the impact of resveratrol on the antitumor effects of temozolomide (TMZ), a standard treatment regiment of glioblastoma (GBM), in vitro and in vivo." | 7.78 | Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway. ( Guo, RB; Hu, G; Sun, XL; Xue, X; Yuan, Y, 2012) |
| "Interferon-beta (IFN-β) is reported to augment anti-tumor effects by temozolomide in glioblastoma via down-regulation of MGMT." | 7.78 | Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma. ( Hara, K; Kageji, T; Kitazato, KT; Kuwayama, K; Matsuzaki, K; Mizobuchi, Y; Morigaki, R; Mure, H; Nagahiro, S; Okazaki, T, 2012) |
| "The effectiveness of temozolomide (TMZ) dosing schemes and the "rechallenge" of recurrent glioblastoma (GBM) with TMZ are controversial." | 7.78 | Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines. ( Beier, CP; Beier, D; Brawanski, K; Hau, P; Schriefer, B; Schulz, JB; Weis, J, 2012) |
| "Temozolomide (TMZ) is an alkylating chemotherapeutic agent that prolongs the survival of patients with glioblastoma." | 7.78 | Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. ( Florea, AM; Happold, C; Reifenberger, G; Roth, P; Schmidt, N; Silginer, M; Weller, M; Wick, W, 2012) |
| "Radiotherapy plus concomitant and adjuvant temozolomide (RCAT) is now standard treatment for grade IV glioblastoma (GBM)." | 7.78 | Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival. ( Hargreaves, S; Kooner, I; Liu, ZW; Menashy, R; Michalarea, V; Williams, M; Wilson, E; Woolf, D, 2012) |
| "The combination of hyperbaric oxygen with temozolomide produced an important reduction in glioma growth and effective approach to the treatment of glioblastoma." | 7.78 | Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model. ( Bilir, A; Bozkurt, ER; Dagıstan, Y; Karaca, I; Ozar, E; Toklu, A; Yagmurlu, K, 2012) |
| "The therapeutic benefit of temozolomide in glioblastoma multiforme (GBM) is limited by resistance." | 7.78 | Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. ( Carlson, BL; Cen, L; Decker, PA; Gupta, SK; Kitange, GJ; Lomberk, GA; Mladek, AC; Pokorny, JL; Sarkaria, JN; Schroeder, MA; Urrutia, RA; Wu, W, 2012) |
| " In the present study, temozolomide (TMZ) triggered loss of K(+)(i) and Cl(-)(i) and AVD in primary glioblastoma multiforme (GBM) cancer cells (GC) and GC cancer stem cells (GSC)." | 7.78 | Inhibition of Na(+)-K(+)-2Cl(-) cotransporter isoform 1 accelerates temozolomide-mediated apoptosis in glioblastoma cancer cells. ( Algharabil, J; Begum, G; Clark, PA; Kahle, KT; Kintner, DB; Kuo, JS; Lin, SH; Sun, D; Wang, Q; Yang, SS, 2012) |
| "Temozolomide (TMZ) is standard chemotherapy for glioblastoma multiforme (GBM)." | 7.78 | Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide. ( Fung, CF; Lee, D; Lee, NP; Leung, GK; Lui, WM; Pu, JK; Sun, S; Wong, ST, 2012) |
| "The effect of temozolomide (TMZ) and radiotherapy (RT) in the treatment of glioblastoma multiforme (GBM) has been well documented in randomized controlled trials." | 7.78 | A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. ( Helseth, E; Johannesen, TB; Meling, TR; Rønning, PA, 2012) |
| "Temozolomide (TMZ) is the primary chemotherapeutic agent for treatment of glioblastoma multiforme (GBM) yet it has a fast rate of degradation under physiological conditions to the 'active' MTIC, which has poor penetration of the blood-brain barrier and cellular absorption." | 7.78 | Enhanced stability and activity of temozolomide in primary glioblastoma multiforme cells with cucurbit[n]uril. ( Appel, EA; Heywood, RM; Loh, XJ; Rowland, MJ; Scherman, OA; Watts, C, 2012) |
| "Treatment of patients with glioblastoma improved dramatically when concomitant and adjuvant temozolomide was added to external radiation therapy." | 7.78 | A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma. ( Bergqvist, M; Bergström, S; Blomquist, E; Ekman, S; Henriksson, R; Johansson, F, 2012) |
| "Implementation of chemotherapy with the drug temozolomide increased the overall survival of patients with glioblastoma multiforme (GBM; WHO grade IV), in particular when the O(6)-methylguanine DNA methyltransferase (MGMT) promoter is epigenetically silenced." | 7.78 | Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma. ( Beier, CP; Bettstetter, M; Gempt, J; Hoepner, I; Koeritzer, J; Meyer, B; Rasper, M; Ringel, F; Schäfer, A; Schlegel, J; Schmidt-Graf, F; Teufel, J, 2012) |
| "To investigate the new mechanism of temozolomide (TMZ) induced anti-tumor effects on glioblastoma cells in vitro." | 7.78 | [Mechanism of temozolomide-induced anti-tumor effects on glioblastoma cells in vitro is via ROS-dependent SIRT1 signaling pathway]. ( Jiang, Y; Sun, Y; Yuan, Y, 2012) |
| "We analyzed 62 consecutive patients with newly diagnosed glioblastoma treated between 2006 and 2008 with standard fractionation to a total dose of 60 Gy with concurrent temozolomide (97%) or arsenic trioxide (3%)." | 7.77 | Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. ( Crocker, IR; Curran, WJ; McDonald, MW; Shu, HK, 2011) |
| "To evaluate the safety and efficacy of hypofractionated radiotherapy (RT) with a standard temozolomide (TMZ) regimen for adults with newly diagnosed glioblastoma multiforme (GBM), twenty-six consecutive adults (range 39-79 years) who met our enrollment criteria received short courses of hypofractionated RT (45 Gy in 15 fractions over three weeks) with concomitant TMZ at 75 mg/m(2)/d." | 7.77 | A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme. ( Eto, T; Nakashima, S; Ogo, E; Okada, Y; Shigemori, M; Sugita, Y; Terasaki, M; Tokutomi, T, 2011) |
| " A 56-year-old man with a left parietal glioblastoma was treated with resection, radiation and concomitant and adjuvant temozolomide chemotherapy." | 7.77 | Kitten-transmitted Bordetella bronchiseptica infection in a patient receiving temozolomide for glioblastoma. ( Grommes, C; Papanicolaou, G; Redelman-Sidi, G, 2011) |
| "Temozolomide in combination with radiation has been in use for more than 5 years for the therapy of glioblastoma." | 7.77 | Hepatic encephalopathy after treatment with temozolomide. ( Goldbecker, A; Herrmann, J; Raab, P; Tryc, AB; Weissenborn, K; Worthmann, H, 2011) |
| "Patients with non-resectable glioblastoma generally exhibit a poor prognosis, even after radiotherapy plus concomitant and adjuvant temozolomide (XRT/TMZ→TMZ)." | 7.77 | Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide. ( Belka, C; Eigenbrod, S; Grasbon-Frodl, EM; Kreth, FW; Kreth, S; Kretzschmar, HA; Lutz, J; Popperl, G; Thon, N; Tonn, JC, 2011) |
| "The aim of this paper is to evaluate the efficacy of fractionated stereotactic radiotherapy (FSRT) and concomitant temozolomide (TMZ) as a salvage treatment option in patients with recurrent glioblastoma (GBM)." | 7.77 | Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. ( Armosini, V; Caporello, P; Lanzetta, G; Maurizi, RE; Mei, M; Minniti, G; Osti, MF; Salvati, M, 2011) |
| "The alkylating agent temozolomide, in combination with surgery and radiation, is the current standard of care for patients with glioblastoma." | 7.77 | Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. ( Chen, TC; Golden, EB; Hofman, FM; Louie, SG; Schönthal, AH; Sivakumar, W; Thomas, S; Wang, W, 2011) |
| "Concomitant radiation therapy (RT) and temozolomide (TMZ) therapy after surgery is the standard treatment for glioblastoma multiforme (GBM)." | 7.77 | Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. ( Côté, AL; Ernstoff, MS; Fadul, CE; Fisher, JL; Gui, J; Hampton, TH, 2011) |
| "We investigated the molecular mechanisms underlying the cytotoxic effect of Temozolomide (TMZ) in both O(6)-methylguanine-DNA methyl transferase (MGMT) depleted as well as undepleted glioblastoma cell lines." | 7.77 | Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells. ( Brunetti, E; Bucci, B; D'agnano, I; De Paula, U; De Salvo, M; Gagliassi, R; Marchese, R; Maresca, G; Raza, GH; Stigliano, A, 2011) |
| "Temozolomide has significantly improved the outcome of patients with glioblastoma." | 7.77 | [Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma]. ( Auberdiac, P; Cartier, L; Chargari, C; Forest, F; Fotso, MJ; Magné, N; Malkoun, N; Nuti, C; Pacaut, C; Peoc'h, M; Schmitt, T; Thorin, J, 2011) |
| "Temozolomide (TMZ), an alkylating agent widely used for patients with glioblastoma multiforme (GBM), has the potential to enhance the acquired immune response to GBM." | 7.77 | Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - . ( Enomoto, T; Ishikawa, E; Matsumura, A; Morishita, Y; Nakai, K; Ohno, T; Sakamoto, N; Sato, M; Satomi, K; Takano, S; Tsuboi, K; Yamamoto, T, 2011) |
| "To report pancytopenia caused by temozolomide, a second-generation alkylating agent." | 7.77 | Another cause of pancytopenia in a patient receiving temozolomide. ( Camci, C; Dirier, A; Kalender, ME; Pehlivan, Y; Sevinc, A; Turkbeyler, IH, 2011) |
| "Here we investigate the effects of the novel transforming growth factor-β receptor I (TGF-βRI) serine/threonine kinase inhibitor LY2109761 on glioblastoma when combined with the present clinical standard combination regimen radiotherapy and temozolomide (TMZ)." | 7.77 | Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761. ( Han, N; Hauser, K; Herion, TW; Huber, PE; Lahn, M; Peschke, P; Timke, C; Weber, KJ; Wirkner, U; Zhang, M, 2011) |
| "The goal of this study was to evaluate accelerated radiotherapy with and without temozolomide (TMZ) for glioblastoma multiforme (GBM)." | 7.77 | Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme. ( Buttmann, M; Flentje, M; Guckenberger, M; Mayer, M; Sweeney, RA; Vince, GH, 2011) |
| "Overcoming the resistance of glioblastoma cells against temozolomide, the first-line chemotherapeutic agent of choice for newly diagnosed glioblastoma, is a major therapeutic challenge in the management of this deadly brain tumor." | 7.77 | MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis. ( Kayama, T; Kitanaka, C; Matsuda, K; Sato, A; Seino, S; Sunayama, J; Suzuki, K; Tachibana, K; Tomiyama, A; Watanabe, E, 2011) |
| "A 61-year-old man with glioblastoma and positive for hepatitis B surface antigen (HBsAg) developed acute hepatitis due to hepatitis B virus (HBV) reactivation after concomitant postoperative treatment with temozolomide (75 mg/m(2)/day) and radiation therapy (60 Gy in 30 fractions)." | 7.77 | Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide--case report. ( Kayama, T; Miyakita, Y; Narita, Y; Ohno, M; Shibui, S; Ueno, H, 2011) |
| "The objective of this retrospective analysis was to assess long-term outcome and prognostic factors of unselected patients treated for glioblastoma (GB) at a single center with surgery, standard radiotherapy (RT), and concomitant temozolomide (TMZ)." | 7.77 | Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution. ( Franz, K; Gerstein, J; Rödel, C; Seifert, V; Steinbach, JP; Weiss, C, 2011) |
| "To evaluate the incidence and impact of early post-chemoradiation (cRT) 'pseudoprogression' (PsPD) amongst glioblastoma multiforme (GBM) patients treated with the current standard of care - 60 Gy conformal radiotherapy with concurrent low-dose temozolomide, followed by six cycles of high-dose temozolomide (the 'Stupp protocol')." | 7.77 | Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis. ( Gunjur, A; Lau, E; Ryan, G; Taouk, Y, 2011) |
| "The aim of this study was to evaluate cognitive functioning in newly-diagnosed glioblastoma multiforme (GBM) patients during treatment with radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ)." | 7.76 | Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings. ( Bosma, I; Buter, J; Heimans, JJ; Hilverda, K; Klein, M; Peter Vandertop, W; Postma, TJ; Reijneveld, JC; Slotman, BJ, 2010) |
| "Concomitant daily temozolomide and radiation followed by adjuvant temozolomide is a tolerable and reasonable treatment option and has a good performance status for elderly patients diagnosed with glioblastoma." | 7.76 | Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme? ( Collichio, F; Ewend, MG; Grabowski, S; Kimple, RJ; Morris, DE; Papez, M, 2010) |
| "We present two patients with glioblastoma with an unusually stable clinical course and long-term survival who were treated after surgery and radiotherapy with adjuvant temozolomide (TMZ) chemotherapy for 17 and 20 cycles, respectively." | 7.76 | Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. ( Backes, H; Brunn, A; Burghaus, L; Galldiks, N; Heiss, WD; Jacobs, AH; Kracht, LW; Ullrich, RT, 2010) |
| "O(6)-Methylguanine DNA methyltransferase (MGMT) is implicated as a major predictive factor for treatment response to alkylating agents including temozolomide (TMZ) of glioblastoma multiforme (GBM) patients." | 7.76 | O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. ( Berger, W; Buchroithner, J; Filipits, M; Fischer, J; Lötsch, D; Micksche, M; Pichler, J; Pirker, C; Silye, R; Spiegl-Kreinecker, S; Weis, S, 2010) |
| "One hundred and fourteen patients with glioblastoma multiforme received a median of 6 cycles of adjuvant first-line temozolomide (range 1-57)." | 7.76 | Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution. ( Freyschlag, CF; Krafft, U; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F, 2010) |
| "To determine recurrence patterns of glioblastoma treated with temozolomide-based chemoradiation." | 7.76 | Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. ( Donatello, RS; Korones, DN; Milano, MT; Mohile, NA; Okunieff, P; Sul, J; Walter, KA, 2010) |
| "Treatment for glioblastoma multiforme includes the alkylating agent temozolomide combined with ionizing radiation." | 7.76 | Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. ( Bradshaw, TD; Laughton, CA; Madhusudan, S; Stevens, MF; Zhang, J, 2010) |
| "Novel agents are currently combined with radiation and temozolomide (RT + TMZ) in newly diagnosed glioblastoma using overall survival as the primary end point." | 7.76 | Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. ( Desideri, S; Fisher, J; Grossman, SA; Nabors, LB; Piantadosi, S; Rosenfeld, M; Ye, X, 2010) |
| "To identify microRNAs (miRNAs) specifically involved in the acquisition of temozolomide (TMZ) resistance in glioblastoma multiforme (GBM), we first established a resistant variant, U251R cells from TMZ-sensitive GBM cell line, U251MG." | 7.76 | miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. ( Hayashi, K; Kamada, K; Matsuo, T; Matsuse, M; Mitsutake, N; Nagata, I; Saenko, V; Suzuki, K; Takakura, S; Ujifuku, K; Yamashita, S, 2010) |
| "Concurrent treatment with the methylating agent temozolomide during radiotherapy has yielded the first significant improvement in the survival of adult glioblastomas (GBM) in the last three decades." | 7.76 | Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression. ( Blank, A; Bobola, MS; Kolstoe, DD; Silber, JR, 2010) |
| "To evaluate perfusion parameter changes in patients with glioblastoma multiforme by comparing the perfusion magnetic resonance (MR) imaging measurements obtained before combined radiation and temozolomide therapy (RT-TMZ) with the follow-up MR imaging measurements obtained 1 month after completion of this treatment." | 7.76 | Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. ( Ekholm, SE; Korones, DN; Mangla, R; Milano, MT; Singh, G; Zhong, J; Ziegelitz, D, 2010) |
| "O(6)-methylguanine-DNA methyltransferase (MGMT) expression in glioblastoma correlates with temozolomide resistance." | 7.76 | Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival. ( Donze, J; Liu, L; McGraw, M; Palomo, JM; Rahmathulla, G; Robinson, CG; Vogelbaum, MA, 2010) |
| "Standard treatment of glioblastoma multiforme consists of postoperative radiochemotherapy with temozolomide, followed by a 6-month chemotherapy." | 7.76 | Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide. ( Kopecký, J; Kopecký, O; Macingova, Z; Petera, J; Priester, P; Slovácek, L, 2010) |
| "We report a case of prolonged survival in a patient with cervical intramedullary glioblastoma multiforme (GBM) treated with total resection, radiotherapy, and temozolomide." | 7.76 | Prolonged survival of a patient with cervical intramedullary glioblastoma multiforme treated with total resection, radiation therapy, and temozolomide. ( Huang, CY; Kuo, LT; Lien, HC; Liu, KL; Liu, MT; Tseng, HM, 2010) |
| "The addition of temozolomide (TMZ) to radiotherapy (RT) improves survival of patients with glioblastoma (GB) when compared to postoperative RT alone in patients up to 65 years of age." | 7.76 | Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. ( Franz, K; Fraunholz, I; Gerstein, J; Rödel, C; Seifert, V; Steinbach, JP; Weiss, C, 2010) |
| "To analyze the recurrence patterns in patients with newly diagnosed glioblastoma (GBM) treated with conformal radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ), and to compare the patterns of failure according to different target volume delineations." | 7.76 | Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. ( Amelio, D; Amichetti, M; Arcella, A; Bozzao, A; Enrici, RM; Lanzetta, G; Minniti, G; Muni, R; Salvati, M; Scarpino, S, 2010) |
| "Methylating drugs such as temozolomide (TMZ) are widely used in the treatment of brain tumors including malignant glioblastoma." | 7.76 | Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. ( Jin, YH; Liu, HY; Shu, F; Wang, QJ; Wang, Z; Yang, Y; Zhang, WB, 2010) |
| "The case of a 63 year old woman with glioblastoma multiforme and concomitant radiochemotherapy with temozolomide is described." | 7.76 | Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report. ( Bartels, C; Brueggemann, I; Elolf, E; Gademann, G; Galazky, I; Prox-Vagedes, V; Schreiber, S, 2010) |
| "Sensitivity to temozolomide is restricted to a subset of glioblastoma patients, with the major determinant of resistance being a lack of promoter methylation of the gene encoding the repair protein DNA methyltransferase MGMT, although other mechanisms are thought to be active." | 7.76 | MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. ( Bax, DA; Gaspar, N; Hargrave, D; Jones, C; Little, SE; Marshall, L; Pearson, AD; Perryman, L; Reis, RM; Sharp, SY; Vassal, G; Viana-Pereira, M; Workman, P, 2010) |
| " This case report documents an adolescent harboring brain stem glioblastoma who had complete radiological response to temozolomide after partial tumor resection and survived for more than 3 years." | 7.76 | Temozolomide for adult brain stem glioblastoma: case report of a long-term survivor. ( Chen, Z; Mao, Y; Wang, Y; Wu, J; Yao, Y; Zhang, C; Zhou, L, 2010) |
| "Concurrent temozolomide (TMZ) and radiotherapy became the new standard of care for patients diagnosed with glioblastoma multiforme (GBM)." | 7.76 | Pseudoprogression following concurrent temozolomide and radiotherapy in a patient with glioblastoma: findings on functional imaging techniques. ( Abe, K; Amano, T; Hiwatashi, A; Honda, H; Kamano, H; Nakamizo, A; Shioyama, Y; Shirakawa, Y; Suzuki, S; Torisu, R; Yamashita, K; Yoshimoto, K; Yoshiura, T, 2010) |
| "Some patients with glioblastoma multiform do not respond to temozolomide even though they have aberrant promoter methylation of the DNA repair enzyme O(6)-methylguanine methyltransferase (MGMT)." | 7.75 | A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. ( Dill, C; Ehninger, G; Illmer, T; Kestel, L; Kramer, M; Krex, D; Pfirrmann, M; Robel, K; Schackert, G; Schaich, M, 2009) |
| "Temozolomide (TMZ)-based therapy is the standard of care for patients with glioblastoma multiforme (GBM), and resistance to this drug in GBM is modulated by the DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT)." | 7.75 | Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. ( Carlson, BL; Decker, PA; Grogan, PT; James, CD; Kitange, GJ; Lamont, JD; Sarkaria, JN; Schroeder, MA; Wu, W, 2009) |
| "CpG methylation within the O6-methylguanine-DNA-methyltransferase (MGMT) promoter is associated with enhanced survival of glioblastoma multiforme (GBM) patients treated with temozolomide (TMZ)." | 7.75 | Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. ( Ballman, KV; Buckner, JC; Carlson, BL; Decker, PA; Giannini, C; Grogan, PT; James, CD; Kitange, GJ; Mladek, AC; Sarkaria, JN; Schroeder, MA; Wu, W, 2009) |
| "We report a case of a 51-year-old woman with newly diagnosed glioblastoma multiforme (GBM) who was treated with surgery followed by the standard concomitant temozolomide (TMZ) and radiotherapy (RT)." | 7.75 | Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status. ( Fujioka, Y; Homori, M; Kurita, H; Miyazaki, H; Nagane, M; Nozue, K; Shimizu, S; Shiokawa, Y; Waha, A, 2009) |
| "Gliadel (BCNU) wafer and concomitant temozolomide (TMZ) therapy, when used individually as adjuvant therapies, extend survival from that achieved by resection and radiation therapy (XRT) for glioblastoma multiforme (GBM)." | 7.75 | Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. ( Attenello, FJ; Brem, H; Chaichana, KL; Grossman, SA; Kleinberg, LR; Laterra, J; McGirt, MJ; Olivi, A; Quiñones-Hinojosa, A; Than, KD; Weingart, JD, 2009) |
| "Early radionecrosis after the Stupp protocol is not a rare event due to the radiosensitization effect of temozolomide." | 7.75 | Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? ( Del Basso De Caro, ML; Elefante, A; Giamundo, A; Maiuri, F; Mariniello, G; Pacelli, R; Peca, C; Vergara, P, 2009) |
| "Temozolomide, used for anaplastic gliomas and glioblastoma multiforme, is an oral drug that is stable under acidic, but labile under neutral and basic conditions." | 7.75 | Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery. ( Beumer, JH; Egorin, MJ; Park, DM; Shah, DD, 2009) |
| "Resistance to temozolomide and radiotherapy is a major problem for patients with glioblastoma but may be overcome using the poly(ADP-ribose) polymerase inhibitor ABT-888." | 7.75 | Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. ( Carlson, BL; Clarke, MJ; Curtin, NJ; Decker, PA; Grogan, PT; Lou, Z; Mladek, AC; Mulligan, EA; Plummer, ER; Sarkaria, JN; Schroeder, MA; Wu, W, 2009) |
| "The aim of the present study was to evaluate factors predicting the recurrence pattern after the administration of temozolomide (TMZ), initially concurrent with radiotherapy (RT) and subsequently as maintenance therapy, which has become standard treatment for patients with newly diagnosed glioblastoma (GBM)." | 7.75 | Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. ( Amistà, P; Brandes, AA; Ermani, M; Franceschi, E; Frezza, G; Morandi, L; Sotti, G; Spagnolli, F; Tosoni, A, 2009) |
| "To evaluate long-term survival in a prospective series of patients newly diagnosed with glioblastoma and treated with a combination of lomustine (CCNU), temozolomide (TMZ), and radiotherapy." | 7.75 | Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. ( Bähr, O; Glas, M; Happold, C; Herrlinger, U; Kortmann, RD; Reifenberger, G; Rieger, J; Steinbach, JP; Weller, M; Wick, W; Wiewrodt, D, 2009) |
| "To investigate the cytotoxic effect of high linear-energy transfer (LET) carbon irradiation on glioblastoma cells lines in combination with temozolomide (TMZ)." | 7.75 | Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines. ( Bohl, J; Combs, SE; Debus, J; Elsasser, T; Schulz-Ertner, D; Weber, KJ; Weyrather, WK, 2009) |
| "Temozolomide (TMZ) is an alkylating agent used in the management of gliomas." | 7.75 | Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? ( Bell, D; Khasraw, M; Wheeler, H, 2009) |
| " Using multiparameter cytometry we explored effects of etoposide and temozolomide (TMZ) on three glioblastoma cell lines with different p53 status (A172, T98G, YKG-1) and on normal human astrocytes (NHA) correlating the drug-induced phosphorylated H2AX (gammaH2AX) with cell cycle phase and induction of apoptosis." | 7.75 | Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide. ( Darzynkiewicz, Z; Kurose, A; Ogasawara, K; Ogawa, A; Sato, Y; Sawai, T; Traganos, F, 2009) |
| "A 46-year-old man developed Stevens-Johnson syndrome and toxic epidermal necrolysis overlap, with severe localized denudation of the skin on the head and neck, following radiotherapy and oral temozolomide therapy for cranial glioblastoma multiforme." | 7.75 | Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy. ( Sarma, N, 2009) |
| "A recent randomized study conducted on newly diagnosed glioblastoma (GBM) patients demonstrated that concomitant and adjuvant temozolomide added to standard radiotherapy had a survival advantage compared with radiotherapy alone." | 7.75 | Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. ( Agati, R; Bacci, A; Benevento, F; Brandes, AA; Calbucci, F; Ermani, M; Franceschi, E; Mazzocchi, V; Scopece, L; Tosoni, A, 2009) |
| "To perform a systematic review on the costs and cost-effectiveness of concomitant and adjuvant temozolomide with radiotherapy for the treatment of newly diagnosed glioblastoma compared with initial radiotherapy alone." | 7.75 | Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. ( Stupp, R; Uyl-de Groot, CA; van der Bent, M, 2009) |
| " This study aimed to determine the resistant phenotype of glioblastoma stem cells (GSCs) to temozolomide (TMZ) and to explore the possible molecular mechanisms underlying TMZ resistance." | 7.75 | Glioblastoma stem cells resistant to temozolomide-induced autophagy. ( Chen, FR; Chen, ZP; Fu, J; Liu, XM; Liu, ZG; Ng, HK; Pangjesse, CS; Shi, HL, 2009) |
| "Over the past few years, the alkylating agent temozolomide has become the standard-of-care therapy for patients with glioblastoma, the most common brain tumor." | 7.75 | MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. ( Aldape, K; Cahill, DP; Iafrate, AJ; Louis, DN; Miao, J; Nutt, CL; Yip, S, 2009) |
| " Current standard therapy in the treatment of glioblastoma multiforme (GBM) is a combination of surgery, radiation, and chemotherapy using the drug temozolomide (TMZ)." | 7.75 | A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. ( Bektas, M; Bigner, DD; Friedman, HS; Johnson, SP; Poe, WE, 2009) |
| "Concurrent temozolomide (TMZ) and radiation therapy (RT) followed by adjuvant TMZ is standard treatment for patients with glioblastoma multiforme (GBM), although the relative contribution of concurrent versus adjuvant TMZ is unknown." | 7.75 | Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. ( Ballman, KA; Carlson, BL; Decker, PA; Giannini, C; Grogan, PT; James, CD; Kitange, GJ; Mladek, AC; Sarkaria, JN; Schroeder, MA; Wu, W, 2009) |
| "Although high AGT levels may mediate resistance in a portion of these samples, MMR deficiency does not seem to be responsible for mediating temozolomide resistance in adult malignant glioma." | 7.74 | Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. ( Ali-Osman, F; Bigner, DD; Friedman, AH; Friedman, HS; Horne, KS; Johnson, SP; Lister, DW; Maxwell, JA; McLendon, RE; Modrich, PL; Quinn, JA; Rasheed, A, 2008) |
| " Convection-enhanced delivery (CED) of either the replication-defective, ICP0-producing HSV-1 mutant, d106, or the recombinant d109, devoid of all viral genome expression, was performed to determine the in vivo efficacy of ICP0 in combination with ionizing radiation (IR) or systemic temozolomide (TMZ) in the treatment of glioblastoma multiforme (GBM)." | 7.74 | Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery. ( Deluca, NA; Fellows-Mayle, W; Hadjipanayis, CG, 2008) |
| "In this study, we investigated the precursor and active forms of a p53 small-molecule inhibitor for their effects on temozolomide (TMZ) antitumor activity against glioblastoma (GBM), using both in vitro and in vivo experimental approaches." | 7.74 | p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. ( Berger, MS; Dinca, EB; Haas-Kogan, DA; James, CD; Lu, KV; Pieper, RO; Prados, MD; Sarkaria, JN; Vandenberg, SR, 2008) |
| "Glioblastoma patients undergoing treatment with surgery followed by radiation and temozolomide chemotherapy often develop a state of immunosuppression and are at risk for opportunistic infections and reactivation of hepatitis and herpes viruses." | 7.74 | Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. ( Hoorens, A; Neyns, B; Stupp, R, 2008) |
| " This epigenetic modification has been associated with a favorable prognosis in adult patients with glioblastoma (GBM) who receive temozolomide and other alkylating agents." | 7.74 | MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. ( Addo-Yobo, SO; Donson, AM; Foreman, NK; Gore, L; Handler, MH, 2007) |
| "Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival." | 7.74 | Fatal outcome related to carmustine implants in glioblastoma multiforme. ( Barcia, JA; Barcia-Mariño, C; Gallego, JM, 2007) |
| "Glioblastomas are treated by surgical resection followed by radiotherapy [X-ray therapy (XRT)] and the alkylating chemotherapeutic agent temozolomide." | 7.74 | Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. ( Batchelor, TT; Betensky, RA; Cahill, DP; Codd, PJ; Curry, WT; Futreal, PA; Iafrate, AJ; Levine, KK; Louis, DN; Reavie, LB; Romany, CA; Stratton, MR, 2007) |
| "We report the case of a 30-year-old woman with glioblastoma multiforme (GBM) treated with surgery followed by concomitant Temozolomide (TMZ) and external beam radiation, which she tolerated well without any interruptions." | 7.74 | Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide. ( Gujral, S; Jalali, R; Menon, H; Singh, P, 2007) |
| "The use of adjuvant temozolomide (TMZ) in patients managed with surgery and adjuvant radiation therapy (RT) for glioblastoma multiforme (GBM) has been demonstrated to improve median and 2-year survival in a recent large international multicentre study." | 7.74 | Improved median survival for glioblastoma multiforme following introduction of adjuvant temozolomide chemotherapy. ( Ang, EL; Back, MF; Chan, SP; Lim, CC; Ng, WH; See, SJ; Yeo, TT, 2007) |
| "To investigate the radiosensitizing potential of temozolomide (TMZ) for human glioblastoma multiforme (GBM) cell lines using single-dose and fractionated gamma-irradiation." | 7.74 | Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. ( Hulsebos, TJ; Lafleur, MV; Leenstra, S; Slotman, BJ; Sminia, P; Stalpers, LJ; van den Berg, J; van Nifterik, KA, 2007) |
| "To evaluate efficacy and toxicity in elderly patients with glioblastoma multiforme (GBM) treated with postoperative radiochemotherapy with temozolomide (TMZ)." | 7.74 | Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. ( Bischof, M; Combs, SE; Debus, J; Schulz-Ertner, D; Wagner, F; Wagner, J; Welzel, T, 2008) |
| "The purpose of this study was to report our experience with concomitant and adjuvant temozolomide (TMZ) with radiotherapy in patients with newly diagnosed glioblastoma multiforme (GBM)." | 7.74 | Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience. ( Basu, A; Goel, A; Gupta, T; Jalali, R; Menon, H; Munshi, A; Sarin, R, 2007) |
| " Temozolomide is an effective chemotherapeutic agent for patients with glioblastoma multiforme, but it induces significant lymphopenia." | 7.74 | Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. ( Aldape, K; Archer, GE; Bigner, DD; Crutcher, L; Dey, M; Gilbert, M; Hassenbusch, SJ; Heimberger, AB; Hussain, SF; Mitchell, DA; Sampson, JH; Sawaya, R; Schmittling, B; Sun, W, 2008) |
| "Temozolomide (TMZ) is active against newly diagnosed glioblastoma (GBM), and O(6)-methylguanine-DNA methyltransferase (MGMT) is implicated in resistance to TMZ and nitrosoureas." | 7.74 | Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. ( Kobayashi, K; Nagane, M; Ohnishi, A; Shimizu, S; Shiokawa, Y, 2007) |
| "Temozolomide (TMZ), given concurrently with radiotherapy (RT) and as adjuvant monotherapy afterwards, has led to improved survival in glioblastoma multiforme (GBM)." | 7.74 | The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. ( Avutu, B; Barker, FG; Batchelor, TT; Chakravarti, A; Henson, JW; Hochberg, FH; Loeffler, JS; Martuza, RL; Sher, DJ, 2008) |
| "32 patients 70 years of age or older with a newly diagnosed glioblastoma and a Karnofsky performance status (KPS) > or = 70 were treated with RT (daily fractions of 2 Gy for a total of 60 Gy) plus temozolomide at the dose of 75 mg/m(2) per day followed by six cycles of adjuvant temozolomide (150-200 mg/m(2) for 5 days during each 28-day cycle)." | 7.74 | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. ( Bozzao, A; De Paula, U; De Sanctis, V; Filippone, F; Lanzetta, G; Maurizi Enrici, R; Minniti, G; Muni, R; Osti, MF; Tombolini, V; Valeriani, M, 2008) |
| "Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit." | 7.73 | MGMT gene silencing and benefit from temozolomide in glioblastoma. ( Bromberg, JE; Cairncross, JG; de Tribolet, N; Diserens, AC; Gorlia, T; Hainfellner, JA; Hamou, MF; Hau, P; Hegi, ME; Janzer, RC; Kros, JM; Mariani, L; Mason, W; Mirimanoff, RO; Stupp, R; Weller, M, 2005) |
| "The aim of this study was to evaluate the efficacy and safety of carmustine (BCNU) in combination with temozolomide as first-line chemotherapy before and after radiotherapy (RT) in patients with inoperable, newly diagnosed glioblastoma multiforme (GBM)." | 7.73 | Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. ( Barrié, M; Braguer, D; Chinot, O; Couprie, C; Dufour, H; Figarella-Branger, D; Grisoli, F; Hoang-Xuan, K; Martin, PM; Muracciole, X; Peragut, JC, 2005) |
| "Cimetidine added to temozolomide compared with temozolomide alone induced survival benefits in nude mice with U373 human glioblastoma multiforme (GBM) cells orthotopically xenografted in the brain." | 7.73 | Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts. ( Brotchi, J; Camby, I; Darro, F; Gabius, J; Gaussin, JF; James, S; Kiss, R; Lefranc, F, 2005) |
| "There are new scientific data concerning the treatment of patients with glioblastoma multiforme with concomitant and adjuvant temozolomide following surgery and radiotherapy." | 7.73 | [Temozolomide in patients with a glioblastoma multiforme: new developments]. ( Bromberg, JE; Postma, TJ, 2005) |
| "Temozolomide (TMZ) is an oral alkylating agent with demonstrated efficacy as therapy for glioblastoma multiforme (GBM) and anaplastic astrocytoma." | 7.73 | Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme. ( Hallinen, T; Kivioja, A; Martikainen, JA; Vihinen, P, 2005) |
| " Treatment of glioblastoma multiforme by temozolomide is considered as a paradigm." | 7.73 | Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo. ( Antipas, VP; Stamatakos, GS; Uzunoglu, NK, 2006) |
| "Severe temozolomide-induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma." | 7.73 | Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide. ( Bally, F; Christen, G; de Ribaupierre, S; Ganière, V; Guillou, L; Pica, A; Stupp, R, 2006) |
| "In this study, we investigated the mechanisms by which temozolomide enhances radiation response in glioblastoma cells." | 7.73 | Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. ( Aldape, K; Black, PM; Chakravarti, A; Erkkinen, MG; Gilbert, MR; Loeffler, JS; Mehta, M; Nestler, U; Stupp, R, 2006) |
| " The special case of glioblastoma multiforme treated by temozolomide is addressed as a simulation paradigm." | 7.73 | A spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in vivo: the paradigm of glioblastoma multiforme treated by temozolomide. ( Antipas, VP; Stamatakos, GS; Uzunoglu, NK, 2006) |
| "To assess whether the survival of patients with recurrent malignant glioma receiving temozolomide in everyday practice is comparable to that reported in previous studies." | 7.72 | Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study. ( Maltoni, S; Messori, A; Pelagotti, F; Trippoli, S; Vacca, F; Vaiani, M, 2003) |
| "Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity in recent clinical trials against high grade gliomas, metastatic melanoma, and brain lymphoma." | 7.72 | Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. ( D'Amati, G; Graziani, G; Kalish, V; Leonetti, C; Portarena, I; Scarsella, M; Tentori, L; Vergati, M; Xu, W; Zhang, J; Zupi, G, 2003) |
| "To analyze the effect of different therapies -surgery, radiotherapy, and chemotherapy (temozolomide)- on the survival of various groups of patients with glioblastoma multiforme (GBM)." | 7.72 | [Survival analysis following the addition of temozolomide to surgery and radiotherapy in patients with glioblastoma multiforme]. ( Benítez, E; Gil-Salú, JL; López-Escobar, M; Maestro, E; Pérez-Requena, J; Román, P, 2004) |
| "The phase III randomised European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trail Group (NCIC) Intergroup trial (EORTC 26981/22981; CE3) compares irradiation alone with irradiation plus temozolomide for patients with glioblastoma multiforme (GBM)." | 7.72 | Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review. ( Ataman, F; Fisher, B; Mirimanoff, RO; Poortmans, P; Stupp, R, 2004) |
| "Temozolomide is an oral alkylating agent shown to have modest efficacy in the treatment of glioblastoma multiforme." | 7.72 | Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma. ( Gillespie, GY; Kufe, DW; Weichselbaum, RR; Yamini, B; Yu, X, 2004) |
| "Temozolomide (TZM) is a novel methylating agent currently under investigation for treatment of recurrent high-grade gliomas." | 7.71 | Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. ( Graziani, G; Navarra, P; Portarena, I; Scerrati, M; Tentori, L; Torino, F, 2002) |
| "Glioblastoma is the most common and most aggressive type of primary brain tumor." | 7.30 | Granulocyte-macrophage colony stimulating factor enhances efficacy of nimustine rendezvousing with temozolomide plus irradiation in patients with glioblastoma. ( Bu, XY; Cheng, X; Kong, LF; Luo, JC; Qu, MQ; Wang, YW; Yan, ZY; Yang, DY; Zhao, YW, 2023) |
| "Glioblastoma is the most frequent and malignant primary brain tumor." | 7.11 | Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial. ( Becker, A; Burger, MC; Clusmann, H; Delev, D; Giordano, FA; Glas, M; Goldbrunner, R; Grauer, O; Güresir, E; Hau, P; Heiland, DH; Herrlinger, U; Krex, D; Nemeth, R; Potthoff, AL; Radbruch, A; Sabel, M; Schaub, C; Schilling, J; Schlegel, U; Schmid, M; Schneider, M; Schnell, O; Schuss, P; Seidel, C; Steinbach, JP; Tabatabai, G; Thon, N; Vatter, H; Weller, J; Winkler, F; Zeyen, T, 2022) |
| " Only one possibly treatment-related treatment emergent adverse event (TEAE), Grade 1 gingival swelling, was observed." | 7.01 | Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study. ( Chen, KT; Hsu, PW; Huang, HL; Jung, SM; Ke, YX; Lin, YJ; Toh, CH; Tsai, HC; Tseng, CK; Wei, KC, 2021) |
| "Glioblastoma is the most common and lethal brain tumor in adults." | 7.01 | Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment. ( Iturrioz-Rodríguez, N; Matheu, A; Sampron, N, 2023) |
| "Atorvastatin was not shown to improve PFS-6." | 7.01 | Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II study. ( Aldanan, S; Alghareeb, WA; Alhussain, H; AlNajjar, FH; Alsaeed, E; Alsharm, AA; Altwairgi, AK; Balbaid, AAO; Orz, Y, 2021) |
| " Common adverse events (AEs) were blurred vision (63%), fatigue (38%), and photophobia (35%)." | 6.90 | Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. ( Ansell, PJ; Bain, E; Butowski, N; Gan, HK; Gomez, E; Holen, KD; Kumthekar, P; Lassman, AB; Lee, HJ; Lwin, Z; Maag, D; Merrell, R; Mikkelsen, T; Nabors, LB; Papadopoulos, KP; Penas-Prado, M; Reardon, DA; Roberts-Rapp, L; Scott, AM; Simes, J; van den Bent, MJ; Walbert, T; Wheeler, H; Xiong, H, 2019) |
| " The aim of this study was to evaluate the efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with temozolomide (TMZ) for the postoperative treatment of GBM." | 6.90 | Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience. ( Chen, G; Chen, L; Li, G; Li, Q; Luo, W; Lv, S; Zhong, L; Zhou, P, 2019) |
| "Lapatinib was administered at 2500 mg twice daily for two consecutive days per week on a weekly basis throughout concomitant and adjuvant standard therapy." | 6.84 | Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. ( Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A, 2017) |
| "Apatinib is a novel, oral, small-molecule tyrosine kinase inhibitor that mainly targets vascular endothelial growth factor receptor-2 (VEGFR-2) to inhibit angiogenesis." | 6.82 | Combining apatinib and temozolomide for brainstem glioblastoma: a case report and review of literature. ( Sun, X; Xu, X; Xu, Y; Zhan, W; Zhao, L; Zhu, Y, 2022) |
| "Glioblastoma is a fatal brain tumor with a bleak prognosis." | 6.82 | Glioblastoma and Methionine Addiction. ( Sowers, LC; Sowers, ML, 2022) |
| "Cilengitide was continued for up to 12 months or until disease progression or unacceptable toxicity." | 6.82 | Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. ( Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H, 2016) |
| "Retreatment with temozolomide (TMZ) is one treatment option." | 6.80 | Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. ( Ancelet, LR; Bauer, E; Dzhelali, M; Findlay, MP; Gasser, O; Hamilton, DA; Hermans, IF; Hunn, MK; Mester, B; Sharples, KJ; Wood, CE, 2015) |
| "Everolimus (70 mg/wk) was started 1 week prior to radiation and TMZ, followed by adjuvant TMZ, and continued until disease progression." | 6.80 | A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. ( Anderson, SK; Brown, PD; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Ligon, KL; Ma, DJ; McGraw, S; Peller, PJ; Sarkaria, JN; Schiff, D; Uhm, JH, 2015) |
| "Cilengitide was administered intravenously in combination with daily temozolomide (TMZ) and concomitant radiotherapy (RT; wk 1-6), followed by TMZ maintenance therapy (TMZ/RT→TMZ)." | 6.80 | Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. ( Ashby, L; Depenni, R; Fink, KL; Grujicic, D; Hegi, ME; Hicking, C; Lhermitte, B; Mazurkiewicz, M; Mikkelsen, T; Nabors, LB; Nam, DH; Perry, JR; Picard, M; Reardon, DA; Salacz, M; Tarnawski, R; Zagonel, V, 2015) |
| "The upfront approach to treatment of glioblastoma in the unresectable population warrants further investigation in randomized controlled phase III trials." | 6.78 | Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. ( Bailey, L; Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; Lipp, ES; Lou, E; Peters, KB; Reardon, DA; Sumrall, AL; Turner, S; Vredenburgh, JJ, 2013) |
| "Seventy-one eligible patients 70 years of age or older with newly diagnosed GBM and a Karnofsky performance status ≥60 were treated with a short course of RT (40 Gy in 15 fractions over 3 weeks) plus TMZ at the dosage of 75 mg/m(2) per day followed by 12 cycles of adjuvant TMZ (150-200 mg/m(2) for 5 days during each 28-day cycle)." | 6.77 | Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. ( Arcella, A; Caporello, P; De Sanctis, V; Enrici, RM; Giangaspero, F; Lanzetta, G; Minniti, G; Salvati, M; Scaringi, C, 2012) |
| " In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy to further enhance its anti-tumor activity." | 6.76 | Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011) |
| "Vatalanib was well tolerated with only 2 DLTs (thrombocytopenia and elevated transaminases)." | 6.76 | Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. ( Batchelor, TT; Doyle, CL; Drappatz, J; Duda, DG; Eichler, AF; Gerstner, ER; Jain, RK; Plotkin, SR; Wen, PY; Xu, L, 2011) |
| " On the basis of promising preclinical data, the safety and tolerability of therapy with the mTOR inhibitor RAD001 in combination with radiation (RT) and temozolomide (TMZ) was evaluated in this Phase I study." | 6.76 | North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. ( Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W, 2011) |
| " The major differences of our protocol from the other past studies were simultaneous use of both sodium borocapate and boronophenylalanine, and combination with fractionated X-ray irradiation." | 6.76 | Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme--study design and current status report. ( Hiramatsu, R; Hirota, Y; Kawabata, S; Kirihata, M; Kuroiwa, T; Maruhashi, A; Miyata, S; Miyatake, S; Ono, K; Sakurai, Y; Takekita, Y, 2011) |
| "Temozolomide has an acceptable tolerance in elderly patients with GBM and KPS less than 70." | 6.76 | Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. ( Barrie, M; Beauchesne, P; Campello, C; Cartalat-Carel, S; Catry-Thomas, I; Chinot, O; Delattre, JY; Ducray, F; Gállego Pérez-Larraya, J; Guillamo, JS; Honnorat, J; Huchet, A; Matta, M; Mokhtari, K; Monjour, A; Taillandier, L; Tanguy, ML, 2011) |
| "Glioblastoma is a highly vascularised tumour with a high expression of both vascular endothelial growth factor (VEGF) and VEGFR." | 6.75 | EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. ( Brandes, AA; Gorlia, T; Hau, P; Kros, JM; Lacombe, D; Mirimanoff, RO; Stupp, R; Tosoni, A; van den Bent, MJ, 2010) |
| " PCB was administered as an oral dosage of 450 mg on days 1-2 and a total dose of 300 mg on day 3." | 6.73 | Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. ( Boiardi, A; Botturi, A; Eoli, M; Falcone, C; Filippini, G; Fiumani, A; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A, 2008) |
| "Glioblastoma is the most common primary malignant brain tumor that is usually considered fatal even with treatment." | 6.72 | Dissecting the mechanism of temozolomide resistance and its association with the regulatory roles of intracellular reactive oxygen species in glioblastoma. ( Chang, KY; Chien, CH; Chuang, JY; Hsueh, WT, 2021) |
| "GBM is the grade IV glioma brain cancer which is life-threatening to many individuals affected by this cancer." | 6.72 | Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy. ( Shetty, K; Yadav, KS; Yasaswi, PS, 2021) |
| "Decision making at disease progression is critical, and classical T1 and T2 imaging remain the gold standard." | 6.72 | Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. ( Buff, E; Leimgruber, A; Maeder, PP; Meuli, RA; Ostermann, S; Stupp, R; Yeon, EJ, 2006) |
| "Temozolomide is an oral chemotherapeutic agent with efficacy against malignant gliomas and a favorable safety profile." | 6.71 | Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. ( Barrie, M; Braguer, D; Chinot, OL; Dufour, H; Figarella-Branger, D; Frauger, E; Grisoli, F; Hoang-Xuan, K; Martin, PM; Moktari, K; Palmari, J; Peragut, JC, 2004) |
| "We conducted a study to determine the dose-limiting toxicity of an extended dosing schedule of temozolomide (TMZ) when used with a fixed dose of BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine), taking advantage of TMZ's ability to deplete O6-alkylguanine-DNA-alkyltransferase and the synergistic activity of these two agents." | 6.71 | Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. ( Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ, 2004) |
| "Temozolomide was administered starting the first day of RT at 150 mg/m(2) daily for 5 days every 4 weeks for the first cycle and escalated to a maximum dose of 200 mg/m(2)." | 6.71 | Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. ( Chang, SM; Lamborn, KR; Larson, D; Malec, M; Nicholas, MK; Page, M; Prados, MD; Rabbitt, J; Sneed, P; Wara, W, 2004) |
| "Temozolomide was administered orally each therapy day at a dose of 50 mg/m(2)." | 6.71 | Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. ( Combs, SE; Debus, J; Edler, L; Gutwein, S; Schulz-Ertner, D; Thilmann, C; van Kampen, M; Wannenmacher, MM, 2005) |
| "Temozolomide is a new cytotoxic alkylating agent that has recently been approved in Portugal for the treatment of recurrent high-grade glioma." | 6.70 | Temozolomide in second-line treatment after prior nitrosurea-based chemotherapy in glioblastoma multiforme: experience from a Portuguese institution. ( Albano, J; Cernuda, M; Garcia, I; Lima, L; Oliveira, C; Portela, I; Teixeira, MM, 2002) |
| "Ifosfamide treatment might be a feasible approach, but it necessitates hospitalization." | 6.69 | Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. ( Bamberg, M; Becker, G; Belka, C; Classen, J; Hoffmann, W; Kortmann, RD; Paulsen, F; Weinmann, M, 1999) |
| "Glioblastoma is the most invasive form of brain tumor." | 6.61 | Glioblastoma vs temozolomide: can the red queen race be won? ( Arora, A; Somasundaram, K, 2019) |
| "Glioblastoma (GBM), the most common primary brain tumor, is the most aggressive human cancers, with a median survival rate of only 14." | 6.61 | Aberrant Transcriptional Regulation of Super-enhancers by RET Finger Protein-histone Deacetylase 1 Complex in Glioblastoma: Chemoresistance to Temozolomide. ( Aoki, K; Hirano, M; Natsume, A; Ranjit, M; Wakabayashi, T, 2019) |
| "Glioblastoma is a unique model of non-metastasising disease that kills the vast majority of patients through local growth, despite surgery and local irradiation." | 6.53 | Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve. ( Giatromanolaki, A; Koukourakis, MI; Mitrakas, AG, 2016) |
| "radiotherapy for treating glioblastoma (GBM), Medline, Current Contents, and Cochrane database were searched." | 6.50 | Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review. ( Lin, ZX; Yang, LJ; Zhou, CF, 2014) |
| "Many physicians are reluctant to treat elderly glioblastoma (GBM) patients as aggressively as younger patients, which is not evidence based due to the absence of validated data from primary studies." | 6.49 | Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis. ( Cheng, JX; Dong, Y; Han, N; Liu, BL; Yin, AA; Zhang, LH; Zhang, X, 2013) |
| " Hematotoxicity is listed as a frequent adverse drug reaction in the US prescribing information and hepatotoxicity has been reported infrequently in the postmarketing period." | 6.48 | Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. ( Bronder, E; Garbe, E; Herbst, H; Kauffmann, W; Klimpel, A; Orzechowski, HD; Sarganas, G; Thomae, M, 2012) |
| "Glioblastoma is the most frequent primary malignant brain tumor in adults." | 6.48 | Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. ( Caporello, P; Enrici, RM; Minniti, G; Scaringi, C, 2012) |
| " Several preliminary studies have been initiated to address the issue of resistance and suppression of MGMT activity, and have used alternative temozolomide dosing schedules and O(6)-guanine mimetic agents as substrates for MGMT." | 6.44 | Mechanisms of disease: temozolomide and glioblastoma--look to the future. ( Chamberlain, MC; Mrugala, MM, 2008) |
| "Temozolomide, a new drug, has shown promise in treating malignant gliomas and other difficult-to-treat tumors." | 6.41 | Temozolomide and treatment of malignant glioma. ( Calvert, H; Friedman, HS; Kerby, T, 2000) |
| " For patients with recurrent malignant glioma, temozolomide provides a therapeutic option with a predictable safety profile, clinical efficacy, and convenient dosing that can provide important quality-of-life benefits." | 6.41 | Temozolomide for recurrent high-grade glioma. ( Macdonald, DR, 2001) |
| "Glioblastoma is the most common primary malignant tumor of the central nervous system." | 5.91 | Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98). ( Ahmadi-Zeidabadi, M; Amirinejad, M; Jomehzadeh, A; Khoei, S; Kordestani, Z; Larizadeh, MH; Yahyapour, R, 2023) |
| "Glioblastoma (GBM) is the most lethal primary brain tumor in adults and harbors a subpopulation of glioma stem cells (GSCs)." | 5.91 | EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma. ( Li, M; Tian, W; Wang, B; Wang, Y; Xu, R; Yu, T; Zeng, A; Zhang, J; Zhou, F; Zhou, Z, 2023) |
| "Glioblastoma (GBM) is the most frequent brain cancer and more lethal than other cancers." | 5.91 | Erythrose inhibits the progression to invasiveness and reverts drug resistance of cancer stem cells of glioblastoma. ( Agredano-Moreno, LT; Gallardo-Pérez, JC; Jimenez-García, LF; López-Marure, R; Robledo-Cadena, DX; Sánchez-Lozada, LG; Trejo-Solís, MC, 2023) |
| "Givinostat is a pan-histone deacetylase (HDAC) inhibitor that has demonstrated excellent tolerability as well as efficacy in patients with polycythemia vera." | 5.91 | Givinostat Inhibition of Sp1-dependent MGMT Expression Sensitizes Glioma Stem Cells to Temozolomide. ( Kitanaka, C; Mitobe, Y; Nakagawa-Saito, Y; Okada, M; Sugai, A; Suzuki, S; Togashi, K, 2023) |
| " Based on the genetic testing results, almonertinib combined with anlotinib and temozolomide was administered and obtained 12 months of progression-free survival after the diagnosis of recurrence as the fourth-line treatment." | 5.91 | Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation. ( Dong, S; Hou, Z; Li, S; Luo, N; Tao, R; Wu, H; Zhang, H; Zhang, X; Zhu, D, 2023) |
| "Temozolomide (TMZ) is a first line agent used in the clinic for glioblastoma and it has been useful in increasing patient survival rates." | 5.91 | Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma. ( Ahmed-Cox, A; Akhter, DT; Cao, Y; Fletcher, NL; Janjua, TI; Kavallaris, M; Moniruzzaman, M; Popat, A; Raza, A; Thurecht, KJ, 2023) |
| "Glioblastoma is the most common malignant brain tumor in adults." | 5.91 | Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide. ( Birkl-Toeglhofer, AM; Brawanski, KR; Freyschlag, CF; Haybaeck, J; Hoeftberger, R; Manzl, C; Sprung, S; Ströbel, T; Thomé, C, 2023) |
| "Temozolomide (TMZ) is a common chemotherapy drug used to treatment of glioblastoma, but drug resistance against this drug is an important barrier to successful treatment of this cancer." | 5.91 | Combination of SIX4-siRNA and temozolomide inhibits the growth and migration of A-172 glioblastoma cancer cells. ( Baghbanzadeh, A; Baradaran, B; Barpour, N; Doustvandi, MA; Javadrashid, D; Mohammadpour, ZJ; Mohammadzadeh, R, 2023) |
| " In this paper, we present the effects of juglone alone and in combination with temozolomide on glioblastoma cells." | 5.91 | Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line. ( Barciszewska, AM; Belter, A; Gawrońska, I; Giel-Pietraszuk, M; Naskręt-Barciszewska, MZ, 2023) |
| "Glioblastomas are highly aggressive and deadly brain tumours, with a median survival time of 14-18 months post-diagnosis." | 5.91 | P2X7 receptor antagonism by AZ10606120 significantly reduced in vitro tumour growth in human glioblastoma. ( Drill, M; Drummond, KJ; Galea, E; Hunn, M; Jayakrishnan, PC; Kan, LK; Monif, M; O'Brien, TJ; Sanfilippo, PG; Sequeira, RP; Todaro, M; Williams, DA, 2023) |
| "Glioblastoma is the most aggressive and fatal form of brain cancer." | 5.91 | The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma. ( Castresana, JS; Denizler-Ebiri, FN; Güven, M; Taşpınar, F; Taşpınar, M, 2023) |
| "New approaches to the treatment of glioblastoma, including immune checkpoint blockade and oncolytic viruses, offer the possibility of improving glioblastoma outcomes and have as such been under intense study." | 5.91 | Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma. ( Craig, M; Fiset, B; Jenner, AL; Karimi, E; Quail, DF; Surendran, A; Walsh, LA, 2023) |
| " The most common adverse events were leukocytopenia (66." | 5.91 | Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. ( Bu, L; Cai, J; Chen, Q; Huang, K; Meng, X; Weng, Y; Xu, Q; Zhan, R; Zhang, L; Zheng, X, 2023) |
| "Neuroblastoma is the most common tumour in children under 1 year old, accounting for 12-15% of childhood cancer deaths." | 5.91 | Autophagy Inhibition via Hydroxychloroquine or 3-Methyladenine Enhances Chemotherapy-Induced Apoptosis in Neuro-Blastoma and Glioblastoma. ( Balachandar, A; Bhagirath, E; Pandey, S; Vegh, C; Wear, D, 2023) |
| "Temozolomide (TMZ) is a commonly used drug for GBM management." | 5.72 | Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2. ( Chen, L; Deng, Q; Guo, S; Hao, P; Hu, S; Li, Z, 2022) |
| "Allopregnanolone (allo) is a physiological regulator of neuronal activity that treats multiple neurological disorders." | 5.72 | Allopregnanolone suppresses glioblastoma survival through decreasing DPYSL3 and S100A11 expression. ( Feng, YH; Hsu, SP; Hsu, TI; Kao, TJ; Ko, CY; Lim, SW; Lin, HY; Wang, SA, 2022) |
| "Glioblastoma multiforme (GBM) is a primary brain tumor with devastating prognosis." | 5.72 | Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma. ( Huang, G; Lin, R; Liu, Y; Ni, B; Qi, ST; Song, H; Wang, H; Wang, Z; Xie, S; Xu, Y; Yi, GZ; Zhang, Y, 2022) |
| " Therefore, localised approaches that treat GB straight into the tumour site provide an alternative to enhance chemotherapy bioavailability and efficacy, reducing systemic toxicity." | 5.72 | Nek1-inhibitor and temozolomide-loaded microfibers as a co-therapy strategy for glioblastoma treatment. ( Arantes, PR; Borges, GR; Braganhol, E; Dalanhol, CS; de Barros Dias, MCH; de Oliveira Merib, J; de Souza, PO; Ferro, MB; Henn, JG; Morás, AM; Moura, DJ; Nugent, M; Reinhardt, LS, 2022) |
| " Additionally, by lowering the effective dosage of TMZ, the combination liposomes reduced systemic TMZ-induced toxicity, highlighting the preclinical potential of this novel integrative strategy to deliver combination therapies to brain tumors." | 5.72 | Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma. ( Chai, T; Du, Q; Hanif, S; Ismail, M; Li, Y; Muhammad, P; Shi, B; Yang, W; Zhang, D; Zheng, M, 2022) |
| " Non-ionising electromagnetic fields represent an emerging option given the potential advantages of safety, low toxicity and the possibility to be combined with other therapies." | 5.72 | Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide. ( Astori, G; Belli, R; Bernardi, M; Bozza, A; Catanzaro, D; Celli, P; Chieregato, K; Menarin, M; Merlo, A; Milani, G; Peroni, D; Pozzato, A; Pozzato, G; Raneri, FA; Ruggeri, M; Volpin, L, 2022) |
| "Temozolomide (TMZ) is a chemotherapeutic drug for the treatment of GBM." | 5.72 | Temozolomide increases heat shock proteins in extracellular vesicles released from glioblastoma cells. ( Adıgüzel, Z; Kıyga, E; Önay Uçar, E, 2022) |
| "Glioblastoma multiforme is a malignant neoplasia with a median survival of less than two years and without satisfactory therapeutic options." | 5.72 | The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells. ( Buchner, A; Lyu, C; Pohla, H; Schrader, I; Sroka, R; Stadlbauer, B; Stepp, H; Werner, M, 2022) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic agent for glioblastoma, but the emergence of drug resistance limits its anti-tumor activity." | 5.72 | GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair. ( Chen, CC; Chen, Y; Grigore, FN; Jin, J; Lan, Q; Li, M; Li, S; Ma, J; Wang, J; Wang, Q; Wu, G; Xu, H; Zhu, H, 2022) |
| "Metformin is a biguanide drug utilized as the first-line medication in treating type 2 diabetes." | 5.72 | Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin. ( Chang, PC; Chen, HY; Feng, SW; Huang, SM; Hueng, DY; Li, YF, 2022) |
| "Thymol treatment increased the expression of Bax and p53, and also increased apoptotic cell death, and excessive generation of ROS." | 5.72 | Thymol has anticancer effects in U-87 human malignant glioblastoma cells. ( Afshari, AR; Ahmadi, SS; Bahrami, A; Ferns, GA; Heravi-Faz, N; Qoorchi Moheb Seraj, F; Shahbeiki, F; Soltani, A; Talebpour, A, 2022) |
| "Glioblastoma is the most prevalent and malignant brain tumor identified in adults." | 5.72 | Matteucinol combined with temozolomide inhibits glioblastoma proliferation, invasion, and progression: an in vitro, in silico, and in vivo study. ( Chagas, RCR; Gonçalves, AS; Melo, ESA; Netto, JB; Oliveira, AGS; Reis, RM; Ribeiro, RIMA; Santiago, LR; Santos, DM; Santos, HB; Sousa, LR; Thomé, RG, 2022) |
| "Temozolomide (TMZ) is a first-line clinical chemotherapeutic drug." | 5.72 | Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment. ( Chen, KC; Chen, PH; Ho, KH; Kuo, YY; Liu, AJ; Shih, CM, 2022) |
| "Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with tumors harboring an unmethylated MGMT promoter derive minimal benefit." | 5.69 | Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. ( Baehring, J; Bähr, O; Brandes, AA; Butowski, N; Carpentier, AF; Chalamandaris, AG; Cloughesy, T; Di Giacomo, AM; Fu, AZ; Idbaih, A; Khasraw, M; Lassen, U; Lim, M; Liu, Y; Lombardi, G; Mulholland, P; Muragaki, Y; Omuro, A; Potter, V; Qian, X; Reardon, DA; Roth, P; Sepulveda, JM; Sumrall, A; Tabatabai, G; Tatsuoka, K; van den Bent, M; Vauleon, E; Weller, M, 2023) |
| " Investigation of adjuvant trotabresib + temozolomide and concomitant trotabresib + temozolomide + radiotherapy in patients with newly diagnosed glioblastoma is ongoing (NCT04324840)." | 5.69 | Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study. ( Amoroso, B; Aronchik, I; Chang, H; Filvaroff, E; González León, P; Hanna, B; Manuel Sepúlveda, J; Mendez, C; Moreno, V; Nikolova, Z; Pérez-Núñez, Á; Reardon, DA; Sanchez-Perez, T; Stephens, D; Vogelbaum, MA; Zuraek, M, 2023) |
| "Despite intensive treatment with surgery, radiation therapy, temozolomide (TMZ) chemotherapy, and tumor-treating fields, mortality of newly diagnosed glioblastoma (nGBM) remains very high." | 5.69 | Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. ( Abad, AP; Ahluwalia, MS; Belal, AN; Birkemeier, MT; Casucci, DM; Ciesielski, MJ; Curry, WT; Dharma, SS; Dhawan, A; Fenstermaker, RA; Figel, SA; Hutson, AD; Liu, S; Mechtler, LL; Mogensen, KM; Peereboom, DM; Qiu, J; Reardon, DA; Withers, HG; Wong, ET, 2023) |
| "In the randomized phase III trial CeTeG/NOA-09, temozolomide (TMZ)/lomustine (CCNU) combination therapy was superior to TMZ in newly diagnosed MGMT methylated glioblastoma, albeit reporting more frequent hematotoxicity." | 5.69 | Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial. ( Brehmer, S; Bullinger, L; Giordano, FA; Glas, M; Goldbrunner, R; Grauer, O; Hau, P; Herrlinger, U; Kowalski, T; Krex, D; Potthoff, AL; Ringel, F; Sabel, M; Schäfer, N; Schaub, C; Schmidt-Graf, F; Schneider, M; Schnell, O; Seidel, C; Steinbach, JP; Tabatabai, G; Tonn, JC; Tzaridis, T; Vajkoczy, P; Vatter, H; Weller, J; Zeiner, PS; Zeyen, T, 2023) |
| "Despite standard treatments including chemoradiotherapy with temozolomide (TMZ) (STUPP protocol), the prognosis of glioblastoma patients remains poor." | 5.69 | Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol). ( Biau, J; Casile, M; De Beaumont, O; Dufort, S; Durando, X; Le Duc, G; Loeffler, M; Molnar, I; Moreau, J; Seddik, K; Thivat, E, 2023) |
| "Disulfiram (DSF) is an anti-alcoholism drug which functions by inhibiting ALDHs." | 5.62 | Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor. ( Gean, PW; Lin, MX; Liu, CC; Sze, CI; Wu, CL, 2021) |
| "Glioblastoma is the most aggressive central nervous system (CNS) neoplasm with high proliferation and tissue invasion capacity and is resistant to radio and chemotherapy." | 5.62 | Interaction Between Near-Infrared Radiation and Temozolomide in a Glioblastoma Multiform Cell Line: A Treatment Strategy? ( da Silva Marques, M; de Moraes Vaz Batista Filgueira, D; de Souza Votto, AP; Horn, AP; Lettnin, AP; Marinho, MAG, 2021) |
| "Glioblastoma multiforme is a malignant central nervous system (CNS) disease with dismal prognosis." | 5.62 | Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab. ( Fioretzaki, RG; Kosmas, C; Papageorgiou, GI; Tsakatikas, SA, 2021) |
| "GBM (glioblastoma multiforme) is the most common and aggressive brain tumor." | 5.62 | Regorafenib in glioblastoma recurrence: A case report. ( Desideri, I; Detti, B; Ganovelli, M; Greto, D; Livi, L; Lorenzetti, V; Lucidi, S; Maragna, V; Scoccianti, S; Scoccimarro, E; Teriaca, MA, 2021) |
| "Temozolomide (TMZ) has been widely used as a first-line treatment for GBM." | 5.62 | Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting. ( Li, N; Li, Y; Lv, Y; Sha, C; Sun, K; Tang, S; Wang, A; Wang, L; Yan, X; Yu, Y, 2021) |
| "Glioblastoma is the most malignant brain tumor and presents high resistance to chemotherapy and radiotherapy." | 5.62 | APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells. ( Castresana, JS; De La Rosa, J; Idoate, MA; Meléndez, B; Rey, JA; Urdiciain, A; Zazpe, I; Zelaya, MV, 2021) |
| "Glioblastoma is the most common primary brain tumor and remains uniformly fatal, highlighting the dire need for developing effective therapeutics." | 5.62 | Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma. ( Boockvar, J; Brahmbhatt, H; Gao, S; Gonzalez, C; Jamil, E; Khan, MB; MacDiarmid, J; Mugridge, N; Ruggieri, R; Sarkaria, JN; Symons, M; Tran, NL, 2021) |
| "Celecoxib and 2,5-DMC were the most cytotoxic." | 5.62 | COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells. ( Kleszcz, R; Krajka-Kuźniak, V; Kruhlenia, N; Majchrzak-Celińska, A; Misiorek, JO; Przybyl, L; Rolle, K, 2021) |
| "Temozolomide was labeled with [11C], and serial PET-MRI scans were performed in patients with recurrent GBM treated with bevacizumab and daily temozolomide." | 5.56 | Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. ( Batchelor, T; Beers, AL; Catana, C; Chang, K; Dietrich, J; Duda, DG; Emblem, KE; Gerstner, ER; Hooker, JM; Jain, RK; Kalpathy-Cramer, J; Plotkin, SR; Rosen, B; Vakulenko-Lagun, B; Yen, YF, 2020) |
| "Glioblastoma is the most common primary tumor of the central nervous system that develops chemotherapy resistance." | 5.56 | Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT. ( Chen, J; Chen, L; Hao, B; He, M; Li, X; Wang, C; Wu, H; Zhang, G; Zhang, T, 2020) |
| "Calpeptin could inhibit the effect." | 5.56 | Calpain suppresses cell growth and invasion of glioblastoma multiforme by producing the cleavage of filamin A. ( Cai, L; Li, Q; Li, W; Lu, X; Su, Z; Tu, M; Wang, C; Zhu, Z, 2020) |
| "Temozolomide (TMZ) is an effective drug for prolonging the overall survival time of patients, while drug-resistance is an important clinical problem at present." | 5.56 | A steroidal saponin form Paris vietnamensis (Takht.) reverses temozolomide resistance in glioblastoma cells via inducing apoptosis through ROS/PI3K/Akt pathway. ( Fang, F; Ji, Y; Li, H; Lu, Y; Qiu, P; Tang, H; Zhang, S, 2020) |
| "Glioblastoma is the most devastating primary brain tumor and effective therapies are not available." | 5.56 | CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model. ( Azambuja, JH; Battastini, AMO; Beckenkamp, LR; Braganhol, E; de Oliveira, FH; Gelsleichter, NE; Lenz, GS; Michels, LR; Schuh, RS; Stefani, MA; Teixeira, HF; Wink, MR, 2020) |
| " However, low bioavailability and extractive yield limit the clinical applications of XN." | 5.56 | Xanthohumol regulates miR-4749-5p-inhibited RFC2 signaling in enhancing temozolomide cytotoxicity to glioblastoma. ( Chen, KC; Chen, PH; Cheng, CH; Ho, KH; Kuo, TC; Lee, CC; Lee, YT; Liu, AJ; Shih, CM, 2020) |
| "Glioblastoma is the most common primary malignant tumor of the central nervous system which is the most lethal type of primary brain tumor in adults with the survival time of 12-15 months after the initial diagnosis." | 5.56 | Evaluation of frequency magnetic field, static field, and Temozolomide on viability, free radical production and gene expression (p53) in the human glioblastoma cell line (A172). ( Ahmadi-Zeidabadi, M; Ashta, A; Motalleb, G, 2020) |
| "Methadone is an analgesic drug used for pain treatment and heroin substitution." | 5.56 | Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells. ( Beltzig, L; Haas, B; Kaina, B; Piee-Staffa, A, 2020) |
| " Current treatments for glioblastoma patients consist of surgery followed by radiation in combination with temozolomide." | 5.56 | The effect of temozolomide in combination with doxorubicin in glioblastoma cells ( Alexandru, O; Artene, SA; Danoiu, S; Dricu, A; Elena Cioc, C; Horescu, C; Sevastre, AS; Stefana Oana, P; Tache, DE; Tuta, C, 2020) |
| "Glioblastoma is the most frequent aggressive primary brain tumor amongst human adults." | 5.56 | Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction. ( Arús, C; Candiota, AP; Julià-Sapé, M; Ledesma-Carbayo, MJ; Núñez, LM; Romero, E; Santos, A; Vellido, A, 2020) |
| "Metformin has been linked to improve survival of patients with various cancers." | 5.56 | Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis. ( Chinot, O; Genbrugge, E; Gorlia, T; Hau, P; Nabors, B; Seliger, C; Stupp, R; Weller, M, 2020) |
| "In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular features of glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase-wildtype (IDH-wt) in the 2021 World Health Organization (WHO) classification of central nervous system tumors]." | 5.51 | Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. ( Aldape, K; Atmodimedjo, PN; Baumert, BG; Baurain, JF; Brandes, AA; Brouwer, RWW; Cheung, KJ; Chinot, OL; Clement, PM; de Heer, I; Dubbink, HJ; Erridge, SC; French, PJ; Gill, S; Golfinopoulos, V; Gorlia, T; Griffin, M; Hoogstrate, Y; Jenkins, RB; Kros, JM; Mason, WP; McBain, C; Nowak, AK; Rogers, L; Rudà, R; Sanson, M; Taal, W; Tesileanu, CMS; van den Bent, MJ; van IJcken, WFJ; van Linde, ME; Vogelbaum, MA; von Deimling, A; Weller, M; Wesseling, P; Wheeler, H; Wick, W, 2022) |
| "Temozolomide is applied as the standard chemotherapy agent in patients with glioblastoma (GBM) after surgery." | 5.51 | The efficacy of temozolomide combined with levetiracetam for glioblastoma (GBM) after surgery: a study protocol for a double-blinded and randomized controlled trial. ( Cheng, Y; Huang, N; Liu, G; Mao, J; Sun, M; Tao, Y; Wen, R; Xie, Z; Zhang, X; Zhao, G, 2022) |
| "Nearly all patients with newly diagnosed glioblastoma experience recurrence following standard-of-care radiotherapy (RT) + temozolomide (TMZ)." | 5.51 | Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. ( Ansstas, G; Baehring, J; De Vos, F; Finocchiaro, G; Honnorat, J; Idbaih, A; Kinoshita, M; Lee, M; Leung, D; Lim, M; Mellinghoff, IK; Omuro, A; Petrecca, K; Raval, RR; Reardon, DA; Roberts, M; Sahebjam, S; Slepetis, R; Steinbach, J; Sumrall, A; Taylor, JW; Warad, D; Weller, M; Wick, A, 2022) |
| "Current standard of care for glioblastoma (GBM) includes concurrent chemoradiation and maintenance temozolomide (TMZ) with Tumor Treating Fields (TTFields)." | 5.51 | Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study. ( Ali, AS; Alnahhas, I; Andrews, DW; Judy, KD; Lombardo, J; Martinez, NL; Miller, RC; Niazi, MZ; Shi, W, 2022) |
| "Fresh suspected glioblastoma tissue was collected during surgery, and patients with pathology-confirmed GBM enrolled before starting concurrent Radiation Therapy and Temozolomide (RT/TMZ) with Intent to Treat (ITT) after recovery from RT/TMZ." | 5.51 | Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment. ( Abedi, M; Aiken, RD; Bota, DA; Bota, PG; Carrillo, JA; Dillman, RO; Duma, CM; Hsieh, C; Hsu, FPK; Keirstead, HS; Kesari, S; Kong, XT; LaRocca, RV; Nistor, GI; Piccioni, DE; Taylor, TH, 2022) |
| "Palbociclib treatment significantly reduced tumorigenesis in TMZ-R/HMC3 bearing mice and SNHG15 and CDK6 expression was significantly reduced while miR-627-5p level was increased." | 5.51 | Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme. ( Bao, H; Jin, H; Li, C; Li, Z; Liang, P; Wang, W; Xiong, J; Zhang, J; Zheng, H, 2019) |
| "Papaverine is a potential anticancer drug in GBM treatment." | 5.51 | Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth. ( Akasaki, Y; Ichimura, K; Inada, M; Sato, A; Shindo, M; Tanuma, SI; Yamamoto, Y, 2019) |
| "Euphol is a tetracyclic triterpene alcohol, and it is the main constituent of the sap of the medicinal plant Euphorbia tirucalli." | 5.51 | Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells. ( Carloni, AC; Costa, AM; Evangelista, AF; Jones, C; Lima, JP; Martinho, O; Miranda-Gonçalves, V; Pianowski, LF; Reis, RM; Rosa, MN; Silva, VAO; Tansini, A, 2019) |
| " This study aimed to investigate the antitumor effects of natural killer cells in combination with temozolomide as the standard chemotherapeutic agent for glioblastoma." | 5.51 | Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro. ( Matsuda, R; Morita, H; Motoyama, Y; Murakami, T; Nakagawa, I; Nakamura, M; Nakase, H; Nakazawa, T; Nishimura, F; Omoto, K; Shida, Y; Tanaka, Y; Tsujimura, T, 2019) |
| "The aim of the present study was to treat glioblastoma cells with a selective HDAC6 inhibitor, tubastatin A, to determine if the malignant phenotype may be reverted." | 5.51 | Tubastatin A, an inhibitor of HDAC6, enhances temozolomide‑induced apoptosis and reverses the malignant phenotype of glioblastoma cells. ( Castresana, JS; Erausquin, E; Idoate, MA; Meléndez, B; Rey, JA; Urdiciain, A, 2019) |
| " Combinatorial therapy of diosgenin and TMZ significantly reduced the dosage regimen of TMZ and also showed affectivity in hitherto TMZ resistant GBM cells." | 5.51 | Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma. ( Banerjee, I; Banik, P; Bharti, R; Biswas, A; Das, S; Ghosh, SK; Kumar, U; Mandal, M; Nayak, S; Rajesh, Y, 2019) |
| "Temozolomide treatment inhibited p50 recruitment to its cognate element as a function of Ser329 phosphorylation while concomitantly increasing p53 recruitment." | 5.51 | Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma. ( Bernal, GM; Cahill, KE; Crawley, CD; Khodarev, NN; Larsen, G; Mansour, NM; Nunez, L; Raleigh, DR; Spretz, R; Szymura, SJ; Uppal, A; Voce, DJ; Weichselbaum, RR; Wu, L; Yamini, B; Zhang, W, 2019) |
| "Long‑term local treatment of glioblastoma is rarely achieved and the majority of the patients undergo relapse." | 5.51 | Synergistic effect of arsenic trioxide, vismodegib and temozolomide on glioblastoma. ( Bureta, C; Komiya, S; Maeda, S; Nagano, S; Saitoh, Y; Sasaki, H; Setoguchi, T; Taniguchi, N; Tokumoto, H, 2019) |
| "Temozolomide (TMZ) is an important agent against GBM." | 5.51 | Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation. ( Chen, Z; Liang, H; Sun, L, 2019) |
| "Temozolomide (TMZ) has been the first-line chemotherapeutic agent used, although to achieve a satisfactory clinical effect." | 5.51 | Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists. ( Gao, L; Huang, X; Jiang, X; Li, J; Liu, X; Liu, Z; Zeng, T, 2019) |
| "Temozolomide (TMZ) is an alkylating agent widely used to treat cancer, resistance to this drug is often found." | 5.51 | Impact of extremely low-frequency electromagnetic field (100 Hz, 100 G) exposure on human glioblastoma U87 cells during Temozolomide administration. ( Ahmadi-Zeidabadi, M; Akbarnejad, Z; Eskandary, H; Esmaeeli, M; Masoumi-Ardakani, Y; Mohammadipoor-Ghasemabad, L, 2019) |
| "The therapeutic treatment of glioblastoma multiforme (GBM) remains a major challenge." | 5.51 | Angiopep-2 Modified Cationic Lipid-Poly-Lactic-Co-Glycolic Acid Delivery Temozolomide and DNA Repair Inhibitor Dbait to Achieve Synergetic Chemo-Radiotherapy Against Glioma. ( Hua, L; Li, S; Liang, J; Liu, H; Xu, Q; Ye, C; Yu, R; Zhao, L, 2019) |
| "Glioblastoma multiforme is an astrocyte-derived tumour representing the most aggressive primary brain malignancy." | 5.51 | Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme. ( Aleixo, GF; Batalini, F; Drews, R; Kaufmann, MR, 2019) |
| " Proliferation, cell cycle, and apoptotic assays were performed with ML00253764, whereas the synergism of the simultaneous combination with temozolomide was evaluated by the combination index method." | 5.48 | Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo. ( Bocci, G; Di Desidero, T; Giuliani, D; Guarini, S; Orlandi, P; Ottani, A; Pacini, S; Pardini, C; Pasqualetti, F; Vaglini, F, 2018) |
| " The aim of our research was the synthesis of a nanocarrier of quercetin combined with temozolomide, to enhance the specificity and efficacy of this anticancer drug commonly used in glioblastoma treatment." | 5.48 | Novel nanohydrogel of hyaluronic acid loaded with quercetin alone and in combination with temozolomide as new therapeutic tool, CD44 targeted based, of glioblastoma multiforme. ( Armenia, E; Barbarisi, A; Barbarisi, M; De Sena, G; Iaffaioli, RV; Quagliariello, V; Schiavo, L; Tafuto, S, 2018) |
| "Glioblastoma is the most frequent and aggressive form of high-grade malignant glioma." | 5.48 | XRCC3 contributes to temozolomide resistance of glioblastoma cells by promoting DNA double-strand break repair. ( Frohnapfel, L; Kaina, B; Quiros, S; Ringel, F; Roos, WP, 2018) |
| "Glioblastomas are the most frequently diagnosed and worst primary malignancy of the central nervous system, with very poor prognosis." | 5.48 | Regulation of Integrated Stress Response Sensitizes U87MG Glioblastoma Cells to Temozolomide Through the Mitochondrial Apoptosis Pathway. ( Fan, L; Gao, Y; He, Y; Meng, H; Sun, L; Xu, B; Xu, H; Zhou, Z, 2018) |
| "Glioblastoma is the most common and aggressive primitive brain tumor in adults." | 5.48 | Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases. ( Bellu, L; Bergo, E; Berti, F; Caccese, M; Dal Pos, S; Della Puppa, A; Denaro, L; Gardiman, MP; Lombardi, G; Pambuku, A; Zagonel, V, 2018) |
| "Glioblastoma is the most common malignant brain tumor." | 5.48 | Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting. ( Chu, L; Liu, S; Mu, H; Ni, L; Song, Y; Sun, K; Wang, A; Wu, Z; Yan, X; Zhang, C; Zhao, M, 2018) |
| "Glioblastoma (GBM) is one of the lethal central nervous system tumors." | 5.48 | The Effect of Ascorbic Acid over the Etoposide- and Temozolomide-Mediated Cytotoxicity in Glioblastoma Cell Culture: A Molecular Study. ( Ceylan, S; Gokturk, D; Kelebek, H; Yilmaz, DM, 2018) |
| "Glioblastomas (GBM) comprise 17% of all primary brain tumors." | 5.46 | Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition. ( Balça-Silva, J; do Carmo, A; Dubois, LG; Echevarria-Lima, J; Ferrer, VP; Lopes, MC; Matias, D; Moura-Neto, V; Pontes, B; Rosário, L; Sarmento-Ribeiro, AB, 2017) |
| "Glioblastomas are characterized by amplification of EGFR." | 5.46 | Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma. ( Asuthkar, S; Bach, SE; Guda, MR; Lathia, JD; Sahu, K; Tsung, AJ; Tuszynski, J; Velpula, KK, 2017) |
| "Glioblastoma is one of the most frequent and aggressive brain tumors." | 5.46 | MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT. ( Jin, X; Liu, N; Nie, E; Shi, Z; Wu, W; You, Y; Yu, T; Zhang, J; Zhou, X, 2017) |
| "Temozolomide (TMZ) is an alkylating agent that has been widely used to treat GBM; resistance to this drug is often found." | 5.46 | Cytotoxicity of temozolomide on human glioblastoma cells is enhanced by the concomitant exposure to an extremely low-frequency electromagnetic field (100Hz, 100G). ( Abadi, MFS; Ahmadi, M; Akbarnejad, Z; Dini, L; Eskandary, H; Farsinejad, A; Nematollahi-Mahani, SN; Vergallo, C, 2017) |
| "Temozolomide (TMZ) is an alkylating chemotherapeutic agent widely used in anti-glioma treatment." | 5.46 | Genomic profiling of long non-coding RNA and mRNA expression associated with acquired temozolomide resistance in glioblastoma cells. ( Fu, Z; Guo, H; Lian, C; Liu, B; Liu, Y; Xu, N; Yang, Z; Zeng, H, 2017) |
| " In vivo, we implanted the cells orthotopically in nude mice and administered CBL0137 in various dosing regimens to assess brain and tumor accumulation of CBL0137, its effect on tumor cell proliferation and apoptosis, and on survival of mice with and without temozolomide (TMZ)." | 5.46 | Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. ( Barone, TA; Burkhart, CA; Gudkov, AV; Gurova, KV; Haderski, G; Plunkett, RJ; Purmal, AA; Safina, A, 2017) |
| "Glioblastoma is the most malignant form of brain tumor." | 5.46 | Combined delivery of temozolomide and the thymidine kinase gene for treatment of glioblastoma. ( Choi, E; Han, J; Lee, D; Lee, M; Oh, J; Rhim, T; Tan, X, 2017) |
| "Temozolomide is a commonly used chemotherapy drug and frequently causes lymphocytopenia." | 5.46 | Cutaneous invasive aspergillosis in a patient with glioblastoma receiving long-term temozolomide and corticosteroid therapy. ( Hatakeyama, S; Ikeda, T; Morisawa, Y; Norizuki, M; Okabe, T; Onishi, T; Sasahara, T; Suzuki, J; Toshima, M; Yokota, H, 2017) |
| "Temozolomide (TMZ) is a novel cytotoxic agent used as first-line chemotherapy for GBM, however, some individual cells can't be isolated for surgical resection and show treatment-resistance, thus inducing poor prognosis." | 5.46 | MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. ( Chen, C; Chen, W; Ge, XS; He, J; Kong, KK; Li, FC; Li, H; Li, JL; Li, P; Wang, F; Xu, XK, 2017) |
| "Glioblastoma is the deadliest brain tumor in humans." | 5.43 | Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo. ( Chakrabarti, M; Ray, SK, 2016) |
| "Valproic acid (VPA) is an anti-epileptic drug with properties of a histone deacetylase inhibitor (HDACi)." | 5.43 | Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. ( Dietrich, J; Le, A; McDonnell, E; Nahed, BV; Redjal, N; Reinshagen, C; Walcott, BP, 2016) |
| "There is no standard treatment for glioblastoma with elements of PNET (GBM-PNET)." | 5.43 | Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component. ( Fersht, N; Mandeville, HC; Mycroft, J; O'Leary, B; Saran, F; Solda, F; Vaidya, S; Zacharoulis, S, 2016) |
| " Treatment of TMZ along with a sublethal dosage range of SU1498, a chemical inhibitor of the VEGF receptor signaling, induced significant cell death in both TMZ-sensitive and TMZ-resistant GBM cells without changing the status of the MGMT promoter methylation." | 5.43 | Combined inhibition of vascular endothelial growth factor receptor signaling with temozolomide enhances cytotoxicity against human glioblastoma cells via downregulation of Neuropilin-1. ( Choi, C; Choi, K; Kim, E; Lee, J; Ryu, SW, 2016) |
| "Glioblastoma is one of the most lethal cancers in humans, and with existing therapy, survival remains at 14." | 5.43 | Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. ( Aman, A; Cairncross, JG; Dang, NH; Datti, A; Easaw, JC; Grinshtein, N; Hao, X; Kaplan, DR; King, JC; Luchman, A; Lun, X; Robbins, SM; Senger, DL; Uehling, D; Wang, X; Weiss, S; Wells, JC; Wrana, JL, 2016) |
| " We show that GSI in combination with RT and TMZ attenuates proliferation, decreases 3D spheroid growth and results into a marked reduction in clonogenic survival in primary and established glioma cell lines." | 5.43 | NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. ( Barbeau, LM; Chalmers, AJ; Eekers, DB; Granton, PV; Groot, AJ; Habets, R; Iglesias, VS; King, H; Prickaerts, J; Short, SC; Theys, J; van Hoof, SJ; Verhaegen, F; Vooijs, M; Yahyanejad, S, 2016) |
| "Glioblastoma multiforme is the most aggressive malignant primary brain tumor in adults." | 5.43 | Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance. ( Aboody, KS; Cassady, K; Cherryholmes, GA; Marinov, GK; Polewski, MD; Reveron-Thornton, RF, 2016) |
| "Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14." | 5.43 | Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam. ( Ajit, NE; Burton, GV; El-Osta, H; Peddi, P, 2016) |
| "Glioblastoma is an aggressive malignancy, which is notorious for its poor prognosis." | 5.42 | Hispidulin enhances the anti-tumor effects of temozolomide in glioblastoma by activating AMPK. ( Fei, Z; He, X; Liu, W; Wang, Y, 2015) |
| "Temozolomide (TMZ) has been showed to be an effective chemotherapeutic agent for glioblastoma treatment; however, the response rate is not satisfactory." | 5.42 | Synergistic Anti-Cancer Effects of Icariin and Temozolomide in Glioblastoma. ( Guo, H; Guo, M; Wang, Y; Yang, L, 2015) |
| "Glioblastoma is a devastating primary brain tumor resistant to conventional therapies." | 5.42 | Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas. ( Battastini, AM; Bishop, AJR; Braganhol, E; Bristot, IJ; Figueiró, F; Forcelini, CM; Gelain, DP; Klafke, K; Moreira, JCF; Morrone, M; Paludo, FJ; Terra, SR; Zanotto-Filho, A, 2015) |
| "Glioblastoma is the most frequent primary malignant brain tumor in adults." | 5.42 | Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation. ( Benoit, JP; Danhier, F; Lagarce, F; Lemaire, L; Messaoudi, K, 2015) |
| " Primary GBM cells were treated with VPA as a monotherapy and in combination with temozolomide and irradiation." | 5.42 | The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. ( Cosgrove, L; Day, B; Fay, M; Head, R; Hosein, AN; Lim, YC; Martin, JH; Rose, S; Sminia, P; Stringer, B, 2015) |
| "Glioblastoma is the most malignant brain tumor, exhibiting remarkable resistance to treatment." | 5.42 | A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide. ( Correia, S; Costa, BM; Costa, S; Gonçalves, CS; Gonçalves, T; Lopes, JM; Oliveira, AI; Pinto, AA; Pinto, L; Pojo, M; Reis, RM; Rocha, M; Rodrigues, AJ; Sousa, N; Xavier-Magalhães, A, 2015) |
| "Glioblastoma is the most frequent primary malignant brain tumor in adults." | 5.42 | Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma. ( Danhier, F; des Rieux, A; Fourniols, T; Leprince, JG; Préat, V; Randolph, LD; Staub, A; Vanvarenberg, K, 2015) |
| "Evidence suggests hyperglycemia is associated with worse outcomes in glioblastoma (GB)." | 5.42 | Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. ( Chung, C; Kiehl, TR; Laperriere, N; Lovblom, LE; Mason, W; McNamara, MG; Ménard, C; Millar, BA; Perkins, BA; Tieu, MT, 2015) |
| " Abemaciclib antitumor activity was assessed in subcutaneous and orthotopic glioma models alone and in combination with standard of care temozolomide (TMZ)." | 5.42 | Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft. ( Ajamie, RT; De Dios, A; Gelbert, LM; Kulanthaivel, P; Raub, TJ; Sanchez-Martinez, C; Sawada, GA; Shannon, HE; Staton, BA; Wishart, GN, 2015) |
| "Chemotherapy with the oral alkylating agent temozolomide still prevails as a linchpin in the therapeutic regimen of glioblastoma alongside radiotherapy." | 5.41 | Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond ( Chamallamudi, MR; Kumar, G; Kumar, N; Nandakumar, K; Rao, V; Thorat, ND; Vibhavari, RJA, 2023) |
| " Temozolomide (TMZ) has anti-proliferative and cytotoxic effects and is indicated for glioblastoma multiforme and recurrent mesenchymal astrocytoma." | 5.41 | Progress in research and development of temozolomide brain-targeted preparations: a review. ( Chen, J; Fan, W; Fu, Z; Wu, X; Xu, Y; Yang, J, 2023) |
| "Glioblastoma (GBM) remains a fatal diagnosis despite the current standard of care of maximal surgical resection, radiation, and temozolomide (TMZ) therapy." | 5.41 | Modeling glioblastoma complexity with organoids for personalized treatments. ( Babak, MV; Balyasnikova, IV; Duffy, JT; Pawlowski, KD, 2023) |
| "Temozolomide is an oral alkylating agent that is used as the first line treatment for glioblastoma multiform, and in recurrent anaplastic astrocytoma, as well as having demonstrable activity in patients with metastatic melanoma." | 5.41 | Is Autophagy Inhibition in Combination with Temozolomide a Therapeutically Viable Strategy? ( Elshazly, AM; Gewirtz, DA, 2023) |
| "A significant proportion of the human transcriptome, long noncoding RNAs (lncRNAs) play pivotal roles in several aspects of glioblastoma (GBM) pathophysiology including proliferation, invasion, radiation and temozolomide resistance, and immune modulation." | 5.41 | The Role of Long Noncoding Ribonucleic Acids in Glioblastoma: What the Neurosurgeon Should Know. ( Chiocca, EA; Villa, GR, 2023) |
| "Standard treatment for glioblastoma includes maximal safe resection followed by adjuvant radiation and concurrent temozolomide for 6 weeks, followed by 6 months of maintenance temozolomide; additionally, concurrent high doses of corticosteroids are required for many patients to reduce intracranial pressure and reduce inflammatory side effects." | 5.41 | Radiotherapy, lymphopenia and improving the outcome for glioblastoma: a narrative review. ( Kleinberg, L; Kut, C, 2023) |
| "Glioblastoma (GBM) is a highly aggressive and lethal brain tumor with limited treatment options, such as the chemotherapeutic agent, temozolomide (TMZ)." | 5.41 | Dysregulated lipid metabolism in TMZ-resistant glioblastoma: pathways, proteins, metabolites and therapeutic opportunities. ( Hsu, TI; Kao, TJ; Li, HY; Lin, CL; Yang, WB, 2023) |
| " We performed a phase I study to determine the maximum tolerated dose and preliminary efficacy of pegylated nanoliposomal irinotecan (nal-IRI)+metronomic temozolomide (TMZ) in patients with recurrent glioblastoma." | 5.41 | Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial. ( Baekey, J; Carcieri, A; Cielo, D; Disano, D; Donnelly, J; Elinzano, H; MacKinnon, K; Mohler, A; Robison, J; Safran, H; Sturtevant, A; Toms, S; Vatketich, J; Wood, R, 2021) |
| "Temozolomide offers minimal benefit in patients with glioblastoma with unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promoter status, hence, the need for novel therapies." | 5.41 | A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. ( Ashley, DM; Back, M; Barnes, EH; Buckland, ME; Fisher, L; Foote, MC; Hall, M; Khasraw, M; Koh, ES; Leonard, R; Lwin, Z; McDonald, KL; Rosenthal, M; Sim, HW; Simes, J; Sulman, EP; Wheeler, H; Yip, S, 2021) |
| "However, TMZ-related acute lymphoblastic leukemia is rare." | 5.40 | Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient. ( Chang, PY; Chou, KN; Lin, YC; Liu, MY, 2014) |
| "Glioblastoma is the most common malignant primary brain tumor." | 5.40 | EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma. ( Boots-Sprenger, SH; Hiddingh, L; Hulleman, E; Jeuken, J; Kaspers, GJ; Noske, DP; Tannous, BA; Teng, J; Tops, B; Vandertop, WP; Wesseling, P; Wurdinger, T, 2014) |
| "optimal treatment of glioblastoma (gBM) in the elderly remains unclear." | 5.40 | Glioblastoma treatment in the elderly in the temozolomide therapy era. ( Al-Zahrani, A; Coate, L; Laperriere, N; Lwin, Z; Macfadden, D; Mason, WP; Massey, C; McNamara, MG; Menard, C; Millar, BA; Sahgal, A, 2014) |
| "Drug resistance is a major issue in the treatment of glioblastoma." | 5.40 | Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis. ( Hiddingh, L; Hulleman, E; Jeuken, J; Kaspers, GJ; Noske, DP; Raktoe, RS; Vandertop, WP; Wesseling, P; Wurdinger, T, 2014) |
| "Temozolomide (TMZ) is an oral alkylating agent which is widely used in the treatment of GBM following surgery." | 5.40 | miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. ( Cui, Y; Lei, Q; Li, G; She, X; Wang, Z; Wu, M; Xiang, J; Xu, G; Yu, Z, 2014) |
| "Non-invasive monitoring of response to treatment of glioblastoma (GB) is nowadays carried out using MRI." | 5.40 | Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma. ( Arús, C; Candiota, AP; Delgado-Goñi, T; Julià-Sapé, M; Pumarola, M, 2014) |
| " In the present work, TMZ was combined with a specific SKI, and the cytotoxic effect of each drug alone or in combination was tested on GBM cell lines." | 5.40 | A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy. ( Choi, J; Kopp-Schneider, A; Noack, J; Régnier-Vigouroux, A; Richter, K, 2014) |
| "Temozolomide (TMZ) has been used for the treatment of glioblastoma." | 5.40 | Inhibition of JNK potentiates temozolomide-induced cytotoxicity in U87MG glioblastoma cells via suppression of Akt phosphorylation. ( Chun, W; Kim, SS; Lee, HJ; Lee, JW; Lim, SY; Vo, VA, 2014) |
| "Here, we propose a new strategy to treat glioblastoma based on transferrin (Tf)-targeted self-assembled nanoparticles (NPs) incorporating zoledronic acid (ZOL) (NPs-ZOL-Tf)." | 5.40 | Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid. ( Artuso, S; Balestrieri, ML; Caraglia, M; De Rosa, G; Leonetti, C; Luce, A; Lusa, S; Porru, M; Salzano, G; Stoppacciaro, A; Zappavigna, S, 2014) |
| "Glioblastoma multiforme is the most aggressive primary brain tumour." | 5.39 | Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I, 2013) |
| "Lymphopenia is known to precipitate dramatic elevation in serum BLyS; however, the use of this effect to enhance humoral responses following vaccination has not been evaluated." | 5.39 | BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. ( Archer, GE; Bigner, DD; Choi, BD; Heimberger, AB; Herndon, JE; Mitchell, DA; Norberg, P; Reap, EA; Sampson, JH; Sanchez-Perez, L; Sayour, EJ; Schmittling, RJ, 2013) |
| " In the present analysis, we retrospectively investigated the feasibility and effectiveness of bevacizumab combined with ICE in patients with glioblastoma at second relapse during ICE treatment." | 5.39 | Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. ( Arakawa, Y; Fujimoto, K; Kikuchi, T; Kunieda, T; Miyamoto, S; Mizowaki, T; Murata, D; Takagi, Y; Takahashi, JC, 2013) |
| "Glioblastoma multiforme is the most common primary tumor of the central nervous system." | 5.39 | NETRIN-4 protects glioblastoma cells FROM temozolomide induced senescence. ( Chen, P; Hu, Y; Hyytiäinen, M; Keski-Oja, J; Li, H; Li, L; Ylivinkka, I, 2013) |
| "Glioblastoma is a deadly cancer with intrinsic chemoresistance." | 5.38 | Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and Paclitaxel. ( Anelli, V; Bassi, R; Brioschi, L; Campanella, R; Caroli, M; De Zen, F; Gaini, SM; Giussani, P; Riboni, L; Riccitelli, E; Viani, P, 2012) |
| "Glioblastomas are highly aggressive brain tumors of adults with poor clinical outcome." | 5.38 | Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies. ( Balabanov, S; Bokemeyer, C; Braig, M; Hagel, C; Hauber, J; Lamszus, K; Pällmann, N; Preukschas, M; Schulte, A; Sievert, H; Weber, K, 2012) |
| "These brain tumors are often resistant to chemotherapies like temozolomide (TMZ) and there are very few treatment options available to patients." | 5.38 | Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. ( Berns, R; Dunn, SE; Fotovati, A; Hu, K; Kast, RE; Kong, E; Lee, C; Luk, M; Pambid, M; Toyota, B; Toyota, E; Triscott, J; Yip, S, 2012) |
| " We evaluated the preclinical potential of a novel, orally bioavailable PI3K/mTOR dual inhibitor (XL765) in in vitro and in vivo studies." | 5.37 | Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. ( Aftab, DT; Berger, MS; Haas-Kogan, DA; James, CD; Mueller, S; Ozawa, T; Polley, MY; Prados, MD; Prasad, G; Sottero, T; Weiss, WA; Yang, X, 2011) |
| "The prognostic value of postoperative residual tumor volume in FET PET, TBR(mean,) TBR(max) and Gd-volume was evaluated using Kaplan-Maier estimates for disease-free survival (DFS) and overall survival (OS)." | 5.37 | Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. ( Coenen, HH; Eble, MJ; Galldiks, N; Herzog, H; Holy, R; Kaiser, HJ; Langen, KJ; Pinkawa, M; Piroth, MD; Stoffels, G, 2011) |
| "Glioblastoma multiforme is the most common and most malignant primary brain tumour." | 5.36 | Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib. ( Freyschlag, CF; Nölte, I; Pechlivanis, I; Schmieder, K; Seiz, M; Tuettenberg, J; Vajkoczy, P, 2010) |
| "Glioblastomas (GBM) are lethal brain tumors that are highly resistant to therapy." | 5.36 | PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. ( Bachoo, RM; Burma, S; Camacho, CV; Hahm, B; McEllin, B; Mukherjee, B; Tomimatsu, N, 2010) |
| "Bortezomib proved to be a more potent inductor of apoptosis than gefitinib and alkylating agents." | 5.35 | Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. ( Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP, 2008) |
| "Glioblastoma multiforme is a primary malignant brain tumor with a prognosis of typically less than 2 years." | 5.35 | Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: treatment-related or dual-pathology? ( Binello, E; Germano, IM, 2009) |
| "Carmustine wafer was not an independent predictor (P=." | 5.35 | Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. ( Affronti, ML; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Heery, CR; Herndon, JE; Reardon, DA; Rich, JN; Vredenburgh, JJ, 2009) |
| " Thus, the implantation of BCNU wafers prior to TMZ and radiotherapy appears safe in newly diagnosed GBM patients." | 5.35 | A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. ( Mitchell, SB; Pan, E; Tsai, JS, 2008) |
| "Temozolomide (TMZ) is used for treating glioblastoma." | 5.35 | Modulatory effects of acetazolomide and dexamethasone on temozolomide-mediated apoptosis in human glioblastoma T98G and U87MG cells. ( Banik, NL; Das, A; Ray, SK, 2008) |
| " We investigated Depatux-M in combination with temozolomide or as a single agent in a randomized controlled phase II trial in recurrent EGFR amplified glioblastoma." | 5.34 | INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. ( Ansell, P; Brilhante, J; Chinot, O; Clement, PM; Coens, C; De Vos, F; Dey, J; Dubbink, HJ; Eoli, M; Franceschi, E; French, P; Frenel, JS; Golfinopoulos, V; Gorlia, T; Krause, S; Looman, J; Nuyens, S; Sanghera, P; Sepulveda, JM; Smits, M; Spruyt, M; Van Den Bent, M; Walenkamp, A; Weller, M; Whenham, N, 2020) |
| "We sought to determine the maximum tolerated dose (MTD) of 5-fraction stereotactic radiosurgery (SRS) with 5-mm margins delivered with concurrent temozolomide in newly diagnosed glioblastoma (GBM)." | 5.34 | A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes. ( Adler, JR; Azoulay, M; Chang, SD; Choi, CYH; Fujimoto, D; Gibbs, IC; Hancock, SL; Harraher, C; Harsh, GR; Hayden Gephart, M; Jacobs, LR; Li, G; Modlin, LA; Nagpal, S; Pollom, EL; Recht, LD; Seiger, K; Soltys, SG; Thomas, RP; Usoz, M; von Eyben, R; Wynne, J, 2020) |
| " TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 trial." | 5.34 | Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial. ( Chang, JH; Hong, YK; Kim, CY; Kim, JH; Kim, OL; Kim, SH; Nam, DH; Paek, SH, 2020) |
| "We performed the first clinical trial to assess VEGFR1 and 2 vaccination along with temozolomide (TMZ) -based chemoradiotherapy for the patients with primary glioblastomas." | 5.34 | Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series. ( Hikichi, T; Kawakami, Y; Kikuchi, R; Kosugi, K; Morimoto, Y; Nagashima, H; Noji, S; Oishi, Y; Sasaki, H; Sato, M; Tamura, R; Toda, M; Ueda, R; Yoshida, K, 2020) |
| "Ipi-Glio is a phase II, open label, randomised study of ipilimumab with temozolomide (Arm A) versus temozolomide alone (Arm B) after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma." | 5.34 | A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol. ( Blagden, S; Brooks, C; Brown, NF; Coutts, T; Elhussein, L; Holmes, J; Hoskin, P; Maughan, T; Mulholland, P; Ng, SM; Roberts, C, 2020) |
| "Standard of care for glioblastoma includes concurrent chemoradiation and maintenance temozolomide with tumor treatment fields (TTFields)." | 5.34 | Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma. ( Andrews, DW; Bar-Ad, V; Chervoneva, I; Evans, JJ; Farrell, CJ; Glass, J; Judy, K; Liu, H; Ly, M; Martinez, N; Palmer, JD; Shi, W; Song, A; Werner-Wasik, M, 2020) |
| "Temozolomide (TMZ) has been the standard-of-care chemotherapy for glioblastoma (GBM) patients for more than a decade." | 5.34 | Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma. ( Bendok, BR; Doyle, T; Hawkins-Daarud, A; Hu, LS; Jackson, PR; Johnston, SK; Massey, SC; Mrugala, MM; Porter, AB; Sarkaria, JN; Singleton, KW; Swanson, KR; Vora, S; White, H; Whitmire, P, 2020) |
| "Standard treatment for glioblastoma is radiation with concomitant and adjuvant temozolomide for 6 cycles, although the optimal number of cycles of adjuvant temozolomide has long been a subject of debate." | 5.34 | A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). ( Alonso, M; Balana, C; Berrocal, A; Carrato, C; Covela, M; de Las Peñas, R; Del Barco, S; Domenech, M; Esteve, A; Estival, A; Fuster, J; Gallego, O; Gil-Gil, M; Gironés, R; Herrero, A; Luque, R; Manuel Sepúlveda, J; Martinez-García, M; Mesia, C; Munne, N; Muñoz-Langa, J; Navarro, LM; Olier, C; Peralta, S; Perez-Martín, FJ; Perez-Segura, P; Pineda, E; Sanz, C; Vaz, MA; Villa, S, 2020) |
| "The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib potentiated radiation and temozolomide (TMZ) chemotherapy in preclinical glioblastoma models but brain penetration was poor." | 5.34 | Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. ( Carruthers, R; Chalmers, AJ; Cruickshank, G; Dunn, L; Erridge, S; Godfrey, L; Halford, S; Hanna, C; Jackson, A; Jefferies, S; Kurian, KM; McBain, C; McCormick, A; Pittman, M; Sleigh, R; Strathdee, K; Watts, C; Williams, K, 2020) |
| "This study aimed to explore the genetic alterations and to identify good responders in the experimental arm in the tumor samples from newly diagnosed glioblastoma (GBM) patients enrolled in JCOG0911; a randomized phase II trial was conducted to compare the efficacy of interferonβ (IFNβ) plus temozolomide (TMZ) with that of TMZ alone." | 5.34 | Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone. ( Abe, T; Adilijiang, A; Aoki, K; Aoki, T; Arakawa, Y; Asai, A; Asano, K; Beppu, T; Hashimoto, N; Hirano, H; Hirano, M; Ishikawa, E; Ito, T; Iwadate, Y; Kayama, T; Kobayashi, H; Kumabe, T; Kurisu, K; Maeda, S; Maruyama, T; Matsumura, A; Matsuo, T; Mishima, K; Motomura, K; Mukasa, A; Muragaki, Y; Nagane, M; Nakamura, H; Nakasu, Y; Narita, Y; Natsume, A; Nishikawa, R; Ohka, F; Okuno, Y; Onishi, T; Sasaki, H; Sato, S; Shibui, S; Shinoura, N; Sugiyama, K; Sumi, M; Terasaki, M; Wakabayashi, T; Yamasaki, F; Yoshimoto, K; Yoshino, A, 2020) |
| "In this open-label, randomized, phase 3 clinical trial, 439 patients with glioblastoma at first recurrence following standard radiation and temozolomide therapy were enrolled, and 369 were randomized." | 5.34 | Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. ( Ahluwalia, MS; Baehring, J; Bähr, O; Brandes, AA; Carleton, M; De Souza, P; Lim, M; Mulholland, P; Omuro, A; Phuphanich, S; Reardon, DA; Roth, P; Sahebjam, S; Sampson, J; Sepulveda, JM; Taitt, C; Tatsuoka, K; Weller, M; Wick, A; Zwirtes, R, 2020) |
| " In a previously-published multi-centre randomized clinical trial of 562 elderly glioblastoma patients, temozolomide plus short-course radiotherapy conferred a survival benefit over radiotherapy alone." | 5.34 | Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients. ( Brandes, AA; Cairncross, JG; Climans, SA; Ding, K; Fay, M; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Perry, JR; Phillips, C; Roa, W; Wick, W; Winch, C, 2020) |
| "This was a phase I, two-stage, multicentre, open-label, dose-escalation study of buparlisib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma." | 5.34 | Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. ( Beck, JT; DeGroot, J; Donnet, V; El-Hashimy, M; Mason, W; Mills, D; Rodon, JA; Rosenthal, M; Wen, PY, 2020) |
| "Glioblastomas are malignant brain tumors that are very difficult to cure, even with aggressive therapy consisting of surgery, chemotherapy, and radiation." | 5.34 | Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. ( Bernhard, EJ; Cerniglia, GJ; Georgescu, MM; Gupta, AK; Hahn, SM; Jiang, Z; Maity, A; Mick, R; Pore, N, 2007) |
| "Surgical cure of glioblastomas is virtually impossible and their clinical course is mainly determined by the biologic behavior of the tumor cells and their response to radiation and chemotherapy." | 5.33 | Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. ( Beerenwinkel, N; Feiden, W; Hartmann, C; Ketter, R; Lengauer, T; Meese, E; Rahnenführer, J; Steudel, WI; Stockhammer, F; Strowitzki, M; Urbschat, S; von Deimling, A; Wemmert, S; Zang, KD, 2005) |
| "Tamoxifen and hypericin were able to greatly increase the growth-inhibitory and apoptosis-stimulatory potency of temozolomide via the downregulation of critical cell cycle-regulatory and prosurvival components." | 5.33 | Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin. ( Chen, TC; Gupta, V; Hofman, FM; Kardosh, A; Liebes, LF; Schönthal, AH; Su, YS; Wang, W, 2006) |
| "Temozolomide (TMZ) is a methylating agent with promising antitumor efficacy for the treatment of melanomas and intermediate-grade gliomas." | 5.32 | The piperidine nitroxide Tempol potentiates the cytotoxic effects of temozolomide in human glioblastoma cells. ( Cereda, E; Gariboldi, MB; Monti, E; Ravizza, R, 2004) |
| "Glioblastoma is the deadliest and most prevalent brain tumor." | 5.32 | Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities. ( Banik, NL; Das, A; Patel, SJ; Ray, SK, 2004) |
| "Temozolomide (TMZ) is a DNA-methylating agent that has recently been introduced into Phase II and III trials for the treatment of gliomas." | 5.31 | p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. ( Berger, MS; Hirose, Y; Pieper, RO, 2001) |
| "To determine the efficacy of the thrombopoietin receptor agonist romiplostim for the prevention of temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma." | 5.30 | Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial. ( Cartalat, S; Chinot, O; Devos, P; Di Stefano, AL; Dubois, F; Houillier, C; Le Rhun, E; Lepage, C; Reyns, N; Weller, M, 2019) |
| " The present standard treatment for newly diagnosed glioblastoma is maximal resection followed by chemoradiotherapy with temozolomide." | 5.30 | A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703 ( Ichimura, K; Igaki, H; Kadota, T; Katayama, H; Kinoshita, M; Komori, T; Kumabe, T; Mizusawa, J; Narita, Y; Nishikawa, R; Saito, R; Sumi, M, 2019) |
| " We assessed the efficacy and safety of iniparib with standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma (GBM)." | 5.30 | Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. ( Ahluwalia, MS; Blakeley, JO; Chi, AS; Desideri, S; Eichler, A; Grossman, SA; Mikkelsen, T; Nabors, LB; Ribas, IG; Rosenfeld, MR; Ye, X, 2019) |
| "Patients with glioblastoma without O6-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation are unlikely to benefit from alkylating chemotherapy with temozolomide (TMZ)." | 5.30 | N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. ( Bendszus, M; Berberich, A; Brors, B; Debus, J; Dettmer, S; Eisenmenger, A; Herold-Mende, C; Jones, DTW; Karapanagiotou-Schenkel, I; Kessler, T; Pfaff, E; Pfister, SM; Platten, M; Sahm, F; Unterberg, A; von Deimling, A; Wick, A; Wick, W; Winkler, F, 2019) |
| "Memantine, mefloquine, and metformin can be combined safely with TMZ in patients with newly diagnosed glioblastoma." | 5.30 | Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. ( Aldape, KD; Alfred Yung, WK; Conrad, CA; de Groot, JF; Gilbert, MR; Groves, MD; Hess, KR; Loghin, ME; Mammoser, AG; Maraka, S; Melguizo-Gavilanes, I; O'Brien, BJ; Penas-Prado, M; Puduvalli, VK; Sulman, EP; Tremont-Lukats, IW, 2019) |
| "To evaluate the toxicity and efficacy of adjuvant temozolomide (TMZ) and irinotecan (CPT-11) for 12 months after concurrent chemoradiation in patients with newly diagnosed glioblastoma (GBM)." | 5.30 | Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. ( Curran, WJ; Hartford, AC; Lieberman, FS; Mehta, MP; Robins, HI; Schultz, C; Smith, RP; Tsien, CI; Wang, M; Werner-Wasik, M; Zhang, P, 2019) |
| "Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ)." | 5.30 | A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. ( Boockvar, J; Campian, JL; Chaudhary, R; Chinnaiyan, P; Cohen, AL; Fink, K; Goldlust, S; Huang, J; Marcus, S; Wan, L, 2019) |
| "In RPA V-VI glioblastoma patients both hypofractionated radiotherapy and exclusive temozolomide can be used; the purpose of this trial is to compare these treatment regimens in terms of survival and quality of life." | 5.30 | Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial. ( Borghetti, P; Bruni, A; Buglione, M; Fusco, V; Gatta, R; Krengli, M; Magrini, SM; Masini, L; Meduri, B; Pedretti, S; Pegurri, L; Pirtoli, L; Ricardi, U; Riva, N; Santoni, R; Scoccianti, S; Triggiani, L; Turco, E, 2019) |
| "The phase II GLARIUS trial assigned patients with newly diagnosed, O-6-methylguanine-DNA methyltransferase promoter non-methylated glioblastoma to experimental bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ)." | 5.30 | Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. ( Bähr, O; Belka, C; Borchers, C; Galldiks, N; Gerlach, R; Glas, M; Goldbrunner, R; Hänel, M; Hattingen, E; Hau, P; Herrlinger, U; Junold, N; Kebir, S; Krex, D; Mack, F; Proescholdt, M; Rohde, V; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schmidt-Graf, F; Seidel, C; Steinbach, JP; Tabatabai, G; Tzaridis, T; Vatter, H; Weller, J; Weyerbrock, A, 2019) |
| "A multicenter phase II study for assessing the efficacy and the toxicity of hypofractionated radiotherapy with SIB plus temozolomide in patients with glioblastoma was carried out by the Brain Study Group of the Italian Association of Radiation Oncology." | 5.27 | Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO). ( Buglione, M; Detti, B; Doino, D; Fiorentino, A; Fusco, V; Greto, D; Krengli, M; Livi, L; Lonardi, F; Magrini, SM; Marrazzo, L; Marzano, S; Masini, L; Migliaccio, F; Pirtoli, L; Ricardi, U; Rubino, G; Santoni, R; Scoccianti, S, 2018) |
| "Vorinostat combined with standard chemoradiation had acceptable tolerability in newly diagnosed glioblastoma." | 5.27 | Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. ( Ahluwalia, MS; Anderson, SK; Ballman, KV; Buckner, JC; Cerhan, J; Galanis, E; Gerstner, ER; Giannini, C; Grossman, SA; Jaeckle, K; Lee, EQ; Lesser, GJ; Ligon, KL; Loboda, A; Miller, CR; Moore, DF; Nebozhyn, M; Prados, M; Sarkaria, JN; Schiff, D; Wen, PY, 2018) |
| "In this exploratory analysis of AVAglio, a randomized phase III clinical study that investigated the addition of bevacizumab (Bev) to radiotherapy/temozolomide in newly diagnosed glioblastoma, we aim to radiologically characterize glioblastoma on therapy until progression and investigate whether the type of radiologic progression differs between treatment arms and is related to survival and molecular data." | 5.27 | Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio. ( Abrey, LE; Bendszus, M; Chinot, OL; Cloughesy, TF; Ellingson, BM; Garcia, J; Henriksson, R; Kickingereder, P; Mason, WP; Nishikawa, R; Nowosielski, M; Platten, M; Radbruch, A; Revil, C; Sandmann, T; Saran, F; Wick, W, 2018) |
| "We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly called ABT-414, plus radiation and temozolomide in newly diagnosed glioblastoma (arm A)." | 5.27 | Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. ( Ansell, PJ; Butowski, N; Fichtel, L; Fischer, J; Gan, HK; Gomez, EJ; Holen, KD; Kumthekar, P; Lassman, AB; Lee, HJ; Lwin, Z; Mandich, H; Merrell, R; Munasinghe, WP; Reardon, DA; Roberts-Rapp, LA; Scott, AM; van den Bent, M; Wheeler, H; Xiong, H, 2018) |
| "To determine the impact on overall survival with different salvage therapies, including no treatment, reirradiation, systemic therapy, or radiation and systemic therapy, in participants of a phase 3 clinical trial evaluating dose-dense versus standard-dose temozolomide for patients with newly diagnosed glioblastoma." | 5.27 | Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. ( Andrews, DW; Blumenthal, DT; Brown, PD; Dignam, JJ; Gilbert, MR; Hopkins, K; Howard, SP; Lessard, N; Mehta, MP; Scannell Bryan, M; Shi, W; Souhami, L; Tzuk-Shina, T; Valeinis, E; Werner-Wasik, M; Youssef, EF, 2018) |
| "The GLARIUS trial, which investigated the efficacy of bevacizumab (BEV)/irinotecan (IRI) compared with standard temozolomide in the first-line therapy of O6-methylguanine-DNA methyltransferase (MGMT)-nonmethylated glioblastoma, showed that progression-free survival was significantly prolonged by BEV/IRI, while overall survival was similar in both arms." | 5.27 | Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. ( Belka, C; Friedrich, F; Glas, M; Goldbrunner, R; Grau, S; Grauer, O; Hänel, M; Hau, P; Herrlinger, U; Kebir, S; Krex, D; Leutgeb, B; Mack, F; Nießen, M; Proescholdt, M; Ringel, F; Rohde, V; Ronellenfitsch, MW; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schnell, O; Steinbach, JP; Stummer, W; Tabatabai, G; Tzaridis, T; Uhl, M; Urbach, H; Vajkoczy, P; Weyerbrock, A, 2018) |
| "This phase II study was designed to determine the efficacy of the mammalian target of rapamycin (mTOR) inhibitor everolimus administered daily with conventional radiation therapy and chemotherapy in patients with newly diagnosed glioblastoma." | 5.27 | A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913. ( Ahluwalia, MS; Ashby, LS; Chinnaiyan, P; Fiveash, JB; Kee, AY; Malone, SC; Mehta, MP; Michael Yu, HH; Mohile, NA; Rojiani, AM; Shih, HA; Stella, PJ; Stieber, VW; Wen, PY; Wendland, MM; Werner-Wasik, M; Won, M, 2018) |
| "Disulfiram has shown promising activity including proteasome inhibitory properties and synergy with temozolomide in preclinical glioblastoma (GBM) models." | 5.27 | Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. ( Ansstas, G; Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, C, 2018) |
| "This secondary analysis of EF-14, a phase 3 randomized clinical trial, compares TTFields and temozolomide or temozolomide alone in 695 patients with glioblastoma after completion of radiochemotherapy." | 5.27 | Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. ( Bruna, J; Chen, TC; David, C; Desai, R; Dirven, L; Easaw, JC; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kew, Y; Kim, CY; Kirson, ED; Lavy-Shahaf, G; Ram, Z; Roth, P; Sroubek, J; Stupp, R; Taillibert, S; Taphoorn, MJB; Toms, SA; Villano, JL; Weinberg, U, 2018) |
| "Concomitant radiochemotherapy followed by six cycles of temozolomide (= short term) is considered as standard therapy for adults with newly diagnosed glioblastoma." | 5.27 | Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany. ( Arefian, H; Hartmann, M; Kalff, R; Maschmann, J; Walter, J; Waschke, A, 2018) |
| "Results suggest that the combination of bevacizumab plus temozolomide is active in terms of response rate, survival, performance, quality of life, and cognition in elderly patients with glioblastoma multiforme with poor performance status." | 5.27 | Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG). ( Barrie, M; Barrière, J; Beauchesne, P; Benouaich-Amiel, A; Campello, C; Cartalat-Carel, S; Catry-Thomas, I; Chinot, OL; Delattre, JY; Fabbro, M; Frappaz, D; Ghiringhelli, F; Guillamo, JS; Honnorat, J; Le Rhun, E; Mokhtari, K; Reyes-Botero, G; Taillandier, L; Tanguy, ML; Tennevet, I, 2018) |
| "ACRIN 6686/RTOG 0825 was a phase III trial of conventional chemoradiation plus adjuvant temozolomide with bevacizumab or without (placebo) in newly diagnosed glioblastoma." | 5.27 | Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686. ( Barboriak, DP; Boxerman, JL; Gilbert, MR; Marques, H; Mohan, S; Rogg, JM; Safriel, Y; Sorensen, AG; Wolf, RL; Zhang, Z, 2018) |
| "In this phase II study, we investigate clinical outcomes and tolerability of hypofractionated radiotherapy (HRT) combined with temozolomide (TMZ) to treat elderly patients with glioblastoma (GBM)." | 5.27 | Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma. ( Amsbaugh, M; Boakye, M; Burton, E; Hattab, EM; Nelson, M; Ugiliweneza, B; Williams, B; Woo, S; Yusuf, M, 2018) |
| "In total, 111 newly, histologically diagnosed glioblastoma patients treated at our oncology center with radiotherapy and temozolomide were prospectively enrolled." | 5.27 | Quality of Life Perception, Cognitive Function, and Psychological Status in a Real-world Population of Glioblastoma Patients Treated With Radiotherapy and Temozolomide: A Single-center Prospective Study. ( Bellu, L; Bergo, E; Caccese, M; Del Bianco, P; Lombardi, G; Pambuku, A; Trentin, L; Zagonel, V, 2018) |
| "We evaluated patterns of tumor growth in patients with newly diagnosed MGMT-non-methylated glioblastoma who were assigned to undergo radiotherapy in conjunction with bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ) within the randomized phase II GLARIUS trial." | 5.27 | Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. ( Bähr, O; Belka, C; Braun, C; Gerlach, R; Glas, M; Goldbrunner, R; Hänel, M; Hattingen, E; Hau, P; Herrlinger, U; Junold, N; Kebir, S; Kortmann, RD; Krex, D; Mack, F; Niessen, M; Proescholdt, M; Rohde, V; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schmidt-Graf, F; Steinbach, JP; Stuplich, M; Tzaridis, T; Vatter, H; Weyerbrock, A, 2018) |
| "This post hoc analysis of the EF-14 trial (NCT00916409) of tumor-treating fields (TTFields) plus temozolomide versus temozolomide alone in newly diagnosed glioblastoma compared the efficacy of TTFields plus chemotherapy (physician's choice) versus chemotherapy alone after first recurrence." | 5.24 | Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. ( Kesari, S; Ram, Z, 2017) |
| "We report a longitudinal assessment of health-related quality of life (HRQOL) in patients with glioblastoma (GBM) treated on a prospective dose escalation trial of 5-fraction stereotactic radiosurgery (25-40 Gy in 5 fractions) with concurrent and adjuvant temozolomide." | 5.24 | Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results. ( Adler, JR; Azoulay, M; Chang, SD; Choi, CYH; Fujimoto, D; Gibbs, IC; Hancock, SL; Harraher, C; Harsh, GR; Jacobs, LR; Li, G; Modlin, LA; Nagpal, S; Pollom, EL; Recht, LD; Seiger, K; Soltys, SG; Thomas, RP; Tupper, L; von Eyben, R; Wynne, J, 2017) |
| "Bevacizumab plus bi-weekly temozolomide was well tolerated and may be a salvage regimen to be considered in a subset of patients with recurrent glioblastoma." | 5.24 | Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma. ( Ahmadi, MM; Badruddoja, MA; Kuzma, K; Mahadevan, D; Norton, T; Pazzi, M; Sanan, A; Schroeder, K; Scully, T, 2017) |
| "We characterized health-related quality of life (HRQoL), cognitive, and functional status in newly diagnosed glioblastoma (GBM) patients receiving Tumor treating fields (TTFields) with temozolomide (TMZ) versus TMZ alone in a planned interim analysis of a randomized phase III trial [NCT00916409], which showed significant improvement in progression-free and overall survival with TTFields/TMZ." | 5.24 | Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. ( Avgeropoulos, N; Benouaich-Amiel, A; David, C; Demireva, P; Goldlust, S; Kanner, AA; Mehdorn, M; Pannullo, S; Salmaggi, A; Silvani, A; Zhu, JJ, 2017) |
| "In the final analysis of this randomized clinical trial of patients with glioblastoma who had received standard radiochemotherapy, the addition of TTFields to maintenance temozolomide chemotherapy vs maintenance temozolomide alone, resulted in statistically significant improvement in progression-free survival and overall survival." | 5.24 | Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. ( Ahluwalia, MS; Brem, S; Bruna, J; Di Meco, F; Fink, K; Hegi, ME; Hirte, H; Hottinger, A; Idbaih, A; Kanner, A; Kim, CY; Kirson, ED; Lavy-Shahaf, G; Lhermitte, B; Lieberman, F; Nicholas, G; Paek, SH; Palti, Y; Ram, Z; Read, W; Steinberg, D; Stragliotto, G; Stupp, R; Taillibert, S; Toms, S; Tran, D; Weinberg, U; Weller, M; Zhu, JJ, 2017) |
| " We evaluated the efficacy and safety of CIK cell immunotherapy with radiotherapy-temozolomide (TMZ) for the treatment of newly diagnosed glioblastomas." | 5.24 | Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea. ( Chang, JH; Chung, YG; Kang, SH; Kim, CH; Kim, JH; Kim, JM; Koh, YC; Kong, DS; Lee, JW; Lim, YJ; Nam, DH, 2017) |
| "We performed a phase 2 trial of neoadjuvant temozolomide (TMZ), followed by hypofractionated accelerated radiation therapy (HART) with concurrent TMZ, and adjuvant TMZ in patients with newly diagnosed glioblastoma to determine whether neoadjuvant TMZ would safely improve outcomes in this group of patients prior to subsequent cytotoxic therapy." | 5.24 | A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma. ( Abdulkarim, B; Corredor, AG; Guiot, MC; Owen, S; Panet-Raymond, V; Petrecca, K; Shenouda, G; Souhami, L, 2017) |
| "The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II dose (RPTD), safety, and pharmacokinetics of ABT-414 plus radiation and temozolomide in newly diagnosed glioblastoma." | 5.24 | Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. ( Ansell, P; Fichtel, L; Fischer, J; Gan, HK; Gomez, E; Holen, KD; Kumthekar, P; Lassman, AB; Lee, HJ; Mandich, H; Merrell, R; Munasinghe, W; Reardon, DA; Roberts-Rapp, L; Scott, AM; Sulman, EP; van den Bent, M; Xiong, H, 2017) |
| "There is a need for a more refined, molecularly based classification model for glioblastoma (GBM) in the temozolomide era." | 5.24 | Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525. ( Aldape, K; Barnholtz-Sloan, JS; Becker, AP; Bell, EH; Blumenthal, DT; Brachman, D; Bredel, M; Brown, PD; Chakravarti, A; Curran, W; Flickinger, J; Gilbert, MR; Glass, J; Grosu, AL; Klimowicz, AC; Lee, RJ; Magliocco, A; McElroy, JP; Mehta, M; Pugh, SL; Robe, P; Salavaggione, AL; Souhami, L; Stupp, R; Won, M, 2017) |
| "In glioblastoma multiforme (GBM), both temozolomide (TMZ) and cisplatin are very active at various toxic levels." | 5.24 | Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients. ( Guo, Y; Kong, X; Ma, W; Wang, R; Wang, Y, 2017) |
| "In elderly patients with glioblastoma, the addition of temozolomide to short-course radiotherapy resulted in longer survival than short-course radiotherapy alone." | 5.24 | Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. ( Back, M; Baumert, BG; Brandes, AA; Cairncross, JG; Chinot, O; Ding, K; Fariselli, L; Fay, M; Feuvret, L; Franceschi, E; Golfinopoulos, V; Hirte, H; Laigle-Donadey, F; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Osoba, D; Perry, JR; Phillips, C; Roa, W; Rossiter, JP; Sahgal, A; Tills, M; Wick, A; Wick, W; Winch, C, 2017) |
| "Despite an aggressive standard of care involving radiation therapy, temozolomide-based chemotherapy, and surgical resection, glioblastoma multiforme (GBM) continues to exhibit very high recurrence and mortality rates partly due to the highly plastic and heterogenous nature of the tumor." | 5.22 | Checkpoint: Inspecting the barriers in glioblastoma immunotherapies. ( Ahmed, AU; Miska, J; Nandoliya, K; Preddy, I, 2022) |
| "Temozolomide (TMZ) is an imidazotetrazine prodrug used to treat glioblastoma multiforme." | 5.22 | Temozolomide: An Overview of Biological Properties, Drug Delivery Nanosystems, and Analytical Methods. ( Carvalho, SG; Chorilli, M; Di Filippo, LD; Dutra, JAP; Luiz, MT; Tavares Junior, AG, 2022) |
| "Temozolomide (TMZ), an imidazotetrazine, is a second-generation DNA alkylating agent used as a first-line treatment of glioblastoma multiforme (GBM)." | 5.22 | Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme. ( Chitkara, D; Jatyan, R; Karthik, YG; Mittal, A; Sahel, DK; Singh, P, 2022) |
| "Glioblastoma multiforme (GBM) is a brain tumor notorious for its propensity to recur after the standard treatments of surgical resection, ionizing radiation (IR), and temozolomide (TMZ)." | 5.22 | Intersections of Ubiquitin-Proteosome System and Autophagy in Promoting Growth of Glioblastoma Multiforme: Challenges and Opportunities. ( Ray, SK; Visintin, R, 2022) |
| "To evaluate the safety and efficacy of nimotuzumab, a humanized monoclonal antibody specific for the epidermal growth factor receptor (EGFR), in combination with temozolomide (TMZ) and radiation therapy (RT) in the treatment of newly diagnosed glioblastoma (GBM) in Chinese patients." | 5.22 | Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients. ( Chen, S; Dai, JZ; Pan, L; Sheng, XF; Wang, Y, 2016) |
| "Survival for glioblastoma (GBM) patients with an unmethyated MGMT promoter in their tumor is generally worse than methylated MGMT tumors, as temozolomide (TMZ) response is limited." | 5.22 | A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. ( Aldape, K; Chamberlain, M; Conrad, C; De Groot, J; Giglio, P; Gilbert, MR; Grimm, S; Groves, M; Hu, J; Liu, D; Loghin, M; Merrell, R; Paleologos, N; Phuphanich, S; Puduvalli, VK; Rademaker, A; Raizer, JJ; Rudnick, J; Tremont-Lukats, IW; Vaillant, B; Vick, N; Yuan, Y; Yung, WK, 2016) |
| "We report on a phase II clinical trial to determine the effect of a concurrent ultra-fractionated radiotherapy and temozolomide treatment in inoperable glioblastoma patients." | 5.22 | A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma. ( Beauchesne, P; Bernier, V; Carnin, C; Faure, G; Gorlia, T; Noel, G; Pedeux, R; Quetin, P; Quillien, V, 2016) |
| "This study tested the hypothesis that ABT-888 (velparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, can modulate temozolomide (TMZ) resistance in recurrent TMZ refractory glioblastoma patients." | 5.22 | A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. ( Cavaliere, R; Chakravarti, A; Chmura, SJ; Colman, H; de Groot, JF; Gilbert, MR; Grimm, SA; Kee, AY; Kesari, S; Krauze, A; Lieberman, FS; Mehta, M; Mohile, N; Robins, HI; Trotti, AM; Wang, F; Zhang, P, 2016) |
| "This phase II study was conducted to determine the efficacy and safety of metronomic temozolomide (TMZ) in combination with irinotecan in glioblastoma (GB) at first relapse." | 5.22 | Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Benavides, M; Fleitas, T; Gallego, O; Gil-Gil, M; Martínez-Sales, V; Palomero, I; Pérez-Segura, P; Reche, E; Reynés, G; Vaz, MA; Vila, V, 2016) |
| "Cabozantinib inhibits mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2) and has demonstrated activity in patients with recurrent glioblastoma, warranting evaluation of the addition of cabozantinib to radiotherapy (RT) and temozolomide (TMZ) for patients with newly diagnosed high-grade glioma." | 5.22 | Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. ( Chamberlain, MC; Cloughesy, T; Desjardins, A; Glantz, M; Mikkelsen, T; Reardon, DA; Schiff, D; Wen, PY, 2016) |
| "The proposed use of bevacizumab with radiotherapy/temozolomide for newly diagnosed glioblastoma raised potential safety concerns." | 5.22 | Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. ( Chinot, OL; Cloughesy, T; Dhar, S; Garcia, J; Henriksson, R; Mason, W; Nishikawa, R; Pozzi, E; Saran, F; Wick, W, 2016) |
| "Disulfiram, a generic alcohol aversion drug, has promising preclinical activity against glioblastoma (GBM)." | 5.22 | A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy. ( Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, CI, 2016) |
| "In patients with newly diagnosed glioblastoma that harbors a nonmethylated O(6)-methylguanine-DNA methyltransferase promotor, standard temozolomide (TMZ) has, at best, limited efficacy." | 5.22 | Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. ( Belka, C; Brehmer, S; Dunkl, E; Fietkau, R; Friedrich, F; Gerlach, R; Glas, M; Goldbrunner, R; Grau, S; Hänel, M; Hau, P; Herrlinger, U; Kebir, S; Kohnen, R; Kortmann, RD; Krex, D; Leutgeb, B; Maciaczyk, J; Mack, F; Mayer-Steinacker, R; Mehdorn, M; Pietsch, T; Proescholdt, M; Ringel, F; Rohde, V; Ronellenfitsch, MW; Sabel, M; Schäfer, N; Schlegel, U; Schnell, O; Steinbach, JP; Stummer, W; Stuplich, M; Tüttenberg, J; Uhl, M; Urbach, H; Vajkoczy, P; Weyerbrock, A, 2016) |
| "To evaluate the maximum tolerated dose of simultaneous integrated-boost intensity-modulated radiotherapy (SIB-IMRT) associated with temozolomide in patients with glioblastoma." | 5.22 | A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma. ( Bernier, V; Blanchard, N; Bonnetain, F; Dalban, C; Lagneau, É; Maingon, P; Mazoyer, F; Mirjolet, C; Noël, G; Truc, G, 2016) |
| " Patients with MGMT unmethylated glioblastoma (n = 111) were randomized 1:1 between standard chemo-radiotherapy with temozolomide or radiotherapy plus weekly temsirolimus (25 mg)." | 5.22 | Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). ( Bady, P; Brandes, AA; Campone, M; Frenel, JS; Golfinopoulos, V; Gorlia, T; Hamou, MF; Hegi, ME; Homicsko, K; Hopkins, K; Kosch, M; Lhermitte, B; Marosi, C; Pesce, G; Platten, M; Ricard, D; Roth, P; Steuve, J; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Villa, S; Weller, M; Weyerbrock, A; Wick, A; Wick, W, 2016) |
| "This trial was designed to evaluate the safety and clinical responses to a combination of temozolomide (TMZ) chemotherapy and immunotherapy with fusions of DCs and glioma cells in patients with glioblastoma (GBM)." | 5.22 | Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma. ( Akasaki, Y; Arai, T; Hayashi, K; Homma, S; Joki, T; Kikuchi, T; Koido, S; Komita, H; Mori, R; Murayama, Y; Ohkusa, T; Suzuki, Y; Tanaka, T; Tasaki, T; Watanabe, N; Yamamoto, Y; Yanagisawa, T, 2016) |
| "Temozolomide (TMZ) administered daily with radiation therapy (RT) for 6 weeks, followed by adjuvant TMZ for 6 cycles, is the standard therapy for newly diagnosed glioblastoma (GBM) patients." | 5.20 | Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study. ( Amadori, A; Berti, F; Bertorelle, R; Della Puppa, A; Farina, P; Lombardi, G; Marcato, R; Rumiato, E; Sacchetto, V; Saggioro, D; Zagonel, V; Zustovich, F, 2015) |
| "This phase I/II trial evaluated the maximum tolerated dose (MTD) and pharmacokinetics of afatinib plus temozolomide as well as the efficacy and safety of afatinib as monotherapy (A) or with temozolomide (AT) vs temozolomide monotherapy (T) in patients with recurrent glioblastoma (GBM)." | 5.20 | Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. ( Cong, J; Cseh, A; Eisenstat, DD; Fu, Y; Kavan, P; Mason, WP; Mathieu, D; Nabors, LB; Perry, JR; Phuphanich, S; Reardon, DA; Shapiro, W; Wind, S, 2015) |
| "Chemoradiation, followed by adjuvant temozolomide, is the standard treatment for newly diagnosed glioblastoma." | 5.20 | Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. ( Aldape, KD; Chang, EL; Colman, H; Conrad, CA; De Groot, JF; Fisch, MJ; Floyd, JD; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, KR; Hsu, SH; Lagrone, LW; Levin, VA; Loghin, ME; Mahajan, A; Penas-Prado, M; Puduvalli, VK; Salacz, ME; Volas-Redd, G; Woo, SY; Yung, WK, 2015) |
| " We evaluated the efficacy and toxicity of hypofractionated intensity-modulated radiation therapy with concurrent and adjuvant temozolomide and bevacizumab in patients with newly diagnosed glioblastoma." | 5.20 | Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. ( Carlson, JA; Chen, C; Damek, DM; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, KO; Ney, DE; Reddy, K; Waziri, AE, 2015) |
| "Patients with a newly diagnosed glioblastoma multiforme (GBM) have a high risk of recurrent disease with a dismal outcome despite intensive treatment of sequential surgery and chemoradiotherapy with temozolomide (TMZ), followed by TMZ as a single agent." | 5.20 | Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme. ( Reijneveld, JC; Richel, DJ; Stalpers, LJ; van Furth, WR; van Linde, ME; Verheul, HM; Verhoeff, JJ, 2015) |
| "Rindopepimut and standard adjuvant temozolomide chemotherapy were administered to 65 patients with newly diagnosed EGFRvIII-expressing (EGFRvIII+) glioblastoma after gross total resection and chemoradiation." | 5.20 | A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. ( Archer, GE; Baehring, JM; Bigner, DD; Cruickshank, S; Davis, TA; Green, JA; Groves, MD; Heimberger, AB; Jensen, R; Keler, T; Lai, RK; Mrugala, MM; Paleologos, NA; Reardon, DA; Recht, LD; Sampson, JH; Schuster, J; Sloan, A, 2015) |
| "Neoplastic cells of Glioblastoma multiforme (GBM) may or may not show sustained response to temozolomide (TMZ) chemotherapy." | 5.20 | Variant allele frequency enrichment analysis in vitro reveals sonic hedgehog pathway to impede sustained temozolomide response in GBM. ( Basu, A; Basu, P; Basu, SK; Bhattacharya, RN; Biswas, NK; Chandra, V; Chatterjee, A; Chattopadhyay, A; Das, S; Das, T; Dhara, S; Kumar, S; Maitra, A; Mukherjee, A; Sarkar-Roy, N; Tripathy, LN, 2015) |
| "Rechallenge with temozolomide (TMZ) at first progression of glioblastoma after temozolomide chemoradiotherapy (TMZ/RT→TMZ) has been studied in retrospective and single-arm prospective studies, applying temozolomide continuously or using 7/14 or 21/28 days schedules." | 5.20 | MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. ( Bähr, O; Felsberg, J; Goldbrunner, R; Hau, P; Herrlinger, U; Homicsko, K; Hüsing, J; Kästner, B; Ketter, R; Kollias, S; Marosi, C; Meixensberger, J; Nikkhah, G; Pichler, J; Platten, M; Reifenberger, G; Sabel, MC; Schlegel, U; Schnell, O; Steinbach, JP; Stupp, R; Tabatabai, G; Tonn, JC; Vajkoczy, P; Weller, M; Wick, A; Wick, W; Wirsching, HG, 2015) |
| "To investigate the safety of combined Wilms tumor 1 peptide vaccination and temozolomide treatment of glioblastoma, a phase I clinical trial was designed." | 5.20 | Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response. ( Arita, N; Chiba, Y; Hashimoto, N; Hosen, N; Izumoto, S; Kagawa, N; Kijima, N; Kinoshita, M; Morimoto, S; Morita, S; Nakajima, H; Nishida, S; Oji, Y; Oka, Y; Sakamoto, J; Sugiyama, H; Tsuboi, A; Yoshimine, T, 2015) |
| "The purpose of phase 1 was to determine the maximum tolerated dose (MTD) of motexafin gadolinium (MGd) given concurrently with temozolomide (TMZ) and radiation therapy (RT) in patients with newly diagnosed supratentorial glioblastoma multiforme (GBM)." | 5.20 | Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513. ( Ashby, LS; Bovi, JA; Brachman, DG; Curran, WP; Dunbar, EM; Narayan, S; Pugh, SL; Robins, HI; Rockhill, JK; Thomas, TA; Won, M, 2015) |
| " We conducted a randomized, noncomparative, phase II study of radiation (RT) and temozolomide with or without vandetanib in patients with newly diagnosed glioblastoma (GBM)." | 5.20 | A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. ( Alexander, BM; Ancukiewicz, M; Batchelor, TT; Beroukhim, R; Drappatz, J; Duda, DG; Gerard, M; Huse, JT; Jain, RK; Kaley, TJ; Lassman, AB; Lee, EQ; Ligon, KL; McCluskey, CS; Mikkelsen, T; Muzikansky, A; Norden, AD; Purow, BW; Ramkissoon, S; Schiff, D; Smith, KH; Weiss, SE; Wen, PY; Wong, ET, 2015) |
| "The aim of this prospective and multicentric phase II study was to evaluate the efficacy and safety of temozolomide (TMZ) and bevacizumab (BV) in patients (pts) with recurrent glioblastoma (GB), previously treated with chemoradiotherapy and at least three cycles of adjuvant TMZ." | 5.20 | A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Belda-Iniesta, C; Berrocal, A; Capellades, J; Gallego, O; Gil-Gil, M; La Orden, B; Ordoñez, JM; Pérez-Segura, P; Reynés, G; Sepúlveda, JM, 2015) |
| "Valproic acid (VPA) is an antiepileptic agent with histone deacetylase inhibitor (HDACi) activity shown to sensitize glioblastoma (GBM) cells to radiation in preclinical models." | 5.20 | A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. ( Camphausen, K; Chang, MG; Fine, HA; Holdford, DJ; Krauze, AV; Myrehaug, SD; Shih, J; Smith, S; Tofilon, PJ, 2015) |
| "The radiochemotherapy regimen concomitantly employing temozolomide (TMZ) chemotherapy and radiotherapy (RT) 4 weeks after surgery, followed by 6 cycles of TMZ is a common treatment for glioblastoma (GBM)." | 5.20 | Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial. ( Chen, JX; Chen, ZP; Li, ZY; Lu, YC; Ma, WB; Mao, Y; Qi, ST; Shen, H; Wang, JS; Wang, RZ; Wang, X; Yang, QY; Yang, SY; Yang, XJ; Yao, Y; You, C; Zhang, JM; Zhang, LW; Zhang, X; Zhen, HN; Zhou, LF, 2015) |
| "To evaluate the efficacy and safety of TTFields used in combination with temozolomide maintenance treatment after chemoradiation therapy for patients with glioblastoma." | 5.20 | Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. ( Barnett, GH; Caroli, M; Chen, TC; Desai, R; Engelhard, HH; Fink, KL; Hegi, ME; Henson, JW; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kesari, S; Kew, Y; Kirson, ED; Landolfi, J; Lieberman, F; Palti, Y; Ram, Z; Silvani, A; Sroubek, J; Steinberg, DM; Stupp, R; Taillibert, S; Taylor, LP; Toms, SA; Tran, DD; Tran, ND; Weinberg, U; Zhu, JJ, 2015) |
| "To evaluate the efficacy of limited margins intensity-modulated radiotherapy (IMRT) with temozolomide chemotherapy in patients with malignant glioma, and explore the prognostic factors of malignant glioma." | 5.20 | [Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma]. ( Cao, Y; Sun, J; Yang, X; Zhang, W, 2015) |
| "We conducted a phase I trial to examine the maximally tolerated dose (MTD) of the oral protease inhibitor nelfinavir (NFV) in combination with temozolomide and concurrent radiotherapy in patients with glioblastoma and to gather preliminary data for response." | 5.19 | A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme. ( Alonso-Basanta, M; Dorsey, JF; Fang, P; Hahn, SM; Lustig, RA; Maity, A, 2014) |
| "Adult patients with newly surgical diagnosed glioblastoma were randomly assigned to receive either temozolomide or semustine after radiation treatment." | 5.19 | Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide. ( Chen, JX; Liu, JP; Liu, YH; Mao, Q; Wang, X; You, C, 2014) |
| " We sought to determine whether the addition of a vascular endothelial growth factor (VEGF) signaling inhibitor (cediranib) to conventional CRT had an impact on the frequency of PsP, by comparing two groups of patients with newly diagnosed glioblastoma before, during, and after CRT." | 5.19 | Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. ( Batchelor, TT; Emblem, KE; Gerstner, ER; Jain, RK; Jennings, D; Kalpathy-Cramer, J; Pinho, MC; Polaskova, P; Rosen, BR; Sorensen, AG; Wen, PY, 2014) |
| "To determine the maximum tolerated dose of irinotecan administered every 2 weeks, in combination with a fixed and continuous administration of temozolomide, in patients with glioblastoma at first relapse." | 5.19 | A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma. ( Balañá, C; Gallego, O; García, JL; Iglesias, L; Pérez, P; Reynés, G, 2014) |
| "We conducted a phase I study to determine (a) the maximum tolerated dose of peri-radiation therapy temozolomide (TMZ) and (b) the safety of a selected hypofractionated intensity modulated radiation therapy (HIMRT) regimen in glioblastoma multiforme (GBM) patients." | 5.19 | Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme. ( Ammirati, M; Chotai, S; Grecula, J; Lamki, T; Newton, H; Wei, L, 2014) |
| "The integrin antagonist cilengitide has been explored as an adjunct with anti-angiogenic properties to standard of care temozolomide chemoradiotherapy (TMZ/RT → TMZ) in newly diagnosed glioblastoma." | 5.19 | Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. ( Clément, PM; Eisele, AC; Eisele, G; Krex, D; Neyns, B; Nikkhah, G; Ochsenbein, A; Picard, M; Schlegel, U; Simon, M; Stupp, R; Tabatabai, G; Tonn, J; Weller, M; Wick, A; Wick, W, 2014) |
| "Surgery followed by radiotherapy and concomitant and adjuvant temozolomide is standard therapy in newly diagnosed glioblastoma multiforme (GBM)." | 5.19 | Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study. ( Ask, A; Costa, JC; Engelholm, S; Grunnet, K; Hansen, S; Hofland, KF; Kristiansen, C; Lassen, U; Muhic, A; Poulsen, HS; Schultz, HP; Sorensen, M; Thomsen, C, 2014) |
| "To assess the effect and toxicity of hypofractionated high-dose intensity modulated radiation therapy (IMRT) with concurrent and adjuvant temozolomide (TMZ) in 46 patients with newly diagnosed glioblastoma multiforme (GBM)." | 5.19 | Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. ( Hara, R; Hasegawa, Y; Hatano, K; Iuchi, T; Kawasaki, K; Kodama, T; Sakaida, T; Yokoi, S, 2014) |
| "Standard therapy for newly diagnosed glioblastoma is radiotherapy plus temozolomide." | 5.19 | Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. ( Abrey, L; Brandes, AA; Carpentier, AF; Cernea, D; Chinot, OL; Cloughesy, T; Henriksson, R; Hilton, M; Hoang-Xuan, K; Kavan, P; Mason, W; Nishikawa, R; Saran, F; Wick, W, 2014) |
| "Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma." | 5.19 | A randomized trial of bevacizumab for newly diagnosed glioblastoma. ( Aldape, KD; Armstrong, TS; Blumenthal, DT; Brachman, DG; Brown, PD; Chakravarti, A; Colman, H; Curran, WJ; Dignam, JJ; Gilbert, MR; Jaeckle, KA; Jeraj, R; Mehta, MP; Pugh, S; Schiff, D; Stieber, VW; Sulman, EP; Tremont-Lukats, IW; Vogelbaum, MA; Wefel, JS; Werner-Wasik, M; Won, M, 2014) |
| "Prognosis of unresectable glioblastoma (GB) remains poor, despite temozolomide (TMZ)-based chemoradiation." | 5.19 | Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†. ( Bonnetain, F; Campello, C; Castera, D; Chauffert, B; Chinot, O; Dalban, C; Durando, X; Fabbro, M; Feuvret, L; Frappaz, D; Frenay, M; Ghiringhelli, F; Guillamo, JS; Honnorat, J; Schott, R; Skrzypski, J; Taillandier, L; Taillia, H; Tennevet, I, 2014) |
| "The objective of this study was to report the patterns of failure in patients with glioblastoma multiforme (GBM) treated on a phase II trial of hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concurrent and adjuvant temozolomide (TMZ)." | 5.19 | Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme. ( Chen, C; Gaspar, LE; Kavanagh, BD; Reddy, K, 2014) |
| " The primary objective of this trial was to determine the maximum tolerated dose (MTD) and efficacy of HCQ in combination with radiation therapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma (GB)." | 5.19 | A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. ( Amaravadi, RK; Brem, S; Chang, YC; Davis, LE; Desideri, S; Fisher, J; Grossman, SA; Heitjan, DF; Hu, J; McAfee, Q; Mikkelson, T; O'Dwyer, PJ; Piao, S; Pontiggia, L; Rosenfeld, MR; Supko, JG; Tan, KS; Troxel, AB; Wang, D; Ye, X, 2014) |
| "Temozolomide (TMZ) may enhance antitumor immunity in patients with glioblastoma multiforme (GBM)." | 5.19 | Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. ( Abe, T; Hashimoto, K; Ikuta, S; Ishihara, T; Ishikawa, E; Karasawa, K; Maruyama, T; Matsuda, M; Matsumura, A; Matsutani, M; Muragaki, Y; Nakazato, Y; Ohno, T; Tsuboi, K; Uemae, Y; Yamamoto, T, 2014) |
| "Temozolomide (TMZ) is one of the most potent chemotherapy agents for the treatment of glioblastoma." | 5.19 | Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. ( Adair, JE; Baldock, AL; Beard, BC; Born, DE; Bridge, CA; Gonzalez-Cuyar, LF; Gori, JL; Guyman, LA; Hawkins-Daarud, A; Johnston, SK; Kiem, HP; Mrugala, MM; Rockhill, JK; Rockne, RC; Silbergeld, DL; Storer, BE; Swanson, KR, 2014) |
| " We conducted a phase II trial in newly diagnosed glioblastoma utilizing a novel hypofractionated stereotactic radiotherapy (HFSRT) schedule combined with temozolomide and bevacizumab." | 5.19 | Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. ( Abrey, LE; Barradas-Panchal, R; Baser, RE; Beal, K; Brennan, CW; Chan, TA; Correa, DD; DeAngelis, LM; Faivre, G; Gavrilovic, IT; Grommes, C; Gutin, P; Hormigo, A; Huse, JT; Kaley, TJ; Karimi, S; Lassman, AB; Mellinghoff, I; Nolan, C; Omuro, A; Panageas, KS; Pentsova, E; Reiner, AS; Sanchez, J; Tabar, V; Zhang, J, 2014) |
| " Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in combination with standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly in tumours with methylated MGMT promoter)." | 5.19 | Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. ( Adamska, K; Aldape, KD; Brandes, AA; Erridge, SC; Gorlia, T; Grujicic, D; Gupta, T; Hau, P; Hegi, ME; Herrlinger, U; Hicking, C; Hong, YK; Kim, CY; Kortmann, RD; Lhermitte, B; Markivskyy, A; McBain, C; Nabors, LB; Nam, DH; Perry, J; Picard, M; Pietsch, T; Rao, N; Reardon, DA; Schnell, O; Shen, CC; Steinbach, JP; Stupp, R; Taphoorn, MJ; Tarnawski, R; Thurzo, L; Tonn, JC; van den Bent, MJ; Weller, M; Weyerbrock, A; Wick, W; Wiegel, T, 2014) |
| "We investigate the patterns of failure in the treatment of glioblastoma (GBM) based on clinical target volume (CTV) margin size, dose delivered to the site of initial failure, and the use of temozolomide and intensity-modulated radiotherapy (IMRT)." | 5.19 | Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. ( Chan, MD; Debinski, W; Ellis, TL; Hinson, WH; Johnson, AJ; Kearns, WT; Lesser, GJ; McMullen, KP; Paulsson, AK; Peiffer, AM; Shaw, EG; Tatter, SB, 2014) |
| "To determine the safety and efficacy of hypofractionated intensity modulated radiation therapy (Hypo-IMRT) using helical tomotherapy (HT) with concurrent low dose temozolomide (TMZ) followed by adjuvant TMZ in patients with glioblastoma multiforme (GBM)." | 5.17 | Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. ( Abdulkarim, B; Fallone, G; Field, C; Fulton, D; Ghosh, S; Jastaniyah, N; Le, D; Mackenzie, M; Murtha, A; Patel, S; Pervez, N; Roa, W, 2013) |
| "Among patients with glioblastoma (GBM) who progress on standard temozolomide, the optimal therapy is unknown." | 5.17 | Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. ( Batchelor, TT; Beroukhim, R; Doherty, L; Drappatz, J; Fadul, CE; Hammond, SN; Lafrankie, D; Lee, EQ; Lesser, GJ; Ligon, KL; Lis, R; Muzikansky, A; Norden, AD; Plotkin, SR; Reardon, DR; Rosenfeld, MR; Smith, K; Stack, EC; Tafoya, V; Wen, PY; Zhu, JJ, 2013) |
| "To evaluate the efficacy and safety of temozolomide (TMZ) versus semustine (Me-CCNU) in the treatment of recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA)." | 5.17 | [Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma]. ( Sun, J; Yang, SY; Yang, XJ, 2013) |
| " Temozolomide (TMZ) is an alkylating agent that is the first-line chemotherapy for glioblastoma." | 5.17 | Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. ( Colman, H; Conrad, C; Gilbert, MR; Groves, M; Hsu, S; Kang, S; Levin, V; Liu, D; Liu, V; Puduvalli, V; Yuan, Y; Yung, WK; Yust-Katz, S, 2013) |
| "To describe the quality of life (QOL) in elderly patients with glioblastoma (GBM) treated with an abbreviated course of radiation therapy (RT; 40 Gy in 15 fractions) plus concomitant and adjuvant temozolomide (TMZ)." | 5.17 | Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. ( Baldoni, A; De Sanctis, V; Enrici, RM; Esposito, V; Lanzetta, G; Minniti, G; Scaringi, C, 2013) |
| "Thirteen patients with recurrent glioblastoma were enrolled in RTOG 0625/ACRIN 6677, a prospective multicenter trial in which bevacizumab was used in combination with either temozolomide or irinotecan." | 5.17 | Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. ( Barboriak, DP; Bokstein, F; Boxerman, JL; Gilbert, MR; McKinstry, RC; Ratai, EM; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z, 2013) |
| "The prognostic role of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastoma patients treated with carmustine (BCNU) wafer implantation is unclear." | 5.17 | MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers. ( Bock, HC; Brück, W; Doerner, L; Felsberg, J; Giese, A; Gutenberg, A; Mehdorn, HM; Reifenberger, G; Roggendorf, W; Westphal, M, 2013) |
| "To determine the safety of the mammalian target of rapamycin inhibitor everolimus (RAD001) administered daily with concurrent radiation and temozolomide in newly diagnosed glioblastoma patients." | 5.17 | RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. ( Chinnaiyan, P; Corn, BW; Dipetrillo, TA; Mehta, MP; Rojiani, AM; Wen, PY; Wendland, M; Won, M, 2013) |
| "To report health-related quality of life (HRQOL) in glioblastoma (GBM) patients treated on a phase II trial of hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with temozolomide (TMZ)." | 5.17 | Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide. ( Chen, C; Damek, DM; Gaspar, LE; Kavanagh, BD; Lillehei, KO; Ney, D; Reddy, K; Waziri, A, 2013) |
| "RTOG 0625/ACRIN 6677 is a multicenter, randomized, phase II trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma (GBM)." | 5.17 | Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. ( Barboriak, DP; Boxerman, JL; Chi, TL; Gilbert, MR; Jain, R; Larvie, M; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z, 2013) |
| "The current standard-of-care for glioblastoma (GBM) is represented by concomitant radiotherapy (RT) and temozolomide (TMZ), according to Stupp's protocol." | 5.17 | Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. ( Caroli, M; Carrabba, G; DI Cristofori, A; Lanfranchi, G; Menghetti, C; Rampini, P, 2013) |
| "To investigate the impact of nonstandard concomitant temozolomide (TMZ) administration in two prospective phase II studies for glioblastoma (GBM)." | 5.17 | Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials. ( Alitto, AR; Anile, C; Balducci, M; Chiesa, S; Colosimo, C; D'Agostino, GR; De Bonis, P; Fiorentino, A; Frascino, V; Mangiola, A; Mantini, G; Mattiucci, GC; Valentini, V, 2013) |
| "Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM)." | 5.17 | Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. ( Aldape, KD; Armstrong, TS; Baumert, B; Blumenthal, DT; Brown, PD; Chakravarti, A; Curran, WJ; Erridge, S; Gilbert, MR; Hegi, ME; Hopkins, KI; Jaeckle, KA; Mahajan, A; Mehta, MP; Schultz, CJ; Stupp, R; Tzuk-Shina, T; Wang, M; Wefel, JS; Won, M, 2013) |
| "Radiation Therapy Oncology Group trial 0525 tested whether dose-intensifying temozolomide versus standard chemoradiotherapy improves overall survival (OS) or progression-free survival (PFS) in newly diagnosed glioblastoma." | 5.17 | Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. ( Armstrong, TS; Bottomley, A; Brachman, DG; Choucair, AK; Coens, C; Gilbert, MR; Mehta, M; Mendoza, TR; Wang, M; Wefel, JS; Werner-Wasik, M; Won, M, 2013) |
| "We performed a dose-escalation trial to determine the maximum tolerated dose (MTD) of intensity-modulated radiotherapy (IMRT) with standard concurrent and sequential-dose temozolomide (TMZ) in patients with glioblastoma multiforme." | 5.17 | Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1). ( Balducci, M; Cilla, S; Deodato, F; Ferro, M; Macchia, G; Massaccesi, M; Morganti, AG; Valentini, V, 2013) |
| "Locoregional chemotherapy with carmustine wafers, positioned at surgery and followed by radiation therapy, has been shown to prolong survival in patients with newly diagnosed glioblastoma, as has concomitant radiochemotherapy with temozolomide." | 5.17 | Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. ( Casali, C; Ciusani, E; Dimeco, F; Fariselli, L; Gaviani, P; Guzzetti, S; Maccagnano, C; Marchetti, M; Milanesi, I; Pollo, B; Salmaggi, A; Silvani, A; Solero, CL, 2013) |
| "To determine the safety of the addition of bevacizumab to standard radiation therapy and daily temozolomide for newly diagnosed glioblastoma multiforme (GBM)." | 5.16 | Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. ( Bailey, L; Desjardins, A; Friedman, A; Friedman, HS; Herndon, JE; Kirkpatrick, JP; Marcello, J; Peters, KB; Reardon, DA; Sampson, J; Threatt, S; Vredenburgh, JJ, 2012) |
| "The new standard treatment of glioblastoma multiforme is concurrent radiotherapy (RT) and temozolomide." | 5.16 | Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma. ( Amin, P; Cheston, S; Dhople, A; DiBiase, S; Flannery, T; Meisenberg, B; Patel, A; Patel, S, 2012) |
| "The authors performed a phase 2 trial of combined protracted daily temozolomide and biweekly bevacizumab for patients with recurrent glioblastoma who had previously received radiation therapy and temozolomide." | 5.16 | Bevacizumab and daily temozolomide for recurrent glioblastoma. ( Bailey, L; Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; Marcello, J; Peters, KB; Reardon, DA; Vredenburgh, JJ, 2012) |
| "Radiotherapy with concomitant and adjuvant temozolomide has been the standard of care for newly diagnosed glioblastoma in adults since the pivotal trial by Roger Stupp and colleagues." | 5.16 | Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation. ( Chambers, CR; Lam, N, 2012) |
| "This phase I trial was designed to determine the recommended phase II dose(s) of everolimus (RAD001) with temozolomide (TMZ) in patients with glioblastoma (GBM)." | 5.16 | A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study. ( Easaw, J; Eisenhauer, E; Kavan, P; Lwin, Z; Macdonald, D; Macneil, M; Mason, WP; McIntosh, L; Thiessen, B; Urva, S, 2012) |
| "To report toxicity and overall survival (OS) in patients with newly diagnosed glioblastoma multiforme (GBM) treated with hypofractionated intensity-modulated radiotherapy (hypo-IMRT) with concurrent and adjuvant temozolomide (TMZ)." | 5.16 | Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. ( Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Lillehei, K; Ney, D; Reddy, K; Stuhr, K; Waziri, A, 2012) |
| " The primary objectives of this randomized phase 2 trial were to determine the safety and efficacy of cilengitide when combined with radiation and temozolomide for patients with newly diagnosed glioblastoma multiforme and to select a dose for comparative clinical testing." | 5.16 | A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). ( Batchelor, T; Brem, S; Fisher, JD; Grossman, SA; Hegi, ME; Lesser, G; Mikkelsen, T; Nabors, LB; Olsen, J; Peereboom, D; Rosenfeld, MR; Ye, X, 2012) |
| "To evaluate the efficacy of adding bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, and everolimus, a mammalian target of rapamycin (mTOR inhibitor), to standard radiation therapy/temozolomide in the first-line treatment of patients with glioblastoma." | 5.16 | Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. ( Brinker, BT; Hainsworth, JD; Shepard, GC; Shih, KC; Spigel, DR; Tillinghast, GW, 2012) |
| " Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma." | 5.16 | Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. ( Abacioglu, U; Frappaz, D; Grønberg, BH; Hegi, ME; Henriksson, R; Lhermitte, B; Malmström, A; Marosi, C; Rosell, J; Schultz, H; Stupp, R; Tavelin, B, 2012) |
| "To determine whether the pattern of progressive disease (PD) for glioblastoma multiforme (GBM) patients has changed with the introduction of the current standard of care protocol - postoperative conformal radiotherapy to a dose of 60 Gray in 30 fractions with concurrent low-dose (75-100 mg/m(2) ) temozolomide, followed by six cycles of adjuvant high-dose (150-200 mg/m(2) ) temozolomide - as compared with radiotherapy alone." | 5.16 | The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy. ( Bressel, M; Gunjur, A; Ryan, G, 2012) |
| "Chemotherapy-induced nausea and vomiting (CINV) is a side effect related to administration of the adjuvant temozolomide (TMZ) in patients affected by glioblastoma." | 5.15 | Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. ( Bria, E; Corona, M; Fabi, A; Lanzetta, G; Minniti, G; Nardoni, C; Restuccia, MR; Rozzi, A, 2011) |
| "In the present study we investigated the feasibility and effectiveness of a new biweekly schedule of fotemustine (FTM) in patients with recurrent glioblastoma, after at least one previous treatment." | 5.15 | A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. ( Abbruzzese, A; Addeo, R; Caraglia, M; Carraturo, M; Cennamo, G; De Santi, MS; Del Prete, S; Faiola, V; Genovese, M; Montella, L; Parlato, C; Vincenzi, B, 2011) |
| "We evaluated the efficacy of metronomic etoposide or temozolomide administered with bevacizumab among recurrent glioblastoma (GBM) patients who progressed on prior bevacizumab therapy in a phase 2, open-label, two-arm trial." | 5.15 | Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. ( Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Marcello, J; McLendon, R; Peters, K; Reardon, DA; Rich, JN; Sampson, J; Threatt, S; Vredenburgh, JJ, 2011) |
| "To determine the maximal tolerated biologic dose intensification of radiotherapy using fractional dose escalation with temozolomide (TMZ) chemotherapy in patients with newly diagnosed glioblastoma multiforme." | 5.15 | Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. ( Chen, C; Damek, D; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, K; Robischon, M; Rusthoven, KE; Stuhr, K; Waziri, A, 2011) |
| "To determine the maximum tolerated dose (MTD) of tipifarnib in combination with conventional radiotherapy for patients with newly diagnosed glioblastoma." | 5.15 | A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. ( Abrey, L; Chang, SM; Cloughesy, TF; DeAngelis, LM; Demopoulos, A; Drappatz, J; Fine, HA; Fink, K; Kesari, S; Lamborn, KR; Lassman, AB; Lieberman, FS; Malkin, MG; Mehta, MP; Nghiemphu, PL; Prados, MD; Robins, HI; Torres-Trejo, A; Wen, PY, 2011) |
| "A prospective randomized controlled multicenter phase III trial was conducted to evaluate the effects of neoadjuvant chemotherapy with nimustine (ACNU)-cisplatin (CDDP) when used in conjunction with radiotherapy plus adjuvant temozolomide in patients with newly diagnosed glioblastoma." | 5.15 | Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. ( Han, JH; Heo, DS; Jung, HW; Kim, CY; Kim, DG; Kim, DW; Kim, IA; Kim, IH; Kim, JE; Kim, JH; Kim, TM; Kim, YJ; Lee, SH; Nam, DH; Paek, SH; Park, BJ; Park, CK; Rhee, CH, 2011) |
| "This open-label, prospective, multicenter single-arm phase II study combined bevacizumab (BV) with radiation therapy (RT) and temozolomide (TMZ) for the treatment of newly diagnosed glioblastoma (GBM)." | 5.15 | Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. ( Black, K; Cloughesy, T; Elashoff, R; Fehrenbacher, L; Filka, E; Green, RM; Kolevska, T; Lai, A; Liau, LM; Mischel, PS; Nghiemphu, PL; Peak, S; Phuphanich, S; Polikoff, J; Pope, WB; Selch, M; Solis, OE; Spier, CE; Tran, A; Yong, WH, 2011) |
| "To analyse patterns of failure in patients with glioblastoma multiforme treated with concurrent radiation and temozolomide." | 5.15 | Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. ( Burnett Iii, OL; Dobelbower, MC; Fiveash, JB; Hyatt, MD; Markert, JM; Nabors, LB; Nordal, RA, 2011) |
| "The quantitative expression of CD133 stem cell antigen mRNA using real-time QRT-PCR was assessed in a cohort of 48 consecutive primary glioblastoma patients treated by chemoradiation with temozolomide." | 5.15 | Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. ( Barrie, M; Chinot, O; Colin, C; Coulibaly, B; Delfino, C; Figarella-Branger, D; Fina, F; Loundou, A; Metellus, P; Nanni-Metellus, I; Ouafik, L; Tchogandjian, A, 2011) |
| "Patients with glioblastoma multiforme (GBM) are profoundly immunosuppressed and may benefit from restoration of an antitumor immune response in combination with conventional radiation therapy and temozolomide (TMZ)." | 5.15 | Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. ( Ernstoff, MS; Fadul, CE; Fisher, JL; Gui, J; Hampton, TH; Lallana, EC; Lewis, LD; Li, Z; Rhodes, CH; Szczepiorkowski, ZM; Tosteson, TD; Wishart, HA, 2011) |
| "To determine if the addition of bevacizumab to radiation therapy and temozolomide, followed by bevacizumab, temozolomide, and irinotecan, for newly diagnosed glioblastoma patients is safe and effective." | 5.15 | The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. ( Bailey, L; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Kirkpatrick, JP; Marcello, J; Peters, KB; Reardon, DA; Sampson, JH; Threatt, S; Vredenburgh, JJ, 2011) |
| "Forty-two patients with glioblastoma and 16 patients with anaplastic glioma who had received concurrent radiation and temozolomide and adjuvant temozolomide were enrolled at first relapse." | 5.15 | Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. ( Aldape, K; Chang, SM; Chen, A; Cloughesy, TF; de Groot, JF; Deangelis, LM; Gilbert, MR; Jackson, EF; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Yao, J; Yung, WK, 2011) |
| " We report that the lymphopenia induced by the chemotherapeutic agent temozolomide (TMZ) enhances vaccine-driven immune responses and significantly reduces malignant growth in an established model of murine tumorigenesis." | 5.15 | Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. ( Archer, GE; Bigner, DD; Congdon, KL; Cui, X; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; McLendon, RE; Mitchell, DA; Reardon, DA; Sampson, JH; Sanchez-Perez, L; Schmittling, RJ; Snyder, DJ; Vredenburgh, JJ, 2011) |
| "Concurrent and post-radiotherapy temozolomide (T) significantly improves survival in patient with newly diagnosed glioblastoma multiforme." | 5.15 | Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. ( Ananda, S; Brown, C; Cher, L; Dowling, A; Nowak, AK; Rosenthal, MA; Simes, J, 2011) |
| "This analysis was performed to assess whether antiepileptic drugs (AEDs) modulate the effectiveness of temozolomide radiochemotherapy in patients with newly diagnosed glioblastoma." | 5.15 | Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. ( Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Forsyth, P; Gorlia, T; Lacombe, D; Macdonald, DR; Mason, W; Mirimanoff, RO; Rossetti, AO; Stupp, R; van den Bent, MJ; Vecht, CJ; Weller, M, 2011) |
| "This open-label, single-arm, phase II study combined enzastaurin with temozolomide plus radiation therapy (RT) to treat glioblastoma multiforme (GBM) and gliosarcoma." | 5.15 | Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. ( Butowski, N; Chang, SM; Clarke, J; Costa, BM; Costello, JF; Hristova-Kazmierski, M; Hsieh, E; Lamborn, KR; Nicol, SJ; Nicole, A; Parvataneni, R; Pieper, R; Polley, MY; Prados, MD; Reis, RM; Sneed, PK; Thornton, DE; Vandenberg, S, 2011) |
| "To determine whether increased uptake on 11C-methionine-PET (MET-PET) imaging obtained before radiation therapy and temozolomide is associated with the site of subsequent failure in newly diagnosed glioblastoma multiforme (GBM)." | 5.14 | Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. ( Cao, Y; Gomez-Hassan, D; Hayman, J; Junck, L; Lawrence, TS; Lee, IH; Piert, M; Rogers, L; Ten Haken, RK; Tsien, C, 2009) |
| "This open-label, prospective, single-arm, phase II study combined erlotinib with radiation therapy (XRT) and temozolomide to treat glioblastoma multiforme (GBM) and gliosarcoma." | 5.14 | Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. ( Ayers-Ringler, J; Berger, MS; Butowski, N; Carliner, H; Chang, SM; DeBoer, R; Fedoroff, A; Haas-Kogan, DA; James, CD; Kabuubi, P; Lamborn, KR; McDermott, MW; Page, M; Parsa, AT; Parvataneni, R; Prados, MD; Rabbitt, J; Sneed, PK; Stokoe, D; Vandenberg, S, 2009) |
| "Standardized salvage treatment has not yet proved effective in glioblastoma multiforme (GBM) patients who receive prior standard radiotherapy plus concomitant and adjuvant temozolomide." | 5.14 | Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). ( Amistà, P; Bianchini, C; Blatt, V; Brandes, AA; Ermani, M; Faedi, M; Franceschi, E; Gardiman, M; Labianca, R; Reni, M; Santoro, A; Tosoni, A, 2009) |
| "In 2004, a randomised phase III trial by the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NCIC) reported improved median and 2-year survival for patients with glioblastoma treated with concomitant and adjuvant temozolomide and radiotherapy." | 5.14 | Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. ( Allgeier, A; Belanger, K; Brandes, AA; Cairncross, JG; Eisenhauer, E; Fisher, B; Gijtenbeek, J; Gorlia, T; Hau, P; Hegi, ME; Janzer, RC; Lacombe, D; Ludwin, SK; Marosi, C; Mason, WP; Mirimanoff, RO; Mokhtari, K; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Vecht, CJ; Villa, S; Weller, M; Wesseling, P, 2009) |
| "Alternative dosing schedules of temozolomide may improve survival in patients with newly diagnosed glioblastoma (GBM) by increasing the therapeutic index, overcoming common mechanisms of temozolomide resistance, or both." | 5.14 | Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. ( Abrey, LE; Clarke, JL; DeAngelis, LM; Gavrilovic, I; Hormigo, A; Iwamoto, FM; Karimi, S; Lassman, AB; Nolan, CP; Panageas, K; Sul, J, 2009) |
| "This phase II trial evaluated efficacy and safety of temozolomide (TMZ) in combination with irinotecan (CPT-11) before radiotherapy in patients with newly diagnosed glioblastoma multiforme (GBM)." | 5.14 | Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. ( Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2009) |
| "Temozolomide has been used as a standard therapy for the treatment of newly diagnosed glioblastoma multiforme since 2005." | 5.14 | Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice. ( Baumert, BG; Leffers, P; Tjon-A-Fat, H; Twijnstra, A; van Genugten, JA, 2010) |
| "This trial was designed to estimate overall survival in adults with newly diagnosed glioblastoma treated with talampanel in addition to standard radiation (RT) and temozolomide (TMZ)." | 5.14 | Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. ( Batchelor, T; Chamberlain, M; Desideri, S; Fine, HA; Fisher, J; Grossman, SA; Mikkelsen, T; Piantadosi, S; Ye, X, 2009) |
| "The use of radiotherapy plus temozolomide administered concomitantly with and after radiotherapy for glioblastoma was recently shown to improve median and 2-year survival in a large international multicenter study." | 5.14 | Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience. ( Jeon, HJ; Kim, JH; Kim, ST; Kim, WS; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Park, K; Park, KB, 2009) |
| "Because of the poor outcomes for patients with recurrent glioblastoma multiforme (GBM), and some laboratory and clinical evidence of efficacy using interferon in GBM, we assessed the toxicity and efficacy of temozolomide (TMZ) combined with either short-acting (IFN) or long-acting (pegylated) interferon alpha2b (PEG) in two single-arm phase II studies, and compared the results to 6-month progression-free survival (PFS-6) data from historical controls." | 5.14 | Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. ( Alfred Yung, WK; Conrad, CA; Gilbert, MR; Groves, MD; Hess, KR; Hunter, K; Levin, VA; Liu, VH; Meyers, C; Puduvalli, VK, 2009) |
| "To determine the maximum tolerated dose (MTD) of fractionated intensity-modulated radiotherapy (IMRT) with temozolomide (TMZ) in patients with glioblastoma." | 5.14 | A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma. ( Balducci, M; Calista, F; Cantore, GP; Cellini, N; Cilla, S; Deodato, F; Digesù, C; Esposito, V; Ferro, M; Ianiri, M; Macchia, G; Morganti, AG; Piermattei, A; Romanelli, P; Salvati, M; Valentini, V, 2010) |
| "Although Temozolomide is effective against glioblastoma, the prognosis remains dismal and new regimens with synergistic activity are sought for." | 5.14 | RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study. ( Beier, CP; Beier, D; Bogdahn, U; Brawanski, A; Dietmaier, C; Gorlia, T; Grauer, O; Hau, P; Hegi, M; Hirschmann, B; Jauch-Worley, T; Kleinletzenberger, C; Kölbl, O; Muigg, A; Pietsch, T; Proescholdt, M; Rümmele, P; Schmid, C; Steinbrecher, A; Stockhammer, G, 2009) |
| "Chemoradiotherapy followed by monthly temozolomide (TMZ) is the standard of care for patients with glioblastoma multiforme (GBM)." | 5.14 | Population-based study of pseudoprogression after chemoradiotherapy in GBM. ( Cairncross, JG; de Robles, PA; Dharmawardene, M; Easaw, JC; Forsyth, PA; Hamilton, MG; Magliocco, AM; McIntyre, JB; Parney, IF; Roldán, GB; Scott, JN; Yan, ES, 2009) |
| "To evaluate the toxicity and efficacy of chemoradiotherapy with temozolomide (TMZ) administered in an intensified 1-week on/1-week off schedule plus indomethacin in patients with newly diagnosed glioblastoma." | 5.14 | Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. ( Bähr, O; Bamberg, M; Gorlia, T; Hartmann, C; Herrlinger, U; Meyermann, R; Tatagiba, M; von Deimling, A; Weiler, M; Weller, M; Wick, W; Wiewrodt, D, 2010) |
| "We conducted a phase I study to determine the safety and recommended phase II dose of enzastaurin (oral inhibitor of the protein kinase C-beta [PKCbeta] and the PI3K/AKT pathways) when given in combination with radiation therapy (RT) plus temozolomide to patients with newly diagnosed glioblastoma multiforme or gliosarcoma." | 5.14 | Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. ( Butowski, N; Chang, SM; Hristova-Kazmierski, M; Lamborn, KR; Musib, L; Nicol, SJ; Parvataneni, R; Polley, MY; Prados, MD; Thornton, DE, 2010) |
| "We assessed six-month progression-free survival (PFS) as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma multiforme (GBM) patients receiving temozolomide (TMZ)." | 5.14 | Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. ( Butowski, N; Chang, SM; Clarke, JL; Lamborn, KR; Polley, MY; Prados, M, 2010) |
| "To determine the maximum tolerated dose of ABT-510, a thrombospondin-1 mimetic drug with antiangiogenic properties, when used concurrently with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma." | 5.14 | A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. ( Fathallah-Shaykh, HM; Fiveash, JB; Gillespie, GY; Gladson, CL; Huang, Z; Johnson, MJ; Kekan, MS; Kuo, H; Markert, JM; Meleth, S; Nabors, LB, 2010) |
| "PURPOSE Concomitant temozolomide (TMZ)/radiotherapy followed by adjuvant TMZ has increased survival in patients with glioblastoma multiforme (GBM)." | 5.14 | Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. ( Bélanger, K; Easaw, J; Eisenstat, DD; Forsyth, P; Fulton, D; Kavan, P; Kirby, S; Macdonald, DR; Mason, WP; Perry, JR; Pouliot, JF; Shields, C; Thiessen, B, 2010) |
| "The aim of this clinical trial was to investigate safety and efficacy when combining cetuximab with bevacizumab and irinotecan in patients with recurrent primary glioblastoma multiforme (GBM)." | 5.14 | Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. ( Broholm, H; Hansen, S; Hasselbalch, B; Holmberg, M; Kosteljanetz, M; Lassen, U; Poulsen, HS; Stockhausen, MT; Sørensen, M, 2010) |
| "Compared with historical controls, the addition of concomitant and adjuvant cilengitide to standard chemoradiotherapy demonstrated promising activity in patients with glioblastoma with MGMT promoter methylation." | 5.14 | Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. ( Clement, PM; Dietrich, PY; Diserens, AC; Goldbrunner, R; Grabenbauer, GG; Hegi, ME; Hermisson, M; Hicking, C; Krueger, S; Neyns, B; Ochsenbein, AF; Pica, A; Picard, M; Pietsch, T; Schlegel, U; Simon, M; Stupp, R; Tonn, JC; Weller, M, 2010) |
| "The current study was conducted to evaluate the efficacy of sorafenib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, when added to standard radiotherapy and temozolomide in the first-line treatment of patients with glioblastoma multiforme." | 5.14 | Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. ( Clark, BL; Ervin, T; Friedman, E; Hainsworth, JD; Lamar, RE; Murphy, PB; Priego, V, 2010) |
| "The objectives of this study were to determine the safety and efficacy of polyinosinic-polycytidylic acid stabilized with poly-l-lysine and carboxymethylcellulose (poly-ICLC) when added to radiation and temozolomide (TMZ) in adults with newly diagnosed glioblastoma (GB)." | 5.14 | A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. ( Batchelor, TT; Chamberlain, MC; Desideri, S; Grossman, SA; Lesser, GJ; Peereboom, DM; Rosenfeld, MR; Salazar, AM; Ye, X, 2010) |
| "External beam radiation therapy (XRT) with concomitant temozolomide and 6 cycles of adjuvant temozolomide (5/28-day schedule) improves survival in patients with newly diagnosed glioblastoma compared with XRT alone." | 5.14 | A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. ( Chang, E; Colman, H; Conrad, C; de Groot, J; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, K; Hunter, K; Levin, V; Mahajan, A; Puduvalli, V; Woo, S; Yung, WK, 2010) |
| "Treatment standard for patients with primary glioblastoma (GBM) is combined radiochemotherapy with temozolomide (TMZ)." | 5.14 | Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. ( Combs, SE; Debus, J; Haberer, T; Habermehl, D; Haselmann, R; Jäkel, O; Kieser, M; Nikoghosyan, A; Rieken, S; Unterberg, A; Wick, W, 2010) |
| "To evaluate efficacy and safety of fotemustine chemotherapy in temozolomide (TMZ) pretreated adults with recurrent glioblastoma multiforme (GBM)." | 5.13 | Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. ( Ammannati, F; Biti, G; Bordi, L; Borghesi, S; Detti, B; Iannalfi, A; Leonulli, BG; Martinelli, F; Meattini, I; Sardaro, A; Scoccianti, S, 2008) |
| "This study was designed to assess the clinical outcomes of MGMT low expression glioblastomas with different p53 statuses to the treatment of temozolomide capsule chemotherapy." | 5.13 | Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results. ( Jiang, T; Li, G; Li, S; Wang, Z, 2008) |
| "To evaluate the efficacy of simultaneous postoperative temozolomide radiochemotherapy in glioblastoma patients." | 5.13 | Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. ( Becker, G; Borberg, SK; Fischedick, AR; Frommolt, P; Grauthoff, H; Herfarth, K; Kocher, M; Müller, RP; Niewald, M; Rühl, U; Staar, S; Steingräber, M; Stuschke, M, 2008) |
| "This is a phase-I study of gefitinib in combination with temozolomide in patients with gliomas." | 5.13 | Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. ( Chang, S; Cloughesy, T; Dancey, J; Fink, K; Junck, L; Kuhn, J; Prados, MD; Robins, HI; Wen, PY; Yung, WK, 2008) |
| "3) showed that addition of temozolomide to radiotherapy in the treatment of patients with newly diagnosed glioblastoma significantly improved survival." | 5.13 | Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. ( Allgeier, A; Belanger, K; Brandes, AA; Cairncross, JG; Eisenhauer, E; Gorlia, T; Hegi, ME; Lacombe, D; Mirimanoff, RO; Stupp, R; van den Bent, MJ; Weller, M, 2008) |
| "The study aimed to compare the cost-effectiveness of concomitant and adjuvant temozolomide (TMZ) for the treatment of newly diagnosed glioblastoma multiforme versus initial radiotherapy alone from a public health care perspective." | 5.13 | Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. ( Al, MJ; Crott, R; Gorlia, T; Jin Seung, S; Lamers, LM; Mittmann, N; Stupp, R; Uyl-de Groot, CA; van den Bent, MJ; Wasserfallen, JB, 2008) |
| "To evaluate toxicity and outcomes in patients with primary glioblastoma (GB) treated with postoperative radiochemotherapy (RCHT) with temozolomide (TMZ) comparing two dose regimens." | 5.13 | Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. ( Bischof, M; Combs, SE; Debus, J; Edler, L; Rausch, R; Schulz-Ertner, D; Wagner, F; Wagner, J; Welzel, T; Zabel-du Bois, A, 2008) |
| "To assess interim safety and tolerability of a 10-patient, Phase II pilot study using bevacizumab (BV) in combination with temozolomide (TMZ) and regional radiation therapy (RT) in the up-front treatment of patients with newly diagnosed glioblastoma." | 5.13 | Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. ( Bergsneider, M; Cloughesy, T; Filka, E; Graham, C; Lai, A; Liau, LM; McGibbon, B; Mischel, P; Nghiemphu, PL; Pope, W; Selch, M; Yong, WH, 2008) |
| "We conducted a phase II study of the combination of temozolomide and angiogenesis inhibitors for treating adult patients with newly diagnosed glioblastoma." | 5.13 | Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. ( Batchelor, TT; Black, PM; Ciampa, A; Doherty, L; Drappatz, J; Folkman, J; Gigas, DC; Henson, JW; Kesari, S; Kieran, M; Laforme, A; Ligon, KL; Longtine, JA; Muzikansky, A; Ramakrishna, N; Schiff, D; Weaver, S; Wen, PY, 2008) |
| "We performed a Cochrane Review to examine studies using different techniques to measure MGMT and predict survival in glioblastoma patients treated with temozolomide." | 5.12 | MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. ( Brandner, S; Cheng, HY; Dawson, S; Faulkner, CL; Higgins, JPT; Jefferies, S; Kelly, C; Kurian, KM; McAleenan, A; Schmidt, L; Spiga, F; Wragg, C, 2021) |
| "Temozolomide is an oral alkylating agent incorporated in the treatment of glioblastoma multiforme (GBM) that can lead to lymphopenia." | 5.12 | Temozolomide is a risk factor for invasive pulmonary aspergillosis: A case report and literature review. ( Brault, C; Chouaki, T; Maizel, J; Nyga, R; Zerbib, Y, 2021) |
| "Steroids are commonly used for managing brain edema in patients with glioblastoma multiforme (GBM), treated with surgery and concomitant temozolomide-based chemoradiotherapy (CTRT)." | 5.12 | Steroids use and survival in patients with glioblastoma multiforme: a pooled analysis. ( Bruschieri, L; De Stefani, A; Dottorini, L; Ghidini, A; Iaculli, A; Petrelli, F; Riboldi, V; Trevisan, F; Zaniboni, A, 2021) |
| "Temozolomide (TMZ) is an oral alkylating agent principally indicated for neurological malignancies including glioblastoma (GBM) and astrocytoma." | 5.12 | Temozolomide-induced aplastic anaemia: Case report and review of the literature. ( Gilbar, PJ; Mangos, HM; Pokharel, K, 2021) |
| "To determine which method for assessing MGMT methylation status best predicts overall survival in people diagnosed with glioblastoma who are treated with temozolomide." | 5.12 | Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. ( Brandner, S; Cheng, HY; Dawson, S; Faulkner, CL; Higgins, JPT; Howell, A; Jefferies, S; Kelly, C; Kernohan, A; Kurian, KM; McAleenan, A; Robinson, T; Schmidt, L; Spiga, F; Vale, L; Wragg, C, 2021) |
| "The standard of care treatment for glioblastoma is surgical resection followed by radiotherapy to 60 Gy with concurrent and adjuvant temozolomide with or without tumor-treating fields." | 5.12 | Novel Radiation Approaches. ( Kotecha, R; Mehta, MP; Tom, MC, 2021) |
| "Limited evidence is available on the utility of dose-escalated radiation therapy (DE-RT) with or without temozolomide (TMZ) versus standard-of-care radiation therapy (SoC-RT) for patients with newly diagnosed glioblastoma multiforme." | 5.12 | Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials. ( Bovi, J; Brown, PD; Gondi, V; Lehrer, EJ; Navarria, P; Palmer, JD; Perlow, HK; Scoccianti, S; Singh, R; Trifiletti, DM; Wang, M; Zaorsky, NG, 2021) |
| "(1) Background: Studies in elderly patients over the age of 65 with glioblastoma have shown survival benefits of short-course radiation therapy with concurrent and adjuvant temozolomide, making it the standard of care adopted at Juravinski Cancer Center." | 5.12 | Outcomes in Elderly Patients with Glioblastoma Multiforme Treated with Short-Course Radiation Alone Compared to Short-Course Radiation and Concurrent and Adjuvant Temozolomide Based on Performance Status and Extent of Resection. ( Greenspoon, JN; Mir, T; Pond, G, 2021) |
| "Temozolomide (TMZ) is a first-choice alkylating agent inducted as a gold standard therapy for glioblastoma multiforme (GBM) and astrocytoma." | 5.12 | Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. ( Kumar, A; Shrivastava, A; Srivastava, C; Tomar, MS, 2021) |
| "Temozolomide (TMZ) a recent, oral, second generation alkylating agent is a chemotherapeutic with demonstrated efficacy for the treatment of high-grade gliomas." | 5.12 | Surgery, radiotherapy and temozolomide in treating high-grade gliomas. ( Barbarisi, M; Moraci, A; Moraci, M; Parlato, C, 2006) |
| "The implementation of combined radiochemotherapy (RCHT) with temozolomide (TMZ) has lead to a significant increase in overall survival times in patients with Glioblastoma multiforme (GBM), however, outcome still remains unsatisfactory." | 5.12 | Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol. ( Combs, SE; Debus, J; Edler, L; Haselmann, R; Heeger, S; Schulz-Ertner, D, 2006) |
| "The European Organisation for Research and Treatment of Cancer and National Cancer Institute of Canada trial on temozolomide (TMZ) and radiotherapy (RT) in glioblastoma (GBM) has demonstrated that the combination of TMZ and RT conferred a significant and meaningful survival advantage compared with RT alone." | 5.12 | Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. ( Allgeier, A; Brandes, AA; Cairncross, G; Curschmann, J; Fisher, B; Gorlia, T; Kortmann, RD; Lacombe, D; Mason, W; Mirimanoff, RO; Reni, M; Stupp, R; Van den Bent, MJ; Villa, S, 2006) |
| "Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma." | 5.12 | Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. ( Chalmers, L; Chamberlain, MC; Glantz, MJ; Sloan, AE; Van Horn, A, 2007) |
| "To evaluate toxicity and efficacy of the combination of lomustine, temozolomide (TMZ) and involved-field radiotherapy in patients with newly diagnosed glioblastoma (GBM)." | 5.12 | Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. ( Bamberg, M; Blaschke, B; Herrlinger, U; Hundsberger, T; Koch, D; Kortmann, RD; Loeser, S; Meyermann, R; Reifenberger, G; Rieger, J; Sommer, C; Steinbach, JP; Tan, TC; Weller, M; Wick, W, 2006) |
| " The aim of this pilot study was to evaluate the efficacy and safety of metronomic temozolomide (TMZ) treatment in twelve consecutive patients with recurrent TMZ-refractory glioblastoma." | 5.12 | A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. ( Eoh, W; Kim, JH; Kim, ST; Kim, WS; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Park, K; Son, MJ, 2006) |
| "Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)." | 5.12 | A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. ( Abrey, LE; Chang, SM; Cloughesy, TF; Conrad, CA; DeAngelis, LM; Gilbert, MR; Greenberg, H; Groves, MD; Hess, KR; Lamborn, KR; Liu, TJ; Peterson, P; Prados, MD; Puduvalli, VK; Schiff, D; Tremont-Lukats, IW; Wen, PY; Yung, WK, 2007) |
| "To evaluate if timing of chemotherapy with Temozolomide (TMZ) was able to modify the outcome of glioblastoma (GBM), we analyzed two comparable series of supratentorial GBM patients, treated with surgery and radiotherapy, in which the administration of TMZ has been performed in the first group at first relapse and in the second group in newly diagnosed cases." | 5.12 | Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol? ( Borsa, S; Campanella, R; Caroli, M; Gaini, SM; Locatelli, M; Martinelli-Boneschi, F; Mora, A; Motta, F; Prada, F; Saladino, A, 2007) |
| "This phase II study evaluated the efficacy and safety of a 7-day on/7-day off regimen of temozolomide before radiotherapy (RT) in patients with inoperable newly diagnosed glioblastoma." | 5.12 | Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. ( Barrié, M; Braguer, D; Chinot, OL; Dufour, H; Eudes, N; Figarella-Branger, D; Fuentes, S; Lancelot, S; Martin, PM; Metellus, P; Muracciole, X; Ouafik, L, 2007) |
| "A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy (capecitabine or temozolomide) in patients with high-grade gliomas (glioblastoma or anaplastic glioma)." | 5.12 | Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. ( Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E, 2007) |
| "The purpose of this study was to evaluate the activity, measured in terms of progression-free survival (PFS) and response rates, of 1,3-bis(chloro-ethyl)-1-nitrosourea (BCNU) plus temozolomide in adult patients with recurrent glioblastoma multiforme." | 5.11 | Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. ( Chang, SM; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schold, SC; Yung, WK, 2004) |
| "Temozolomide has established activity in the treatment of recurrent glioblastoma multiforme (GBM)." | 5.11 | Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. ( Ashley, DM; Cher, LM; Chua, SL; Dowling, A; Rosenthal, MA; Wong, SS; Woods, AM, 2004) |
| "The primary objective of the current prospective Phase II study of cyclophosphamide (CYC) in adult patients with recurrent, temozolomide-refractory glioblastoma multiforme was to evaluate 6-month progression-free survival (PFS)." | 5.11 | Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. ( Chamberlain, MC; Tsao-Wei, DD, 2004) |
| "In the setting of a prospective clinical trial, we determined the predictive value of the methylation status of the O-6-methylguanine-DNA methyltransferase (MGMT) promoter for outcome in glioblastoma patients treated with the alkylating agent temozolomide." | 5.11 | Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. ( de Tribolet, N; Dietrich, PY; Diserens, AC; Godard, S; Hegi, ME; Ostermann, S; Otten, P; Regli, L; Stupp, R; Van Melle, G, 2004) |
| "Cisplatin and temozolomide (TMZ) are active in glioblastoma multiforme (GBM), with different profiles of toxicity." | 5.11 | First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. ( Basso, U; Brandes, AA; Cavallo, G; Ermani, M; Ferreri, AJ; Monfardini, S; Panucci, MG; Reni, M; Scopece, L; Tosoni, A; Vastola, F, 2004) |
| "Twenty-one patients with recurrent or progressive glioblastoma were enrolled in a prospective phase II trial to determine the safety and efficacy of a 1-week on/1-week off regimen of temozolomide administered at 150 mg/m2 on days 1 to 7 and days 15 to 21 of 28-day treatment cycles." | 5.11 | One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. ( Bamberg, M; Dichgans, J; Küker, WM; Steinbach, JP; Weller, M; Wick, W, 2004) |
| "An analysis of 73 patients with hystologically confirmed glioblastoma multiforme (GBM), treated with the ''3 step'' (90)Y-biotin based LR-RIT, is herein reported." | 5.11 | Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. ( Bartolomei, M; Bodei, L; Grana, C; Handkiewicz-Junak, D; Maira, G; Mazzetta, C; Paganelli, G; Rocca, P; Sturiale, C; Villa, G, 2004) |
| "Seventy-five consecutive patients with recurrent malignant astrocytomas and glioblastomas had been treated at our institute with per os temozolomide for five days every month." | 5.11 | Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas. ( Afra, D; Sipos, L; Vitanovics, D, 2004) |
| "This phase II study evaluates the activity of temozolomide and cisplatin administered before radiation therapy in newly diagnosed glioblastoma multiforme patients, in terms of response, time to progression and survival." | 5.11 | Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM). ( Balaña, C; Balart, J; Ballester, R; Benavides, M; Berrocal, A; Capellades, J; Cerdá-Nicolás, M; García, JL; Herrero, A; López-Pousa, A; Martín-Broto, J; Yaya-Tur, R, 2004) |
| "Patients with newly diagnosed, histologically confirmed glioblastoma were randomly assigned to receive radiotherapy alone (fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy) or radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle)." | 5.11 | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. ( Allgeier, A; Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Curschmann, J; Eisenhauer, E; Fisher, B; Gorlia, T; Janzer, RC; Lacombe, D; Ludwin, SK; Marosi, C; Mason, WP; Mirimanoff, RO; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Weller, M, 2005) |
| "This Phase II study was designed to determine the median survival time of adults with supratentorial glioblastoma treated with a combination of temozolomide (TMZ) and 13-cis-retinoic acid (cRA) given daily with conventional radiation therapy (XRT)." | 5.11 | A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. ( Butowski, N; Chang, SM; Lamborn, KR; Larson, DA; Malec, M; Page, M; Prados, MD; Rabbitt, J; Sneed, PK; Wara, WM, 2005) |
| " Food and Drug Administration approved temozolomide (Temodar capsules, Schering-Plough Research Institute) for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment." | 5.11 | Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. ( Cohen, MH; Johnson, JR; Pazdur, R, 2005) |
| "To investigate the efficacy of temozolomide (TMZ) in relationship to progression free survival at 6 months (PFS-6), median time to progression (TTP), response rate and toxicity, a phase II study was conducted in patients with recurrent glioblastoma multiforme (GBM) following surgery plus radiotherapy and a first-line regimen based on nitrosourea, procarbazine and vincristine." | 5.10 | Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. ( Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Iuzzolino, P; Lumachi, F; Monfardini, S; Paris, MK; Turazzi, S, 2002) |
| "Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma." | 5.10 | Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003) |
| "Temozolomide is a novel oral alkylating agent with demonstrated efficacy as second-line therapy for patients with recurrent anaplastic astrocytoma and glioblastoma multiforme (GBM)." | 5.10 | Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. ( de Tribolet, N; Dietrich, PY; Janzer, R; Leyvraz, S; Maeder, P; Maillard, I; Meuli, R; Miralbell, R; Mirimanoff, RO; Ostermann Kraljevic, S; Pica, A; Pizzolato, G; Porchet, F; Regli, L; Stupp, R, 2002) |
| "To determine whether chemotherapy with temozolomide (TMZ) versus procarbazine (PCB) for recurrent glioblastoma multiforme (GBM) was associated with improvement in health-related quality of life (HRQOL)." | 5.09 | Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. ( Brada, M; Osoba, D; Prados, M; Yung, WK, 2000) |
| "A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse." | 5.09 | A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. ( Albright, RE; Brada, M; Bruner, J; Fink, K; Fredericks, R; Friedman, H; Glantz, M; Greenberg, H; Hohl, RJ; Levin, VA; Olson, J; Osoba, D; Phillips, P; Prados, MD; Rampling, R; Selker, RG; Shapiro, W; Spence, A; Vick, NA; Yue, N; Yung, WK; Zaknoen, S, 2000) |
| "We report an open-label, uncontrolled, multicenter phase II trial of temozolomide in 138 patients (intent-to-treat [ITT] population) with glioblastoma multiforme at first relapse and a Karnofsky performance status (KPS) > or = 70." | 5.09 | Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. ( Brada, M; Bravo-Marques, JM; Bruner, J; Dietrich, PY; Dirix, LY; Dugan, M; Heimans, JJ; Henriksson, R; Hoang-Xuan, K; Macdonald, D; Rampling, R; Rao, S; Stupp, R; Yue, N; Zaknoen, S; Zonnenberg, BA, 2001) |
| "The efficacy of radiotherapy with adjuvant temozolomide for glioblastoma remains controversial." | 5.05 | The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies. ( Feng, Y; Wang, Y, 2020) |
| "Glioblastoma (GB) is one of the most common malignancies with limited standard therapies such as surgery, radiotherapy (RT) plus temozolomide (TMZ)." | 5.01 | Prognosis of patients with newly diagnosed glioblastoma treated with molecularly targeted drugs combined with radiotherapy vs temozolomide monotherapy: A meta-analysis. ( Aru, N; Ding, YM; Jin, WY; Liu, Z; Qin, HH; Shen, X; Wang, WL; Wu, SJ, 2019) |
| "Temozolomide is a first-line treatment for newly diagnosed glioblastoma." | 5.01 | Evidence-Based Practice: Temozolomide Beyond Glioblastoma. ( Chua, J; Leung, D; Nafziger, E, 2019) |
| "Here we review tumoricidal efficacy of Vitamin D analogues in glioblastoma multiforme (GBM) and potential synergisms with retinoic acid and temozolomide based on epidemiological and cellular studies." | 5.01 | From epidemiology and neurometabolism to treatment: Vitamin D in pathogenesis of glioblastoma Multiforme (GBM) and a proposal for Vitamin D + all-trans retinoic acid + Temozolomide combination in treatment of GBM. ( Altinoz, MA; Elmaci, I; Ozpinar, A; Perez, JL, 2019) |
| "Although reoperation likely confers survival benefit for glioblastoma, whether the extent of resection (EOR) of the reoperation affects survival outcome has yet to be thoroughly evaluated in the current temozolomide (TMZ) era." | 5.01 | Survival Benefit of Maximal Resection for Glioblastoma Reoperation in the Temozolomide Era: A Meta-Analysis. ( Burns, TC; Chaichana, KL; Goyal, A; Graffeo, CS; Lu, VM; Parney, IF; Perry, A; Quinones-Hinojosa, A, 2019) |
| " For glioblastoma, the irradiation dose of 60 Gy in 30 fractions with concomitant and adjuvant temozolomide is currently considered as a standard of treatment, and further dose escalation has failed to be of benefit in clinical trials." | 4.98 | Fractionated Radiotherapy of Intracranial Gliomas. ( Ghia, AJ, 2018) |
| " Temozolomide, a monofunctional alkylator, was the first chemotherapeutic agent to definitively improve survival in adults with newly diagnosed glioblastoma used in combination with radiation therapy with the most pronounced effect being in a subgroup of tumors with MGMT promoter methylation." | 4.98 | Chemotherapy of High-Grade Astrocytomas in Adults. ( Hoang, N; Puduvalli, VK, 2018) |
| "Temozolomide is the most widely used chemotherapy for patients with glioblastoma (GBM) despite the fact that approximately half of treated patients have temozolomide resistance and all patients eventually fail therapy." | 4.98 | Temozolomide for immunomodulation in the treatment of glioblastoma. ( Dastmalchi, F; Karachi, A; Mitchell, DA; Rahman, M, 2018) |
| "Resistance of malignant glioma, including glioblastoma (GBM), to the chemotherapeutic temozolomide (TMZ) remains a key obstacle in treatment strategies." | 4.98 | Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics. ( Ghatnekar, GG; Gourdie, RG; Grek, CL; Naus, CC; Sheng, Z; Sin, WC, 2018) |
| "This review focuses on a carotenoid and a phlorotannin present in seaweed, namely fucoxanthin and phloroglucinol, and their anticancer activity against glioblastoma." | 4.98 | Drug resistance in glioblastoma and cytotoxicity of seaweed compounds, alone and in combination with anticancer drugs: A mini review. ( Almeida, T; Azqueta, A; Ferreira, J; Ramos, AA; Rocha, E, 2018) |
| "New therapeutic agents in combination with the standard Stupp protocol (a protocol about the temozolomide combined with radiotherapy treatment with glioblastoma was research by Stupp R in 2005) were assessed to evaluate whether they were superior to the Stupp protocol alone, to determine the optimum treatment regimen for patients with newly diagnosed glioblastoma." | 4.95 | The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: A network meta-analysis. ( Chen, T; Fu, A; Li, J; Li, M; Song, X; Zhu, J, 2017) |
| "Tumor treating fields (TTFields) are an integral treatment modality in the management of glioblastoma and extend overall survival when combined with maintenance temozolomide in newly diagnosed patients." | 4.95 | A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. ( Battiste, J; Bota, DA; Connelly, J; Damek, D; Dunbar, E; Iwamoto, F; Mohile, N; Trusheim, J, 2017) |
| "The current meta-analysis evaluated the survival outcomes of newly diagnosed glioblastoma patients treated with radiotherapy (RT) alone and with RT + temozolomide (TMZ)." | 4.95 | Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis. ( Feng, E; Sui, C; Sun, G; Wang, T, 2017) |
| "Since 2005, the standard of care for patients with newly diagnosed glioblastoma (GBM) has consisted of maximal resection followed by radiotherapy plus daily temozolomide (TMZ), followed by maintenance TMZ." | 4.95 | Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. ( Mehta, M; Nishikawa, R; Peters, K; Reardon, D; Wen, P, 2017) |
| "In the last decade, phase III trials on novel compounds largely failed to introduce efficacious pharmacotherapies beyond temozolomide in glioblastoma." | 4.93 | Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives. ( Gramatzki, D; Roth, P; Seystahl, K; Weller, M, 2016) |
| "Glioblastoma (GBM) has proven to be incurable despite recent progress on its standard of care using temozolomide (TMZ) as the main trunk of initial therapy for newly diagnosed GBM." | 4.91 | Dose-dense temozolomide: is it still promising? ( Nagane, M, 2015) |
| "Temozolomide is the current standard of therapy for postoperative patients with glioblastoma starting adjuvant radiotherapy." | 4.91 | Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature. ( Balducci, N; Biolato, M; Di Napoli, N; Diletto, B; Grieco, A; Miele, L; Tafuri, MA; Vecchio, FM, 2015) |
| "Long-term temozolomide might be an optimal choice for patients with multifocal glioblastoma, especially with deep-seated structure involvement." | 4.91 | Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature review. ( Gao, Z; Hao, S; Liu, Y; Yu, L, 2015) |
| "The Avastin in Glioblastoma trial has shown that patients newly diagnosed with glioblastoma multiforme (GBM) treated with bevacizumab plus radiotherapy and temozolomide versus radiotherapy and temozolomide alone showed improvement in progression-free survival, possibly leading to a new indication for first-line use of bevacizumab in GBM." | 4.91 | Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. ( Kovic, B; Xie, F, 2015) |
| "Since virtually no trials have evaluated the effectiveness of temozolomide (TMZ) in the treatment of spinal cord (SC) glioblastoma multiforme (GBM), we conducted a systematic review to evaluate its efficacy." | 4.91 | Primary spinal cord glioblastoma multiforme treated with temozolomide. ( Bregy, A; Hanft, S; Hernández-Durán, S; Komotar, RJ; Manzano, GR; Shah, AH, 2015) |
| "Temozolomide (TMZ) alone has been proposed as a promising alternative to radiotherapy (RT) in elderly glioblastoma (GBM) patients." | 4.90 | A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. ( Cai, S; Cheng, JX; Dong, Y; Liu, BL; Yin, AA; Zhang, LH; Zhang, X, 2014) |
| "Postoperative external beam radiotherapy was considered the standard adjuvant treatment for patients with glioblastoma multiforme until the advent of using the drug temozolomide (TMZ) in addition to radiotherapy." | 4.90 | Radiation and concomitant chemotherapy for patients with glioblastoma multiforme. ( Balañà, C; Comas, S; Villà, S, 2014) |
| "Temozolomide is recommended as superior to procarbazine in patients with first relapse of glioblastoma after having received nitrosourea chemotherapy or no prior cytotoxic chemotherapy at the time of initial therapy." | 4.90 | The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. ( Kalkanis, SN; Nayak, L; Olson, JJ; Ormond, DR; Wen, PY, 2014) |
| "Pseudoprogression constitutes a typical posttherapeutic phenomenon in patients with glioblastoma treated with radiochemotherapy with temozolomide." | 4.90 | Neuroimaging of therapy-associated brain tissue abnormalities. ( Linn, J, 2014) |
| " While temozolomide, an alkylating agent, has demonstrated a survival benefit, median survival in the past decade of patients with glioblastoma (GBM) remains an obdurate 15 months and add-on therapies have not significantly prolonged life." | 4.90 | Molecular neuro-oncology and the challenge of the blood-brain barrier. ( Aiken, R, 2014) |
| "Glioblastoma is the most common primary malignant brain tumor, but despite multimodal treatment with surgery, radiotherapy, and temozolomide chemotherapy, the prognosis is poor, with a median survival of 16 to 19 months and poor quality of life throughout the disease course." | 4.90 | Emerging therapies for glioblastoma. ( Brennan, CW; DeAngelis, LM; Omuro, AM; Thomas, AA, 2014) |
| "For primary therapy three RCTs were identified, enrolling a total of 745 patients, that investigated temozolomide in combination with radiotherapy versus radiotherapy alone for glioblastoma multiforme (GBM)." | 4.89 | Temozolomide for high grade glioma. ( Garside, R; Grant, R; Hart, MG; Rogers, G; Stein, K, 2013) |
| "The efficacy of temozolomide (TMZ) in recurrent glioblastoma multiforme (GBM) has been evaluated by several clinical trials." | 4.89 | The efficacy of temozolomide for recurrent glioblastoma multiforme. ( Chen, C; Chen, J; Lu, Y; Wu, S; Xu, T, 2013) |
| " Recent evidence suggests that temozolomide (TMZ), an orally-active alkylating agent used principally in the management of glioblastoma, may also be effective in controlling aggressive/invasive pituitary adenomas/carcinomas." | 4.88 | Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature. ( Annamalai, AK; Antoun, NM; Burnet, NG; Burton, H; Cheow, HK; Dean, AF; Gurnell, M; Halsall, DJ; Jefferies, SJ; Kandasamy, N; Kirollos, RW; Kovacs, K; Pickard, JD; Shaw, AS; Simpson, HL, 2012) |
| "The landmark Stupp study demonstrated a survival advantage with concomitant and adjuvant temozolomide (TMZ) with standard radiotherapy (RT) in glioblastoma multiforme (GBM) patients but excluded those older than 70 years." | 4.88 | Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience. ( Bauman, GS; Cao, JQ; Fisher, BJ; Macdonald, DR; Megyesi, JF; Watling, CJ, 2012) |
| "This article provides historical and recent perspectives related to the use of temozolomide for the treatment of glioblastoma multiforme." | 4.88 | Temozolomide and other potential agents for the treatment of glioblastoma multiforme. ( Chow, F; Cremer, N; Kim, W; Nagasawa, DT; Yang, I; Yew, A, 2012) |
| " Attempted gross total surgical resection followed by concurrent temozolomide and radiation therapy has become standard of care for glioblastoma." | 4.88 | Potential usefulness of radiosensitizers in glioblastoma. ( Harasaki, Y; Waziri, A, 2012) |
| "Glioblastoma is a brain tumor with poor prognosis in the therapy of which operation, postoperative temozolomide sensitized radiochemotherapy followed by temozolomide monotherapy offer the best chances." | 4.88 | [Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme]. ( Bassam, A; Nagy, KA; Pikó, B; Puskásné Szatmári, K; Török, E; Vághy, R; Vargáné Tamás, R, 2012) |
| "In patients with glioblastoma multiforme (GBM), there is no consensus on the sequential use of two existing regimens: post-operative Gliadel implantation into the surgical cavity and concomitant temozolomide with radiotherapy followed by adjuvant temozolomide ('Stupp protocol')." | 4.87 | The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review. ( Achawal, S; Dixit, S; Hingorani, M; Scott, I, 2011) |
| "Loco-regional chemotherapy with carmustine wafers (Gliadel) positioned at surgery and followed by radiotherapy has been shown to prolong survival in first-diagnosis glioblastoma, as well as concomitant radiochemotherapy with temozolomide." | 4.87 | Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel. ( Casali, C; Di Meco, F; Duri, S; Gaviani, P; Milanesi, I; Salmaggi, A; Silvani, A, 2011) |
| "Temozolomide chemotherapy has become part of the therapy used to treat glioblastoma multiforme and refractory anaplastic astrocytoma." | 4.86 | Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review. ( Aguado, JM; García-Reyne, A; Juan, RS; Lalueza, A; Lizasoain, M; López-Medrano, F; Martínez, P; Meije, Y; Rodríguez, V, 2010) |
| "Temozolomide-based chemotherapy represents an incremental improvement in the treatment of patients with high-grade gliomas." | 4.86 | Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. ( Chamberlain, MC, 2010) |
| "Temozolomide (TMZ) is an oral anticancer agent approved for the treatment of newly diagnosed glioblastoma in combination with radiotherapy." | 4.85 | Recent approaches to improve the antitumor efficacy of temozolomide. ( Graziani, G; Tentori, L, 2009) |
| " The standard care for glioblastoma is surgery and concomitant radio- and chemotherapy with temozolomide (TMZ), followed by adjuvant treatment with TMZ." | 4.85 | Insights into pharmacotherapy of malignant glioma in adults. ( D'Elia, A; Formichella, AI; Frati, A; Salvati, M, 2009) |
| "Glioblastoma multiforme (GBM), the most aggressive primary malignant brain tumor, is resistant to conventional radiotherapies and chemotherapies, including temozolomide (TMZ)." | 4.84 | Downregulation of long noncoding RNA ( Ogino, Y; Okamoto, R; Sato, A; Toya, K, 2024) |
| "Temozolomide (TMZ) offers substantial therapeutic benefits for glioblastoma (GB), yet its efficacy is hindered the development of chemoresistance." | 4.84 | CREB-induced LINC00473 promotes chemoresistance to TMZ in glioblastoma by regulating O6-methylguanine-DNA-methyltransferase expression via CEBPα binding. ( Fang, X; Feng, M; Jiang, CM; Jiang, LY; Li, XL; Lin, XY; Wang, GH; Xu, JJ; Zhang, HX, 2024) |
| "In primary disease two RCTs were identified, enrolling a total of 703 patients, that investigated concomitant and adjuvant temozolomide in Glioblastoma Multiforme (GBM)." | 4.84 | Temozolomide for high grade glioma. ( Garside, R; Grant, R; Hart, MG; Rogers, G; Somerville, M; Stein, K, 2008) |
| "Carmustine wafers (Gliadel) and temozolomide (Temodal) were recently approved for initial management of glioblastoma." | 4.84 | [What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?]. ( Ducray, F; Honnorat, J, 2007) |
| " Temozolomide is a novel second-generation alkylating agent that has shown efficacy for the treatment of high-grade gliomas." | 4.84 | [Glioma therapy up-date]. ( Dalmau, J; de la Fuente, BP; Rosenfeld, M, 2007) |
| " The most striking evidence for proautophagic chemotherapy to overcome apoptosis resistance in cancer cells comes from the use of temozolomide, a proautophagic cytotoxic drug, which has demonstrated real therapeutic benefits in glioblastoma patients and is in clinical trials for several types of apoptosis-resistant cancers." | 4.84 | Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. ( Facchini, V; Kiss, R; Lefranc, F, 2007) |
| "The dismal prognosis of glioblastoma had remained unchanged for the past 30 years until the association of temozolomide and radiotherapy in the breakthrough European Organization for Cancer/National Cancer Institute of Canada (EORTC/NCIC) trial brought new hope for patients." | 4.83 | The evolution of chemoradiation for glioblastoma: a modern success story. ( Mirimanoff, RO, 2006) |
| "Following the seminal trial conducted by the European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC), concurrent temozolomide and radiotherapy has become the new standard of care for patients with newly diagnosed glioblastoma multiforme (GBM)." | 4.83 | Treatment options for glioblastoma. ( Chamberlain, MC, 2006) |
| "Concomitant and adjuvant treatment with Temozolomide, an oral alkylating agent, has significantly improved the survival of patients with newly diagnosed glioblastoma multiforme (study EORTC 26981/22981, NCIC CE3)." | 4.83 | Chemotherapy for malignant gliomas. ( Marosi, C, 2006) |
| " The place of chemotherapy is growing not only for anaplastic oligodendrogliomas, more chemosensitive (particularly when they harbor 1p19q codeletions), but also for glioblastomas patients, which have been shown to benefit from radiotherapy plus concomitant and adjuvant temozolomide." | 4.83 | [Pattern of care of high-grade gliomas]. ( Laigle-Donadey, F; Sanson, M, 2006) |
| " In this paper we address different clinical outcomes measures separately and we illustrate the value of multiple outcome measures using the results of a recent clinical trial comparing temozolomide with procarbazine in the treatment of Glioblastoma Multiforme." | 4.82 | Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. ( Kiebert, G; Macdonald, DR; Olson, J; Prados, M; Yung, A, 2005) |
| "Temozolomide (TMZ) is a new, orally administered, second-generation imidazotetrazine prodrug with essentially 100% oral bioavailability that has demonstrated meaningful efficacy and an acceptable safety profile in the treatment of patients with recurrent glioblastoma multiforme." | 4.80 | Future directions in the treatment of malignant gliomas with temozolomide. ( Prados, MD, 2000) |
| "Temozolomide (TMZ) has been used as standard-of-care for glioblastoma multiforme (GBM), but the resistance to TMZ develops quickly and frequently." | 4.31 | Involvement of cell shape and lipid metabolism in glioblastoma resistance to temozolomide. ( An, YJ; Choo, M; Kim, DH; Kim, HS; Ku, JL; Lee, SK; Mai, VH; Park, CK; Park, S, 2023) |
| "The present study will investigate whether guggulsterone potentiates the anti-glioblastoma efficacy of temozolomide by down-regulating EGFR/PI3K/Akt signaling and NF-κB activation." | 4.31 | Guggulsterone from Commiphora mukul potentiates anti-glioblastoma efficacy of temozolomide in vitro and in vivo via down-regulating EGFR/PI3K/Akt signaling and NF-κB activation. ( Chen, XZ; Xu, HB; Xue, F; Yu, ZL, 2023) |
| "Temozolomide (TMZ) is the recommended drug for glioblastoma (GBM) treatment, but its clinical effect is restricted due to drug resistance." | 4.31 | Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma. ( Dong, J; Jiang, Z; Peng, Y; Wang, K; Wu, Y; Xie, Z; Zhong, M, 2023) |
| "Temozolomide (TMZ) has been determined to be the chemotherapeutic drug with efficacy for glioblastoma (GBM)." | 4.31 | Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma. ( Song, S; Tong, X; Wang, F; Wang, Y; Wen, B; Wu, H; Wu, Q; Xu, L; Yan, H; Zhou, Y, 2023) |
| "Complete resection of glioblastoma via a supraorbital transciliary approach with 5-Aminolevulinic Acid use was performed without any complications, as demonstrated on postoperative MRI." | 4.31 | Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note. ( Aboukaïs, R; Bourgeois, P; Devalckeneer, A; Lejeune, JP; Reyns, N, 2023) |
| " Based on CRISPR-Cas9 library screening, we found that mucin1 (MUC1) is essential for EGFRvIII glioma cell survival and temozolomide (TMZ) resistance." | 4.31 | MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII. ( Cui, XT; Fang, ZY; Fu, JQ; Kang, CS; Liu, SZ; Liu, X; Qiu, ZJ; Su, DY; Tong, F; Wang, GX; Wang, JC; Wang, QX; Zhao, JX; Zhou, JH, 2023) |
| " Even with aggressive treatment, tumor recurrence is almost universal and patient prognosis is poor because many GBM cell subpopulations, especially the mesenchymal and glioma stem cell populations, are resistant to temozolomide (TMZ), the most commonly used chemotherapeutic in GBM." | 4.31 | αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform. ( Che, J; DePalma, TJ; Mezache, LS; Sivakumar, H; Skardal, A; Swindle-Reilly, K; Tallman, MM; Veeraraghavan, R; Venere, M, 2023) |
| "Temozolomide (TMZ) delivery was investigated in CT2A and PDGFB-driven RCAS/tv-a orthotopic glioma models." | 4.31 | Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma. ( Cao, H; Chao, M; Dimberg, A; He, L; Huang, H; Li, Y; Shi, X; Tang, J; Uhrbom, L; Wang, J; Wang, L; Xiao, B; Xie, Y; Xin, L; Yang, F; Zhang, L; Zhang, X; Zhang, Y, 2023) |
| " In this study, we investigated the role of KDM1A/LSD1 in DNA double-strand break (DSB) repair and a combination of KDM1A inhibitor and temozolomide (TMZ) in vitro and in vivo using patient-derived glioma stem cells (GSCs)." | 4.31 | Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma. ( Alejo, S; Brenner, AJ; Chen, Y; Clarke, K; Gilbert, AR; He, Y; Jayamohan, S; Johnson, JD; Lai, Z; Li, W; Lv, Y; Palacios, BE; Pratap, UP; Sareddy, GR; Suzuki, T; Tekmal, RR; Vadlamudi, RK; Venkata, PP; Viswanadhapalli, S; Weldon, K; Ye, Z; Zhao, W; Zheng, S; Zou, Y, 2023) |
| "Hypofractionated radiotherapy (HypoRT) has recently been implemented in patients with glioblastoma (GBM) receiving concurrent temozolomide." | 4.31 | Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma. ( Choi, JW; Kim, N; Kong, DS; Lee, JI; Lim, DH; Nam, DH; Seol, HJ, 2023) |
| "Our study aimed to assess the benefit of prolonging adjuvant temozolomide (TMZ) therapy beyond 6 cycles in glioblastoma multiform patients." | 4.31 | Impact of Extended Adjuvant Temozolamide Beyond 6 Months in the Management of Glioblastoma Patients. ( Elsaid, AA; Elsaka, R; Kitagwa, JM; Mahmoud, AA; Meheissen, MAM; Refaat, T; Shaikh, H, 2023) |
| "For treatment of glioblastoma (GBM), temozolomide (TMZ) and radiotherapy (RT) exert antitumor effects by inducing DNA double-strand breaks (DSBs), mainly via futile DNA mismatch repair (MMR) and inducing apoptosis." | 4.31 | RBBP4 regulates the expression of the Mre11-Rad50-NBS1 (MRN) complex and promotes DNA double-strand break repair to mediate glioblastoma chemoradiotherapy resistance. ( Chen, L; Gu, J; Li, C; Li, H; Li, J; Lu, Y; Qi, S; Shi, L; Song, C; Wang, T; Zang, W; Zhou, M; Zhu, L, 2023) |
| "Although temozolomide (TMZ) provides significant clinical benefit for glioblastoma (GBM), responses are limited by the emergence of acquired resistance." | 4.31 | Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustaining ErbB downstream signaling. ( Cao, Z; Gao, G; Gu, J; Guan, Z; Guo, Q; Hao, Q; Jia, B; Li, M; Li, W; Liu, X; Wang, S; Wang, W; Zhang, K; Zhang, W; Zhang, Y, 2023) |
| "The development of resistance to temozolomide (TMZ), a standard chemotherapeutic, limits the effective treatment of glioblastoma (GBM)." | 4.31 | The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model. ( Kucheryavykh, L; Kucheryavykh, Y; Nuñez, R; Ortiz-Rivera, J, 2023) |
| "Although temozolomide (TMZ) has been used as a standard adjuvant chemotherapeutic agent for primary glioblastoma (GBM), treating isocitrate dehydrogenase wild-type (IDH-wt) cases remains challenging due to intrinsic and acquired drug resistance." | 4.31 | Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma. ( Cho, HJ; Choi, SW; Kim, D; Kim, Y; Kong, DS; Koo, H; Kwon, YJ; Lee, HW; Lee, JI; Lee, K; Mu, Q; Nam, Y; Oh, JW; Park, CK; Park, WY; Sa, JK; Seo, YJ; Seol, HJ; Shin, S; Wang, J; Yang, Y; Yoon, Y; Zhu, Z, 2023) |
| "Temozolomide (TMZ) is one of the best choices for treating glioblastoma." | 4.31 | Exploring temozolomide encapsulated PEGylated liposomes and lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies. ( Laxmi Swetha, K; Narayan Saha, R; Roy, A; Singhvi, G; Waghule, T, 2023) |
| " Protein disulfide isomerase (PDI) is a molecular chaperone known to be highly expressed in glioblastomas with acquired resistance to temozolomide (TMZ)." | 4.31 | Targeting unfolded protein response using albumin-encapsulated nanoparticles attenuates temozolomide resistance in glioblastoma. ( Kiang, KM; Lam, TL; Leung, GK; Li, N; Liu, J; Shum, HC; Song, Q; Tang, W; Zhu, Z, 2023) |
| "Temozolomide is extensively applied in chemotherapy for glioblastoma with unclear exact action mechanisms." | 4.31 | Temozolomide protects against the progression of glioblastoma via SOX4 downregulation by inhibiting the LINC00470-mediated transcription factor EGR2. ( Cui, Y; He, J; Li, W; Liu, P; Ma, W; Wang, M; Zhang, M, 2023) |
| "The therapeutic efficacy of radiotherapy/temozolomide treatment for glioblastoma (GBM) is limited by the augmented invasiveness mediated by invadopodia activity of surviving GBM cells." | 4.31 | Small extracellular vesicles promote invadopodia activity in glioblastoma cells in a therapy-dependent manner. ( Drummond, KJ; Fang, H; Greening, DW; Hanssen, E; Kaye, AH; Mantamadiotis, T; Morokoff, AP; Nowell, CJ; Stylli, SS; Su, H; Vella, LJ; Whitehead, CA, 2023) |
| " TTFields therapy is approved for treatment of newly-diagnosed glioblastoma (GBM) concurrent with maintenance temozolomide (TMZ)." | 4.31 | Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines. ( Dor-On, E; Fishman, H; Giladi, M; Haber, A; Kinzel, A; Monin, R; Palti, Y; Weinberg, U, 2023) |
| "Glioblastoma (GBM) is a malignant brain tumor, commonly treated with temozolomide (TMZ)." | 4.31 | ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression. ( Chen, JC; Chong, ZY; Huang, C; Huang, HC; Lee, IN; Wu, YP; Yang, JT, 2023) |
| "Patients with glioblastoma (GBM) have poor prognosis and limited therapeutic options, largely because of chemoresistance to temozolomide (TMZ) treatment." | 4.31 | UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway. ( Gao, G; Wang, Y; Wei, X; Yu, J; Zhang, Y, 2023) |
| "Resistance to temozolomide (TMZ) remains an important cause of treatment failure in patients with glioblastoma multiforme (GBM)." | 4.31 | TRIM25 promotes temozolomide resistance in glioma by regulating oxidative stress and ferroptotic cell death via the ubiquitination of keap1. ( Hu, Z; Liu, X; Ma, L; Sun, T; Wan, J; Wang, L; Wei, J; Zhang, C; Zhang, Y; Zhou, L, 2023) |
| " In this study, we showed that after continuous oral consumption of high-fat (HF) diets containing M4N, the M4N concentration in most of the organs in mice reached ~1 μM (the M4N concentration in intestines and fat pads was as high as 20-40 μM) and treatment with the combination of M4N with temozolomide (TMZ) suppressed glycolysis and the tricarboxylic acid cycle in LN229 human glioblastoma implanted in xenograft mice." | 4.31 | Tetra-O-methyl-nordihydroguaiaretic acid inhibits energy metabolism and synergistically induces anticancer effects with temozolomide on LN229 glioblastoma tumors implanted in mice while preventing obesity in normal mice that consume high-fat diets. ( Chun, JH; Huang, RCC; Jackson, TLB; Kimura, K; Liang, YC; Lin, YL, 2023) |
| "This study aims to elucidate the mechanism underlying temozolomide resistance in patients with MGMT promoter hypomethylated glioblastoma, which is correlated with poor prognosis." | 4.31 | AHR, a novel inhibitory immune checkpoint receptor, is a potential therapeutic target for chemoresistant glioblastoma. ( Bian, Y; Li, P; Li, S; Liu, J; Liu, Z; Pan, J; Song, S; Sun, Z; Tan, N; Wang, Y; Zhao, W, 2023) |
| "Temozolomide resistance remains a major obstacle in the treatment of glioblastoma (GBM)." | 4.31 | The DRD2 Antagonist Haloperidol Mediates Autophagy-Induced Ferroptosis to Increase Temozolomide Sensitivity by Promoting Endoplasmic Reticulum Stress in Glioblastoma. ( Chen, H; Chen, K; Chen, L; Huang, A; Huang, Y; Li, C; Li, H; Lu, Y; Qi, S; Shi, L; Song, C; Wang, T; Zhong, C, 2023) |
| "Temozolomide (TMZ) treatment efficacy in glioblastoma (GBM) has been limited by resistance." | 4.31 | EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT. ( Cui, X; Fang, C; Hong, B; Kang, C; Tan, Y; Tian, S; Wang, C; Wang, Q; Xiao, M; Xin, L; Xu, C; Xu, J; Yuan, X; Zhao, J; Zhu, Y, 2023) |
| "Chemoresistance blunts the efficacy of temozolomide (TMZ) in the treatment of glioblastoma (GBM)." | 4.31 | Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation. ( Ahmad, N; Cheng, X; Deng, S; Li, H; Shu, X; Song, D; Wang, Q; Wu, M; Xu, H; Yang, X, 2023) |
| "Glioblastoma multiforme (GBM) is the deadliest glioma and its resistance to temozolomide (TMZ) remains intractable." | 4.31 | HOXD-AS2-STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma. ( Cao, YY; Chen, JX; Chen, QZ; Huang, GH; Li, Y; Liu, GL; Lv, SQ; Pei, YC; Ren, P; Wang, TT; Xiang, Y; Yang, L; Yang, W; Zhang, ZX; Zhou, S, 2023) |
| "The standard treatment of glioblastoma, an aggressive brain tumour, includes radiotherapy combined with temozolomide." | 4.31 | [Regional variation in usage of TTF (Optune)]. ( Henriksson, R; Kinhult, S; Löfgren, D; Rosenlund, L; Sandström, M; Strandeus, M; Tavelin, B, 2023) |
| "Temozolomide (TMZ) is considered a first line chemotherapy drug for glioblastoma (GBM)." | 4.31 | Label-Free Raman Spectromicroscopy Unravels the Relationship between MGMT Methylation and Intracellular Lipid Accumulation in Glioblastoma. ( Ji, N; Wang, J; Wang, N; Wang, P; Yue, S, 2023) |
| "Temozolomide (TMZ) therapy offers minimal clinical benefits in patients with glioblastoma multiforme (GBM) with high EGFR activity, underscoring the need for effective combination therapy." | 4.31 | Lysine methylation promotes NFAT5 activation and determines temozolomide efficacy in glioblastoma. ( Gao, Z; Hu, R; Li, M; Li, Y; Liu, C; Mei, M; Pang, B; Ren, Y; Wang, Y; Yang, J; Zhang, B; Zhang, X; Zhou, X, 2023) |
| "The potential targets and mechanisms of quercetin in glioma treatment were predicted based on network pharmacology and molecular docking." | 4.31 | Quercetin induces MGMT ( Chen, J; Li, B; Mu, J; Wang, Q; Wang, W; Wu, X; Xu, L; Yin, Z; Yuan, X; Zeng, Z; Zhu, X; Zou, Y, 2023) |
| " Glioblastoma is the most frequent and practically incurable neoplasm of the central nervous system; thus, new treatment modalities have been investigated to find a solution more effective than the currently applied standards based on temozolomide." | 4.31 | Autophagy Inhibition with Chloroquine Increased Pro-Apoptotic Potential of New Aziridine-Hydrazide Hydrazone Derivatives against Glioblastoma Cells. ( Głowacka, P; Jaskólski, DJ; Pieczonka, AM; Pudlarz, A; Rachwalski, M; Świderska, E; Szemraj, J; Szymańska, J; Witusik-Perkowska, M; Zakrzewska, M, 2023) |
| "In our study, we included 169 glioblastoma patients who were admitted to our clinic between 2009 and 2019 and received concurrent radiotherapy (RT) + temozolomide (TMZ) after surgery." | 4.31 | The Assessment of Clinical Outcomes and Prognostic Factors in Glioblastoma Patients. ( Bora, H; Demircan, NV; Erpolat, OP; Guzel, C; Karahacioglu, E; Senturk, E, 2023) |
| "To explore the role of forkhead box protein O1 (FOXO1) in the progression of glioblastoma multiforme (GBM) and related drug resistance, we deciphered the roles of FOXO1 and miR-506 in proliferation, apoptosis, migration, invasion, autophagy, and temozolomide (TMZ) sensitivity in the U251 cell line using in vitro and in vivo experiments." | 4.31 | FOXO1-miR-506 axis promotes chemosensitivity to temozolomide and suppresses invasiveness in glioblastoma through a feedback loop of FOXO1/miR-506/ETS1/FOXO1. ( Chen, C; Chen, J; Liu, Y; Shi, Y; Wang, H; Zhang, X, 2023) |
| "The cytotoxic effects of shikonin against murine glioblastoma cells, SB28 and CT-2A, were reported resistance to temozolomide, were evaluated using an allophycocyanin-conjugated annexin V and propidium iodide assay with flow cytometry." | 4.31 | Local administration of shikonin improved the overall survival in orthotopic murine glioblastoma models with temozolomide resistance. ( Maeoka, R; Matsuda, R; Morimoto, T; Nakagawa, I; Nakase, H; Nakazawa, T; Nishimura, F; Ouji, Y; Park, YS; Yamada, S; Yokoyama, S; Yoshikawa, M, 2023) |
| "Glioblastoma patients commonly develop resistance to temozolomide chemotherapy." | 4.31 | Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion. ( Bindila, L; Geiß, C; Kim, E; Lieberwirth, I; Régnier-Vigouroux, A; Sousa, N, 2023) |
| "The median survival of patients diagnosed with glioblastoma is very poor, despite efforts to improve the therapeutic effects of surgery, followed by treatment with temozolomide (TMZ) and ionizing radiation (IR)." | 4.31 | Impact of Ferroptosis Inducers on Chronic Radiation-exposed Survivor Glioblastoma Cells. ( Erdem, İS, 2023) |
| "To study the effect of cordycepin combined with temozolomide on glioblastoma, we explored the effect of the combination based on network pharmacology and biological verification." | 4.31 | Cordycepin improves sensitivity to temozolomide in glioblastoma cells by down-regulating MYC. ( Chen, J; Shi, SS; Zhang, GL; Zhang, Q; Zheng, SX; Zhuang, BB, 2023) |
| "In our previous study, we found for the first time that temozolomide (TMZ), the first-line chemotherapeutic agent for glioblastoma (GBM), can generate a large amount of reactive oxygen species (ROS) under ultrasound irradiation." | 4.31 | Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma. ( Jiao, J; Tong, X; Wen, B; Wu, Q; Xu, L; Yan, H; Yang, R; Zhou, Y, 2023) |
| "Temozolomide (TMZ) is a common alkylating chemotherapeutic agent used to treat brain tumors such as glioblastoma multiforme (GBM) and anaplastic astrocytoma." | 4.31 | LncRNA-associated competing endogenous RNA network analysis uncovered key lncRNAs involved in temozolomide resistance and tumor recurrence of glioblastoma. ( Mallick, B; Nayak, R, 2023) |
| "The purpose of this study was to explore the role of coixendide (Coix) combine with temozolomide (TMZ) in the treatment of Glioblastoma (GBM) and explore its possible mechanism." | 4.31 | Coixendide efficacy in combination with temozolomide in glioblastoma and transcriptome analysis of the mechanism. ( Ban, X; Jin, P; Li, Y; Liu, S; Yue, Y; Zhang, L; Zhang, X; Zhao, C; Zhao, Z, 2023) |
| "In the randomized CeTeG/NOA-09 trial, lomustine/temozolomide (CCNU/TMZ) was superior to TMZ therapy regarding overall survival (OS) in MGMT promotor-methylated glioblastoma." | 4.31 | Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses. ( Duffy, C; Galldiks, N; Glas, M; Goldbrunner, R; Grauer, O; Hattingen, E; Hau, P; Herrlinger, U; Krex, D; Nitsch, L; Paech, D; Potthoff, AL; Radbruch, A; Schäfer, N; Schaub, C; Schlegel, U; Schneider, M; Seidel, C; Steinbach, JP; Stummer, W; Tabatabai, G; Tzaridis, T; Weller, J; Zeiner, PS; Zeyen, T, 2023) |
| "Temozolomide (TMZ) is a standard treatment for glioblastoma (GBM) patients." | 4.31 | Hypoxanthine phosphoribosyl transferase 1 metabolizes temozolomide to activate AMPK for driving chemoresistance of glioblastomas. ( Agnihotri, S; Cao, Y; Chen, D; Ding, F; Ge, X; Ge, Z; Huang, G; Ji, J; Lin, F; Lu, Z; Qian, X; Shi, Z; Wang, Q; Wang, X; Yin, J; You, Y; Zhang, J; Zhao, N; Zhou, Q, 2023) |
| "Temozolomide (TMZ) is a commonly used chemotherapeutic agent for glioblastoma (GBM), but acquired drug resistance prevents its therapeutic efficacy." | 4.31 | NFYB increases chemosensitivity in glioblastoma by promoting HDAC5-mediated transcriptional inhibition of SHMT2. ( Huang, H; Liu, P; Xie, Y; Zhang, Y, 2023) |
| "Altogether, our results indicate that using nanoemulsion containing temozolomide in combination with ferrocene is an effective approach to improve glioblastoma therapy outcomes." | 4.31 | Development and characterization of a temozolomide-loaded nanoemulsion and the effect of ferrocene pre and co-treatments in glioblastoma cell models. ( Bernardes Ferro, M; da Rosa, RG; da Silva, LF; de Oliveira, JVR; de Souza, BM; Henn, JG; Lopes Alves, GA; Morás, AM; Moura, DJ; Nugent, M; Pires Peña, F; Rapack Jacinto Silva, V; Silva Pinheiro, AC; Silveira Aguirre, TA; Steffens Reinhardt, L, 2023) |
| "Temozolomide (TMZ) treatment efficacy in glioblastoma (GBM) patients has been limited by resistance in the clinic." | 4.31 | Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis. ( Huang, G; Li, Z; Qi, S; Qu, S; Wang, K; Ye, R; Yi, GZ; Zhang, H; Zhang, W; Zhu, T, 2023) |
| "Temozolomide (TMZ) is standard treatment for glioblastoma (GBM); nonetheless, resistance and tumor recurrence are still major problems." | 4.31 | Enhanced Sensitivity to ALDH1A3-Dependent Ferroptosis in TMZ-Resistant Glioblastoma Cells. ( Franzmeier, S; Liesche-Starnecker, F; Schlegel, J; Wu, Y, 2023) |
| "Chemotherapy using temozolomide is the standard treatment for patients with glioblastoma." | 4.31 | Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells. ( Arijs, I; Beerens, C; Biswas, A; Byrne, AT; Chien, MP; Connor, K; Dilcan, G; Fabro, F; Feller, KJ; Idbaih, A; Kers, TV; Kremer, A; Lambrechts, D; Lamfers, MLM; Leenstra, S; Lodi, F; Ntafoulis, I; O'Farrell, AC; Prehn, JHM; Salvucci, M; Tching Chi Yen, R; Verreault, M, 2023) |
| "In this study, to screen for candidate markers of temozolomide (TMZ) resistance in glioblastoma, we artificially established TMZ drug-resistant glioblastoma (GBM) cell lines, U251-TMZ and U87-TMZ." | 4.31 | Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics. ( Bian, L; Li, D; Li, K; Lin, B; Liu, X; Xi, Z; Yan, J; Yang, Q, 2023) |
| "Hematological adverse events (HAEs) are common during treatment for glioblastoma (GBM), usually associated with temozolomide (TMZ)." | 4.12 | Hematological adverse events in the management of glioblastoma. ( Butts, AR; Garcia, CR; Jayswal, R; Morgan, RM; Myint, ZW; Villano, JL; Wang, C; Weiss, HL, 2022) |
| "To our knowledge, there are minimal reports of temozolomide-induced DRESS syndrome." | 4.12 | Drug-induced hypersensitivity syndrome following temozolimide for glioblastoma multiforme and the role of desensitization therapy. ( Ambur, A; Ambur, L; Khan, L; Nathoo, R, 2022) |
| "Survival of patients with glioblastoma (GBM) increased in the 2000s, most prominently after the addition of temozolomide to the standard-of-care treatment protocol." | 4.12 | Temporal Trends in Glioblastoma Survival: Progress then Plateau. ( Carabenciov, ID; Johnson, DR; Neth, BJ; Ruff, MW, 2022) |
| "An insufficient oxygen supply within the intratumoral environment, also known as hypoxia, induces glioblastoma multiforme (GBM) invasion, stemness, and temozolomide (TMZ) drug resistance." | 4.12 | Hypoxia-inducible lncRNA MIR210HG interacting with OCT1 is involved in glioblastoma multiforme malignancy. ( Chen, KC; Ho, KH; Liu, AJ; Shih, CM, 2022) |
| "The standard treatment of glioblastoma patients consists of surgery followed by normofractionated radiotherapy (NFRT) with concomitant and adjuvant temozolomide chemotherapy." | 4.12 | Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis. ( Ehret, F; Grosu, AL; Kaul, D; Klement, RJ; Lewitzki, V; Polat, B; Popp, I; Sweeney, RA, 2022) |
| "Resistance to temozolomide (TMZ) chemotherapy is the main reason for treatment failure in patients with glioblastoma (GBM)." | 4.12 | Biochanin A Sensitizes Glioblastoma to Temozolomide by Inhibiting Autophagy. ( Dong, Q; Duan, L; Li, L; Li, Q; Liu, Y; Pan, Y; Wang, D; Wang, J; Wang, X; Yin, H; Yuan, G, 2022) |
| " The current study evaluated the role and molecular mechanisms of anlotinib in glioblastoma, and the effects of anlotinib in combination with temozolomide (TMZ)." | 4.12 | Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway. ( Chen, J; Deng, C; Pan, H; Wang, H; Xu, P, 2022) |
| "The standard of care for elderly glioblastoma patients is 40 Gy in 15 fraction radiotherapy with temozolomide (TMZ)." | 4.12 | Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma. ( Ammirati, M; Arnett, A; Beyer, S; Blakaj, DM; Brown, PD; Chakravarti, A; Elder, JB; Giglio, P; Gondi, V; Goranovich, J; Grecula, J; Hardesty, D; Klamer, B; Lonser, R; Matsui, J; Ong, S; Palmer, JD; Perlow, HK; Pillainayagam, C; Raval, RR; Yaney, A; Yang, M, 2022) |
| "Patients with glioblastoma (GBM) are treated with radiotherapy (RT) and temozolomide (TMZ)." | 4.12 | Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models. ( Campian, JL; Chheda, MG; Ferrando-Martinez, S; Ghosh, S; Hallahan, D; Hu, T; Jash, A; Kapoor, V; Lee, BH; Mahadevan, A; Page, L; Rifai, K; Thotala, D; Thotala, S; Wolfarth, AA; Yan, R; Yang, SH, 2022) |
| "Glioblastoma (GBM) is a rapidly fatal malignancy typically treated with radiation and temozolomide (TMZ), an alkylating chemotherapeutic." | 4.12 | Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL Inhibition. ( Brown, D; Burma, S; Burns, TC; Carlstrom, LP; Chen, S; Decker, PA; Howard, A; Kirkland, JL; Mansour, M; Olson, I; Parney, IF; Rahman, M; Rajani, K; Rodriguez, M; Saber, R; Sananikone, EF; Sarkaria, JN; Schroeder, M; Sutiwisesak, R; Tchkonia, T; Warrington, AE; Zhu, Y, 2022) |
| "Although temozolomide (TMZ) is recommended for glioblastoma (GBM) treatment, patients treated with TMZ usually develop TMZ resistance." | 4.12 | Oncogenic Forkhead box D3 antisense RNA 1 promotes cell survival and confers temozolomide resistance in glioblastoma cells through the miR-128-3p/WEE1 G2 checkpoint kinase axis. ( Ling, Z; Liu, Q; Zhang, J, 2022) |
| " The present study was designed to investigate the role of hsa_circ_0072309 in autophagy and temozolomide (TMZ) sensitivity in glioblastoma (GBM)." | 4.12 | Hsa_circ_0072309 enhances autophagy and TMZ sensitivity in glioblastoma. ( Chen, Q; Deng, G; Liu, B; Sun, Q; Xu, Y; Xu, Z; Ye, L; Yuan, F; Zhang, S, 2022) |
| "It is necessary to elucidate the individual effects of temozolomide (TMZ) on carcinogenesis and tumor resistance to chemotherapy mechanisms." | 4.12 | The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro. ( Alonso, MM; Balnytė, I; Damanskienė, E; Preikšaitis, A; Stakišaitis, D; Valančiūtė, A, 2022) |
| "Temozolomide (TMZ) is a standard-of-care chemotherapeutic drug for the treatment of glioblastoma (GBM), but TMZ-acquired resistance limits its therapeutic effect." | 4.12 | Efficacy of Temozolomide-Conjugated Gold Nanoparticle Photothermal Therapy of Drug-Resistant Glioblastoma and Its Mechanism Study. ( Chu, L; Liu, X; Sha, C; Sun, K; Sun, Y; Wang, A; Wang, S; Xu, L; Yang, X; Yu, Y; Zhou, L, 2022) |
| "Temozolomide (TMZ) monotherapy is known to be insufficient for resistant/relapsed glioblastoma (GBM), thus seeking a sensitization agent for TMZ is necessary." | 4.12 | Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma. ( Ali, AAA; Chiang, IT; Chou, SY; Hsu, FT; Hsu, TI; Liu, HS; Liu, YC, 2022) |
| "This retrospective study enrolled 65 patients with IDH wild-type recurrent glioblastoma who received standard therapy and then received either bevacizumab (46 patients) or temozolomide (19 patients) as a secondary treatment." | 4.12 | Contrast enhancing pattern on pre-treatment MRI predicts response to anti-angiogenic treatment in recurrent glioblastoma: comparison of bevacizumab and temozolomide treatment. ( Kim, HS; Kim, JH; Kim, YH; Moon, HH; Park, JE, 2022) |
| "Myelosuppression is the major toxicity encountered during temozolomide chemoradiotherapy for newly diagnosed glioblastoma." | 4.12 | Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. ( Chinot, O; Gorlia, T; Le Rhun, E; Nabors, B; Oppong, FB; Preusser, M; Stupp, R; Vanlancker, M; Weller, M; Wick, W, 2022) |
| "Sp1 is involved in the recurrence of glioblastoma (GBM) due to the acquirement of resistance to temozolomide (TMZ)." | 4.12 | Reprogramming of arachidonate metabolism confers temozolomide resistance to glioblastoma through enhancing mitochondrial activity in fatty acid oxidation. ( Chang, KY; Chang, WC; Chen, PY; Chuang, JY; Hsu, TI; Hung, CY; Kao, TJ; Kikkawa, U; Ko, CY; Lo, WL; Tsai, YT; Yang, WB, 2022) |
| " Temozolomide is widely used first-line chemotherapy drug to treat glioma patients, but development of temozolomide resistance is almost inevitable." | 4.12 | Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain. ( Bian, XW; Cai, XW; Cao, MF; Gai, QJ; He, J; He, MM; Leng, P; Lu, HM; Mao, M; Qin, Y; Wang, C; Wang, Y; Wang, YX; Wen, XM; Yang, FC; Yao, XH; Yao, XX; Zhu, J, 2022) |
| " We herein investigate the therapeutic potential of bioinformatically identified HOTAIR transferred by serum-derived EVs (serum-EVs) in temozolomide (TMZ) resistance of glioblastoma (GBM) and the downstream mechanisms." | 4.12 | Serum-derived extracellular vesicles facilitate temozolomide resistance in glioblastoma through a HOTAIR-dependent mechanism. ( Han, J; Wang, S; Wang, X; Wang, Y; Wei, K; Xu, H; Yu, X, 2022) |
| "Temozolomide is drug of choice for the treatment of glioblastoma, but dose-related side effects limit its use." | 4.12 | DoE Engineered Development and Validation of an RP-HPLC Method for Simultaneous Estimation of Temozolomide and Resveratrol in Nanostructured Lipid Carrier. ( Ali, J; Baboota, S; Mittal, S, 2022) |
| "Gliosarcoma is an uncommon glioblastoma subtype, for which MGMT promoter methylation's relationship with response to temozolomide chemotherapy is unclear." | 4.12 | Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients. ( Iorgulescu, JB; Kavouridis, VK; Ligon, KL; Wen, PY, 2022) |
| "The standard treatment for glioblastoma is maximal surgical resection followed by postoperative temozolomide administration combined with radiation therapy." | 4.12 | [Glioblastoma That Does Not Improve with Standard Treatment: Standard and Personalized Treatment Making The Most of Limited Modalities]. ( Imai, R; Sasaki, H, 2022) |
| " However, the role of lncRNAs in temozolomide (TMZ) resistance in glioblastoma multiforme (GBM) remains largely undefined." | 4.12 | lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma. ( Guo, H; He, Z; Lenahan, C; Liu, B; Tang, W; Wang, C; Xu, N; Zeng, H; Zhou, J, 2022) |
| "To investigate the function of primary cilia in regulating the cellular response to temozolomide (TMZ) and ionizing radiation (IR) in glioblastoma (GBM)." | 4.12 | Inhibition of Ciliogenesis Enhances the Cellular Sensitivity to Temozolomide and Ionizing Radiation in Human Glioblastoma Cells. ( Cai, H; Gao, L; He, JP; Ma, W; Peng, SP; Tian, HB; Wang, JF; Wei, L, 2022) |
| "Glioblastoma multiforme (GBM) is an aggressive brain tumor, often occurring with seizures managed with antiepileptic drugs, such as levetiracetam (LEV)." | 4.12 | Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients. ( Banchi, M; Bocci, G; Cucchiara, F; Danesi, R; Di Paolo, A; Giannini, N; Giorgi, FS; Luci, G; Orlandi, P; Pasqualetti, F, 2022) |
| "Temozolomide (TMZ) is the primary chemotherapeutic drug for treating glioblastoma (GBM); however, the final clinical outcome is considerably limited by the poor response and resistance to TMZ." | 4.12 | SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy. ( Han, L; Hu, L; Yang, F; Yu, J; Zhao, M; Zhou, H, 2022) |
| "Temozolomide (TMZ) is a chemotherapeutic agent that has been the first-line standard of care for the aggressive brain cancer glioblastoma (GBM) since 2005." | 4.12 | Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas. ( Alamillo-Ferrer, C; Cheng, SY; Drewry, DH; Erdogdu, B; Goenka, A; Goldlust, SA; Haddad, BR; Hogg, JR; Hu, B; Jin, L; Pertea, M; Pickett, JE; Razaghi, R; Riggins, RB; Sadowski, N; Song, X; Tiek, DM; Timp, W; Wells, CI; Zuercher, WJ, 2022) |
| "This study assessed the effects of single or combined administration of temozolomide (TMZ) and interferon-gamma (IFN-ᵞ) on anxiety-like behaviors, balance disorders, learning and memory, TNF-α, IL-10, some oxidant and antioxidants factors with investigating the toll-like receptor-4 (TLR4) and p-CREB signaling pathway in C6-induced glioblastoma of rats." | 4.12 | Combination therapy with interferon-gamma as a potential therapeutic medicine in rat's glioblastoma: A multi-mechanism evaluation. ( Amiresmaili, S; Bashiri, H; Faramarz, S; Jafari, E; Khaksari, M; Kheirandish, R; Moslemizadeh, A; Nematollahi, MH; Rezaei, N, 2022) |
| "Glioblastoma patients have a poor prognosis mainly due to temozolomide (TMZ) resistance." | 4.12 | High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1/MRP1 upregulation. ( Andrade-Tomaz, M; Contieri, B; de Souza, I; Gomes, LR; Guedes, CB; Latancia, MT; Lazarini, M; Mendes, D; Monteiro, LKS; Porchia, BFMM; Rocha, CRR; Silva, MM, 2022) |
| "Temozolomide (TMZ) is the first-line drug for the clinical treatment of glioblastoma (GBM), but drug resistance limits its treatment benefits." | 4.12 | Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression. ( Yun, K; Zhao, W, 2022) |
| "The mechanism by which glioblastoma evades temozolomide (TMZ)-induced cytotoxicity is largely unknown." | 4.12 | SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against temozolomide in glioblastoma. ( Chang, KY; Chen, PY; Chen, SH; Cheng, SM; Chi, PI; Chien, CH; Chu, JM; Chuang, JY; Huang, CY; Hwang, DY; Lai, CC; Lee, JS; Liao, WA; Liu, CC; Wu, AC; Yang, ST; Yang, WB, 2022) |
| "Resistance to temozolomide (TMZ) is a major obstacle to preventing glioblastoma (GBM) recurrence after surgery." | 4.12 | PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition. ( Deng, L; Fan, Y; Gao, Z; Guo, X; Li, G; Qi, Y; Sun, C; Wang, S; Xu, J; Xue, H; Zhang, P; Zhao, R; Zhao, S, 2022) |
| "Temozolomide (TMZ) resistance remains the main therapy challenge in patients with glioblastoma multiforme (GBM)." | 4.12 | TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma. ( Gao, G; Wang, Y; Wei, X; Yu, J, 2022) |
| "We included 41 patients with isocitrate dehydrogenase 1/2-wildtype glioblastoma, who received 12 or more cycles of temozolomide therapy between June 2006 and December 2019." | 4.12 | Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma. ( Miyakita, Y; Narita, Y; Ohno, M; Takahashi, M; Tamura, Y; Yanagisawa, S, 2022) |
| " Optical microscopy and flow cytometry were employed to assess the differences in glioblastoma cells morphology, proliferation, and cytotoxicity of anticancer drug temozolomide (TMZ) due to increased substrate viscosity." | 4.12 | Substrate viscosity impairs temozolomide-mediated inhibition of glioblastoma cells' growth. ( Bucki, R; Cieśluk, M; Kochanowicz, J; Kułakowska, A; Piktel, E; Pogoda, K; Skłodowski, K; Wnorowska, U, 2022) |
| "A first-line therapeutic for high-grade glioma, notably glioblastoma (GBM), is the DNA methylating drug temozolomide (TMZ)." | 4.12 | Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics. ( Beltzig, L; Christmann, M; Kaina, B, 2022) |
| "The DNA alkylating agent temozolomide (TMZ), is the first-line therapeutic for the treatment of glioblastoma (GBM)." | 4.12 | Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole. ( DasGupta, B; Dave, N; Desai, JM; Desai, PB; Gudelsky, GA; Karve, AS; Phoenix, TN; Plas, DR; Sengupta, S; Wise-Draper, TM, 2022) |
| "A MEX3A/CCR4-NOT/MSH2 axis plays a crucial role in promoting temozolomide resistance, providing new insights into the function of MEX3A and suggesting MEX3A as a potential therapeutic target in therapy-resistant glioblastoma." | 4.12 | MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma. ( Gan, T; Miao, F; Nie, E; Qian, X; Shen, Z; Shi, Q; Wang, P; Wang, Q; Wang, Y; Xie, M; Zhao, S, 2022) |
| "Systemic chemotherapy including monotherapy with temozolomide (TMZ) or bevacizumab (BEV); two-drug combinations, such as irinotecan (IRI) and BEV, TMZ and BEV and a three-drug combination with TMZ, IRI and BEV (TIB) have been used in treating patients with progressive high-grade gliomas including glioblastoma (GBM)." | 4.12 | Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab. ( Ballester, LY; Bhattacharjee, MB; Brown, RE; Buja, LM; Chen, L; Glass, WF; Hergenroeder, GW; Hunter, RL; Linendoll, N; Lu, G; Pilichowska, M; Pillai, AK; Rao, M; Tian, X; Wu, JK; Zhang, R; Zhu, JJ; Zhu, P, 2022) |
| " The status of PTEN remains therapeutic effectiveness for chemoresistance of the DNA alkylating agent temozolomide (TMZ) in glioblastoma (GB)." | 4.12 | Smurf1 Suppression Enhances Temozolomide Chemosensitivity in Glioblastoma by Facilitating PTEN Nuclear Translocation. ( Dong, L; Han, D; Li, S; Li, Y; Liu, L; Meng, X; Xia, Q; Xiao, Z, 2022) |
| "Temozolomide (TMZ) resistance limits its use in glioblastoma (GBM)." | 4.12 | Hsa_circ_0043949 reinforces temozolomide resistance via upregulating oncogene ITGA1 axis in glioblastoma. ( Leng, H; Li, X; Wang, N; Xu, L; Yuan, H, 2022) |
| "The alkylating agent temozolomide (TMZ) has a significant impact on the prognosis of glioblastoma (GBM) patients." | 4.12 | NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells. ( Hara, H; Iwama, T; Nakamura, S; Nakayama, N; Shimazawa, M; Shoda, K; Tsuji, S; Yamada, T, 2022) |
| "Brain radiotherapy combined with concomitant and six cycles of adjuvant temozolomide (TMZ) is the standard treatment for newly diagnosed high-grade gliomas (HGGs)." | 4.12 | Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis. ( Ai, P; Chen, J; He, L; Huang, Y; Li, R; Liu, Z; Pei, Y; Peng, X; Wang, J; Wei, Z; Zhao, F, 2022) |
| "Although temozolomide is the primary chemotherapeutic agent in glioblastoma, current studies have focused on its combinational applications to overcome resistance by targeting multiple pathways." | 4.12 | Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes. ( Biray Avci, C; Goker Bagca, B; Ozates, NP, 2022) |
| "Radiotherapy combined with temozolomide chemotherapy (STUPP regimen) is the standard treatment regimen for newly diagnosed glioblastoma (GBM)." | 4.12 | The efficacy and safety of low-dose temozolomide maintenance therapy in elderly patients with glioblastoma: a retrospective cohort study. ( Ge, X; Gong, S; Guo, J; Tao, Q; Zhu, T, 2022) |
| "The purpose of this study was to determine the predictive significance of pretreatment pan-immune-inflammation value (PIV) in patients with newly diagnosed glioblastoma multiforme (GBM) who received postsurgical radiation (RT) and concurrent plus adjuvant temozolomide (TMZ)." | 4.12 | Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide. ( Kucuk, A; Selek, U; Topkan, E, 2022) |
| " The main cause is the presence of glioma stem cells (GSCs), exceptionally resistant to temozolomide (TMZ) treatment." | 4.12 | TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients. ( Amantini, C; Maggi, F; Morelli, MB; Nabissi, M; Pallini, R; Ricci-Vitiani, L; Santoni, G, 2022) |
| "It was found that radiotherapy combined with temozolomide administration often increased the size of the original lesion or produced a new glioblastoma lesion." | 4.12 | Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report. ( Cheng, P; Han, Q; Ma, H; Yang, H; Zhao, M; Zhao, Y, 2022) |
| " Therefore, we aimed to examine the Synergistic effects of Gefitinib (GFI) in combination with Temozolomide on VEGF and MMPs in glioma cell line (U87MG)." | 4.12 | Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis. ( Hossienpour, M; Karami, A; Kiani, A; Mohammadi Noori, E; Najafi, K; Rahpyma, M, 2022) |
| "Glioblastomas (GBM) often acquire resistance against temozolomide (TMZ) after continuous treatment and recur as TMZ-resistant GBM (TMZ-R-GBM)." | 4.02 | Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. ( Fujii, T; Ichimura, K; Kawauchi, D; Kobayashi, T; Kondo, A; Nakano, T; Narita, Y; Sasaki, N; Satomi, K; Takahashi, M; Tomiyama, A; Uchida, E; Wada, K; Yamamuro, S; Yoshino, A, 2021) |
| "Despite the development of new treatment protocols for glioblastoma (GBM), temozolomide (TMZ) resistance remains a primary hindrance." | 4.02 | Interplay of m ( Chen, S; Gao, Z; Li, F; Li, Y; Liu, Q; Long, T; Long, W; Pan, Y; Qin, C; Sun, Z; Yi, Y; Yu, J; Zhang, C; Zhao, W, 2021) |
| " To validate this approach, we determined ex vivo response to temozolomide in a retrospective cohort of 69 glioblastoma patient-derived neurosphere models with matched patient survival and genomics." | 4.02 | Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models. ( Chow, KH; Geduldig, J; Kim, AS; Ligon, KL; Malinowski, S; Manalis, SR; Mirza, M; Stockslager, MA; Touat, M; Wen, PY; Yoon, JC, 2021) |
| "Bortezomib and temozolomide effectively destroy cells of a radioresistant recurrent human glioblastoma; proteome mapping of the recurrent GBM cancer cells allows to identify new targets for therapy to improve the treatment results." | 4.02 | Effectiveness of bortezomib and temozolomide for eradication of recurrent human glioblastoma cells, resistant to radiation. ( Bryukhovetskiy, I; Pak, O; Sharma, A; Sharma, HS; Shevchenko, V; Zaitsev, S, 2021) |
| " Here, we show that NSUN6 methylates both large and small RNA in glioblastoma and controls glioblastoma response to temozolomide with or without influence of the MGMT promoter status, with high NSUN6 expression conferring survival benefit to glioblastoma patients and in other cancers." | 4.02 | NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to temozolomide (TMZ) via NELFB and RPS6KB2 interaction. ( Awah, CU; Mazdoom, CM; Ogunwobi, OO; Winter, J, 2021) |
| " CDC20 expression is increased in a variety of tumors and associated with temozolomide (TMZ) resistance in glioma cells." | 4.02 | Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. ( Ding, Y; He, L; Pan, Y; Song, X; Yu, S; Zhang, C; Zheng, C, 2021) |
| "Temozolomide (TMZ) is a prodrug of 5-(3-methyltriazene-1-yl)imidazole-4-carboxamide (MTIC, short-lived) and used as a first-line therapy drug for glioblastoma multiforme (GBM)." | 4.02 | Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy. ( Du, K; Feng, F; Sun, J; Xia, Q, 2021) |
| "Mesenchymal glioblastoma stem cells (GSCs), a subpopulation in glioblastoma that are responsible for therapy resistance and tumor spreading in the brain, reportedly upregulate aldehyde dehydrogenase isoform-1A3 (ALDH1A3) which can be inhibited by disulfiram (DSF), an FDA-approved drug formerly prescribed in alcohol use disorder." | 4.02 | Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study. ( Eckert, F; Ganser, K; Handgretinger, R; Huber, SM; Klumpp, L; Prause, L; Schleicher, S; Stransky, N; Zips, D; Zirjacks, L, 2021) |
| "We describe a pharmacological strategy for selectively targeting glioblastoma using a redox-active combination drug menadione/ascorbate (M/A), compared to the chemotherapeutic standard-of-care temozolomide (TMZ)." | 4.02 | Pharmacological Strategy for Selective Targeting of Glioblastoma by Redox-active Combination Drug - Comparison With the Chemotherapeutic Standard-of-care Temozolomide. ( Aoki, I; Bakalova, R; Lazarova, D; Miller, T; Shibata, S; Sumiyoshi, A; Zhelev, Z; Zlateva, G, 2021) |
| "The combination treatment is a way to improve the therapeutic strategy of temozolomide (TMZ) -resistant glioblastoma (GBM)." | 4.02 | Synergistic Effects of Taurine and Temozolomide Via Cell Proliferation Inhibition and Apoptotic Induction on U-251 MG Human Glioblastoma Cells. ( Chantree, P; Sangpairoj, K; Surarak, T, 2021) |
| "The short half-life of temozolomide (TMZ) limits its therapeutic effect on highly aggressive glioblastoma (GBM)." | 4.02 | Biomimetic Polymer-Templated Copper Nanoparticles Stabilize a Temozolomide Intermediate for Chemotherapy against Glioblastoma Multiforme. ( Du, K; Feng, F; Hu, A; Wang, X, 2021) |
| "About 95% of Glioblastoma (GBM) patients experience tumor relapse as a consequence of resistance to the first-line standard chemotherapy using temozolomide (TMZ)." | 4.02 | Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells. ( Bartsch, JW; Culmsee, C; Elsässer, K; Nimsky, C; Pagenstecher, A; Schäfer, A; Zhang, Z; Zhao, K; Zhong, L, 2021) |
| "To explore whether or not aberrant expression of miR-29b in glioblastoma multiforme (GBM) cells was associated with temozolomide (TMZ) resistance and to elucidate potential underlying mechanisms." | 4.02 | Micro-RNA29b enhances the sensitivity of glioblastoma multiforme cells to temozolomide by promoting autophagy. ( Luan, XP; Xu, JX; Yang, Y; Zhang, X, 2021) |
| "The study includes 132 IDH-wildtype glioblastoma patients treated between 2013 and 2017 with open resection followed by radiotherapy with concomitant and maintenance temozolomide." | 4.02 | Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide. ( Berger, K; Budach, W; Felsberg, J; Hänggi, D; Haussmann, J; Kamp, MA; Knipps, J; Malzkorn, B; Mijderwijk, HJ; Rapp, M; Reifenberger, G; Sabel, M; Steiger, HJ; Turowski, B, 2021) |
| "Overexpression of TGF-β1 contributed to temozolomide resistance in MGMT promoter hypomethylated glioblastoma cells in vitro and in vivo." | 4.02 | TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT. ( Jin, X; Miao, F; Nie, E; Shi, Z; Wang, Y; Xie, M; You, Y; Yu, T; Zhang, J; Zhi, T, 2021) |
| "We report a case of acute interstitial nephritis with associated nephrogenic diabetes insipidus in a patient treated with temozolomide and sulfamethoxazole-trimethoprim for glioblastoma multiforme." | 4.02 | Acute interstitial nephritis and nephrogenic diabetes insipidus following treatment with sulfamethoxazole-trimethoprim and temozolomide. ( Athavale, A; Gallagher, M; Jardine, M; Morris, J; Ritchie, A; Sen, S; Wang, AY, 2021) |
| " Temozolomide is an oral DNA-alkylating agent capable of crossing the blood-brain barrier and used as chemotherapy primarily to treat glioblastoma and other brain cancers." | 4.02 | Central diabetes insipidus induced by temozolomide: A report of two cases. ( Capes, A; Duck, L; Duprez, T; Labriola, L; Mahiat, C; Whenham, N, 2021) |
| "8% of actual body weight calculated body surface area dosing was determined for concurrent phase temozolomide." | 4.02 | Actual body weight dosing of temozolomide and overall survival in patients with glioblastoma. ( Chambers, C; Coppens, R; de Robles, P; Dersch-Mills, D; Folkman, F; Ghosh, S; Hsu, PYH; Leckie, C, 2021) |
| "Limited therapeutic efficacy of temozolomide (TMZ) against glioblastomas highlights the importance of exploring new drugs for clinical therapy." | 4.02 | Guanabenz Sensitizes Glioblastoma Cells to Sunitinib by Inhibiting GADD34-Mediated Autophagic Signaling. ( Chen, KC; Chen, PH; Cheng, CH; Ho, KH; Lee, YT; Shih, CM, 2021) |
| "Temozolomide (TMZ) resistance in glioblastoma multiforme (GBM) is mediated by the DNA repair protein O6-methylguanine DNA methyltransferase (MGMT)." | 4.02 | PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. ( de Groot, JF; Gao, F; Koul, D; Li, X; Wu, S; Yung, WKA, 2021) |
| " Temozolomide (TMZ) is widely used in the treatment of glioblastoma and is considered as the primary treatment modality." | 4.02 | Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line. ( Abbaszade, Z; Avci, CB; Bagca, BG, 2021) |
| " The chemotherapy drug temozolomide (TMZ), embedded in nanobubbles (NBs) and combined with persistent luminescent nanoparticles (PLNs), has been used to treat glioblastoma (GBM) effectively through image tracking." | 4.02 | Long-Term Near-Infrared Signal Tracking of the Therapeutic Changes of Glioblastoma Cells in Brain Tissue with Ultrasound-Guided Persistent Luminescent Nanocomposites. ( Chan, MH; Cheng, CL; Feng, SJ; Hsiao, M; Liu, RS, 2021) |
| " Treatment of patients suffering from relapsed/refractory glioblastoma (GBM) with a combination of depatux-m and temozolomide (TMZ) tended to increase overall survival." | 4.02 | Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR. ( Alvey, C; Anderson, M; Ansell, P; Boghaert, ER; Falls, HD; Mishra, S; Mitten, MJ; Oleksijew, A; Palma, J; Phillips, AC; Reilly, EB; Vaidya, KS; Zelaya-Lazo, AL, 2021) |
| "Temozolomide (TMZ), an alkylating agent with a broad-spectrum antitumor activity, ability to cross blood-brain barrier (BBB), shown to be effective against malignant glioma." | 4.02 | Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population. ( Baburaj, G; Jose, A; Kumar, JP; Munisamy, M; Munisamy, S; Subbiah, V; Thomas, L, 2021) |
| "To assess the recurrence interval and predictive significance of TP53 expression and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in glioblastomas treated with radiotherapy and combined chemotherapies, including temozolomide, lomustine, procarbazine and bevacizumab." | 4.02 | Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies. ( Alghamdi, B; Alkhayyat, S; Baeesa, S; Bardeesi, A; Bari, MO; Butt, NS; Dallol, A; Kurdi, M; Lary, AI; Maghrabi, Y; Mohamed, F; Saeedi, R; Samkari, A, 2021) |
| "In this retrospective analysis, only adult patients with supratentorial IDHwt glioblastoma were included who were treated with temozolomide-based chemoradiotherapy after surgery." | 4.02 | Survival impact of incidental subventricular zone irradiation in IDH-wildtype glioblastoma. ( Boterberg, T; Hallaert, G; Kalala, JP; Pinson, H; Sweldens, C; Van den Broecke, C; Van Roost, D, 2021) |
| "The alkylating agent, temozolomide (TMZ), is the most commonly used chemotherapeutic for the treatment of glioblastoma (GBM)." | 4.02 | CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma. ( Arina, A; Bernal, GM; Cahill, KE; Campbell, PS; Crawley, CD; Mansour, N; Voce, DJ; Weichselbaum, RR; Wu, L; Yamini, B, 2021) |
| "Glioblastoma is the most common malignant brain tumor, currently treated by surgery followed by concomitant radiotherapy and temozolomide-based chemotherapy." | 4.02 | Adjuvant therapeutic potential of moderate hypothermia for glioblastoma. ( Chabardès, S; Fulbert, C; Ratel, D, 2021) |
| " The present study evaluates the effects of AT101, alone or in combination with temozolomide (TMZ), in a microenvironmental glioma stem cell niche model of two GBM cell lines (U251MG and U87MG)." | 4.02 | Effects of the Anti-Tumorigenic Agent AT101 on Human Glioblastoma Cells in the Microenvironmental Glioma Stem Cell Niche. ( Caylioglu, D; Held-Feindt, J; Hellmold, D; Kubelt, C; Meyer, RJ; Synowitz, M, 2021) |
| " Previous results with the preclinical GL261 glioblastoma (GB) showed that combination treatment of temozolomide (TMZ) + CX-4945 (protein kinase CK2 inhibitor) outperformed single treatments, provided an immune-friendly schedule was followed." | 4.02 | Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells. ( Arús, C; Candiota, AP; Martínez-Escardó, L; Villamañan, L; Yuste, VJ, 2021) |
| "Treatment for the lethal primary adult brain tumor glioblastoma (GBM) includes the chemotherapy temozolomide (TMZ), but TMZ resistance is common and correlates with promoter methylation of the DNA repair enzyme O-6-methylguanine-DNA methyltransferase (MGMT)." | 4.02 | Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells. ( Ananthan, S; Ayokanmbi, A; Cooper, SJ; Gordillo, JJ; Gordon, ER; Griguer, C; Hjelmeland, AB; Li, Y; Libby, CJ; Napierala, M; Otamias, A; Redmann, M; Williford, SE; Zhang, J, 2021) |
| "Glioblastoma multiforme (GBM) is a lethal disease with a high rate of chemoresistance to temozolomide (TMZ)." | 4.02 | Establishment of a Novel Temozolomide Resistant Subline of Glioblastoma Multiforme Cells and Comparative Transcriptome Analysis With Parental Cells. ( Cheng, YD; Chiu, YJ; Ha, HA; Hour, MJ; Li, CW; Li, J; Tsai, FJ; Yang, JS, 2021) |
| "The aim of the study was to investigate the anticancer potential of LY294002 (PI3K inhibitor) and temozolomide using glioblastoma multiforme (T98G) and anaplastic astrocytoma (MOGGCCM) cells." | 4.02 | Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment. ( Bądziul, D; Hułas-Stasiak, M; Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Pawelec, J; Pawlikowska-Pawlęga, B; Reichert, M; Rzeski, W; Sumorek-Wiadro, J; Wasiak, M; Wertel, I; Zając, A, 2021) |
| "Although histone deacetylase 8 (HDAC8) plays a role in glioblastoma multiforme (GBM), whether its inhibition facilitates the treatment of temozolomide (TMZ)-resistant GBM (GBM-R) remains unclear." | 4.02 | NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition. ( Cheng, TS; Chiou, SJ; Chuang, JY; Chuang, TH; Hong, YR; Hou, CC; Hsu, TI; Huang, CF; Huang, ZY; Javaria, T; Ko, HJ; Kwan, AL; Lai, YL; Loh, JK; Tsai, CY, 2021) |
| " The nanoantidote, consisting of a dendrimer core wrapped by reductive cysteine, captures Temozolomide (TMZ, the glioblastoma standard chemotherapy)." | 4.02 | A Nanoantidote Alleviates Glioblastoma Chemotoxicity without Efficacy Compromise. ( Guan, J; Tian, M; Xing, R; Yang, B; Yang, J; Zhan, C; Zhang, S; Zhao, X, 2021) |
| "Glioblastoma (GBM) is a malignant brain tumor with a poor long-term prognosis due to recurrence from highly resistant GBM cancer stem cells (CSCs), for which the current standard of treatment with temozolomide (TMZ) alone will unlikely produce a viable cure." | 4.02 | Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells. ( Ayyagari, P; Das, SK; Pollok, KE; Shannon, HE; Smiley, SB; Vannier, MW; Veronesi, MC; Yun, Y, 2021) |
| "To clarify whether differential compartmentalization of Survivin impacts temozolomide (TMZ)-triggered end points, we established a well-defined glioblastoma cell model in vitro (LN229 and A172) and in vivo, distinguishing between its nuclear and cytoplasmic localization." | 4.02 | Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination. ( Baymaz, HI; Beli, P; Christmann, M; Mühlhäusler, F; Nikolova, T; Poplawski, A; Reich, TR; Schwarzenbach, C; Tomicic, MT; Unger, S; Vilar, JB, 2021) |
| "Retrospective data from IDH-wildtype glioblastoma preclinical experiments evaluating a uniform regimen of fractionated radiation (RT), temozolomide (TMZ) chemotherapy, and concurrent RT/TMZ across 27 PDX lines were used to evaluate experimental designs and empirically estimate statistical power for ANOVA and Cox regression." | 4.02 | Experimental design of preclinical experiments: number of PDX lines vs subsampling within PDX lines. ( Burgenske, DM; Decker, PA; Eckel-Passow, JE; Kitange, GJ; Kosel, ML; Oberg, AL; Sarkaria, JN, 2021) |
| "Currently, clinical treatment for temozolomide (TMZ)-resistant glioblastoma multiforme (GBM) is still a difficult problem." | 4.02 | Chemoattractants driven and microglia based biomimetic nanoparticle treating TMZ-resistant glioblastoma multiforme. ( Cheng, Y; Ji, Q; Liu, D; Liu, M; Mei, Q; Qiao, S; Zhang, B; Zhou, S, 2021) |
| "Glioblastoma multiforme (GBM) is the most fatal cancer among brain tumors, and the standard treatment of GBM patients is surgical tumor resection followed by radiotherapy and temozolomide (TMZ) chemotherapy." | 4.02 | 17β-estradiol induces temozolomide resistance through NRF2-mediated redox homeostasis in glioblastoma. ( Chen, GY; Hsu, SP; Hsu, TI; Hung, CY; Ko, CY; Liao, KH; Lin, HY, 2021) |
| "Intrinsic or acquired resistance to temozolomide (TMZ) is a frequent occurrence in patients with glioblastoma (GBM)." | 4.02 | Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7. ( Li, T; Wang, B; Wang, J, 2021) |
| "To evaluate the predictive significance of the duration of temozolomide (TMZ) in patients with glioblastoma multiforme (GBM) who were treated with bevacizumab (Beva) as second-line setting." | 4.02 | Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting? ( Besiroglu, M; Demir, T; Shbair, ATM; Topcu, A; Turk, HM; Yasin, AI, 2021) |
| "Temozolomide (TMZ) is the first-line chemotherapy drug for glioblastoma (GBM) but acquired TMZ resistance is frequently observed." | 4.02 | LINC00511 facilitates Temozolomide resistance of glioblastoma cells via sponging miR-126-5p and activating Wnt/β-catenin signaling. ( Liu, J; Lu, Y; Tian, M; Wang, K, 2021) |
| "This is the first study to demonstrate that PDL1-SPIO can specifically target temozolomide-resistant glioblastoma with PD-L1 expression in the brain and can be quantified through MRI analysis, thus making it suitable for the diagnosis of PD-L1 expression in temozolomide-resistant glioblastoma in vivo." | 4.02 | Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid‑Coated Superparamagnetic Iron Oxide. ( Chang, YW; Chen, CY; Chen, YC; Hsu, JB; Huang, SW; Kuo, DP; Lee, GA; Li, YT; Lin, WL, 2021) |
| " We investigated the effects of dopamine in combination with platinum on human glioblastoma U-251MG cells upon X-ray irradiation, comparing with L-DOPA, 2-phenylethylamine and temozolomide." | 4.02 | Effects of platinum-coexisting dopamine with X-ray irradiation upon human glioblastoma cell proliferation. ( Kato, S, 2021) |
| "Improving the chemotherapy resistance of temozolomide (TMZ) is of great significance in the treatment of glioblastoma multiforme (GBM)." | 4.02 | Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic glycolysis and temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multiforme cells. ( Jiang, XB; Li, XD; Wang, MJ; Wang, X; Wu, YH; Zheng, JL, 2021) |
| "Temozolomide is used in first-line treatment for glioblastoma." | 4.02 | Temozolomide Drives Ferroptosis via a DMT1-Dependent Pathway in Glioblastoma Cells. ( Heng, X; Peng, S; Song, Q; Sun, Z; Zhu, X, 2021) |
| "Glioblastoma (GBM) is one of the most aggressive primary brain tumors with frequent recurrences following the standard methods of treatment-temozolomide (TMZ), ionizing radiation and surgical resection." | 3.96 | TMZ regulates GBM stemness via MMP14-DLL4-Notch3 pathway. ( Gonzalez-Buendia, E; Lesniak, MS; Mijanovic, O; Savchuk, S; Sonabend, A; Timashev, P; Ulasov, IV; Xiao, T, 2020) |
| "We identified patients newly diagnosed with glioblastoma who were treated with temozolomide-based chemoradiotherapy between 2006 and 2016 at three large-volume hospitals." | 3.96 | Validation and optimization of a web-based nomogram for predicting survival of patients with newly diagnosed glioblastoma. ( Chang, JH; Chang, JS; Cho, J; Choe, G; Choi, SH; Hong, CK; Kang, SG; Kim, CY; Kim, E; Kim, EH; Kim, IA; Kim, IH; Kim, JH; Kim, JW; Kim, N; Kim, SH; Kim, TM; Kim, YJ; Lee, HS; Lee, ST; Park, CK; Park, SH; Suh, CO; Wee, CW; Yoon, HI, 2020) |
| "Temozolomide (TMZ) is a chemotherapy agent used to treat Grade IV astrocytoma, also known as glioblastoma (GBM)." | 3.96 | Simvastatin increases temozolomide-induced cell death by targeting the fusion of autophagosomes and lysosomes. ( Aghaei, M; Akbari, M; Albokashy, M; Alizadeh, J; Butterfield, Y; Cole, LK; Eftekharpour, E; Ghavami, S; Hatch, GM; Hombach-Klonisch, S; Islam, MI; Kardami, E; Klonisch, T; Koleini, N; Marzban, H; Samiei, E; Shojaei, S; Thliveris, J; Vosoughi, AR; Xu, F, 2020) |
| "Standard treatment for glioblastoma (GBM) patients is surgery and radiochemotherapy (RCT) with temozolomide (TMZ)." | 3.96 | ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide. ( Åkesson, L; Bratthäll, C; Broholm, H; Fomichov, V; Green, H; Grunnet, K; Hallbeck, M; Jakobsen, I; Malmström, A; Milos, P; Mudaisi, M; Papagiannopoulou, A; Poulsen, HS; Söderkvist, P; Stenmark-Askmalm, M; Strandeus, M; Łysiak, M, 2020) |
| "Temozolomide (TMZ) is one of the most commonly used clinical drugs for glioblastoma (GBM) treatment, but its drug sensitivity needs to be improved." | 3.96 | Gamabufotalin induces a negative feedback loop connecting ATP1A3 expression and the AQP4 pathway to promote temozolomide sensitivity in glioblastoma cells by targeting the amino acid Thr794. ( Chen, C; Hu, JL; Lan, YL; Lou, JC; Lyu, W; Wang, X; Xing, JS; Zhang, B; Zou, S, 2020) |
| "Current treatment against glioblastoma consists of surgical resection followed by temozolomide, with or without combined radiotherapy." | 3.96 | The synergistic effect of DZ‑NEP, panobinostat and temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells. ( Castresana, JS; De La Rosa, J; Idoate, MA; Meléndez, B; Rey, JA; Urdiciain, A; Zazpe, I; Zelaya, MV, 2020) |
| " The impact of the chemotherapeutic temozolomide (TMZ) in combination with valproic acid (VPA) was tested in two pediatric glioblastoma-derived cell lines." | 3.96 | Musashi1 enhances chemotherapy resistance of pediatric glioblastoma cells in vitro. ( Gielen, G; Hüttelmaier, S; Klusmann, JH; Kramm, C; Kühnöl, CD; Pietsch, T; Pötschke, R, 2020) |
| "Temozolomide is a first line anti-tumor drug used for the treatment of patients with Glioblastoma multiforme (GBM)." | 3.96 | Microarray expression profiles and bioinformatics analysis of mRNAs, lncRNAs, and circRNAs in the secondary temozolomide-resistant glioblastoma. ( Gao, Y; Guo, R; Li, H; Yang, B; Zhao, C, 2020) |
| "In the EF-14 trial for newly diagnosed glioblastoma (ndGBM) patients addition of Tumour Treating Fields (TTFields) to temozolomide treatment resulted in a significantly improved overall survival (OS)." | 3.96 | Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. ( Blau, T; Deuschl, C; Glas, M; Herrlinger, U; Kebir, S; Keyvani, K; Kleinschnitz, C; Lazaridis, L; Oster, C; Pierscianek, D; Schäfer, N; Scheffler, B; Schmidt, T; Stuschke, M; Sure, U; Teuber-Hanselmann, S; Tzaridis, T; Weller, J, 2020) |
| "In this study, we demonstrated that IKBKE enhances the resistance of glioblastoma cells to temozolomide (TMZ) by activating the AKT/NF-κB signaling pathway to upregulate the expression of the DNA repair enzyme o6-methylguanine-dna methyltransferase (MGMT)." | 3.96 | IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma. ( Guo, C; Guo, G; Hong, R; Huang, Q; Liu, Y; Lu, J; Lu, Y; Nan, Y; Sun, Y; Xiong, J; Zhang, Z, 2020) |
| "Temozolomide is an alkylating agent which is used in glioblastoma treatment." | 3.96 | Effects of temozolomide on U87MG glioblastoma cell expression of CXCR4, MMP2, MMP9, VEGF, anti-proliferatory cytotoxic and apoptotic properties. ( Elieh Ali Komi, D; Kiani, A; Mirabdaly, S; Moini, A; Shakiba, Y, 2020) |
| "This analysis aimed to investigate whether the long-term administration of temozolomide (TMZ) claimed a survival advantage for patients with glioblastoma in China." | 3.96 | Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide. ( Li, X; Li, Z; Quan, R; Zhang, H, 2020) |
| "We evaluated clinical and survival data of glioblastoma patients who underwent treatment with bevacizumab after progression under temozolomide, at CHUSJ between 2010 and 2017." | 3.96 | Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients. ( Caeiro, C; Carvalho, B; Costa, A; Fernandes, AC; Linhares, P; Lopes, RG; Osório, L; Tavares, N; Vaz, R, 2020) |
| "Chemo-induced thrombocytopenia is a limiting toxicity among patients receiving temozolomide (TMZ) as first-line treatment for glioblastoma." | 3.96 | Deleterious impact of a generic temozolomide formulation compared with brand-name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma. ( Alexandru, C; Basuyau, F; Clatot, F; Di Fiore, F; Fontanilles, A; Fontanilles, M; Hanzen, C; Joannidès, R; Lamoureux, F; Langlois, O; Massy, N; Pereira, T; Rouvet, J; Tennevet, I, 2020) |
| "The isocitrate dehydrogenase (IDH) 1 wild-type glioblastoma (GBM) is a major population of GBM that should be of concern in terms of the efficacy of using Temozolomide (TMZ) in adjuvant treatment." | 3.96 | Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching. ( Sangkhathat, S; Tunthanathip, T, 2020) |
| " In this report, we present the case of a 3-year-old girl with glioblastoma who continues to experience an exceptional and durable response (>2 years) to the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib." | 3.96 | Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. ( Britt, N; Chudnovsky, Y; Duncan, D; Edgerly, C; Elvin, J; Erlich, RL; Gay, L; Gorelyshev, S; Hemmerich, A; Huang, RSP; Konovalov, A; Kram, DE; McCorkle, J; Miller, V; Ramkissoon, SH; Rankin, A; Ross, JS; Savateev, A; Severson, E; Trunin, Y; Valiakhmetova, A, 2020) |
| "This is the long-term update of NOA-08 (NCT01502241), which compared efficacy and safety of radiotherapy (RT, n = 176) and temozolomide (TMZ, n = 193) at 7/14 days in patients >65 years old with anaplastic astrocytoma or glioblastoma." | 3.96 | Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. ( Bamberg, M; Bölting, H; Debus, J; Felsberg, J; Herrlinger, U; Hertler, C; Kessler, T; Ketter, R; Mayer-Steinacker, R; Meisner, C; Meixensberger, J; Papsdorf, K; Platten, M; Reifenberger, G; Reuss, D; Sabel, M; Sahm, F; Steinbach, JP; Vesper, J; von Deimling, A; Weisang, S; Weller, M; Weyerbrock, A; Wick, A; Wick, W, 2020) |
| "Temozolomide (TMZ) is a drug of choice in glioblastoma treatment." | 3.96 | Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions. ( Barciszewska, AM; Barciszewski, J; Belter, A, 2020) |
| "Radiotherapy, surgery and the chemotherapeutic agent temozolomide (TMZ) are frontline treatments for glioblastoma multiforme (GBM)." | 3.96 | Neurological Impairments in Mice Subjected to Irradiation and Chemotherapy. ( Ahmed, F; Angulo, MC; Baulch, JE; Dey, D; Goldman, J; Klein, PM; Limoli, CL; Merriott, D; Moayyad, J; Murry, A; Nguyen, B; Nguyen, QA; Parihar, VK; Piomelli, D; Soltesz, I; Szabo, GG; Tran, J, 2020) |
| "Temozolomide (TMZ)-induced chemoresistance to human glioblastomas is a critical challenge now." | 3.96 | Major Contribution of Caspase-9 to Honokiol-Induced Apoptotic Insults to Human Drug-Resistant Glioblastoma Cells. ( Chen, RM; Wu, GJ; Yang, ST, 2020) |
| "Glioblastoma multiforme (GBM) is the most frequent primary brain tumor in adults and Temozolomide (TMZ) is an effective chemotherapeutic agent for its treatment." | 3.96 | Reinforcement learning for optimal scheduling of Glioblastoma treatment with Temozolomide. ( Ebrahimi Zade, A; Shahabi Haghighi, S; Soltani, M, 2020) |
| "Temozolomide (TMZ) resistance is a major cause of recurrence and poor prognosis in glioblastoma (GBM)." | 3.96 | LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma. ( Chi, Y; Fu, Z; Guo, H; Huang, Q; Lian, C; Liao, C; Liu, B; Wang, C; Wei, Q; Xu, N; Yang, Z; Zeng, H; Zhou, J, 2020) |
| "Temozolomide (TMZ) chemotherapy is a current standard of care for glioblastoma (GBM), however it has only extended overall survival by a few months." | 3.96 | Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma. ( Martuza, RL; Rabkin, SD; Saha, D, 2020) |
| "Temozolomide is a first line anti-tumor drug used for the treatment of patients with Glioblastoma multiforme (GBM)." | 3.96 | MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT. ( Guan, F; Guo, R; Li, H; Li, M; Liu, X; Ma, S; Wu, J; Yang, B; Zhao, C, 2020) |
| "Temozolomide (TMZ) is a DNA-alkylating agent used for chemo-radiotherapy of glioblastoma, which is also a target cancer for boron neutron capture therapy (BNCT)." | 3.96 | The combined effect of neutron irradiation and temozolomide on glioblastoma cell lines with different MGMT and P53 status. ( Ikawa, T; Kinashi, Y; Takahashi, S, 2020) |
| "Temozolomide (TMZ) is a life prolonging DNA alkylating agent active against glioblastomas (GBM) in which the O6-methylguanine-DNA methyltransferase (MGMT) gene is silenced by promoter methylation." | 3.96 | PARP inhibition suppresses the emergence of temozolomide resistance in a model system. ( Bering, EA; Black, S; Blough, MD; Cairncross, JG; Liao, J; Maxwell, L; Meode, M; Pedersen, H; Tan, M; Willms, J; Yuan, AL, 2020) |
| "To evaluate the potential prognostic utility of pretreatment systemic immune-inflammation index (SII) in newly diagnosed glioblastoma multiforme (GBM) patients who underwent postneurosurgical radiotherapy and concurrent plus adjuvant temozolomide." | 3.96 | Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide. ( Besen, AA; Kucuk, A; Mertsoylu, H; Ozdemir, Y; Pehlivan, B; Selek, U; Topkan, E, 2020) |
| "To analyze retrospectively the efficacy of temozolomide (TMZ) in various treatment regimens in glioblastoma patients accounting for varying parameters of their treatment." | 3.96 | Temozolomide in glioblastoma treatment: 15-year clinical experience and analysis of its efficacy. ( Glavatskyi, OY; Kardash, KA; Khmelnytskyi, HV; Shuba, IM; Stuley, VA; Zemskova, OV, 2020) |
| "5, 1 g/kg) or temozolomide (10 mg/kg) treatment alone inhibited tumor growth in glioblastoma U87 and U251 xenografts." | 3.96 | Xihuang pill potentiates the anti-tumor effects of temozolomide in glioblastoma xenografts through the Akt/mTOR-dependent pathway. ( Fu, J; Kong, PS; Wang, J; Wang, X; Xu, HB; Xu, YQ; Zhu, SH, 2020) |
| "Temozolomide (TMZ) is a chemotherapeutic used for the treatment of glioblastoma." | 3.96 | A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status. ( Bello-Rivero, I; Leenstra, S; van der Kaaij, M; Vázquez-Blomquist, D; Villarreal, A, 2020) |
| "This study was conducted to assess whether levetiracetam (LEV) affects the survival of patients with glioblastoma (GBM) treated with concurrent temozolomide (TMZ) chemotherapy." | 3.96 | Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy. ( Chang, JH; Hong, CK; Kang, SG; Kim, EH; Kim, SH; Moon, JH; Park, HH; Roh, TH, 2020) |
| "Glioblastoma is an extremely aggressive glioma, resistant to radio and chemotherapy usually performed with temozolomide." | 3.96 | Cyclopamine sensitizes glioblastoma cells to temozolomide treatment through Sonic hedgehog pathway. ( Arrais-Neto, AM; Carballo, GB; Matias, D; Pessoa, LS; Ribeiro, JH; Spohr, TCLSE, 2020) |
| "We designed a conjugated compound by coupling temozolomide (TMZ) with doxorubicin (DOX) via an acylhydrazone linkage as a potential prodrug used for glioblastoma multiforme (GBM) treatment." | 3.96 | Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy. ( Du, K; Feng, F; Heng, H; Xia, Q, 2020) |
| "Surgical resection and systemic chemotherapy with temozolomide remain the mainstay for treatment of glioblastoma." | 3.96 | Injectable diblock copolypeptide hydrogel provides platform to deliver effective concentrations of paclitaxel to an intracranial xenograft model of glioblastoma. ( Bernstein, AM; Deming, TJ; Garrett, MC; Hung, D; Kornblum, HI; O'Shea, TM; Sofroniew, MV; Soto, H; Staarman, B; Wollenberg, AL, 2020) |
| "Resistance of glioblastoma to the chemotherapeutic compound temozolomide is associated with the presence of glioblastoma stem cells in glioblastoma and is a key obstacle for the poor prognosis of glioblastoma." | 3.96 | Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity. ( Hwang, WC; Kang, DW; Min, DS; Noh, YN; Park, KS, 2020) |
| "Temozolomide (TMZ) therapy is the standard of care for patients with glioblastoma (GBM)." | 3.96 | Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment. ( Alshareef, M; Cachia, D; Das, A; Infinger, LK; Lindhorst, SM; Patel, SJ; Porto, GBF; Vandergrift, WA; Varma, AK, 2020) |
| " In glioblastoma (GBM), predictive biomarkers of cellular responses to temozolomide (TMZ) combined with poly‑ADP‑ribose polymerase inhibitor (PARPi) remain largely unidentified." | 3.96 | PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency. ( Godoy, PRDV; Lima, SCG; Montaldi, AP; Sakamoto-Hojo, ET; Xavier, DJ, 2020) |
| " The transfection efficiency was determined with flow cytometry, and the therapeutic efficacy of CD::UPRT::GFP expressing MSCs was evaluated in cocultures with temozolomide (TMZ)-sensitive or TMZ-resistant human glioblastoma cell lines." | 3.96 | A facile and scalable in production non-viral gene engineered mesenchymal stem cells for effective suppression of temozolomide-resistant (TMZR) glioblastoma growth. ( Ho, YK; Ng, ZX; Teo, KJ; Too, HP; Tu, GXE; Yeo, TT, 2020) |
| "To assess the patterns of failure and prognostic factors in Brazilian patients with glioblastoma multiforme (GBM) treated with radiotherapy (RT) and concurrent and adjuvant temozolomide (TMZ)." | 3.96 | Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide. ( Faustino, AC; Hamamura, AC; Viani, GA, 2020) |
| "Temozolomide (TMZ) is widely used for treating glioblastoma multiforme (GBM), however, the treatment of such brain tumors remains a challenge due to the development of resistance." | 3.96 | Wnt/β-catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma. ( Baek, ST; Hsieh, JT; Kim, S; Yun, EJ, 2020) |
| " In this study, we explore whether CAP, an ionized gas produced in laboratory settings and that operates at near room temperature, can enhance Temozolomide (TMZ) cytotoxicity on a glioblastoma cell line (U87MG)." | 3.96 | Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells. ( Gjika, E; Keidar, M; Kirschner, ME; Lin, L; Pal-Ghosh, S; Sherman, JH; Stepp, MA, 2020) |
| "Despite aggressive treatment with temozolomide and radiotherapy and extensive research into alternative therapies there has been little improvement in Glioblastoma patient survival." | 3.96 | Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma. ( Areeb, Z; Gomez, J; Jones, J; Kaye, AH; Luwor, RB; Morokoff, AP; Nguyen, HPT; Paradiso, L; Stuart, SF; West, AJ; Zulkifli, A, 2020) |
| "Glioblastoma (GBM) is a malignant brain tumour with a dismal prognosis, despite best treatment by surgical resection, radiation therapy (RT) and chemotherapy with temozolomide (TMZ)." | 3.96 | Cytotoxic lanthanum oxide nanoparticles sensitize glioblastoma cells to radiation therapy and temozolomide: an in vitro rationale for translational studies. ( Jue, TR; Lu, VM; McDonald, KL, 2020) |
| " This prospective study included 52 consecutive newly diagnosed glioblastoma (n = 49) or gliosarcoma (n = 3) patients treated with concomitant temozolomide and radiotherapy (RT-TMZ), followed by a TMZ maintenance phase." | 3.96 | Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma. ( Alexandru, C; Beaussire, L; Clatot, F; Di Fiore, F; Fontanilles, M; Hanzen, C; Jardin, F; Langlois, O; Laquerrière, A; Magne, N; Marguet, F; Pépin, LF; Sarafan-Vasseur, N; Tennevet, I, 2020) |
| "Objective To investigate the expression of cathepsin S (CTSS) in temozolomide-resistant glioblastoma T98G (T98G-R) cells." | 3.96 | [Cathepsin S (CTSS) is highly expressed in temozolomide-resistant glioblastoma T98G cells and associated with poor prognosis]. ( Guo, Q; Jia, B; Liu, W; Lyu, W, 2020) |
| " In this study, we investigated whether selective add-on BEV for patients with newly diagnosed glioblastoma (GBM) and anaplastic astrocytoma (AA) improves prognosis, in cases where tumors were continuously growing during radiotherapy concomitant with temozolomide (TMZ)." | 3.96 | The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma. ( Hirata, K; Houkin, K; Ishi, Y; Kobayashi, H; Motegi, H; Oda, Y; Okamoto, M; Tanaka, S; Terasaka, S; Yamaguchi, S, 2020) |
| " The potential importance of the detected metabolic heterogeneity was tested in three glioma cell lines (grade III-IV) using protein expression analyses (Western blot and WES Simple) and therapeutic drug (temozolomide), metabolic inhibitor treatments (including glutaminase inhibitor) to compare the effects of rapamycin (RAPA) and glutaminase inhibitor combinations in vitro (Alamar Blue and SRB tests)." | 3.96 | Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells. ( Dankó, T; Hujber, Z; Jeney, A; Krencz, I; Pápay, J; Petővári, G; Raffay, R; Rajnai, H; Sebestyén, A; Vetlényi, E, 2020) |
| "Stem cell chemoresistance remains challenging the efficacy of the front-line temozolomide against glioblastoma." | 3.96 | Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside. ( Bahri, M; Birklé, S; Faraj, S; Fleurence, J; Fougeray, S; Geraldo, F; Gratas, C; Marquet, P; Oliver, L; Paris, F; Pecqueur, C; Pinault, E; Rabé, M; Vallette, F; Vermeulen, S; Véziers, J, 2020) |
| "The natural product primary sulfonamide, psammaplin C (1), when used in combination with clinically used chemotherapeutic drugs, including temozolomide, reverses multidrug resistance and increases survival in glioblastoma, a highly aggressive primary brain tumor." | 3.91 | Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma. ( Bua, S; Kopecka, J; Mujumdar, P; Poulsen, SA; Riganti, C; Supuran, CT, 2019) |
| " These new molecules displayed cytotoxic activities towards human glioblastoma cell lines, including the U251-MG cells that are highly resistant to the conventional chemotherapeutic agent Temozolomide." | 3.91 | Chemical modifications of imidazole-containing alkoxyamines increase C-ON bond homolysis rate: Effects on their cytotoxic properties in glioblastoma cells. ( Audran, G; Braguer, D; Brémond, P; Buric, D; Carré, M; Chacon, C; Marque, SRA; Yamasaki, T, 2019) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic agent used against glioblastoma multiforme (GBM), but this disease exhibits recurrence and high lethality." | 3.91 | miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme. ( Chen, KC; Chen, PH; Cheng, CH; Chou, CM; Ho, KH; Lin, CW; Liu, AJ; Shih, CM, 2019) |
| "Temozolomide is an alkylating agent used as the first line of treatment for glioblastoma." | 3.91 | Temozolomide has anti-tumor effects through the phosphorylation of cPLA ( Hara, H; Iwama, T; Nakamura, S; Noda, Y; Ohno, Y; Saio, M; Shimazawa, M; Tsuji, S; Yamada, T, 2019) |
| " In this study, we investigate the underlying mechanism by which glioblastoma (GBM) cells acquire resistance to Temozolomide (TMZ) through Aurora kinase B (AURKB) thus to identify novel therapeutic targets and prognostic biomarkers for GBM." | 3.91 | Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide. ( Alafate, W; Liu, C; Sun, L; Wang, J; Wang, M; Wu, W; Xie, W; Zuo, J, 2019) |
| "To investigate the underlying mechanism by which glioblastoma (GBM) cells gain temozolomide (TMZ) resistance and to clarify novel therapeutic targets and new prognostic biomarkers for GBM." | 3.91 | Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. ( Li, R; Mao, P; Wahafu, A; Wang, J; Wang, M; Wu, W; Xie, W; Yu, X; Zuo, J, 2019) |
| "Current treatment of recurrent glioblastoma multiforme (GBM) demands dose-intense temozolomide (TMZ), a prodrug of 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide (MTIC), based on the spontaneous hydrolysis of TMZ at basic pH." | 3.91 | Enhanced Copper-Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme. ( Du, K; Feng, F; Li, X; Shao, F; Sun, J; Sun, Y, 2019) |
| "Temozolomide is the current first-line treatment for glioblastoma patients but, because many patients are resistant to it, there is an urgent need to develop antitumor agents to treat temozolomide-resistant glioblastoma." | 3.91 | Gossypol Suppresses Growth of Temozolomide-Resistant Glioblastoma Tumor Spheres. ( Jang, H; Jeon, JH; Kang, SG; Kang, SW; Kim, DK; Kim, HY; Kim, SY; Lee, BI; Shim, JK, 2019) |
| "Drug resistance to temozolomide (TMZ) contributes to the majority of tumor recurrence and treatment failure in patients with glioblastoma multiforme (GBM)." | 3.91 | Lovastatin Enhances Cytotoxicity of Temozolomide via Impairing Autophagic Flux in Glioblastoma Cells. ( Cheng, SY; Kiang, KMY; Leung, GK; Li, N; Wong, VK; Zhang, P; Zhu, Z, 2019) |
| "The purpose of this study was to evaluate the outcomes of elderly patients (aged ≥75 years) with newly diagnosed glioblastoma (GBM), who were treated with hypofractionated radiotherapy comprising 45 Gy in 15 fractions combined with temozolomide (TMZ) or TMZ and bevacizumab (TMZ/Bev)." | 3.91 | Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years. ( Ichimura, K; Igaki, H; Matsushita, Y; Miyakita, Y; Narita, Y; Ohno, M; Takahashi, M, 2019) |
| "Temozolomide (TMZ) is the most commonly used chemotherapeutic agent used to treat glioblastoma (GBM), which causes significant DNA damage to highly proliferative cells." | 3.91 | Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells. ( Harder, BG; Kitange, GJ; Loftus, JC; Peng, S; Sarkaria, JN; Sereduk, CP; Sodoma, AM; Tran, NL, 2019) |
| "In the management of patients with newly diagnosed glioblastoma, there is no standard duration for adjuvant temozolomide treatment." | 3.91 | Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma. ( Hasegawa, Y; Hatano, K; Hirono, S; Iuchi, T; Sakaida, T; Uchino, Y, 2019) |
| "Current standard of treatment for newly diagnosed patients with glioblastoma (GBM) is surgical resection with adjuvant normofractionated radiotherapy (NFRT) combined with temozolomide (TMZ) chemotherapy." | 3.91 | Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma. ( Flentje, M; Klement, RJ; Kosmala, R; Lewitzki, V; Lisowski, D; Polat, B, 2019) |
| "Temozolomide (TMZ) is known to induce thrombocytopenia but no early predictive test has yet been clearly established." | 3.91 | Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients. ( Alexandru, C; Clatot, F; David, M; Di Fiore, F; Fontanilles, M; Gilard, V; Hanzen, C; Langlois, O; Laquerriere, A; Marguet, F; Tennevet, I; Veresezan, O, 2019) |
| "Glioblastoma multiforme (GBM) has a poor prognosis with an overall survival of 14-15 months after surgery, radiation and chemotherapy using temozolomide (TMZ)." | 3.91 | Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide. ( Bjerkvig, R; Denisova, O; Grudic, A; Hasan-Olive, MM; Janji, B; Johannessen, TC; Latif, MA; Lund-Johansen, M; Nordal, A; Prestegarden, L; Røsland, GV; Saed, H; Simonsen, A; Sundstrøm, T; Tronstad, KJ; Varughese, JK; Wang, J; Westermarck, J; Yang, N; Zhu, H, 2019) |
| " In the EF-14 phase 3 trial in newly diagnosed glioblastoma, TTFields plus temozolomide (TTFields/TMZ) improved progression free (PFS) and overall survival (OS) versus TMZ alone." | 3.91 | Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. ( Kim, CY; Nicholas, G; Ram, Z; Toms, SA, 2019) |
| "To describe oncological patterns of care, prognostic factors, and survival for all patients in France with newly-diagnosed and histologically confirmed glioblastoma, and evaluate the impact of extended temozolomide use at the population level." | 3.91 | Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. ( Amelot, A; Bauchet, F; Bauchet, L; Bessaoud, F; Charissoux, M; Darlix, A; Duffau, H; Fabbro, M; Fabbro-Peray, P; Figarella-Branger, D; Mandonnet, E; Mathieu-Daude, H; Pallud, J; Rigau, V; Riondel, A; Sorbets, E; Taillandier, L; Tretarre, B; Zouaoui, S, 2019) |
| "Despite the clinical success of temozolomide (TMZ), its sensitivity remains a major challenge in glioblastoma (GBM)." | 3.91 | PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma. ( Han, L; Huang, K; Liang, H; Liu, Y; Wang, G; Wang, Q; Wang, Z; Wei, C; Zhang, A; Zhang, W; Zhang, Z; Zhen, Y; Zhou, J, 2019) |
| "Temozolomide was recognized as the first-line therapy for glioblastoma to prolong the survival of patients noticeably, while recent clinical studies found that some patients were not sensitive to temozolomide treatment." | 3.91 | Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma. ( Jin, X; Liu, N; Miao, F; Nie, E; Shi, Z; Wang, Y; Wu, W; You, Y; Yu, T; Zeng, A; Zhang, J; Zhi, T; Zhou, X, 2019) |
| "Glioblastoma multiforme (GBM) is the most malignant tumor of the central nervous system, and chemoresistance blunts the effect of temozolomide (TMZ) in the treatment of GBM." | 3.91 | MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1. ( Gu, J; Guo, Q; Hao, Q; Jia, B; Liu, W; Lv, W; Mu, N; Pang, Z; Wang, J; Zhang, W, 2019) |
| " We investigated the anticancer potential of combination of biochanin A and temozolomide against U-87 MG and T98 G [glioblastoma multiforme (GBM)] cells." | 3.91 | Combination of Biochanin A and Temozolomide Impairs Tumor Growth by Modulating Cell Metabolism in Glioblastoma Multiforme. ( Bhushan, A; Desai, V; Jain, A; Lai, JCK; Shaghaghi, H; Summer, R, 2019) |
| "At present, there is no uniform consensus on the treatment of recurrent glioblastoma, especially the re-irradiation dose and temozolomide (TMZ) dose." | 3.91 | Conventionally fractionated stereotactic radiotherapy (CFRT) in combination with dose-dense temozolomide (TMZ) in relapsed malignant glioma: A case report. ( Li, Y; Qie, S; Shi, HY; Yuan, L; Zhang, X, 2019) |
| "For our studies, we have particularly chosen C6 rat glioma cell line due to several reasons: i) We previously showed that MPA reduced growth and induced procarbazine-sensitization in C6 cells; ii) temozolomide has a triazene-type molecular structure like procarbazine; iii) other groups previously showed that C6 glioma cell line is more resistant to temozolomide than human glioma cells; hence it may provide a native model of chemoresistance." | 3.91 | Medroxyprogesterone effects on colony growth, autophagy and mitochondria of C6 glioma cells are augmented with tibolone and temozolomide: Cell kinetic and electron microscopical studies with a broad review of the literature. ( Altinoz, MA; Bilir, A; Elmaci, İ; Ozpinar, A, 2019) |
| "Chemotherapy with temozolomide (TMZ) is the traditional treatment for glioblastoma (GBM)." | 3.91 | MCCK1 enhances the anticancer effect of temozolomide in attenuating the invasion, migration and epithelial-mesenchymal transition of glioblastoma cells in vitro and in vivo. ( Li, A; Liu, T; Xin, Y; Xu, Y, 2019) |
| "Temozolomide (TMZ) is an alkylating agent commonly used as a first‑line treatment for high‑grade glioblastoma." | 3.91 | Synergistic anticancer effect of acteoside and temozolomide-based glioblastoma chemotherapy. ( Choi, DE; Hwang, TW; Jang, TW; Kim, DB; Kim, DH; Kim, GH; Kim, JJ; Moon, M; Park, JH; Yoon, KA, 2019) |
| "Temozolomide (TMZ) is a widely used chemotherapeutic agent for glioblastoma multiforme (GBM)." | 3.91 | Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition. ( Li, A; Liu, T; Xin, Y; Xu, Y, 2019) |
| " Temozolomide is the most common chemotherapy used to treat glioblastoma (GBM) and has been shown to have variable effects on immune response to immunotherapy." | 3.91 | Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. ( Azari, H; Dastmalchi, F; Flores, C; Huang, J; Karachi, A; Long, Y; Mitchell, DA; Rahman, M; Sayour, EJ; Yang, C, 2019) |
| "Temozolomide (TMZ) is the first-line treatment for Glioblastoma Multiforme (GBM)." | 3.91 | Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy. ( Andrade, S; Coelho, MÁN; Loureiro, JA; Pereira, MC; Ramalho, MJ, 2019) |
| "Despite advances in cancer therapies, glioblastoma multiforme treatment remains inefficient due to the brain-blood barrier (BBB) inhibitory activity and to the low temozolomide (TMZ) chemotherapeutic selectivity." | 3.91 | Targeted and Synergic Glioblastoma Treatment: Multifunctional Nanoparticles Delivering Verteporfin as Adjuvant Therapy for Temozolomide Chemotherapy. ( de Melo, MT; Paula, LB; Pellosi, DS; Tedesco, AC, 2019) |
| "Despite intensive treatments including temozolomide (TMZ) administration, glioblastoma patient prognosis remains dismal and innovative therapeutic strategies are urgently needed." | 3.91 | pH as a potential therapeutic target to improve temozolomide antitumor efficacy : A mechanistic modeling study. ( Ballesta, A; Stéphanou, A, 2019) |
| "Standard-of-care treatment of glioblastomas involves maximal safe resection and adjuvant temozolomide chemo-radiotherapy." | 3.91 | Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study. ( Chan, DTM; Chan, KY; Ho, JMK; Lam, SW; Lee, MWY; Mak, CHK; Poon, WS; Tse, TPK; Wong, ST; Woo, PYM, 2019) |
| "The aims of the present study were to compare the longitudinal changes of glioblastoma multiforme after radiotherapy (RT) between 11C-methionine positron emission tomography (MET-PET) and gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) and to clarify whether these changes were predictive of survival." | 3.91 | Dissociation Between 11C-Methionine-Positron Emission Tomography and Gadolinium-Enhanced Magnetic Resonance Imaging in Longitudinal Features of Glioblastoma After Postoperative Radiotherapy. ( Asano, Y; Ikegame, Y; Iwama, T; Kawasaki, T; Miwa, K; Shinoda, J; Takei, H; Yano, H; Yokoyama, K, 2019) |
| "We identified DDIT4 as a cell-intrinsic regulator for adaptive responses and therapy resistance in glioblastoma cells which may interfere with cell death induction by temozolomide, radiotherapy or hypoxia by inhibiting mTORC1 activity." | 3.91 | The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma. ( Foltyn, M; Harter, PN; Lorenz, NI; Luger, AL; Mittelbronn, M; Ronellenfitsch, MW; Sauer, B; Steinbach, JP, 2019) |
| "Tumor recurrence in glioblastoma multiforme (GBM) is often attributed to acquired resistance to the standard chemotherapeutic agent, temozolomide (TMZ)." | 3.91 | Glioblastoma Recurrence and the Role of O ( Ahmed, AU; Foo, J; Hawkins-Daarud, A; Leder, K; Rockne, RC; Storey, K; Swanson, K, 2019) |
| " We evaluated the modulatory effects of RFP knockdown on cis-regulatory elements, gene expression, and chemosensitivity to temozolomide both in glioblastoma cells and in an intracranial glioblastoma model." | 3.91 | Aberrant Active cis-Regulatory Elements Associated with Downregulation of RET Finger Protein Overcome Chemoresistance in Glioblastoma. ( Aoki, K; Enomoto, A; Hirano, M; Ino, Y; Kato, A; Kato, T; Maeda, S; Matsuo, K; Motomura, K; Natsume, A; Ohka, F; Okuno, Y; Ranjit, M; Takahashi, M; Todo, T; Wakabayashi, T; Yamamichi, A, 2019) |
| "Together, our findings reveal the indispensable role of HERC3 in regulating canonical SMAD2/3-dependent TGFβ pathway involvement in autophagy-induced EMT, providing insights toward a better understanding of the mechanism of resistance to temozolomide and peripheral recurrence of glioblastoma." | 3.91 | HERC3-Mediated SMAD7 Ubiquitination Degradation Promotes Autophagy-Induced EMT and Chemoresistance in Glioblastoma. ( Chen, L; Hu, Z; Huang, A; Li, H; Li, J; Lu, Y; Ma, L; Qi, S; Shi, L; Weng, Z; Xin, Z; Yu, S; Zhou, Q, 2019) |
| "When only treated with D,L-methadone, 1 µM of the opioid was sufficient to reduce viability of fibroblasts, whereas 10 µM was needed to significantly reduce glioblastoma cell viability." | 3.91 | D,L-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro. ( Baran-Schmidt, R; Dietterle, J; Gaunitz, F; Glasow, A; Matusova, M; Meixensberger, J; Neumann, K; Oppermann, H, 2019) |
| "Although temozolomide (TMZ) resistance is a significant clinical problem in glioblastoma (GBM), its underlying molecular mechanisms are poorly understood." | 3.91 | Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma. ( Shi, Z; Yan, W; Yin, J; You, Y; Zeng, A; Zhang, Z, 2019) |
| "Temozolomide (TMZ) is an alkylating agent used in the treatment of high-grade malignant glioma, notably glioblastoma multiforme, the most aggressive form of brain cancer." | 3.91 | Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide? ( He, Y; Kaina, B, 2019) |
| " In this preliminary study, the purpose was to evaluate the feasibility of APT imaging in monitoring the early therapeutic response to nitroxoline (NTX) in a temozolomide (TMZ)-resistant glioblastoma multiforme (GBM) mouse model, which was compared with diffusion-weighted imaging (DWI)." | 3.91 | Assessment of Early Therapeutic Response to Nitroxoline in Temozolomide-Resistant Glioblastoma by Amide Proton Transfer Imaging: A Preliminary Comparative Study with Diffusion-weighted Imaging. ( Cho, HR; Choi, SH; Kumari, N; Thakur, N, 2019) |
| " Following tumor resection, the patient underwent concomitant radiation and temozolomide therapy that was complicated by CMV colitis and abdominal abscesses." | 3.91 | Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report. ( Bloch, O; Grimm, SA; Horbinski, CM; Kumthekar, PU; Lamano, JB; Quaggin-Smith, JA; Tate, MC, 2019) |
| "The acquired drug resistance has been regarded as a main barrier for the effective treatment of temozolomide (TMZ) in glioblastoma (GBM)." | 3.91 | miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2. ( Li, X; Liu, X; Luo, W; Song, Z; Yan, D; Zhao, S; Zhu, X, 2019) |
| "Constructed from a theoretical framework, the coordinated undermining of survival paths in glioblastoma (GBM) is a combination of nine drugs approved for non-oncological indications (CUSP9; aprepitant, auranofin, captopril, celecoxib, disulfiram, itraconazole, minocycline, quetiapine, and sertraline) combined with temozolomide (TMZ)." | 3.91 | The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy. ( Grieg, Z; Langmoen, IA; Sandberg, CJ; Skaga, E; Skaga, IØ; Vik-Mo, EO, 2019) |
| " However, the mechanisms underlying lncRNA-mediated temozolomide (TMZ) resistance in glioblastoma (GBM) remain largely unknown." | 3.91 | Lnc-TALC promotes O ( Cai, J; Chen, Q; Duan, C; Han, B; Jiang, C; Kang, C; Li, Y; Li, Z; Lin, L; Meng, X; Wang, R; Wu, P, 2019) |
| "Temozolomide (TMZ) is widely used as a chemotherapeutic agent in the treatment of glioma; however, the development of drug resistance remains a major obstacle in the effective treatment of glioblastoma." | 3.91 | Downregulation of miR‑186 promotes the proliferation and drug resistance of glioblastoma cells by targeting Twist1. ( Chen, R; Tu, Y; Wang, C; Wang, L; Wang, S; Xiong, Y; Zhu, L, 2019) |
| "To identify novel epigenetic signatures that could provide predictive information that is complementary to promoter methylation status of the O-6-methylguanine-DNA methyltransferase (MGMT) gene for predicting temozolomide (TMZ) response, among glioblastomas (GBMs) without glioma-CpGs island methylator phenotype (G-CIMP) METHODS: Different cohorts of primary non-G-CIMP GBMs with genome-wide DNA methylation microarray data were included for discovery and validation of a multimarker signature, combined using a RISK score model." | 3.91 | Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. ( Aubry, M; Barnholtz-Sloan, J; Etcheverry, A; He, YL; Liu, BL; Liu, YH; Lu, ZF; Mosser, J; Yin, AA; Zhang, X, 2019) |
| " In the present study, we examined the anticancer effects of papaverine in human glioblastoma (GBM) temozolomide (TMZ; as a first-line anticancer medicine)-sensitive U87MG and TMZ-resistant T98G cells." | 3.91 | Anticancer effects of a non-narcotic opium alkaloid medicine, papaverine, in human glioblastoma cells. ( Akasaki, Y; Ichimura, K; Inada, M; Kobayashi, K; Sato, A; Shindo, M; Tanuma, SI; Yamamoto, Y, 2019) |
| "Gene signatures (GS) were developed from 31 orthotopic glioblastoma patient-derived xenografts (PDXs), treated with standard therapies, to predict benefit from radiotherapy (RT-GS), temozolomide (Chemo-GS), or the combination (ChemoRT-GS)." | 3.91 | Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. ( Carlson, BL; Chang, SL; Feng, FY; Kim, MM; Lawrence, TS; Mladek, AC; Sarkaria, JN; Speers, CW; Spratt, DE; Wahl, DR; Yu, M; Zhao, SG, 2019) |
| "A first cost-effectiveness analysis has raised a strong concern regarding the cost of tumor treatment fields (TTF) added to maintenance temozolomide for patients with glioblastoma." | 3.91 | Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model. ( Armoiry, X; Auguste, P; Connock, M; Dussart, C; Guyotat, J, 2019) |
| "Despite the increased understanding of the oncological mechanisms underlying Glioblastoma multiforme (GBM) pathophysiology, and recent advances in therapeutic strategies such as maximal surgical resection and post-operative radiotherapy with concomitant and adjuvant temozolomide chemotherapy, the prognosis for patients with brain tumors remains limited." | 3.91 | microRNA-181d associated with the methylation status of the MGMT gene in Glioblastoma multiforme cancer stem cells submitted to treatments with ionizing radiation and temozolomide. ( Carlotti, CG; de Assis Cirino, ML; Lizarte Neto, FS; Matias, CCMS; Pereira-da-Silva, G; Peria, FM; Rodrigues, AR; Tirapelli, DPDC; Trevisan, FA, 2019) |
| "The acquisition of temozolomide resistance is a major clinical challenge for glioblastoma treatment." | 3.91 | Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2. ( Chen, Z; Deng, S; Guo, M; Huang, G; Lei, B; Li, Y; Li, Z; Liu, Y; Pan, J; Qi, S; Wang, H; Xiang, W; Yi, GZ; Yu, L; Zhang, X, 2019) |
| "Glioblastoma (GBM) is an aggressive brain tumor with temozolomide (TMZ)-based chemotherapy as the main therapeutic strategy." | 3.88 | Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells. ( Kipper, FC; Lenz, G; Lopez, PLDC; Silva, AO; Villodre, ES, 2018) |
| "Standard treatment for patients with primary glioblastoma (GBM) includes surgery, radiotherapy, and concomitant and adjuvant temozolomide (TMZ)." | 3.88 | Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients. ( Hama, S; Kawamata, T; Kurisu, K; Muragaki, Y; Nosaka, R; Saito, T; Sugiyama, K; Takayasu, T; Yamasaki, F, 2018) |
| "Evaluate survival of patients diagnosed with glioblastoma multiforme (GBM) managed with adjuvant intensity modulated radiation therapy and temozolomide since the introduction of the European Organisation for Research and Treatment of Cancer and National Cancer Institute of Canada Clinical Trials Group (EORTC-NCIC) protocol." | 3.88 | Survival improvements with adjuvant therapy in patients with glioblastoma. ( Back, MF; Brazier, D; Cook, R; Guo, L; Jayamanne, D; Kastelan, M; Schembri, G; Teo, C; Wheeler, H, 2018) |
| " Having established that CUX1 is expressed at high levels in most glioblastomas, we next show that the resistance of glioblastoma cells to temozolomide and to a combined treatment of temozolomide and ionizing radiation is reduced following CUX1 knockdown, but increased by overexpression of CUX1 or a short protein containing only 2 CUT domains, which is active in DNA repair but devoid of transcriptional activity." | 3.88 | CUX1 stimulates APE1 enzymatic activity and increases the resistance of glioblastoma cells to the mono-alkylating agent temozolomide. ( Abdulkarim, B; Guiot, MC; Kaur, S; Leduy, L; Li, L; Nepveu, A; Ramdzan, ZM; Ramotar, D; Sabri, S, 2018) |
| "Our study tested the diagnostic accuracy of increased signal intensity (SI) within FLAIR MR images of resection cavities in differentiating early progressive disease (ePD) from pseudoprogression (PsP) in patients with glioblastoma treated with radiotherapy with concomitant temozolomide therapy." | 3.88 | Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy. ( Agrawal, JP; Erickson, BJ; Korfiatis, P; Perry, LA, 2018) |
| " By manipulation of Cx43 expression or gap junction function, we found that there were gap junction-dependent and independent effect of Cx43 on temozolomide (TMZ) sensitivity in U87 glioblastoma cells." | 3.88 | Tramadol attenuates the sensitivity of glioblastoma to temozolomide through the suppression of Cx43‑mediated gap junction intercellular communication. ( Huang, H; Ma, L; Peng, J; Peng, Y; Shao, M; Wang, L; Xia, Z; Zhong, G; Zhu, Z, 2018) |
| "Development of resistance against temozolomide (TMZ) in glioblastoma (GBM) after continuous treatment with TMZ is one of the critical problems in clinical GBM therapy." | 3.88 | Intracellular cholesterol level regulates sensitivity of glioblastoma cells against temozolomide-induced cell death by modulation of caspase-8 activation via death receptor 5-accumulation and activation in the plasma membrane lipid raft. ( Ichimura, K; Kumagai, K; Mori, K; Nakashima, K; Namba, H; Narita, Y; Otani, N; Sakai, R; Sasaki, N; Shirakihara, T; Takeuchi, S; Tomiyama, A; Toyooka, T; Wada, K; Yamaguchi, H; Yamamoto, Y, 2018) |
| "The purpose of the study is to investigate the efficacy of combined treatment with temozolomide (TMZ) and metformin for glioblastoma (GBM) in vitro and in vivo." | 3.88 | High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy. ( Hong, YK; Lee, JE; Lim, JH; Yang, SH, 2018) |
| "The impact of DNA mismatch repair (MMR) on resistance to temozolomide (TMZ) therapy in patients with glioblastoma (GBM) is recently reported but the mechanisms are not understood." | 3.88 | Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma. ( Dong, T; Dong, Y; Gao, Y; Gong, Y; Li, Q; Pei, C; Ren, H; Su, J; Sun, Q; Xiao, Y; Xing, W; Zhen, Z; Zhou, P, 2018) |
| "0 years) diagnosed with glioblastoma undergoing adjuvant photon (n = 47) or proton (n = 19) radiochemotherapy with temozolomide after tumor resection underwent T1-weighted and arterial spin labeling MRI." | 3.88 | Photon vs. proton radiochemotherapy: Effects on brain tissue volume and perfusion. ( Asllani, I; Baumann, M; Beuthien-Baumann, B; Gommlich, A; Hofheinz, F; Jentsch, C; Krause, M; Krukowski, P; Maus, J; Mutsaerts, HJMM; Petr, J; Platzek, I; Seidlitz, A; Troost, EGC; van den Hoff, J; van Osch, MJP, 2018) |
| " Localized FRT to total dose of 60 Gy with concurrent and adjuvant temozolomide (TMZ) resulted in a statistically significant survival improvement of patients with newly diagnosed glioblastoma compared to those treated with FRT alone, and has emerged as the cornerstone of therapy." | 3.88 | Role of Radiosensitizers in Radiation Treatment of Gliomas. ( Cohen, RJ; Mehta, MP, 2018) |
| " In this study we aimed to evaluate the relationship of FBW7 with glioma pathology and prognosis, and examine its effect in glioma malignancies and temozolomide (TMZ)-based therapy." | 3.88 | FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells. ( Cui, Y; Feng, H; He, H; Ji, A; Li, J; Li, S; Lin, J; Lu, Y; Qiu, G; Song, C; Zou, Y, 2018) |
| "To retrospectively determine the safety and efficacy of combined chemotherapy with carmustine (BCNU) wafer, bevacizumab, and temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma (GBM)." | 3.88 | Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. ( Akiyama, Y; Enatsu, R; Kimura, Y; Mikami, T; Mikuni, N; Wanibuchi, M, 2018) |
| "A total of 210 patients with supratentorial/nonmetastatic glioblastoma were treated with radiation therapy (RT) plus temozolomide from 2007 to 2016 and had laboratory data on total lymphocyte counts." | 3.88 | Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma. ( Campian, JL; Chang, X; Fergus, S; Hallahan, D; Huang, J; Hui, C; Lin, AJ; Mullen, D; Rao, YJ; Rudra, S; Samson, P; Thotala, D; Tsien, C; Yang, D, 2018) |
| "MGMT promoter methylation has been associated with improved survival in glioblastoma multiforme treated with temozolomide." | 3.88 | MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme. ( Aprile, G; De Carlo, E; De Maglio, G; Fasola, G; Follador, A; Gerratana, L; Gurrieri, L; Macerelli, M; Masiero, E; Pisa, FE; Pizzolitto, S; Puglisi, F; Rizzato, S, 2018) |
| "We collected paraffin blocks from resection specimens from 114 glioblastoma patients who had received temozolomide treatment and radiotherapy." | 3.88 | Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients. ( Chen, YY; Ho, HL; Ho, TD; Hsu, CY; Lin, SC, 2018) |
| " This phenomenon, which has deleterious outcomes for the patient, has long been observed in patients with glioblastoma receiving temozolomide (TMZ)-based radiochemotherapy." | 3.88 | Characterizing the molecular mechanisms of acquired temozolomide resistance in the U251 glioblastoma cell line by protein microarray. ( Cui, Y; Feng, H; He, H; Li, J; Li, S; Lin, J; Qiu, G; Song, C; Wei, W; Wu, X; Xu, Q; Zuo, J, 2018) |
| "Glioblastoma is a malignant brain tumor that inevitably develops resistance to standard of care drug temozolomide (TMZ) due to a population of cells called cancer stem cells (CSCs)." | 3.88 | Outlining involvement of stem cell program in regulation of O6-methylguanine DNA methyltransferase and development of temozolomide resistance in glioblastoma: An Editorial Highlight for 'Transcriptional control of O ( Chumakova, A; Lathia, JD, 2018) |
| "Multi-institutional data from 159 patients with newly diagnosed glioblastoma who received adjuvant temozolomide concomitant chemoradiotherapy (CCRT) were collected." | 3.88 | A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location. ( Chan, D; Chan, KY; Ho, J; Lam, S; Lee, M; Ma, E; Mak, C; Poon, WS; Wong, ST; Wong, WK; Woo, P, 2018) |
| "To evaluate the prognostic value of the Glasgow Prognostic Score (GPS), the combination of C-reactive protein (CRP) and albumin, in glioblastoma multiforme (GBM) patients treated with radiotherapy (RT) and concurrent plus adjuvant temozolomide (GPS)." | 3.88 | Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide. ( Ciner, F; Guler, OC; Mertsoylu, H; Ozdemir, Y; Selek, U; Topkan, E; Tufan, K; Yildirim, BA, 2018) |
| "To identify patients with recurrent glioblastoma after temozolomide (TMZ) concurrent with and adjuvant to radiotherapy who could benefit from TMZ rechallenge at the time of disease progression." | 3.88 | Temozolomide rechallenge in recurrent glioblastoma: when is it useful? ( Bartolini, S; Brandes, AA; Cubeddu, A; De Biase, D; Di Battista, M; Franceschi, E; Lamberti, G; Minichillo, S; Mura, A; Paccapelo, A; Pession, A; Tallini, G; Tosoni, A; Visani, M, 2018) |
| "Human glioblastoma U251 and T98 cells and normal astrocytes C8D1A were loaded with coenzyme Q10 (CoQ)." | 3.88 | Regulation of the oxidative balance with coenzyme Q10 sensitizes human glioblastoma cells to radiation and temozolomide. ( Alcaín, FJ; Ariza, J; Arjona-Gutiérrez, J; De la Mata, M; Durán-Prado, M; Ferrín, G; Frontiñán-Rubio, J; Gil-Agudo, A; Gómez, MV; Lozano, E; Martínez-González, A; Moreno, M; Nieva-Velasco, CM; Peinado, JR; Pérez-García, VM; Pérez-Romasanta, L; Pesic, M; Santiago-Mora, RM; Villalba, JM, 2018) |
| "We describe the first case of a novel treatment for a newly diagnosed glioblastoma (GBM) using superselective intraarterial cerebral infusion (SIACI) of cetuximab after osmotic disruption of the blood-brain barrier (BBB) with mannitol." | 3.88 | Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma. ( Alter, RA; Boockvar, JA; Chakraborty, S; Demopoulos, A; Filippi, CG; Fralin, S; Kulason, KO; Langer, DJ; Ortiz, R; Pramanik, B; Ray, A; Schneider, JR; Tan, K; Wong, T, 2018) |
| "We retrospectively analyzed the safety and efficacy of hypofractionated radiotherapy (45 Gy/15 fr) combined with temozolomide (TMZ) followed by bevacizumab (BEV) salvage treatment in 18 glioblastoma patients aged > 75 years." | 3.88 | Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged > 75 years. ( Kayama, T; Matsuda, KI; Nemoto, K; Sakurada, K; Sonoda, Y, 2018) |
| "Chemoresistance to temozolomide (TMZ) is a major challenge in the treatment of glioblastoma (GBM)." | 3.88 | miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway. ( Chen, L; Gao, L; Huang, A; Li, H; Li, JJ; Liu, WW; Lu, YT; Qi, ST; Wang, K; Zhou, Q, 2018) |
| "Temozolomide (TMZ) is the preferred chemotherapeutic drug approved for the Glioblastoma multiforme (GBM) treatment." | 3.88 | miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma. ( Deng, S; Guo, M; Li, Y; Liu, Y; Peng, Y; Qi, S; Ren, J; Shu, S; Yi, G; Zhao, L, 2018) |
| "To investigate the anti-glioblastoma effects of myricetin, GBM cells were treated with myricetin alone or in combination with temozolomide." | 3.88 | A Multi-targeted Natural Flavonoid Myricetin Suppresses Lamellipodia and Focal Adhesions Formation and Impedes Glioblastoma Cell Invasiveness and Abnormal Motility. ( Chen, ZP; Li, WP; To, ST; Wang, G; Wang, J; Wu, CP; Zhao, HF; Zhou, XM, 2018) |
| "Recently, D,L-methadone has been put forward as adjuvant treatment in glioblastoma (GBM)." | 3.88 | Efficacy of D,L-methadone in the treatment of glioblastoma in vitro. ( Brawanski, A; Brawanski, K; Brockhoff, G; Freyschlag, C; Hau, P; Lohmeier, A; Proescholdt, MA; Riemenschneider, MJ; Thomé, C; Vollmann-Zwerenz, A, 2018) |
| " In temozolomide resistance glioblastoma, nZn-CuO NPs disturb cell growth and sphere formation by inhibiting AKT and ERK1/2 activation." | 3.88 | Zinc-doped copper oxide nanocomposites reverse temozolomide resistance in glioblastoma by inhibiting AKT and ERK1/2. ( Gedanken, A; Lin, X; Shi, D; Song, L; Wang, C; Wu, N; Yao, W; Zhang, C, 2018) |
| "Temozolomide (TMZ) is the current first-line chemotherapy for treatment of glioblastoma multiforme (GBM)." | 3.88 | Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells. ( Arcella, A; Capriotti, AL; Caracciolo, G; Digiacomo, L; Frati, L; Mahmoudi, M; Oliva, MA; Palchetti, S; Pozzi, D; Rota, R; Screpanti, I; Tsaouli, G, 2018) |
| "We assessed survival associations of anticoagulant use from baseline up to the start of temozolomide chemoradiotherapy (TMZ/RT) (period I) and from there to the start of maintenance TMZ chemotherapy (period II) by pooling data of three randomised clinical trials in newly diagnosed glioblastoma including 1273 patients." | 3.88 | Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. ( Chinot, OL; Cloughesy, T; Genbrugge, E; Gorlia, T; Le Rhun, E; Nabors, LB; Reardon, DA; Stupp, R; Weller, M; Wick, W, 2018) |
| "Temozolomide (TMZ) is the first-line chemotherapeutic agent in the treatment of glioblastoma multiforme (GBM)." | 3.88 | Caffeine Sensitizes U87-MG Human Glioblastoma Cells to Temozolomide through Mitotic Catastrophe by Impeding G2 Arrest. ( Cheng, YS; Kiang, KMY; Leung, GKK; Li, N; Zhang, P, 2018) |
| "Temozolomide (TMZ) was used for the treatment of glioblastoma (GBM) for over a decade, but its treatment benefits are limited by acquired resistance, a process that remains incompletely understood." | 3.88 | A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. ( Chen, X; Fang, D; Gan, H; Giannini, C; He, L; Hu, Z; Kitange, GJ; Lee, JH; Meyer, FB; Parney, IF; Sarkaria, JN; Wang, H; Zhang, M; Zhang, Z, 2018) |
| " Multidrug resistance, particularly resistance to temozolomide (TMZ), is a challenge in combating glioma, and more effective therapies are needed." | 3.88 | Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo. ( Bai, Y; Chen, Y; Dong, X; Hong, X; Li, S; Li, Y; Liu, X; Su, X; Zhao, G, 2018) |
| " For example, temozolomide (TMZ), of use for glioblastoma (GBM) treatment, appears as capable of inducing autophagy partially inhibiting cancer cell proliferation." | 3.88 | Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis. ( Ascione, B; Buccarelli, M; D'Alessandris, QG; De Pascalis, I; Larocca, LM; Malorni, W; Marconi, M; Martini, M; Matarrese, P; Pacioni, S; Pallini, R; Ricci-Vitiani, L, 2018) |
| "Chemoresistance blunts the effect of Temozolomide (TMZ) in the treatment of glioblastoma multiforme (GBM)." | 3.88 | Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. ( Huang, X; Li, R; Shen, F; Wang, X; Wei, Z; Wu, W; Yan, W; Yin, J; You, Y; Zeng, A; Zhou, X, 2018) |
| "In this study, we aimed to evaluate the expression and functions of MAPK8 in temozolomide (TMZ) -resistant glioblastoma cells as well as to explore the mechanism of TMZ resistance in glioblastoma cells." | 3.88 | MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway. ( Hou, S; Sha, LG; Xu, P; Zhang, G, 2018) |
| "To estimate the mean lifetime survival benefit, an essential component of health economic evaluations in oncology, of adding tumor treating fields (TTFields) to maintenance temozolomide (TMZ) for newly diagnosed glioblastoma patients." | 3.88 | Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients. ( Guzauskas, GF; Salzberg, M; Wang, BC, 2018) |
| "A novel molecular recursive partitioning analysis classification has recently been reported integrating the MGMT promoter methylation (MGMTmeth) and IDH1 mutation (IDH1mut) status for glioblastoma (GBM-molRPA) patients treated with temozolomide-based chemoradiation." | 3.88 | Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study. ( Aoki, K; Chang, JH; Cho, O; Cho, WK; Choi, JW; Chung, WK; Dho, YS; Kim, CY; Kim, E; Kim, IA; Kim, IH; Kim, JW; Kim, N; Kim, SH; Lim, DH; Motomura, K; Nam, DH; Natsume, A; Oh, YT; Ohka, F; Park, CK; Suh, CO; Wee, CW, 2018) |
| "Discriminating between tumor recurrence and treatment effects in glioblastoma patients undergoing radiation-temozolomide (RT/TMZ) therapy remains a major clinical challenge." | 3.88 | Diagnostic utility of restriction spectrum imaging (RSI) in glioblastoma patients after concurrent radiation-temozolomide treatment: A pilot study. ( Bartsch, H; Chen, CC; Dale, AM; Farid, N; Khan, UA; Rennert, RC; White, NS, 2018) |
| "Even in the era of personalized medicine and immunotherapy, temozolomide (TMZ), a small molecule DNA alkylating agent, remains the standard-of-care for glioblastoma (GBM)." | 3.88 | Tunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma. ( Fan, TM; Furiassi, L; Hergenrother, PJ; Riggins, GJ; Skibinski, CG; Svec, RL, 2018) |
| "To investigate the efficacy of lactoferrin nanoparticles (LfNPs) in delivering siRNA across the blood-brain barrier to treat glioblastoma multiforme (GBM) and with an additional objective of potentiation of conventional temozolomide (TMZ) chemotherapy." | 3.88 | Aurora kinase B siRNA-loaded lactoferrin nanoparticles potentiate the efficacy of temozolomide in treating glioblastoma. ( Bhattacharya, D; Chakarvarty, S; Kondapi, AK; Kumari, S; Rangaraj, N; Rao, NM, 2018) |
| "A series of polymer-drug conjugates based on 2-methacryloyloxyethyl phosphorylcholine (MPC) was prepared with the glioblastoma drug temozolomide (TMZ) as pendent groups." | 3.88 | Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma. ( Emrick, T; Saha, B; Skinner, M; Ward, SM, 2018) |
| "Temozolomide (TMZ) and radiation therapy combination for glioblastoma (GB) patients has been considered as the most effective therapy after surgical procedure." | 3.88 | Long noncoding RNA AC003092.1 promotes temozolomide chemosensitivity through miR-195/TFPI-2 signaling modulation in glioblastoma. ( Doycheva, DM; Fu, Z; Guo, H; He, Z; Huang, Q; Lian, C; Liu, B; Liu, Y; Xu, N; Yang, Z; Zeng, H; Zhou, J, 2018) |
| "To explore the effects of pulsed, focused, and microbubble contrast agent-enhanced ultrasonography (mCEUS) on blood-brain barrier (BBB) permeability and the efficacy temozolomide for glioblastoma." | 3.88 | Opening the Blood-Brain Barrier and Improving the Efficacy of Temozolomide Treatments of Glioblastoma Using Pulsed, Focused Ultrasound with a Microbubble Contrast Agent. ( Chen, L; Deng, Q; Dong, Q; He, L, 2018) |
| "Glioblastoma multiform (GBM) is a devastating brain tumor with maximum surgical resection, radiotherapy plus concomitant and adjuvant temozolomide (TMZ) as the standard treatment." | 3.88 | Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients. ( Gao, WZ; Guo, LM; Jia, F; Xu, TQ; Yin, YH, 2018) |
| "The efficacy of temozolomide (TMZ) chemotherapy for treating newly diagnosed glioblastoma (GBM), a primary brain tumor with short survival, was demonstrated in a clinical trial in 2005, and since then, the standard-of-care for newly diagnosed GBM has been maximal safe surgery followed by 60 Gray of radiation with concomitant and adjuvant TMZ (standard radiotherapy and TMZ)." | 3.88 | Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice. ( Carter, TC; Lawler, BE; Medina-Flores, R, 2018) |
| " The aim of the present study was to investigate the effect of temozolomide and thymoquinone combination on apoptotic pathway of human glioblastoma multiforme cell line (U87MG)." | 3.85 | Temozolomide-Mediated Apoptotic Death Is Improved by Thymoquinone in U87MG Cell Line. ( Khazaei, M; Pazhouhi, M, 2017) |
| "The impact of prolonging temozolomide (TMZ) maintenance beyond six cycles in newly diagnosed glioblastoma (GBM) remains a topic of discussion." | 3.85 | Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma. ( Behling, F; Bisdas, S; Borchers, C; Dangel, E; Gohde, J; Koch, M; Lepski, G; Naumann, A; Noell, S; Paulsen, F; Ritz, R; Schittenhelm, J; Skardelly, M; Tabatabai, G; Tatagiba, MS; von Hehn, U; Zips, D, 2017) |
| "Radiation with concurrent and adjuvant (6 cycles) temozolomide (TMZ) is the established standard of postsurgical care for newly diagnosed glioblastoma (GBM)." | 3.85 | Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. ( Baumert, BG; Blumenthal, DT; Brown, PD; Burt Nabors, L; Corn, BW; Erridge, SC; Gilbert, MR; Golfinopoulos, V; Gorlia, T; Hegi, ME; Hyun Nam, D; Kim, MM; Mason, WP; Mehta, MP; Mirimanoff, RO; Perry, JR; Reardon, DA; Stupp, R; van den Bent, MJ; Weller, M; Zhang, P, 2017) |
| "To determine if there is an association between the incidental radiation dose to the subventricular zone and survival in patients with glioblastoma multiforme treated with surgery, radiotherapy and temozolomide." | 3.85 | Influence of incidental radiation dose in the subventricular zone on survival in patients with glioblastoma multiforme treated with surgery, radiotherapy, and temozolomide. ( Algara, M; Foro Arnalot, P; Granados, R; Membrive, I; Ortiz, A; Pera, O; Reig, A; Rodriguez, N; Sanz, X, 2017) |
| "In glioblastoma several histone demethylase genes (KDM) are overexpressed compared to normal brain tissue and the development of Temozolomide (TMZ) resistance is accompanied by the transient further increased expression of KDM5A and other KDMs following a mechanism that we defined as "epigenetic resilience"." | 3.85 | Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells. ( Allemanni, G; Banelli, B; Daga, A; Forlani, A; Marubbi, D; Pistillo, MP; Profumo, A; Romani, M, 2017) |
| "Few population-based analyses have investigated survival change in glioblastoma multiforme (GBM) patients treated with concomitant radiotherapy-temozolomide (RT-TMZ) and adjuvant temozolomide (TMZ) and then bevacizumab (BEV) after Food and Drug Administration (FDA) approval, respectively." | 3.85 | Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study. ( Du, XL; Lu, G; Zhu, JJ; Zhu, P, 2017) |
| " This study aimed to improve the treatment of glioblastoma (GBM), the most common brain cancer, by testing whether the efficacy of the DNA alkylator temozolomide (TMZ) varies with the time of its administration." | 3.85 | Cell-intrinsic, Bmal1-dependent Circadian Regulation of Temozolomide Sensitivity in Glioblastoma. ( Binz, A; Herzog, ED; Kfoury, N; Kim, A; Marpegan, L; Rubin, JB; Simon, T; Slat, EA; Sponagel, J, 2017) |
| "Glioblastoma multiforme (GBM) exhibits high resistance to the standard treatment of temozolomide (TMZ) combined with radiotherapy, due to its remarkable cell heterogeneity." | 3.85 | Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines. ( Abdollahi, A; Dokic, I; Klein, C; Oancea-Castillo, LR; Régnier-Vigouroux, A; Weber, KJ, 2017) |
| "Temozolomide (TMZ) is a promising chemotherapeutic agent to treat Glioblastoma multiforme (GBM)." | 3.85 | MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor. ( Chen, Y; Li, R; Liu, N; Pan, M; Shi, Z; Wang, X; Yan, W; You, Y; Zhang, J, 2017) |
| "Resistance to temozolomide (TMZ) chemotherapy poses a significant challenge in the treatment of glioblastoma (GBM)." | 3.85 | Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. ( Dai, J; Ma, K; Niu, L; Pan, Y; Wang, X; Yin, H; Yuan, G; Zhang, Y; Zhou, W, 2017) |
| " For these reasons, the anti-glioblastoma drug temozolomide was tested in vitro for activity against bloodstream forms of T." | 3.85 | Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine. ( Rushworth, SA; Steverding, D, 2017) |
| "Temozolomide (TMZ) chemotherapy, in combination with maximal safe resection and radiotherapy, is the current standard of care for patients with glioblastoma (GBM)." | 3.85 | Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus. ( Jahan, N; Lee, JM; Shah, K; Wakimoto, H, 2017) |
| "Mean CBF1 expression is significantly increased in isocitrate dehydrogenase 1 (IDH1) R132H mutant glioblastoma and serves as prognostic marker for prolonged overall survival in brain tumours, particularly after therapy with temozolomide." | 3.85 | CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells. ( Herrera-Rios, D; Hoerbelt, T; Jiang, T; Kahlert, UD; Koch, K; Li, G; Maciaczyk, D; Maciaczyk, J; Marquardt, V; Ouwens, DM; Pauck, D; Picard, D; Remke, M; Steiger, HJ; Zhang, W; Zhao, L, 2017) |
| "Limited benefits and clinical utility of temozolomide (TMZ) for glioblastoma (GB) are frequently compromised by the development of acquired drug resistance." | 3.85 | Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling. ( Fu, Z; Guo, H; Lian, C; Liu, B; Xu, N; Yang, Z; Zeng, H, 2017) |
| " In the present study, whether MALAT1 contributes to the resistance of glioblastoma cell lines to temozolomide (TMZ) was investigated." | 3.85 | Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide. ( Dong, Y; Guan, F; Li, D; Li, H; Liu, X; Wang, H; Yan, D; Yang, B; Yuan, X, 2017) |
| "The present study analyzed outcomes of surgery followed by concomitant chemoradiotherapy (CCRT) with temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) at a single institution." | 3.85 | Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis. ( Ahn, SS; Chang, JH; Cho, J; Choi, HJ; Hong, CK; Kang, SG; Kim, DS; Kim, EH; Kim, SH; Lee, KS; Lee, SK; Moon, JH; Park, HH; Roh, TH; Suh, CO, 2017) |
| "Recent experimental data showed that the PI3K pathway contributes to resistance to temozolomide (TMZ) in paediatric glioblastoma and that this effect is reversed by combination treatment of TMZ with a PI3K inhibitor." | 3.85 | In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells. ( Agliano, A; Al-Saffar, NMS; Balarajah, G; Clarke, PA; Jackson, LE; Jones, C; Leach, MO; Marshall, LV; Pearson, ADJ; Sidhu, J; Workman, P, 2017) |
| "Temozolomide (TMZ) is used to treat adult patients with glioblastoma multiforme (GBM)." | 3.85 | Risk of severe acute liver injury among patients with brain cancer treated with temozolomide: a nested case-control study using the healthcore integrated research database. ( Deitz, AC; Desai, VCA; He, J; Holick, CN; Lanes, S; Quinlan, SC, 2017) |
| "Assessment of perfusion in early post-treatment MR imaging can stratify TTP in patients with glioblastoma for adjuvant temozolomide therapy." | 3.85 | Perfusion of surgical cavity wall enhancement in early post-treatment MR imaging may stratify the time-to-progression in glioblastoma. ( Choi, CG; Jung, SC; Kim, HS; Kim, HW; Kim, JH; Kim, SJ; Park, JE; Ryu, KH; Shim, WH, 2017) |
| " In the current study we examined the hypothesis that LDHA and anaerobic glycolysis, may contribute to the resistance of glioblastoma to radiotherapy and to temozolomide." | 3.85 | Blocking LDHA glycolytic pathway sensitizes glioblastoma cells to radiation and temozolomide. ( Ananiadou, D; Giatromanolaki, A; Ilemosoglou, M; Kostoglou, G; Koukourakis, M; Lamprou, I; Papadopoulou, M; Pouliliou, S; Sivridis, E; Tsolou, A, 2017) |
| "In this reported case, a 64-year-old woman with right temporo-parietal glioblastoma IDH-WT was treated with nivolumab, temozolomide and radiation therapy on a clinical trial." | 3.85 | Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. ( Bergin, P; Blackley, E; Gill, S; Haydon, A; McLean, C; Moore, M; Tay, RY, 2017) |
| "Temozolomide is the first chemotherapeutic agent proven effective for patients with newly diagnosed glioblastoma." | 3.85 | Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma. ( Chan, DT; Hsieh, SY; Kam, MK; Loong, HH; Ng, SC; Poon, DM; Poon, WS; Tsang, WK, 2017) |
| "Acquisition of temozolomide (TMZ) resistance is a major factor leading to the failure of glioblastoma (GBM) treatment." | 3.85 | Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O ( Chang, KY; Chang, WC; Chen, KY; Chou, SW; Chuang, CK; Chuang, JY; Hsu, CC; Hsu, TI; Hung, JJ; Kao, TJ; Ko, CY; Liou, JP; Liu, JJ; Liu, MS; Tsai, SY, 2017) |
| " Hydrogen peroxide- and serum deprivation-induced stresses were performed in glioblastoma (GBM) cells and patient-derived cells, and the effect of the Sp1 inhibitor mithramycin A (MA) on these stress-induced stem cells and temozolomide (TMZ)-resistant cells was evaluated." | 3.85 | Stress stimuli induce cancer-stemness gene expression via Sp1 activation leading to therapeutic resistance in glioblastoma. ( Chang, KY; Chang, WC; Chuang, CK; Chuang, JY; Hsu, CC; Hsu, TI; Huang, CT; Hung, JJ; Liu, JJ; Tsai, KK, 2017) |
| "Temozolomide (TMZ) is the main chemotherapeutic agent used for treating newly diagnosed Glioblastoma Multiforme (GBM), the most frequent malignant brain tumors in adults." | 3.85 | HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide. ( Gratas, C; Oliver, L; Rabé, M; Séry, Q; Vallette, FM, 2017) |
| "Temozolomide (TMZ) is commonly used in glioblastoma (GBM) chemotherapy." | 3.85 | PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma. ( Chen, H; Chen, Q; Han, C; Lan, J; Liu, Q; Lou, M; Que, S; Wang, L; Xue, Y; Zhang, X, 2017) |
| "Temozolomide (TMZ), as a kind of alkylating agent, is widely utilized for the treatment of glioblastoma (GBM)." | 3.85 | miR‑146b‑5p suppresses glioblastoma cell resistance to temozolomide through targeting TRAF6. ( Lan, J; Lin, Y; Qian, Z; Qiu, Y; Que, S; Yang, X; Zhou, S; Zhou, Z, 2017) |
| "Temozolomide is the primary chemotherapeutic agent used to treat glioblastoma." | 3.85 | Probing the Oncolytic and Chemosensitizing Effects of Dihydrotanshinone in an ( Kumar, V; Leonardi, D; Radin, D, 2017) |
| "To assess the efficacy and cost-effectiveness of modulated electrohyperthermia (mEHT) concurrent to dose-dense temozolomide (ddTMZ) 21/28 days regimen versus ddTMZ 21/28 days alone in patients with recurrent glioblastoma (GBM)." | 3.85 | Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison ( Roussakow, SV, 2017) |
| "To compare the therapeutic results of two radiotherapy (RT) dose schedules in combined temozolomide- (TMZ-) RT treatment in newly diagnosed glioblastoma (GB), according to the O(6)-methylguanine-DNA methyltransferase (MGMT) methylation status." | 3.85 | Patients Affected by Unmethylated O(6)-Methylguanine-DNA Methyltransferase Glioblastoma Undergoing Radiochemotherapy May Benefit from Moderately Dose-Escalated Radiotherapy. ( Battaglia, G; Cerase, A; Miracco, C; Nardone, V; Pastina, P; Pirtoli, L; Rubino, G; Sebaste, L; Tini, P, 2017) |
| " Standard of care for glioblastoma (GBM) includes temozolomide chemotherapy, which is not curative, due, in part, to residual therapy-resistant brain tumor-initiating cells (BTICs)." | 3.85 | Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. ( Audia, A; Bar, EE; Benavides, GA; Bevensee, MO; Bhat, KP; Boyd, NH; Cooper, SJ; Darley-Usmar, V; Dedhar, S; Fried, J; Gillespie, GY; Gordon, E; Griguer, C; Hackney, JR; Hjelmeland, AB; Landis, CJ; McDonald, PC; Nabors, B; Nozell, S; Scott, SE; Spina, R; Tran, AN; Walker, K; Xu, B, 2017) |
| "It is controversial whether concurrent chemoradiotherapy (CRT) with temozolomide is feasible and beneficial in elderly patients with glioblastoma." | 3.85 | A Model to Predict the Feasibility of Concurrent Chemoradiotherapy With Temozolomide in Glioblastoma Multiforme Patients Over Age 65. ( Fietkau, R; Knippen, S; Lahmer, G; Putz, F; Semrau, S, 2017) |
| " However, vital safety and efficacy issues related to combined therapy with temozolomide, the first-line cytostatic in patients diagnosed with glioblastoma multiforme, and antidepressant drugs have yet to be addressed." | 3.85 | Antidepressant drugs can modify cytotoxic action of temozolomide. ( Bielecka, AM; Obuchowicz, E, 2017) |
| "The current standard treatment protocol for patients with newly diagnosed glioblastoma (GBM) includes surgery, radiotherapy, and concomitant and adjuvant temozolomide (TMZ)." | 3.85 | Permeability Surface Area Product Using Perfusion Computed Tomography Is a Valuable Prognostic Factor in Glioblastomas Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide. ( Ikawa, F; Ishifuro, M; Kawamata, T; Kurisu, K; Muragaki, Y; Nishibuchi, I; Nosaka, R; Saito, T; Sugiyama, K; Takayasu, T; Yamasaki, F, 2017) |
| "It is unknown whether the addition of temozolomide (TMZ) to radiotherapy (RT) is associated with improved overall survival (OS) among older glioblastoma patients." | 3.85 | Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma. ( Arvold, ND; Cefalu, M; Dominici, F; Schrag, D; Wang, Y; Zigler, C, 2017) |
| " This model, developed using FM-HCR and drug sensitivity measurements in 24 human lymphoblastoid cell lines, was applied to a panel of 12 patient-derived xenograft (PDX) models of glioblastoma to predict glioblastoma response to treatment with the chemotherapeutic DNA-damaging agent temozolomide." | 3.85 | DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme. ( Chaim, IA; Gupta, SK; Joughin, BA; Kitange, GJ; Lauffenburger, DA; Mazzucato, P; Nagel, ZD; Samson, LD; Sarkaria, JN, 2017) |
| "A recent Phase 3 study of newly diagnosed glioblastoma (GBM) demonstrated the addition of tumor treating fields (TTFields) to temozolomide (TMZ) after combined radiation/TMZ significantly increased survival and progression free survival." | 3.85 | The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells. ( Clark, PA; Deming, DA; Gaal, JT; Kuo, JS; Pasch, CA; Robins, HI; Strebe, JK, 2017) |
| "In 2011, we reported a predominant prognostic/predictive role of MGMT promoter methylation status on progression-free survival (PFS) in unresectable glioblastoma patients undergoing upfront radiotherapy plus concomitant and maintenance temozolomide (RTX/TMZ → TMZ)." | 3.85 | Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference. ( Belka, C; Eigenbrod, S; Kreth, FW; Kreth, S; Lutz, J; Niyazi, M; Schüller, U; Thon, N; Thorsteinsdottir, J; Tonn, JC, 2017) |
| " We previously reported the immunomodulatory effects of radiation and temozolomide (TMZ) in newly diagnosed glioblastoma." | 3.85 | Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma. ( Christensen, BC; Davis, MC; Ernstoff, MS; Fadul, CE; Fisher, JL; Gaur, AB; Hampton, TH; Lewis, LD; Rahme, GJ; Steel, SE; Thomas, AA; Tsongalis, GJ; Whipple, CA, 2017) |
| "Temozolomide-resistant (TMZ-R) glioblastoma is very difficult to treat, and a novel approach to overcome resistance is needed." | 3.85 | Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line. ( Akiyama, Y; Asai, A; Ashizawa, T; Hayashi, N; Iizuka, A; Kondou, R; Mitsuya, K; Miyata, H; Nakasu, Y; Nonomura, C; Sugino, T; Urakami, K; Yamaguchi, K, 2017) |
| "Temozolomide-(TMZ)-based chemoradiotherapy defines the current gold standard for the treatment of newly diagnosed glioblastoma." | 3.85 | Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival. ( Ballhausen, H; Belka, C; Nachbichler, SB; Niyazi, M; Schupp, G, 2017) |
| "Glioblastoma multiforme (GBM), the most common malignant brain tumor, is currently treated with temozolomide (TMZ), but GBM often exhibits resistance to TMZ." | 3.85 | FoxO3a induces temozolomide resistance in glioblastoma cells via the regulation of β-catenin nuclear accumulation. ( Li, L; Pei, H; Wang, H; Xia, Q; Xu, K; Zhang, Z, 2017) |
| "The chemotherapeutic agent temozolomide (TMZ) is widely used in the treatment of glioblastoma multiforme (GBM)." | 3.85 | Rutin increases the cytotoxicity of temozolomide in glioblastoma via autophagy inhibition. ( Cheng, YS; Ho, ASW; Kiang, KMY; Lee, D; Leung, GKK; Li, N; Poon, MW; Pu, JKS; Sun, S; Zhang, P; Zhang, X, 2017) |
| "To explore an association with survival of modifying the current standard of care for patients with newly diagnosed glioblastoma of surgery followed by radiotherapy plus concurrent and 6 cycles of maintenance temozolomide chemotherapy (TMZ/RT → TMZ) by extending TMZ beyond 6 cycles." | 3.85 | Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. ( Bendszus, M; Felsberg, J; Gramatzki, D; Hentschel, B; Herrlinger, U; Kickingereder, P; Loeffler, M; Pietsch, T; Reifenberger, G; Sabel, M; Schackert, G; Schlegel, U; Tonn, JC; Weller, M; Westphal, M; Wick, W, 2017) |
| "A novel RPA classification for glioblastoma was formulated highlighting the impact of MGMTmeth and IDH1mut in the temozolomide era." | 3.85 | Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. ( Chang, JH; Choe, G; Choi, SH; Kim, CY; Kim, E; Kim, IA; Kim, IH; Kim, JH; Kim, JW; Kim, N; Kim, SH; Kim, TM; Kim, YJ; Lee, ST; Park, CK; Park, SH; Suh, CO; Wee, CW, 2017) |
| " Then, knockdown of hnRNP A2/B1 expression induced by RNA interference (RNAi) method was used to analyze the role of hnRNP A2/B1 in glioblastoma cell viability, adhesion, migration, invasion, and chemoresistance for temozolomide (TMZ)." | 3.83 | Effects of hnRNP A2/B1 Knockdown on Inhibition of Glioblastoma Cell Invasion, Growth and Survival. ( Chen, S; Cheng, Y; Deng, J; Liang, P; Wang, F; Xie, Z; Xu, Z; Zhai, X; Zhang, Q; Zhao, H, 2016) |
| "Arginine-glycine-aspartic acid peptide (RGD)-modified nanostructured lipid carriers (NLCs) were used for the delivery of temozolomide (TMZ) into the GBM to provide a new paradigm in gliomatosis cerebri treatment." | 3.83 | Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. ( Du, J; Mao, G; Song, S; Zhu, X, 2016) |
| "The standard of care for patients with newly diagnosed glioblastoma (GBM) is maximal safe resection followed by adjuvant radiation therapy (RT) and temozolomide (TMZ)." | 3.83 | Timing of Adjuvant Radiotherapy in Glioblastoma Patients: A Single-Institution Experience With More Than 400 Patients. ( Bruce, JN; Cheng, SK; Chow, DS; Estrada, JP; Gartrell, R; Isaacson, SR; Jani, A; Lassman, AB; McKhann, GM; Qureshi, YH; Saad, S; Sisti, MB; Soun, JE; Ung, TH; Wang, TJ, 2016) |
| "Resistance of glioblastoma (GBM) to the front-line chemotherapeutic agent temozolomide (TMZ) continues to challenge GBM treatment efforts." | 3.83 | Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide. ( Gourdie, RG; Guo, S; Jourdan, J; Kanabur, P; Lamouille, S; Murphy, SF; Osimani, AM; Pridham, KJ; Rodgers, CM; Sharma, S; Sheng, Z; Simonds, GR; Varghese, RT, 2016) |
| "In the effort to find better treatments for glioblastoma we tested several currently marketed non-chemotherapy drugs for their ability to enhance the standard cytotoxic drug currently used to treat glioblastoma- temozolomide." | 3.83 | Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells. ( Coveñas, R; Kast, RE; Lladó, S; Muñoz, M; Ramiro, S; Toro, S, 2016) |
| " In this study, in vivo efficacy of veliparib combined with temozolomide (TMZ) was evaluated in a large panel of glioblastoma multiforme (GBM) patient-derived xenografts (PDX) and potential biomarkers were analyzed." | 3.83 | Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma. ( Bakken, KK; Ballman, KV; Boakye-Agyeman, F; Carlson, BL; Cen, L; Decker, PA; Eckel-Passow, JE; Gupta, SK; Jenkins, RB; Kitange, GJ; Kizilbash, SH; Mladek, AC; Pokorny, JL; Reid, JM; Sarkar, G; Sarkaria, JN; Schroeder, MA; Sulman, EP; Verhaak, RG, 2016) |
| "The survival benefits of patients with glioblastoma (GBM) remain unsatisfactory due to the intrinsic or acquired resistance to temozolomide (TMZ)." | 3.83 | Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression. ( Han, J; Lan, F; Wu, Q; Yang, Y; Yu, H; Yue, X, 2016) |
| "Resistance to temozolomide (TMZ) greatly limits chemotherapeutic effectiveness in glioblastoma (GBM)." | 3.83 | Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant. ( Boyd, AW; Byrne, AT; Day, BW; Flanagan, L; Kögel, D; Murray, DW; O'Brien, DF; Prehn, JH; Rehm, M; Salvucci, M; Stringer, BW; Tivnan, A; Zakaria, Z, 2016) |
| "O6-methylguanine-DNA methyltransferase (MGMT) protein expression using immunohistochemical analysis was proposed as a prognostic marker for patients with newly diagnosed glioblastoma (GBM) treated with radiation therapy with concurrent and adjuvant Temozolomide (TMZ)." | 3.83 | Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide. ( El-Shorbagy, SH; Khedr, RA; Younis, SG, 2016) |
| "Management of patients with glioblastoma (GBM) often includes radiation (RT) and temozolomide (TMZ)." | 3.83 | Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma. ( Campian, JL; Gao, F; Govindan, A; Huang, J; Leong, J; Mendez, JS, 2016) |
| " We have previously shown that serum BLyS levels are elevated, and directly associated, with increased antigen-specific antibody titers in patients with glioblastoma (GBM) undergoing lymphodepletive temozolomide chemotherapy and vaccination." | 3.83 | Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. ( Archer, GE; Choi, BD; Congdon, KL; Healy, P; Herndon, JE; Norberg, PK; Reap, EA; Sampson, JH; Sanchez-Perez, L; Saraswathula, A; Sayour, EJ; Schmittling, RJ, 2016) |
| "To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741)." | 3.83 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. ( Chinot, O; Cloughesy, T; Gilbert, MR; Gorlia, T; Happold, C; Hegi, M; Mehta, MP; Nabors, LB; Perry, JR; Pugh, SL; Reardon, DA; Roth, P; Stupp, R; Weller, M; Wick, W, 2016) |
| " Triple-mutant astrocytes formed serially transplantable glioblastoma allografts that were sensitive to radiation but expressed MGMT and were resistant to temozolomide." | 3.83 | Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide. ( Bash, RE; Ewend, MG; Huey, L; McNeill, RS; Miller, CR; Schmid, RS; Simon, JM; Vitucci, M; Werneke, AM; White, KK; Wu, J, 2016) |
| "Temozolomide is an alkylating agent used along with concurrent radiation therapy in the treatment of glioblastoma." | 3.83 | Temozolomide-induced biliary ductopenia: a case report. ( Balakrishnan, A; Jaglal, M; Ledford, R, 2016) |
| "Methylation of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene is a predictive and prognostic marker in newly diagnosed glioblastoma patients treated with temozolomide but how MGMT methylation should be assessed to ensure optimal detection accuracy is debated." | 3.83 | Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma. ( Aslan, D; Broholm, H; Christensen, IJ; Dyrbye, H; Grunnet, K; Grønbæk, K; Kristensen, LS; Michaelsen, SR; Poulsen, HS, 2016) |
| "The current standard of care for glioblastoma (GBM) is surgical resection, radiotherapy, and treatment with temozolomide (TMZ)." | 3.83 | MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival. ( Chaumeil, MM; Eriksson, P; Phillips, JJ; Radoul, M; Ronen, SM; Wang, AS, 2016) |
| "Despite the use of ionizing radiation (IR) and temozolomide (TMZ), outcome for glioblastoma (GBM) patients remains dismal." | 3.83 | Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model. ( Chenevert, TL; Galbán, CJ; Galbán, S; Heist, KA; Holland, EC; Lemasson, B; Li, Y; Rehemtulla, A; Ross, BD; Tsein, C; Wang, H; Zhu, Y, 2016) |
| "The role of temozolomide concurrent with and adjuvant to radiotherapy (RT/TMZ) in elderly patients with glioblastoma (GBM) remains unclear." | 3.83 | Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. ( Baruzzi, A; Bertolini, F; Biasini, C; Brandes, AA; Cavallo, MA; Crisi, G; Dazzi, C; Depenni, R; Ermani, M; Faedi, M; Franceschi, E; Michiara, M; Mucciarini, C; Paccapelo, A; Pasini, G; Pavesi, G; Pisanello, A; Servadei, F; Sturiale, C; Urbini, B, 2016) |
| " O(6)-methylguanine DNA methyltransferase (MGMT), N-methylpurine DNA glycosylase (MPG), and Rad51 are DNA damage repair proteins that mediate resistance to temozolomide in glioblastoma." | 3.83 | Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51. ( Acanda, AM; Alonso, MM; Aragón, T; Fueyo, J; Garzón, AG; Gomez-Manzano, C; Gonzalez-Huarriz, M; Idoate, MA; Jones, C; Lang, FF; Martínez-Irujo, JJ; Martínez-Velez, N; Vera, B; Xipell, E, 2016) |
| "To get better chemotherapy efficacy, the optimal synergic effect of Paclitaxel (PTX) and Temozolomide (TMZ) on glioblastoma cells lines was investigated." | 3.83 | The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells. ( Duan, Y; Li, Y; Shen, M; Sun, Y; Teng, Y; Wang, Y; Xu, Y, 2016) |
| "The combination of radiotherapy, temozolomide and valproic acid (VPA) has shown some promise in retrospective analyses of patients with glioblastoma, although their mechanisms of action remain unknown." | 3.83 | Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma. ( Bumes, E; Eyüpoglu, IY; Hau, P; Hutterer, M; Proske, J; Savaskan, NE; Seliger, C; Uhl, M; Vollmann-Zwerenz, A; Walter, L, 2016) |
| "Temozolomide (TMZ) is, in combination with radiotherapy (RT), the treatment of choice for glioblastoma multiforme." | 3.83 | Persistent bone marrow depression following short-term treatment with temozolomide. ( Brandal, P; Johannesen, TB; Tjønnfjord, GE; Vandraas, K, 2016) |
| "Temozolomide (TMZ) is an alkylating agent used to treat glioblastoma." | 3.83 | Sulfasalazine intensifies temozolomide cytotoxicity in human glioblastoma cells. ( Castilho, RF; De Melo, DR; Facchini, G; Ignarro, RS; Lopes-Cendes, I; Rogerio, F; Vieira, AS, 2016) |
| "Temozolomide (TMZ) improves Glioblastoma Multiforme (GBM) patient survival." | 3.83 | Temozolomide induces the expression of the glioma Big Potassium (gBK) ion channel, while inhibiting fascin-1 expression: possible targets for glioma therapy. ( Ahluwalia, A; Chau, V; Ge, L; Hoa, NT; Jadus, MR; Kruse, CA; Martini, F, 2016) |
| "Temozolomide (TMZ) is the main chemotherapeutic drug utilized for the treatment of glioblastoma multiforme (GMB), however, drug resistance often leads to tumor recurrence and poor outcomes." | 3.83 | Expression of dynein, cytoplasmic 2, heavy chain 1 (DHC2) associated with glioblastoma cell resistance to temozolomide. ( Chen, Z; Feng, W; He, M; Lei, B; Li, H; Liu, Y; Lu, Y; Qi, S; Sun, X; Wang, H; Xiang, W; Zhao, L, 2016) |
| "Glioblastoma has a dismal prognosis, with an average overall survival of about one year despite maximal safe resection, concomitant radiochemotherapy with temozolomide followed by adjuvant temozolomide therapy." | 3.83 | Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy. ( Blaes, J; Dong, Z; Green, E; Hertenstein, A; Jugold, M; Lemke, D; Löw, S; Ott, M; Platten, M; Pledl, HW; Sahm, F; Steffen, AC; Weiler, M; Wick, W; Winkler, F; Zorn, M, 2016) |
| "Glioblastoma (GB) recurrences are rarely removed, therefore, tissue modifications induced by radiotherapy, and temozolomide chemotherapy are scarcely known." | 3.83 | Cyclin D1 Co-localizes with Beclin-1 in Glioblastoma Recurrences: A Clue to a Therapy-induced, Autophagy-mediated Degradative Mechanism? ( Belmonte, G; Miracco, C; Pirtoli, L; Tini, P; Toscano, M, 2016) |
| "Maximal safe surgical resection followed by radiotherapy with concurrent and adjuvant temozolomide significantly prolonged overall survival times and was well tolerated in elderly patients with glioblastomas." | 3.83 | Analysis of Treatment Tolerance and Factors Associated with Overall Survival in Elderly Patients with Glioblastoma. ( Gao, Z; Hao, S; Ji, N; Li, Y; Song, G; Su, Z; Wang, J; Wang, X; Xie, J; Yu, L; Zhang, C; Zhang, P, 2016) |
| "Genotoxic chemotherapy with temozolomide (TMZ) is a mainstay of treatment for glioblastoma (GBM); however, at best, TMZ provides only modest survival benefit to a subset of patients." | 3.83 | Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide. ( Johnston, G; Lincoln, FA; Murphy, BM; Noonan, J; Rehm, M; Weyhenmeyer, BC; Würstle, ML, 2016) |
| "Glioblastoma remains an aggressive brain malignancy with poor prognosis despite advances in multimodal therapy that include standard use of Temozolomide." | 3.83 | Tailored Nanoparticle Codelivery of antimiR-21 and antimiR-10b Augments Glioblastoma Cell Kill by Temozolomide: Toward a "Personalized" Anti-microRNA Therapy. ( Ananta, JS; Massoud, TF; Paulmurugan, R, 2016) |
| "Even with aggressive treatment involving radiation therapy plus temozolomide (TMZ), the prognosis for glioblastoma remains poor." | 3.83 | Inhibition of STAT3 enhances the radiosensitizing effect of temozolomide in glioblastoma cells in vitro and in vivo. ( Cho, BJ; Choi, EJ; Han, TJ; Kim, DH; Kim, IA; Paek, SH; Song, SH, 2016) |
| "To evaluate the safety and efficacy of postoperative proton beam therapy (PBT) combined with nimustine hydrochloride (ACNU) or temozolomide (TMZ) for glioblastoma multiforme (GBM)." | 3.83 | Proton beam therapy with concurrent chemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride and temozolomide. ( Ishikawa, E; Ishikawa, H; Matsuda, M; Matsumura, A; Mizumoto, M; Okumura, T; Sakurai, H; Takano, S; Tsuboi, K; Yamamoto, T, 2016) |
| " 1) VPA treatment clearly sensitized glioma cells to temozolomide: A protruding VPA-induced molecular feature in this context was the transcriptional upregulation/reexpression of numerous solute carrier (SLC) transporters that was also reflected by euchromatinization on the histone level and a reexpression of SLC transporters in human biopsy samples after VPA treatment." | 3.83 | Molecular dissection of the valproic acid effects on glioma cells. ( Hau, P; Herold-Mende, C; Hoja, S; Proescholdt, M; Rehli, M; Riemenschneider, MJ; Schulze, M, 2016) |
| "Temozolomide (TMZ) is an alkylating agent that has become the mainstay treatment of the most malignant brain cancer, glioblastoma multiforme (GBM)." | 3.83 | Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems. ( Assoulin, M; Constantini, S; Daniels, D; Fisher, T; Freedman, S; Guez, D; Last, D; Mardor, Y; Mehrian-Shai, R; Moshe, I; Pismenyuk, T; Reichardt, JK; Simon, AJ; Toren, A; Yalon, M, 2016) |
| " The purpose of this study was determining the effects of HL156A, a newly designed biguanide with improved pharmacokinetics, on glioblastoma TSs (GMB TSs) and assess the feasibility of this drug as a new line of therapy against glioblastoma, alone or combined with a conventional therapeutic agent, temozolomide(TMZ)." | 3.83 | Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). ( Chang, JH; Cheong, JH; Choi, J; Huh, YM; Jeon, JY; Kang, SG; Kim, EH; Kim, P; Kim, SH; Koh, I; Lee, JH; Lee, SJ; Park, J; Pollak, M; Shim, JK; Yook, JI; Yun, M, 2016) |
| "Concomitant and adjuvant temozolomide along with radiotherapy following surgery (the Stupp regimen) is the preferred therapy for young patients with glioblastoma as well as for elderly (>70 years) ones with favorable risk factors." | 3.83 | Survival Trends in Elderly Patients with Glioblastoma in the United States: a Population-based Study. ( Bista, A; Shah, BK; Sharma, S, 2016) |
| "Twenty patients with recurrent glioblastoma were treated with biweekly BEV plus temozolomide." | 3.83 | MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma. ( Beppu, T; Kato, K; Ogasawara, K; Sasaki, M; Sasaki, T; Sato, Y; Terasaki, K; Tomabechi, M, 2016) |
| " Here we investigated the in vitro short- and long-term responses of six glioblastoma cell lines to clinically relevant doses of temozolomide for 5 days followed by 23 days of recovery, mimicking the standard schedule used in glioblastoma patient for this drug." | 3.83 | The regrowth kinetic of the surviving population is independent of acute and chronic responses to temozolomide in glioblastoma cell lines. ( Dalsin, E; Filippi-Chiela, EC; Lenz, G; Onzi, GR; Silva, AO, 2016) |
| " By focusing on interactions existing between DNMT3A and DNMT3A-binding protein (D3A-BP), our work identifies the DNMT3A/ISGF3γ interaction such as a biomarker whose the presence level is associated with a poor survival prognosis and with a poor prognosis of response to the conventional chemotherapeutic treatment of glioblastoma multiforme (radiation plus temozolomide)." | 3.83 | Specific Inhibition of DNMT3A/ISGF3γ Interaction Increases the Temozolomide Efficiency to Reduce Tumor Growth. ( Cartron, PF; Cheray, M; Nadaradjane, A; Oliver, L; Pacaud, R; Vallette, FM, 2016) |
| "To observe the effect of RITA, a small molecule that targets p53, combined with temozolomide (TMZ) on proliferation, colony formation and apoptosis of human glioblastoma U87 cells and explore the underlying mechanism." | 3.83 | [RITA combined with temozolomide inhibits the proliferation of human glioblastoma U87 cells]. ( Cao, ZX; Feng, XL; He, XY; Song, XP; Wu, QH; Xiao, WW; Zeng, HC; Zhang, B, 2016) |
| "It has been reported that metformin acts synergistically with temozolomide (TMZ) to inhibit proliferation of glioma cells including glioblastoma multiforme (GBM)." | 3.83 | Metformin treatment reduces temozolomide resistance of glioblastoma cells. ( Kim, DH; Li, S; Liu, Y; Lu, G; Xue, H; Yang, SH; Zhu, JJ, 2016) |
| "To analyze the enhancement patterns and apparent diffusion coefficient (ADC) values of non-measurable surgical cavity wall enhancement pattern, newly appearing after completion of standard concurrent chemoradiotherapy (CCRT) with temozolomide in glioblastoma patients for the prognosis prediction." | 3.83 | MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction. ( Choi, SH; Kim, BR; Kim, IH; Kim, JH; Kim, TM; Lee, ST; Park, CK; Park, SH; Park, SW; Sohn, CH; Yun, TJ, 2016) |
| "Overcoming temozolomide (TMZ) resistance is a great challenge in glioblastoma (GBM) treatment." | 3.83 | Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway. ( Feng, J; Feng, M; Yan, PF; Zhang, FC; Zhao, HY; Zhao, WH, 2016) |
| "Herein, we report new quinazoline-urea based compounds with potent cytotoxic activities against TMZ-resistant glioblastoma multiforme (GBM) cells." | 3.81 | Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). ( Cho, H; Elkamhawy, A; Heo, JC; Kim, HY; Kim, KH; Lee, CO; Nam, DH; Pae, AN; Park, WK; Roh, EJ; Seol, HJ; Viswanath, AN; Yang, H, 2015) |
| "Epidermal growth factor receptor (EGFR)vIII is the most common EGFR mutant found in glioblastoma (GBM)." | 3.81 | EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma. ( Boothman, DA; Burma, S; Chakraborty, S; Habib, AA; Hatanpaa, KJ; Koduru, P; Li, L; Puliyappadamba, VT; Rehman, A; Saha, D; Souza, RF; Vemireddy, V, 2015) |
| "Concurrent chemoradiotherapy with temozolomide, the current standard treatment after surgery for glioblastoma, could be shortened without increasing side effects for patients with poor prognostic features." | 3.81 | Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features. ( Choi, SH; Han, TJ; Kim, IH; Kim, TM; Lee, SH; Lim, YJ; Paek, SH; Park, CK; Park, SH, 2015) |
| "Development of temozolomide (TMZ) resistance contributes to the poor prognosis for glioblastoma multiforme (GBM) patients." | 3.81 | A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. ( Chang, EH; Kim, E; Kim, SS; Pirollo, KF; Rait, A, 2015) |
| "Glioblastoma multiforme (GBM) treatment includes temozolomide (TMZ) chemotherapy." | 3.81 | N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death. ( Bradshaw, TD; Hummersone, M; Matthews, CS; Stevens, MF; Zhang, J, 2015) |
| "To explore the role of dynamic contrast material-enhanced magnetic resonance (MR) imaging in the differentiation of true progression from pseudoprogression in patients with glioblastoma on the basis of findings in entirely newly developed or enlarged enhancing lesions after concurrent radiation therapy and chemotherapy with temozolomide and to evaluate the diagnostic performance of the quantitative pharmacokinetic parameters obtained at dynamic contrast-enhanced MR imaging, such as the volume transfer constant (K(trans)), the extravascular extracellular space per unit volume of tissue(ve), and the blood plasma volume per unit volume of tissue(vp)." | 3.81 | Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yun, TJ, 2015) |
| "The cellular responses to two new temozolomide (TMZ) analogues, DP68 and DP86, acting against glioblastoma multiforme (GBM) cell lines and primary culture models are reported." | 3.81 | Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth. ( Gynther, M; Mladek, AC; Phillips, RM; Ramirez, YP; Rautio, J; Ross, AH; Sakaria, JN; Wheelhouse, RT, 2015) |
| "The upregulation of Livin expression and downregulation of caspase activity were observed under cycling and chronic hypoxia in glioblastoma cells and xenografts, concomitant with increased TR to ionizing radiation and temozolomide." | 3.81 | Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme. ( Hsieh, CH; Lee, HT; Lin, YJ; Shyu, WC; Wang, CC; Wu, CP, 2015) |
| "The present in vitro study aimed to assess the effects of combining the mTOR inhibitor RAD001 and temozolomide (TMZ) together with irradiation by either low-linear energy transfer (LET) radiation (γ-rays) or high-LET radiation (fast neutrons) on the growth and cell survival of the human glioblastoma cell line U-87." | 3.81 | Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture. ( Bischoff, P; Burckel, H; Denis, JM; Gueulette, J; Josset, E; Noël, G; Slabbert, J, 2015) |
| " In this report, we describe the induction of a severe (grade 3) immunologic reaction in a patient with newly diagnosed glioblastoma (GBM) receiving autologous RNA-pulsed dendritic cell (DC) vaccines admixed with GM-CSF and administered coordinately with cycles of dose-intensified temozolomide." | 3.81 | Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide. ( Archer, G; DeLeon, G; Desjardins, A; Friedman, AH; Friedman, HS; Mitchell, DA; Norberg, P; Reap, E; Sampson, JH; Sayour, EJ; Schmittling, R, 2015) |
| "To evaluate 2 specific radiation schedules, each combined with temozolomide (TMZ), assessing their efficacy and safety in patients aged ≥65 years with newly diagnosed glioblastoma (GBM)." | 3.81 | Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. ( Arcella, A; Bozzao, A; Enrici, RM; Esposito, V; Giangaspero, F; Lanzetta, G; Minniti, G; Pace, A; Scaringi, C; Terrenato, I, 2015) |
| "Glioblastoma (GBM) is a highly proliferative, angiogenic grade IV astrocytoma that develops resistance to the alkylating agents used in chemotherapy, such as temozolomide (TMZ), which is considered the gold standard." | 3.81 | Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines. ( Balça-Silva, J; do Carmo, A; Girão, H; Lopes, MC; Matias, D; Moura-Neto, V; Sarmento-Ribeiro, AB, 2015) |
| "Glioblastoma Multiforme (GBM), the most common and lethal adult primary tumor of the brain, showed a link between Sonic Hedgehog (SHH) pathway in the resistance to temozolomide (TMZ)." | 3.81 | Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level. ( Greco, SJ; Ligon, KL; Munoz, JL; Rameshwar, P; Ramkissoon, SH; Rodriguez-Cruz, V, 2015) |
| "Wee1 regulates key DNA damage checkpoints, and in this study, the efficacy of the Wee1 inhibitor MK-1775 was evaluated in glioblastoma multiforme (GBM) xenograft models alone and in combination with radiation and/or temozolomide." | 3.81 | The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. ( Agar, NY; Bakken, KK; Calligaris, D; Carlson, BL; Decker, PA; Eckel-Passow, JE; Elmquist, WF; Evans, DL; Gupta, SK; Iyekegbe, DO; Lou, Z; Ma, B; Mueller, D; Pokorny, JL; Pucci, V; Sarkaria, JN; Schroeder, MA; Shumway, SD, 2015) |
| "The aim of this prospective longitudinal study was to identify static and dynamic O-(2-[(18)F]fluoroethyl)-L-tyrosine PET ((18)FET-PET)-derived imaging biomarkers in patients with glioblastoma (GBM)." | 3.81 | Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. ( Eigenbrod, S; Jansen, NL; Janssen, H; Kreth, FW; Kretzschmar, H; la Fougere, C; Linn, J; Pöpperl, G; Simon, M; Suchorska, B; Tonn, JC; Weller, M, 2015) |
| " Chemotherapy has been observed to prolong overall survival rate and temozolomide (TMZ), a promising chemotherapeutic agent for treating glioblastoma (GBM), possesses the most effective clinical activity at present, although drug resistance limits its clinical outcome." | 3.81 | p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis. ( Fan, Y; Guo, G; Li, Q; Lian, S; Liu, X; Miao, W; Wang, H; Wang, S; Wang, X; Yang, X, 2015) |
| "Temozolomide (TMZ) is an alkylating agent used for the treatment of glioblastoma." | 3.81 | The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells. ( Hong, SH; Hong, YK; Joe, YA; Kim, HK; Kim, HS; Lee, NH; Lee, SW; Yi, HY, 2015) |
| "Lack of robust predictive biomarkers, other than MGMT promoter methylation, makes temozolomide responsiveness in newly diagnosed glioblastoma (GBM) patients difficult to predict." | 3.81 | EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide. ( Bonetti, MF; Branca, C; Buglione, M; Buttolo, L; Cominelli, M; Dalerba, P; Facchetti, F; Finocchiaro, G; Furlan, D; Galli, R; Grisanti, S; Liserre, B; Liserre, R; Mazzoleni, S; Medicina, D; Pellegatta, S; Pellegrini, V; Pizzi, M; Poliani, PL, 2015) |
| "In this study, we developed and characterized a delivery system for the epigenetic demethylating drug, decitabine, to sensitize temozolomide-resistant human glioblastoma multiforme (GBM) cells to alkylating chemotherapy." | 3.81 | Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide. ( Cui, Y; Irudayaraj, J; Naz, A; Thompson, DH, 2015) |
| "Despite multimodal treatment, glioblastoma (GBM) therapy with temozolomide (TMZ) remains inefficient due to chemoresistance." | 3.81 | The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells. ( Bartsch, JW; Biniossek, ML; Carl, B; Conrad, C; Culmsee, C; Dolga, AM; Dong, F; Eibach, M; Koller, G; Nimsky, C; Schieber, S; Schilling, O; Schlomann, U; Strik, H, 2015) |
| "High-grade gliomas, glioblastomas (GB), are refractory to conventional treatment combining surgery, chemotherapy, mainly temozolomide, and radiotherapy." | 3.81 | Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response. ( Brem, H; Cohen-Jonathan Moyal, E; Dahan, P; Dang, VT; Lemarié, A; Saland, E; Sarry, JE; Scotland, SJ; Sesen, J; Skuli, N; Toulas, C; Tyler, BM, 2015) |
| "Temozolomide (TMZ) is widely used for treating glioblastoma (GBM), which can effectively inhibit the GBM growth for some months; however, it still could not prevent the invariable recurrence of GBM." | 3.81 | Demethoxycurcumin was prior to temozolomide on inhibiting proliferation and induced apoptosis of glioblastoma stem cells. ( Fei, X; Shi, L; Wang, Z, 2015) |
| "Currently, O6-methylguanine-DNA methyltransferase(MGMT) promoter methylation is the most convincing predictive biomarker for temozolomide (TMZ) response in patients with glioblastoma multiforme (GBM)." | 3.81 | miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase. ( Chen, H; Li, W; Li, X; Zheng, H, 2015) |
| "We examined whether the amino acid PET tracers, trans-1-amino-3-(18)F-fluorocyclobutanecarboxylic acid (anti-(18)F-FACBC) and (11)C-methyl-l-methionine ((11)C-Met), are suitable for detecting early responses to combination therapies including temozolomide (TMZ), interferon-β (IFN), and bevacizumab (Bev) in glioblastoma." | 3.81 | Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma. ( Baden, A; Doi, Y; Kanagawa, M; Mizoi, K; Oka, S; Ono, M; Ono, T; Sasajima, T; Shimizu, H, 2015) |
| "Two independent temozolomide-treated glioblastoma cohorts-one Australian (Australian Genomics and Clinical Outcomes of Glioma, n = 163) and the other American (University of California Los Angeles/Kaiser Permanente Los Angeles, n = 159)-were studied." | 3.81 | The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. ( Cloughesy, TF; Ha, W; Hitchins, MP; Lai, A; McDonald, KL; Nguyen, HN; Nowak, AK; Rapkins, RW; Wang, F, 2015) |
| "Resistance to temozolomide (TMZ) is a major obstacle in the treatment of glioblastoma multiforme (GBM)." | 3.81 | miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression. ( Mo, L; Qi, X; Wan, Y; Wang, Y; Wei, J; Xie, D; Xie, J; Yan, Q; Yang, S; Zhan, Q; Zhou, D, 2015) |
| " The objective of this study was to assess the survival benefit of LEV compared with other antiepileptic drugs as a chemosensitizer to temozolomide for patients with glioblastoma." | 3.81 | Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. ( Han, JH; Joo, JD; Kim, CY; Kim, IA; Kim, T; Kim, YH; Kim, YJ; Yun, CH, 2015) |
| "Temozolomide (TMZ) has been widely used in the treatment of glioblastoma (GBM), although inherent or acquired resistance restricts the application." | 3.81 | Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma. ( Lan, F; Pan, Q; Yu, H; Yue, X, 2015) |
| "Glioblastoma (GBM) is often treated with the cytotoxic drug temozolomide, but the disease inevitably recurs in a drug-resistant form after initial treatment." | 3.81 | Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide. ( Barford, K; Braun, CJ; Cerniauskas, E; Chen, Y; Hemann, MT; Lees, JA; Mazzucato, P; McFaline-Figueroa, JL; Nagel, ZD; Samson, LD; Sangaraju, D; Stanciu, M; Tretyakova, N; Vargas, A; White, FM, 2015) |
| "Temozolomide is a novel cytotoxic agent currently used as first-line chemotherapy for glioblastoma multiforme (GBM)." | 3.81 | TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells. ( Li, A; Li, Z; Lu, H; Luo, R; Tian, T; Zhang, M, 2015) |
| "Despite surgery, radiotherapy (RT) and temozolomide (TMZ), the prognosis of glioblastoma (GBM) patients remains dismal." | 3.81 | Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma. ( Alkhafaji, A; Belin, C; Carpentier, AF; Doridam, J; Januel, E; Levy-Piedbois, C; Marantidou, A; Ursu, R, 2015) |
| "Glioblastoma multiforme (GBM), a tumor associated with poor prognosis, is known to be resistant to radiotherapy and alkylating agents such as temozolomide (TMZ)." | 3.81 | β-elemene enhances both radiosensitivity and chemosensitivity of glioblastoma cells through the inhibition of the ATM signaling pathway. ( Liu, S; Yuan, Y; Zhao, Y; Zhou, L, 2015) |
| "The objective of the study was to determine whether astrocytes and brain endothelial cells protect glioma cells from temozolomide through an endothelin-dependent signaling mechanism and to examine the therapeutic efficacy of the dual endothelin receptor antagonist, macitentan, in orthotopic models of human glioblastoma." | 3.81 | Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice. ( Aldape, K; Choi, HJ; Conrad, CA; Fidler, IJ; He, J; Kim, MS; Kim, SJ; Langley, RR; Lee, HJ; Lehembre, F; Regenass, U; Weinberg, JS; Wu, Q; Yung, WK, 2015) |
| " Cutoff values of MGMT methylation specific for metastatic colorectal cancer (mCRC) tissue samples were established in a cohort of 60 patients treated with dacarbazine." | 3.81 | Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. ( Amatu, A; Barault, L; Bardelli, A; Bleeker, FE; Cassingena, A; Cassoni, P; De Braud, F; de Witt Hamer, P; Di Nicolantonio, F; Esteller, M; Falcomatà, C; Fiano, V; Milione, M; Moutinho, C; Pietrantonio, F; Rudà, R; Sartore-Bianchi, A; Siena, S; Siravegna, G; Soffietti, R; Venesio, T; Wesseling, P, 2015) |
| "The AVAglio (Avastin in Glioblastoma) and RTOG-0825 randomized, placebo-controlled phase III trials in newly diagnosed glioblastoma reported prolonged progression-free survival (PFS), but not overall survival (OS), with the addition of bevacizumab to radiotherapy plus temozolomide." | 3.81 | Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. ( Abrey, LE; Bais, C; Bourgon, R; Chinot, OL; Cloughesy, T; Garcia, J; Hegde, P; Henriksson, R; Kharbanda, S; Lai, A; Li, C; Mason, W; Moore, N; Nishikawa, R; Peale, F; Phillips, HS; Sandmann, T; Saran, F; Wick, W, 2015) |
| " We investigated whether the widely used chemotherapeutic agent temozolomide (TMZ) can sensitize glioma stem-like cells (GSCs) from human glioblastoma multiforme (GBM) to TRAIL-induced apoptosis." | 3.81 | Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein. ( Anhua, W; Jia, L; Long, L; Yunchao, B; Zhitao, J, 2015) |
| "Temozolomide (TMZ) is a promising chemotherapeutic agent for treating glioblastomas." | 3.81 | PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/β-catenin signaling pathway. ( Fei, X; Shi, L; Wang, Z; You, Y, 2015) |
| " The aim of this study was to investigate the effects of HLF alone and in combination with temozolomide (TMZ), a conventional chemotherapeutic, on human glioblastoma (GBM) cells." | 3.81 | In vitro and in vivo effect of human lactoferrin on glioblastoma growth. ( Aalberti, S; Arcella, A; Bartolo, M; Cantore, G; Frati, A; Giangaspero, F; Grillea, G; Madonna, M; Oliva, MA; Pavone, L; Staffieri, S, 2015) |
| " Glioblastoma (GBM) has poor survival rate and uniformly acquired chemoresistance to its frontline agent, Temozolomide (TMZ)." | 3.81 | Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells. ( Munoz, JL; Rameshwar, P; Scotto, KW; Walker, ND, 2015) |
| " The present study was undertaken to determine whether the cytotoxicity of curcumin (diferuloylmethane), a natural polyphenolic compound isolated from turmeric (Curcuma longa Linn), in glioblastoma cells is mediated through upregulation of miR‑146a." | 3.81 | Induction of microRNA-146a is involved in curcumin-mediated enhancement of temozolomide cytotoxicity against human glioblastoma. ( Cai, T; Chen, YD; Liu, Q; Wang, ZF; Wu, H, 2015) |
| " Our aim was to determine whether the subependymal enhancement pattern and ADC can differentiate true progression from pseudoprogression in patients with glioblastoma multiforme treated with concurrent chemoradiotherapy by using temozolomide." | 3.81 | Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yoo, RE; Yun, TJ, 2015) |
| " A 48-year-old patient had supratentorial glioblastoma, treated with radiotherapy (RT) and concurrent temozolomide followed by six cycles of adjuvant temozolomide." | 3.81 | Diagnosis and Management of Spinal Metastasis of Glioblastoma. ( Dubey, A; Koul, R; Salim, M; Tai, P; Vu, K, 2015) |
| "The constitutive activation of signal transducer and activator of transcription 3 (STAT3) contributes to resistance to temozolomide (TMZ) in glioblastoma multiforme (GBM)." | 3.81 | Growth-inhibitory and chemosensitizing effects of microRNA-31 in human glioblastoma multiforme cells. ( Bai, CF; Cai, MQ; Dai, WZ; Jia, SZ; Lin, L; Liu, BX; Wang, LM; Wang, WH; Xu, XY; Zhang, XF; Zhou, RJ, 2015) |
| "Although temozolomide (TMZ) is the current first-line chemotherapy for glioblastoma multiforme (GBM), most patients either do not respond or ultimately fail TMZ treatment." | 3.81 | Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. ( Chang, EH; DeMarco, J; Kim, E; Kim, SS; Pirollo, KF; Rait, A, 2015) |
| " Interestingly, our findings showed an association of metformin therapy and prolonged progression-free survival in glioblastoma patients with diabetes and therefore serve as a foundation for further preclinical and clinical investigations." | 3.81 | Metformin influences progression in diabetic glioblastoma patients. ( Adeberg, S; Ben Harrabi, S; Bernhardt, D; Bostel, T; Debus, J; Diehl, C; Koelsche, C; Mohr, A; Rieken, S, 2015) |
| " In addition, in contrast to IDH1-mutated gliomas, IDH1-wild-type primary GBMs rarely developed hypermutation following temozolomide (TMZ) treatment, indicating low risk for TMZ-induced hypermutation for these tumors under the standard regimen." | 3.81 | Spatiotemporal Evolution of the Primary Glioblastoma Genome. ( Cho, HJ; Johnson, MD; Joo, KM; Jung, YS; Kim, BS; Kim, J; Kim, Y; Kong, DS; Lee, IH; Lee, J; Lee, JI; Nam, DH; Nam, SH; Park, CK; Park, PJ; Park, WY; Seol, HJ; Yoon, Y, 2015) |
| " We previously reported that the Smac (second mitochondria-derived activator of caspases) mimetic BV6, which antagonizes IAP proteins, sensitizes glioblastoma cells to temozolomide (TMZ)-induced cell death in a nuclear factor-κB (NF-κB)-dependent manner." | 3.81 | Smac mimetic-induced upregulation of interferon-β sensitizes glioblastoma to temozolomide-induced cell death. ( Fulda, S; Marschall, V, 2015) |
| "The efficacy of temozolomide (TMZ) plus radiation therapy (RT) in elderly patients with glioblastoma is unclear." | 3.81 | Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). ( Anghileri, E; Bazzoli, E; Bellu, L; Berti, F; D'Avella, D; Dall'Agata, M; Della Puppa, A; Eoli, M; Fabi, A; Faedi, M; Ferrazza, P; Gurrieri, L; Lombardi, G; Nicolotto, E; Pace, A; Pambuku, A; Pasqualetti, F; Rizzato, S; Rudà, R; Villani, V; Zagonel, V, 2015) |
| "PARP inhibition can enhance the efficacy of temozolomide and prolong survival in orthotopic glioblastoma (GBM) xenografts." | 3.81 | Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. ( Agar, NY; Boddy, AV; Calligaris, D; Carlson, BL; Cen, L; Curtin, NJ; Elmquist, WF; Kizilbash, S; Mittapalli, RK; Murray, J; Parrish, KE; Sarkaria, JN; Schroeder, MA; Sludden, J, 2015) |
| "The use of temozolomide (TMZ) has improved the prognosis for glioblastoma multiforme patients." | 3.81 | Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. ( Berdasco, M; Caba, O; Cabeza, L; Gónzalez, B; Melguizo, C; Ortiz, R; Perazzoli, G; Prados, J, 2015) |
| "Resistance to temozolomide poses a major clinical challenge in glioblastoma multiforme treatment, and the mechanisms underlying the development of temozolomide resistance remain poorly understood." | 3.81 | c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma. ( Chen, D; Chen, W; Chen, Y; Chen, Z; Cheng, G; Jiang, T; Liu, N; Lu, D; Luo, H; Peng, C; Qiu, W; Wang, H; Wang, HW; Wang, S; Wu, W; Xu, R; Yang, J; You, Y; Zhang, R; Zhang, S; Zhang, X; Zhao, C; Zhao, L, 2015) |
| "Temozolomide (TMZ) is widely used for treating glioblastoma (GBM), which can effectively inhibit the GBM growth for some months; however, it still cannot prevent the invariable recurrence of GBM." | 3.81 | Low-Dose DMC Significantly Enhances the Effect of TMZ on Glioma Cells by Targeting Multiple Signaling Pathways Both In Vivo and In Vitro. ( Shi, L; Sun, G, 2015) |
| "For glioblastoma patients who underwent Temozolomide and Radiation Therapy, OS and PFS was most favorable for those with tumors harboring both mIDH and methMGMT (median OS: 35." | 3.81 | IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. ( Chen, B; Chen, CC; Jiang, T; Li, G; Li, J; Li, S; Li, W; Peng, X; Qiu, X; Wang, Y; Wu, C; Yan, W; Yang, P; Yao, K; You, Y; Zhang, W, 2015) |
| "Temozolomide (TMZ) is widely used for patients with glioblastoma (GBM); however, tumor cells frequently exhibit drug-resistance." | 3.81 | APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line. ( Godoy, PR; Montaldi, AP; Sakamoto-Hojo, ET, 2015) |
| "Our laboratory reported that Irinophore C™ (IrC™; a lipid-based nanoparticulate formulation of irinotecan) is effective against an orthotopic model of glioblastoma (GBM) and that treatment with IrC™ was associated with vascular normalization within the tumor." | 3.81 | Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma. ( Anantha, M; Backstrom, I; Bally, MB; Chu, F; Kalra, J; Masin, D; Strutt, D; Verreault, M; Walker, D; Waterhouse, D; Wehbe, M; Yapp, DT, 2015) |
| "This study was performed to validate the effectiveness and safety of concurrent chemoradiotherapy and adjuvant therapy with temozolomide for newly diagnosed glioblastoma multiforme as a standard treatment protocol." | 3.81 | Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution. ( Han, JH; Joo, JD; Kim, CY; Kim, H; Kim, YH, 2015) |
| "Temozolomide (TMZ) is an oral DNA-alkylating agent used for treating patients with glioblastoma." | 3.81 | Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. ( Bui, Y; Cloughesy, TF; Hong, I; Lai, A; Liau, LM; McBride, WH; Menjivar, JC; Nelson, SF; Stream, A; Tso, CL; Tso, JL; Yamada, K; Yang, S; Yong, WH; Zhang, Y, 2015) |
| "Glioblastoma (GBM) generally exhibits high IC50 values for its standard drug treatment, temozolomide (TMZ)." | 3.81 | Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells. ( Ananta, JS; Massoud, TF; Paulmurugan, R, 2015) |
| "Notwithstanding current multimodal treatment, including surgery, radiotherapy and chemotherapy with temozolomide (TMZ), median survival of glioblastoma (GBM) patients is about 14 months, due to the rapid emergence of cell clones resistant to treatment." | 3.81 | The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. ( Allemanni, G; Banelli, B; Barbieri, F; Carosio, R; Carra, E; Daga, A; Florio, T; Forlani, A; Marubbi, D; Parodi, F; Pattarozzi, A; Romani, M; Würth, R, 2015) |
| "Glioma stem cells are associated for temozolomide-resistance in glioblastoma." | 3.81 | Co-expression of Cytoskeletal Protein Adducin 3 and CD133 in Neurospheres and a Temozolomide-resistant Subclone of Glioblastoma. ( Leung, GK; Poon, MW; Sun, S; Wong, ST; Zhang, XQ; Zhuang, JT, 2015) |
| "In this work, we have reported the preparation and optimization of paclitaxel (PTX) and temozolomide (TMZ) loaded monomethoxy (polyethylene glycol)-poly(D, L-lactide-co-glycolide) (mPEG-PLGA) nanocomposite which is a thermo-sensitive gel delivery system to glioblastoma." | 3.81 | Polymer Nanocomposites Based Thermo-Sensitive Gel for Paclitaxel and Temozolomide Co-Delivery to Glioblastoma Cells. ( Duan, Y; Gao, P; Shen, M; Sun, Y; Xu, Y, 2015) |
| "The current standard treatment of glioblastoma includes maximal safe surgical resection, radiation, and temozolomide." | 3.80 | Isotretinoin maintenance therapy for glioblastoma: a retrospective review. ( Chen, SE; Choi, SS; De Groot, JF; Lei, X; Rogers, JE, 2014) |
| "The standard adjuvant treatment for glioblastoma is temozolomide concomitant with radiotherapy, followed by a further six cycles of temozolomide." | 3.80 | Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain. ( Arranz, JL; Balañá, C; Benavides, M; Bugés, C; Cano, JM; de la Peñas, R; García-Bueno, JM; Gil, M; Lopez, D; Martin, JM; Molina-Garrido, MJ; Perez-Segura, P; Rodriguez, A; Sanz, SM; Sepúlveda, JM; Vaz, MA, 2014) |
| "Temozolomide, an alkylating agent, is a promising chemotherapeutic agent for treating glioblastoma." | 3.80 | miR-125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3. ( Shi, L; Sun, G; Wan, Y; Wang, Z; Zeng, Y; Zhang, S, 2014) |
| "Although temozolomide (TMZ) replaced nitrosoureas as the standard initial chemotherapy for glioblastoma (GBM), no studies have compared TMZ with nimustine (ACNU), a nitrosourea agent widely used in central Europe and most Asian regions." | 3.80 | Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma. ( Chen, B; Chen, L; Chen, X; Jiang, T; Li, S; Wang, J; Wang, L; Wang, Y; Wu, C; Zhang, X; Zhang, Z, 2014) |
| "It is now accepted that the concomitant administration of temozolomide with radiotherapy (Stupp regime), in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM), significantly improves survival and this practice has been adopted locally since 2004." | 3.80 | A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regime. ( Clark, B; Mackinnon, M; Martin, S; Nowicki, S; Owusu-Agyemang, K; Paul, J; St George, J; Stewart, W; Teo, M, 2014) |
| "Our purpose was to analyze the pattern of failure in glioblastoma (GBM) patients at first recurrence after radiotherapy and temozolomide and its relationship with different factors." | 3.80 | Factors associated with a higher rate of distant failure after primary treatment for glioblastoma. ( Aldave, G; de Gallego, J; Díez-Valle, R; Domínguez, PD; Gállego Pérez-Larraya, J; Marigil, M; Tejada, S, 2014) |
| "Radiotherapy (RT) and temozolomide (TMZ) for glioblastoma (GBM) has resulted in longer survival." | 3.80 | Employment following chemoradiotherapy in glioblastoma: a prospective case series. ( Back, M; Guo, L; Gzell, C; Kastelan, M; Wheeler, H, 2014) |
| "Radiation therapy with concomitant and adjuvant temozolomide (TMZ) is the standard therapy for nonelderly patients with glioblastoma." | 3.80 | Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study. ( Mukasa, A; Narita, Y; Saito, K; Saito, N; Shibui, S; Shinoura, N; Tabei, Y, 2014) |
| "Patients with glioblastoma treated with BCNU wafer implantation for recurrence frequently receive frontline chemoradiotherapy with temozolomide as part of the Stupp protocol." | 3.80 | Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma. ( Ewelt, C; Hänggi, D; Isik, G; Sabel, M; Samis Zella, MA; Schroeteler, J; Slotty, PJ; Steiger, HJ; Wallocha, M, 2014) |
| " O6-methylguanine DNA methyltransferase (MGMT), which is frequently expressed in cancer stem cells of glioblastoma, has been implicated in their resistance to temozolomide, the first-line chemotherapeutic agent against newly diagnosed glioblastoma." | 3.80 | JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression. ( Kayama, T; Kitanaka, C; Narita, Y; Okada, M; Sato, A; Seino, M; Seino, S; Shibui, S; Shibuya, K; Suzuki, S; Watanabe, E, 2014) |
| " NVP-BEZ235 also sensitized a subset of subcutaneous tumors to temozolomide, a drug routinely used concurrently with ionizing radiation for the treatment of glioblastoma." | 3.80 | Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. ( Bachoo, R; Burma, S; Gao, X; Gil del Alcazar, CR; Habib, AA; Hardebeck, MC; Li, L; Mukherjee, B; Tomimatsu, N; Xie, XJ; Yan, J, 2014) |
| "With standard treatment for glioblastoma (GBM) consisting of surgery followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ), median survival is ~14." | 3.80 | Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era. ( Chung, C; Jiang, H; Laperriere, N; Lwin, Z; Mason, WP; McNamara, MG; Millar, BA; Sahgal, A, 2014) |
| "Wild-type or immunodeficient mice bearing intracranial glioblastoma multiforme or metastatic melanoma were treated with an intratumoral injection of Ad-Flt3L alone or in combination with the conditionally cytotoxic enzyme thymidine kinase (Ad-TK), followed by systemic administration of ganciclovir and temozolomide." | 3.80 | Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models. ( Ahlzadeh, GE; Candolfi, M; Castro, MG; Ghiasi, H; Kamran, N; Lowenstein, PR; Paran, C; Puntel, M; Wibowo, M; Yagiz, K, 2014) |
| "As chemotherapy with temozolomide is far from providing satisfactory clinical outcomes for patients with glioblastoma, more efficient drugs and drug combinations are urgently needed." | 3.80 | Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. ( Debatin, KM; Dwucet, A; Halatsch, ME; Karpel-Massler, G; Kast, RE; Nonnenmacher, L; Westhoff, MA; Wirtz, CR, 2014) |
| "Ependymoma SC lines were highly sensitive to temozolomide and etoposide in vitro, but only temozolomide impaired tumor-initiation properties." | 3.80 | Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models. ( Arena, V; Binda, E; Lamorte, G; Meco, D; Riccardi, R; Servidei, T, 2014) |
| "Bevacizumab (BZM) and temozolomide (TMZ) have been shown to be beneficial in the treatment of patients with glioblastoma." | 3.80 | Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era. ( Wachtel, MS; Yang, S, 2014) |
| "Temozolomide (TMZ) is a promising chemotherapeutic agent for treating glioblastomas." | 3.80 | miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. ( Chen, J; Fu, X; Jiang, D; Shi, L; Wan, Y; Wang, Z, 2014) |
| "Little is known about the optimal clinical use of ABT-888 (veliparib) for treatment of glioblastoma." | 3.80 | ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. ( Beijnen, JH; Beumer, JH; Buil, LC; Christner, SM; de Gooijer, MC; Lin, F; Roig, EM; van Tellingen, O; Würdinger, T, 2014) |
| "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma." | 3.80 | Liver toxicity during temozolomide chemotherapy caused by Chinese herbs. ( Egle, A; Greil, R; Grundbichler, M; Hufnagl, C; Magnes, T; Melchardt, T; Moik, M; Strasser, M; Weiss, L, 2014) |
| "Temozolomide (TMZ) is widely used to treat glioblastoma multiforme (GBM)." | 3.80 | microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells. ( Bekar, A; Berghoff, AS; Budak, F; Cecener, G; Egeli, U; Kocaeli, H; Preusser, M; Ricken, G; Taskapılıoglu, MO; Tezcan, G; Tolunay, S; Tunca, B, 2014) |
| "Glioblastoma (GBM) remains the most aggressive and lethal brain tumor due to its molecular heterogeneity and high motility and invasion capabilities of its cells, resulting in high resistance to current standard treatments (surgery, followed by ionizing radiation combined with Temozolomide chemotherapy administration)." | 3.80 | Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells. ( Allavena, G; Angeletti, F; Comincini, S; Manai, F; Miracco, C; Palumbo, S; Pirtoli, L; Tini, P; Toscano, M, 2014) |
| " However, the role of NHE1 in glioblastoma and the interaction of NHE1 expression and function in glioblastoma cells with cytotoxic temozolomide (TMZ) therapy remain unknown." | 3.80 | Upregulation of NHE1 protein expression enables glioblastoma cells to escape TMZ-mediated toxicity via increased H⁺ extrusion, cell migration and survival. ( Clark, PA; Cong, D; Hu, S; Kuo, JS; Pointer, KB; Shen, H; Shi, Y; Sun, D; Zhu, W, 2014) |
| "Temozolomide (TMZ) has remained the chemotherapy of choice in patients with glioblastoma multiforme (GBM) primarily due to the lack of more effective drugs." | 3.80 | Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation. ( Cohen, MS; Grogan, PT; Sarkaria, JN; Timmermann, BN, 2014) |
| "Temozolomide (TMZ)-resistance in glioblastoma multiforme (GBM) has been linked to upregulation of O(6)-methylguanine-DNA methyltransferase (MGMT)." | 3.80 | A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ( Chang, EH; Dagata, JA; Farkas, N; Kim, E; Kim, SS; Nishida, M; Pirollo, KF; Rait, A, 2014) |
| "Glioblastoma multiforme (GBM) represents the most common and deadly primary brain malignancy, particularly due to temozolomide (TMZ) and radiation (RT) resistance." | 3.80 | Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines. ( Anderson, JC; Bonner, JA; Bredel, M; Choradia, NV; Duarte, CW; Rohrbach, TD; Thottassery, JV; Welaya, K; Willey, CD; Yancey Gillespie, G; Yang, ES, 2014) |
| "Effective sensitizing strategies potentially can extend the benefit of temozolomide (TMZ) therapy in patients with glioblastoma (GBM)." | 3.80 | Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. ( Bakken, KK; Boakye-Agyeman, F; Carlson, BL; Gupta, SK; Kizilbash, SH; Mladek, AC; Reid, J; Sarkaria, JN; Schroeder, MA, 2014) |
| "The frequent recurrence of glioblastoma multiforme (GBM) after standard treatment with temozolomide (TMZ) is a crucial issue to be solved in the clinical field." | 3.80 | YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line. ( Akiyama, Y; Ashizawa, T; Hayashi, N; Iizuka, A; Komiyama, M; Kume, A; Mitsuya, K; Miyata, H; Nakasu, Y; Omiya, M; Oshita, C; Sugino, T; Yamaguchi, K, 2014) |
| " Temozolomide (TMZ) in combination with radiotherapy is currently used for the treatment of glioblastoma (GBM) patients, but less than half of the patients respond to therapy and chemoresistance develops rapidly." | 3.80 | miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas. ( Baumgartner, U; Glück, A; Haemmig, S; Kappeler, A; Mariani, L; Tschan, MP; Vajtai, I; Vassella, E; Zbinden, S, 2014) |
| " The aim of this study was to investigate whether quercetin could sensitize human glioblastoma cells to temozolomide (TMZ) in vitro." | 3.80 | Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27. ( Lan, Q; Li, RJ; Sang, DP, 2014) |
| "To analyze patterns of failure in patients with glioblastoma multiforme (GBM) treated with limited-margin radiation therapy and concurrent temozolomide." | 3.80 | Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. ( Bag, AK; Dobelbower, MC; Ennis, WH; Fiveash, JB; Gebhardt, BJ; Markert, JM, 2014) |
| " Here we show the potential of (1)H NMR in the investigation of the uptake of two different kinds of nanostructures, that is, maghemite and gold nanoparticles, and of a chemotherapy drug (Temozolomide) in glioblastoma tumor cells." | 3.80 | NMR as evaluation strategy for cellular uptake of nanoparticles. ( Clementi, E; Corti, M; Guari, Y; Larionova, J; Lascialfari, A; Nano, R; Orlando, T; Paolini, A; Pasi, F; Pineider, F; Sacchi, L, 2014) |
| "To evaluate the role of bevacizumab and irinotecan as secondline treatment of glioblastoma in patients with progression after radiotherapy and temozolomide." | 3.80 | Bevacizumab as secondline treatment of glioblastoma - worth the effort? ( Rovere, RK, 2014) |
| "We examined changes to key UPR modulators in temozolomide-sensitive and -resistant human GBM cells (D54 and U87) treated with/without temozolomide at different oxygen concentrations using western blotting, and cytotoxic benefits of overexpressing key chaperone, P4HB, in GBM cells (U87 and U251) under normoxia and hyperoxia." | 3.80 | Hyperoxia resensitizes chemoresistant glioblastoma cells to temozolomide through unfolded protein response. ( Ho, AS; Kiang, KM; Lee, D; Leung, GK; Sun, S; Xu, FF; Zhang, XQ, 2014) |
| "Eighteen patients with newly diagnosed, histologically confirmed glioblastoma had 3D-MR proton spectroscopic imaging (MRSI) along with T2 and T1 gadolinium-enhanced MR images at simulation and at boost treatment planning after 17 to 20 fractions of radiation therapy." | 3.80 | 3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy. ( Anderson, CM; Bayouth, JE; Buatti, JM; Capizzano, AA; Clerkin, PP; Magnotta, V; McGuire, SM; Morris, A; Muruganandham, M; Smith, BJ; Smith, MC, 2014) |
| "The EORTC-NCIC regimen for glioblastoma requires different dosing of temozolomide (TMZ) during radiation and maintenance therapy." | 3.80 | Analyzing temozolomide medication errors: potentially fatal. ( Bressler, LR; Gabay, MP; Letarte, N; Long, KE; Stachnik, JM; Villano, JL, 2014) |
| "Temozolomide (TMZ), a DNA alkylating agent, represents the most important chemotherapeutic option for the treatment of glioblastoma in the clinic." | 3.80 | Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling. ( Hu, X; Shao, J; Wang, L; Wen, C; Yin, H; You, C; Zhang, W; Zhou, C; Zhou, Y, 2014) |
| "Glioblastoma multiforme (GBM) commonly resists the frontline chemotherapy treatment temozolomide." | 3.80 | Temozolomide induces the production of epidermal growth factor to regulate MDR1 expression in glioblastoma cells. ( Greco, SJ; Munoz, JL; Nagula, V; Rameshwar, P; Rodriguez-Cruz, V; Scotto, KW, 2014) |
| "The aim of the present study was to evaluate the toxicity and clinical outcome of radio-chemotherapy with temozolomide in patients with glioblastoma aged more than 65 years." | 3.80 | Radio-chemotherapy with temozolomide in elderly patients with glioblastoma. A mono-institutional experience. ( Cocuzza, P; Fabbrini, MG; Fatigante, L; Ferrazza, P; Monzani, F; Pasqualetti, F; Pasqualetti, G, 2014) |
| "The current standard of care for glioblastoma (GBM) involves a combination of surgery, radiotherapy, and temozolomide chemotherapy, but this regimen fails to achieve long-term tumor control." | 3.80 | Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. ( Cairncross, JG; Luchman, HA; Lun, XQ; Nguyen, SA; Robbins, SM; Senger, DL; Stechishin, OD; Weiss, S, 2014) |
| "Therapeutic options for the management of glioblastoma (GBM) have greatly evolved over the last decade with the emergence of new regimens combining radiotherapy plus temozolomide and the use of bevacizumab at recurrence." | 3.80 | Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital. ( Armoiry, X; Aulagner, G; Breant, V; Cartalat-Carel, S; Diebold, G; Ducray, F; Fouquet, A; Frappaz, D; Guyotat, J; Henaine, AM; Honnorat, J, 2014) |
| " Finally, human T98G glioblastoma cells that are resistant to the chemotherapy drug temozolomide (TMZ) showed a unique high expression of the Na+/K+-ATPase α2 and α3 subunits compared to the TMZ-sensitive cell line LN229 and normal human astrocytes." | 3.80 | Inhibition of Na+/K+-ATPase induces hybrid cell death and enhanced sensitivity to chemotherapy in human glioblastoma cells. ( Chen, D; Mohamad, O; Song, M; Yu, SP, 2014) |
| " honey (ESH), beebread (EBB), and royal jelly (ERJ) with and without temozolomide (TMZ) on cell lines derived from a patient with diffuse astrocytoma (DASC), human glioblastoma multiforme (U87MG), and normal human astroglia (SVGp12)." | 3.80 | The interaction of bee products with temozolomide in human diffuse astrocytoma, glioblastoma multiforme and astroglia cell lines. ( Bartosiuk, E; Borawska, MH; Kochanowicz, J; Mariak, Z; Markiewicz-Żukowska, R; Moskwa, J; Naliwajko, SK; Socha, K; Surażyński, A, 2014) |
| "To review clinical outcomes of moderate dose escalation using high-dose radiation therapy (HDRT) in the setting of concurrent temozolomide (TMZ) in patients with newly diagnosed glioblastoma multiforme (GBM), compared with standard-dose radiation therapy (SDRT)." | 3.80 | Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide. ( Badiyan, SN; Chicoine, MR; Dacey, R; DeWees, T; Dowling, JL; Huang, J; Jalalizadeh, R; Kim, AH; Leuthardt, EC; Linette, G; Markovina, S; Rich, KM; Robinson, CG; Simpson, JR; Tran, DD; Zipfel, GJ, 2014) |
| " Next, we treated all eGFP/Luc GBM cell lines with Temozolomide (TMZ) or Doxorubicin, comparing co-cultures of glioblastoma (GBM) cells and TNC-1 astrocytes with mono-cultures of eGFP/Luc GBM cells." | 3.80 | A co-culture model with brain tumor-specific bioluminescence demonstrates astrocyte-induced drug resistance in glioblastoma. ( Costea, DE; Enger, PØ; Huang, B; Leiss, L; Li, X; Liang, X; Sakariassen, PØ; Skaftnesmo, KO; Wang, J; Yan, T; Yang, N; Zhu, H, 2014) |
| "Prophylaxis against Pneumocystis jiroveci pneumonia (PJP) is currently recommended for patients receiving chemoradiation with temozolomide for newly diagnosed glioblastoma multiforme." | 3.80 | Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis. ( Barnes, PD; Bubalo, J; Fu, R; Gahramanov, S; Lacy, C; Nasseri, M; Neuwelt, AJ; Neuwelt, EA; Nguyen, TM; Tyson, RM, 2014) |
| "Standard treatment for glioblastoma comprises surgical resection, chemotherapy with temozolomide, and radiotherapy." | 3.80 | KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis. ( Ham, Y; Jin, J; Joo, KM; Kang, W; Kim, S; Nam, DH; Woo, SR; Yang, H, 2014) |
| "Recent findings show that exposure to temozolomide (TMZ), a DNA-damaging drug used to treat glioblastoma (GBM), can suppress the conversion of pyruvate to lactate." | 3.80 | Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells. ( Chaumeil, MM; Gaensler, K; Ito, M; Jalbert, LE; Mukherjee, J; Nelson, SJ; Park, I; Pieper, RO; Ronen, SM, 2014) |
| "To assess the prognosis predictability of a measurable enhancing lesion using histogram parameters produced by the normalized cerebral blood volume (nCBV) and normalized apparent diffusion coefficient (nADC) after completion of standard concomitant chemoradiotherapy (CCRT) and adjuvant temozolomide (TMZ) medication in glioblastoma multiforme (GBM) patients." | 3.80 | Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Ryoo, I; Sohn, CH; Yun, TJ, 2014) |
| "Temozolomide, an oral alkylating agent, is used in the treatment of glioblastoma." | 3.80 | Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma. ( Adeyi, O; Fung, S; Mason, M; Millar, BA, 2014) |
| "In a recent clinical trial, patients with newly diagnosed glioblastoma multiforme benefited from chloroquine (CQ) in combination with conventional therapy (resection, temozolomide [TMZ], and radiation therapy)." | 3.80 | Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy. ( Chen, TC; Cho, HY; Golden, EB; Hofman, FM; Jahanian, A; Louie, SG; Schönthal, AH, 2014) |
| "The objective of this study was to report the authors' experience with the long-term administration of temozolomide (TMZ; > 6 cycles, up to 101) in patients with newly diagnosed glioblastoma and to analyze its feasibility and safety as well as its impact on survival." | 3.80 | Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. ( Albanese, V; Barbagallo, GM; Caltabiano, R; Certo, F; Lanzafame, S; Longo, A; Motta, F; Palmucci, S; Paratore, S; Parra, HS; Privitera, G; Scaglione, G, 2014) |
| " Temozolomide (TMZ) is an alkylating agent used for the treatment of glioblastoma multiforme (GBM), the most common and deadliest of malignant primary brain tumors." | 3.80 | Glioblastoma multiforme and hepatitis B: do the right thing(s). ( Begini, P; Delle Fave, G; Gallina, S; Marignani, M; Minniti, G; Purchiaroni, F, 2014) |
| "The benefit of the introduction of alkylating chemotherapy in the treatment of glioblastoma multiforme (GBM) patients has been demonstrated by comparing radiotherapy with concomitant plus intermittent temozolomide (iTMZ) to radiation therapy." | 3.79 | The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study. ( Felsberg, J; Goeppert, M; Rapp, M; Sabel, M; Steiger, HJ, 2013) |
| "Temozolomide (TMZ) is important chemotherapy for glioblastoma multiforme (GBM), but the optimal dosing schedule is unclear." | 3.79 | Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models. ( Anderson, SK; Ballman, KV; Carlson, BL; Cen, L; Decker, PA; Giannini, C; Grogan, PT; Kitange, GJ; Mladek, AC; Pokorny, JL; Sarkaria, JN; Schroeder, MA; Wu, W, 2013) |
| " The current study investigates the trimodal combination of ABT-888, a potent inhibitor of PARP1-2, ionizing radiation and temozolomide(TMZ)-based chemotherapy in glioblastoma (GBM) cells." | 3.79 | Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma. ( Barazzuol, L; Burnet, NG; Jena, R; Jeynes, JC; Kirkby, KJ; Kirkby, NF; Meira, LB, 2013) |
| " In this study, we investigated the predictive value of SLC22A18 promoter methylation and protein expression in glioblastoma multiforme (GBM) patients receiving temozolomide (TMZ) therapy." | 3.79 | Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy. ( Chu, SH; Feng, DF; Jiang, PC; Li, ZQ; Ma, YB, 2013) |
| "Temozolomide (TMZ) is commonly used in the treatment of glioblastoma (GBM)." | 3.79 | Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells. ( Canpinar, H; Castresana, JS; Ilgaz, S; Ozdemir, M; Ozkan, T; Oztuna, D; Rey, JA; Sunguroğlu, A; Taspinar, M; Ugur, HC, 2013) |
| "Temozolomide (TMZ) is the most widely used drug to treat glioblastoma (GBM), which is the most common and aggressive primary tumor of the Central Nervous System and one of the hardest challenges in oncotherapy." | 3.79 | Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomide-induced senescence in glioma cells. ( Bueno e Silva, MM; Filippi-Chiela, EC; Garicochea, B; Ledur, PF; Lenz, G; Pelegrini, AL; Thomé, MP; Zamin, LL, 2013) |
| "Valproic acid (VA) is an antiepileptic drug (AED) and histone deacetylase (HDAC) inhibitor taken by patients with glioblastoma (GB) to manage seizures, and it can modulate the biologic effects of radiation therapy (RT)." | 3.79 | Valproic acid use during radiation therapy for glioblastoma associated with improved survival. ( Barker, CA; Beal, K; Bishop, AJ; Chan, TA; Chang, M, 2013) |
| "The purpose of this study is to assess the preclinical therapeutic efficacy of magnetic resonance imaging (MRI)-monitored focused ultrasound (FUS)-induced blood-brain barrier (BBB) disruption to enhance Temozolomide (TMZ) delivery for improving Glioblastoma Multiforme (GBM) treatment." | 3.79 | Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study. ( Chen, PY; Chu, PC; Feng, LY; Hsu, PW; Huang, CY; Lee, PY; Liu, HL; Lu, YJ; Tsai, HC; Tseng, IC; Wang, HY; Wei, KC; Yen, TC, 2013) |
| " In addition, microsatellite instability, leading to the putative mechanism of temozolomide (TMZ) resistance, was frequently detected." | 3.79 | Pediatric glioblastoma with oligodendroglioma component: aggressive clinical phenotype with distinct molecular characteristics. ( Amano, T; Fujioka, Y; Hata, N; Iwaki, T; Mizoguchi, M; Murata, H; Nakamizo, A; Sasaki, T; Suzuki, SO; Yoshimoto, K, 2013) |
| "We investigated the pattern of failure in glioblastoma multiforma (GBM) patients treated with concurrent radiation, bevacizumab (BEV), and temozolomide (TMZ)." | 3.79 | Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme. ( Kadner, R; Shields, LB; Spalding, AC; Vitaz, TW, 2013) |
| "Murine orthotopic xenografts generated from temozolomide-sensitive and -resistant glioblastoma neurosphere lines were treated with the γ-secretase inhibitor MRK003." | 3.79 | Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade. ( Bar, EE; Chu, Q; Eberhart, CG; Orr, BA; Semenkow, S, 2013) |
| "We have studied the consequences of the combination of the mammalian target of rapamycin (mTOR) inhibitor RAD001 and temozolomide on the growth and cell death of the glioblastoma cell line U-87 in vitro." | 3.79 | The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line. ( Bischoff, P; Burckel, H; Josset, E; Noël, G, 2013) |
| "To determine whether immediate post-operative brachytherapy can be safely applied to newly diagnosed glioblastomas to retard tumor progression prior to initiation of external beam radiation therapy (EBRT) and temozolomide." | 3.79 | Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma. ( Alksne, JF; Carter, BS; Chen, CC; Gonda, DD; Lawson, J; Murphy, K; Rose, B; Russell, M; Scanderbeg, DJ; Waters, JD, 2013) |
| "Pseudoprogression is a frequent phenomenon observed since the introduction of postoperative therapy with radiotherapy and temozolomide (RT/TMZ) in glioblastoma multiforme (GBM) patients." | 3.79 | Defining pseudoprogression in glioblastoma multiforme. ( Bechter, OE; Clement, PM; De Vleeschouwer, S; Demaerel, P; Geussens, Y; Menten, J; Sciot, R; Van Calenbergh, F; Van Gool, S; Van Mieghem, E; Wilms, G; Wozniak, A, 2013) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 3.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| "Global gene expressions and drug sensitivities to three chemotherapeutic drugs (imatinib, camptothecin and temozolomide) were measured in six human glioblastoma-derived cell lines." | 3.79 | Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines. ( Andersson, C; Bergqvist, M; Blomquist, E; Ekman, S; Gullbo, J; Isaksson, A; Johansson, F; Kultima, HG; Lennartsson, J; Sooman, L, 2013) |
| "In glioblastoma multiforme (GBM), a tumor still characterized by dismal prognosis, recent research focuses on novel-targeted compounds, in addition to standard temozolomide (TMZ) chemotherapy." | 3.79 | Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers. ( Classen, CF; Linnebacher, M; Mullins, CS; Schneider, B; Schubert, J, 2013) |
| "To explore the role of histogram analysis of apparent diffusion coefficient (ADC) maps obtained at standard- and high-b-value (1000 and 3000 sec/mm(2), respectively) diffusion-weighted (DW) imaging in the differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide." | 3.79 | Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. ( Choi, SH; Chu, HH; Jung, SC; Kim, IH; Kim, JH; Kim, SC; Kim, TM; Lee, AL; Lee, SH; Park, CK; Park, SH; Ryoo, I; Shin, H; Sohn, CH; Yeom, JA; Yoon, TJ, 2013) |
| "Glioblastomas are the most frequent and aggressive intracranial neoplasms in humans, and despite advances and the introduction of the alkylating agent temozolomide in therapy have improved patient survival, resistance mechanisms limit benefits." | 3.79 | Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival. ( Caroli, M; Condomitti, G; Di Vito, C; Galli, R; Giussani, P; Riboni, L; Riccitelli, E; Tringali, C; Viani, P, 2013) |
| "To evaluate the efficacy of pulsed low-dose radiation therapy (PLRT) combined with temozolomide (TMZ) as a novel treatment approach for radioresistant glioblastoma multiforme (GBM) in a murine model." | 3.79 | Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme. ( Chunta, JL; Grills, IS; Huang, J; Krueger, SA; Lee, DY; Marples, B; Martinez, AA; Park, SS; Wilson, GD, 2013) |
| "Addition of temozolomide (TMZ) to radiation therapy is the standard treatment for patients with glioblastoma (GBM)." | 3.79 | Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging. ( Faber, C; Jacobs, AH; Kopka, K; Kuhlmann, M; Schäfers, M; Schelhaas, S; Schwegmann, K; Viel, T; Wachsmuth, L; Wagner, S, 2013) |
| " Such chemoresistance was overcome by apparently noncytotoxic doses of temozolomide, which chemosensitized glioblastoma cells to doxorubicin, vinblastine, and etoposide." | 3.79 | Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway. ( Annovazzi, L; Bosia, A; Caldera, V; Campia, I; Ghigo, D; Kopecka, J; Mellai, M; Riganti, C; Salaroglio, IC; Schiffer, D, 2013) |
| "Radiotherapy with concomitant and adjuvant temozolomide (six cycles) is the standard treatment after surgery in glioblastoma patients." | 3.79 | Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. ( Baumann, C; Beauchesne, P; Blonski, M; Chauffert, B; Darlix, A; Ghiringhelli, F; Lorgis, V; Pinelli, C; Rech, F; Taillandier, L; Zouaoui, S, 2013) |
| "The objective of this work was to determine the cost-effectiveness of temozolomide compared with that of radiotherapy alone in the adjuvant treatment of newly diagnosed glioblastoma." | 3.79 | The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. ( Hay, JW; Messali, A; Villacorta, R, 2013) |
| "Standard treatment for glioblastoma (GBM) is surgery followed by radiation (RT) and temozolomide (TMZ)." | 3.79 | Chemoirradiation for glioblastoma multiforme: the national cancer institute experience. ( Camphausen, K; Fine, HA; Ho, J; Iwamoto, F; Kim, L; Krauze, A; Kreisl, T; McNeil, K; Ning, H; Ondos, J; Shankavaram, U; Smith, S; Sul, J, 2013) |
| "A retrospective analysis was conducted to identify patients (N=117) who received standard oral temozolomide for glioblastoma at our institution from 2003 to 2010." | 3.79 | An automated system for detecting nonadherence in laboratory testing and monitoring for myelosuppression in patients receiving self-administered oral chemotherapy. ( Carter, AF; DeTroye, AT; Harmon, MS; Lesser, GJ; Morrell, RM; Tooze, JA, 2013) |
| "The major cytotoxic DNA adduct induced by temozolomide and other methylating agents used in malignant glioma and metastasized melanoma therapy is O(6)-methylguanine (O(6)-MeG)." | 3.79 | Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide. ( Eich, M; Kaina, B; Nikolova, T; Roos, WP, 2013) |
| " Temozolomide (TMZ) with radiation is the most frequently used first-line treatment for patients with glioblastoma, the most common and aggressive form of primary brain cancer in adults." | 3.79 | Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. ( Espinoza, FL; Gruber, HE; Gunzburg, W; Hlavaty, J; Huang, TT; Ibañez, CE; Jolly, DJ; Kasahara, N; Martin, B; Ostertag, D; Pertschuk, D; Petznek, H; Robbins, JM; Rodriguez-Aguirre, M, 2013) |
| "Temozolomide (TMZ) during and after radiotherapy (RT) is recommended for patients with newly diagnosed glioblastoma (GBM)." | 3.79 | Glioblastoma management in the temozolomide era: have we improved outcome? ( Al-Zahrani, A; Atenafu, E; Laperriere, N; Lwin, Z; MacFadden, D; Mason, WP; Menard, C; Miller, BA; Sahgal, A, 2013) |
| "The effect of concomitant and adjuvant temozolomide in glioblastoma patients above the age of 65 years lacks evidence." | 3.79 | Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients. ( Behm, T; Bock, HC; Horowski, A; Mielke, D; Rohde, V; Schneider, S; Stockhammer, F, 2013) |
| "Although implementation of temozolomide (TMZ) as a part of primary therapy for glioblastoma multiforme (GBM) has resulted in improved patient survival, the disease is still incurable." | 3.79 | Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. ( Broholm, H; Christensen, IJ; Grunnet, K; Kosteljanetz, M; Michaelsen, SR; Poulsen, HS; Stockhausen, MT, 2013) |
| "The goal of the present study was to compare the efficacy of treatment with irradiation (IR), temozolomide, and quercetin, alone, or in combinations, on 2 glioblastoma cell lines, DBTRG-05 and U-251." | 3.79 | Quercetin increases the efficacy of glioblastoma treatment compared to standard chemoradiotherapy by the suppression of PI-3-kinase-Akt pathway. ( Bellyei, S; Boronkai, A; Cseh, A; Hocsak, E; Pozsgai, E; Racz, B; Sumegi, B; Szabo, A, 2013) |
| "In 2005, maximum safe surgical resection, followed by radiotherapy with concomitant temozolomide (TMZ), followed by adjuvant TMZ became the standard of care for glioblastoma (GBM)." | 3.79 | Time trends in glioblastoma multiforme survival: the role of temozolomide. ( Darefsky, AS; Dubrow, R; Jacobs, DI; King, JT; Laurans, MS; Park, LS; Rose, MG, 2013) |
| "Bortezomib induced caspase-3 activation and apoptotic cell death in stable glioma cell lines and in glioma stem-like cells (GSCs) derived from malignant tumor specimens Furthermore, TMZ-resistant glioma cell lines retained susceptibility to the proteasome inhibition." | 3.79 | Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. ( Alexandru, D; Bigner, D; Bota, DA; Friedman, HS; Keir, ST; Vredenburgh, J, 2013) |
| "The aim of the present study was to investigate whether silencing of Hsp27 or Hsp72 expression in glioblastoma multiforme T98G and anaplastic astrocytoma MOGGCCM cells increases their sensitivity to programmed cell death induction upon temozolomide and/or quercetin treatment." | 3.79 | Silencing of Hsp27 and Hsp72 in glioma cells as a tool for programmed cell death induction upon temozolomide and quercetin treatment. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I, 2013) |
| "To examine whether adjuvant temozolomide treatment improved glioblastoma patients` survival in a large Canadian cohort." | 3.79 | Effectiveness of adjuvant temozolomide treatment in patients with glioblastoma. ( Al-Nuaimi, SK; Alnaami, IM; Gourishankar, S; Mehta, V; Murtha, AD; Senthilselvan, A; Walling, S, 2013) |
| "Although there is a relationship between DNA repair deficiency and temozolomide (TMZ) resistance in glioblastoma (GBM), it remains unclear which molecule is associated with GBM recurrence." | 3.79 | Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma. ( Arita, K; Furukawa, T; Hirano, H; Ikeda, R; Kawahara, K; Minami, K; Nishizawa, Y; Shinsato, Y; Tokimura, H; Yamamoto, M; Yonezawa, H; Yunoue, S, 2013) |
| "This study was conducted to investigate the feasibility and survival benefits of combined treatment with radiotherapy and temozolomide (TMZ), which has been covered by the national health insurance in Japanese patients with glioblastoma since September 2006." | 3.79 | Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results. ( Nagaishi, M; Nakano, T; Nakazato, Y; Noda, SE; Oike, T; Shirai, K; Sugawara, K; Suzuki, Y; Tamaki, T; Yokoo, H, 2013) |
| " Human glioblastoma is highly resistant to chemotherapy with temozolomide." | 3.79 | Lobarstin enhances chemosensitivity in human glioblastoma T98G cells. ( Chung, H; Jo, S; Kim, IC; Kim, S; Kim, TU; Lee, H; Yim, JH, 2013) |
| "To analyze initial recurrence patterns in patients with newly diagnosed glioblastoma after radiotherapy plus concurrent and adjuvant temozolomide, and to investigate cumulative recurrence patterns after salvage treatment, including surgery, stereotactic radiotherapy, and chemotherapy." | 3.79 | Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution. ( Arakawa, Y; Hiraoka, M; Miyamoto, S; Mizowaki, T; Ogura, K; Ogura, M; Sakanaka, K, 2013) |
| "A retrospective analysis of overall survival and progression-free survival in patients with newly diagnosed glioblastoma multiforme aged > or = 60 years treated with post-operative radiotherapy with or without temozolomide chemotherapy was conducted at our institutions." | 3.79 | Post-operative management of primary glioblastoma multiforme in patients over 60 years of age. ( Bakó, G; Barzó, P; Bognár, L; Daróczi, B; Hideghéty, K; Mózes, P; Szántó, E; Szántó, J; Tóth, J, 2013) |
| " Here, we report for the first time that the second mitochondria-derived activator of caspases (Smac) mimetic BV6 sensitizes glioblastoma cells toward Temozolomide (TMZ), the first-line chemotherapeutic agent in the treatment of glioblastoma." | 3.79 | Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner. ( Cristofanon, S; Debatin, KM; Deshayes, K; Fulda, S; Karl, S; Marschall, V; Vucic, D; Wagner, L; Zobel, K, 2013) |
| " We retrospectively surveyed 32 patients with GBM or GBM with oligodendroglioma component (GBMO) who underwent biopsy or maximal tumor resection followed by concurrent radiotherapy and temozolomide (TMZ)." | 3.79 | IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy. ( Houkin, K; Kamoshima, Y; Kobayashi, H; Motegi, H; Murata, J; Tanino, M; Terasaka, S; Yamaguchi, S, 2013) |
| " The aim of this study was to evaluate the cellular responses to temozolomide treatment associated with methoxyamine (blocker of base excision repair) in glioblastoma cell lines, in order to test the hypothesis that the blockage of base excision repair pathway might sensitize glioblastoma cells to temozolomide." | 3.79 | Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide. ( Montaldi, AP; Sakamoto-Hojo, ET, 2013) |
| "Clinical studies in patients with newly diagnosed glioblastoma treated with temozolomide have shown that the methylation status of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene is both predictive and prognostic of outcome." | 3.79 | The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients. ( Brewer, J; Hitchins, MP; Kuroiwa-Trzmielina, J; Lu, D; McDonald, KL; Nozue, K; Olivier, J; Rapkins, RW; Tiwari, S; Wheeler, HR; Zhao, L, 2013) |
| "We investigated whether high levels of activated mitogen-activated protein kinase (p-MAPK) were associated with poor survival among patients with newly diagnosed glioblastoma during the temozolomide era." | 3.79 | High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era. ( Bannykh, SI; Black, KL; Carico, C; Dantis, J; Elramsisy, A; Fan, X; Hu, J; Mukherjee, D; Nuño, M; Patil, CG; Yu, JS, 2013) |
| " This study aimed to investigate the possible mechanism of mutant TP53 inducing temozolomide resistance in glioblastoma cells." | 3.79 | Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase. ( Chen, JX; Liu, YH; Mao, Q; Wang, X; You, C, 2013) |
| "To compare survival and hematological toxicity rates between two postoperative therapy regimens in patients with primary glioblastoma (GBM), namely temozolomide (TMZ) concomitant to radiation, followed by adjuvant TMZ, versus adjuvant TMZ after radiation only." | 3.79 | Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis. ( Bock, HC; Brück, W; Giese, A; Gutenberg, A; Reifenberger, G, 2013) |
| " MRSI and CE abnormalities are now integrated for glioblastoma SIB-IMRT, concomitant with temozolomide, in an ongoing multi-institutional phase-III clinical trial." | 3.79 | Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost. ( Berry, I; Cassol, E; Celsis, P; Cohen-Jonathan, EM; Delannes, M; Filleron, T; Franceries, X; Ken, S; Laprie, A; Lotterie, JA; Lubrano, V; Simon, L; Supper, C; Vieillevigne, L, 2013) |
| "We evaluated the predictive value of O6-methylguanine-DNA methyltransferase (MGMT) protein expression and MGMT promoter methylation status in glioblastomas (GBM) treated with temozolomide (TMZ) in a Taiwan medical center." | 3.79 | Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma. ( Chang-Chien, YC; Chen, MH; Guo, WY; Ho, DM; Ho, HL; Hsu, CY; Hsu, SP; Lin, SC; Yen, YS, 2013) |
| "Glioblastoma (GBM), one of the most malignant human neoplasias, responds poorly to current treatment modalities, with temozolomide (TMZ) being the drug most frequently used for its treatment." | 3.79 | Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells. ( Borges, KS; Carlotti, CG; Castro-Gamero, AM; de Oliveira, HF; de Paula Gomes Queiroz, R; Fujinami, MM; Moreno, DA; Scrideli, CA; Suazo, VK; Tone, LG, 2013) |
| "For elderly patients with glioblastoma multiforme (GBM), radiotherapy plus concomitant and adjuvant temozolomide has resulted in longer survival." | 3.79 | Performance status during and after radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme. ( Jang, WY; Jeong, EH; Jung, S; Jung, TY; Kim, IY; Lee, JH; Moon, KS, 2013) |
| "The goal of this study was to investigate whether the amount of hypointense signal on susceptibility-weighted imaging within the contrast-enhancing lesion (%SWI-h) on the pretreatment scan could determine response in patients with newly diagnosed glioblastoma multiforme who received external beam radiation therapy with concomitant anti-angiogenic therapy (enzastaurin) and cytotoxic chemotherapy (temozolomide)." | 3.79 | Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme. ( Butowski, N; Cha, S; Chang, SM; Essock-Burns, E; Lupo, JM; Molinaro, AM; Nelson, SJ, 2013) |
| "To evaluate pathologically confirmed incidence of pseudoprogression and its impact on survival in glioblastoma multiforme (GBM) patients treated with radiotherapy and concurrent temozolomide (TMZ), followed by 6 months of TMZ maintenance therapy." | 3.78 | Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide. ( Oymak, E; Parlak, C; Pehlivan, B; Topkan, E; Topuk, S, 2012) |
| "We report retrospective data on the feasibility and efficacy of prolonging adjuvant temozolomide (TMZ) more than 6 months after chemoradiotherapy completion in patients with glioblastoma (GBM)." | 3.78 | Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. ( Auberdiac, P; Cartier, L; Chargari, C; Forest, F; Fotso, MJ; Magné, N; Malkoun, N; Nuti, C; Pacaut, C; Peoc'h, M; Schmitt, T; Thorin, J, 2012) |
| " Temozolomide (TMZ) is a promising chemotherapeutic agent for treating glioblastomas." | 3.78 | MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. ( Feng, K; Fu, Z; Shi, L; Wan, Y; Wang, Y; Wang, Z; Wu, F; Yan, W; You, Y; Zhang, J; Zhang, S, 2012) |
| "The standard-of-care treatment for newly diagnosed glioblastoma changed in 2005, when radiation therapy plus temozolomide chemotherapy replaced radiation therapy alone." | 3.78 | Glioblastoma survival in the United States before and during the temozolomide era. ( Johnson, DR; O'Neill, BP, 2012) |
| "To determine the maximum-tolerated dose (MTD) of radiation (RT) with concurrent temozolomide in patients with newly diagnosed glioblastoma (GBM), to estimate their progression-free (PFS) and overall survival (OS), and to assess the role of (11)C methionine PET (MET-PET) imaging in predicting recurrence." | 3.78 | Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. ( Brown, D; Cao, Y; Chenevert, T; Gomez-Hassan, D; Heth, J; Junck, L; Lawrence, T; Normolle, D; Piert, M; Schipper, M; Ten Haken, RK; Tsien, CI, 2012) |
| "Although both the alkylating agent temozolomide (TMZ) and oncolytic viruses hold promise for treating glioblastoma, which remains uniformly lethal, the effectiveness of combining the two treatments and the mechanism of their interaction on cancer stem cells are unknown." | 3.78 | Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. ( Hirose, Y; Kanai, R; Louis, DN; Martuza, RL; Rabkin, SD; Sgubin, D; Wakimoto, H; Yip, S; Zaupa, CM, 2012) |
| "Two glioblastoma multiforme patients underwent (18)F-FMISO (fluoromisonidazole) positron emission tomography study to access the tumor oxygenation status before and immediately after fractionated radiotherapy concomitant with temozolomide chemotherapy." | 3.78 | Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: changes defined by 18F-fluoromisonidazole positron emission tomography: two case reports. ( Aoyama, H; Hirata, K; Houkin, K; Kobayashi, H; Murata, J; Narita, T; Onodera, S; Shiga, T; Tanaka, S; Terasaka, S, 2012) |
| "We prospectively analyzed 65 patients suffering from glioblastoma (GBM) who underwent radiotherapy with concomitant adjuvant temozolomide." | 3.78 | Volumetric and MGMT parameters in glioblastoma patients: survival analysis. ( Chatzisotiriou, A; Eleftheraki, AG; Fountzilas, G; Iliadis, G; Kotoula, V; Lambaki, S; Misailidou, D; Selviaridis, P; Televantou, D, 2012) |
| "Standard treatment for glioblastoma multiforme (GBM) changed in 2005 when addition of temozolomide (TMZ) to maximal surgical resection followed by radiation therapy (RT) was shown to prolong survival in a clinical trial." | 3.78 | Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006. ( Abrams, J; Harlan, L; Mann, B; Yabroff, KR; Zeruto, C, 2012) |
| "We report progressive necrotizing fungal cellulitis and myositis in the leg of a patient with glioblastoma multiforme treated with temozolomide and corticosteroids." | 3.78 | Invasive Mycoleptodiscus fungal cellulitis and myositis. ( Hofstra, DE; Koo, S; Marty, FM; Shearer, JF; Sigler, L; Sutton, DA; Thompson, EH; Wickes, BL; Yeh, WW, 2012) |
| "To illustrate this, we report the case of a 60-year-old male patient confronted with an inoperable glioblastoma multiforme on the splenium of the corpus callosum, of poor prognosis, treated by concomitant radiochemotherapy with temozolomide, who developed psychotic depression with Cotard's syndrome." | 3.78 | Cotard's syndrome with glioblastoma multiforme. ( Comet, B; Le Rhun, E; Ramirez, C; Reich, M, 2012) |
| "The standard of care for newly diagnosed glioblastoma multiforme (GBM) is temozolomide (TMZ) chemotherapy given concurrently with radiation for 6 weeks followed by 6 months of adjuvant TMZ." | 3.78 | Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. ( Easaw, JC; Roldán Urgoiti, GB; Singh, AD, 2012) |
| "Alkylating agents, such as temozolomide (TMZ) and fotemustine (FTM) are widely used in recurrent glioblastoma (GBM) regimes." | 3.78 | Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma. ( Burattini, L; Cascinu, S; Onofri, A; Paccapelo, A; Santoni, M, 2012) |
| "Hypermethylation in the promoter region of the MGMT gene encoding the DNA repair protein O(6)-methylguanine-DNA methyltransferase is among the most important prognostic factors for patients with glioblastoma and predicts response to treatment with alkylating agents like temozolomide." | 3.78 | Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. ( Benner, A; Christians, A; Hartmann, C; Meyer, J; von Deimling, A; Weiler, M; Weller, M; Wick, W, 2012) |
| "Temozolomide is an oral alkylating agent with clinical activity against glioblastoma multiforme (GM)." | 3.78 | Temozolomide-associated bronchiolitis obliterans organizing pneumonia successfully treated with high-dose corticosteroid. ( Ban, HJ; Chi, SY; Kang, HW; Kim, KS; Kim, TO; Kim, YC; Kim, YI; Kwon, YS; Lim, SC; Oh, IJ, 2012) |
| "Cox regressions for survival with 314,635 inherited autosomal single-nucleotide polymorphisms (SNP) among 315 San Francisco Adult Glioma Study patients for discovery and three independent validation data sets [87 Mayo Clinic, 232 glioma patients recruited from several medical centers in Southeastern United States (GliomaSE), and 115 The Cancer Genome Atlas patients] were used to identify SNPs associated with overall survival for Caucasian glioblastoma patients treated with the current standard of care, resection, radiation, and temozolomide (total n = 749)." | 3.78 | SSBP2 variants are associated with survival in glioblastoma patients. ( Berger, MS; Brem, S; Browning, JE; Buckner, JC; Chang, SM; Decker, PA; Egan, KM; Fridley, BL; Hansen, HM; Jenkins, RB; Kosel, ML; Lachance, DH; Madden, MH; McCoy, LS; Nabors, LB; O'Neill, BP; Olson, JJ; Patoka, JS; Prados, MD; Rice, T; Smirnov, I; Thompson, RC; Tihan, T; Wiemels, JL; Wiencke, JK; Wrensch, MR; Xiao, Y, 2012) |
| "The aim of this research was to evaluate the economic outcomes of radiotherapy (RT), temozolomide (TMZ) and nitrosourea (NT) strategies for glioblastoma patients with different prognostic factors." | 3.78 | Subgroup economic analysis for glioblastoma in a health resource-limited setting. ( Bai, Y; Chen, H; Miao, Y; Qiu, Y; Shen, J; Wu, B; Xu, Y; Ye, M, 2012) |
| " The present study was to investigate the impact of resveratrol on the antitumor effects of temozolomide (TMZ), a standard treatment regiment of glioblastoma (GBM), in vitro and in vivo." | 3.78 | Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway. ( Guo, RB; Hu, G; Sun, XL; Xue, X; Yuan, Y, 2012) |
| "Interferon-beta (IFN-β) is reported to augment anti-tumor effects by temozolomide in glioblastoma via down-regulation of MGMT." | 3.78 | Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma. ( Hara, K; Kageji, T; Kitazato, KT; Kuwayama, K; Matsuzaki, K; Mizobuchi, Y; Morigaki, R; Mure, H; Nagahiro, S; Okazaki, T, 2012) |
| "The effectiveness of temozolomide (TMZ) dosing schemes and the "rechallenge" of recurrent glioblastoma (GBM) with TMZ are controversial." | 3.78 | Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines. ( Beier, CP; Beier, D; Brawanski, K; Hau, P; Schriefer, B; Schulz, JB; Weis, J, 2012) |
| "Temozolomide (TMZ) is an alkylating chemotherapeutic agent that prolongs the survival of patients with glioblastoma." | 3.78 | Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. ( Florea, AM; Happold, C; Reifenberger, G; Roth, P; Schmidt, N; Silginer, M; Weller, M; Wick, W, 2012) |
| "Genome-wide microRNA (miRNA) profiling of 82 glioblastomas demonstrated that miR-181d was inversely associated with patient overall survival after correcting for age, Karnofsky performance status, extent of resection, and temozolomide (TMZ) treatment." | 3.78 | miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. ( Chen, CC; Hoadley, K; Jiang, C; Jiang, T; Kang, C; Kushwaha, D; Li, S; Ramakrishnan, V; Song, SW; You, Y; Zhang, J; Zhang, W, 2012) |
| "To assess the role of comorbidity on outcome in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant Temozolomide, patients over 65 years with glioblastoma, who underwent surgical resection or biopsy and radiochemotherapy, were evaluated." | 3.78 | Comorbidity assessment and adjuvant radiochemotherapy in elderly affected by glioblastoma. ( Caivano, R; Chiumento, C; Clemente, S; Cozzolino, M; Fiorentino, A; Fusco, V; Pedicini, P, 2012) |
| " In this study, we show that high expression of the α5 integrin subunit compromises temozolomide-induced tumor suppressor p53 activity in human glioblastoma cells." | 3.78 | Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma. ( Bossert, C; Chastagner, P; Dontenwill, M; Entz-Werle, N; Godet, J; Guenot, D; Guerin, E; Janouskova, H; Leger, DY; Lehmann-Che, J; Maglott, A; Martin, S; Noulet, F; Pinel, S; Plenat, F; Teisinger, J, 2012) |
| "Chemotherapy with 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) and temozolomide (TMZ) is commonly used for the treatment of glioblastoma multiforme (GBM) and other cancers." | 3.78 | In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model. ( Beard, BC; Gori, JL; Ironside, C; Karponi, G; Kiem, HP, 2012) |
| "Radiotherapy plus concomitant and adjuvant temozolomide (RCAT) is now standard treatment for grade IV glioblastoma (GBM)." | 3.78 | Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival. ( Hargreaves, S; Kooner, I; Liu, ZW; Menashy, R; Michalarea, V; Williams, M; Wilson, E; Woolf, D, 2012) |
| "The combination of hyperbaric oxygen with temozolomide produced an important reduction in glioma growth and effective approach to the treatment of glioblastoma." | 3.78 | Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model. ( Bilir, A; Bozkurt, ER; Dagıstan, Y; Karaca, I; Ozar, E; Toklu, A; Yagmurlu, K, 2012) |
| "The therapeutic benefit of temozolomide in glioblastoma multiforme (GBM) is limited by resistance." | 3.78 | Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. ( Carlson, BL; Cen, L; Decker, PA; Gupta, SK; Kitange, GJ; Lomberk, GA; Mladek, AC; Pokorny, JL; Sarkaria, JN; Schroeder, MA; Urrutia, RA; Wu, W, 2012) |
| "Firstly, the anti-proliferative activity of OLE and the nature of the interaction with temozolomide (TMZ) of OLE were tested in human glioblastoma cell line T98G cells by trypan blue and WST-1 assays and than realized miRNA PCR array analysis." | 3.78 | Olea europaea leaf extract alters microRNA expression in human glioblastoma cells. ( Ak, S; Bilir, A; Cecener, G; Egeli, U; Malyer, H; Tezcan, G; Tumen, G; Tunca, B, 2012) |
| " In the present study, temozolomide (TMZ) triggered loss of K(+)(i) and Cl(-)(i) and AVD in primary glioblastoma multiforme (GBM) cancer cells (GC) and GC cancer stem cells (GSC)." | 3.78 | Inhibition of Na(+)-K(+)-2Cl(-) cotransporter isoform 1 accelerates temozolomide-mediated apoptosis in glioblastoma cancer cells. ( Algharabil, J; Begum, G; Clark, PA; Kahle, KT; Kintner, DB; Kuo, JS; Lin, SH; Sun, D; Wang, Q; Yang, SS, 2012) |
| "Temozolomide (TMZ) is standard chemotherapy for glioblastoma multiforme (GBM)." | 3.78 | Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide. ( Fung, CF; Lee, D; Lee, NP; Leung, GK; Lui, WM; Pu, JK; Sun, S; Wong, ST, 2012) |
| "Outcomes for patients with glioblastoma have improved with the addition of temozolomide (TMZ) chemotherapy to radiation therapy followed by adjuvant TMZ for up to 1 year." | 3.78 | Helping patients make the best decision regarding duration of temozolomide chemotherapy treatment. ( Groves, MD; Plummer, AB, 2012) |
| "The effect of temozolomide (TMZ) and radiotherapy (RT) in the treatment of glioblastoma multiforme (GBM) has been well documented in randomized controlled trials." | 3.78 | A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. ( Helseth, E; Johannesen, TB; Meling, TR; Rønning, PA, 2012) |
| "Temozolomide (TMZ) is the primary chemotherapeutic agent for treatment of glioblastoma multiforme (GBM) yet it has a fast rate of degradation under physiological conditions to the 'active' MTIC, which has poor penetration of the blood-brain barrier and cellular absorption." | 3.78 | Enhanced stability and activity of temozolomide in primary glioblastoma multiforme cells with cucurbit[n]uril. ( Appel, EA; Heywood, RM; Loh, XJ; Rowland, MJ; Scherman, OA; Watts, C, 2012) |
| "We have investigated on the potentiation of etoposide (ETP) and temozolomide (TMZ) cytotoxicity in U-87MG glioblastoma and D283 medulloblastoma cell lines by curcumin (CUR) and turmeric force (TF), a nutraceutical formulation of turmeric, with the objective of assessing the potential for their adjuvant use in brain tumor chemotherapy." | 3.78 | Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force™ in brain tumor cell lines. ( Escalon, E; Melnick, SJ; Nair, SM; Ramachandran, C, 2012) |
| " Concurrent temozolomide (TMZ) improves survival in non-elderly patients with glioblastoma treated with standard schedule of 60 Gy in 30 fractions." | 3.78 | Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status. ( Beal, K; Chan, TA; Gutin, PH; Lassman, AB; Reyngold, M; Yamada, Y, 2012) |
| "To test the effect of starvation on glioma cells in vitro, we treated primary mouse glia, murine GL26, rat C6 and human U251, LN229 and A172 glioma cells with Temozolomide in ad lib and STS mimicking conditions." | 3.78 | Fasting enhances the response of glioma to chemo- and radiotherapy. ( Brandhorst, S; Chen, TC; Conti, PS; Hwang, S; Lee, C; Longo, VD; Safdie, F; Wang, W; Wei, M, 2012) |
| "Treatment of patients with glioblastoma improved dramatically when concomitant and adjuvant temozolomide was added to external radiation therapy." | 3.78 | A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma. ( Bergqvist, M; Bergström, S; Blomquist, E; Ekman, S; Henriksson, R; Johansson, F, 2012) |
| "To identify genes that contribute to chemotherapy resistance in glioblastoma, we conducted a synthetic lethal screen in a chemotherapy-resistant glioblastoma-derived cell line with the clinical alkylator temozolomide (TMZ) and an siRNA library tailored toward "druggable" targets." | 3.78 | Alkylation sensitivity screens reveal a conserved cross-species functionome. ( Begley, TJ; Braganza, A; Brown, AR; Dyavaiah, M; Lazo, JS; Li, J; Maniar, S; McDonald, PR; Pollack, IF; Shun, TY; Sobol, RW; St Croix, CM; Svilar, D; Tang, JB; Wang, XH, 2012) |
| "Implementation of chemotherapy with the drug temozolomide increased the overall survival of patients with glioblastoma multiforme (GBM; WHO grade IV), in particular when the O(6)-methylguanine DNA methyltransferase (MGMT) promoter is epigenetically silenced." | 3.78 | Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma. ( Beier, CP; Bettstetter, M; Gempt, J; Hoepner, I; Koeritzer, J; Meyer, B; Rasper, M; Ringel, F; Schäfer, A; Schlegel, J; Schmidt-Graf, F; Teufel, J, 2012) |
| "To investigate the new mechanism of temozolomide (TMZ) induced anti-tumor effects on glioblastoma cells in vitro." | 3.78 | [Mechanism of temozolomide-induced anti-tumor effects on glioblastoma cells in vitro is via ROS-dependent SIRT1 signaling pathway]. ( Jiang, Y; Sun, Y; Yuan, Y, 2012) |
| "We analyzed 62 consecutive patients with newly diagnosed glioblastoma treated between 2006 and 2008 with standard fractionation to a total dose of 60 Gy with concurrent temozolomide (97%) or arsenic trioxide (3%)." | 3.77 | Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. ( Crocker, IR; Curran, WJ; McDonald, MW; Shu, HK, 2011) |
| "The identification and consideration of these factors associated with prolonged functional outcome (preoperative KPS score ≥ 90, seizures, primary glioblastoma, gross-total resection, temozolomide) and decreased functional outcome (older age, coronary artery disease, new postoperative motor deficit) may help guide treatment strategies aimed at improving QOL for patients with glioblastoma." | 3.77 | Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article. ( Brem, H; Chaichana, KL; Halthore, AN; Olivi, A; Parker, SL; Quinones-Hinojosa, A; Weingart, JD, 2011) |
| "To evaluate the safety and efficacy of hypofractionated radiotherapy (RT) with a standard temozolomide (TMZ) regimen for adults with newly diagnosed glioblastoma multiforme (GBM), twenty-six consecutive adults (range 39-79 years) who met our enrollment criteria received short courses of hypofractionated RT (45 Gy in 15 fractions over three weeks) with concomitant TMZ at 75 mg/m(2)/d." | 3.77 | A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme. ( Eto, T; Nakashima, S; Ogo, E; Okada, Y; Shigemori, M; Sugita, Y; Terasaki, M; Tokutomi, T, 2011) |
| " A 56-year-old man with a left parietal glioblastoma was treated with resection, radiation and concomitant and adjuvant temozolomide chemotherapy." | 3.77 | Kitten-transmitted Bordetella bronchiseptica infection in a patient receiving temozolomide for glioblastoma. ( Grommes, C; Papanicolaou, G; Redelman-Sidi, G, 2011) |
| "Temozolomide in combination with radiation has been in use for more than 5 years for the therapy of glioblastoma." | 3.77 | Hepatic encephalopathy after treatment with temozolomide. ( Goldbecker, A; Herrmann, J; Raab, P; Tryc, AB; Weissenborn, K; Worthmann, H, 2011) |
| "Patients with non-resectable glioblastoma generally exhibit a poor prognosis, even after radiotherapy plus concomitant and adjuvant temozolomide (XRT/TMZ→TMZ)." | 3.77 | Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide. ( Belka, C; Eigenbrod, S; Grasbon-Frodl, EM; Kreth, FW; Kreth, S; Kretzschmar, HA; Lutz, J; Popperl, G; Thon, N; Tonn, JC, 2011) |
| "The aim of this paper is to evaluate the efficacy of fractionated stereotactic radiotherapy (FSRT) and concomitant temozolomide (TMZ) as a salvage treatment option in patients with recurrent glioblastoma (GBM)." | 3.77 | Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. ( Armosini, V; Caporello, P; Lanzetta, G; Maurizi, RE; Mei, M; Minniti, G; Osti, MF; Salvati, M, 2011) |
| " Using this approach, we have been able to monitor caspase-3 activation and subsequent apoptosis induction after camptothecin and temozolomide treatment on xenograft mouse models of colon cancer and glioblastoma, respectively." | 3.77 | In vivo imaging of early stage apoptosis by measuring real-time caspase-3/7 activation. ( Cappella, P; Pesenti, E; Rizzitano, S; Scabini, M; Stellari, F; Texido, G, 2011) |
| "The alkylating agent temozolomide, in combination with surgery and radiation, is the current standard of care for patients with glioblastoma." | 3.77 | Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. ( Chen, TC; Golden, EB; Hofman, FM; Louie, SG; Schönthal, AH; Sivakumar, W; Thomas, S; Wang, W, 2011) |
| "Concomitant radiation therapy (RT) and temozolomide (TMZ) therapy after surgery is the standard treatment for glioblastoma multiforme (GBM)." | 3.77 | Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. ( Côté, AL; Ernstoff, MS; Fadul, CE; Fisher, JL; Gui, J; Hampton, TH, 2011) |
| "We investigated the molecular mechanisms underlying the cytotoxic effect of Temozolomide (TMZ) in both O(6)-methylguanine-DNA methyl transferase (MGMT) depleted as well as undepleted glioblastoma cell lines." | 3.77 | Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells. ( Brunetti, E; Bucci, B; D'agnano, I; De Paula, U; De Salvo, M; Gagliassi, R; Marchese, R; Maresca, G; Raza, GH; Stigliano, A, 2011) |
| "Epigenetic silencing of the O(6) -methylguanine-DNA methyltransferase (MGMT) gene promoter is associated with prolonged survival in glioblastoma patients treated with temozolomide (TMZ)." | 3.77 | Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. ( Eigenbrod, S; Felsberg, J; Hentschel, B; Kreth, FW; Löffler, M; Pietsch, T; Reifenberger, G; Sabel, MC; Schackert, G; Thon, N; Tonn, JC; Weller, M; Westphal, M, 2011) |
| "Temozolomide has significantly improved the outcome of patients with glioblastoma." | 3.77 | [Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma]. ( Auberdiac, P; Cartier, L; Chargari, C; Forest, F; Fotso, MJ; Magné, N; Malkoun, N; Nuti, C; Pacaut, C; Peoc'h, M; Schmitt, T; Thorin, J, 2011) |
| "Temozolomide (TMZ), an alkylating agent widely used for patients with glioblastoma multiforme (GBM), has the potential to enhance the acquired immune response to GBM." | 3.77 | Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - . ( Enomoto, T; Ishikawa, E; Matsumura, A; Morishita, Y; Nakai, K; Ohno, T; Sakamoto, N; Sato, M; Satomi, K; Takano, S; Tsuboi, K; Yamamoto, T, 2011) |
| "Nimustine (ACNU) and temozolomide (TMZ) are DNA alkylating agents which are commonly used in chemotherapy for glioblastomas." | 3.77 | FANCD1/BRCA2 plays predominant role in the repair of DNA damage induced by ACNU or TMZ. ( Hasegawa, M; Helleday, T; Kinashi, Y; Kondo, N; Masunaga, S; Mori, E; Noda, T; Ohnishi, T; Ono, K; Suzuki, M; Takahashi, A; Thompson, LH; Zdzienicka, MZ, 2011) |
| "To report pancytopenia caused by temozolomide, a second-generation alkylating agent." | 3.77 | Another cause of pancytopenia in a patient receiving temozolomide. ( Camci, C; Dirier, A; Kalender, ME; Pehlivan, Y; Sevinc, A; Turkbeyler, IH, 2011) |
| "5 years, ranging from 25-82 years, 19 female and 29 male) with histologically proven glioblastoma received surgery (16 biopsies, 18 partial and 14 complete resections) and postoperative chemo-irradiation with concomitant and adjuvant temozolomide." | 3.77 | Overall survival and extent of surgery in adult versus elderly glioblastoma patients: A population based retrospective study. ( Cejna, M; DeVries, A; Eiter, H; Maier, R; Muxel, B; Muxel, M; Roessler, K; Zachenhofer, I, 2011) |
| "To demonstrate the feasibility of using DNP hyperpolarized [1-(13)C]-pyruvate to measure early response to temozolomide (TMZ) therapy using an orthotopic human glioblastoma xenograft model." | 3.77 | Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging. ( Bok, R; James, CD; Nelson, SJ; Ozawa, T; Park, I; Phillips, JJ; Ronen, SM; Vigneron, DB, 2011) |
| "It is controversial if distant recurrence of glioblastoma is more common after temozolomide (TMZ) concurrent with radiotherapy (RT)." | 3.77 | Glioblastoma: patterns of recurrence and efficacy of salvage treatments. ( Aviv, R; Davey, P; Lam, K; Oh, J; Perry, JR; Sahgal, A; Sanghera, P; Symons, S; Tsao, MN, 2011) |
| "Here we investigate the effects of the novel transforming growth factor-β receptor I (TGF-βRI) serine/threonine kinase inhibitor LY2109761 on glioblastoma when combined with the present clinical standard combination regimen radiotherapy and temozolomide (TMZ)." | 3.77 | Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761. ( Han, N; Hauser, K; Herion, TW; Huber, PE; Lahn, M; Peschke, P; Timke, C; Weber, KJ; Wirkner, U; Zhang, M, 2011) |
| "Promoter methylation of the O⁶-methylguanine-DNA-methyltransferase (MGMT) gene is widely recognized as an important predictive factor in the treatment of glioblastoma (GBM) patients with temozolomide." | 3.77 | MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA. ( Cho, BK; Kim, SK; Lee, JY; Park, CK; Park, SH; Wang, KC, 2011) |
| "The goal of this study was to evaluate accelerated radiotherapy with and without temozolomide (TMZ) for glioblastoma multiforme (GBM)." | 3.77 | Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme. ( Buttmann, M; Flentje, M; Guckenberger, M; Mayer, M; Sweeney, RA; Vince, GH, 2011) |
| "A group of 160 patients with primary glioblastoma treated with radiotherapy and temozolomide was analyzed for the impact of O6-methly-guanly-methyl-transferase (MGMT)-promoter methylation as well as isocitrate dehydrogenase (IDH)1-mutational status." | 3.77 | Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back? ( Abdollahi, A; Combs, SE; Debus, J; Hartmann, C; Rieken, S; von Deimling, A; Wick, W, 2011) |
| " Treatment of glioblastoma multiforme (GBM) with temozolomide (TMZ), its current standard of care, is problematic because the tumor generally recurs and is then resistant to this drug." | 3.77 | Noscapine inhibits tumor growth in TMZ-resistant gliomas. ( Chen, TC; Cho, H; Hofman, FM; Jhaveri, N; Louie, SG; Petasis, NA; Schönthal, AH; Torres, S; Wang, W, 2011) |
| "Overcoming the resistance of glioblastoma cells against temozolomide, the first-line chemotherapeutic agent of choice for newly diagnosed glioblastoma, is a major therapeutic challenge in the management of this deadly brain tumor." | 3.77 | MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis. ( Kayama, T; Kitanaka, C; Matsuda, K; Sato, A; Seino, S; Sunayama, J; Suzuki, K; Tachibana, K; Tomiyama, A; Watanabe, E, 2011) |
| "Our results highlight involvement of miRNAs in the induction of apoptosis in glioma cells by fatty acids and temozolomide." | 3.77 | MicroRNA profile of polyunsaturated fatty acid treated glioma cells reveal apoptosis-specific expression changes. ( Das, UN; Faragó, N; Fehér, LZ; Kitajka, K; Puskás, LG, 2011) |
| " There was particular interest in RTOG 0525, a Phase III study of newly diagnosed glioblastoma treated with different schedules of temozolomide." | 3.77 | American Society of Clinical Oncology 2011 CNS tumors update. ( Ahluwalia, MS, 2011) |
| "A 61-year-old man with glioblastoma and positive for hepatitis B surface antigen (HBsAg) developed acute hepatitis due to hepatitis B virus (HBV) reactivation after concomitant postoperative treatment with temozolomide (75 mg/m(2)/day) and radiation therapy (60 Gy in 30 fractions)." | 3.77 | Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide--case report. ( Kayama, T; Miyakita, Y; Narita, Y; Ohno, M; Shibui, S; Ueno, H, 2011) |
| "The objective of this retrospective analysis was to assess long-term outcome and prognostic factors of unselected patients treated for glioblastoma (GB) at a single center with surgery, standard radiotherapy (RT), and concomitant temozolomide (TMZ)." | 3.77 | Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution. ( Franz, K; Gerstein, J; Rödel, C; Seifert, V; Steinbach, JP; Weiss, C, 2011) |
| "To identify different cell death modalities using U87 glioblastoma cell line after radio-chemotherapy treatments by analyzing the expression of HSP70 after γ-ray irradiation and temozolomide treatment." | 3.77 | Cell death forms and HSP70 expression in U87 cells after ionizing radiation and/or chemotherapy. ( Corbella, F; Di Liberto, R; Facoetti, A; Mazzini, G; Nano, R; Paolini, A; Pasi, F, 2011) |
| "A 62-year female received radiotherapy over six weeks with daily 75 mg/m2 Temozolomide (TMZ) for Glioblastoma (GB)." | 3.77 | Temozolomide induced liver injury. ( Afzal, P; Campbell, AP; Dixit, S; Hingorani, M, 2011) |
| "To evaluate the incidence and impact of early post-chemoradiation (cRT) 'pseudoprogression' (PsPD) amongst glioblastoma multiforme (GBM) patients treated with the current standard of care - 60 Gy conformal radiotherapy with concurrent low-dose temozolomide, followed by six cycles of high-dose temozolomide (the 'Stupp protocol')." | 3.77 | Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis. ( Gunjur, A; Lau, E; Ryan, G; Taouk, Y, 2011) |
| "The aim of this study was to evaluate cognitive functioning in newly-diagnosed glioblastoma multiforme (GBM) patients during treatment with radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ)." | 3.76 | Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings. ( Bosma, I; Buter, J; Heimans, JJ; Hilverda, K; Klein, M; Peter Vandertop, W; Postma, TJ; Reijneveld, JC; Slotman, BJ, 2010) |
| "Concomitant daily temozolomide and radiation followed by adjuvant temozolomide is a tolerable and reasonable treatment option and has a good performance status for elderly patients diagnosed with glioblastoma." | 3.76 | Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme? ( Collichio, F; Ewend, MG; Grabowski, S; Kimple, RJ; Morris, DE; Papez, M, 2010) |
| "We present two patients with glioblastoma with an unusually stable clinical course and long-term survival who were treated after surgery and radiotherapy with adjuvant temozolomide (TMZ) chemotherapy for 17 and 20 cycles, respectively." | 3.76 | Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. ( Backes, H; Brunn, A; Burghaus, L; Galldiks, N; Heiss, WD; Jacobs, AH; Kracht, LW; Ullrich, RT, 2010) |
| "O(6)-Methylguanine DNA methyltransferase (MGMT) is implicated as a major predictive factor for treatment response to alkylating agents including temozolomide (TMZ) of glioblastoma multiforme (GBM) patients." | 3.76 | O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. ( Berger, W; Buchroithner, J; Filipits, M; Fischer, J; Lötsch, D; Micksche, M; Pichler, J; Pirker, C; Silye, R; Spiegl-Kreinecker, S; Weis, S, 2010) |
| "Epigenetic silencing of the MGMT gene by promoter methylation is associated with loss of MGMT expression, diminished DNA-repair activity and longer overall survival in patients with glioblastoma who, in addition to radiotherapy, received alkylating chemotherapy with carmustine or temozolomide." | 3.76 | Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference. ( Brandes, A; de Biase, D; Ermani, M; Franceschi, E; Marucci, G; Morandi, L; Pession, A; Tallini, G; Tosoni, A, 2010) |
| "Pseudoprogression (psPD) is now recognised following radiotherapy with concurrent temozolomide (RT/TMZ) for glioblastoma multiforme (GBM)." | 3.76 | Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. ( Aviv, R; Davey, P; Lam, K; Morrison, M; Perry, J; Sahgal, A; Sanghera, P; Symons, S; Tsao, MN, 2010) |
| "One hundred and fourteen patients with glioblastoma multiforme received a median of 6 cycles of adjuvant first-line temozolomide (range 1-57)." | 3.76 | Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution. ( Freyschlag, CF; Krafft, U; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F, 2010) |
| "To determine recurrence patterns of glioblastoma treated with temozolomide-based chemoradiation." | 3.76 | Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. ( Donatello, RS; Korones, DN; Milano, MT; Mohile, NA; Okunieff, P; Sul, J; Walter, KA, 2010) |
| "Treatment for glioblastoma multiforme includes the alkylating agent temozolomide combined with ionizing radiation." | 3.76 | Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. ( Bradshaw, TD; Laughton, CA; Madhusudan, S; Stevens, MF; Zhang, J, 2010) |
| "Novel agents are currently combined with radiation and temozolomide (RT + TMZ) in newly diagnosed glioblastoma using overall survival as the primary end point." | 3.76 | Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. ( Desideri, S; Fisher, J; Grossman, SA; Nabors, LB; Piantadosi, S; Rosenfeld, M; Ye, X, 2010) |
| "Glioblastoma patients have a poor prognosis, even after surgery, radiotherapy, and chemotherapy with temozolomide or 1,3-bis(2-chloroethy)-1-nitrosourea." | 3.76 | Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres. ( Cochran, BH; Daou, MC; Gilbert, CA; Li, L; Mihaliak, AM; Moser, RP; Reeves, A; Ross, AH, 2010) |
| "The current standard of care for patients with Glioblastoma multiforme (GBM) is surgery, followed by radiation in combination with Temozolomide (TMZ), followed by adjuvant TMZ." | 3.76 | Tonsillar pseudotumor: complications of chronically-administered temozolomide. ( Grisdale, K; Groves, MD; Hunter, K; Ritterhouse, M; Williams, MD, 2010) |
| "To identify microRNAs (miRNAs) specifically involved in the acquisition of temozolomide (TMZ) resistance in glioblastoma multiforme (GBM), we first established a resistant variant, U251R cells from TMZ-sensitive GBM cell line, U251MG." | 3.76 | miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. ( Hayashi, K; Kamada, K; Matsuo, T; Matsuse, M; Mitsutake, N; Nagata, I; Saenko, V; Suzuki, K; Takakura, S; Ujifuku, K; Yamashita, S, 2010) |
| "Concurrent treatment with the methylating agent temozolomide during radiotherapy has yielded the first significant improvement in the survival of adult glioblastomas (GBM) in the last three decades." | 3.76 | Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression. ( Blank, A; Bobola, MS; Kolstoe, DD; Silber, JR, 2010) |
| "The purpose of this study was to evaluate diffusion parameters at pre-, mid-, and post-radiation therapy (RT) in contrast-enhancing and nonenhancing lesions of postsurgical glioblastoma multiforme patients treated with the standard of care RT concurrently with temozolomide (TMZ) followed by adjuvant TMZ and an antiangiogenic drug." | 3.76 | Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme. ( Butowski, NA; Cha, S; Chang, SM; Elkhaled, A; Jalbert, L; Khayal, IS; Nelson, SJ; Polley, MY, 2010) |
| "To evaluate perfusion parameter changes in patients with glioblastoma multiforme by comparing the perfusion magnetic resonance (MR) imaging measurements obtained before combined radiation and temozolomide therapy (RT-TMZ) with the follow-up MR imaging measurements obtained 1 month after completion of this treatment." | 3.76 | Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. ( Ekholm, SE; Korones, DN; Mangla, R; Milano, MT; Singh, G; Zhong, J; Ziegelitz, D, 2010) |
| "Temozolomide, an oral alkylating agent, is a commonly used medicine in the treatment of anaplastic astrocytoma and glioblastoma multiforme." | 3.76 | Temozolomide (Temodar). ( Mukherji, SK; Rajdev, P; Wesolowski, JR, 2010) |
| "O(6)-methylguanine-DNA methyltransferase (MGMT) expression in glioblastoma correlates with temozolomide resistance." | 3.76 | Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival. ( Donze, J; Liu, L; McGraw, M; Palomo, JM; Rahmathulla, G; Robinson, CG; Vogelbaum, MA, 2010) |
| " We have compiled the treatment experience of seven neurosurgical centers using implantation of carmustine wafers at primary surgery followed by 6 weeks of radiation therapy (59-60 Gy) and 75 mg/m(2)/day TMZ in patients with newly diagnosed glioblastoma followed by TMZ monochemotherapy." | 3.76 | First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. ( Bock, HC; Buchalla, R; Giese, A; Kantelhardt, SR; Ketter, R; Koll, S; Lohmann, F; Puchner, MJ; Rainov, N; Rohde, V; Schütze, M, 2010) |
| "Standard treatment of glioblastoma multiforme consists of postoperative radiochemotherapy with temozolomide, followed by a 6-month chemotherapy." | 3.76 | Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide. ( Kopecký, J; Kopecký, O; Macingova, Z; Petera, J; Priester, P; Slovácek, L, 2010) |
| "We report a case of prolonged survival in a patient with cervical intramedullary glioblastoma multiforme (GBM) treated with total resection, radiotherapy, and temozolomide." | 3.76 | Prolonged survival of a patient with cervical intramedullary glioblastoma multiforme treated with total resection, radiation therapy, and temozolomide. ( Huang, CY; Kuo, LT; Lien, HC; Liu, KL; Liu, MT; Tseng, HM, 2010) |
| "The addition of temozolomide (TMZ) to radiotherapy (RT) improves survival of patients with glioblastoma (GB) when compared to postoperative RT alone in patients up to 65 years of age." | 3.76 | Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. ( Franz, K; Fraunholz, I; Gerstein, J; Rödel, C; Seifert, V; Steinbach, JP; Weiss, C, 2010) |
| "To analyze the recurrence patterns in patients with newly diagnosed glioblastoma (GBM) treated with conformal radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ), and to compare the patterns of failure according to different target volume delineations." | 3.76 | Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. ( Amelio, D; Amichetti, M; Arcella, A; Bozzao, A; Enrici, RM; Lanzetta, G; Minniti, G; Muni, R; Salvati, M; Scarpino, S, 2010) |
| "Methylating drugs such as temozolomide (TMZ) are widely used in the treatment of brain tumors including malignant glioblastoma." | 3.76 | Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. ( Jin, YH; Liu, HY; Shu, F; Wang, QJ; Wang, Z; Yang, Y; Zhang, WB, 2010) |
| "The case of a 63 year old woman with glioblastoma multiforme and concomitant radiochemotherapy with temozolomide is described." | 3.76 | Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report. ( Bartels, C; Brueggemann, I; Elolf, E; Gademann, G; Galazky, I; Prox-Vagedes, V; Schreiber, S, 2010) |
| "Sensitivity to temozolomide is restricted to a subset of glioblastoma patients, with the major determinant of resistance being a lack of promoter methylation of the gene encoding the repair protein DNA methyltransferase MGMT, although other mechanisms are thought to be active." | 3.76 | MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. ( Bax, DA; Gaspar, N; Hargrave, D; Jones, C; Little, SE; Marshall, L; Pearson, AD; Perryman, L; Reis, RM; Sharp, SY; Vassal, G; Viana-Pereira, M; Workman, P, 2010) |
| " This case report documents an adolescent harboring brain stem glioblastoma who had complete radiological response to temozolomide after partial tumor resection and survived for more than 3 years." | 3.76 | Temozolomide for adult brain stem glioblastoma: case report of a long-term survivor. ( Chen, Z; Mao, Y; Wang, Y; Wu, J; Yao, Y; Zhang, C; Zhou, L, 2010) |
| "Concurrent temozolomide (TMZ) and radiotherapy became the new standard of care for patients diagnosed with glioblastoma multiforme (GBM)." | 3.76 | Pseudoprogression following concurrent temozolomide and radiotherapy in a patient with glioblastoma: findings on functional imaging techniques. ( Abe, K; Amano, T; Hiwatashi, A; Honda, H; Kamano, H; Nakamizo, A; Shioyama, Y; Shirakawa, Y; Suzuki, S; Torisu, R; Yamashita, K; Yoshimoto, K; Yoshiura, T, 2010) |
| "Some patients with glioblastoma multiform do not respond to temozolomide even though they have aberrant promoter methylation of the DNA repair enzyme O(6)-methylguanine methyltransferase (MGMT)." | 3.75 | A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. ( Dill, C; Ehninger, G; Illmer, T; Kestel, L; Kramer, M; Krex, D; Pfirrmann, M; Robel, K; Schackert, G; Schaich, M, 2009) |
| "Temozolomide (TMZ)-based therapy is the standard of care for patients with glioblastoma multiforme (GBM), and resistance to this drug in GBM is modulated by the DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT)." | 3.75 | Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. ( Carlson, BL; Decker, PA; Grogan, PT; James, CD; Kitange, GJ; Lamont, JD; Sarkaria, JN; Schroeder, MA; Wu, W, 2009) |
| "CpG methylation within the O6-methylguanine-DNA-methyltransferase (MGMT) promoter is associated with enhanced survival of glioblastoma multiforme (GBM) patients treated with temozolomide (TMZ)." | 3.75 | Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. ( Ballman, KV; Buckner, JC; Carlson, BL; Decker, PA; Giannini, C; Grogan, PT; James, CD; Kitange, GJ; Mladek, AC; Sarkaria, JN; Schroeder, MA; Wu, W, 2009) |
| " In this study, we investigated whether, intravenously administered, ATP-sensitive potassium channel (K(ATP)) activator (minoxidil sulfate; MS) increases temozolomide and Herceptin delivery to brain tumors to induce anti-tumor activity and increase survival in nude mice with Glioblastoma multiforme (GBM) cells." | 3.75 | Activation of KATP channels increases anticancer drug delivery to brain tumors and survival. ( Khaitan, D; Meister, EA; Ningaraj, NS; Sankpal, UT; Vats, T, 2009) |
| "We report a case of a 51-year-old woman with newly diagnosed glioblastoma multiforme (GBM) who was treated with surgery followed by the standard concomitant temozolomide (TMZ) and radiotherapy (RT)." | 3.75 | Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status. ( Fujioka, Y; Homori, M; Kurita, H; Miyazaki, H; Nagane, M; Nozue, K; Shimizu, S; Shiokawa, Y; Waha, A, 2009) |
| "Gliadel (BCNU) wafer and concomitant temozolomide (TMZ) therapy, when used individually as adjuvant therapies, extend survival from that achieved by resection and radiation therapy (XRT) for glioblastoma multiforme (GBM)." | 3.75 | Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. ( Attenello, FJ; Brem, H; Chaichana, KL; Grossman, SA; Kleinberg, LR; Laterra, J; McGirt, MJ; Olivi, A; Quiñones-Hinojosa, A; Than, KD; Weingart, JD, 2009) |
| "Early radionecrosis after the Stupp protocol is not a rare event due to the radiosensitization effect of temozolomide." | 3.75 | Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? ( Del Basso De Caro, ML; Elefante, A; Giamundo, A; Maiuri, F; Mariniello, G; Pacelli, R; Peca, C; Vergara, P, 2009) |
| "Temozolomide, used for anaplastic gliomas and glioblastoma multiforme, is an oral drug that is stable under acidic, but labile under neutral and basic conditions." | 3.75 | Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery. ( Beumer, JH; Egorin, MJ; Park, DM; Shah, DD, 2009) |
| " Moreover, enhanced growth delay with the addition of E7016 to temozolomide and radiotherapy in a glioma mouse model suggests a potential role for this drug in the treatment of glioblastoma multiforme." | 3.75 | In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. ( Beam, K; Burgan, WE; Camphausen, K; Carter, D; Chakravarti, A; Kwon, HC; Russo, AL; Slusher, BS; Tofilon, PJ; Weizheng, X; Zhang, J, 2009) |
| "Resistance to temozolomide and radiotherapy is a major problem for patients with glioblastoma but may be overcome using the poly(ADP-ribose) polymerase inhibitor ABT-888." | 3.75 | Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. ( Carlson, BL; Clarke, MJ; Curtin, NJ; Decker, PA; Grogan, PT; Lou, Z; Mladek, AC; Mulligan, EA; Plummer, ER; Sarkaria, JN; Schroeder, MA; Wu, W, 2009) |
| "The aim of the present study was to evaluate factors predicting the recurrence pattern after the administration of temozolomide (TMZ), initially concurrent with radiotherapy (RT) and subsequently as maintenance therapy, which has become standard treatment for patients with newly diagnosed glioblastoma (GBM)." | 3.75 | Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. ( Amistà, P; Brandes, AA; Ermani, M; Franceschi, E; Frezza, G; Morandi, L; Sotti, G; Spagnolli, F; Tosoni, A, 2009) |
| "To evaluate long-term survival in a prospective series of patients newly diagnosed with glioblastoma and treated with a combination of lomustine (CCNU), temozolomide (TMZ), and radiotherapy." | 3.75 | Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. ( Bähr, O; Glas, M; Happold, C; Herrlinger, U; Kortmann, RD; Reifenberger, G; Rieger, J; Steinbach, JP; Weller, M; Wick, W; Wiewrodt, D, 2009) |
| "Recently, there has been greater awareness that combination radiation and temozolomide used to treat glioblastomas may cause increased contrast enhancement on the first post radiation MRI scan." | 3.75 | Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. ( Gerstner, ER; Lafrankie, D; McNamara, MB; Norden, AD; Wen, PY, 2009) |
| "To investigate the cytotoxic effect of high linear-energy transfer (LET) carbon irradiation on glioblastoma cells lines in combination with temozolomide (TMZ)." | 3.75 | Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines. ( Bohl, J; Combs, SE; Debus, J; Elsasser, T; Schulz-Ertner, D; Weber, KJ; Weyrather, WK, 2009) |
| "Temozolomide (TMZ) is an alkylating agent used in the management of gliomas." | 3.75 | Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? ( Bell, D; Khasraw, M; Wheeler, H, 2009) |
| " Using multiparameter cytometry we explored effects of etoposide and temozolomide (TMZ) on three glioblastoma cell lines with different p53 status (A172, T98G, YKG-1) and on normal human astrocytes (NHA) correlating the drug-induced phosphorylated H2AX (gammaH2AX) with cell cycle phase and induction of apoptosis." | 3.75 | Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide. ( Darzynkiewicz, Z; Kurose, A; Ogasawara, K; Ogawa, A; Sato, Y; Sawai, T; Traganos, F, 2009) |
| "We evaluated the benefit of preradiation chemotherapy with ACNU (nimustine) and CDDP (cisplatin) in patients with newly diagnosed glioblastoma by retrospective analysis." | 3.75 | Preradiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: a retrospective analysis. ( Han, JH; Heo, DS; Jung, HW; Kim, CY; Kim, DG; Kim, DW; Kim, IH; Lee, SH; Paek, SH; Park, CK, 2009) |
| "A 46-year-old man developed Stevens-Johnson syndrome and toxic epidermal necrolysis overlap, with severe localized denudation of the skin on the head and neck, following radiotherapy and oral temozolomide therapy for cranial glioblastoma multiforme." | 3.75 | Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy. ( Sarma, N, 2009) |
| "A recent randomized study conducted on newly diagnosed glioblastoma (GBM) patients demonstrated that concomitant and adjuvant temozolomide added to standard radiotherapy had a survival advantage compared with radiotherapy alone." | 3.75 | Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. ( Agati, R; Bacci, A; Benevento, F; Brandes, AA; Calbucci, F; Ermani, M; Franceschi, E; Mazzocchi, V; Scopece, L; Tosoni, A, 2009) |
| "To perform a systematic review on the costs and cost-effectiveness of concomitant and adjuvant temozolomide with radiotherapy for the treatment of newly diagnosed glioblastoma compared with initial radiotherapy alone." | 3.75 | Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. ( Stupp, R; Uyl-de Groot, CA; van der Bent, M, 2009) |
| "Temozolomide (TMZ) is an oral alkylating agent with significant activity against glioblastoma multiforme (GBM) and melanoma." | 3.75 | Non-Hodgkin lymphoma following temozolomide. ( Das, P; Dwary, A; Goyal, S; Gupta, D; Mohanti, BK; Muzumder, S; Sharma, A; Thulkar, S, 2009) |
| " This study aimed to determine the resistant phenotype of glioblastoma stem cells (GSCs) to temozolomide (TMZ) and to explore the possible molecular mechanisms underlying TMZ resistance." | 3.75 | Glioblastoma stem cells resistant to temozolomide-induced autophagy. ( Chen, FR; Chen, ZP; Fu, J; Liu, XM; Liu, ZG; Ng, HK; Pangjesse, CS; Shi, HL, 2009) |
| "Over the past few years, the alkylating agent temozolomide has become the standard-of-care therapy for patients with glioblastoma, the most common brain tumor." | 3.75 | MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. ( Aldape, K; Cahill, DP; Iafrate, AJ; Louis, DN; Miao, J; Nutt, CL; Yip, S, 2009) |
| " Current standard therapy in the treatment of glioblastoma multiforme (GBM) is a combination of surgery, radiation, and chemotherapy using the drug temozolomide (TMZ)." | 3.75 | A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. ( Bektas, M; Bigner, DD; Friedman, HS; Johnson, SP; Poe, WE, 2009) |
| "A 65-year-old female patient with glioblastoma multiforme (GBM) developed aplastic anemia following treatment with temozolomide." | 3.75 | A rare case of aplastic anemia caused by temozolomide. ( Eichinger, JB; George, BJ; Richard, TJ, 2009) |
| "Concurrent temozolomide (TMZ) and radiation therapy (RT) followed by adjuvant TMZ is standard treatment for patients with glioblastoma multiforme (GBM), although the relative contribution of concurrent versus adjuvant TMZ is unknown." | 3.75 | Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. ( Ballman, KA; Carlson, BL; Decker, PA; Giannini, C; Grogan, PT; James, CD; Kitange, GJ; Mladek, AC; Sarkaria, JN; Schroeder, MA; Wu, W, 2009) |
| "Eighty-three patients with glioblastoma underwent surgery followed by radiotherapy and temozolomide chemotherapy between October 2000 and June 2008." | 3.75 | The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. ( Cao, VT; Chae, HJ; Jin, SG; Jung, S; Jung, TY; Kang, SS; Kim, IY; Lee, KH; Moon, KS; Park, CS, 2009) |
| "Despite aggressive therapy comprising radical radiation and temozolomide (TMZ) chemotherapy, the prognosis for patients with glioblastoma multiforme (GBM) remains poor, particularly if tumors express O(6)-methylguanine-DNA-methyltransferase (MGMT)." | 3.75 | Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. ( Chalmers, AJ; Lovegrove, N; Martindale, C; Ruff, EM; Short, SC, 2009) |
| "Although high AGT levels may mediate resistance in a portion of these samples, MMR deficiency does not seem to be responsible for mediating temozolomide resistance in adult malignant glioma." | 3.74 | Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. ( Ali-Osman, F; Bigner, DD; Friedman, AH; Friedman, HS; Horne, KS; Johnson, SP; Lister, DW; Maxwell, JA; McLendon, RE; Modrich, PL; Quinn, JA; Rasheed, A, 2008) |
| " Convection-enhanced delivery (CED) of either the replication-defective, ICP0-producing HSV-1 mutant, d106, or the recombinant d109, devoid of all viral genome expression, was performed to determine the in vivo efficacy of ICP0 in combination with ionizing radiation (IR) or systemic temozolomide (TMZ) in the treatment of glioblastoma multiforme (GBM)." | 3.74 | Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery. ( Deluca, NA; Fellows-Mayle, W; Hadjipanayis, CG, 2008) |
| "Temozolomide is an alkylating agent approved for treatment of glioblastoma in association with radiotherapy." | 3.74 | [Alveolo-interstitial pneumonia due to Temozolamide]. ( Autret-Leca, E; Beau Salinas, F; Carré, P; de Luca, K; Diot, P; Guilleminault, L; Narciso, B, 2008) |
| "In this study, we investigated the precursor and active forms of a p53 small-molecule inhibitor for their effects on temozolomide (TMZ) antitumor activity against glioblastoma (GBM), using both in vitro and in vivo experimental approaches." | 3.74 | p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. ( Berger, MS; Dinca, EB; Haas-Kogan, DA; James, CD; Lu, KV; Pieper, RO; Prados, MD; Sarkaria, JN; Vandenberg, SR, 2008) |
| "Glioblastoma patients undergoing treatment with surgery followed by radiation and temozolomide chemotherapy often develop a state of immunosuppression and are at risk for opportunistic infections and reactivation of hepatitis and herpes viruses." | 3.74 | Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. ( Hoorens, A; Neyns, B; Stupp, R, 2008) |
| " This epigenetic modification has been associated with a favorable prognosis in adult patients with glioblastoma (GBM) who receive temozolomide and other alkylating agents." | 3.74 | MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. ( Addo-Yobo, SO; Donson, AM; Foreman, NK; Gore, L; Handler, MH, 2007) |
| "Two patients, a 58-year-old man and a 55-year-old woman, both under treatment for glioblastoma multiforme, were admitted with fever and neutropenia a few weeks after starting to take the oncolytic agent temozolomide." | 3.74 | [Temozolomide, an oral chemotherapeutic agent with potential severe toxicity]. ( Gijtenbeek, JM; Kappelle, AC; Soetekouw, PM; van der Maazen, RW; van Herpen, CM, 2007) |
| "Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival." | 3.74 | Fatal outcome related to carmustine implants in glioblastoma multiforme. ( Barcia, JA; Barcia-Mariño, C; Gallego, JM, 2007) |
| "Glioblastomas are treated by surgical resection followed by radiotherapy [X-ray therapy (XRT)] and the alkylating chemotherapeutic agent temozolomide." | 3.74 | Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. ( Batchelor, TT; Betensky, RA; Cahill, DP; Codd, PJ; Curry, WT; Futreal, PA; Iafrate, AJ; Levine, KK; Louis, DN; Reavie, LB; Romany, CA; Stratton, MR, 2007) |
| "We report the case of a 30-year-old woman with glioblastoma multiforme (GBM) treated with surgery followed by concomitant Temozolomide (TMZ) and external beam radiation, which she tolerated well without any interruptions." | 3.74 | Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide. ( Gujral, S; Jalali, R; Menon, H; Singh, P, 2007) |
| "The majority of glioblastoma multiforme (GBM) cells express the epidermal growth factor receptor (EGFR)." | 3.74 | In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. ( Combs, SE; Debus, J; Herold-Mende, C; Roth, W; Schulz-Ertner, D; Weber, KJ, 2007) |
| "The use of adjuvant temozolomide (TMZ) in patients managed with surgery and adjuvant radiation therapy (RT) for glioblastoma multiforme (GBM) has been demonstrated to improve median and 2-year survival in a recent large international multicentre study." | 3.74 | Improved median survival for glioblastoma multiforme following introduction of adjuvant temozolomide chemotherapy. ( Ang, EL; Back, MF; Chan, SP; Lim, CC; Ng, WH; See, SJ; Yeo, TT, 2007) |
| "Temozolomide is an oral alkylating agent recently approved for the treatment of glioblastoma multiforme." | 3.74 | Temozolomide-associated organizing pneumonitis. ( Aubrey, MC; Lim, KG; Limper, AH; Maldonado, F, 2007) |
| " The potential therapeutic value of MGMT hypermethylation evaluation using MS-MLPA was shown in a group of 20 glioblastoma patients receiving temozolomide chemotherapy." | 3.74 | MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. ( Boots-Sprenger, SH; Cornelissen, SJ; Dekkers, MM; Errami, A; Jeuken, JW; Sijben, A; Vriezen, M; Wesseling, P, 2007) |
| "To investigate the radiosensitizing potential of temozolomide (TMZ) for human glioblastoma multiforme (GBM) cell lines using single-dose and fractionated gamma-irradiation." | 3.74 | Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. ( Hulsebos, TJ; Lafleur, MV; Leenstra, S; Slotman, BJ; Sminia, P; Stalpers, LJ; van den Berg, J; van Nifterik, KA, 2007) |
| "To evaluate efficacy and toxicity in elderly patients with glioblastoma multiforme (GBM) treated with postoperative radiochemotherapy with temozolomide (TMZ)." | 3.74 | Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. ( Bischof, M; Combs, SE; Debus, J; Schulz-Ertner, D; Wagner, F; Wagner, J; Welzel, T, 2008) |
| "Methylation of the promoter region of the O ( 6 ) -methylguanine-DNA methyltransferase (MGMT) gene is known to be predictive of response to temozolomide treatment in patients with glioblastoma." | 3.74 | Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. ( Biggs, MT; Clarkson, A; Cook, RJ; Little, NS; McDonald, KL; McKenzie, CA; Messina, M; Parkinson, JF; Robinson, BG; Wheeler, HR, 2008) |
| "The purpose of this study was to report our experience with concomitant and adjuvant temozolomide (TMZ) with radiotherapy in patients with newly diagnosed glioblastoma multiforme (GBM)." | 3.74 | Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience. ( Basu, A; Goel, A; Gupta, T; Jalali, R; Menon, H; Munshi, A; Sarin, R, 2007) |
| " Temozolomide is an effective chemotherapeutic agent for patients with glioblastoma multiforme, but it induces significant lymphopenia." | 3.74 | Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. ( Aldape, K; Archer, GE; Bigner, DD; Crutcher, L; Dey, M; Gilbert, M; Hassenbusch, SJ; Heimberger, AB; Hussain, SF; Mitchell, DA; Sampson, JH; Sawaya, R; Schmittling, B; Sun, W, 2008) |
| "Temozolomide (TMZ) is active against newly diagnosed glioblastoma (GBM), and O(6)-methylguanine-DNA methyltransferase (MGMT) is implicated in resistance to TMZ and nitrosoureas." | 3.74 | Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide. ( Kobayashi, K; Nagane, M; Ohnishi, A; Shimizu, S; Shiokawa, Y, 2007) |
| "Temozolomide (TMZ), given concurrently with radiotherapy (RT) and as adjuvant monotherapy afterwards, has led to improved survival in glioblastoma multiforme (GBM)." | 3.74 | The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. ( Avutu, B; Barker, FG; Batchelor, TT; Chakravarti, A; Henson, JW; Hochberg, FH; Loeffler, JS; Martuza, RL; Sher, DJ, 2008) |
| "32 patients 70 years of age or older with a newly diagnosed glioblastoma and a Karnofsky performance status (KPS) > or = 70 were treated with RT (daily fractions of 2 Gy for a total of 60 Gy) plus temozolomide at the dose of 75 mg/m(2) per day followed by six cycles of adjuvant temozolomide (150-200 mg/m(2) for 5 days during each 28-day cycle)." | 3.74 | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. ( Bozzao, A; De Paula, U; De Sanctis, V; Filippone, F; Lanzetta, G; Maurizi Enrici, R; Minniti, G; Muni, R; Osti, MF; Tombolini, V; Valeriani, M, 2008) |
| "The oral alkylating agent, temozolomide (Temodal: TMZ), is the only anticancer drug that has been shown in a phase III study to improve survival in glioblastoma (GBM) when administered with concomitant radiotherapy." | 3.74 | [Temozolomide: Temodal]. ( Nakamura, O; Saito, K; Shinoura, N; Tabei, Y; Takahashi, M; Yamada, R, 2008) |
| "Standard therapy for glioblastoma (GBM) is temozolomide (TMZ) administration, initially concurrent with radiotherapy (RT), and subsequently as maintenance therapy." | 3.74 | MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. ( Andreoli, A; Bartolini, S; Bertorelle, R; Blatt, V; Brandes, AA; Calbucci, F; Ermani, M; Franceschi, E; Frezza, G; Leonardi, M; Pession, A; Spagnolli, F; Tallini, G; Tosoni, A, 2008) |
| "Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit." | 3.73 | MGMT gene silencing and benefit from temozolomide in glioblastoma. ( Bromberg, JE; Cairncross, JG; de Tribolet, N; Diserens, AC; Gorlia, T; Hainfellner, JA; Hamou, MF; Hau, P; Hegi, ME; Janzer, RC; Kros, JM; Mariani, L; Mason, W; Mirimanoff, RO; Stupp, R; Weller, M, 2005) |
| "The aim of this study was to evaluate the efficacy and safety of carmustine (BCNU) in combination with temozolomide as first-line chemotherapy before and after radiotherapy (RT) in patients with inoperable, newly diagnosed glioblastoma multiforme (GBM)." | 3.73 | Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. ( Barrié, M; Braguer, D; Chinot, O; Couprie, C; Dufour, H; Figarella-Branger, D; Grisoli, F; Hoang-Xuan, K; Martin, PM; Muracciole, X; Peragut, JC, 2005) |
| "Cimetidine added to temozolomide compared with temozolomide alone induced survival benefits in nude mice with U373 human glioblastoma multiforme (GBM) cells orthotopically xenografted in the brain." | 3.73 | Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts. ( Brotchi, J; Camby, I; Darro, F; Gabius, J; Gaussin, JF; James, S; Kiss, R; Lefranc, F, 2005) |
| "There are new scientific data concerning the treatment of patients with glioblastoma multiforme with concomitant and adjuvant temozolomide following surgery and radiotherapy." | 3.73 | [Temozolomide in patients with a glioblastoma multiforme: new developments]. ( Bromberg, JE; Postma, TJ, 2005) |
| "Temozolomide (TMZ) is an oral alkylating agent with demonstrated efficacy as therapy for glioblastoma multiforme (GBM) and anaplastic astrocytoma." | 3.73 | Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme. ( Hallinen, T; Kivioja, A; Martikainen, JA; Vihinen, P, 2005) |
| "To develop a valid treatment strategy for recurrent high-grade gliomas using stereotactic hypofractionated reirradiation based on biologic imaging and temozolomide." | 3.73 | Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. ( Franz, M; Grosu, AL; Gumprecht, H; Molls, M; Nieder, C; Piert, M; Schwaiger, M; Stärk, S; Thamm, R; Weber, WA, 2005) |
| " Treatment of glioblastoma multiforme by temozolomide is considered as a paradigm." | 3.73 | Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo. ( Antipas, VP; Stamatakos, GS; Uzunoglu, NK, 2006) |
| " Here, we report administration of celecoxib rather than dexamethasone to prevent brain edema in a patient with a cerebellar glioblastoma multiforme WHO grade IV (GBM) upon the patient's request, as well as determining cerebrospinal fluid (CSF) and serum concentrations." | 3.73 | Avoiding glucocorticoid administration in a neurooncological case. ( Bernays, RL; Gutteck-Amsler, U; Hofer, S; Meier, UR; Meier-Abt, PJ; Peghini, PE; Rentsch, K; Rutz, HP, 2005) |
| "Human glioblastoma cells (U87, T98, and U373) and U87 cells transfected with the gene for the DNA repair enzyme O6-methylguanine DNA methyltransferase (MGMT) were treated with G207 and/or temozolomide." | 3.73 | Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. ( Aghi, M; Martuza, RL; Rabkin, S, 2006) |
| "This is a report of a 53 year-old man with a glioblastoma multiforme (GBM) treated with an excessive dose of temozolomide (TMZ)." | 3.73 | Complications of a temozolomide overdose: a case report. ( Kiem, HP; Partap, S; Peterson, RA; Schuetze, S; Silber, JR; Spence, AM, 2006) |
| "Severe temozolomide-induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma." | 3.73 | Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide. ( Bally, F; Christen, G; de Ribaupierre, S; Ganière, V; Guillou, L; Pica, A; Stupp, R, 2006) |
| " These studies evaluated the antitumor efficacy of CEP-7055 using orthotopic models of glioblastoma and colon carcinoma in combination with temozolomide, and irinotecan and oxaliplatin, respectively, for their effects on primary and metastatic tumor burden and median survival." | 3.73 | The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. ( Hunter, K; Jones-Bolin, S; Klein-Szanto, A; Ruggeri, B; Zhao, H, 2006) |
| "In this study, we investigated the mechanisms by which temozolomide enhances radiation response in glioblastoma cells." | 3.73 | Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. ( Aldape, K; Black, PM; Chakravarti, A; Erkkinen, MG; Gilbert, MR; Loeffler, JS; Mehta, M; Nestler, U; Stupp, R, 2006) |
| " The special case of glioblastoma multiforme treated by temozolomide is addressed as a simulation paradigm." | 3.73 | A spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in vivo: the paradigm of glioblastoma multiforme treated by temozolomide. ( Antipas, VP; Stamatakos, GS; Uzunoglu, NK, 2006) |
| "To assess whether the survival of patients with recurrent malignant glioma receiving temozolomide in everyday practice is comparable to that reported in previous studies." | 3.72 | Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study. ( Maltoni, S; Messori, A; Pelagotti, F; Trippoli, S; Vacca, F; Vaiani, M, 2003) |
| "Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity in recent clinical trials against high grade gliomas, metastatic melanoma, and brain lymphoma." | 3.72 | Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. ( D'Amati, G; Graziani, G; Kalish, V; Leonetti, C; Portarena, I; Scarsella, M; Tentori, L; Vergati, M; Xu, W; Zhang, J; Zupi, G, 2003) |
| "To analyze the effect of different therapies -surgery, radiotherapy, and chemotherapy (temozolomide)- on the survival of various groups of patients with glioblastoma multiforme (GBM)." | 3.72 | [Survival analysis following the addition of temozolomide to surgery and radiotherapy in patients with glioblastoma multiforme]. ( Benítez, E; Gil-Salú, JL; López-Escobar, M; Maestro, E; Pérez-Requena, J; Román, P, 2004) |
| "The phase III randomised European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trail Group (NCIC) Intergroup trial (EORTC 26981/22981; CE3) compares irradiation alone with irradiation plus temozolomide for patients with glioblastoma multiforme (GBM)." | 3.72 | Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review. ( Ataman, F; Fisher, B; Mirimanoff, RO; Poortmans, P; Stupp, R, 2004) |
| "Temozolomide is an oral alkylating agent shown to have modest efficacy in the treatment of glioblastoma multiforme." | 3.72 | Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma. ( Gillespie, GY; Kufe, DW; Weichselbaum, RR; Yamini, B; Yu, X, 2004) |
| "Temozolomide (TZM) is a novel methylating agent currently under investigation for treatment of recurrent high-grade gliomas." | 3.71 | Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. ( Graziani, G; Navarra, P; Portarena, I; Scerrati, M; Tentori, L; Torino, F, 2002) |
| "The activity of temozolomide combined with irinotecan (CPT-11) was evaluated against eight independent xenografts (four neuroblastomas, three rhabdomyosarcomas, and one glioblastoma)." | 3.70 | Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. ( Brent, TP; Cheshire, PJ; Friedman, HS; Houghton, PJ; Kirstein, MN; Poquette, CA; Richmond, LB; Stewart, CF; Tan, M, 2000) |
| "The in vitro cytotoxicity of 8-carbamoyl-3-methylimidazo [5,1-d]-1,2,3,5-tetrazine-4(3H)-one (temozolomide) with concurrent X-irradiation was examined in a human glioblastoma cell line (U373MG) as a potential radio-chemotherapeutic treatment for malignant glioma." | 3.69 | In vitro evaluation of temozolomide combined with X-irradiation. ( Glaser, MG; Marcus, K; Newlands, ES; Porteous, JK; Wedge, SR, 1997) |
| "Glioblastoma is the most common and most aggressive type of primary brain tumor." | 3.30 | Granulocyte-macrophage colony stimulating factor enhances efficacy of nimustine rendezvousing with temozolomide plus irradiation in patients with glioblastoma. ( Bu, XY; Cheng, X; Kong, LF; Luo, JC; Qu, MQ; Wang, YW; Yan, ZY; Yang, DY; Zhao, YW, 2023) |
| "Glioblastoma is the most lethal primary brain cancer." | 3.30 | Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. ( Abram, S; Aiken, RD; Ansstas, G; Ashkan, K; Avigan, DE; Baskin, DS; Battiste, JD; Bosch, ML; Bota, DA; Boynton, AL; Brem, S; Brenner, AJ; Campian, JL; Chaudhary, R; Cobbs, CS; D'Andre, S; Dunbar, EM; Elinzano, H; Etame, AB; Ewend, MG; Fink, KL; Geoffroy, FJ; Giglio, P; Gligich, O; Goldlust, SA; Grewal, J; Heth, JA; Iwamoto, FM; Kesari, S; Khagi, S; Kim, L; Krex, D; Lacroix, M; Lee, IY; Liau, LM; Lillehei, K; Lindhorst, SM; Loudon, WG; Lovick, DS; Lutzky, J; Martinez, NL; Mathieu, D; May, SA; Meisel, HJ; Mikkelsen, T; Moshel, YA; Mulholland, PJ; Nadji-Ohl, M; Nam, JY; New, PZ; Peak, S; Pearlman, ML; Petrecca, K; Piccioni, DE; Pillainayagam, CP; Pluard, TJ; Portnow, J; Prins, RM; Salacz, ME; Sanchin, L; Schulder, M; Sloan, A; Taylor, LP; Thompson, RC; Toms, SA; Tran, DD; Trusheim, JE; Tse, V; Villano, JL; Wagner, SA; Walbert, T; Walter, KA; Wu, JK, 2023) |
| "Standard treatment of glioblastoma consisting of maximal safe resection, adjuvant radiotherapy and chemotherapy with temozolomide, results in an overall median survival of 14." | 3.11 | Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial. ( Burgess, C; FitzJohn, T; Kaye, AH; O'Rawe, M; Pandey, R; Sim, D; Tan, ST; Wickremesekera, AC; Young, D, 2022) |
| "Glioblastoma is the most frequent and malignant primary brain tumor." | 3.11 | Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial. ( Becker, A; Burger, MC; Clusmann, H; Delev, D; Giordano, FA; Glas, M; Goldbrunner, R; Grauer, O; Güresir, E; Hau, P; Heiland, DH; Herrlinger, U; Krex, D; Nemeth, R; Potthoff, AL; Radbruch, A; Sabel, M; Schaub, C; Schilling, J; Schlegel, U; Schmid, M; Schneider, M; Schnell, O; Schuss, P; Seidel, C; Steinbach, JP; Tabatabai, G; Thon, N; Vatter, H; Weller, J; Winkler, F; Zeyen, T, 2022) |
| "Obesity was associated with shorter survival in patients with MGMT methylated glioblastoma (median OS 22." | 3.11 | Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS. ( Borger, V; Goldbrunner, R; Güresir, E; Hau, P; Herrlinger, U; Krex, D; Pietsch, T; Potthoff, AL; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schneider, M; Seidel, C; Steinbach, JP; Tzaridis, T; Vatter, H; Weller, J; Zeyen, T, 2022) |
| "The most frequently diagnosed primary brain tumor is glioblastoma (GBM)." | 3.11 | A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSCK-010 trial protocol. ( Dai, J; Gong, X; Guan, Y; Han, L; Li, J; Liu, X; Liu, Y; Lu, Q; Mei, G; Pan, L; Pan, M; Wang, E; Wang, X; Wang, Y; Yang, J; Zhu, H, 2022) |
| " Only one possibly treatment-related treatment emergent adverse event (TEAE), Grade 1 gingival swelling, was observed." | 3.01 | Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study. ( Chen, KT; Hsu, PW; Huang, HL; Jung, SM; Ke, YX; Lin, YJ; Toh, CH; Tsai, HC; Tseng, CK; Wei, KC, 2021) |
| " Glioblastoma is the most aggressive and diffusely infiltrative primary brain tumor." | 3.01 | Updates in the Management of Recurrent Glioblastoma Multiforme. ( Ansari, A; Prajapati, HP, 2023) |
| "Malignant primary brain tumors cause more than 15 000 deaths per year in the United States." | 3.01 | Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. ( Mellinghoff, IK; Schaff, LR, 2023) |
| "As the most malignant primary brain tumor in adults, a diagnosis of glioblastoma multiforme (GBM) continues to carry a poor prognosis." | 3.01 | Advanced Bioinformatics Analysis and Genetic Technologies for Targeting Autophagy in Glioblastoma Multiforme. ( Manea, AJ; Ray, SK, 2023) |
| "Temozolomide (TMZ) is a DNA alkylating agent that can cross the blood-brain barrier." | 3.01 | Expert opinion on translational research for advanced glioblastoma treatment. ( Cui, X; Kang, C; Wang, Q; Wang, Y; Zhou, J, 2023) |
| "Glioblastoma Multiforme (GBM) is the primary brain tumor and accounts for 200,000 deaths each year worldwide." | 3.01 | Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme. ( Adusumilli, K; Angirekula, HSR; Chamarthy, S; Mekala, JR, 2023) |
| "Glioblastoma is the most common and lethal brain tumor in adults." | 3.01 | Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment. ( Iturrioz-Rodríguez, N; Matheu, A; Sampron, N, 2023) |
| "Glioblastoma is the most aggressive form of brain tumor originating from glial cells with a maximum life expectancy of 14." | 3.01 | A Comprehensive Review of miRNAs and Their Epigenetic Effects in Glioblastoma. ( Afzal, M; Castresana, JS; Hasan, H; Shahi, MH, 2023) |
| "TMZ is utilized in brain cancer removal, but resistance is a drawback." | 3.01 | Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: Function of non-coding RNAs. ( Ajdari, A; Aref, AR; Etemad, S; Eydivandi, S; Fan, X; Hushmandi, K; Karimi, AS; Khorrami, R; Nabavi, N; Rahmanian, P; Rajabi, R; Rashidi, M; Rezaee, A; Sanadgol, N; Tehrany, PM; Tirabadi, FJ; Zandieh, MA; Zou, R, 2023) |
| "Atorvastatin was not shown to improve PFS-6." | 3.01 | Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II study. ( Aldanan, S; Alghareeb, WA; Alhussain, H; AlNajjar, FH; Alsaeed, E; Alsharm, AA; Altwairgi, AK; Balbaid, AAO; Orz, Y, 2021) |
| " Common adverse events (AEs) were blurred vision (63%), fatigue (38%), and photophobia (35%)." | 2.90 | Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. ( Ansell, PJ; Bain, E; Butowski, N; Gan, HK; Gomez, E; Holen, KD; Kumthekar, P; Lassman, AB; Lee, HJ; Lwin, Z; Maag, D; Merrell, R; Mikkelsen, T; Nabors, LB; Papadopoulos, KP; Penas-Prado, M; Reardon, DA; Roberts-Rapp, L; Scott, AM; Simes, J; van den Bent, MJ; Walbert, T; Wheeler, H; Xiong, H, 2019) |
| " We aimed to describe the development and comparison of 2 population pharmacokinetic modeling approaches." | 2.90 | An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR. ( Bain, E; Friedel, A; Menon, RM; Mensing, S; Mittapalli, RK; Stodtmann, S; Xiong, H, 2019) |
| "Cerebral edema was assessed at 4, 12, 22 and 34 weeks post-surgery, together with steroids consumption and patients' psychological status." | 2.90 | A novel lecithin-based delivery form of Boswellic acids as complementary treatment of radiochemotherapy-induced cerebral edema in patients with glioblastoma multiforme: a longitudinal pilot experience. ( Bertuccioli, A; Botta, L; Bruzzone, MG; Cuccarini, V; Di Pierro, F; Fariselli, L; Lamperti, E; Petruzzi, A; Simonetti, G, 2019) |
| " The aim of this study was to evaluate the efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with temozolomide (TMZ) for the postoperative treatment of GBM." | 2.90 | Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience. ( Chen, G; Chen, L; Li, G; Li, Q; Luo, W; Lv, S; Zhong, L; Zhou, P, 2019) |
| "Lapatinib was administered at 2500 mg twice daily for two consecutive days per week on a weekly basis throughout concomitant and adjuvant standard therapy." | 2.84 | Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. ( Cloughesy, TF; Faiq, N; Green, R; Green, S; Hu, J; Lai, A; Mellinghoff, I; Nghiemphu, PL; Yu, A, 2017) |
| "Apatinib is a novel, oral, small-molecule tyrosine kinase inhibitor that mainly targets vascular endothelial growth factor receptor-2 (VEGFR-2) to inhibit angiogenesis." | 2.82 | Combining apatinib and temozolomide for brainstem glioblastoma: a case report and review of literature. ( Sun, X; Xu, X; Xu, Y; Zhan, W; Zhao, L; Zhu, Y, 2022) |
| " There is insufficient data to make a recommendation about which alternative TMZ dosing provides the best benefits." | 2.82 | Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults. ( Germano, IM; Olson, JJ; Ormond, DR; Wen, P; Ziu, M, 2022) |
| " Although these beneficial effects are promising, the efficacy of natural compounds in glioblastoma is limited due to their bioavailability and blood-brain barrier permeability." | 2.82 | Natural Compounds as Promising Adjuvant Agents in The Treatment of Gliomas. ( Gigli, G; Leporatti, S; Persano, F, 2022) |
| " TMZ is an orally bioavailable prodrug, which is well absorbed from the gastrointestinal tract and is converted to its active alkylating metabolite 5-(3-methyl triazen-1-yl)imidazole-4-carbozamide (MTIC) spontaneously in physiological condition that does not require hepatic involvement." | 2.82 | Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems. ( Alyautdin, R; Chubarev, V; Grigorevskikh, E; Ismail, N; Merkulov, V; Petrenko, D; Smolyarchuk, E; Sologova, S; Syzrantsev, N, 2022) |
| " In addition, OS, PFS and adverse event (AE) data on ndGBM and recurrent GBM (rGBM) were assessed." | 2.82 | Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis. ( Li, H; Ma, W; Qu, T; Wang, Y; Wu, J; Xia, Y; Xing, H; Zhao, B, 2022) |
| "Glioblastoma is the most aggressive form of brain tumor, accounting for the highest mortality and morbidity rates." | 2.82 | Nanomedicine for glioblastoma: Progress and future prospects. ( Baig, MH; Cho, JY; Dong, JJ; Hatiboglu, MA; Imran, MA; Khan, I; Khan, MI; Mahfooz, S, 2022) |
| "Glioblastoma is a fatal brain tumor with a bleak prognosis." | 2.82 | Glioblastoma and Methionine Addiction. ( Sowers, LC; Sowers, ML, 2022) |
| "(1) Background: Glioblastoma is the most frequent and lethal primary tumor of the central nervous system." | 2.82 | Glioblastoma Treatment: State-of-the-Art and Future Perspectives. ( Celis-López, MÁ; Cid-Sánchez, DR; Contreras-Palafox, GA; Flores-Vázquez, JG; Gutiérrez-Aceves, GA; Heredia-Gutiérrez, JC; Hernández-Sánchez, LC; Macías-González, MDS; Moreno-Jiménez, S; Moscardini-Martelli, J; Olmos-Guzmán, A; Ortiz-Arce, CS; Pérez, SR; Rodríguez-Camacho, A; Suárez-Campos, JJE; Torres-Ríos, JA, 2022) |
| "Glioblastoma, the most common malignant primary brain tumor, remains a lethal disease with few therapeutic options." | 2.82 | Immune-checkpoint inhibitors for glioblastoma: what have we learned? ( Omuro, A, 2022) |
| "Therefore, brain cancer research models need to aim to recapitulate glioblastoma stem cell function, whilst remaining amenable for analysis." | 2.82 | Utility of the Cerebral Organoid Glioma 'GLICO' Model for Screening Applications. ( Gray, C; Paterson, E; Peng, L; Tan, ST; Weth, FR, 2022) |
| "Glioblastoma is the most frequently diagnosed type of primary brain tumour in adults." | 2.82 | DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies. ( Collis, SJ; Rominiyi, O, 2022) |
| "Cilengitide was continued for up to 12 months or until disease progression or unacceptable toxicity." | 2.82 | Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. ( Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H, 2016) |
| "Glioblastoma is the most common malignant brain tumor in adults." | 2.82 | Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma. ( Anota, A; Bonnetain, F; Campello, C; Castera, D; Chauffert, B; Chinot, O; Dabakuyo, S; Dalban, C; Ducray, F; Durando, X; Fabbro, M; Feuvret, L; Frappaz, D; Frenay, M; Ghiringhelli, F; Guillamo, JS; Paquette, B; Schott, R; Skrzypski, J; Taillandier, L; Taillia, H; Tennevet, I; Vernerey, D, 2016) |
| "Treatment was bortezomib 1." | 2.82 | A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas. ( Bredel, M; Chandler, JP; Ferrarese, R; Grimm, SA; Helenowski, I; Levy, RM; Muro, K; Paton, M; Rademaker, A; Raizer, JJ; Rosenow, J, 2016) |
| "Retreatment with temozolomide (TMZ) is one treatment option." | 2.80 | Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. ( Ancelet, LR; Bauer, E; Dzhelali, M; Findlay, MP; Gasser, O; Hamilton, DA; Hermans, IF; Hunn, MK; Mester, B; Sharples, KJ; Wood, CE, 2015) |
| "Everolimus (70 mg/wk) was started 1 week prior to radiation and TMZ, followed by adjuvant TMZ, and continued until disease progression." | 2.80 | A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. ( Anderson, SK; Brown, PD; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Ligon, KL; Ma, DJ; McGraw, S; Peller, PJ; Sarkaria, JN; Schiff, D; Uhm, JH, 2015) |
| "The rate of dying after disease progression is about 6." | 2.80 | Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525. ( Curran, W; Dignam, JJ; Gilbert, MR; Mehta, M; Wang, M; Won, M, 2015) |
| "Cilengitide was administered intravenously in combination with daily temozolomide (TMZ) and concomitant radiotherapy (RT; wk 1-6), followed by TMZ maintenance therapy (TMZ/RT→TMZ)." | 2.80 | Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. ( Ashby, L; Depenni, R; Fink, KL; Grujicic, D; Hegi, ME; Hicking, C; Lhermitte, B; Mazurkiewicz, M; Mikkelsen, T; Nabors, LB; Nam, DH; Perry, JR; Picard, M; Reardon, DA; Salacz, M; Tarnawski, R; Zagonel, V, 2015) |
| "Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as a potent radiosensitizer by arresting cells in the most radiosensitive cell cycle phase." | 2.79 | Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. ( Ben Aissa, A; Bodmer, A; Dietrich, PY; Dunkel, N; Espeli, V; Hottinger, AF; Hundsberger, T; Mach, N; Schaller, K; Squiban, D; Vargas, MI; Weber, DC, 2014) |
| "The upfront approach to treatment of glioblastoma in the unresectable population warrants further investigation in randomized controlled phase III trials." | 2.78 | Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. ( Bailey, L; Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; Lipp, ES; Lou, E; Peters, KB; Reardon, DA; Sumrall, AL; Turner, S; Vredenburgh, JJ, 2013) |
| "The results suggest that Cyberknife re-treatments are relatively safe using selected dose/fraction schemes." | 2.77 | Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas. ( Arpa, D; Cardali, S; Conti, A; De Renzis, C; Granata, F; Pontoriero, A; Romanelli, P; Siragusa, C; Tomasello, C; Tomasello, F, 2012) |
| "Seventy-one eligible patients 70 years of age or older with newly diagnosed GBM and a Karnofsky performance status ≥60 were treated with a short course of RT (40 Gy in 15 fractions over 3 weeks) plus TMZ at the dosage of 75 mg/m(2) per day followed by 12 cycles of adjuvant TMZ (150-200 mg/m(2) for 5 days during each 28-day cycle)." | 2.77 | Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. ( Arcella, A; Caporello, P; De Sanctis, V; Enrici, RM; Giangaspero, F; Lanzetta, G; Minniti, G; Salvati, M; Scaringi, C, 2012) |
| " In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy to further enhance its anti-tumor activity." | 2.76 | Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011) |
| "Vatalanib was well tolerated with only 2 DLTs (thrombocytopenia and elevated transaminases)." | 2.76 | Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. ( Batchelor, TT; Doyle, CL; Drappatz, J; Duda, DG; Eichler, AF; Gerstner, ER; Jain, RK; Plotkin, SR; Wen, PY; Xu, L, 2011) |
| " On the basis of promising preclinical data, the safety and tolerability of therapy with the mTOR inhibitor RAD001 in combination with radiation (RT) and temozolomide (TMZ) was evaluated in this Phase I study." | 2.76 | North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. ( Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W, 2011) |
| " The major differences of our protocol from the other past studies were simultaneous use of both sodium borocapate and boronophenylalanine, and combination with fractionated X-ray irradiation." | 2.76 | Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme--study design and current status report. ( Hiramatsu, R; Hirota, Y; Kawabata, S; Kirihata, M; Kuroiwa, T; Maruhashi, A; Miyata, S; Miyatake, S; Ono, K; Sakurai, Y; Takekita, Y, 2011) |
| "Temozolomide has an acceptable tolerance in elderly patients with GBM and KPS less than 70." | 2.76 | Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. ( Barrie, M; Beauchesne, P; Campello, C; Cartalat-Carel, S; Catry-Thomas, I; Chinot, O; Delattre, JY; Ducray, F; Gállego Pérez-Larraya, J; Guillamo, JS; Honnorat, J; Huchet, A; Matta, M; Mokhtari, K; Monjour, A; Taillandier, L; Tanguy, ML, 2011) |
| "Glioblastoma is a highly vascularised tumour with a high expression of both vascular endothelial growth factor (VEGF) and VEGFR." | 2.75 | EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. ( Brandes, AA; Gorlia, T; Hau, P; Kros, JM; Lacombe, D; Mirimanoff, RO; Stupp, R; Tosoni, A; van den Bent, MJ, 2010) |
| "Glioblastomas are notorious for resistance to therapy, which has been attributed to DNA-repair proficiency, a multitude of deregulated molecular pathways, and, more recently, to the particular biologic behavior of tumor stem-like cells." | 2.73 | Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. ( Cairncross, JG; de Tribolet, N; Delorenzi, M; Dietrich, PY; Domany, E; Gorlia, T; Hainfellner, JA; Hamou, MF; Hegi, ME; Heppner, FL; Janzer, RC; Kouwenhoven, MC; Lambiv, WL; Migliavacca, E; Murat, A; Regli, L; Shay, T; Stupp, R; Wick, W; Zimmer, Y, 2008) |
| " PCB was administered as an oral dosage of 450 mg on days 1-2 and a total dose of 300 mg on day 3." | 2.73 | Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. ( Boiardi, A; Botturi, A; Eoli, M; Falcone, C; Filippini, G; Fiumani, A; Gaviani, P; Lamperti, E; Salmaggi, A; Silvani, A, 2008) |
| "Glioblastoma is the most common primary malignant brain tumor that is usually considered fatal even with treatment." | 2.72 | Dissecting the mechanism of temozolomide resistance and its association with the regulatory roles of intracellular reactive oxygen species in glioblastoma. ( Chang, KY; Chien, CH; Chuang, JY; Hsueh, WT, 2021) |
| "GBM is the grade IV glioma brain cancer which is life-threatening to many individuals affected by this cancer." | 2.72 | Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy. ( Shetty, K; Yadav, KS; Yasaswi, PS, 2021) |
| "Decision making at disease progression is critical, and classical T1 and T2 imaging remain the gold standard." | 2.72 | Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. ( Buff, E; Leimgruber, A; Maeder, PP; Meuli, RA; Ostermann, S; Stupp, R; Yeon, EJ, 2006) |
| "Temozolomide is an oral chemotherapeutic agent with efficacy against malignant gliomas and a favorable safety profile." | 2.71 | Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. ( Barrie, M; Braguer, D; Chinot, OL; Dufour, H; Figarella-Branger, D; Frauger, E; Grisoli, F; Hoang-Xuan, K; Martin, PM; Moktari, K; Palmari, J; Peragut, JC, 2004) |
| "The optimal therapy for gliomatosis cerebri is unclear, and the rate of response to chemotherapy is not known." | 2.71 | Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide. ( Gomori, JM; Levin, N; Siegal, T, 2004) |
| "We conducted a study to determine the dose-limiting toxicity of an extended dosing schedule of temozolomide (TMZ) when used with a fixed dose of BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine), taking advantage of TMZ's ability to deplete O6-alkylguanine-DNA-alkyltransferase and the synergistic activity of these two agents." | 2.71 | Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. ( Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ, 2004) |
| "Temozolomide was administered starting the first day of RT at 150 mg/m(2) daily for 5 days every 4 weeks for the first cycle and escalated to a maximum dose of 200 mg/m(2)." | 2.71 | Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. ( Chang, SM; Lamborn, KR; Larson, D; Malec, M; Nicholas, MK; Page, M; Prados, MD; Rabbitt, J; Sneed, P; Wara, W, 2004) |
| "Temozolomide was administered orally each therapy day at a dose of 50 mg/m(2)." | 2.71 | Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. ( Combs, SE; Debus, J; Edler, L; Gutwein, S; Schulz-Ertner, D; Thilmann, C; van Kampen, M; Wannenmacher, MM, 2005) |
| "Temozolomide is a new cytotoxic alkylating agent that has recently been approved in Portugal for the treatment of recurrent high-grade glioma." | 2.70 | Temozolomide in second-line treatment after prior nitrosurea-based chemotherapy in glioblastoma multiforme: experience from a Portuguese institution. ( Albano, J; Cernuda, M; Garcia, I; Lima, L; Oliveira, C; Portela, I; Teixeira, MM, 2002) |
| " The recommended dosage for TEMO for a phase II study of this combination is 200 mg/m2 per day for 5 days." | 2.70 | Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. ( Affronti, ML; Cokgor, L; Early, M; Edwards, S; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, JH; Stafford-Fox, V; Tourt-Uhlig, S; Zaknoen, S, 2001) |
| "Ifosfamide treatment might be a feasible approach, but it necessitates hospitalization." | 2.69 | Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. ( Bamberg, M; Becker, G; Belka, C; Classen, J; Hoffmann, W; Kortmann, RD; Paulsen, F; Weinmann, M, 1999) |
| "Glioblastoma is the most common primary malignant brain tumor." | 2.66 | MGMT Status as a Clinical Biomarker in Glioblastoma. ( Aldape, K; Butler, M; Pommier, Y; Pongor, L; Quezado, M; Raffeld, M; Su, YT; Trepel, J; Wu, J; Xi, L, 2020) |
| "Glioblastoma is the most common malignant primary brain tumor." | 2.66 | Management of glioblastoma: State of the art and future directions. ( Ashley, DM; Friedman, HS; Khasraw, M; López, GY; Malinzak, M; Tan, AC, 2020) |
| "Brain tissue necrosis (treatment necrosis [TN]) as a consequence of brain directed cancer therapy remains an insufficiently characterized condition with diagnostic and therapeutic difficulties and is frequently associated with significant patient morbidity." | 2.61 | Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. ( Batchelor, TT; Dietrich, J; Loebel, F; Loeffler, J; Martinez-Lage, M; Vajkoczy, P; Winter, SF, 2019) |
| "Glioblastoma is the most invasive form of brain tumor." | 2.61 | Glioblastoma vs temozolomide: can the red queen race be won? ( Arora, A; Somasundaram, K, 2019) |
| "Glioblastoma (GBM), the most common primary brain tumor, is the most aggressive human cancers, with a median survival rate of only 14." | 2.61 | Aberrant Transcriptional Regulation of Super-enhancers by RET Finger Protein-histone Deacetylase 1 Complex in Glioblastoma: Chemoresistance to Temozolomide. ( Aoki, K; Hirano, M; Natsume, A; Ranjit, M; Wakabayashi, T, 2019) |
| "Glioma is the most common primary cancer of the central nervous system, and around 50% of patients present with the most aggressive form of the disease, glioblastoma." | 2.58 | Current state of immunotherapy for glioblastoma. ( Bettegowda, C; Lim, M; Weller, M; Xia, Y, 2018) |
| "The approach to treat glioblastoma has not suffered major changes over the last decade and temozolomide (TMZ) remains the mainstay for chemotherapy." | 2.58 | Repurposing drugs for glioblastoma: From bench to bedside. ( Basso, J; Miranda, A; Pais, A; Sousa, J; Vitorino, C, 2018) |
| "Glioblastomas are rich in blood vessels (i." | 2.58 | Anti-angiogenic therapy for high-grade glioma. ( Ameratunga, M; Grant, R; Khasraw, M; Pavlakis, N; Simes, J; Wheeler, H, 2018) |
| "Glioblastoma is the most common primary CNS malignancy and it is becoming more frequently diagnosed in the elderly population." | 2.55 | Glioblastoma in the elderly: initial management. ( de Moraes, FY; Laperriere, N, 2017) |
| " This review summarizes the mechanism of action, efficacy, and adverse events based on pre-clinical studies and clinical trials for TTF in GBM." | 2.55 | Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives. ( Zhu, JJ; Zhu, P, 2017) |
| "Glioblastoma is the most common and most aggressive form of primary brain tumor in adults and contributes to high social and medical burden as a result of its incurable nature and significant neurologic morbidity." | 2.55 | Treatment of Glioblastoma. ( de Groot, JF; Nam, JY, 2017) |
| "Glioblastoma is the most common primary malignant brain tumor diagnosed in the USA and is associated with a poor prognosis." | 2.55 | Treatment of Glioblastoma in Older Adults. ( Ahluwalia, MS; Braun, K, 2017) |
| "Glioblastoma is the most common and the most lethal primary brain tumor in adults." | 2.53 | Guidelines, "minimal requirements" and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working party. ( , 2016) |
| "Glioblastoma is almost always incurable and most older patients survive less than 6 months." | 2.53 | How I treat glioblastoma in older patients. ( Mohile, NA, 2016) |
| "To enhance the benefit of TMZ in the treatment of glioblastomas, effective combination strategies are needed to sensitize glioblastoma cells to TMZ." | 2.53 | Targeting autophagy to sensitive glioma to temozolomide treatment. ( Dai, S; Gong, Z; Qian, L; Sun, L; Xu, Z; Yan, Y, 2016) |
| "Glioblastoma is a unique model of non-metastasising disease that kills the vast majority of patients through local growth, despite surgery and local irradiation." | 2.53 | Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve. ( Giatromanolaki, A; Koukourakis, MI; Mitrakas, AG, 2016) |
| "Glioblastoma is a malignant tumor of astrocytic origin that is highly invasive, proliferative and angiogenic." | 2.53 | Microglia in Cancer: For Good or for Bad? ( Amaral, R; da Fonseca, AC; Garcia, C; Geraldo, LH; Lima, FR; Matias, D, 2016) |
| "Temozolomide (TMZ) is a DNA-methylating agent." | 2.53 | Current and Future Drug Treatments for Glioblastomas. ( Hirose, Y; Ohba, S, 2016) |
| "radiotherapy for treating glioblastoma (GBM), Medline, Current Contents, and Cochrane database were searched." | 2.50 | Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review. ( Lin, ZX; Yang, LJ; Zhou, CF, 2014) |
| " Patients aged over 70 years with favorable KPS, or patients aged 60-70 years with borderline KPS, should be considered for monotherapy utilizing standard TMZ dosing for patients with MGMT-methylated tumors, and hypofractionated RT (34 Gy in ten fractions or 40 Gy in 15 fractions) for patients with MGMT-unmethylated tumors." | 2.50 | Treatment options and outcomes for glioblastoma in the elderly patient. ( Arvold, ND; Reardon, DA, 2014) |
| "Temozolomide has demonstrated a 2." | 2.50 | A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments. ( Hay, JW; Messali, A; Villacorta, R, 2014) |
| "Glioblastoma is the most aggressive primary brain tumor in adults." | 2.50 | Predictive biomarkers investigated in glioblastoma. ( Chinot, O; Delattre, JY; Hoang-Xuan, K; Idbaih, A; Loundou, A; Sanson, M; Tabouret, E, 2014) |
| "Glioblastoma is the most common malignant brain tumor in adults and carries a particularly poor prognosis." | 2.50 | Glioblastoma survival: has it improved? Evidence from population-based studies. ( Barnholtz-Sloan, JS; Bauchet, L; Woehrer, A, 2014) |
| "Glioblastoma multiforme is the most common and most lethal pri- mary malignant tumor of the central nervous system." | 2.50 | Astrocytoma malignum in glioblastoma multiforme vertens with long term survival--case report and a literature review. ( Bochenek-Cibor, J; Krupa, M; Moskała, M; Trojanowski, T, 2014) |
| "Many physicians are reluctant to treat elderly glioblastoma (GBM) patients as aggressively as younger patients, which is not evidence based due to the absence of validated data from primary studies." | 2.49 | Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis. ( Cheng, JX; Dong, Y; Han, N; Liu, BL; Yin, AA; Zhang, LH; Zhang, X, 2013) |
| " Hematotoxicity is listed as a frequent adverse drug reaction in the US prescribing information and hepatotoxicity has been reported infrequently in the postmarketing period." | 2.48 | Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. ( Bronder, E; Garbe, E; Herbst, H; Kauffmann, W; Klimpel, A; Orzechowski, HD; Sarganas, G; Thomae, M, 2012) |
| "Glioblastoma is the most frequent primary malignant brain tumor in adults." | 2.48 | Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. ( Caporello, P; Enrici, RM; Minniti, G; Scaringi, C, 2012) |
| " These may include TMZ concentrations in the brain parenchyma, TMZ dosing schemes, hypoxic microenvironments, niche factors, and the re-acquisition of stem cell properties by non-stem cells." | 2.47 | Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. ( Beier, CP; Beier, D; Schulz, JB, 2011) |
| "Temozolomide is a new drug which has shown promise in treating malignant gliomas and other difficult-to-treat tumors." | 2.45 | Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. ( Beli, I; Chaldeopoulos, D; Fotineas, A; Koukourakis, GV; Kouloulias, V; Kouvaris, J; Maravelis, G; Pantelakos, P; Papadimitriou, C; Zacharias, G, 2009) |
| "Temozolomide is an oral alkylating cytotoxic agent of second generation, used in the treatment of high-grade gliomas." | 2.45 | [Prescription guidebook for temozolomide usage in brain tumors]. ( Borget, I; Brignone, M; Cartalat-Carel, S; Chinot, O; Hassani, Y; Taillandier, L; Taillibert, S; Tilleul, P, 2009) |
| " Alternative dosing regimens, such as 1-week on/1-week off, or 3-week on/1-week off, that deliver more prolonged exposure have been observed to result in higher cumulative doses than the standard 5-day regimen and may deplete tumor-derived O6-methylguanine-DNA methyltransferase (MGMT) in tumor cells, thus sensitizing tumor cells to the effects of TMZ." | 2.45 | [Treatment of glioma with temozolomide]. ( Nishikawa, R, 2009) |
| "High-grade gliomas (WHO grade III anaplastic astrocytoma and grade IV glioblastoma multiforme) are the most common primary tumors in the central nervous system in adults." | 2.45 | High-grade glioma mouse models and their applicability for preclinical testing. ( Beijnen, JH; de Vries, NA; van Tellingen, O, 2009) |
| "Glioblastoma is a severe brain tumor characterized by an extremely poor survival rate of patients." | 2.44 | NRF2 connects Src tyrosine kinase to ferroptosis resistance in glioblastoma. ( Barilà, D; Borsellino, G; Cirotti, C; Contadini, C; De Bardi, M; Di Girolamo, C; Helmer-Citterich, M; Pepe, G; Taddei, I, 2024) |
| " Several preliminary studies have been initiated to address the issue of resistance and suppression of MGMT activity, and have used alternative temozolomide dosing schedules and O(6)-guanine mimetic agents as substrates for MGMT." | 2.44 | Mechanisms of disease: temozolomide and glioblastoma--look to the future. ( Chamberlain, MC; Mrugala, MM, 2008) |
| "Temozolomide is an alkylating agent used frequently in the management of gliomas." | 2.44 | Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature. ( Brown, MP; Selva-Nayagam, S; Singhal, N, 2007) |
| "Temozolomide (TMZ) has emerged as an active agent against malignant gliomas." | 2.44 | Management of glioblastoma. ( Aoki, T; Hashimoto, N; Matsutani, M, 2007) |
| "Glioblastomas are the most frequent and the most aggressive primary brain tumors in adults." | 2.43 | [Concomitant radiotherapy with chemotherapy in patients with glioblastoma]. ( Benouaich-Amiel, A; Delattre, JY; Simon, JM, 2005) |
| "Glioblastoma multiforme is the most common primary brain tumor in adults." | 2.43 | Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial. ( Cairncross, JG; Mason, WP, 2005) |
| "Temozolomide was effective in delaying disease progression and maintaining health-related quality of life." | 2.41 | Temozolomide in malignant gliomas. ( Yung, WK, 2000) |
| "Temozolomide, a new drug, has shown promise in treating malignant gliomas and other difficult-to-treat tumors." | 2.41 | Temozolomide and treatment of malignant glioma. ( Calvert, H; Friedman, HS; Kerby, T, 2000) |
| " For patients with recurrent malignant glioma, temozolomide provides a therapeutic option with a predictable safety profile, clinical efficacy, and convenient dosing that can provide important quality-of-life benefits." | 2.41 | Temozolomide for recurrent high-grade glioma. ( Macdonald, DR, 2001) |
| "Temozolomide appears to produce few serious adverse effects and may also have a positive impact on health-related quality of life." | 2.41 | A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. ( Cave, C; Dinnes, J; Huang, S; Milne, R, 2002) |
| "Glioblastoma (GBM) is a fast-growing primary brain tumor characterized by high invasiveness and resistance." | 1.91 | Targeting integrin α2 as potential strategy for radiochemosensitization of glioblastoma. ( Cordes, N; Korovina, I; Temme, A; Vehlow, A, 2023) |
| " However, poor site-specific delivery and bioavailability significantly restrict the efficient permeability of regorafenib to brain lesions and compromise its treatment efficacy." | 1.91 | Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma. ( Ding, N; Huang, C; Jia, W; Jiang, J; Li, L; Luo, M; Nice, EC; Tian, H; Zhang, H; Zhou, L, 2023) |
| "Temozolomide was successfully up-titrated to the full dose." | 1.91 | Safe administration of temozolomide in end-stage renal disease patients. ( Hundal, J; Pereira, MK; Singh, A; Vredenburg, J, 2023) |
| "Glioblastoma is the most common primary malignant tumor of the central nervous system." | 1.91 | Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98). ( Ahmadi-Zeidabadi, M; Amirinejad, M; Jomehzadeh, A; Khoei, S; Kordestani, Z; Larizadeh, MH; Yahyapour, R, 2023) |
| "Glioblastoma (GBM) is the most lethal primary brain tumor in adults and harbors a subpopulation of glioma stem cells (GSCs)." | 1.91 | EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma. ( Li, M; Tian, W; Wang, B; Wang, Y; Xu, R; Yu, T; Zeng, A; Zhang, J; Zhou, F; Zhou, Z, 2023) |
| "Glioblastoma is among the most lethal cancers, with no known cure." | 1.91 | A high-density 3-dimensional culture model of human glioblastoma for rapid screening of therapeutic resistance. ( Bhatt, H; Brown, JMC; Gray, WP; Ormonde, C; Sharouf, F; Siebzehnrubl, FA; Spencer, R; Zaben, M, 2023) |
| " The primary endpoints were skin, neurological and psychiatric adverse events." | 1.91 | Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study. ( Arakawa, Y; Kanamori, M; Mukasa, A; Muragaki, Y; Narita, Y; Nishikawa, R; Tanaka, S; Yamaguchi, S; Yamasaki, F, 2023) |
| "Glioblastoma is characterized by extensive vascularization and is highly resistant to current therapy." | 1.91 | Inhibition of eukaryotic initiation factor 4E by tomivosertib suppresses angiogenesis, growth, and survival of glioblastoma and enhances chemotherapy's efficacy. ( Xu, T; Zhang, Q; Zhao, J, 2023) |
| "Gliosarcoma is a histopathological variant of glioblastoma, which is characterized by a biphasic growth pattern consisting of glial and sarcoma components." | 1.91 | Prognostic Factors of Gliosarcoma in the Real World: A Retrospective Cohort Study. ( Shen, J; Song, K; Wei, L; Xu, H; Xu, M; Yu, Z; Zhou, Z; Zhu, W, 2023) |
| " Safety was determined by the number of treatment-related adverse events." | 1.91 | Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma. ( Belting, M; Bengzon, J; Cederberg, D; Darabi, A; Edvardsson, C; Ehinger, E; Kopecky, J; Siesjö, P; Tomasevic, G; Visse, E, 2023) |
| "Glioblastoma (GBM) is the most frequent brain cancer and more lethal than other cancers." | 1.91 | Erythrose inhibits the progression to invasiveness and reverts drug resistance of cancer stem cells of glioblastoma. ( Agredano-Moreno, LT; Gallardo-Pérez, JC; Jimenez-García, LF; López-Marure, R; Robledo-Cadena, DX; Sánchez-Lozada, LG; Trejo-Solís, MC, 2023) |
| "Givinostat is a pan-histone deacetylase (HDAC) inhibitor that has demonstrated excellent tolerability as well as efficacy in patients with polycythemia vera." | 1.91 | Givinostat Inhibition of Sp1-dependent MGMT Expression Sensitizes Glioma Stem Cells to Temozolomide. ( Kitanaka, C; Mitobe, Y; Nakagawa-Saito, Y; Okada, M; Sugai, A; Suzuki, S; Togashi, K, 2023) |
| " Based on the genetic testing results, almonertinib combined with anlotinib and temozolomide was administered and obtained 12 months of progression-free survival after the diagnosis of recurrence as the fourth-line treatment." | 1.91 | Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation. ( Dong, S; Hou, Z; Li, S; Luo, N; Tao, R; Wu, H; Zhang, H; Zhang, X; Zhu, D, 2023) |
| "Temozolomide (TMZ) is a first line agent used in the clinic for glioblastoma and it has been useful in increasing patient survival rates." | 1.91 | Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma. ( Ahmed-Cox, A; Akhter, DT; Cao, Y; Fletcher, NL; Janjua, TI; Kavallaris, M; Moniruzzaman, M; Popat, A; Raza, A; Thurecht, KJ, 2023) |
| "Glioblastoma is the most common malignant brain tumor in adults." | 1.91 | Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide. ( Birkl-Toeglhofer, AM; Brawanski, KR; Freyschlag, CF; Haybaeck, J; Hoeftberger, R; Manzl, C; Sprung, S; Ströbel, T; Thomé, C, 2023) |
| "Temozolomide (TMZ) is a common chemotherapy drug used to treatment of glioblastoma, but drug resistance against this drug is an important barrier to successful treatment of this cancer." | 1.91 | Combination of SIX4-siRNA and temozolomide inhibits the growth and migration of A-172 glioblastoma cancer cells. ( Baghbanzadeh, A; Baradaran, B; Barpour, N; Doustvandi, MA; Javadrashid, D; Mohammadpour, ZJ; Mohammadzadeh, R, 2023) |
| " In this paper, we present the effects of juglone alone and in combination with temozolomide on glioblastoma cells." | 1.91 | Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line. ( Barciszewska, AM; Belter, A; Gawrońska, I; Giel-Pietraszuk, M; Naskręt-Barciszewska, MZ, 2023) |
| "Glioblastoma (GBM) is an incurable primary brain tumor with a poor prognosis." | 1.91 | Acetogenins-Rich Fractions of ( Alexandre, GP; Arantes, A; Junqueira, JGM; Kim, B; Oliveira, AGS; Reis, RM; Ribeiro, RIMA; Severino, VGP; Sousa, LR, 2023) |
| "Temozolomide (TMZ) treatment is the mainstay drug for GBM despite the rapid development of resistance in mesenchymal GBM." | 1.91 | NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation. ( Fong, IH; Lin, CM; Liu, HW; Setiawan, SA; Su, IC; Su, YK; Yadav, VK; Yeh, CT, 2023) |
| "Glioblastomas are highly aggressive and deadly brain tumours, with a median survival time of 14-18 months post-diagnosis." | 1.91 | P2X7 receptor antagonism by AZ10606120 significantly reduced in vitro tumour growth in human glioblastoma. ( Drill, M; Drummond, KJ; Galea, E; Hunn, M; Jayakrishnan, PC; Kan, LK; Monif, M; O'Brien, TJ; Sanfilippo, PG; Sequeira, RP; Todaro, M; Williams, DA, 2023) |
| "Temozolomide (TMZ) is a standard chemotherapeutic for GBM, but TMZ treatment benefits are compromised by chemoresistance." | 1.91 | Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance. ( Cui, X; Kang, C; Liu, X; Tong, F; Wang, G; Wang, Q; Wang, Y; Zhao, J; Zhou, J, 2023) |
| "Glioblastoma is the most aggressive and fatal form of brain cancer." | 1.91 | The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma. ( Castresana, JS; Denizler-Ebiri, FN; Güven, M; Taşpınar, F; Taşpınar, M, 2023) |
| "New approaches to the treatment of glioblastoma, including immune checkpoint blockade and oncolytic viruses, offer the possibility of improving glioblastoma outcomes and have as such been under intense study." | 1.91 | Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma. ( Craig, M; Fiset, B; Jenner, AL; Karimi, E; Quail, DF; Surendran, A; Walsh, LA, 2023) |
| " The most common adverse events were leukocytopenia (66." | 1.91 | Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. ( Bu, L; Cai, J; Chen, Q; Huang, K; Meng, X; Weng, Y; Xu, Q; Zhan, R; Zhang, L; Zheng, X, 2023) |
| "GBM (Glioblastoma) is the most lethal CNS (Central nervous system) tumor in adults, which inevitably develops resistance to standard treatments leading to recurrence and mortality." | 1.91 | TRIB1 confers therapeutic resistance in GBM cells by activating the ERK and Akt pathways. ( Becker, AP; Becker, V; Bell, EH; Chakravarti, A; Cui, T; Fleming, JL; Grosu, AL; Han, C; Haque, SJ; Johnson, B; Kumar, A; Manring, HR; McElroy, J; Meng, X; Robe, PA; Schrock, MS; Sebastian, E; Showalter, CA; Singh, K; Summers, MK; Tong, ZY; Venere, M, 2023) |
| "Neuroblastoma is the most common tumour in children under 1 year old, accounting for 12-15% of childhood cancer deaths." | 1.91 | Autophagy Inhibition via Hydroxychloroquine or 3-Methyladenine Enhances Chemotherapy-Induced Apoptosis in Neuro-Blastoma and Glioblastoma. ( Balachandar, A; Bhagirath, E; Pandey, S; Vegh, C; Wear, D, 2023) |
| "A critical challenge in the treatment of glioblastoma (GBM) is its highly invasive nature which promotes cell migration throughout the brain and hinders surgical resection and effective drug delivery." | 1.91 | Invadopodia associated Thrombospondin-1 contributes to a post-therapy pro-invasive response in glioblastoma cells. ( Drummond, KJ; Kaye, AH; Mantamadiotis, T; Morokoff, AP; Stylli, SS; Whitehead, CA, 2023) |
| "Temozolomide (TMZ) was given to 24 patients and 11 patients received TMZ plus other chemotherapies." | 1.91 | The effect of chemotherapies on the crosstalk interaction between CD8 cytotoxic T-cells and MHC-I peptides in the microenvironment of WHO grade 4 astrocytoma. ( Alkhayyat, S; Alkhotani, A; Almansouri, M; Alshanqiti, M; Alsinani, T; Baeesa, S; Bamaga, AK; Butt, N; Enani, M; Fadul, MM; Faizo, E; Hassan, A; Karami, MM; Kurdi, M, 2023) |
| "Temozolomide (TMZ) is a commonly used drug for GBM management." | 1.72 | Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2. ( Chen, L; Deng, Q; Guo, S; Hao, P; Hu, S; Li, Z, 2022) |
| "Allopregnanolone (allo) is a physiological regulator of neuronal activity that treats multiple neurological disorders." | 1.72 | Allopregnanolone suppresses glioblastoma survival through decreasing DPYSL3 and S100A11 expression. ( Feng, YH; Hsu, SP; Hsu, TI; Kao, TJ; Ko, CY; Lim, SW; Lin, HY; Wang, SA, 2022) |
| "Glioblastoma (GBM) is the most lethal primary brain tumor." | 1.72 | Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell Culture. ( Berry, MR; Fan, TM; Hergenrother, PJ; Kelly, AM; McKee, SA; Svec, RL, 2022) |
| "Since high grade gliomas are aggressive brain tumors, intensive search for new treatment options is ongoing." | 1.72 | Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report. ( Dohmen, H; Gött, H; Kiez, S; Kolodziej, M; Stein, M, 2022) |
| "Glioblastoma multiforme (GBM) is a primary brain tumor with devastating prognosis." | 1.72 | Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma. ( Huang, G; Lin, R; Liu, Y; Ni, B; Qi, ST; Song, H; Wang, H; Wang, Z; Xie, S; Xu, Y; Yi, GZ; Zhang, Y, 2022) |
| " Therefore, localised approaches that treat GB straight into the tumour site provide an alternative to enhance chemotherapy bioavailability and efficacy, reducing systemic toxicity." | 1.72 | Nek1-inhibitor and temozolomide-loaded microfibers as a co-therapy strategy for glioblastoma treatment. ( Arantes, PR; Borges, GR; Braganhol, E; Dalanhol, CS; de Barros Dias, MCH; de Oliveira Merib, J; de Souza, PO; Ferro, MB; Henn, JG; Morás, AM; Moura, DJ; Nugent, M; Reinhardt, LS, 2022) |
| "Glioblastomas are the most aggressive brain tumors for which therapeutic options are limited." | 1.72 | Anti-glioblastoma effects of phenolic variants of benzoylphenoxyacetamide (BPA) with high potential for blood brain barrier penetration. ( Carson, SC; Colley, SB; Faia, C; Ingraham Iv, CH; Jursic, BS; Lassak, A; Peruzzi, F; Plaisance-Bonstaff, K; Reiss, K; Stalinska, J; Vittori, C, 2022) |
| "Temozolomide (TMZ) has been widely used in GBM therapy with noticeable side effects." | 1.72 | Cold Plasma Discharge Tube Enhances Antitumoral Efficacy of Temozolomide. ( Keidar, M; Keir, ST; Lin, L; Peters, KB; Sherman, JH; Yan, D; Yao, X, 2022) |
| "Temozolomide use was affected by age, performance and MGMT promoter (all P < 0." | 1.72 | Current trend of radiotherapy for glioblastoma in the elderly: a survey study by the brain tumor Committee of the Korean Radiation Oncology Group (KROG 21-05). ( In Yoon, H; Lee, SW; Lim, DH; Wee, CW, 2022) |
| " Additionally, by lowering the effective dosage of TMZ, the combination liposomes reduced systemic TMZ-induced toxicity, highlighting the preclinical potential of this novel integrative strategy to deliver combination therapies to brain tumors." | 1.72 | Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma. ( Chai, T; Du, Q; Hanif, S; Ismail, M; Li, Y; Muhammad, P; Shi, B; Yang, W; Zhang, D; Zheng, M, 2022) |
| " Non-ionising electromagnetic fields represent an emerging option given the potential advantages of safety, low toxicity and the possibility to be combined with other therapies." | 1.72 | Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide. ( Astori, G; Belli, R; Bernardi, M; Bozza, A; Catanzaro, D; Celli, P; Chieregato, K; Menarin, M; Merlo, A; Milani, G; Peroni, D; Pozzato, A; Pozzato, G; Raneri, FA; Ruggeri, M; Volpin, L, 2022) |
| "Temozolomide (TMZ) is a chemotherapeutic drug for the treatment of GBM." | 1.72 | Temozolomide increases heat shock proteins in extracellular vesicles released from glioblastoma cells. ( Adıgüzel, Z; Kıyga, E; Önay Uçar, E, 2022) |
| "Glioblastoma multiforme is a malignant neoplasia with a median survival of less than two years and without satisfactory therapeutic options." | 1.72 | The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells. ( Buchner, A; Lyu, C; Pohla, H; Schrader, I; Sroka, R; Stadlbauer, B; Stepp, H; Werner, M, 2022) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic agent for glioblastoma, but the emergence of drug resistance limits its anti-tumor activity." | 1.72 | GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair. ( Chen, CC; Chen, Y; Grigore, FN; Jin, J; Lan, Q; Li, M; Li, S; Ma, J; Wang, J; Wang, Q; Wu, G; Xu, H; Zhu, H, 2022) |
| "Metformin is a biguanide drug utilized as the first-line medication in treating type 2 diabetes." | 1.72 | Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin. ( Chang, PC; Chen, HY; Feng, SW; Huang, SM; Hueng, DY; Li, YF, 2022) |
| "Furthermore, miR-147a mimic-treated human glioblastoma cells exhibited higher sensitivity to TMZ chemotherapy than those treated with the mimic control in vitro." | 1.72 | MicroRNA-147a Targets SLC40A1 to Induce Ferroptosis in Human Glioblastoma. ( Ge, FH; Hao, RR; Li, WX; Shen, JL; Wang, XL; Xu, AB; Xu, P; Xu, Z, 2022) |
| "Thymol treatment increased the expression of Bax and p53, and also increased apoptotic cell death, and excessive generation of ROS." | 1.72 | Thymol has anticancer effects in U-87 human malignant glioblastoma cells. ( Afshari, AR; Ahmadi, SS; Bahrami, A; Ferns, GA; Heravi-Faz, N; Qoorchi Moheb Seraj, F; Shahbeiki, F; Soltani, A; Talebpour, A, 2022) |
| "Glioblastoma is the most prevalent and malignant brain tumor identified in adults." | 1.72 | Matteucinol combined with temozolomide inhibits glioblastoma proliferation, invasion, and progression: an in vitro, in silico, and in vivo study. ( Chagas, RCR; Gonçalves, AS; Melo, ESA; Netto, JB; Oliveira, AGS; Reis, RM; Ribeiro, RIMA; Santiago, LR; Santos, DM; Santos, HB; Sousa, LR; Thomé, RG, 2022) |
| "After surgical treatment, glioblastoma (GBM) patients require prompt therapy within 14 days in a patient-specific manner." | 1.72 | Tissue Niche Miniature of Glioblastoma Patient Treated with Nano-Awakeners to Induce Suicide of Cancer Stem Cells. ( Baek, S; Chang, JH; Choi, RJ; Jo, E; Kang, SG; Kim, EH; Lee, D; Lee, JB; Moon, JH; Park, J; Park, JS; Shim, JK; Sung, HJ; Yoon, SJ; Yu, SE, 2022) |
| "Glioblastoma is one of the most common intracranial malignant tumors with an unfavorable prognosis, and iron metabolism as well as ferroptosis are implicated in the pathogenesis of glioblastoma." | 1.72 | TRIM7 modulates NCOA4-mediated ferritinophagy and ferroptosis in glioblastoma cells. ( Chen, B; Ge, F; Hao, K; Hao, R; Jiang, W; Li, K; Shen, J; Wang, Z; Xu, A; Yang, W; Zheng, Y, 2022) |
| "Glioblastoma is a malignant primary brain tumor that affects approximately 250,000 new patients per year worldwide." | 1.72 | Current therapeutic options for glioblastoma and future perspectives. ( Aquilanti, E; Wen, PY, 2022) |
| "Temozolomide (TMZ) is a first-line clinical chemotherapeutic drug." | 1.72 | Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment. ( Chen, KC; Chen, PH; Ho, KH; Kuo, YY; Liu, AJ; Shih, CM, 2022) |
| "Glioblastoma is the most common brain tumor." | 1.72 | ( Balkanov, AS; Belyaev, AY; Glazkov, AA; Kobyakov, GL; Rozanov, ID; Shmakov, PN; Strunina, YV; Telysheva, EN; Usachev, DY, 2022) |
| " In a drug screening assay, diffusion of temozolomide and carmustine to hydrogel-encapsulated U87 cells from the perfusion solution is measured, and dose-response curves are generated, demonstrating utility as an in vitro mimic of the glioblastoma microenvironment." | 1.72 | Hydrogel-based microfluidic device with multiplexed 3D in vitro cell culture. ( Bruns, J; Chen, D; Clancy, A; Nadella, J; Stealey, S; Timperman, A; Zhang, Y; Zustiak, SP, 2022) |
| " The efficacy and optimal deployment schedule of the orally bioavailable small-molecule tumor checkpoint controller lisavanbulin alone, and in combination with, standards of care were assessed using a panel of IDH-wildtype GBM patient-derived xenografts." | 1.72 | Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules. ( Bachmann, F; Bakken, KK; Burgenske, DM; Carlson, BL; Decker, PA; Eckel-Passow, JE; Elmquist, WF; Gampa, G; Giannini, C; He, L; Hu, Z; Kitange, GJ; Kosel, ML; Lane, HA; McSheehy, P; Mladek, AC; Pokorny, JL; Sarkaria, JN; Schmitt-Hoffmann, A; Schroeder, MA; Talele, S; Vaubel, RA, 2022) |
| "Malignant gliomas are the most common brain tumors, with generally dismal prognosis, early clinical deterioration and high mortality." | 1.62 | Non-alkylator anti-glioblastoma agents induced cell cycle G2/M arrest and apoptosis: Design, in silico physicochemical and SAR studies of 2-aminoquinoline-3-carboxamides. ( Gu, X; Liu, J; Ni, X; Qi, Y; Qian, X; Shao, X; Xu, X; Yuan, P, 2021) |
| "Disulfiram (DSF) is an anti-alcoholism drug which functions by inhibiting ALDHs." | 1.62 | Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor. ( Gean, PW; Lin, MX; Liu, CC; Sze, CI; Wu, CL, 2021) |
| "Glioma is the most common and malignant primary brain tumour in adults and has a dismal prognosis." | 1.62 | Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH ( Chen, H; Gu, J; Jiang, J; Li, C; Li, Y; Luo, C; Qian, J; Wan, Z; Wang, J; Zhu, J, 2021) |
| "The highly lethal brain cancer glioblastoma (GBM) poses a daunting challenge because the blood-brain barrier renders potentially druggable amplified or mutated oncoproteins relatively inaccessible." | 1.62 | Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. ( Armando, AM; Bi, J; Cloughesy, TF; Cravatt, BF; Curtis, EJ; Furnari, FB; Gimple, RC; Gu, Y; Jing, H; Khan, A; Koga, T; Kornblum, HI; Miki, S; Mischel, PS; Prager, B; Quehenberger, O; Reed, A; Rich, JN; Rzhetsky, A; Tang, J; Wainwright, DA; Wong, IT; Wu, S; Yang, H; Zhang, W, 2021) |
| "Temozolomide is an alkylating agent most commonly used with a few other second line options." | 1.62 | Nanomedicine in the treatment of Glioblastoma. ( Bukhari, SS; Kishwar Jafri, SK; Shamim, MS, 2021) |
| " Furthermore, the non-cytolytic and non-cytotoxic metronomic dosage of hydroxyurea and temozolomide had increased the DBM therapy outcome by strengthening anti-tumor capability." | 1.62 | A retrospective observational study on cases of anaplastic brain tumors treated with the Di Bella Method: A rationale and effectiveness. ( Borghetto, V; Costanzo, E; Di Bella, G, 2021) |
| "Glioblastoma is the most aggressive central nervous system (CNS) neoplasm with high proliferation and tissue invasion capacity and is resistant to radio and chemotherapy." | 1.62 | Interaction Between Near-Infrared Radiation and Temozolomide in a Glioblastoma Multiform Cell Line: A Treatment Strategy? ( da Silva Marques, M; de Moraes Vaz Batista Filgueira, D; de Souza Votto, AP; Horn, AP; Lettnin, AP; Marinho, MAG, 2021) |
| "Brain cancer is a devastating disease given its extreme invasiveness and intricate location." | 1.62 | Gradient hydrogels for screening stiffness effects on patient-derived glioblastoma xenograft cellfates in 3D. ( Grant, GA; Li, J; Trinh, P; Yang, F; Zhu, D, 2021) |
| "Glioblastoma multiforme is a malignant central nervous system (CNS) disease with dismal prognosis." | 1.62 | Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab. ( Fioretzaki, RG; Kosmas, C; Papageorgiou, GI; Tsakatikas, SA, 2021) |
| "Glioblastoma multiforme is one of the most common malignant types of tumor arising from the central nervous system known for its devastating intracranial progress and dismal prognosis." | 1.62 | FDG PET/CT in Recurrent Glioblastoma Multiforme With Leptomeningeal and Diffuse Spinal Cord Metastasis. ( Malik, D, 2021) |
| "Glioblastoma is a highly malignant brain tumor with limited treatment options and short survival times." | 1.62 | Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma. ( Efferth, T; Giordano, FA; Greten, HJ; Kadioglu, O; Mayr, K; Saeed, MEM; Wenz, F; Yildirim, A, 2021) |
| "GBM (glioblastoma multiforme) is the most common and aggressive brain tumor." | 1.62 | Regorafenib in glioblastoma recurrence: A case report. ( Desideri, I; Detti, B; Ganovelli, M; Greto, D; Livi, L; Lorenzetti, V; Lucidi, S; Maragna, V; Scoccianti, S; Scoccimarro, E; Teriaca, MA, 2021) |
| "Temozolomide (TMZ) has been widely used as a first-line treatment for GBM." | 1.62 | Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting. ( Li, N; Li, Y; Lv, Y; Sha, C; Sun, K; Tang, S; Wang, A; Wang, L; Yan, X; Yu, Y, 2021) |
| "In this work, we constructed LPHNs-cRGD for targeting delivery of the CRISPR/Cas9 system, in combination with FUS-MBs to open the BBB." | 1.62 | Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanoparticles Combined with Focused Ultrasound. ( Chen, J; Cheng, Y; Huang, N; Wang, Z; Yang, Q; Zhou, Y, 2021) |
| " However, clinical trials show that treatment schedule and drug dosage significantly affect patient survival." | 1.62 | A neuro evolutionary algorithm for patient calibrated prediction of survival in Glioblastoma patients. ( Ebrahimi Zade, A; Shahabi Haghighi, S; Soltani, M, 2021) |
| "Glioblastoma multiforme is the most aggressive and lethal form of brain tumour due to the high degree of cancer cells infiltration into surrounding brain tissue." | 1.62 | Bioresorbable, electrospun nonwoven for delayed and prolonged release of temozolomide and nimorazole. ( Janeczek, H; Karpeta-Jarząbek, P; Kasperczyk, J; Musiał-Kulik, M; Pastusiak, M; Stojko, M; Włodarczyk, J, 2021) |
| "Glioblastoma is the most malignant brain tumor and presents high resistance to chemotherapy and radiotherapy." | 1.62 | APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells. ( Castresana, JS; De La Rosa, J; Idoate, MA; Meléndez, B; Rey, JA; Urdiciain, A; Zazpe, I; Zelaya, MV, 2021) |
| "Glioblastoma is the most common primary brain tumor and remains uniformly fatal, highlighting the dire need for developing effective therapeutics." | 1.62 | Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma. ( Boockvar, J; Brahmbhatt, H; Gao, S; Gonzalez, C; Jamil, E; Khan, MB; MacDiarmid, J; Mugridge, N; Ruggieri, R; Sarkaria, JN; Symons, M; Tran, NL, 2021) |
| "Glioblastoma is a primary brain cancer with a near 100% recurrence rate." | 1.62 | De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma. ( Ahmed, AU; Ali, ES; Atashi, F; Baisiwala, S; Ben-Sahra, I; Horbinski, CM; James, CD; Kumthekar, P; Lee, G; Lesniak, MS; Miska, J; Park, CH; Saathoff, MR; Savchuk, S; Shireman, JM; Stupp, R, 2021) |
| "Celecoxib and 2,5-DMC were the most cytotoxic." | 1.62 | COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells. ( Kleszcz, R; Krajka-Kuźniak, V; Kruhlenia, N; Majchrzak-Celińska, A; Misiorek, JO; Przybyl, L; Rolle, K, 2021) |
| "Temozolomide (TMZ) treatment failed to induce apoptotic death in shBeclin1-transfected cells, contrary to control." | 1.62 | Autophagy inhibition reinforces stemness together with exit from dormancy of polydisperse glioblastoma stem cells. ( Antonietti, P; Barthout, E; Battu, S; Begaud, G; Bessette, B; Brunel, A; Deluche, E; Durand, S; Hombourger, S; Jauberteau, MO; Kögel, D; Lalloué, F; Saada, S; Verdier, M, 2021) |
| "Glioblastoma is a highly malignant brain tumor with no curative treatment options, and immune checkpoint blockade has not yet shown major impact." | 1.62 | Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin). ( Bachmann, F; Dietrich, PY; Espinoza, FI; Genoud, V; Lane, HA; Marinari, E; McSheehy, P; Rochemont, V; Walker, PR, 2021) |
| "Temozolomide was labeled with [11C], and serial PET-MRI scans were performed in patients with recurrent GBM treated with bevacizumab and daily temozolomide." | 1.56 | Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. ( Batchelor, T; Beers, AL; Catana, C; Chang, K; Dietrich, J; Duda, DG; Emblem, KE; Gerstner, ER; Hooker, JM; Jain, RK; Kalpathy-Cramer, J; Plotkin, SR; Rosen, B; Vakulenko-Lagun, B; Yen, YF, 2020) |
| "Glioblastoma is the most frequent and lethal primary brain tumor." | 1.56 | Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma. ( Berens, ME; Burns, TC; Califano, A; Carlson, BL; Caron, A; Decker, PA; Dhruv, HD; Eckel-Passow, JE; Evers, L; Giannini, C; Grove, R; Jenkins, RB; Kitange, GJ; Klee, EW; Kollmeyer, TM; LaChance, DH; Ma, DJ; Marin, BM; Meyer, FB; Mladek, AC; O'Neill, BP; Parney, IF; Peng, S; Remonde, D; Sarkar, G; Sarkaria, JN; Schroeder, MA; Sulman, EP; Tian, S; Tran, NL; Vaubel, RA; Verhaak, RG; Wang, Q; Yan, H, 2020) |
| "Glioblastoma is the most common primary tumor of the central nervous system that develops chemotherapy resistance." | 1.56 | Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT. ( Chen, J; Chen, L; Hao, B; He, M; Li, X; Wang, C; Wu, H; Zhang, G; Zhang, T, 2020) |
| "Calpeptin could inhibit the effect." | 1.56 | Calpain suppresses cell growth and invasion of glioblastoma multiforme by producing the cleavage of filamin A. ( Cai, L; Li, Q; Li, W; Lu, X; Su, Z; Tu, M; Wang, C; Zhu, Z, 2020) |
| "Temozolomide (TMZ) is an effective drug for prolonging the overall survival time of patients, while drug-resistance is an important clinical problem at present." | 1.56 | A steroidal saponin form Paris vietnamensis (Takht.) reverses temozolomide resistance in glioblastoma cells via inducing apoptosis through ROS/PI3K/Akt pathway. ( Fang, F; Ji, Y; Li, H; Lu, Y; Qiu, P; Tang, H; Zhang, S, 2020) |
| "Niacin treatment of mice bearing intracranial BTICs increased macrophage/microglia representation within the tumor, reduced tumor size, and prolonged survival." | 1.56 | Control of brain tumor growth by reactivating myeloid cells with niacin. ( Bose, P; Dunn, JF; Kelly, J; Mirzaei, R; Mishra, MK; Poon, C; Rawji, K; Sarkar, S; Yang, R; Yong, VW; Zemp, FJ, 2020) |
| "Trametinib has a strong anti-proliferative effect on established GB cell lines, stem cell-like cells and their differentiated progeny and while it does not enhance anti-proliferative and cell death-inducing properties of the standard treatment, i." | 1.56 | The limitations of targeting MEK signalling in Glioblastoma therapy. ( Debatin, KM; Hadzalic, A; Halatsch, ME; Karpel-Massler, G; Payer, C; Schuster, A; Selvasaravanan, KD; Siegelin, MD; Strobel, H; Westhoff, MA; Wiederspohn, N, 2020) |
| "Glioblastoma is the most devastating primary brain tumor and effective therapies are not available." | 1.56 | CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model. ( Azambuja, JH; Battastini, AMO; Beckenkamp, LR; Braganhol, E; de Oliveira, FH; Gelsleichter, NE; Lenz, GS; Michels, LR; Schuh, RS; Stefani, MA; Teixeira, HF; Wink, MR, 2020) |
| " However, low bioavailability and extractive yield limit the clinical applications of XN." | 1.56 | Xanthohumol regulates miR-4749-5p-inhibited RFC2 signaling in enhancing temozolomide cytotoxicity to glioblastoma. ( Chen, KC; Chen, PH; Cheng, CH; Ho, KH; Kuo, TC; Lee, CC; Lee, YT; Liu, AJ; Shih, CM, 2020) |
| "Gliomas are intrinsic brain tumours, which are classified by the World Health Organization (WHO) into different grades of malignancy, with glioblastoma being the most frequent and most malignant subtype (WHO grade IV)." | 1.56 | A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. ( Hofer, S; Hottinger, AF; Hundsberger, T; Läubli, H; Mamot, C; Pesce, G; Reinert, M; Roelcke, U; Roth, P; Schucht, P; Weller, M, 2020) |
| "Glioblastoma is the most common primary malignant tumor of the central nervous system which is the most lethal type of primary brain tumor in adults with the survival time of 12-15 months after the initial diagnosis." | 1.56 | Evaluation of frequency magnetic field, static field, and Temozolomide on viability, free radical production and gene expression (p53) in the human glioblastoma cell line (A172). ( Ahmadi-Zeidabadi, M; Ashta, A; Motalleb, G, 2020) |
| "Glioblastoma is devastating cancer with a high frequency of occurrence and poor survival rate and it is urgent to discover novel glioblastoma-specific antigens for the therapy." | 1.56 | Suppressing Dazl modulates tumorigenicity and stemness in human glioblastoma cells. ( Liu, C; Liu, R; Lu, Y; Zhang, F; Zhang, H, 2020) |
| "The major difficulty in treating glioblastoma stems from the intrinsic privileged nature of the brain." | 1.56 | Vascularized Temporoparietal Fascial Flap: A Novel Surgical Technique to Bypass the Blood-Brain Barrier in Glioblastoma. ( Abrams, M; Anderson, T; Boockvar, JA; D'Amico, R; Faltings, L; Filippi, CG; Fralin, S; Khatri, D; Langer, DJ; Li, M; Patel, NV; Ratzon, F; Reichman, N; Wong, T, 2020) |
| "Methadone is an analgesic drug used for pain treatment and heroin substitution." | 1.56 | Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells. ( Beltzig, L; Haas, B; Kaina, B; Piee-Staffa, A, 2020) |
| " Current treatments for glioblastoma patients consist of surgery followed by radiation in combination with temozolomide." | 1.56 | The effect of temozolomide in combination with doxorubicin in glioblastoma cells ( Alexandru, O; Artene, SA; Danoiu, S; Dricu, A; Elena Cioc, C; Horescu, C; Sevastre, AS; Stefana Oana, P; Tache, DE; Tuta, C, 2020) |
| "Temozolomide (TMZ) is an oral chemotherapy drug constituting the backbone of chemotherapy regimens utilized as first-line treatment of GBM." | 1.56 | LncRNA NEAT1 promotes malignant phenotypes and TMZ resistance in glioblastoma stem cells by regulating let-7g-5p/MAP3K1 axis. ( Bi, CL; Fang, JS; Lan, S; Liu, JF; Yang, ZY; Zhang, MY, 2020) |
| "Glioblastoma (GBM) is a lethal type of primary brain tumor with a median survival less than 15 months." | 1.56 | Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling. ( Alafate, W; Bai, X; Ma, X; Wang, J; Wang, M; Wu, W; Xiang, J; Xie, W; Xu, D, 2020) |
| "Glioblastoma is the most frequent aggressive primary brain tumor amongst human adults." | 1.56 | Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction. ( Arús, C; Candiota, AP; Julià-Sapé, M; Ledesma-Carbayo, MJ; Núñez, LM; Romero, E; Santos, A; Vellido, A, 2020) |
| "Glioblastoma multiforme (GBM) is a primary brain tumor with a very high degree of malignancy and is classified by WHO as a glioma IV." | 1.56 | Comparison of Elemental Anomalies Following Implantation of Different Cell Lines of Glioblastoma Multiforme in the Rat Brain: A Total Reflection X-ray Fluorescence Spectroscopy Study. ( Chwiej, J; Drozdz, A; Janeczko, K; Janik-Olchawa, N; Matusiak, K; Ostachowicz, B; Planeta, K; Ryszawy, D; Setkowicz, Z, 2020) |
| "Glioblastoma is a severe type of brain tumor with a poor prognosis and few therapy options." | 1.56 | Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries. ( Andrade Tomaz, M; de Souza, I; Karolynne Seregni Monteiro, L; Menck, CFM; Molina Silva, M; Reily Rocha, A; Rocha, CRR; Rodrigues Gomes, L; Teatin Latancia, M, 2020) |
| "Metformin has been linked to improve survival of patients with various cancers." | 1.56 | Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis. ( Chinot, O; Genbrugge, E; Gorlia, T; Hau, P; Nabors, B; Seliger, C; Stupp, R; Weller, M, 2020) |
| "Palbociclib treatment significantly reduced tumorigenesis in TMZ-R/HMC3 bearing mice and SNHG15 and CDK6 expression was significantly reduced while miR-627-5p level was increased." | 1.51 | Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme. ( Bao, H; Jin, H; Li, C; Li, Z; Liang, P; Wang, W; Xiong, J; Zhang, J; Zheng, H, 2019) |
| "Controlling seizures is essential during GBM treatment because they are often present and closely associated with the quality of life of GBM patients." | 1.51 | Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study. ( Chang, MJ; Min, KL; Ryu, JY, 2019) |
| "Tumor recurrence is the main cause of poor prognosis of GBM." | 1.51 | Reactive oxygen species metabolism-based prediction model and drug for patients with recurrent glioblastoma. ( Li, P; Liu, J; Pan, J; Sun, Z; Tan, N; Zhao, W, 2019) |
| "Papaverine is a potential anticancer drug in GBM treatment." | 1.51 | Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth. ( Akasaki, Y; Ichimura, K; Inada, M; Sato, A; Shindo, M; Tanuma, SI; Yamamoto, Y, 2019) |
| "Euphol is a tetracyclic triterpene alcohol, and it is the main constituent of the sap of the medicinal plant Euphorbia tirucalli." | 1.51 | Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells. ( Carloni, AC; Costa, AM; Evangelista, AF; Jones, C; Lima, JP; Martinho, O; Miranda-Gonçalves, V; Pianowski, LF; Reis, RM; Rosa, MN; Silva, VAO; Tansini, A, 2019) |
| "Glioblastoma is the worst and most common primary brain tumor." | 1.51 | CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth. ( Azambuja, JH; Battastini, AMO; Beckenkamp, LR; Braganhol, E; de Oliveira, FH; Fernandes, MC; Figueiró, F; Gelsleichter, NE; Iser, IC; Scholl, JN; Sévigny, J; Spanevello, RM; Stefani, MA; Teixeira, HF; Wink, MR, 2019) |
| "Glioblastoma is the most common and lethal adult brain tumor." | 1.51 | SOX3 can promote the malignant behavior of glioblastoma cells. ( Aldaz, P; Anastasov, N; Atkinson, MJ; Drakulic, D; Garcia, I; Garros-Regulez, L; Marjanovic Vicentic, J; Matheu, A; Nikolic, I; Puskas, N; Raicevic, S; Sampron, N; Stevanovic, M; Tasic, G; Vukovic, V, 2019) |
| "Human glioblastoma is a malignant and aggressive primary human brain solid tumor characterized by severe hypoxia." | 1.51 | The HIF‑1α/miR‑224‑3p/ATG5 axis affects cell mobility and chemosensitivity by regulating hypoxia‑induced protective autophagy in glioblastoma and astrocytoma. ( He, X; Huang, S; Li, F; Qi, P; Zhang, T, 2019) |
| "Isofuranodiene (IFD) is a bioactive sesquiterpene occurring in the essential oils obtained from Alexanders (Smyrnium olusatrum L." | 1.51 | Isofuranodiene synergizes with temozolomide in inducing glioma cells death. ( Amantini, C; Brunetti, A; Iannarelli, R; Maggi, F; Marinelli, O; Morelli, MB; Nabissi, M; Russotti, D; Santoni, G, 2019) |
| " This study aimed to investigate the antitumor effects of natural killer cells in combination with temozolomide as the standard chemotherapeutic agent for glioblastoma." | 1.51 | Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro. ( Matsuda, R; Morita, H; Motoyama, Y; Murakami, T; Nakagawa, I; Nakamura, M; Nakase, H; Nakazawa, T; Nishimura, F; Omoto, K; Shida, Y; Tanaka, Y; Tsujimura, T, 2019) |
| "The aim of the present study was to treat glioblastoma cells with a selective HDAC6 inhibitor, tubastatin A, to determine if the malignant phenotype may be reverted." | 1.51 | Tubastatin A, an inhibitor of HDAC6, enhances temozolomide‑induced apoptosis and reverses the malignant phenotype of glioblastoma cells. ( Castresana, JS; Erausquin, E; Idoate, MA; Meléndez, B; Rey, JA; Urdiciain, A, 2019) |
| " Combinatorial therapy of diosgenin and TMZ significantly reduced the dosage regimen of TMZ and also showed affectivity in hitherto TMZ resistant GBM cells." | 1.51 | Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma. ( Banerjee, I; Banik, P; Bharti, R; Biswas, A; Das, S; Ghosh, SK; Kumar, U; Mandal, M; Nayak, S; Rajesh, Y, 2019) |
| "Temozolomide treatment inhibited p50 recruitment to its cognate element as a function of Ser329 phosphorylation while concomitantly increasing p53 recruitment." | 1.51 | Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma. ( Bernal, GM; Cahill, KE; Crawley, CD; Khodarev, NN; Larsen, G; Mansour, NM; Nunez, L; Raleigh, DR; Spretz, R; Szymura, SJ; Uppal, A; Voce, DJ; Weichselbaum, RR; Wu, L; Yamini, B; Zhang, W, 2019) |
| "Long‑term local treatment of glioblastoma is rarely achieved and the majority of the patients undergo relapse." | 1.51 | Synergistic effect of arsenic trioxide, vismodegib and temozolomide on glioblastoma. ( Bureta, C; Komiya, S; Maeda, S; Nagano, S; Saitoh, Y; Sasaki, H; Setoguchi, T; Taniguchi, N; Tokumoto, H, 2019) |
| "Temozolomide (TMZ) is an important agent against GBM." | 1.51 | Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation. ( Chen, Z; Liang, H; Sun, L, 2019) |
| "Temozolomide (TMZ) has been the first-line chemotherapeutic agent used, although to achieve a satisfactory clinical effect." | 1.51 | Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists. ( Gao, L; Huang, X; Jiang, X; Li, J; Liu, X; Liu, Z; Zeng, T, 2019) |
| "Temozolomide (TMZ) is an alkylating agent widely used to treat cancer, resistance to this drug is often found." | 1.51 | Impact of extremely low-frequency electromagnetic field (100 Hz, 100 G) exposure on human glioblastoma U87 cells during Temozolomide administration. ( Ahmadi-Zeidabadi, M; Akbarnejad, Z; Eskandary, H; Esmaeeli, M; Masoumi-Ardakani, Y; Mohammadipoor-Ghasemabad, L, 2019) |
| "The therapeutic treatment of glioblastoma multiforme (GBM) remains a major challenge." | 1.51 | Angiopep-2 Modified Cationic Lipid-Poly-Lactic-Co-Glycolic Acid Delivery Temozolomide and DNA Repair Inhibitor Dbait to Achieve Synergetic Chemo-Radiotherapy Against Glioma. ( Hua, L; Li, S; Liang, J; Liu, H; Xu, Q; Ye, C; Yu, R; Zhao, L, 2019) |
| "Glioblastoma multiforme is an astrocyte-derived tumour representing the most aggressive primary brain malignancy." | 1.51 | Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme. ( Aleixo, GF; Batalini, F; Drews, R; Kaufmann, MR, 2019) |
| "Glioblastoma is the most common primary brain tumor in adults." | 1.51 | ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma. ( Al-Omaishi, S; Celebre, A; Chan, J; Das, S; Dirks, PB; Ghannad-Zadeh, K; Guan, J; Isaev, K; Kaskun, O; Moran, MF; Morrissy, AS; Munoz, DG; Reimand, J; Sachdeva, R; Smiljanic, S; Taylor, MD; Tong, J; Wilson, TM; Wu, M, 2019) |
| " Proliferation, cell cycle, and apoptotic assays were performed with ML00253764, whereas the synergism of the simultaneous combination with temozolomide was evaluated by the combination index method." | 1.48 | Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo. ( Bocci, G; Di Desidero, T; Giuliani, D; Guarini, S; Orlandi, P; Ottani, A; Pacini, S; Pardini, C; Pasqualetti, F; Vaglini, F, 2018) |
| " The aim of our research was the synthesis of a nanocarrier of quercetin combined with temozolomide, to enhance the specificity and efficacy of this anticancer drug commonly used in glioblastoma treatment." | 1.48 | Novel nanohydrogel of hyaluronic acid loaded with quercetin alone and in combination with temozolomide as new therapeutic tool, CD44 targeted based, of glioblastoma multiforme. ( Armenia, E; Barbarisi, A; Barbarisi, M; De Sena, G; Iaffaioli, RV; Quagliariello, V; Schiavo, L; Tafuto, S, 2018) |
| "OBJECTIVE Glioblastoma is the most common primary central nervous system tumor in adults." | 1.48 | Enhancement of invadopodia activity in glioma cells by sublethal doses of irradiation and temozolomide. ( Kaye, AH; Luwor, RB; Mao, L; Morokoff, AP; Paradiso, L; Stylli, SS; Whitehead, CA, 2018) |
| "Glioblastoma (GBM) is the most malignant primary brain tumor and contains tumorigenic cancer stem cells (CSCs), which support the progression of tumor growth." | 1.48 | Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype. ( Chen, PY; Lee, IC; Liu, YC, 2018) |
| "Glioblastoma is the most frequent and aggressive form of high-grade malignant glioma." | 1.48 | XRCC3 contributes to temozolomide resistance of glioblastoma cells by promoting DNA double-strand break repair. ( Frohnapfel, L; Kaina, B; Quiros, S; Ringel, F; Roos, WP, 2018) |
| "Glioblastomas are the most frequently diagnosed and worst primary malignancy of the central nervous system, with very poor prognosis." | 1.48 | Regulation of Integrated Stress Response Sensitizes U87MG Glioblastoma Cells to Temozolomide Through the Mitochondrial Apoptosis Pathway. ( Fan, L; Gao, Y; He, Y; Meng, H; Sun, L; Xu, B; Xu, H; Zhou, Z, 2018) |
| "Glioblastoma is the most common and aggressive glioma, characterized by brain invasion capability." | 1.48 | Tacrine derivatives stimulate human glioma SF295 cell death and alter important proteins related to disease development: An old drug for new targets. ( Bonacorso, HG; Costa Nunes, F; Creczynski-Pasa, TB; de Melo, LJ; Feitosa, SC; Martins, MAP; Rode, M; Silva, AH; Silva, LB; Winter, E; Zanatta, N, 2018) |
| "Glioblastoma multiforme is the most lethal type of brain tumor and the established therapy only extends patients survival to approximately one year." | 1.48 | Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment. ( Coelho, MAN; Gosselet, F; Lima, J; Loureiro, JA; Pereira, MC; Ramalho, MJ; Sevin, E, 2018) |
| " In addition, TMZ could increase the levels of miR-505 and combination with pri-miR-505 and TMZ promoted the suppressive role mediated by miR-505 in GBM cells." | 1.48 | Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway. ( Fu, C; Liu, X; Yang, X; Zhang, C, 2018) |
| "Glioblastoma is the most common and aggressive primitive brain tumor in adults." | 1.48 | Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases. ( Bellu, L; Bergo, E; Berti, F; Caccese, M; Dal Pos, S; Della Puppa, A; Denaro, L; Gardiman, MP; Lombardi, G; Pambuku, A; Zagonel, V, 2018) |
| "Glioblastoma is the most common malignant brain tumor." | 1.48 | Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting. ( Chu, L; Liu, S; Mu, H; Ni, L; Song, Y; Sun, K; Wang, A; Wu, Z; Yan, X; Zhang, C; Zhao, M, 2018) |
| "GBM is a deadly brain cancer that doesn't discriminate between sexes and knows no age limit." | 1.48 | A Novel Venom-Derived Peptide for Brachytherapy of Glioblastoma: Preclinical Studies in Mice. ( Chen, TC; Markland, FS; Minea, RO; Swenson, S; Thein, TZ; Tuan, CD, 2018) |
| "Temozolomide (TMZ) is a drug used to treat GBM, while the survival period of GBM patients with positive treatment remains less than 15 months." | 1.48 | Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma. ( Cao, Z; Li, L; Wu, Q; Xiao, W; Xie, Q; Zhang, B; Zhao, W; Zhu, L, 2018) |
| "Glioblastoma (GBM) is one of the lethal central nervous system tumors." | 1.48 | The Effect of Ascorbic Acid over the Etoposide- and Temozolomide-Mediated Cytotoxicity in Glioblastoma Cell Culture: A Molecular Study. ( Ceylan, S; Gokturk, D; Kelebek, H; Yilmaz, DM, 2018) |
| "Optic nerve glioblastoma is a rare entity that usually presents with rapidly progressive vision loss, which eventually results in blindness and, ultimately, death." | 1.48 | Transtentorial dissemination of optic nerve glioblastoma: case report. ( Beatriz Lopes, M; Caruso, JP; Chen, CJ; Ding, D; Hays, MA; Mastorakos, P; Shaffrey, ME; Taylor, DG, 2018) |
| "Glioblastomas (GBM) comprise 17% of all primary brain tumors." | 1.46 | Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition. ( Balça-Silva, J; do Carmo, A; Dubois, LG; Echevarria-Lima, J; Ferrer, VP; Lopes, MC; Matias, D; Moura-Neto, V; Pontes, B; Rosário, L; Sarmento-Ribeiro, AB, 2017) |
| "Glioblastomas are characterized by amplification of EGFR." | 1.46 | Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma. ( Asuthkar, S; Bach, SE; Guda, MR; Lathia, JD; Sahu, K; Tsung, AJ; Tuszynski, J; Velpula, KK, 2017) |
| "Glioblastoma is one of the most frequent and aggressive brain tumors." | 1.46 | MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT. ( Jin, X; Liu, N; Nie, E; Shi, Z; Wu, W; You, Y; Yu, T; Zhang, J; Zhou, X, 2017) |
| "Temozolomide (TMZ) is an alkylating agent that has been widely used to treat GBM; resistance to this drug is often found." | 1.46 | Cytotoxicity of temozolomide on human glioblastoma cells is enhanced by the concomitant exposure to an extremely low-frequency electromagnetic field (100Hz, 100G). ( Abadi, MFS; Ahmadi, M; Akbarnejad, Z; Dini, L; Eskandary, H; Farsinejad, A; Nematollahi-Mahani, SN; Vergallo, C, 2017) |
| "Glioblastoma (GBM) is a grade IV astrocytoma." | 1.46 | Glioblastoma entities express subtle differences in molecular composition and response to treatment. ( Balça-Silva, J; Canedo, NHS; Correia, AH; De Souza, JM; Do Carmo, A; Dubois, LG; Girão, H; Gonçalves, AC; Lopes, MC; Matias, D; Moura-Neto, V; Sarmento-Ribeiro, AB, 2017) |
| "Temozolomide (TMZ) is an alkylating chemotherapeutic agent widely used in anti-glioma treatment." | 1.46 | Genomic profiling of long non-coding RNA and mRNA expression associated with acquired temozolomide resistance in glioblastoma cells. ( Fu, Z; Guo, H; Lian, C; Liu, B; Liu, Y; Xu, N; Yang, Z; Zeng, H, 2017) |
| "The current treatment of glioblastoma multiforme (GBM) is limited by the restricted arsenal of agents which effectively cross the blood brain barrier (BBB)." | 1.46 | The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts. ( Adhikari, B; Akers, J; Brandel, MG; Carter, BS; Chen, CC; Deming, T; Futalan, D; Li, J, 2017) |
| "Glioblastoma is a highly lethal brain cancer that frequently recurs in proximity to the original resection cavity." | 1.46 | Zika virus has oncolytic activity against glioblastoma stem cells. ( Chai, JN; Chheda, MG; Diamond, MS; Fernandez, E; Gorman, MJ; Hubert, CG; McKenzie, LD; Prager, BC; Rich, JN; Richner, JM; Shan, C; Shi, PY; Tycksen, E; Wang, X; Zhang, R; Zhu, Z, 2017) |
| "Glioblastoma is the most common and aggressive primary brain tumor and has a high mortality in humans." | 1.46 | Identification of WISP1 as a novel oncogene in glioblastoma. ( Jing, D; Shen, L; Yu, H; Zhang, Q; Zhao, Y, 2017) |
| "Among 350 glioma and ganglioglioma cases, the MGMT promoter tested positive for methylation in 53." | 1.46 | Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas. ( Chen, L; Hu, Z; Li, Z; Liu, C; Liu, L; Lu, D; Teng, L; Wang, L; Zhao, L, 2017) |
| " In vivo, systemic treatment with pacritinib demonstrated blood-brain barrier penetration and led to improved overall median survival in combination with TMZ, in mice orthotopically xenografted with an aggressive recurrent GBM BTIC culture." | 1.46 | The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. ( Aman, A; Cseh, O; Jensen, KV; Luchman, HA; Weiss, S, 2017) |
| " In vivo, we implanted the cells orthotopically in nude mice and administered CBL0137 in various dosing regimens to assess brain and tumor accumulation of CBL0137, its effect on tumor cell proliferation and apoptosis, and on survival of mice with and without temozolomide (TMZ)." | 1.46 | Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. ( Barone, TA; Burkhart, CA; Gudkov, AV; Gurova, KV; Haderski, G; Plunkett, RJ; Purmal, AA; Safina, A, 2017) |
| "Glioblastoma is the most malignant form of brain tumor." | 1.46 | Combined delivery of temozolomide and the thymidine kinase gene for treatment of glioblastoma. ( Choi, E; Han, J; Lee, D; Lee, M; Oh, J; Rhim, T; Tan, X, 2017) |
| "Temozolomide is a commonly used chemotherapy drug and frequently causes lymphocytopenia." | 1.46 | Cutaneous invasive aspergillosis in a patient with glioblastoma receiving long-term temozolomide and corticosteroid therapy. ( Hatakeyama, S; Ikeda, T; Morisawa, Y; Norizuki, M; Okabe, T; Onishi, T; Sasahara, T; Suzuki, J; Toshima, M; Yokota, H, 2017) |
| "Temozolomide (TMZ) is a novel cytotoxic agent used as first-line chemotherapy for GBM, however, some individual cells can't be isolated for surgical resection and show treatment-resistance, thus inducing poor prognosis." | 1.46 | MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. ( Chen, C; Chen, W; Ge, XS; He, J; Kong, KK; Li, FC; Li, H; Li, JL; Li, P; Wang, F; Xu, XK, 2017) |
| "Glioblastoma is the deadliest brain tumor in humans." | 1.43 | Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo. ( Chakrabarti, M; Ray, SK, 2016) |
| "The study included 26 patients with anaplastic astrocytoma and 37 patients with glioblastoma; all patients were aged ≤18 years." | 1.43 | High-grade glioma in children and adolescents: a single-center experience. ( Akalan, N; Akyuz, C; Cengiz, M; Eren, G; Gurkaynak, M; Ozyigit, G; Varan, A; Yazici, G; Yüce, D; Zorlu, F, 2016) |
| "Valproic acid (VPA) is an anti-epileptic drug with properties of a histone deacetylase inhibitor (HDACi)." | 1.43 | Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide. ( Dietrich, J; Le, A; McDonnell, E; Nahed, BV; Redjal, N; Reinshagen, C; Walcott, BP, 2016) |
| "There is no standard treatment for glioblastoma with elements of PNET (GBM-PNET)." | 1.43 | Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component. ( Fersht, N; Mandeville, HC; Mycroft, J; O'Leary, B; Saran, F; Solda, F; Vaidya, S; Zacharoulis, S, 2016) |
| "Glioblastoma is the most common and deadly primary brain tumor in adults." | 1.43 | Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro. ( Feng, F; Ling, Z; Sun, C; Wang, L; Wang, S; Wu, B; Xia, L; Yu, Y, 2016) |
| " Treatment of TMZ along with a sublethal dosage range of SU1498, a chemical inhibitor of the VEGF receptor signaling, induced significant cell death in both TMZ-sensitive and TMZ-resistant GBM cells without changing the status of the MGMT promoter methylation." | 1.43 | Combined inhibition of vascular endothelial growth factor receptor signaling with temozolomide enhances cytotoxicity against human glioblastoma cells via downregulation of Neuropilin-1. ( Choi, C; Choi, K; Kim, E; Lee, J; Ryu, SW, 2016) |
| "Glioblastoma multiforme is a devastating disease with no curative options due to the difficulty in achieving sufficient quantities of effective chemotherapies into the tumor past the blood-brain barrier." | 1.43 | Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers. ( Bredlau, AL; Broome, AM; Dixit, S; McKinnon, E; Miller, K; Moore, A, 2016) |
| "Glioblastoma is one of the most lethal cancers in humans, and with existing therapy, survival remains at 14." | 1.43 | Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. ( Aman, A; Cairncross, JG; Dang, NH; Datti, A; Easaw, JC; Grinshtein, N; Hao, X; Kaplan, DR; King, JC; Luchman, A; Lun, X; Robbins, SM; Senger, DL; Uehling, D; Wang, X; Weiss, S; Wells, JC; Wrana, JL, 2016) |
| "Glioblastomas (GBM), deadly brain tumors, have greater incidence in males than females." | 1.43 | Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma. ( Brenner, A; Cavazos, D; Garcia, L; Garcia, M; Gruslova, A; Gustafsson, JA; Li, X; Liu, J; Sareddy, GR; Strom, AM; Tekmal, RR; Vadlamudi, RK; Viswanadhapalli, S, 2016) |
| "Glioblastoma is a malignant brain tumor originating in the central nervous system." | 1.43 | Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy? ( Chen, Z; Gao, Z; Lai, X; Mao, G; Qu, J; Zhang, L; Zhu, J; Zhu, X, 2016) |
| " We show that GSI in combination with RT and TMZ attenuates proliferation, decreases 3D spheroid growth and results into a marked reduction in clonogenic survival in primary and established glioma cell lines." | 1.43 | NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. ( Barbeau, LM; Chalmers, AJ; Eekers, DB; Granton, PV; Groot, AJ; Habets, R; Iglesias, VS; King, H; Prickaerts, J; Short, SC; Theys, J; van Hoof, SJ; Verhaegen, F; Vooijs, M; Yahyanejad, S, 2016) |
| " We investigated the pharmacologic characteristics of OTX015 as a single agent and combined with targeted therapy or conventional chemotherapies in glioblastoma cell lines." | 1.43 | OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. ( Astorgues-Xerri, L; Bekradda, M; Berenguer-Daizé, C; Cayol, M; Cvitkovic, E; Lokiec, F; MacKenzie, S; Noel, K; Odore, E; Ouafik, L; Rezai, K; Riveiro, ME, 2016) |
| " As a comparison group 33 patients with bevacizumab for at least 6 months continuously dosed at 10 mg/kg every 2 weeks were selected." | 1.43 | Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. ( Hertenstein, A; Hielscher, T; Menn, O; Platten, M; Wick, A; Wick, W; Wiestler, B; Winkler, F, 2016) |
| "Glioblastoma multiforme is the most aggressive malignant primary brain tumor in adults." | 1.43 | Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance. ( Aboody, KS; Cassady, K; Cherryholmes, GA; Marinov, GK; Polewski, MD; Reveron-Thornton, RF, 2016) |
| "Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14." | 1.43 | Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam. ( Ajit, NE; Burton, GV; El-Osta, H; Peddi, P, 2016) |
| "Glioblastoma is a highly aggressive, common brain tumor with poor prognosis." | 1.42 | RIST: a potent new combination therapy for glioblastoma. ( Corbacioglu, S; Debatin, KM; Engelke, J; Fulda, S; Halatsch, ME; Karpel-Massler, G; Nonnenmacher, L; Simmet, T; Westhoff, MA, 2015) |
| "Glioblastoma is an aggressive malignancy, which is notorious for its poor prognosis." | 1.42 | Hispidulin enhances the anti-tumor effects of temozolomide in glioblastoma by activating AMPK. ( Fei, Z; He, X; Liu, W; Wang, Y, 2015) |
| "Temozolomide (TMZ) has been showed to be an effective chemotherapeutic agent for glioblastoma treatment; however, the response rate is not satisfactory." | 1.42 | Synergistic Anti-Cancer Effects of Icariin and Temozolomide in Glioblastoma. ( Guo, H; Guo, M; Wang, Y; Yang, L, 2015) |
| "Although glioblastoma multiforme is more common in patients older than 65 years, the elderly population is often excluded from clinical studies." | 1.42 | Treatment results and outcome in elderly patients with glioblastoma multiforme--a retrospective single institution analysis. ( Asslaber, M; Bruckmann, L; Hoffermann, M; Kariem Mahdy, A; Payer, F; von Campe, G, 2015) |
| "Glioblastoma is the most aggressive primary brain tumor, and is associated with a very poor prognosis." | 1.42 | Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature. ( Alder, JE; Boissinot, M; Droop, A; Hayes, J; Hughes, TA; Lawler, SE; Shaw, L; Short, SC; Thygesen, H; Tumilson, C; Westhead, D, 2015) |
| "Glioblastoma is a devastating primary brain tumor resistant to conventional therapies." | 1.42 | Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas. ( Battastini, AM; Bishop, AJR; Braganhol, E; Bristot, IJ; Figueiró, F; Forcelini, CM; Gelain, DP; Klafke, K; Moreira, JCF; Morrone, M; Paludo, FJ; Terra, SR; Zanotto-Filho, A, 2015) |
| "Glioblastoma is the most frequent primary malignant brain tumor in adults." | 1.42 | Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation. ( Benoit, JP; Danhier, F; Lagarce, F; Lemaire, L; Messaoudi, K, 2015) |
| " Primary GBM cells were treated with VPA as a monotherapy and in combination with temozolomide and irradiation." | 1.42 | The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. ( Cosgrove, L; Day, B; Fay, M; Head, R; Hosein, AN; Lim, YC; Martin, JH; Rose, S; Sminia, P; Stringer, B, 2015) |
| "Glioblastoma is the most malignant brain tumor, exhibiting remarkable resistance to treatment." | 1.42 | A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide. ( Correia, S; Costa, BM; Costa, S; Gonçalves, CS; Gonçalves, T; Lopes, JM; Oliveira, AI; Pinto, AA; Pinto, L; Pojo, M; Reis, RM; Rocha, M; Rodrigues, AJ; Sousa, N; Xavier-Magalhães, A, 2015) |
| "Irinotecan has shown some efficacy in recurrent malignant gliomas." | 1.42 | Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide. ( Beccaria, K; Carpentier, A; Farinotti, R; Fernandez, C; Goldwirt, L; Idbaih, A; Labussiere, M; Levasseur, C; Milane, A; Schmitt, C, 2015) |
| "Temozolomide treatment significantly induced mRNA expression of nearly all investigated EMT markers in T98G glioma cells." | 1.42 | Epithelial-to-mesenchymal transition in paired human primary and recurrent glioblastomas. ( Hattermann, K; Held-Feindt, J; Kubelt, C; Mehdorn, HM; Sebens, S, 2015) |
| "Thromboembolic events, seizures, neurologic symptoms and adverse effects from corticosteroids and chemotherapies are frequent clinical complications seen in Glioblastoma (GB) patients." | 1.42 | Risk factors for glioblastoma therapy associated complications. ( Brenke, C; Capper, D; Ening, G; Osterheld, F; Schmieder, K, 2015) |
| "Glioblastoma is the most frequent primary malignant brain tumor in adults." | 1.42 | Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma. ( Danhier, F; des Rieux, A; Fourniols, T; Leprince, JG; Préat, V; Randolph, LD; Staub, A; Vanvarenberg, K, 2015) |
| "Evidence suggests hyperglycemia is associated with worse outcomes in glioblastoma (GB)." | 1.42 | Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. ( Chung, C; Kiehl, TR; Laperriere, N; Lovblom, LE; Mason, W; McNamara, MG; Ménard, C; Millar, BA; Perkins, BA; Tieu, MT, 2015) |
| " Abemaciclib antitumor activity was assessed in subcutaneous and orthotopic glioma models alone and in combination with standard of care temozolomide (TMZ)." | 1.42 | Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft. ( Ajamie, RT; De Dios, A; Gelbert, LM; Kulanthaivel, P; Raub, TJ; Sanchez-Martinez, C; Sawada, GA; Shannon, HE; Staton, BA; Wishart, GN, 2015) |
| "Glioblastoma multiforme is the most common malignant brain tumor." | 1.42 | An image guided small animal radiation therapy platform (SmART) to monitor glioblastoma progression and therapy response. ( Barbeau, LM; Granton, PV; Paesmans, K; Theys, J; van Hoof, SJ; Verhaegen, F; Vooijs, M; Yahyanejad, S, 2015) |
| "Glioblastoma multiforme is the most lethal of brain cancer, and it comprises a heterogeneous mixture of functionally distinct cancer cells that affect tumor progression." | 1.42 | Heterogeneous glioblastoma cell cross-talk promotes phenotype alterations and enhanced drug resistance. ( Gruden, K; Koren, A; Lah, TT; Motaln, H; Ramšak, Ž; Schichor, C, 2015) |
| "However, TMZ-related acute lymphoblastic leukemia is rare." | 1.40 | Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient. ( Chang, PY; Chou, KN; Lin, YC; Liu, MY, 2014) |
| "Glioblastoma is the most common malignant primary brain tumor." | 1.40 | EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma. ( Boots-Sprenger, SH; Hiddingh, L; Hulleman, E; Jeuken, J; Kaspers, GJ; Noske, DP; Tannous, BA; Teng, J; Tops, B; Vandertop, WP; Wesseling, P; Wurdinger, T, 2014) |
| "Glioblastoma is the most common malignant brain tumor in adults and characterized by a poor prognosis." | 1.40 | Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. ( Deenen, R; Florea, AM; Frei, K; Happold, C; Lamszus, K; Reifenberger, G; Roth, P; Silginer, M; Weller, M, 2014) |
| "optimal treatment of glioblastoma (gBM) in the elderly remains unclear." | 1.40 | Glioblastoma treatment in the elderly in the temozolomide therapy era. ( Al-Zahrani, A; Coate, L; Laperriere, N; Lwin, Z; Macfadden, D; Mason, WP; Massey, C; McNamara, MG; Menard, C; Millar, BA; Sahgal, A, 2014) |
| "Glioblastoma is the most prevalent primary brain tumor and is essentially universally fatal within 2 years of diagnosis." | 1.40 | Molecular targeting of TRF2 suppresses the growth and tumorigenesis of glioblastoma stem cells. ( Bai, Y; Flavahan, W; Lathia, JD; Mattson, MP; Rich, JN; Zhang, P, 2014) |
| "Drug resistance is a major issue in the treatment of glioblastoma." | 1.40 | Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis. ( Hiddingh, L; Hulleman, E; Jeuken, J; Kaspers, GJ; Noske, DP; Raktoe, RS; Vandertop, WP; Wesseling, P; Wurdinger, T, 2014) |
| "Temozolomide (TMZ) is an oral alkylating agent which is widely used in the treatment of GBM following surgery." | 1.40 | miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. ( Cui, Y; Lei, Q; Li, G; She, X; Wang, Z; Wu, M; Xiang, J; Xu, G; Yu, Z, 2014) |
| "Non-invasive monitoring of response to treatment of glioblastoma (GB) is nowadays carried out using MRI." | 1.40 | Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma. ( Arús, C; Candiota, AP; Delgado-Goñi, T; Julià-Sapé, M; Pumarola, M, 2014) |
| "GBM is a primary brain tumor known to frequently demonstrate resistance to apoptosis-inducing therapeutics." | 1.40 | SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma. ( Chakravarti, A; Chu, Z; Denton, N; Dmitrieva, N; Hardcastle, J; Jacob, NK; Kaur, B; Kwon, CH; Marsh, R; Meisen, WH; Qi, X; Thorne, AH; Van Meir, EG; Wojton, J, 2014) |
| " In the present work, TMZ was combined with a specific SKI, and the cytotoxic effect of each drug alone or in combination was tested on GBM cell lines." | 1.40 | A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy. ( Choi, J; Kopp-Schneider, A; Noack, J; Régnier-Vigouroux, A; Richter, K, 2014) |
| "Temozolomide (TMZ) has been used for the treatment of glioblastoma." | 1.40 | Inhibition of JNK potentiates temozolomide-induced cytotoxicity in U87MG glioblastoma cells via suppression of Akt phosphorylation. ( Chun, W; Kim, SS; Lee, HJ; Lee, JW; Lim, SY; Vo, VA, 2014) |
| "Here, we propose a new strategy to treat glioblastoma based on transferrin (Tf)-targeted self-assembled nanoparticles (NPs) incorporating zoledronic acid (ZOL) (NPs-ZOL-Tf)." | 1.40 | Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid. ( Artuso, S; Balestrieri, ML; Caraglia, M; De Rosa, G; Leonetti, C; Luce, A; Lusa, S; Porru, M; Salzano, G; Stoppacciaro, A; Zappavigna, S, 2014) |
| " In a human GBM xenograft model, a single daily dosage of MB does not activate AMP-activated protein kinase signaling, and no tumor regression was observed." | 1.39 | Reversing the Warburg effect as a treatment for glioblastoma. ( Bigner, DD; Choudhury, GR; Ghorpade, A; Keir, ST; Li, W; Liu, R; Poteet, E; Ryou, MG; Simpkins, JW; Tang, L; Wen, Y; Winters, A; Yan, H; Yang, SH; Yuan, F, 2013) |
| " Sufficient information on steroid dosing was available in 72 patients included in the final analysis." | 1.39 | Steroid management in newly diagnosed glioblastoma. ( Deangelis, LM; Deutsch, MB; Lassman, AB; Panageas, KS, 2013) |
| "Glioblastoma multiforme is the most common lethal brain tumor in human adults, with no major therapeutic breakthroughs in recent decades." | 1.39 | Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. ( Bauer, M; Bechmann, I; Dehghani, F; Durante, M; Gaunitz, F; Giese, A; Gutenberg, A; Hellwig, C; Meixensberger, J; Merz, F; Renner, C; Schäfer, M; Schopow, K; Stöcker, H; Taucher-Scholz, G, 2013) |
| "Glioblastoma multiforme is the most aggressive primary brain tumour." | 1.39 | Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I, 2013) |
| "Lymphopenia is known to precipitate dramatic elevation in serum BLyS; however, the use of this effect to enhance humoral responses following vaccination has not been evaluated." | 1.39 | BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. ( Archer, GE; Bigner, DD; Choi, BD; Heimberger, AB; Herndon, JE; Mitchell, DA; Norberg, P; Reap, EA; Sampson, JH; Sanchez-Perez, L; Sayour, EJ; Schmittling, RJ, 2013) |
| "Glioblastoma is the most lethal brain cancer." | 1.39 | Antitumor activity of (2E,5Z)-5-(2-hydroxybenzylidene)-2-((4-phenoxyphenyl)imino) thiazolidin-4-one, a novel microtubule-depolymerizing agent, in U87MG human glioblastoma cells and corresponding mouse xenograft model. ( Li, C; Li, X; Liu, X; Yan, B; Zhang, Q; Zhou, H, 2013) |
| "Glioblastoma is a highly aggressive malignant disease with notable resistance to chemotherapy." | 1.39 | High expression of leptin receptor leads to temozolomide resistance with exhibiting stem/progenitor cell features in gliobalastoma. ( Han, G; Hu, X; Li, Y; Liu, J; Wang, L; Yue, Z; Zhao, R; Zhao, W; Zhou, X, 2013) |
| " In the present analysis, we retrospectively investigated the feasibility and effectiveness of bevacizumab combined with ICE in patients with glioblastoma at second relapse during ICE treatment." | 1.39 | Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. ( Arakawa, Y; Fujimoto, K; Kikuchi, T; Kunieda, T; Miyamoto, S; Mizowaki, T; Murata, D; Takagi, Y; Takahashi, JC, 2013) |
| "Glioblastoma multiforme is the most common primary tumor of the central nervous system." | 1.39 | NETRIN-4 protects glioblastoma cells FROM temozolomide induced senescence. ( Chen, P; Hu, Y; Hyytiäinen, M; Keski-Oja, J; Li, H; Li, L; Ylivinkka, I, 2013) |
| "Pseudoprogression (PP) during adjuvant treatment of glioblastoma (GBM) is frequent and is a clinically and radiologically challenging problem." | 1.39 | Is there pseudoprogression in secondary glioblastomas? ( Cerhova, J; Chakravarti, A; Engellandt, K; Geiger, KD; Juratli, TA; Krex, D; Lautenschlaeger, T; Schackert, G; von Kummer, R, 2013) |
| "We analyzed the data of 210 patients treated for glioblastoma between 2005 and 2013." | 1.39 | [Results of postoperative radiochemotherapy of glioblastoma multiforme]. ( Bagó, A; Bajcsay, A; Fedorcsák, I; Kásler, M; Lövey, J; Mangel, L; Sipos, L, 2013) |
| "Glioblastoma multiforme is the most common malignant central nervous system tumor, and also among the most difficult to treat due to a lack of response to chemotherapeutics." | 1.39 | Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity. ( Payne, CA; Safdar, S; Taite, LJ; Tu, NH, 2013) |
| " This drug combination significantly impaired the sphere-forming ability of GSCs in vitro and tumor formation in vivo, leading to increase in the overall survival of mice bearing orthotopic inoculation of GSCs." | 1.39 | Effective elimination of cancer stem cells by a novel drug combination strategy. ( Chen, G; Colman, H; Feng, L; Huang, P; Keating, MJ; Li, X; Wang, F; Wang, J; Wang, L; Xu, RH; Yuan, S; Zhang, H, 2013) |
| "We here show that glioblastomas are capable to downregulate MGMT expression independently of promoter methylation by elongation of the 3'-UTR of the mRNA, rendering the alternatively polyadenylated transcript susceptible to miRNA-mediated suppression." | 1.39 | In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing. ( Egensperger, R; Hinske, LC; Hoefig, K; Kreth, FW; Kreth, S; Limbeck, E; Schütz, SV; Thon, N, 2013) |
| "Glioblastoma multiforme is the most common aggressive adult primary tumour of the central nervous system." | 1.38 | Temozolomide: mechanisms of action, repair and resistance. ( Bradshaw, TD; Stevens, MF; Zhang, J, 2012) |
| "Glioblastoma is a deadly cancer with intrinsic chemoresistance." | 1.38 | Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and Paclitaxel. ( Anelli, V; Bassi, R; Brioschi, L; Campanella, R; Caroli, M; De Zen, F; Gaini, SM; Giussani, P; Riboni, L; Riccitelli, E; Viani, P, 2012) |
| "Glioblastoma is the most common and most malignant primary brain tumor in adults." | 1.38 | Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients. ( Hedderich, J; Mehdorn, HM; Nabavi, A; Stark, AM; van de Bergh, J, 2012) |
| "Thrombocytopenia was operationalized as a continuous platelet count and a dichotomic variable (cut-off <100." | 1.38 | Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy. ( Blasco, J; Bruna, J; Gil, M; Graus, F; Pineda, E; Simó, M; Velasco, R; Verger, E, 2012) |
| " It could therefore be used as an important platform for better prediction of drug dosing and schedule towards personalized medicine." | 1.38 | Towards personalized medicine with a three-dimensional micro-scale perfusion-based two-chamber tissue model system. ( Barker, J; Foltz, G; Honkakoski, P; Küblbeck, J; Li, W; Lin, B; Ma, L; Zhang, J; Zhou, C, 2012) |
| " These results suggest that GBMs with EGFR amplification are a heterogenous group of tumors and that behavior might differ according to the degree of amplification, although not in a straightforward dose-response manner." | 1.38 | Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas. ( Bortoluzzi, S; Cieply, K; Fardo, DW; Hamilton, RL; Hobbs, J; Horbinski, C; Nikiforova, MN, 2012) |
| "Combining Gliadel wafers and radiochemotherapy with TMZ may carry the risk of increased adverse events (AE)." | 1.38 | Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma. ( Anile, C; Balducci, M; Chiesa, S; De Bonis, P; Fiorentino, A; Maira, G; Mangiola, A; Pompucci, A, 2012) |
| "Glioblastoma multiforme is the most common primary malignant brain tumour, with a median survival of about one year." | 1.38 | A restricted cell population propagates glioblastoma growth after chemotherapy. ( Burns, DK; Chen, J; Kernie, SG; Li, Y; McKay, RM; Parada, LF; Yu, TS, 2012) |
| "The temozolomide was stopped and the lymphoma was successfully treated with chemotherapy." | 1.38 | Non-Hodgkin's lymphoma in a patient on treatment with temozolomide. ( Otty, Z; Sabesan, S, 2012) |
| "Glioblastomas are highly aggressive brain tumors of adults with poor clinical outcome." | 1.38 | Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies. ( Balabanov, S; Bokemeyer, C; Braig, M; Hagel, C; Hauber, J; Lamszus, K; Pällmann, N; Preukschas, M; Schulte, A; Sievert, H; Weber, K, 2012) |
| "These brain tumors are often resistant to chemotherapies like temozolomide (TMZ) and there are very few treatment options available to patients." | 1.38 | Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. ( Berns, R; Dunn, SE; Fotovati, A; Hu, K; Kast, RE; Kong, E; Lee, C; Luk, M; Pambid, M; Toyota, B; Toyota, E; Triscott, J; Yip, S, 2012) |
| " We evaluated the preclinical potential of a novel, orally bioavailable PI3K/mTOR dual inhibitor (XL765) in in vitro and in vivo studies." | 1.37 | Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. ( Aftab, DT; Berger, MS; Haas-Kogan, DA; James, CD; Mueller, S; Ozawa, T; Polley, MY; Prados, MD; Prasad, G; Sottero, T; Weiss, WA; Yang, X, 2011) |
| "Metformin or olanzapine have been shown independently to enhance AMPK activation." | 1.37 | Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin? ( Halatsch, ME; Karpel-Massler, G; Kast, RE, 2011) |
| " When this regimen was administered to mice containing humanized bone marrow, flow cytometric analyses indicated that the human bone marrow cells were significantly more sensitive to treatment than the murine bone marrow cells and that the regimen was highly toxic to human-derived hematopoietic cells of all lineages (progenitor, lymphoid, and myeloid)." | 1.37 | Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity. ( Bailey, B; Baluyut, AR; Cai, S; Chan, RJ; Ernstberger, A; Goebel, WS; Jones, DR; Juliar, BE; Mayo, LD; Pollok, KE; Sinn, AL; Wang, H, 2011) |
| "The prognostic value of postoperative residual tumor volume in FET PET, TBR(mean,) TBR(max) and Gd-volume was evaluated using Kaplan-Maier estimates for disease-free survival (DFS) and overall survival (OS)." | 1.37 | Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. ( Coenen, HH; Eble, MJ; Galldiks, N; Herzog, H; Holy, R; Kaiser, HJ; Langen, KJ; Pinkawa, M; Piroth, MD; Stoffels, G, 2011) |
| "Glioblastoma is the most common primary brain tumor with a dismal prognosis, highlighting the need for novel treatment strategies." | 1.37 | Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275. ( Bangert, A; Cristofanon, S; Debatin, KM; Fulda, S; Häcker, S, 2011) |
| " The aim of the present study was to evaluate the efficacy and side effects of nimotuzumab in combination with chemotherapy for patients with malignant gliomas." | 1.37 | [Nimotuzumab in combination with chemotherapy for patients with malignant gliomas]. ( Chen, ZP; Jiang, XB; Mu, YG; Sai, K; Shen, D; Yang, QY; Zhang, XH, 2011) |
| "Communicating hydrocephalus is an uncommon complication in patients treated for glioblastoma multiforme (GBM)." | 1.37 | Communicating hydrocephalus following surgery and adjuvant radiochemotherapy for glioblastoma. ( Bianchi, F; D'Alessandris, QG; Doglietto, F; Fernandez, E; Lauretti, L; Maira, G; Montano, N; Pallini, R, 2011) |
| "Glioblastoma multiforme is the most common and most malignant primary brain tumour." | 1.36 | Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib. ( Freyschlag, CF; Nölte, I; Pechlivanis, I; Schmieder, K; Seiz, M; Tuettenberg, J; Vajkoczy, P, 2010) |
| "Glioblastoma multiforme is the most commonly diagnosed malignant primary brain tumour in adults." | 1.36 | Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma. ( Bendinelli, S; Casalini, F; Costa, B; Da Pozzo, E; Da Settimo, F; Gabelloni, P; Martini, C; Nuti, E; Orlandini, E; Rossello, A, 2010) |
| "Glioblastomas (GBM) are lethal brain tumors that are highly resistant to therapy." | 1.36 | PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. ( Bachoo, RM; Burma, S; Camacho, CV; Hahm, B; McEllin, B; Mukherjee, B; Tomimatsu, N, 2010) |
| "A major barrier to progress in treatment of glioblastoma is the relative inaccessibility of tumors to chemotherapeutic agents." | 1.36 | Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts. ( Kumabe, T; Nishihara, M; Saito, R; Satoh, T; Sonoda, Y; Sugiyama, S; Tominaga, T; Yamashita, Y; Yokosawa, M; Yokoyama, M, 2010) |
| "Glioblastoma is the most common primary malignant brain tumor; however, glioblastoma in children is less common than in adults, and little is known about its clinical outcome in children." | 1.36 | Long-term outcomes in children with glioblastoma. ( Ahn, HS; Cho, BK; Kim, DG; Kim, IH; Kim, SK; Lee, JY; Park, SH; Phi, JH; Song, KS; Wang, KC, 2010) |
| "Bortezomib proved to be a more potent inductor of apoptosis than gefitinib and alkylating agents." | 1.35 | Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. ( Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP, 2008) |
| "There is a large number of effective cytotoxic drugs whose side effect profile, efficacy, and long-term use in man are well understood and documented over decades of use in clinical routine e." | 1.35 | TMZ-BioShuttle--a reformulated temozolomide. ( Braun, K; Debus, J; Didinger, B; Ehemann, V; Langowski, J; Mueller, G; Pipkorn, R; Spring, H; Waldeck, W; Wiessler, M, 2008) |
| "Temozolomide (TMZ) is a cytotoxic agent of the imidazotetrazine class, chemically related to dacarbazine." | 1.35 | Tuberculosis in a patient on temozolomide: a case report. ( de Barros e Silva, MJ; de Paiva, TF; Fanelli, MF; Gimenes, DL; Rinck, JA, 2009) |
| "Glioblastoma multiforme is a primary malignant brain tumor with a prognosis of typically less than 2 years." | 1.35 | Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: treatment-related or dual-pathology? ( Binello, E; Germano, IM, 2009) |
| "Carmustine wafer was not an independent predictor (P=." | 1.35 | Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. ( Affronti, ML; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Heery, CR; Herndon, JE; Reardon, DA; Rich, JN; Vredenburgh, JJ, 2009) |
| " Thus, the implantation of BCNU wafers prior to TMZ and radiotherapy appears safe in newly diagnosed GBM patients." | 1.35 | A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. ( Mitchell, SB; Pan, E; Tsai, JS, 2008) |
| "Temozolomide is a proautophagic (type II programmed cell death) drug and can thus circumvent part of the glioblastoma resistance to apoptosis." | 1.35 | [The sodium pump could constitute a new target to combat glioblastomas]. ( Kiss, R; Lefranc, F; Mijatovic, T, 2008) |
| " Noninvasive imaging of apoptosis facilitates optimization of therapeutic protocols regarding dosing and schedule and enables identification of efficacious combination therapies." | 1.35 | Noninvasive imaging of apoptosis and its application in cancer therapeutics. ( Coppola, JM; Rehemtulla, A; Ross, BD, 2008) |
| "Temozolomide (TMZ) is used for treating glioblastoma." | 1.35 | Modulatory effects of acetazolomide and dexamethasone on temozolomide-mediated apoptosis in human glioblastoma T98G and U87MG cells. ( Banik, NL; Das, A; Ray, SK, 2008) |
| "The anterior temporal lesion was a ganglioglioma and did not recur." | 1.34 | Ganglioglioma occurring with glioblastoma multiforme: separate lesions or the same lesion? ( Dickerman, RD; Howes, G; Lee, JM; Nardone, EM; Stevens, QE, 2007) |
| "Glioblastoma multiforme is a malignant astrocytic tumor characterized by rapid growth, extensive invasiveness and high vascularity." | 1.34 | Interindividual differences in anticancer drug cytotoxicity in primary human glioblastoma cells. ( Cambar, J; L'Azou, B; Liguoro, D; Pédeboscq, S; Pometan, JP, 2007) |
| "Intramedullary gangliogliomas are indolent tumors of the spine with rare cases of malignant transformation." | 1.34 | Malignant transformation of conus medullaris ganglioglioma: case report. ( Amini, A; Chin, SS; Schmidt, MH, 2007) |
| "Glioblastoma multiforme is characterised by invasive growth and frequent recurrence." | 1.34 | Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma. ( Berger, W; Buchroithner, J; Fischer, J; Marosi, C; Micksche, M; Pichler, J; Pirker, C; Silye, R; Spiegl-Kreinecker, S, 2007) |
| "Glioblastomas are malignant brain tumors that are very difficult to cure, even with aggressive therapy consisting of surgery, chemotherapy, and radiation." | 1.34 | Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. ( Bernhard, EJ; Cerniglia, GJ; Georgescu, MM; Gupta, AK; Hahn, SM; Jiang, Z; Maity, A; Mick, R; Pore, N, 2007) |
| "For patients with anaplastic astrocytoma, the 12-month survival rate was 73%." | 1.34 | Salvage chemotherapy in progressive high-grade astrocytoma. ( See, SJ; Ty, A; Wong, MC, 2007) |
| "Human glioblastoma is a deadly brain tumor that is often treated with a combination of drugs." | 1.33 | Dexamethasone decreases temozolomide-induced apoptosis in human gliobastoma T98G cells. ( Banik, NL; Patel, SJ; Ray, SK; Sribnick, EA; Sur, P, 2005) |
| "Temozolomide-treated control cells activated the DNA damage signal transducers Chk1, Chk2, and p38, leading to Cdc25C and Cdc2 inactivation, prolonged G2 arrest, and loss of clonagenicity by a combination of senescence and mitotic catastrophe." | 1.33 | Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. ( Berger, MS; Hirose, Y; Katayama, M; Mirzoeva, OK; Pieper, RO, 2005) |
| "Surgical cure of glioblastomas is virtually impossible and their clinical course is mainly determined by the biologic behavior of the tumor cells and their response to radiation and chemotherapy." | 1.33 | Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. ( Beerenwinkel, N; Feiden, W; Hartmann, C; Ketter, R; Lengauer, T; Meese, E; Rahnenführer, J; Steudel, WI; Stockhammer, F; Strowitzki, M; Urbschat, S; von Deimling, A; Wemmert, S; Zang, KD, 2005) |
| "At the time of the initial disease recurrence, 13 patients were readministered TMZ." | 1.33 | Salvage temozolomide for prior temozolomide responders. ( Abrey, LE; Demopoulos, A; Franceschi, E; Lassman, AB; Nolan, C; Omuro, AM, 2005) |
| "We identified a transcriptomic signature that predicts a common in vitro and in vivo resistance phenotype to these agents, a proportion of which is imprinted recurrently by gene dosage changes in the resistant glioblastoma genome." | 1.33 | Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. ( Bredel, C; Bredel, M; Duran, GE; Harsh, GR; Juric, D; Recht, LD; Scheck, AC; Sikic, BI; Vogel, H; Yu, RX, 2006) |
| "Tamoxifen and hypericin were able to greatly increase the growth-inhibitory and apoptosis-stimulatory potency of temozolomide via the downregulation of critical cell cycle-regulatory and prosurvival components." | 1.33 | Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin. ( Chen, TC; Gupta, V; Hofman, FM; Kardosh, A; Liebes, LF; Schönthal, AH; Su, YS; Wang, W, 2006) |
| "Temozolomide (TMZ) has demonstrated activity and acceptable toxicity for the treatment of recurrent high-grade gliomas in prospective phase II studies." | 1.32 | Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium. ( Branle, F; Everaert, E; Joosens, E; Menten, J; Neyns, B; Strauven, T, 2004) |
| "Temozolomide (TMZ) is a methylating agent with promising antitumor efficacy for the treatment of melanomas and intermediate-grade gliomas." | 1.32 | The piperidine nitroxide Tempol potentiates the cytotoxic effects of temozolomide in human glioblastoma cells. ( Cereda, E; Gariboldi, MB; Monti, E; Ravizza, R, 2004) |
| "Glioblastoma is the deadliest and most prevalent brain tumor." | 1.32 | Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities. ( Banik, NL; Das, A; Patel, SJ; Ray, SK, 2004) |
| "Temozolomide has recently been introduced by Schering-Plough Ltd (Welwyn Garden City, UK) as a new treatment which merits further investigation in this situation." | 1.31 | Temozolomide (Temodal) for treatment of primary brain tumours. ( MacConnachie, AM, 2000) |
| "Temozolomide (TMZ) is a DNA-methylating agent that has recently been introduced into Phase II and III trials for the treatment of gliomas." | 1.31 | p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. ( Berger, MS; Hirose, Y; Pieper, RO, 2001) |
| "Thirty-three patients with newly diagnosed glioblastoma multiforme (GBM) and five patients with newly diagnosed anaplastic astrocytoma (AA) were treated with Temodal at a starting dose of 200 mg/m2 daily for 5 consecutive days with repeat dosing every 28 days after the first daily dose." | 1.30 | DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. ( Ashley, DM; Bigner, DD; Bigner, SH; Cokgor, I; Colvin, OM; Dugan, M; Friedman, AH; Friedman, HS; Haglund, MM; Henry, AJ; Kerby, T; Krischer, J; Lovell, S; Marchev, F; McLendon, RE; Modrich, PL; Provenzale, JM; Rasheed, K; Rich, J; Seman, AJ; Stewart, E, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (0.18) | 18.2507 |
| 2000's | 319 (11.50) | 29.6817 |
| 2010's | 1587 (57.23) | 24.3611 |
| 2020's | 862 (31.09) | 2.80 |
| Authors | Studies |
|---|---|
| Clarion, L | 1 |
| Jacquard, C | 1 |
| Sainte-Catherine, O | 1 |
| Loiseau, S | 1 |
| Filippini, D | 1 |
| Hirlemann, MH | 1 |
| Volle, JN | 1 |
| Virieux, D | 1 |
| Lecouvey, M | 1 |
| Pirat, JL | 1 |
| Bakalara, N | 1 |
| Goffin, E | 1 |
| Lamoral-Theys, D | 1 |
| Tajeddine, N | 1 |
| de Tullio, P | 1 |
| Mondin, L | 1 |
| Lefranc, F | 11 |
| Gailly, P | 1 |
| Rogister, B | 1 |
| Kiss, R | 8 |
| Pirotte, B | 1 |
| Elkamhawy, A | 1 |
| Viswanath, AN | 1 |
| Pae, AN | 1 |
| Kim, HY | 2 |
| Heo, JC | 1 |
| Park, WK | 1 |
| Lee, CO | 1 |
| Yang, H | 8 |
| Kim, KH | 2 |
| Nam, DH | 25 |
| Seol, HJ | 8 |
| Cho, H | 2 |
| Roh, EJ | 1 |
| Sestito, S | 1 |
| Nesi, G | 1 |
| Daniele, S | 4 |
| Martelli, A | 1 |
| Digiacomo, M | 1 |
| Borghini, A | 1 |
| Pietra, D | 1 |
| Calderone, V | 1 |
| Lapucci, A | 1 |
| Falasca, M | 1 |
| Parrella, P | 1 |
| Notarangelo, A | 1 |
| Breschi, MC | 1 |
| Macchia, M | 1 |
| Martini, C | 5 |
| Rapposelli, S | 1 |
| La Pietra, V | 2 |
| Barresi, E | 2 |
| Di Maro, S | 1 |
| Da Pozzo, E | 2 |
| Robello, M | 1 |
| La Motta, C | 1 |
| Cosconati, S | 1 |
| Taliani, S | 3 |
| Marinelli, L | 2 |
| Novellino, E | 2 |
| Da Settimo, F | 4 |
| de Moura Sperotto, ND | 1 |
| Deves Roth, C | 1 |
| Rodrigues-Junior, VS | 1 |
| Ev Neves, C | 1 |
| Reisdorfer Paula, F | 1 |
| da Silva Dadda, A | 1 |
| Bergo, P | 1 |
| Freitas de Freitas, T | 1 |
| Souza Macchi, F | 1 |
| Moura, S | 1 |
| Duarte de Souza, AP | 1 |
| Campos, MM | 1 |
| Valim Bizarro, C | 1 |
| Santos, DS | 1 |
| Basso, LA | 1 |
| Machado, P | 1 |
| Mujumdar, P | 2 |
| Kopecka, J | 3 |
| Bua, S | 1 |
| Supuran, CT | 1 |
| Riganti, C | 4 |
| Poulsen, SA | 2 |
| Yamasaki, T | 1 |
| Buric, D | 1 |
| Chacon, C | 1 |
| Audran, G | 1 |
| Braguer, D | 4 |
| Marque, SRA | 1 |
| Carré, M | 1 |
| Brémond, P | 1 |
| Choi, PJ | 3 |
| Cooper, E | 3 |
| Schweder, P | 3 |
| Mee, E | 3 |
| Faull, R | 3 |
| Denny, WA | 3 |
| Dragunow, M | 3 |
| Park, TI | 2 |
| Jose, J | 3 |
| Ding, Y | 2 |
| Xue, Q | 1 |
| Liu, S | 11 |
| Hu, K | 4 |
| Wang, D | 8 |
| Wang, T | 10 |
| Li, Y | 50 |
| Guo, H | 11 |
| Hao, X | 3 |
| Ge, W | 1 |
| Zhang, Y | 38 |
| Li, A | 5 |
| Li, J | 36 |
| Chen, Y | 30 |
| Zhang, Q | 14 |
| Turner, C | 3 |
| Dai, Z | 1 |
| Liu, H | 10 |
| Wang, B | 8 |
| Yang, D | 5 |
| Zhu, YY | 1 |
| Yan, H | 8 |
| Zhu, PF | 1 |
| Liu, YP | 1 |
| Chen, HC | 1 |
| Zhao, YL | 1 |
| Zhao, LX | 1 |
| Zhao, XD | 1 |
| Liu, HY | 2 |
| Luo, XD | 1 |
| Zhang, MM | 1 |
| Jia, Y | 1 |
| Li, P | 11 |
| Qiao, Y | 3 |
| Han, KL | 1 |
| Nguyen, P | 3 |
| Doan, P | 3 |
| Rimpilainen, T | 2 |
| Konda Mani, S | 1 |
| Murugesan, A | 3 |
| Yli-Harja, O | 3 |
| Candeias, NR | 3 |
| Kandhavelu, M | 3 |
| He, Z | 6 |
| Charleton, C | 1 |
| Devine, RW | 1 |
| Kelada, M | 1 |
| Walsh, JMD | 1 |
| Conway, GE | 1 |
| Gunes, S | 1 |
| Mondala, JRM | 1 |
| Tian, F | 1 |
| Tiwari, B | 1 |
| Kinsella, GK | 1 |
| Malone, R | 1 |
| O'Shea, D | 1 |
| Devereux, M | 1 |
| Wang, W | 12 |
| Cullen, PJ | 1 |
| Stephens, JC | 1 |
| Curtin, JF | 1 |
| Yuan, P | 2 |
| Gu, X | 2 |
| Ni, X | 2 |
| Qi, Y | 3 |
| Shao, X | 1 |
| Xu, X | 8 |
| Liu, J | 16 |
| Qian, X | 5 |
| Lu, Y | 16 |
| Feng, Y | 3 |
| Li, Z | 16 |
| Zhang, H | 18 |
| Hu, X | 6 |
| Jiang, W | 4 |
| Shi, T | 1 |
| Wang, Z | 35 |
| He, Y | 11 |
| Yang, C | 5 |
| Wang, Y | 65 |
| Sacher, JR | 1 |
| Sims, MM | 1 |
| Pfeffer, LM | 4 |
| Miller, DD | 2 |
| Gerlach, SL | 1 |
| Dunlop, RA | 1 |
| Metcalf, JS | 1 |
| Banack, SA | 1 |
| Cox, PA | 1 |
| Delello Di Filippo, L | 1 |
| Hofstätter Azambuja, J | 1 |
| Paes Dutra, JA | 1 |
| Tavares Luiz, M | 1 |
| Lobato Duarte, J | 1 |
| Nicoleti, LR | 1 |
| Olalla Saad, ST | 1 |
| Chorilli, M | 2 |
| Brandner, S | 3 |
| McAleenan, A | 2 |
| Kelly, C | 2 |
| Spiga, F | 2 |
| Cheng, HY | 2 |
| Dawson, S | 2 |
| Schmidt, L | 2 |
| Faulkner, CL | 2 |
| Wragg, C | 2 |
| Jefferies, S | 4 |
| Higgins, JPT | 2 |
| Kurian, KM | 4 |
| Warfield, BM | 1 |
| Matheson, CJ | 1 |
| McArthur, DG | 1 |
| Backos, DS | 1 |
| Reigan, P | 1 |
| Lukas, RV | 4 |
| Razis, ED | 1 |
| Huse, JT | 4 |
| Gondi, V | 5 |
| Yin, D | 1 |
| Jin, G | 2 |
| He, H | 6 |
| Zhou, W | 6 |
| Fan, Z | 1 |
| Gong, C | 2 |
| Zhao, J | 15 |
| Xiong, H | 5 |
| Sharma, AB | 1 |
| Erasimus, H | 1 |
| Pinto, L | 2 |
| Caron, MC | 1 |
| Gopaul, D | 1 |
| Peterlini, T | 1 |
| Neumann, K | 3 |
| Nazarov, PV | 3 |
| Fritah, S | 2 |
| Klink, B | 2 |
| Herold-Mende, CC | 1 |
| Niclou, SP | 3 |
| Pasero, P | 1 |
| Calsou, P | 1 |
| Masson, JY | 1 |
| Britton, S | 1 |
| Van Dyck, E | 1 |
| Yamamuro, S | 2 |
| Takahashi, M | 8 |
| Satomi, K | 3 |
| Sasaki, N | 3 |
| Kobayashi, T | 2 |
| Uchida, E | 2 |
| Kawauchi, D | 3 |
| Nakano, T | 3 |
| Fujii, T | 2 |
| Narita, Y | 19 |
| Kondo, A | 1 |
| Wada, K | 4 |
| Yoshino, A | 2 |
| Ichimura, K | 12 |
| Tomiyama, A | 5 |
| Li, C | 16 |
| Li, W | 17 |
| Dai, S | 2 |
| Sharma, A | 5 |
| Sharma, HS | 2 |
| Wu, Y | 8 |
| Brault, C | 1 |
| Zerbib, Y | 1 |
| Chouaki, T | 1 |
| Maizel, J | 1 |
| Nyga, R | 1 |
| Yang, WB | 7 |
| Wu, AC | 3 |
| Hsu, TI | 12 |
| Liou, JP | 2 |
| Lo, WL | 5 |
| Chang, KY | 8 |
| Chen, PY | 8 |
| Kikkawa, U | 2 |
| Yang, ST | 5 |
| Kao, TJ | 6 |
| Chen, RM | 3 |
| Chang, WC | 6 |
| Ko, CY | 6 |
| Chuang, JY | 11 |
| Li, F | 5 |
| Chen, S | 9 |
| Yu, J | 5 |
| Gao, Z | 8 |
| Sun, Z | 8 |
| Yi, Y | 1 |
| Long, T | 2 |
| Zhang, C | 12 |
| Pan, Y | 4 |
| Qin, C | 2 |
| Long, W | 1 |
| Liu, Q | 10 |
| Zhao, W | 7 |
| Stockslager, MA | 1 |
| Malinowski, S | 1 |
| Touat, M | 2 |
| Yoon, JC | 1 |
| Geduldig, J | 1 |
| Mirza, M | 1 |
| Kim, AS | 1 |
| Wen, PY | 29 |
| Chow, KH | 2 |
| Ligon, KL | 17 |
| Manalis, SR | 1 |
| Yang, Z | 9 |
| Jiang, J | 6 |
| Shi, Z | 13 |
| Mao, Y | 4 |
| Qin, N | 1 |
| Tao, TH | 1 |
| Jin, L | 5 |
| Kiang, KM | 4 |
| Cheng, SY | 4 |
| Leung, GK | 9 |
| Chuang, HY | 2 |
| Hsu, LY | 1 |
| Pan, CM | 1 |
| Pikatan, NW | 1 |
| Yadav, VK | 2 |
| Fong, IH | 3 |
| Chen, CH | 1 |
| Yeh, CT | 5 |
| Chiu, SC | 2 |
| Liu, CC | 3 |
| Wu, CL | 1 |
| Lin, MX | 1 |
| Sze, CI | 1 |
| Gean, PW | 1 |
| Larrouquère, L | 1 |
| Berthier, S | 1 |
| Chovelon, B | 1 |
| Garrel, C | 1 |
| Vacchina, V | 1 |
| Paucot, H | 1 |
| Boutonnat, J | 1 |
| Faure, P | 1 |
| Hazane-Puch, F | 1 |
| Lavogina, D | 1 |
| Laasfeld, T | 1 |
| Vardja, M | 1 |
| Lust, H | 1 |
| Jaal, J | 1 |
| Wan, Z | 1 |
| Gu, J | 5 |
| Qian, J | 3 |
| Zhu, J | 8 |
| Wang, J | 48 |
| Chen, H | 9 |
| Luo, C | 2 |
| Rotondo, R | 2 |
| Ragucci, S | 2 |
| Castaldo, S | 2 |
| Oliva, MA | 7 |
| Landi, N | 2 |
| Pedone, PV | 2 |
| Arcella, A | 13 |
| Di Maro, A | 2 |
| Urbantat, RM | 1 |
| Jelgersma, C | 1 |
| Brandenburg, S | 1 |
| Nieminen-Kelhä, M | 1 |
| Kremenetskaia, I | 2 |
| Zollfrank, J | 1 |
| Mueller, S | 2 |
| Rubarth, K | 1 |
| Koch, A | 2 |
| Vajkoczy, P | 10 |
| Acker, G | 1 |
| Pai, FC | 1 |
| Huang, HW | 1 |
| Tsai, YL | 1 |
| Tsai, WC | 3 |
| Cheng, YC | 3 |
| Chang, HH | 3 |
| Pak, O | 1 |
| Zaitsev, S | 1 |
| Shevchenko, V | 1 |
| Bryukhovetskiy, I | 2 |
| Vengoji, R | 2 |
| Atri, P | 1 |
| Macha, MA | 2 |
| Seshacharyulu, P | 1 |
| Perumal, N | 1 |
| Mallya, K | 2 |
| Liu, Y | 48 |
| Smith, LM | 1 |
| Rachagani, S | 2 |
| Mahapatra, S | 1 |
| Ponnusamy, MP | 2 |
| Jain, M | 2 |
| Batra, SK | 2 |
| Shonka, N | 2 |
| Awah, CU | 1 |
| Winter, J | 1 |
| Mazdoom, CM | 1 |
| Ogunwobi, OO | 1 |
| Haryuni, RD | 1 |
| Tanaka, T | 3 |
| Takahashi, JI | 1 |
| Onuma, I | 1 |
| Zhou, Y | 12 |
| Yokoyama, S | 2 |
| Sakurai, H | 2 |
| Bao, Q | 1 |
| Chen, Z | 15 |
| Yao, L | 3 |
| Ci, Z | 1 |
| Wei, X | 4 |
| Sun, K | 5 |
| Zhou, G | 3 |
| Li, S | 29 |
| Ma, W | 10 |
| Tao, K | 1 |
| Huang, B | 2 |
| Yu, Z | 11 |
| Liang, R | 1 |
| Bi, J | 1 |
| Khan, A | 1 |
| Tang, J | 4 |
| Armando, AM | 1 |
| Wu, S | 6 |
| Zhang, W | 25 |
| Gimple, RC | 1 |
| Reed, A | 1 |
| Jing, H | 1 |
| Koga, T | 2 |
| Wong, IT | 1 |
| Gu, Y | 1 |
| Miki, S | 1 |
| Prager, B | 1 |
| Curtis, EJ | 1 |
| Wainwright, DA | 1 |
| Furnari, FB | 2 |
| Rich, JN | 8 |
| Cloughesy, TF | 17 |
| Kornblum, HI | 4 |
| Quehenberger, O | 1 |
| Rzhetsky, A | 1 |
| Cravatt, BF | 1 |
| Mischel, PS | 6 |
| Jiang, T | 19 |
| Ruan, W | 1 |
| Zhang, D | 10 |
| Yang, Q | 7 |
| Wang, G | 9 |
| Chen, Q | 9 |
| Zhu, F | 2 |
| Yin, J | 9 |
| Zou, Y | 6 |
| Qian, R | 1 |
| Zheng, M | 5 |
| Shi, B | 5 |
| Cui, P | 2 |
| Chen, F | 2 |
| Ma, G | 1 |
| Liu, W | 9 |
| Chen, L | 27 |
| Wang, S | 24 |
| Huang, G | 11 |
| He, L | 7 |
| Song, X | 4 |
| Zheng, C | 1 |
| Yu, S | 4 |
| Vaugier, L | 1 |
| Ah-Thiane, L | 1 |
| Aumont, M | 2 |
| Jouglar, E | 1 |
| Campone, M | 3 |
| Colliard, C | 1 |
| Doucet, L | 1 |
| Frenel, JS | 3 |
| Gourmelon, C | 1 |
| Robert, M | 1 |
| Martin, SA | 1 |
| Riem, T | 1 |
| Roualdes, V | 2 |
| Campion, L | 1 |
| Mervoyer, A | 1 |
| Zampieri, LX | 1 |
| Sboarina, M | 1 |
| Cacace, A | 1 |
| Grasso, D | 1 |
| Thabault, L | 1 |
| Hamelin, L | 1 |
| Vazeille, T | 1 |
| Dumon, E | 1 |
| Rossignol, R | 1 |
| Frédérick, R | 1 |
| Sonveaux, E | 1 |
| Sonveaux, P | 1 |
| Tabouret, E | 4 |
| Kishwar Jafri, SK | 1 |
| Bukhari, SS | 1 |
| Shamim, MS | 1 |
| Saran, F | 11 |
| Welsh, L | 1 |
| James, A | 1 |
| McBain, C | 4 |
| Gattamaneni, R | 1 |
| Harris, F | 1 |
| Pemberton, K | 1 |
| Schaible, J | 1 |
| Bender, S | 1 |
| Cseh, A | 4 |
| Brada, M | 6 |
| Du, K | 4 |
| Xia, Q | 5 |
| Sun, J | 7 |
| Feng, F | 5 |
| Fazzari, FGT | 1 |
| Rose, F | 1 |
| Pauls, M | 1 |
| Guay, E | 1 |
| Ibrahim, MFK | 1 |
| Basulaiman, B | 1 |
| Tu, M | 2 |
| Hutton, B | 1 |
| Nicholas, G | 3 |
| Ng, TL | 1 |
| Garcia, CR | 1 |
| Myint, ZW | 1 |
| Jayswal, R | 1 |
| Wang, C | 22 |
| Morgan, RM | 1 |
| Butts, AR | 1 |
| Weiss, HL | 1 |
| Villano, JL | 8 |
| Ambur, A | 1 |
| Ambur, L | 1 |
| Khan, L | 2 |
| Nathoo, R | 1 |
| Zirjacks, L | 1 |
| Stransky, N | 1 |
| Klumpp, L | 2 |
| Prause, L | 1 |
| Eckert, F | 2 |
| Zips, D | 4 |
| Schleicher, S | 1 |
| Handgretinger, R | 1 |
| Huber, SM | 2 |
| Ganser, K | 1 |
| Ashfaque, A | 1 |
| Hanif, F | 2 |
| Simjee, SU | 2 |
| Bari, MF | 1 |
| Faizi, S | 1 |
| Zehra, S | 1 |
| Mirza, T | 1 |
| Begum, S | 1 |
| Sumiyoshi, A | 1 |
| Shibata, S | 2 |
| Zhelev, Z | 1 |
| Miller, T | 1 |
| Lazarova, D | 1 |
| Zlateva, G | 1 |
| Aoki, I | 1 |
| Bakalova, R | 1 |
| Neth, BJ | 1 |
| Carabenciov, ID | 1 |
| Ruff, MW | 1 |
| Johnson, DR | 3 |
| Qu, H | 1 |
| Xue, X | 2 |
| Xu, J | 10 |
| Song, J | 5 |
| Xiao, M | 6 |
| Yuan, X | 5 |
| Tian, S | 5 |
| Ho, KH | 6 |
| Shih, CM | 6 |
| Liu, AJ | 4 |
| Chen, KC | 6 |
| Wei, KC | 4 |
| Hsu, PW | 2 |
| Tsai, HC | 3 |
| Lin, YJ | 3 |
| Chen, KT | 2 |
| Toh, CH | 1 |
| Huang, HL | 1 |
| Jung, SM | 1 |
| Tseng, CK | 1 |
| Ke, YX | 1 |
| Haehnel, S | 1 |
| Rade, M | 1 |
| Kaiser, N | 1 |
| Reiche, K | 1 |
| Horn, A | 1 |
| Loeffler, D | 1 |
| Blumert, C | 1 |
| Rapp, F | 1 |
| Horn, F | 1 |
| Meixensberger, J | 6 |
| Renner, C | 2 |
| Mueller, W | 2 |
| Gaunitz, F | 4 |
| Bechmann, I | 2 |
| Winter, K | 1 |
| O'Rawe, M | 1 |
| Wickremesekera, AC | 1 |
| Pandey, R | 1 |
| Young, D | 1 |
| Sim, D | 1 |
| FitzJohn, T | 1 |
| Burgess, C | 1 |
| Kaye, AH | 8 |
| Tan, ST | 2 |
| Klement, RJ | 2 |
| Popp, I | 1 |
| Kaul, D | 2 |
| Ehret, F | 1 |
| Grosu, AL | 5 |
| Polat, B | 2 |
| Sweeney, RA | 2 |
| Lewitzki, V | 2 |
| Hirtz, A | 1 |
| Lebourdais, N | 1 |
| Rech, F | 2 |
| Bailly, Y | 1 |
| Vaginay, A | 1 |
| Smaïl-Tabbone, M | 1 |
| Dubois-Pot-Schneider, H | 1 |
| Dumond, H | 1 |
| Schmitt, RR | 1 |
| Mahajan, SD | 1 |
| Pliss, A | 1 |
| Prasad, PN | 1 |
| Wang, N | 4 |
| Huang, R | 1 |
| Yang, K | 6 |
| Gao, Y | 9 |
| Dong, D | 1 |
| Xue, YY | 1 |
| Lu, YY | 1 |
| Sun, GQ | 1 |
| Fang, F | 2 |
| Ji, YQ | 1 |
| Tang, HF | 1 |
| Qiu, PC | 1 |
| Cheng, G | 3 |
| Surarak, T | 1 |
| Chantree, P | 1 |
| Sangpairoj, K | 1 |
| Kim, M | 3 |
| Yoo, J | 3 |
| Chang, JH | 19 |
| Kim, SH | 20 |
| Dong, Q | 2 |
| Li, L | 16 |
| Li, Q | 9 |
| Duan, L | 1 |
| Yin, H | 3 |
| Wang, X | 35 |
| Yuan, G | 2 |
| Xu, P | 3 |
| Wang, H | 30 |
| Pan, H | 4 |
| Chen, J | 19 |
| Deng, C | 1 |
| Ando, S | 1 |
| Moyama, C | 1 |
| Kojima, N | 1 |
| Fujita, M | 2 |
| Ohta, K | 1 |
| Kohno, Y | 1 |
| Ii, H | 1 |
| Nakata, S | 1 |
| Hu, A | 1 |
| Zhao, K | 3 |
| Schäfer, A | 2 |
| Zhang, Z | 24 |
| Elsässer, K | 1 |
| Culmsee, C | 2 |
| Zhong, L | 2 |
| Pagenstecher, A | 1 |
| Nimsky, C | 2 |
| Bartsch, JW | 2 |
| Perlow, HK | 3 |
| Yaney, A | 1 |
| Yang, M | 3 |
| Klamer, B | 2 |
| Matsui, J | 2 |
| Raval, RR | 3 |
| Blakaj, DM | 1 |
| Arnett, A | 2 |
| Beyer, S | 2 |
| Elder, JB | 2 |
| Ammirati, M | 3 |
| Lonser, R | 3 |
| Hardesty, D | 1 |
| Ong, S | 1 |
| Giglio, P | 7 |
| Pillainayagam, C | 1 |
| Goranovich, J | 1 |
| Grecula, J | 2 |
| Chakravarti, A | 13 |
| Brown, PD | 13 |
| Palmer, JD | 4 |
| Ramesh, T | 1 |
| Campian, JL | 9 |
| Ghosh, S | 4 |
| Kapoor, V | 2 |
| Yan, R | 1 |
| Thotala, S | 1 |
| Jash, A | 1 |
| Hu, T | 2 |
| Mahadevan, A | 1 |
| Rifai, K | 1 |
| Page, L | 1 |
| Lee, BH | 1 |
| Ferrando-Martinez, S | 1 |
| Wolfarth, AA | 1 |
| Yang, SH | 4 |
| Hallahan, D | 2 |
| Chheda, MG | 4 |
| Thotala, D | 3 |
| Ma, Z | 2 |
| Cai, S | 4 |
| Xiong, Q | 1 |
| Xia, H | 1 |
| Zhu, Z | 8 |
| Huang, Z | 4 |
| Yan, X | 5 |
| Wang, Q | 22 |
| Picca, A | 1 |
| Desjardins, C | 1 |
| Bihan, K | 1 |
| Weiss, N | 1 |
| Guihot, A | 1 |
| Nichelli, L | 1 |
| Feuvret, L | 7 |
| Pourcher, V | 1 |
| Dehais, C | 2 |
| Hu, S | 3 |
| Deng, Q | 2 |
| Hao, P | 1 |
| Guo, S | 3 |
| Zeyen, T | 4 |
| Potthoff, AL | 4 |
| Nemeth, R | 1 |
| Heiland, DH | 5 |
| Burger, MC | 1 |
| Steinbach, JP | 20 |
| Hau, P | 22 |
| Tabatabai, G | 10 |
| Glas, M | 14 |
| Schlegel, U | 12 |
| Grauer, O | 6 |
| Krex, D | 17 |
| Schnell, O | 9 |
| Goldbrunner, R | 12 |
| Sabel, M | 16 |
| Thon, N | 6 |
| Delev, D | 3 |
| Clusmann, H | 1 |
| Seidel, C | 9 |
| Güresir, E | 2 |
| Schmid, M | 2 |
| Schuss, P | 1 |
| Giordano, FA | 6 |
| Radbruch, A | 3 |
| Becker, A | 1 |
| Weller, J | 8 |
| Schaub, C | 9 |
| Vatter, H | 6 |
| Schilling, J | 1 |
| Winkler, F | 6 |
| Herrlinger, U | 19 |
| Schneider, M | 6 |
| Scherschinski, L | 1 |
| Prem, M | 1 |
| Tinhofer, I | 1 |
| Karbe, AG | 1 |
| Onken, JS | 1 |
| McKelvey, KJ | 1 |
| Hudson, AL | 2 |
| Donaghy, H | 1 |
| Stoner, SP | 1 |
| Wheeler, HR | 5 |
| Diakos, CI | 1 |
| Howell, VM | 2 |
| Lustig, SD | 1 |
| Kodali, SK | 1 |
| Longo, SL | 1 |
| Kundu, S | 1 |
| Viapiano, MS | 1 |
| Tesileanu, CMS | 2 |
| Gorlia, T | 28 |
| Golfinopoulos, V | 7 |
| French, PJ | 3 |
| van den Bent, MJ | 22 |
| Feng, YH | 1 |
| Lim, SW | 2 |
| Lin, HY | 3 |
| Wang, SA | 1 |
| Hsu, SP | 3 |
| Svec, RL | 2 |
| McKee, SA | 1 |
| Berry, MR | 1 |
| Kelly, AM | 1 |
| Fan, TM | 2 |
| Hergenrother, PJ | 2 |
| Yuen, CA | 1 |
| Barbaro, M | 1 |
| Haggiagi, A | 2 |
| Wu, PJ | 1 |
| Lai, TH | 1 |
| Sharma, P | 2 |
| Canella, A | 1 |
| Welker, AM | 2 |
| Beattie, CE | 2 |
| Easley, M | 1 |
| Jacob, NK | 2 |
| Pietrzak, M | 1 |
| Timmers, CM | 1 |
| Lang, F | 1 |
| Sampath, D | 1 |
| Puduvalli, VK | 9 |
| Zhu, Y | 9 |
| Zhao, L | 12 |
| Xu, Y | 15 |
| Zhan, W | 2 |
| Sun, X | 6 |
| Preddy, I | 2 |
| Nandoliya, K | 1 |
| Miska, J | 3 |
| Ahmed, AU | 7 |
| Li, T | 4 |
| Mehraein-Ghomi, F | 1 |
| Forbes, ME | 1 |
| Namjoshi, SV | 1 |
| Ballard, EA | 1 |
| Song, Q | 3 |
| Chou, PC | 1 |
| Parker Kerrigan, BC | 1 |
| Lang, FF | 3 |
| Lesser, G | 2 |
| Debinski, W | 3 |
| Yang, X | 14 |
| Maciaczyk, J | 4 |
| Schmidt-Wolf, IGH | 1 |
| Lombardi, F | 1 |
| Augello, FR | 1 |
| Artone, S | 1 |
| Gugu, MK | 1 |
| Cifone, MG | 2 |
| Cinque, B | 2 |
| Palumbo, P | 1 |
| Shi, R | 1 |
| Pan, P | 1 |
| Lv, R | 1 |
| Ma, C | 1 |
| Wu, E | 1 |
| Guo, R | 3 |
| Zhao, Z | 6 |
| Song, H | 7 |
| Zhou, J | 12 |
| Xu, G | 4 |
| Hou, T | 1 |
| Kang, Z | 1 |
| Van Gool, SW | 3 |
| Makalowski, J | 1 |
| Bitar, M | 1 |
| Van de Vliet, P | 1 |
| Schirrmacher, V | 1 |
| Stuecker, W | 1 |
| Gött, H | 1 |
| Kiez, S | 1 |
| Dohmen, H | 1 |
| Kolodziej, M | 1 |
| Stein, M | 2 |
| Lin, R | 1 |
| Xie, S | 2 |
| Yi, GZ | 6 |
| Ni, B | 1 |
| Qi, ST | 5 |
| Rahman, M | 4 |
| Olson, I | 1 |
| Mansour, M | 1 |
| Carlstrom, LP | 1 |
| Sutiwisesak, R | 1 |
| Saber, R | 1 |
| Rajani, K | 1 |
| Warrington, AE | 1 |
| Howard, A | 1 |
| Schroeder, M | 1 |
| Decker, PA | 16 |
| Sananikone, EF | 1 |
| Tchkonia, T | 1 |
| Parney, IF | 5 |
| Burma, S | 8 |
| Brown, D | 4 |
| Rodriguez, M | 1 |
| Sarkaria, JN | 37 |
| Kirkland, JL | 1 |
| Burns, TC | 4 |
| Ling, Z | 2 |
| Zhang, J | 36 |
| Chatterjee, A | 3 |
| Bhadane, M | 1 |
| Manjali, JJ | 1 |
| Dasgupta, A | 2 |
| Epari, S | 2 |
| Sahay, A | 1 |
| Patil, V | 3 |
| Moiyadi, A | 2 |
| Shetty, P | 2 |
| Gupta, T | 5 |
| Fu, WJ | 1 |
| Chen, XQ | 1 |
| Deng, RS | 1 |
| Tang, XP | 1 |
| Yang, KD | 2 |
| Niu, Q | 1 |
| Zhou, H | 6 |
| Li, QR | 2 |
| Lin, Y | 5 |
| Liang, M | 1 |
| Li, SS | 1 |
| Ping, YF | 2 |
| Liu, XD | 1 |
| Bian, XW | 3 |
| Yao, XH | 2 |
| Germano, IM | 2 |
| Ziu, M | 1 |
| Wen, P | 3 |
| Ormond, DR | 3 |
| Olson, JJ | 3 |
| Reinhardt, LS | 1 |
| Morás, AM | 2 |
| Henn, JG | 2 |
| Arantes, PR | 1 |
| Ferro, MB | 1 |
| Braganhol, E | 6 |
| de Souza, PO | 2 |
| de Oliveira Merib, J | 1 |
| Borges, GR | 1 |
| Dalanhol, CS | 1 |
| de Barros Dias, MCH | 1 |
| Nugent, M | 2 |
| Moura, DJ | 2 |
| Yuan, F | 3 |
| Zhang, S | 24 |
| Sun, Q | 2 |
| Ye, L | 5 |
| Xu, Z | 7 |
| Deng, G | 1 |
| Liu, B | 12 |
| Damanskienė, E | 1 |
| Balnytė, I | 1 |
| Valančiūtė, A | 1 |
| Alonso, MM | 2 |
| Preikšaitis, A | 1 |
| Stakišaitis, D | 1 |
| Bao, G | 1 |
| Zhang, M | 22 |
| Xiang, J | 4 |
| Wahafu, A | 3 |
| Wu, W | 20 |
| Ma, X | 5 |
| Huo, L | 1 |
| Bai, X | 2 |
| Xie, W | 4 |
| Liu, P | 8 |
| Wang, M | 18 |
| Cheng, M | 1 |
| Zhao, D | 2 |
| Scheffel, TB | 1 |
| Rockenbach, L | 1 |
| Cruz, FF | 1 |
| Kist, LW | 1 |
| Bogo, MR | 1 |
| Scholl, JN | 2 |
| Figueiró, F | 3 |
| Lenz, G | 5 |
| Morrone, FB | 1 |
| Mladek, AC | 14 |
| Burgenske, DM | 3 |
| Bakken, K | 1 |
| Hu, Z | 7 |
| Connors, MA | 1 |
| Carlson, BL | 17 |
| Wilson, J | 1 |
| Bommi-Reddy, A | 1 |
| Conery, A | 1 |
| Eckel-Passow, JE | 6 |
| Kitange, GJ | 14 |
| Stalinska, J | 1 |
| Vittori, C | 1 |
| Ingraham Iv, CH | 1 |
| Carson, SC | 1 |
| Plaisance-Bonstaff, K | 1 |
| Lassak, A | 1 |
| Faia, C | 1 |
| Colley, SB | 1 |
| Peruzzi, F | 1 |
| Reiss, K | 1 |
| Jursic, BS | 1 |
| Yu, Y | 6 |
| Wang, A | 5 |
| Sun, Y | 12 |
| Chu, L | 3 |
| Zhou, L | 13 |
| Liu, X | 29 |
| Sha, C | 3 |
| Xu, L | 7 |
| Chiang, IT | 1 |
| Liu, YC | 3 |
| Liu, HS | 1 |
| Ali, AAA | 1 |
| Chou, SY | 1 |
| Hsu, FT | 1 |
| Essien, EI | 1 |
| Hofer, TP | 1 |
| Atkinson, MJ | 2 |
| Anastasov, N | 2 |
| Pulvirenti, L | 1 |
| Monforte, F | 1 |
| Lo Presti, F | 1 |
| Li Volti, G | 1 |
| Carota, G | 1 |
| Sinatra, F | 1 |
| Bongiorno, C | 1 |
| Mannino, G | 1 |
| Cambria, MT | 1 |
| Condorelli, GG | 1 |
| Sanson, M | 13 |
| Wick, W | 42 |
| Brandes, AA | 32 |
| Clement, PM | 6 |
| Erridge, SC | 3 |
| Vogelbaum, MA | 9 |
| Nowak, AK | 6 |
| Baurain, JF | 2 |
| Mason, WP | 21 |
| Wheeler, H | 13 |
| Chinot, OL | 13 |
| Gill, S | 2 |
| Griffin, M | 1 |
| Rogers, L | 3 |
| Taal, W | 2 |
| Rudà, R | 4 |
| Weller, M | 55 |
| van Linde, ME | 2 |
| Aldape, K | 13 |
| Jenkins, RB | 5 |
| Kros, JM | 6 |
| Wesseling, P | 10 |
| von Deimling, A | 12 |
| Hoogstrate, Y | 1 |
| de Heer, I | 1 |
| Atmodimedjo, PN | 1 |
| Dubbink, HJ | 2 |
| Brouwer, RWW | 1 |
| van IJcken, WFJ | 1 |
| Cheung, KJ | 1 |
| Baumert, BG | 6 |
| Moon, HH | 1 |
| Park, JE | 5 |
| Kim, YH | 5 |
| Kim, JH | 26 |
| Kim, HS | 9 |
| Alanazi, R | 1 |
| Nakatogawa, H | 1 |
| Ji, D | 1 |
| Luo, Z | 3 |
| Golbourn, B | 3 |
| Feng, ZP | 1 |
| Rutka, JT | 2 |
| Sun, HS | 1 |
| Vidomanova, E | 1 |
| Majercikova, Z | 1 |
| Dibdiakova, K | 1 |
| Pilchova, I | 1 |
| Racay, P | 1 |
| Hatok, J | 1 |
| Basu Achari, R | 1 |
| Chakraborty, S | 5 |
| Goyal, L | 1 |
| Saha, S | 1 |
| Roy, P | 1 |
| Zameer, L | 1 |
| Mishra, D | 1 |
| Parihar, M | 1 |
| Das, A | 7 |
| Chandra, A | 2 |
| Biswas, B | 1 |
| Mallick, I | 2 |
| Arunsingh, MA | 1 |
| Chatterjee, S | 2 |
| Bhattacharyya, T | 1 |
| Serafim, RB | 1 |
| Cardoso, C | 1 |
| Arfelli, VC | 1 |
| Valente, V | 1 |
| Archangelo, LF | 1 |
| Le Rhun, E | 6 |
| Oppong, FB | 1 |
| Vanlancker, M | 1 |
| Stupp, R | 51 |
| Nabors, B | 4 |
| Chinot, O | 20 |
| Preusser, M | 3 |
| Márquez, M | 1 |
| Olausson, KH | 1 |
| Alaiya, A | 1 |
| Nilsson, S | 1 |
| Meurling, L | 1 |
| Holmberg, AR | 1 |
| Prasad, RN | 1 |
| Marrazzo, L | 2 |
| Detti, B | 5 |
| Scorsetti, M | 2 |
| Clerici, E | 2 |
| Navarria, P | 3 |
| Scoccianti, S | 7 |
| Grecula, JC | 1 |
| Yao, X | 3 |
| Yan, D | 4 |
| Lin, L | 6 |
| Sherman, JH | 2 |
| Peters, KB | 8 |
| Keir, ST | 4 |
| Keidar, M | 2 |
| Maimó-Barceló, A | 1 |
| Martín-Saiz, L | 1 |
| Fernández, JA | 1 |
| Pérez-Romero, K | 1 |
| Garfias-Arjona, S | 1 |
| Lara-Almúnia, M | 1 |
| Piérola-Lopetegui, J | 1 |
| Bestard-Escalas, J | 1 |
| Barceló-Coblijn, G | 1 |
| Persano, F | 1 |
| Gigli, G | 1 |
| Leporatti, S | 1 |
| Bady, P | 5 |
| Marosi, C | 11 |
| Grønberg, BH | 2 |
| Schultz, H | 2 |
| Taphoorn, MJB | 2 |
| Gijtenbeek, JMM | 1 |
| Malmström, A | 3 |
| Hegi, ME | 26 |
| Moujalled, D | 1 |
| Southon, AG | 1 |
| Saleh, E | 1 |
| Brinkmann, K | 1 |
| Ke, F | 1 |
| Iliopoulos, M | 1 |
| Cross, RS | 1 |
| Jenkins, MR | 1 |
| Nhu, D | 1 |
| Shi, MX | 1 |
| Kluck, RM | 1 |
| Lessene, G | 1 |
| Grabow, S | 1 |
| Bush, AI | 1 |
| Strasser, A | 1 |
| Tsai, YT | 2 |
| Hung, CY | 2 |
| Rehman, FU | 1 |
| Liu, R | 5 |
| Muhammad, P | 2 |
| Hanif, S | 2 |
| Ismail, M | 2 |
| Sun, M | 1 |
| Huang, N | 2 |
| Tao, Y | 1 |
| Wen, R | 1 |
| Zhao, G | 4 |
| Zhang, X | 27 |
| Xie, Z | 5 |
| Cheng, Y | 7 |
| Mao, J | 1 |
| Liu, G | 1 |
| Yang, FC | 1 |
| Gai, QJ | 1 |
| Mao, M | 2 |
| He, J | 8 |
| Qin, Y | 1 |
| Yao, XX | 1 |
| Wang, YX | 1 |
| Lu, HM | 1 |
| Cao, MF | 1 |
| He, MM | 1 |
| Wen, XM | 1 |
| Leng, P | 1 |
| Cai, XW | 1 |
| Yao, J | 2 |
| Feng, X | 2 |
| Dai, X | 2 |
| Peng, G | 2 |
| Guo, Z | 3 |
| Liu, Z | 12 |
| Guo, W | 1 |
| Zhang, P | 14 |
| Rao, V | 1 |
| Kumar, G | 1 |
| Vibhavari, RJA | 1 |
| Nandakumar, K | 1 |
| Thorat, ND | 1 |
| Chamallamudi, MR | 1 |
| Kumar, N | 3 |
| Huang, X | 8 |
| Li, H | 26 |
| Huang, H | 9 |
| Ganesa, S | 1 |
| Sule, A | 1 |
| Sundaram, RK | 2 |
| Bindra, RS | 5 |
| Aldoghachi, AF | 2 |
| Breyne, K | 1 |
| Ling, KH | 1 |
| Cheah, PS | 1 |
| Liang, L | 1 |
| Yan, B | 2 |
| Jiang, S | 2 |
| Huang, J | 11 |
| Xie, L | 1 |
| Majchrzak-Celińska, A | 3 |
| Kleszcz, R | 2 |
| Studzińska-Sroka, E | 1 |
| Łukaszyk, A | 1 |
| Szoszkiewicz, A | 1 |
| Stelcer, E | 1 |
| Jopek, K | 1 |
| Rucinski, M | 1 |
| Cielecka-Piontek, J | 1 |
| Krajka-Kuźniak, V | 2 |
| Lozinski, M | 2 |
| Bowden, NA | 2 |
| Graves, MC | 2 |
| Fay, M | 5 |
| Day, BW | 3 |
| Stringer, BW | 3 |
| Tooney, PA | 2 |
| Yu, X | 3 |
| Xu, H | 6 |
| Wei, K | 1 |
| Han, J | 5 |
| Omuro, A | 5 |
| Carpentier, AF | 5 |
| Idbaih, A | 13 |
| Reardon, DA | 39 |
| Cloughesy, T | 16 |
| Sumrall, A | 3 |
| Baehring, J | 3 |
| van den Bent, M | 6 |
| Bähr, O | 7 |
| Lombardi, G | 10 |
| Mulholland, P | 3 |
| Lassen, U | 4 |
| Sepulveda, JM | 7 |
| Khasraw, M | 11 |
| Vauleon, E | 4 |
| Muragaki, Y | 10 |
| Di Giacomo, AM | 1 |
| Butowski, N | 15 |
| Roth, P | 11 |
| Fu, AZ | 1 |
| Potter, V | 1 |
| Chalamandaris, AG | 1 |
| Tatsuoka, K | 2 |
| Lim, M | 6 |
| Schnöller, LE | 2 |
| Albrecht, V | 1 |
| Brix, N | 2 |
| Nieto, AE | 2 |
| Fleischmann, DF | 3 |
| Niyazi, M | 7 |
| Hess, J | 2 |
| Belka, C | 13 |
| Unger, K | 2 |
| Lauber, K | 2 |
| Orth, M | 2 |
| Mittal, S | 1 |
| Ali, J | 1 |
| Baboota, S | 1 |
| Wee, CW | 7 |
| In Yoon, H | 1 |
| Lee, SW | 3 |
| Lim, DH | 9 |
| Kavouridis, VK | 1 |
| Iorgulescu, JB | 1 |
| Di Bella, G | 1 |
| Borghetto, V | 1 |
| Costanzo, E | 1 |
| Zeng, Z | 3 |
| Geng, X | 1 |
| Wen, X | 2 |
| Yan, Q | 2 |
| Ling, C | 1 |
| Duan, J | 1 |
| Zheng, K | 2 |
| Steinbach, J | 2 |
| Finocchiaro, G | 5 |
| Ansstas, G | 5 |
| Taylor, JW | 4 |
| Honnorat, J | 12 |
| Petrecca, K | 10 |
| De Vos, F | 2 |
| Wick, A | 12 |
| Sahebjam, S | 2 |
| Mellinghoff, IK | 2 |
| Kinoshita, M | 6 |
| Roberts, M | 1 |
| Slepetis, R | 1 |
| Warad, D | 1 |
| Leung, D | 4 |
| Lee, M | 4 |
| Stepanović, A | 1 |
| Nikitović, M | 2 |
| Stanojković, TP | 1 |
| Grujičić, D | 4 |
| Bukumirić, Z | 1 |
| Srbljak, I | 1 |
| Ilić, R | 1 |
| Milošević, S | 2 |
| Arsenijević, T | 1 |
| Petrović, N | 1 |
| Arakawa, Y | 5 |
| Mineharu, Y | 1 |
| Uto, M | 1 |
| Mizowaki, T | 3 |
| Feldheim, J | 1 |
| Kessler, AF | 1 |
| Feldheim, JJ | 1 |
| Schulz, E | 1 |
| Wend, D | 1 |
| Lazaridis, L | 2 |
| Kleinschnitz, C | 2 |
| Ernestus, RI | 1 |
| Monoranu, CM | 1 |
| Löhr, M | 1 |
| Hagemann, C | 1 |
| Shervington, LA | 1 |
| Ingham, O | 1 |
| Imai, R | 1 |
| Sasaki, H | 4 |
| McAleavey, PG | 1 |
| Walls, GM | 1 |
| Chalmers, AJ | 5 |
| Smiley, SB | 2 |
| Zarrinmayeh, H | 1 |
| Das, SK | 3 |
| Pollok, KE | 4 |
| Vannier, MW | 2 |
| Veronesi, MC | 2 |
| Yeo, AT | 1 |
| Rawal, S | 1 |
| Delcuze, B | 1 |
| Christofides, A | 1 |
| Atayde, A | 1 |
| Strauss, L | 1 |
| Balaj, L | 2 |
| Rogers, VA | 1 |
| Uhlmann, EJ | 2 |
| Varma, H | 1 |
| Carter, BS | 5 |
| Boussiotis, VA | 1 |
| Charest, A | 1 |
| Xu, N | 6 |
| Lenahan, C | 1 |
| Tang, W | 3 |
| Zeng, H | 6 |
| Lan, XY | 1 |
| Li, D | 8 |
| Zhong, LZ | 1 |
| Zhao, H | 11 |
| Xi, YL | 1 |
| Sun, ZW | 1 |
| Dutra, JAP | 1 |
| Luiz, MT | 1 |
| Tavares Junior, AG | 1 |
| Di Filippo, LD | 1 |
| Carvalho, SG | 1 |
| Bruns, J | 2 |
| Egan, T | 1 |
| Mercier, P | 1 |
| Zustiak, SP | 2 |
| Yang, E | 2 |
| Wang, L | 24 |
| Jin, W | 1 |
| Tan, Y | 6 |
| Cui, X | 7 |
| Tong, F | 7 |
| Hong, B | 4 |
| Fang, C | 4 |
| Kang, C | 11 |
| Wei, L | 5 |
| Cai, H | 1 |
| Peng, SP | 1 |
| Tian, HB | 1 |
| Wang, JF | 1 |
| Gao, L | 4 |
| He, JP | 1 |
| Cucchiara, F | 1 |
| Luci, G | 1 |
| Giannini, N | 1 |
| Giorgi, FS | 1 |
| Orlandi, P | 2 |
| Banchi, M | 1 |
| Di Paolo, A | 1 |
| Pasqualetti, F | 6 |
| Danesi, R | 1 |
| Bocci, G | 3 |
| Petrenko, D | 1 |
| Chubarev, V | 1 |
| Syzrantsev, N | 1 |
| Ismail, N | 1 |
| Merkulov, V | 1 |
| Sologova, S | 1 |
| Grigorevskikh, E | 1 |
| Smolyarchuk, E | 1 |
| Alyautdin, R | 1 |
| Yang, W | 5 |
| Chai, T | 1 |
| Du, Q | 1 |
| Drljača, J | 1 |
| Popović, A | 1 |
| Bulajić, D | 1 |
| Stilinović, N | 1 |
| Vidičević Novaković, S | 1 |
| Sekulić, S | 1 |
| Milenković, I | 1 |
| Ninković, S | 1 |
| Ljubković, M | 1 |
| Čapo, I | 1 |
| Schäfer, N | 11 |
| Pietsch, T | 12 |
| Tzaridis, T | 8 |
| Borger, V | 1 |
| Catanzaro, D | 1 |
| Milani, G | 1 |
| Bozza, A | 1 |
| Bernardi, M | 1 |
| Chieregato, K | 1 |
| Menarin, M | 1 |
| Merlo, A | 2 |
| Celli, P | 1 |
| Belli, R | 1 |
| Peroni, D | 1 |
| Pozzato, A | 1 |
| Pozzato, G | 1 |
| Raneri, FA | 1 |
| Volpin, L | 2 |
| Ruggeri, M | 1 |
| Astori, G | 1 |
| McMahon, DJ | 1 |
| Gleeson, JP | 1 |
| O'Reilly, S | 1 |
| Bambury, RM | 1 |
| Zhao, B | 4 |
| Wu, J | 13 |
| Xia, Y | 2 |
| Qu, T | 1 |
| Xing, H | 2 |
| Fu, X | 2 |
| Xiong, B | 1 |
| Zhao, M | 7 |
| Wan, W | 1 |
| Wu, X | 6 |
| Han, L | 5 |
| Yang, F | 5 |
| Hu, L | 2 |
| Tiek, DM | 2 |
| Erdogdu, B | 1 |
| Razaghi, R | 1 |
| Sadowski, N | 1 |
| Alamillo-Ferrer, C | 1 |
| Hogg, JR | 1 |
| Haddad, BR | 2 |
| Drewry, DH | 1 |
| Wells, CI | 1 |
| Pickett, JE | 1 |
| Goenka, A | 1 |
| Hu, B | 1 |
| Goldlust, SA | 5 |
| Zuercher, WJ | 1 |
| Pertea, M | 1 |
| Timp, W | 1 |
| Riggins, RB | 2 |
| Xu, S | 3 |
| Lovejoy, DB | 1 |
| Liang, XJ | 1 |
| Park, JB | 1 |
| Efremov, YM | 1 |
| Ulasov, I | 1 |
| Kıyga, E | 1 |
| Adıgüzel, Z | 1 |
| Önay Uçar, E | 1 |
| Minaei, SE | 2 |
| Khoei, S | 5 |
| Khoee, S | 3 |
| Mahdavi, SR | 1 |
| Khan, I | 1 |
| Baig, MH | 1 |
| Mahfooz, S | 1 |
| Imran, MA | 1 |
| Khan, MI | 1 |
| Dong, JJ | 1 |
| Cho, JY | 1 |
| Hatiboglu, MA | 1 |
| Werner, M | 1 |
| Lyu, C | 1 |
| Stadlbauer, B | 1 |
| Schrader, I | 1 |
| Buchner, A | 1 |
| Stepp, H | 1 |
| Sroka, R | 1 |
| Pohla, H | 1 |
| Nakod, PS | 1 |
| Kondapaneni, RV | 1 |
| Edney, B | 1 |
| Kim, Y | 10 |
| Rao, SS | 1 |
| Prajapati, HP | 1 |
| Ansari, A | 1 |
| Jin, J | 4 |
| Wu, G | 3 |
| Zhu, H | 6 |
| Grigore, FN | 1 |
| Ma, J | 5 |
| Chen, CC | 14 |
| Lan, Q | 2 |
| Li, M | 17 |
| Moslemizadeh, A | 1 |
| Nematollahi, MH | 1 |
| Amiresmaili, S | 1 |
| Faramarz, S | 1 |
| Jafari, E | 1 |
| Khaksari, M | 1 |
| Rezaei, N | 1 |
| Bashiri, H | 1 |
| Kheirandish, R | 1 |
| de Souza, I | 2 |
| Monteiro, LKS | 1 |
| Guedes, CB | 1 |
| Silva, MM | 1 |
| Andrade-Tomaz, M | 1 |
| Contieri, B | 1 |
| Latancia, MT | 1 |
| Mendes, D | 1 |
| Porchia, BFMM | 1 |
| Lazarini, M | 1 |
| Gomes, LR | 1 |
| Rocha, CRR | 2 |
| Sowers, ML | 1 |
| Sowers, LC | 1 |
| Rodríguez-Camacho, A | 1 |
| Flores-Vázquez, JG | 1 |
| Moscardini-Martelli, J | 1 |
| Torres-Ríos, JA | 1 |
| Olmos-Guzmán, A | 1 |
| Ortiz-Arce, CS | 1 |
| Cid-Sánchez, DR | 1 |
| Pérez, SR | 1 |
| Macías-González, MDS | 1 |
| Hernández-Sánchez, LC | 1 |
| Heredia-Gutiérrez, JC | 1 |
| Contreras-Palafox, GA | 1 |
| Suárez-Campos, JJE | 1 |
| Celis-López, MÁ | 1 |
| Gutiérrez-Aceves, GA | 1 |
| Moreno-Jiménez, S | 1 |
| Yun, K | 3 |
| Chien, CH | 4 |
| Lee, JS | 2 |
| Liao, WA | 1 |
| Huang, CY | 7 |
| Lai, CC | 2 |
| Chi, PI | 1 |
| Chu, JM | 3 |
| Cheng, SM | 1 |
| Hwang, DY | 2 |
| Chen, SH | 3 |
| Paul, S | 1 |
| Sadeghipour, N | 1 |
| Kumar, SU | 1 |
| Massoud, TF | 5 |
| Paulmurugan, R | 5 |
| Fan, Y | 6 |
| Zhao, S | 5 |
| Guo, X | 3 |
| Xue, H | 2 |
| Deng, L | 2 |
| Zhao, R | 2 |
| Sun, C | 3 |
| Li, G | 16 |
| Melnick, KF | 1 |
| Miller, P | 2 |
| Carmichael, E | 1 |
| McGrath, K | 1 |
| Ghiaseddin, A | 1 |
| Tran, DD | 9 |
| Lassman, AB | 15 |
| Pugh, SL | 4 |
| Wang, TJC | 2 |
| Gan, HK | 7 |
| Sulman, EP | 8 |
| Won, M | 10 |
| Moazami, G | 1 |
| Macsai, MS | 1 |
| Gilbert, MR | 29 |
| Bain, EE | 1 |
| Blot, V | 1 |
| Ansell, PJ | 3 |
| Samanta, S | 1 |
| Kundu, MG | 1 |
| Armstrong, TS | 5 |
| Wefel, JS | 4 |
| de Vos, FY | 1 |
| Hsu, S | 2 |
| Cardona, AF | 1 |
| Bentsion, D | 1 |
| Peterson, RA | 2 |
| Gedye, C | 2 |
| Bourg, V | 1 |
| Curran, WJ | 7 |
| Mehta, MP | 19 |
| Gao, G | 3 |
| Zhang, K | 4 |
| Yang, Y | 9 |
| Zhuang, J | 1 |
| Guo, G | 4 |
| Chao, X | 1 |
| Ohno, M | 7 |
| Miyakita, Y | 6 |
| Yanagisawa, S | 2 |
| Tamura, Y | 1 |
| Jiao, W | 1 |
| Zhu, S | 1 |
| Shao, J | 2 |
| Wang, R | 9 |
| Zhong, Y | 1 |
| Kong, D | 4 |
| Wan, Q | 1 |
| Ye, Y | 1 |
| Lin, J | 4 |
| Yang, J | 11 |
| Lu, N | 1 |
| Feng, SW | 2 |
| Chang, PC | 1 |
| Chen, HY | 1 |
| Hueng, DY | 2 |
| Li, YF | 1 |
| Huang, SM | 2 |
| Lin, K | 1 |
| Gueble, SE | 1 |
| Huseman, ED | 1 |
| Herzon, SB | 1 |
| Thakur, S | 1 |
| Salunke, P | 1 |
| Ahuja, C | 1 |
| Madan, R | 2 |
| Guan, Y | 1 |
| Pan, M | 2 |
| Lu, Q | 1 |
| Gong, X | 4 |
| Mei, G | 1 |
| Pan, L | 2 |
| Dai, J | 3 |
| Wang, E | 2 |
| Raghava Kurup, R | 1 |
| Oakes, EK | 1 |
| Vadlamani, P | 1 |
| Nwosu, O | 1 |
| Danthi, P | 1 |
| Hundley, HA | 1 |
| Schulz, JA | 1 |
| Rodgers, LT | 1 |
| Kryscio, RJ | 1 |
| Hartz, AMS | 1 |
| Bauer, B | 1 |
| Cieśluk, M | 1 |
| Piktel, E | 1 |
| Wnorowska, U | 1 |
| Skłodowski, K | 1 |
| Kochanowicz, J | 2 |
| Kułakowska, A | 1 |
| Bucki, R | 1 |
| Pogoda, K | 1 |
| Ge, FH | 1 |
| Li, WX | 1 |
| Wang, XL | 1 |
| Shen, JL | 1 |
| Xu, AB | 1 |
| Hao, RR | 1 |
| Tseng, AJ | 1 |
| Tu, TH | 1 |
| Hua, WJ | 1 |
| Yeh, H | 1 |
| Chen, CJ | 2 |
| Lin, ZH | 1 |
| Hsu, WH | 1 |
| Chen, YL | 1 |
| Hsu, CC | 3 |
| Lin, TY | 2 |
| Hesse, F | 1 |
| Wright, AJ | 1 |
| Somai, V | 1 |
| Bulat, F | 1 |
| Kreis, F | 1 |
| Brindle, KM | 1 |
| Shi, DD | 1 |
| Youssef, GC | 1 |
| Nassar, AH | 1 |
| Lim-Fat, MJ | 1 |
| Rahman, R | 3 |
| Hu, H | 1 |
| Zhang, B | 8 |
| Tao, S | 1 |
| Zou, Q | 1 |
| He, C | 1 |
| Dong, S | 2 |
| Jatyan, R | 2 |
| Singh, P | 6 |
| Sahel, DK | 2 |
| Karthik, YG | 1 |
| Mittal, A | 3 |
| Chitkara, D | 3 |
| Qoorchi Moheb Seraj, F | 1 |
| Heravi-Faz, N | 1 |
| Soltani, A | 1 |
| Ahmadi, SS | 1 |
| Shahbeiki, F | 1 |
| Talebpour, A | 1 |
| Afshari, AR | 1 |
| Ferns, GA | 1 |
| Bahrami, A | 1 |
| Netto, JB | 1 |
| Melo, ESA | 1 |
| Oliveira, AGS | 2 |
| Sousa, LR | 2 |
| Santiago, LR | 1 |
| Santos, DM | 1 |
| Chagas, RCR | 1 |
| Gonçalves, AS | 1 |
| Thomé, RG | 1 |
| Santos, HB | 1 |
| Reis, RM | 7 |
| Ribeiro, RIMA | 3 |
| Sandbhor, P | 1 |
| Goda, JS | 3 |
| Mohanty, B | 1 |
| Chaudhari, P | 2 |
| Dutt, S | 1 |
| Banerjee, R | 1 |
| Drakulic, D | 2 |
| Schwirtlich, M | 1 |
| Petrovic, I | 1 |
| Mojsin, M | 1 |
| Milivojevic, M | 1 |
| Kovacevic-Grujicic, N | 1 |
| Stevanovic, M | 2 |
| Beltzig, L | 2 |
| Christmann, M | 4 |
| Kaina, B | 8 |
| Fu, Z | 7 |
| Fan, W | 1 |
| Zhang, G | 5 |
| Tao, X | 1 |
| Ji, B | 3 |
| Gong, J | 1 |
| Yoon, SJ | 1 |
| Baek, S | 1 |
| Yu, SE | 1 |
| Jo, E | 1 |
| Lee, D | 5 |
| Shim, JK | 6 |
| Choi, RJ | 2 |
| Park, J | 6 |
| Moon, JH | 5 |
| Kim, EH | 8 |
| Lee, JB | 1 |
| Park, JS | 1 |
| Sung, HJ | 1 |
| Kang, SG | 10 |
| Karve, AS | 1 |
| Desai, JM | 1 |
| Dave, N | 1 |
| Wise-Draper, TM | 1 |
| Gudelsky, GA | 1 |
| Phoenix, TN | 1 |
| DasGupta, B | 1 |
| Sengupta, S | 2 |
| Plas, DR | 1 |
| Desai, PB | 1 |
| Shidoh, S | 1 |
| Savjani, RR | 1 |
| Cho, NS | 1 |
| Ullman, HE | 1 |
| Hagiwara, A | 1 |
| Raymond, C | 2 |
| Lai, A | 10 |
| Nghiemphu, PL | 9 |
| Liau, LM | 11 |
| Pope, WB | 7 |
| Kaprealian, TB | 1 |
| Salamon, N | 1 |
| Ellingson, BM | 8 |
| Li, K | 6 |
| Chen, B | 7 |
| Xu, A | 1 |
| Shen, J | 7 |
| Hao, K | 1 |
| Hao, R | 1 |
| Zheng, Y | 4 |
| Ge, F | 1 |
| Huang, L | 2 |
| Wang, K | 9 |
| Chen, X | 15 |
| Chen, W | 8 |
| Jiang, X | 8 |
| Feng, M | 3 |
| Choo, M | 1 |
| Mai, VH | 1 |
| Kim, DH | 4 |
| Ku, JL | 1 |
| Lee, SK | 3 |
| Park, CK | 24 |
| An, YJ | 1 |
| Park, S | 2 |
| Aquilanti, E | 1 |
| Gan, T | 1 |
| Xie, M | 2 |
| Wang, P | 3 |
| Shi, Q | 1 |
| Miao, F | 3 |
| Shen, Z | 1 |
| Nie, E | 6 |
| Lan, B | 1 |
| Kadhim, ZA | 1 |
| Sulaiman, GM | 1 |
| Al-Shammari, AM | 1 |
| Khan, RA | 1 |
| Al Rugaie, O | 1 |
| Mohammed, HA | 1 |
| Cheng, F | 1 |
| Wan, X | 2 |
| Peng, P | 2 |
| Han, C | 4 |
| Mao, F | 1 |
| Guo, D | 3 |
| Mai, A | 2 |
| Ye, SW | 1 |
| Tu, JY | 1 |
| Gao, J | 6 |
| Kang, ZF | 1 |
| Yao, QM | 1 |
| Ting, WJ | 1 |
| Su, J | 2 |
| She, L | 1 |
| Su, L | 1 |
| Liu, C | 12 |
| Lee, J | 4 |
| Kim, E | 10 |
| Chong, K | 1 |
| Ryu, SW | 2 |
| Kim, C | 2 |
| Choi, K | 2 |
| Choi, C | 2 |
| Yadav, A | 1 |
| Alnakhli, A | 1 |
| Vemana, HP | 1 |
| Bhutkar, S | 1 |
| Muth, A | 1 |
| Dukhande, VV | 1 |
| Kuo, YY | 1 |
| Chen, PH | 5 |
| Lu, G | 4 |
| Zhu, P | 4 |
| Rao, M | 1 |
| Linendoll, N | 1 |
| Buja, LM | 1 |
| Bhattacharjee, MB | 1 |
| Brown, RE | 1 |
| Ballester, LY | 1 |
| Tian, X | 1 |
| Pilichowska, M | 1 |
| Wu, JK | 4 |
| Hergenroeder, GW | 1 |
| Glass, WF | 1 |
| Zhang, R | 5 |
| Pillai, AK | 1 |
| Hunter, RL | 1 |
| Zhu, JJ | 9 |
| Su, X | 3 |
| Xie, Y | 6 |
| Liu, F | 3 |
| Korovina, I | 1 |
| Vehlow, A | 1 |
| Temme, A | 1 |
| Cordes, N | 1 |
| Jang, BS | 1 |
| Park, AJ | 1 |
| Kim, IA | 11 |
| Chang, CY | 1 |
| Chen, JT | 1 |
| Chen, TH | 1 |
| Kebir, S | 8 |
| Ullrich, V | 2 |
| Berger, P | 1 |
| Dobersalske, C | 2 |
| Langer, S | 1 |
| Rauschenbach, L | 2 |
| Trageser, D | 1 |
| Till, A | 2 |
| Lorbeer, FK | 1 |
| Wieland, A | 2 |
| Wilhelm-Buchstab, T | 1 |
| Ahmad, A | 2 |
| Fröhlich, H | 2 |
| Cima, I | 1 |
| Prasad, S | 1 |
| Matschke, J | 1 |
| Jendrossek, V | 2 |
| Remke, M | 4 |
| Grüner, BM | 1 |
| Roesch, A | 1 |
| Siveke, JT | 1 |
| Herold-Mende, C | 6 |
| Blau, T | 2 |
| Keyvani, K | 3 |
| van Landeghem, FKH | 1 |
| Felsberg, J | 11 |
| Reifenberger, G | 18 |
| Sure, U | 4 |
| Brüstle, O | 2 |
| Simon, M | 7 |
| Scheffler, B | 3 |
| Balkanov, AS | 1 |
| Rozanov, ID | 1 |
| Glazkov, AA | 1 |
| Belyaev, AY | 1 |
| Kobyakov, GL | 3 |
| Shmakov, PN | 1 |
| Telysheva, EN | 1 |
| Strunina, YV | 1 |
| Usachev, DY | 1 |
| Radtke, L | 1 |
| Awortwe, C | 1 |
| Vater, I | 1 |
| Nagel, I | 1 |
| Sebens, S | 4 |
| Cascorbi, I | 1 |
| Kaehler, M | 1 |
| Zhu, TC | 1 |
| Que, TS | 1 |
| Li, ZY | 5 |
| Huang, GL | 1 |
| Yang, S | 9 |
| Xin, L | 3 |
| Xu, C | 4 |
| Clancy, A | 1 |
| Chen, D | 7 |
| Nadella, J | 1 |
| Stealey, S | 1 |
| Timperman, A | 1 |
| Xu, HB | 2 |
| Chen, XZ | 1 |
| Yu, ZL | 1 |
| Xue, F | 2 |
| Gallitto, M | 2 |
| Savacool, M | 1 |
| Lee, A | 4 |
| Sisti, MB | 2 |
| Cheng, B | 1 |
| Ayanlaja, AA | 1 |
| Kambey, PA | 1 |
| Qiu, Z | 1 |
| Hu, W | 5 |
| Dong, L | 3 |
| Liu, L | 10 |
| Meng, X | 4 |
| Han, D | 3 |
| Xiao, Z | 2 |
| Hosoya, T | 1 |
| Davey, C | 1 |
| Sese, J | 1 |
| Honda-Kitahara, M | 2 |
| Omura, T | 1 |
| Ozeki, Y | 1 |
| Kikuchi, M | 1 |
| Yoshida, A | 2 |
| Igaki, H | 3 |
| Matsushita, Y | 4 |
| Li, X | 33 |
| Leng, H | 1 |
| Yuan, H | 2 |
| Jones, D | 1 |
| Whitehead, CA | 4 |
| Dinevska, M | 1 |
| Widodo, SS | 1 |
| Furst, LM | 1 |
| Morokoff, AP | 6 |
| Drummond, KJ | 5 |
| Mantamadiotis, T | 5 |
| Stylli, SS | 5 |
| Tsuji, S | 3 |
| Nakamura, S | 3 |
| Shoda, K | 1 |
| Yamada, T | 3 |
| Shimazawa, M | 3 |
| Nakayama, N | 2 |
| Iwama, T | 4 |
| Hara, H | 3 |
| Yang, DY | 2 |
| Cheng, X | 5 |
| Bu, XY | 2 |
| Yan, ZY | 2 |
| Qu, MQ | 2 |
| Zhao, YW | 2 |
| Kong, LF | 2 |
| Wang, YW | 2 |
| Luo, JC | 2 |
| Lu, X | 2 |
| Liu, M | 2 |
| Xiao, H | 2 |
| Tang, X | 2 |
| Miller, R | 3 |
| Niazi, M | 2 |
| Russial, O | 1 |
| Poiset, S | 2 |
| Shi, W | 9 |
| Ali, AS | 1 |
| Lombardo, J | 1 |
| Niazi, MZ | 1 |
| Miller, RC | 1 |
| Alnahhas, I | 2 |
| Martinez, NL | 4 |
| Andrews, DW | 3 |
| Judy, KD | 1 |
| Chidley, P | 1 |
| Shanker, M | 1 |
| Phillips, C | 3 |
| Haghighi, N | 1 |
| Pinkham, MB | 1 |
| Whittle, JR | 1 |
| Sia, J | 1 |
| Huang, Y | 6 |
| Zhao, F | 1 |
| Pei, Y | 1 |
| Wei, Z | 2 |
| Li, R | 7 |
| Ai, P | 1 |
| Peng, X | 6 |
| Jovanović, N | 2 |
| Lazarević, M | 1 |
| Cvetković, VJ | 2 |
| Nikolov, V | 2 |
| Kostić Perić, J | 1 |
| Ugrin, M | 1 |
| Pavlović, S | 1 |
| Mitrović, T | 2 |
| Anwer, F | 1 |
| Waseem, M | 1 |
| Fatima, A | 1 |
| Malik, N | 1 |
| Ali, A | 2 |
| Zahid, S | 1 |
| Luo, L | 2 |
| Oh, CR | 1 |
| Kim, JE | 3 |
| Kim, SY | 4 |
| Kim, TW | 1 |
| Choi, J | 5 |
| Kim, J | 6 |
| Park, IJ | 1 |
| Lim, SB | 1 |
| Park, JH | 2 |
| Choi, MK | 1 |
| Cha, Y | 1 |
| Baek, JY | 1 |
| Beom, SH | 1 |
| Hong, YS | 1 |
| Ashkan, K | 3 |
| Brem, S | 10 |
| Trusheim, JE | 3 |
| Iwamoto, FM | 5 |
| Cobbs, CS | 3 |
| Heth, JA | 4 |
| Salacz, ME | 4 |
| D'Andre, S | 3 |
| Aiken, RD | 5 |
| Moshel, YA | 3 |
| Nam, JY | 4 |
| Pillainayagam, CP | 3 |
| Wagner, SA | 3 |
| Walter, KA | 5 |
| Chaudhary, R | 4 |
| Lee, IY | 3 |
| Bota, DA | 8 |
| Elinzano, H | 4 |
| Grewal, J | 4 |
| Lillehei, K | 7 |
| Mikkelsen, T | 15 |
| Walbert, T | 6 |
| Abram, S | 3 |
| Brenner, AJ | 4 |
| Ewend, MG | 5 |
| Khagi, S | 3 |
| Lovick, DS | 3 |
| Portnow, J | 3 |
| Kim, L | 4 |
| Loudon, WG | 3 |
| Thompson, RC | 4 |
| Avigan, DE | 3 |
| Fink, KL | 6 |
| Geoffroy, FJ | 4 |
| Gligich, O | 3 |
| Lindhorst, SM | 5 |
| Lutzky, J | 3 |
| Meisel, HJ | 3 |
| Nadji-Ohl, M | 3 |
| Sanchin, L | 3 |
| Sloan, A | 5 |
| Taylor, LP | 4 |
| Dunbar, EM | 4 |
| Etame, AB | 6 |
| Kesari, S | 16 |
| Mathieu, D | 4 |
| Piccioni, DE | 5 |
| Baskin, DS | 3 |
| Lacroix, M | 4 |
| May, SA | 3 |
| New, PZ | 3 |
| Pluard, TJ | 3 |
| Toms, SA | 8 |
| Tse, V | 3 |
| Peak, S | 4 |
| Battiste, JD | 3 |
| Mulholland, PJ | 3 |
| Pearlman, ML | 3 |
| Schulder, M | 3 |
| Prins, RM | 3 |
| Boynton, AL | 3 |
| Bosch, ML | 3 |
| Jia, W | 4 |
| Tian, H | 4 |
| Luo, M | 4 |
| Ding, N | 3 |
| Nice, EC | 3 |
| Huang, C | 5 |
| Guo, Y | 8 |
| Ning, W | 3 |
| Zhao, C | 7 |
| Qu, Y | 5 |
| Cui, Q | 3 |
| Khristov, V | 3 |
| Nesterova, D | 3 |
| Trifoi, M | 3 |
| Clegg, T | 3 |
| Daya, A | 3 |
| Barrett, T | 3 |
| Tufano, E | 3 |
| Shenoy, G | 3 |
| Pandya, B | 3 |
| Beselia, G | 3 |
| Smith, N | 3 |
| Mrowczynski, O | 3 |
| Zacharia, B | 3 |
| Waite, K | 3 |
| Lathia, J | 3 |
| Barnholtz-Sloan, J | 5 |
| Connor, J | 4 |
| Yavuz, M | 3 |
| Demircan, T | 3 |
| Liu, YF | 3 |
| Yao, Y | 7 |
| Ji, YS | 3 |
| Etcheverry, A | 5 |
| Chen, K | 6 |
| Song, BQ | 3 |
| Lin, W | 5 |
| Yin, A | 3 |
| He, YL | 4 |
| Zhou, Z | 8 |
| Zhong, Z | 3 |
| Zhang, L | 23 |
| Chen, ZS | 3 |
| Claret, FX | 3 |
| Elkabets, M | 3 |
| Wang, F | 13 |
| Sun, F | 3 |
| Liang, H | 5 |
| Lin, HW | 3 |
| Moreno, V | 3 |
| Manuel Sepúlveda, J | 4 |
| Pérez-Núñez, Á | 3 |
| González León, P | 3 |
| Hanna, B | 3 |
| Filvaroff, E | 3 |
| Aronchik, I | 3 |
| Chang, H | 3 |
| Amoroso, B | 3 |
| Zuraek, M | 3 |
| Sanchez-Perez, T | 3 |
| Mendez, C | 3 |
| Stephens, D | 3 |
| Nikolova, Z | 4 |
| Beige, A | 3 |
| Ghiringhelli, F | 7 |
| Lecuelle, J | 3 |
| Truntzer, C | 3 |
| Truc, G | 6 |
| Vincent, J | 3 |
| Farah, W | 3 |
| Borsotti, F | 3 |
| Mazilu, I | 3 |
| Ilie, SM | 3 |
| Hundal, J | 3 |
| Singh, A | 4 |
| Pereira, MK | 3 |
| Vredenburg, J | 3 |
| Goker Bagca, B | 4 |
| Ozates, NP | 4 |
| Biray Avci, C | 4 |
| Dong, J | 4 |
| Peng, Y | 5 |
| Zhong, M | 3 |
| Jiang, Z | 5 |
| Tao, Q | 3 |
| Zhu, T | 5 |
| Ge, X | 6 |
| Gong, S | 3 |
| Guo, J | 5 |
| Ge, R | 2 |
| Jiang, H | 5 |
| Topkan, E | 6 |
| Kucuk, A | 3 |
| Selek, U | 4 |
| Lin, D | 3 |
| Lin, Z | 2 |
| Lin, G | 2 |
| Schatz, J | 2 |
| Ladinig, A | 2 |
| Fietkau, R | 6 |
| Putz, F | 4 |
| Gaipl, US | 3 |
| Frey, B | 3 |
| Derer, A | 3 |
| Wen, B | 3 |
| Song, S | 4 |
| Wu, H | 8 |
| Wu, Q | 11 |
| Tong, X | 3 |
| Morelli, MB | 4 |
| Nabissi, M | 4 |
| Amantini, C | 3 |
| Maggi, F | 3 |
| Ricci-Vitiani, L | 9 |
| Pallini, R | 12 |
| Santoni, G | 4 |
| Staffieri, S | 4 |
| Sanchez, M | 3 |
| Devalckeneer, A | 2 |
| Aboukaïs, R | 3 |
| Bourgeois, P | 2 |
| Reyns, N | 3 |
| Lejeune, JP | 2 |
| Yahyapour, R | 2 |
| Kordestani, Z | 2 |
| Larizadeh, MH | 2 |
| Jomehzadeh, A | 2 |
| Amirinejad, M | 2 |
| Ahmadi-Zeidabadi, M | 4 |
| Tancredi, A | 2 |
| Gusyatiner, O | 2 |
| Buri, MC | 2 |
| Lomazzi, R | 2 |
| Chiesi, D | 2 |
| Messerer, M | 2 |
| Zhao, JX | 2 |
| Fang, ZY | 2 |
| Cui, XT | 2 |
| Su, DY | 2 |
| Zhou, JH | 2 |
| Wang, GX | 2 |
| Qiu, ZJ | 2 |
| Liu, SZ | 2 |
| Fu, JQ | 2 |
| Kang, CS | 4 |
| Wang, JC | 3 |
| Wang, QX | 3 |
| Yu, T | 6 |
| Zhou, F | 2 |
| Tian, W | 2 |
| Xu, R | 5 |
| Zeng, A | 8 |
| Taylor, TH | 2 |
| Duma, CM | 2 |
| LaRocca, RV | 2 |
| Carrillo, JA | 3 |
| Abedi, M | 2 |
| Hsu, FPK | 2 |
| Kong, XT | 2 |
| Hsieh, C | 2 |
| Bota, PG | 2 |
| Nistor, GI | 2 |
| Keirstead, HS | 2 |
| Dillman, RO | 2 |
| Ahluwalia, MS | 10 |
| Abad, AP | 2 |
| Curry, WT | 5 |
| Wong, ET | 8 |
| Figel, SA | 2 |
| Mechtler, LL | 2 |
| Peereboom, DM | 4 |
| Hutson, AD | 2 |
| Withers, HG | 2 |
| Belal, AN | 2 |
| Qiu, J | 3 |
| Mogensen, KM | 2 |
| Dharma, SS | 2 |
| Dhawan, A | 2 |
| Birkemeier, MT | 2 |
| Casucci, DM | 2 |
| Ciesielski, MJ | 2 |
| Fenstermaker, RA | 2 |
| Son, M | 2 |
| Mehra, P | 2 |
| Nguyen, FT | 2 |
| Jin, X | 7 |
| Koman, VB | 2 |
| Lee, MA | 2 |
| Bakh, NA | 2 |
| Strano, MS | 2 |
| Che, J | 1 |
| DePalma, TJ | 1 |
| Sivakumar, H | 1 |
| Mezache, LS | 1 |
| Tallman, MM | 1 |
| Venere, M | 2 |
| Swindle-Reilly, K | 1 |
| Veeraraghavan, R | 1 |
| Skardal, A | 1 |
| Visintin, R | 1 |
| Ray, SK | 8 |
| Chao, M | 1 |
| Cao, H | 3 |
| Xiao, B | 2 |
| Shi, X | 2 |
| Uhrbom, L | 2 |
| Dimberg, A | 1 |
| Faghani, S | 1 |
| Khosravi, B | 1 |
| Moassefi, M | 1 |
| Conte, GM | 1 |
| Erickson, BJ | 4 |
| Zeiner, PS | 2 |
| Kowalski, T | 1 |
| Ringel, F | 5 |
| Schmidt-Graf, F | 5 |
| Brehmer, S | 3 |
| Tonn, JC | 13 |
| Bullinger, L | 1 |
| Weth, FR | 1 |
| Peng, L | 2 |
| Paterson, E | 1 |
| Gray, C | 1 |
| Chang, SM | 24 |
| Youssef, G | 1 |
| de Groot, JF | 11 |
| Galanis, E | 6 |
| Al-Holou, WN | 1 |
| Ravikumar, V | 1 |
| Shankar, S | 1 |
| Oneka, M | 1 |
| Fehmi, Z | 1 |
| Verhaak, RG | 3 |
| Kim, H | 6 |
| Pratt, D | 1 |
| Camelo-Piragua, S | 1 |
| Speers, C | 2 |
| Wahl, DR | 4 |
| Hollon, T | 1 |
| Sagher, O | 1 |
| Muraszko, KM | 1 |
| Lawrence, TS | 7 |
| de Carvalho, AC | 1 |
| Rao, A | 1 |
| Rehemtulla, A | 4 |
| Ma, H | 3 |
| Cheng, P | 1 |
| Zhao, Y | 8 |
| Han, Q | 2 |
| Brown, JMC | 1 |
| Zaben, M | 1 |
| Ormonde, C | 1 |
| Sharouf, F | 1 |
| Spencer, R | 1 |
| Bhatt, H | 1 |
| Siebzehnrubl, FA | 2 |
| Gray, WP | 1 |
| Saini, A | 2 |
| Ballesta, A | 2 |
| Gallo, JM | 1 |
| Nishikawa, R | 17 |
| Yamasaki, F | 6 |
| Tanaka, S | 10 |
| Yamaguchi, S | 3 |
| Mukasa, A | 4 |
| Kanamori, M | 2 |
| Mizuhata, M | 1 |
| Takamatsu, S | 1 |
| Sakurai, T | 1 |
| Minamikawa, R | 1 |
| Yamazaki, M | 1 |
| Miyashita, K | 2 |
| Kumano, T | 1 |
| Nakada, M | 7 |
| Gabata, T | 1 |
| Alejo, S | 1 |
| Palacios, BE | 1 |
| Venkata, PP | 2 |
| Johnson, JD | 1 |
| Jayamohan, S | 1 |
| Pratap, UP | 1 |
| Clarke, K | 1 |
| Lv, Y | 2 |
| Weldon, K | 1 |
| Viswanadhapalli, S | 3 |
| Lai, Z | 1 |
| Ye, Z | 2 |
| Gilbert, AR | 1 |
| Suzuki, T | 1 |
| Tekmal, RR | 3 |
| Zheng, S | 1 |
| Vadlamudi, RK | 3 |
| Sareddy, GR | 3 |
| Bastiancich, C | 1 |
| Newland, B | 1 |
| Marsland, M | 1 |
| Dowdell, A | 1 |
| Faulkner, S | 1 |
| Jobling, P | 1 |
| Rush, RA | 1 |
| Lynam, J | 2 |
| Griffin, CP | 1 |
| Baker, M | 1 |
| Marsland, J | 1 |
| Jiang, CC | 1 |
| Hondermarck, H | 1 |
| Amelot, A | 2 |
| Terrier, LM | 1 |
| Mathon, B | 1 |
| Joubert, C | 2 |
| Picart, T | 1 |
| Jecko, V | 1 |
| Bauchet, L | 5 |
| Bernard, F | 1 |
| Castel, X | 1 |
| Chenin, L | 1 |
| Cook, AR | 1 |
| Emery, E | 3 |
| Figarella-Branger, D | 12 |
| Gauchotte, G | 1 |
| Graillon, T | 3 |
| Jouvet, A | 2 |
| Kalamarides, M | 1 |
| Knafo, S | 1 |
| Lazard, A | 1 |
| Lubrano, V | 3 |
| Mokhtari, K | 6 |
| Rigau, V | 3 |
| Rousseau, A | 2 |
| Seizeur, R | 1 |
| Uro-Coste, E | 2 |
| Voirin, J | 1 |
| Metellus, P | 5 |
| Pallud, J | 2 |
| Zemmoura, I | 1 |
| Jiang, Y | 6 |
| Lu, H | 5 |
| Xu, T | 3 |
| McGillion-Moore, J | 1 |
| Sampath, P | 1 |
| Kim, N | 6 |
| Choi, JW | 3 |
| Lee, JI | 10 |
| Kong, DS | 11 |
| Zhong, X | 1 |
| Wei, G | 1 |
| Cui, W | 2 |
| Blakstad, H | 1 |
| Brekke, J | 2 |
| Rahman, MA | 2 |
| Arnesen, VS | 1 |
| Miletic, H | 2 |
| Brandal, P | 2 |
| Lie, SA | 2 |
| Chekenya, M | 2 |
| Goplen, D | 2 |
| Michels, LR | 2 |
| Fachel, FNS | 1 |
| Schuh, RS | 2 |
| Azambuja, JH | 3 |
| Gelsleichter, NE | 3 |
| Lenz, GS | 2 |
| Visioli, F | 1 |
| Teixeira, HF | 3 |
| Elsaka, R | 1 |
| Kitagwa, JM | 1 |
| Refaat, T | 1 |
| Mahmoud, AA | 1 |
| Shaikh, H | 1 |
| Meheissen, MAM | 1 |
| Elsaid, AA | 1 |
| Song, C | 6 |
| Zang, W | 1 |
| Shi, L | 12 |
| Zhu, L | 5 |
| Zhou, M | 3 |
| Qi, S | 9 |
| Malik, S | 1 |
| Suh, HW | 1 |
| Xiao, Y | 3 |
| Deng, Y | 1 |
| Fan, R | 1 |
| Huttner, A | 1 |
| Singh, V | 1 |
| Saltzman, WM | 1 |
| Bahal, R | 1 |
| Guo, Q | 4 |
| Cao, Z | 2 |
| Guan, Z | 1 |
| Jia, B | 3 |
| Hao, Q | 2 |
| Xu, M | 2 |
| Song, K | 1 |
| Zhu, W | 3 |
| Liang, Z | 1 |
| Ortiz-Rivera, J | 1 |
| Nuñez, R | 1 |
| Kucheryavykh, Y | 1 |
| Kucheryavykh, L | 1 |
| Ehinger, E | 1 |
| Kopecky, J | 2 |
| Darabi, A | 1 |
| Visse, E | 1 |
| Edvardsson, C | 1 |
| Tomasevic, G | 1 |
| Cederberg, D | 1 |
| Belting, M | 1 |
| Bengzon, J | 1 |
| Siesjö, P | 1 |
| Pawlowski, KD | 1 |
| Duffy, JT | 1 |
| Babak, MV | 1 |
| Balyasnikova, IV | 2 |
| Schaff, LR | 2 |
| Glavatskyi, OY | 2 |
| Griazov, AB | 1 |
| Chuvashova, OY | 1 |
| Kruchok, IV | 1 |
| Griazov, AA | 1 |
| Khmelnytskyi, HV | 2 |
| Shuba, IM | 2 |
| Stuley, VA | 2 |
| Zemskova, OV | 2 |
| Gallardo-Pérez, JC | 1 |
| Trejo-Solís, MC | 1 |
| Robledo-Cadena, DX | 1 |
| López-Marure, R | 1 |
| Agredano-Moreno, LT | 1 |
| Jimenez-García, LF | 1 |
| Sánchez-Lozada, LG | 1 |
| Elshazly, AM | 1 |
| Gewirtz, DA | 1 |
| Nakagawa-Saito, Y | 1 |
| Mitobe, Y | 1 |
| Togashi, K | 1 |
| Suzuki, S | 3 |
| Sugai, A | 1 |
| Kitanaka, C | 3 |
| Okada, M | 3 |
| Bosio, A | 1 |
| Cerretti, G | 1 |
| Padovan, M | 1 |
| Caccese, M | 3 |
| Denaro, L | 2 |
| Chioffi, F | 1 |
| Della Puppa, A | 6 |
| Aldegheri, V | 1 |
| Guarneri, V | 1 |
| Zagonel, V | 7 |
| Yang, L | 6 |
| Huang, Q | 4 |
| Villa, GR | 1 |
| Chiocca, EA | 6 |
| Zhou, P | 4 |
| Tang, S | 3 |
| Tan, Z | 1 |
| Shen, L | 3 |
| Peng, J | 2 |
| Pfau, LC | 1 |
| Glasow, A | 3 |
| Patties, I | 1 |
| Piehlmaier, D | 1 |
| Weber, P | 2 |
| Selmansberger, M | 1 |
| Heider, T | 1 |
| Hou, Z | 1 |
| Luo, N | 1 |
| Zhu, D | 2 |
| Tao, R | 1 |
| Nam, Y | 2 |
| Koo, H | 1 |
| Shin, S | 1 |
| Kim, D | 2 |
| Cho, HJ | 3 |
| Mu, Q | 4 |
| Choi, SW | 2 |
| Sa, JK | 4 |
| Seo, YJ | 1 |
| Lee, K | 2 |
| Oh, JW | 1 |
| Kwon, YJ | 2 |
| Park, WY | 3 |
| Lee, HW | 2 |
| Yoon, Y | 2 |
| Kut, C | 1 |
| Kleinberg, L | 3 |
| Waghule, T | 1 |
| Laxmi Swetha, K | 1 |
| Roy, A | 1 |
| Narayan Saha, R | 1 |
| Singhvi, G | 1 |
| Li, N | 6 |
| Lam, TL | 1 |
| Shum, HC | 1 |
| Gherardini, L | 1 |
| Vetri Buratti, V | 1 |
| Maturi, M | 1 |
| Inzalaco, G | 1 |
| Locatelli, E | 1 |
| Sambri, L | 1 |
| Gargiulo, S | 1 |
| Barone, V | 1 |
| Bonente, D | 1 |
| Bertelli, E | 1 |
| Tortorella, S | 1 |
| Franci, L | 1 |
| Fioravanti, A | 2 |
| Comes Franchini, M | 1 |
| Chiariello, M | 1 |
| Janjua, TI | 1 |
| Cao, Y | 10 |
| Ahmed-Cox, A | 1 |
| Raza, A | 1 |
| Moniruzzaman, M | 1 |
| Akhter, DT | 1 |
| Fletcher, NL | 2 |
| Kavallaris, M | 1 |
| Thurecht, KJ | 2 |
| Popat, A | 1 |
| You, F | 1 |
| Zhang, T | 6 |
| Meng, Q | 1 |
| Yu, R | 3 |
| Gao, S | 2 |
| Manea, AJ | 1 |
| Shi, ZF | 1 |
| Li, GZ | 1 |
| Zhai, Y | 1 |
| Pan, CQ | 1 |
| Yu, MC | 1 |
| Yu, XG | 1 |
| Salerno, S | 1 |
| Baglini, E | 1 |
| Poggetti, V | 1 |
| Cui, Y | 9 |
| Zha, B | 1 |
| Dang, Q | 1 |
| Shi, S | 2 |
| Cui, H | 3 |
| Huangfu, L | 1 |
| Gong, Z | 2 |
| Law, J | 1 |
| Wanggou, S | 2 |
| Ying, B | 1 |
| Francisco, M | 1 |
| Dong, W | 3 |
| Xiong, Y | 4 |
| Fan, JJ | 1 |
| MacLeod, G | 2 |
| Angers, S | 2 |
| Dirks, PB | 7 |
| Erthal, LCS | 1 |
| Shi, Y | 7 |
| Sweeney, KJ | 1 |
| Gobbo, OL | 1 |
| Ruiz-Hernandez, E | 1 |
| Fang, H | 1 |
| Su, H | 2 |
| Hanssen, E | 1 |
| Nowell, CJ | 2 |
| Greening, DW | 1 |
| Vella, LJ | 1 |
| Mousavi, SM | 1 |
| Hosseindoost, S | 1 |
| Mahdian, SMA | 1 |
| Vousooghi, N | 1 |
| Rajabi, A | 1 |
| Jafari, A | 1 |
| Ostadian, A | 1 |
| Hamblin, MR | 2 |
| Hadjighassem, M | 1 |
| Mirzaei, H | 2 |
| Brawanski, KR | 1 |
| Sprung, S | 1 |
| Freyschlag, CF | 4 |
| Hoeftberger, R | 1 |
| Ströbel, T | 1 |
| Haybaeck, J | 2 |
| Thomé, C | 4 |
| Manzl, C | 1 |
| Birkl-Toeglhofer, AM | 2 |
| Kong, YS | 1 |
| Vincent, KM | 1 |
| Dieters-Castator, D | 1 |
| Bukhari, AB | 1 |
| Glubrecht, D | 1 |
| Liu, RZ | 1 |
| Quilty, D | 1 |
| Findlay, SD | 1 |
| Yang, RZ | 1 |
| Tang, E | 1 |
| Lajoie, G | 1 |
| Eisenstat, DD | 4 |
| Gamper, AM | 1 |
| Fahlman, R | 1 |
| Godbout, R | 1 |
| Postovit, LM | 1 |
| Fu, Y | 3 |
| Thivat, E | 1 |
| Casile, M | 1 |
| Moreau, J | 1 |
| Molnar, I | 1 |
| Dufort, S | 1 |
| Seddik, K | 1 |
| Le Duc, G | 1 |
| De Beaumont, O | 1 |
| Loeffler, M | 3 |
| Durando, X | 6 |
| Biau, J | 3 |
| Nozhat, Z | 1 |
| Heydarzadeh, S | 1 |
| Shahriari-Khalaji, M | 1 |
| Iqbal, MZ | 1 |
| Kong, X | 4 |
| Cui, L | 1 |
| Miao, W | 3 |
| Ju, Y | 2 |
| Chen, T | 2 |
| Gu, N | 1 |
| Alalami, H | 1 |
| Bannykh, S | 1 |
| Fan, X | 4 |
| Hu, J | 12 |
| Mohammadpour, ZJ | 1 |
| Mohammadzadeh, R | 1 |
| Javadrashid, D | 1 |
| Baghbanzadeh, A | 1 |
| Doustvandi, MA | 1 |
| Barpour, N | 1 |
| Baradaran, B | 3 |
| Barciszewska, AM | 2 |
| Belter, A | 2 |
| Gawrońska, I | 1 |
| Giel-Pietraszuk, M | 1 |
| Naskręt-Barciszewska, MZ | 1 |
| Colardo, M | 1 |
| Gargano, D | 1 |
| Russo, M | 3 |
| Petraroia, M | 1 |
| Pensabene, D | 1 |
| D'Alessandro, G | 1 |
| Santoro, A | 4 |
| Limatola, C | 1 |
| Segatto, M | 1 |
| Di Bartolomeo, S | 1 |
| Fishman, H | 1 |
| Monin, R | 1 |
| Dor-On, E | 1 |
| Kinzel, A | 2 |
| Haber, A | 1 |
| Giladi, M | 1 |
| Weinberg, U | 4 |
| Palti, Y | 3 |
| Chu, W | 1 |
| Houston, ZH | 1 |
| Huda, P | 1 |
| Ahamed, M | 1 |
| Lim, TX | 1 |
| Pinkham, M | 1 |
| Xiao, J | 4 |
| Sim, HW | 3 |
| Lorrey, S | 1 |
| Regli, LKP | 1 |
| Huijs, SMH | 1 |
| Pasmans, RCOS | 1 |
| Leue, C | 1 |
| Dijkstra, JB | 1 |
| Eekers, DBP | 2 |
| Hovinga, KE | 1 |
| Anten, MHME | 1 |
| Hoeben, A | 3 |
| Broen, MPG | 1 |
| Arantes, A | 1 |
| Junqueira, JGM | 1 |
| Alexandre, GP | 1 |
| Severino, VGP | 1 |
| Kim, B | 1 |
| Yang, JT | 2 |
| Lee, IN | 2 |
| Huang, HC | 1 |
| Wu, YP | 3 |
| Chong, ZY | 1 |
| Chen, JC | 2 |
| Su, IC | 1 |
| Su, YK | 3 |
| Setiawan, SA | 1 |
| Lin, CM | 3 |
| Liu, HW | 1 |
| Brandt, B | 1 |
| Németh, M | 1 |
| Berta, G | 1 |
| Szünstein, M | 1 |
| Heffer, M | 1 |
| Rauch, TA | 1 |
| Pap, M | 1 |
| Sakhuja, R | 1 |
| Wei, J | 2 |
| Sun, T | 1 |
| Wan, J | 1 |
| Ma, L | 5 |
| Perrault, EN | 1 |
| Shireman, JM | 3 |
| Ali, ES | 2 |
| Lin, P | 1 |
| Park, C | 2 |
| Budhiraja, S | 1 |
| Baisiwala, S | 3 |
| Dixit, K | 1 |
| James, CD | 15 |
| Ben-Sahra, I | 2 |
| Pott, S | 1 |
| Basu, A | 3 |
| Uribe-Robles, M | 1 |
| Ortiz-Islas, E | 1 |
| Rodriguez-Perez, E | 1 |
| Valverde, FF | 1 |
| Lim, T | 1 |
| Martinez-Morales, AA | 1 |
| Wan, S | 1 |
| Abbas, MN | 1 |
| Kan, LK | 1 |
| Drill, M | 1 |
| Jayakrishnan, PC | 1 |
| Sequeira, RP | 1 |
| Galea, E | 1 |
| Todaro, M | 1 |
| Sanfilippo, PG | 1 |
| Hunn, M | 1 |
| Williams, DA | 1 |
| O'Brien, TJ | 1 |
| Monif, M | 1 |
| Kimura, K | 1 |
| Chun, JH | 1 |
| Lin, YL | 2 |
| Liang, YC | 1 |
| Jackson, TLB | 1 |
| Huang, RCC | 1 |
| Tan, N | 2 |
| Pan, J | 4 |
| Bian, Y | 1 |
| Hellmold, D | 3 |
| Kubelt, C | 5 |
| Daunke, T | 1 |
| Beckinger, S | 1 |
| Janssen, O | 1 |
| Hauck, M | 1 |
| Schütt, F | 1 |
| Adelung, R | 3 |
| Lucius, R | 4 |
| Haag, J | 1 |
| Synowitz, M | 7 |
| Held-Feindt, J | 8 |
| Shahmir, S | 1 |
| Zahmatkesh, N | 1 |
| Mirzaahmadi, S | 1 |
| Asaadi Tehrani, G | 1 |
| Allahyarzadeh Khiabani, N | 1 |
| Amin Doustvandi, M | 1 |
| Mohammadnejad, F | 1 |
| Salmani Hassan Kohal, E | 1 |
| Boushehri, N | 1 |
| Jafarlou, M | 1 |
| Zemskova, O | 1 |
| Yu, NY | 1 |
| Trillenberg, P | 1 |
| Bonsanto, MM | 1 |
| Leppert, J | 1 |
| Rades, D | 1 |
| Tong, S | 1 |
| Zhong, C | 2 |
| Huang, A | 4 |
| Mekala, JR | 1 |
| Adusumilli, K | 1 |
| Chamarthy, S | 1 |
| Angirekula, HSR | 1 |
| Summers, HS | 1 |
| Lewis, W | 1 |
| Williams, HEL | 1 |
| Bradshaw, TD | 4 |
| Moody, CJ | 1 |
| Stevens, MFG | 1 |
| Helal, DO | 1 |
| Abdel-Mottaleb, MMA | 1 |
| Kamel, AO | 1 |
| Rouatbi, N | 1 |
| Han, S | 5 |
| Geneidi, AS | 1 |
| Al-Jamal, KT | 1 |
| Awad, GAS | 1 |
| Merenzon, MA | 1 |
| Hincapie Arias, E | 1 |
| Bhatia, S | 1 |
| Shah, AH | 3 |
| Higgins, DMO | 1 |
| Villaverde, M | 1 |
| Belgorosky, D | 1 |
| Eijan, AM | 1 |
| Iturrioz-Rodríguez, N | 2 |
| Sampron, N | 4 |
| Matheu, A | 4 |
| Lv, W | 2 |
| He, W | 1 |
| Min, Z | 1 |
| Gong, L | 1 |
| Teng, C | 1 |
| Sun, S | 7 |
| Lv, L | 1 |
| Xin, H | 1 |
| Pibuel, MA | 1 |
| Poodts, D | 1 |
| Sias, SA | 1 |
| Byrne, A | 1 |
| Hajos, SE | 1 |
| Franco, PG | 1 |
| Lompardía, SL | 1 |
| Esser, D | 1 |
| Ahmeti, H | 1 |
| Wu, ZS | 1 |
| Chiu, YL | 1 |
| Wu, M | 10 |
| Song, D | 1 |
| Ahmad, N | 1 |
| Deng, S | 3 |
| Shu, X | 1 |
| Paradossi, G | 1 |
| Grossman, R | 2 |
| Riccitelli, F | 1 |
| Todaro, F | 1 |
| Ram, Z | 6 |
| Schioppa, S | 1 |
| Domenici, F | 1 |
| Peleli, M | 1 |
| Antoniadou, I | 1 |
| Rodrigues-Junior, DM | 2 |
| Savvoulidou, O | 1 |
| Caja, L | 2 |
| Katsouda, A | 1 |
| Ketelhuth, DFJ | 1 |
| Stubbe, J | 1 |
| Madsen, K | 1 |
| Moustakas, A | 2 |
| Papapetropoulos, A | 1 |
| Zhang, ZX | 1 |
| Ren, P | 1 |
| Cao, YY | 1 |
| Wang, TT | 1 |
| Huang, GH | 1 |
| Zhou, S | 4 |
| Liu, GL | 1 |
| Xiang, Y | 3 |
| Pei, YC | 1 |
| Chen, QZ | 1 |
| Chen, JX | 4 |
| Lv, SQ | 2 |
| Hasan, H | 1 |
| Afzal, M | 1 |
| Castresana, JS | 6 |
| Shahi, MH | 1 |
| Smith, J | 1 |
| Field, M | 1 |
| Sugaya, K | 1 |
| Nakhle, J | 1 |
| Khattar, K | 1 |
| Özkan, T | 2 |
| Boughlita, A | 1 |
| Abba Moussa, D | 1 |
| Darlix, A | 3 |
| Lorcy, F | 1 |
| Gerbal-Chaloin, S | 1 |
| Daujat-Chavanieu, M | 1 |
| Bellvert, F | 1 |
| Turchi, L | 1 |
| Virolle, T | 1 |
| Hugnot, JP | 1 |
| Buisine, N | 1 |
| Galloni, M | 1 |
| Dardalhon, V | 1 |
| Rodriguez, AM | 1 |
| Vignais, ML | 1 |
| Barberis, A | 1 |
| Zanotti, S | 1 |
| Montemurro, N | 1 |
| De Salvo, GL | 1 |
| Soffietti, R | 3 |
| Mazzanti, CM | 1 |
| Ius, T | 1 |
| Caffo, M | 1 |
| Paiar, F | 1 |
| Harris, AL | 1 |
| Buffa, FM | 1 |
| Kinhult, S | 1 |
| Tavelin, B | 2 |
| Löfgren, D | 1 |
| Rosenlund, L | 1 |
| Sandström, M | 1 |
| Strandeus, M | 3 |
| Henriksson, R | 12 |
| Güven, M | 1 |
| Taşpınar, F | 1 |
| Denizler-Ebiri, FN | 1 |
| Taşpınar, M | 2 |
| Rosenberg, H | 1 |
| Dawood, O | 1 |
| Hertan, L | 1 |
| Vega, RA | 1 |
| Anderson, M | 2 |
| Cappelli, L | 1 |
| Khan, MM | 1 |
| Kayne, A | 1 |
| Ji, N | 2 |
| Yue, S | 2 |
| Qi, J | 3 |
| Gu, L | 2 |
| Zhao, Q | 4 |
| Zhou, X | 11 |
| Lin, WH | 1 |
| Feathers, RW | 1 |
| Cooper, LM | 1 |
| Lewis-Tuffin, LJ | 1 |
| Anastasiadis, PZ | 1 |
| Pang, B | 2 |
| Hu, R | 1 |
| Mei, M | 2 |
| Ren, Y | 2 |
| Onyiah, C | 1 |
| Shepard, MJ | 1 |
| Surendran, A | 1 |
| Jenner, AL | 1 |
| Karimi, E | 1 |
| Fiset, B | 1 |
| Quail, DF | 1 |
| Walsh, LA | 1 |
| Craig, M | 1 |
| Mu, J | 2 |
| Zhu, X | 9 |
| Li, B | 4 |
| Yin, Z | 1 |
| Okamoto, R | 1 |
| Toya, K | 1 |
| Ogino, Y | 1 |
| Sato, A | 5 |
| Mallick, S | 3 |
| Gupta, S | 3 |
| Amariyil, A | 1 |
| Kunhiparambath, H | 2 |
| Laviraj, MA | 2 |
| Sharma, S | 6 |
| Sagiraju, HKR | 1 |
| Julka, PK | 2 |
| Sharma, D | 2 |
| Rath, GK | 2 |
| Krajcer, A | 1 |
| Grzywna, E | 1 |
| Lewandowska-Łańcucka, J | 1 |
| Czarnywojtek, A | 1 |
| Borowska, M | 1 |
| Dyrka, K | 1 |
| Van Gool, S | 2 |
| Sawicka-Gutaj, N | 1 |
| Moskal, J | 1 |
| Kościński, J | 1 |
| Graczyk, P | 1 |
| Hałas, T | 1 |
| Lewandowska, AM | 1 |
| Czepczyński, R | 1 |
| Ruchała, M | 1 |
| Xu, Q | 4 |
| Huang, K | 3 |
| Weng, Y | 1 |
| Bu, L | 1 |
| Zheng, X | 3 |
| Cai, J | 3 |
| Zhan, R | 2 |
| Ballo, MT | 1 |
| Conlon, P | 1 |
| Lavy-Shahaf, G | 3 |
| Vymazal, J | 2 |
| Rulseh, AM | 2 |
| Rezaee, A | 1 |
| Tehrany, PM | 1 |
| Tirabadi, FJ | 1 |
| Sanadgol, N | 1 |
| Karimi, AS | 1 |
| Ajdari, A | 1 |
| Eydivandi, S | 1 |
| Etemad, S | 1 |
| Rajabi, R | 1 |
| Rahmanian, P | 1 |
| Khorrami, R | 1 |
| Nabavi, N | 1 |
| Aref, AR | 1 |
| Zou, R | 2 |
| Rashidi, M | 1 |
| Zandieh, MA | 1 |
| Hushmandi, K | 1 |
| Witusik-Perkowska, M | 1 |
| Głowacka, P | 1 |
| Pieczonka, AM | 1 |
| Świderska, E | 1 |
| Pudlarz, A | 1 |
| Rachwalski, M | 1 |
| Szymańska, J | 1 |
| Zakrzewska, M | 1 |
| Jaskólski, DJ | 1 |
| Szemraj, J | 1 |
| Salvatori, L | 1 |
| Malatesta, S | 1 |
| Illi, B | 1 |
| Somma, MP | 1 |
| Fionda, C | 1 |
| Stabile, H | 1 |
| Fontanella, RA | 1 |
| Gaetano, C | 1 |
| Singh, K | 1 |
| Fleming, JL | 1 |
| Becker, AP | 2 |
| McElroy, J | 1 |
| Cui, T | 1 |
| Johnson, B | 1 |
| Kumar, A | 3 |
| Sebastian, E | 1 |
| Showalter, CA | 1 |
| Schrock, MS | 1 |
| Summers, MK | 1 |
| Becker, V | 1 |
| Tong, ZY | 1 |
| Manring, HR | 1 |
| Bell, EH | 2 |
| Robe, PA | 2 |
| Haque, SJ | 1 |
| Demircan, NV | 1 |
| Erpolat, OP | 1 |
| Guzel, C | 1 |
| Senturk, E | 1 |
| Bora, H | 1 |
| Karahacioglu, E | 1 |
| Albert, NL | 1 |
| Nelwan, DV | 1 |
| Quach, S | 1 |
| von Rohr, K | 1 |
| Kaiser, L | 1 |
| Teske, N | 1 |
| Unterrainer, LM | 1 |
| Bartos, LM | 1 |
| Ruf, VC | 1 |
| Brendel, M | 1 |
| Riemenschneider, MJ | 3 |
| Wetzel, C | 1 |
| Herms, J | 1 |
| Rupprecht, R | 1 |
| Bartenstein, P | 1 |
| von Baumgarten, L | 1 |
| Unterrainer, M | 1 |
| Holzgreve, A | 1 |
| Lin, CL | 3 |
| Li, HY | 1 |
| Ou, M | 1 |
| Cho, HY | 2 |
| Fu, J | 3 |
| Thein, TZ | 2 |
| Swenson, SD | 1 |
| Minea, RO | 2 |
| Stathopoulos, A | 1 |
| Schönthal, AH | 6 |
| Hofman, FM | 6 |
| Tang, L | 2 |
| Chen, TC | 10 |
| Chen, C | 15 |
| Ni, H | 1 |
| Zhou, B | 3 |
| Maeoka, R | 1 |
| Ouji, Y | 1 |
| Nakazawa, T | 2 |
| Matsuda, R | 2 |
| Morimoto, T | 1 |
| Yamada, S | 1 |
| Nishimura, F | 2 |
| Nakagawa, I | 2 |
| Park, YS | 1 |
| Yoshikawa, M | 1 |
| Nakase, H | 3 |
| Nizar, R | 1 |
| Cazacu, S | 1 |
| Xiang, C | 1 |
| Krasner, M | 1 |
| Barbiro-Michaely, E | 1 |
| Gerber, D | 1 |
| Schwartz, J | 1 |
| Fried, I | 1 |
| Yuval, S | 1 |
| Brodie, A | 1 |
| Kazimirsky, G | 1 |
| Amos, N | 1 |
| Unger, R | 1 |
| Brown, S | 1 |
| Penning, DH | 1 |
| Brodie, C | 1 |
| Wear, D | 1 |
| Bhagirath, E | 1 |
| Balachandar, A | 1 |
| Vegh, C | 1 |
| Pandey, S | 1 |
| Sousa, N | 2 |
| Geiß, C | 1 |
| Bindila, L | 1 |
| Lieberwirth, I | 1 |
| Régnier-Vigouroux, A | 4 |
| McKinnon, PJ | 1 |
| Shahani, V | 1 |
| Lickliter, JD | 1 |
| Ruben, J | 1 |
| Kichenadasse, G | 3 |
| Jennens, R | 1 |
| Gzell, C | 4 |
| Mason, RP | 1 |
| Becker, J | 1 |
| Unger, E | 1 |
| Stea, B | 2 |
| Ntafoulis, I | 2 |
| Kleijn, A | 1 |
| Ju, J | 1 |
| Jimenez-Cowell, K | 1 |
| Fabro, F | 2 |
| Klein, M | 2 |
| Chi Yen, RT | 1 |
| Balvers, RK | 1 |
| Stubbs, AP | 1 |
| Kers, TV | 2 |
| Lawler, SE | 4 |
| Beerepoot, LV | 1 |
| Kremer, A | 2 |
| Verreault, M | 4 |
| Byrne, AT | 3 |
| O'Farrell, AC | 2 |
| Connor, K | 2 |
| Biswas, A | 5 |
| Salvucci, M | 3 |
| Prehn, JHM | 2 |
| Lambrechts, D | 2 |
| Dilcan, G | 2 |
| Lodi, F | 2 |
| Arijs, I | 2 |
| Dirven, CMF | 1 |
| Leenstra, S | 6 |
| Lamfers, MLM | 2 |
| Erdem, İS | 1 |
| Russo, V | 1 |
| Alborghetti, M | 1 |
| Leske, H | 1 |
| Camenisch Gross, U | 1 |
| Hofer, S | 3 |
| Neidert, MC | 1 |
| Leske, S | 1 |
| Lehnick, D | 1 |
| Rushing, EJ | 1 |
| Peruzzi, P | 2 |
| Dominas, C | 1 |
| Fell, G | 2 |
| Bernstock, JD | 1 |
| Blitz, S | 1 |
| Mazzetti, D | 1 |
| Zdioruk, M | 1 |
| Dawood, HY | 1 |
| Triggs, DV | 1 |
| Ahn, SW | 1 |
| Bhagavatula, SK | 1 |
| Davidson, SM | 1 |
| Tatarova, Z | 1 |
| Pannell, M | 1 |
| Truman, K | 1 |
| Ball, A | 1 |
| Gold, MP | 1 |
| Pister, V | 1 |
| Fraenkel, E | 1 |
| Jonas, O | 1 |
| Paglia, G | 1 |
| Minacori, M | 1 |
| Meschiari, G | 1 |
| Fiorini, S | 1 |
| Chichiarelli, S | 1 |
| Eufemi, M | 1 |
| Altieri, F | 1 |
| Zheng, SX | 1 |
| Zhuang, BB | 1 |
| Shi, SS | 1 |
| Zhang, GL | 1 |
| Tang, D | 1 |
| Hu, Y | 3 |
| Gao, W | 3 |
| Fekete, A | 1 |
| Beilhartz, GL | 1 |
| Bahrampour, S | 1 |
| Kong, T | 1 |
| Morioka, MS | 1 |
| Jung, G | 1 |
| Schramek, D | 1 |
| Song, Y | 6 |
| Kim, TH | 1 |
| Melnyk, RA | 1 |
| Wang, LY | 1 |
| Beola, L | 1 |
| Pucci, C | 1 |
| Bertorelli, R | 1 |
| Ciofani, G | 3 |
| Jiao, J | 1 |
| Yang, R | 4 |
| Nayak, R | 1 |
| Mallick, B | 1 |
| Yue, Y | 1 |
| Ban, X | 1 |
| Jin, P | 1 |
| Paech, D | 1 |
| Duffy, C | 1 |
| Nitsch, L | 1 |
| Galldiks, N | 6 |
| Stummer, W | 5 |
| Hattingen, E | 3 |
| Ding, F | 1 |
| Ge, Z | 1 |
| Zhao, N | 1 |
| Agnihotri, S | 6 |
| Ji, J | 1 |
| Lin, F | 2 |
| Zhou, Q | 5 |
| You, Y | 21 |
| Lu, Z | 2 |
| Deng, H | 1 |
| Jamalpour, S | 1 |
| Alinezhad, A | 1 |
| Sabah, JT | 1 |
| Vazifehmand, R | 2 |
| Behrooz, AB | 2 |
| Hamzah, ASA | 1 |
| Davazdahemami, AA | 1 |
| Homaie, FM | 1 |
| Maddah, SM | 1 |
| Vincent, CA | 1 |
| Nissen, I | 1 |
| Dakhel, S | 1 |
| Hörnblad, A | 1 |
| Remeseiro, S | 1 |
| Butt, N | 1 |
| Enani, M | 1 |
| Alshanqiti, M | 1 |
| Alkhotani, A | 1 |
| Alsinani, T | 1 |
| Karami, MM | 1 |
| Fadul, MM | 1 |
| Almansouri, M | 1 |
| Hassan, A | 1 |
| Baeesa, S | 2 |
| Bamaga, AK | 1 |
| Alkhayyat, S | 2 |
| Faizo, E | 1 |
| Kurdi, M | 2 |
| Lin, IC | 1 |
| Chang, CH | 1 |
| Chong, YB | 1 |
| Kuo, SH | 1 |
| Cheng, YW | 1 |
| Lieu, AS | 1 |
| Tseng, TT | 1 |
| Lin, CJ | 2 |
| Tsai, HP | 1 |
| Kwan, AL | 2 |
| Bernardes Ferro, M | 1 |
| Lopes Alves, GA | 1 |
| Pires Peña, F | 1 |
| de Oliveira, JVR | 1 |
| de Souza, BM | 1 |
| da Silva, LF | 1 |
| Rapack Jacinto Silva, V | 1 |
| Silva Pinheiro, AC | 1 |
| Steffens Reinhardt, L | 1 |
| da Rosa, RG | 1 |
| Silveira Aguirre, TA | 1 |
| Habiboglu, R | 1 |
| Kayali, I | 1 |
| Saricanbaz, I | 1 |
| Tezcan, Y | 1 |
| Umlauf, BJ | 1 |
| Frampton, G | 1 |
| Cooper, A | 2 |
| Greene, HF | 1 |
| De Silva, MI | 1 |
| Greenberg, Z | 1 |
| Noreña Puerta, A | 1 |
| Adams, R | 1 |
| Milky, B | 1 |
| Zabolocki, M | 1 |
| van den Hurk, M | 1 |
| Ebert, LM | 1 |
| Fairly Bishop, C | 1 |
| Conn, SJ | 1 |
| Michael, MZ | 1 |
| Ormsby, RJ | 1 |
| Poonoose, S | 1 |
| Bardy, C | 1 |
| Cirotti, C | 1 |
| Taddei, I | 1 |
| Contadini, C | 1 |
| Di Girolamo, C | 1 |
| Pepe, G | 1 |
| De Bardi, M | 1 |
| Borsellino, G | 1 |
| Helmer-Citterich, M | 1 |
| Barilà, D | 2 |
| Dumitru, CA | 1 |
| Schröder, H | 1 |
| Schäfer, FTA | 1 |
| Aust, JF | 1 |
| Kreße, N | 1 |
| Siebert, CLR | 1 |
| Stein, KP | 1 |
| Haghikia, A | 1 |
| Wilkens, L | 1 |
| Mawrin, C | 1 |
| Sandalcioglu, IE | 1 |
| Qu, S | 1 |
| Ye, R | 1 |
| Krauze, AV | 2 |
| Li, MC | 1 |
| Shih, J | 2 |
| Tasci, E | 1 |
| Cooley Zgela, T | 1 |
| Sproull, M | 1 |
| Mackey, M | 1 |
| Shankavaram, U | 2 |
| Tofilon, P | 1 |
| Camphausen, K | 5 |
| Berglund, AE | 2 |
| Macaulay, RJ | 2 |
| Bassi, R | 2 |
| Dei Cas, M | 1 |
| Tringali, C | 2 |
| Compostella, F | 1 |
| Paroni, R | 1 |
| Giussani, P | 3 |
| Krassnig, S | 1 |
| Leber, SL | 1 |
| Orthmann, A | 1 |
| Golob-Schwarzl, N | 1 |
| Huber, HJ | 2 |
| Wohlrab, C | 1 |
| Skofler, C | 1 |
| Pennauer, M | 1 |
| Raicht, A | 1 |
| Naumann, M | 1 |
| Mahdy-Ali, K | 1 |
| von Campe, G | 2 |
| Leoni, M | 1 |
| Alcaniz, J | 1 |
| Hoffmann, J | 1 |
| Wälchli, T | 1 |
| Weis, S | 3 |
| Benesch, M | 1 |
| Tan, IL | 1 |
| Perez, AR | 1 |
| Lew, RJ | 2 |
| Baldwin, A | 1 |
| Zhu, YK | 1 |
| Shah, MM | 1 |
| Berger, MS | 19 |
| Doudna, JA | 2 |
| Fellmann, C | 2 |
| Zhan, Q | 3 |
| Yi, K | 1 |
| Franzmeier, S | 1 |
| Liesche-Starnecker, F | 2 |
| Schlegel, J | 4 |
| Feller, KJ | 1 |
| Beerens, C | 1 |
| Tching Chi Yen, R | 1 |
| Chien, MP | 1 |
| Jiang, LY | 1 |
| Wang, GH | 2 |
| Xu, JJ | 1 |
| Li, XL | 1 |
| Lin, XY | 1 |
| Fang, X | 1 |
| Zhang, HX | 1 |
| Jiang, CM | 1 |
| Mu, Y | 1 |
| Guan, Q | 1 |
| Zhou, C | 3 |
| Ma, Y | 3 |
| Ji, G | 1 |
| Sun, D | 4 |
| Sun, H | 3 |
| Wu, N | 2 |
| Jin, Y | 2 |
| Frandsen, S | 1 |
| Pedersen, AJ | 1 |
| Gredal, O | 1 |
| Møller, S | 1 |
| Geissler, UW | 1 |
| Nørøxe, DS | 1 |
| Chinyama, HA | 1 |
| Mokgautsi, N | 1 |
| Lawal, B | 1 |
| Wu, ATH | 1 |
| Huang, HS | 1 |
| Olatunji, G | 1 |
| Aderinto, N | 1 |
| Adefusi, T | 1 |
| Kokori, E | 1 |
| Akinmoju, O | 1 |
| Yusuf, I | 1 |
| Olusakin, T | 1 |
| Muzammil, MA | 1 |
| Yan, J | 3 |
| Bian, L | 1 |
| Lin, B | 2 |
| Xi, Z | 1 |
| Bittencourt, LFF | 1 |
| Negreiros-Lima, GL | 1 |
| Sousa, LP | 1 |
| Silva, AG | 1 |
| Souza, IBS | 1 |
| Dutra, MF | 1 |
| Silva, RF | 1 |
| Dias, ACF | 1 |
| Soriani, FM | 1 |
| Martins, WK | 1 |
| Barcelos, LS | 1 |
| Cheng, CH | 4 |
| Chou, CM | 2 |
| Lin, CW | 1 |
| Tan, MSY | 1 |
| Sandanaraj, E | 1 |
| Chong, YK | 2 |
| Koh, LWH | 1 |
| Ng, WH | 3 |
| Tan, NS | 2 |
| Tan, P | 1 |
| Ang, BT | 2 |
| Tang, C | 2 |
| Gras Navarro, A | 1 |
| Engelsen, A | 1 |
| Bindesbøll, C | 1 |
| Sarowar, S | 1 |
| Bahador, M | 1 |
| Bifulco, E | 1 |
| Waha, A | 2 |
| Gjertsen, BT | 1 |
| Selheim, F | 1 |
| Enger, PØ | 3 |
| Simonsen, A | 2 |
| von Rosenstiel, C | 1 |
| Wiestler, B | 2 |
| Haller, B | 1 |
| Gempt, J | 2 |
| Bettstetter, M | 2 |
| Rihani, L | 1 |
| Meyer, B | 2 |
| Kovaleva, K | 1 |
| Oleshko, O | 1 |
| Mamontova, E | 1 |
| Yarovaya, O | 1 |
| Zakharova, O | 1 |
| Zakharenko, A | 1 |
| Kononova, A | 1 |
| Dyrkheeva, N | 1 |
| Cheresiz, S | 1 |
| Pokrovsky, A | 1 |
| Lavrik, O | 1 |
| Salakhutdinov, N | 1 |
| Cameron, BD | 1 |
| Traver, G | 1 |
| Roland, JT | 1 |
| Brockman, AA | 1 |
| Dean, D | 1 |
| Johnson, L | 1 |
| Boyd, K | 2 |
| Ihrie, RA | 1 |
| Freeman, ML | 1 |
| Schwendeman, SP | 1 |
| Ohno, Y | 1 |
| Noda, Y | 1 |
| Saio, M | 1 |
| Ulasov, IV | 1 |
| Mijanovic, O | 1 |
| Savchuk, S | 2 |
| Gonzalez-Buendia, E | 1 |
| Sonabend, A | 1 |
| Xiao, T | 1 |
| Timashev, P | 1 |
| Lesniak, MS | 6 |
| Adilijiang, A | 2 |
| Hirano, M | 4 |
| Okuno, Y | 3 |
| Aoki, K | 5 |
| Ohka, F | 4 |
| Maeda, S | 4 |
| Tanahashi, K | 1 |
| Motomura, K | 6 |
| Shimizu, H | 2 |
| Yamaguchi, J | 1 |
| Wakabayashi, T | 7 |
| Natsume, A | 8 |
| Zheng, H | 2 |
| Xiong, J | 3 |
| Bao, H | 1 |
| Jin, H | 1 |
| Liang, P | 6 |
| Yoo, RE | 5 |
| Yun, TJ | 6 |
| Hwang, I | 1 |
| Hong, EK | 1 |
| Kang, KM | 2 |
| Choi, SH | 19 |
| Won, JK | 1 |
| Sohn, CH | 7 |
| Petrova, L | 1 |
| Korfiatis, P | 2 |
| Petr, O | 1 |
| LaChance, DH | 3 |
| Parney, I | 1 |
| Buckner, JC | 7 |
| Chang, JS | 2 |
| Lee, HS | 1 |
| Yoon, HI | 1 |
| Kim, JW | 7 |
| Hong, CK | 4 |
| Cho, J | 5 |
| Kim, TM | 14 |
| Kim, YJ | 6 |
| Kim, CY | 16 |
| Park, SH | 13 |
| Choe, G | 2 |
| Lee, ST | 6 |
| Kim, IH | 17 |
| Suh, CO | 8 |
| Yang, CH | 2 |
| Sims, M | 2 |
| Cai, C | 2 |
| Çetin, A | 2 |
| Biltekin, B | 2 |
| Qiao, Q | 1 |
| Skarkova, V | 1 |
| Krupova, M | 1 |
| Vitovcova, B | 1 |
| Skarka, A | 1 |
| Kasparova, P | 1 |
| Krupa, P | 1 |
| Kralova, V | 1 |
| Rudolf, E | 1 |
| Sharifi, Z | 1 |
| Abdulkarim, B | 7 |
| Meehan, B | 2 |
| Rak, J | 2 |
| Daniel, P | 2 |
| Schmitt, J | 1 |
| Lauzon, N | 1 |
| Eppert, K | 1 |
| Duncan, HM | 1 |
| Guiot, MC | 9 |
| Jean-Claude, B | 1 |
| Sabri, S | 4 |
| Shojaei, S | 4 |
| Koleini, N | 2 |
| Samiei, E | 1 |
| Aghaei, M | 1 |
| Cole, LK | 1 |
| Alizadeh, J | 2 |
| Islam, MI | 1 |
| Vosoughi, AR | 1 |
| Albokashy, M | 1 |
| Butterfield, Y | 1 |
| Marzban, H | 1 |
| Xu, F | 2 |
| Thliveris, J | 2 |
| Kardami, E | 2 |
| Hatch, GM | 2 |
| Eftekharpour, E | 1 |
| Akbari, M | 2 |
| Hombach-Klonisch, S | 4 |
| Klonisch, T | 4 |
| Ghavami, S | 4 |
| Gholamin, S | 1 |
| Youssef, OA | 1 |
| Rafat, M | 1 |
| Esparza, R | 1 |
| Kahn, S | 1 |
| Shahin, M | 1 |
| Giaccia, AJ | 1 |
| Graves, EE | 1 |
| Weissman, I | 1 |
| Mitra, S | 3 |
| Cheshier, SH | 1 |
| Gerstner, ER | 10 |
| Emblem, KE | 5 |
| Chang, K | 1 |
| Vakulenko-Lagun, B | 2 |
| Yen, YF | 1 |
| Beers, AL | 1 |
| Dietrich, J | 6 |
| Plotkin, SR | 5 |
| Catana, C | 1 |
| Hooker, JM | 1 |
| Duda, DG | 5 |
| Rosen, B | 1 |
| Kalpathy-Cramer, J | 5 |
| Jain, RK | 6 |
| Batchelor, T | 5 |
| Alafate, W | 2 |
| Zuo, J | 4 |
| Sun, L | 6 |
| Bouchart, C | 1 |
| Trépant, AL | 1 |
| Hein, M | 1 |
| Van Gestel, D | 1 |
| Demetter, P | 1 |
| Mulé, JJ | 2 |
| Devos, P | 1 |
| Houillier, C | 2 |
| Cartalat, S | 1 |
| Di Stefano, AL | 2 |
| Lepage, C | 1 |
| Dubois, F | 1 |
| Fu, W | 1 |
| You, C | 6 |
| Zhou, R | 2 |
| Sachdeva, R | 2 |
| Johnson, K | 1 |
| Celebre, A | 2 |
| Shahzad, U | 1 |
| Graham, MS | 1 |
| Kessler, JA | 1 |
| Chuang, JH | 1 |
| Karamchandani, J | 1 |
| Bredel, M | 6 |
| Verhaak, R | 1 |
| Das, S | 8 |
| Honorato, JR | 1 |
| Hauser-Davis, RA | 1 |
| Saggioro, EM | 1 |
| Correia, FV | 1 |
| Sales-Junior, SF | 1 |
| Soares, LOS | 1 |
| Lima, LDR | 1 |
| Moura-Neto, V | 5 |
| Lopes, GPF | 2 |
| Spohr, TCLS | 1 |
| Mao, P | 2 |
| Łysiak, M | 1 |
| Åkesson, L | 1 |
| Jakobsen, I | 1 |
| Mudaisi, M | 1 |
| Milos, P | 2 |
| Hallbeck, M | 2 |
| Fomichov, V | 1 |
| Broholm, H | 4 |
| Grunnet, K | 4 |
| Poulsen, HS | 5 |
| Bratthäll, C | 1 |
| Papagiannopoulou, A | 1 |
| Stenmark-Askmalm, M | 1 |
| Green, H | 1 |
| Söderkvist, P | 1 |
| Johannessen, TA | 1 |
| Bjerkvig, R | 6 |
| Yang, KY | 1 |
| Liu, MS | 2 |
| Chung, PH | 1 |
| Liu, JJ | 4 |
| Chou, SW | 2 |
| Youssef, M | 1 |
| Ludmir, EB | 1 |
| Mandel, JJ | 1 |
| Patel, AJ | 1 |
| Jalali, A | 1 |
| Treiber, J | 1 |
| McAleer, MF | 1 |
| Shao, F | 1 |
| Lo Dico, A | 1 |
| Salvatore, D | 1 |
| Martelli, C | 1 |
| Ronchi, D | 1 |
| Diceglie, C | 1 |
| Lucignani, G | 1 |
| Ottobrini, L | 1 |
| Lee, BI | 1 |
| Jeon, JH | 1 |
| Kim, DK | 1 |
| Kang, SW | 1 |
| Jang, H | 1 |
| Kiang, KMY | 3 |
| Wong, VK | 1 |
| Marino, A | 2 |
| Camponovo, A | 1 |
| Degl'Innocenti, A | 1 |
| Bartolucci, M | 1 |
| Tapeinos, C | 2 |
| Martinelli, C | 1 |
| De Pasquale, D | 1 |
| Santoro, F | 1 |
| Mollo, V | 1 |
| Arai, S | 1 |
| Suzuki, M | 2 |
| Harada, Y | 1 |
| Petretto, A | 1 |
| Dietterle, J | 2 |
| Oppermann, H | 2 |
| Lee, SF | 1 |
| Yip, PL | 1 |
| Wong, FCS | 1 |
| Pinson, H | 2 |
| Hallaert, G | 2 |
| Van der Meulen, J | 1 |
| Dedeurwaerdere, F | 1 |
| Vanhauwaert, D | 1 |
| Van den Broecke, C | 2 |
| Van Dorpe, J | 1 |
| Van Roost, D | 2 |
| Kalala, JP | 2 |
| Boterberg, T | 2 |
| Wang, WL | 1 |
| Aru, N | 1 |
| Shen, X | 2 |
| Ding, YM | 1 |
| Wu, SJ | 1 |
| Qin, HH | 1 |
| Jin, WY | 1 |
| Saito, T | 6 |
| Maruyama, T | 4 |
| Komori, T | 4 |
| Nitta, M | 4 |
| Tsuzuki, S | 1 |
| Fukui, A | 1 |
| Kawamata, T | 6 |
| Drumm, MR | 1 |
| Dixit, KS | 1 |
| Grimm, S | 2 |
| Kumthekar, P | 5 |
| Raizer, JJ | 4 |
| Kam, KL | 1 |
| McCord, M | 1 |
| Sachdev, S | 1 |
| Kruser, T | 1 |
| Steffens, A | 1 |
| Javier, R | 1 |
| McCortney, K | 1 |
| Horbinski, C | 2 |
| Cho, HR | 2 |
| Kumari, N | 2 |
| Thakur, N | 2 |
| Vu, HT | 2 |
| Tsai, CK | 1 |
| Huang, LC | 1 |
| Kan, IY | 1 |
| Jana, A | 1 |
| Narula, P | 1 |
| Chugh, A | 1 |
| Kulshreshtha, R | 2 |
| Schmitt, C | 4 |
| Adamski, V | 3 |
| Rasch, F | 1 |
| Hattermann, K | 5 |
| Harder, BG | 2 |
| Peng, S | 4 |
| Sereduk, CP | 1 |
| Sodoma, AM | 1 |
| Loftus, JC | 5 |
| Tran, NL | 8 |
| Mukherjee, S | 2 |
| Wood, J | 1 |
| Liaquat, I | 1 |
| Stapleton, SR | 1 |
| Martin, AJ | 1 |
| Draaisma, K | 1 |
| Chatzipli, A | 1 |
| Taphoorn, M | 1 |
| Kerkhof, M | 2 |
| Weyerbrock, A | 8 |
| Lukacova, S | 1 |
| Hanse, M | 1 |
| Fleischeuer, R | 1 |
| Watts, C | 3 |
| McAbee, J | 1 |
| Angelopoulos, N | 1 |
| Verhaak, RGW | 1 |
| Bours, V | 1 |
| McDermott, U | 1 |
| Lan, YL | 1 |
| Lou, JC | 1 |
| Xing, JS | 1 |
| Zou, S | 2 |
| Hu, JL | 1 |
| Lyu, W | 4 |
| De La Rosa, J | 2 |
| Urdiciain, A | 3 |
| Zazpe, I | 2 |
| Zelaya, MV | 2 |
| Meléndez, B | 3 |
| Rey, JA | 4 |
| Idoate, MA | 5 |
| Bernardo, PS | 1 |
| Guimarães, GHC | 1 |
| De Faria, FCC | 1 |
| Longo, GMDC | 1 |
| Netto, CD | 1 |
| Costa, PRR | 1 |
| Maia, RC | 1 |
| Eoli, M | 7 |
| Smits, M | 1 |
| Walenkamp, A | 1 |
| Franceschi, E | 14 |
| Whenham, N | 2 |
| Sanghera, P | 4 |
| French, P | 1 |
| Looman, J | 1 |
| Dey, J | 1 |
| Krause, S | 1 |
| Ansell, P | 3 |
| Nuyens, S | 1 |
| Spruyt, M | 1 |
| Brilhante, J | 1 |
| Coens, C | 2 |
| Ru, Y | 1 |
| Fei, Z | 2 |
| Čančer, M | 1 |
| Drews, LF | 1 |
| Bengtsson, J | 1 |
| Bolin, S | 1 |
| Rosén, G | 1 |
| Westermark, B | 1 |
| Nelander, S | 1 |
| Forsberg-Nilsson, K | 1 |
| Weishaupt, H | 1 |
| Swartling, FJ | 1 |
| Pötschke, R | 1 |
| Gielen, G | 1 |
| Kramm, C | 1 |
| Klusmann, JH | 1 |
| Hüttelmaier, S | 1 |
| Kühnöl, CD | 1 |
| Tomar, VS | 1 |
| Somasundaram, K | 3 |
| Hirono, S | 2 |
| Hasegawa, Y | 2 |
| Sakaida, T | 2 |
| Uchino, Y | 1 |
| Hatano, K | 2 |
| Iuchi, T | 3 |
| Ryu, JY | 1 |
| Min, KL | 1 |
| Chang, MJ | 1 |
| Neumann, DM | 1 |
| Stazi, G | 1 |
| Taglieri, L | 1 |
| Nicolai, A | 1 |
| Romanelli, A | 1 |
| Fioravanti, R | 1 |
| Morrone, S | 1 |
| Sabatino, M | 1 |
| Ragno, R | 1 |
| Taurone, S | 1 |
| Nebbioso, M | 1 |
| Carletti, R | 1 |
| Artico, M | 1 |
| Valente, S | 1 |
| Scarpa, S | 1 |
| Panje, CM | 1 |
| Putora, PM | 1 |
| Hundsberger, T | 6 |
| Hottinger, AF | 7 |
| Roelcke, U | 3 |
| Pesce, G | 3 |
| Herrmann, E | 1 |
| Matter-Walstra, K | 1 |
| Kadota, T | 1 |
| Saito, R | 4 |
| Kumabe, T | 4 |
| Mizusawa, J | 1 |
| Katayama, H | 1 |
| Sumi, M | 2 |
| Kim, GW | 1 |
| Lee, DH | 1 |
| Yeon, SK | 1 |
| Jeon, YH | 1 |
| Kwon, SH | 1 |
| Inada, M | 2 |
| Shindo, M | 2 |
| Yamamoto, Y | 5 |
| Akasaki, Y | 3 |
| Tanuma, SI | 2 |
| Yang, B | 5 |
| Thyparambil, S | 1 |
| Tian, Y | 2 |
| Cecchi, F | 1 |
| Rosenblum, M | 1 |
| Reiner, AS | 2 |
| Panageas, KS | 3 |
| Hembrough, T | 1 |
| Lin, AL | 1 |
| Teuber-Hanselmann, S | 1 |
| Schmidt, T | 1 |
| Oster, C | 1 |
| Pierscianek, D | 2 |
| Stuschke, M | 2 |
| Deuschl, C | 1 |
| Kosmala, R | 1 |
| Lisowski, D | 1 |
| Flentje, M | 2 |
| Guo, M | 4 |
| Oliveira, M | 1 |
| de Santana, LLB | 1 |
| Serafim, JC | 1 |
| Santos, AO | 1 |
| Quintino, MP | 1 |
| Correia, JTM | 1 |
| Damasceno, F | 1 |
| Sabino, JR | 1 |
| Pires, TRC | 1 |
| Coelho, PLC | 1 |
| de Faria Lopes, GP | 1 |
| Ulrich, H | 1 |
| Costa, SL | 1 |
| Cunha, S | 1 |
| Vaubel, RA | 2 |
| Remonde, D | 1 |
| Schroeder, MA | 14 |
| Caron, A | 1 |
| Kollmeyer, TM | 1 |
| Grove, R | 1 |
| Ma, DJ | 2 |
| Sarkar, G | 2 |
| Evers, L | 1 |
| Dhruv, HD | 3 |
| Berens, ME | 3 |
| Marin, BM | 1 |
| Klee, EW | 1 |
| Califano, A | 1 |
| Meyer, FB | 2 |
| O'Neill, BP | 3 |
| Giannini, C | 10 |
| Vaz Salgado, MA | 1 |
| Torres, J | 1 |
| Esteban, J | 1 |
| Gutiérrez, JA | 1 |
| Ley, L | 1 |
| Carrato, A | 1 |
| Hong, R | 1 |
| Lu, J | 4 |
| Guo, C | 1 |
| Nan, Y | 1 |
| Mirabdaly, S | 1 |
| Elieh Ali Komi, D | 1 |
| Shakiba, Y | 1 |
| Moini, A | 1 |
| Kiani, A | 2 |
| Higuchi, F | 2 |
| Nagashima, H | 2 |
| Ning, J | 3 |
| Koerner, MVA | 1 |
| Wakimoto, H | 4 |
| Cahill, DP | 4 |
| Rabé, M | 3 |
| Dumont, S | 1 |
| Álvarez-Arenas, A | 1 |
| Janati, H | 1 |
| Belmonte-Beitia, J | 1 |
| Calvo, GF | 1 |
| Thibault-Carpentier, C | 1 |
| Séry, Q | 2 |
| Chauvin, C | 1 |
| Joalland, N | 1 |
| Briand, F | 1 |
| Blandin, S | 1 |
| Scotet, E | 1 |
| Pecqueur, C | 2 |
| Clairambault, J | 1 |
| Oliver, L | 4 |
| Perez-Garcia, V | 1 |
| Nadaradjane, A | 3 |
| Cartron, PF | 3 |
| Gratas, C | 3 |
| Vallette, FM | 4 |
| Quan, R | 1 |
| Lee, YT | 3 |
| Calero-Pérez, P | 2 |
| Villamañan, L | 2 |
| Arias-Ramos, N | 1 |
| Pumarola, M | 3 |
| Ortega-Martorell, S | 2 |
| Julià-Sapé, M | 4 |
| Arús, C | 6 |
| Candiota, AP | 6 |
| Hu, C | 2 |
| Lal, B | 1 |
| Wei, S | 1 |
| Xia, S | 1 |
| Lv, S | 3 |
| Laterra, J | 2 |
| Umphlett, M | 1 |
| Shea, S | 1 |
| Tome-Garcia, J | 1 |
| Hormigo, A | 3 |
| Fowkes, M | 1 |
| Tsankova, NM | 1 |
| Yong, RL | 2 |
| Sorribes, IC | 1 |
| Handelman, SK | 1 |
| Jain, HV | 1 |
| Carvalho, B | 1 |
| Lopes, RG | 1 |
| Linhares, P | 2 |
| Costa, A | 1 |
| Caeiro, C | 2 |
| Fernandes, AC | 1 |
| Tavares, N | 1 |
| Osório, L | 2 |
| Vaz, R | 1 |
| Hwang, JW | 1 |
| Loisel-Duwattez, J | 1 |
| Desterke, C | 1 |
| Latsis, T | 1 |
| Pagliaro, S | 1 |
| Griscelli, F | 1 |
| Bennaceur-Griscelli, A | 1 |
| Turhan, AG | 2 |
| Rezaei, V | 1 |
| Rabiee, A | 1 |
| Khademi, F | 1 |
| Fontanilles, M | 5 |
| Fontanilles, A | 1 |
| Massy, N | 1 |
| Rouvet, J | 1 |
| Pereira, T | 1 |
| Alexandru, C | 4 |
| Hanzen, C | 3 |
| Basuyau, F | 1 |
| Langlois, O | 4 |
| Clatot, F | 4 |
| Tennevet, I | 7 |
| Di Fiore, F | 4 |
| Joannidès, R | 1 |
| Lamoureux, F | 1 |
| Pham, A | 1 |
| Yoo, S | 1 |
| Attenello, FJ | 3 |
| Jennelle, R | 1 |
| Wagle, N | 1 |
| Chang, EL | 2 |
| Zada, G | 1 |
| Azoulay, M | 3 |
| Chang, SD | 2 |
| Gibbs, IC | 2 |
| Hancock, SL | 2 |
| Pollom, EL | 4 |
| Harsh, GR | 3 |
| Adler, JR | 2 |
| Harraher, C | 2 |
| Hayden Gephart, M | 1 |
| Nagpal, S | 2 |
| Thomas, RP | 2 |
| Recht, LD | 5 |
| Jacobs, LR | 2 |
| Modlin, LA | 2 |
| Wynne, J | 2 |
| Seiger, K | 2 |
| Fujimoto, D | 2 |
| Usoz, M | 1 |
| von Eyben, R | 2 |
| Choi, CYH | 2 |
| Soltys, SG | 2 |
| Petrelli, F | 1 |
| De Stefani, A | 1 |
| Ghidini, A | 1 |
| Bruschieri, L | 1 |
| Riboldi, V | 1 |
| Dottorini, L | 1 |
| Iaculli, A | 1 |
| Zaniboni, A | 1 |
| Trevisan, F | 1 |
| Paek, SH | 7 |
| Hong, YK | 5 |
| Kim, OL | 1 |
| Hata, N | 3 |
| Mizoguchi, M | 3 |
| Kuga, D | 2 |
| Hatae, R | 3 |
| Akagi, Y | 1 |
| Sangatsuda, Y | 2 |
| Amemiya, T | 1 |
| Michiwaki, Y | 2 |
| Fujioka, Y | 4 |
| Takigawa, K | 2 |
| Suzuki, SO | 2 |
| Yoshitake, T | 1 |
| Togao, O | 3 |
| Hiwatashi, A | 3 |
| Yoshimoto, K | 6 |
| Iihara, K | 1 |
| Molinaro, AM | 6 |
| Hervey-Jumper, S | 2 |
| Morshed, RA | 1 |
| Young, J | 1 |
| Han, SJ | 3 |
| Chunduru, P | 1 |
| Phillips, JJ | 6 |
| Shai, A | 1 |
| Lafontaine, M | 1 |
| Crane, J | 2 |
| Flanigan, P | 1 |
| Jahangiri, A | 2 |
| Cioffi, G | 1 |
| Ostrom, Q | 1 |
| Anderson, JE | 1 |
| Badve, C | 1 |
| Sloan, AE | 2 |
| Kosel, ML | 4 |
| LaChance, D | 1 |
| Eckel-Passow, J | 1 |
| Jenkins, R | 1 |
| Villanueva-Meyer, J | 1 |
| Rice, T | 2 |
| Wrensch, M | 1 |
| Wiencke, JK | 2 |
| Oberheim Bush, NA | 1 |
| Taylor, J | 2 |
| Prados, M | 9 |
| Clarke, J | 5 |
| Chang, S | 6 |
| Chang, E | 4 |
| Aghi, M | 3 |
| Theodosopoulos, P | 1 |
| McDermott, M | 1 |
| Choi, BD | 3 |
| Tunthanathip, T | 2 |
| Sangkhathat, S | 2 |
| Lu, C | 5 |
| Wei, Y | 7 |
| Lyu, X | 2 |
| Yan, W | 14 |
| Valiakhmetova, A | 1 |
| Gorelyshev, S | 1 |
| Konovalov, A | 1 |
| Trunin, Y | 1 |
| Savateev, A | 1 |
| Kram, DE | 1 |
| Severson, E | 1 |
| Hemmerich, A | 1 |
| Edgerly, C | 1 |
| Duncan, D | 1 |
| Britt, N | 1 |
| Huang, RSP | 1 |
| Elvin, J | 1 |
| Miller, V | 1 |
| Ross, JS | 1 |
| Gay, L | 1 |
| McCorkle, J | 1 |
| Rankin, A | 1 |
| Erlich, RL | 1 |
| Chudnovsky, Y | 1 |
| Ramkissoon, SH | 3 |
| Kessler, T | 3 |
| Platten, M | 10 |
| Meisner, C | 1 |
| Bamberg, M | 6 |
| Papsdorf, K | 1 |
| Vesper, J | 1 |
| Debus, J | 15 |
| Ketter, R | 5 |
| Hertler, C | 1 |
| Mayer-Steinacker, R | 4 |
| Weisang, S | 1 |
| Bölting, H | 1 |
| Reuss, D | 1 |
| Sahm, F | 3 |
| Struve, N | 1 |
| Binder, ZA | 2 |
| Stead, LF | 2 |
| Brend, T | 1 |
| Bagley, SJ | 1 |
| Faulkner, C | 1 |
| Ott, L | 1 |
| Müller-Goebel, J | 1 |
| Weik, AS | 1 |
| Hoffer, K | 1 |
| Krug, L | 1 |
| Rieckmann, T | 1 |
| Bußmann, L | 1 |
| Henze, M | 1 |
| Morrissette, JJD | 1 |
| Schüller, U | 3 |
| Petersen, C | 1 |
| Rothkamm, K | 1 |
| O Rourke, DM | 1 |
| Short, SC | 6 |
| Kriegs, M | 1 |
| Lwin, Z | 9 |
| He, M | 2 |
| Hao, B | 1 |
| Barciszewski, J | 1 |
| Huang, M | 2 |
| Wu, JY | 1 |
| Xing, K | 1 |
| Yeo, E | 2 |
| Holland, E | 1 |
| Qin, L | 2 |
| O'Rourke, DM | 3 |
| Koumenis, C | 2 |
| Gong, Y | 3 |
| Cai, L | 1 |
| Su, Z | 2 |
| Dey, D | 1 |
| Parihar, VK | 1 |
| Szabo, GG | 1 |
| Klein, PM | 1 |
| Tran, J | 2 |
| Moayyad, J | 1 |
| Ahmed, F | 1 |
| Nguyen, QA | 1 |
| Murry, A | 1 |
| Merriott, D | 1 |
| Nguyen, B | 1 |
| Goldman, J | 1 |
| Angulo, MC | 1 |
| Piomelli, D | 1 |
| Soltesz, I | 1 |
| Baulch, JE | 1 |
| Limoli, CL | 1 |
| El Husseini, K | 1 |
| Marguet, F | 4 |
| Lamy, A | 1 |
| Magne, N | 7 |
| Lobbous, M | 1 |
| Nabors, LB | 13 |
| Tamura, R | 1 |
| Morimoto, Y | 1 |
| Kosugi, K | 1 |
| Sato, M | 2 |
| Oishi, Y | 1 |
| Ueda, R | 1 |
| Kikuchi, R | 1 |
| Hikichi, T | 1 |
| Noji, S | 1 |
| Kawakami, Y | 1 |
| Yoshida, K | 1 |
| Toda, M | 1 |
| Brown, NF | 1 |
| Ng, SM | 1 |
| Brooks, C | 1 |
| Coutts, T | 1 |
| Holmes, J | 1 |
| Roberts, C | 1 |
| Elhussein, L | 1 |
| Hoskin, P | 1 |
| Maughan, T | 1 |
| Blagden, S | 1 |
| Wei, F | 1 |
| Hou, J | 3 |
| Su, Y | 2 |
| Kong, L | 3 |
| Qiu, X | 5 |
| Lu, JJ | 2 |
| Egashira, Y | 1 |
| Yano, H | 3 |
| Ji, Y | 1 |
| Tang, H | 3 |
| Qiu, P | 1 |
| Cheng He, R | 1 |
| Inocencio, JF | 1 |
| Deikus, G | 1 |
| Wasserman, I | 1 |
| Strahl, M | 1 |
| Smith, M | 1 |
| Sebra, R | 1 |
| von Roemeling, CA | 1 |
| Qie, Y | 1 |
| Deng, W | 1 |
| Bruno, KA | 1 |
| Chan, CK | 1 |
| Lee, AS | 2 |
| Rosenfeld, SS | 2 |
| Johnson, AJ | 2 |
| Mitchell, DA | 9 |
| Kim, BYS | 1 |
| Song, A | 1 |
| Bar-Ad, V | 1 |
| Martinez, N | 1 |
| Glass, J | 2 |
| Judy, K | 1 |
| Evans, JJ | 1 |
| Farrell, CJ | 1 |
| Werner-Wasik, M | 8 |
| Chervoneva, I | 1 |
| Ly, M | 1 |
| Wu, GJ | 1 |
| Massey, SC | 1 |
| White, H | 1 |
| Whitmire, P | 1 |
| Doyle, T | 1 |
| Johnston, SK | 2 |
| Singleton, KW | 1 |
| Jackson, PR | 1 |
| Hawkins-Daarud, A | 3 |
| Bendok, BR | 1 |
| Porter, AB | 2 |
| Vora, S | 1 |
| Hu, LS | 1 |
| Mrugala, MM | 4 |
| Swanson, KR | 2 |
| Marinho, MAG | 1 |
| da Silva Marques, M | 1 |
| Lettnin, AP | 1 |
| de Souza Votto, AP | 1 |
| de Moraes Vaz Batista Filgueira, D | 1 |
| Horn, AP | 1 |
| Sarkar, S | 1 |
| Mirzaei, R | 1 |
| Rawji, K | 1 |
| Poon, C | 1 |
| Mishra, MK | 1 |
| Zemp, FJ | 1 |
| Bose, P | 1 |
| Kelly, J | 2 |
| Dunn, JF | 1 |
| Yong, VW | 1 |
| Hermann, RM | 1 |
| Merten, R | 1 |
| Xu, JX | 1 |
| Luan, XP | 1 |
| Lan, Y | 1 |
| Lou, J | 1 |
| Weathers, SP | 1 |
| Penas-Prado, M | 5 |
| Pei, BL | 1 |
| Ling, X | 1 |
| Kassab, C | 1 |
| Banerjee, P | 2 |
| Bdiwi, M | 1 |
| Shaim, H | 1 |
| Alsuliman, A | 1 |
| Shanley, M | 1 |
| O'Brien, BJ | 2 |
| Harrison, R | 1 |
| Majd, N | 1 |
| Kamiya-Matsuoka, C | 1 |
| Fuller, GN | 2 |
| Chi, L | 1 |
| Rao, G | 1 |
| Weinberg, JS | 2 |
| Sawaya, R | 6 |
| Shpall, EJ | 1 |
| Rezvani, K | 1 |
| Heimberger, AB | 8 |
| Ruminy, P | 1 |
| Basset, C | 1 |
| Noel, A | 1 |
| Beaussire, L | 2 |
| Viennot, M | 1 |
| Viailly, PJ | 1 |
| Cassinari, K | 1 |
| Chambon, P | 1 |
| Richard, D | 1 |
| Laquerrière, A | 3 |
| Sarafan-Vasseur, N | 2 |
| Laigle-Donadey, F | 7 |
| Greffard, S | 1 |
| Ebrahimi Zade, A | 2 |
| Shahabi Haghighi, S | 2 |
| Soltani, M | 2 |
| Lee, CAA | 1 |
| Wilson, BJ | 1 |
| Berg, G | 1 |
| Karpova, S | 1 |
| Mishra, A | 1 |
| Lian, JW | 1 |
| Emmerich, M | 1 |
| Murphy, GF | 1 |
| Frank, MH | 1 |
| Frank, NY | 1 |
| Balana, C | 14 |
| Vaz, MA | 5 |
| Mesia, C | 1 |
| Del Barco, S | 1 |
| Pineda, E | 2 |
| Muñoz-Langa, J | 1 |
| Estival, A | 2 |
| de Las Peñas, R | 2 |
| Fuster, J | 1 |
| Gironés, R | 1 |
| Navarro, LM | 1 |
| Gil-Gil, M | 3 |
| Alonso, M | 1 |
| Herrero, A | 3 |
| Peralta, S | 2 |
| Olier, C | 1 |
| Perez-Segura, P | 5 |
| Covela, M | 1 |
| Martinez-García, M | 2 |
| Berrocal, A | 4 |
| Gallego, O | 5 |
| Luque, R | 2 |
| Perez-Martín, FJ | 1 |
| Esteve, A | 2 |
| Munne, N | 1 |
| Domenech, M | 2 |
| Villa, S | 8 |
| Sanz, C | 3 |
| Carrato, C | 5 |
| Cohrs, G | 1 |
| Hanna, C | 1 |
| Williams, K | 1 |
| Jackson, A | 1 |
| Carruthers, R | 1 |
| Strathdee, K | 1 |
| Cruickshank, G | 3 |
| Dunn, L | 1 |
| Erridge, S | 2 |
| Godfrey, L | 1 |
| Sleigh, R | 1 |
| McCormick, A | 1 |
| Pittman, M | 1 |
| Halford, S | 1 |
| Butler, M | 1 |
| Pongor, L | 1 |
| Su, YT | 2 |
| Xi, L | 1 |
| Raffeld, M | 1 |
| Quezado, M | 1 |
| Trepel, J | 1 |
| Pommier, Y | 1 |
| Oh, YT | 2 |
| Chung, WK | 2 |
| Selvasaravanan, KD | 1 |
| Wiederspohn, N | 1 |
| Hadzalic, A | 1 |
| Strobel, H | 1 |
| Payer, C | 1 |
| Schuster, A | 1 |
| Karpel-Massler, G | 8 |
| Siegelin, MD | 3 |
| Halatsch, ME | 8 |
| Debatin, KM | 7 |
| Westhoff, MA | 5 |
| Ito, T | 1 |
| Beppu, T | 2 |
| Nakamura, H | 2 |
| Kayama, T | 6 |
| Sato, S | 1 |
| Nagane, M | 5 |
| Mishima, K | 1 |
| Nakasu, Y | 7 |
| Kurisu, K | 6 |
| Sugiyama, K | 6 |
| Onishi, T | 2 |
| Iwadate, Y | 3 |
| Terasaki, M | 4 |
| Kobayashi, H | 4 |
| Matsumura, A | 5 |
| Ishikawa, E | 5 |
| Matsuo, T | 2 |
| Hirano, H | 3 |
| Shinoura, N | 3 |
| Hashimoto, N | 5 |
| Aoki, T | 4 |
| Asai, A | 4 |
| Abe, T | 4 |
| Asano, K | 1 |
| Shibui, S | 6 |
| Feng, J | 4 |
| Ren, X | 5 |
| Fu, H | 1 |
| Kim, KS | 2 |
| Han, JH | 6 |
| Hsu, BH | 1 |
| Lee, WH | 1 |
| Han, CT | 1 |
| Tseng, YY | 2 |
| Gawley, M | 1 |
| Almond, L | 1 |
| Daniel, S | 1 |
| Lastakchi, S | 1 |
| Kaur, S | 2 |
| Detta, A | 1 |
| Hingtgen, S | 1 |
| Sheets, K | 1 |
| McConville, C | 1 |
| Rajesh, Y | 2 |
| Kumar, U | 2 |
| Banerjee, I | 2 |
| Maji, S | 1 |
| Emdad, L | 1 |
| Cavenee, WK | 3 |
| Mandal, M | 2 |
| Fisher, PB | 1 |
| Trippa, L | 1 |
| Alden, S | 1 |
| Abbasi, T | 1 |
| Mundkur, Y | 1 |
| Singh, NK | 1 |
| Talawdekar, A | 1 |
| Husain, Z | 1 |
| Vali, S | 1 |
| Alexander, BM | 5 |
| Beckenkamp, LR | 2 |
| de Oliveira, FH | 2 |
| Wink, MR | 2 |
| Stefani, MA | 2 |
| Battastini, AMO | 2 |
| Kuo, TC | 1 |
| Lee, CC | 1 |
| Phuphanich, S | 4 |
| De Souza, P | 1 |
| Carleton, M | 1 |
| Taitt, C | 1 |
| Zwirtes, R | 1 |
| Sampson, J | 3 |
| Chi, Y | 1 |
| Wei, Q | 2 |
| Lian, C | 4 |
| Liao, C | 1 |
| Liang, C | 2 |
| Lian, M | 1 |
| Saha, D | 2 |
| Rabkin, SD | 2 |
| Martuza, RL | 4 |
| Tan, AC | 1 |
| Ashley, DM | 5 |
| López, GY | 1 |
| Malinzak, M | 1 |
| Friedman, HS | 25 |
| Kotecha, R | 2 |
| Tanvejsilp, P | 1 |
| Kanjanapradit, K | 1 |
| Gui, C | 1 |
| Vannorsdall, TD | 1 |
| Kleinberg, LR | 2 |
| Assadi, R | 1 |
| Moore, JA | 1 |
| Quiñones-Hinojosa, A | 11 |
| Redmond, KJ | 1 |
| Ngo, MT | 2 |
| Karvelis, E | 1 |
| Harley, BAC | 2 |
| Sahli, F | 1 |
| Courcelle, M | 1 |
| Palama, T | 1 |
| Djaker, N | 1 |
| Savarin, P | 1 |
| Spadavecchia, J | 1 |
| Guan, F | 2 |
| Ma, S | 2 |
| Läubli, H | 1 |
| Schucht, P | 1 |
| Reinert, M | 1 |
| Mamot, C | 1 |
| Kinashi, Y | 2 |
| Ikawa, T | 1 |
| Takahashi, S | 1 |
| Yuan, AL | 1 |
| Meode, M | 1 |
| Tan, M | 3 |
| Maxwell, L | 1 |
| Bering, EA | 1 |
| Pedersen, H | 1 |
| Willms, J | 1 |
| Liao, J | 2 |
| Black, S | 1 |
| Cairncross, JG | 15 |
| Blough, MD | 2 |
| Besen, AA | 1 |
| Ozdemir, Y | 2 |
| Mertsoylu, H | 3 |
| Pehlivan, B | 3 |
| Bu, X | 1 |
| Yan, Z | 4 |
| Wu, T | 2 |
| Bhawe, K | 1 |
| Felty, Q | 1 |
| Yoo, C | 1 |
| Ehtesham, NZ | 1 |
| Hasnain, SE | 1 |
| Singh, VP | 1 |
| Mohapatra, I | 1 |
| Roy, D | 1 |
| Kardash, KA | 1 |
| Zhu, SH | 1 |
| Xu, YQ | 1 |
| Kong, PS | 1 |
| Vázquez-Blomquist, D | 1 |
| van der Kaaij, M | 1 |
| Villarreal, A | 1 |
| Bello-Rivero, I | 1 |
| Roh, TH | 2 |
| Park, HH | 3 |
| Uram, Ł | 1 |
| Markowicz, J | 1 |
| Misiorek, M | 1 |
| Filipowicz-Rachwał, A | 1 |
| Wołowiec, S | 1 |
| Wałajtys-Rode, E | 1 |
| Carballo, GB | 1 |
| Matias, D | 5 |
| Ribeiro, JH | 1 |
| Pessoa, LS | 1 |
| Arrais-Neto, AM | 1 |
| Spohr, TCLSE | 1 |
| Gudbergsson, JM | 1 |
| Christensen, E | 1 |
| Kostrikov, S | 1 |
| Moos, T | 1 |
| Duroux, M | 1 |
| Kjær, A | 1 |
| Johnsen, KB | 1 |
| Andresen, TL | 1 |
| Climans, SA | 1 |
| Ding, K | 2 |
| Laperriere, N | 9 |
| Menten, J | 5 |
| O'Callaghan, CJ | 2 |
| Perry, JR | 12 |
| Roa, W | 4 |
| Winch, C | 2 |
| Couturier, CP | 1 |
| Ayyadhury, S | 1 |
| Le, PU | 2 |
| Nadaf, J | 1 |
| Monlong, J | 1 |
| Riva, G | 2 |
| Allache, R | 1 |
| Baig, S | 1 |
| Bourgey, M | 1 |
| Lee, C | 4 |
| Wang, YCD | 1 |
| Wee Yong, V | 1 |
| Najafabadi, H | 1 |
| Misic, B | 1 |
| Antel, J | 1 |
| Bourque, G | 1 |
| Ragoussis, J | 1 |
| Heng, H | 1 |
| Barrascout, E | 1 |
| Lamuraglia, M | 1 |
| Rodon, JA | 1 |
| Mason, W | 9 |
| Beck, JT | 1 |
| DeGroot, J | 1 |
| Donnet, V | 1 |
| Mills, D | 1 |
| El-Hashimy, M | 1 |
| Rosenthal, M | 2 |
| Ferri, A | 1 |
| Stagni, V | 1 |
| Bagherian, A | 1 |
| Mardani, R | 1 |
| Roudi, B | 1 |
| Taghizadeh, M | 1 |
| Banfshe, HR | 1 |
| Ghaderi, A | 1 |
| Davoodvandi, A | 1 |
| Shamollaghamsari, S | 1 |
| Richard, S | 1 |
| Tachon, G | 1 |
| Milin, S | 2 |
| Wager, M | 3 |
| Karayan-Tapon, L | 6 |
| Ashta, A | 1 |
| Motalleb, G | 1 |
| Poon, MTC | 1 |
| Sudlow, CLM | 1 |
| Figueroa, JD | 1 |
| Brennan, PM | 1 |
| Zhang, F | 3 |
| Man, W | 1 |
| Jing, L | 1 |
| Shukla, A | 1 |
| Srivastava, S | 1 |
| Darokar, J | 1 |
| Garrett, MC | 1 |
| O'Shea, TM | 1 |
| Wollenberg, AL | 1 |
| Bernstein, AM | 1 |
| Hung, D | 1 |
| Staarman, B | 1 |
| Soto, H | 1 |
| Deming, TJ | 1 |
| Sofroniew, MV | 1 |
| Bazzazzadeh, A | 1 |
| Dizaji, BF | 1 |
| Kianinejad, N | 1 |
| Nouri, A | 1 |
| Irani, M | 2 |
| Henderson, FC | 1 |
| Alshareef, M | 2 |
| Porto, GBF | 2 |
| Kanginakudru, I | 1 |
| Infinger, LK | 2 |
| Vandergrift, WA | 2 |
| Varma, AK | 2 |
| Patel, SJ | 4 |
| Cachia, D | 2 |
| Patel, NV | 1 |
| Khatri, D | 1 |
| D'Amico, R | 1 |
| Abrams, M | 1 |
| Reichman, N | 1 |
| Filippi, CG | 3 |
| Anderson, T | 1 |
| Ratzon, F | 1 |
| Wong, T | 2 |
| Fralin, S | 2 |
| Faltings, L | 1 |
| Langer, DJ | 2 |
| Boockvar, JA | 6 |
| Oh, HC | 1 |
| Lee, JH | 6 |
| Kim, NH | 2 |
| Yook, JI | 3 |
| Kang, DW | 1 |
| Hwang, WC | 1 |
| Noh, YN | 1 |
| Park, KS | 1 |
| Min, DS | 1 |
| Comas, S | 2 |
| Luguera, E | 1 |
| Molero, J | 1 |
| Castañer, S | 1 |
| Hostalot, C | 2 |
| Teixidor, P | 1 |
| Berger, K | 1 |
| Turowski, B | 2 |
| Malzkorn, B | 1 |
| Steiger, HJ | 6 |
| Budach, W | 2 |
| Haussmann, J | 1 |
| Knipps, J | 1 |
| Rapp, M | 4 |
| Hänggi, D | 2 |
| Mijderwijk, HJ | 1 |
| Kamp, MA | 2 |
| Wei, M | 2 |
| Cheng, C | 1 |
| Dammer, E | 1 |
| Le, W | 1 |
| Avci, NG | 1 |
| Ebrahimzadeh-Pustchi, S | 1 |
| Akay, YM | 1 |
| Esquenazi, Y | 1 |
| Tandon, N | 1 |
| Akay, M | 1 |
| Lin, JW | 1 |
| Shih, JW | 1 |
| Li, PC | 1 |
| Chen, SY | 2 |
| Xiangfei, D | 1 |
| Mao, C | 1 |
| Wu, CH | 1 |
| Shih, JC | 1 |
| Zhi, T | 3 |
| Hotchkiss, KM | 1 |
| Sampson, JH | 16 |
| de Melo, SM | 1 |
| Marta, GN | 1 |
| Yan, M | 1 |
| Cruz, C | 1 |
| Moraes, FY | 1 |
| Riera, R | 1 |
| Chen, WJ | 1 |
| Han, H | 1 |
| Lv, JN | 1 |
| Kang, EM | 1 |
| Zhang, YL | 1 |
| Liu, WP | 1 |
| He, XS | 1 |
| Yu, YB | 1 |
| Tsiailanis, AD | 2 |
| Renziehausen, A | 3 |
| Kiriakidi, S | 1 |
| Vrettos, EI | 1 |
| Markopoulos, GS | 1 |
| Sayyad, N | 1 |
| Hirmiz, B | 1 |
| Aguilar, MI | 1 |
| Del Borgo, MP | 1 |
| Kolettas, E | 1 |
| Widdop, RE | 1 |
| Mavromoustakos, T | 1 |
| Crook, T | 3 |
| Syed, N | 3 |
| Tzakos, AG | 2 |
| Altwairgi, AK | 1 |
| Alghareeb, WA | 1 |
| AlNajjar, FH | 1 |
| Alhussain, H | 1 |
| Alsaeed, E | 1 |
| Balbaid, AAO | 1 |
| Aldanan, S | 1 |
| Orz, Y | 1 |
| Alsharm, AA | 1 |
| Trinh, P | 1 |
| Grant, GA | 1 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Yu, D | 2 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 2 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Huang, W | 1 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Dong, X | 3 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 3 |
| Dong, JH | 1 |
| Dong, XR | 1 |
| Tao, F | 1 |
| Xiang, W | 4 |
| Tao, H | 1 |
| Lei, Y | 2 |
| Gan, H | 2 |
| Shan, A | 1 |
| Ma, Q | 2 |
| Zhang, E | 1 |
| Meng, J | 1 |
| Chen, G | 5 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, YS | 1 |
| Zhang, A | 2 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Yao, H | 1 |
| Lee, DF | 1 |
| Wen, L | 1 |
| Xie, X | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Wan, L | 2 |
| Wen, Q | 2 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Lee, HJ | 6 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 6 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 2 |
| Cheng, J | 2 |
| Yang, T | 4 |
| Dong, Y | 7 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Mei, Z | 1 |
| Yu, K | 2 |
| Zhu, C | 1 |
| Ge, J | 1 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Chang, X | 3 |
| Rathore, MG | 1 |
| Reddy, K | 6 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 2 |
| Mu, W | 1 |
| Gao, F | 3 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Ying, S | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Wu, D | 3 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Cong, Z | 1 |
| Fu, D | 1 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Xi, J | 1 |
| Wei, H | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Lyu, Y | 1 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 2 |
| Gupta, A | 2 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 2 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 4 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 2 |
| Luo, T | 2 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 1 |
| Guan, H | 1 |
| Tan, H | 2 |
| Maji, TK | 1 |
| J R, A | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Karmakar, D | 1 |
| Zhou, T | 2 |
| Ye, C | 2 |
| He, X | 4 |
| Jiang, F | 1 |
| Yuan, D | 1 |
| Hong, M | 1 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 2 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Chen, WF | 2 |
| Luo, R | 2 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 2 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 1 |
| Zhang, YY | 1 |
| Lu, DZ | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 2 |
| Yu, PL | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| Du, X | 2 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Fei, P | 1 |
| Xie, Q | 2 |
| Feng, H | 4 |
| Chang, Y | 2 |
| Kang, H | 1 |
| Xing, M | 1 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Gao, R | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Cao, T | 1 |
| Guo, L | 5 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 2 |
| Sun, B | 1 |
| Cao, P | 2 |
| Gu, S | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 2 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Hou, G | 2 |
| Cui, J | 1 |
| Xie, H | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| White, K | 1 |
| Park, HJ | 1 |
| Ding, D | 2 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Qian, Y | 1 |
| Cheng, Q | 3 |
| Pan, W | 1 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 2 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Liao, W | 1 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 3 |
| Woo, YC | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Zuo, W | 1 |
| Yang, P | 4 |
| Ratner, B | 1 |
| Montaldi, AP | 3 |
| Lima, SCG | 1 |
| Godoy, PRDV | 1 |
| Xavier, DJ | 1 |
| Sakamoto-Hojo, ET | 3 |
| Ryu, S | 1 |
| Sim, K | 1 |
| Shin, I | 1 |
| Kim, SS | 7 |
| Lee, YS | 2 |
| Park, JY | 1 |
| Sim, T | 1 |
| Tu, GXE | 1 |
| Ho, YK | 1 |
| Ng, ZX | 1 |
| Teo, KJ | 1 |
| Yeo, TT | 2 |
| Too, HP | 1 |
| Athavale, A | 1 |
| Morris, J | 1 |
| Jardine, M | 1 |
| Gallagher, M | 1 |
| Sen, S | 1 |
| Ritchie, A | 1 |
| Wang, AY | 1 |
| Faustino, AC | 1 |
| Viani, GA | 1 |
| Hamamura, AC | 1 |
| Yun, EJ | 1 |
| Kim, S | 3 |
| Hsieh, JT | 1 |
| Baek, ST | 1 |
| Gy, S | 1 |
| Dracham, CB | 1 |
| Dey, T | 1 |
| Khosla, D | 1 |
| Oinum, A | 1 |
| Kapoor, R | 1 |
| Kolodziej, MA | 1 |
| Al Barim, B | 1 |
| Nagl, J | 1 |
| Weigand, MA | 1 |
| Uhl, E | 1 |
| Uhle, F | 1 |
| Di Fazio, P | 1 |
| Schwarm, FP | 1 |
| Jusue-Torres, I | 2 |
| Hulbert, A | 1 |
| Barton, K | 1 |
| Melian, E | 1 |
| Anderson, DE | 1 |
| Prabhu, VC | 1 |
| Piee-Staffa, A | 1 |
| Haas, B | 2 |
| Forrest, WF | 1 |
| Alicke, B | 1 |
| Mayba, O | 1 |
| Osinska, M | 1 |
| Jakubczak, M | 1 |
| Piatkowski, P | 1 |
| Choniawko, L | 1 |
| Starr, A | 1 |
| Gould, SE | 1 |
| Strawderman, MS | 1 |
| Warren, KT | 1 |
| Richardson, M | 1 |
| Serventi, JN | 1 |
| Mohile, NA | 4 |
| Milano, MT | 3 |
| Mahiat, C | 1 |
| Capes, A | 1 |
| Duprez, T | 1 |
| Duck, L | 1 |
| Labriola, L | 1 |
| Fuster-Garcia, E | 1 |
| Lorente Estellés, D | 1 |
| Álvarez-Torres, MDM | 1 |
| Juan-Albarracín, J | 1 |
| Chelebian, E | 1 |
| Rovira, A | 1 |
| Acosta, CA | 1 |
| Pineda, J | 1 |
| Oleaga, L | 1 |
| Mollá-Olmos, E | 1 |
| Filice, S | 1 |
| Due-Tønnessen, P | 1 |
| Meling, TR | 2 |
| García-Gómez, JM | 1 |
| Golebiewska, A | 2 |
| Hau, AC | 1 |
| Oudin, A | 1 |
| Stieber, D | 2 |
| Yabo, YA | 1 |
| Baus, V | 1 |
| Barthelemy, V | 1 |
| Klein, E | 1 |
| Bougnaud, S | 1 |
| Keunen, O | 1 |
| Wantz, M | 1 |
| Michelucci, A | 2 |
| Neirinckx, V | 1 |
| Muller, A | 2 |
| Kaoma, T | 1 |
| Azuaje, F | 2 |
| De Falco, A | 1 |
| Flies, B | 1 |
| Richart, L | 1 |
| Poovathingal, S | 2 |
| Arns, T | 1 |
| Grzyb, K | 1 |
| Mock, A | 1 |
| Steino, A | 1 |
| May, P | 1 |
| Malta, TM | 1 |
| Noushmehr, H | 1 |
| Jahn, W | 1 |
| Tanner, G | 1 |
| Mittelbronn, M | 5 |
| Skupin, A | 2 |
| Hertel, F | 2 |
| Moon, BS | 1 |
| Cai, M | 1 |
| Lee, G | 5 |
| Giannotta, SL | 1 |
| Yu, M | 3 |
| Lu, W | 4 |
| Gjika, E | 1 |
| Pal-Ghosh, S | 1 |
| Kirschner, ME | 1 |
| Stepp, MA | 1 |
| Horescu, C | 1 |
| Elena Cioc, C | 1 |
| Tuta, C | 1 |
| Sevastre, AS | 2 |
| Tache, DE | 2 |
| Alexandru, O | 2 |
| Artene, SA | 1 |
| Danoiu, S | 2 |
| Dricu, A | 1 |
| Stefana Oana, P | 1 |
| Bi, CL | 1 |
| Liu, JF | 1 |
| Zhang, MY | 1 |
| Lan, S | 1 |
| Yang, ZY | 1 |
| Fang, JS | 1 |
| Grossman, SA | 13 |
| Anselmo, P | 1 |
| Maranzano, E | 1 |
| Selimi, A | 1 |
| Lupattelli, M | 2 |
| Palumbo, I | 1 |
| Bini, V | 1 |
| Casale, M | 1 |
| Trippa, F | 1 |
| Bufi, A | 1 |
| Arcidiacono, F | 1 |
| Aristei, C | 1 |
| Banstola, A | 1 |
| Duwa, R | 1 |
| Emami, F | 1 |
| Jeong, JH | 1 |
| Yook, S | 1 |
| Areeb, Z | 1 |
| Stuart, SF | 1 |
| West, AJ | 1 |
| Gomez, J | 1 |
| Nguyen, HPT | 1 |
| Paradiso, L | 2 |
| Zulkifli, A | 1 |
| Jones, J | 1 |
| Luwor, RB | 3 |
| Gilbar, PJ | 1 |
| Pokharel, K | 1 |
| Mangos, HM | 1 |
| Reinartz, R | 1 |
| Darkwah Oppong, M | 1 |
| Jabbarli, R | 1 |
| Lu, VM | 3 |
| Jue, TR | 1 |
| McDonald, KL | 7 |
| Dastghaib, S | 1 |
| Mostafavi-Pour, Z | 1 |
| Patterson, JB | 1 |
| Samali, A | 2 |
| Mokarram, P | 1 |
| Asik, A | 1 |
| Caglar, HO | 1 |
| Gunduz, C | 1 |
| Karakurt, S | 1 |
| Seidel, S | 1 |
| Coch, C | 1 |
| Fimmers, R | 1 |
| Egaña, L | 1 |
| Auzmendi-Iriarte, J | 1 |
| Andermatten, J | 1 |
| Villanua, J | 2 |
| Ruiz, I | 2 |
| Elua-Pinin, A | 1 |
| Aldaz, P | 3 |
| Querejeta, A | 1 |
| Sarasqueta, C | 1 |
| Zubia, F | 1 |
| Hsu, PYH | 1 |
| Folkman, F | 1 |
| de Robles, P | 1 |
| Leckie, C | 1 |
| Dersch-Mills, D | 1 |
| Coppens, R | 1 |
| Chambers, C | 1 |
| Su, W | 1 |
| Dey, A | 1 |
| Islam, SMA | 1 |
| Patel, R | 1 |
| Acevedo-Duncan, M | 1 |
| Pépin, LF | 1 |
| Jardin, F | 1 |
| Wu, B | 3 |
| Cheng, H | 1 |
| Zimmerman, MA | 1 |
| Wilkison, S | 1 |
| Qi, Q | 1 |
| Li, PA | 1 |
| Panzarini, E | 1 |
| Tacconi, S | 1 |
| Carata, E | 1 |
| Mariano, S | 1 |
| Tata, AM | 2 |
| Dini, L | 2 |
| Xu, D | 1 |
| Núñez, LM | 1 |
| Romero, E | 1 |
| Ledesma-Carbayo, MJ | 1 |
| Santos, A | 1 |
| Vellido, A | 1 |
| Fei, M | 1 |
| Tang, T | 1 |
| Niu, W | 1 |
| Hanihara, M | 1 |
| Miyake, K | 1 |
| Watanabe, A | 1 |
| Yamada, Y | 3 |
| Oishi, N | 1 |
| Kawataki, T | 1 |
| Inukai, T | 1 |
| Kondo, T | 2 |
| Kinouchi, H | 1 |
| Planeta, K | 1 |
| Setkowicz, Z | 1 |
| Janik-Olchawa, N | 1 |
| Matusiak, K | 1 |
| Ryszawy, D | 2 |
| Drozdz, A | 1 |
| Janeczko, K | 1 |
| Ostachowicz, B | 1 |
| Chwiej, J | 1 |
| Ironside, SA | 1 |
| Sahgal, A | 10 |
| Detsky, J | 1 |
| Papageorgiou, GI | 1 |
| Tsakatikas, SA | 1 |
| Fioretzaki, RG | 1 |
| Kosmas, C | 1 |
| Malik, D | 1 |
| Akimoto, J | 2 |
| Chao, CN | 1 |
| Lin, HP | 1 |
| Huang, HY | 1 |
| Fang, CY | 1 |
| Kashyap, L | 1 |
| Bakhshi, S | 1 |
| Reily Rocha, A | 1 |
| Molina Silva, M | 1 |
| Rodrigues Gomes, L | 1 |
| Teatin Latancia, M | 1 |
| Andrade Tomaz, M | 1 |
| Karolynne Seregni Monteiro, L | 1 |
| Menck, CFM | 1 |
| Kim, HM | 1 |
| Lee, SH | 14 |
| Lim, J | 2 |
| Toms, S | 2 |
| Robison, J | 1 |
| Mohler, A | 1 |
| Carcieri, A | 1 |
| Cielo, D | 1 |
| Donnelly, J | 1 |
| Disano, D | 1 |
| Vatketich, J | 1 |
| Baekey, J | 1 |
| Sturtevant, A | 1 |
| MacKinnon, K | 1 |
| Wood, R | 1 |
| Safran, H | 1 |
| Feng, Z | 1 |
| Xiao, F | 2 |
| Saeed, MEM | 1 |
| Kadioglu, O | 1 |
| Greten, HJ | 1 |
| Yildirim, A | 1 |
| Mayr, K | 1 |
| Wenz, F | 6 |
| Efferth, T | 4 |
| Amini, A | 3 |
| Dandapani, S | 1 |
| Lucidi, S | 1 |
| Maragna, V | 1 |
| Teriaca, MA | 1 |
| Ganovelli, M | 1 |
| Desideri, I | 1 |
| Lorenzetti, V | 1 |
| Scoccimarro, E | 1 |
| Greto, D | 2 |
| Livi, L | 2 |
| Seidlitz, A | 2 |
| Beuthien-Baumann, B | 2 |
| Löck, S | 1 |
| Jentsch, C | 2 |
| Platzek, I | 2 |
| Zöphel, K | 1 |
| Linge, A | 1 |
| Kotzerke, J | 1 |
| Petr, J | 2 |
| van den Hoff, J | 2 |
| Schmitz-Schackert, G | 1 |
| Falk, M | 1 |
| Baumann, M | 2 |
| Krause, M | 2 |
| Yu, C | 2 |
| Immanuel, SRC | 2 |
| Ghanate, AD | 2 |
| Parmar, DS | 2 |
| Yadav, R | 1 |
| Uthup, R | 1 |
| Panchagnula, V | 2 |
| Raghunathan, A | 2 |
| Farshchian, M | 1 |
| Bardhi, R | 1 |
| Daveluy, S | 1 |
| Koul, D | 1 |
| Yung, WKA | 1 |
| Oprita, A | 1 |
| Baloi, SC | 1 |
| Staicu, GA | 1 |
| Micu, ES | 1 |
| Ren, C | 1 |
| Du, S | 2 |
| Kamson, DO | 1 |
| Toor, H | 1 |
| Savla, P | 1 |
| Podkovik, S | 1 |
| Patchana, T | 1 |
| Ghanchi, H | 1 |
| Kashyap, S | 1 |
| Tashjian, V | 1 |
| Miulli, D | 1 |
| Abbaszade, Z | 1 |
| Bagca, BG | 1 |
| Avci, CB | 1 |
| Cheng, CL | 1 |
| Chan, MH | 1 |
| Feng, SJ | 1 |
| Hsiao, M | 2 |
| Liu, RS | 1 |
| Vaidya, KS | 1 |
| Mitten, MJ | 1 |
| Zelaya-Lazo, AL | 1 |
| Oleksijew, A | 1 |
| Alvey, C | 1 |
| Falls, HD | 1 |
| Mishra, S | 1 |
| Palma, J | 1 |
| Phillips, AC | 1 |
| Reilly, EB | 1 |
| Boghaert, ER | 1 |
| Park, YW | 1 |
| Choi, D | 1 |
| Ahn, SS | 2 |
| Musiał-Kulik, M | 1 |
| Włodarczyk, J | 1 |
| Stojko, M | 1 |
| Karpeta-Jarząbek, P | 1 |
| Pastusiak, M | 1 |
| Janeczek, H | 1 |
| Kasperczyk, J | 1 |
| Day, EK | 1 |
| Zhong, Q | 1 |
| Purow, B | 1 |
| Lazzara, MJ | 1 |
| Benouaich-Amiel, A | 5 |
| Khasminsky, V | 1 |
| Gal, O | 1 |
| Weiss, T | 3 |
| Fichman, S | 1 |
| Kanner, AA | 4 |
| Berkowitz, S | 1 |
| Laviv, Y | 1 |
| Mandel, J | 1 |
| Dudnik, E | 1 |
| Siegal, T | 2 |
| Yust-Katz, S | 2 |
| Ohnishi, K | 1 |
| Tani, T | 1 |
| Tojo, N | 1 |
| Sagara, JI | 1 |
| Munisamy, M | 1 |
| Munisamy, S | 1 |
| Kumar, JP | 1 |
| Jose, A | 1 |
| Thomas, L | 1 |
| Baburaj, G | 1 |
| Subbiah, V | 1 |
| Che Mat, MF | 1 |
| Mohamad Hanif, EA | 1 |
| Abdul Murad, NA | 1 |
| Ibrahim, K | 1 |
| Harun, R | 1 |
| Jamal, R | 1 |
| Yan, Y | 2 |
| Doherty, GJ | 1 |
| de Paula, BHR | 1 |
| Twelves, C | 1 |
| Checketts, D | 1 |
| Miller, S | 1 |
| Tayo, B | 1 |
| Jove, M | 1 |
| Brazil, L | 1 |
| Chai, R | 1 |
| Wu, F | 2 |
| Butt, NS | 1 |
| Alghamdi, B | 1 |
| Maghrabi, Y | 1 |
| Bardeesi, A | 1 |
| Saeedi, R | 1 |
| Dallol, A | 1 |
| Mohamed, F | 1 |
| Bari, MO | 1 |
| Samkari, A | 1 |
| Lary, AI | 1 |
| Siller, S | 1 |
| Lauseker, M | 1 |
| Karschnia, P | 1 |
| Eigenbrod, S | 5 |
| Giese, A | 5 |
| Hsueh, WT | 1 |
| Sweldens, C | 1 |
| Kast, RE | 9 |
| Chan, AA | 1 |
| Voce, DJ | 2 |
| Bernal, GM | 2 |
| Cahill, KE | 2 |
| Wu, L | 6 |
| Mansour, N | 1 |
| Crawley, CD | 2 |
| Campbell, PS | 1 |
| Arina, A | 1 |
| Weichselbaum, RR | 3 |
| Yamini, B | 3 |
| Kernohan, A | 1 |
| Robinson, T | 1 |
| Howell, A | 1 |
| Vale, L | 1 |
| Pellecchia, S | 1 |
| De Martino, M | 1 |
| Esposito, F | 1 |
| Quintavalle, C | 1 |
| Fusco, A | 2 |
| Pallante, P | 1 |
| Fulbert, C | 1 |
| Chabardès, S | 1 |
| Ratel, D | 1 |
| Efremov, L | 1 |
| Abera, SF | 1 |
| Bedir, A | 1 |
| Vordermark, D | 1 |
| Medenwald, D | 1 |
| Rosas-Alonso, R | 1 |
| Colmenarejo-Fernandez, J | 1 |
| Pernia, O | 1 |
| Rodriguez-Antolín, C | 1 |
| Esteban, I | 1 |
| Ghanem, I | 1 |
| Sanchez-Cabrero, D | 1 |
| Losantos-Garcia, I | 1 |
| Palacios-Zambrano, S | 1 |
| Moreno-Bueno, G | 1 |
| de Castro, J | 1 |
| Martinez-Marin, V | 1 |
| Ibanez-de-Caceres, I | 1 |
| Menyhárt, O | 1 |
| Fekete, JT | 1 |
| Győrffy, B | 1 |
| Amen, AM | 1 |
| Soczek, KM | 1 |
| Ren, SM | 1 |
| Knott, GJ | 1 |
| McKinney, AM | 1 |
| Mancini, A | 1 |
| Costello, JF | 4 |
| Khan, MB | 1 |
| Ruggieri, R | 2 |
| Jamil, E | 1 |
| Gonzalez, C | 1 |
| Mugridge, N | 1 |
| MacDiarmid, J | 1 |
| Brahmbhatt, H | 1 |
| Boockvar, J | 2 |
| Symons, M | 2 |
| Laack, NN | 1 |
| Pafundi, D | 1 |
| Anderson, SK | 4 |
| Kaufmann, T | 1 |
| Lowe, V | 1 |
| Hunt, C | 1 |
| Vogen, D | 1 |
| Yan, E | 1 |
| Sarkaria, J | 1 |
| Brown, P | 1 |
| Kizilbash, S | 2 |
| Uhm, J | 1 |
| Ruff, M | 1 |
| Zakhary, M | 1 |
| Seaberg, M | 1 |
| Wan Chan Tseung, HS | 1 |
| Kabat, B | 1 |
| Kemp, B | 1 |
| Brinkmann, D | 1 |
| Leelatian, N | 1 |
| Hong, CS | 1 |
| Tom, MC | 1 |
| Mahinfar, P | 1 |
| Davoudian, S | 1 |
| Vahidian, F | 1 |
| Cho, WC | 1 |
| Mansoori, B | 1 |
| Caylioglu, D | 1 |
| Meyer, RJ | 1 |
| Martínez-Escardó, L | 1 |
| Yuste, VJ | 1 |
| Xing, B | 2 |
| Jiménez-Alcázar, M | 1 |
| Curiel-García, Á | 1 |
| Nogales, P | 1 |
| Perales-Patón, J | 1 |
| Schuhmacher, AJ | 1 |
| Galán-Ganga, M | 1 |
| Lowe, SW | 1 |
| Al-Shahrour, F | 1 |
| Squatrito, M | 1 |
| Kaneda, MM | 1 |
| Shepard, RM | 1 |
| Patel, K | 1 |
| Sarver, A | 1 |
| Furnari, F | 2 |
| Xu, B | 4 |
| Dhawan, S | 1 |
| Wu, A | 3 |
| You, G | 3 |
| Venteicher, AS | 1 |
| Glass, CK | 1 |
| Varner, JA | 1 |
| Atashi, F | 2 |
| Saathoff, MR | 1 |
| Park, CH | 2 |
| Horbinski, CM | 3 |
| Cheng, HS | 1 |
| Marvalim, C | 1 |
| Law, CLD | 1 |
| Low, ZYJ | 1 |
| Randles, A | 1 |
| Wirsching, HG | 2 |
| Dean, JA | 1 |
| Cheng, YK | 1 |
| Emerson, S | 1 |
| Pattwell, SS | 1 |
| Holland, EC | 3 |
| Michor, F | 1 |
| Precilla, DS | 1 |
| Kuduvalli, SS | 1 |
| Purushothaman, M | 1 |
| Marimuthu, P | 1 |
| Muralidharan, AR | 1 |
| Anitha, TS | 1 |
| Geng, W | 1 |
| Zou, H | 1 |
| Dai, Y | 1 |
| Ding, X | 1 |
| Kochanowski, P | 1 |
| Catapano, J | 1 |
| Pudełek, M | 1 |
| Wróbel, T | 1 |
| Madeja, Z | 1 |
| Czyż, J | 1 |
| Misiorek, JO | 1 |
| Kruhlenia, N | 1 |
| Przybyl, L | 1 |
| Rolle, K | 1 |
| Williford, SE | 1 |
| Libby, CJ | 1 |
| Ayokanmbi, A | 1 |
| Otamias, A | 1 |
| Gordillo, JJ | 1 |
| Gordon, ER | 1 |
| Cooper, SJ | 2 |
| Redmann, M | 1 |
| Griguer, C | 2 |
| Napierala, M | 1 |
| Ananthan, S | 1 |
| Hjelmeland, AB | 3 |
| Werner, JM | 1 |
| Ceccon, G | 1 |
| Tscherpel, C | 1 |
| Lohmann, P | 1 |
| Bauer, EK | 1 |
| Stoffels, G | 3 |
| Baues, C | 1 |
| Celik, E | 1 |
| Marnitz, S | 1 |
| Kabbasch, C | 1 |
| Gielen, GH | 1 |
| Fink, GR | 1 |
| Langen, KJ | 4 |
| Ha, HA | 1 |
| Yang, JS | 1 |
| Tsai, FJ | 1 |
| Li, CW | 1 |
| Cheng, YD | 1 |
| Hour, MJ | 1 |
| Chiu, YJ | 1 |
| Barnes, EH | 1 |
| Foote, MC | 1 |
| Koh, ES | 1 |
| Back, M | 6 |
| Buckland, ME | 1 |
| Fisher, L | 1 |
| Leonard, R | 1 |
| Hall, M | 1 |
| Yip, S | 4 |
| Simes, J | 4 |
| Filppu, P | 1 |
| Tanjore Ramanathan, J | 1 |
| Granberg, KJ | 1 |
| Gucciardo, E | 1 |
| Haapasalo, H | 1 |
| Lehti, K | 1 |
| Nykter, M | 1 |
| Le Joncour, V | 1 |
| Laakkonen, P | 1 |
| Singh, R | 1 |
| Lehrer, EJ | 1 |
| Zaorsky, NG | 1 |
| Trifiletti, DM | 1 |
| Bovi, J | 1 |
| Zhai, X | 3 |
| Li, LS | 1 |
| Zhou, YD | 1 |
| Ji, WY | 1 |
| Schou Nørøxe, D | 1 |
| Flynn, A | 1 |
| Westmose Yde, C | 1 |
| Østrup, O | 1 |
| Cilius Nielsen, F | 1 |
| Skjøth-Rasmussen, J | 1 |
| Brennum, J | 1 |
| Hamerlik, P | 1 |
| Weischenfeldt, J | 1 |
| Skovgaard Poulsen, H | 1 |
| Rominiyi, O | 1 |
| Collis, SJ | 1 |
| Zając, A | 1 |
| Sumorek-Wiadro, J | 1 |
| Langner, E | 3 |
| Wertel, I | 3 |
| Maciejczyk, A | 1 |
| Pawlikowska-Pawlęga, B | 1 |
| Pawelec, J | 1 |
| Wasiak, M | 1 |
| Hułas-Stasiak, M | 1 |
| Bądziul, D | 3 |
| Rzeski, W | 3 |
| Reichert, M | 1 |
| Jakubowicz-Gil, J | 3 |
| Kong, Z | 1 |
| Tsai, CY | 1 |
| Ko, HJ | 1 |
| Chiou, SJ | 1 |
| Lai, YL | 1 |
| Hou, CC | 1 |
| Javaria, T | 1 |
| Huang, ZY | 1 |
| Cheng, TS | 1 |
| Chuang, TH | 1 |
| Huang, CF | 1 |
| Loh, JK | 1 |
| Hong, YR | 1 |
| Yang, TC | 1 |
| Liu, SJ | 1 |
| Chen, SM | 1 |
| Tang, YL | 1 |
| Cheng, HW | 1 |
| Huang, CH | 1 |
| Wang, HT | 1 |
| Tian, M | 2 |
| Xing, R | 1 |
| Guan, J | 3 |
| Zhao, X | 2 |
| Zhan, C | 1 |
| Yun, Y | 1 |
| Ayyagari, P | 1 |
| Shannon, HE | 3 |
| Reich, TR | 1 |
| Schwarzenbach, C | 1 |
| Vilar, JB | 1 |
| Unger, S | 1 |
| Mühlhäusler, F | 1 |
| Nikolova, T | 2 |
| Poplawski, A | 1 |
| Baymaz, HI | 1 |
| Beli, P | 1 |
| Tomicic, MT | 3 |
| Castro, M | 1 |
| Pampana, A | 1 |
| Alam, A | 1 |
| Parashar, R | 1 |
| Rajagopalan, S | 1 |
| Lala, DA | 1 |
| Roy, KGG | 1 |
| Basu, S | 1 |
| Prakash, A | 1 |
| Nair, P | 1 |
| Joseph, V | 1 |
| Agarwal, A | 3 |
| G, P | 1 |
| Behura, L | 1 |
| Kulkarni, S | 1 |
| Choudhary, NR | 1 |
| Kapoor, S | 1 |
| Oberg, AL | 1 |
| Qiao, S | 1 |
| Ji, Q | 1 |
| Mei, Q | 1 |
| Liu, D | 3 |
| Jiao, Y | 3 |
| Luo, W | 3 |
| Inoue, A | 1 |
| Nishikawa, M | 1 |
| Ohnishi, T | 2 |
| Kanemura, Y | 2 |
| Ohtsuka, Y | 1 |
| Ozaki, S | 1 |
| Nakamura, Y | 1 |
| Matsumoto, S | 1 |
| Suehiro, S | 1 |
| Yamashita, D | 1 |
| Shigekawa, S | 1 |
| Watanabe, H | 1 |
| Kitazawa, R | 1 |
| Tanaka, J | 1 |
| Kunieda, T | 2 |
| Xi, X | 1 |
| Kan, R | 1 |
| Liao, KH | 1 |
| Chen, GY | 1 |
| Kang, RH | 1 |
| Chowdhury, T | 1 |
| Oh, JH | 1 |
| Shin, J | 1 |
| Lee, S | 1 |
| Lee, JY | 3 |
| Mir, T | 1 |
| Pond, G | 1 |
| Greenspoon, JN | 1 |
| Chen, NF | 1 |
| Wen, ZH | 1 |
| Yao, ZK | 1 |
| Tsui, KH | 1 |
| Kuo, HM | 1 |
| Zheng, Z | 1 |
| Meng, L | 2 |
| Yasaswi, PS | 1 |
| Shetty, K | 1 |
| Yadav, KS | 1 |
| Smit, AM | 1 |
| Kilian, S | 1 |
| Emsley, RA | 1 |
| Luckhoff, HK | 1 |
| Swartz, L | 1 |
| Seedat, S | 1 |
| Asmal, L | 1 |
| Kloppers, JF | 1 |
| de Kock, A | 1 |
| Cronjé, J | 1 |
| van Marle, AC | 1 |
| Aouad, MR | 1 |
| Khan, DJO | 1 |
| Said, MA | 1 |
| Al-Kaff, NS | 1 |
| Rezki, N | 1 |
| Ali, AA | 1 |
| Bouqellah, N | 1 |
| Hagar, M | 1 |
| Sanga, G | 1 |
| Jao, I | 1 |
| Mumba, N | 1 |
| Mwalukore, S | 1 |
| Kamuya, D | 1 |
| Davies, A | 1 |
| McGready, R | 1 |
| Rijken, MJ | 1 |
| Than, HH | 1 |
| Tun, NW | 1 |
| Min, AM | 1 |
| Hla, S | 1 |
| Wai, NS | 1 |
| Proux, K | 1 |
| Min, TH | 1 |
| Gilder, ME | 1 |
| Sneddon, A | 1 |
| Sorbera, M | 1 |
| Fischetti, B | 1 |
| Khaimova, R | 1 |
| Niewinski, M | 1 |
| Wen, K | 1 |
| Tarke, A | 1 |
| Sidney, J | 1 |
| Methot, N | 1 |
| Yu, ED | 1 |
| Dan, JM | 1 |
| Goodwin, B | 1 |
| Rubiro, P | 1 |
| Sutherland, A | 1 |
| Frazier, A | 1 |
| Ramirez, SI | 1 |
| Rawlings, SA | 1 |
| Smith, DM | 1 |
| da Silva Antunes, R | 1 |
| Peters, B | 1 |
| Scheuermann, RH | 1 |
| Weiskopf, D | 1 |
| Crotty, S | 1 |
| Grifoni, A | 1 |
| Sette, A | 1 |
| Yan, P | 1 |
| Liang, DY | 1 |
| Xu, WH | 1 |
| Xue, L | 1 |
| Yu, MF | 1 |
| Shen, JH | 1 |
| Liu, QH | 1 |
| Peng, YB | 1 |
| Arenas, M | 1 |
| Algara, M | 2 |
| De Febrer, G | 1 |
| Rubio, C | 1 |
| Sanz, X | 2 |
| de la Casa, MA | 1 |
| Vasco, C | 1 |
| Marín, J | 1 |
| Fernández-Letón, P | 1 |
| Villar, J | 1 |
| Torres-Royo, L | 1 |
| Villares, P | 1 |
| Membrive, I | 2 |
| Acosta, J | 1 |
| López-Cano, M | 1 |
| Araguas, P | 1 |
| Quera, J | 1 |
| Rodríguez-Tomás, F | 1 |
| Montero, A | 1 |
| Buchler, A | 1 |
| Munch, M | 1 |
| Farber, G | 1 |
| Al-Haddad, R | 1 |
| Farber, E | 1 |
| Rotstein, BH | 1 |
| Yang, N | 3 |
| Zeng, S | 1 |
| Liao, G | 1 |
| De Gregori, S | 1 |
| De Silvestri, A | 1 |
| Molinaro, MD | 1 |
| Monzillo, V | 1 |
| Biscarini, S | 1 |
| Colaneri, M | 1 |
| Gallazzi, I | 1 |
| Bartoli, A | 1 |
| Bruno, R | 1 |
| Seminari, E | 1 |
| Dang, W | 1 |
| Miao, J | 2 |
| Cao, M | 1 |
| Bian, X | 1 |
| Norlin, JM | 1 |
| Kellerborg, K | 1 |
| Odin, P | 1 |
| Talele, S | 1 |
| Pokorny, JL | 5 |
| Bakken, KK | 4 |
| Gampa, G | 1 |
| Schmitt-Hoffmann, A | 1 |
| Bachmann, F | 2 |
| McSheehy, P | 2 |
| Lane, HA | 2 |
| Elmquist, WF | 3 |
| Fadera, S | 1 |
| Liu, HL | 3 |
| Lee, IC | 2 |
| Lorenz, NI | 2 |
| Sittig, ACM | 1 |
| Urban, H | 1 |
| Luger, AL | 2 |
| Engel, AL | 1 |
| Münch, C | 1 |
| Ronellenfitsch, MW | 4 |
| Zhang, XN | 1 |
| He, ZC | 1 |
| Wang, QH | 1 |
| Tan, YY | 1 |
| Wang, WY | 1 |
| Li, TR | 1 |
| Che, LR | 1 |
| Qin, ZY | 1 |
| Wu, LX | 2 |
| Luo, CH | 1 |
| Liu, YQ | 1 |
| Yin, W | 1 |
| Guo, HT | 1 |
| Zuo, M | 1 |
| Ozaki, K | 1 |
| Hara, A | 1 |
| Yamaki, T | 2 |
| Matsutani, T | 1 |
| Campos-Sandoval, JA | 1 |
| Gómez-García, MC | 1 |
| Santos-Jiménez, JL | 1 |
| Matés, JM | 1 |
| Alonso, FJ | 1 |
| Márquez, J | 1 |
| Maier, JP | 1 |
| Ravi, VM | 2 |
| Kueckelhaus, J | 1 |
| Behringer, SP | 1 |
| Garrelfs, N | 2 |
| Will, P | 1 |
| Sun, N | 1 |
| von Ehr, J | 1 |
| Goeldner, JM | 1 |
| Pfeifer, D | 1 |
| Follo, M | 2 |
| Hannibal, L | 1 |
| Walch, AK | 1 |
| Hofmann, UG | 2 |
| Beck, J | 2 |
| Joseph, K | 2 |
| Karami, A | 1 |
| Hossienpour, M | 1 |
| Mohammadi Noori, E | 1 |
| Rahpyma, M | 1 |
| Najafi, K | 1 |
| Hernandez, A | 1 |
| Kresbach, C | 1 |
| Bronsema, A | 1 |
| Guerreiro, H | 1 |
| Rutkowski, S | 1 |
| Winkler, B | 1 |
| Brunel, A | 1 |
| Hombourger, S | 1 |
| Barthout, E | 1 |
| Battu, S | 1 |
| Kögel, D | 3 |
| Antonietti, P | 1 |
| Deluche, E | 1 |
| Saada, S | 1 |
| Durand, S | 1 |
| Lalloué, F | 1 |
| Jauberteau, MO | 1 |
| Begaud, G | 1 |
| Bessette, B | 1 |
| Verdier, M | 1 |
| Adegboyega, G | 1 |
| Ozair, A | 1 |
| Kanmounye, US | 1 |
| Bandyopadhyay, S | 1 |
| Vaqas, B | 1 |
| Besiroglu, M | 1 |
| Demir, T | 1 |
| Shbair, ATM | 1 |
| Yasin, AI | 1 |
| Topcu, A | 1 |
| Turk, HM | 1 |
| Yonezawa, H | 3 |
| Funakoshi, Y | 1 |
| Otsuji, R | 1 |
| Sako, A | 1 |
| Yoshiura, T | 2 |
| Dadras, MS | 1 |
| Mezheyeuski, A | 1 |
| Webb, AT | 1 |
| Gomez-Puerto, MC | 1 |
| Ten Dijke, P | 1 |
| Heldin, CH | 1 |
| Lee, GA | 1 |
| Lin, WL | 1 |
| Kuo, DP | 1 |
| Li, YT | 1 |
| Chang, YW | 1 |
| Chen, YC | 1 |
| Huang, SW | 1 |
| Hsu, JB | 1 |
| Chen, CY | 1 |
| Verma, V | 1 |
| Mohania, D | 1 |
| Babbar, AK | 1 |
| Rathi, B | 1 |
| Dhanda, RS | 1 |
| Yadav, M | 1 |
| Kato, S | 1 |
| Li, XD | 1 |
| Wang, MJ | 1 |
| Zheng, JL | 1 |
| Wu, YH | 1 |
| Jiang, XB | 2 |
| Genoud, V | 1 |
| Espinoza, FI | 1 |
| Marinari, E | 1 |
| Rochemont, V | 1 |
| Dietrich, PY | 9 |
| Walker, PR | 1 |
| Tajudin, AA | 1 |
| Masarudin, MJ | 1 |
| Sekawi, Z | 1 |
| Masomian, M | 1 |
| Syahir, A | 1 |
| Tomar, MS | 1 |
| Srivastava, C | 1 |
| Shrivastava, A | 1 |
| Heng, X | 1 |
| Gautam, M | 1 |
| Gabrani, R | 1 |
| Fu, T | 1 |
| Mu, Z | 1 |
| Sun, R | 1 |
| I-H Park, T | 1 |
| Guerriero, C | 1 |
| Matera, C | 1 |
| Del Bufalo, D | 1 |
| De Amici, M | 1 |
| Conti, L | 1 |
| Dallanoce, C | 1 |
| Press, RH | 1 |
| Chhabra, AM | 1 |
| Choi, JI | 1 |
| Hasan, S | 1 |
| Garg, M | 1 |
| Lazarev, S | 1 |
| Yang, TJ | 1 |
| Yamada, J | 1 |
| Simone, CB | 1 |
| Schöttler, U | 2 |
| Krishna, S | 2 |
| Schmiedek, P | 3 |
| Narayan, RS | 2 |
| Fedrigo, CA | 2 |
| Brands, E | 1 |
| Dik, R | 1 |
| Stalpers, LJ | 5 |
| Slotman, BJ | 4 |
| Westerman, BA | 1 |
| Peters, GJ | 1 |
| Sminia, P | 5 |
| Huang, BS | 1 |
| Luo, QZ | 1 |
| Han, Y | 3 |
| Huang, D | 1 |
| Tang, QP | 1 |
| Huang, WC | 1 |
| Lu, IL | 1 |
| Chiang, WH | 1 |
| Lin, YW | 1 |
| Tsai, YC | 1 |
| Chen, HH | 1 |
| Chang, CW | 1 |
| Chiang, CS | 1 |
| Chiu, HC | 1 |
| Cheng, W | 2 |
| Khazaei, M | 1 |
| Pazhouhi, M | 1 |
| Tie, X | 1 |
| Xia, J | 1 |
| Skardelly, M | 2 |
| Dangel, E | 1 |
| Gohde, J | 1 |
| Noell, S | 1 |
| Behling, F | 1 |
| Lepski, G | 1 |
| Borchers, C | 3 |
| Koch, M | 1 |
| Schittenhelm, J | 2 |
| Bisdas, S | 1 |
| Naumann, A | 1 |
| Paulsen, F | 3 |
| von Hehn, U | 1 |
| Ritz, R | 1 |
| Tatagiba, MS | 1 |
| Carroll, KT | 1 |
| Hirshman, B | 1 |
| Ali, MA | 1 |
| Alattar, AA | 1 |
| Brandel, MG | 2 |
| Lochte, B | 1 |
| Lanman, T | 1 |
| Carter, B | 2 |
| Pietrobono, D | 1 |
| Costa, B | 3 |
| Giustiniano, M | 1 |
| Giacomelli, C | 1 |
| La Regina, G | 1 |
| Silvestri, R | 1 |
| Trincavelli, ML | 2 |
| Blumenthal, DT | 6 |
| Kim, MM | 5 |
| Burt Nabors, L | 1 |
| Hyun Nam, D | 1 |
| Corn, BW | 3 |
| Mirimanoff, RO | 13 |
| Sita, TL | 1 |
| Kouri, FM | 2 |
| Hurley, LA | 1 |
| Merkel, TJ | 1 |
| Chalastanis, A | 1 |
| May, JL | 1 |
| Ghelfi, ST | 1 |
| Cole, LE | 1 |
| Cayton, TC | 1 |
| Barnaby, SN | 1 |
| Sprangers, AJ | 1 |
| Savalia, N | 1 |
| Mirkin, CA | 1 |
| Stegh, AH | 2 |
| Lou, S | 1 |
| Huang, S | 5 |
| Russell, L | 1 |
| Bolyard, C | 2 |
| Banasavadi-Siddegowda, Y | 3 |
| Weiss, A | 1 |
| Shakya, R | 1 |
| Powell, K | 1 |
| Kaur, B | 3 |
| Foro Arnalot, P | 1 |
| Pera, O | 1 |
| Rodriguez, N | 1 |
| Reig, A | 1 |
| Ortiz, A | 1 |
| Granados, R | 1 |
| Balça-Silva, J | 3 |
| Dubois, LG | 2 |
| Pontes, B | 2 |
| Ferrer, VP | 1 |
| Rosário, L | 1 |
| do Carmo, A | 3 |
| Echevarria-Lima, J | 1 |
| Sarmento-Ribeiro, AB | 3 |
| Lopes, MC | 3 |
| Suzuki, Y | 3 |
| Fujioka, K | 1 |
| Ikeda, K | 1 |
| Murayama, Y | 2 |
| Manome, Y | 1 |
| Velpula, KK | 1 |
| Guda, MR | 1 |
| Sahu, K | 1 |
| Tuszynski, J | 1 |
| Asuthkar, S | 1 |
| Bach, SE | 1 |
| Lathia, JD | 3 |
| Tsung, AJ | 1 |
| Ye, MH | 1 |
| Lv, SG | 1 |
| Wu, MJ | 1 |
| Zhu, XG | 1 |
| Sadeghi, GMM | 1 |
| Haririan, I | 1 |
| Furuta, T | 4 |
| Sabit, H | 3 |
| Uchiyama, N | 1 |
| Hayashi, Y | 6 |
| Minamoto, T | 3 |
| Liu, N | 6 |
| Takeshima, Y | 1 |
| Amatya, VJ | 1 |
| Takayasu, T | 4 |
| Nosaka, R | 4 |
| Banelli, B | 2 |
| Daga, A | 2 |
| Forlani, A | 2 |
| Allemanni, G | 2 |
| Marubbi, D | 2 |
| Pistillo, MP | 1 |
| Profumo, A | 1 |
| Romani, M | 2 |
| Emery, IF | 1 |
| Gopalan, A | 1 |
| Wood, S | 1 |
| Battelli, C | 1 |
| George, J | 1 |
| Blaszyk, H | 1 |
| Florman, J | 1 |
| Baernreuther, J | 1 |
| Yu, Q | 2 |
| Xue, Y | 3 |
| Lan, T | 1 |
| Du, XL | 1 |
| Slat, EA | 1 |
| Sponagel, J | 1 |
| Marpegan, L | 1 |
| Simon, T | 1 |
| Kfoury, N | 1 |
| Kim, A | 1 |
| Binz, A | 1 |
| Herzog, ED | 1 |
| Rubin, JB | 1 |
| Alter, RA | 2 |
| White, TG | 1 |
| Fanous, AA | 1 |
| Pisapia, DJ | 1 |
| Tsiouris, AJ | 1 |
| Flanigan, PM | 1 |
| Kuang, R | 1 |
| Truong, A | 1 |
| Choi, S | 1 |
| Chou, A | 1 |
| McDermott, MW | 3 |
| Aghi, MK | 2 |
| Liu, YJ | 1 |
| Ma, YC | 1 |
| Zhang, WJ | 1 |
| Yang, ZZ | 1 |
| Liang, DS | 1 |
| Wu, ZF | 1 |
| Qi, XR | 1 |
| Oancea-Castillo, LR | 1 |
| Klein, C | 1 |
| Abdollahi, A | 2 |
| Weber, KJ | 5 |
| Dokic, I | 1 |
| Bielecka-Wajdman, AM | 1 |
| Lesiak, M | 1 |
| Ludyga, T | 1 |
| Sieroń, A | 1 |
| Obuchowicz, E | 2 |
| Zeng, AL | 1 |
| Liu, YW | 4 |
| Hu, Q | 2 |
| Wang, XF | 1 |
| You, YP | 2 |
| Fu, A | 1 |
| Niu, L | 1 |
| Ma, K | 1 |
| Moquin, A | 2 |
| Bomal, E | 1 |
| Na, L | 1 |
| Maysinger, D | 2 |
| Kakkar, A | 1 |
| Illic, R | 1 |
| Somma, T | 1 |
| Savic, D | 1 |
| Frio, F | 1 |
| Milicevic, M | 1 |
| Solari, D | 1 |
| Lavrnic, S | 1 |
| Raicevic, S | 2 |
| Cavallo, LM | 1 |
| Cappabianca, P | 1 |
| Jaros, BD | 1 |
| An, M | 1 |
| Akbarnejad, Z | 2 |
| Eskandary, H | 2 |
| Vergallo, C | 1 |
| Nematollahi-Mahani, SN | 1 |
| Farsinejad, A | 1 |
| Abadi, MFS | 1 |
| Ahmadi, M | 2 |
| Steverding, D | 1 |
| Rushworth, SA | 1 |
| Wei, W | 2 |
| Long, C | 1 |
| Jahan, N | 1 |
| Lee, JM | 2 |
| Shah, K | 1 |
| Maciaczyk, D | 2 |
| Picard, D | 2 |
| Koch, K | 2 |
| Herrera-Rios, D | 1 |
| Marquardt, V | 1 |
| Pauck, D | 1 |
| Hoerbelt, T | 1 |
| Ouwens, DM | 1 |
| Kahlert, UD | 2 |
| Tupper, L | 1 |
| Harris, G | 1 |
| Jayamanne, D | 2 |
| Kastelan, M | 4 |
| Schembri, G | 2 |
| Brazier, D | 2 |
| Cook, R | 2 |
| Parkinson, J | 1 |
| Louw, S | 1 |
| Hama, S | 2 |
| Onishi, S | 1 |
| Villodre, ES | 1 |
| Kipper, FC | 1 |
| Silva, AO | 2 |
| Lopez, PLDC | 1 |
| Snyder, J | 1 |
| Italiya, K | 1 |
| Mohanty, S | 1 |
| Morais, GR | 1 |
| Klockow, J | 1 |
| Yerneni, K | 1 |
| Pisani, L | 1 |
| Chin, FT | 1 |
| Cheshier, S | 1 |
| Gambhir, SS | 2 |
| Rao, J | 1 |
| Loadman, PM | 1 |
| Falconer, RA | 1 |
| Daldrup-Link, HE | 1 |
| Nordling-David, MM | 1 |
| Yaffe, R | 1 |
| Guez, D | 2 |
| Meirow, H | 1 |
| Last, D | 2 |
| Grad, E | 1 |
| Salomon, S | 1 |
| Sharabi, S | 1 |
| Levi-Kalisman, Y | 1 |
| Golomb, G | 1 |
| Mardor, Y | 2 |
| Yu, A | 1 |
| Faiq, N | 1 |
| Green, S | 1 |
| Green, R | 2 |
| Mellinghoff, I | 3 |
| Choi, HJ | 2 |
| Kim, DS | 2 |
| Lee, KS | 2 |
| Rampazzo, E | 2 |
| Dettin, M | 1 |
| Maule, F | 1 |
| Scabello, A | 1 |
| Calvanese, L | 1 |
| D'Auria, G | 1 |
| Falcigno, L | 1 |
| Porcù, E | 1 |
| Zamuner, A | 1 |
| Boso, D | 1 |
| Basso, G | 2 |
| Persano, L | 2 |
| Nakao, J | 1 |
| Matsuda, M | 3 |
| Yamamoto, T | 5 |
| Takano, S | 3 |
| Al-Saffar, NMS | 1 |
| Agliano, A | 1 |
| Marshall, LV | 1 |
| Jackson, LE | 1 |
| Balarajah, G | 1 |
| Sidhu, J | 1 |
| Clarke, PA | 1 |
| Jones, C | 6 |
| Workman, P | 3 |
| Pearson, ADJ | 1 |
| Leach, MO | 1 |
| Fariselli, L | 5 |
| Cuppini, L | 1 |
| Gaviani, P | 5 |
| Marchetti, M | 3 |
| Pinzi, V | 1 |
| Milanesi, I | 3 |
| Simonetti, G | 2 |
| Tramacere, I | 1 |
| DiMeco, F | 2 |
| Salmaggi, A | 8 |
| Silvani, A | 9 |
| Gonçalves, AC | 1 |
| Girão, H | 2 |
| Canedo, NHS | 1 |
| Correia, AH | 1 |
| De Souza, JM | 2 |
| Akiyama, Y | 5 |
| Nonomura, C | 2 |
| Ashizawa, T | 4 |
| Iizuka, A | 4 |
| Kondou, R | 2 |
| Miyata, H | 4 |
| Sugino, T | 4 |
| Mitsuya, K | 5 |
| Hayashi, N | 4 |
| Ito, M | 3 |
| Kiyohara, Y | 1 |
| Yamaguchi, K | 4 |
| Fujikawa, A | 1 |
| Sugawara, H | 1 |
| Matsumoto, M | 1 |
| Kuboyama, K | 1 |
| Suzuki, R | 1 |
| Tanga, N | 1 |
| Ogata, A | 1 |
| Masumura, M | 1 |
| Noda, M | 1 |
| Desai, VCA | 1 |
| Quinlan, SC | 1 |
| Deitz, AC | 1 |
| Holick, CN | 1 |
| Lanes, S | 1 |
| Prabhu, S | 1 |
| Mutalik, S | 1 |
| Mohanty, BS | 1 |
| Rai, S | 1 |
| Udupa, N | 1 |
| Rao, BSS | 1 |
| Ryu, KH | 1 |
| Kim, HW | 1 |
| Shim, WH | 3 |
| Jung, SC | 2 |
| Choi, CG | 2 |
| Kim, SJ | 4 |
| Koukourakis, M | 1 |
| Tsolou, A | 1 |
| Pouliliou, S | 1 |
| Lamprou, I | 1 |
| Papadopoulou, M | 1 |
| Ilemosoglou, M | 1 |
| Kostoglou, G | 1 |
| Ananiadou, D | 1 |
| Sivridis, E | 1 |
| Giatromanolaki, A | 2 |
| Magrath, JW | 1 |
| Cui, C | 1 |
| Vaglini, F | 1 |
| Pardini, C | 1 |
| Di Desidero, T | 1 |
| Ottani, A | 1 |
| Pacini, S | 1 |
| Giuliani, D | 1 |
| Guarini, S | 1 |
| Tay, RY | 1 |
| Blackley, E | 1 |
| McLean, C | 1 |
| Moore, M | 1 |
| Bergin, P | 1 |
| Haydon, A | 1 |
| Hsieh, SY | 1 |
| Chan, DT | 1 |
| Kam, MK | 1 |
| Loong, HH | 1 |
| Tsang, WK | 1 |
| Poon, DM | 1 |
| Ng, SC | 1 |
| Poon, WS | 3 |
| Chow, RD | 1 |
| Guzman, CD | 1 |
| Schmidt, F | 1 |
| Youngblood, MW | 1 |
| Errami, Y | 1 |
| Dong, MB | 1 |
| Martinez, MA | 1 |
| Renauer, P | 1 |
| Bilguvar, K | 1 |
| Gunel, M | 1 |
| Sharp, PA | 1 |
| Platt, RJ | 1 |
| Jbeli, AH | 1 |
| Badruddoja, MA | 1 |
| Pazzi, M | 1 |
| Sanan, A | 1 |
| Schroeder, K | 1 |
| Kuzma, K | 1 |
| Norton, T | 1 |
| Scully, T | 1 |
| Mahadevan, D | 1 |
| Ahmadi, MM | 1 |
| Tsai, SY | 2 |
| Chen, KY | 1 |
| Hung, JJ | 2 |
| Chuang, CK | 2 |
| Stritzelberger, J | 1 |
| Distel, L | 1 |
| Buslei, R | 2 |
| Burri, SH | 1 |
| de Moraes, FY | 1 |
| Tan, Q | 2 |
| Song, L | 2 |
| Yi, H | 1 |
| Sun, G | 6 |
| Hirte, H | 3 |
| Ashby, L | 3 |
| Mechtler, L | 1 |
| Iwamoto, F | 3 |
| Drappatz, J | 10 |
| Wong, M | 1 |
| Hamilton, MG | 2 |
| Perry, J | 4 |
| Green, J | 1 |
| Turner, CD | 1 |
| Yellin, MJ | 1 |
| Keler, T | 2 |
| Davis, TA | 2 |
| Demireva, P | 1 |
| Pannullo, S | 1 |
| Mehdorn, M | 3 |
| Avgeropoulos, N | 1 |
| Goldlust, S | 2 |
| David, C | 2 |
| Moroney, C | 1 |
| Tsang, DS | 1 |
| Bilodeau, D | 1 |
| Mueller, C | 1 |
| Soliman, H | 2 |
| Myrehaug, S | 2 |
| Tseng, CL | 1 |
| Tsao, MN | 3 |
| Adhikari, B | 1 |
| Futalan, D | 2 |
| Akers, J | 2 |
| Deming, T | 1 |
| Kim, WJ | 1 |
| Newman, WC | 1 |
| Amankulor, NM | 1 |
| Gorman, MJ | 1 |
| McKenzie, LD | 1 |
| Chai, JN | 1 |
| Hubert, CG | 1 |
| Prager, BC | 1 |
| Fernandez, E | 2 |
| Richner, JM | 1 |
| Shan, C | 1 |
| Tycksen, E | 1 |
| Shi, PY | 1 |
| Diamond, MS | 1 |
| Krengli, M | 3 |
| Magrini, SM | 4 |
| Fusco, V | 7 |
| Pirtoli, L | 9 |
| Doino, D | 1 |
| Fiorentino, A | 10 |
| Masini, L | 2 |
| Buglione, M | 5 |
| Rubino, G | 4 |
| Lonardi, F | 1 |
| Migliaccio, F | 1 |
| Marzano, S | 1 |
| Santoni, R | 3 |
| Ricardi, U | 3 |
| Cheng, ZX | 1 |
| Yin, WB | 1 |
| Wang, ZY | 1 |
| Jing, D | 1 |
| Yu, H | 7 |
| Teo, C | 1 |
| Back, MF | 2 |
| Huang, CT | 1 |
| Tsai, KK | 1 |
| Vieira de Castro, J | 1 |
| Gomes, ED | 1 |
| Granja, S | 1 |
| Anjo, SI | 1 |
| Baltazar, F | 1 |
| Manadas, B | 1 |
| Salgado, AJ | 1 |
| Costa, BM | 4 |
| Elia, AEH | 1 |
| Batchelor, TT | 18 |
| Miller, CR | 2 |
| Jaeckle, K | 1 |
| Ballman, KV | 4 |
| Moore, DF | 1 |
| Nebozhyn, M | 1 |
| Loboda, A | 1 |
| Schiff, D | 10 |
| Lee, EQ | 4 |
| Lesser, GJ | 5 |
| Cerhan, J | 1 |
| Garnier, D | 1 |
| Kislinger, T | 1 |
| Sinha, A | 1 |
| Nakano, I | 3 |
| Nowosielski, M | 1 |
| Garcia, J | 5 |
| Revil, C | 2 |
| Kickingereder, P | 3 |
| Sandmann, T | 2 |
| Abrey, LE | 10 |
| Bendszus, M | 4 |
| Barbarisi, M | 3 |
| Iaffaioli, RV | 2 |
| Armenia, E | 2 |
| Schiavo, L | 1 |
| De Sena, G | 2 |
| Tafuto, S | 1 |
| Barbarisi, A | 2 |
| Quagliariello, V | 2 |
| Ramdzan, ZM | 1 |
| Leduy, L | 1 |
| Ramotar, D | 1 |
| Nepveu, A | 1 |
| Que, S | 2 |
| Lou, M | 1 |
| Lan, J | 2 |
| Qian, Z | 2 |
| Qiu, Y | 3 |
| Tini, P | 5 |
| Nardone, V | 2 |
| Pastina, P | 2 |
| Battaglia, G | 3 |
| Miracco, C | 6 |
| Carbone, SF | 1 |
| Sebaste, L | 2 |
| Cerase, A | 2 |
| Kumar, V | 2 |
| Radin, D | 2 |
| Leonardi, D | 2 |
| Xue, W | 1 |
| Xie, T | 1 |
| Tong, H | 1 |
| Belmans, J | 1 |
| Van Woensel, M | 1 |
| Creyns, B | 1 |
| Dejaegher, J | 1 |
| Bullens, DM | 1 |
| Nam, JG | 1 |
| Lim, WH | 1 |
| Braun, K | 2 |
| Merrell, R | 4 |
| Fichtel, L | 2 |
| Scott, AM | 3 |
| Gomez, EJ | 1 |
| Fischer, J | 4 |
| Mandich, H | 2 |
| Munasinghe, WP | 1 |
| Roberts-Rapp, LA | 1 |
| Holen, KD | 3 |
| Mehrpour, M | 1 |
| Harlos, C | 1 |
| Pitz, M | 2 |
| Hamai, A | 1 |
| Siemianowicz, K | 1 |
| Likus, W | 1 |
| Wiechec, E | 1 |
| Toyota, BD | 1 |
| Hoshyar, R | 1 |
| Seyfoori, A | 1 |
| Sepehri, Z | 1 |
| Ande, SR | 1 |
| Khadem, F | 1 |
| Gorman, AM | 1 |
| Teng, J | 2 |
| Hejazi, S | 1 |
| Hiddingh, L | 3 |
| Carvalho, L | 1 |
| de Gooijer, MC | 2 |
| Barazas, M | 1 |
| Tannous, M | 1 |
| Chi, AS | 4 |
| Noske, DP | 3 |
| Wurdinger, T | 4 |
| Tannous, BA | 2 |
| Scannell Bryan, M | 1 |
| Valeinis, E | 2 |
| Hopkins, K | 4 |
| Souhami, L | 7 |
| Tzuk-Shina, T | 2 |
| Howard, SP | 2 |
| Youssef, EF | 1 |
| Lessard, N | 1 |
| Dignam, JJ | 3 |
| Roussakow, SV | 1 |
| Perry, LA | 1 |
| Agrawal, JP | 1 |
| Lu, D | 3 |
| Teng, L | 3 |
| Du, Y | 1 |
| Ren, J | 2 |
| Ying, G | 1 |
| Shao, M | 1 |
| Zhong, G | 1 |
| Xia, Z | 1 |
| Proescholdt, M | 7 |
| Friedrich, F | 2 |
| Rohde, V | 7 |
| Uhl, M | 3 |
| Grau, S | 2 |
| Hänel, M | 4 |
| Mack, F | 5 |
| Nießen, M | 1 |
| Leutgeb, B | 2 |
| Urbach, H | 3 |
| Chinnaiyan, P | 5 |
| Rojiani, AM | 3 |
| Shih, HA | 1 |
| Ashby, LS | 3 |
| Michael Yu, HH | 1 |
| Stieber, VW | 3 |
| Malone, SC | 1 |
| Fiveash, JB | 5 |
| Wendland, MM | 2 |
| Stella, PJ | 1 |
| Kee, AY | 2 |
| Mao, L | 1 |
| Puente, P | 1 |
| Fettig, N | 1 |
| Luderer, MJ | 1 |
| Jin, A | 1 |
| Shah, S | 1 |
| Muz, B | 1 |
| Goddu, SM | 1 |
| Salama, NN | 1 |
| Tsien, C | 5 |
| Shoghi, K | 1 |
| Rogers, B | 1 |
| Azab, AK | 1 |
| Yamaguchi, H | 1 |
| Shirakihara, T | 1 |
| Nakashima, K | 1 |
| Kumagai, K | 2 |
| Takeuchi, S | 3 |
| Toyooka, T | 3 |
| Otani, N | 3 |
| Sakai, R | 1 |
| Namba, H | 3 |
| Mori, K | 3 |
| Schneider, H | 1 |
| Silginer, M | 4 |
| Steinle, A | 1 |
| Pruschy, M | 1 |
| Polić, B | 1 |
| Puri, RK | 1 |
| Sharif, S | 1 |
| Ghahremani, MH | 1 |
| Soleimani, M | 1 |
| Marques-Torrejon, MA | 1 |
| Gangoso, E | 1 |
| Pollard, SM | 1 |
| Harford, JB | 1 |
| Moghe, M | 1 |
| Rait, A | 4 |
| Pirollo, KF | 4 |
| Chang, EH | 4 |
| Chautard, E | 2 |
| De Schlichting, E | 1 |
| Dupic, G | 1 |
| Pereira, B | 1 |
| Fogli, A | 1 |
| Müller-Barthélémy, M | 1 |
| Dalloz, P | 2 |
| Khalil, T | 2 |
| Dillies, AF | 1 |
| Godfraind, C | 1 |
| Verrelle, P | 3 |
| Kamdar, MR | 1 |
| Berger, G | 1 |
| Grauwet, K | 1 |
| Hussey, AM | 1 |
| Nowicki, MO | 2 |
| Wang, DI | 1 |
| Lippard, SJ | 1 |
| Taghipour Zahir, S | 1 |
| Mortaz, M | 1 |
| Baghi Yazdi, M | 1 |
| Sefidrokh Sharahjin, N | 1 |
| Shabani, M | 1 |
| Marriage, F | 1 |
| Day, PJ | 2 |
| Jensen, KV | 1 |
| Cseh, O | 1 |
| Aman, A | 2 |
| Weiss, S | 6 |
| Luchman, HA | 4 |
| Chen, R | 3 |
| Chen, LY | 1 |
| Lappin, H | 1 |
| Vasconcelos, G | 1 |
| Lita, A | 1 |
| Maric, D | 1 |
| Celiku, O | 1 |
| Meetze, K | 1 |
| Estok, T | 1 |
| Larion, M | 1 |
| Abu-Asab, M | 1 |
| Zhuang, Z | 2 |
| Taillibert, S | 5 |
| Kanner, A | 1 |
| Read, W | 1 |
| Steinberg, D | 1 |
| Lhermitte, B | 6 |
| Fink, K | 5 |
| Di Meco, F | 3 |
| Lieberman, F | 3 |
| Stragliotto, G | 1 |
| Tran, D | 1 |
| Hottinger, A | 1 |
| Kirson, ED | 3 |
| Bruna, J | 4 |
| Boyd, NH | 1 |
| Walker, K | 1 |
| Fried, J | 1 |
| Hackney, JR | 1 |
| McDonald, PC | 1 |
| Benavides, GA | 1 |
| Spina, R | 1 |
| Audia, A | 1 |
| Scott, SE | 1 |
| Landis, CJ | 1 |
| Tran, AN | 2 |
| Bevensee, MO | 1 |
| Nozell, S | 1 |
| Gillespie, GY | 4 |
| Bhat, KP | 1 |
| Bar, EE | 2 |
| Darley-Usmar, V | 1 |
| Gordon, E | 1 |
| Dedhar, S | 1 |
| Vanza, J | 1 |
| Jani, P | 1 |
| Pandya, N | 1 |
| Tandel, H | 1 |
| Schecker, J | 1 |
| Würstle, S | 1 |
| Schneider, F | 1 |
| Schönfelder, M | 1 |
| Jackson, S | 1 |
| Weingart, J | 2 |
| Nduom, EK | 1 |
| Harfi, TT | 1 |
| George, RT | 1 |
| McAreavey, D | 1 |
| Ye, X | 10 |
| Anders, NM | 1 |
| Peer, C | 1 |
| Figg, WD | 1 |
| Gilbert, M | 3 |
| Rudek, MA | 2 |
| Lee, JE | 2 |
| Lim, JH | 1 |
| William, D | 1 |
| Walther, M | 1 |
| Schneider, B | 3 |
| Linnebacher, M | 4 |
| Classen, CF | 4 |
| Pei, C | 1 |
| Dong, T | 1 |
| Xing, W | 1 |
| Zhen, Z | 1 |
| Ren, H | 1 |
| Hofheinz, F | 1 |
| Mutsaerts, HJMM | 1 |
| Asllani, I | 1 |
| van Osch, MJP | 1 |
| Krukowski, P | 1 |
| Gommlich, A | 1 |
| Maus, J | 1 |
| Troost, EGC | 1 |
| Gujar, AD | 2 |
| DeWees, TA | 2 |
| Lockhart, AC | 2 |
| Kim, AH | 3 |
| Jackson, WC | 1 |
| Tsien, CI | 6 |
| Junck, L | 6 |
| Orringer, D | 2 |
| Heth, J | 3 |
| Spratt, DE | 4 |
| Dirven, L | 1 |
| Sroubek, J | 2 |
| Easaw, JC | 5 |
| Kew, Y | 2 |
| Desai, R | 2 |
| Ghia, AJ | 1 |
| Cohen, RJ | 1 |
| Hoang, N | 1 |
| Shang, C | 1 |
| Pan, C | 1 |
| Hong, Y | 1 |
| Mehrabian, H | 1 |
| Stanisz, GJ | 1 |
| Ji, A | 1 |
| Qiu, G | 2 |
| André-Grégoire, G | 1 |
| Bidère, N | 1 |
| Gavard, J | 1 |
| Bokstein, F | 2 |
| Brachman, DG | 4 |
| Hunter, GK | 1 |
| Lieberman, FS | 5 |
| Shrieve, DC | 1 |
| Robinson, CG | 3 |
| Waschke, A | 1 |
| Arefian, H | 1 |
| Walter, J | 2 |
| Hartmann, M | 1 |
| Maschmann, J | 1 |
| Kalff, R | 2 |
| Reyes-Botero, G | 1 |
| Cartalat-Carel, S | 8 |
| Barrie, M | 6 |
| Taillandier, L | 10 |
| Beauchesne, P | 5 |
| Catry-Thomas, I | 2 |
| Barrière, J | 1 |
| Guillamo, JS | 6 |
| Fabbro, M | 4 |
| Frappaz, D | 7 |
| Campello, C | 4 |
| Tanguy, ML | 2 |
| Delattre, JY | 11 |
| Kimura, Y | 1 |
| Enatsu, R | 1 |
| Mikami, T | 1 |
| Wanibuchi, M | 1 |
| Mikuni, N | 1 |
| Cai, T | 3 |
| Happold, C | 5 |
| Stojcheva, N | 1 |
| Ahmed, EM | 1 |
| Bandopadhyay, G | 1 |
| Coyle, B | 1 |
| Grabowska, A | 1 |
| Rudra, S | 1 |
| Hui, C | 1 |
| Rao, YJ | 1 |
| Samson, P | 1 |
| Lin, AJ | 1 |
| Fergus, S | 1 |
| Mullen, D | 1 |
| Zhou, ZL | 2 |
| Ma, CX | 1 |
| Dréan, A | 1 |
| Rosenberg, S | 1 |
| Lejeune, FX | 1 |
| Goli, L | 1 |
| Nadaradjane, AA | 1 |
| Guehennec, J | 1 |
| Bielle, F | 1 |
| Carpentier, A | 2 |
| Gurrieri, L | 2 |
| De Carlo, E | 1 |
| Gerratana, L | 1 |
| De Maglio, G | 1 |
| Macerelli, M | 1 |
| Pisa, FE | 1 |
| Masiero, E | 1 |
| Aprile, G | 1 |
| Follador, A | 1 |
| Puglisi, F | 1 |
| Fasola, G | 1 |
| Rizzato, S | 2 |
| Pizzolitto, S | 1 |
| Chen, YY | 1 |
| Ho, HL | 2 |
| Lin, SC | 2 |
| Ho, TD | 1 |
| Hsu, CY | 2 |
| Pawlowska, E | 1 |
| Szczepanska, J | 1 |
| Szatkowska, M | 1 |
| Blasiak, J | 1 |
| Roos, WP | 2 |
| Frohnapfel, L | 1 |
| Quiros, S | 1 |
| Boxerman, JL | 4 |
| Safriel, Y | 3 |
| Rogg, JM | 1 |
| Wolf, RL | 1 |
| Mohan, S | 2 |
| Marques, H | 1 |
| Sorensen, AG | 6 |
| Barboriak, DP | 4 |
| Salazar, N | 1 |
| Carlson, JC | 1 |
| Oderup, C | 1 |
| Gross, J | 1 |
| Jang, AD | 1 |
| Burke, TM | 1 |
| Lewén, S | 1 |
| Scholz, A | 1 |
| Nease, L | 1 |
| Kosek, J | 1 |
| Butcher, EC | 1 |
| Tu, H | 1 |
| Zabel, BA | 1 |
| Shioyama, T | 1 |
| Yasuda, T | 1 |
| Hosono, J | 1 |
| Okamoto, S | 1 |
| Bettegowda, C | 1 |
| Chumakova, A | 1 |
| Nelson, SJ | 9 |
| Kaufmann, TJ | 2 |
| Colman, H | 8 |
| de Groot, J | 3 |
| Young, RJ | 2 |
| Colen, R | 1 |
| Arrillaga-Romany, I | 1 |
| Mehta, A | 2 |
| Huang, RY | 1 |
| Reardon, D | 2 |
| Baroni, M | 1 |
| Marie, SKN | 1 |
| Fedatto, PF | 1 |
| Andrade, AF | 1 |
| Suazo, VK | 2 |
| Cruzeiro, GAV | 1 |
| de Paula Queiroz, R | 1 |
| Tone, LG | 4 |
| Scrideli, CA | 4 |
| Woo, P | 1 |
| Ho, J | 2 |
| Lam, S | 1 |
| Ma, E | 1 |
| Chan, D | 1 |
| Wong, WK | 1 |
| Mak, C | 1 |
| Wong, ST | 5 |
| Chan, KY | 2 |
| Feng, WY | 1 |
| Chen, ZY | 1 |
| Li, YM | 1 |
| Deng, SZ | 1 |
| Guo, ML | 1 |
| Sun, XG | 1 |
| He, MY | 1 |
| Yusuf, M | 1 |
| Ugiliweneza, B | 1 |
| Amsbaugh, M | 1 |
| Boakye, M | 1 |
| Williams, B | 1 |
| Nelson, M | 1 |
| Hattab, EM | 1 |
| Woo, S | 2 |
| Burton, E | 1 |
| Yildirim, BA | 1 |
| Guler, OC | 1 |
| Ciner, F | 1 |
| Tufan, K | 2 |
| Meng, H | 1 |
| Fan, L | 2 |
| Costa Nunes, F | 1 |
| Silva, LB | 1 |
| Winter, E | 1 |
| Silva, AH | 1 |
| de Melo, LJ | 1 |
| Rode, M | 1 |
| Martins, MAP | 1 |
| Zanatta, N | 1 |
| Feitosa, SC | 1 |
| Bonacorso, HG | 1 |
| Creczynski-Pasa, TB | 1 |
| Yuan, Y | 7 |
| Kwan, K | 1 |
| Schneider, JR | 2 |
| Ramalho, MJ | 2 |
| Sevin, E | 1 |
| Gosselet, F | 1 |
| Lima, J | 1 |
| Coelho, MAN | 2 |
| Loureiro, JA | 2 |
| Pereira, MC | 2 |
| Yamashita, S | 2 |
| Yokogami, K | 1 |
| Matsumoto, F | 1 |
| Saito, K | 4 |
| Mizuguchi, A | 1 |
| Ohta, H | 1 |
| Takeshima, H | 2 |
| Basso, J | 1 |
| Miranda, A | 1 |
| Sousa, J | 1 |
| Pais, A | 1 |
| Vitorino, C | 1 |
| Karachi, A | 2 |
| Dastmalchi, F | 2 |
| Rone, JD | 1 |
| Graham, GT | 1 |
| Pannkuk, EL | 1 |
| Lamberti, G | 2 |
| Visani, M | 1 |
| Paccapelo, A | 4 |
| Mura, A | 1 |
| Tallini, G | 4 |
| Pession, A | 4 |
| De Biase, D | 3 |
| Minichillo, S | 1 |
| Tosoni, A | 13 |
| Di Battista, M | 1 |
| Cubeddu, A | 1 |
| Bartolini, S | 3 |
| Tong, L | 1 |
| Yi, L | 2 |
| Abeysekera, IR | 1 |
| Hai, L | 1 |
| Tao, Z | 1 |
| Bergo, E | 2 |
| Del Bianco, P | 1 |
| Bellu, L | 3 |
| Pambuku, A | 3 |
| Trentin, L | 1 |
| Malakhov, N | 1 |
| Sheth, N | 1 |
| Han, P | 1 |
| Schreiber, D | 1 |
| Fujihara, T | 1 |
| Mizobuchi, Y | 2 |
| Kageji, T | 2 |
| Matsuzaki, K | 2 |
| Kitazato, KT | 2 |
| Otsuka, R | 1 |
| Hara, K | 2 |
| Mure, H | 2 |
| Okazaki, T | 2 |
| Kuwayama, K | 2 |
| Nagahiro, S | 2 |
| Takagi, Y | 2 |
| Frontiñán-Rubio, J | 1 |
| Santiago-Mora, RM | 1 |
| Nieva-Velasco, CM | 1 |
| Ferrín, G | 1 |
| Martínez-González, A | 1 |
| Gómez, MV | 1 |
| Moreno, M | 1 |
| Ariza, J | 1 |
| Lozano, E | 1 |
| Arjona-Gutiérrez, J | 1 |
| Gil-Agudo, A | 1 |
| De la Mata, M | 1 |
| Pesic, M | 2 |
| Peinado, JR | 1 |
| Villalba, JM | 1 |
| Pérez-Romasanta, L | 1 |
| Pérez-García, VM | 2 |
| Alcaín, FJ | 1 |
| Durán-Prado, M | 1 |
| Holdhoff, M | 1 |
| Kulason, KO | 1 |
| Pramanik, B | 1 |
| Tan, K | 1 |
| Ray, A | 1 |
| Ortiz, R | 4 |
| Demopoulos, A | 3 |
| Matsuda, KI | 1 |
| Sakurada, K | 1 |
| Nemoto, K | 1 |
| Sonoda, Y | 4 |
| Loaiza, S | 1 |
| Carvajal, S | 1 |
| Giraldo, D | 1 |
| Galvis, A | 1 |
| Ortiz, L | 1 |
| Grek, CL | 1 |
| Sheng, Z | 2 |
| Naus, CC | 1 |
| Sin, WC | 1 |
| Gourdie, RG | 2 |
| Ghatnekar, GG | 1 |
| Jin, S | 1 |
| Liang, T | 1 |
| Liang, J | 3 |
| Junold, N | 2 |
| Niessen, M | 1 |
| Stuplich, M | 3 |
| Kortmann, RD | 8 |
| Braun, C | 1 |
| Gerlach, R | 3 |
| Li, JJ | 1 |
| Liu, WW | 1 |
| Lu, YT | 1 |
| Abe, H | 1 |
| Natsumeda, M | 2 |
| Kanemaru, Y | 1 |
| Watanabe, J | 1 |
| Tsukamoto, Y | 2 |
| Yoshimura, J | 2 |
| Oishi, M | 1 |
| Fujii, Y | 2 |
| Ceynowa, F | 1 |
| Yi, G | 1 |
| Shu, S | 1 |
| Bruhn, H | 1 |
| Vrethem, M | 1 |
| Lind, J | 1 |
| Zhao, HF | 1 |
| Wu, CP | 2 |
| Zhou, XM | 1 |
| Chen, ZP | 5 |
| To, ST | 1 |
| Li, WP | 4 |
| Kazantseva, M | 1 |
| Eiholzer, RA | 1 |
| Mehta, S | 1 |
| Taha, A | 1 |
| Bowie, S | 1 |
| Roth, I | 1 |
| Joruiz, SM | 1 |
| Royds, JA | 2 |
| Hung, NA | 1 |
| Slatter, TL | 1 |
| Braithwaite, AW | 1 |
| Lukács, G | 1 |
| Tóth, Z | 1 |
| Sipos, D | 1 |
| Csima, M | 1 |
| Hadjiev, J | 1 |
| Bajzik, G | 1 |
| Cselik, Z | 1 |
| Semjén, D | 1 |
| Repa, I | 1 |
| Kovács, Á | 1 |
| Erickson, AE | 1 |
| Lan Levengood, SK | 1 |
| Chang, FC | 1 |
| Hersh, DS | 1 |
| Roos, A | 3 |
| Heath, JE | 1 |
| Legesse, T | 1 |
| Kim, AJ | 1 |
| Woodworth, GF | 1 |
| Winkles, JA | 2 |
| Harris, RJ | 2 |
| Leu, K | 1 |
| Woodworth, DC | 2 |
| Chakhoyan, A | 1 |
| Hegazy, AM | 1 |
| Tadokoro, Y | 1 |
| Ueno, M | 1 |
| Kasahara, A | 1 |
| Takase, Y | 1 |
| Nomura, N | 1 |
| Peng, H | 1 |
| Ito, C | 1 |
| Ino, Y | 2 |
| Todo, T | 3 |
| Hirao, A | 2 |
| Fu, C | 1 |
| Cheng, WY | 2 |
| Shen, CC | 3 |
| Chiao, MT | 1 |
| Liang, YJ | 1 |
| Mao, TF | 1 |
| Liu, BS | 1 |
| Chen, JP | 1 |
| Brawanski, K | 2 |
| Brockhoff, G | 1 |
| Vollmann-Zwerenz, A | 2 |
| Freyschlag, C | 1 |
| Lohmeier, A | 1 |
| Brawanski, A | 3 |
| Proescholdt, MA | 1 |
| Baratta, MG | 1 |
| Arulananda, S | 1 |
| Sem Liew, M | 1 |
| Wada, M | 1 |
| Cher, L | 4 |
| Silva, VAO | 1 |
| Rosa, MN | 1 |
| Miranda-Gonçalves, V | 1 |
| Costa, AM | 1 |
| Tansini, A | 1 |
| Evangelista, AF | 1 |
| Martinho, O | 2 |
| Carloni, AC | 1 |
| Lima, JP | 1 |
| Pianowski, LF | 1 |
| Benson, R | 1 |
| Upadhyay, AD | 1 |
| Provost, C | 1 |
| Rozenblum-Beddok, L | 1 |
| Nataf, V | 1 |
| Merabtene, F | 1 |
| Prignon, A | 1 |
| Talbot, JN | 1 |
| Thanasupawat, T | 1 |
| Glogowska, A | 1 |
| Burg, M | 1 |
| Krcek, J | 1 |
| Beiko, J | 1 |
| Zhang, GJ | 1 |
| Yao, W | 1 |
| Gedanken, A | 1 |
| Lin, X | 1 |
| Shi, D | 1 |
| Veresezan, O | 1 |
| Gilard, V | 1 |
| David, M | 1 |
| Marinelli, A | 1 |
| Cerbone, L | 1 |
| Cordua, N | 1 |
| Buonerba, C | 1 |
| Peluso, G | 1 |
| Di Lorenzo, G | 1 |
| De Placido, S | 1 |
| Tao, B | 1 |
| Peng, T | 1 |
| Xia, X | 2 |
| Papadopoulos, KP | 1 |
| Gomez, E | 2 |
| Roberts-Rapp, L | 2 |
| Bain, E | 2 |
| Maag, D | 1 |
| Kriel, J | 1 |
| Müller-Nedebock, K | 1 |
| Maarman, G | 1 |
| Mbizana, S | 1 |
| Ojuka, E | 1 |
| Klumperman, B | 1 |
| Loos, B | 1 |
| Noh, H | 1 |
| Kong, LY | 1 |
| Gabrusiewicz, K | 1 |
| Hong, S | 1 |
| Perveen, K | 1 |
| Malhi, SM | 1 |
| Jawed, H | 1 |
| Palchetti, S | 1 |
| Digiacomo, L | 1 |
| Pozzi, D | 1 |
| Capriotti, AL | 1 |
| Frati, L | 1 |
| Tsaouli, G | 1 |
| Rota, R | 1 |
| Screpanti, I | 1 |
| Mahmoudi, M | 1 |
| Caracciolo, G | 1 |
| Ishi, Y | 1 |
| Motegi, H | 2 |
| Okamoto, M | 1 |
| Hirata, K | 2 |
| Oda, Y | 1 |
| Terasaka, S | 3 |
| Houkin, K | 3 |
| Genbrugge, E | 2 |
| Harrison, RA | 1 |
| Dos Santos, CJ | 1 |
| Ferreira Castro, FL | 1 |
| de Aguiar, RB | 1 |
| Menezes, IG | 1 |
| Santos, AC | 1 |
| Paulus, C | 1 |
| Nevels, M | 1 |
| Carlan da Silva, MC | 1 |
| Cheng, YS | 2 |
| Leung, GKK | 2 |
| Fang, D | 1 |
| Fortunato, JT | 1 |
| Reys, B | 1 |
| Pan, E | 4 |
| Bai, Y | 4 |
| Hong, X | 3 |
| Tsao, MJ | 1 |
| Berti, F | 6 |
| Gardiman, MP | 1 |
| Dal Pos, S | 1 |
| Buccarelli, M | 2 |
| Marconi, M | 1 |
| Pacioni, S | 1 |
| De Pascalis, I | 1 |
| D'Alessandris, QG | 5 |
| Martini, M | 4 |
| Ascione, B | 1 |
| Malorni, W | 1 |
| Larocca, LM | 7 |
| Matarrese, P | 1 |
| Shen, F | 1 |
| Kim, JY | 1 |
| Jo, Y | 1 |
| Nam, SJ | 1 |
| Iser, IC | 1 |
| Fernandes, MC | 1 |
| Spanevello, RM | 1 |
| Sévigny, J | 1 |
| Hou, S | 1 |
| Sha, LG | 1 |
| Guzauskas, GF | 2 |
| Salzberg, M | 1 |
| Wang, BC | 1 |
| Finiuk, N | 1 |
| Klyuchivska, O | 1 |
| Ivasechko, I | 1 |
| Hreniukh, V | 1 |
| Ostapiuk, Y | 1 |
| Shalai, Y | 1 |
| Panchuk, R | 1 |
| Matiychuk, V | 1 |
| Obushak, M | 1 |
| Stoika, R | 1 |
| Babsky, A | 1 |
| Pessina, F | 1 |
| Cozzi, L | 1 |
| Tomatis, S | 1 |
| Reggiori, G | 1 |
| Simonelli, M | 2 |
| Franzese, C | 1 |
| Carta, G | 1 |
| Conti Nibali, M | 1 |
| Bello, L | 2 |
| Blakeley, JO | 1 |
| Rosenfeld, MR | 5 |
| Eichler, A | 1 |
| Ribas, IG | 1 |
| Desideri, S | 5 |
| Respondek, M | 1 |
| Beberok, A | 1 |
| Rok, J | 1 |
| Rzepka, Z | 1 |
| Wrześniok, D | 1 |
| Buszman, E | 1 |
| Ma, YB | 2 |
| Chu, SH | 2 |
| Navone, SE | 1 |
| Guarnaccia, L | 1 |
| Cordiglieri, C | 1 |
| Crisà, FM | 1 |
| Caroli, M | 6 |
| Locatelli, M | 2 |
| Schisano, L | 1 |
| Rampini, P | 2 |
| Miozzo, M | 1 |
| La Verde, N | 1 |
| Riboni, L | 3 |
| Campanella, R | 3 |
| Marfia, G | 1 |
| Taylor, MA | 1 |
| Das, BC | 2 |
| Jin, T | 1 |
| Ni, L | 1 |
| Mu, H | 1 |
| Wu, Z | 1 |
| López-Valero, I | 1 |
| Saiz-Ladera, C | 1 |
| Torres, S | 3 |
| Hernández-Tiedra, S | 2 |
| García-Taboada, E | 2 |
| Rodríguez-Fornés, F | 2 |
| Barba, M | 1 |
| Dávila, D | 1 |
| Salvador-Tormo, N | 1 |
| Guzmán, M | 2 |
| Sánchez-Gómez, P | 1 |
| Lorente, M | 2 |
| Velasco, G | 2 |
| Ferreira, J | 1 |
| Ramos, AA | 1 |
| Almeida, T | 1 |
| Azqueta, A | 1 |
| Rocha, E | 1 |
| Grube, S | 1 |
| Ewald, C | 1 |
| Kögler, C | 1 |
| Lawson McLean, A | 1 |
| Barnes, JM | 1 |
| Kaushik, S | 1 |
| Bainer, RO | 1 |
| Woods, EC | 1 |
| Kai, F | 1 |
| Przybyla, L | 1 |
| Tung, JC | 1 |
| Maller, O | 1 |
| Barrett, AS | 1 |
| Lu, KV | 2 |
| Lakins, JN | 1 |
| Hansen, KC | 1 |
| Obernier, K | 1 |
| Alvarez-Buylla, A | 1 |
| Bergers, G | 1 |
| Bertozzi, CR | 1 |
| Weaver, VM | 1 |
| Marjanovic Vicentic, J | 1 |
| Garcia, I | 3 |
| Vukovic, V | 1 |
| Puskas, N | 1 |
| Nikolic, I | 1 |
| Tasic, G | 1 |
| Garros-Regulez, L | 2 |
| Han, G | 2 |
| Yue, Z | 2 |
| Ding, Z | 1 |
| Dhruv, H | 2 |
| Kwiatkowska-Piwowarczyk, A | 1 |
| Kloss, J | 3 |
| Pirrotte, P | 1 |
| Eschbacher, JM | 2 |
| Bernal Rubio, YL | 1 |
| González-Reymúndez, A | 1 |
| Wu, KH | 1 |
| Griguer, CE | 2 |
| Steibel, JP | 1 |
| de Los Campos, G | 1 |
| Doseff, A | 1 |
| Gallo, K | 1 |
| Vazquez, AI | 1 |
| Oliva, CR | 1 |
| Halloran, B | 1 |
| Vazquez, A | 1 |
| Bailey, SM | 1 |
| Dho, YS | 1 |
| Cho, WK | 1 |
| Cho, O | 1 |
| Schütte, L | 1 |
| Wos-Maganga, M | 1 |
| Weickhardt, S | 1 |
| Timmer, M | 1 |
| Eckstein, N | 1 |
| Jiapaer, S | 2 |
| Kitabayashi, T | 2 |
| Khan, UA | 1 |
| Rennert, RC | 1 |
| White, NS | 1 |
| Bartsch, H | 1 |
| Farid, N | 1 |
| Dale, AM | 1 |
| Schwartz, C | 1 |
| Romagna, A | 1 |
| Machegger, L | 1 |
| Weiss, L | 2 |
| Huemer, F | 1 |
| Fastner, G | 1 |
| Kleindienst, W | 1 |
| Greil, R | 2 |
| Winkler, PA | 1 |
| Salaroglio, IC | 2 |
| Annovazzi, L | 4 |
| Mellai, M | 4 |
| Schiffer, D | 4 |
| Melamed, JR | 1 |
| Ioele, SA | 1 |
| Hannum, AJ | 1 |
| Ullman, VM | 1 |
| Day, ES | 1 |
| Tsai, NM | 1 |
| Chang, KF | 1 |
| Ren, S | 1 |
| Qu, Z | 1 |
| Kong, P | 1 |
| Dettmer, S | 1 |
| Berberich, A | 1 |
| Karapanagiotou-Schenkel, I | 1 |
| Pfaff, E | 1 |
| Brors, B | 1 |
| Unterberg, A | 2 |
| Eisenmenger, A | 1 |
| Jones, DTW | 1 |
| Pfister, SM | 1 |
| Johannessen, TC | 3 |
| Hasan-Olive, MM | 1 |
| Denisova, O | 1 |
| Grudic, A | 2 |
| Latif, MA | 1 |
| Saed, H | 1 |
| Varughese, JK | 1 |
| Røsland, GV | 1 |
| Sundstrøm, T | 1 |
| Nordal, A | 1 |
| Tronstad, KJ | 1 |
| Lund-Johansen, M | 1 |
| Janji, B | 1 |
| Westermarck, J | 1 |
| Prestegarden, L | 2 |
| Furiassi, L | 1 |
| Skibinski, CG | 1 |
| Riggins, GJ | 1 |
| Kumari, S | 1 |
| Bhattacharya, D | 1 |
| Rangaraj, N | 1 |
| Chakarvarty, S | 1 |
| Kondapi, AK | 1 |
| Rao, NM | 1 |
| Bi, Y | 2 |
| Yi, D | 1 |
| Zhong, S | 1 |
| Ward, SM | 1 |
| Skinner, M | 1 |
| Saha, B | 1 |
| Emrick, T | 1 |
| Maraka, S | 2 |
| Groves, MD | 11 |
| Mammoser, AG | 2 |
| Melguizo-Gavilanes, I | 1 |
| Conrad, CA | 6 |
| Tremont-Lukats, IW | 4 |
| Loghin, ME | 2 |
| Hess, KR | 7 |
| Aldape, KD | 8 |
| Alfred Yung, WK | 2 |
| Nickel, AC | 1 |
| Wan, XY | 1 |
| Saban, DV | 1 |
| Weng, YL | 1 |
| Swenson, S | 1 |
| Tuan, CD | 1 |
| Markland, FS | 1 |
| Eisemann, T | 1 |
| Harter, PN | 2 |
| Angel, P | 1 |
| Peterziel, H | 1 |
| Kan, P | 1 |
| Pan, MH | 1 |
| Jiang, C | 5 |
| Abouzid, K | 1 |
| Liu, LZ | 1 |
| Jiang, BH | 1 |
| Horibe, T | 1 |
| Torisawa, A | 1 |
| Masuda, Y | 1 |
| Kawakami, K | 2 |
| Doycheva, DM | 1 |
| Ly, KI | 1 |
| Ou, Y | 1 |
| Da, X | 1 |
| Betensky, RA | 2 |
| Sorensen, G | 1 |
| Rosen, BR | 3 |
| Savatovsky, J | 1 |
| Villa, C | 1 |
| Reina, V | 1 |
| Pha, M | 1 |
| Berzero, G | 1 |
| Psimaras, D | 1 |
| Ameratunga, M | 1 |
| Pavlakis, N | 2 |
| Grant, R | 4 |
| Robins, HI | 8 |
| Smith, RP | 1 |
| Schultz, C | 1 |
| Hartford, AC | 1 |
| Yao, Z | 1 |
| Fabbro-Peray, P | 1 |
| Zouaoui, S | 2 |
| Mathieu-Daude, H | 1 |
| Bessaoud, F | 1 |
| Bauchet, F | 1 |
| Riondel, A | 1 |
| Sorbets, E | 1 |
| Charissoux, M | 2 |
| Mandonnet, E | 1 |
| Duffau, H | 1 |
| Tretarre, B | 1 |
| Wei, C | 1 |
| Zhen, Y | 1 |
| Lee, Y | 1 |
| Iavarone, A | 2 |
| Rabadan, R | 2 |
| Almici, E | 1 |
| Migliorin, S | 1 |
| Battaglini, M | 1 |
| Cappello, V | 1 |
| de Vito, G | 1 |
| Cicchi, R | 1 |
| Pavone, FS | 1 |
| Przystal, JM | 1 |
| Hajji, N | 1 |
| Khozoie, C | 1 |
| Zeng, Q | 1 |
| Abaitua, F | 1 |
| Hajitou, A | 1 |
| Suwan, K | 1 |
| Want, E | 1 |
| Bomalaski, J | 1 |
| Szlosarek, P | 1 |
| O'Neill, K | 1 |
| Atkins, RJ | 1 |
| Kurganovs, N | 1 |
| Mangiola, S | 1 |
| Ware, TM | 1 |
| Corcoran, NM | 1 |
| Brown, DV | 2 |
| Morokoff, A | 1 |
| Hovens, CM | 1 |
| Dai, D | 1 |
| Xiao, W | 2 |
| Qi, P | 1 |
| Gao, WZ | 1 |
| Guo, LM | 1 |
| Xu, TQ | 1 |
| Yin, YH | 1 |
| Jia, F | 1 |
| Pang, Z | 1 |
| Mu, N | 1 |
| Desai, V | 1 |
| Jain, A | 2 |
| Shaghaghi, H | 1 |
| Summer, R | 1 |
| Lai, JCK | 1 |
| Bhushan, A | 1 |
| Sachkova, A | 1 |
| Sperling, S | 1 |
| Mielke, D | 2 |
| Schatlo, B | 1 |
| Ninkovic, M | 1 |
| Brunetti, A | 1 |
| Marinelli, O | 1 |
| Iannarelli, R | 1 |
| Russotti, D | 1 |
| Shapira-Furman, T | 1 |
| Serra, R | 1 |
| Gorelick, N | 2 |
| Doglioli, M | 1 |
| Tagliaferri, V | 1 |
| Cecia, A | 1 |
| Peters, M | 1 |
| Rottenberg, Y | 1 |
| Langer, R | 1 |
| Brem, H | 7 |
| Tyler, B | 3 |
| Domb, AJ | 1 |
| Qie, S | 1 |
| Yuan, L | 1 |
| Shi, HY | 1 |
| Lee, DJ | 1 |
| Elmaci, İ | 2 |
| Ozpinar, A | 3 |
| Bilir, A | 4 |
| Altinoz, MA | 2 |
| Liu, T | 4 |
| Xin, Y | 2 |
| Emamgholizadeh Minaei, S | 1 |
| Karimi, MR | 1 |
| Hwang, TW | 1 |
| Kim, DB | 1 |
| Jang, TW | 1 |
| Kim, GH | 1 |
| Moon, M | 1 |
| Yoon, KA | 1 |
| Choi, DE | 1 |
| Kim, JJ | 1 |
| Sayour, EJ | 4 |
| Azari, H | 1 |
| Long, Y | 1 |
| Flores, C | 1 |
| Andrade, S | 1 |
| Bhaskaran, V | 1 |
| Idriss, M | 1 |
| Jimenez, MA | 1 |
| Lugli, G | 1 |
| Hayes, JL | 1 |
| Mahmoud, AB | 1 |
| Zane, RE | 1 |
| Passaro, C | 1 |
| Haas-Kogan, D | 1 |
| Bronisz, A | 1 |
| Godlewski, J | 1 |
| Carter, TC | 1 |
| Medina-Flores, R | 1 |
| Lawler, BE | 1 |
| Musah-Eroje, A | 1 |
| Watson, S | 1 |
| Pellosi, DS | 1 |
| Paula, LB | 1 |
| de Melo, MT | 1 |
| Tedesco, AC | 1 |
| Stéphanou, A | 1 |
| Nevin, RL | 1 |
| Heynckes, S | 1 |
| Daka, K | 1 |
| Franco, P | 2 |
| Gaebelein, A | 1 |
| Frenking, JH | 1 |
| Doria-Medina, R | 1 |
| Mader, I | 2 |
| Woo, PYM | 1 |
| Ho, JMK | 1 |
| Tse, TPK | 1 |
| Lam, SW | 1 |
| Mak, CHK | 1 |
| Chan, DTM | 1 |
| Lee, MWY | 1 |
| Kawasaki, T | 1 |
| Miwa, K | 1 |
| Shinoda, J | 1 |
| Asano, Y | 1 |
| Takei, H | 1 |
| Ikegame, Y | 1 |
| Yokoyama, K | 1 |
| Tošić, S | 1 |
| Vitorović, J | 1 |
| Stamenković, S | 1 |
| Kostić, A | 1 |
| Vidović, N | 1 |
| Krstić, M | 1 |
| Jevtović-Stoimenov, T | 1 |
| Pavlović, D | 1 |
| Plummer, S | 1 |
| Wallace, S | 1 |
| Ball, G | 1 |
| Lloyd, R | 1 |
| Schiapparelli, P | 1 |
| Hartung, T | 1 |
| Pamies, D | 1 |
| Foltyn, M | 1 |
| Sauer, B | 1 |
| Hribar, KC | 1 |
| Wheeler, CJ | 1 |
| Bazarov, A | 1 |
| Varshneya, K | 1 |
| Yamada, R | 3 |
| Buckley, P | 1 |
| Patil, CG | 5 |
| Storey, K | 1 |
| Leder, K | 1 |
| Swanson, K | 1 |
| Rockne, RC | 2 |
| Foo, J | 1 |
| Rodriguez de Anda, DA | 1 |
| Ohannesian, N | 1 |
| Martirosyan, KS | 1 |
| Chew, SA | 1 |
| Cohen, AL | 1 |
| Marcus, S | 1 |
| Lu, R | 1 |
| Laprie, A | 2 |
| Ken, S | 2 |
| Filleron, T | 2 |
| Vieillevigne, L | 2 |
| Tensaouti, F | 1 |
| Catalaa, I | 1 |
| Boetto, S | 1 |
| Khalifa, J | 1 |
| Attal, J | 1 |
| Peyraga, G | 1 |
| Gomez-Roca, C | 1 |
| Noel, G | 8 |
| Sunyach, MP | 3 |
| Supiot, S | 1 |
| Bernier, V | 4 |
| Mounier, M | 1 |
| Poublanc, M | 1 |
| Fabre, A | 1 |
| Delord, JP | 1 |
| Cohen-Jonathan Moyal, E | 2 |
| Killock, D | 1 |
| Ranjit, M | 2 |
| Yamamichi, A | 1 |
| Kato, A | 1 |
| Matsuo, K | 1 |
| Enomoto, A | 1 |
| Kato, T | 3 |
| Ha, W | 2 |
| Sevim-Nalkiran, H | 1 |
| Zaman, AM | 1 |
| Matsuda, K | 2 |
| Chung, L | 1 |
| Baxter, RC | 1 |
| Ornelas, AS | 1 |
| Knox, MG | 1 |
| Marks, LA | 1 |
| Wingerchuk, DM | 1 |
| O'Carroll, CB | 1 |
| Winter, SF | 1 |
| Loebel, F | 1 |
| Loeffler, J | 1 |
| Martinez-Lage, M | 1 |
| Lesueur, P | 1 |
| Lequesne, J | 1 |
| Grellard, JM | 1 |
| Dugué, A | 1 |
| Coquan, E | 1 |
| Brachet, PE | 1 |
| Geffrelot, J | 1 |
| Kao, W | 1 |
| Berro, DH | 1 |
| Castera, L | 1 |
| Goardon, N | 1 |
| Lacroix, J | 1 |
| Lange, M | 1 |
| Capel, A | 1 |
| Leconte, A | 1 |
| Andre, B | 1 |
| Léger, A | 1 |
| Lelaidier, A | 1 |
| Clarisse, B | 1 |
| Stefan, D | 1 |
| Chua, J | 1 |
| Nafziger, E | 1 |
| Tanaka, Y | 1 |
| Nakamura, M | 2 |
| Omoto, K | 1 |
| Shida, Y | 1 |
| Murakami, T | 1 |
| Motoyama, Y | 1 |
| Morita, H | 1 |
| Tsujimura, T | 1 |
| Sabelström, H | 1 |
| Quigley, DA | 1 |
| Fenster, T | 1 |
| Foster, DJ | 1 |
| Fuchshuber, CAM | 1 |
| Saxena, S | 1 |
| Yuan, E | 1 |
| Paterno, F | 1 |
| Norling, B | 1 |
| Persson, AI | 1 |
| Weng, Z | 1 |
| Xin, Z | 2 |
| Erausquin, E | 1 |
| Mazor, G | 1 |
| Levin, L | 1 |
| Ahmadov, U | 1 |
| Carén, H | 1 |
| Borkhardt, A | 1 |
| Leprivier, G | 1 |
| Rotblat, B | 1 |
| Hettiarachchi, SD | 1 |
| Graham, RM | 1 |
| Mintz, KJ | 1 |
| Vanni, S | 1 |
| Peng, Z | 1 |
| Leblanc, RM | 1 |
| Banik, P | 1 |
| Bharti, R | 1 |
| Nayak, S | 1 |
| Ghosh, SK | 1 |
| Jeong, H | 1 |
| Matusova, M | 1 |
| Baran-Schmidt, R | 1 |
| Norden, AD | 5 |
| Korytowsky, B | 1 |
| You, M | 1 |
| Kim Le, T | 1 |
| Dastani, H | 1 |
| Bobiak, S | 1 |
| Kerezoudis, P | 1 |
| Brown, DA | 1 |
| Chaichana, KL | 6 |
| Aurilio, C | 1 |
| Libutti, M | 1 |
| Botti, G | 1 |
| Maurea, N | 1 |
| Hasan, T | 1 |
| Caragher, SP | 1 |
| Wang, JY | 2 |
| Dey, M | 3 |
| Perez, JL | 1 |
| Mansour, NM | 1 |
| Szymura, SJ | 1 |
| Uppal, A | 1 |
| Raleigh, DR | 1 |
| Spretz, R | 1 |
| Nunez, L | 1 |
| Larsen, G | 1 |
| Khodarev, NN | 1 |
| Goyal, A | 1 |
| Graffeo, CS | 1 |
| Perry, A | 2 |
| Lamano, JB | 1 |
| Quaggin-Smith, JA | 1 |
| Tate, MC | 1 |
| Grimm, SA | 3 |
| Kumthekar, PU | 1 |
| Bloch, O | 2 |
| Antonopoulos, M | 1 |
| Dionysiou, D | 1 |
| Graf, N | 1 |
| Stamatakos, G | 1 |
| Huang, BR | 1 |
| Tsai, CH | 1 |
| Way, TD | 2 |
| Kao, JY | 1 |
| Liu, YS | 1 |
| Lai, SW | 1 |
| Lu, DY | 1 |
| Schipper, M | 2 |
| Umemura, Y | 1 |
| Seliger, C | 2 |
| Song, Z | 1 |
| Pang, HH | 1 |
| Chou, YW | 1 |
| Shiue, YL | 1 |
| Yang, HW | 1 |
| Burić, SS | 1 |
| Podolski-Renić, A | 1 |
| Dinić, J | 1 |
| Stanković, T | 1 |
| Jovanović, M | 1 |
| Hadžić, S | 1 |
| Ayuso, JM | 1 |
| Virumbrales-Muñoz, M | 1 |
| Fernández, LJ | 1 |
| Ochoa, I | 1 |
| Mittapalli, RK | 2 |
| Stodtmann, S | 1 |
| Friedel, A | 1 |
| Menon, RM | 1 |
| Mensing, S | 1 |
| Dirkse, A | 1 |
| Buder, T | 1 |
| Brons, NHC | 1 |
| Leite, S | 1 |
| Sauvageot, N | 1 |
| Sarkisjan, D | 1 |
| Seyfrid, M | 1 |
| Deutsch, A | 1 |
| Voss-Böhme, A | 1 |
| Luo, Y | 1 |
| Brenner, A | 3 |
| Bozek, DA | 1 |
| Rajakulendran, N | 1 |
| Monteiro, V | 1 |
| Steinhart, Z | 1 |
| Kushida, MM | 1 |
| Coutinho, FJ | 1 |
| Cavalli, FMG | 1 |
| Restall, I | 1 |
| Hart, T | 1 |
| Bureta, C | 1 |
| Saitoh, Y | 1 |
| Tokumoto, H | 1 |
| Nagano, S | 1 |
| Komiya, S | 1 |
| Taniguchi, N | 1 |
| Setoguchi, T | 1 |
| Yan, JL | 1 |
| Torheim, T | 1 |
| McLean, MA | 1 |
| Boonzaier, NR | 1 |
| Zou, J | 1 |
| Yuan, J | 1 |
| van Dijken, BRJ | 1 |
| Matys, T | 1 |
| Markowetz, F | 1 |
| Price, SJ | 1 |
| Giaccherini, L | 1 |
| Galaverni, M | 1 |
| Renna, I | 1 |
| Timon, G | 1 |
| Galeandro, M | 2 |
| Pisanello, A | 4 |
| Botti, A | 2 |
| Iotti, C | 2 |
| Ciammella, P | 2 |
| Zheng, YY | 1 |
| Liu, WL | 1 |
| Huang, GD | 1 |
| Seyfried, TN | 1 |
| Shelton, L | 1 |
| Arismendi-Morillo, G | 1 |
| Kalamian, M | 1 |
| Elsakka, A | 1 |
| Maroon, J | 1 |
| Mukherjee, P | 1 |
| Skaga, E | 1 |
| Skaga, IØ | 1 |
| Grieg, Z | 1 |
| Sandberg, CJ | 1 |
| Langmoen, IA | 1 |
| Vik-Mo, EO | 1 |
| Sohrabi, A | 1 |
| Ehsanipour, A | 1 |
| Bierman, RD | 1 |
| Nathanson, DA | 1 |
| Seidlits, SK | 1 |
| Vafashoar, F | 1 |
| Mahabadi, VP | 1 |
| Bamodu, OA | 1 |
| Tzeng, YM | 1 |
| Xue, D | 1 |
| Ou-Yang, Y | 1 |
| Mai, J | 1 |
| Sheng, L | 1 |
| Lu, B | 1 |
| Xing, F | 1 |
| Mou, Y | 1 |
| Yan, G | 1 |
| Sai, K | 3 |
| Zeng, T | 1 |
| Wang, BCM | 1 |
| Garrison, LP | 1 |
| Wu, P | 1 |
| Han, B | 2 |
| Duan, C | 1 |
| Pedretti, S | 2 |
| Turco, E | 1 |
| Triggiani, L | 2 |
| Meduri, B | 1 |
| Borghetti, P | 2 |
| Pegurri, L | 1 |
| Riva, N | 1 |
| Gatta, R | 1 |
| Bruni, A | 1 |
| Tu, Y | 1 |
| Arora, A | 1 |
| Megías, J | 1 |
| Martínez, A | 1 |
| San-Miguel, T | 1 |
| Gil-Benso, R | 1 |
| Muñoz-Hidalgo, L | 1 |
| Albert-Bellver, D | 1 |
| Carratalá, A | 1 |
| Gozalbo, D | 1 |
| López-Ginés, C | 1 |
| Gil, ML | 1 |
| Cerdá-Nicolás, M | 2 |
| Forte, IM | 1 |
| Indovina, P | 1 |
| Iannuzzi, CA | 1 |
| Cirillo, D | 1 |
| Di Marzo, D | 1 |
| Barone, D | 1 |
| Capone, F | 1 |
| Pentimalli, F | 1 |
| Giordano, A | 2 |
| Yin, AA | 3 |
| Liu, YH | 3 |
| Aubry, M | 2 |
| Liu, BL | 3 |
| Mosser, J | 3 |
| Lu, ZF | 1 |
| Jin, C | 1 |
| Liu, K | 2 |
| Di Pierro, F | 1 |
| Petruzzi, A | 1 |
| Bertuccioli, A | 1 |
| Botta, L | 1 |
| Bruzzone, MG | 1 |
| Cuccarini, V | 1 |
| Lamperti, E | 5 |
| Kobayashi, K | 3 |
| Chiu, SP | 1 |
| Batsaikhan, B | 1 |
| Huang, HM | 1 |
| van Leyen, K | 1 |
| Gruber, P | 1 |
| Remonda, L | 1 |
| Berberat, J | 2 |
| Zhao, SG | 1 |
| Chang, SL | 1 |
| Feng, FY | 1 |
| Speers, CW | 1 |
| Connock, M | 1 |
| Auguste, P | 1 |
| Dussart, C | 1 |
| Guyotat, J | 4 |
| Armoiry, X | 3 |
| Aulakh, S | 1 |
| DeDeo, MR | 1 |
| Free, J | 1 |
| Paulus, A | 1 |
| Manna, A | 1 |
| Manochakian, R | 1 |
| Chanan-Khan, AA | 1 |
| Ailawadhi, S | 1 |
| Yi, HG | 1 |
| Jeong, YH | 1 |
| Choi, YJ | 1 |
| Moon, HE | 1 |
| Kang, KS | 1 |
| Bae, M | 1 |
| Jang, J | 2 |
| Youn, H | 1 |
| Cho, DW | 1 |
| Choi, Y | 1 |
| Ahn, KJ | 2 |
| Shin, NY | 1 |
| Choi, HS | 1 |
| Jung, SL | 1 |
| Kim, BS | 3 |
| Liu, SA | 1 |
| Sullivan, T | 1 |
| Bryce, C | 1 |
| Chan, AM | 1 |
| Cilmi, S | 1 |
| Tezcan, G | 4 |
| Aksoy, SA | 1 |
| Tunca, B | 4 |
| Bekar, A | 3 |
| Mutlu, M | 1 |
| Cecener, G | 4 |
| Egeli, U | 4 |
| Kocaeli, H | 2 |
| Demirci, H | 1 |
| Taskapilioglu, MO | 3 |
| Jablonska, PA | 1 |
| Diez-Valle, R | 2 |
| Pérez-Larraya, JG | 1 |
| Moreno-Jiménez, M | 1 |
| Arbea, L | 1 |
| Tejada, S | 2 |
| Garcia de Eulate, MR | 1 |
| Ramos, L | 1 |
| Arbizu, J | 1 |
| Domínguez, P | 1 |
| Aristu, JJ | 1 |
| Zeng, W | 1 |
| Elbaroody, M | 1 |
| Lin, S | 1 |
| Esmaeeli, M | 1 |
| Masoumi-Ardakani, Y | 1 |
| Mohammadipoor-Ghasemabad, L | 1 |
| Petővári, G | 1 |
| Dankó, T | 1 |
| Krencz, I | 1 |
| Hujber, Z | 1 |
| Rajnai, H | 1 |
| Vetlényi, E | 1 |
| Raffay, R | 1 |
| Pápay, J | 1 |
| Jeney, A | 1 |
| Sebestyén, A | 1 |
| Iyoda, T | 1 |
| Fujisawa, T | 1 |
| Sasada, M | 1 |
| Nagai, R | 1 |
| Kudo, C | 1 |
| Otsuka, K | 1 |
| Kamiya, S | 1 |
| Kodama, H | 1 |
| Fukai, F | 1 |
| Hua, L | 1 |
| Xingyi, J | 1 |
| Guonan, C | 1 |
| Naijie, L | 1 |
| Nimmakayala, RK | 1 |
| Siddiqui, JA | 1 |
| Gorantla, S | 1 |
| Lizarte Neto, FS | 1 |
| Rodrigues, AR | 1 |
| Trevisan, FA | 1 |
| de Assis Cirino, ML | 1 |
| Matias, CCMS | 1 |
| Pereira-da-Silva, G | 1 |
| Peria, FM | 1 |
| Tirapelli, DPDC | 1 |
| Carlotti, CG | 4 |
| Chai, Y | 1 |
| Fleurence, J | 1 |
| Bahri, M | 1 |
| Fougeray, S | 1 |
| Faraj, S | 1 |
| Vermeulen, S | 1 |
| Pinault, E | 1 |
| Geraldo, F | 1 |
| Véziers, J | 1 |
| Marquet, P | 1 |
| Vallette, F | 1 |
| Paris, F | 1 |
| Birklé, S | 1 |
| Wurm, J | 1 |
| Behringer, S | 1 |
| d'Errico, P | 1 |
| Naseri, Y | 1 |
| Meyer-Luehmann, M | 1 |
| Sankowski, R | 1 |
| Shah, MJ | 1 |
| Batalini, F | 1 |
| Kaufmann, MR | 1 |
| Aleixo, GF | 1 |
| Drews, R | 1 |
| Friger, M | 1 |
| Geffen, DB | 1 |
| Kaisman-Elbaz, T | 1 |
| Lavrenkov, K | 1 |
| Smiljanic, S | 1 |
| Kaskun, O | 1 |
| Ghannad-Zadeh, K | 1 |
| Isaev, K | 1 |
| Morrissy, AS | 1 |
| Tong, J | 1 |
| Chan, J | 1 |
| Wilson, TM | 1 |
| Al-Omaishi, S | 1 |
| Munoz, DG | 1 |
| Moran, MF | 1 |
| Taylor, MD | 2 |
| Reimand, J | 2 |
| Domoto, T | 1 |
| Bozzato, E | 1 |
| Joudiou, N | 1 |
| Ghiassinejad, S | 1 |
| Danhier, F | 3 |
| Gallez, B | 1 |
| Préat, V | 2 |
| Wang, MD | 1 |
| Li, RC | 1 |
| Xie, WF | 1 |
| Sukumar, UK | 1 |
| Bose, RJC | 1 |
| Malhotra, M | 1 |
| Babikir, HA | 1 |
| Afjei, R | 1 |
| Robinson, E | 1 |
| Zeng, Y | 2 |
| Habte, F | 1 |
| Sinclair, R | 1 |
| Wu, ZH | 1 |
| Lou, PY | 1 |
| Chai, C | 1 |
| Han, SY | 1 |
| Ning, JF | 1 |
| Yu, L | 3 |
| Lei, B | 3 |
| Gong, K | 1 |
| Puliyappadamba, VT | 3 |
| Panchani, N | 1 |
| Mukherjee, B | 5 |
| Damanwalla, Z | 1 |
| Bharia, S | 1 |
| Hatanpaa, KJ | 4 |
| Gerber, DE | 1 |
| Mickey, BE | 2 |
| Patel, TR | 1 |
| Habib, AA | 5 |
| Chung, CY | 1 |
| Lee, MH | 1 |
| Lin, MH | 1 |
| Ke, C | 1 |
| Xiu, R | 1 |
| Tian, Q | 1 |
| Zou, L | 1 |
| Ma, T | 1 |
| Ji, X | 1 |
| Duan, Q | 1 |
| Joshi, K | 2 |
| Mo, X | 1 |
| Kig, C | 1 |
| Nardini, D | 1 |
| Sobol, RW | 4 |
| Chow, LM | 1 |
| Waclaw, R | 1 |
| Beullens, M | 1 |
| Poteet, E | 1 |
| Choudhury, GR | 1 |
| Winters, A | 1 |
| Ryou, MG | 1 |
| Ghorpade, A | 1 |
| Wen, Y | 1 |
| Bigner, DD | 14 |
| Simpkins, JW | 1 |
| Kumar, S | 2 |
| Narang, J | 1 |
| Schultz, L | 1 |
| Siddiqui, S | 1 |
| Poptani, H | 2 |
| Jain, R | 2 |
| Goeppert, M | 1 |
| Jastaniyah, N | 1 |
| Murtha, A | 1 |
| Pervez, N | 1 |
| Le, D | 1 |
| Patel, S | 2 |
| Mackenzie, M | 1 |
| Fulton, D | 2 |
| Field, C | 1 |
| Fallone, G | 1 |
| Friedman, GK | 1 |
| Spiller, SE | 1 |
| Harrison, DK | 1 |
| Reddy, AT | 1 |
| Markiewicz-Żukowska, R | 3 |
| Borawska, MH | 3 |
| Fiedorowicz, A | 1 |
| Naliwajko, SK | 3 |
| Sawicka, D | 1 |
| Car, H | 1 |
| D'Abbiero, N | 2 |
| Podgornii, A | 1 |
| Cagni, E | 1 |
| Iori, M | 1 |
| Graus, F | 2 |
| Pardo, J | 1 |
| Escudero, D | 1 |
| Vilas, D | 1 |
| Barceló, I | 1 |
| Brell, M | 1 |
| Pascual, C | 1 |
| Crespo, JA | 1 |
| Erro, E | 1 |
| García-Romero, JC | 1 |
| Estela, J | 1 |
| Martino, J | 1 |
| García-Castaño, A | 1 |
| Mata, E | 1 |
| Lema, M | 1 |
| Gelabert, M | 1 |
| Fuentes, R | 1 |
| Pérez, P | 2 |
| Manzano, A | 1 |
| Aguas, J | 1 |
| Belenguer, A | 1 |
| Simón, A | 1 |
| Henríquez, I | 2 |
| Murcia, M | 1 |
| Vivanco, R | 1 |
| Rojas-Marcos, I | 1 |
| Muñoz-Carmona, D | 1 |
| Navas, I | 1 |
| de Andrés, P | 1 |
| Mas, G | 1 |
| Gil, M | 3 |
| Verger, E | 2 |
| Deutsch, MB | 1 |
| Deangelis, LM | 8 |
| Orza, A | 1 |
| Soriţău, O | 1 |
| Tomuleasa, C | 1 |
| Olenic, L | 1 |
| Florea, A | 1 |
| Pana, O | 1 |
| Bratu, I | 1 |
| Pall, E | 1 |
| Florian, S | 1 |
| Casciano, D | 1 |
| Biris, AS | 1 |
| Cen, L | 4 |
| Grogan, PT | 7 |
| Grah, JJ | 1 |
| Katalinic, D | 1 |
| Stern-Padovan, R | 1 |
| Paladino, J | 1 |
| Santek, F | 1 |
| Juretic, A | 1 |
| Zarkovic, K | 1 |
| Plestina, S | 1 |
| Supe, M | 1 |
| Misaki, K | 1 |
| Sato, Y | 3 |
| Nakanuma, Y | 1 |
| Hamada, J | 2 |
| Barazzuol, L | 2 |
| Jena, R | 2 |
| Burnet, NG | 3 |
| Meira, LB | 1 |
| Jeynes, JC | 2 |
| Kirkby, KJ | 2 |
| Kirkby, NF | 2 |
| Feng, DF | 1 |
| Li, ZQ | 2 |
| Jiang, PC | 1 |
| Ilgaz, S | 1 |
| Ozdemir, M | 1 |
| Oztuna, D | 1 |
| Canpinar, H | 1 |
| Sunguroğlu, A | 1 |
| Ugur, HC | 1 |
| Filippi-Chiela, EC | 2 |
| Thomé, MP | 1 |
| Bueno e Silva, MM | 1 |
| Pelegrini, AL | 1 |
| Ledur, PF | 1 |
| Garicochea, B | 1 |
| Zamin, LL | 1 |
| Barker, CA | 2 |
| Bishop, AJ | 1 |
| Chang, M | 2 |
| Beal, K | 5 |
| Chan, TA | 4 |
| Chu, PC | 1 |
| Wang, HY | 1 |
| Lu, YJ | 1 |
| Lee, PY | 1 |
| Tseng, IC | 1 |
| Feng, LY | 1 |
| Yen, TC | 1 |
| Murata, H | 1 |
| Amano, T | 2 |
| Nakamizo, A | 2 |
| Iwaki, T | 1 |
| Sasaki, T | 2 |
| Guerrero-Cazares, H | 1 |
| Ford, E | 1 |
| McNutt, T | 1 |
| Chaichana, K | 1 |
| Redmond, K | 1 |
| Santoni, M | 2 |
| Burattini, L | 2 |
| Berardi, R | 1 |
| Cascinu, S | 2 |
| Hammond, SN | 1 |
| Reardon, DR | 1 |
| Fadul, CE | 4 |
| Beroukhim, R | 2 |
| Muzikansky, A | 5 |
| Doherty, L | 2 |
| Lafrankie, D | 2 |
| Smith, K | 1 |
| Tafoya, V | 1 |
| Lis, R | 1 |
| Stack, EC | 1 |
| Yang, XJ | 2 |
| Yang, SY | 2 |
| Merz, F | 1 |
| Dehghani, F | 1 |
| Gutenberg, A | 3 |
| Schopow, K | 1 |
| Hellwig, C | 1 |
| Schäfer, M | 1 |
| Bauer, M | 1 |
| Stöcker, H | 1 |
| Taucher-Scholz, G | 1 |
| Durante, M | 1 |
| Harrabi, S | 3 |
| Combs, SE | 11 |
| Brons, S | 1 |
| Haberer, T | 2 |
| Sanchez-Perez, L | 3 |
| Reap, EA | 2 |
| Norberg, P | 2 |
| Schmittling, RJ | 4 |
| Archer, GE | 7 |
| Herndon, JE | 15 |
| Brüning, A | 1 |
| Cappello, F | 1 |
| Chang, WW | 1 |
| Cvek, B | 1 |
| Dou, QP | 1 |
| Duenas-Gonzalez, A | 1 |
| Focosi, D | 1 |
| Ghaffari, SH | 1 |
| Ketola, K | 1 |
| Khoshnevisan, A | 2 |
| Keizman, D | 1 |
| McDonald, K | 1 |
| Muñoz, M | 2 |
| Paranjpe, A | 1 |
| Pourgholami, MH | 1 |
| Sardi, I | 1 |
| Sella, A | 1 |
| Srivenugopal, KS | 1 |
| Tuccori, M | 1 |
| Wirtz, CR | 4 |
| Quann, K | 1 |
| Gonzales, DM | 1 |
| Mercier, I | 1 |
| Sotgia, F | 1 |
| Pestell, RG | 1 |
| Lisanti, MP | 1 |
| Jasmin, JF | 1 |
| Shields, LB | 2 |
| Kadner, R | 1 |
| Vitaz, TW | 1 |
| Spalding, AC | 2 |
| Chu, Q | 1 |
| Orr, BA | 1 |
| Semenkow, S | 1 |
| Eberhart, CG | 1 |
| Hart, MG | 2 |
| Garside, R | 2 |
| Rogers, G | 2 |
| Stein, K | 2 |
| Liu, V | 1 |
| Kang, S | 1 |
| Groves, M | 2 |
| Puduvalli, V | 2 |
| Levin, V | 2 |
| Conrad, C | 5 |
| Yung, WK | 16 |
| Lou, E | 3 |
| Sumrall, AL | 1 |
| Desjardins, A | 15 |
| Lipp, ES | 2 |
| Coan, A | 3 |
| Bailey, L | 4 |
| Turner, S | 2 |
| Vredenburgh, JJ | 13 |
| Minniti, G | 11 |
| Scaringi, C | 4 |
| Baldoni, A | 1 |
| Lanzetta, G | 9 |
| De Sanctis, V | 5 |
| Esposito, V | 4 |
| Enrici, RM | 6 |
| Ratai, EM | 1 |
| Snyder, BS | 3 |
| McKinstry, RC | 1 |
| Josset, E | 2 |
| Burckel, H | 2 |
| Bischoff, P | 2 |
| Bock, HC | 4 |
| Brück, W | 2 |
| Doerner, L | 1 |
| Mehdorn, HM | 5 |
| Roggendorf, W | 1 |
| Westphal, M | 5 |
| Waters, JD | 1 |
| Rose, B | 1 |
| Gonda, DD | 1 |
| Scanderbeg, DJ | 1 |
| Russell, M | 1 |
| Alksne, JF | 1 |
| Murphy, K | 1 |
| Lawson, J | 1 |
| Chen, SE | 1 |
| Choi, SS | 1 |
| Rogers, JE | 1 |
| Lei, X | 1 |
| Van Mieghem, E | 1 |
| Wozniak, A | 1 |
| Geussens, Y | 1 |
| De Vleeschouwer, S | 1 |
| Van Calenbergh, F | 1 |
| Sciot, R | 2 |
| Bechter, OE | 1 |
| Demaerel, P | 1 |
| Wilms, G | 1 |
| Dielemans, JC | 1 |
| van Breemen, MS | 1 |
| Zwinkels, H | 1 |
| Walchenbach, R | 1 |
| Taphoorn, MJ | 7 |
| Vecht, CJ | 3 |
| Murphy, ÁC | 1 |
| Weyhenmeyer, B | 1 |
| Schmid, J | 1 |
| Kilbride, SM | 1 |
| Rehm, M | 3 |
| Senft, C | 2 |
| Weissenberger, J | 1 |
| Seifert, V | 4 |
| Dunst, M | 1 |
| Prehn, JH | 2 |
| Murphy, BM | 2 |
| Clark, SW | 1 |
| Wang, DL | 1 |
| Abramson, JS | 1 |
| Tuncali, S | 3 |
| Schumacher, CA | 1 |
| Cao, B | 1 |
| Williams, BO | 1 |
| Ross, JT | 1 |
| Pyko, IV | 1 |
| Furuyama, N | 1 |
| Fedulau, AS | 1 |
| Wendland, M | 1 |
| Dipetrillo, TA | 1 |
| Gaspar, LE | 8 |
| Kavanagh, BD | 8 |
| Waziri, A | 5 |
| Damek, DM | 3 |
| Ney, D | 3 |
| Lillehei, KO | 2 |
| St-Coeur, PD | 2 |
| Touaibia, M | 2 |
| Cuperlovic-Culf, M | 2 |
| Morin, P | 2 |
| Sooman, L | 1 |
| Ekman, S | 2 |
| Andersson, C | 1 |
| Kultima, HG | 1 |
| Isaksson, A | 1 |
| Johansson, F | 2 |
| Bergqvist, M | 2 |
| Blomquist, E | 2 |
| Lennartsson, J | 1 |
| Gullbo, J | 1 |
| Mullins, CS | 2 |
| Schubert, J | 1 |
| Chu, HH | 1 |
| Ryoo, I | 2 |
| Kim, SC | 1 |
| Yeom, JA | 1 |
| Shin, H | 1 |
| Lee, AL | 1 |
| Yoon, TJ | 1 |
| Larvie, M | 1 |
| Chi, TL | 1 |
| Comincini, S | 3 |
| Allavena, G | 2 |
| Palumbo, S | 3 |
| Morini, M | 1 |
| Durando, F | 1 |
| Angeletti, F | 2 |
| Lopez, D | 1 |
| de la Peñas, R | 1 |
| García-Bueno, JM | 1 |
| Molina-Garrido, MJ | 1 |
| Cano, JM | 1 |
| Bugés, C | 1 |
| Sanz, SM | 1 |
| Arranz, JL | 1 |
| Rodriguez, A | 1 |
| Martin, JM | 1 |
| Benavides, M | 3 |
| Penas, C | 1 |
| Pastori, C | 1 |
| Komotar, RJ | 2 |
| Bregy, A | 2 |
| Wahlestedt, C | 1 |
| Ayad, NG | 1 |
| Silver, DJ | 1 |
| Tugertimur, B | 1 |
| Deleyrolle, LP | 1 |
| Siebzehnrubl, D | 1 |
| Sarkisian, MR | 1 |
| Devers, KG | 1 |
| Yachnis, AT | 1 |
| Kupper, MD | 1 |
| Neal, D | 1 |
| Nabilsi, NH | 1 |
| Kladde, MP | 1 |
| Suslov, O | 1 |
| Brabletz, S | 1 |
| Brabletz, T | 1 |
| Reynolds, BA | 2 |
| Steindler, DA | 1 |
| Riccitelli, E | 2 |
| Di Vito, C | 1 |
| Condomitti, G | 1 |
| Galli, R | 2 |
| Viani, P | 2 |
| Wan, Y | 6 |
| Lee, DY | 1 |
| Chunta, JL | 1 |
| Park, SS | 1 |
| Martinez, AA | 1 |
| Grills, IS | 1 |
| Krueger, SA | 1 |
| Wilson, GD | 1 |
| Marples, B | 1 |
| Qi, XC | 1 |
| Xie, DJ | 1 |
| Yan, QF | 1 |
| Wang, YR | 1 |
| Zhu, YX | 1 |
| Qian, C | 2 |
| Yang, SX | 1 |
| Viel, T | 2 |
| Schelhaas, S | 2 |
| Wagner, S | 1 |
| Wachsmuth, L | 1 |
| Schwegmann, K | 1 |
| Kuhlmann, M | 1 |
| Faber, C | 1 |
| Kopka, K | 1 |
| Schäfers, M | 1 |
| Jacobs, AH | 4 |
| Blume, C | 1 |
| von Lehe, M | 1 |
| van Landeghem, F | 1 |
| Greschus, S | 1 |
| Boström, J | 1 |
| Pezuk, JA | 1 |
| Brassesco, MS | 2 |
| Morales, AG | 1 |
| de Oliveira, JC | 1 |
| de Paula Queiroz, RG | 2 |
| Machado, HR | 1 |
| Neder, L | 1 |
| Dilnawaz, F | 1 |
| Sahoo, SK | 1 |
| Caldera, V | 2 |
| Campia, I | 1 |
| Bosia, A | 1 |
| Ghigo, D | 1 |
| DI Cristofori, A | 1 |
| Carrabba, G | 1 |
| Lanfranchi, G | 1 |
| Menghetti, C | 1 |
| Baumann, C | 1 |
| Lorgis, V | 1 |
| Blonski, M | 1 |
| Chauffert, B | 3 |
| Pinelli, C | 1 |
| Zustovich, F | 2 |
| Landi, L | 1 |
| Porta, C | 1 |
| Galli, L | 1 |
| Fontana, A | 1 |
| Amoroso, D | 1 |
| Galli, C | 1 |
| Andreuccetti, M | 1 |
| Falcone, A | 1 |
| Raisanen, J | 1 |
| Boothman, DA | 3 |
| Cochran, B | 1 |
| Wu, C | 2 |
| Tobias, AL | 2 |
| Thaci, B | 1 |
| Auffinger, B | 2 |
| Rincón, E | 1 |
| Kim, CK | 1 |
| Aboody, KS | 2 |
| Messali, A | 2 |
| Hay, JW | 2 |
| Villacorta, R | 2 |
| Ondos, J | 1 |
| Ning, H | 1 |
| Smith, S | 2 |
| Kreisl, T | 1 |
| Sul, J | 3 |
| McNeil, K | 1 |
| Krauze, A | 2 |
| Fine, HA | 6 |
| Morrell, RM | 1 |
| Tooze, JA | 1 |
| Harmon, MS | 1 |
| Carter, AF | 1 |
| DeTroye, AT | 1 |
| Stockhammer, F | 6 |
| Krohn, M | 1 |
| Zakaria, Z | 2 |
| Fenton, E | 1 |
| Khalil, A | 1 |
| Sattar, MT | 1 |
| Molnar, P | 1 |
| Eich, M | 1 |
| Huang, TT | 1 |
| Hlavaty, J | 1 |
| Ostertag, D | 1 |
| Espinoza, FL | 1 |
| Martin, B | 1 |
| Petznek, H | 1 |
| Rodriguez-Aguirre, M | 1 |
| Ibañez, CE | 1 |
| Kasahara, N | 1 |
| Gunzburg, W | 1 |
| Gruber, HE | 1 |
| Pertschuk, D | 1 |
| Jolly, DJ | 1 |
| Robbins, JM | 1 |
| Balducci, M | 10 |
| De Bonis, P | 6 |
| Chiesa, S | 6 |
| Mangiola, A | 7 |
| Mattiucci, GC | 2 |
| D'Agostino, GR | 4 |
| Frascino, V | 4 |
| Mantini, G | 4 |
| Alitto, AR | 1 |
| Colosimo, C | 1 |
| Anile, C | 7 |
| Valentini, V | 7 |
| Kuo, LT | 2 |
| Yang, CY | 1 |
| Lin, LW | 1 |
| MacFadden, D | 2 |
| Al-Zahrani, A | 2 |
| Atenafu, E | 1 |
| Miller, BA | 1 |
| Menard, C | 3 |
| Behm, T | 1 |
| Horowski, A | 1 |
| Schneider, S | 1 |
| Michaelsen, SR | 2 |
| Christensen, IJ | 2 |
| Stockhausen, MT | 2 |
| Kosteljanetz, M | 2 |
| Zairi, F | 1 |
| Maurage, CA | 2 |
| Assaker, R | 1 |
| Eisele, G | 2 |
| Wolpert, F | 1 |
| Decrey, G | 1 |
| Pozsgai, E | 1 |
| Bellyei, S | 1 |
| Boronkai, A | 1 |
| Racz, B | 1 |
| Szabo, A | 1 |
| Sumegi, B | 1 |
| Hocsak, E | 1 |
| Dubrow, R | 2 |
| Darefsky, AS | 2 |
| Jacobs, DI | 1 |
| Park, LS | 1 |
| Rose, MG | 1 |
| Laurans, MS | 1 |
| King, JT | 2 |
| You, WC | 1 |
| Chiou, SH | 3 |
| Chiang, SF | 1 |
| Yang, CL | 1 |
| Sudhakar, JN | 1 |
| Chiang, IP | 1 |
| Lin, JC | 1 |
| Shieh, SH | 1 |
| Chow, KC | 1 |
| Rumiato, E | 1 |
| Bertorelle, R | 3 |
| Saggioro, D | 1 |
| Farina, P | 1 |
| Sacchetto, V | 1 |
| Marcato, R | 1 |
| Amadori, A | 1 |
| Cong, ZX | 1 |
| Wang, HD | 1 |
| Wang, JW | 1 |
| Zhang, DD | 1 |
| Zhang, LH | 2 |
| Cheng, JX | 2 |
| Han, N | 2 |
| Alexandru, D | 1 |
| Bigner, D | 1 |
| Vredenburgh, J | 1 |
| Jaeckle, KA | 7 |
| Mahajan, A | 3 |
| Schultz, CJ | 1 |
| Baumert, B | 1 |
| Hopkins, KI | 1 |
| Bottomley, A | 2 |
| Mendoza, TR | 1 |
| Choucair, AK | 1 |
| Mehta, M | 7 |
| Teo, M | 1 |
| Martin, S | 2 |
| Owusu-Agyemang, K | 1 |
| Nowicki, S | 1 |
| Clark, B | 1 |
| Mackinnon, M | 1 |
| Stewart, W | 1 |
| Paul, J | 1 |
| St George, J | 1 |
| Seong, S | 1 |
| Lim, SH | 1 |
| Aldave, G | 1 |
| Marigil, M | 1 |
| Gállego Pérez-Larraya, J | 2 |
| de Gallego, J | 1 |
| Domínguez, PD | 1 |
| Polley, MY | 8 |
| Freidlin, B | 1 |
| Korn, EL | 1 |
| Conley, BA | 1 |
| Abrams, JS | 1 |
| McShane, LM | 1 |
| Murata, D | 1 |
| Fujimoto, K | 1 |
| Kikuchi, T | 2 |
| Takahashi, JC | 1 |
| Miyamoto, S | 2 |
| Chonan, M | 1 |
| Mano, Y | 1 |
| Shibahara, I | 1 |
| Kawaguchi, T | 2 |
| Kato, H | 1 |
| Yamashita, Y | 2 |
| Kawagishi, J | 1 |
| Jokura, H | 1 |
| Watanabe, M | 1 |
| Katakura, R | 1 |
| Tominaga, T | 2 |
| Alnaami, IM | 1 |
| Al-Nuaimi, SK | 1 |
| Senthilselvan, A | 1 |
| Murtha, AD | 1 |
| Walling, S | 1 |
| Mehta, V | 1 |
| Gourishankar, S | 1 |
| Folkert, M | 1 |
| Zumsteg, ZS | 1 |
| Gutin, PH | 3 |
| Pentsova, E | 2 |
| Snuderl, M | 1 |
| Ancukiewicz, M | 2 |
| Polaskova, P | 3 |
| Pinho, MC | 2 |
| Jennings, D | 2 |
| Eichler, AF | 2 |
| Hochberg, FH | 3 |
| Lu-Emerson, C | 1 |
| Iafrate, AJ | 3 |
| Ivy, SP | 1 |
| Loeffler, JS | 3 |
| Alonso-Basanta, M | 1 |
| Fang, P | 1 |
| Maity, A | 2 |
| Hahn, SM | 2 |
| Lustig, RA | 1 |
| Dorsey, JF | 1 |
| Chamberlain, MC | 13 |
| Liu, JP | 1 |
| Mao, Q | 2 |
| Tabei, Y | 2 |
| Saito, N | 3 |
| Shinsato, Y | 1 |
| Furukawa, T | 1 |
| Yunoue, S | 2 |
| Minami, K | 1 |
| Nishizawa, Y | 1 |
| Ikeda, R | 1 |
| Kawahara, K | 1 |
| Yamamoto, M | 1 |
| Tokimura, H | 2 |
| Arita, K | 2 |
| Ye, F | 1 |
| Yamada, K | 2 |
| Tso, JL | 2 |
| Menjivar, JC | 2 |
| Tian, JY | 1 |
| Yong, WH | 6 |
| Schaue, D | 1 |
| Nelson, SF | 2 |
| McBride, W | 1 |
| Tso, CL | 2 |
| Oike, T | 1 |
| Sugawara, K | 1 |
| Shirai, K | 1 |
| Noda, SE | 1 |
| Tamaki, T | 1 |
| Nagaishi, M | 1 |
| Yokoo, H | 2 |
| Nakazato, Y | 2 |
| Ylivinkka, I | 1 |
| Chen, P | 1 |
| Keski-Oja, J | 1 |
| Hyytiäinen, M | 1 |
| Juratli, TA | 1 |
| Engellandt, K | 1 |
| Lautenschlaeger, T | 1 |
| Geiger, KD | 1 |
| von Kummer, R | 1 |
| Cerhova, J | 1 |
| Schackert, G | 5 |
| Samis Zella, MA | 1 |
| Wallocha, M | 1 |
| Slotty, PJ | 2 |
| Isik, G | 1 |
| Schroeteler, J | 1 |
| Ewelt, C | 2 |
| Chou, KN | 1 |
| Lin, YC | 2 |
| Liu, MY | 1 |
| Chang, PY | 1 |
| Teixeira, S | 1 |
| Fouse, SD | 1 |
| Nakamura, JL | 1 |
| Shibuya, K | 1 |
| Watanabe, E | 2 |
| Seino, S | 2 |
| Seino, M | 1 |
| Reynés, G | 4 |
| Iglesias, L | 1 |
| García, JL | 2 |
| Jo, S | 1 |
| Lee, H | 2 |
| Kim, TU | 1 |
| Kim, IC | 1 |
| Yim, JH | 1 |
| Chung, H | 1 |
| Yang, LJ | 1 |
| Zhou, CF | 1 |
| Lin, ZX | 1 |
| Han, K | 1 |
| Ren, M | 1 |
| Abrey, L | 3 |
| Lövey, J | 1 |
| Fedorcsák, I | 1 |
| Bajcsay, A | 1 |
| Sipos, L | 2 |
| Mangel, L | 1 |
| Kásler, M | 1 |
| Bagó, A | 1 |
| Kiss, E | 1 |
| Lahm, E | 1 |
| Vachaja, J | 1 |
| Nagy, P | 1 |
| Bazsó, P | 1 |
| Fekete, Z | 1 |
| Takácsi-Nagy, Z | 1 |
| Pápai, Z | 1 |
| Rehman, A | 1 |
| Vemireddy, V | 2 |
| Souza, RF | 1 |
| Koduru, P | 1 |
| Gil del Alcazar, CR | 2 |
| Hardebeck, MC | 1 |
| Tomimatsu, N | 3 |
| Gao, X | 2 |
| Xie, XJ | 1 |
| Bachoo, R | 1 |
| Sander, A | 1 |
| Wosniok, W | 1 |
| Gabel, D | 1 |
| Chotai, S | 1 |
| Newton, H | 1 |
| Lamki, T | 1 |
| Dhermain, F | 1 |
| Tsai, JP | 1 |
| Petrescu, N | 1 |
| Casaubon, LK | 1 |
| Capdevila, L | 1 |
| Cros, S | 1 |
| Ramirez, JL | 3 |
| Romeo, M | 1 |
| Etxaniz, O | 1 |
| Massuet, A | 1 |
| Cuadra, JL | 1 |
| Balzarini, L | 1 |
| Mancini, C | 1 |
| Marvisi, M | 1 |
| Ali, AN | 1 |
| Ogunleye, T | 1 |
| Hardy, CW | 1 |
| Shu, HK | 2 |
| Crocker, IR | 2 |
| Quillien, V | 5 |
| Lavenu, A | 2 |
| Legrain, M | 2 |
| Dubus, P | 1 |
| Eisele, AC | 1 |
| Tonn, J | 1 |
| Ochsenbein, A | 1 |
| Neyns, B | 5 |
| Nikkhah, G | 2 |
| Picard, M | 4 |
| Donovan, P | 1 |
| Cato, K | 1 |
| Legaie, R | 1 |
| Jayalath, R | 1 |
| Olsson, G | 1 |
| Hall, B | 1 |
| Olson, S | 1 |
| Boros, S | 1 |
| Harding, A | 1 |
| Hofland, KF | 1 |
| Hansen, S | 2 |
| Sorensen, M | 1 |
| Engelholm, S | 1 |
| Schultz, HP | 1 |
| Muhic, A | 1 |
| Ask, A | 1 |
| Costa, JC | 1 |
| Kristiansen, C | 1 |
| Thomsen, C | 1 |
| Stevens, BM | 1 |
| Folts, CJ | 1 |
| Bardin, AL | 1 |
| Walter, K | 1 |
| Carson-Walter, E | 1 |
| Vescovi, A | 1 |
| Noble, M | 1 |
| Magnuson, W | 1 |
| Ian Robins, H | 1 |
| Mohindra, P | 1 |
| Howard, S | 1 |
| McNamara, MG | 4 |
| Templeton, AJ | 1 |
| Zadeh, G | 3 |
| Bernstein, M | 2 |
| Chung, C | 3 |
| Millar, BA | 5 |
| Zeng, L | 2 |
| Di, C | 1 |
| Fee, BE | 1 |
| Rivas, M | 1 |
| Adamson, DC | 1 |
| Kodama, T | 1 |
| Yokoi, S | 2 |
| Kawasaki, K | 1 |
| Hara, R | 1 |
| Tops, B | 1 |
| Jeuken, J | 2 |
| Hulleman, E | 2 |
| Boots-Sprenger, SH | 2 |
| Vandertop, WP | 2 |
| Kaspers, GJ | 2 |
| Ogura, K | 1 |
| Ogura, M | 1 |
| Sakanaka, K | 1 |
| Hiraoka, M | 1 |
| Candolfi, M | 1 |
| Yagiz, K | 1 |
| Wibowo, M | 1 |
| Ahlzadeh, GE | 1 |
| Puntel, M | 1 |
| Ghiasi, H | 1 |
| Kamran, N | 1 |
| Paran, C | 1 |
| Lowenstein, PR | 2 |
| Castro, MG | 2 |
| Panosyan, EH | 1 |
| Xia, P | 1 |
| Lee, WN | 1 |
| Pak, Y | 1 |
| Laks, DR | 1 |
| Lin, HJ | 1 |
| Moore, TB | 1 |
| Lasky, JL | 1 |
| Dwucet, A | 2 |
| Nonnenmacher, L | 4 |
| Lau, PK | 1 |
| Bynevelt, M | 1 |
| Florea, AM | 2 |
| Lamszus, K | 2 |
| Frei, K | 1 |
| Deenen, R | 1 |
| Meco, D | 1 |
| Servidei, T | 1 |
| Lamorte, G | 1 |
| Binda, E | 1 |
| Arena, V | 1 |
| Riccardi, R | 1 |
| Hoang-Xuan, K | 6 |
| Kavan, P | 7 |
| Cernea, D | 1 |
| Hilton, M | 2 |
| Pugh, S | 1 |
| Jeraj, R | 1 |
| Oh, SW | 1 |
| Jee, TK | 1 |
| Daróczi, B | 1 |
| Szántó, E | 1 |
| Tóth, J | 1 |
| Barzó, P | 1 |
| Bognár, L | 1 |
| Bakó, G | 1 |
| Szántó, J | 1 |
| Mózes, P | 1 |
| Hideghéty, K | 1 |
| Allen, JE | 1 |
| Huang, SY | 1 |
| Berg, A | 1 |
| Webb, BS | 1 |
| Liu, CG | 1 |
| El-Deiry, WS | 1 |
| Yang, JM | 1 |
| Moen, EL | 1 |
| Stark, AL | 1 |
| Dolan, ME | 1 |
| Godley, LA | 1 |
| Sheng, XF | 1 |
| Dai, JZ | 1 |
| She, X | 2 |
| Lei, Q | 3 |
| Badaoui, N | 1 |
| Meyronet, D | 1 |
| Jouanneau, E | 1 |
| d'Hombres, A | 2 |
| Louis-Tisserand, G | 1 |
| Archinet, A | 1 |
| Ducray, F | 9 |
| Arvold, ND | 3 |
| Tentori, L | 4 |
| Muzi, A | 1 |
| Ciccarone, F | 1 |
| Pelacchi, F | 3 |
| Calabrese, R | 1 |
| Runci, D | 3 |
| Caiafa, P | 1 |
| Graziani, G | 4 |
| Moskwa, J | 2 |
| Puscion-Jakubik, A | 1 |
| Socha, K | 2 |
| Soroczynska, J | 1 |
| Wachtel, MS | 1 |
| Kaulich, K | 1 |
| Hentschel, B | 3 |
| Gramatzki, D | 3 |
| Davis, T | 1 |
| Weiss, WA | 2 |
| Sagiyama, K | 1 |
| Mashimo, T | 1 |
| Maher, EA | 1 |
| Sherry, AD | 1 |
| Bachoo, RM | 3 |
| O'Donnell, JP | 1 |
| Salazar, CR | 1 |
| Van Brocklyn, JR | 2 |
| Barnett, KD | 1 |
| Pearl, DK | 1 |
| deCarvalho, AC | 1 |
| Ecsedy, JA | 1 |
| Brown, SL | 1 |
| Lehman, NL | 1 |
| Clarke, JL | 5 |
| Butowski, NA | 4 |
| DeSilva, AA | 1 |
| Rabbitt, JE | 1 |
| Prados, MD | 19 |
| Jiang, D | 1 |
| Roig, EM | 1 |
| Buil, LC | 1 |
| Christner, SM | 1 |
| Beumer, JH | 2 |
| Beijnen, JH | 2 |
| van Tellingen, O | 2 |
| Elicin, O | 1 |
| Inac, E | 1 |
| Uzel, EK | 1 |
| Karacam, S | 1 |
| Uzel, OE | 1 |
| Munoz, JL | 4 |
| Rodriguez-Cruz, V | 3 |
| Greco, SJ | 3 |
| Rameshwar, P | 4 |
| Rubner, Y | 1 |
| Muth, C | 1 |
| Strnad, A | 1 |
| Sieber, R | 1 |
| Melchardt, T | 1 |
| Magnes, T | 1 |
| Grundbichler, M | 1 |
| Strasser, M | 1 |
| Hufnagl, C | 1 |
| Moik, M | 1 |
| Egle, A | 1 |
| Oborski, MJ | 1 |
| Laymon, CM | 1 |
| Hamilton, RL | 3 |
| Mountz, JM | 1 |
| Berghoff, AS | 1 |
| Ricken, G | 1 |
| Budak, F | 2 |
| Tolunay, S | 1 |
| Toscano, M | 3 |
| Manai, F | 1 |
| Yoo, B | 1 |
| Ifediba, MA | 1 |
| Medarova, Z | 1 |
| Moore, A | 2 |
| Lim, YJ | 2 |
| Han, TJ | 2 |
| Messaoudi, K | 3 |
| Saulnier, P | 1 |
| Boesen, K | 1 |
| Benoit, JP | 2 |
| Lagarce, F | 3 |
| Cong, D | 1 |
| Pointer, KB | 1 |
| Clark, PA | 3 |
| Shen, H | 3 |
| Kuo, JS | 3 |
| Coate, L | 1 |
| Massey, C | 1 |
| Timmermann, BN | 1 |
| Cohen, MS | 1 |
| Bonnetain, F | 3 |
| Taillia, H | 2 |
| Schott, R | 4 |
| Castera, D | 2 |
| Frenay, M | 3 |
| Dalban, C | 3 |
| Skrzypski, J | 2 |
| Nayak, L | 2 |
| Kalkanis, SN | 2 |
| Berthois, Y | 1 |
| Delfino, C | 4 |
| Fina, F | 3 |
| Nanni-Metellus, I | 2 |
| Al Aswy, H | 1 |
| Pirisi, V | 1 |
| Ouafik, L | 5 |
| Boudouresque, F | 1 |
| Smirnova, ZS | 1 |
| Ermakova, KV | 1 |
| Kubasova, IY | 1 |
| Borisova, LM | 1 |
| Kiselyova, MP | 1 |
| Oborotova, NA | 1 |
| Meerovich, GA | 1 |
| Luk'yanets, EA | 1 |
| Ben Aissa, A | 1 |
| Espeli, V | 1 |
| Squiban, D | 1 |
| Dunkel, N | 1 |
| Vargas, MI | 1 |
| Mach, N | 1 |
| Schaller, K | 1 |
| Weber, DC | 1 |
| Bodmer, A | 1 |
| Bandey, I | 1 |
| Huang, AP | 1 |
| Tsai, JC | 1 |
| Tu, PH | 1 |
| Signore, M | 2 |
| di Martino, S | 1 |
| Biffoni, M | 2 |
| Giannetti, S | 1 |
| Morgante, L | 1 |
| De Majo, M | 1 |
| Petricoin, EF | 1 |
| Stancato, L | 2 |
| De Maria, R | 4 |
| Nishida, M | 1 |
| Farkas, N | 1 |
| Dagata, JA | 1 |
| Anderson, JC | 1 |
| Duarte, CW | 1 |
| Welaya, K | 1 |
| Rohrbach, TD | 1 |
| Yang, ES | 1 |
| Choradia, NV | 1 |
| Thottassery, JV | 1 |
| Yancey Gillespie, G | 1 |
| Bonner, JA | 1 |
| Willey, CD | 1 |
| Komiyama, M | 2 |
| Kume, A | 2 |
| Omiya, M | 2 |
| Boakye-Agyeman, F | 2 |
| Kizilbash, SH | 2 |
| Reid, J | 1 |
| Zhu, TZ | 2 |
| Li, XM | 2 |
| Luo, LH | 2 |
| Song, ZQ | 1 |
| Su, JY | 1 |
| Liang, GB | 2 |
| Oshita, C | 1 |
| Xu, YH | 1 |
| Turner, SG | 1 |
| Gergel, T | 1 |
| Haemmig, S | 1 |
| Baumgartner, U | 1 |
| Glück, A | 1 |
| Zbinden, S | 1 |
| Tschan, MP | 1 |
| Kappeler, A | 1 |
| Mariani, L | 2 |
| Vajtai, I | 1 |
| Vassella, E | 1 |
| Sang, DP | 1 |
| Li, RJ | 1 |
| Gebhardt, BJ | 1 |
| Dobelbower, MC | 2 |
| Ennis, WH | 1 |
| Bag, AK | 1 |
| Markert, JM | 3 |
| Flavahan, W | 1 |
| Mattson, MP | 1 |
| Orlando, T | 1 |
| Paolini, A | 3 |
| Pineider, F | 1 |
| Clementi, E | 1 |
| Pasi, F | 4 |
| Guari, Y | 1 |
| Larionova, J | 1 |
| Sacchi, L | 1 |
| Nano, R | 4 |
| Corti, M | 1 |
| Lascialfari, A | 1 |
| Rovere, RK | 1 |
| Raktoe, RS | 1 |
| Ho, AS | 1 |
| Zhang, XQ | 4 |
| Xu, FF | 1 |
| Linn, J | 2 |
| Ladizinski, B | 1 |
| Sankey, C | 1 |
| Muruganandham, M | 1 |
| Clerkin, PP | 1 |
| Smith, BJ | 1 |
| Anderson, CM | 1 |
| Morris, A | 1 |
| Capizzano, AA | 1 |
| Magnotta, V | 1 |
| McGuire, SM | 1 |
| Smith, MC | 1 |
| Bayouth, JE | 1 |
| Buatti, JM | 1 |
| Supko, JG | 1 |
| Mikkelson, T | 1 |
| Chang, YC | 1 |
| McAfee, Q | 1 |
| Fisher, J | 3 |
| Troxel, AB | 1 |
| Piao, S | 1 |
| Heitjan, DF | 1 |
| Tan, KS | 1 |
| Pontiggia, L | 1 |
| O'Dwyer, PJ | 1 |
| Davis, LE | 1 |
| Amaravadi, RK | 1 |
| Tsuboi, K | 3 |
| Ikuta, S | 1 |
| Hashimoto, K | 1 |
| Uemae, Y | 1 |
| Ishihara, T | 1 |
| Matsutani, M | 2 |
| Karasawa, K | 1 |
| Ohno, T | 2 |
| Mansour, J | 1 |
| Fields, B | 1 |
| Macomson, S | 1 |
| Rixe, O | 1 |
| Letarte, N | 2 |
| Gabay, MP | 1 |
| Bressler, LR | 2 |
| Long, KE | 1 |
| Stachnik, JM | 1 |
| Tan, CW | 1 |
| See, SJ | 3 |
| Tham, CK | 2 |
| Ang, AL | 1 |
| Oh, T | 1 |
| Rutkowski, MJ | 1 |
| Safaee, M | 1 |
| Sun, MZ | 1 |
| Sayegh, ET | 1 |
| Tihan, T | 3 |
| Parsa, AT | 3 |
| Wen, C | 1 |
| Nagula, V | 1 |
| Scotto, KW | 2 |
| Wicks, RT | 1 |
| Azadi, J | 1 |
| Mangraviti, A | 2 |
| Zhang, I | 2 |
| Hwang, L | 1 |
| Joshi, A | 1 |
| Bow, H | 1 |
| Hutt-Cabezas, M | 1 |
| Martin, KL | 1 |
| Tyler, BM | 2 |
| Ferrazza, P | 2 |
| Cocuzza, P | 1 |
| Fatigante, L | 2 |
| Pasqualetti, G | 1 |
| Fabbrini, MG | 1 |
| Monzani, F | 1 |
| Nguyen, SA | 2 |
| Stechishin, OD | 2 |
| Lun, XQ | 2 |
| Senger, DL | 2 |
| Robbins, SM | 2 |
| Loundou, A | 2 |
| Di Liberto, R | 2 |
| Capelli, E | 2 |
| Burrell, K | 1 |
| Buczkowicz, P | 1 |
| Chornenkyy, Y | 1 |
| Gajadhar, A | 2 |
| Fernandez, NA | 1 |
| Clarke, ID | 3 |
| Barszczyk, MS | 1 |
| Pajovic, S | 1 |
| Ternamian, C | 2 |
| Head, R | 3 |
| Sabha, N | 2 |
| Hawkins, C | 4 |
| Adair, JE | 1 |
| Beard, BC | 2 |
| Guyman, LA | 1 |
| Baldock, AL | 1 |
| Bridge, CA | 1 |
| Gori, JL | 2 |
| Born, DE | 1 |
| Gonzalez-Cuyar, LF | 1 |
| Silbergeld, DL | 1 |
| Storer, BE | 1 |
| Rockhill, JK | 2 |
| Kiem, HP | 3 |
| Oka, H | 1 |
| Tashiro, T | 1 |
| Gutin, P | 1 |
| Karimi, S | 2 |
| Correa, DD | 1 |
| Kaley, TJ | 2 |
| Gavrilovic, IT | 1 |
| Nolan, C | 2 |
| Grommes, C | 2 |
| Baser, RE | 1 |
| Tabar, V | 1 |
| Sanchez, J | 1 |
| Barradas-Panchal, R | 1 |
| Faivre, G | 1 |
| Brennan, CW | 2 |
| Yusubalieva, GM | 1 |
| Baklaushev, VP | 1 |
| Gurina, OI | 1 |
| Zorkina, YA | 1 |
| Gubskii, IL | 1 |
| Golanov, AV | 1 |
| Goryainov, SA | 1 |
| Gorlachev, GE | 1 |
| Konovalov, AN | 1 |
| Potapov, AA | 1 |
| Chekhonin, VP | 1 |
| Fulda, S | 4 |
| Engelke, J | 1 |
| Simmet, T | 1 |
| Corbacioglu, S | 1 |
| Bao, ZS | 1 |
| Chen, HM | 1 |
| Yang, MY | 1 |
| Zhang, CB | 1 |
| Ye, WL | 1 |
| Hu, BQ | 1 |
| Ramakrishnan, V | 2 |
| Hu, HM | 1 |
| Li, MY | 1 |
| Yao, K | 2 |
| Qiu, XG | 1 |
| Fan, XL | 1 |
| Song, WS | 1 |
| Li, RQ | 1 |
| Su, XD | 1 |
| Shapiro, W | 2 |
| Wind, S | 1 |
| Hamisch, C | 1 |
| Suchorska, B | 3 |
| Visser-Vandewalle, V | 1 |
| Kocher, M | 2 |
| Treuer, H | 1 |
| Voges, J | 1 |
| Ruge, MI | 1 |
| Tarnawski, R | 2 |
| Rao, N | 1 |
| Thurzo, L | 1 |
| Adamska, K | 1 |
| Wiegel, T | 1 |
| Hicking, C | 3 |
| Markivskyy, A | 1 |
| Diebold, G | 2 |
| Henaine, AM | 2 |
| Breant, V | 1 |
| Fouquet, A | 1 |
| Aulagner, G | 2 |
| Aiken, R | 1 |
| Lemos, AM | 1 |
| Gokaslan, A | 1 |
| Cabrera-Aldana, EE | 1 |
| Ashary, A | 1 |
| Olivi, A | 5 |
| Delgado-Goñi, T | 2 |
| Wojton, J | 2 |
| Meisen, WH | 1 |
| Thorne, AH | 1 |
| Hardcastle, J | 1 |
| Denton, N | 1 |
| Chu, Z | 1 |
| Dmitrieva, N | 2 |
| Marsh, R | 1 |
| Van Meir, EG | 1 |
| Kwon, CH | 1 |
| Qi, X | 2 |
| Yalcin, M | 1 |
| Sahin, S | 1 |
| Demir, C | 1 |
| Guvenc, G | 1 |
| Yilmaz, G | 1 |
| Erkan, LG | 1 |
| Malyer, H | 2 |
| Evrensel, T | 1 |
| Adeberg, S | 3 |
| König, L | 1 |
| Bostel, T | 3 |
| Welzel, T | 4 |
| Marie, Y | 2 |
| Menei, P | 2 |
| Boniface, R | 1 |
| de Tayrac, M | 1 |
| Fisch, MJ | 1 |
| Lagrone, LW | 1 |
| Levin, VA | 5 |
| Volas-Redd, G | 1 |
| Floyd, JD | 1 |
| Hsu, SH | 2 |
| Gonzalez, J | 2 |
| Woo, SY | 1 |
| Ameratunga, MS | 1 |
| Thomas, AA | 3 |
| Omuro, AM | 2 |
| Cheng, Z | 1 |
| Kavitha, CV | 1 |
| Jain, AK | 1 |
| Agarwal, C | 1 |
| Pierce, A | 1 |
| Keating, A | 1 |
| Huber, KM | 1 |
| Serkova, NJ | 1 |
| Wempe, MF | 1 |
| Agarwal, R | 1 |
| Deep, G | 1 |
| Noack, J | 1 |
| Richter, K | 1 |
| Kopp-Schneider, A | 1 |
| Song, M | 1 |
| Mohamad, O | 1 |
| Yu, SP | 1 |
| Bartosiuk, E | 1 |
| Surażyński, A | 1 |
| Mariak, Z | 1 |
| Badiyan, SN | 1 |
| Markovina, S | 1 |
| Simpson, JR | 1 |
| DeWees, T | 1 |
| Linette, G | 1 |
| Jalalizadeh, R | 1 |
| Dacey, R | 1 |
| Rich, KM | 1 |
| Chicoine, MR | 1 |
| Dowling, JL | 1 |
| Leuthardt, EC | 1 |
| Zipfel, GJ | 1 |
| Vo, VA | 1 |
| Lee, JW | 2 |
| Chun, W | 1 |
| Lim, SY | 1 |
| Hummersone, M | 1 |
| Matthews, CS | 1 |
| Stevens, MF | 3 |
| Yan, T | 2 |
| Liang, X | 1 |
| Leiss, L | 2 |
| Sakariassen, PØ | 1 |
| Skaftnesmo, KO | 2 |
| Costea, DE | 1 |
| Neuwelt, AJ | 1 |
| Nguyen, TM | 1 |
| Fu, R | 1 |
| Bubalo, J | 1 |
| Tyson, RM | 1 |
| Lacy, C | 1 |
| Gahramanov, S | 1 |
| Nasseri, M | 1 |
| Barnes, PD | 1 |
| Neuwelt, EA | 2 |
| Liao, CL | 1 |
| Chen, CM | 2 |
| Chang, YZ | 1 |
| Liu, GY | 1 |
| Hung, HC | 1 |
| Hsieh, TY | 1 |
| Woo, SR | 1 |
| Ham, Y | 1 |
| Kang, W | 2 |
| Joo, KM | 5 |
| Kawano, H | 1 |
| Yatsushiro, K | 1 |
| Ogita, M | 1 |
| Hiraki, Y | 1 |
| Uchida, H | 1 |
| Habu, M | 1 |
| Fujio, S | 1 |
| Oyoshi, T | 1 |
| Bakhtiar, Y | 1 |
| Sugata, S | 1 |
| Yamahata, H | 1 |
| Hanaya, R | 1 |
| Yeom, SY | 1 |
| Park, I | 3 |
| Mukherjee, J | 2 |
| Chaumeil, MM | 2 |
| Jalbert, LE | 1 |
| Gaensler, K | 1 |
| Ronen, SM | 3 |
| Pieper, RO | 7 |
| Jalilian, L | 1 |
| Lupo, JM | 4 |
| Ramirez, YP | 1 |
| Phillips, RM | 1 |
| Gynther, M | 1 |
| Rautio, J | 1 |
| Ross, AH | 4 |
| Wheelhouse, RT | 1 |
| Sakaria, JN | 1 |
| Woehrer, A | 1 |
| Barnholtz-Sloan, JS | 3 |
| Hunn, MK | 1 |
| Bauer, E | 1 |
| Wood, CE | 1 |
| Gasser, O | 1 |
| Dzhelali, M | 1 |
| Ancelet, LR | 1 |
| Mester, B | 1 |
| Sharples, KJ | 1 |
| Findlay, MP | 1 |
| Hamilton, DA | 2 |
| Hermans, IF | 1 |
| Hsieh, CH | 1 |
| Lee, HT | 1 |
| Shyu, WC | 1 |
| Wang, CC | 1 |
| Denis, JM | 1 |
| Gueulette, J | 1 |
| Slabbert, J | 1 |
| Breshears, JD | 1 |
| Ivan, ME | 1 |
| Cotter, JA | 1 |
| Bollen, AW | 1 |
| Theodosopoulos, PV | 1 |
| Reap, E | 1 |
| Schmittling, R | 2 |
| DeLeon, G | 1 |
| Friedman, AH | 13 |
| Archer, G | 1 |
| Shah, N | 1 |
| Schroeder, B | 1 |
| Cobbs, C | 1 |
| Fan, TY | 1 |
| Xiang, P | 1 |
| Li, HZ | 1 |
| Lei, BX | 1 |
| Zappelli, E | 1 |
| Natali, L | 1 |
| Porru, M | 1 |
| Zappavigna, S | 1 |
| Salzano, G | 1 |
| Luce, A | 1 |
| Stoppacciaro, A | 1 |
| Balestrieri, ML | 1 |
| Artuso, S | 1 |
| Lusa, S | 1 |
| De Rosa, G | 1 |
| Leonetti, C | 2 |
| Caraglia, M | 2 |
| Mason, M | 1 |
| Adeyi, O | 1 |
| Fung, S | 1 |
| Bu, G | 1 |
| Golden, EB | 2 |
| Jahanian, A | 1 |
| Louie, SG | 3 |
| Barbagallo, GM | 1 |
| Paratore, S | 1 |
| Caltabiano, R | 1 |
| Palmucci, S | 1 |
| Parra, HS | 1 |
| Privitera, G | 1 |
| Motta, F | 2 |
| Lanzafame, S | 1 |
| Scaglione, G | 1 |
| Longo, A | 1 |
| Albanese, V | 1 |
| Certo, F | 1 |
| Terrenato, I | 1 |
| Pace, A | 2 |
| Giangaspero, F | 4 |
| Bozzao, A | 4 |
| Ding, J | 2 |
| Tian, D | 1 |
| Dong, H | 2 |
| Hoffermann, M | 1 |
| Bruckmann, L | 1 |
| Kariem Mahdy, A | 1 |
| Asslaber, M | 1 |
| Payer, F | 3 |
| Hayes, J | 1 |
| Thygesen, H | 1 |
| Tumilson, C | 1 |
| Droop, A | 1 |
| Boissinot, M | 1 |
| Hughes, TA | 1 |
| Westhead, D | 1 |
| Alder, JE | 1 |
| Shaw, L | 1 |
| Welscher, N | 1 |
| Hlavac, M | 1 |
| Ney, DE | 2 |
| Carlson, JA | 2 |
| Kleinschmidt-DeMasters, BK | 3 |
| Waziri, AE | 1 |
| Peller, PJ | 2 |
| Uhm, JH | 3 |
| McGraw, S | 2 |
| Flynn, PJ | 1 |
| Purchiaroni, F | 1 |
| Begini, P | 1 |
| Gallina, S | 1 |
| Delle Fave, G | 1 |
| Marignani, M | 1 |
| Tan, C | 1 |
| Zanotto-Filho, A | 1 |
| Klafke, K | 1 |
| Terra, SR | 1 |
| Paludo, FJ | 1 |
| Morrone, M | 1 |
| Bristot, IJ | 1 |
| Battastini, AM | 2 |
| Forcelini, CM | 1 |
| Bishop, AJR | 1 |
| Gelain, DP | 1 |
| Moreira, JCF | 1 |
| Ramachandran, C | 2 |
| Lollett, IV | 1 |
| Escalon, E | 2 |
| Quirin, KW | 1 |
| Melnick, SJ | 2 |
| Bochenek-Cibor, J | 1 |
| Krupa, M | 1 |
| Moskała, M | 1 |
| Trojanowski, T | 1 |
| Pacaud, R | 2 |
| Cheray, M | 2 |
| Meyer, M | 1 |
| Lan, X | 1 |
| Kushida, M | 1 |
| Bayani, J | 1 |
| Pressey, JC | 1 |
| Lionel, AC | 1 |
| Cusimano, M | 1 |
| Squire, JA | 1 |
| Scherer, SW | 1 |
| Woodin, MA | 1 |
| Bader, GD | 1 |
| Verhoeff, JJ | 1 |
| Richel, DJ | 1 |
| van Furth, WR | 1 |
| Reijneveld, JC | 2 |
| Verheul, HM | 1 |
| Yu, B | 1 |
| Deng, J | 1 |
| Schuster, J | 1 |
| Lai, RK | 1 |
| Paleologos, NA | 1 |
| Jensen, R | 1 |
| Baehring, JM | 1 |
| Cruickshank, S | 1 |
| Green, JA | 1 |
| Kim, HR | 1 |
| Biswas, NK | 1 |
| Chandra, V | 1 |
| Sarkar-Roy, N | 1 |
| Das, T | 1 |
| Bhattacharya, RN | 1 |
| Tripathy, LN | 1 |
| Basu, SK | 1 |
| Mukherjee, A | 1 |
| Basu, P | 1 |
| Maitra, A | 1 |
| Chattopadhyay, A | 1 |
| Dhara, S | 1 |
| Xiao, L | 2 |
| Calligaris, D | 2 |
| Iyekegbe, DO | 1 |
| Mueller, D | 1 |
| Evans, DL | 1 |
| Lou, Z | 2 |
| Pucci, V | 1 |
| Ma, B | 1 |
| Shumway, SD | 1 |
| Agar, NY | 2 |
| Jansen, NL | 1 |
| Kretzschmar, H | 1 |
| Janssen, H | 1 |
| Pöpperl, G | 2 |
| Kreth, FW | 5 |
| la Fougere, C | 1 |
| Lok, E | 1 |
| Swanson, KD | 1 |
| Lian, S | 1 |
| Paff, M | 1 |
| Alexandru-Abrams, D | 1 |
| Hsu, FP | 1 |
| Lemaire, L | 1 |
| Schmainda, KM | 1 |
| Prah, M | 1 |
| Hosein, AN | 1 |
| Lim, YC | 1 |
| Day, B | 1 |
| Stringer, B | 1 |
| Rose, S | 1 |
| Cosgrove, L | 1 |
| Martin, JH | 1 |
| Kästner, B | 1 |
| Sabel, MC | 2 |
| Homicsko, K | 3 |
| Pichler, J | 4 |
| Kollias, S | 1 |
| Hüsing, J | 1 |
| Chang-Halpenny, CN | 1 |
| Yeh, J | 1 |
| Lien, WW | 1 |
| Kim, HK | 1 |
| Lee, NH | 1 |
| Yi, HY | 1 |
| Hong, SH | 1 |
| Joe, YA | 1 |
| Curran, W | 3 |
| Yu, F | 2 |
| Gao, H | 2 |
| Lei, T | 2 |
| Sayari, AJ | 2 |
| Iaccarino, C | 1 |
| Orlandi, E | 1 |
| Ruggeri, F | 1 |
| Nicoli, D | 1 |
| Torricelli, F | 1 |
| Maggi, M | 1 |
| Cerasti, D | 1 |
| Pedrazzi, G | 1 |
| Froio, E | 1 |
| Crafa, P | 1 |
| Michiara, M | 2 |
| Ghadirpour, R | 1 |
| Servadei, F | 3 |
| Favero, F | 1 |
| McGranahan, N | 1 |
| Salm, M | 1 |
| Birkbak, NJ | 1 |
| Sanborn, JZ | 1 |
| Benz, SC | 1 |
| Becq, J | 1 |
| Peden, JF | 1 |
| Kingsbury, Z | 1 |
| Grocok, RJ | 1 |
| Humphray, S | 1 |
| Bentley, D | 1 |
| Spencer-Dene, B | 1 |
| Gutteridge, A | 1 |
| Roger, S | 1 |
| Forshew, T | 1 |
| Gerlinger, M | 1 |
| Rowan, A | 1 |
| Stamp, G | 1 |
| Eklund, AC | 1 |
| Szallasi, Z | 1 |
| Swanton, C | 1 |
| Hager, MO | 1 |
| Ouédraogo, ZG | 1 |
| Lemaire, JJ | 1 |
| Cominelli, M | 1 |
| Grisanti, S | 2 |
| Mazzoleni, S | 1 |
| Branca, C | 1 |
| Buttolo, L | 1 |
| Furlan, D | 1 |
| Liserre, B | 1 |
| Bonetti, MF | 1 |
| Medicina, D | 1 |
| Pellegrini, V | 1 |
| Liserre, R | 2 |
| Pellegatta, S | 1 |
| Dalerba, P | 1 |
| Facchetti, F | 1 |
| Pizzi, M | 1 |
| Poliani, PL | 1 |
| Clavreul, A | 1 |
| Daniel, PM | 1 |
| D'Abaco, GM | 1 |
| Gogos, A | 1 |
| Ng, W | 2 |
| Naz, A | 1 |
| Thompson, DH | 1 |
| Irudayaraj, J | 1 |
| Stephen, ZR | 2 |
| Kievit, FM | 1 |
| Chiu, DT | 1 |
| Press, OW | 1 |
| Mazurkiewicz, M | 1 |
| Salacz, M | 1 |
| Depenni, R | 2 |
| Pojo, M | 1 |
| Gonçalves, CS | 1 |
| Xavier-Magalhães, A | 1 |
| Oliveira, AI | 1 |
| Gonçalves, T | 1 |
| Correia, S | 1 |
| Rodrigues, AJ | 1 |
| Pinto, AA | 1 |
| Lopes, JM | 2 |
| Rocha, M | 1 |
| Lai, IC | 1 |
| Shih, PH | 1 |
| Yao, CJ | 1 |
| Wang-Peng, J | 1 |
| Lui, TN | 1 |
| Chuang, SE | 1 |
| Hu, TS | 1 |
| Lai, TY | 1 |
| Lai, GM | 1 |
| Tsuboi, A | 1 |
| Kagawa, N | 2 |
| Chiba, Y | 1 |
| Izumoto, S | 1 |
| Kijima, N | 1 |
| Oka, Y | 1 |
| Morimoto, S | 1 |
| Nakajima, H | 1 |
| Morita, S | 1 |
| Sakamoto, J | 1 |
| Nishida, S | 1 |
| Hosen, N | 1 |
| Oji, Y | 1 |
| Arita, N | 1 |
| Yoshimine, T | 2 |
| Sugiyama, H | 1 |
| Fontanella, MM | 1 |
| Spena, G | 1 |
| Poliani, LP | 1 |
| Gipponi, S | 1 |
| Spiazzi, L | 1 |
| Olmez, I | 1 |
| Shen, W | 1 |
| McDonald, H | 1 |
| Ozpolat, B | 1 |
| Goldwirt, L | 1 |
| Beccaria, K | 1 |
| Levasseur, C | 1 |
| Labussiere, M | 1 |
| Milane, A | 1 |
| Farinotti, R | 1 |
| Fernandez, C | 1 |
| Daofeng, T | 1 |
| Grieco, A | 1 |
| Tafuri, MA | 1 |
| Biolato, M | 1 |
| Diletto, B | 3 |
| Di Napoli, N | 1 |
| Balducci, N | 1 |
| Vecchio, FM | 1 |
| Miele, L | 1 |
| Zarnett, OJ | 1 |
| Gosio, J | 1 |
| Dong, F | 1 |
| Eibach, M | 1 |
| Dolga, AM | 1 |
| Schlomann, U | 1 |
| Schieber, S | 1 |
| Schilling, O | 1 |
| Biniossek, ML | 1 |
| Strik, H | 1 |
| Koller, G | 1 |
| Carl, B | 1 |
| Thomas, TA | 1 |
| Narayan, S | 1 |
| Bovi, JA | 1 |
| Curran, WP | 1 |
| Tanguturi, SK | 1 |
| Aizer, AA | 1 |
| Christianson, LW | 1 |
| Horvath, MC | 1 |
| Dunn, IF | 1 |
| Golby, AJ | 1 |
| Johnson, MD | 2 |
| Claus, EB | 1 |
| Rutledge, WC | 1 |
| Tchoghandjian, A | 1 |
| Denicolai, E | 2 |
| Boucard, C | 2 |
| Nanni, I | 2 |
| Padovani, L | 2 |
| Sesen, J | 2 |
| Dahan, P | 1 |
| Scotland, SJ | 2 |
| Saland, E | 1 |
| Dang, VT | 1 |
| Lemarié, A | 1 |
| Toulas, C | 1 |
| Sarry, JE | 1 |
| Skuli, N | 2 |
| Fei, X | 2 |
| Chong, DQ | 1 |
| Toh, XY | 1 |
| Ho, IA | 1 |
| Sia, KC | 1 |
| Newman, JP | 1 |
| Yulyana, Y | 1 |
| Lai, SH | 1 |
| Ho, MM | 1 |
| Dinesh, N | 1 |
| Lam, PY | 1 |
| Hao, S | 2 |
| Battaglia, L | 1 |
| Chirio, D | 1 |
| Melcarne, A | 2 |
| Ono, T | 1 |
| Sasajima, T | 1 |
| Doi, Y | 1 |
| Oka, S | 1 |
| Ono, M | 1 |
| Kanagawa, M | 1 |
| Baden, A | 1 |
| Mizoi, K | 1 |
| Rapkins, RW | 2 |
| Nguyen, HN | 1 |
| Hitchins, MP | 2 |
| Purow, BW | 1 |
| Ramkissoon, S | 1 |
| Weiss, SE | 3 |
| McCluskey, CS | 1 |
| Gerard, M | 2 |
| Smith, KH | 1 |
| Sadat, H | 1 |
| Damek, D | 4 |
| Santos, F | 1 |
| Panet-Raymond, V | 4 |
| Owen, S | 3 |
| Patyka, M | 1 |
| Shenouda, G | 3 |
| Ening, G | 1 |
| Osterheld, F | 1 |
| Capper, D | 1 |
| Schmieder, K | 3 |
| Brenke, C | 1 |
| Cattaneo, M | 1 |
| Storaci, AM | 1 |
| Cassoni, P | 2 |
| De Blasio, P | 1 |
| Biunno, I | 1 |
| Bryukhovetsky, A | 1 |
| Khotimchenko, Y | 1 |
| Mischenko, P | 1 |
| Tolok, E | 1 |
| Khotimchenko, R | 1 |
| Shao, H | 1 |
| Chung, J | 1 |
| Min, C | 1 |
| Breakefield, XO | 1 |
| Weissleder, R | 1 |
| Zhou, D | 1 |
| Mo, L | 1 |
| Xie, D | 1 |
| Xie, J | 2 |
| Rivoirard, R | 1 |
| Falk, AT | 1 |
| Chargari, C | 3 |
| Guy, JB | 1 |
| Mery, B | 1 |
| Nuti, C | 3 |
| Peoc'h, M | 3 |
| Forest, F | 3 |
| Garin, C | 1 |
| Adjabi, A | 1 |
| Hoarau, D | 1 |
| Kawaye, S | 1 |
| Almokhles, H | 1 |
| Fournel, P | 1 |
| Kim, T | 1 |
| Joo, JD | 2 |
| Yun, CH | 1 |
| D'Alimonte, I | 1 |
| Nargi, E | 1 |
| Zuccarini, M | 1 |
| Lanuti, P | 1 |
| Di Iorio, P | 1 |
| Giuliani, P | 1 |
| Caciagli, F | 1 |
| Ciccarelli, R | 1 |
| Fourniols, T | 1 |
| Randolph, LD | 1 |
| Staub, A | 1 |
| Vanvarenberg, K | 1 |
| Leprince, JG | 1 |
| des Rieux, A | 1 |
| Lan, F | 3 |
| Pan, Q | 1 |
| Yue, X | 3 |
| Kovic, B | 1 |
| Xie, F | 1 |
| Theodore-Oklota, C | 1 |
| Ravelo, A | 1 |
| Tieu, MT | 1 |
| Lovblom, LE | 1 |
| Kiehl, TR | 1 |
| Perkins, BA | 1 |
| Knippen, S | 1 |
| Lahmer, G | 1 |
| Semrau, S | 1 |
| Rösche, J | 1 |
| Piek, J | 1 |
| Hildebrandt, G | 2 |
| Grossmann, A | 1 |
| Kirschstein, T | 1 |
| Benecke, R | 1 |
| McFaline-Figueroa, JL | 1 |
| Braun, CJ | 1 |
| Stanciu, M | 1 |
| Nagel, ZD | 2 |
| Mazzucato, P | 2 |
| Sangaraju, D | 1 |
| Cerniauskas, E | 1 |
| Barford, K | 1 |
| Vargas, A | 1 |
| Tretyakova, N | 1 |
| Lees, JA | 1 |
| Hemann, MT | 1 |
| White, FM | 1 |
| Samson, LD | 2 |
| Miller, E | 1 |
| McSherry, F | 1 |
| Belda-Iniesta, C | 1 |
| Capellades, J | 3 |
| Ordoñez, JM | 1 |
| La Orden, B | 1 |
| Cabrini, G | 1 |
| Fabbri, E | 1 |
| Lo Nigro, C | 1 |
| Dechecchi, MC | 1 |
| Gambari, R | 1 |
| Krossa, S | 1 |
| Schmitt, AD | 1 |
| Fritsch, J | 1 |
| Scheidig, AJ | 1 |
| Lewis, S | 1 |
| Churi, S | 1 |
| Padmavati, A | 1 |
| Jalali, R | 4 |
| Stegen, B | 1 |
| Butz, L | 1 |
| Dittmann, K | 1 |
| Ruth, P | 1 |
| Guo, A | 2 |
| Qu, X | 2 |
| Tian, T | 2 |
| Welzel, G | 1 |
| Gehweiler, J | 1 |
| Appelt, JU | 1 |
| Seiz-Rosenhagen, M | 1 |
| Januel, E | 1 |
| Ursu, R | 1 |
| Alkhafaji, A | 1 |
| Marantidou, A | 1 |
| Doridam, J | 1 |
| Belin, C | 1 |
| Levy-Piedbois, C | 1 |
| Shen, Y | 1 |
| Steed, T | 1 |
| Treiber, JM | 1 |
| Taich, Z | 1 |
| Stevens, D | 1 |
| Wykosky, J | 1 |
| Chen, HZ | 1 |
| Becher, OJ | 1 |
| Kennedy, R | 1 |
| Esashi, F | 1 |
| Desai, A | 1 |
| Trouve, C | 1 |
| Le Meunier, F | 1 |
| Solomalalarivelo, F | 1 |
| Delentaigne Delogivieres, X | 1 |
| Drouard, M | 1 |
| Suguenot, R | 1 |
| Lecuyer, E | 1 |
| Bentayeb, H | 1 |
| Rault, I | 1 |
| Douadi, Y | 1 |
| Dayen, C | 1 |
| Yan, C | 1 |
| Pramanik, PP | 1 |
| Parmar, HA | 1 |
| Junck, LR | 1 |
| Kim, MS | 1 |
| Langley, RR | 1 |
| Lehembre, F | 1 |
| Regenass, U | 1 |
| Fidler, IJ | 1 |
| Atif, F | 1 |
| Patel, NR | 1 |
| Yousuf, S | 1 |
| Stein, DG | 1 |
| Barault, L | 1 |
| Amatu, A | 1 |
| Bleeker, FE | 1 |
| Moutinho, C | 1 |
| Falcomatà, C | 1 |
| Fiano, V | 1 |
| Cassingena, A | 1 |
| Siravegna, G | 1 |
| Milione, M | 1 |
| De Braud, F | 1 |
| Venesio, T | 1 |
| Bardelli, A | 1 |
| de Witt Hamer, P | 1 |
| Pietrantonio, F | 1 |
| Siena, S | 1 |
| Esteller, M | 1 |
| Sartore-Bianchi, A | 1 |
| Di Nicolantonio, F | 1 |
| Rosenthal, MA | 5 |
| Dally, M | 1 |
| Drummond, K | 1 |
| Murphy, M | 1 |
| Thursfield, V | 1 |
| Ströbele, S | 1 |
| Schneele, L | 1 |
| Karpel-Massle, G | 1 |
| Bourgon, R | 1 |
| Moore, N | 2 |
| Kharbanda, S | 1 |
| Peale, F | 1 |
| Hegde, P | 1 |
| Phillips, HS | 1 |
| Bais, C | 1 |
| Zhitao, J | 1 |
| Long, L | 1 |
| Jia, L | 1 |
| Yunchao, B | 1 |
| Anhua, W | 1 |
| Raub, TJ | 1 |
| Wishart, GN | 1 |
| Kulanthaivel, P | 1 |
| Staton, BA | 1 |
| Ajamie, RT | 1 |
| Sawada, GA | 1 |
| Gelbert, LM | 2 |
| Sanchez-Martinez, C | 1 |
| De Dios, A | 1 |
| Yahyanejad, S | 2 |
| van Hoof, SJ | 2 |
| Theys, J | 2 |
| Barbeau, LM | 2 |
| Granton, PV | 2 |
| Paesmans, K | 1 |
| Verhaegen, F | 2 |
| Vooijs, M | 2 |
| Moukhlissi, M | 1 |
| Naciri, F | 1 |
| Aalberti, S | 1 |
| Grillea, G | 1 |
| Madonna, M | 1 |
| Bartolo, M | 1 |
| Pavone, L | 1 |
| Cantore, G | 1 |
| Frati, A | 3 |
| Myrehaug, SD | 1 |
| Chang, MG | 1 |
| Holdford, DJ | 1 |
| Tofilon, PJ | 4 |
| Mao, G | 2 |
| Du, J | 1 |
| Walker, ND | 1 |
| Prust, MJ | 1 |
| Jafari-Khouzani, K | 1 |
| Bernhardt, D | 2 |
| Farace, C | 1 |
| Oliver, JA | 2 |
| Melguizo, C | 3 |
| Alvarez, P | 1 |
| Bandiera, P | 1 |
| Rama, AR | 1 |
| Malaguarnera, G | 1 |
| Madeddu, R | 2 |
| Prados, J | 3 |
| Chen, YD | 1 |
| Wang, ZF | 1 |
| Burger, P | 1 |
| Soudry, E | 1 |
| Gallia, GL | 1 |
| Sidransky, D | 1 |
| Hu, M | 1 |
| Xia, T | 1 |
| Arevalo-Perez, J | 1 |
| Kaley, T | 1 |
| Lyo, J | 1 |
| Peck, KK | 1 |
| Tai, P | 1 |
| Dubey, A | 2 |
| Salim, M | 1 |
| Vu, K | 1 |
| Koul, R | 1 |
| Zhou, RJ | 1 |
| Xu, XY | 1 |
| Liu, BX | 1 |
| Dai, WZ | 1 |
| Cai, MQ | 1 |
| Bai, CF | 1 |
| Zhang, XF | 1 |
| Wang, LM | 1 |
| Jia, SZ | 1 |
| Wang, WH | 1 |
| Poitras, JJ | 1 |
| DeMarco, J | 1 |
| Syu, JP | 1 |
| Huang, LJ | 1 |
| Kuo, SC | 1 |
| Lin, CT | 1 |
| Ben Harrabi, S | 1 |
| Mohr, A | 1 |
| Koelsche, C | 1 |
| Diehl, C | 1 |
| Rieken, S | 3 |
| Lee, IH | 3 |
| Jung, YS | 1 |
| Nam, SH | 1 |
| Park, PJ | 1 |
| Marschall, V | 2 |
| Tan, J | 1 |
| Meise, R | 1 |
| Aasland, D | 1 |
| Berte, N | 2 |
| Kitzinger, R | 1 |
| Krämer, OH | 1 |
| Alshami, J | 1 |
| Gibson, N | 1 |
| Solca, F | 1 |
| Muanza, T | 2 |
| Faedi, M | 3 |
| Anghileri, E | 1 |
| Nicolotto, E | 1 |
| Bazzoli, E | 1 |
| Villani, V | 1 |
| Fabi, A | 3 |
| Dall'Agata, M | 1 |
| D'Avella, D | 1 |
| Tai, L | 1 |
| Xie, C | 3 |
| Lu, L | 1 |
| Xie, G | 1 |
| Parrish, KE | 1 |
| Murray, J | 1 |
| Sludden, J | 1 |
| Boddy, AV | 1 |
| Curtin, NJ | 2 |
| Wang, TJ | 1 |
| Jani, A | 1 |
| Estrada, JP | 1 |
| Ung, TH | 1 |
| Chow, DS | 1 |
| Soun, JE | 1 |
| Saad, S | 1 |
| Qureshi, YH | 1 |
| Gartrell, R | 1 |
| Isaacson, SR | 1 |
| Cheng, SK | 1 |
| McKhann, GM | 1 |
| Bruce, JN | 1 |
| Perazzoli, G | 2 |
| Caba, O | 1 |
| Cabeza, L | 1 |
| Berdasco, M | 1 |
| Gónzalez, B | 2 |
| Bulik, M | 1 |
| Kazda, T | 1 |
| Slampa, P | 1 |
| Jancalek, R | 1 |
| Luo, H | 2 |
| Qiu, W | 2 |
| Peng, C | 2 |
| Wang, HW | 2 |
| Ahmed, KA | 1 |
| Fulp, WJ | 1 |
| Eschrich, S | 1 |
| Torres-Roca, JF | 1 |
| Caudell, JJ | 1 |
| Babu, R | 1 |
| Komisarow, JM | 1 |
| Agarwal, VJ | 1 |
| Rahimpour, S | 1 |
| Iyer, A | 1 |
| Britt, D | 1 |
| Karikari, IO | 1 |
| Grossi, PM | 1 |
| Thomas, S | 2 |
| Adamson, C | 1 |
| Neagu, MR | 1 |
| Loghin, M | 1 |
| Paleologos, N | 1 |
| Rademaker, A | 2 |
| Vaillant, B | 1 |
| Rudnick, J | 2 |
| Chamberlain, M | 2 |
| Vick, N | 1 |
| Zhang, LW | 1 |
| Lu, YC | 1 |
| Zhang, JM | 1 |
| Wang, RZ | 1 |
| Wang, JS | 1 |
| Yang, QY | 2 |
| Ma, WB | 1 |
| Zhen, HN | 1 |
| Zhou, LF | 1 |
| Ellsworth, S | 1 |
| Faure, G | 1 |
| Quetin, P | 2 |
| Carnin, C | 1 |
| Pedeux, R | 1 |
| Ritner, C | 1 |
| Zhu, N | 1 |
| An, Z | 1 |
| Trotti, AM | 1 |
| Mohile, N | 2 |
| Cavaliere, R | 1 |
| Chmura, SJ | 1 |
| Motaln, H | 1 |
| Koren, A | 1 |
| Gruden, K | 1 |
| Ramšak, Ž | 1 |
| Schichor, C | 1 |
| Lah, TT | 1 |
| Godoy, PR | 1 |
| Shelton, BJ | 1 |
| Shearer, AJ | 1 |
| Sun, DA | 1 |
| Parsons, S | 1 |
| Bourne, TD | 1 |
| LaRocca, R | 2 |
| Wehbe, M | 1 |
| Strutt, D | 1 |
| Masin, D | 1 |
| Anantha, M | 1 |
| Walker, D | 1 |
| Chu, F | 1 |
| Backstrom, I | 1 |
| Kalra, J | 1 |
| Waterhouse, D | 1 |
| Yapp, DT | 1 |
| Bally, MB | 1 |
| Benedetti, E | 1 |
| Antonosante, A | 1 |
| d'Angelo, M | 1 |
| Cristiano, L | 1 |
| Galzio, R | 1 |
| Destouches, D | 1 |
| Florio, TM | 1 |
| Dhez, AC | 1 |
| Astarita, C | 1 |
| Fidoamore, A | 1 |
| Rosati, F | 1 |
| Ippoliti, R | 1 |
| Courty, J | 1 |
| Cimini, A | 1 |
| Murphy, SF | 1 |
| Varghese, RT | 1 |
| Lamouille, S | 1 |
| Pridham, KJ | 1 |
| Kanabur, P | 1 |
| Osimani, AM | 1 |
| Jourdan, J | 1 |
| Rodgers, CM | 1 |
| Simonds, GR | 1 |
| Hong, I | 1 |
| Bui, Y | 1 |
| Stream, A | 1 |
| McBride, WH | 1 |
| Ananta, JS | 3 |
| Carra, E | 1 |
| Barbieri, F | 1 |
| Würth, R | 1 |
| Parodi, F | 1 |
| Pattarozzi, A | 1 |
| Carosio, R | 1 |
| Florio, T | 1 |
| Chakrabarti, M | 1 |
| Martínez-Sales, V | 1 |
| Vila, V | 1 |
| Palomero, I | 1 |
| Fleitas, T | 1 |
| Reche, E | 1 |
| Glantz, M | 2 |
| Hernández-Durán, S | 1 |
| Hanft, S | 1 |
| Manzano, GR | 1 |
| Ramiro, S | 1 |
| Lladó, S | 1 |
| Toro, S | 1 |
| Coveñas, R | 1 |
| Arita, H | 2 |
| Yonezawa, M | 1 |
| Fukushima, S | 2 |
| Takami, H | 2 |
| Reid, JM | 1 |
| Poon, MW | 2 |
| Zhuang, JT | 2 |
| Zhuang, Y | 1 |
| Tivnan, A | 1 |
| Flanagan, L | 1 |
| Murray, DW | 1 |
| Boyd, AW | 1 |
| O'Brien, DF | 1 |
| Steinberg, DM | 1 |
| Barnett, GH | 2 |
| Henson, JW | 3 |
| Engelhard, HH | 1 |
| Tran, ND | 1 |
| Landolfi, J | 1 |
| Ortega, A | 1 |
| Sarmiento, JM | 1 |
| Ly, D | 1 |
| Nuño, M | 4 |
| Mukherjee, D | 4 |
| Black, KL | 4 |
| Yazici, G | 1 |
| Zorlu, F | 1 |
| Cengiz, M | 1 |
| Ozyigit, G | 1 |
| Eren, G | 1 |
| Yüce, D | 1 |
| Varan, A | 1 |
| Akyuz, C | 1 |
| Akalan, N | 1 |
| Gurkaynak, M | 1 |
| Shen, M | 2 |
| Gao, P | 1 |
| Duan, Y | 2 |
| Younis, SG | 1 |
| Khedr, RA | 1 |
| El-Shorbagy, SH | 1 |
| Cho, K | 1 |
| Hou, X | 1 |
| Peng, F | 1 |
| Shen, C | 1 |
| Xu, HU | 1 |
| Bihari, F | 1 |
| Whitehead, S | 1 |
| Wong, E | 1 |
| Schmid, S | 1 |
| Hebb, MO | 1 |
| Mendez, JS | 1 |
| Govindan, A | 1 |
| Leong, J | 1 |
| Paubel, N | 1 |
| Hartmann, D | 1 |
| Saraswathula, A | 1 |
| Norberg, PK | 1 |
| Healy, P | 1 |
| Congdon, KL | 2 |
| Ensign, SP | 1 |
| Mathews, IT | 2 |
| Symons, MH | 1 |
| Cho, YJ | 1 |
| Paddison, PJ | 1 |
| Hwang, YI | 1 |
| Hegi, M | 3 |
| Dhar, S | 1 |
| Pozzi, E | 1 |
| Schmid, RS | 1 |
| Simon, JM | 3 |
| Vitucci, M | 1 |
| McNeill, RS | 1 |
| Bash, RE | 1 |
| Werneke, AM | 1 |
| Huey, L | 1 |
| White, KK | 1 |
| Redjal, N | 1 |
| Reinshagen, C | 1 |
| Le, A | 1 |
| Walcott, BP | 1 |
| McDonnell, E | 1 |
| Nahed, BV | 2 |
| Qian, L | 1 |
| O'Leary, B | 1 |
| Mandeville, HC | 1 |
| Fersht, N | 1 |
| Solda, F | 1 |
| Mycroft, J | 1 |
| Zacharoulis, S | 1 |
| Vaidya, S | 1 |
| Balakrishnan, A | 1 |
| Ledford, R | 1 |
| Jaglal, M | 1 |
| Gil-Gil, MJ | 1 |
| Vieitez, JM | 1 |
| Garcia, A | 1 |
| Vazquez-Estevez, S | 1 |
| Fernandez, I | 1 |
| De la Cruz, JJ | 1 |
| Giner, P | 1 |
| Qu, J | 2 |
| Cheng, S | 1 |
| Leung, K | 1 |
| Akgoz, A | 1 |
| Seethamraju, R | 1 |
| Ai, L | 1 |
| Young, GS | 1 |
| Xia, L | 1 |
| Arrizabalaga, O | 1 |
| Moncho-Amor, V | 1 |
| Carrasco-Garcia, E | 1 |
| Manterola, L | 1 |
| Moreno-Cugnon, L | 1 |
| Barrena, C | 1 |
| Pollard, S | 1 |
| Lovell-Badge, R | 1 |
| Kristensen, LS | 1 |
| Dyrbye, H | 1 |
| Aslan, D | 1 |
| Grønbæk, K | 1 |
| Radoul, M | 1 |
| Eriksson, P | 1 |
| Wang, AS | 1 |
| Berglund, A | 1 |
| Kenchappa, RS | 1 |
| Forsyth, PA | 2 |
| Koukourakis, MI | 1 |
| Mitrakas, AG | 1 |
| Paul-Samojedny, M | 1 |
| Pudełko, A | 1 |
| Kowalczyk, M | 1 |
| Fila-Daniłow, A | 1 |
| Suchanek-Raif, R | 1 |
| Borkowska, P | 1 |
| Kowalski, J | 1 |
| McCowatt, S | 1 |
| Kerestes, Z | 1 |
| Buyse, ME | 1 |
| Ackland, S | 1 |
| Lemasson, B | 2 |
| Galbán, S | 2 |
| Heist, KA | 2 |
| Tsein, C | 1 |
| Chenevert, TL | 2 |
| Galbán, CJ | 2 |
| Ross, BD | 3 |
| Parker, NR | 1 |
| Khong, P | 1 |
| Parkinson, JF | 2 |
| Dwight, T | 1 |
| Ikin, RJ | 1 |
| Cheng, ZJ | 1 |
| Vafaee, F | 1 |
| Ermani, M | 12 |
| Sturiale, C | 3 |
| Pavesi, G | 1 |
| Urbini, B | 1 |
| Crisi, G | 1 |
| Cavallo, MA | 1 |
| Dazzi, C | 1 |
| Biasini, C | 1 |
| Bertolini, F | 1 |
| Mucciarini, C | 1 |
| Pasini, G | 1 |
| Baruzzi, A | 1 |
| Xipell, E | 1 |
| Aragón, T | 1 |
| Martínez-Velez, N | 1 |
| Vera, B | 1 |
| Martínez-Irujo, JJ | 1 |
| Garzón, AG | 1 |
| Gonzalez-Huarriz, M | 1 |
| Acanda, AM | 1 |
| Fueyo, J | 1 |
| Gomez-Manzano, C | 1 |
| Teng, Y | 1 |
| Pokorny, JC | 1 |
| Nair, AA | 1 |
| Ferguson, SD | 1 |
| Srinivasan, VM | 1 |
| Ghali, MG | 1 |
| Tüttenberg, J | 2 |
| Kohnen, R | 1 |
| Dunkl, E | 1 |
| Proske, J | 1 |
| Walter, L | 1 |
| Bumes, E | 1 |
| Hutterer, M | 1 |
| Eyüpoglu, IY | 1 |
| Savaskan, NE | 1 |
| Jiang, P | 1 |
| Pellerino, A | 1 |
| Knisely, JP | 1 |
| Butta, V | 1 |
| Cilibrasi, C | 1 |
| Baronchelli, S | 1 |
| Redaelli, S | 1 |
| Dalprà, L | 1 |
| Lavitrano, M | 1 |
| Bentivegna, A | 1 |
| Miller, K | 1 |
| Dixit, S | 4 |
| Bredlau, AL | 1 |
| McKinnon, E | 1 |
| Broome, AM | 1 |
| Lun, X | 1 |
| Wells, JC | 1 |
| Grinshtein, N | 1 |
| King, JC | 1 |
| Dang, NH | 1 |
| Uehling, D | 1 |
| Datti, A | 1 |
| Wrana, JL | 1 |
| Luchman, A | 1 |
| Kaplan, DR | 1 |
| Gorospe Sarasúa, L | 1 |
| Ureña-Vacas, A | 1 |
| Muñoz Del Toro, JR | 1 |
| Ma, P | 1 |
| Mitteer, RA | 1 |
| Kim, HJ | 1 |
| Cai, P | 1 |
| Roccograndi, L | 1 |
| Dahmane, N | 1 |
| Raj, S | 1 |
| Pandit, PN | 1 |
| Kishor, K | 1 |
| Seystahl, K | 1 |
| Ciezka, M | 1 |
| Olier, I | 1 |
| Fernández, F | 1 |
| Lisboa, PJ | 1 |
| Chawla, S | 1 |
| Verma, G | 1 |
| Skolnik, A | 1 |
| Ohtsu, N | 1 |
| Echizenya, S | 1 |
| Otsuguro, S | 1 |
| Ogura, R | 1 |
| Isogawa, M | 1 |
| Aoki, H | 3 |
| Ichikawa, S | 1 |
| Sakaitani, M | 1 |
| Matsuda, A | 1 |
| Maenaka, K | 1 |
| Li, KC | 1 |
| Chan, MD | 2 |
| Paulsson, A | 1 |
| Mirjolet, C | 1 |
| Mazoyer, F | 1 |
| Blanchard, N | 1 |
| Lagneau, É | 1 |
| Maingon, P | 1 |
| Drachsler, M | 1 |
| Kleber, S | 1 |
| Mateos, A | 1 |
| Volk, K | 1 |
| Mohr, N | 1 |
| Cirovic, B | 1 |
| Gieffers, C | 1 |
| Sykora, J | 1 |
| Martin-Villalba, A | 1 |
| Garcia, L | 1 |
| Gruslova, A | 1 |
| Cavazos, D | 1 |
| Garcia, M | 1 |
| Strom, AM | 1 |
| Gustafsson, JA | 1 |
| Vandraas, K | 1 |
| Tjønnfjord, GE | 1 |
| Johannesen, TB | 2 |
| Stetson, LC | 1 |
| Dazard, JE | 1 |
| Steuve, J | 1 |
| Hamou, MF | 4 |
| Kosch, M | 1 |
| Ricard, D | 1 |
| Safari, M | 1 |
| Bailey, BJ | 1 |
| Reza Saadatzadeh, M | 1 |
| Tonsing-Carter, E | 1 |
| Georgiadis, TM | 1 |
| Zachary Gunter, T | 1 |
| Long, EC | 1 |
| Minto, RE | 1 |
| Gordon, KR | 1 |
| Sen, SE | 1 |
| Cai, W | 1 |
| Eitel, JA | 1 |
| Waning, DL | 1 |
| Bringman, LR | 1 |
| Wells, CD | 1 |
| Murray, ME | 1 |
| Jones, DR | 2 |
| Cohen-Gadol, AA | 1 |
| Mayo, LD | 2 |
| Lai, X | 1 |
| King, H | 1 |
| Iglesias, VS | 1 |
| Groot, AJ | 1 |
| Habets, R | 1 |
| Prickaerts, J | 1 |
| Eekers, DB | 1 |
| Florange, J | 1 |
| Badakhshi, H | 1 |
| Grün, A | 1 |
| Ghadjar, P | 1 |
| Exner, S | 1 |
| Budach, V | 1 |
| Rusthoven, CG | 1 |
| Koshy, M | 1 |
| Sher, DJ | 2 |
| Jones, BL | 1 |
| Karam, SD | 1 |
| Youssef, AS | 1 |
| Paquette, B | 1 |
| Vernerey, D | 1 |
| Dabakuyo, S | 1 |
| Anota, A | 1 |
| Stavrovskaya, AA | 2 |
| Shushanov, SS | 1 |
| Rybalkina, EY | 2 |
| Hu, P | 1 |
| Tang, F | 1 |
| Lian, H | 1 |
| Cazzato, E | 1 |
| Ladewig, E | 1 |
| Frattini, V | 1 |
| Rosenbloom, DI | 1 |
| Zairis, S | 1 |
| Abate, F | 1 |
| Elliott, O | 1 |
| Shin, YJ | 1 |
| Lee, JK | 1 |
| Blumberg, AJ | 1 |
| Lasorella, A | 1 |
| Weatherbee, JL | 1 |
| Kraus, JL | 1 |
| Chandler, JP | 1 |
| Ferrarese, R | 1 |
| Levy, RM | 1 |
| Muro, K | 1 |
| Rosenow, J | 1 |
| Helenowski, I | 1 |
| Paton, M | 1 |
| Moiseeva, NI | 1 |
| Susova, OY | 1 |
| Mitrofanov, AA | 1 |
| Panteleev, DY | 1 |
| Pavlova, GV | 1 |
| Pustogarov, NA | 1 |
| Matsumura, N | 1 |
| Nakajima, N | 1 |
| Yamazaki, T | 1 |
| Nagano, T | 1 |
| Kagoshima, K | 1 |
| Nobusawa, S | 1 |
| Ikota, H | 1 |
| Jalota, A | 1 |
| Kumar, M | 1 |
| Yadav, AK | 1 |
| Chosdol, K | 1 |
| Sinha, S | 1 |
| Bracci, S | 1 |
| Hitchcock, K | 1 |
| Duran-Peña, A | 1 |
| Navarro, S | 1 |
| Chevalier, A | 1 |
| Jacob, J | 1 |
| Troussier, I | 1 |
| Mazeron, JJ | 3 |
| Ignarro, RS | 1 |
| Facchini, G | 1 |
| Vieira, AS | 1 |
| De Melo, DR | 1 |
| Lopes-Cendes, I | 1 |
| Castilho, RF | 1 |
| Rogerio, F | 1 |
| Todorova, PK | 1 |
| Hoa, NT | 1 |
| Ge, L | 1 |
| Martini, F | 1 |
| Chau, V | 1 |
| Ahluwalia, A | 1 |
| Kruse, CA | 1 |
| Jadus, MR | 1 |
| Barone, TA | 1 |
| Burkhart, CA | 1 |
| Safina, A | 1 |
| Haderski, G | 1 |
| Gurova, KV | 1 |
| Purmal, AA | 1 |
| Gudkov, AV | 1 |
| Plunkett, RJ | 1 |
| Feng, W | 1 |
| Cho, YH | 1 |
| Yoon, SM | 1 |
| Jung, TY | 4 |
| Lee, KH | 3 |
| Yoo, H | 1 |
| Kang, SH | 2 |
| Kang, MK | 1 |
| Kim, EY | 1 |
| Chung, DS | 1 |
| Hwang, SC | 1 |
| Song, JH | 1 |
| Cho, SJ | 1 |
| Lee, SI | 1 |
| Gwak, HS | 1 |
| Berenguer-Daizé, C | 1 |
| Astorgues-Xerri, L | 1 |
| Odore, E | 1 |
| Cayol, M | 1 |
| Cvitkovic, E | 1 |
| Noel, K | 1 |
| Bekradda, M | 1 |
| MacKenzie, S | 1 |
| Rezai, K | 1 |
| Lokiec, F | 1 |
| Riveiro, ME | 1 |
| Choi, E | 1 |
| Tan, X | 1 |
| Oh, J | 2 |
| Rhim, T | 1 |
| Hertenstein, A | 2 |
| Hielscher, T | 1 |
| Menn, O | 1 |
| Lemke, D | 1 |
| Pledl, HW | 1 |
| Zorn, M | 1 |
| Jugold, M | 1 |
| Green, E | 1 |
| Blaes, J | 1 |
| Löw, S | 1 |
| Ott, M | 1 |
| Steffen, AC | 1 |
| Weiler, M | 3 |
| Belmonte, G | 1 |
| Kim, SK | 4 |
| Heo, DS | 4 |
| Kim, DG | 5 |
| Jung, HW | 5 |
| Lorimer, CF | 1 |
| Brock, J | 1 |
| Bielecka, AM | 1 |
| Song, G | 1 |
| Colamaio, M | 1 |
| Tosti, N | 1 |
| Puca, F | 1 |
| Mari, A | 1 |
| Gattordo, R | 1 |
| Kuzay, Y | 1 |
| Federico, A | 1 |
| Pepe, A | 1 |
| Sarnataro, D | 1 |
| Ragozzino, E | 1 |
| Raia, M | 1 |
| Hirata, H | 1 |
| Gemei, M | 1 |
| Mimori, K | 1 |
| Del Vecchio, L | 1 |
| Battista, S | 1 |
| Diesler, K | 1 |
| Majhen, D | 1 |
| Steigerwald, C | 1 |
| Freund, H | 1 |
| Stojanović, N | 1 |
| Osmak, M | 1 |
| Ambriović-Ristov, A | 1 |
| Weyhenmeyer, BC | 1 |
| Noonan, J | 1 |
| Würstle, ML | 1 |
| Lincoln, FA | 1 |
| Johnston, G | 1 |
| Yamasaki, K | 1 |
| Nakamura, T | 1 |
| Shimokawa, A | 1 |
| Shirahata, M | 1 |
| Shimizu, S | 3 |
| Suzuki, K | 3 |
| Uzuka, T | 1 |
| Otani, R | 1 |
| Tamura, K | 1 |
| Sumita, K | 1 |
| Shinojima, N | 2 |
| Okita, Y | 1 |
| Ishibashi, K | 1 |
| Shofuda, T | 1 |
| Kodama, Y | 1 |
| Tomogane, Y | 1 |
| Fukai, J | 1 |
| Fujita, K | 1 |
| Terakawa, Y | 1 |
| Tsuyuguchi, N | 1 |
| Moriuchi, S | 1 |
| Nonaka, M | 1 |
| Suzuki, H | 1 |
| Shibuya, M | 1 |
| Maehara, T | 1 |
| Kawahara, N | 1 |
| Ueki, K | 1 |
| Miyaoka, E | 1 |
| Cho, BJ | 1 |
| Choi, EJ | 1 |
| Song, SH | 1 |
| Kerloeguen, Y | 1 |
| Mizumoto, M | 1 |
| Ishikawa, H | 1 |
| Okumura, T | 1 |
| Olson, M | 2 |
| Crane, JC | 1 |
| Molinaro, A | 2 |
| Roy, R | 2 |
| Cha, S | 5 |
| Joly, MO | 1 |
| Carpentier, C | 1 |
| Rivet, P | 1 |
| Entz-Werle, N | 2 |
| Zalcman, EL | 1 |
| Levallet, G | 2 |
| Escande, F | 1 |
| Ramirez, C | 3 |
| Chiforeanu, D | 1 |
| Hoja, S | 1 |
| Schulze, M | 1 |
| Rehli, M | 1 |
| Toren, A | 1 |
| Pismenyuk, T | 1 |
| Yalon, M | 1 |
| Freedman, S | 1 |
| Simon, AJ | 1 |
| Fisher, T | 1 |
| Moshe, I | 1 |
| Reichardt, JK | 1 |
| Constantini, S | 1 |
| Daniels, D | 1 |
| Assoulin, M | 1 |
| Mehrian-Shai, R | 1 |
| Smith, KA | 1 |
| Wilson, TJ | 1 |
| Zamler, DB | 1 |
| Doherty, R | 1 |
| Kadambi, AK | 1 |
| Koh, I | 1 |
| Jeon, JY | 1 |
| Yun, M | 1 |
| Huh, YM | 1 |
| Lee, SJ | 3 |
| Pollak, M | 1 |
| Kim, P | 1 |
| Cheong, JH | 1 |
| Vartanian, A | 1 |
| Wilson, MR | 1 |
| Burrell, KE | 1 |
| Tonge, PD | 1 |
| Alamsahebpour, A | 1 |
| Jalali, S | 1 |
| Taccone, MS | 1 |
| Mansouri, S | 1 |
| Gao, YT | 1 |
| Chen, XB | 1 |
| Trusheim, J | 1 |
| Dunbar, E | 1 |
| Battiste, J | 1 |
| Connelly, J | 1 |
| Shah, BK | 1 |
| Bista, A | 1 |
| Li, QZ | 2 |
| Chen, BD | 2 |
| Zhang, XJ | 2 |
| Terasaki, K | 1 |
| Tomabechi, M | 1 |
| Kato, K | 1 |
| Sasaki, M | 1 |
| Ogasawara, K | 2 |
| Polewski, MD | 1 |
| Reveron-Thornton, RF | 1 |
| Cherryholmes, GA | 1 |
| Marinov, GK | 1 |
| Cassady, K | 1 |
| Dalsin, E | 1 |
| Onzi, GR | 1 |
| Homma, S | 1 |
| Koido, S | 1 |
| Ohkusa, T | 1 |
| Tasaki, T | 1 |
| Hayashi, K | 2 |
| Komita, H | 1 |
| Watanabe, N | 1 |
| Mori, R | 1 |
| Arai, T | 1 |
| Joki, T | 1 |
| Yanagisawa, T | 1 |
| Koh, YC | 1 |
| Chung, YG | 1 |
| Kim, JM | 1 |
| Kim, CH | 1 |
| Ikawa, F | 1 |
| Ishifuro, M | 1 |
| Nishibuchi, I | 1 |
| Amiri, A | 1 |
| Machkalyan, G | 1 |
| Gillard, JW | 1 |
| Yoganathan, N | 1 |
| Hartmann, R | 1 |
| Schröter, F | 1 |
| Suwala, AK | 1 |
| Krüger, AC | 1 |
| Willbold, D | 1 |
| He, P | 1 |
| Yue, J | 1 |
| Boop, FA | 1 |
| Pfeffer, SR | 1 |
| da Fonseca, AC | 1 |
| Amaral, R | 1 |
| Garcia, C | 2 |
| Geraldo, LH | 2 |
| Lima, FR | 2 |
| Cisneros Castillo, LR | 1 |
| Oancea, AD | 1 |
| Stüllein, C | 1 |
| Zha, Y | 1 |
| Vaios, EJ | 1 |
| Fathi, AT | 1 |
| Ohba, S | 1 |
| Hirose, Y | 5 |
| Cefalu, M | 1 |
| Zigler, C | 1 |
| Schrag, D | 1 |
| Dominici, F | 1 |
| He, XY | 1 |
| Feng, XL | 1 |
| Song, XP | 1 |
| Zeng, HC | 1 |
| Cao, ZX | 1 |
| Xiao, WW | 1 |
| Wu, QH | 1 |
| Mingyi, M | 1 |
| Joughin, BA | 1 |
| Chaim, IA | 1 |
| Lauffenburger, DA | 1 |
| Fassina, L | 1 |
| Mognaschi, ME | 1 |
| Lupo, G | 1 |
| Corbella, F | 2 |
| Kim, BR | 1 |
| Park, SW | 1 |
| Gaal, JT | 1 |
| Strebe, JK | 1 |
| Pasch, CA | 1 |
| Deming, DA | 1 |
| Sahuc, P | 1 |
| Nguyen, AT | 1 |
| Fouet, B | 1 |
| Wybrecht, D | 1 |
| Faivre, A | 1 |
| Alla, P | 1 |
| Dagain, A | 1 |
| Ikeda, T | 1 |
| Suzuki, J | 1 |
| Norizuki, M | 1 |
| Okabe, T | 1 |
| Sasahara, T | 1 |
| Toshima, M | 1 |
| Yokota, H | 1 |
| Hatakeyama, S | 1 |
| Morisawa, Y | 1 |
| Ismaila, N | 1 |
| Lovely, M | 1 |
| Mumber, MP | 1 |
| Thorsteinsdottir, J | 1 |
| Lutz, J | 2 |
| Kreth, S | 3 |
| Gebhart, RN | 1 |
| Jeon, M | 1 |
| Blair, AA | 1 |
| Ellenbogen, RG | 1 |
| Silber, JR | 4 |
| Casaos, J | 1 |
| Frikeche, J | 1 |
| Lott, T | 1 |
| Felder, R | 1 |
| Eisinger-Mathason, TSK | 1 |
| Fisher, JL | 3 |
| Hampton, TH | 3 |
| Christensen, BC | 1 |
| Tsongalis, GJ | 1 |
| Rahme, GJ | 1 |
| Whipple, CA | 1 |
| Steel, SE | 1 |
| Davis, MC | 1 |
| Gaur, AB | 1 |
| Lewis, LD | 2 |
| Ernstoff, MS | 3 |
| Afghani, N | 1 |
| Mehta, T | 1 |
| Tang, N | 1 |
| Skalli, O | 1 |
| Quick, QA | 1 |
| Di Tommaso, L | 1 |
| Baretti, M | 1 |
| Corredor, AG | 1 |
| Peddi, P | 1 |
| Ajit, NE | 1 |
| Burton, GV | 1 |
| El-Osta, H | 1 |
| Connelly, KE | 1 |
| Martin, EC | 1 |
| Dykhuizen, EC | 1 |
| Zwirner, K | 1 |
| Urakami, K | 1 |
| Sheng, R | 1 |
| Lee, TY | 1 |
| Peng, R | 1 |
| Jiang, B | 1 |
| Munasinghe, W | 1 |
| Pinel, B | 1 |
| Duchesne, M | 1 |
| Godet, J | 2 |
| Berger, A | 1 |
| Jaime-Ramirez, AC | 1 |
| Yoo, JY | 1 |
| Relation, T | 1 |
| Yan, PF | 1 |
| Zhao, HY | 1 |
| Zhang, FC | 1 |
| Zhao, WH | 1 |
| McElroy, JP | 1 |
| Klimowicz, AC | 1 |
| Magliocco, A | 1 |
| Robe, P | 1 |
| Salavaggione, AL | 1 |
| Lee, RJ | 1 |
| Brachman, D | 1 |
| Flickinger, J | 1 |
| Inge, LJ | 1 |
| Hartman, LK | 1 |
| Chow, D | 1 |
| Millard, N | 1 |
| Yin, HH | 1 |
| Absalyamova, OV | 1 |
| Ryzhova, MV | 1 |
| Poddubskiy, AA | 1 |
| Inozemtseva, MV | 1 |
| Lodygina, KS | 1 |
| Shi, F | 1 |
| Cho, JH | 1 |
| Xu, XK | 1 |
| Li, JL | 1 |
| Kong, KK | 1 |
| Ge, XS | 1 |
| Li, FC | 1 |
| Achari, R | 1 |
| Arunsingh, M | 1 |
| Badgami, RK | 1 |
| Saha, A | 1 |
| Shrimali, RK | 1 |
| Arun, B | 1 |
| Gokturk, D | 1 |
| Kelebek, H | 1 |
| Ceylan, S | 1 |
| Yilmaz, DM | 1 |
| Feng, E | 1 |
| Sui, C | 1 |
| Nachbichler, SB | 1 |
| Schupp, G | 1 |
| Ballhausen, H | 1 |
| Cenci, T | 3 |
| Im, CN | 1 |
| Yun, HH | 1 |
| Qiao, W | 2 |
| Guo, B | 1 |
| Xu, W | 2 |
| Liang, Y | 1 |
| Dong, B | 1 |
| Peters, K | 3 |
| Xu, K | 1 |
| Pei, H | 1 |
| Ghimenton, C | 1 |
| Danieli, D | 1 |
| Zunarelli, E | 1 |
| Lanza, G | 1 |
| Silini, EM | 1 |
| Talacchi, A | 1 |
| Pia Foschini, M | 1 |
| Ho, ASW | 1 |
| Pu, JKS | 1 |
| Osoba, D | 3 |
| Rossiter, JP | 1 |
| Tills, M | 1 |
| Mastorakos, P | 1 |
| Hays, MA | 1 |
| Caruso, JP | 1 |
| Taylor, DG | 1 |
| Beatriz Lopes, M | 1 |
| Shaffrey, ME | 1 |
| Sardaro, A | 1 |
| Iannalfi, A | 1 |
| Meattini, I | 1 |
| Leonulli, BG | 1 |
| Borghesi, S | 1 |
| Martinelli, F | 1 |
| Bordi, L | 1 |
| Ammannati, F | 1 |
| Biti, G | 2 |
| Roberge, D | 2 |
| Shakibnia, L | 1 |
| Lambert, C | 1 |
| Leblanc, R | 1 |
| Del Maestro, R | 1 |
| Murat, A | 1 |
| Migliavacca, E | 1 |
| Lambiv, WL | 2 |
| Shay, T | 1 |
| de Tribolet, N | 4 |
| Regli, L | 4 |
| Kouwenhoven, MC | 3 |
| Hainfellner, JA | 2 |
| Heppner, FL | 1 |
| Zimmer, Y | 1 |
| Janzer, RC | 5 |
| Domany, E | 1 |
| Delorenzi, M | 1 |
| Jenkinson, MD | 1 |
| Yokoyama, T | 2 |
| Iwado, E | 2 |
| Kondo, Y | 4 |
| Georgescu, MM | 2 |
| Mills, GB | 1 |
| Kawamura, H | 1 |
| Hashimoto, Y | 1 |
| Urata, Y | 1 |
| Fujiwara, T | 1 |
| Kondo, S | 2 |
| Riffkin, CD | 1 |
| Lovric, MM | 1 |
| Mikeska, T | 1 |
| Dobrovic, A | 1 |
| Maxwell, JA | 2 |
| Johns, TG | 1 |
| Hawkins, CJ | 1 |
| Maira, G | 5 |
| Sica, G | 1 |
| Lama, G | 1 |
| Lauriola, L | 1 |
| Beier, D | 4 |
| Röhrl, S | 1 |
| Pillai, DR | 1 |
| Schwarz, S | 1 |
| Kunz-Schughart, LA | 1 |
| Leukel, P | 1 |
| Bogdahn, U | 5 |
| Trampe-Kieslich, A | 1 |
| Giebel, B | 1 |
| Wischhusen, J | 1 |
| Beier, CP | 5 |
| Beule, AC | 1 |
| Bromberg, J | 1 |
| Ernemann, U | 1 |
| Rorden, C | 1 |
| Karnath, HO | 1 |
| Johnson, SP | 2 |
| McLendon, RE | 8 |
| Lister, DW | 1 |
| Horne, KS | 1 |
| Rasheed, A | 1 |
| Quinn, JA | 3 |
| Ali-Osman, F | 1 |
| Modrich, PL | 2 |
| Schaich, M | 1 |
| Kestel, L | 1 |
| Pfirrmann, M | 1 |
| Robel, K | 1 |
| Illmer, T | 1 |
| Kramer, M | 1 |
| Dill, C | 1 |
| Ehninger, G | 1 |
| Hadjipanayis, CG | 1 |
| Fellows-Mayle, W | 1 |
| Deluca, NA | 1 |
| Muni, R | 3 |
| Rasio, D | 1 |
| Osti, MF | 4 |
| Salvati, M | 9 |
| Valeriani, M | 3 |
| Cantore, GP | 2 |
| Maurizi Enrici, R | 3 |
| Pédeboscq, S | 2 |
| L'Azou, B | 2 |
| Passagne, I | 1 |
| De Giorgi, F | 1 |
| Ichas, F | 1 |
| Pometan, JP | 2 |
| Cambar, J | 2 |
| Bracht, LK | 1 |
| Meyerhardt, JA | 1 |
| Kulke, MH | 1 |
| Hornick, JL | 1 |
| Redston, M | 1 |
| LaFrankie, DC | 2 |
| Black, PM | 3 |
| Norden, A | 1 |
| Waldeck, W | 1 |
| Wiessler, M | 1 |
| Ehemann, V | 1 |
| Pipkorn, R | 1 |
| Spring, H | 1 |
| Didinger, B | 1 |
| Mueller, G | 1 |
| Langowski, J | 1 |
| Vinjamuri, M | 1 |
| Adumala, RR | 1 |
| Altaha, R | 1 |
| Hobbs, GR | 1 |
| Crowell, EB | 1 |
| Ang, KK | 1 |
| Zhang, HZ | 1 |
| Hammond, E | 1 |
| Piert, M | 3 |
| Gomez-Hassan, D | 2 |
| Hayman, J | 1 |
| Ten Haken, RK | 2 |
| Sridhar, T | 1 |
| Gore, A | 1 |
| Boiangiu, I | 1 |
| Machin, D | 1 |
| Symonds, RP | 1 |
| Somerville, M | 1 |
| Sadones, J | 1 |
| Michotte, A | 1 |
| Veld, P | 1 |
| Chaskis, C | 1 |
| Joossens, EJ | 1 |
| Strauven, T | 2 |
| D'Hondt, LA | 1 |
| Sartenaer, D | 1 |
| Califice, SF | 1 |
| Bierau, K | 1 |
| Svensson, C | 1 |
| De Grève, J | 1 |
| Guilleminault, L | 1 |
| Carré, P | 1 |
| de Luca, K | 1 |
| Beau Salinas, F | 1 |
| Autret-Leca, E | 1 |
| Narciso, B | 1 |
| Diot, P | 1 |
| Lamont, JD | 1 |
| Krishnan, S | 1 |
| Arusell, R | 1 |
| Kitange, G | 1 |
| Kugler, JW | 1 |
| Morton, RF | 1 |
| Rowland, KM | 1 |
| Mischel, P | 2 |
| Scheithauer, BW | 1 |
| de Paiva, TF | 1 |
| de Barros e Silva, MJ | 1 |
| Rinck, JA | 1 |
| Fanelli, MF | 1 |
| Gimenes, DL | 1 |
| Frommolt, P | 1 |
| Borberg, SK | 1 |
| Rühl, U | 1 |
| Steingräber, M | 1 |
| Niewald, M | 2 |
| Staar, S | 1 |
| Becker, G | 2 |
| Fischedick, AR | 1 |
| Herfarth, K | 1 |
| Grauthoff, H | 1 |
| Müller, RP | 1 |
| Ningaraj, NS | 1 |
| Sankpal, UT | 1 |
| Khaitan, D | 1 |
| Meister, EA | 1 |
| Vats, T | 1 |
| Nozue, K | 2 |
| Miyazaki, H | 1 |
| Kurita, H | 1 |
| Homori, M | 1 |
| Shiokawa, Y | 2 |
| McGirt, MJ | 1 |
| Than, KD | 1 |
| Weingart, JD | 2 |
| Mathieu, V | 2 |
| De Nève, N | 1 |
| Le Mercier, M | 3 |
| Dewelle, J | 1 |
| Gaussin, JF | 2 |
| Dehoux, M | 1 |
| Dinca, EB | 2 |
| Haas-Kogan, DA | 3 |
| Vandenberg, SR | 2 |
| DeBoer, R | 1 |
| Parvataneni, R | 3 |
| Carliner, H | 1 |
| Kabuubi, P | 1 |
| Ayers-Ringler, J | 2 |
| Rabbitt, J | 3 |
| Page, M | 3 |
| Fedoroff, A | 1 |
| Sneed, PK | 3 |
| Vandenberg, S | 2 |
| Lamborn, KR | 11 |
| Stokoe, D | 1 |
| Kubicek, GJ | 1 |
| Machtay, M | 1 |
| Mallon, G | 1 |
| Myers, T | 1 |
| Ramirez, M | 1 |
| Andrews, D | 1 |
| Dicker, AP | 1 |
| Heymann, S | 1 |
| Karamanoukian, D | 1 |
| Oliveira-Ferrer, L | 1 |
| Hauschild, J | 1 |
| Fiedler, W | 1 |
| Bokemeyer, C | 2 |
| Nippgen, J | 1 |
| Celik, I | 1 |
| Schuch, G | 1 |
| Peca, C | 1 |
| Pacelli, R | 1 |
| Elefante, A | 1 |
| Del Basso De Caro, ML | 1 |
| Vergara, P | 1 |
| Mariniello, G | 1 |
| Giamundo, A | 1 |
| Maiuri, F | 1 |
| Park, DM | 2 |
| Shah, DD | 1 |
| Egorin, MJ | 1 |
| de Oliveira, MS | 1 |
| Cechim, G | 1 |
| Santos, DG | 1 |
| Meurer, L | 1 |
| de Castro, CG | 1 |
| Brunetto, AL | 1 |
| Schwartsmann, G | 1 |
| Schwarstmann, G | 1 |
| Roesler, R | 1 |
| Russo, AL | 1 |
| Kwon, HC | 1 |
| Burgan, WE | 2 |
| Carter, D | 2 |
| Beam, K | 2 |
| Weizheng, X | 1 |
| Slusher, BS | 1 |
| Blatt, V | 3 |
| Amistà, P | 4 |
| Gardiman, M | 3 |
| Labianca, R | 1 |
| Bianchini, C | 1 |
| Reni, M | 4 |
| Clarke, MJ | 1 |
| Mulligan, EA | 1 |
| Plummer, ER | 1 |
| Sotti, G | 3 |
| Frezza, G | 2 |
| Morandi, L | 2 |
| Spagnolli, F | 2 |
| Rieger, J | 2 |
| Wiewrodt, D | 2 |
| Binello, E | 1 |
| Rampling, R | 4 |
| Armand, JP | 1 |
| Kletzl, H | 1 |
| Klughammer, B | 1 |
| Lacombe, D | 8 |
| McNamara, MB | 1 |
| Hoorens, A | 1 |
| Gaspar, N | 2 |
| Sharp, SY | 2 |
| Pacey, S | 1 |
| Walton, M | 1 |
| Vassal, G | 2 |
| Eccles, S | 1 |
| Pearson, A | 1 |
| Codd, PJ | 2 |
| Louis, DN | 4 |
| Ludwin, SK | 2 |
| Allgeier, A | 4 |
| Fisher, B | 4 |
| Belanger, K | 5 |
| Gijtenbeek, J | 1 |
| Eisenhauer, E | 4 |
| Bohl, J | 1 |
| Elsasser, T | 1 |
| Schulz-Ertner, D | 6 |
| Weyrather, WK | 1 |
| Bell, D | 1 |
| Kurose, A | 1 |
| Ogawa, A | 1 |
| Traganos, F | 1 |
| Darzynkiewicz, Z | 1 |
| Sawai, T | 1 |
| Burton, TR | 1 |
| Gibson, SB | 1 |
| Koukourakis, GV | 1 |
| Kouloulias, V | 1 |
| Zacharias, G | 1 |
| Papadimitriou, C | 1 |
| Pantelakos, P | 1 |
| Maravelis, G | 1 |
| Fotineas, A | 1 |
| Beli, I | 1 |
| Chaldeopoulos, D | 1 |
| Kouvaris, J | 1 |
| Kim, DW | 2 |
| Oshiro, S | 1 |
| Tsugu, H | 1 |
| Komatsu, F | 1 |
| Ohmura, T | 1 |
| Ohta, M | 1 |
| Sakamoto, S | 1 |
| Fukushima, T | 2 |
| McEllin, B | 2 |
| Camacho, CV | 2 |
| Sirasanagandala, S | 1 |
| Nannepaga, S | 1 |
| Mickey, B | 1 |
| Madden, C | 1 |
| Maher, E | 1 |
| Yuki, K | 2 |
| Yokoyama, H | 1 |
| Chansakul, P | 1 |
| Kim, SU | 1 |
| Tilleul, P | 1 |
| Brignone, M | 1 |
| Hassani, Y | 1 |
| Borget, I | 1 |
| Sarma, N | 1 |
| Panageas, K | 1 |
| Nolan, CP | 1 |
| Gavrilovic, I | 1 |
| Affronti, ML | 2 |
| Heery, CR | 1 |
| Benevento, F | 1 |
| Scopece, L | 2 |
| Mazzocchi, V | 1 |
| Bacci, A | 1 |
| Agati, R | 1 |
| Calbucci, F | 2 |
| Uyl-de Groot, CA | 2 |
| van der Bent, M | 1 |
| Jiang, SX | 1 |
| Gupta, D | 1 |
| Mohanti, BK | 1 |
| Thulkar, S | 1 |
| Dwary, A | 1 |
| Goyal, S | 1 |
| Muzumder, S | 1 |
| Das, P | 1 |
| Dunn, J | 1 |
| Baborie, A | 1 |
| Alam, F | 1 |
| Joyce, K | 1 |
| Moxham, M | 1 |
| Sibson, R | 1 |
| Crooks, D | 1 |
| Husband, D | 1 |
| Shenoy, A | 1 |
| Brodbelt, A | 1 |
| Wong, H | 1 |
| Liloglou, T | 1 |
| Haylock, B | 1 |
| Walker, C | 1 |
| Gauden, AJ | 1 |
| Hunn, A | 1 |
| Erasmus, A | 1 |
| Waites, P | 1 |
| Gauden, SJ | 1 |
| Kovach, JS | 1 |
| Johnson, F | 1 |
| Chiang, J | 1 |
| Hodes, R | 1 |
| Liu, ZG | 1 |
| Liu, XM | 1 |
| Chen, FR | 1 |
| Shi, HL | 2 |
| Pangjesse, CS | 1 |
| Ng, HK | 1 |
| van Genugten, JA | 1 |
| Leffers, P | 1 |
| Tjon-A-Fat, H | 1 |
| Twijnstra, A | 1 |
| Nutt, CL | 1 |
| Hall, JR | 1 |
| Russillo, M | 1 |
| Metro, G | 1 |
| Vidiri, A | 1 |
| Di Giovanni, S | 1 |
| Cognetti, F | 1 |
| Bektas, M | 1 |
| Poe, WE | 1 |
| Shimada, K | 1 |
| Konishi, N | 1 |
| Montano, N | 4 |
| Piantadosi, S | 2 |
| Jeon, HJ | 1 |
| Park, KB | 2 |
| Park, K | 3 |
| Kim, ST | 4 |
| Kim, WS | 4 |
| Fabrini, MG | 1 |
| Perrone, F | 1 |
| De Franco, L | 1 |
| Grespi, S | 1 |
| Vannozzi, R | 1 |
| Cionini, L | 1 |
| D'Elia, A | 2 |
| Formichella, AI | 1 |
| George, BJ | 1 |
| Eichinger, JB | 1 |
| Richard, TJ | 1 |
| Liu, VH | 1 |
| Hunter, K | 4 |
| Meyers, C | 1 |
| Morganti, AG | 4 |
| Romanelli, P | 2 |
| Ferro, M | 2 |
| Calista, F | 1 |
| Digesù, C | 1 |
| Macchia, G | 2 |
| Ianiri, M | 1 |
| Deodato, F | 2 |
| Cilla, S | 2 |
| Piermattei, A | 1 |
| Cellini, N | 2 |
| Dresemann, G | 1 |
| Wedding, U | 1 |
| Wagner, W | 1 |
| Engel, E | 1 |
| Heinrich, B | 1 |
| Karup-Hansen, A | 1 |
| Fluge, O | 1 |
| Nowak, A | 1 |
| Schleyer, E | 1 |
| Olver, IN | 1 |
| Hosius, C | 1 |
| Sieder, C | 1 |
| Sorenson, G | 1 |
| Parker, R | 1 |
| Ballman, KA | 1 |
| Manfrida, S | 3 |
| De Renzi, F | 1 |
| Colicchio, G | 2 |
| Apicella, G | 1 |
| De Bari, B | 3 |
| Pompucci, A | 2 |
| Rhee, DJ | 1 |
| Suh, YL | 2 |
| Song, SY | 1 |
| Hilverda, K | 1 |
| Bosma, I | 1 |
| Heimans, JJ | 3 |
| Postma, TJ | 3 |
| Peter Vandertop, W | 1 |
| Buter, J | 1 |
| Schmid, C | 1 |
| Kleinletzenberger, C | 1 |
| Steinbrecher, A | 2 |
| Hirschmann, B | 2 |
| Dietmaier, C | 1 |
| Jauch-Worley, T | 1 |
| Kölbl, O | 1 |
| Rümmele, P | 1 |
| Muigg, A | 1 |
| Stockhammer, G | 1 |
| de Vries, NA | 1 |
| Inamasu, J | 1 |
| Kuramae, T | 1 |
| Nakatsukasa, M | 1 |
| Yang, I | 3 |
| Otero, JJ | 1 |
| Ahn, BJ | 1 |
| Kimple, RJ | 1 |
| Grabowski, S | 1 |
| Papez, M | 1 |
| Collichio, F | 1 |
| Morris, DE | 1 |
| Song, SW | 3 |
| Roldán, GB | 1 |
| Scott, JN | 1 |
| McIntyre, JB | 1 |
| Dharmawardene, M | 1 |
| de Robles, PA | 1 |
| Magliocco, AM | 1 |
| Yan, ES | 1 |
| Cao, VT | 1 |
| Jung, S | 3 |
| Jin, SG | 1 |
| Moon, KS | 3 |
| Kim, IY | 3 |
| Kang, SS | 2 |
| Park, CS | 2 |
| Chae, HJ | 1 |
| Hartmann, C | 5 |
| Meyermann, R | 2 |
| Tatagiba, M | 1 |
| Bocangel, D | 1 |
| Bhakat, KK | 1 |
| Park, TS | 1 |
| Suh, B | 1 |
| Jang, SJ | 1 |
| Lee, CH | 1 |
| Choi, JR | 1 |
| Xing, JZ | 1 |
| Small, C | 1 |
| Kortmann, R | 1 |
| Miriamanoff, R | 1 |
| Okunieff, P | 2 |
| Shibamoto, Y | 1 |
| Jeremic, B | 1 |
| Iliadis, G | 3 |
| Selviaridis, P | 3 |
| Kalogera-Fountzila, A | 1 |
| Fragkoulidi, A | 1 |
| Baltas, D | 1 |
| Tselis, N | 1 |
| Chatzisotiriou, A | 2 |
| Misailidou, D | 3 |
| Zamboglou, N | 1 |
| Fountzilas, G | 3 |
| Poelen, J | 1 |
| Prick, MJ | 1 |
| Jeuken, JW | 2 |
| Bernsen, HJ | 1 |
| Ruff, EM | 1 |
| Martindale, C | 1 |
| Lovegrove, N | 1 |
| Shepard, DR | 1 |
| Brewer, CJ | 1 |
| Agarwal, N | 1 |
| Stevens, GH | 1 |
| Suh, JH | 1 |
| Weil, RJ | 1 |
| Elson, P | 1 |
| Fotovati, A | 2 |
| Cote, G | 1 |
| Guns, E | 1 |
| Toyota, B | 2 |
| Faury, D | 1 |
| Jabado, N | 1 |
| Dunn, SE | 2 |
| Sheehan, J | 1 |
| Cifarelli, CP | 1 |
| Dassoulas, K | 1 |
| Olson, C | 1 |
| Rainey, J | 1 |
| Kataoka, H | 1 |
| Kaloshi, G | 1 |
| Sathornsumetee, S | 1 |
| Kracht, LW | 1 |
| Burghaus, L | 1 |
| Ullrich, RT | 1 |
| Backes, H | 1 |
| Brunn, A | 1 |
| Heiss, WD | 1 |
| Doherty, LM | 2 |
| Ciampa, A | 2 |
| Sceppa, C | 1 |
| Phan, P | 1 |
| Young, G | 1 |
| Spiegl-Kreinecker, S | 2 |
| Pirker, C | 2 |
| Filipits, M | 1 |
| Lötsch, D | 1 |
| Buchroithner, J | 2 |
| Silye, R | 2 |
| Micksche, M | 2 |
| Berger, W | 2 |
| Linz, U | 1 |
| Hristova-Kazmierski, M | 2 |
| Musib, L | 1 |
| Nicol, SJ | 2 |
| Thornton, DE | 2 |
| Marucci, G | 1 |
| Brandes, A | 1 |
| Dong, SM | 1 |
| Symons, S | 2 |
| Aviv, R | 2 |
| Morrison, M | 1 |
| Lam, K | 2 |
| Davey, P | 2 |
| Seiz, M | 3 |
| Krafft, U | 1 |
| Weiss, C | 3 |
| Lohr, F | 1 |
| Tuettenberg, J | 4 |
| Chahal, M | 1 |
| Lesniak, D | 1 |
| Graham, K | 1 |
| Famulski, K | 1 |
| Christensen, JG | 1 |
| Jacques, A | 1 |
| Murray, D | 1 |
| Gautschi, OP | 1 |
| Cadosch, D | 1 |
| Collen, TD | 1 |
| Land, M | 1 |
| Hoederath, P | 1 |
| Fournier, JY | 1 |
| Donatello, RS | 1 |
| Korones, DN | 2 |
| Kekan, MS | 1 |
| Johnson, MJ | 1 |
| Meleth, S | 1 |
| Kuo, H | 1 |
| Gladson, CL | 1 |
| Fathallah-Shaykh, HM | 1 |
| Ng, K | 1 |
| Kung, A | 1 |
| D'Andrea, A | 1 |
| Nölte, I | 1 |
| Pechlivanis, I | 1 |
| Hashizume, R | 1 |
| Gupta, N | 2 |
| Banerjee, A | 1 |
| Easaw, J | 2 |
| Shields, C | 1 |
| Kirby, S | 1 |
| Macdonald, DR | 5 |
| Thiessen, B | 2 |
| Forsyth, P | 2 |
| Pouliot, JF | 1 |
| Quang, TS | 1 |
| Gracely, EJ | 1 |
| Emrich, JG | 1 |
| Yaeger, TE | 1 |
| Jenrette, JM | 1 |
| Cohen, SC | 1 |
| Black, P | 1 |
| Brady, LW | 1 |
| Slaby, O | 1 |
| Lakomy, R | 1 |
| Fadrus, P | 1 |
| Hrstka, R | 1 |
| Kren, L | 1 |
| Lzicarova, E | 1 |
| Smrcka, M | 1 |
| Svoboda, M | 1 |
| Dolezalova, H | 1 |
| Novakova, J | 1 |
| Valik, D | 1 |
| Vyzula, R | 1 |
| Michalek, J | 1 |
| Laughton, CA | 1 |
| Madhusudan, S | 1 |
| Rosenfeld, M | 2 |
| Gabelloni, P | 1 |
| Bendinelli, S | 1 |
| Nuti, E | 1 |
| Casalini, F | 1 |
| Orlandini, E | 1 |
| Rossello, A | 1 |
| Westgate, MR | 1 |
| Beauchamp, D | 1 |
| Kelly, JJ | 1 |
| Stechishin, O | 1 |
| Ramirez, AL | 1 |
| McDonald, MW | 1 |
| Hasselbalch, B | 1 |
| Holmberg, M | 1 |
| Sørensen, M | 1 |
| Guimarães, I | 1 |
| Jaraquemada, T | 1 |
| Augusto, I | 1 |
| Castro, L | 1 |
| Honavar, M | 1 |
| Resende, M | 1 |
| Braga, F | 1 |
| Silva, A | 1 |
| Pardal, F | 1 |
| Amorim, J | 1 |
| Nabiço, R | 1 |
| Almeida, R | 1 |
| Alegria, C | 1 |
| Pires, M | 1 |
| Pinheiro, C | 1 |
| Carvalho, E | 1 |
| Costa, P | 1 |
| Damasceno, M | 1 |
| Mihaliak, AM | 1 |
| Gilbert, CA | 2 |
| Daou, MC | 2 |
| Moser, RP | 2 |
| Reeves, A | 1 |
| Cochran, BH | 1 |
| Birol Sarica, F | 1 |
| Cekinmez, M | 1 |
| Sen, O | 1 |
| Cem Onal, H | 1 |
| Erdogan, B | 1 |
| Nur Altinors, M | 1 |
| Grabenbauer, GG | 1 |
| Ochsenbein, AF | 1 |
| Diserens, AC | 4 |
| Pica, A | 5 |
| Hermisson, M | 1 |
| Krueger, S | 1 |
| Grisdale, K | 1 |
| Ritterhouse, M | 1 |
| Williams, MD | 1 |
| Gururangan, S | 3 |
| Marcello, J | 5 |
| Janney, D | 1 |
| Ujifuku, K | 1 |
| Mitsutake, N | 1 |
| Takakura, S | 1 |
| Matsuse, M | 1 |
| Saenko, V | 1 |
| Kamada, K | 1 |
| Nagata, I | 1 |
| Misch, M | 1 |
| Czabanka, M | 1 |
| Plotkin, M | 1 |
| Blechschmidt, C | 1 |
| Meije, Y | 1 |
| Lizasoain, M | 1 |
| García-Reyne, A | 1 |
| Martínez, P | 1 |
| Rodríguez, V | 1 |
| López-Medrano, F | 1 |
| Juan, RS | 1 |
| Lalueza, A | 1 |
| Aguado, JM | 1 |
| Bobola, MS | 2 |
| Kolstoe, DD | 2 |
| Blank, A | 2 |
| Rozzi, A | 1 |
| Nardoni, C | 1 |
| Corona, M | 1 |
| Restuccia, MR | 1 |
| Bria, E | 1 |
| Villalva, C | 1 |
| Martin-Lannerée, S | 1 |
| Cortes, U | 1 |
| Dkhissi, F | 1 |
| Le Corf, A | 1 |
| Tourani, JM | 1 |
| Dusanter-Fourt, I | 1 |
| Khayal, IS | 1 |
| Jalbert, L | 1 |
| Elkhaled, A | 1 |
| van Nifterik, KA | 2 |
| van den Berg, J | 2 |
| van der Meide, WF | 1 |
| Ameziane, N | 1 |
| Wedekind, LE | 1 |
| Steenbergen, RD | 1 |
| Lafleur, MV | 2 |
| Toda, H | 1 |
| Iwamizu, H | 1 |
| Sugita, T | 1 |
| Hachisu, R | 1 |
| Watanabe, R | 2 |
| Bankiewicz, K | 1 |
| Márquez-Rivas, J | 1 |
| Ramirez, G | 1 |
| Ollero-Ortiz, A | 1 |
| Giménez-Pando, J | 1 |
| Emmerich, J | 1 |
| Quiroga-Cantero, E | 1 |
| Rivas, E | 1 |
| Gómez-González, E | 1 |
| Halthore, AN | 1 |
| Parker, SL | 1 |
| Bobustuc, GC | 2 |
| Baker, CH | 1 |
| Limaye, A | 1 |
| Jenkins, WD | 1 |
| Pearl, G | 1 |
| Avgeropoulos, NG | 1 |
| Konduri, SD | 1 |
| Mangla, R | 1 |
| Singh, G | 1 |
| Ziegelitz, D | 1 |
| Zhong, J | 1 |
| Ekholm, SE | 1 |
| Hahm, B | 1 |
| McDonnell, J | 1 |
| Muntoni, A | 1 |
| Henson, JD | 1 |
| Cook, RJ | 2 |
| Biggs, MT | 2 |
| Little, NS | 2 |
| Robinson, BG | 2 |
| Reddel, RR | 1 |
| Wesolowski, JR | 1 |
| Rajdev, P | 1 |
| Mukherji, SK | 1 |
| Hainsworth, JD | 2 |
| Ervin, T | 1 |
| Friedman, E | 1 |
| Priego, V | 1 |
| Murphy, PB | 1 |
| Clark, BL | 1 |
| Lamar, RE | 1 |
| Srivastava, A | 1 |
| Jha, P | 1 |
| Suri, V | 1 |
| Sharma, MC | 1 |
| Puri, T | 1 |
| Gupta, DK | 1 |
| Sarkar, C | 1 |
| Sköld, K | 1 |
| Pellettieri, L | 1 |
| Giusti, V | 1 |
| H-Stenstam, B | 1 |
| Hopewell, JW | 1 |
| Salazar, AM | 1 |
| Yokosawa, M | 1 |
| Sugiyama, S | 1 |
| Nishihara, M | 1 |
| Satoh, T | 1 |
| Yokoyama, M | 1 |
| Franz, K | 3 |
| Blasel, S | 1 |
| Oszvald, A | 1 |
| Rathert, J | 1 |
| Gasser, T | 1 |
| Palomo, JM | 1 |
| Rahmathulla, G | 1 |
| McGraw, M | 1 |
| Donze, J | 1 |
| Pan, T | 2 |
| Eto, T | 1 |
| Nakashima, S | 1 |
| Okada, Y | 1 |
| Ogo, E | 2 |
| Sugita, Y | 1 |
| Tokutomi, T | 1 |
| Shigemori, M | 2 |
| Maluta, S | 1 |
| Parisi, S | 1 |
| Bertoni, F | 1 |
| Mantovani, C | 1 |
| Tombolini, V | 3 |
| De Renzis, C | 2 |
| Lioce, M | 1 |
| Muto, P | 1 |
| Cipressi, S | 1 |
| Piroth, MD | 3 |
| Pinkawa, M | 3 |
| Holy, R | 2 |
| Klotz, J | 1 |
| Nussen, S | 1 |
| Coenen, HH | 2 |
| Kaiser, HJ | 2 |
| Eble, MJ | 3 |
| Bekele, BN | 1 |
| Song, KS | 1 |
| Phi, JH | 1 |
| Cho, BK | 2 |
| Wang, KC | 2 |
| Ahn, HS | 1 |
| Redelman-Sidi, G | 1 |
| Papanicolaou, G | 1 |
| Łata, S | 1 |
| Molczyk, A | 1 |
| Buttarelli, F | 1 |
| Scarpino, S | 2 |
| Addeo, R | 1 |
| De Santi, MS | 1 |
| Montella, L | 1 |
| Abbruzzese, A | 1 |
| Parlato, C | 2 |
| Vincenzi, B | 1 |
| Carraturo, M | 1 |
| Faiola, V | 1 |
| Genovese, M | 1 |
| Cennamo, G | 1 |
| Del Prete, S | 1 |
| Puchner, MJ | 1 |
| Lohmann, F | 1 |
| Schütze, M | 1 |
| Koll, S | 1 |
| Buchalla, R | 1 |
| Rainov, N | 1 |
| Kantelhardt, SR | 1 |
| Hess, K | 2 |
| Goldbecker, A | 1 |
| Tryc, AB | 1 |
| Raab, P | 1 |
| Worthmann, H | 1 |
| Herrmann, J | 1 |
| Weissenborn, K | 1 |
| Rusthoven, KE | 2 |
| Olsen, C | 1 |
| Franklin, W | 1 |
| Pedretti, M | 1 |
| Verpelli, C | 1 |
| Mårlind, J | 1 |
| Bertani, G | 1 |
| Sala, C | 1 |
| Neri, D | 1 |
| Priester, P | 1 |
| Slovácek, L | 1 |
| Petera, J | 1 |
| Kopecký, O | 1 |
| Macingova, Z | 1 |
| Tzadok, S | 1 |
| Beery, E | 1 |
| Israeli, M | 1 |
| Uziel, O | 1 |
| Lahav, M | 1 |
| Fenig, E | 1 |
| Gil-Ad, I | 1 |
| Weizman, A | 1 |
| Nordenberg, J | 1 |
| Kieser, M | 1 |
| Habermehl, D | 1 |
| Jäkel, O | 1 |
| Nikoghosyan, A | 1 |
| Haselmann, R | 2 |
| Doyle, CL | 1 |
| Le Calvé, B | 1 |
| Rynkowski, M | 1 |
| Bruyère, C | 1 |
| Lonez, C | 1 |
| Gras, T | 1 |
| Haibe-Kains, B | 2 |
| Bontempi, G | 2 |
| Decaestecker, C | 2 |
| Ruysschaert, JM | 1 |
| Tseng, HM | 1 |
| Lien, HC | 1 |
| Liu, KL | 1 |
| Liu, MT | 1 |
| Thompson, EM | 1 |
| Dosa, E | 1 |
| Kraemer, DF | 1 |
| Gerstein, J | 2 |
| Fraunholz, I | 1 |
| Rödel, C | 2 |
| McLendon, R | 1 |
| Threatt, S | 3 |
| Amelio, D | 1 |
| Amichetti, M | 1 |
| Grasbon-Frodl, EM | 1 |
| Kretzschmar, HA | 1 |
| Zhang, WB | 1 |
| Shu, F | 1 |
| Jin, YH | 1 |
| Wang, QJ | 1 |
| Schreiber, S | 1 |
| Prox-Vagedes, V | 1 |
| Elolf, E | 1 |
| Brueggemann, I | 1 |
| Gademann, G | 1 |
| Galazky, I | 1 |
| Bartels, C | 1 |
| Robischon, M | 1 |
| Stuhr, K | 2 |
| Malkin, MG | 2 |
| Torres-Trejo, A | 1 |
| Marshall, L | 1 |
| Perryman, L | 1 |
| Bax, DA | 1 |
| Little, SE | 1 |
| Viana-Pereira, M | 1 |
| Pearson, AD | 1 |
| Hargrave, D | 1 |
| Schwartz, F | 1 |
| Dawirs, S | 1 |
| Hedderich, J | 2 |
| Dörner, L | 1 |
| Nabavi, A | 2 |
| Kirkpatrick, JP | 2 |
| Friedman, A | 1 |
| Essock-Burns, E | 2 |
| Armosini, V | 1 |
| Caporello, P | 3 |
| Maurizi, RE | 1 |
| Rhee, CH | 1 |
| Park, BJ | 1 |
| Ang, C | 1 |
| Ramanakumar, AV | 1 |
| Yim, SY | 1 |
| Lee, AR | 1 |
| Scabini, M | 1 |
| Stellari, F | 1 |
| Cappella, P | 1 |
| Rizzitano, S | 1 |
| Texido, G | 1 |
| Pesenti, E | 1 |
| Jo, MY | 2 |
| Kim, JK | 1 |
| Ahn, JM | 1 |
| Yoon, MJ | 1 |
| Nieder, C | 4 |
| Tran, A | 2 |
| Solis, OE | 2 |
| Selch, M | 2 |
| Filka, E | 2 |
| Black, K | 1 |
| Green, RM | 1 |
| Spier, CE | 1 |
| Kolevska, T | 1 |
| Polikoff, J | 1 |
| Fehrenbacher, L | 1 |
| Elashoff, R | 1 |
| Fujimaki, T | 1 |
| Kajiwara, K | 1 |
| Sawamura, Y | 1 |
| Mineta, T | 1 |
| Yamada, A | 1 |
| Itoh, K | 1 |
| Paravati, AJ | 1 |
| Heron, DE | 1 |
| Landsittel, D | 1 |
| Flickinger, JC | 1 |
| Mintz, A | 1 |
| Chen, YF | 1 |
| Huq, MS | 1 |
| Salazar, M | 1 |
| Barcia, J | 1 |
| Wolf, A | 2 |
| Micallef, J | 1 |
| Cairns, R | 1 |
| Guha, A | 3 |
| Sivakumar, W | 1 |
| Froelich, S | 1 |
| Gaub, MP | 1 |
| Boyer, P | 1 |
| Fischer-Lokou, D | 1 |
| Dufour, P | 1 |
| Kehrli, P | 1 |
| Maitrot, D | 1 |
| Herbert, C | 1 |
| Williams, M | 2 |
| Sawyer, H | 1 |
| Greenslade, M | 1 |
| Cornes, P | 1 |
| Prasad, G | 1 |
| Sottero, T | 1 |
| Ozawa, T | 2 |
| Aftab, DT | 1 |
| Tashiro, H | 1 |
| Ito, I | 1 |
| Nakasu, S | 1 |
| Nakajima, T | 1 |
| Gui, J | 2 |
| Côté, AL | 1 |
| Cohen, KJ | 1 |
| Pollack, IF | 2 |
| Buxton, A | 1 |
| Holmes, EJ | 1 |
| Burger, PC | 1 |
| Brat, DJ | 1 |
| Rosenblum, MK | 1 |
| Lavey, RS | 1 |
| Heideman, RL | 1 |
| Hingorani, M | 3 |
| Achawal, S | 1 |
| Scott, I | 1 |
| DiBiase, S | 1 |
| Meisenberg, B | 1 |
| Flannery, T | 1 |
| Patel, A | 1 |
| Dhople, A | 1 |
| Cheston, S | 1 |
| Amin, P | 1 |
| Burnett Iii, OL | 1 |
| Nordal, RA | 1 |
| Hyatt, MD | 1 |
| Topuk, S | 1 |
| Oymak, E | 1 |
| Parlak, C | 1 |
| De Salvo, M | 1 |
| Maresca, G | 1 |
| D'agnano, I | 1 |
| Marchese, R | 1 |
| Stigliano, A | 1 |
| Gagliassi, R | 1 |
| Brunetti, E | 1 |
| Raza, GH | 1 |
| De Paula, U | 2 |
| Bucci, B | 1 |
| Goellner, EM | 1 |
| Grimme, B | 1 |
| Brown, AR | 2 |
| Wang, XH | 2 |
| Sugrue, KF | 1 |
| Mitchell, L | 1 |
| Trivedi, RN | 1 |
| Tang, JB | 2 |
| Löffler, M | 1 |
| de La Motte Rouge, T | 1 |
| Zeaiter, A | 1 |
| Phillips, H | 1 |
| Modrusan, Z | 1 |
| Malkoun, N | 2 |
| Fotso, MJ | 2 |
| Cartier, L | 2 |
| Auberdiac, P | 2 |
| Thorin, J | 2 |
| Pacaut, C | 2 |
| Schmitt, T | 2 |
| Kawabata, S | 1 |
| Miyatake, S | 1 |
| Hiramatsu, R | 1 |
| Hirota, Y | 1 |
| Miyata, S | 1 |
| Takekita, Y | 1 |
| Kuroiwa, T | 1 |
| Kirihata, M | 1 |
| Sakurai, Y | 1 |
| Maruhashi, A | 1 |
| Ono, K | 2 |
| Gevertz, JL | 1 |
| Munoz, DM | 1 |
| Smith, CJ | 1 |
| Restrepo, A | 1 |
| McGlade, CJ | 1 |
| Stanford, WL | 1 |
| Kishida, Y | 1 |
| Higashi, H | 1 |
| Wakai, K | 1 |
| Shirakawa, Y | 1 |
| Yamashita, K | 1 |
| Kamano, H | 1 |
| Shioyama, Y | 1 |
| Abe, K | 1 |
| Honda, H | 2 |
| Torisu, R | 1 |
| Colin, C | 1 |
| Tchogandjian, A | 1 |
| Coulibaly, B | 1 |
| Bailey, B | 1 |
| Ernstberger, A | 1 |
| Juliar, BE | 1 |
| Sinn, AL | 1 |
| Chan, RJ | 1 |
| Baluyut, AR | 1 |
| Goebel, WS | 1 |
| Herzog, H | 1 |
| Lallana, EC | 1 |
| Szczepiorkowski, ZM | 1 |
| Tosteson, TD | 1 |
| Rhodes, CH | 1 |
| Wishart, HA | 1 |
| Sakamoto, N | 1 |
| Nakai, K | 1 |
| Enomoto, T | 1 |
| Morishita, Y | 1 |
| Bangert, A | 1 |
| Häcker, S | 1 |
| Cristofanon, S | 2 |
| Kondo, N | 1 |
| Takahashi, A | 1 |
| Mori, E | 2 |
| Noda, T | 1 |
| Zdzienicka, MZ | 1 |
| Thompson, LH | 1 |
| Helleday, T | 1 |
| Masunaga, S | 1 |
| Hasegawa, M | 1 |
| Shen, D | 1 |
| Mu, YG | 2 |
| Zhang, XH | 2 |
| Pehlivan, Y | 1 |
| Sevinc, A | 1 |
| Turkbeyler, IH | 1 |
| Dirier, A | 1 |
| Kalender, ME | 1 |
| Camci, C | 1 |
| Zachenhofer, I | 1 |
| Maier, R | 1 |
| Eiter, H | 1 |
| Muxel, M | 1 |
| Muxel, B | 1 |
| Cejna, M | 1 |
| DeVries, A | 1 |
| Roessler, K | 1 |
| Bok, R | 1 |
| Vigneron, DB | 1 |
| Jackson, EF | 1 |
| Chen, A | 1 |
| Davis, ME | 1 |
| Stoiber, AM | 1 |
| Schönsteiner, SS | 1 |
| Bommer, M | 1 |
| Haenle, MM | 1 |
| Klaus, B | 1 |
| Scheuerle, A | 1 |
| Herion, TW | 1 |
| Timke, C | 1 |
| Hauser, K | 1 |
| Peschke, P | 1 |
| Wirkner, U | 1 |
| Lahn, M | 1 |
| Huber, PE | 1 |
| Monjour, A | 1 |
| Huchet, A | 2 |
| Matta, M | 1 |
| Snyder, DJ | 1 |
| Matsko, MV | 1 |
| Luchin, EI | 1 |
| Ievleva, AG | 1 |
| Bakholdin, DV | 1 |
| Abysheva, SN | 1 |
| Zavgorodniaia, EV | 1 |
| Potapova, ON | 1 |
| Imianitov, EN | 1 |
| Ulitin, AIu | 1 |
| Matsko, DE | 1 |
| Ananda, S | 1 |
| Dowling, A | 2 |
| Brown, C | 1 |
| Rogers, S | 1 |
| Bodis, S | 1 |
| Demir, H | 1 |
| Miyazaki, T | 1 |
| Ray-Chaudhury, A | 1 |
| Guckenberger, M | 1 |
| Mayer, M | 1 |
| Buttmann, M | 1 |
| Vince, GH | 1 |
| Feng, K | 1 |
| Rossetti, AO | 1 |
| Brower, V | 1 |
| Bao, Z | 2 |
| Pieper, R | 1 |
| Nicole, A | 1 |
| Hsieh, E | 1 |
| Bianchi, F | 2 |
| Lauretti, L | 1 |
| Doglietto, F | 1 |
| Jhaveri, N | 1 |
| Petasis, NA | 1 |
| Sunayama, J | 1 |
| Tachibana, K | 1 |
| Faragó, N | 1 |
| Fehér, LZ | 1 |
| Kitajka, K | 1 |
| Das, UN | 1 |
| Puskás, LG | 1 |
| Wong, TS | 1 |
| Pu, JK | 2 |
| Lee, NP | 2 |
| Ng, GK | 1 |
| Lui, WM | 2 |
| Salem, A | 2 |
| Hashem, SA | 2 |
| Al-Rashdan, A | 2 |
| Ezam, N | 2 |
| Nour, A | 2 |
| Alsharbaji, A | 2 |
| Sughayer, M | 2 |
| Mohamad, I | 2 |
| Elyan, M | 2 |
| Addas, A | 1 |
| Al-Hussaini, M | 2 |
| Almousa, A | 2 |
| Duri, S | 1 |
| Casali, C | 2 |
| Conti, A | 1 |
| Pontoriero, A | 1 |
| Arpa, D | 1 |
| Siragusa, C | 1 |
| Tomasello, C | 1 |
| Cardali, S | 1 |
| Granata, F | 1 |
| Tomasello, F | 1 |
| Schulz, JB | 2 |
| Albanese, A | 1 |
| Micciche', F | 1 |
| De Rose, F | 2 |
| Berdel, C | 1 |
| Fleckenstein, J | 1 |
| Licht, N | 1 |
| Rübe, C | 1 |
| Ueno, H | 1 |
| SongTao, Q | 1 |
| Si, G | 1 |
| YanQing, D | 1 |
| HuiXia, H | 1 |
| XueLin, Z | 1 |
| LanXiao, W | 1 |
| Fei, Y | 1 |
| Narayana, A | 1 |
| Gruber, D | 1 |
| Kunnakkat, S | 1 |
| Golfinos, JG | 1 |
| Parker, E | 1 |
| Raza, S | 1 |
| Zagzag, D | 1 |
| Eagan, P | 1 |
| Gruber, ML | 1 |
| Normolle, D | 1 |
| Chenevert, T | 1 |
| Lawrence, T | 1 |
| Lam, N | 1 |
| Chambers, CR | 1 |
| Ferruzzi, P | 1 |
| Mennillo, F | 1 |
| De Rosa, A | 1 |
| Giordano, C | 1 |
| Rossi, M | 1 |
| Benedetti, G | 1 |
| Magrini, R | 1 |
| Pericot Mohr, Gl | 1 |
| Miragliotta, V | 1 |
| Magnoni, L | 1 |
| Thomas, R | 1 |
| Tunici, P | 1 |
| Bakker, A | 1 |
| Annamalai, AK | 1 |
| Dean, AF | 1 |
| Kandasamy, N | 1 |
| Kovacs, K | 1 |
| Burton, H | 1 |
| Halsall, DJ | 1 |
| Shaw, AS | 1 |
| Antoun, NM | 1 |
| Cheow, HK | 1 |
| Kirollos, RW | 1 |
| Pickard, JD | 1 |
| Simpson, HL | 1 |
| Jefferies, SJ | 1 |
| Gurnell, M | 1 |
| Yang, YP | 1 |
| Chien, Y | 1 |
| Chiou, GY | 1 |
| Cherng, JY | 1 |
| Wang, ML | 1 |
| Chang, YL | 1 |
| Huang, PI | 1 |
| Chen, YW | 1 |
| Shih, YH | 1 |
| Chen, MT | 1 |
| Arivazhagan, A | 1 |
| Kumar, DM | 1 |
| Sagar, V | 1 |
| Patric, IR | 1 |
| Sridevi, S | 1 |
| Thota, B | 1 |
| Srividya, MR | 1 |
| Prasanna, K | 1 |
| Thennarasu, K | 1 |
| Mondal, N | 1 |
| Hegde, AS | 1 |
| Chandramouli, BA | 1 |
| Santosh, V | 1 |
| Rao, MR | 1 |
| Kondaiah, P | 1 |
| Cao, JQ | 1 |
| Fisher, BJ | 1 |
| Bauman, GS | 1 |
| Megyesi, JF | 1 |
| Watling, CJ | 2 |
| Alksne, J | 1 |
| Mundt, AJ | 1 |
| Murphy, KT | 1 |
| Cornell, M | 1 |
| Lawson, JD | 1 |
| Facoetti, A | 1 |
| Mazzini, G | 1 |
| Céfaro, GA | 1 |
| Genovesi, D | 1 |
| Vinciguerra, A | 1 |
| Trignani, M | 1 |
| Taraborrelli, M | 1 |
| Augurio, A | 1 |
| Buonaguidi, R | 1 |
| Galzio, RJ | 1 |
| Di Nicola, M | 1 |
| Schmitt, A | 1 |
| Casalegno-Garduno, R | 1 |
| Enders, A | 1 |
| Mani, J | 1 |
| Freund, M | 1 |
| Schmitt, M | 2 |
| Afzal, P | 1 |
| Campbell, AP | 1 |
| Gunjur, A | 2 |
| Lau, E | 1 |
| Taouk, Y | 1 |
| Ryan, G | 2 |
| Gajadhar, AS | 1 |
| Diefes, KL | 1 |
| McGown, G | 1 |
| Thorncroft, M | 1 |
| Margison, GP | 1 |
| Borges, KS | 2 |
| Castro-Gamero, AM | 2 |
| Moreno, DA | 2 |
| da Silva Silveira, V | 1 |
| de Oliveira, HF | 2 |
| Macneil, M | 1 |
| Macdonald, D | 2 |
| Urva, S | 1 |
| McIntosh, L | 1 |
| Kanai, R | 1 |
| Sgubin, D | 1 |
| Zaupa, CM | 1 |
| Sleire, L | 1 |
| Black, J | 1 |
| Webb, S | 1 |
| Narita, T | 2 |
| Aoyama, H | 1 |
| Onodera, S | 1 |
| Shiga, T | 1 |
| Murata, J | 2 |
| Kilickap, S | 1 |
| Oztoprak, I | 1 |
| Yucel, B | 1 |
| Kotoula, V | 2 |
| Televantou, D | 2 |
| Eleftheraki, AG | 1 |
| Lambaki, S | 1 |
| Rock, K | 1 |
| McArdle, O | 1 |
| Forde, P | 1 |
| Dunne, M | 1 |
| Fitzpatrick, D | 1 |
| O'Neill, B | 1 |
| Faul, C | 1 |
| Schwarz, SB | 1 |
| Anelli, V | 1 |
| Brioschi, L | 1 |
| De Zen, F | 1 |
| Gaini, SM | 2 |
| Yabroff, KR | 1 |
| Harlan, L | 1 |
| Zeruto, C | 1 |
| Abrams, J | 1 |
| Mann, B | 1 |
| Martinet, D | 1 |
| Besuchet Schmutz, N | 1 |
| Mesbah, H | 1 |
| Gedouin, D | 1 |
| Lecouillard, I | 1 |
| Louvel, G | 1 |
| Hamlat, A | 1 |
| Riffaud, L | 1 |
| Carsin, B | 1 |
| Audrain, O | 1 |
| Lesimple, T | 1 |
| Alexiou, GA | 1 |
| Goussia, A | 1 |
| Voulgaris, S | 1 |
| Fotopoulos, AD | 1 |
| Fotakopoulos, G | 1 |
| Ntoulia, A | 1 |
| Zikou, A | 1 |
| Tsekeris, P | 1 |
| Argyropoulou, MI | 1 |
| Kyritsis, AP | 1 |
| Lai, C | 1 |
| Gharib, M | 1 |
| Stoffregen, C | 1 |
| Decker, R | 1 |
| Meinel, T | 1 |
| Martus, P | 1 |
| Jakobs, O | 1 |
| Koo, S | 1 |
| Sutton, DA | 1 |
| Yeh, WW | 1 |
| Thompson, EH | 1 |
| Sigler, L | 1 |
| Shearer, JF | 1 |
| Hofstra, DE | 1 |
| Wickes, BL | 1 |
| Marty, FM | 1 |
| Cevenini, G | 1 |
| Calderaro, F | 1 |
| Estrada-Bernal, A | 1 |
| Palanichamy, K | 1 |
| Ray Chaudhury, A | 1 |
| Lechapt-Zalcman, E | 1 |
| Dugué, AE | 1 |
| Vital, A | 1 |
| Diebold, MD | 1 |
| Colin, P | 2 |
| Peruzzy, P | 1 |
| Bernaudin, M | 2 |
| Chapon, F | 1 |
| Reich, M | 1 |
| Comet, B | 1 |
| Golding, SE | 1 |
| Adams, BR | 1 |
| Wignarajah, S | 1 |
| Beckta, JM | 1 |
| O'Connor, MJ | 1 |
| Valerie, K | 1 |
| Stark, AM | 1 |
| van de Bergh, J | 1 |
| Roldán Urgoiti, GB | 1 |
| Singh, AD | 1 |
| Siu, IM | 1 |
| Thomale, UW | 1 |
| Jallo, GI | 1 |
| Sarganas, G | 1 |
| Orzechowski, HD | 1 |
| Klimpel, A | 1 |
| Thomae, M | 1 |
| Kauffmann, W | 1 |
| Herbst, H | 1 |
| Bronder, E | 1 |
| Garbe, E | 1 |
| Onofri, A | 1 |
| Simó, M | 1 |
| Velasco, R | 1 |
| Blasco, J | 1 |
| Kim, YS | 1 |
| Lin, H | 1 |
| Christians, A | 1 |
| Benner, A | 1 |
| Meyer, J | 1 |
| Barker, J | 1 |
| Foltz, G | 1 |
| Küblbeck, J | 1 |
| Honkakoski, P | 1 |
| Nagasawa, DT | 1 |
| Chow, F | 1 |
| Yew, A | 1 |
| Kim, W | 1 |
| Cremer, N | 1 |
| Shin, BJ | 1 |
| Burkhardt, JK | 1 |
| Riina, HA | 1 |
| McGrane, J | 1 |
| Bedford, T | 1 |
| Kelly, S | 1 |
| Miglierini, P | 1 |
| Bouchekoua, M | 1 |
| Rousseau, B | 1 |
| Hieu, PD | 1 |
| Malhaire, JP | 1 |
| Pradier, O | 1 |
| McPherson, CM | 1 |
| Gerena-Lewis, M | 1 |
| Breneman, JC | 1 |
| Warnick, RE | 1 |
| Kim, TO | 1 |
| Oh, IJ | 1 |
| Kang, HW | 1 |
| Chi, SY | 1 |
| Ban, HJ | 1 |
| Kwon, YS | 1 |
| Kim, YI | 1 |
| Lim, SC | 1 |
| Kim, YC | 1 |
| Merchant, MJ | 1 |
| Wagner, L | 1 |
| Karl, S | 1 |
| Zobel, K | 1 |
| Deshayes, K | 1 |
| Vucic, D | 1 |
| McCoy, LS | 1 |
| Smirnov, I | 1 |
| Patoka, JS | 1 |
| Hansen, HM | 1 |
| Wiemels, JL | 1 |
| Fridley, BL | 1 |
| Madden, MH | 1 |
| Browning, JE | 1 |
| Egan, KM | 1 |
| Wrensch, MR | 1 |
| Hobbs, J | 1 |
| Nikiforova, MN | 1 |
| Fardo, DW | 1 |
| Bortoluzzi, S | 1 |
| Cieply, K | 1 |
| Carico, C | 2 |
| Elramsisy, A | 3 |
| Dantis, J | 2 |
| Yu, JS | 3 |
| Bannykh, SI | 3 |
| Rejeeth, C | 1 |
| Addasi, A | 1 |
| Kim, YG | 1 |
| Kim, MH | 1 |
| Kim, HH | 1 |
| Crough, T | 1 |
| Beagley, L | 1 |
| Smith, C | 1 |
| Jones, L | 1 |
| Walker, DG | 1 |
| Khanna, R | 1 |
| Miao, Y | 1 |
| Ye, M | 1 |
| Peereboom, D | 1 |
| Olsen, J | 1 |
| Fisher, JD | 1 |
| Guo, RB | 1 |
| Sun, XL | 1 |
| Hu, G | 1 |
| Kohsaka, S | 2 |
| Yachi, K | 1 |
| Mahabir, R | 1 |
| Itoh, T | 1 |
| Tanino, M | 3 |
| Kimura, T | 2 |
| Nishihara, H | 2 |
| Williams, TM | 1 |
| Johnson, TD | 1 |
| Leopold, JS | 1 |
| Morigaki, R | 1 |
| Schriefer, B | 1 |
| Weis, J | 1 |
| Zamani, N | 1 |
| Mohammad Alizadeh, A | 1 |
| Schmidt, N | 1 |
| Hoadley, K | 1 |
| Kushwaha, D | 1 |
| Caivano, R | 2 |
| Chiumento, C | 2 |
| Cozzolino, M | 2 |
| Clemente, S | 1 |
| Pedicini, P | 2 |
| Janouskova, H | 1 |
| Maglott, A | 1 |
| Leger, DY | 1 |
| Bossert, C | 1 |
| Noulet, F | 1 |
| Guerin, E | 1 |
| Guenot, D | 1 |
| Pinel, S | 1 |
| Chastagner, P | 1 |
| Plenat, F | 1 |
| Lehmann-Che, J | 1 |
| Teisinger, J | 1 |
| Dontenwill, M | 1 |
| Ironside, C | 1 |
| Karponi, G | 1 |
| Liu, ZW | 1 |
| Woolf, D | 1 |
| Hargreaves, S | 1 |
| Michalarea, V | 1 |
| Menashy, R | 1 |
| Kooner, I | 1 |
| Wilson, E | 1 |
| Maire, JP | 1 |
| Thillays, F | 1 |
| Henzen, C | 1 |
| Missohou, F | 1 |
| de Crevoisier, R | 1 |
| Bondiau, PY | 1 |
| Collin, P | 1 |
| Kerr, C | 1 |
| Clavier, JB | 1 |
| Atlani, D | 1 |
| Vinchon-Petit, S | 1 |
| Lagrange, JL | 1 |
| Dagıstan, Y | 1 |
| Karaca, I | 1 |
| Bozkurt, ER | 1 |
| Ozar, E | 1 |
| Yagmurlu, K | 1 |
| Toklu, A | 1 |
| Miccichè, F | 1 |
| Gambacorta, MA | 1 |
| Lomberk, GA | 1 |
| Urrutia, RA | 1 |
| Chou, JF | 1 |
| Hadizadeh, DR | 1 |
| Kuchelmeister, K | 1 |
| Scorzin, J | 1 |
| Filss, C | 1 |
| Schüller, H | 1 |
| Shih, KC | 1 |
| Shepard, GC | 1 |
| Tillinghast, GW | 1 |
| Brinker, BT | 1 |
| Spigel, DR | 1 |
| Barr, JG | 1 |
| Grundy, PL | 1 |
| Goldenberg, F | 1 |
| Nicholas, MK | 3 |
| Ak, S | 1 |
| Tumen, G | 1 |
| Gimenez, M | 1 |
| Marie, SK | 1 |
| Oba-Shinjo, SM | 1 |
| Uno, M | 1 |
| da Silva, R | 1 |
| Laure, HJ | 1 |
| Izumi, C | 1 |
| Otake, A | 1 |
| Chammas, R | 1 |
| Rosa, JC | 1 |
| Harasaki, Y | 1 |
| Kamoshima, Y | 1 |
| Chan, HL | 1 |
| Li, CH | 1 |
| Algharabil, J | 1 |
| Kintner, DB | 1 |
| Begum, G | 1 |
| Yang, SS | 1 |
| Lin, SH | 1 |
| Kahle, KT | 1 |
| Fung, CF | 1 |
| Plummer, AB | 1 |
| Yu, TS | 1 |
| McKay, RM | 1 |
| Burns, DK | 1 |
| Kernie, SG | 1 |
| Parada, LF | 1 |
| Langsenlehner, T | 1 |
| Groll, MJ | 1 |
| Quehenberger, F | 1 |
| Mokry, M | 1 |
| Kapp, KS | 1 |
| Rønning, PA | 1 |
| Helseth, E | 1 |
| Abacioglu, U | 1 |
| Rosell, J | 1 |
| Massaccesi, M | 1 |
| Miller, RJ | 1 |
| Gui, X | 1 |
| Tsang, RY | 1 |
| Otty, Z | 1 |
| Sabesan, S | 1 |
| Chiang, MF | 1 |
| Yeh, ST | 1 |
| Liao, HF | 1 |
| Chang, NS | 1 |
| Chen, YJ | 1 |
| Aguilar, LK | 1 |
| Arvizu, M | 1 |
| Aguilar-Cordova, E | 1 |
| Falchetti, ML | 1 |
| Annibali, D | 1 |
| Savino, M | 1 |
| Pierconti, F | 1 |
| Nasi, S | 1 |
| Gilbertson, RJ | 1 |
| Graham, TA | 1 |
| Yi, A | 1 |
| Irvin, DK | 1 |
| Chedid, K | 1 |
| Preukschas, M | 1 |
| Hagel, C | 1 |
| Schulte, A | 1 |
| Weber, K | 1 |
| Sievert, H | 1 |
| Pällmann, N | 1 |
| Hauber, J | 1 |
| Braig, M | 1 |
| Balabanov, S | 1 |
| Appel, EA | 1 |
| Rowland, MJ | 1 |
| Loh, XJ | 1 |
| Heywood, RM | 1 |
| Scherman, OA | 1 |
| Nair, SM | 1 |
| Olivier, J | 1 |
| Tiwari, S | 1 |
| Kuroiwa-Trzmielina, J | 1 |
| Brewer, J | 1 |
| Zhang, N | 1 |
| Zhou, A | 1 |
| Reyngold, M | 1 |
| Safdie, F | 1 |
| Brandhorst, S | 1 |
| Hwang, S | 1 |
| Conti, PS | 1 |
| Longo, VD | 1 |
| Negretti, L | 1 |
| Bergström, S | 1 |
| Pikó, B | 1 |
| Bassam, A | 1 |
| Nagy, KA | 1 |
| Török, E | 1 |
| Vághy, R | 1 |
| Vargáné Tamás, R | 1 |
| Puskásné Szatmári, K | 1 |
| Svilar, D | 1 |
| Dyavaiah, M | 1 |
| McDonald, PR | 1 |
| Shun, TY | 1 |
| Braganza, A | 1 |
| Maniar, S | 1 |
| St Croix, CM | 1 |
| Lazo, JS | 1 |
| Begley, TJ | 1 |
| Bressel, M | 1 |
| Triscott, J | 1 |
| Berns, R | 1 |
| Pambid, M | 1 |
| Luk, M | 1 |
| Kong, E | 1 |
| Toyota, E | 1 |
| Nadkarni, A | 1 |
| Shrivastav, M | 1 |
| Schwingler, PM | 1 |
| Pistollato, F | 1 |
| Abbadi, S | 1 |
| Frasson, C | 1 |
| Indraccolo, S | 1 |
| Scienza, R | 2 |
| Gray, LA | 1 |
| Shinomiya, N | 1 |
| Shimazaki, H | 1 |
| Nakanishi, K | 1 |
| Nagatani, K | 1 |
| Osada, H | 1 |
| Uozumi, Y | 1 |
| Matsuo, H | 1 |
| Nawashiro, H | 1 |
| Tanaka, M | 1 |
| Tsuno, NH | 1 |
| Takahashi, K | 2 |
| Corroyer-Dulmont, A | 1 |
| Pérès, EA | 1 |
| Petit, E | 1 |
| Varoqueaux, N | 1 |
| Roussel, S | 1 |
| Toutain, J | 1 |
| Divoux, D | 1 |
| MacKenzie, ET | 1 |
| Delamare, J | 1 |
| Ibazizène, M | 1 |
| Lecocq, M | 1 |
| Barré, L | 1 |
| Valable, S | 1 |
| Safdar, S | 1 |
| Payne, CA | 1 |
| Tu, NH | 1 |
| Taite, LJ | 1 |
| Teufel, J | 1 |
| Hoepner, I | 1 |
| Rasper, M | 1 |
| Koeritzer, J | 1 |
| Yuan, S | 1 |
| Feng, L | 1 |
| Keating, MJ | 1 |
| Xu, RH | 1 |
| Huang, P | 1 |
| Bartolotti, M | 1 |
| Kahn, SA | 1 |
| Biasoli, D | 1 |
| Sobrinho, M | 1 |
| Frauches, AC | 1 |
| Romão, L | 1 |
| Soletti, RC | 1 |
| Assunção, Fdos S | 1 |
| Tovar-Moll, F | 1 |
| Anderluh, G | 1 |
| Ciceroni, C | 1 |
| Bonelli, M | 1 |
| Mastrantoni, E | 1 |
| Niccolini, C | 1 |
| Laurenza, M | 1 |
| Traficante, A | 1 |
| Spinsanti, P | 1 |
| Nicoletti, F | 1 |
| Melchiorri, D | 1 |
| Paulsson, AK | 1 |
| McMullen, KP | 1 |
| Peiffer, AM | 1 |
| Hinson, WH | 1 |
| Kearns, WT | 1 |
| Ellis, TL | 1 |
| Tatter, SB | 1 |
| Shaw, EG | 1 |
| Kerschbaumer, J | 1 |
| Bauer, R | 1 |
| Obwegeser, AA | 1 |
| Schubert, GA | 1 |
| Vellayappan, BA | 1 |
| Bharwani, L | 1 |
| Golubovskaya, VM | 1 |
| Ho, B | 2 |
| Yemma, M | 1 |
| Morrison, CD | 1 |
| Eliceiri, BP | 1 |
| Cance, WG | 1 |
| Concha, A | 1 |
| Alvarez, PJ | 1 |
| López, R | 1 |
| Rodríguez-Serrano, F | 1 |
| Aránega, A | 1 |
| Karkavelas, G | 1 |
| Hytiroglou, P | 1 |
| Lampaki, S | 1 |
| Polyzoidis, KS | 1 |
| Tysnes, BB | 1 |
| Franceries, X | 1 |
| Simon, L | 1 |
| Supper, C | 1 |
| Lotterie, JA | 1 |
| Berry, I | 1 |
| Cassol, E | 1 |
| Delannes, M | 1 |
| Celsis, P | 1 |
| Cohen-Jonathan, EM | 1 |
| Chang-Chien, YC | 1 |
| Yen, YS | 1 |
| Chen, MH | 1 |
| Guo, WY | 1 |
| Ho, DM | 1 |
| Fujinami, MM | 1 |
| de Paula Gomes Queiroz, R | 1 |
| Jang, WY | 1 |
| Jeong, EH | 1 |
| Monfared, P | 1 |
| Fricke, IB | 1 |
| Kuhlmann, MT | 1 |
| Fraefel, C | 1 |
| Lamb, LS | 1 |
| Bowersock, J | 1 |
| Johnson, A | 1 |
| Spencer, HT | 1 |
| Lalezari, S | 1 |
| Chou, AP | 1 |
| Khanlou, N | 1 |
| Chowdhury, R | 1 |
| Selfridge, J | 1 |
| Sanchez, DE | 1 |
| Wilson, RW | 1 |
| Zurayk, M | 1 |
| Lalezari, J | 1 |
| Lou, JJ | 1 |
| Ormiston, L | 1 |
| Ancheta, K | 1 |
| Hanna, R | 1 |
| Piccioni, D | 1 |
| Buchanan, C | 1 |
| Wang, HJ | 1 |
| Elashoff, RM | 1 |
| Jiang, R | 1 |
| Limbeck, E | 1 |
| Hinske, LC | 1 |
| Schütz, SV | 1 |
| Hoefig, K | 1 |
| Egensperger, R | 1 |
| Solero, CL | 1 |
| Maccagnano, C | 1 |
| Guzzetti, S | 1 |
| Pollo, B | 1 |
| Ciusani, E | 1 |
| Suenaga, Y | 1 |
| Alagu, J | 1 |
| Takatori, A | 1 |
| Itami, M | 1 |
| Araki, A | 1 |
| Ohira, M | 1 |
| Inoue, M | 1 |
| Kageyama, H | 1 |
| Saeki, N | 1 |
| Nakagawara, A | 1 |
| Sherriff, J | 1 |
| Tamangani, J | 1 |
| Senthil, L | 1 |
| Spooner, D | 1 |
| Jones, B | 1 |
| Brookes, C | 1 |
| Conroy, J | 1 |
| Qiang, H | 1 |
| Golubovskaya, V | 1 |
| De Filippo, L | 1 |
| Autorino, R | 1 |
| Rinaldi, C | 1 |
| Fersino, S | 1 |
| Matteucci, P | 1 |
| Ciurlia, E | 1 |
| Salvage, D | 1 |
| Rajaraman, C | 1 |
| Rowland-Hill, C | 1 |
| Basso, U | 4 |
| Paris, MK | 1 |
| Lumachi, F | 1 |
| Iuzzolino, P | 1 |
| Turazzi, S | 1 |
| Monfardini, S | 4 |
| Schoeler, KD | 1 |
| Haroldson, PD | 1 |
| Huynh, MB | 1 |
| Portarena, I | 2 |
| Torino, F | 1 |
| Scerrati, M | 1 |
| Navarra, P | 1 |
| Teixeira, MM | 1 |
| Portela, I | 1 |
| Cernuda, M | 1 |
| Oliveira, C | 1 |
| Albano, J | 1 |
| Lima, L | 1 |
| Zheludkova, OG | 1 |
| Tarasova, IS | 1 |
| Gorbatykh, SV | 1 |
| Belogurova, MB | 1 |
| Kumirova, EV | 1 |
| Borodina, ID | 1 |
| Prityko, AG | 1 |
| Melikian, AG | 1 |
| Shcherbenko, OI | 1 |
| Vastola, F | 2 |
| Pinna, G | 1 |
| Rotilio, A | 1 |
| Vos, MJ | 1 |
| Uitdehaag, BM | 1 |
| Barkhof, F | 1 |
| Baayen, HC | 1 |
| Boogerd, W | 1 |
| Castelijns, JA | 1 |
| Elkhuizen, PH | 1 |
| Taron, M | 1 |
| Roussos, Y | 1 |
| Ariza, A | 1 |
| Ballester, R | 2 |
| Sarries, C | 1 |
| Mendez, P | 1 |
| Sanchez, JJ | 1 |
| Rosell, R | 1 |
| Newlands, ES | 3 |
| Foster, T | 1 |
| Zaknoen, S | 4 |
| Trippoli, S | 1 |
| Pelagotti, F | 1 |
| Messori, A | 1 |
| Vacca, F | 1 |
| Vaiani, M | 1 |
| Maltoni, S | 1 |
| Piccirilli, M | 1 |
| Caroli, E | 1 |
| Brogna, C | 1 |
| Artizzu, S | 1 |
| Mizutani, T | 1 |
| Ishikawa, M | 1 |
| Scarsella, M | 1 |
| D'Amati, G | 1 |
| Vergati, M | 1 |
| Kalish, V | 1 |
| Zupi, G | 1 |
| Hartmann, P | 1 |
| Herholz, K | 1 |
| Salzberger, B | 1 |
| Petereit, HF | 1 |
| Keles, GE | 1 |
| Greenberg, HS | 1 |
| Kuhn, J | 2 |
| Schold, SC | 2 |
| Chua, SL | 1 |
| Wong, SS | 1 |
| Woods, AM | 1 |
| Cher, LM | 1 |
| Tsao-Wei, DD | 1 |
| Godard, S | 1 |
| Ostermann, S | 3 |
| Otten, P | 1 |
| Van Melle, G | 1 |
| Cavallo, G | 2 |
| Ferreri, AJ | 1 |
| Panucci, MG | 1 |
| Michielin, O | 1 |
| Udry, E | 1 |
| Périard, D | 1 |
| Matzinger, O | 1 |
| Lobrinus, JA | 1 |
| Frauger, E | 1 |
| Dufour, H | 3 |
| Palmari, J | 1 |
| Moktari, K | 1 |
| Peragut, JC | 2 |
| Martin, PM | 3 |
| Grisoli, F | 2 |
| Gil-Salú, JL | 1 |
| Román, P | 1 |
| Benítez, E | 1 |
| Maestro, E | 1 |
| Pérez-Requena, J | 1 |
| López-Escobar, M | 1 |
| Küker, WM | 1 |
| Dichgans, J | 1 |
| Leuraud, P | 1 |
| Medioni, J | 1 |
| Aguirre-Cruz, L | 1 |
| Crinière, E | 1 |
| Kujas, M | 1 |
| Golmard, JL | 1 |
| Duprez, A | 1 |
| Poupon, MF | 1 |
| Ataman, F | 1 |
| Poortmans, P | 1 |
| Levin, N | 1 |
| Gomori, JM | 1 |
| Kleber, M | 1 |
| Kufe, DW | 1 |
| Malec, M | 2 |
| Larson, D | 1 |
| Wara, W | 1 |
| Sneed, P | 1 |
| Wasserfallen, JB | 2 |
| Leyvraz, S | 2 |
| Villemure, JG | 1 |
| Bringas, JR | 1 |
| Panner, A | 1 |
| Tamas, M | 1 |
| Bankiewicz, KS | 1 |
| Bartolomei, M | 2 |
| Mazzetta, C | 1 |
| Handkiewicz-Junak, D | 1 |
| Bodei, L | 1 |
| Rocca, P | 1 |
| Grana, C | 1 |
| Villa, G | 1 |
| Paganelli, G | 1 |
| Alliot, C | 1 |
| Everaert, E | 1 |
| Joosens, E | 1 |
| Branle, F | 1 |
| Ravizza, R | 1 |
| Cereda, E | 1 |
| Monti, E | 1 |
| Gariboldi, MB | 1 |
| Grobholz, R | 1 |
| Korn, T | 1 |
| Erber, R | 1 |
| Valduga, F | 1 |
| Nicolardi, L | 1 |
| Banik, NL | 3 |
| Vitanovics, D | 1 |
| Afra, D | 1 |
| López-Pousa, A | 1 |
| Yaya-Tur, R | 1 |
| Martín-Broto, J | 1 |
| Balart, J | 1 |
| Menniti, A | 1 |
| Moschettoni, L | 1 |
| Liccardo, G | 1 |
| Lunardi, P | 1 |
| Sur, P | 1 |
| Sribnick, EA | 1 |
| Curschmann, J | 2 |
| Bromberg, JE | 2 |
| Athanassiou, H | 1 |
| Synodinou, M | 1 |
| Maragoudakis, E | 1 |
| Paraskevaidis, M | 1 |
| Verigos, C | 1 |
| Antonadou, D | 1 |
| Saris, G | 1 |
| Beroukas, K | 1 |
| Karageorgis, P | 1 |
| Kiebert, G | 1 |
| Yung, A | 1 |
| Olson, J | 2 |
| Larson, DA | 1 |
| Wara, WM | 1 |
| Shirato, H | 1 |
| Couprie, C | 1 |
| Muracciole, X | 2 |
| James, S | 1 |
| Camby, I | 1 |
| Darro, F | 1 |
| Brotchi, J | 1 |
| Gabius, J | 1 |
| Gutwein, S | 1 |
| van Kampen, M | 1 |
| Thilmann, C | 1 |
| Edler, L | 3 |
| Wannenmacher, MM | 1 |
| Katayama, M | 1 |
| Mirzoeva, OK | 2 |
| Seiter, K | 1 |
| Ryken, T | 1 |
| Altundag, O | 1 |
| Altundag, K | 1 |
| Boruban, C | 1 |
| Altundag, MB | 1 |
| Turen, S | 1 |
| Toubiana, T | 1 |
| Lang, P | 1 |
| Martikainen, JA | 1 |
| Kivioja, A | 1 |
| Hallinen, T | 1 |
| Vihinen, P | 1 |
| Weber, WA | 1 |
| Franz, M | 1 |
| Stärk, S | 1 |
| Thamm, R | 1 |
| Gumprecht, H | 1 |
| Schwaiger, M | 1 |
| Molls, M | 1 |
| Cohen, MH | 1 |
| Johnson, JR | 1 |
| Pazdur, R | 1 |
| Stamatakos, GS | 2 |
| Antipas, VP | 2 |
| Uzunoglu, NK | 2 |
| Leimgruber, A | 1 |
| Yeon, EJ | 1 |
| Buff, E | 1 |
| Maeder, PP | 1 |
| Meuli, RA | 1 |
| Wemmert, S | 1 |
| Rahnenführer, J | 1 |
| Beerenwinkel, N | 1 |
| Strowitzki, M | 1 |
| Feiden, W | 1 |
| Lengauer, T | 1 |
| Zang, KD | 1 |
| Meese, E | 1 |
| Steudel, WI | 1 |
| Urbschat, S | 1 |
| Rutz, HP | 1 |
| Peghini, PE | 1 |
| Gutteck-Amsler, U | 1 |
| Rentsch, K | 1 |
| Meier-Abt, PJ | 1 |
| Meier, UR | 1 |
| Bernays, RL | 1 |
| Boiardi, A | 4 |
| Botturi, A | 4 |
| Broggi, G | 3 |
| Bissola, L | 1 |
| Bredel, C | 1 |
| Juric, D | 1 |
| Duran, GE | 1 |
| Yu, RX | 1 |
| Vogel, H | 1 |
| Scheck, AC | 1 |
| Sikic, BI | 1 |
| Moraci, M | 1 |
| Moraci, A | 1 |
| Hamilton, D | 1 |
| Metcalfe, S | 1 |
| Crausaz, S | 1 |
| Moodie, P | 1 |
| McNee, W | 1 |
| Rabkin, S | 1 |
| Roitberg, B | 1 |
| Rasiah, D | 1 |
| Pelissou-Guyotat, I | 1 |
| Mahla, K | 1 |
| Audra, P | 1 |
| Gaucherand, P | 1 |
| Trouillas, P | 1 |
| Donson, AM | 1 |
| Addo-Yobo, SO | 1 |
| Handler, MH | 1 |
| Gore, L | 1 |
| Foreman, NK | 1 |
| Spence, AM | 1 |
| Partap, S | 1 |
| Schuetze, S | 1 |
| Collins, CA | 1 |
| Manasanch, EE | 1 |
| Ramaprasad, C | 1 |
| van Besien, K | 1 |
| Gupta, V | 1 |
| Su, YS | 1 |
| Kardosh, A | 1 |
| Liebes, LF | 1 |
| Dehdashti, AR | 1 |
| Heeger, S | 1 |
| Cairncross, G | 1 |
| Ganière, V | 1 |
| Christen, G | 1 |
| Bally, F | 1 |
| Guillou, L | 1 |
| de Ribaupierre, S | 1 |
| Schwarzmaier, HJ | 1 |
| Eickmeyer, F | 1 |
| von Tempelhoff, W | 1 |
| Fiedler, VU | 1 |
| Niehoff, H | 1 |
| Ulrich, SD | 1 |
| Ulrich, F | 1 |
| Jones-Bolin, S | 1 |
| Klein-Szanto, A | 1 |
| Ruggeri, B | 1 |
| Erkkinen, MG | 1 |
| Nestler, U | 1 |
| Mazzarella, G | 1 |
| Alfó, M | 1 |
| Banelli, E | 1 |
| Glantz, MJ | 1 |
| Chalmers, L | 2 |
| Van Horn, A | 1 |
| Koch, D | 2 |
| Loeser, S | 1 |
| Blaschke, B | 1 |
| Tan, TC | 1 |
| Sommer, C | 1 |
| Son, MJ | 1 |
| Eoh, W | 1 |
| Gioia, V | 1 |
| Biscuola, M | 1 |
| Crinò, L | 1 |
| Boor, S | 1 |
| Liu, TJ | 1 |
| Peterson, P | 2 |
| Greenberg, H | 2 |
| Stevens, QE | 1 |
| Howes, G | 1 |
| Dickerman, RD | 1 |
| Nardone, EM | 1 |
| Liguoro, D | 1 |
| Chin, SS | 1 |
| Schmidt, MH | 1 |
| Zhang, JP | 1 |
| Yue, WY | 1 |
| Mineo, JF | 1 |
| Bordron, A | 1 |
| Baroncini, M | 1 |
| Blond, S | 1 |
| Dam-Hieu, P | 1 |
| Soetekouw, PM | 1 |
| Gijtenbeek, JM | 1 |
| van der Maazen, RW | 1 |
| Kappelle, AC | 1 |
| van Herpen, CM | 1 |
| Gallego, JM | 1 |
| Barcia, JA | 1 |
| Barcia-Mariño, C | 1 |
| Mora, A | 1 |
| Prada, F | 1 |
| Borsa, S | 1 |
| Martinelli-Boneschi, F | 1 |
| Saladino, A | 1 |
| de la Fuente, BP | 1 |
| Dalmau, J | 1 |
| Greenberger, NJ | 1 |
| Gigas, DC | 2 |
| Levine, KK | 1 |
| Romany, CA | 1 |
| Reavie, LB | 1 |
| Futreal, PA | 1 |
| Stratton, MR | 1 |
| Goldman, B | 1 |
| Dellinger, CA | 1 |
| O'Toole, L | 1 |
| Khanduri, S | 1 |
| Gerrard, GE | 1 |
| Fuentes, S | 1 |
| Eudes, N | 1 |
| Lancelot, S | 1 |
| Pore, N | 1 |
| Cerniglia, GJ | 1 |
| Mick, R | 1 |
| Bernhard, EJ | 1 |
| Gupta, AK | 1 |
| Menon, H | 2 |
| Gujral, S | 1 |
| Singhal, N | 1 |
| Selva-Nayagam, S | 1 |
| Brown, MP | 1 |
| Roth, W | 1 |
| Ang, EL | 1 |
| Lim, CC | 1 |
| Chan, SP | 1 |
| Ty, A | 1 |
| Wong, MC | 1 |
| Maldonado, F | 1 |
| Limper, AH | 1 |
| Lim, KG | 1 |
| Aubrey, MC | 1 |
| Fiumani, A | 2 |
| Falcone, C | 2 |
| Filippini, G | 2 |
| Tartarone, A | 1 |
| Ardito, R | 1 |
| Romano, C | 1 |
| Maxwell, J | 1 |
| Dancey, J | 1 |
| Cornelissen, SJ | 1 |
| Vriezen, M | 1 |
| Dekkers, MM | 1 |
| Errami, A | 1 |
| Sijben, A | 1 |
| Sakata, K | 1 |
| Miyagi, N | 1 |
| Voicu, R | 1 |
| Pyrko, P | 1 |
| Sinkovics, J | 1 |
| Taylor, RE | 1 |
| Hulsebos, TJ | 1 |
| Wagner, J | 2 |
| Bischof, M | 2 |
| Wagner, F | 2 |
| Clarkson, A | 1 |
| McKenzie, CA | 1 |
| Messina, M | 1 |
| Gagel, B | 1 |
| Stanzel, S | 1 |
| Asadpour, B | 1 |
| Munshi, A | 1 |
| Sarin, R | 1 |
| Goel, A | 1 |
| Sun, W | 1 |
| Hussain, SF | 1 |
| Crutcher, L | 1 |
| Hassenbusch, SJ | 1 |
| Schmittling, B | 1 |
| Ohnishi, A | 1 |
| Facchini, V | 1 |
| Lamers, LM | 1 |
| Al, MJ | 1 |
| Mittmann, N | 1 |
| Jin Seung, S | 1 |
| Crott, R | 1 |
| Avutu, B | 1 |
| Barker, FG | 1 |
| Kil, WJ | 1 |
| Cerna, D | 1 |
| Steeg, PS | 1 |
| Filippone, F | 1 |
| Rausch, R | 1 |
| Zabel-du Bois, A | 1 |
| Yamamoto, A | 1 |
| Hollingsworth, EF | 1 |
| Kobayashi, R | 1 |
| Shingu, T | 1 |
| Tamada, Y | 1 |
| Bogler, O | 1 |
| Mills, G | 1 |
| Solari, A | 1 |
| Kunz-Schughart, L | 1 |
| Baumgart, U | 1 |
| Weimann, E | 1 |
| Muhleisen, H | 1 |
| Ruemmele, P | 1 |
| Reichle, A | 1 |
| Nakamura, O | 1 |
| McGibbon, B | 1 |
| Graham, C | 1 |
| Bergsneider, M | 1 |
| Pope, W | 1 |
| Steckley, JL | 1 |
| Mitchell, SB | 1 |
| Tsai, JS | 1 |
| Mijatovic, T | 2 |
| Adam, M | 1 |
| Longtine, JA | 1 |
| Weaver, S | 1 |
| Laforme, A | 1 |
| Ramakrishna, N | 1 |
| Folkman, J | 1 |
| Kieran, M | 1 |
| Benveniste, RJ | 1 |
| Manzano, G | 1 |
| Petito, CK | 1 |
| Coppola, JM | 1 |
| Andreoli, A | 1 |
| Leonardi, M | 1 |
| Salgaller, ML | 1 |
| Wedge, SR | 2 |
| Porteous, JK | 1 |
| Glaser, MG | 1 |
| Marcus, K | 1 |
| Kerby, T | 2 |
| Dugan, M | 2 |
| Bigner, SH | 1 |
| Henry, AJ | 1 |
| Krischer, J | 1 |
| Lovell, S | 1 |
| Rasheed, K | 1 |
| Marchev, F | 1 |
| Seman, AJ | 1 |
| Cokgor, I | 1 |
| Rich, J | 1 |
| Stewart, E | 1 |
| Colvin, OM | 1 |
| Provenzale, JM | 2 |
| Haglund, MM | 1 |
| Sankar, A | 1 |
| Thomas, DG | 1 |
| Darling, JL | 1 |
| Hoffmann, W | 1 |
| Weinmann, M | 1 |
| Classen, J | 1 |
| MacConnachie, AM | 1 |
| Calvert, H | 1 |
| Albright, RE | 1 |
| Fredericks, R | 1 |
| Spence, A | 1 |
| Hohl, RJ | 1 |
| Selker, RG | 1 |
| Vick, NA | 1 |
| Friedman, H | 1 |
| Phillips, P | 1 |
| Bruner, J | 2 |
| Yue, N | 2 |
| Houghton, PJ | 1 |
| Stewart, CF | 1 |
| Cheshire, PJ | 1 |
| Richmond, LB | 1 |
| Kirstein, MN | 1 |
| Poquette, CA | 1 |
| Brent, TP | 1 |
| Dirix, LY | 1 |
| Zonnenberg, BA | 1 |
| Bravo-Marques, JM | 1 |
| Rao, S | 1 |
| Kokkinakis, DM | 1 |
| Hoffman, RM | 1 |
| Frenkel, EP | 1 |
| Wick, JB | 1 |
| Cokgor, L | 1 |
| Edwards, S | 1 |
| Tourt-Uhlig, S | 1 |
| Stafford-Fox, V | 1 |
| Early, M | 1 |
| Ostermann Kraljevic, S | 1 |
| Maillard, I | 1 |
| Maeder, P | 1 |
| Meuli, R | 1 |
| Janzer, R | 1 |
| Pizzolato, G | 1 |
| Miralbell, R | 1 |
| Porchet, F | 1 |
| Dinnes, J | 1 |
| Cave, C | 1 |
| Milne, R | 1 |
| Croteau, D | 1 |
| Ashley, DL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I, Open Label Trial to Explore Safety of Combining BIBW 2992 and Radiotherapy With or Without Temozolomide in Newly Diagnosed GBM[NCT00977431] | Phase 1 | 36 participants (Actual) | Interventional | 2009-09-17 | Completed | ||
| A Phase I Study of CAN008 Plus Concomitant Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme[NCT02853565] | Phase 1 | 10 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| Effect of rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide[NCT03687957] | Phase 1/Phase 2 | 70 participants (Anticipated) | Interventional | 2019-01-04 | Recruiting | ||
| Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial.[NCT00626990] | Phase 3 | 751 participants (Actual) | Interventional | 2007-12-31 | Active, not recruiting | ||
| A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma[NCT02667587] | Phase 3 | 716 participants (Actual) | Interventional | 2016-05-09 | Active, not recruiting | ||
| The Combination of Hypofractionated Stereotactic Radiotherapy and Chemoradiotherapy Using Intensity-Modulated Radiotherapy for Newly Diagnosed Glioblastoma Multiforme: A Prospective, Single-Center, Single-Arm Phase II Clinical Trial[NCT04547621] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2020-09-01 | Active, not recruiting | ||
| EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma[NCT04471844] | 950 participants (Anticipated) | Interventional | 2020-12-08 | Recruiting | |||
| SPARE-Scalp Preservation and Radiation Plus Alternating Electric Tumor Treatment Field (NovoTTF, Optune) for Patients With Glioblastoma: A Pilot Study[NCT03477110] | Early Phase 1 | 30 participants (Actual) | Interventional | 2018-05-04 | Active, not recruiting | ||
| A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)[NCT00045968] | Phase 3 | 348 participants (Anticipated) | Interventional | 2006-12-31 | Active, not recruiting | ||
| Secondary Prophylaxis Use of Romiplostim for the Prevention of Thrombocytopenia Induced by Temozolomide in Newly Diagnosed Glioblastoma Patients[NCT02227576] | Phase 2 | 20 participants (Actual) | Interventional | 2014-07-10 | Terminated (stopped due to Study halted for efficacy following the results of the interim analysis provided for in the protocol on 20 patients.) | ||
| INTELLANCE-2: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group[NCT02343406] | Phase 2 | 266 participants (Actual) | Interventional | 2015-02-17 | Completed | ||
| A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM.[NCT00916409] | Phase 3 | 700 participants (Anticipated) | Interventional | 2009-06-30 | Completed | ||
| Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem)[NCT01502241] | Phase 3 | 412 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Clinical Trial Phase IIB Randomized, Multicenter, of Continuation or Non Continuation With 6 Cycles of Temozolomide After the First 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.[NCT02209948] | Phase 2 | 166 participants (Actual) | Interventional | 2014-08-22 | Completed | ||
| A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma[NCT02017717] | Phase 3 | 529 participants (Actual) | Interventional | 2014-02-07 | Active, not recruiting | ||
| Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing Data[NCT04792437] | 120 participants (Anticipated) | Observational | 2021-03-10 | Recruiting | |||
| A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients[NCT00482677] | Phase 3 | 562 participants (Actual) | Interventional | 2007-11-14 | Completed | ||
| A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma[NCT01473901] | Phase 1 | 38 participants (Actual) | Interventional | 2011-12-30 | Completed | ||
| Phase III Trial of CCNU/Temozolomide (TMZ) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT-methylated Glioblastoma Patients[NCT01149109] | Phase 3 | 141 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Impact of the Platelet Level During Radiotherapy Associated With Temozolomide in Patients Treated for Glioblastoma[NCT02617745] | Phase 2 | 244 participants (Actual) | Interventional | 2015-11-30 | Active, not recruiting | ||
| BrUOG 329: Onivyde (Nanoliposomal Irinotecan) and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: A Phase IB/IIA Brown University Oncology Research Group Study[NCT03119064] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2017-11-30 | Terminated (stopped due to lack of response to study therapy) | ||
| A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma[NCT01812603] | Phase 1/Phase 2 | 6 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma[NCT01812616] | Phase 1/Phase 2 | 21 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| Evaluating the Impact of 18F-DOPA-PET on Radiotherapy Planning for Newly Diagnosed Gliomas[NCT01991977] | Phase 2 | 91 participants (Actual) | Interventional | 2013-12-31 | Active, not recruiting | ||
| 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme With Rapid Early Progression Patients Prior to Adjuvant Oncological Therapy (GlioMET)[NCT05608395] | Phase 2 | 71 participants (Anticipated) | Interventional | 2020-12-04 | Recruiting | ||
| The Use of TTFields for Newly Diagnosed GBM Patients in Germany in Routine Clinical Care - TIGER Study[NCT03258021] | 710 participants (Actual) | Observational | 2017-08-31 | Active, not recruiting | |||
| Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)[NCT05120284] | Phase 2 | 40 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| Phase II Trial of Pulse Dosing of Lapatinib in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-Diagnosed Glioblastoma Multiforme[NCT01591577] | Phase 2 | 50 participants (Actual) | Interventional | 2012-12-07 | Active, not recruiting | ||
| Doxycycline Injection of Cutaneous Schwannoma in Neurofibromatosis Type 2[NCT05521048] | Phase 1/Phase 2 | 19 participants (Anticipated) | Interventional | 2022-09-19 | Recruiting | ||
| An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma[NCT01480479] | Phase 3 | 745 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)[NCT02573324] | Phase 3 | 691 participants (Actual) | Interventional | 2015-01-04 | Completed | ||
| [NCT00967330] | Phase 2 | 182 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma[NCT01062399] | Phase 1/Phase 2 | 279 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer[NCT04892472] | Phase 2 | 100 participants (Anticipated) | Interventional | 2021-07-12 | Recruiting | ||
| ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer[NCT03940196] | Phase 3 | 540 participants (Actual) | Interventional | 2019-03-22 | Active, not recruiting | ||
| Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma[NCT03377491] | Phase 3 | 556 participants (Anticipated) | Interventional | 2018-02-10 | Active, not recruiting | ||
| A Prospective Trial of NovoTTF-200A Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM[NCT03780569] | 10 participants (Anticipated) | Interventional | 2017-04-27 | Active, not recruiting | |||
| HEPANOVA: A Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC)[NCT03606590] | Phase 2 | 25 participants (Actual) | Interventional | 2019-02-15 | Active, not recruiting | ||
| EF-33: An Open-Label Pilot Study of OPTUNE® (TTFields, 200 Khz) With High Density Transducer Arrays for the Treatment of Recurrent Glioblastoma[NCT04492163] | Phase 2 | 25 participants (Anticipated) | Interventional | 2020-07-14 | Recruiting | ||
| Use of TTFields in Germany in Routine Clinical Care Study PROgram - Daily Activity, Sleep and Neurocognitive Functioning in Newly Diagnosed Glioblastoma Patients Study[NCT04717739] | 500 participants (Anticipated) | Observational | 2021-12-30 | Recruiting | |||
| A Modified Ketogenic, Anti-Inflammatory Diet for Patients With High-Grade Gliomas[NCT05373381] | 10 participants (Anticipated) | Interventional | 2022-05-18 | Recruiting | |||
| A Phase 2, Single Arm, Multi-center, Open-Label Trial to Evaluate the Safety and Efficacy of Treatment With Tumor Treating Fields (TTFields) and Chemotherapy as First-Line Treatment for Subjects With Unresectable Gastroesophageal Junction (GEJ) Adenocarci[NCT04281576] | 28 participants (Anticipated) | Interventional | 2019-12-19 | Recruiting | |||
| Temozolomide Plus Bevacizumab Chemotherapy in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status (KPS<70)[NCT02898012] | Phase 2 | 70 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme[NCT01800695] | Phase 1 | 202 participants (Actual) | Interventional | 2013-04-02 | Completed | ||
| A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma[NCT03034135] | Phase 2 | 23 participants (Actual) | Interventional | 2017-03-09 | Completed | ||
| Phase III Randomized Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma : Standard 3D Conformational Radiotherapy Versus Intensity-modulated Radiotherapy With Simultaneous-integrated Boost[NCT01507506] | Phase 3 | 180 participants (Actual) | Interventional | 2011-03-15 | Terminated | ||
| Ependymomics: Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents[NCT05151718] | 370 participants (Anticipated) | Observational | 2021-09-30 | Recruiting | |||
| Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma[NCT05532397] | 10 participants (Anticipated) | Interventional | 2023-02-17 | Recruiting | |||
| Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients[NCT03212742] | Phase 1/Phase 2 | 91 participants (Anticipated) | Interventional | 2017-09-04 | Recruiting | ||
| Safety of Intensity-modulated Radiotherapy Treatment With Inhomogeneous Dose Distribution in Patients With Relapsed High-grade Gliomas.[NCT04610229] | 12 participants (Actual) | Interventional | 2016-02-01 | Completed | |||
| A FIH Feasibility Study to Evaluate the Safety of Transient Disruption of Blood-brain Barrier in Recurrent Glioblastoma Multiforme (GBM) Patients Using NaviFUS System[NCT03626896] | 6 participants (Actual) | Interventional | 2018-08-17 | Completed | |||
| Phase I Study of Subventricular Zone Tumor Stem Cell Stereotactic Radiosurgery With Standard of Care Chemoradiation Therapy in Newly Diagnosed Malignant Gliomas (WHO III and WHO IV Astrocytomas)[NCT03956706] | 0 participants (Actual) | Interventional | 2018-12-24 | Withdrawn (stopped due to no partipants enrolled and investigator left the institution) | |||
| The Prospective Trial for Validation of the Role of Levetiracetam as a Sensitizer of Temozolomide in the Treatment of Newly Diagnosed Glioblastoma Patients[NCT02815410] | Phase 2 | 73 participants (Anticipated) | Interventional | 2016-07-31 | Not yet recruiting | ||
| Neural Stem Cell Oncolytic Adenoviral Virotherapy of Newly Diagnosed Malignant Glioma[NCT03072134] | Phase 1 | 12 participants (Actual) | Interventional | 2017-04-24 | Completed | ||
| Glioblastoma Multiforme Patients in Clinical Trials: An Examination of Their Clinical Trial Experiences[NCT05958485] | 500 participants (Anticipated) | Observational | 2024-08-31 | Not yet recruiting | |||
| Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma[NCT00304031] | Phase 3 | 1,173 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma[NCT01790503] | Phase 1/Phase 2 | 65 participants (Actual) | Interventional | 2013-07-18 | Completed | ||
| Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic[NCT05504681] | 200 participants (Anticipated) | Observational | 2021-11-03 | Recruiting | |||
| Validity and Reliability Evaluation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) for Adult-type Diffuse Gliomas Patients in Chinese Population[NCT05486923] | 450 participants (Anticipated) | Observational | 2022-09-19 | Recruiting | |||
| A Phase Ib/II Study of AZD2171 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma Not Taking Enzyme-Inducing Anti-epileptic Drugs[NCT00662506] | Phase 1/Phase 2 | 46 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Quantitative Assessment of the Early and Late Effects of Radiation and Chemotherapy on Glioblastoma Using Multiple MRI Techniques[NCT00756106] | 15 participants (Actual) | Interventional | 2008-07-31 | Terminated (stopped due to Funding ended) | |||
| A Phase II, Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Autologous Dendritic Cell Vaccination (ADCV01) as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients[NCT04115761] | Phase 2 | 24 participants (Anticipated) | Interventional | 2019-06-06 | Recruiting | ||
| A Phase I Trial of Hypofraction Radiotherapy + Temozolomide in the Treatment of Patients With Glioblastoma Multiforme and Anaplastic Astrocytoma of the Brain[NCT00841555] | Phase 1 | 9 participants (Actual) | Interventional | 2009-02-13 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patie[NCT00943826] | Phase 3 | 921 participants (Actual) | Interventional | 2009-06-29 | Completed | ||
| Precoce Medical Care by the Mobil Support for Patients With Glioblastoma Receiving Specific Medical Oncology Treatment[NCT04516733] | 35 participants (Actual) | Interventional | 2019-05-10 | Completed | |||
| Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma[NCT00884741] | Phase 3 | 637 participants (Actual) | Interventional | 2009-04-15 | Completed | ||
| Pre-operative Radiation Therapy (RT) and Temozolomide (TMZ) in Patients With Newly Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)[NCT03480867] | Phase 1 | 0 participants (Actual) | Interventional | 2017-03-31 | Withdrawn (stopped due to competing study was opened by the surgeon after this trial was opened) | ||
| A Phase II Study of Bevacizumab Plus Temodar and Tarceva After Radiation Therapy and Temodar in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Who Are Stable Following Radiation[NCT00525525] | Phase 2 | 74 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Evaluation of the Irinotecan/Bevacizumab Association as Neo-adjuvant and Adjuvant Treatment of Chemoradiation With Temozolomide for Naive Unresectable Glioblastoma. Phase II Randomized Study With Comparison to Chemoradiation With Temozolomide[NCT01022918] | Phase 2 | 134 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Phase I Dose Finding Study of Sorafenib in Combination With Radiation Therapy and Temozolomide as a First Line Treatment of Patients With High Grade Glioma[NCT00884416] | Phase 1 | 17 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A Phase I/II Trial of Hydroxychloroquine in Conjunction With Radiation Therapy and Concurrent and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme[NCT00486603] | Phase 1/Phase 2 | 92 participants (Actual) | Interventional | 2007-10-29 | Completed | ||
| Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas[NCT00669669] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2009-02-25 | Terminated (stopped due to Terminated due to loss in funding.) | ||
| Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Thera[NCT00689221] | Phase 3 | 545 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| A Randomized, Factorial-Design, Phase II Trial of Temozolomide Alone and in Combination With Possible Permutations of Thalidomide, Isotretinoin and/or Celecoxib as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme[NCT00112502] | Phase 2 | 178 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| A Phase II Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme[NCT00458601] | Phase 2 | 82 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Prospective Observational Study of Imaging-based Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastomas[NCT04143425] | 50 participants (Anticipated) | Observational | 2020-02-06 | Recruiting | |||
| An Italian Multicenter Phase II Trial of Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study[NCT05554003] | Phase 2 | 46 participants (Anticipated) | Interventional | 2022-01-14 | Recruiting | ||
| Phase 1/2 Open Single-arm Monocentric Study Evaluating the Tolerance and Interest of Transient Opening of the Blood-Brain Barrier by Low Intensity Pulsed Ultrasound With the SONOCLOUD® Implantable Medical Device in Mild Alzheimer's Disease Patients (MMSE [NCT03119961] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2017-06-26 | Completed | ||
| A PHASE I/II TRIAL OF TEMOZOLOMIDE, MOTEXAFIN GADOLINIUM, AND 60 GY FRACTIONATED RADIATION FOR NEWLY DIAGNOSED SUPRATENTORIAL GLIOBLASTOMA MULTIFORME[NCT00305864] | Phase 1/Phase 2 | 118 participants (Actual) | Interventional | 2006-02-09 | Completed | ||
| A Prospective Phase II Study in Patients With Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era[NCT03138642] | Phase 2 | 30 participants (Anticipated) | Interventional | 2010-07-01 | Recruiting | ||
| Improvement of Functional Outcome for Patients With Newly Diagnosed Grade II or III Glioma With Co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 Trial[NCT05331521] | Phase 3 | 406 participants (Anticipated) | Interventional | 2021-04-07 | Recruiting | ||
| Avastin in Combination With Temozolomide and Irinotecan for Unresectable or Multifocal Glioblastoma Multiformes and Gliosarcomas[NCT00979017] | Phase 2 | 41 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326] | Phase 2 | 21 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | ||
| Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Dynamic Hypermutation Status[NCT03519412] | Phase 2 | 102 participants (Anticipated) | Interventional | 2019-01-23 | Active, not recruiting | ||
| Glioblastoma Lines as the Disease Model[NCT04180046] | 10 participants (Anticipated) | Observational | 2019-06-26 | Recruiting | |||
| An Open-label, Single-arm, Phase II Study to Evaluate Safety and Efficacy of Doxorubicin in Combination With Radiotherapy, Temozolomide and Valproic Acid in Patients With Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG)[NCT02758366] | Phase 2 | 21 participants (Actual) | Interventional | 2016-02-29 | Terminated (stopped due to Study was terminated due to high heterogeneity of enrolled patients) | ||
| A Clinical Study of Standard TEMODAL® Regimen Versus Standard Regimen Plus Early Post-Surgery TEMODAL® Chemotherapy in Treatment on Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)[NCT00686725] | Phase 4 | 99 participants (Actual) | Interventional | 2008-06-24 | Completed | ||
| Restrictive Use of Dexamethasone in Glioblastoma[NCT04266977] | 50 participants (Anticipated) | Interventional | 2020-05-08 | Recruiting | |||
| A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation[NCT02152982] | Phase 2/Phase 3 | 447 participants (Actual) | Interventional | 2014-12-15 | Active, not recruiting | ||
| HUMC 1612: A Phase I Trial of the Optune NovoTTF-200A System With Concomitant Temozolomide and Bevacizumab in Pediatric Patients With High-grade Glioma[NCT03128047] | Phase 1 | 6 participants (Actual) | Interventional | 2017-04-06 | Active, not recruiting | ||
| Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).[NCT02831959] | Phase 3 | 270 participants (Anticipated) | Interventional | 2016-07-31 | Active, not recruiting | ||
| LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure[NCT02973789] | Phase 3 | 276 participants (Actual) | Interventional | 2016-12-31 | Active, not recruiting | ||
| Simultaneous Integrated Boost FDOPA PET Guided in Patients With Partially- or Non-operated Glioblastoma[NCT05653622] | Phase 2 | 75 participants (Anticipated) | Interventional | 2023-03-01 | Not yet recruiting | ||
| [NCT01702610] | 50 participants (Actual) | Interventional | 2008-12-31 | Completed | |||
| A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME[NCT00002545] | Phase 3 | 200 participants (Anticipated) | Interventional | 1994-02-28 | Completed | ||
| A Pilot and Phase II Study of OSI-774 and Temozolomide in Combination With Radiation Therapy in Glioblastoma Multiforme[NCT00039494] | Phase 2 | 171 participants (Anticipated) | Interventional | 2002-12-31 | Completed | ||
| Phase II Study of Tarceva Plus Temodar During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme and Gliosarcoma[NCT00187486] | Phase 2 | 66 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Randomized Phase II of TARCEVA™ (Erlotinib) Versus Temozolomide Or BCNU in Patients With Recurrent Glioblastoma Multiforme[NCT00086879] | Phase 2 | 110 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study[NCT00006353] | Phase 3 | 575 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| A Prospective Study of Concurrent Chemoradiotherapy With Temozolomide Versus Radiation Therapy Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas[NCT02766270] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2016-09-26 | Recruiting | ||
| Spatial Analysis and Validation of Glioblastoma on 7 T MRI[NCT02062372] | 5 participants (Actual) | Interventional | 2014-12-10 | Terminated (stopped due to Expectation that within the set time period insufficient patients will be included, so endpoints will not be achieved) | |||
| Pilot Study of Concomitant NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma[NCT03232424] | Phase 1 | 12 participants (Actual) | Interventional | 2017-07-26 | Completed | ||
| Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiotherapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)[NCT02780024] | Phase 2 | 50 participants (Anticipated) | Interventional | 2015-03-31 | Active, not recruiting | ||
| Use of PET/CT Imaging With 18F-fluoroethylcholine (FEC) in the Evaluation of Patients Treated With Radiotherapy and Temozolomide Following a Diagnosis of Glioblastoma Multiforme[NCT00943462] | 0 participants (Actual) | Observational | 2009-06-30 | Withdrawn (stopped due to No eligible patients could be recruited.) | |||
| Demeclocycline Fluorescence for Intraoperative Delineation Brain Tumors[NCT02740933] | Phase 1 | 40 participants (Anticipated) | Interventional | 2016-04-30 | Not yet recruiting | ||
| Phase II Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma[NCT03291314] | Phase 2 | 52 participants (Actual) | Interventional | 2017-05-03 | Completed | ||
| Retrospective Evaluation of Prognostic and/or Predictive Profile of Melanocortin Receptor-4 Gene Polymorphisms in Patient With a Diagnosis of Glioblastoma Treated With Upfront Concomitant Radio-chemotherapy or Chemotherapy[NCT02458508] | 65 participants (Actual) | Observational | 2015-03-31 | Completed | |||
| Effect of stRess and exeRcize on the Outcome After Chemo-Radiation[NCT05431348] | 40 participants (Anticipated) | Observational | 2022-06-01 | Recruiting | |||
| Prospective Randomized Phase II Trial of Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme[NCT01464177] | Phase 2 | 40 participants (Anticipated) | Interventional | 2011-10-31 | Active, not recruiting | ||
| RNOP-09: Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma - a Phase II Study[NCT00944801] | Phase 1/Phase 2 | 63 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Phase I/II Study on Concomitant and Adjuvant Temozolomide and Radiotherapy With or Without PTK787/ZK222584 in Newly Diagnosed GBM[NCT00128700] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| A Phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients With an Unmethylated MGMT Gene Promoter[NCT02928575] | Phase 2 | 45 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | ||
| Phase II Study of Neoadjuvant Chemoradiation for Resectable Glioblastoma (NeoGlio)[NCT04209790] | Phase 2 | 30 participants (Anticipated) | Interventional | 2020-04-01 | Recruiting | ||
| The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial[NCT01847235] | Phase 2 | 23 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| The Temozolomide RESCUE Study: A Phase II Trial of Continuous (28/28) Dose-intense Temozolomide (CDIT) Chemotherapy After Progression on Conventional 5/28 Day Temozolomide in Patients With Recurrent Malignant Glioma[NCT00392171] | Phase 2 | 120 participants (Actual) | Interventional | 2006-06-09 | Completed | ||
| A Phase II Study o the Adjuvant Use of Anti-Epidermal Growth Factor Receptor-425 (Anti-EGFR-425) Monoclonal Antibody Radiolabeled With I-125 for High Grade Gliomas[NCT00589706] | Phase 2 | 11 participants (Actual) | Interventional | 1985-01-31 | Completed | ||
| Phase 2 Study of Sorafenib Plus Protracted Temozolomide in Recurrent Glioblastoma Multiforme[NCT00597493] | Phase 2 | 32 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| A Phase II Trial of Concurrent Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib in the First-Line Treatment of Patients With Glioblastoma Multiforme[NCT00544817] | Phase 2 | 47 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Phase I Study of In Situ Autologous Vaccination Against Prostate Cancer With Intratumoral and Systemic Hiltonol® (Poly-ICLC) Prior To Radical Prostatectomy[NCT03262103] | Phase 1 | 13 participants (Actual) | Interventional | 2017-06-16 | Completed | ||
| A Phase II Trial of Radiation Plus Temozolomide Followed by Adjuvant Temozolomide and Poly-ICLC in Patients With Newly Diagnosed Glioblastoma Multiforme[NCT00262730] | Phase 2 | 97 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Phase I-Ib, Double-blinded, Randomized Repeated Dose Single Center, Safety and Immunogenicity Study of Nasal Poly-ICLC (Hiltonol®) in Healthy COVID-19 Vaccinated Adults[NCT04672291] | Phase 1 | 43 participants (Actual) | Interventional | 2021-07-21 | Completed | ||
| Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma[NCT04525859] | Phase 1 | 19 participants (Anticipated) | Interventional | 2020-08-19 | Recruiting | ||
| Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC): A Phase II Clinical Study[NCT01984892] | Phase 2 | 8 participants (Actual) | Interventional | 2013-11-30 | Terminated (stopped due to PI discretion, low enrollment) | ||
| Randomized Phase II Study Evaluating a Carbon Ion Boost Applied After Combined Radiochemotherapy With Temozolomide Versus a Proton Boost After Radiochemotherapy With Temozolomide in Patients With Primary Glioblastoma[NCT01165671] | 100 participants (Actual) | Interventional | 2010-07-31 | Completed | |||
| A Phase I Study of PRK787/ZK 222584 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma[NCT00385853] | Phase 1 | 19 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma[NCT00553150] | Phase 1/Phase 2 | 122 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A Complementary Trial of an Immunotherapy Vaccine Against Tumor-Specific EGFRvIII[NCT00643097] | Phase 2 | 40 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Hypofractionated Stereotactic Radiation Treatments (SBRT) on Children, Teenagers and Young Adults Malignant Tumors[NCT02013297] | 61 participants (Actual) | Interventional | 2013-12-03 | Completed | |||
| A Phase II Study of Temozolomide in the Treatment of Children With High Grade Glioma[NCT00028795] | Phase 2 | 170 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| A Phase II, Multicenter, Study for Newly Diagnosed Glioblastomas Using Boron Neutron Capture Therapy, Additional X-ray Treatment and Chemotherapy[NCT00974987] | Phase 2 | 32 participants (Actual) | Interventional | 2009-09-01 | Completed | ||
| A Phase II Feasibility Study of Adjuvant Intra-Nodal Autologous Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme[NCT00323115] | Phase 2 | 11 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas[NCT00369590] | Phase 2 | 58 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| REGULATory T-Cell Inhibition With Basiliximab (Simulect®) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme[NCT00626483] | Phase 1 | 34 participants (Actual) | Interventional | 2007-04-24 | Completed | ||
| A Phase II Study of Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma[NCT00501891] | Phase 2 | 32 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Valproic Acid for Children With Recurrent and Progressive Brain Tumors[NCT01861990] | Phase 1 | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to Feasibility of the trial was proven to be absent.) | ||
| A Multi-center, Prospective, Observational Study of Analysis of Q Cell Markers in Patients With Newly Diagnosed Primary Glioblastoma (Phase IV)[NCT02047058] | 240 participants (Anticipated) | Observational [Patient Registry] | 2014-03-31 | Not yet recruiting | |||
| A Phase I Study of Temozolomide and RAD001C in Patients With Malignant Glioblastoma Multiforme[NCT00387400] | Phase 1 | 32 participants (Actual) | Interventional | 2007-03-20 | Completed | ||
| Phase I Study of Enzastaurin and Temozolomide in Patients With Gliomas[NCT00516607] | Phase 1 | 28 participants (Actual) | Interventional | 2007-07-31 | Active, not recruiting | ||
| Hypofractionated IMRT (VMAT-RA) With Temozolomide for Patients With Newly Diagnosed High Grade Glioma (HGG)[NCT02082119] | 82 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| A Phase I Dose Per Fraction Escalation Study of Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining With Temozolomide (TMZ) Chemotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)[NCT00792012] | Phase 1 | 37 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A Safety Run-in/Randomized Phase II Trial of EMD 121974 in Conjunction With Concomitant and Adjuvant Temozolomide With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme[NCT00085254] | Phase 1/Phase 2 | 112 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| A Phase II Study of Concurrent Radiation Therapy, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in the First-line of Treatment of Patients With Glioblastoma Multiforme[NCT00805961] | Phase 2 | 68 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients[NCT01819233] | 38 participants (Actual) | Interventional | 2013-03-08 | Completed | |||
| Can Fasting Decrease the Side Effects of Chemotherapy?[NCT04027478] | 39 participants (Anticipated) | Interventional | 2019-09-01 | Enrolling by invitation | |||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas[NCT00003176] | Phase 2 | 82 participants | Interventional | 1998-03-25 | Completed | ||
| Using Genomic Analysis to Guide Individual Treatment in Glioblastoma[NCT02725684] | 36 participants (Actual) | Observational | 2015-03-12 | Completed | |||
| Phase II, Single Arm, Open Label Clinical Trial With Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas[NCT01574092] | Phase 2 | 39 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| [NCT05491928] | 0 participants | Expanded Access | Available | ||||
| Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)[NCT05163080] | Phase 2 | 265 participants (Anticipated) | Interventional | 2021-11-18 | Recruiting | ||
| Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiforme (Phase II)[NCT01349660] | Phase 1/Phase 2 | 88 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Immunophenotype Characterization of Circulating and Tumor Infiltrating Immune Cells in Malignant Brain Tumors.[NCT05831631] | 200 participants (Anticipated) | Observational | 2022-08-01 | Recruiting | |||
| Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma[NCT02942264] | Phase 1/Phase 2 | 53 participants (Actual) | Interventional | 2016-12-14 | Completed | ||
| Role of Repeat Resection in Recurrent Glioblastoma (4rGBM) Trial: a Randomized Care Trial for Patients With Recurrent GBM[NCT04838782] | 250 participants (Anticipated) | Interventional | 2021-08-26 | Recruiting | |||
| Role of Glutamate-mediate Excitotoxicity in Invasion and Progression Processes of Glioblastoma Multiforme[NCT05775458] | 50 participants (Anticipated) | Observational | 2020-06-01 | Recruiting | |||
| Comparative Assessment of Methods to Analyze MGMT as a Predictive Factor of Response to Temozolomide in Glioblastomas.[NCT01345370] | 300 participants (Actual) | Observational | 2009-03-31 | Completed | |||
| (Cost)Effectiveness of MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma: a Prospective Multicenter Randomized Controlled Trial (EMITT)[NCT05318612] | Phase 3 | 238 participants (Anticipated) | Interventional | 2022-04-08 | Recruiting | ||
| Prospective, Phase II Clinical Trial to Evaluate Efficacy and Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme Patients After Complete Surgical Resection With Fluorescence Microscope[NCT01006044] | Phase 2 | 26 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| A Phase I Study of Repeated Neural Stem Cell Based Virotherapy in Combination With N-Acetylcysteine Amid (NACA) and Standard Radiation and Chemotherapy for Newly Diagnosed High Grade Glioma[NCT06169280] | Phase 1 | 20 participants (Anticipated) | Interventional | 2024-01-02 | Not yet recruiting | ||
| Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas[NCT01849952] | 200 participants (Anticipated) | Observational | 2020-02-28 | Recruiting | |||
| Phase I Study of Escalated Pharmacologic Dose, of Oral Folinic Acid in Combination With Temozolomide, According to Stupp R. Regimen, in Patients With Operated Grade-IV Astocytoma and a Non-methylated Gene Status of MGMT.[NCT01700569] | Phase 1 | 24 participants (Actual) | Interventional | 2013-01-31 | Terminated (stopped due to changing the standard of care) | ||
| Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975] | Phase 2 | 35 participants (Anticipated) | Interventional | 2022-05-02 | Recruiting | ||
| Prospective, Randomized Controlled Trial of Surgical Resection Prior to Bevacizumab Therapy for Recurrent Glioblastoma Multiforme[NCT01413438] | Phase 2 | 0 participants (Actual) | Interventional | 2011-07-15 | Withdrawn | ||
| A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII[NCT01454596] | Phase 1/Phase 2 | 18 participants (Actual) | Interventional | 2012-05-16 | Completed | ||
| Open-label Phase 1/2 (Safety Lead-in) Study of Trans Sodium Crocetinate (TSC) With Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy[NCT01465347] | Phase 1/Phase 2 | 59 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Re-irradiation of High Grade Gliomas: a Quality of Life Study[NCT01711580] | 0 participants (Actual) | Observational | 2013-03-31 | Withdrawn (stopped due to Another study was commenced for this patient group) | |||
| Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients[NCT03542097] | 82 participants (Actual) | Observational | 2014-04-15 | Completed | |||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme - a Randomised Phase II Trial[NCT01252459] | Phase 2 | 200 participants (Anticipated) | Interventional | 2011-07-31 | Not yet recruiting | ||
| Phase II Evaluation of Temozolomide (SCH52365) and Thalidomide for the Treatment of Recurrent and Progressive Glioblastoma Multiforme[NCT00006358] | Phase 2 | 44 participants (Actual) | Interventional | 2000-06-13 | Completed | ||
| A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents[NCT03557359] | Phase 2 | 20 participants (Actual) | Interventional | 2018-06-12 | Active, not recruiting | ||
| A Phase I Study Of ZD 1839 And Temozolomide For The Treatment Of Gliomas[NCT00027625] | Phase 1 | 0 participants | Interventional | 2002-01-28 | Completed | ||
| Phase I Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy[NCT01308034] | Phase 1 | 25 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Phase II Study Of Temozolomide, Thalidomide And Celecoxib In Patients With Newly Diagnosed Glioblastoma Multiforme In The Post-Radiation Setting[NCT00047294] | Phase 2 | 0 participants | Interventional | 2001-04-30 | Completed | ||
| Imaging After Stereotactic Radiosurgery for Brain Metastases or Primary Tumor Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease ?[NCT03068520] | 140 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | |||
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors[NCT00994071] | Phase 1 | 9 participants (Actual) | Interventional | 2009-09-22 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The MTD was defined as the highest afatinib dose level, at which no more than 1 out of 6 patients experienced drug-related DLT, i.e. the highest afatinib dose with a DLT incidence ≤17%. A separate MTD was determined for afatinib and RT (Regimen U), and for afatinib, TMZ, and RT (Regimen M). (NCT00977431)
Timeframe: 6 weeks
| Intervention | Milligram (mg) (Number) |
|---|---|
| Total - Regimen M | 30 |
| Total - Regimen U | 40 |
"Adverse event (AE) related to afatinib with any one criteria; Hematological: Common terminology criteria for adverse events (CTCAE) Grade 4 neutropenia (Absolute neutrophil count, including bands <500/cubic millimeter (mm³)) for >7 days, CTCAE Grade 3 or 4 neutropenia of any duration associated with fever >38.3 Celsius, CTCAE Grade 3 thrombocytopenia (platelet count <50000 - 25000/mm³), All other toxicities of CTCAE Grade ≥3 leading interruption of treatment > 14 days.~Non-hematological: CTCAE Grade ≥3 nausea or vomiting despite appropriate use of standard anti-emetics for ≥3 days, CTCAE Grade ≥3 diarrhea despite appropriate use of standard anti-diarrheal therapy for ≥3 days, CTCAE Grade ≥3 rash despite standard medical management and lasting >7 days, CTCAE Grade ≥2 cardiac left ventricular function, CTCAE Grade ≥2 worsening of renal function as measured by serum creatinine, newly developed proteinuria or decrease in glomerular filtration rate, All other toxicities of CTCAE Grade ≥3. (NCT00977431)
Timeframe: 6 weeks
| Intervention | Participants (Number) |
|---|---|
| Afatinib 20 Milligram, Radiotherapy + Temozolomide - Regimen M | 1 |
| Afatinib 30 mg, Radiotherapy + Temozolomide - Regimen M | 0 |
| Afatinib 40 mg, Radiotherapy + Temozolomide - Regimen M | 2 |
| Afatinib 20 mg, Radiotherapy - Regimen U | 0 |
| Afatinib 40 mg, Radiotherapy - Regimen U | 1 |
Concentration of afatinib in plasma at steady state pre-dose (Cpre,ss) on days 8, 15 and 29. (NCT00977431)
Timeframe: Pharmacokinetic blood sample were taken at 5 minutes before drug on days 8, 15 and 29 and 1, 3 and 6 hours after drug administration on day 15
| Intervention | nanograms per milliliter (ng/mL) (Geometric Mean) | ||
|---|---|---|---|
| Cpre, ss, 8 | Cpre, ss, 15 | Cpre, ss, 29 | |
| Afatinib 20 mg, Radiotherapy - Regimen U | 4.9 | 4.4 | 5.0 |
| Afatinib 20 Milligram, Radiotherapy + Temozolomide - Regimen M | 4.4 | 5.6 | 5.3 |
| Afatinib 30 mg, Radiotherapy + Temozolomide - Regimen M | 10.7 | 9.6 | 17.8 |
| Afatinib 40 mg, Radiotherapy - Regimen U | 16.7 | 18.9 | 16.1 |
| Afatinib 40 mg, Radiotherapy + Temozolomide - Regimen M | 15.7 | 16.8 | 17.4 |
Incidence and intensity of adverse events (AE) according to Common Terminology Criteria of Adverse Events (CTCAE v.3.0). The CTCAE grades are: 1 (mild AE), 2 (moderate AE), 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related to AE). (NCT00977431)
Timeframe: From the first administration of trial medication until 4 weeks after the last administration of trial medication, up to approximately 338 weeks
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Afatinib 20 mg, Radiotherapy - Regimen U | 0 | 1 | 2 | 0 | 0 |
| Afatinib 20 Milligram, Radiotherapy + Temozolomide - Regimen M | 0 | 0 | 4 | 3 | 0 |
| Afatinib 30 mg, Radiotherapy + Temozolomide - Regimen M | 0 | 2 | 4 | 0 | 0 |
| Afatinib 40 mg, Radiotherapy - Regimen U | 1 | 2 | 5 | 2 | 3 |
| Afatinib 40 mg, Radiotherapy + Temozolomide - Regimen M | 1 | 1 | 4 | 1 | 0 |
Objective response was defined as a best overall response of complete response (CR) or partial response (PR). The best overall response was the best overall response to trial medication according to the Macdonald criteria recorded since the first administration of trial medication and until the earliest of disease progression, death, or start of further anti-cancer treatment. Tumour response was assessed based on local radiological image evaluation by the investigators according to the Macdonald criteria: Complete Response (CR): Disappearance of all enhancing tumour on consecutive Magnetic resonance imaging (MRI) scans at least 28 days apart, off steroids, and neurologically stable or improved. Partial Response (PR): At least 50% reduction in size of enhancing tumour on consecutive MRI scans at least 28 days apart, steroids stable or reduced, and neurologically stable or improved. (NCT00977431)
Timeframe: From the first administration of trial medication until 4 weeks after the last administration of trial medication, up to approximately 338 weeks
| Intervention | Participants (Number) | ||
|---|---|---|---|
| No | Yes | Missing | |
| Afatinib 20 mg, Radiotherapy - Regimen U | 3 | 0 | 0 |
| Afatinib 20 Milligram, Radiotherapy + Temozolomide - Regimen M | 5 | 2 | 0 |
| Afatinib 30 mg, Radiotherapy + Temozolomide - Regimen M | 3 | 3 | 0 |
| Afatinib 40 mg, Radiotherapy - Regimen U | 10 | 1 | 2 |
| Afatinib 40 mg, Radiotherapy + Temozolomide - Regimen M | 5 | 0 | 2 |
The duration of survival is the time interval between randomization and the date of death due to any cause. Patients not reported dead or lost to follow up will be censored at the date of the last follow up examination. (NCT00626990)
Timeframe: from date from enrollment till the date of death (time till death is up to 10.9 years after patient enrollment in the study)
| Intervention | Months (Median) |
|---|---|
| Absence of Concomitant Temozolomide (TMZ) | 60.42 |
| Presence of Concomitant Temozolomide (TMZ) | 66.92 |
| Absence of Adjuvant Temozolomide (TMZ) | 46.92 |
| Presence of Adjuvant Temozolomide (TMZ) | 82.33 |
Disease progression is defined as radiological or neurological/clinical progression (whichever occurs first); progression free survival (PFS) is the time interval between the date of randomization and the date of disease progression or death whichever occurs first. If neither event has been observed, the patient is censored at the date of the last follow up examination. Radiological progression was defined as increase of contrast enhancing area on MRI or CT scans of more than 25% as measured by two perpendicular diameters compared to the smallest measurements ever recorded for the same lesion by the same technique. The appearance of new lesions with or without contrast enhancement Neurological/clinical progression was defined as:decrease in WHO performance status,deterioration of neurological functions,appearance of signs/symptoms of increased intracranial pressure,and/or start of corticosteroid or increase of corticosteroid dosage by 50% for control of neurological symptoms. (NCT00626990)
Timeframe: from randomization till the date of disease progression or death (time till death is up to 10.9 years after patient enrollment in the study)
| Intervention | Months (Median) |
|---|---|
| Absence of Concomitant TMZ | 20.9 |
| Presence of Concomitant TMZ | 33.02 |
| Absence of Adjuvant TMZ | 19.09 |
| Presence of Adjuvant TMZ | 42.81 |
Overall Survival (OS) rate is defined as the percentage of participants surviving at 12 months (NCT02667587)
Timeframe: From randomization to 12 months after first dose
| Intervention | percentage of participants (Number) |
|---|---|
| Radiotherapy, Temozolomide Plus Nivolumab | 82.7 |
| Radiotherapy, Temozolomide Plus Placebo | 87.7 |
Overall Survival (OS) rate is defined as the percentage of participants surviving at 24 months (NCT02667587)
Timeframe: From randomization to 24 months after first dose
| Intervention | percentage of participants (Number) |
|---|---|
| Radiotherapy, Temozolomide Plus Nivolumab | 55.9 |
| Radiotherapy, Temozolomide Plus Placebo | 63.3 |
The time from randomization to the date of the first documented tumor progression or death by any cause. PFS will be determined by investigator assessment based Radiologic Assessment in Neuro-Oncology (RANO) criteria. Specifically, RANO response criteria indicates that within the first 12 weeks of completion of radiotherapy, progression can only be assessed if the majority of the new enhancement is outside of the radiation field or if there is pathologic confirmation of progressive disease. (NCT02667587)
Timeframe: From randomization to the date of the first documented tumor progression or death by any cause. (up to approximately 4.5 years)
| Intervention | Months (Median) |
|---|---|
| Radiotherapy, Temozolomide Plus Nivolumab | 14.09 |
| Radiotherapy, Temozolomide Plus Placebo | 15.18 |
The time from randomization to the date of the first documented tumor progression or death by any cause. PFS will be determined by a Blinded Independent Central Review (BICR) assessed based on Radiologic Assessment in Neuro-Oncology (RANO) criteria. Specifically, RANO response criteria indicates that within the first 12 weeks of completion of radiotherapy, progression can only be assessed if the majority of the new enhancement is outside of the radiation field or if there is pathologic confirmation of progressive disease. (NCT02667587)
Timeframe: From randomization to the date of the first documented tumor progression or death by any cause. (up to approximately 4.5 years)
| Intervention | Months (Median) |
|---|---|
| Radiotherapy, Temozolomide Plus Nivolumab | 10.64 |
| Radiotherapy, Temozolomide Plus Placebo | 10.32 |
The time from the date of randomization to the date of death. who have not died by the end of the study will be censored to last known date alive. OS is assessed in the randomized population with no corticosteroids at baseline population and in the overall randomized population. (NCT02667587)
Timeframe: From randomization to date of death (up to approximately 4.5 years)
| Intervention | Months (Median) | |
|---|---|---|
| All randomized participants | All randomized participants without baseline corticosteroids | |
| Radiotherapy, Temozolomide Plus Nivolumab | 28.91 | 31.34 |
| Radiotherapy, Temozolomide Plus Placebo | 32.07 | 32.99 |
The objective response rate (ORR) included best overall responses - complete response (CR) and partial response (PR) - assessed by the independent review committee per response assessment in neurooncology criteria (RANO) criteria from the date of randomization until disease progression or death, whichever came first. All objective responses (CR and PR) must be have been confirmed by repeat MRI 4 weeks after the first time when CR or PR is identified. Any subject who did not meet CR or PR including those who did not have post-baseline radiological assessments was considered a nonresponder. (NCT02343406)
Timeframe: Every 8 weeks at each assessment of disease, up to 28 months
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-414/Temozolomide | 14.3 |
| ABT-414_adult | 7.7 |
| Control (Temozolomide/Lomustine) | 4.4 |
AUC is a measure of how long and how much drug is present in the body after dosing. The AUC of depatuxizumab mafodotin (ABT-414) in the pediatric population was measured following treatment to confirm that this was comparable to adults, and that the dosing levels are appropriate for a pediatric population. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2,3,5,8,15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 5 Day 1; Day 1 of every two cycles starting with Cycle 5; and 35 days after the last dose
| Intervention | µg*h/mL (Mean) |
|---|---|
| ABT-414_ Pediatric | 3170 |
AUC is a measure of how long and how much drug or drug metabolite is present in the body after dosing. The AUC of Cys-mcMMAF, a toxic metabolite of depatuxizumab mafodotin, in the pediatric population was measured following treatment to confirm that this was comparable to adults, and that the dosing levels are appropriate for a pediatric population. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2, 3, 5, 8
| Intervention | ng*h/mL (Mean) |
|---|---|
| ABT-414_ Pediatric | 14.1 |
Half-life is the calculated time it takes for half of the drug to leave the body. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2,3,5,8,15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 5 Day 1; Day 1 of every two cycles starting with Cycle 5; and 35 days after the last dose
| Intervention | days (Mean) |
|---|---|
| ABT-414_ Pediatric | 9.0 |
Half-life is the calculated time it takes for half of the drug or drug metabolite to leave the body. CysmcMMAF is a toxic metabolite of depatuxizumab mafodotin. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2, 3, 5, 8
| Intervention | days (Mean) |
|---|---|
| ABT-414_ Pediatric | 11.2 |
Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose. Cys-mcMMAF is a toxic metabolite of depatuxizumab mafodotin. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2, 3, 5, 8
| Intervention | ng/mL (Mean) |
|---|---|
| ABT-414_ Pediatric | 0.272 |
Cmax is the peak concentration that a drug achieves in a specified compartment after the drug has been administrated and before administration of a second dose. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2,3,5,8,15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 5 Day 1; Day 1 of every two cycles starting with Cycle 5; and 35 days after the last dose
| Intervention | µg/mL (Mean) |
|---|---|
| ABT-414_ Pediatric | 31.4 |
The severity of each adverse event was rated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE Version 4.0) (NCT02343406)
Timeframe: From participant's first visit until 49 days after the participant's last dose of study drug, up to 63 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-414_ Pediatric | 100 |
Overall Survival (OS) was defined as time from randomization to death due to any cause, regardless of whether the event occurred on or off study drug (depatuxizumab mafodotin/temozolomide/lomustine). (NCT02343406)
Timeframe: From the date of randomization up to the date of participant's death; participants who completed treatment were to be assessed every 12 weeks, up to 28 months.
| Intervention | months (Number) | ||
|---|---|---|---|
| 25th quartile | 50th quartile | 75th quartile | |
| ABT-414_adult | 4.6 | 7.9 | 15.5 |
| ABT-414/Temozolomide | 5.7 | 9.6 | 16.9 |
| Control (Temozolomide/Lomustine) | 4.9 | 8.2 | 12.6 |
Overall Survival (OS) was defined as time from randomization to death due to any cause, regardless of whether the event occurred on or off study drug (depatuxizumab mafodotin/temozolomide/lomustine) for all randomized participants that had the Epidermal Growth Factor Receptor (EGFRvIII) mutation. (NCT02343406)
Timeframe: From the date of randomization up to the date of participant's death; participants who completed treatment were to be assessed every 12 weeks, up to 28 months
| Intervention | months (Number) | ||
|---|---|---|---|
| 25th quartile | 50th quartile | 75th quartile | |
| ABT-414_adult | 5.0 | 8.4 | 13.9 |
| ABT-414/Temozolomide | 6.3 | 9.4 | 14.4 |
| Control (Temozolomide/Lomustine) | 4.7 | 7.5 | 12.4 |
Progression-free survival was assessed per response assessment in neuro-oncology criteria (RANO) criteria and assessed by an independent review committee and was defined as the length of time during and after the treatment of a disease, that the participant lived with the disease but did not get worse. (NCT02343406)
Timeframe: Measured every 8 weeks from date of randomization until the date of first objective progression or subject's death, whichever occurred first, up to 2 years
| Intervention | months (Number) | ||
|---|---|---|---|
| 25th quartile | 50th quartile | 75th quartile | |
| ABT-414_adult | 1.5 | 1.9 | 3.5 |
| ABT-414/Temozolomide | 1.8 | 2.7 | 4.9 |
| Control (Temozolomide/Lomustine) | 1.6 | 1.9 | 4.2 |
Median OS depending on treatment arm in patients with methylated MGMT (NCT02209948)
Timeframe: Through the whole study. 4 years. The median follow up for each patient was 33.4 months
| Intervention | months (Median) |
|---|---|
| Temozolomide | 20.7 |
| Without Treatment | 27.1 |
Median Progression Free Survival depending on treatment arm in patients with MGMT methylation (NCT02209948)
Timeframe: Through the whole study. 4 years. The median follow up for each patient was 33.4 months
| Intervention | months (Median) |
|---|---|
| Temozolomide | 11.4 |
| Without Treatment | 8.5 |
Time between start of treatment and death (NCT02209948)
Timeframe: Through the whole study. 4 years. The median follow up for each patient was 33.4 months
| Intervention | months (Median) |
|---|---|
| Temozolomide | 18.2 |
| Without Treatment | 23.3 |
It will be measured following Response assessment in neuro-oncology (RANO) guidelines: progression-free survival (NCT02209948)
Timeframe: Through the whole study. 4 years. The median follow up for each patient was 33.4 months
| Intervention | months (Median) |
|---|---|
| Temozolomide | 9.5 |
| Without Treatment | 7.77 |
"Percentage of patients without progression of disease and time between start of treatment and progression of disease.~The progression disease is defined as the time from the date of randomization to the date of progression defined according to the RANO criteria." (NCT02209948)
Timeframe: 6 month
| Intervention | percentage of patients (Number) |
|---|---|
| Temozolomide | 61.3 |
| Without Treatment | 55.7 |
Total number of patients presenting adverse events, stratified by type of event and grade. Adverse Events of special interest: Only relevant differences in toxicity by arm. (NCT02209948)
Timeframe: Through the whole study. 4 years
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lymphopenia72025836 | Lymphopenia72025835 | Thrombocytopenia72025835 | Thrombocytopenia72025836 | Nausea and vomiting72025835 | Nausea and vomiting72025836 | Fatigue72025836 | Fatigue72025835 | Leucopenia72025835 | Leucopenia72025836 | |||||||||||||||||||||
| Grade 1-2 | Grade 3-4 | not affected | ||||||||||||||||||||||||||||
| Temozolomide | 52 | |||||||||||||||||||||||||||||
| Without Treatment | 33 | |||||||||||||||||||||||||||||
| Temozolomide | 3 | |||||||||||||||||||||||||||||
| Temozolomide | 25 | |||||||||||||||||||||||||||||
| Without Treatment | 46 | |||||||||||||||||||||||||||||
| Temozolomide | 36 | |||||||||||||||||||||||||||||
| Without Treatment | 17 | |||||||||||||||||||||||||||||
| Temozolomide | 2 | |||||||||||||||||||||||||||||
| Temozolomide | 42 | |||||||||||||||||||||||||||||
| Without Treatment | 62 | |||||||||||||||||||||||||||||
| Temozolomide | 30 | |||||||||||||||||||||||||||||
| Without Treatment | 10 | |||||||||||||||||||||||||||||
| Without Treatment | 0 | |||||||||||||||||||||||||||||
| Temozolomide | 50 | |||||||||||||||||||||||||||||
| Without Treatment | 69 | |||||||||||||||||||||||||||||
| Temozolomide | 35 | |||||||||||||||||||||||||||||
| Without Treatment | 21 | |||||||||||||||||||||||||||||
| Temozolomide | 0 | |||||||||||||||||||||||||||||
| Temozolomide | 45 | |||||||||||||||||||||||||||||
| Without Treatment | 58 | |||||||||||||||||||||||||||||
| Temozolomide | 29 | |||||||||||||||||||||||||||||
| Without Treatment | 20 | |||||||||||||||||||||||||||||
| Temozolomide | 1 | |||||||||||||||||||||||||||||
| Without Treatment | 59 | |||||||||||||||||||||||||||||
"ORR was measured by the percentage of participants whose best overall response (BOR) is confirmed Complete Response (CR) or Partial Response (PR) divided by response evaluable participants. The best overall response (BOR) is determined once all the data for the participant is known. BOR is defined as the best response designation, as determined by investigators, recorded between the date of randomization and the date of objectively documented progression per RANO criteria, the date of subsequent therapy, or date of surgical resection, whichever occurs first.~Confidence interval based on the Clopper and Pearson method. For the comparison of the odds ratio of Nivolumab over Bevacizumab, the Cochran-Mantel-Haenszel (CMH) method of weighting was utilized." (NCT02017717)
Timeframe: Time from randomization to the date of the first documented tumor progression or death due to any cause (up to approximately 31 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Cohort 2: Arm N3 | 7.8 |
| Cohort 2: Arm B | 23.1 |
OS(12) is measured as the percentage of participants alive at 12 months per Kaplan-Meier curve of OS. Z test with variance estimation based on Greenwood formula using log(-log) transformation. (NCT02017717)
Timeframe: From randomization to 12 months following randomization
| Intervention | Percentage of Participants (Number) |
|---|---|
| Cohort 2: Arm N3 | 41.8 |
| Cohort 2: Arm B | 42.4 |
"OS was measured in months from the time of randomization to the event date (death) due to any cause. A participant who has not died will be censored at the last known alive date.~Based on Kaplan-Meier Estimates. Hazard ratio from Cox proportional hazard model stratified by presence of measurable lesions at baseline per IVRS. P-value from log-rank test stratified by presence of measurable lesions at baseline per IVRS." (NCT02017717)
Timeframe: Time between the date of randomization and the date of death due to any cause (up to 17Jun2019, approximately 5 years)
| Intervention | Months (Median) |
|---|---|
| Cohort 2: Arm N3 | 9.77 |
| Cohort 2: Arm B | 10.05 |
"OS was measured in months from the time of randomization (Part B) or time of treatment (Part A) to the event date (death) due to any cause. A participant who has not died will be censored at the last known alive date.~Based on Kaplan-Meier Estimates." (NCT02017717)
Timeframe: Time between the date of randomization and the date of death due to any cause (up to 17Jun2019, approximately 5 years)
| Intervention | Months (Median) |
|---|---|
| Part A Cohort 1c: Arm N3+RT+TMZ | 22.08 |
| Part A Cohort 1d: Arm N3+RT | 14.41 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 15.95 |
| Part B Cohort 1d: Arm N3+RT | 13.96 |
PFS was measured in months from the time of randomization to the date of the first documented tumor progression or death due to any cause. Based on Kaplan-Meier Estimates. Hazard ratio from Cox proportional hazard model stratified by presence of measurable lesions at baseline per IVRS. (NCT02017717)
Timeframe: Time from randomization to the date of the first documented tumor progression or death due to any cause (up to 17Jun2019, approximately 5 years)
| Intervention | Months (Median) |
|---|---|
| Cohort 2: Arm N3 | 1.51 |
| Cohort 2: Arm B | 3.61 |
The percentage of participants who experienced an adverse event by worst grade in each treatment arm. Toxicities were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. MedDRA Version: 24.1 (NCT02017717)
Timeframe: From first dose to 30 days post last dose (up to approximately 34 months).
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Cohort 1: Arm N1+I3 | 0 | 10.0 | 70.0 | 20.0 | 0 |
| Cohort 1: Arm N3 | 20.0 | 30.0 | 40.0 | 10.0 | 0 |
| Cohort 1b: Arm N3+I1 | 5.0 | 25.0 | 50.0 | 20.0 | 0 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 6.5 | 12.9 | 58.1 | 22.6 | 0 |
| Part A Cohort 1d: Arm N3+RT | 13.3 | 26.7 | 33.3 | 20.0 | 3.3 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 3.6 | 28.6 | 50.0 | 10.7 | 3.6 |
| Part B Cohort 1d: Arm N3+RT | 17.9 | 25.0 | 35.7 | 21.4 | 0 |
The percentage of participants who experienced a drug-related adverse event leading to drug discontinuation by worst grade (grade 5 being the worst) prior to complete four-dose treatment. Toxicities were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. MedDRA Version: 24.1 (NCT02017717)
Timeframe: Includes events reported between first dose and 30 days after last dose of study therapy (up to 3 doses, up to approximately 2 months)
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Cohort 1: Arm N1+I3 | 0 | 0 | 16.7 | 33.3 | 0 |
| Cohort 1: Arm N3 | 0 | 0 | 0 | 0 | 0 |
| Cohort 1b: Arm N3+I1 | 0 | 0 | 0 | 0 | 0 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 0 | 0 | 66.7 | 0 | 0 |
| Part A Cohort 1d: Arm N3+RT | 0 | 0 | 0 | 0 | 0 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 0 | 0 | 0 | 0 | 0 |
| Part B Cohort 1d: Arm N3+RT | 0 | 0 | 50.0 | 0 | 0 |
The percentage of participants who experienced a serious adverse event by worst grade in each treatment arm. Toxicities were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. MedDRA Version: 24.1 (NCT02017717)
Timeframe: From first dose to 30 days post last dose (up to approximately 34 months).
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Cohort 1: Arm N1+I3 | 0 | 0 | 60.0 | 20.0 | 0 |
| Cohort 1: Arm N3 | 0 | 10.0 | 40.0 | 0 | 0 |
| Cohort 1b: Arm N3+I1 | 0 | 5.0 | 35.0 | 15.0 | 0 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 3.2 | 0 | 45.2 | 16.1 | 0 |
| Part A Cohort 1d: Arm N3+RT | 0 | 16.7 | 16.7 | 16.7 | 3.3 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 0 | 3.6 | 35.7 | 3.6 | 3.6 |
| Part B Cohort 1d: Arm N3+RT | 0 | 10.7 | 32.1 | 14.3 | 0 |
"The percentage of participants who experienced a laboratory abnormality of the liver in each treatment arm.~MedDRA Version: 24.1~Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN) Denominator corresponds to participants with at least on one treatment measurement of the corresponding laboratory parameter. Includes laboratory results reported after the first dose and within 30 days of last dose of study therapy." (NCT02017717)
Timeframe: From first dose to 30 days post last dose (up to approximately 34 months).
| Intervention | Percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ALT OR AST > 3*ULN | ALT OR AST > 5*ULN | ALT OR AST > 10*ULN | ALT OR AST > 20*ULN | TOTAL BILIRUBIN (Tbili) > 2*ULN | ALP > 1.5*ULN | ALT or AST > 3xULN w/ Tbili > 1.5*ULN within 1 day | ALT or AST > 3*ULN w/ Tbili > 1.5*ULN within 30 days | ALT or AST > 3xULN w/ Tbili > 2*ULN within 1 day | ALT or AST > 3*ULN w/ Tbili > 2*ULN within 30 days | |
| Cohort 1: Arm N1+I3 | 30.0 | 20.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 |
| Cohort 1: Arm N3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cohort 1b: Arm N3+I1 | 15.8 | 10.5 | 5.3 | 5.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 22.6 | 12.9 | 6.5 | 3.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Part A Cohort 1d: Arm N3+RT | 10.0 | 3.3 | 3.3 | 3.3 | 0.0 | 3.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 18.5 | 11.1 | 3.7 | 0.0 | 7.4 | 0.0 | 3.7 | 3.7 | 3.7 | 3.7 |
| Part B Cohort 1d: Arm N3+RT | 14.8 | 3.7 | 3.7 | 3.7 | 0.0 | 3.7 | 0.0 | 0.0 | 0.0 | 0.0 |
"The percentage of participants who experienced a laboratory abnormality of the thyroid in each treatment arm.~MedDRA Version: 24.1~Free T3 (FT3) Free T4 (FT4) Lower Limit of Normal (LLN)~(A) Within a 2-week window after the abnormal TSH test date. (B) Includes participants with TSH abnormality and with no FT3/FT4 test values in the 2-week window or with non-abnormal value(s) from only one of the two tests and no value from the other test." (NCT02017717)
Timeframe: From first dose to 30 days post last dose (up to approximately 34 months).
| Intervention | Percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TSH > ULN | TSH > ULN, WITH TSH <= ULN AT BASELINE | TSH > ULN, WITH AT LEAST ONE FT3/FT4 TEST < LLN | TSH > ULN, WITH ALL OTHER FT3/FT4 TEST >= LLN | TSH > ULN, WITH FT3/FT4 TEST MISSING | TSH < LLN | TSH < LLN, WITH TSH >= LLN AT BASELINE | TSH | TSH < LLN, WITH ALL OTHER FT3/FT4 TEST <= ULN | TSH < LLN, WITH FT3/FT4 TEST MISSING | |
| Cohort 1: Arm N1+I3 | 20.0 | 20.0 | 20.0 | 0.0 | 0.0 | 60.0 | 60.0 | 30.0 | 20.0 | 10.0 |
| Cohort 1: Arm N3 | 50.0 | 30.0 | 30.0 | 10.0 | 10.0 | 30.0 | 30.0 | 10.0 | 20.0 | 0.0 |
| Cohort 1b: Arm N3+I1 | 10.5 | 10.5 | 10.5 | 0.0 | 0.0 | 31.6 | 31.6 | 15.8 | 10.5 | 5.3 |
| Part A Cohort 1c: Arm N3+RT+TMZ | 23.3 | 20.0 | 13.3 | 6.7 | 3.3 | 43.3 | 33.3 | 10.0 | 30.0 | 3.3 |
| Part A Cohort 1d: Arm N3+RT | 16.7 | 16.7 | 13.3 | 0.0 | 3.3 | 40.0 | 40.0 | 13.3 | 16.7 | 10.0 |
| Part B Cohort 1c: Arm N3+RT+TMZ | 11.1 | 11.1 | 7.4 | 3.7 | 0.0 | 22.2 | 18.5 | 11.1 | 11.1 | 0.0 |
| Part B Cohort 1d: Arm N3+RT | 7.4 | 7.4 | 0.0 | 7.4 | 0.0 | 33.3 | 18.5 | 0.0 | 29.6 | 3.7 |
Overall survival for patients by Methylation status of the O6-methylguanine-DNA methyltransferase promoter (NCT00482677)
Timeframe: 7 years
| Intervention | Months (Median) |
|---|---|
| Temozolomide | 13.47 |
| Radiation | 7.69 |
Time from date of randomization to the date of death of any causes, or censored at last known alive date. (NCT00482677)
Timeframe: 7 years
| Intervention | Months (Median) |
|---|---|
| Temozolomide | 9.33 |
| Radiation | 7.62 |
Time from date of randomization to the date of disease progression or death whichever came first, or censored at last disease assessment date. (NCT00482677)
Timeframe: 7 years
| Intervention | Months (Median) |
|---|---|
| Temozolomide | 5.29 |
| Radiation | 3.94 |
To evaluate the maximum tolerated dose of nanoliposomal irinotecan with continuous low-dose temozolomide for patients with recurrent glioblastoma. (NCT03119064)
Timeframe: Every two weeks for 4 weeks
| Intervention | mg/m^2 (Number) |
|---|---|
| All Participants | 50 |
"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT03119064)
Timeframe: Every 2 months on study treatment then very 3 months once treatment has stopped, until progression of disease up to 2 years.
| Intervention | participants (Number) | |
|---|---|---|
| Partial Response | Progressive Disease | |
| Dose 1 | 1 | 8 |
| Dose 2 | 1 | 2 |
Treatment emergent toxicities of nanoliposomal irinotecan with continuous low-dose temozolomide using CTCAE version 4.03, grades 2 through 4 (NCT03119064)
Timeframe: Baseline through 30 days post off study treatment
| Intervention | events (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | ALT/AST | Hypokalemia | Hypophosphatemia | Nausea | Fatigue | Diarrhea | Anorexia | Dehydration | Urticaria | |
| Dose 1 | 0 | 2 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 1 |
| Dose 2 | 1 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 2 | 0 |
"The proportion of Grade IV MGMT un-methylated patients that experience confirmed-progression-free survival at 6 months (CPFS6). Progression is defined by any of the following:~≥25% increase in the sum of products of perpendicular diameters of enhancing lesions compared to the smallest tumor measurement obtained either at baseline or best response, on stable or increasing doses of corticosteroids~Significant increase in T2/FLAIR non-enhancing lesion on stable or increasing doses of corticosteroids compared to baseline scan or best response following initiation of therapy, not due to co-morbid events~Any new lesion~Clear clinical deterioration not attributable to other causes apart from the tumor or changes in corticosteroid dose.~Failure to return for evaluation due to death or deteriorating condition~Clear progression of non-measurable disease" (NCT01991977)
Timeframe: Time from registration to the confirmed disease progression, assessed at 6 months
| Intervention | proportion of participants (Number) |
|---|---|
| Diagnostic (PET, pMRI, DTI, IMRT, Temozolomide) | 0.795 |
The MDASI-BT assesses the severity of multiple brain tumor-related symptoms and the impact of these symptoms on daily functioning in the last 24 hours. It consists of 22 symptom items and 6 interference items, each rated from 0 to 10. MDASI-BT symptom severity score is defined as average over 13 core symptom items and 9 brain tumor symptom items, with a total score of 0 to 10, with higher score indicating worse symptoms/interference. Changes in symptom severity score were classified into 3 categories: improved (≤ -1), stable (> -1 and < 1), and deteriorated (≥ 1). Deterioration is defined as satisfying the deterioration criteria (i.e., increase in symptom severity score by ≥ 1 unit) without further improvement (i.e., failing to satisfy deterioration criteria) within 8 weeks or occurrence of death. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 11.0 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 6.1 |
The MDASI-BT assesses the severity of multiple brain tumor-related symptoms and the impact of these symptoms on daily functioning in the last 24 hours. It consists of 22 symptom items and 6 interference items, each rated from 0 to 10. MDASI-BT symptom interference score is defined as an average of 6 interference items, with a total score of 0 to 10, where higher scores indicate worse interference. Changes in symptom interference score were classified into 3 categories: improved (≤ -1), stable (> -1 and < 1), and deteriorated (≥ 1). Deterioration is defined as satisfying the deterioration criteria (i.e., increase in symptom interference score by ≥ 1 unit) without further improvement (i.e., failing to satisfy deterioration criteria) within 8 weeks or occurrence of death. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 9.7 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 6.1 |
The HVLT-R consists of 3 parts. Free call has a range of 0 to 36, delayed recall has a range from 0 to 12, and delayed recognition has a range of -12 to 12. Higher scores indicating better function in all 3 parts. When scoring the HVLT-R, the 3 learning trials are combined to calculate a total recall score (range -12 to 60). Deterioration is defined as satisfying the deterioration criteria (i.e., decrease in HVLT-R total recall score by 5 units) without further improvement within 8 weeks or occurrence of death. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 13.2 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 10.7 |
Time to OS is defined as the number of days from the date of randomization to the date of death due to any cause. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 18.2 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 19.8 |
Time to OS is defined as the number of days from the date of randomization to the date of death due to any cause. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | NA |
| Depatuxizumab Mafodotin, Radiation and TMZ | 25.4 |
"Time to OS is defined as the number of days from the date of randomization to the date of death due to any cause.~Unmethylated MGMT promoter is associated with a worse prognosis in GBM" (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 16.2 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 16.1 |
Time to OS is defined as the number of days from the date of randomization to the date of death due to any cause. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 18.7 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 18.9 |
PFS will be defined as the number of days from the date of randomization to the date of earliest disease progression based on Response Assessment in Neuro-Oncology (RANO) criteria or to the date of death, if disease progression does not occur. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 5.9 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 8.3 |
PFS will be defined as the number of days from the date of randomization to the date of earliest disease progression based on Response Assessment in Neuro-Oncology (RANO) criteria (see Wen et al. J Clin Oncol. 2010 Apr 10;28(11):1963-72) or to the date of death, if disease progression does not occur. (NCT02573324)
Timeframe: Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).
| Intervention | months (Median) |
|---|---|
| Placebo, Radiation and TMZ | 6.3 |
| Depatuxizumab Mafodotin, Radiation and TMZ | 8.0 |
KPS is an 11-level score (0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100) which ranges between 0 (death) to 100 (complete healthy status); a higher score represents a higher ability to perform daily tasks. Deterioration in KPS was defined as decrease of 20 or more points in KPS score. (NCT00967330)
Timeframe: Baseline, Post-Baseline (up to Month 30)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Bevacizumab + Irinotecan | -3.3399 |
| Temozolomide | -5.4909 |
Overall survival was defined as the time from randomization to death from any cause. OS was estimated using Kaplan-Meier method. (NCT00967330)
Timeframe: From baseline until death (up to 4.5 years)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + Irinotecan | 16.64 |
| Temozolomide | 17.30 |
Progression-free survival was defined as the time from randomization to objective tumor progression or death from any cause, whichever came first. Progression was defined as 25 percent (%) increase in size of enhancing tumor or any new tumor on gadolinium contrast agent magnetic resonance imaging (Gd-MRI) scans, or neurologically worse, and steroids stable or increased. Percentage of participants achieving PFS without disease progression or death was reported. (NCT00967330)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab + Irinotecan | 79.31 |
| Temozolomide | 42.59 |
Participants used corticosteroids for the glioblastoma condition. Corticosteroids included dexamethasone, methylprednisone, fortecortin, hydrocortisone, urbason, and prednisolone. (NCT00967330)
Timeframe: From baseline to Month 6
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab + Irinotecan | 80.0 |
| Temozolomide | 78.7 |
Progression-free survival was defined as the time from randomization to objective tumor progression or death from any cause, whichever came first. Progression was defined as 25% increase in size of enhancing tumor or any new tumor on Gd-MRI scans, or neurologically worse, and steroids stable or increased. PFS was estimated using Kaplan-Meier method. (NCT00967330)
Timeframe: From baseline to the end of the study (up to 4.5 years)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + Irinotecan | 9.74 |
| Temozolomide | 5.99 |
(NCT00967330)
Timeframe: From baseline until end of study (up to 4.5 years)
| Intervention | years (Median) |
|---|---|
| Bevacizumab + Irinotecan | NA |
| Temozolomide | NA |
EORTC QLQ-BN20 consisted of 20 items assessing visual disorders, motor dysfunction, communication deficit, various disease symptoms (e.g. headaches and seizures), treatment toxicities (e.g. hair loss) and future uncertainty. All of the 20 items are rated on a 4 point Likert scale from 1=not at all, 2=a little, 3=quite a bit and 4=very much, and were linearly transformed to a 0-100 scale, with higher scores indicating more severe symptoms. (NCT00967330)
Timeframe: Baseline, Post-Baseline (up to Month 30)
| Intervention | units on a scale (Least Squares Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Future uncertainty | Visual disorder | Motor dysfunction | Communication deficit | Headaches | Drowsines | Hair loss | Itchy skin | Weakness of legs | Bladder control | |
| Bevacizumab + Irinotecan | -5.2779 | -2.0869 | 5.4416 | 4.7440 | 4.3905 | 11.7204 | 11.9235 | 5.4882 | 8.9586 | 1.5020 |
| Temozolomide | -8.5478 | -3.202 | 6.5429 | 4.6431 | -3.9389 | 8.2805 | 7.3328 | 6.4690 | 7.9245 | 1.9710 |
The MMSE briefly measures orientation to time and place, immediate recall, short-term verbal memory, calculation, language and construct ability. Each area tested had a designated point value, the total score can range from 0 to 30, with a higher score indicating better function. (NCT00967330)
Timeframe: Baseline, Post-Baseline (up to Month 30)
| Intervention | units on a scale (Least Squares Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Orientation to time and place | Immediate recall | Repetitions required | Calculations | Short-term verbal memory | Language and construct ability | Total Score | |
| Bevacizumab + Irinotecan | -0.01771 | -0.00264 | -0.05763 | -0.2153 | 0.2012 | -0.1254 | -0.2871 |
| Temozolomide | -0.2110 | -0.03219 | 0.08530 | -0.2120 | 0.1634 | -0.2057 | -0.5999 |
The EORTC QLQ-C30 incorporates: 5 functional scales (physical, role, cognitive, emotional, and social); 9 symptom scales (fatigue, pain, nausea and vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties); and a global health and quality-of-life scale. Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to 0-100 scale; higher score for Global Qol/functional scales=better level of functioning or a higher score for symptom scale=greater degree of symptoms. The change in global health status was determined to be the difference in values at baseline and each specific visit. The term ''baseline'' refers to the time of randomization to the maintenance phase. (NCT00967330)
Timeframe: Baseline, Post-Baseline (up to Month 30)
| Intervention | units on a scale (Least Squares Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical Functioning | Role Functioning | Emotional Functioning | Cognitive Functioning | Social Functioning | Global health Status /QoL (ql) | Fatique | Nausea/Vomitting | Pain | Dyspnoea | Insomnia | Appetite loss | Constipation | Diarrhoea | Financial Problems | |
| Bevacizumab + Irinotecan | -8.3513 | -0.7635 | 2.2774 | -2.0188 | -6.2324 | -3.1134 | 5.5228 | 8.9557 | 10.6876 | 3.7134 | -2.6266 | 13.7423 | 8.0230 | 6.0230 | 4.8435 |
| Temozolomide | -6.2511 | -2.2339 | 2.2547 | -3.8401 | -4.6198 | 0.3855 | 2.1779 | 4.7597 | 1.5926 | 0.5046 | -7.5026 | 10.9601 | 4.0855 | -0.1455 | 2.1140 |
BOR was defined as the best response observed for a participant during assessment. Number of participants who had BOR as CR and number of participants who had BOR as CR or PR were reported. Complete response was defined as disappearance of all enhancing tumor on consecutive Gd-MRI scans at least 1 month apart, off steroids, and neurologically stable or improved. Partial response was defined as 50% reduction in size of enhancing tumor on consecutive Gd-MRI scans at least 1 month apart, steroids stable or reduced, and neurologically stable or improved. (NCT00967330)
Timeframe: 4 week after radiotherapy (RT) (up to Week 4), >4 Week after RT (up to Week 8) and Month 6
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| CR at 4 weeks after RT (n=110,46) | CR at >4 weeks after RT (n=95,35) | CR at Month 6 (n=91,28) | CR or PR at 4 Week after RT (n=110,46) | CR or PR at >4 Week after RT (n=95,35) | CR or PR at Month 6 (n=91,28) | |
| Bevacizumab + Irinotecan | 11 | 11 | 3 | 42 | 18 | 5 |
| Temozolomide | 2 | 1 | 1 | 6 | 3 | 3 |
Discontinuation was defined as the percentage of participants who permanently discontinued treatment in either treatment arm. Percentage of participant with individual discontinuation reason are reported. CNS: central nervous system; CTCAE: Common Terminology Criteria for Adverse Events . Other reason refers to any other reason than the specified ones. (NCT00967330)
Timeframe: From baseline until death (up to 4.5 years)
| Intervention | percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Persisting non-hematological toxicity CTCAE Grade3 | CNS hemorrhagic event (CTCAE Grade >1) | Gastro-intestinal perforation (CTCAE Grade 1-4) | Other | Participant's wish | Progressive disease | Proteinuria (nephrotic syndrome) (CTCAE Grade 4) | Regular | Repeated CTCAE Grade 4 hematological toxicity | Venous thrombosis/embolism | Wound dehiscence requiring medical intervention | Wound dehiscence requiring surgical intervention | |
| Bevacizumab + Irinotecan | 0 | 0.9 | 0.9 | 9.5 | 6 | 74.1 | 0.9 | 1.7 | 0 | 0.9 | 0.9 | 4.3 |
| Temozolomide | 1.9 | 0 | 0 | 5.6 | 5.6 | 57.4 | 0 | 27.8 | 0.9 | 0 | 0 | 0 |
"FLAIR lesions were determined as stable, progressive or decreased. FLAIR lesions was determined as progressive only if they were not be attributed to causes apart from tumor infiltration (sequelae of radiation therapy, demyelination, ischemia, infection, seizures, or other treatment effects). Percentage of participants are based on ITT population.~Dis.=Discontinuation." (NCT00967330)
Timeframe: At screening, Baseline, Month 6 and Therapy Discontinuation (Up to 4.5 years)
| Intervention | percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Screening: Initial Flair Lesion (n=116,54) | Screening:Stable Flair Lesion (n=116,54) | Baseline:Decreased FLAIR Lesions (n=105,46) | Baseline:Initial FLAIR Lesions (n=105,46) | Baseline:Progressive FLAIR Lesions (n=105,46) | Baseline: Stable FLAIR Lesions (n=105,46) | Month 6:Progressive FLAIR Lesions (n=91,28) | Month 6: Stable FLAIR Lesions (n=91,28) | Therapy Dis.:Decreased FLAIR Lesions (n=55,31) | Therapy Dis.:Progressiv FLAIR Lesions (n=55,31) | Therapy Dis.:Stable FLAIR Lesions (n=55,31) | |
| Bevacizumab + Irinotecan | 72.4 | 17.2 | 16.4 | 18.1 | 14.7 | 41.4 | 16.4 | 62.1 | 0.9 | 29.3 | 17.2 |
| Temozolomide | 72.2 | 16.7 | 20.4 | 18.5 | 11.1 | 35.2 | 22.2 | 29.6 | 0.0 | 27.8 | 29.6 |
DLT is defined as any of the following events occurring during the first 8 weeks of treatment with RAD001 and temozolomide and attributable to the study drugs: any grade 3 or 4 thrombocytopenia, grade 4 anemia, or grade 4 neutropenia lasting more than 7 days; any non-hematologic grade 3 or greater adverse event (AE), excluding alopecia, despite maximal medical therapy; any grade 4 radiation-induced skin changes; failure to recover from adverse events to be eligible for re-treatment with RAD001 and temozolomide within 14 days of the last dose of either drug; or any episode of non-infectious pneumonitis grade 2, 3, or 4 of any duration. Adverse events are graded using CTCAE v4.0. Grade refers to the severity of the AE. The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE (NCT01062399)
Timeframe: From start of treatment to eight weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ph I: RT + TMZ + RAD001 2.5 mg/Day | 2 |
| Ph I: RT + TMZ + RAD001 5 mg/Day | 2 |
| Ph I: RT + TMZ + RAD001 10 mg/Day | 2 |
Overall survival time is defined as time from/randomization to the date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. (NCT01062399)
Timeframe: Analysis occured after 134 events (progression or death) were reported. Patients were followed from randomization to death or study termination whichever occurs first, up to 36.7 months.
| Intervention | months (Median) |
|---|---|
| Ph II: RT + TMZ | 21.2 |
| Ph II: RT + TMZ + RAD001 | 16.5 |
Using the Response Assessment in Neuro- Oncology (RANO) criteria, the progression is defined by any of the following: > 25% increase in sum of the products of perpendicular diameters of enhancing lesions compared to the smallest tumor measurement obtained either at baseline (if no decrease) or best response, on stable or increasing doses of corticosteroids; Significant increase in T2/FLAIR non-enhancing lesion on stable or increasing doses of corticosteroids compared to baseline scan or best response following initiation of therapy, not due to co-morbid events; Any new lesion; Clear clinical deterioration not attributable to other causes apart from the tumor or changes in corticosteroid dose; Failure to return for evaluation due to death or deteriorating condition; Clear progression of non-measurable disease. PFS time is defined as time from registration to date of progression, death, or last known follow-up (censored). PFS rates are estimated using the Kaplan-Meier method. (NCT01062399)
Timeframe: Analysis occured after 134 events (progression or death) were reported. Patients were followed from randomization to death or study termination whichever occurs first, up to 36.7 months.
| Intervention | months (Median) |
|---|---|
| Ph II: RT + TMZ | 10.2 |
| Ph II: RT + TMZ + RAD001 | 8.2 |
"AE reporting in Phase I was split up by treatment timing: concurrent treatment (RT, TMZ, RAD001); post-RT treatment (TMZ, RAD001) along with all AE's reported in follow-up.~The worst/highest grade of any adverse event reported in each time period was determined for each patient. The percentage of patients in each grade level is reported. Adverse events are graded using CTCAE v4.0. Grade refers to the severity of the AE. The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE." (NCT01062399)
Timeframe: Analysis occured after 134 events (progression or death) were reported. Patients were followed from randomization to death or study termination whichever occurs first, up to 36.7 months.
| Intervention | percentage of participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Concurrent treatment: Grade 1 | Concurrent treatment: Grade 2 | Concurrent treatment: Grade 3 | Concurrent treatment: Grade 4 | Concurrent treatment: Grade 5 | Post-RT treatment: Grade 1 | Post-RT treatment: Grade 2 | Post-RT treatment: Grade 3 | Post-RT treatment: Grade 4 | Post-RT treatment: Grade 5 | |
| Ph I: RT + TMZ + RAD001 10 mg/Day | 12.5 | 0.0 | 87.5 | 0.0 | 0.0 | 0.0 | 100.0 | 0.0 | 0.0 | 0.0 |
| Ph I: RT + TMZ + RAD001 2.5 mg/Day | 0.0 | 0.0 | 50.0 | 50.0 | 0.0 | 0.0 | 0.0 | 71.4 | 14.3 | 14.3 |
| Ph I: RT + TMZ + RAD001 5 mg/Day | 11.1 | 33.3 | 44.4 | 11.1 | 0.0 | 0.0 | 42.9 | 28.6 | 0.0 | 0.0 |
The worst/highest grade of any adverse event reported was determined for each patient. The percentage of patients in each grade level is reported. Adverse events are graded using CTCAE v4.0. Grade refers to the severity of the AE. The CTCAE v4.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. (NCT01062399)
Timeframe: Analysis occured after 134 events (progression or death) were reported. Patients were followed from randomization to death or study termination whichever occurs first, up to 36.7 months.
| Intervention | percentage of patients (Number) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Ph II: RT + TMZ | 0 | 0 | 3 | 3 | 2 |
| Ph II: RT + TMZ + RAD001 | 0 | 3 | 5 | 0 | 1 |
Duration of overall survival for patients that are alive (NCT03034135)
Timeframe: 14 months
| Intervention | months (Median) |
|---|---|
| DSF-Cu | 7.1 |
Duration of progression free survival according to RANO criteria (NCT03034135)
Timeframe: 12 months
| Intervention | months (Median) |
|---|---|
| DSF-Cu | 1.7 |
Number of Participants with Grade 3 and 4 serious adverse events (NCT03034135)
Timeframe: 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| DSF-Cu | 2 |
Percentage of patients that are free from progressive disease per RANO criteria (NCT03034135)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| DSF-Cu | 14 |
ORR will be defined as the percentage of patients with complete response (CR) or partial response (PR) according to the RANO criteria. (NCT03034135)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Complete response | Partial Response | |
| DSF-Cu | 0 | 0 |
Percentage of patients that are alive (NCT03034135)
Timeframe: 6 months and 12 months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 6 months | 12 months | |
| DSF-Cu | 61 | 35 |
Median overall survival (NCT03072134)
Timeframe: Two years
| Intervention | Months (Median) |
|---|---|
| Total Cohort | 18.4 |
Using a 3+3 dose escalation design, three to six patients were to be enrolled per dose in each of the 3 cohorts. If no patients in the cohort experienced a dose-limiting toxicity (DLT), then the next cohort enrolled a minimum of 3 patients. If one of three patients experienced a DLT, then 3 more patients were evaluated at that dose level. If none of these three additional patients experienced a DLT, then dose escalation occurs, unless this is the highest dose, in which case dose escalation is stopped and the highest dose is declared the MTD. If 1 or more of these additional 3 patients had a DLT, then three additional patients may be entered, after discussion with the sponsor, at the next lowest does level if only three patients were treated previously at that dose. If two or more patients experienced a DLT Dose escalation will be stopped; 3 more patients could be added with sponsor approval at the next lower dose level. (NCT03072134)
Timeframe: Two years
| Intervention | Percentage of dose-limiting toxicities (Number) |
|---|---|
| Arm B/Cohort 1 | 0 |
| Arm B/Cohort 2 | 0 |
| ArmB/Cohort 3 | 17 |
Median progression-free survival (NCT03072134)
Timeframe: two years
| Intervention | Months (Median) |
|---|---|
| Total Cohort | 9.1 |
Per Response Assessment in Neuro-Oncology Criteria (RANO, 2017) for target lesions as assessed by MRI: Complete Response (CR): The enhancing tumor is no longer seen by neuroimaging; Partial Response (PR): Decrease of ≥ 50% in the product of two diameters with the patient on a stable or decreasing dose of steroids; Minor Response (MR): Decrease in diameter products of < 50% with the patient on a stable or decreasing dose of steroids; Stable Disease (SD): The scan shows no change. Patients should be receiving stable or decreasing doses of steroids; Progression (P): Increase of > 25% in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. A concomitant decrease in steroid dose will rule out a progression designation during the first two months after completion of radiation; Pseudoprogression (PP): Radiological changes without concomitant neurological changes. (NCT03072134)
Timeframe: Two years
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Percentage of participants with tumor response: Partial | Percentage of participants with tumor response: Pseudoprogression | Percentage of participants with tumor response: Stable disease | |
| Total Cohort | 8 | 8 | 84 |
Overall survival time is defined as time from registration/randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30 subscales are calculated as the mean of component items, then standardized such that subscale scores range from 0 to 100. A high score for a functional scale represents a healthy level of functioning. Controlled Oral Word Association (COWA) score is the sum of correct responses with a range of 0 to infinity. A higher score indicates better functioning. Hopkins Verbal Learning Test - Revised (HVLT-R) score ranges from 0 to 36 for total recall is 0 to 36, 0 to 12 for delayed recall, and -12 to 12 for recognition. A higher score indicates better functioning. (NCT00304031)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
| Intervention | months (Median) |
|---|---|
| Both Arms Combined | 17.5 |
"Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline." (NCT00304031)
Timeframe: Baseline and mid-cycle 1 (approximately 12 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | -4.58 |
| Dose-dense Adjuvant TMZ | -2.63 |
"Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline." (NCT00304031)
Timeframe: Baseline and mid-cycle 4 (approximately 24 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | -2.78 |
| Dose-dense Adjuvant TMZ | -0.72 |
The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration. Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline. (NCT00304031)
Timeframe: Baseline and mid-cycle 1 (approximately 12 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | 0.48 |
| Dose-dense Adjuvant TMZ | 0.39 |
The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration. Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline. (NCT00304031)
Timeframe: Baseline and mid-cycle 4 (approximately 24 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | -0.23 |
| Dose-dense Adjuvant TMZ | 0.19 |
"Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best)." (NCT00304031)
Timeframe: Baseline and cycle 10 (approximately 46 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | 73.3 |
| Dose-dense Adjuvant TMZ | 69.7 |
The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. (NCT00304031)
Timeframe: Baseline and cycle 10 (approximately 46 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | 1.17 |
| Dose-dense Adjuvant TMZ | 1.18 |
The NCF Composite score is the arithmetic mean of the Hopkins Verbal Learning Test - Revised (HVLT-R) (Free Recall, Delayed Recall, Delayed Recognition), Trail Making Test Part A (TMTA), Trail Making Test Part B (TMTB), and Controlled Oral Word Association (COWA) test scores, all of which are standardized, adjusting for age, education, and gender as necessary, such that mean is 0 and standard deviation is 1. A participant must have at least 5 of the 6 scores. A higher composite score indicates better neurocognitive function. (NCT00304031)
Timeframe: Baseline and cycle 10 (approximately 46 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | -0.95 |
| Dose-dense Adjuvant TMZ | -1.19 |
Overall survival time is defined as time from registration/randomization to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Analysis occurred after 647 deaths were reported. (NCT00304031)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
| Intervention | months (Median) |
|---|---|
| Conventional Adjuvant TMZ | 16.6 |
| Dose-dense Adjuvant TMZ | 14.9 |
Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. A concomitant decrease in steroid dose will rule out a progression designation during the first 2 months after completion of radiation therapy. Analysis occurred after 647 deaths were reported. (NCT00304031)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
| Intervention | months (Median) |
|---|---|
| Conventional Adjuvant TMZ | 5.5 |
| Dose-dense Adjuvant TMZ | 6.7 |
The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (did not interfere) to 10 (interfered completely). The symptom interference score is the average of the symptom interference items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration. (NCT00304031)
Timeframe: baseline and cycle 4 (approximately 22 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Conventional Adjuvant TMZ | 7 |
| Dose-dense Adjuvant TMZ | 13 |
The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration. (NCT00304031)
Timeframe: baseline and cycle 4 (approximately 22 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Conventional Adjuvant TMZ | 5 |
| Dose-dense Adjuvant TMZ | 11 |
Overall survival time is defined as time from registration to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. (NCT00304031)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
| Intervention | months (Median) |
|---|---|
| No Progression at 6 Months | 20.7 |
| Progression at 6 Months | 10.1 |
"Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change from baseline was calculated as time point value - baseline value with a positive change value indicating improved QOL from baseline." (NCT00304031)
Timeframe: Baseline, 10,12, 22, 24, and 46 weeks
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 10 (Cycle 1) | Week 12 (Cycle 1.5) | Week 22 (Cycle 4) | Week 24 (Cycle 4.5) | Week 46 (Cycle 10) | |
| Conventional Adjuvant TMZ | 0.0 | -4.6 | 3.9 | -2.8 | 5.4 |
| Dose-dense Adjuvant TMZ | -2.9 | -2.7 | -4.4 | -0.7 | -1.9 |
The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. (NCT00304031)
Timeframe: Baseline, 10, 12, 22, 24, and 46 weeks
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Week 10 (Cycle 1) | Week 12 (Cycle 1.5) | Week 22 (Cycle 4) | Week 24 (Cycle 4.5) | Week 46 (Cycle 10) | |
| Conventional Adjuvant TMZ | 1.3 | 1.4 | 1.6 | 1.0 | 1.0 | 1.2 |
| Dose-dense Adjuvant TMZ | 1.1 | 1.4 | 1.5 | 1.2 | 1.1 | 1.1 |
The NCF Composite score is the arithmetic mean of the HVLT-R (Free Recall, Delayed Recall, Delayed Recognition), TMTA, TMTB, and COWA scores, all of which are standardized, adjusting for age, education, and gender as necessary, such that mean is 0 and standard deviation is 1. A participant must have at least 5 of the 6 scores. A higher composite score indicates better neurocognitive function. (NCT00304031)
Timeframe: Baseline, 10, 22, and 46 weeks
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | Week 10 (Cycle 1) | Week 22 (Cycle 4) | Week 46 (Cycle 10) | |
| Conventional Adjuvant TMZ | -1.2 | -1.3 | -1.1 | -1.0 |
| Dose-dense Adjuvant TMZ | -1.5 | -1.45 | -1.3 | -1.2 |
Overall survival time is defined as time from randomization to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Tumor tissue submitted at baseline was analyzed to determine MGMT (O[6]-methylguanine-DNA methyltransferase) promoter methylation status (methylated / unmethylated). Analysis occurred after 647 deaths were reported. (NCT00304031)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
| Intervention | months (Median) | |
|---|---|---|
| Unmethylated MGMT | Methylated MGMT | |
| Conventional Adjuvant TMZ | 14.6 | 21.4 |
| Dose-dense Adjuvant TMZ | 13.3 | 20.2 |
Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. A concomitant decrease in steroid dose will rule out a progression designation during the first 2 months after completion of radiation therapy. Tumor tissue submitted at baseline was analyzed to determine MGMT (O[6]-methylguanine-DNA methyltransferase) promoter methylation status (methylated / unmethylated). Analysis occurred after 647 deaths were reported. (NCT00304031)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
| Intervention | months (Median) | |
|---|---|---|
| Unmethylated MGMT | Methylated MGMT | |
| Conventional Adjuvant TMZ | 5.1 | 6.5 |
| Dose-dense Adjuvant TMZ | 6.0 | 10.1 |
mPFS was based on model parameters estimated by maximum likelihood with a Newton-Raphson algorithm. The Radiation Therapy Oncology Group (RTOG) 0525 study was the main historical control used for statistical analysis. Additionally, RTOG-0825 was also used to support this outcome measure. (NCT01790503)
Timeframe: Assessed from date of first dose administered to date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years 4 months.
| Intervention | months (Median) |
|---|---|
| RP2D | 7.7 |
| RP2D-0525 (Cycle 1, Day 1) | 7.6 |
| RP2D-0825 | 7.0 |
| RP2D-0525 (Rest Period, Day 15) | 6.1 |
Overall Survival was calculated using a parametric model. The Radiation Therapy Oncology Group (RTOG) 0525 study was the main historical control used for statistical analysis. Additionally, RTOG-0825 was also used to support this outcome measure (NCT01790503)
Timeframe: Assessed from date of first dose administered to the date of death from any cause, assessed up to 4 years 4 months.
| Intervention | months (Median) |
|---|---|
| RP2D | 18.8 |
| RP2D-0525 (Cycle 1, Day 1) | 20.2 |
| RP2D-0825 | 17.0 |
| RP2D-0525 (Rest Period, Day 15) | 16.9 |
(NCT01790503)
Timeframe: Baseline up to 30 days after last dose, up to 4 years 4 months
| Intervention | Participants (Count of Participants) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thrombocytopenia | Neutropenia | Anaemia | Lymphopenia | AST increased | Platelet count decreased | Neutrophil count decreased | Leukopenia | Febrile neutropenia | ALT increased | Bone marrow failure | Haemolysis | White blood cell decreased | Lymphocyte count decreased | |
| Phase 1b Dose Escalation - 600 mg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Phase 1b Dose Escalation - 600 mg/1000 mg | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 600 mg/600 mg | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 600 mg/800 mg | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 800 mg (5 Days) | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Phase 1b Dose Escalation - 800 mg/1000 mg | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 800 mg/600 mg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 800 mg/800 mg | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escation - 800 mg (No Adjuvant Therapy) | 1 | 1 | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
(NCT01790503)
Timeframe: Baseline up to 30 days after last dose, up to 4 years 4 months
| Intervention | Participants (Count of Participants) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | Thrombocytopenia | Anaemia | ALT increased | AST increased | Platelet count decreased | Lymphopenia | White blood cell count decreased | Neutrophil count decreased | Leukopenia | Febrile neutropenia | Lymphocyte count decreased | Blood alkaline phosphatase increased | Blood creatinine increased | DRESS | Liver function test abnormal | Bone marrow failure | Haemolysis | Blood bilirubin increased | Blood iron decreased | |
| Combined 800 mg, 5 Days/Week | 9 | 6 | 7 | 8 | 8 | 7 | 4 | 5 | 2 | 2 | 2 | 3 | 3 | 3 | 1 | 1 | 0 | 1 | 1 | 1 |
| Phase 2 - 800 mg | 1 | 1 | 1 | 5 | 4 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 0 | 0 | 1 | 0 |
| Phase 2 - 800 mg/800 mg | 6 | 3 | 5 | 2 | 2 | 4 | 2 | 4 | 2 | 1 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 |
| Phase 2 Total | 7 | 4 | 6 | 7 | 6 | 5 | 3 | 5 | 2 | 2 | 1 | 2 | 3 | 3 | 1 | 1 | 0 | 0 | 1 | 1 |
(NCT01790503)
Timeframe: Baseline up to 30 days after last dose, up to 4 years 4 months
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General Disorders and Administrative Site | Nervous System Disorders | Skin and Subcutaneous Tissue Disorders | Gastrointestinal Disorders | Metabolism and Nutrition Disorders | Psychiatric Disorders | Infections and Infestations | Investigations | Respiratory, Thoracic, and Mediastinal Disorders | Musculoskeletal and Connective Tissue Disorders | Blood and Lymphatic Tissue Disorders | Vascular Disorders | Renal and Urinary Disorders | Eye Disorders | Injury, Poisoning, and Procedural Complications | Ear and Labyrinth | Endocrine Disorders | Cardiac Disorders | Hepatobiliary Disorders | Reproductive System and Breast Disorders | Immune System Disorders | Neoplasms Benign, Malignant, and Unspecified | |
| Phase 1b Dose Escalation - 600 mg | 1 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 600 mg/1000 mg | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 600 mg/600 mg | 2 | 3 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 600 mg/800 mg | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 800 mg | 5 | 4 | 4 | 3 | 2 | 1 | 1 | 2 | 3 | 3 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 800 mg/1000 mg | 5 | 5 | 5 | 5 | 4 | 3 | 5 | 4 | 3 | 2 | 1 | 3 | 3 | 2 | 2 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| Phase 1b Dose Escalation - 800 mg/600 mg | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escalation - 800 mg/800 mg | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase 1b Dose Escation - 800 mg | 3 | 2 | 1 | 2 | 2 | 1 | 3 | 3 | 2 | 1 | 1 | 2 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
(NCT01790503)
Timeframe: Baseline up to 30 days after last dose, up to 4 years 4 months
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General Disorders and Administration Site | Skin and Subcutaneous Tissue Disorders | Nervous System Disorders | Gastrointestinal Disorders | Metabolism and Nutrition Disorders | Psychiatric Disorders | Investigations | Musculoskeletal and Connective Tissue Disorders | Blood and Lymphatic System Disorders | Injury, Poisoning, and Procedural Complications | Eye Disorders | Vascular Disorders | Respiratory, Thoracic, and Mediastinal Disorders | Renal and Urinary Disorders | Cardiac Disorders | Endocrine Disorders | Ear and Labyrinth Disorders | Reproductive System and Breast Disorders | Neoplasms Benign, Malignant, and Unspecified | Hepatobiliary Disorders | Immune System Disorders | |
| Combined 800 mg, 5 Days/Week | 47 | 45 | 43 | 41 | 30 | 27 | 27 | 25 | 18 | 18 | 16 | 18 | 16 | 13 | 8 | 7 | 5 | 3 | 2 | 1 | 1 |
| Phase 2 - 800 mg | 13 | 12 | 12 | 12 | 8 | 6 | 9 | 7 | 2 | 6 | 6 | 4 | 3 | 2 | 2 | 1 | 1 | 0 | 0 | 1 | 0 |
| Phase 2 - 800 mg/800 mg | 24 | 24 | 22 | 21 | 16 | 17 | 12 | 13 | 14 | 10 | 7 | 9 | 7 | 7 | 5 | 5 | 3 | 2 | 2 | 0 | 1 |
| Phase 2 Total | 37 | 36 | 34 | 33 | 24 | 23 | 21 | 20 | 16 | 16 | 13 | 13 | 10 | 9 | 7 | 6 | 4 | 2 | 2 | 1 | 1 |
"Progression was determined by Response Assessment in Neuro-Oncology (RANO) criteria and progression-free survival (PFS) was analyzed based on the non-parametric Kaplan-Meier method. mPFS was analyzed by age group, extent of surgery, baseline Karnofsky Performance Status (KPS), and O6-methylguanine-DNA methyltransferase status (MGMT).~The scale range for the baseline Karnofsky Performance Status is from 0-100, with 0 indicating that the participant is dead and 100 indicating that the participant is Normal no complaints, no evidence of disease. The higher the number, the better the outcome." (NCT01790503)
Timeframe: Assessed from date of first dose administered to date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years 4 months.
| Intervention | months (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Age: 18-64 years | Age: 65+ years | Extent of surgery: complete resection | Extent of surgery: partial resection | Baseline KPS: 70-89 | Baseline KPS: 90-100 | MGMT status: methylated | MGMT status: unmethylated | |
| Combined 800 mg, 5 Days/Week | 6 | 10 | 6 | 9 | 4 | 11 | 10 | 4 |
Progression was determined by Response Assessment in Neuro-Oncology (RANO) criteria and progression-free survival (PFS) was analyzed based on the non-parametric Kaplan-Meier method. (NCT01790503)
Timeframe: Assessed from date of first dose administered to date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years 4 months.
| Intervention | months (Median) | |
|---|---|---|
| mITT RP2D | PP RP2D | |
| Combined 800 mg, 5 Days/Week | 6.7 | 6.9 |
"Overall Survival was calculated using a non-parametric Kaplan-Meier analysis method. Median OS was analyzed by age group, extent of surgery, baseline Karnofsky Performance Status (KPS), and O6-methylguanine-DNA methyltransferase status (MGMT).~The scale range for the baseline Karnofsky Performance Status is from 0-100, with 0 indicating that the participant is dead and 100 indicating that the participant is Normal no complaints, no evidence of disease. The higher the number, the better the outcome." (NCT01790503)
Timeframe: Assessed from date of first dose administered to the date of death from any cause, assessed up to 4 years 4 months.
| Intervention | months (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Age group: 18-64 years | Age group: 65+ years | Extent of surgery: complete resection | Extent of surgery: partial resection | Basline KPS: 70-89 | Baseline KPS: 90-100 | MGMT status: methylated | MGMT: unmethylated | |
| Combined 800 mg, 5 Days/Week | 14.3 | 11 | 14 | 13 | 8 | 24 | 15 | 12 |
Overall Survival (OS) was defined as the number of days from the first day of treatment (C1D1) to the date of death and analyzed using a non-parametric Kaplan Meier method. (NCT01790503)
Timeframe: Assessed from date of first dose administered to date of death from any cause, assessed up to 4 years 4 months
| Intervention | months (Median) | |
|---|---|---|
| mITT RP2D | PP RP2D | |
| Combined 800 mg, 5 Days/Week | 13.1 | 12.4 |
Best Overall Response (based on the RANO response) was defined as the highest overall response recorded from the start of study treatment until the end of treatment. Per the Response Assessment in Neuro-Oncology (RANO) criteria for measurable lesions and assessed by Cranial MRI scan, summarized as: Complete Response (CR), Disappearance of all enhancing disease (measurable and non-measurable); Partial Response (PR), >=50% decrease of all measurable enhancing lesions; Stable disease, does not qualify for complete response, partial response, or progression, and progression, >25% increase in enhancing lesions despite stable or increasing steroid use or any new lesions. (NCT01790503)
Timeframe: Assessed from Baseline and every 8 weeks, up to 4 years 4 months
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age group: 18-64 years72008643 | Age group: 65+ years72008643 | Complete resection72008643 | Partial resection72008643 | Baseline KPS: 70-8972008643 | Baseline KPS: 90-10072008643 | MGMT status: methylated72008643 | MGMT status: unmethylated72008643 | |||||||||||||||||||||||||||||||||||||||||||||||||
| Complete response (CR) | Partial response (PR) | CR+PR | Stable disease | Progressive disease | Unable to access | Unknown | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Combined 800 mg, 5 Days/Week | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
"Apparent diffusion coefficient (ADC) is a measure of the magnitude of diffusion (of water molecules) within tissue. ADC was assessed using post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point.~CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide" (NCT00756106)
Timeframe: Baseline, weekly during treatment, monthly following treatment for up to six months
| Intervention | mm2/s (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline 1 | Baseline 2 | Week 1 CRT | Week 2 CRT | Week 3 CRT | Week 4 CRT | Week 5 CRT | Week 6 CRT | Pre-C1 TMZ | Pre-C2 TMZ | Pre-C3 TMZ | Pre-C4 TMZ | Pre-C5 TMZ | Pre-C6 TMZ | Post-TMZ | |
| Temozolomide and Radiation Therapy | 0.00110 | 0.00113 | 0.00106 | 0.00110 | 0.00118 | 0.00122 | 0.00125 | 0.00125 | 0.00132 | 0.00127 | 0.00108 | 0.00133 | 0.00148 | 0.00179 | 0.00140 |
"Permeability-surface Area Product (Ktrans). Ktrans reflects the efflux rate of contrast from blood plasma into the tissue extravascular extracellular space (EES). Ktrans was assessed using post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point.~CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide" (NCT00756106)
Timeframe: Baseline, weekly during treatment, monthly following treatment for up to six months
| Intervention | min ^-1 (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline 1 | Baseline 2 | Week 1 CRT | Week 2 CRT | Week 3 CRT | Week 4 CRT | Week 5 CRT | Week 6 CRT | Pre-C1 TMZ | Pre-C2 TMZ | Pre-C3 TMZ | Pre-C4 TMZ | Pre-C5 TMZ | Pre-C6 TMZ | Post-TMZ | |
| Temozolomide and Radiation Therapy | 0.053 | 0.039 | 0.055 | 0.048 | 0.055 | 0.053 | 0.058 | 0.059 | 0.063 | 0.042 | 0.050 | 0.058 | 0.056 | 0.060 | 0.032 |
"Relative cerebral blood flow (rCBF) is the blood flow rate (the volume of blood passing through the specified are over a specified period of time) in the region of interest (ROI) divided by the blood flow rate in the symmetrical region on the other side of the normal brain (control region). CBF was assessed using spin-echo post-contrast T1-weighted images. CBF was assessed using spin-echo post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point. The baseline value was measured twice (representing baseline 1 and 2) to make sure that the value was reproducible and to account for any variation attributable to measurement variation.~CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide" (NCT00756106)
Timeframe: Baseline, weekly during treatment, monthly following treatment for up to six months
| Intervention | ratio (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline 1 | Baseline 2 | Week 1 CRT | Week 2 CRT | Week 3 CRT | Week 4 CRT | Week 5 CRT | Week 6 CRT | Pre-C1 TMZ | Pre-C2 TMZ | Pre-C3 TMZ | Pre-C4 TMZ | Pre-C5 TMZ | Pre-C6 TMZ | Post-TMZ | |
| Temozolomide and Radiation Therapy | 0.83 | 0.86 | 0.92 | 0.94 | 0.80 | 0.79 | 0.83 | 0.73 | 0.63 | 0.59 | 0.60 | 0.60 | 0.52 | 0.47 | 0.37 |
"Relative cerebral blood volume (rCBV) is the blood volume in the region of interest (ROI) divided by the blood volume in the symmetrical region on the other side of the normal brain (control region). CBV was assessed using spin-echo post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point. The baseline value was measured twice (representing baseline 1 and 2) to make sure that the value was reproducible and to account for any variation attributable to measurement variation.~CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide" (NCT00756106)
Timeframe: Baseline, weekly during treatment, monthly following treatment for up to six months
| Intervention | ratio (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline 1 | Baseline 2 | Week 1 CRT | Week 2 CRT | Week 3 CRT | Week 4 CRT | Week 5 CRT | Week 6 CRT | Pre-C1 TMZ | Pre-C2 TMZ | Pre-C3 TMZ | Pre-C4 TMZ | Pre-C5 TMZ | Pre-C6 TMZ | Post-TMZ | |
| Temozolomide and Radiation Therapy | 0.88 | 0.90 | 0.95 | 1.0 | 0.88 | 0.83 | 0.86 | 0.76 | 0.68 | 0.61 | 0.59 | 0.65 | 0.61 | 0.64 | 0.32 |
This study is designed as a phase I dose escalation trial using the Standard Method of dose escalation of three patients per dose level to determine the MTD of TMZ (up to 75 mg/m 2 /day) when TMZ is used with HIMRT for patients with glioblastoma multiforme(GBM) or Anaplastic Astrocytoma(AA)of the brain. The 3 dose levels will be evaluated using the standard method to determine if either represents an MTD based on DLT. If DLT is not observed at all doses level, the greater of the three levels will be recommended for phase II evaluations of treatment effect. (NCT00841555)
Timeframe: up to 12-16 months
| Intervention | mg/m^2 (Number) |
|---|---|
| Hypofractionation Radiotherapy+Temozolomide | 75 |
All patients will be followed to death. Active follow-up with disease evaluation with scans will be terminated if the patient's physician deems it in the patient's interest not to continue or upon patient request. (NCT00841555)
Timeframe: up to 2 years
| Intervention | months (Median) |
|---|---|
| Hypofractionation Radiotherapy+Temozolomide | 12.7 |
Time spent in a KPS ≥70 was calculated from the date of diagnosis of Karonofsky Performance Status decline (KPS<70) or censored at the last date the patient was known with KPS ≥70. The KPS higher scores indicates normal activity status. (NCT00841555)
Timeframe: up to 12-16 months
| Intervention | months (Median) |
|---|---|
| Hypofractionation Radiotherapy+Temozolomide | 8.1 |
Overall Survival was defined as the time from randomization to death due to any cause. (NCT00943826)
Timeframe: Randomization until OS Event (Until data cutoff= 28 February 2013 [up to 42.2 months])
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + RT + Temozolomide | 16.8 |
| Placebo + RT + Temozolomide | 16.7 |
PFS is defined as time from randomization to disease progression (PD) or death. PD was assessed using adapted Macdonald response criteria (modified World Health Organization [WHO] criteria) based on 3 components: radiological tumor assessments using Magnetic Resonance Imaging [MRI] scans,neurological assessment and changes in corticosteroid use. PD is assessed as greater than or equal to(>=) 25% increase in sum of products of the longest diameters of all index lesions (enhancing,measurable) compared with the smallest recorded sum (nadir); or unequivocal PD of existing non-index lesions (non-enhancing and enhancing,non-measurable); or unequivocal appearance of new lesions); or neurological worsening (if corticosteroid dose is stable or increased) compared to neurological evaluation at previous disease assessment with no need for a confirmatory scan. Participants without a PFS event were censored at last disease assessment. (NCT00943826)
Timeframe: Randomization until PFS Event [Until data cutoff= 31 March 2012 (up to 31.4 months)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + RT + Temozolomide | 10.6 |
| Placebo + RT + Temozolomide | 6.2 |
KM estimate of one year overall survival (probability to survive for at least 1 year) was reported. Corresponding 95% confidence interval (CI) was calculated using Greenwood's formula. (NCT00943826)
Timeframe: Randomization until Overall Survival Event (Until data cutoff= 28 February 2013 [up to 42.2 months])
| Intervention | probability of being alive (Number) |
|---|---|
| Bevacizumab + RT + Temozolomide | 0.72 |
| Placebo + RT + Temozolomide | 0.66 |
KM estimate of two year overall survival was reported (probability to survive for at least 2 years). Corresponding 95% CI was calculated using Greenwood's formula. (NCT00943826)
Timeframe: Randomization until Overall Survival Event (Until data cutoff= 28 February 2013 [up to 42.2 months])
| Intervention | probability of being alive (Number) |
|---|---|
| Bevacizumab + RT + Temozolomide | 0.34 |
| Placebo + RT + Temozolomide | 0.30 |
An Independent Review Facility reviewed the MRI scans used by investigator to evaluate radiological tumor response. PFS is defined as time from randomization to PD or death. PD was assessed using adapted Macdonald response (modified WHO) criteria based on 3 components: radiological tumor assessments using MRI scans, neurological assessment and changes in corticosteroid use. PD is assessed as >=25% increase in sum of products of the longest diameters of all index lesions (enhancing, measurable) compared with the smallest recorded sum (nadir); or unequivocal PD of existing non-index lesions (non-enhancing and enhancing, non-measurable); or unequivocal appearance of new lesions); or neurological worsening (if corticosteroid dose is stable or increased) compared to neurological evaluation at previous disease assessment with no need for a confirmatory scan. Participants without a PFS event were censored at last disease assessment. (NCT00943826)
Timeframe: Randomization until PFS Event (Until data cutoff= 31 March 2012 [up to 29.5 months])
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + RT +Temozolomide | 8.4 |
| Placebo + RT + Temozolomide | 4.3 |
An adverse event (AE) was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as AE.A serious adverse event (SAE) is any experience that suggests a significant hazard,contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. Non-serious adverse events (Non-SAEs) included all AEs except SAEs (non-SAEs = all AEs - SAEs). Nine participants randomized to the Placebo+RT+Temozolomide arm incorrectly received at least 1 dose of bevacizumab and were added to the Bevacizumab+RT+Temozolomide arm for Safety. (NCT00943826)
Timeframe: Randomization until study completion (Until data cutoff= 09 Sep 2015 [up to 64 months])
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Non-SAEs | SAEs | Death | |
| Bevacizumab + RT + Temozolomide | 437 | 179 | 335 |
| Placebo + RT + Temozolomide | 412 | 115 | 337 |
EORTC QLQ-C30: 30 items; 5 functional scales; 9 symptom scales; & global health status. Most questions used 4-point scale (1:Not at all, 4:Very much), 2 questions used 7-point scale (1:very poor, 7:Excellent). EORTC QLQ-BN20: 20 items rated on a 4 point scale (1:not at all, 4:very much). EORTC QLQ-C30 and BN20 scores were transformed to a 0-100 scale, higher score=better functioning/global health (C30) or more severe symptoms (BN20). Stable HRQoL: change from baseline (BL) within 10 points. Improved HRQoL: an increase from BL >/=10 points for functioning/global health status, & decrease of >/=10 points for symptoms. PFS is reported for participants with Stable/Improved global health; physical, social functioning (C30); motor dysfunction & communication deficit (BN20). PFS: randomization to PD or death. PD: >=25% increase in sum of products of longest diameters of index lesions; or progression of existing non-index lesions; or appearance of new lesions; or neurological worsening. (NCT00943826)
Timeframe: Randomization until PFS Event [Until data cutoff= 31 March 2012 (up to 31.4 months)
| Intervention | Months (Median) | ||||
|---|---|---|---|---|---|
| Global health status (n=354, 309) | Physical functioning (n=353, 318) | Social functioning (n=352, 327) | Motor dysfunction (n=361, 314) | Communication deficit (n=365, 329) | |
| Bevacizumab + RT + Temozolomide | 8 | 7 | 8 | 7 | 8 |
| Placebo + RT + Temozolomide | 4 | 5 | 4 | 4 | 4 |
AEs are graded by using CTCAE 3.0. The difference between the two randomized arms in the percentage of patients with grade 3 or higher toxicities reported as possibly/probably/definitely related to protocol treatment will be tested using a chi square test. (NCT00884741)
Timeframe: Up to 30 days
| Intervention | participants (Number) |
|---|---|
| Randomized Arm 1: TMZ+RT + Placebo | 87 |
| Randomized Arm 2: TMZ+RT + Bevacizumab | 97 |
Survival time was defined as time from randomization to date of death from any cause and was estimated by the Kaplan-Meier method. Patients last known to be alive were censored at the date of last contact. This analysis was planned to occur when 390 deaths had been reported. (NCT00884741)
Timeframe: From randomization to date of death or last follow-up. Analysis occurs after all 390 deaths have been reported.
| Intervention | months (Median) |
|---|---|
| Randomized Arm 1: TMZ+RT + Placebo | 16.1 |
| Randomized Arm 2: TMZ+RT + Bevacizumab | 15.7 |
Progression-free survival was defined as time from randomization to date of progression, death, or last follow-up, and was estimated by the Kaplan-Meier method. Patients last known to be alive were censored at the date of last contact. This analysis was planned to occur when 390 deaths had been reported. (NCT00884741)
Timeframe: From randomization to date of progression, death, or last follow-up for progression-free survival. Analysis occurs after all 390 deaths have been reported.
| Intervention | months (Median) |
|---|---|
| Randomized Arm 1: TMZ+RT + Placebo | 7.3 |
| Randomized Arm 2: TMZ+RT + Bevacizumab | 10.7 |
Overall survival was defined from the date of diagnosis to date of death from any cause (NCT00525525)
Timeframe: Approximately 6-24 months
| Intervention | months (Median) |
|---|---|
| Efficacy Group | 19.8 |
Progression-free survival was defined from the date of diagnosis to the date that progressive disease was first observed on imaging, or the date at which nonreversible neurologic progression or permanently increased corticosteroid requirement, death from any cause, or early discontinuation of treatment. Imaging guidelines were used to evaluate progression: (i) 25% increase in the sum of products of all measurable lesions over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline; (ii) clear worsening of any assessable disease; (iii) appearance of any new lesion/site; and (iv) clear clinical worsening or failure to return for evaluation as a result of death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00525525)
Timeframe: Approximately 6 months to 1 year
| Intervention | months (Median) |
|---|---|
| Efficacy Group | 13.5 |
Unexpected severe study-related adverse events (NCT00525525)
Timeframe: Within 8 weeks of initiating study therapy
| Intervention | Events (Number) |
|---|---|
| Safety Lead-in Group | 0 |
Dose limiting toxicity defined as: Any DLT must be a toxicity considered at least possibly related to HCQ. DLTs will include any possibly, probably, or definitely HCQ-related Grade 3 or 4 toxicity. Known or reasonably suspected TMZ hematological toxicities will not be considered dose limiting unless the treating physician considers the toxicity to be exacerbated by HCQ. Nonhematological toxicities: Any Grades 3-4 severity (except nausea and vomiting without sufficient antiemetic prophylaxis) (NCT00486603)
Timeframe: 10 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase 1: RT+TMZ+HCQ - 200mg | 0 |
| Phase 1: RT+TMZ+HCQ - 400mg | 0 |
| Phase 1: RT+TMZ+HCQ - 600mg | 0 |
| Phase 1: RT+TMZ+HCQ - 800mg | 3 |
Number of participants experiencing Grade 3 and 4 toxicity, as defined by CTCAE v3.0, with a possible, probable or definite relationship to HCQ, TMZ or both (NCT00486603)
Timeframe: up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase 2: RT + TMZ + HCQ | 22 |
Number of months alive after end of study participation (NCT00486603)
Timeframe: 2 years
| Intervention | months (Median) |
|---|---|
| Phase 2: RT + TMZ + HCQ | 15.6 |
The population model PK parameters do not specifically represent steady-state values, as they were determined from multiple repeated single doses taken from multiple repeated doses taken by the individual patient during their period on the study. To obtain steady state PK parameters, individual estimates were simulated from the population model. (NCT00486603)
Timeframe: up to 276 days
| Intervention | hour (Mean) |
|---|---|
| Phase 2: RT + TMZ + HCQ | 1.06 |
The population model PK parameters do not specifically represent steady-state values, as they were determined from multiple repeated single doses taken from multiple repeated doses taken by the individual patient during their period on the study. To obtain steady state PK parameters, individual estimates were simulated from the population model. (NCT00486603)
Timeframe: up to 276 days
| Intervention | Liters (Mean) |
|---|---|
| Phase 2: RT + TMZ + HCQ | 963 |
The population model PK parameters do not specifically represent steady-state values, as they were determined from multiple repeated single doses taken from multiple repeated doses taken by the individual patient during their period on the study. To obtain steady state PK parameters, individual estimates were simulated from the population model. (NCT00486603)
Timeframe: up to 276 days
| Intervention | hours (Mean) |
|---|---|
| Phase 2: RT + TMZ + HCQ | 0.51 |
The population model PK parameters do not specifically represent steady-state values, as they were determined from multiple repeated single doses taken from multiple repeated doses taken by the individual patient during their period on the study. To obtain steady state PK parameters, individual estimates were simulated from the population model. (NCT00486603)
Timeframe: up to 276 days
| Intervention | L/hr (Mean) |
|---|---|
| Phase 2: RT + TMZ + HCQ | 11.85 |
The population model PK parameters do not specifically represent steady-state values, as they were determined from multiple repeated single doses taken from multiple repeated doses taken by the individual patient during their period on the study. To obtain steady state PK parameters, individual estimates were simulated from the population model. (NCT00486603)
Timeframe: up to 276 days
| Intervention | Liters (Mean) |
|---|---|
| Phase 2: RT + TMZ + HCQ | 483.96 |
Number of participants who tolerated doses of HCQ without dose limiting toxicity. The highest dose at which participants did not experience dose limiting toxicity was determined as the MTD. (NCT00486603)
Timeframe: 10 weeks
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| 200mg | 400mg | 600mg | 800mg | |
| Phase 1 - Dose Finding | 3 | 7 | 3 | 0 |
Autophagy inhibition is represented by an increase in autophagic vacuoles (AV) in participants with at least 2 peripheral blood mononuclear cell samples that were amenable to EM. (NCT00486603)
Timeframe: up to 9 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AV Increase | No AV Increase | |
| HCQ Cmax <= 1785 ng/mL | 10 | 12 |
| HCQ Cmax>1785 ng/mL | 12 | 6 |
From the onset of temozolomide to the date at which unequivocal disease progression, assessed up to 65 months. (NCT00669669)
Timeframe: Up to 65 months
| Intervention | months (Median) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 4.5 |
Assessed by gene marking in peripheral blood prior to chemoselection. Gene marking is assessed in whole blood by quantitative PCR and reported as a vector copy number (VCN) or the average copies of integrated transgene per cell. The units here will be reported as copies/cell. (NCT00669669)
Timeframe: Up to 59 months
| Intervention | copies/cell (Mean) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0.78 |
Assessed by gene marking in peripheral blood after chemoselection. Gene marking is assessed in whole blood by quantitative PCR and reported as a vector copy number (VCN) or the average copies of integrated transgene per cell. The units here will be reported as copies/cell. (NCT00669669)
Timeframe: Up to 59 months
| Intervention | copies/cell (Mean) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0.50 |
Defined as any grade 4 nonhematopoietic toxicity that is likely related to the investigational procedures (Part I) (NCT00669669)
Timeframe: Up to 6 weeks after infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 1 |
From the first day of treatment until death, assessed up to 74 months. (NCT00669669)
Timeframe: Up to 74 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0 |
assessed by the ability to increase the Temozolomide dose beyond 472 mg/m^2 (NCT00669669)
Timeframe: Up to 66 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 2 |
assessed by the increase in peripheral blood Vector Copy Number (VCN), the average copies of integrated transgene per cell, after chemotherapy (NCT00669669)
Timeframe: Up to 59 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 4 |
Replication competent retrovirus or diagnosis of leukemia (NCT00669669)
Timeframe: Up to 2 years after infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0 |
Number of patients with reduction in tumor burden of a predefined amount (NCT00669669)
Timeframe: Up to 66 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 1 |
From the first day of treatment (transplant) until unequivocal progression is documented, assessed up to 66 months. (NCT00669669)
Timeframe: Up to 66 months.
| Intervention | months (Median) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 5.5 |
The AUC (0-6) for cilengitide was calculated by non-compartmental analysis using the computer program WinNonlin, Version 6.2.1. (NCT00689221)
Timeframe: Day 1 of Week -1
| Intervention | hour*ng/mL (Mean) |
|---|---|
| Cilengitide + Temozolomide + Radiotherapy | 295171.2 |
The EuroQuol-5D (EQ-5D) questionnaire is a measure of health status that provides a simple descriptive profile and a single index value. The optional part of the questionnaire was not applied. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items are combined to generate health profiles. These profiles were converted to a continuous single index score using a one to one matching. The lowest possible score is -0.594 (death) and the highest is 1.00 (full health). (NCT00689221)
Timeframe: Up to 50 months
| Intervention | units on a scale (Mean) |
|---|---|
| Cilengitide + Temozolomide + Radiotherapy | 0.598 |
| Temozolomide + Radiotherapy | 0.623 |
The Cmax for cilengitide was calculated by non-compartmental analysis using the computer program WinNonlin, Version 6.2.1. (NCT00689221)
Timeframe: Day 1 of Week -1
| Intervention | nanogram per milliliter (ng/mL) (Mean) |
|---|---|
| Cilengitide + Temozolomide + Radiotherapy | 167363.2 |
The OS time is defined as the time (in months) from randomization to death or last day known to be alive. Participants without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00689221)
Timeframe: Time from randomization to death or last day known to be alive, reported between day of first participant randomized, that is, Sep 2008 until cut-off date, (19 Nov 2012)
| Intervention | Months (Median) |
|---|---|
| Cilengitide + Temozolomide + Radiotherapy | 26.3 |
| Temozolomide + Radiotherapy | 26.3 |
The Tmax for cilengitide was calculated by non-compartmental analysis using the computer program WinNonlin, Version 6.2.1. (NCT00689221)
Timeframe: Day 1 of Week -1
| Intervention | hours (Mean) |
|---|---|
| Cilengitide + Temozolomide + Radiotherapy | 1.029 |
The QLQ-BN20 is a questionnaire specifically designed as the QLQ-C30 supplement for the evaluation of quality of life in brain tumor participants. It includes 4 multi-item sub-scales: future uncertainty, visual disorder, motor dysfunction, communication deficits, and 7 single-item scales: headaches, seizures, drowsiness, itchy skin, hair loss, weakness of legs, and bladder control. All items are rated on a 4-point Likert-type scale ('1=not at all', '2=a little', '3=quite a bit' and '4=very much'), and are linearly transformed to a 0-100 scale, with higher scores indicating more severe symptoms. (NCT00689221)
Timeframe: Up to 50 months
| Intervention | units on a scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Future Uncertainty (n=68, 86) | Visual Disorder (n=68, 85) | Motor Dysfunction (n=68, 86) | Communication Deficit (n=68, 86) | Headaches (n=68, 86) | Seizures (n=68, 87) | Drowsiness (n=66, 87) | Itchy Skin (n=68, 86) | Hair Loss (n=66, 86) | Weakness of Legs (n=67, 85) | Bladder Control (n=67, 85) | |
| Cilengitide + Temozolomide + Radiotherapy | 44.49 | 12.99 | 27.45 | 26.14 | 25.98 | 9.31 | 38.38 | 9.80 | 13.13 | 24.38 | 19.40 |
| Temozolomide + Radiotherapy | 39.31 | 17.78 | 23.39 | 19.96 | 21.71 | 8.05 | 35.25 | 13.57 | 15.12 | 20.39 | 10.20 |
The EORTC QLQ-C30 is a questionnaire including following sub-scales: global health status, functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social activity), symptom scales (fatigue, nausea and vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhoea and financial difficulties). Scores are averaged for each scale and transformed to 0-100 scale; higher score indicates better quality of life on global health status and functional scales and worse quality of life on symptom scales and financial difficulty scale. (NCT00689221)
Timeframe: Up to 50 months
| Intervention | units on a scale (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Health Status (n=71, 92) | Physical Functioning (n=71, 92) | Role Functioning (n=71, 92) | Emotional Functioning (n=71, 93) | Cognitive Functioning (n=70, 93) | Social Activity (n=71, 93) | Fatigue (n=71, 92) | Nausea and Vomiting (n=71, 93) | Pain (n=71, 93) | Dyspnoea (n=71, 92) | Insomnia (n=71, 91) | Appetite Loss (n=71, 92) | Constipation (n=71, 93) | Diarrhoea (n=70, 92) | Financial Difficulties (n=71, 93) | |
| Cilengitide + Temozolomide + Radiotherapy | 54.34 | 65.70 | 56.34 | 67.49 | 64.05 | 56.34 | 44.37 | 10.33 | 22.30 | 15.96 | 20.66 | 21.13 | 18.78 | 6.67 | 27.23 |
| Temozolomide + Radiotherapy | 55.43 | 67.46 | 56.34 | 67.00 | 65.41 | 62.72 | 39.73 | 7.71 | 24.37 | 13.04 | 20.51 | 15.94 | 13.98 | 4.35 | 22.94 |
An AE is defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. Treatment-emergent AEs are the events between first dose of study drug and up to 28 days after last dose of study treatment. A Serious AE is an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. Treatment-related AEs are the AEs which are suspected to be reasonably related to the study treatment (cilengitide, or radiotherapy, or temozolomide) as per investigator assessment. The severity of AEs was assessed according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTCAE) (version 3.0): Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling. Note: Death (Grade 5) was regarded as an outcome. (NCT00689221)
Timeframe: Time from first dose up to 28 days after last dose of study treatment, reported between day of first participant randomized, that is, Sep 2008 until cut-off date (19 Nov 2012)
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| AEs | Serious AEs | Treatment-related AEs | Treatment-Related Serious AEs | AEs leading to death | Treatment-related AEs leading to death | AEs with NCI-CTC toxicity Grade 3 or 4 | Treatment-related AEs of Grade 3 or 4 | |
| Cilengitide + Temozolomide + Radiotherapy | 261 | 138 | 229 | 55 | 11 | 3 | 169 | 100 |
| Temozolomide + Radiotherapy | 253 | 115 | 222 | 47 | 9 | 3 | 158 | 101 |
Thromboembolic events (standardized MedDRA query [SMQ]) Grade 3 or 4 AEs encompassed hemiparesis and cerebrovascular accident, pulmonary embolism, and deep vein thrombosis. Thromboembolic events (SMQ) of any grade and of Grade 3 or 4 were generally more frequent in the Cilengitide + Temozolomide/Radiotherapy group than in the Temozolomide/Radiotherapy group but were still in the expected range of this patient population The severity of AEs was assessed according to the National Cancer Institute-Common Toxicity Criteria (NCI-CTCAE) (version 3.0): Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling. Note: Death (Grade 5) was regarded as an outcome. (NCT00689221)
Timeframe: Time from first dose up to 28 days after last dose of study treatment, reported between day of first participant randomized, that is, Sep 2008 until cut-off date (19 Nov 2012)
| Intervention | Participants (Number) | |
|---|---|---|
| SMQ:Thromboembolic events | SMQ: Hemorrhage | |
| Cilengitide + Temozolomide + Radiotherapy | 35 | 4 |
| Temozolomide + Radiotherapy | 23 | 4 |
Number of participants with change from baseline in work status (working full time [FT], part-time [PT], unemployed/retired [U/R]) at end of study (EOS) (up to cut-off date, [19 Nov 2012]) was reported. For the category 'part-time', the following sub-categories were defined: part-time due to basic disease (PT1); part-time not due to basic disease (PT2); part-time reason not known (PT3). (NCT00689221)
Timeframe: Baseline, End of study (up to cut-off date, [19 Nov 2012])
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: FT, EOS: FT | Baseline: FT, EOS: PT1 | Baseline: FT, EOS: PT2 | Baseline: FT, EOS: PT3 | Baseline: FT, EOS: U/R | Baseline: PT1, EOS: FT | Baseline: PT1, EOS: PT1 | Baseline: PT1, EOS: PT2 | Baseline: PT1, EOS: PT3 | Baseline: PT1, EOS: U/R | Baseline: PT2, EOS: FT | Baseline: PT2, EOS: PT1 | Baseline: PT2, EOS: PT2 | Baseline: PT2, EOS: PT3 | Baseline: PT2, EOS: U/R | Baseline: PT3, EOS: FT | Baseline: PT3, EOS: PT1 | Baseline: PT3, EOS: PT2 | Baseline: PT3, EOS: PT3 | Baseline: PT3, EOS: U/R | Baseline: U/R, EOS: FT | Baseline: U/R, EOS: PT1 | Baseline: U/R, EOS: PT2 | Baseline: U/R, EOS: PT3 | Baseline: U/R, EOS: U/R | Baseline: Missing, EOS: FT | Baseline: Missing, EOS: PT1 | Baseline: Missing, EOS: PT2 | Baseline: Missing, EOS: PT3 | Baseline: Missing, EOS: U/R | Baseline: Missing, EOS: Missing | |
| Cilengitide + Temozolomide + Radiotherapy | 3 | 2 | 1 | 0 | 24 | 3 | 3 | 0 | 0 | 9 | 0 | 0 | 0 | 1 | 5 | 0 | 0 | 0 | 0 | 0 | 5 | 5 | 1 | 0 | 199 | 0 | 0 | 0 | 0 | 1 | 1 |
| Temozolomide + Radiotherapy | 6 | 1 | 0 | 0 | 22 | 2 | 1 | 0 | 0 | 12 | 1 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 8 | 7 | 1 | 0 | 191 | 0 | 0 | 0 | 0 | 1 | 1 |
"The PFS time is defined as the duration from randomization to either first observation of progressive disease (PD) or occurrence of death due to any cause. Investigator read is the assessment of all imaging by the treating physician at the local trial site and Independent Read is the assessment of all imaging centrally by an Independent Review Committee (IRC). Investigator's assessed progression according to MacDonald criteria and IRC by Response Assessment in Neuro-Oncology Working Group (RANO) criteria using Gadolinium-enhanced magnetic resonance imaging.~Investigator and IRC read: Progression is defined as greater than 25 percent increase in the sum of the product of the largest perpendicular diameters of enhancing tumor compared to the smallest prior sum, or Worsening of an evaluable lesion(s),or Marked increase in T2/FLAIR non-enhancing lesions (IRC only) or Any new lesion" (NCT00689221)
Timeframe: Time from randomization to disease progression, death or last tumor assessment, reported between day of first participant randomized, that is, Sep 2008 until cut-off date, (19 Nov 2012)
| Intervention | Months (Median) | |
|---|---|---|
| PFS Time: Investigator read | PFS Time: Independent read | |
| Cilengitide + Temozolomide + Radiotherapy | 13.5 | 10.6 |
| Temozolomide + Radiotherapy | 10.7 | 7.9 |
Celecoxib versus not Celecoxib analysis: We compared the median OS outcome of participants in arms III, V, VI and VIII, versus participants in arms I, II, IV and VII. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Celecoxib: Arm III, Arm V, Arm VI and Arm VIII | 20.2 |
| No Celecoxib: Arm I, Arm II, Arm IV and Arm VII | 17.1 |
Doublet (2 agents) versus Triplet (3 agents) therapy analysis: We compared the median OS outcome of participants in arms II, III, IV, versus participants in arms V, VI and VII. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Doublet (2 Agents): Arm II, Arm III and Arm IV | 17.0 |
| Triplet (3 Agents): Arm V, Arm VI and Arm VII | 20.1 |
Isotretinoin versus not Isotretinoin analysis: We compared the median OS outcome of participants in arms IV, V, VII and VIII, versus participants in arms I, II, III and VI. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Isotretinoin: Arm IV, Arm V, Arm VII and ARM VIII | 17.1 |
| No Isotretinoin: Arm I, Arm II, Arm III and ARM VI | 19.9 |
Thalidomide versus not Thalidomide analysis: We compared the median OS outcome of participants in arms II, VI, VII and VIII, versus participants in arms I, III, IV and V. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Thalidomide: Arm II, Arm VI, Arm VII and Arm VIII | 18.3 |
| No Thalidomide: Arm I, Arm III, Arm IV and Arm V | 17.4 |
Celecoxib versus not Celecoxib analysis: We compared the median PFS outcome of participants in arms III, V, VI and VIII, versus participants in arms I, II, IV and VII. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Celecoxib: Arm III, Arm V, Arm VI and Arm VIII | 8.3 |
| No Celecoxib: Arm I, Arm II, Arm IV and Arm VII | 7.4 |
Doublet (2 agents) versus Triplet (3 agents) therapy analysis: We compared the median PFS outcome of participants in arms II, III, IV, versus participants in arms V, VI and VII. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Doublet (2 Agents): Arm II, Arm III and Arm IV | 8.3 |
| Triplet (3 Agents): Arm V, Arm VI and Arm VII | 8.2 |
Isotretinoin versus not Isotretinoin analysis: We compared the median PFS outcome of participants in arms IV, V, VII and VIII, versus participants in arms I, II, III and VI. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Isotretinoin: Arm IV, Arm V, Arm VII and Arm VIII | 6.6 |
| No Isotretinoin: Arm I, Arm II, Arm III and Arm VI | 9.1 |
Thalidomide versus not Thalidomide analysis: Comparison of median PFS outcome of participants in arms II, VI, VII and VIII, versus participants in arms I, III, IV and V. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up, up to one year (12 study cycles).
| Intervention | months (Median) |
|---|---|
| Thalidomide: Arm II, Arm VI, Arm VII and Arm VIII | 7.6 |
| No Thalidomide: Arm I, Arm III, Arm IV and Arm V | 8.7 |
Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Arm I: TMZ | 10.5 |
| Arm II: TMZ + Thalidomide | 7.7 |
| Arm III: TMZ + Celecoxib | 13.4 |
| Arm IV: TMZ + Isotretinoin | 6.5 |
| Arm V: TMZ + Isotretinoin + Celecoxib | 11.6 |
| Arm VI: TMZ + Thalidomide + Celecoxib | 7.9 |
| Arm VII: TMZ + Thalidomide + Isotretinoin | 6.2 |
| Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib | 5.8 |
Overall Survival (OS) was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Arm I: TMZ | 21.2 |
| Arm II: TMZ + Thalidomide | 17.4 |
| Arm III: TMZ + Celecoxib | 18.1 |
| Arm IV: TMZ + Isotretinoin | 11.7 |
| Arm V: TMZ + Isotretinoin + Celecoxib | 23.1 |
| Arm VI: TMZ + Thalidomide + Celecoxib | 20.2 |
| Arm VII: TMZ + Thalidomide + Isotretinoin | 17.9 |
| Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib | 18.5 |
"Patients were to be followed for a minimum of 90 days from the start of radiation therapy (RT) and carefully evaluated with respect to treatment morbidity. A dose limiting toxicity (DLT) was defined as a grade 4 neurologic adverse event (AE) considered to be related to treatment occurring within 21 days of the conclusion of RT. For each dose level, up to seven patients were to be accrued to assure that there would be six eligible for treatment adverse event evaluation. A dose level of MGd was considered acceptable if no more than 1 patient of the 6 experience a DLT. If the current level was considered acceptable, then dose escalation occurred. Otherwise, the preceding dose level would be declared the maximum tolerated dose (MTD). The MTD would be used for the Phase II arm.~Rating scale: 0 = not the MTD, 1 = MTD" (NCT00305864)
Timeframe: From start of radiation therapy to 90 days,
| Intervention | units on a scale (Number) |
|---|---|
| Phase I: MGd 3 mg/kg | 0 |
| Phase I: MGd 4 mg/kg | 0 |
| Phase I: 5 mg/kg | 1 |
Survival time was defined as the time from baseline to date of death from any cause. Patients last known to be alive are censored at date of last contact. (NCT00305864)
Timeframe: From randomization to date of death or last follow-up. Analysis occurs after all patients have been potentially followed for at least 18 months. Patients were followed up to 54.3 months
| Intervention | Months (Median) |
|---|---|
| All MGd 5mg/kg Patients (Phase I and II Arms Combined) | 15.6 |
Progression will be defined as a > 25% increase in tumor area. Progression-free survival time was defined as the time from baseline to date of death from any cause. Patients last known to be alive are censored at date of last contact. (NCT00305864)
Timeframe: From randomization to date of progression, death, or last follow-up. Analysis occurs after all patients have been potentially followed for at least 18 months. Patients were followed up to 54.3 months.
| Intervention | months (Median) |
|---|---|
| All MGd 5mg/kg Patients (Phase I and II Arms Combined) | 7.6 |
Time in months from the start of study treatment to the date of death due to any cause. Patients alive as of the last follow-up had OS censored at the last follow-up date. Median OS was estimated using a Kaplan-Meier curve. (NCT00979017)
Timeframe: 36 months
| Intervention | months (Median) |
|---|---|
| Avastin in Combination With Temozolomide and Irinotecan | 12 |
Time in months from the start of study treatment to the date of first progression according to RANO criteria, or to death due to any cause. Per RANO, progression is a ≥ 25% increase in the sum of the products of perpendicular diameters of enhancing lesions, worsening T2/FLAIR, any new lesion, or clinical deterioration. Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date. Median PFS was estimated using a Kaplan-Meier curve. (NCT00979017)
Timeframe: 36 months
| Intervention | months (Median) |
|---|---|
| Avastin in Combination With Temozolomide and Irinotecan | 8.6 |
The percentage of participants with a complete or partial response as determined by a modification of the Response Assessment in Neuro-Oncology (RANO) criteria. Complete Response (CR) was defined as complete disappearance on MR/CT of all enhancing tumor and mass effect, off all corticosteroids (or receiving only adrenal replacement doses) and accompanied by a stable or improving neurologic examination. Partial Response (PR) was defined as greater than or equal to 50% reduction in tumor size on MR/CT by bi-dimensional measurement, on a stable or decreasing dose of corticosteroids and accompanied by a stable or improving neurologic examination. Per the criteria, confirmation of response was required. Response rate = CR+PR. (NCT00979017)
Timeframe: 4 months
| Intervention | percentage of participants (Number) |
|---|---|
| Avastin in Combination With Temozolomide and Irinotecan | 22 |
Incidence and severity of CNS hemorrhage and systemic hemorrhage- The adverse events for this study were collected using Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, and have been converted to CTCAE version 4.0 for entry into ClinicalTrials.gov. (NCT00979017)
Timeframe: 4 months
| Intervention | participants (Number) | |
|---|---|---|
| CNS hemorrhage (grade 3) | Systemic hemorrhage (all grade 3) | |
| Avastin in Combination With Temozolomide and Irinotecan | 1 | 3 |
Incidence of treatment-related, grade ≥ 4 hematologic and ≥ grade 3 non-hematologic toxicities- The adverse events for this study were collected using Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, and have been converted to CTCAE version 4.0 for entry into ClinicalTrials.gov. (NCT00979017)
Timeframe: 4 months
| Intervention | participants (Number) | |
|---|---|---|
| Grade > or = to 4 hematologic toxicity | Grade > or = to 3 non-hematologic toxicity | |
| Avastin in Combination With Temozolomide and Irinotecan | 7 | 17 |
"OS was defined as the time from randomization to death.~OS was calculated by the Kaplan-Meier method." (NCT00686725)
Timeframe: Up to 2 years
| Intervention | months (Median) |
|---|---|
| Temozolomide + Radiation | 13.17 |
| Temozolomide Alone, Then Temozolomide + Radiation | 17.58 |
"PFS was defined as the length of time from randomization to disease progression (the length of time during which the cancer did not get worse) or death.~PFS was calculated by the Kaplan-Meier method." (NCT00686725)
Timeframe: Up to 2 years
| Intervention | months (Median) |
|---|---|
| Temozolomide + Radiation | 10.38 |
| Temozolomide Alone, Then Temozolomide + Radiation | 8.74 |
"MGMT was measured by IHC.~OS was defined as the length of time from the start of treatment that 1/2 of the participants were still alive.~OS was calculated by the Kaplan-Meier method." (NCT00686725)
Timeframe: Up to 2 years
| Intervention | months (Median) |
|---|---|
| Temozolomide + Radiation | 13.81 |
| Temozolomide Alone, Then Temozolomide + Radiation | 15.12 |
"MGMT was measured by IHC.~PFS: The length of time during and after treatment that a participant lived with the cancer but it does not get worse.~PFS was calculated by the Kaplan-Meier method." (NCT00686725)
Timeframe: Up to 2 years
| Intervention | months (Median) |
|---|---|
| Temozolomide + Radiation | 11.11 |
| Temozolomide Alone, Then Temozolomide + Radiation | 10.46 |
"MGMT was measured by IHC.~PFS: The length of time during and after treatment that a participant lived with the cancer but it does not get worse.~PFS was calculated by the Kaplan-Meier method." (NCT00686725)
Timeframe: Up to 2 years
| Intervention | months (Median) |
|---|---|
| Temozolomide + Radiation | 10.04 |
| Temozolomide Alone, Then Temozolomide + Radiation | 11.19 |
"MGMT was measured by immunohistochemistry (IHC).~OS was defined as the length of time from the start of treatment that 1/2 of the participants were still alive.~OS was calculated by the Kaplan-Meier method." (NCT00686725)
Timeframe: Up to 2 years
| Intervention | months (Median) |
|---|---|
| Temozolomide + Radiation | 14.4 |
| Temozolomide Alone, Then Temozolomide + Radiation | 17.49 |
"Overall response was based on neuroimaging (magnetic resonance imaging [MRI]), clinical neurological examination, and steroid administration.~It was assessed as follows:~Complete Response (CR): Disappearance of all enhancing tumor (measurable~or non-measurable), no corticosteroid use, and neurologically stable or~improved.~Partial Response (PR): ≥50% reduction in size of enhancing tumor~(measurable or non-measurable) for any measurable lesions or definite~improvement for any non-measurable lesions, corticosteroid dosage stable or~reduced, and neurologically stable or improved.~Progressive Disease (PD): ≥25% increase in contrast enhancement for any~measurable lesions or definite worsening for any non-measurable lesions, or~any new tumor on MRI scans, at an increased dose of corticosteroid, with or without neurologic progression. Clinical or radiological worsening resulting from other than tumor factors were excluded.~Stable Disease (SD): All other situations." (NCT00686725)
Timeframe: Up to 2 years
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| CR | PR | SD | PD | No overall response data available | |
| Temozolomide + Radiation | 1 | 0 | 38 | 3 | 5 |
| Temozolomide Alone, Then Temozolomide + Radiation | 0 | 0 | 47 | 4 | 1 |
"MGMT was measured by IHC.~OS rate was defined as the percentage of participants who were still alive 6, 12, & 18 months after starting study treatment.~OS was calculated by the Kaplan-Meier method." (NCT00686725)
Timeframe: 6, 12, & 18 months
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| 6 months | 12 months | 18 months | |
| Temozolomide + Radiation | 87.5 | 57.7 | 44.9 |
| Temozolomide Alone, Then Temozolomide + Radiation | 95.8 | 81.4 | 26.7 |
"MGMT was measured by IHC.~OS rate was defined as the percentage of participants who were still alive 6, 12, & 18 months after starting study treatment.~OS was calculated by the Kaplan-Meier method." (NCT00686725)
Timeframe: 6, 12, & 18 months
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| 6 months | 12 months | 18 months | |
| Temozolomide + Radiation | 80.8 | 69.3 | 36.9 |
| Temozolomide Alone, Then Temozolomide + Radiation | 89.2 | 82.8 | 66.2 |
"Defined as complete response (CR) or partial response (PR) as specified in the Revised Assessment in Neuro-Oncology criteria. An objective tumor response will be evaluated for each patient and the tumor response count will be summarized for each arm and compared using the Chi-square test. For CR, all of the following must be true:~disappearance of all enhancing measurable and non-measurable disease; no new enhancing lesions; stable or improved non-enhancing lesions; patients must be off corticosteroids; stable or improved clinically~A PR requires all of the following: > 50% decrease in sum of products of perpendicular diameters of all measurable enhancing lesions compared with baseline; no progression of non-measurable disease; no new lesions; stable or improved non-enhancing lesions on same or lower dose of corticosteroids compared with baseline scan; steroid dose should be same or lower compared with baseline scan; stable or improved clinically" (NCT02152982)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I (Temozolomide, Veliparib) | 34 |
| Arm II (Temozolomide, Placebo) | 37 |
Assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (version 5 beginning April 1, 2018). The overall adverse event rates for grade 3 or higher adverse events will be summarized and be compared using Chi-Square or Fisher's Exact tests between treatment arms. The maximum grade for each type of treatment-related adverse event will be recorded for each patient, and frequency tables for each arm will be reviewed to determine patterns. Treatment-related adverse events will be tabulated for each arm. (NCT02152982)
Timeframe: 5 years
| Intervention | participants with at least 1 grade 3+ AE (Number) |
|---|---|
| Arm I (Temozolomide, Veliparib) | 94 |
| Arm II (Temozolomide, Placebo) | 137 |
The distribution of OS for each arm will be estimated using the Kaplan-Meier method and compared with a stratified logrank test. (NCT02152982)
Timeframe: 83 months
| Intervention | months (Median) |
|---|---|
| Arm I (Temozolomide, Veliparib) | 24.8 |
| Arm II (Temozolomide, Placebo) | 28.1 |
"The distribution of PFS for each arm will be estimated using the Kaplan-Meier method, and be compared using Cox proportional hazard models with all stratification factors adjusted. Progression (PD): Defined by any of the following:~> 25% increase in sum of products of perpendicular diameters of enhancing lesions, compared with the smallest tumor measurement obtained either at baseline or best response~Significant increase in T2/FLAIR non-enhancing lesion on stable or increasing doses of corticosteroids compared with baseline scan or best response after therapy initiation (stable doses of steroids include patient not on steroids) not caused by comorbid events~Any new lesion~Clear clinical deterioration not attributable to other causes apart from tumor or change in corticosteroid dose~Failure to return for evaluation as a result of death or deteriorating condition~Clear progression of non-measurable disease" (NCT02152982)
Timeframe: 83 months
| Intervention | months (Median) |
|---|---|
| Arm I (Temozolomide, Veliparib) | 12.1 |
| Arm II (Temozolomide, Placebo) | 13.2 |
Cox proportional hazards model will be used to evaluate whether there is a potential interaction between the treatment arm and the Optune device. If an interaction is detected, separate analyses of treatment effect (using Cox models) will be done for patients treated with the Optune device and patients who were not treated with the Optune device. (NCT02152982)
Timeframe: 5 years
| Intervention | participants (Number) | |
|---|---|---|
| Reporting actual Optune use | No actual Optune use | |
| Arm I (Temozolomide, Veliparib) | 33 | 125 |
| Arm II (Temozolomide, Placebo) | 33 | 135 |
Patients were monitored until death (NCT00187486)
Timeframe: assessment of survival was every 2 months, up to 181 weeks
| Intervention | months (Median) |
|---|---|
| Temodar Plus Tarceva Plus Radiotherapy | 19 |
Progression based on MR imaging using the Modified McDonnald Criteria defined as 25% increase in sum of products of all measured lesions or any new lesion (NCT00187486)
Timeframe: every 2 months measure by MR imaging, up to 39 months
| Intervention | months (Median) |
|---|---|
| Temodar Plus Tarceva Plus Radiotherapy | 8.2 |
Progression-free survival as determined by Kaplan-Meier method. (NCT00392171)
Timeframe: 6 months
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Anaplastic Glioma (n=28) | Early Glioblastoma Multiforme (GBM) (n=33) | Extended Glioblastoma Multiforme (GBM) (n=27) | Rechallenge Glioblastoma Multiforme (GBM) (n=28) | |
| Temozolomide | 35.7 | 27.3 | 7.4 | 35.7 |
Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or to death due to any cause. (NCT00597493)
Timeframe: 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Sorafenib + Temozolomide | 9.4 |
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. AUC-24 refers to area under the plasma concentration-time curve from 0 to 24 hours. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAEDs) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months
| Intervention | ug*H/L (Geometric Mean) |
|---|---|
| EIAEDs-Day 1 | 45309.7 |
| EIAEDs-Day 28 | 47148.2 |
| Non-EIAEDs-Day 1 | 45238.7 |
| Non-EIAEDs-Day 28 | 128820.8 |
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. C-max refers to maximum plasma concentration. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months
| Intervention | ug/L (Geometric Mean) |
|---|---|
| EIAEDs-Day 1 | 3397.3 |
| EIAEDs-Day 28 | 3813.9 |
| Non-EIAEDs-Day 1 | 3155.1 |
| Non-EIAEDs-Day 28 | 8118.8 |
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. T-max refers to time to maximum concentration. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months
| Intervention | hours (Median) |
|---|---|
| EIAEDs-Day 1 | 8.2 |
| EIAEDs-Day 28 | 2.1 |
| Non-EIAEDs-Day 1 | 24.0 |
| Non-EIAEDs-Day 28 | 4.2 |
Number of participants experiencing a toxicity of at least grade 3 that was deemed possibly, probably, or definitely related to the treatment. (NCT00597493)
Timeframe: 16 months
| Intervention | participants (Number) |
|---|---|
| Sorafenib + Temozolomide | 19 |
"The number of patients with complete or partial responses measured from the time of initial response to documented tumor progression. Radiologic response was defined using the Macdonald criteria.~The Macdonald criteria divides response into 4 types of response based on imaging (MRI) and clinical features, as follows: 1) complete response (CR); 2) partial response (PR); 3) stable disease (SD); and 4) progression (PD).~Criteria:~CR: disappearance of all enhancing disease (measurable and non-measurable) sustained for at least 4 weeks, no new lesions. No corticosteroids, clinically stable or improved.~PR: >=50% decrease of all measurable enhancing lesions, sustained for at least 4 weeks, no new lesions. Stable or reduced corticosteroids, clinically stable or improved.~SD: does not qualify for complete response, partial response or progression. Clinically stable.~PD: >= 25% increase in enhancing lesions, any new lesions. Clinical deterioration." (NCT00544817)
Timeframe: every 8 weeks until disease progression, estimated 18 months
| Intervention | participants (Number) |
|---|---|
| Combination Therapy | 13 |
Defined as Day 1 of protocol treatment to date of death from any cause. (NCT00544817)
Timeframe: 18 months
| Intervention | Months (Median) |
|---|---|
| Combination Therapy | 12 |
Defined as the duration of time from start of treatment to time of progression or death, whichever comes first. (NCT00544817)
Timeframe: 18 months
| Intervention | Months (Median) |
|---|---|
| Combination Therapy | 6 |
survival time is defined from time of histological diagnosis to death occurrence. (NCT00262730)
Timeframe: 30 months
| Intervention | months (Mean) |
|---|---|
| Treatment Arm - All Subjects | 17.2 |
Patients who are alive on the date of closing follow-up, or 30 months after completing all study treatments, will be censored on that date (NCT01984892)
Timeframe: up to 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Participants With Stage 4 Cancer | 8 |
"Progression-free survival defined as the time in weeks from study entry until tumor progression defined using the Wolchok criteria or death. Patients who are alive and free from progression on the date of closing follow-up will be censored on that date.~In order to minimize the potential for misdiagnosis of pseudoprogression, related to early inflammation, tumor measurement for determination of progression will be made at the earliest at 26 weeks." (NCT01984892)
Timeframe: average 52 weeks
| Intervention | weeks (Number) |
|---|---|
| Participants With Stage 4 Cancer | 41 |
Patients were assessed during RT for dose-limiting toxicities (DLT), which were defined as failure to deliver greater than 75% of the planned doses of TMZ or RAD001 during RT, interruption of RT for more than 5 days because of toxicity, or the following: >= Grade 3 diarrhea or skin rash; >= Grade 4 neutropenia, leukopenia, or thrombocytopenia; >= Grade 4 hypertriglyceridemia, hypercholesterolemia, or hyperglycemia despite optimal medial management, other >= 3 non-hematologic events; or >= Grade 4 radiation dermatitis. Maximum tolerated dose (MTD) was defined a priori as the highest dose level at which 0 or 1 of 6 patients developed DLTs. The number of patients who developed DLTs are reported here by dose level, with the MTD reported in the statistical analysis section. (NCT00553150)
Timeframe: Up to 49 days
| Intervention | participants who developed DLTs (Number) |
|---|---|
| Phase I: Dose Level 0 | 1 |
| Phase I: Dose Level 1 | 1 |
| Phase I: Dose Level 2 | 1 |
"The primary endpoint is overall survival at 12 months (OS12) after entry into this study. The proportion of successes will be estimated using the binomial point estimator (number of successes divided by the total number of evaluable patients) and the binomial 95% confidence interval estimated. A patient who is evaluable and survive more than 12 months (i.e. 365 days or more) after start of therapy will be classified as a success. Patients who die within 12 months after start of therapy will be considered to have failed." (NCT00553150)
Timeframe: at 12 months
| Intervention | proportion of participants (Number) |
|---|---|
| Phase II | 0.64 |
Overall survival: The overall survival or survival time is defined as the time from registration to death due to any cause. The distribution of overall survival will be estimated using the method of Kaplan-Meier method. (NCT00553150)
Timeframe: Up to 15 years
| Intervention | months (Median) |
|---|---|
| Phase II | 15.8 |
Progression-free-survival at 6 months: is the proportion of patients alive and progression-free at 6 months after start of regimen. This proportion will be estimated using the binomial point estimator and the binomial 95% confidence interval estimated. Progression is defined as at least a 25% increase in product of perpendicular diameters of contrast enhancement or mass or unequivocal increase in size of contrast enhancement or increase in mass effect as agreed upon independently by primary physician and quality control physicians or appearance of new lesions. (NCT00553150)
Timeframe: at 6 months
| Intervention | proportion of participants (Number) |
|---|---|
| Phase II | 0.52 |
The response rate is defined as the percentage of patients receiving F-fluorothymidine positron emission tomography (FLT-PET) imaging whose cancer shrinks or disappears after treatment. A reduction in standardized uptake value (SUV) of 30% or greater in the T1-post-gadolinium scan volume of interest (T1-gad VOI) or the total tumor VOI will be considered a responsive tumor. (NCT00553150)
Timeframe: Up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II | 44.4 |
Time-to-disease progression is defined as the time from start of study therapy to documentation of disease progression. Patients who die without documentation of progression will be considered to have had tumor progression at the time of death unless there is documented evidence that no progression occurred before death. Patients who fail to return for evaluation after beginning therapy will be censored for progression on the last day of therapy. Patients who experience major treatment violations will be censored for progression on the date of treatment violation occurred. The time-to-progression distribution will be estimated using the Kaplan-Meier method. Progression is defined as at least a 25% increase in product of perpendicular diameters of contrast enhancement or mass or unequivocal increase in size of contrast enhancement or increase in mass effect as agreed upon independently by primary physician and quality control physicians or appearance of new lesions. (NCT00553150)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| Phase II | 6.4 |
"Time in months from the start of study treatment to the date of first progression according to Macdonald criteria, or to death due to any cause. Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date. Median PFS was estimated using a Kaplan-Meier curve.~Macdonald criteria are standard criteria in neuro-oncology. Tumor assessment was made according to the adapted MacDonald criteria based on the combined evaluation of: 1) assessment of the MRI scan for measurable, evaluable, and new lesions (made by the independent external expert too), 2) overall assessment of neurological performance (made by the investigator), 3) concomitant steroid use (as reported by the investigator)." (NCT00643097)
Timeframe: 58 months
| Intervention | months (Median) |
|---|---|
| Arm I (ACTIVATE) | 14.2 |
| Arm II (ACT II STD) | 12.1 |
| Arm III (ACT II DI) | 11.6 |
Number of patients that developed a delayed-type hypersensitivity (DTH) response at following vaccination. Any skin reaction in response to the intradermal injection of the antigen was measured and recorded. A positive skin test was defined as > 5 mm induration (swelling). (NCT00643097)
Timeframe: 26 months
| Intervention | participants (Number) |
|---|---|
| Arm I (ACTIVATE) | 3 |
| Arm II (ACT II STD) | 0 |
| Arm III (ACT II DI) | 7 |
The objective is to assess the duration of immunosuppressive cytokine secretion and to identify a receptive interval for active immunotherapy. Immunosuppression will determined by monitoring a panel of immunosuppressive serum/plasma cytokines longitudinally and by determining the response of each patient to Recombivax Hepatitis B (HB) vaccination. Response is defined as seropositive or seronegative to the Hepatitis B surface antigen. (NCT00643097)
Timeframe: 26 months
| Intervention | Months (Mean) |
|---|---|
| Arm I (ACTIVATE) | NA |
| Arm II (ACT II STD) | NA |
| Arm III (ACT II DI) | NA |
To assess for any potential toxicity to the PEP-3 vaccine immunization in patients with newly diagnosed glioblastoma, Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 was used to tabulate any toxicities attributable to PEP-3. The number of patients with toxicity attributable to vaccine while on study are tabulated. (NCT00643097)
Timeframe: 26 months
| Intervention | participants (Number) |
|---|---|
| Arm I (ACTIVATE) | 4 |
| Arm II (ACT II STD) | 1 |
| Arm III (ACT II DI) | 7 |
Adverse events attributed to vaccination. Collected and attributed adverse events at each study visit; monitored participants for adverse events for two hours following vaccination procedure. (NCT00323115)
Timeframe: Until death or approximately 24 months after diagnosis
| Intervention | attributable adverse events (Number) |
|---|---|
| Vaccine | 1 |
Pre- and post-vaccine immune assay results (Tumor-specific T-cell Responses) are summarized on a continuous scale as mean. (NCT00323115)
Timeframe: Day 7 (pre-vaccination) and Day 42 (post-vaccination)
| Intervention | spots (Mean) |
|---|---|
| Pre-Vaccine | 1.40 |
| Post-Vaccine | 44.2 |
Pre- and post-vaccine immune assay results (Tumor-specific T-cell Responses) are summarized on a continuous scale as mean. (NCT00323115)
Timeframe: Day 7 (pre-vaccination) and Day 42 (post-vaccination)
| Intervention | spots (Median) |
|---|---|
| Pre-Vaccine | 0 |
| Post-Vaccine | 0 |
To determine the feasibility of this approach, the investigators hypothesize that at least 2/3 of the patients included in the study will be evaluable, meaning that the participants would have received the 3 vaccinations with immunologic outcome parameters measured before and after vaccination. Therefore a maximum of 15 patients would be enrolled in the study to obtain 10 evaluable patients. If after enrolling 15 patients the investigators are unable to obtain 10 evaluable patients, the investigators would consider this approach not feasible. (NCT00323115)
Timeframe: Through enrollment, approximately 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Vaccine | 10 |
Patients with evidence of evaluable enhancing disease on contrast-enhanced MRI performed within four weeks of study entry will be evaluated for response rate. Patients will be evaluated for objective tumor assessments by gadolinium-enhanced magnetic resonance imaging (Gd-MRI). Comparisons of objective assessments, excluding progressive disease, are based upon major changes in tumor size on the Gd-MRI compared to the baseline scan. Determination of progressive disease is based upon comparison to the previous scan with volumetric analysis. (NCT00323115)
Timeframe: baseline and 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Vaccine | 0 |
Overall survival will also be followed. Survival will be assessed from the date of surgery to the date of patient death, due to any cause, or to the last date the patient was known to be alive. (NCT00323115)
Timeframe: Approximately 42 months
| Intervention | Months (Median) |
|---|---|
| Vaccine | 28 |
Progression-free survival will be assessed for each patient as the time from surgery until the patient reaches objective disease progression by MRI criteria. Death will be regarded as a progression event in those patients that die before disease progression. Patients without documented objective progression at the time of the analysis will be censored at the date of their last objective tumor assessment. Since disease free survival and overall survival are secondary endpoints all patients will be followed until death or for a period of 5 years following enrollment. (NCT00323115)
Timeframe: Approximately 42 months
| Intervention | Months (Median) |
|---|---|
| Vaccine | 9.5 |
Peripheral blood obtained before starting radiation/ temozolomide (TMZ), and at first and second leukapheresis will be used to do lymphocyte phenotyping. We will determine percentages of CD3+/CD8+/CD45RO+ (memory T-cells), CD3+/CD8+/CD28- (CD8 suppressor T cell phenotype), and CD4+/CD25+ cells at those 3 time points. An anti-human Foxp3 antibody will be used to determine if the CD4+/CD25+ cells are T regulatory cells (TREG) and how the compartmental shift correlates with immunoresponse by other immune parameters as well as to efficacy. (NCT00323115)
Timeframe: Before starting radiation/Temozolomide and at Day 7 and Day 42.
| Intervention | percentage of cells (Mean) | |||
|---|---|---|---|---|
| % of CD3+/CD8+/CD45RO+ (memory T-cells) | % CD3+/CD8+/CD28- (CD8 suppressor T cell phenotype | %CD4+/CD25+ cells | % of are T regulatory cells (TREG) | |
| Vaccine - Before Starting Radiation/TMZ | 30.8 | 34.6 | 14.9 | 4.0 |
| Vaccine - First Leukapheresis | 25.8 | 30.5 | 14.1 | 3.5 |
| Vaccine - Second Leukapheresis | 19.3 | 23.7 | 11.8 | 1.2 |
Pre- and post-vaccine immune assay results (Tumor-specific T-cells ) are summarized on a continuous scale as mean. (NCT00323115)
Timeframe: Day 7 (pre-vaccination) and Day 42 (post-vaccination)
| Intervention | proportion of cells (Mean) | |
|---|---|---|
| Precursor frequency of CD4+ T cells | Precursor frequency of CD8+ T cells | |
| Post-Vaccine | 0.01 | 0.003 |
| Pre-Vaccine | 0.005 | 0.001 |
Pre- and post-vaccine immune assay results (Tumor-specific T-cells ) are summarized on a continuous scale as median. (NCT00323115)
Timeframe: Day 7 (pre-vaccination) and Day 42 (post-vaccination).
| Intervention | proportion of cells (Median) | |
|---|---|---|
| Precursor frequency of CD4+ T cells | Precursor frequency of CD8+ T cells | |
| Post-Vaccine | 0.01 | 0.001 |
| Pre-Vaccine | 0.003 | 0.001 |
Pre- and post-vaccine immune assay results (Tumor-specific T-cell Responses) are summarized on a continuous scale as median. IFN = interferon. (NCT00323115)
Timeframe: Day 7 (pre-vaccination) and Day 42 (post-vaccination)
| Intervention | percentage of cells (Mean) | |
|---|---|---|
| Percentage of CD4+ proliferating and IFN | Percentage of CD8+ proliferating and IFN | |
| Post-Vaccine | 0.88 | 0.92 |
| Pre-Vaccine | 0.38 | 0.45 |
Pre- and post-vaccine immune assay results (Tumor-specific T-cell Responses) are summarized on a continuous scale as median. (NCT00323115)
Timeframe: Day 7 (pre-vaccination) and Day 42 (post-vaccination)
| Intervention | percentage of cells (Median) | |
|---|---|---|
| Percentage of CD4+ proliferating and IFN | Percentage of CD8+ proliferating and IFN | |
| Post-Vaccine | 0.25 | 0.25 |
| Pre-Vaccine | 0.15 | 0.27 |
MRI & pheresis post vaccine (NCT00323115)
Timeframe: Day 42
| Intervention | 10^9 cells/L (Median) | |
|---|---|---|
| No. CD4+ | No. CD8+ | |
| Vaccine | 0.496 | 0.4836 |
all patients alive as of the last contact were censored for survival on the basis of that contact date (NCT00369590)
Timeframe: 3 years
| Intervention | weeks (Median) |
|---|---|
| Arm I - Anaplastic Glioma | 55 |
| Arm 2 - Glioblastoma | 39 |
"pts with confirmed radiographic response and their rate of progression (PFS).~Response determined by modified MacDonald Criteria Complete Response (CR): Complete disappearance of all measurable and evaluable disease, no new lesions. no steroids Partial Response (PR): Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable lesions. no new lesions. steroid dose no > than maximum dose used in first 8 weeks of treatment.~Stable: Does not qualify for CR, PR, or progression steroid dose no > than maximum dose used in first 8 weeks of treatment.~Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no increase) Clear clinical worsening." (NCT00369590)
Timeframe: up to 3 years
| Intervention | weeks (Median) |
|---|---|
| Arm I - Anaplastic Glioma | 45 |
| Arm 2 - Glioblastoma | 23 |
"This design yields 85% power to detect a true 30% 6-month PFS rate, while maintaining .91 probability of rejecting for a true 15% 6-month PFS rate.~pts had MRIs at screening and at the 3rd and 5th cycles then every 8 weeks until progression.~Response determined by modified MacDonald Criteria Complete Response (CR): Complete disappearance of all measurable and evaluable disease, no new lesions. no steroids Partial Response (PR): Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable lesions. no new lesions. steroid dose no > than maximum dose used in first 8 weeks of treatment.~Stable: Does not qualify for CR, PR, or progression steroid dose no > than maximum dose used in first 8 weeks of treatment.~Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no increase) Clear clinical worsening." (NCT00369590)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I - Anaplastic Glioma | 25 |
| Arm 2 - Glioblastoma | 7.7 |
number of patients who experienced toxicity that led to being taken off treatment (NCT00369590)
Timeframe: Approximately 1 year (start of treatment - end of treatment)
| Intervention | participants (Number) |
|---|---|
| Arm I - Anaplastic Glioma | 8 |
| Arm 2 - Glioblastoma | 6 |
number of cycles patient was able to have before developing a toxicity that required removing the patient from treatment. Treatment: Aflibercept 4mg/kg intravenously on day 1 of every 14-day cycle - 2 week cycle. (NCT00369590)
Timeframe: Start to End of treatment 39 cycles or 1yr 7.5months (78 weeks)
| Intervention | cycles (Median) |
|---|---|
| Arm I - Anaplastic Glioma | 5 |
| Arm 2 - Glioblastoma | 3.5 |
"pts had MRIs at screening and at the 3rd and 5th cycles then every 8 weeks until progression. All responders were centrally reviewed for confirmation~Response determined by modified MacDonald Criteria Complete Response (CR): Complete disappearance of all measurable and evaluable disease, no new lesions. no steroids Partial Response (PR): Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable lesions. no new lesions. steroid dose no > than maximum dose used in first 8 weeks of treatment.~Stable: Does not qualify for CR, PR, or progression steroid dose no > than maximum dose used in first 8 weeks of treatment.~Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no increase) Clear clinical worsening." (NCT00369590)
Timeframe: Up to 2 years
| Intervention | participants (Number) | |
|---|---|---|
| Complete Response | Partial Response | |
| Arm 2 - Glioblastoma | 0 | 7 |
| Arm I - Anaplastic Glioma | 1 | 6 |
Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or to death due to any cause. [Optional: Macdonald criteria are standard criteria in neuro-oncology. Tumor assessment was made according to the adapted MacDonald criteria based on the combined evaluation of: 1) assessment of the MRI scan for measurable, evaluable, and new lesions (made by the independent external expert too), 2) overall assessment of neurological performance (made by the investigator), 3) concomitant steroid use (as reported by the investigator).] (NCT00501891)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab and Metronomic Temozolomide | 18.8 |
The number of participants with complete or partial response as determined by a modification of the Macdonald criteria. Complete response was defined as complete disappearance on MR/CT of all enhancing tumor and mass effect, off all corticosteroids (or receiving only adrenal replacement doses), accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks. Partial Response was defined as greater than or equal to 50% reduction in tumor size on MR/CT by bi-dimensional measurement, on a stable or decreasing dose of corticosteroids, accompanied by a stable or improving neurologic examination, and maintained for at least 4 weeks. (NCT00501891)
Timeframe: 27 months
| Intervention | Number of participants (Number) |
|---|---|
| Bevacizumab and Metronomic Temozolomide | 9 |
Number of participants experiencing a Central Nervous System (CNS) hemorrhage or systemic hemorrhage (NCT00501891)
Timeframe: 27 months
| Intervention | participants (Number) | |
|---|---|---|
| CNS Hemorrhage | Systemic Hemorrhage | |
| Bevacizumab and Metronomic Temozolomide | 0 | 0 |
Number of participants experiencing a grade ≥4 hematologic or grade ≥3 non-hematologic toxicity (NCT00501891)
Timeframe: 27 months
| Intervention | participants (Number) | |
|---|---|---|
| Grade ≥ 4 hematologic toxicities | Grade ≥ 3 non-hematologic toxicities | |
| Bevacizumab and Metromonic Temozolomide | 0 | 14 |
Progression free survival is defined by any of the following: ≥ 25% increase in sum of the products of perpendicular diameters of enhancing lesions (compared with baseline if no decrease) on stable or increasing doses of corticosteroids; a significant increase in T2/FLAIR non-enhancing lesions on stable or increasing dose of corticosteroids compared with baseline scan or best response after initial of therapy, not due to comorbid events; the appearance of any new lesions; clear progression of non-measurable lesions; or definite clinical deterioration not attributable to another causes apart from the tumor, or to decrease in corticosteroid dose. (NCT02082119)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| High Grade Glioma | 82 |
"pts will be evaluated from first dose through end of initiation cycle. (6 weeks of RT+TMZ +EMD and 4 weeks of EMD alone) to review dose limiting toxicity (DLT) using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)~DLT defined as: Known TMZ hematological toxicities will not be considered dose limiting.~Nonhematological toxicities Grades 3-4 severity (except nausea and vomiting without sufficient antiemetic prophylaxis)" (NCT00085254)
Timeframe: 10 weeks
| Intervention | participants (Number) |
|---|---|
| Arm 1 500mg (Safety Run In) | 0 |
| ARM 2 1000mg (Safety run-in) | 0 |
| Arm 3 2000mg (Safety Run-In) | 0 |
The proportion of patients with grade 3 and grade 4 hematologic and non hematologic adverse events per CTCAE 4.0 (NCT00085254)
Timeframe: Up to 1 year
| Intervention | Number of grade 3 or 4 events (Number) |
|---|---|
| Arm 1- Phase 2 (500mg) | 48 |
| Arm 2 - Phase 2 (2000mg) | 35 |
"pts will be evaluated from first dose through end of initiation cycle. (6 weeks of RT+TMZ +EMD and 4 weeks of EMD alone) to review any dose limiting toxicity (DLT) using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (safety run-in)~DLT defined as: Known TMZ hematological toxicities will not be considered dose limiting.~cohorts at these 3 defined doses: 500mg, 1000mg and 2000mg MTD defined as: dose producing DLT in 2 out of 6 patients or dose level below the dose which produced DLT in >/= 2 out of 3 patients, or in >/= 3 out of 6 patients If no MTD (maximum tolerable dose) was defined through 3 steps of dose escalation, phase 2 will proceed with a randomized treatment allocation of the two pre-specified dosage arms: low dose; 500mg and high dose; 2000mg" (NCT00085254)
Timeframe: 10 weeks
| Intervention | mg (Number) |
|---|---|
| Arm 1 - Safety Run In | NA |
The overall survival is calculated from time of histological diagnosis to death occurance - median based on all 112 patients, all dose levels (NCT00085254)
Timeframe: up to 36 months
| Intervention | months (Median) |
|---|---|
| Arm 4 (Overall Study) | 19.7 |
survival calculated from date of initial histologic diagnosis and occurence of death. Pts at 500mg dose compared against Pts treated at 2000mg dose. Calculated using median (NCT00085254)
Timeframe: Up to 3 years
| Intervention | months (Median) |
|---|---|
| Arm 1 - Phase 2 (Treatment 1) | 17.4 |
| Arm 2 - Phase 2 (Treatment 2) | 20.8 |
The toxicity assessments were made according to the common terminology criteria for adverse events (CTCAE version 3.0) of the National Cancer Institute. Number of participants with Grade 1 to 5 adverse events are reported here. (NCT00805961)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Overall Study | 53 |
Response to treatment was assessed by MRI using the MacDonald criteria based on the assessment of the MRI scan for measurable, evaluable, and new lesions. The objective response rate is defined as the proportion of patients with improvement and or decreased extent of lesions compared to baseline. (NCT00805961)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Overall Study | 31 |
Overall survival was defined as the interval from the first day of study treatment until the date of death. (NCT00805961)
Timeframe: 18 months
| Intervention | Months (Number) |
|---|---|
| Overall Study | 13.9 |
Progression-free survival is defined as the duration of time from start of treatment to time of progression or death, whichever comes first. (NCT00805961)
Timeframe: 18 months
| Intervention | Months (Median) |
|---|---|
| Overall Study | 11.3 |
Analyzed via a paired t-test. Change in body fat measurement as determined by the Durnin-Womersley 4-fold technique (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | percentage of change in body fat (Mean) |
|---|---|
| Behavioral Dietary Intervention | -3.1 |
Assessed via mixed-effects regression. Weight changes over time assessed by modeling BMI as a function of time (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | percentage of change in BMI (Mean) |
|---|---|
| Behavioral Dietary Intervention | -1.2 |
Assessed via mixed-effects regression. (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | beats per minute (Mean) |
|---|---|
| Behavioral Dietary Intervention | 67.3 |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
Computed along with a 95% exact confidence interval. Exact binomial test (with a one-sided alpha of 0.05) will be used to test whether adherence is greater than 60%. (NCT01819233)
Timeframe: Up to week 12
| Intervention | participants (Number) |
|---|---|
| Behavioral Dietary Intervention | 28 |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
Assessed via mixed-effects regression. The FACT-B is a questionnaire using a 5-point Likert scale (0-Not at all to 4-Very much) (NCT01819233)
Timeframe: Baseline to 4 weeks after completion of study
| Intervention | score on a scale (Mean) |
|---|---|
| Behavioral Dietary Intervention | 0.8 |
Analyzed via survival methods, specifically the Kaplan-Meier method and the logrank test. (NCT01819233)
Timeframe: Up to 4 weeks after completion of study
| Intervention | Participants (Count of Participants) |
|---|---|
| Behavioral Dietary Intervention | NA |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
Two groups of patients in the Phase II trial will be considered separately, 1) participants who have not received previous bevacizumab and 2) participants who have received bevacizumab as part of first-line treatment. Overall survival is measured as the interval from first study treatment until date of death, or date last known alive. (NCT01349660)
Timeframe: every 12 weeks for up to 60 months
| Intervention | months (Median) |
|---|---|
| Phase II Participants - Prior Bevacizumab | 6.6 |
| Phase II Participants - Bevacizumab Naive | 10.8 |
Two groups of patients in the Phase II trial will be considered separately, 1) participants who have not received previous bevacizumab and 2) participants who have received bevacizumab as part of first-line treatment. PFS is measured from the date of first protocol treatment until date of disease progression or death occurs, or date of last adequate tumor assessment using RANO or McDonald criteria. McDonald disease progression criteria: a 25% or greater increase in sum of the diameters of lesions, new lesions, or clinical deterioration (McDonald et al, 1990). RANO disease progression criteria: a 25% or greater increase in the enhancing lesions sum compared with smallest tumor measurement, significant increase in T2/FLAIR nonenhancing lesion on stable or increasing corticosteroids, new lesions, or clinical deterioration (Wen et al 2010) (NCT01349660)
Timeframe: every 8 weeks for up to 33 months
| Intervention | months (Median) |
|---|---|
| Phase II Patients With Prior Bevacizumab Treatment. | 2.8 |
| Phase II Patients Without Prior Bevacizumab Treatment | 5.3 |
The optimal dose of BKM120 to administer in combination with standard dose bevacizumab determined as the dose at which ≤1 of 6 patients experiences a DLT assessed using NCI CTCAE v4.03 during Cycle 1 (28 days). The optimal dose of BKM120 was determined to be 60 mg by mouth (PO), once a day for each 28 day cycle along with bevacizumab, administered 10 mg/kg intravenously (IV) on Day 1 and Day 15 of each 28 day cycle. (NCT01349660)
Timeframe: Collected from day of first dose to the end of the first treatment cycle, up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I Dose Level 1 (60 mg BKM120, 10mg/kg Bevacizumab) | 0 |
| Phase I Dose Level 2 (80 mg BKM120, 10mg/kg Bevacizumab) | 3 |
Two groups of participants in the Phase II trial will be considered separately, 1) those who have not received previous bevacizumab and 2) those who have received bevacizumab as part of first-line treatment. Overall Response (OR) = number of patients with complete or partial responses (CR or PR) per McDonald or RANO criteria. McDonald: CR as disappearance of all disease for at least four weeks, no new lesions, no steroids; PR as 50% or greater decrease in the sum of all lesions compared with baseline for at least four weeks, no new lesions, stable or reduced steroids (McDonald 1990). RANO: CR as disappearance of all disease for at least 4 weeks, no new lesions, stable or improved nonenhancing lesions, and no steroid usage; and PR as a 50% or greater decrease in the sum of all lesions compared with baseline measurement for at least four weeks, no new lesions, stable or improved nonenhancing lesions on same or lower steroid dose compared to baseline (Wen 2010). (NCT01349660)
Timeframe: every 8 weeks, projected 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase II Participants - Prior Bevacizumab. | 1 |
| Phase II Participants - Bevacizumab Naive | 18 |
Defined as the number of participants with treatment-emergent grade 3/4/5 adverse events/serious adverse events utilizing the National Cancer Institute Common Technology Criteria for Adverse Events (NCI CTCAE) v4.03 (NCT01349660)
Timeframe: every 4 weeks for up to 5.2 years
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fatigue | Confusion | Hyperglycemia | Diarrhea | Alanine aminotransferase increased | Hypertension | Seizure | Asthenia | Aspartate Aminotransferase Increased | Hypertriglyceridemia | Abdominal pain | Altered Mental Status | Gait Disturbance | Ataxia | Lipase Increased | Muscle Weakness | Pneumonia | Sepsis | Respiratory Failure | Thrombocytopenia | Hypercholesterolemia | Mucositis | Anorexia | Memory Impairment | Pruritis | Vomiting | Mood Alteration | Weight Loss | Neutropenia | Dehydration | Dyspnea | Hemorrhage | Somnolence | Taste Alteration | Agitation | Dysarthria | Fall | Hypermagnesemia | Ejection Fraction Decreased | Elevated Liver Enzymes | Hypoalbuminemia | Hypophosphatemia | Psychosis | Suicidal Ideation | Thromboembolic Event | Akathisia | Cellulitis | Chronic Obstructive Pulmonary Disease | Delirium | Diabetic Ketoacidosis | Enteritis | Female Genital Tract Fistula | Gastrointestinal Infection | Hyperlipidemia | Intracranial Hemorrhage | Left Ventricular Systolic Dysfunction | Necrotizing Fasciitis | Palsy | Paralysis | Personality Change | Syncope | Transaminitis | Urine Output Decreased | Vaginal Fistula | Volume Depletion | Headache | Hypokalemia | Hyponatremia | Nausea | Proteinuria | Rash | Urinary Tract Infection | |
| Phase I - Dose Level 1 (60 mg BKM, 10mg/kg Bevacizumab) | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase I - Dose Level 2 (80 mg BKM120, 10mg/kg Bevacizumab) | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 1 | 2 |
| Phase II - (60 mg BKM120, 10mg/kg Bevacizumab) | 8 | 8 | 5 | 5 | 5 | 6 | 6 | 4 | 5 | 2 | 1 | 1 | 1 | 0 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 4 | 3 | 1 | 3 | 2 | 2 |
We first determined the MTDs in each ARM and we then performed the cohort expansion at the MTD in both ARMs separately, until we treated a total of 18 participants at this dose in each ARM. PFS is defined as the duration of time from start of registration to time of progression or death, whichever comes first. Progression was assessed by the Response Assessment in Neuro-Oncology Criteria (RANO). Progression is ≥25% increase in tumor volume compared to baseline in the sum of the products of perpendicular diameters of enhancing lesions compared with the smallest measurement obtained either at baseline or best response with the participant on stable or increasing doses of steroids. Significant increase in T2-weighted-Fluid-Attenuated Inversion Recovery (T2/FLAIR) non-enhancing lesions with the participant on stable or increasing doses of steroids (not caused by comorbid events). Any new lesions. (NCT02942264)
Timeframe: 4 months
| Intervention | percentage of participants (Number) |
|---|---|
| All Participants | 25 |
We first determined the maximum tolerated dose (MTDs) in each ARM and we then performed the cohort expansion at the MTD in both ARMs separately, until we treated a total of 18 participants at this dose in each ARM. PFS is defined as the duration of time from start of registration to time of progression or death, whichever comes first. Progression was assessed by the Response Assessment in Neuro-Oncology Criteria (RANO). Progression is ≥25% increase in tumor volume compared to baseline in the sum of the products of perpendicular diameters of enhancing lesions compared with the smallest measurement obtained either at baseline or best response with the participant on stable or increasing doses of steroids. Significant increase in T2-weighted-Fluid-Attenuated Inversion Recovery (T2/FLAIR) non-enhancing lesions with the participant on stable or increasing doses of steroids (not caused by comorbid events). Any new lesions. (NCT02942264)
Timeframe: 4 months
| Intervention | percentage of participants (Number) |
|---|---|
| All Participants | 40 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT02942264)
Timeframe: Date treatment consent signed to date off study, approximately 15mo(m)/8days(d), 26m, 7m/26d, 13m/17d, 11m/30d, 12m/6d, 19m/11d, 9m/28d and 18m/21d for Group 1-9 respectively.
| Intervention | Participants (Count of Participants) |
|---|---|
| ARM 1 Dose Level 0 - (Starting Dose) | 6 |
| ARM 1 Dose Level 1 - (Dose Escalation) | 13 |
| ARM 2 Dose Level 0 (Starting Dose) | 3 |
| ARM 2 Dose 1 - (Dose Escalation) | 6 |
| ARM 2 Dose 0 - (Dose De-escalation) | 3 |
| ARM 2 Dose Level II - (Dose Escalation) | 2 |
| ARM 2 Dose Level I - (Dose De-escalation) | 7 |
| ARM 1 Dose Level 1 (MTD Level in ARM1) | 6 |
| ARM 2 Dose Level 1 (MTD Level in ARM2) | 7 |
Maximum tolerated dose of metronomic (mn) Zotiraciclib (TG02) was assessed using the Bayesian Optimal Interval (BOIN) design. The MTD is defined as the dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate of 0.35. If there are ties, we select the higher dose level when the isotonic estimate is lower than the target toxicity rate; and we select the lower dose level when the isotonic estimate is greater than the target toxicity rate of 0.35. (NCT02942264)
Timeframe: 4 weeks after initiation of treatment
| Intervention | mg/day (Number) |
|---|---|
| All Participants | 250 |
Maximum tolerated dose of Zotiraciclib (TG02) in combination with dose dense Temozolomide (TMZ) was assessed using the Bayesian Optimal Interval (BOIN) design. The MTD is defined as the dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate of 0.35. If there are ties, we select the higher dose level when the isotonic estimate is lower than the target toxicity rate; and we select the lower dose level when the isotonic estimate is greater than the target toxicity rate of 0.35. (NCT02942264)
Timeframe: 4 weeks after initiation of treatment
| Intervention | mg/day (Number) |
|---|---|
| All Participants | 250 |
DLT is defined as any adverse events attributed to the study drug. For example, Grade 4 neutropenia lasting 5 days or more. Febrile neutropenia defined as grade 3-4 neutropenia with fever ≥38.5ºC and/or infection requiring antibiotic or antifungal treatment. Nausea or vomiting that responds to symptomatic therapy and lasts ≤7 days. Fatigue that responds to symptomatic therapy and lasts ≤7 days. And weight gain (in patients on steroids). (NCT02942264)
Timeframe: 4 weeks after initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| ARM 1 Dose Level 0 - (Starting Dose) | 1 |
| ARM 1 Dose Level 1 - (Dose Escalation) | 3 |
| ARM 2 Dose Level 0 (Starting Dose) | 0 |
| ARM 2 Dose 1 - (Dose Escalation) | 3 |
| ARM 2 Dose 0 - (Dose De-escalation) | 1 |
| ARM 2 Dose Level II - (Dose Escalation) | 1 |
| ARM 2 Dose Level I - (Dose De-escalation) | 4 |
CAR and vector presence were quantitated in peripheral blood mononuclear cell (PBMC) samples using established polymerase chain reaction (PCR) techniques (NCT01454596)
Timeframe: 1 month post transplant
| Intervention | K/µL (Median) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 23 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 70 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 36 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 67 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 7 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 43 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 28 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 25 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 12 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 67.5 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | NA |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 8 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01454596)
Timeframe: 51 dys Grp A, Cohort 1; Cohort 2:68 dys; Cohort 3:40 dys; Grp B, Cohort 1:67 dys; Cohort 2:48 dys; Cohort 3:55 dys; Cohort 4: 46 dys; Cohort 5:147 dys; C. Ster/No Ster Grp, Cohort 6:12 mos, 26 dys; Cohort 7:11 mos, 18 dys; Cohort 8:7 dys; Cohort 9:70 dys.
| Intervention | Participants (Count of Participants) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 1 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 1 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 1 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 1 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 1 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 1 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 1 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 3 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 3 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 3 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 1 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 1 |
Objective response was assessed by comparison with baseline dynamic contrast enhanced magnetic resonance imaging with perfusion using Neuro-oncology Working Group proposed guidelines. Complete Response is disappearance of all measurable and non-measurable disease for at least 4 weeks. Partial Response is >/= 50% decrease in lesions for at least 4 weeks. Stable Disease does not meet the criteria for complete response, partial response or progression and requires stable lesions compared with baseline. Progression is >/= 25% increase in lesions. (NCT01454596)
Timeframe: 4 weeks after cell infusion and monthly as feasible up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 0 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 0 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 0 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 0 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 0 |
Aggregate of all adverse events ≥Grade 3 that are possibly, probably, and definitely related to treatment. Adverse events were assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). Per CTCAE, Grade 3 adverse events are severe, Grade 4 is life threatening, and Grade 5 is death. (NCT01454596)
Timeframe: From 4 weeks after cell infusion up to 77 days
| Intervention | adverse events (Number) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 0 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 0 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 0 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 0 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 1 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 1 |
Progression was assessed by the Response Assessment in Neuro-Oncology (RANO) criteria and is defined as the circumstance when the magnetic resonance imaging (MRI) scan is ranked -2 (definitely worse) or -3 (development of a new lesion). (NCT01454596)
Timeframe: Time from the date of registration to the date of first observation of progressive disease up to 6 months after end of treatment
| Intervention | months (Median) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 1.1 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 1.1 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 1.3 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 1.9 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 2.0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 1.5 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 1.2 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 1.1 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 2.7 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 1.1 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 2.0 |
Number of Participants in Phase 1 with Dose Limiting Toxicities (DLTs) (NCT01465347)
Timeframe: During phase 1
| Intervention | Participants (Count of Participants) |
|---|---|
| TSC 0.25 mg/kg - 9 Dose Group | 0 |
The sum of the product of the diameters of the tumor (using recorded tumor diameter measurements made from brain MRI images) was used to express tumor size. Results were summarized for actual and percentage change from baseline. Individual subjects results were listed, including tumor volume and tumor response from independent reviewers. Investigator data were listed but not used in the analysis. Percent response (according to independent reviewer assessments) by percentage tumor reduction from tumor resection or definitive biopsy to the last MRI were summarized. (NCT01465347)
Timeframe: From Baseline to Week 110
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| tumor not reduced | 0 to 39% tumor reduction | 40 to 63% tumor reduction | 64 to 93% tumor reduction | 94 to 99% tumor reduction | 100% tumor reduction | |
| TSC 0.25 mg/kg - 18 Dose Group - Phase 2 | 10 | 6 | 2 | 6 | 2 | 11 |
| TSC 0.25mg/kg - 9 Dose Group - Phase 1 | 1 | 0 | 0 | 0 | 0 | 2 |
Participants in phase 2 (18 dose group, 6 weeks treatment with TSC) were monitored for up to 3 years (last follow-up - February 16, 2016). Overall Survival (OS) was defined as the length of time from the date of tumor resection surgery or definitive biopsy to the date of death. The OS analyses were performed using the Kaplan-Meier estimate method. The OS rates at 6, 12, 18 and 24 months were estimated. Median OS values were calculated; a corresponding 95% confidence interval for each median value was determined using a log rank analysis. The length of OS (in months) was calculated as follows: date of death or censored - date of surgery or definitive biopsy / 30.4375. (NCT01465347)
Timeframe: 6, 12, 18, 24 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| 6 month OS | 12 month OS | 18 month OS | 24 month OS | |
| TSC 0.25 mg/kg - 18 Dose Group - Phase 2 | 89.3 | 71.2 | 43.8 | 36.3 |
The PFS analyses were performed using the Kaplan-Meier estimate method. The PFS rates at 6, 12, 18 and 24 months were estimated. Median PFS values were calculated; a corresponding 95% confidence interval for each median value was determined using a log rank analysis. Time to disease progression (in months) was calculated as follows: date of event* or censoring - date of surgery or definitive biopsy / 30.4375; *event = first tumor progression or death. (NCT01465347)
Timeframe: 6,12,18, 24 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| 6 months | 12 months | 18 months | 24 months | |
| TSC 0.25 mg/kg - 18 Dose Group - Phase 2 | 30.9 | 9.9 | 4.0 | 0.0 |
254 reviews available for temozolomide and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Carriers; Drug Delivery Systems; D | 2021 |
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2021 |
Temozolomide is a risk factor for invasive pulmonary aspergillosis: A case report and literature review.
Topics: Aged; Brain Neoplasms; Glioblastoma; Humans; Invasive Pulmonary Aspergillosis; Male; Risk Factors; T | 2021 |
The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials.
Topics: Adult; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Progression-F | 2022 |
Newly Diagnosed Glioblastoma in Elderly Patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; Glioblastoma; Humans; Pre | 2022 |
Combining apatinib and temozolomide for brainstem glioblastoma: a case report and review of literature.
Topics: Adult; Brain Neoplasms; Brain Stem; Dacarbazine; Glioblastoma; Humans; Male; Pyridines; Temozolomide | 2022 |
Checkpoint: Inspecting the barriers in glioblastoma immunotherapies.
Topics: Biological Transport; Glioblastoma; Humans; Immunotherapy; Neoadjuvant Therapy; Temozolomide | 2022 |
Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.
Topics: Blood-Brain Barrier; Brain Neoplasms; Glioblastoma; Humans; Immunologic Factors; Immunotherapy; Lymp | 2022 |
Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; | 2022 |
Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: A pooled analysis of patient-level data from 4 prospective trials.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Frail Elderly; Glioblastoma; Humans; Obser | 2022 |
Natural Compounds as Promising Adjuvant Agents in The Treatment of Gliomas.
Topics: Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Temozolomide | 2022 |
Temozolomide Resistance: A Multifarious Review on Mechanisms Beyond
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; Glioblastoma | 2023 |
Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.
Topics: Brain Neoplasms; Glioblastoma; Humans; Immunotherapy; Neoplastic Stem Cells; Temozolomide | 2022 |
NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review).
Topics: Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; RNA, Untranslated; Temozolomide | 2022 |
Optimal managements of elderly patients with glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Quality of Life; Tem | 2022 |
Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Drug Combinations; Gl | 2022 |
Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Therapy, Combination; Glioblastom | 2022 |
Impact of angiogenic inhibition in the treatment of newly diagnosed and recurrent glioblastoma: a meta-analysis based on randomized controlled trials.
Topics: Adult; Angiogenesis Inhibitors; Bevacizumab; Glioblastoma; Humans; Neoplasm Recurrence, Local; Rando | 2022 |
Temozolomide: An Overview of Biological Properties, Drug Delivery Nanosystems, and Analytical Methods.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Guanine; Humans; Temozolomide | 2022 |
Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; | 2022 |
Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Immunotherapy; Temozolomid | 2022 |
Comparative efficacy and safety of therapeutics for elderly glioblastoma patients: A Bayesian network analysis.
Topics: Aged; Antineoplastic Agents, Alkylating; Bayes Theorem; Brain Neoplasms; Dacarbazine; Glioblastoma; | 2022 |
Nanomedicine for glioblastoma: Progress and future prospects.
Topics: Blood-Brain Barrier; Brain Neoplasms; Glioblastoma; Humans; Nanomedicine; Temozolomide | 2022 |
Updates in the Management of Recurrent Glioblastoma Multiforme.
Topics: Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2023 |
Glioblastoma and Methionine Addiction.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Epigenesis, Genetic; Glioblastoma; Humans; Methi | 2022 |
Glioblastoma Treatment: State-of-the-Art and Future Perspectives.
Topics: Bevacizumab; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2022 |
Intracranial dissemination of glioblastoma multiforme: a case report and literature review.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Female; Glioblastoma; Humans; Tem | 2022 |
Immune-checkpoint inhibitors for glioblastoma: what have we learned?
Topics: Brain Neoplasms; Clinical Trials, Phase III as Topic; Glioblastoma; Humans; Immune Checkpoint Inhibi | 2022 |
Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme.
Topics: Alkylating Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Delayed-Act | 2022 |
Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Signal Transduction; Temozolomide | 2022 |
Progress in research and development of temozolomide brain-targeted preparations: a review.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neopla | 2023 |
Tumor treating fields with radiation for glioblastoma: a narrative review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Temozol | 2022 |
Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; COVID-19; Glioblastoma; Humans; Middle Aged; Pan | 2022 |
Intersections of Ubiquitin-Proteosome System and Autophagy in Promoting Growth of Glioblastoma Multiforme: Challenges and Opportunities.
Topics: Autophagy; Glioblastoma; Humans; Proteasome Endopeptidase Complex; Temozolomide; Ubiquitin | 2022 |
Utility of the Cerebral Organoid Glioma 'GLICO' Model for Screening Applications.
Topics: Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Organoids; Temozolomide | 2022 |
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Lomustine; Ne | 2023 |
Injectable local drug delivery systems for glioblastoma: a systematic review and
Topics: Animals; Brain Neoplasms; Drug Delivery Systems; Glioblastoma; Liposomes; Temozolomide | 2023 |
Modeling glioblastoma complexity with organoids for personalized treatments.
Topics: Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; | 2023 |
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Glioblastoma; Glioma; | 2023 |
Is Autophagy Inhibition in Combination with Temozolomide a Therapeutically Viable Strategy?
Topics: Autophagy; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Temozolomide | 2023 |
The Role of Long Noncoding Ribonucleic Acids in Glioblastoma: What the Neurosurgeon Should Know.
Topics: Brain Neoplasms; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Neurosurgeons; RNA, L | 2023 |
Radiotherapy, lymphopenia and improving the outcome for glioblastoma: a narrative review.
Topics: Brain Neoplasms; Glioblastoma; Humans; Lymphopenia; Radiotherapy; Temozolomide; Treatment Outcome | 2023 |
Advanced Bioinformatics Analysis and Genetic Technologies for Targeting Autophagy in Glioblastoma Multiforme.
Topics: Adult; Autophagy; Brain Neoplasms; Glioblastoma; Humans; MicroRNAs; Temozolomide; Tumor Microenviron | 2023 |
Target-Based Anticancer Indole Derivatives for the Development of Anti-Glioblastoma Agents.
Topics: Brain Neoplasms; Glioblastoma; Humans; Indoles; Temozolomide | 2023 |
Advanced biomaterials for human glioblastoma multiforme (GBM) drug delivery.
Topics: Antineoplastic Agents; Bevacizumab; Glioblastoma; Humans; Lomustine; Temozolomide | 2023 |
Expert opinion on translational research for advanced glioblastoma treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Expert Testimony; Glioblastoma; Glioma; Humans; | 2023 |
Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas.
Topics: Antineoplastic Agents; Glioblastoma; Humans; Nanomedicine; Temozolomide; Tissue Distribution | 2023 |
Advances in Treatment of Isocitrate Dehydrogenase (IDH)-Wildtype Glioblastomas.
Topics: Brain Neoplasms; Glioblastoma; Humans; Immunotherapy; Isocitrate Dehydrogenase; Mutation; Prognosis; | 2023 |
Pyroptosis, ferroptosis, and autophagy cross-talk in glioblastoma opens up new avenues for glioblastoma treatment.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Ferroptosis; Glioblastoma; Humans; Pyroptos | 2023 |
Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; MicroRNAs; Precision Medicine; Prognosis; T | 2023 |
Nitric oxide synthase inhibitors as potential therapeutic agents for gliomas: A systematic review.
Topics: Animals; Brain Neoplasms; Enzyme Inhibitors; Glioblastoma; Glioma; Humans; NG-Nitroarginine Methyl E | 2023 |
Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; End | 2023 |
Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions.
Topics: Brain; Glioblastoma; Health Status; Humans; Immunotherapy; Temozolomide | 2023 |
A Comprehensive Review of miRNAs and Their Epigenetic Effects in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Re | 2023 |
The impact of survivorship bias in glioblastoma research.
Topics: Aged; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Repair Enzymes; Glioblas | 2023 |
Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques.
Topics: Brain Neoplasms; Glioblastoma; Glioma; Humans; Oncolytic Virotherapy; Temozolomide | 2023 |
Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.
Topics: Brain Neoplasms; Combined Modality Therapy; Electric Stimulation Therapy; Glioblastoma; Humans; Temo | 2023 |
Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: Function of non-coding RNAs.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epi | 2023 |
Dysregulated lipid metabolism in TMZ-resistant glioblastoma: pathways, proteins, metabolites and therapeutic opportunities.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence.
Topics: Brain Neoplasms; Combined Modality Therapy; Electric Stimulation Therapy; Glioblastoma; Humans; Temo | 2023 |
Prognosis of patients with newly diagnosed glioblastoma treated with molecularly targeted drugs combined with radiotherapy vs temozolomide monotherapy: A meta-analysis.
Topics: Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Humans; Male; Molecular Targeted Therapy; | 2019 |
Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Chemistry, Pharmaceutical; Dendrimers; | 2020 |
Steroids use and survival in patients with glioblastoma multiforme: a pooled analysis.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Disease-Free Survival; Glioblastoma; Humans; Prospective | 2021 |
Management of glioblastomas in the elderly population.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Prospective Studies; | 2020 |
MGMT Status as a Clinical Biomarker in Glioblastoma.
Topics: Biomarkers, Tumor; Brain Neoplasms; Clinical Decision-Making; DNA Methylation; DNA Mismatch Repair; | 2020 |
Management of glioblastoma: State of the art and future directions.
Topics: Antineoplastic Agents; Bevacizumab; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Glioblastom | 2020 |
The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Glioblastoma; Humans; Ra | 2020 |
Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Line, Tumor; Cl | 2020 |
Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis.
Topics: Brain Neoplasms; Cancer Survivors; Chemotherapy, Adjuvant; Disease-Free Survival; Glioblastoma; Huma | 2020 |
Clinical Features and Outcomes of Primary Spinal Cord Glioblastoma: A Single-Center Experience and Literature Review.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immu | 2020 |
Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Immunoth | 2021 |
Management of elderly patients with glioblastoma: current status with a focus on the post-operative radiation therapy.
Topics: Aged; Brain Neoplasms; Combined Modality Therapy; Glioblastoma; Humans; Quality of Life; Temozolomid | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Temozolomide-induced aplastic anaemia: Case report and review of the literature.
Topics: Aged; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Glioblastoma; Gr | 2021 |
Update on the management of elderly patients with glioblastoma: a narrative review.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Quality of Life; Ran | 2021 |
Radiation-Associated Glioblastoma after Prophylactic Cranial Irradiation in a Patient of ALL: Review of Literature and Report of a Rare Case.
Topics: Brain Neoplasms; Child, Preschool; Cranial Irradiation; Glioblastoma; Humans; Male; Neoplasm Recurre | 2020 |
Updated Insights on EGFR Signaling Pathways in Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Gene | 2021 |
The efficacy of hypofractionated radiotherapy (HFRT) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: A meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Gliob | 2021 |
Natural substances to potentiate canonical glioblastoma chemotherapy.
Topics: Anthraquinones; Biological Products; Brain Neoplasms; Catechols; Cell Cycle; Dose-Response Relations | 2021 |
Silencing of ZFP36L2 increases sensitivity to temozolomide through G2/M cell cycle arrest and BAX mediated apoptosis in GBM cells.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proli | 2021 |
Dissecting the mechanism of temozolomide resistance and its association with the regulatory roles of intracellular reactive oxygen species in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Drug Resistance, Neoplasm; Glioblastoma; Humans; Reactiv | 2021 |
Adding high-dose celecoxib to increase effectiveness of standard glioblastoma chemoirradiation.
Topics: Celecoxib; Cyclooxygenase 2; Glioblastoma; Humans; Temozolomide | 2021 |
Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Bias; Brain Neoplasms; Cohort Studies; CpG Islands; DNA Me | 2021 |
The Role of Mismatch Repair in Glioblastoma Multiforme Treatment Response and Resistance.
Topics: Antineoplastic Agents, Alkylating; DNA Mismatch Repair; Glioblastoma; Humans; Temozolomide | 2021 |
Novel Radiation Approaches.
Topics: Brain Neoplasms; Glioblastoma; Humans; Temozolomide | 2021 |
Long Non-Coding RNAs in Multidrug Resistance of Glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene E | 2021 |
Dose Escalated Radiation Therapy for Glioblastoma Multiforme: An International Systematic Review and Meta-Analysis of 22 Prospective Trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Child; DNA Modification Methylases; DNA | 2021 |
DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.
Topics: Adult; Brain Neoplasms; Clinical Trials, Phase III as Topic; Combined Modality Therapy; DNA Damage; | 2022 |
DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Checkpoints; DNA Damage; DNA Repair; | 2021 |
Oncogenesis, Microenvironment Modulation and Clinical Potentiality of FAP in Glioblastoma: Lessons Learned from Other Solid Tumors.
Topics: Animals; Biomarkers; Biomarkers, Tumor; Brain Neoplasms; Cancer-Associated Fibroblasts; Carcinogenes | 2021 |
Outcomes in Elderly Patients with Glioblastoma Multiforme Treated with Short-Course Radiation Alone Compared to Short-Course Radiation and Concurrent and Adjuvant Temozolomide Based on Performance Status and Extent of Resection.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Quality | 2021 |
Progress and prospect in tumor treating fields treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Th | 2021 |
Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2021 |
Antioxidant responses related to temozolomide resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antioxidants; Brain Neoplasms; Drug Resistance, Neoplasm | 2021 |
Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.
Topics: Antineoplastic Agents, Alkylating; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; Temozolo | 2021 |
The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: A network meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2017 |
Managing Glioblastoma in the Elderly Patient: New Opportunities.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disea | 2017 |
Salinomycin's potential to eliminate glioblastoma stem cells and treat glioblastoma multiforme (Review).
Topics: Brain; Dacarbazine; Glioblastoma; Humans; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Pyrans; | 2017 |
The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
Topics: Animals; Brain Neoplasms; Cause of Death; Chemoradiotherapy; Combined Modality Therapy; Disease Mana | 2018 |
Glioblastoma in the elderly: initial management.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, P | 2017 |
Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic; Combined Mo | 2017 |
Glioblastoma in elderly patients: solid conclusions built on shifting sand?
Topics: Aging; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Temozolomide; Treat | 2018 |
Treatment of Glioblastoma.
Topics: Aftercare; Age Factors; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Bra | 2017 |
Treatment of Glioblastoma in Older Adults.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Glioblastoma | 2017 |
Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mod | 2018 |
Fractionated Radiotherapy of Intracranial Gliomas.
Topics: Adult; Brain Neoplasms; Dacarbazine; Dose Fractionation, Radiation; Glioblastoma; Glioma; Humans; Ma | 2018 |
Chemotherapy of High-Grade Astrocytomas in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Grading; Te | 2018 |
An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cellular Senescen | 2018 |
Current state of immunotherapy for glioblastoma.
Topics: Biomarkers, Tumor; Blood-Brain Barrier; Combined Modality Therapy; Drug Resistance, Neoplasm; Gliobl | 2018 |
Repurposing drugs for glioblastoma: From bench to bedside.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Drug Repositioning; Drug Resistanc | 2018 |
Temozolomide for immunomodulation in the treatment of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Immunomodulation; Prognosi | 2018 |
Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Connexin 43; Drug Resistance, N | 2018 |
MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; | 2018 |
Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cholesterol; Drug Resistance, Neopla | 2018 |
Treatment of Glioblastoma in the Elderly.
Topics: Aged; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; O(6)-Methylguanine | 2018 |
Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma.
Topics: Antineoplastic Agents; Autophagosomes; Autophagy; Brain Neoplasms; Cell Death; Drug Resistance, Neop | 2018 |
Drug resistance in glioblastoma and cytotoxicity of seaweed compounds, alone and in combination with anticancer drugs: A mini review.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplas | 2018 |
Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance, Neoplasm; Glioblastoma; Humans; | 2018 |
Statins: a new approach to combat temozolomide chemoresistance in glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Glioblastoma; Humans; Hyd | 2018 |
Anti-angiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brai | 2018 |
Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Diagnosis, Differentia | 2019 |
Evidence-Based Practice: Temozolomide Beyond Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Evidence-Based Practice; Glioblastoma; Humans; T | 2019 |
Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Prognos | 2019 |
From epidemiology and neurometabolism to treatment: Vitamin D in pathogenesis of glioblastoma Multiforme (GBM) and a proposal for Vitamin D + all-trans retinoic acid + Temozolomide combination in treatment of GBM.
Topics: Brain Neoplasms; Glioblastoma; Humans; Receptors, Calcitriol; Temozolomide; Tretinoin; Vitamin D | 2019 |
Survival Benefit of Maximal Resection for Glioblastoma Reoperation in the Temozolomide Era: A Meta-Analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Reoperation; Temozolomide; | 2019 |
Glioblastoma vs temozolomide: can the red queen race be won?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials a | 2019 |
Aberrant Transcriptional Regulation of Super-enhancers by RET Finger Protein-histone Deacetylase 1 Complex in Glioblastoma: Chemoresistance to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance, Neoplasm; Gene Expression Regul | 2019 |
Essential role of Gli proteins in glioblastoma multiforme.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Hedgeh | 2013 |
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Auranofin; Brain Neoplasms | 2013 |
Enhancing radiation therapy for patients with glioblastoma.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Neopla | 2013 |
Temozolomide for high grade glioma.
Topics: Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; | 2013 |
Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Hu | 2013 |
Epigenetic pathways and glioblastoma treatment.
Topics: Adult; Animals; Brain Neoplasms; Dacarbazine; Drug Discovery; Epigenesis, Genetic; Gene Regulatory N | 2013 |
Extracranial glioblastoma with synchronous metastases in the lung, pulmonary lymph nodes, vertebrae, cervical muscles and epidural space in a young patient - case report and review of literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Chemoradiotherapy, Adjuvant; Dacarbazine; Epidural | 2013 |
Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; | 2013 |
Elderly patients with glioblastoma: the treatment challenge.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Gl | 2013 |
A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Databases, | 2014 |
Radiation and concomitant chemotherapy for patients with glioblastoma multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methyl | 2014 |
Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; | 2014 |
Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers; Clinical Trials a | 2014 |
Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Tensor Imaging; Glioblast | 2014 |
Treatment options and outcomes for glioblastoma in the elderly patient.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Hu | 2014 |
The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.
Topics: Absorbable Implants; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
Neuroimaging of therapy-associated brain tissue abnormalities.
Topics: Antineoplastic Agents, Alkylating; Brain Diseases; Chemoradiotherapy; Dacarbazine; Glioblastoma; Hum | 2014 |
A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments.
Topics: Antineoplastic Agents; Carmustine; Chemotherapy, Adjuvant; Cost of Illness; Cost-Benefit Analysis; D | 2014 |
Predictive biomarkers investigated in glioblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Daca | 2014 |
Molecular neuro-oncology and the challenge of the blood-brain barrier.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Chromosome Deletion; Dacarbazine; DNA Modification Me | 2014 |
Antiangiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brai | 2014 |
Emerging therapies for glioblastoma.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell- and Tissue-Based Therapy; Dacarbazine; Glioblas | 2014 |
Glioblastoma survival: has it improved? Evidence from population-based studies.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Community Health Planning; Dacarbazine; Glioblas | 2014 |
Treatment considerations for MGMT-unmethylated glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification M | 2015 |
Glioblastoma in the elderly.
Topics: Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repa | 2015 |
Astrocytoma malignum in glioblastoma multiforme vertens with long term survival--case report and a literature review.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2014 |
The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2014 |
[Elderly patients with glioblastoma: state of the art].
Topics: Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab | 2015 |
Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Drug De | 2015 |
Dose-dense temozolomide: is it still promising?
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dacarbazine; Disease Progression; Dose- | 2015 |
Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Ch | 2015 |
Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases | 2015 |
Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature review.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Ther | 2015 |
Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2015 |
Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
Topics: Biomarkers, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Dr | 2015 |
An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Combined Modality | 2015 |
Radiotherapy with temozolomide provides better survival in the newly diagnosed glioblastoma multiforme: A meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Odd | 2015 |
Primary spinal cord glioblastoma multiforme treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Kaplan-Me | 2015 |
Guidelines, "minimal requirements" and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working party.
Topics: Adult; Africa, Northern; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Medical Oncology; Medit | 2016 |
How I treat glioblastoma in older patients.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Biomarkers, Tumo | 2016 |
Targeting autophagy to sensitive glioma to temozolomide treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell S | 2016 |
Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Dacarbazine; Glioblastoma; | 2016 |
Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?
Topics: Animals; Brain Neoplasms; Cytomegalovirus; Cytomegalovirus Infections; Dacarbazine; Glioblastoma; Hu | 2016 |
Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives.
Topics: Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Neovascu | 2016 |
Cancer Stem Cells and Chemoresistance in Glioblastoma Multiform: A Review Article.
Topics: Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Drug Resistance, Neoplasm; | 2015 |
Problems of Glioblastoma Multiforme Drug Resistance.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain; Brain Neoplasms; Dacarbazine | 2016 |
Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Chemical and Drug In | 2017 |
Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adj | 2016 |
A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma.
Topics: Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazi | 2017 |
Microglia in Cancer: For Good or for Bad?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Communication; Cytokines; Dacarbazine; ErbB | 2016 |
The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-Free Sur | 2016 |
Current and Future Drug Treatments for Glioblastomas.
Topics: Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neop | 2016 |
Glioblastoma Secondary to Meningioma: A Case Report and Literature Review.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glial Fibrillary Acidic Prote | 2017 |
Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiotherapy; Consensus; Cranial Ir | 2017 |
Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2017 |
Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2017 |
Mechanisms of disease: temozolomide and glioblastoma--look to the future.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2008 |
Temozolomide for high grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Neoplasm Recu | 2008 |
Recent approaches to improve the antitumor efficacy of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; DNA | 2009 |
[Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2009 |
[Prescription guidebook for temozolomide usage in brain tumors].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Drug Admi | 2009 |
Management of glioblastoma multiforme in HIV patients: a case series and review of published studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazin | 2009 |
[Clinicopathological diagnosis of gliomas by genotype analysis].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2009 |
Insights into pharmacotherapy of malignant glioma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
High-grade glioma mouse models and their applicability for preclinical testing.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biomark | 2009 |
New advances that enable identification of glioblastoma recurrence.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Diffusion Magnetic Resonance Imaging; Glioblastoma; | 2009 |
Current developments in the radiotherapy approach to elderly and frail patients with glioblastoma multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality | 2009 |
Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; Glioblastoma; | 2009 |
[Glioblastoma multiforme--new hope due to modern therapeutical approaches].
Topics: Algorithms; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Hu | 2010 |
Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review.
Topics: Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Cytomegalovirus Infection | 2010 |
Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DN | 2010 |
Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2010 |
[Drug therapy of patients with recurrent glioblastoma: is there any evidence?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Age | 2011 |
[Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 2011 |
Glioblastoma multiforme: enhancing survival and quality of life.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Neoplas | 2011 |
[Glioblastoma in the elderly].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adju | 2011 |
Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarba | 2011 |
Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dru | 2012 |
Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazin | 2012 |
Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemica | 2012 |
Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide; | 2012 |
Cellular-based immunotherapies for patients with glioblastoma multiforme.
Topics: Aged; Brain Neoplasms; Cancer Vaccines; Cell Extracts; Clinical Trials as Topic; Combined Modality T | 2012 |
Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Recent medical management of glioblastoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Tr | 2012 |
The efficacy of temozolomide for recurrent glioblastoma multiforme.
Topics: Administration, Metronomic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Pha | 2013 |
Optimal management of elderly patients with glioblastoma.
Topics: Age Factors; Aged; Aged, 80 and over; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; | 2013 |
Potential usefulness of radiosensitizers in glioblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2012 |
The spectrum of vaccine therapies for patients with glioblastoma multiforme.
Topics: Acyclovir; Autoantigens; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2012 |
Targeting the Akt-pathway to improve radiosensitivity in glioblastoma.
Topics: Animals; Antineoplastic Agents; Cell Survival; Chemoradiotherapy; Dacarbazine; DNA Damage; Drug Desi | 2013 |
[Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antin | 2012 |
Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Clinical Trials as Top | 2012 |
[Adjuvant radiochemotherapy in the elderly affected by glioblastoma: single-institution experience and literature review].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemoradiothera | 2013 |
Cryptococcemia in a patient with glioblastoma: case report and literature review.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Central Nervous System; Cryptococcosis; Dac | 2012 |
Recent therapeutic advances and insights of recurrent glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agent | 2013 |
Novel chemotherapeutic agents for the treatment of glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineop | 2003 |
Neuro-oncology: the growing role of chemotherapy in glioma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; D | 2005 |
Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; | 2005 |
[Highly quality-controlled radiation therapy].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblas | 2005 |
[New place of the chemotherapy in gliomas].
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Tr | 2005 |
[Radiotherapy for glioblastomas: from radiobiology to concomitant chemotherapy].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2005 |
[Standards and new developments in the chemotherapy of glioblastomas].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2005 |
[Concomitant radiotherapy with chemotherapy in patients with glioblastoma].
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; | 2005 |
The evolution of chemoradiation for glioblastoma: a modern success story.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Gli | 2006 |
Treatment options for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Cytotoxins; Dacarbazin | 2006 |
Autophagy, the Trojan horse to combat glioblastomas.
Topics: Antineoplastic Agents, Phytogenic; Autophagy; Brain Neoplasms; Cell Movement; Dacarbazine; Drug Resi | 2006 |
New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Methy | 2006 |
Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; DNA Modif | 2005 |
Chemotherapy for malignant gliomas.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cl | 2006 |
[Pattern of care of high-grade gliomas].
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Anticonvulsants; Antineoplastic Agents, Alkylatin | 2006 |
[What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine | 2007 |
[Glioma therapy up-date].
Topics: Anticoagulants; Anticonvulsants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothe | 2007 |
Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment- case study and review of literature.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow; Bone Marrow Diseases; Brain Neoplasms; Cranial Irrad | 2007 |
Management of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Dacarbazine; Drug Delivery Systems; Drug Resistance, Ne | 2007 |
Combined modality treatment of glioblastoma multiforme: the role of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblas | 2006 |
Current status of clinical trials for glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain | 2006 |
Temozolomide in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazi | 2000 |
Future directions in the treatment of malignant gliomas with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biological Availa | 2000 |
Temozolomide and treatment of malignant glioma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Gliobl | 2000 |
Temozolomide for recurrent high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous System Neoplasms; Clinical Trials as | 2001 |
A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazi | 2002 |
Adults with newly diagnosed high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2001 |
335 trials available for temozolomide and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.
Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Gliob | 2021 |
Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers; Brain Neoplasms; Combined | 2021 |
Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Quality of Life; Renin-Ang | 2022 |
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial.
Topics: Antineoplastic Agents, Alkylating; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Hu | 2022 |
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA M | 2022 |
The efficacy of temozolomide combined with levetiracetam for glioblastoma (GBM) after surgery: a study protocol for a double-blinded and randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioblastoma; Humans; Levetiracetam | 2022 |
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; DNA Modification Methylas | 2023 |
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA | 2022 |
Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2022 |
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.
Topics: Adult; Antibodies, Monoclonal, Humanized; Brain Neoplasms; ErbB Receptors; Female; Glioblastoma; Hum | 2023 |
A Randomized Study of Short Course (One Week) Radiation Therapy with or without Temozolomide in Elderly and/or Frail Patients with Newly Diagnosed Glioblastoma (GBM).
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Frail Elderly; Glioblastoma; Humans; Quali | 2022 |
A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSCK-010 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase II as | 2022 |
Granulocyte-macrophage colony stimulating factor enhances efficacy of nimustine rendezvousing with temozolomide plus irradiation in patients with glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocytes; Human | 2023 |
Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Electric | 2022 |
Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Capecitabine; Chemoradiotherapy; Dacarbazine; DN | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Topics: Brain Neoplasms; Dendritic Cells; Glioblastoma; Humans; Prospective Studies; Recurrence; Temozolomid | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, "window-of-opportunity" study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Temoz | 2023 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dendritic Cells; Gliobl | 2022 |
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neo | 2023 |
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neo | 2023 |
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neo | 2023 |
Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neo | 2023 |
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Lomus | 2023 |
A phase I clinical trial of sonodynamic therapy combined with temozolomide in the treatment of recurrent glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studi | 2023 |
Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase I as T | 2023 |
Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; Glioblastoma; Humans; Tem | 2023 |
Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblas | 2019 |
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Brain Neoplasms; ErbB Receptor | 2020 |
A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy, Adjuvant; Drug Im | 2019 |
A phase I/II trial of 5-fraction stereotactic radiosurgery with 5-mm margins with concurrent temozolomide in newly diagnosed glioblastoma: primary outcomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Fema | 2020 |
Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; Electric Stimulation | 2020 |
Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Drug Synergism; Fe | 2020 |
A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Cytoreduction Surgical Procedures; Female; Glioblas | 2020 |
Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Thera | 2020 |
Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma.
Topics: Adolescent; Adult; Age Factors; Aged; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; | 2020 |
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial.
Topics: Adult; CD8-Positive T-Lymphocytes; Cytomegalovirus; Cytomegalovirus Infections; Female; Glioblastoma | 2020 |
Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.
Topics: Adult; Aged; Biomarkers; Brain Neoplasms; Chemoradiotherapy; ErbB Receptors; Female; Gene Amplificat | 2020 |
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; Glioblastoma; Humans; Tem | 2020 |
Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Glioblastoma; Humans; Mice; Phthalazines; Piperaz | 2020 |
Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes | 2020 |
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Bevacizumab; Brain Neopl | 2020 |
Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Follow-Up Studi | 2020 |
Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fema | 2020 |
Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: a prospective phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Atorvastatin; Brain Neoplasms; Chemoradiotherapy; Fe | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2021 |
Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital.
Topics: Aged; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; DNA, | 2020 |
Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial.
Topics: Administration, Metronomic; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; B | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Dose-Resp | 2021 |
Initial Results of a Phase 2 Trial of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunologi | 2021 |
A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
Topics: Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; DNA Methylation; DNA Modificatio | 2021 |
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies | 2021 |
The need for geriatric scales in glioblastoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastom | 2021 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2017 |
Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cel | 2017 |
Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chem | 2017 |
Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Administra | 2017 |
Short course radiotherapy concomitant with temozolomide in GBM patients: a phase II study.
Topics: Adult; Aged; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Dose Fractionation, Radi | 2017 |
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2017 |
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Dacar | 2017 |
Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combi | 2017 |
Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2018 |
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Che | 2018 |
Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark | 2018 |
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2018 |
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbaz | 2018 |
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; DNA Methy | 2018 |
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradio | 2018 |
Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease-Free Surviva | 2017 |
The effect of an adenosine A
Topics: Adenosine A2 Receptor Agonists; Administration, Intravenous; Administration, Oral; Adult; Aged; Anti | 2018 |
Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Copper; | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Cytor | 2018 |
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain N | 2018 |
Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Cost-Benefit Ana | 2018 |
Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).
Topics: Aged; Aged, 80 and over; Bevacizumab; Female; Glioblastoma; Humans; Male; Temozolomide | 2018 |
Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain N | 2018 |
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Contrast Media; Female; Follow-Up | 2018 |
Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Pr | 2018 |
Quality of Life Perception, Cognitive Function, and Psychological Status in a Real-world Population of Glioblastoma Patients Treated With Radiotherapy and Temozolomide: A Single-center Prospective Study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Cognition; Female; Follow-Up Stud | 2018 |
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Growth | 2018 |
Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2018 |
Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Female; Follow-U | 2018 |
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; | 2018 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai | 2019 |
Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Su | 2019 |
Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.
Topics: Benzamides; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Female; Glioblastoma; Hum | 2019 |
N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2019 |
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant | 2019 |
Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420.
Topics: Adolescent; Adult; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Glioblastoma | 2019 |
A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplasti | 2019 |
Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Tria | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Diagnostic Imaging; Gl | 2019 |
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Phthala | 2019 |
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Phthala | 2019 |
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Phthala | 2019 |
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Phthala | 2019 |
Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dendriti | 2019 |
An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; ErbB Receptors; Female; Glioblast | 2019 |
Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; H | 2019 |
A novel lecithin-based delivery form of Boswellic acids as complementary treatment of radiochemotherapy-induced cerebral edema in patients with glioblastoma multiforme: a longitudinal pilot experience.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Alkylating; Brain Edema | 2019 |
Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience.
Topics: Aged; Brain Neoplasms; Factor Analysis, Statistical; Female; Glioblastoma; Humans; Magnetic Resonanc | 2019 |
Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblas | 2019 |
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothe | 2019 |
Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Chemoradiotherapy; C | 2013 |
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tu | 2013 |
[Multicenter randomized controlled study of temozolomide versus semustine in the treatment of recurrent malignant glioma].
Topics: Adult; Astrocytoma; Dacarbazine; Female; Glioblastoma; Glioma; Humans; Male; Middle Aged; Neoplasm R | 2013 |
Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Fem | 2013 |
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2013 |
Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combined Mod | 2013 |
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Be | 2013 |
MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2013 |
RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2013 |
Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combined Modality Therap | 2013 |
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response | 2013 |
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2013 |
Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; | 2015 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2013 |
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2013 |
A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Cohort Studies; Dacarbazin | 2014 |
Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methy | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2014 |
Case numbers for a randomized clinical trial of boron neutron capture therapy for Glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Borohydrides; Boron Compounds; Boron Neutron Capture | 2014 |
Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Brain N | 2014 |
Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant | 2014 |
Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradio | 2014 |
Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cause of Death; Chemotherapy, Adjuvant; D | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Com | 2014 |
Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2016 |
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy may alter the patterns of failure in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dos | 2014 |
A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neo | 2014 |
Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combin | 2014 |
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.
Topics: Adult; Bone Marrow; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; DNA Modific | 2014 |
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combinatio | 2015 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarba | 2014 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarba | 2014 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarba | 2014 |
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Confidence Intervals; Dacarba | 2014 |
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cele | 2015 |
Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cancer Vaccines; Combined Mo | 2015 |
Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradi | 2015 |
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Everolimus; Glioblas | 2015 |
Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Surv | 2015 |
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Chemoradiot | 2015 |
Variant allele frequency enrichment analysis in vitro reveals sonic hedgehog pathway to impede sustained temozolomide response in GBM.
Topics: Alleles; Anilides; Cell Division; Cell Line, Tumor; Dacarbazine; Exome; Female; Follow-Up Studies; G | 2015 |
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phyt | 2015 |
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Disease-F | 2015 |
Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Methylatio | 2015 |
Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Cohort Stud | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Femal | 2015 |
Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradi | 2015 |
Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution.
Topics: Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Chemoradiotherapy; Dacarbaz | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbaz | 2015 |
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazi | 2015 |
A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Chemoradi | 2015 |
Standard chemoradiation for glioblastoma results in progressive brain volume loss.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Brain; Brain Neoplasms; Ch | 2015 |
The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping.
Topics: Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Tensor Imaging; Female | 2015 |
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.
Topics: Adult; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA | 2016 |
Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans | 2015 |
A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA | 2016 |
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Bevacizumab; Brai | 2016 |
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neopl | 2016 |
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Topics: Adult; Aged; Alanine Transaminase; Anilides; Antineoplastic Combined Chemotherapy Protocols; Asparta | 2016 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
[Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacar | 2015 |
Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Che | 2016 |
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazi | 2016 |
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine | 2016 |
A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Dacarbazine; Disulfiram | 2016 |
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Dacarbazine; | 2016 |
Tumor-Treating Fields-A Fundamental Change in Locoregional Management for Glioblastoma.
Topics: Adult; Aged; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Magnetic Field Th | 2016 |
A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2016 |
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Meth | 2016 |
Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Ch | 2016 |
A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.
Topics: Adult; Antineoplastic Agents; Bortezomib; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2016 |
Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradi | 2016 |
Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dendritic Cells; Female; Glioblastoma; | 2016 |
Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modalit | 2017 |
A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant | 2017 |
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Brain Neop | 2017 |
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Brain Neop | 2017 |
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Brain Neop | 2017 |
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Brain Neop | 2017 |
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Da | 2017 |
[Outcomes of application of modern first-line chemotherapy regimens in complex treatment of glioblastoma patients].
Topics: Antineoplastic Agents; Antineoplastic Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Da | 2016 |
Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents; China; Cisplatin; Dacarbazine; Disease Progression; Female; Glio | 2017 |
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease P | 2017 |
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease P | 2017 |
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease P | 2017 |
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease P | 2017 |
Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm | 2008 |
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
Topics: Adult; Adult Stem Cells; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality | 2008 |
Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme.
Topics: Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; M | 2008 |
Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results.
Topics: Adult; Antineoplastic Agents, Alkylating; Case-Control Studies; Chemotherapy, Adjuvant; Dacarbazine; | 2008 |
Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality | 2009 |
Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Central Nervous System Neoplasms; Combined Modality T | 2009 |
Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Biopsy; Brain; Brain Neoplasms; Combined | 2009 |
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Comb | 2008 |
Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Combined Modality | 2008 |
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2009 |
Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Boronic Acids; Bortezomib; Central Nerv | 2009 |
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Thera | 2009 |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Recep | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2009 |
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Co | 2009 |
Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Combined Modality | 2010 |
Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplas | 2009 |
Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2009 |
Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazin | 2009 |
A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose Fractionation, Ra | 2010 |
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Brai | 2010 |
Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2010 |
RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study.
Topics: Adolescent; Adult; Aged; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2009 |
RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study.
Topics: Adolescent; Adult; Aged; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2009 |
RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study.
Topics: Adolescent; Adult; Aged; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2009 |
RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study.
Topics: Adolescent; Adult; Aged; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2009 |
Population-based study of pseudoprogression after chemoradiotherapy in GBM.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Alkylating; Brain Neopl | 2010 |
EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant | 2010 |
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2010 |
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Ther | 2010 |
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Combin | 2010 |
Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Gli | 2010 |
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2010 |
A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Mo | 2010 |
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Combined Modality T | 2010 |
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bra | 2011 |
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modali | 2011 |
Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benz | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboxymethylcellulose | 2010 |
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Confidence Intervals; Dacarbazine; Disease-Free | 2011 |
A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Celecoxib; Chemotherapy, Adjuvant; Combined Modality | 2010 |
Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon; Combined Modality Therapy; D | 2010 |
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adju | 2010 |
Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2011 |
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2012 |
Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modalit | 2011 |
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2011 |
Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cancer Vaccines; Central Nervous System Neoplasms; D | 2011 |
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Child | 2011 |
Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradio | 2012 |
Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme--study design and current status report.
Topics: Antineoplastic Agents; Boron Neutron Capture Therapy; Brain Neoplasms; Combined Modality Therapy; Da | 2011 |
Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brai | 2011 |
Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; De | 2011 |
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2011 |
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarba | 2011 |
Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Dacarbazine; | 2011 |
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Topics: Adult; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Al | 2011 |
Bevacizumab and daily temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Dacarbazine; Eu | 2011 |
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2011 |
Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas.
Topics: Antineoplastic Agents, Alkylating; Asthenia; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Fe | 2012 |
A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2012 |
Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation.
Topics: Adult; Aged; Alberta; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; DNA | 2012 |
Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chem | 2012 |
Going past the data for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastom | 2012 |
A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
A clinical review of treatment outcomes in glioblastoma multiforme--the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarb | 2012 |
A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Female; G | 2012 |
Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Daca | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradi | 2012 |
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2012 |
Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Combined Modali | 2012 |
Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2012 |
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Sur | 2012 |
Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1).
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Dose Fractionation, Radiation; | 2013 |
The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2012 |
Human umbilical vein endothelial cell vaccine therapy in patients with recurrent glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Dacarba | 2013 |
Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2014 |
Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Al | 2013 |
Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chem | 2015 |
Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Daca | 2002 |
Temozolomide in second-line treatment after prior nitrosurea-based chemotherapy in glioblastoma multiforme: experience from a Portuguese institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Administration Sc | 2002 |
A prospective study on glioblastoma in the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Mod | 2003 |
Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astro | 2003 |
A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease Progres | 2003 |
Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Human | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence | 2004 |
Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Con | 2004 |
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cyclophosph | 2004 |
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; | 2004 |
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; | 2004 |
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; | 2004 |
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Combined Modality Therapy; | 2004 |
First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispl | 2004 |
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2004 |
One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Prog | 2004 |
Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modalit | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che | 2004 |
Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Biotin; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modalit | 2004 |
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmusti | 2004 |
Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease P | 2004 |
Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Mo | 2004 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2005 |
A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Comb | 2005 |
Concomitant chemoradiotherapy followed by adjuvant temozolomide improves survival in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therap | 2005 |
Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Combined Modality | 2005 |
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2005 |
Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Mag | 2006 |
Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Co | 2006 |
Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
Adding concomitant and adjuvant temozolomide to radiotherapy does not reduce health-related quality of life in people with glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therap | 2006 |
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dac | 2006 |
New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM).
Topics: Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Combined Modality | 2003 |
MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2006 |
Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modalit | 2006 |
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2007 |
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2006 |
A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2006 |
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Constipation; Dacarbazine; | 2006 |
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2007 |
Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2007 |
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Do | 2007 |
Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-F | 2008 |
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Anti | 2008 |
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
Topics: Adult; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female; Glioblasto | 2008 |
Nomograms as clinicobiological predictors of survival in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Dacarbazine; Glioblastoma; Huma | 2008 |
Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; | 2008 |
Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2008 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin | 2007 |
Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2008 |
Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazin | 1999 |
Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2000 |
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2000 |
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2001 |
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Cohort Studies | 2001 |
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2002 |
Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2002 |
2185 other studies available for temozolomide and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Oxaphosphinanes: new therapeutic perspectives for glioblastoma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Surv | 2012 |
N-Aryl-N'-(chroman-4-yl)ureas and thioureas display in vitro anticancer activity and selectivity on apoptosis-resistant glioblastoma cells: screening, synthesis of simplified derivatives, and structure-activity relationship analysis.
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug | 2012 |
Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship | 2015 |
Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme.
Topics: Cell Count; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response | 2015 |
Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas.
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Dipeptides; Dose-Response Relationship, Dr | 2016 |
Design of Novel Inhibitors of Human Thymidine Phosphorylase: Synthesis, Enzyme Inhibition, in Vitro Toxicity, and Impact on Human Glioblastoma Cancer.
Topics: Animals; Area Under Curve; Brain Neoplasms; Cell Line; Cell Line, Tumor; Drug Design; Enzyme Inhibit | 2019 |
Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; | 2019 |
Chemical modifications of imidazole-containing alkoxyamines increase C-ON bond homolysis rate: Effects on their cytotoxic properties in glioblastoma cells.
Topics: Amines; Antineoplastic Agents; Carbon; Cell Line, Tumor; Cell Survival; Glioblastoma; Half-Life; Hum | 2019 |
The synthesis of a novel Crizotinib heptamethine cyanine dye conjugate that potentiates the cytostatic and cytotoxic effects of Crizotinib in patient-derived glioblastoma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Cell Proliferation; Cell Su | 2019 |
Identification of Parthenolide Dimers as Activators of Pyruvate Kinase M2 in Xenografts of Glioblastoma Multiforme in Vivo.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Prodru | 2020 |
PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Cell Proliferation; Cell Su | 2020 |
Structures/cytotoxicity/selectivity relationship of natural steroidal saponins against GSCs and primary mechanism of tribulosaponin A.
Topics: Antineoplastic Agents; Apoptosis; Biological Products; Brain Neoplasms; Cell Proliferation; Cell Sur | 2021 |
New Protocol-Guided Exploitation of a Lysosomal Sulfatase Inhibitor to Suppress Cell Growth in Glioblastoma Multiforme.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Fluorescent Dyes; Gl | 2021 |
Synthesis and Preclinical Validation of Novel Indole Derivatives as a GPR17 Agonist for Glioblastoma Treatment.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Dose-Response Relationshi | 2021 |
Enhanced pyrazolopyrimidinones cytotoxicity against glioblastoma cells activated by ROS-Generating cold atmospheric plasma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Glioblastoma; Humans; Plasma Gases; Pyrazoles; Pyridines; R | 2021 |
Non-alkylator anti-glioblastoma agents induced cell cycle G2/M arrest and apoptosis: Design, in silico physicochemical and SAR studies of 2-aminoquinoline-3-carboxamides.
Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Lin | 2021 |
Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Cycle; Cell Proliferation; Dose-Response Relationsh | 2022 |
Novel structural-related analogs of PFI-3 (SRAPs) that target the BRG1 catalytic subunit of the SWI/SNF complex increase the activity of temozolomide in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Azabicyclo Compounds; Cell Death; Cell Proliferation; DN | 2022 |
Cyclotides Chemosensitize Glioblastoma Cells to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cyclot | 2022 |
Evaluation of Thymidine Phosphorylase Inhibitors in Glioblastoma and Their Capacity for Temozolomide Potentiation.
Topics: Cell Line; Glioblastoma; Humans; Temozolomide; Thymidine Phosphorylase; Uracil | 2021 |
An international perspective on the management of glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Internationality; Temozolomide | 2021 |
Radiotherapy intensification for glioblastoma: enhancing the backbone of treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Radiotherapy, Intensity-Mo | 2021 |
Celecoxib reverses the glioblastoma chemo-resistance to temozolomide through mitochondrial metabolism.
Topics: Celecoxib; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gl | 2021 |
XAB2 promotes Ku eviction from single-ended DNA double-strand breaks independently of the ATM kinase.
Topics: Alkylating Agents; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Line, Tumor; DNA Break | 2021 |
Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Dr | 2021 |
Targeted therapy with anlotinib for a leptomeningeal spread recurrent glioblastoma patient.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Indoles; Quinolines; Temozolomide | 2021 |
Histone deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cells.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; DNA Repair; Gene Expressio | 2021 |
Interplay of m
Topics: Adenosine; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2021 |
Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Size; DNA Methylation; D | 2021 |
Silk Microneedle Patch Capable of On-Demand Multidrug Delivery to the Brain for Glioblastoma Treatment.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Glioblastoma; Humans; Mice | 2022 |
Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; DNA Da | 2022 |
The E3 Ubiquitin Ligase NEDD4-1 Mediates Temozolomide-Resistant Glioblastoma through PTEN Attenuation and Redox Imbalance in Nrf2-HO-1 Axis.
Topics: Aged; Animals; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female | 2021 |
Disulfiram Sensitizes a Therapeutic-Resistant Glioblastoma to the TGF-β Receptor Inhibitor.
Topics: Animals; Cell Line, Tumor; Disulfiram; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Mice, | 2021 |
Preclinical Evaluation of Sodium Selenite in Mice: Toxicological and Tumor Regression Studies after Striatum Implantation of Human Glioblastoma Stem Cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; C | 2021 |
Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain Neoplasms; Cell Cycle; Cell Line, | 2021 |
Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; | 2021 |
Cytotoxicity Effect of Quinoin, Type 1 Ribosome-Inactivating Protein from Quinoa Seeds, on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chenopodiu | 2021 |
Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2021 |
Inhibition of FABP6 Reduces Tumor Cell Invasion and Angiogenesis through the Decrease in MMP-2 and VEGF in Human Glioblastoma Cells.
Topics: Animals; Cell Line, Tumor; Cell Movement; Clone Cells; Disease Progression; Extracellular Matrix; Fa | 2021 |
Effectiveness of bortezomib and temozolomide for eradication of recurrent human glioblastoma cells, resistant to radiation.
Topics: Antineoplastic Agents, Alkylating; Bortezomib; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neop | 2021 |
Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Computational Biology; | 2021 |
NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to temozolomide (TMZ) via NELFB and RPS6KB2 interaction.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2021 |
Temozolomide Induces Endocytosis of EGFRvIII via p38-Mediated Non-canonical Phosphorylation in Glioblastoma Cells.
Topics: Anisomycin; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Electrophoresis, Polyacrylam | 2021 |
Circumventing Drug Resistance Pathways with a Nanoparticle-Based Photodynamic Method.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Ne | 2021 |
Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastom | 2021 |
Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 2021 |
Cation-Free siRNA Micelles as Effective Drug Delivery Platform and Potent RNAi Nanomedicines for Glioblastoma Therapy.
Topics: Acrylic Resins; Animals; Blood-Brain Barrier; Carbocyanines; Cations; Cell Line, Tumor; Drug Carrier | 2021 |
Oxyphyllanene B overcomes temozolomide resistance in glioblastoma: Structure-activity relationship and mitochondria-associated ER membrane dysfunction.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mitochondria; Neoplasm Recurrence | 2022 |
Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carbamates; Cell Line, Tumor; Cell Pr | 2021 |
Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Fo | 2021 |
Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Resistance, | 2021 |
[MGMT and temozolomide sensibility].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA Methylation; DNA Mo | 2021 |
Nanomedicine in the treatment of Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Glioblastoma; Humans; Nanom | 2021 |
Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Deliver | 2021 |
Hematological adverse events in the management of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Randomized Controlled Tria | 2022 |
Drug-induced hypersensitivity syndrome following temozolimide for glioblastoma multiforme and the role of desensitization therapy.
Topics: Drug Hypersensitivity Syndrome; Exanthema; Glioblastoma; Humans; Male; Melanoma; Middle Aged; Temozo | 2022 |
Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study.
Topics: Disulfiram; Drug Repositioning; Glioblastoma; Temozolomide | 2021 |
Opuntiol Inhibits Growth and Induces Apoptosis in Human Glioblastoma Cells by Upregulating Active Caspase 3 Expression.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Growth Processes; Cell Line, Tumor; Cell Survival; | 2021 |
Pharmacological Strategy for Selective Targeting of Glioblastoma by Redox-active Combination Drug - Comparison With the Chemotherapeutic Standard-of-care Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Glioblas | 2021 |
Temporal Trends in Glioblastoma Survival: Progress then Plateau.
Topics: Adult; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Kaplan-Meier Estimate; Temozolomide | 2022 |
Blood-brain barrier penetrating liposomes with synergistic chemotherapy for glioblastoma treatment.
Topics: Blood-Brain Barrier; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Liposomes; T | 2022 |
RUNX1 (RUNX family transcription factor 1), a target of microRNA miR-128-3p, promotes temozolomide resistance in glioblastoma multiform by upregulating multidrug resistance-associated protein 1 (MRP1).
Topics: Adult; Aged; Base Sequence; Cell Line, Tumor; Cell Movement; Cell Proliferation; Core Binding Factor | 2021 |
Hypoxia-inducible lncRNA MIR210HG interacting with OCT1 is involved in glioblastoma multiforme malignancy.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug | 2022 |
RNA sequencing of glioblastoma tissue slice cultures reveals the effects of treatment at the transcriptional level.
Topics: Brain Neoplasms; Exome Sequencing; Glioblastoma; Humans; Sequence Analysis, RNA; Temozolomide | 2022 |
Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Follow-Up Studies; Frailty; G | 2022 |
GPER Agonist G-1 Disrupts Tubulin Dynamics and Potentiates Temozolomide to Impair Glioblastoma Cell Proliferation.
Topics: Animals; Apoptosis; Cell Proliferation; Cyclopentanes; Gene Expression Regulation, Neoplastic; Gliob | 2021 |
Small molecule based EGFR targeting of biodegradable nanoparticles containing temozolomide and Cy5 dye for greatly enhanced image-guided glioblastoma therapy.
Topics: Brain Neoplasms; Carbocyanines; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Nanoparticle | 2022 |
Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
CN-3 increases TMZ sensitivity and induces ROS-dependent apoptosis and autophagy in TMZ-resistance glioblastoma.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Reactive Ox | 2022 |
Synergistic Effects of Taurine and Temozolomide Via Cell Proliferation Inhibition and Apoptotic Induction on U-251 MG Human Glioblastoma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; G2 | 2021 |
Association of
Topics: Aged; Biomarkers, Tumor; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; G | 2022 |
Biochanin A Sensitizes Glioblastoma to Temozolomide by Inhibiting Autophagy.
Topics: Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Genistein; Glioblastoma; Hu | 2022 |
Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Movement; Cell Proliferatio | 2022 |
JCI-20679 suppresses autophagy and enhances temozolomide-mediated growth inhibition of glioblastoma cells.
Topics: Adenosine Triphosphate; Animals; Autophagy; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Gl | 2022 |
Biomimetic Polymer-Templated Copper Nanoparticles Stabilize a Temozolomide Intermediate for Chemotherapy against Glioblastoma Multiforme.
Topics: Biomimetics; Copper; Glioblastoma; Humans; Nanoparticles; Polymers; Temozolomide | 2021 |
Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Carbonic Anhydrases; Cell Line, Tumor | 2021 |
Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Frail Elderly; Glioblastoma; Human | 2022 |
GPR17 signaling activation by CHBC agonist induced cell death via modulation of MAPK pathway in glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Death; Cell Line, Tu | 2022 |
Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models.
Topics: Animals; Brain Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Clinical Trials, Phase I as | 2022 |
WNT signaling modulates chemoresistance to temozolomide in p53-mutant glioblastoma multiforme.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2022 |
Progressive multifocal leukoencephalopathy after first-line radiotherapy and temozolomide for glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Leukoencephalopathy, Progressive Multifocal; Temozolomide | 2022 |
Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Su | 2022 |
Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma.
Topics: Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Brain Neoplasms; Cell Line, Tumor; Cell Proliferat | 2022 |
Differential effects of radiation fractionation regimens on glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Glioblastoma; Mice; Radiation Dose Hypofractionation; Ra | 2022 |
Ko143 Reverses MDR in Glioblastoma
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member | 2022 |
MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas.
Topics: Algorithms; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; DNA Methylation; DNA Mo | 2022 |
Allopregnanolone suppresses glioblastoma survival through decreasing DPYSL3 and S100A11 expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Ne | 2022 |
Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell Culture.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Line, Tum | 2022 |
Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy.
Topics: Animals; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Glioblast | 2022 |
HSP90-CDC37 functions as a chaperone for the oncogenic FGFR3-TACC3 fusion.
Topics: Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Chaperonins; Glioblastoma; Glioma; HSP90 Heat | 2022 |
Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
Topics: Antineoplastic Agents, Alkylating; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Proliferati | 2022 |
High-throughput glycolytic inhibitor discovery targeting glioblastoma by graphite dots-assisted LDI mass spectrometry.
Topics: Artificial Intelligence; Cell Line, Tumor; Glioblastoma; Graphite; Humans; Mass Spectrometry; Temozo | 2022 |
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modific | 2022 |
Tumor treating fields therapy is feasible and safe in a 3-year-old patient with diffuse midline glioma H3K27M - a case report.
Topics: Adult; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Electric Stimulation The | 2022 |
Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma.
Topics: Amino Acid Transport System A; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Lin | 2022 |
Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL Inhibition.
Topics: Apoptosis; Cell Line, Tumor; Cellular Senescence; Glioblastoma; Humans; Proto-Oncogene Proteins c-bc | 2022 |
Oncogenic Forkhead box D3 antisense RNA 1 promotes cell survival and confers temozolomide resistance in glioblastoma cells through the miR-128-3p/WEE1 G2 checkpoint kinase axis.
Topics: Apoptosis; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2022 |
Optimizing Postoperative Adjuvant Therapy in Elderly Patients with Newly Diagnosed Glioblastoma: Single-Institution Audit of Clinical Outcomes from a Tertiary-Care Comprehensive Cancer Center in India.
Topics: Aged; Combined Modality Therapy; Glioblastoma; Humans; India; O(6)-Methylguanine-DNA Methyltransfera | 2022 |
Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Line, Tumor; Glioblastoma; Hu | 2022 |
Nek1-inhibitor and temozolomide-loaded microfibers as a co-therapy strategy for glioblastoma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Gliobl | 2022 |
Hsa_circ_0072309 enhances autophagy and TMZ sensitivity in glioblastoma.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulat | 2022 |
The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carcinogenesis; Cell Line, T | 2022 |
CRB2 enhances malignancy of glioblastoma via activation of the NF-κB pathway.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gliobla | 2022 |
LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways.
Topics: Animals; Carcinoma, Transitional Cell; Cell Line, Tumor; DNA; DNA Damage; DNA Modification Methylase | 2022 |
Inhibition of ATP hydrolysis as a key regulator of temozolomide resistance and migratory phenotype of glioblastoma cells.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Brain Neoplasm | 2022 |
RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma.
Topics: Acetylation; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; E | 2022 |
Anti-glioblastoma effects of phenolic variants of benzoylphenoxyacetamide (BPA) with high potential for blood brain barrier penetration.
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Endothelial Cells; Glioblas | 2022 |
Efficacy of Temozolomide-Conjugated Gold Nanoparticle Photothermal Therapy of Drug-Resistant Glioblastoma and Its Mechanism Study.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2022 |
Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Glioblastoma; Humans; NF-ka | 2022 |
Combining HDAC and MEK Inhibitors with Radiation against Glioblastoma-Derived Spheres.
Topics: Cell Line, Tumor; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Mitogen-Activated Protein Ki | 2022 |
Synthesis of MIL-Modified Fe
Topics: Cell Line, Tumor; Glioblastoma; Humans; Magnetite Nanoparticles; Nanoparticles; Spectroscopy, Fourie | 2022 |
Contrast enhancing pattern on pre-treatment MRI predicts response to anti-angiogenic treatment in recurrent glioblastoma: comparison of bevacizumab and temozolomide treatment.
Topics: Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Recurrence, | 2022 |
Inhibition of TRPM7 with carvacrol suppresses glioblastoma functions in vivo.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cymenes; Glioblastoma; Humans; Mice; | 2022 |
The effect of temozolomide on apoptosis-related gene expression changes in glioblastoma cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Gene Expression; Glioblastoma; Humans; Temozolomide | 2022 |
Evaluating Quality Indicators of Glioblastoma Care: Audit Results From an Indian Tertiary Care Cancer Center.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; Middle | 2022 |
PIMREG expression level predicts glioblastoma patient survival and affects temozolomide resistance and DNA damage response.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; DNA Damage; Glioblastoma; Humans; Temozolomide | 2022 |
Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Humans; | 2022 |
Poly-guanidine shows high cytotoxicity in glioma cell cultures and glioma stem cells.
Topics: Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; | 2022 |
Cold Plasma Discharge Tube Enhances Antitumoral Efficacy of Temozolomide.
Topics: Animals; Cell Line, Tumor; Glioblastoma; Humans; Mice; Plasma Gases; Temozolomide; Xenograft Model A | 2022 |
Polyunsaturated Fatty Acid-Enriched Lipid Fingerprint of Glioblastoma Proliferative Regions Is Differentially Regulated According to Glioblastoma Molecular Subtype.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Fat | 2022 |
DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients.
Topics: Acceleration; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modific | 2022 |
BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Cell Line, Tumor; Ferroptosis; Glioblastom | 2022 |
Reprogramming of arachidonate metabolism confers temozolomide resistance to glioblastoma through enhancing mitochondrial activity in fatty acid oxidation.
Topics: Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Fatty Acids; Glioblastoma; Humans; Mitochond | 2022 |
Heme Oxygenase-1 targeting exosomes for temozolomide resistant glioblastoma synergistic therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Exo | 2022 |
Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain.
Topics: Animals; Apoferritins; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Gl | 2022 |
TMZ magnetic temperature-sensitive liposomes-mediated magnetothermal chemotherapy induces pyroptosis in glioblastoma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Lipos | 2022 |
PSMG3-AS1 enhances glioma resistance to temozolomide via stabilizing c-Myc in the nucleus.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resis | 2022 |
Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; DNA Mismatch Repair; DNA | 2022 |
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Forkhead Transcription Factors; Gliobl | 2022 |
Lichen Secondary Metabolites Inhibit the Wnt/β-Catenin Pathway in Glioblastoma Cells and Improve the Anticancer Effects of Temozolomide.
Topics: beta Catenin; Cell Line, Tumor; Glioblastoma; Humans; Lichens; Temozolomide; Wnt Signaling Pathway | 2022 |
Transcriptomic Profiling of DNA Damage Response in Patient-Derived Glioblastoma Cells before and after Radiation and Temozolomide Treatment.
Topics: Antineoplastic Agents, Alkylating; DNA Damage; Glioblastoma; Humans; Temozolomide; Transcriptome | 2022 |
Serum-derived extracellular vesicles facilitate temozolomide resistance in glioblastoma through a HOTAIR-dependent mechanism.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Vesicles; Glioblastoma; | 2022 |
Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Combined Mo | 2022 |
DoE Engineered Development and Validation of an RP-HPLC Method for Simultaneous Estimation of Temozolomide and Resveratrol in Nanostructured Lipid Carrier.
Topics: Acetic Acid; Chromatography, High Pressure Liquid; Drug Stability; Excipients; Glioblastoma; Humans; | 2022 |
Current trend of radiotherapy for glioblastoma in the elderly: a survey study by the brain tumor Committee of the Korean Radiation Oncology Group (KROG 21-05).
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Republi | 2022 |
Ageritin-The Ribotoxin-like Protein from Poplar Mushroom (
Topics: Agaricales; Antineoplastic Agents, Alkylating; Cell Line, Tumor; DNA Modification Methylases; Drug R | 2022 |
Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification M | 2022 |
A retrospective observational study on cases of anaplastic brain tumors treated with the Di Bella Method: A rationale and effectiveness.
Topics: Acetazolamide; Antioxidants; Brain Neoplasms; Ditiocarb; Glioblastoma; Humans; Hydroxyurea; Melatoni | 2021 |
Association between microRNAs 10b/21/34a and acute toxicity in glioblastoma patients treated with radiotherapy and temozolomide.
Topics: Glioblastoma; Humans; Leukocytes, Mononuclear; MicroRNAs; Real-Time Polymerase Chain Reaction; Temoz | 2022 |
Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; DNA Methylation; DNA Modification M | 2022 |
Investigating the Stability of Six Phenolic TMZ Ester Analogues, Incubated in the Presence of Porcine Liver Esterase and Monitored by HPLC.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromatography, High | 2022 |
[Glioblastoma That Does Not Improve with Standard Treatment: Poor Prognostic Factors and Future Perspectives].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; Glioblastoma; Humans; Pro | 2022 |
[Glioblastoma That Does Not Improve with Standard Treatment: Standard and Personalized Treatment Making The Most of Limited Modalities].
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioblastoma; Humans; Precision Medicine; Te | 2022 |
Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression.
Topics: Animals; Brain Neoplasms; ErbB Receptors; Glioblastoma; Glioma; Humans; Mice; Sequence Analysis, RNA | 2022 |
lncRNA XLOC013218 promotes cell proliferation and TMZ resistance by targeting the PIK3R2-mediated PI3K/AKT pathway in glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
Glioblastoma spheroid growth and chemotherapeutic responses in single and dual-stiffness hydrogels.
Topics: Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Hydrogels; Laminin; Spheroids, Cellu | 2023 |
PTRF/Cavin-1 enhances chemo-resistance and promotes temozolomide efflux through extracellular vesicles in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Ext | 2022 |
Inhibition of Ciliogenesis Enhances the Cellular Sensitivity to Temozolomide and Ionizing Radiation in Human Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA; Glioblastoma; Humans; Rad | 2022 |
Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA | 2022 |
Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apolipoproteins E; Artesunate; Brain Neoplasms; Cell Lin | 2022 |
Diazepam diminishes temozolomide efficacy in the treatment of U87 glioblastoma cell line.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2022 |
Selective cell cycle arrest in glioblastoma cell lines by quantum molecular resonance alone or in combination with temozolomide.
Topics: Brain Neoplasms; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Glioblastoma; Humans; Proteomi | 2022 |
Quinacrine is active in preclinical models of glioblastoma through suppressing angiogenesis, inducing oxidative stress and activating AMPK.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Glioblastom | 2022 |
SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy.
Topics: Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Suppr | 2022 |
Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; DNA; Drug Resistance, Neoplasm; Glioblasto | 2022 |
Brain Co-Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplas | 2022 |
Temozolomide increases heat shock proteins in extracellular vesicles released from glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Ext | 2022 |
Sensitization of glioblastoma cancer cells to radiotherapy and magnetic hyperthermia by targeted temozolomide-loaded magnetite tri-block copolymer nanoparticles as a nanotheranostic agent.
Topics: Cell Line, Tumor; Contrast Media; Ferrosoferric Oxide; Glioblastoma; Humans; Hyperthermia, Induced; | 2022 |
The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells.
Topics: Aminolevulinic Acid; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Naphthoquinones; Neopl | 2022 |
The impact of temozolomide and lonafarnib on the stemness marker expression of glioblastoma cells in multicellular spheroids.
Topics: Cell Line, Tumor; Dibenzocycloheptenes; Drug Resistance, Neoplasm; Endothelial Cells; Glioblastoma; | 2022 |
GBP3 promotes glioblastoma resistance to temozolomide by enhancing DNA damage repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Damage; DNA Modif | 2022 |
Combination therapy with interferon-gamma as a potential therapeutic medicine in rat's glioblastoma: A multi-mechanism evaluation.
Topics: Animals; Glioblastoma; Interferon-alpha; Interferon-gamma; Interleukin-10; Male; Rats; Rats, Sprague | 2022 |
High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1/MRP1 upregulation.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Glioblastoma; Glioma; Humans; Multidrug Re | 2022 |
Propofol enhances the sensitivity of glioblastoma cells to temozolomide by inhibiting macrophage activation in tumor microenvironment to down-regulate HIF-1α expression.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cyclooxygenase 2; Dru | 2022 |
SH3GLB1-related autophagy mediates mitochondrial metabolism to acquire resistance against temozolomide in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2022 |
Capturing the latent space of an Autoencoder for multi-omics integration and cancer subtyping.
Topics: Cluster Analysis; Genomics; Glioblastoma; Humans; Temozolomide | 2022 |
A rationally identified panel of microRNAs targets multiple oncogenic pathways to enhance chemotherapeutic effects in glioblastoma models.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expressi | 2022 |
PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gen | 2022 |
The trial effect in patients with glioblastoma: effect of clinical trial enrollment on overall survival.
Topics: Brain Neoplasms; Clinical Trials as Topic; Cohort Studies; Glioblastoma; Humans; Prognosis; Temozolo | 2022 |
TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Cycle Proteins; Cell Li | 2022 |
Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free S | 2022 |
ZSTK474 Sensitizes Glioblastoma to Temozolomide by Blocking Homologous Recombination Repair.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Repair; Drug Re | 2022 |
TRAF4 Maintains Deubiquitination of Caveolin-1 to Drive Glioblastoma Stemness and Temozolomide Resistance.
Topics: Brain Neoplasms; Caveolin 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neop | 2022 |
Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Diabetes Mellitus, Type 2; DNA | 2022 |
Mechanism-based design of agents that selectively target drug-resistant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; | 2022 |
MIR99AHG/miR-204-5p/TXNIP/Nrf2/ARE Signaling Pathway Decreases Glioblastoma Temozolomide Sensitivity.
Topics: Brain Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, | 2022 |
ADAR3 activates NF-κB signaling and promotes glioblastoma cell resistance to temozolomide.
Topics: Adenosine Deaminase; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; NF-kappa B; RNA-Bindin | 2022 |
Characterization and comparison of human glioblastoma models.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Temozolomide | 2022 |
Substrate viscosity impairs temozolomide-mediated inhibition of glioblastoma cells' growth.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Glioblastoma; Glioma; Humans; Hydrogels; | 2022 |
MicroRNA-147a Targets SLC40A1 to Induce Ferroptosis in Human Glioblastoma.
Topics: Cation Transport Proteins; Cell Line, Tumor; Ferroptosis; Glioblastoma; Humans; MicroRNAs; Temozolom | 2022 |
GMI, Ganoderma microsporum protein, suppresses cell mobility and increases temozolomide sensitivity through induction of Slug degradation in glioblastoma multiforme cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance | 2022 |
Downregulated ferroptosis-related gene SQLE facilitates temozolomide chemoresistance, and invasion and affects immune regulation in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Fer | 2022 |
Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism.
Topics: Animals; Brain Neoplasms; Contrast Media; Fumarates; Glioblastoma; Humans; Magnetic Resonance Imagin | 2022 |
Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Lymphopenia; Temozolomide | 2022 |
Activated TRPA1 plays a therapeutic role in TMZ resistance in glioblastoma by altering mitochondrial dynamics.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mi | 2022 |
MicroRNA-640 Inhibition Enhances the Chemosensitivity of Human Glioblastoma Cells to Temozolomide by Targeting Bcl2 Modifying Factor.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2023 |
Thymol has anticancer effects in U-87 human malignant glioblastoma cells.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumo | 2022 |
Matteucinol combined with temozolomide inhibits glioblastoma proliferation, invasion, and progression: an in vitro, in silico, and in vivo study.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Chromones; Computational Bio | 2022 |
Bio-polymeric transferrin-targeted temozolomide nanoparticles in gel for synergistic post-surgical GBM therapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Glioma; Hydro | 2022 |
Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics.
Topics: Artesunate; Cellular Senescence; Curcumin; Glioblastoma; Humans; Lomustine; Neoplasm Recurrence, Loc | 2022 |
Hypoxia-Driven M2-Polarized Macrophages Facilitate Cancer Aggressiveness and Temozolomide Resistance in Glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Endothelial Cells; Glioblastoma; Humans; Hypoxia; Macrophages; Ph | 2022 |
Tissue Niche Miniature of Glioblastoma Patient Treated with Nano-Awakeners to Induce Suicide of Cancer Stem Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Nanomedicine; Neoplastic Stem Cells; Temozo | 2022 |
Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole.
Topics: Antineoplastic Agents, Alkylating; Aromatase Inhibitors; Brain Neoplasms; Cell Line, Tumor; Drug Res | 2022 |
Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local | 2022 |
TRIM7 modulates NCOA4-mediated ferritinophagy and ferroptosis in glioblastoma cells.
Topics: Autophagy; Ferroptosis; Glioblastoma; Humans; Iron; Nuclear Receptor Coactivators; Temozolomide; Tri | 2022 |
EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal; Brain Neoplasms; Cell Line, Tumor; Glioblas | 2022 |
Involvement of cell shape and lipid metabolism in glioblastoma resistance to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Shape; Drug Resistance, N | 2023 |
Current therapeutic options for glioblastoma and future perspectives.
Topics: Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Glioblas | 2022 |
MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repa | 2022 |
Inhibition of human peptide deformylase by actinonin sensitizes glioblastoma cells to temozolomide chemotherapy.
Topics: Amidohydrolases; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA, Mitochon | 2022 |
Oncolytic Newcastle Disease Virus Co-Delivered with Modified PLGA Nanoparticles Encapsulating Temozolomide against Glioblastoma Cells: Developing an Effective Treatment Strategy.
Topics: Acridine Orange; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Chick Embryo; Em | 2022 |
Establishment and characteristics of GWH04, a new primary human glioblastoma cell line.
Topics: Agar; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Telomerase; Temoz | 2022 |
Thymoquinone induces apoptosis in temozolomide-resistant glioblastoma cells via the p38 mitogen-activated protein kinase signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazin | 2023 |
Identification of SSBP1 as a ferroptosis-related biomarker of glioblastoma based on a novel mitochondria-related gene risk model and in vitro experiments.
Topics: Biomarkers; DNA-Binding Proteins; Ferroptosis; Gene Expression Regulation, Neoplastic; Glioblastoma; | 2022 |
Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; ErbB Receptors; Glioblastoma; Human | 2023 |
Atypical induction of HIF-1α expression by pericellular Notch1 signaling suffices for the malignancy of glioblastoma multiforme cells.
Topics: Amyloid Precursor Protein Secretases; Animals; Cell Line, Tumor; Doxycycline; Glioblastoma; Humans; | 2022 |
Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma.
Topics: Animals; Anticonvulsants; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, | 2022 |
Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dioxolanes; Drug Resistance, N | 2022 |
Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Glioma; | 2022 |
HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Ferr | 2022 |
The road we travel.
Topics: DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Nivolumab; Radiation Oncology | 2023 |
Targeting integrin α2 as potential strategy for radiochemosensitization of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Exploration of biomedical knowledge for recurrent glioblastoma using natural language processing deep learning models.
Topics: Bevacizumab; Chronic Disease; Clinical Trials as Topic; Deep Learning; Glioblastoma; Humans; Lomusti | 2022 |
Enzalutamide Induces Apoptotic Insults to Human Drug-Resistant and -Sensitive Glioblastoma Cells via an Intrinsic Bax-Mitochondrion-Cytochrome C Caspase Cascade Activation Pathway.
Topics: Apoptosis; bcl-2-Associated X Protein; Benzamides; Brain Neoplasms; Caspase 6; Caspase 8; Caspase 9; | 2022 |
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
Topics: Aged; Astrocytoma; Brain Neoplasms; Carbohydrate Metabolism; Dexamethasone; Glioblastoma; Glioma; Gl | 2022 |
CRISPR/Cas9-induced knockout reveals the role of ABCB1 in the response to temozolomide, carmustine and lomustine in glioblastoma multiforme.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member | 2022 |
Individualized combination therapies based on whole-exome sequencing displayed significant clinical benefits in a glioblastoma patient with secondary osteosarcoma: case report and genetic characterization.
Topics: Bone Neoplasms; Brain Neoplasms; Everolimus; Exome Sequencing; Female; Glioblastoma; Humans; Middle | 2022 |
A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; DNA Modification Methylases; DNA Repai | 2023 |
Hydrogel-based microfluidic device with multiplexed 3D in vitro cell culture.
Topics: Carmustine; Cell Culture Techniques; Glioblastoma; Humans; Hydrogels; Lab-On-A-Chip Devices; Polyeth | 2022 |
Guggulsterone from Commiphora mukul potentiates anti-glioblastoma efficacy of temozolomide in vitro and in vivo via down-regulating EGFR/PI3K/Akt signaling and NF-κB activation.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Commiphora; ErbB Receptors; Glioblastoma; | 2023 |
Feasibility of fractionated gamma knife radiosurgery in the management of newly diagnosed Glioblastoma.
Topics: Adult; Brain Neoplasms; Feasibility Studies; Female; Glioblastoma; Humans; Male; Prospective Studies | 2022 |
Glutathione S-Transferases S1, Z1 and A1 Serve as Prognostic Factors in Glioblastoma and Promote Drug Resistance through Antioxidant Pathways.
Topics: Drug Resistance, Neoplasm; Glioblastoma; Glutathione; Glutathione Transferase; Humans; Prognosis; Te | 2022 |
Smurf1 Suppression Enhances Temozolomide Chemosensitivity in Glioblastoma by Facilitating PTEN Nuclear Translocation.
Topics: Alkylating Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Phosphatidylin | 2022 |
Volumetric Analysis of Glioblastoma for Determining Which CpG Sites Should Be Tested by Pyrosequencing to Predict Temozolomide Efficacy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA; DNA Methylation; DNA Repair Enzymes; Gliobl | 2022 |
Hsa_circ_0043949 reinforces temozolomide resistance via upregulating oncogene ITGA1 axis in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Re | 2022 |
Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Repositioning; Glioblastoma; Humans; Temozolomide | 2023 |
NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Line, Tumor; DNA; DNA Modification Me | 2022 |
A hypoxia-dissociable siRNA nanoplatform for synergistically enhanced chemo-radiotherapy of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chemoradiotherapy; DNA; Drug Resistanc | 2022 |
Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Retro | 2022 |
The Significance of
Topics: Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Gli | 2022 |
Molecular Docking and Molecular Dynamics Studies Reveal Secretory Proteins as Novel Targets of Temozolomide in Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
Near infrared-activatable biomimetic nanogels enabling deep tumor drug penetration inhibit orthotopic glioblastoma.
Topics: Animals; Biomimetics; Cell Line, Tumor; Glioblastoma; Indocyanine Green; Mice; Nanogels; Temozolomid | 2022 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Brain-Targeted HFn-Cu-REGO Nanoplatform for Site-Specific Delivery and Manipulation of Autophagy and Cuproptosis in Glioblastoma.
Topics: Apoferritins; Apoptosis; Autophagy; Brain; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Glioblastoma; M | 2023 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
The Effect of Hydroquinidine on Proliferation and Apoptosis of TMZ-sensitive and -resistant GBM Cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel | 2023 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated
Topics: CpG Islands; DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Phenotyp | 2022 |
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; Drug Resistanc | 2023 |
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; Drug Resistanc | 2023 |
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; Drug Resistanc | 2023 |
Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Damage; Drug Resistanc | 2023 |
Efficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study.
Topics: Bevacizumab; Chronic Disease; Cytotoxins; Glioblastoma; Humans; Irinotecan; Recurrence; Retrospectiv | 2022 |
Efficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study.
Topics: Bevacizumab; Chronic Disease; Cytotoxins; Glioblastoma; Humans; Irinotecan; Recurrence; Retrospectiv | 2022 |
Efficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study.
Topics: Bevacizumab; Chronic Disease; Cytotoxins; Glioblastoma; Humans; Irinotecan; Recurrence; Retrospectiv | 2022 |
Efficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study.
Topics: Bevacizumab; Chronic Disease; Cytotoxins; Glioblastoma; Humans; Irinotecan; Recurrence; Retrospectiv | 2022 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Safe administration of temozolomide in end-stage renal disease patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Central Nervous System Neoplasms; Glioblastoma; | 2023 |
Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Janus Kinases; STAT Transcription Fact | 2022 |
Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Janus Kinases; STAT Transcription Fact | 2022 |
Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Janus Kinases; STAT Transcription Fact | 2022 |
Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes.
Topics: Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Janus Kinases; STAT Transcription Fact | 2022 |
Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulatio | 2023 |
Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulatio | 2023 |
Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulatio | 2023 |
Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulatio | 2023 |
The efficacy and safety of low-dose temozolomide maintenance therapy in elderly patients with glioblastoma: a retrospective cohort study.
Topics: Aged; Female; Glioblastoma; Humans; Male; Outpatients; Prospective Studies; Retrospective Studies; T | 2022 |
The efficacy and safety of low-dose temozolomide maintenance therapy in elderly patients with glioblastoma: a retrospective cohort study.
Topics: Aged; Female; Glioblastoma; Humans; Male; Outpatients; Prospective Studies; Retrospective Studies; T | 2022 |
The efficacy and safety of low-dose temozolomide maintenance therapy in elderly patients with glioblastoma: a retrospective cohort study.
Topics: Aged; Female; Glioblastoma; Humans; Male; Outpatients; Prospective Studies; Retrospective Studies; T | 2022 |
The efficacy and safety of low-dose temozolomide maintenance therapy in elderly patients with glioblastoma: a retrospective cohort study.
Topics: Aged; Female; Glioblastoma; Humans; Male; Outpatients; Prospective Studies; Retrospective Studies; T | 2022 |
A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Bindin | 2023 |
A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Bindin | 2023 |
A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Bindin | 2023 |
A Novel Tumor-Promoting Role for Nuclear Factor IX in Glioblastoma Is Mediated through Transcriptional Activation of GINS1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA-Bindin | 2023 |
Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide.
Topics: Glioblastoma; Humans; Retrospective Studies; Temozolomide | 2022 |
Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide.
Topics: Glioblastoma; Humans; Retrospective Studies; Temozolomide | 2022 |
Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide.
Topics: Glioblastoma; Humans; Retrospective Studies; Temozolomide | 2022 |
Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide.
Topics: Glioblastoma; Humans; Retrospective Studies; Temozolomide | 2022 |
LncRNA HOXA-AS2 Promotes Temozolomide Resistance in Glioblastoma by Regulated miR-302a-3p/IGF1 Axis.
Topics: Computational Biology; Drug Resistance, Neoplasm; Glioblastoma; Humans; Insulin-Like Growth Factor I | 2022 |
LncRNA HOXA-AS2 Promotes Temozolomide Resistance in Glioblastoma by Regulated miR-302a-3p/IGF1 Axis.
Topics: Computational Biology; Drug Resistance, Neoplasm; Glioblastoma; Humans; Insulin-Like Growth Factor I | 2022 |
LncRNA HOXA-AS2 Promotes Temozolomide Resistance in Glioblastoma by Regulated miR-302a-3p/IGF1 Axis.
Topics: Computational Biology; Drug Resistance, Neoplasm; Glioblastoma; Humans; Insulin-Like Growth Factor I | 2022 |
LncRNA HOXA-AS2 Promotes Temozolomide Resistance in Glioblastoma by Regulated miR-302a-3p/IGF1 Axis.
Topics: Computational Biology; Drug Resistance, Neoplasm; Glioblastoma; Humans; Insulin-Like Growth Factor I | 2022 |
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Topics: B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2023 |
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Topics: B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2023 |
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Topics: B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2023 |
Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Topics: B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2023 |
Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2022 |
Isoginkgetin-A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle; Cell Line, Tum | 2022 |
Isoginkgetin-A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle; Cell Line, Tum | 2022 |
Isoginkgetin-A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle; Cell Line, Tum | 2022 |
Isoginkgetin-A Natural Compound to Control U87MG Glioblastoma Cell Growth and Migration Activating Apoptosis and Autophagy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle; Cell Line, Tum | 2022 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Supraorbital transciliary approach as primary route to fronto-basal high grade glioma resection with 5-Aminolevulinic Acid use: Technical note.
Topics: Aminolevulinic Acid; Brain Neoplasms; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Temo | 2023 |
Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Electromagnetic Fields; Gli | 2023 |
Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Electromagnetic Fields; Gli | 2023 |
Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Electromagnetic Fields; Gli | 2023 |
Comparative Study of Extremely Low-Frequency Electromagnetic Field, Radiation, and Temozolomide Administration in Spheroid and Monolayer Forms of the Glioblastoma Cell Line (T98).
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Electromagnetic Fields; Gli | 2023 |
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle Proteins; Cell Line, Tumor; Dacarbazine; DNA; DNA Meth | 2022 |
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle Proteins; Cell Line, Tumor; Dacarbazine; DNA; DNA Meth | 2022 |
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle Proteins; Cell Line, Tumor; Dacarbazine; DNA; DNA Meth | 2022 |
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle Proteins; Cell Line, Tumor; Dacarbazine; DNA; DNA Meth | 2022 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Mucin-1; NF-kappa B; Temozolomide | 2023 |
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; G | 2023 |
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; G | 2023 |
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; G | 2023 |
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; G | 2023 |
Molecular Recognition and
Topics: Animals; Coloring Agents; Glioblastoma; Humans; Mice; Nanotubes, Carbon; Swine; Temozolomide | 2023 |
Molecular Recognition and
Topics: Animals; Coloring Agents; Glioblastoma; Humans; Mice; Nanotubes, Carbon; Swine; Temozolomide | 2023 |
Molecular Recognition and
Topics: Animals; Coloring Agents; Glioblastoma; Humans; Mice; Nanotubes, Carbon; Swine; Temozolomide | 2023 |
Molecular Recognition and
Topics: Animals; Coloring Agents; Glioblastoma; Humans; Mice; Nanotubes, Carbon; Swine; Temozolomide | 2023 |
αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform.
Topics: Cell Line, Tumor; Connexin 43; Glioblastoma; Glioma; Humans; Peptides; Signal Transduction; Temozolo | 2023 |
Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelial Cells; Glioblasto | 2023 |
A Comparison of Three Different Deep Learning-Based Models to Predict the MGMT Promoter Methylation Status in Glioblastoma Using Brain MRI.
Topics: Adult; Brain; Brain Neoplasms; Deep Learning; DNA Methylation; DNA Modification Methylases; DNA Repa | 2023 |
Subclonal evolution and expansion of spatially distinct THY1-positive cells is associated with recurrence in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Male; Middle Aged; Neoplas | 2022 |
A high-density 3-dimensional culture model of human glioblastoma for rapid screening of therapeutic resistance.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; H | 2023 |
Cell state-directed therapy - epigenetic modulation of gene transcription demonstrated with a quantitative systems pharmacology model of temozolomide.
Topics: Cell Line, Tumor; Epigenesis, Genetic; Glioblastoma; Humans; Network Pharmacology; Temozolomide; Tra | 2023 |
Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study.
Topics: Adult; Brain Neoplasms; East Asian People; Female; Glioblastoma; Humans; Male; Middle Aged; Prospect | 2023 |
Patterns of failure in glioblastoma multiforme following Standard (60 Gy) or Short course (40 Gy) radiation and concurrent temozolomide.
Topics: Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Retrospective Studies; Temozolomide; Treat | 2023 |
Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA; DNA Breaks, Doub | 2023 |
ProNGF Expression and Targeting in Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Natural Course and Prognosis of Primary Spinal Glioblastoma: A Nationwide Study.
Topics: Adolescent; Adult; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Middle Aged; Prognosis; | 2023 |
Observation of the delineation of the target volume of radiotherapy in adult-type diffuse gliomas after temozolomide-based chemoradiotherapy: analysis of recurrence patterns and predictive factors.
Topics: Adult; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; | 2023 |
Inhibition of eukaryotic initiation factor 4E by tomivosertib suppresses angiogenesis, growth, and survival of glioblastoma and enhances chemotherapy's efficacy.
Topics: Animals; Cell Line, Tumor; Endothelial Cells; Eukaryotic Initiation Factor-4E; Glioblastoma; Humans; | 2023 |
Methylphenidate Reversal of Executive Dysfunction in a Patient with Bi-Frontal Lobe Glioblastoma.
Topics: Aged; Dexamethasone; Frontal Lobe; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Temozolom | 2023 |
Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma.
Topics: Brain; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Radiation Dose Hypofractionation; T | 2023 |
Polyhedral Oligomeric Silsesquioxane-Based Nanoparticles for Efficient Chemotherapy of Glioblastoma.
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Glioblastoma; Mice; Nanoparticles; Temozolomide | 2023 |
Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2023 |
Nasal administration of a temozolomide-loaded thermoresponsive nanoemulsion reduces tumor growth in a preclinical glioblastoma model.
Topics: Administration, Intranasal; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, | 2023 |
Impact of Extended Adjuvant Temozolamide Beyond 6 Months in the Management of Glioblastoma Patients.
Topics: Adjuvants, Immunologic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2023 |
RBBP4 regulates the expression of the Mre11-Rad50-NBS1 (MRN) complex and promotes DNA double-strand break repair to mediate glioblastoma chemoradiotherapy resistance.
Topics: Acid Anhydride Hydrolases; Cell Cycle Proteins; Chemoradiotherapy; DNA; DNA Breaks, Double-Stranded; | 2023 |
Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Mice; Nanoparticles; Peptide Nuclei | 2023 |
Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustaining ErbB downstream signaling.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Exosomes; Glioblastoma; Glyco | 2023 |
Prognostic Factors of Gliosarcoma in the Real World: A Retrospective Cohort Study.
Topics: Brain Neoplasms; Glioblastoma; Gliosarcoma; Humans; Ki-67 Antigen; Neoplasm Recurrence, Local; Progn | 2023 |
Photodynamic therapy enhances the cytotoxicity of temozolomide against glioblastoma via reprogramming anaerobic glycolysis.
Topics: Anaerobiosis; Animals; Apoptosis; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Glioblastoma; Glioma | 2023 |
The PYK2 inhibitor PF-562271 enhances the effect of temozolomide on tumor growth in a C57Bl/6-Gl261 mouse glioma model.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Focal Adhesion Kinase 2; Glioblastoma; Glioma; Humans; M | 2023 |
Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Pilot Projects; Tem | 2023 |
RADIOSURGICAL TREATMENT OF RECURRENT GLIOBLASTOMA AND PROGNOSTIC FACTORS AFFECTING TREATMENT OUTCOMES.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Prognosis; Radiosurgery; R | 2022 |
Erythrose inhibits the progression to invasiveness and reverts drug resistance of cancer stem cells of glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplastic Stem | 2023 |
Givinostat Inhibition of Sp1-dependent MGMT Expression Sensitizes Glioma Stem Cells to Temozolomide.
Topics: DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Glioma; Humans; Neoplastic Stem Cells | 2023 |
Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modific | 2023 |
Letter to the editor regarding "The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies".
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastom | 2023 |
E3 ligase MAEA-mediated ubiquitination and degradation of PHD3 promotes glioblastoma progression.
Topics: Brain Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Cytoskeletal Proteins; Drug Resistance, | 2023 |
Imidazolyl Ethanamide Pentandioic Acid (IEPA) as Potential Radical Scavenger during Tumor Therapy in Human Hematopoietic Stem Cells.
Topics: Cytokines; Glioblastoma; Head and Neck Neoplasms; Hematopoietic Stem Cells; Humans; Reactive Oxygen | 2023 |
Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Prognosis; Signal Transduction; Temozolomid | 2023 |
Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.
Topics: Brain Neoplasms; ErbB Receptors; Glioblastoma; Humans; Mutation; Temozolomide | 2023 |
Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
Topics: Brain Neoplasms; Drug Resistance, Neoplasm; Early Growth Response Transcription Factors; Glioblastom | 2023 |
Exploring temozolomide encapsulated PEGylated liposomes and lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Liposomes; Liquid Crystals; Polyethylene Gl | 2023 |
Targeting unfolded protein response using albumin-encapsulated nanoparticles attenuates temozolomide resistance in glioblastoma.
Topics: Albumins; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Hum | 2023 |
Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; | 2023 |
Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2023 |
EGFRvIII Promotes the Proneural-Mesenchymal Transition of Glioblastoma Multiforme and Reduces Its Sensitivity to Temozolomide by Regulating the NF-κB/ALDH1A3 Axis.
Topics: Animals; Cell Line, Tumor; Glioblastoma; Mice; NF-kappa B; Temozolomide | 2023 |
Temozolomide protects against the progression of glioblastoma via SOX4 downregulation by inhibiting the LINC00470-mediated transcription factor EGR2.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Early Growth Response Pro | 2023 |
Mechanical nanosurgery of chemoresistant glioblastoma using magnetically controlled carbon nanotubes.
Topics: Animals; Brain Neoplasms; Cell Death; Cell Line, Tumor; Glioblastoma; Mice; Nanotubes, Carbon; Temoz | 2023 |
Nanocomposite formulation for a sustained release of free drug and drug-loaded responsive nanoparticles: an approach for a local therapy of glioblastoma multiforme.
Topics: Adult; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Humans; Hydroge | 2023 |
Small extracellular vesicles promote invadopodia activity in glioblastoma cells in a therapy-dependent manner.
Topics: Extracellular Vesicles; Glioblastoma; Humans; Podosomes; Proteomics; Temozolomide | 2023 |
Exosomes released from U87 glioma cells treated with curcumin and/or temozolomide produce apoptosis in naive U87 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Brain-Derived Neurotrophic F | 2023 |
Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA M | 2023 |
RNA cytosine methyltransferase NSUN5 promotes protein synthesis and tumorigenic phenotypes in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplast | 2023 |
In Situ Nitric Oxide Gas Nanogenerator Reprograms Glioma Immunosuppressive Microenvironment.
Topics: Cell Line, Tumor; Glioblastoma; Glioma; Humans; Immunosuppressive Agents; Nitric Oxide; Temozolomide | 2023 |
Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report.
Topics: Brain Neoplasms; Child; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzyme | 2023 |
Combination of SIX4-siRNA and temozolomide inhibits the growth and migration of A-172 glioblastoma cancer cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dru | 2023 |
Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epi | 2023 |
Bromodomain and Extraterminal Domain (BET) Protein Inhibition Hinders Glioblastoma Progression by Inducing Autophagy-Dependent Differentiation.
Topics: Autophagy; Cell Differentiation; Cell Line, Tumor; Glioblastoma; Humans; Proteins; Temozolomide | 2023 |
Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line; Cell Line, Tumor; DNA Modification Me | 2023 |
Development and Validation of a Targeted Treatment for Brain Tumors Using a Multi-Drug Loaded, Relapse-Resistant Polymeric Theranostic.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neoplasm Recurre | 2023 |
Incidence of clinically relevant psychiatric symptoms during glioblastoma treatment: an exploratory study.
Topics: Brain Neoplasms; Glioblastoma; Humans; Incidence; Male; Mental Disorders; Quality of Life; Retrospec | 2023 |
Acetogenins-Rich Fractions of
Topics: Acetogenins; Annona; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gliobl | 2023 |
ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression.
Topics: ADAM17 Protein; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Down-Regulatio | 2023 |
NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
A Promising Way to Overcome Temozolomide Resistance through Inhibition of Protein Neddylation in Glioblastoma Cell Lines.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2023 |
UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway.
Topics: Animals; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neopl | 2023 |
Temozolomide-fatty acid conjugates for glioblastoma multiforme: In vitro and in vivo evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2023 |
TRIM25 promotes temozolomide resistance in glioma by regulating oxidative stress and ferroptotic cell death via the ubiquitination of keap1.
Topics: Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Kelch | 2023 |
Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Ribonucleotide R | 2023 |
GBP3-STING interaction in glioblastoma coordinates autophagy, anti-oxidative, and DNA repair programs in response to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Dacarbazine; DNA Modification Methyla | 2023 |
Targeted delivery of temozolomide by nanocarriers based on folic acid-hollow TiO
Topics: Cell Line, Tumor; Folic Acid; Glioblastoma; Humans; Nanospheres; Temozolomide | 2023 |
P2X7 receptor antagonism by AZ10606120 significantly reduced in vitro tumour growth in human glioblastoma.
Topics: Adamantane; Aminoquinolines; Glioblastoma; Humans; Purinergic P2X Receptor Antagonists; Receptors, P | 2023 |
Tetra-O-methyl-nordihydroguaiaretic acid inhibits energy metabolism and synergistically induces anticancer effects with temozolomide on LN229 glioblastoma tumors implanted in mice while preventing obesity in normal mice that consume high-fat diets.
Topics: Animals; Cell Line, Tumor; Diet, High-Fat; Energy Metabolism; Glioblastoma; Humans; Masoprocol; Mice | 2023 |
AHR, a novel inhibitory immune checkpoint receptor, is a potential therapeutic target for chemoresistant glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2023 |
Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
LncRNA CASC2 Inhibits Progression of Glioblastoma by Regulating the Expression of AKT in T98G Cell Line, Treated by TMZ and Thiosemicarbazone Complex.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Combination of B7H6-siRNA and temozolomide synergistically reduces stemness and migration properties of glioblastoma cancer cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2023 |
Identification of Patients With Glioblastoma Who May Benefit from Hypofractionated Radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification M | 2023 |
Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas.
Topics: Biomarkers; Brain Neoplasms; Glioblastoma; Glioma; Humans; Kinesins; Multigene Family; Prognosis; Te | 2023 |
The DRD2 Antagonist Haloperidol Mediates Autophagy-Induced Ferroptosis to Increase Temozolomide Sensitivity by Promoting Endoplasmic Reticulum Stress in Glioblastoma.
Topics: Autophagy; Brain Neoplasms; Cell Line, Tumor; Dopamine D2 Receptor Antagonists; Drug Resistance, Neo | 2023 |
Discovery of new imidazotetrazinones with potential to overcome tumor resistance.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarba | 2023 |
EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; DNA Modification Methylases; DNA Repair; DNA Re | 2023 |
The interplay of solvent-drug-protein interactions during albumin nanoparticles formulations for temozolomide delivery to brain cancer cells.
Topics: Acetone; Brain Neoplasms; Cell Line, Tumor; Ethanol; Glioblastoma; Humans; Nanoparticles; Serum Albu | 2023 |
Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; E2F1 Transcription Factor; Glioblastoma; Glioma; | 2023 |
Reduced malignant glioblastoma recurrence post-resection through the anti-CD47 antibody and Temozolomide co-embedded in-situ hydrogel system.
Topics: CD8-Positive T-Lymphocytes; Glioblastoma; Glioma; Humans; Receptors, Immunologic; Temozolomide | 2023 |
4-Methylumbelliferone enhances the effects of chemotherapy on both temozolomide-sensitive and resistant glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2023 |
Insights into Gene Regulation under Temozolomide-Promoted Cellular Dormancy and Its Connection to Stemness in Human Glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Tem | 2023 |
Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Tr | 2023 |
Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modification Methylases; D | 2023 |
Toward a theranostic device for gliomas.
Topics: Cell Line, Tumor; Glioblastoma; Glioma; Humans; Microbubbles; Neoplasm Recurrence, Local; Oligopepti | 2023 |
Cystathionine gamma-lyase (CTH) inhibition attenuates glioblastoma formation.
Topics: Animals; Cell Line; Cell Line, Tumor; Cystathionine gamma-Lyase; Glioblastoma; Humans; Mice; Mice, I | 2023 |
HOXD-AS2-STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Fee | 2023 |
Suppression of NANOG Expression Reduces Drug Resistance of Cancer Stem Cells in Glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance; Glioblastoma; Humans; Nanog Homeobox Protein; Ne | 2023 |
Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mesenchymal Stem | 2023 |
[Regional variation in usage of TTF (Optune)].
Topics: Brain Neoplasms; Combined Modality Therapy; Glioblastoma; Humans; Temozolomide | 2023 |
The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repa | 2023 |
Lewy body disease as a potential negative outcome modifier of glioblastoma treatment: a case report.
Topics: Aged; Brain; Glioblastoma; Humans; Lewy Bodies; Lewy Body Disease; Male; Temozolomide | 2023 |
Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Dacarbazine; DNA Methylation; | 2023 |
Label-Free Raman Spectromicroscopy Unravels the Relationship between MGMT Methylation and Intracellular Lipid Accumulation in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification M | 2023 |
A Trojan-Horse-Like Biomimetic Nano-NK to Elicit an Immunostimulatory Tumor Microenvironment for Enhanced GBM Chemo-Immunotherapy.
Topics: Animals; Biomimetics; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Immunotherapy; Interleukin-15 | 2023 |
A Syx-RhoA-Dia1 signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in glioblastoma.
Topics: Cell Division; Cell Line, Tumor; DNA Damage; Glioblastoma; Humans; Signal Transduction; Temozolomide | 2023 |
Lysine methylation promotes NFAT5 activation and determines temozolomide efficacy in glioblastoma.
Topics: ErbB Receptors; Glioblastoma; Humans; Lysine; Methylation; NFATC Transcription Factors; Temozolomide | 2023 |
Letter: are there incidences of clinically relevant psychiatric symptoms during glioblastoma treatment?
Topics: Brain Neoplasms; Glioblastoma; Humans; Incidence; Mental Disorders; Temozolomide | 2023 |
Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide/Immune Checkpoint Blockade to Treat Glioblastoma.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Immune Checkpoint Inhibitors; I | 2023 |
Quercetin induces MGMT
Topics: Apoptosis; Apoptosis Regulatory Proteins; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Drug Resi | 2023 |
Downregulation of long noncoding RNA
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resis | 2024 |
Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Middle Age | 2023 |
Autophagy Inhibition with Chloroquine Increased Pro-Apoptotic Potential of New Aziridine-Hydrazide Hydrazone Derivatives against Glioblastoma Cells.
Topics: Antineoplastic Agents; Autophagy; Aziridines; Chloroquine; Glioblastoma; Humans; Hydrazines; Hydrazo | 2023 |
Nitric Oxide Prevents Glioblastoma Stem Cells' Expansion and Induces Temozolomide Sensitization.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation | 2023 |
Role of SH3GLB1 in the regulation of CD133 expression in GBM cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; RNA Interference | 2023 |
TRIB1 confers therapeutic resistance in GBM cells by activating the ERK and Akt pathways.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Mice | 2023 |
The Assessment of Clinical Outcomes and Prognostic Factors in Glioblastoma Patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Glioblastoma; Humans; Neoplas | 2023 |
Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH-Wild-Type Glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Isocitrate Dehydrogenase; Middle Aged; Positron-Emission Tomo | 2023 |
Inhibition of autophagy and induction of glioblastoma cell death by NEO214, a perillyl alcohol-rolipram conjugate.
Topics: Autophagy; Cell Death; Chloroquine; Glioblastoma; Glioma; Humans; Lysosomes; Monoterpenes; Rolipram; | 2023 |
FOXO1-miR-506 axis promotes chemosensitivity to temozolomide and suppresses invasiveness in glioblastoma through a feedback loop of FOXO1/miR-506/ETS1/FOXO1.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Feedback; | 2023 |
Targeting MAGI2-AS3-modulated Akt-dependent ATP-binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide-resistant glioblastoma cells.
Topics: Adaptor Proteins, Signal Transducing; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Prol | 2023 |
Local administration of shikonin improved the overall survival in orthotopic murine glioblastoma models with temozolomide resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Mice; Mice, | 2023 |
Propofol Inhibits Glioma Stem Cell Growth and Migration and Their Interaction with Microglia via BDNF-AS and Extracellular Vesicles.
Topics: Brain Neoplasms; Brain-Derived Neurotrophic Factor; Extracellular Vesicles; Glioblastoma; Glioma; Hu | 2023 |
Autophagy Inhibition via Hydroxychloroquine or 3-Methyladenine Enhances Chemotherapy-Induced Apoptosis in Neuro-Blastoma and Glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Child; Cisplatin; Gl | 2023 |
Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion.
Topics: Antineoplastic Agents; Cell Death; Glioblastoma; Humans; Neoplasm Recurrence, Local; Neoplastic Proc | 2023 |
Invadopodia associated Thrombospondin-1 contributes to a post-therapy pro-invasive response in glioblastoma cells.
Topics: Brain; Glioblastoma; Humans; Neoplasm Recurrence, Local; Podosomes; Temozolomide | 2023 |
Next-generation bromodomain inhibitors of the SWI/SNF complex enhance DNA damage and cell death in glioblastoma.
Topics: Bleomycin; Cell Death; DNA Damage; Glioblastoma; Humans; Protein Domains; Temozolomide | 2023 |
Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme.
Topics: Emulsions; Glioblastoma; Humans; Hypoxia; Oxygen; Radiation-Sensitizing Agents; Temozolomide | 2023 |
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA; | 2023 |
Impact of Ferroptosis Inducers on Chronic Radiation-exposed Survivor Glioblastoma Cells.
Topics: Cell Line, Tumor; Ferroptosis; Glioblastoma; Humans; Radiation, Ionizing; Temozolomide | 2023 |
Aloe-Emodin Overcomes Anti-Cancer Drug Resistance to Temozolomide and Prevents Colony Formation and Migration in Primary Human Glioblastoma Cell Lines NULU and ZAR.
Topics: Aloe; Cell Line; Emodin; Glioblastoma; Humans; Temozolomide | 2023 |
MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value.
Topics: DNA Modification Methylases; DNA Repair Enzymes; Glioblastoma; Humans; Isocitrate Dehydrogenase; Met | 2023 |
Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
Topics: Drug Delivery Systems; Drug Liberation; Glioblastoma; Glioma; Humans; Temozolomide | 2023 |
Protein Disulfide Isomerase A3 (PDIA3): A Pharmacological Target in Glioblastoma?
Topics: Biological Assay; Glioblastoma; Humans; Phosphorylation; Protein Disulfide-Isomerases; Temozolomide | 2023 |
Cordycepin improves sensitivity to temozolomide in glioblastoma cells by down-regulating MYC.
Topics: Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Glioblastoma | 2023 |
5-lipoxygenase as a target to sensitize glioblastoma to temozolomide treatment via β-catenin-dependent pathway.
Topics: Animals; Arachidonate 5-Lipoxygenase; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Prolifer | 2023 |
A designer peptide against the EAG2-Kvβ2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma.
Topics: Animals; Disease Models, Animal; Ether-A-Go-Go Potassium Channels; Glioblastoma; Humans; Mice; Neuro | 2023 |
Drug-Loaded Lipid Magnetic Nanoparticles for Combined Local Hyperthermia and Chemotherapy against Glioblastoma Multiforme.
Topics: Animals; Glioblastoma; Humans; Hyperthermia, Induced; Lipids; Magnetite Nanoparticles; Mice; Mice, N | 2023 |
Temozolomide-based sonodynamic therapy induces immunogenic cell death in glioma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Immunogenic Cell Death; | 2023 |
LncRNA-associated competing endogenous RNA network analysis uncovered key lncRNAs involved in temozolomide resistance and tumor recurrence of glioblastoma.
Topics: Carrier Proteins; Cell Line, Tumor; Glioblastoma; Humans; MicroRNAs; Neoplasm Recurrence, Local; RNA | 2023 |
Coixendide efficacy in combination with temozolomide in glioblastoma and transcriptome analysis of the mechanism.
Topics: Cholesterol; Gene Expression Profiling; Glioblastoma; Humans; RNA-Seq; Temozolomide | 2023 |
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Lomustine; Ma | 2023 |
Hypoxanthine phosphoribosyl transferase 1 metabolizes temozolomide to activate AMPK for driving chemoresistance of glioblastomas.
Topics: AMP-Activated Protein Kinases; Animals; Drug Resistance, Neoplasm; Glioblastoma; Humans; Hypoxanthin | 2023 |
NFYB increases chemosensitivity in glioblastoma by promoting HDAC5-mediated transcriptional inhibition of SHMT2.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; CCAAT-Binding Factor; Cell Line, Tumor; Cell Pro | 2023 |
Multi-Omics Analyses Reveal Mitochondrial Dysfunction Contributing to Temozolomide Resistance in Glioblastoma Cells.
Topics: Brain; Glioblastoma; Humans; Mitochondria; Multiomics; Temozolomide | 2023 |
Modulating Wnt/β-Catenin Signaling Pathway on U251 and T98G Glioblastoma Cell Lines Using a Combination of Paclitaxel and Temozolomide, A Molecular Docking Simulations and Gene Expression Study.
Topics: beta Catenin; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression; Glio | 2023 |
Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide.
Topics: Brain Neoplasms; Cell Line, Tumor; Epigenomics; ErbB Receptors; Genes, erbB-1; Glioblastoma; Humans; | 2023 |
The effect of chemotherapies on the crosstalk interaction between CD8 cytotoxic T-cells and MHC-I peptides in the microenvironment of WHO grade 4 astrocytoma.
Topics: Astrocytoma; Brain Neoplasms; CD8-Positive T-Lymphocytes; Glioblastoma; Histocompatibility Antigens | 2023 |
Role of Nucleobindin-2 in the Clinical Pathogenesis and Treatment Resistance of Glioblastoma.
Topics: Animals; Cell Line, Tumor; Glioblastoma; Humans; Mice; Nucleobindins; Temozolomide | 2023 |
Development and characterization of a temozolomide-loaded nanoemulsion and the effect of ferrocene pre and co-treatments in glioblastoma cell models.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Metallocenes; Reactive Oxygen Species; Temo | 2023 |
Comparative Analysis of IDH Wild-Type Multifocal and Unifocal Glioblastomas: Prognostic Factors and Survival Outcomes in Focus.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Middle Aged; | 2023 |
A novel strategy to increase the therapeutic potency of GBM chemotherapy via altering parenchymal/cerebral spinal fluid clearance rate.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2023 |
Human cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Glioblastoma; Humans; Temozolomide; Trifluoper | 2023 |
NRF2 connects Src tyrosine kinase to ferroptosis resistance in glioblastoma.
Topics: Ferroptosis; Glioblastoma; Humans; NF-E2-Related Factor 2; src-Family Kinases; Temozolomide | 2024 |
Progesterone Receptor Membrane Component 1 (PGRMC1) Modulates Tumour Progression, the Immune Microenvironment and the Response to Therapy in Glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Membrane Proteins; Neoplastic Processes; Receptors, Progester | 2023 |
Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis.
Topics: Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tu | 2023 |
Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma-Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation.
Topics: Antineoplastic Agents, Alkylating; Glioblastoma; Hedgehog Proteins; Histone Deacetylase Inhibitors; | 2023 |
Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Methylation; | 2023 |
Ceramide Is Involved in Temozolomide Resistance in Human Glioblastoma U87MG Overexpressing EGFR.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Ceramides; Drug Resistance, Ne | 2023 |
Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Glioma; Humans; Phosphatidylinositol 3 | 2023 |
Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Blockage of EGFR/AKT and mevalonate pathways synergize the antitumor effect of temozolomide by reprogramming energy metabolism in glioblastoma.
Topics: Animals; Cell Line, Tumor; Energy Metabolism; ErbB Receptors; Fatty Acids; Glioblastoma; Ligases; Me | 2023 |
Enhanced Sensitivity to ALDH1A3-Dependent Ferroptosis in TMZ-Resistant Glioblastoma Cells.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Ferroptosis; Glioblastoma; Humans; Neop | 2023 |
Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2023 |
CREB-induced LINC00473 promotes chemoresistance to TMZ in glioblastoma by regulating O6-methylguanine-DNA-methyltransferase expression via CEBPα binding.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA; DNA Modification Methylas | 2024 |
RPL22L1, a novel candidate oncogene promotes temozolomide resistance by activating STAT3 in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2023 |
Treatment of glioblastoma in Greenlandic patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glio | 2023 |
Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic Agent.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; CDC2 Protein Kinase; Cell Line, Tumor; Checkpoin | 2023 |
Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Dacarb | 2023 |
G3BP1 knockdown sensitizes U87 glioblastoma cell line to Bortezomib by inhibiting stress granules assembly and potentializing apoptosis.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Bortezomib; Cell Proliferation; | 2019 |
miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cathepsin B; Cell Line, Tumor; Cell Survival; Do | 2019 |
A STAT3-based gene signature stratifies glioma patients for targeted therapy.
Topics: Animals; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Ge | 2019 |
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
Topics: Animals; Antineoplastic Agents; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Drug Administration S | 2019 |
Correlation of the quantitative level of MGMT promoter methylation and overall survival in primary diagnosed glioblastomas using the quantitative MethyQESD method.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; DNA Methylation; | 2020 |
Dehydroabietylamine Ureas and Thioureas as Tyrosyl-DNA Phosphodiesterase 1 Inhibitors That Enhance the Antitumor Effect of Temozolomide on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA, Neoplasm; Drug Synergism; | 2019 |
Bcl2-Expressing Quiescent Type B Neural Stem Cells in the Ventricular-Subventricular Zone Are Resistant to Concurrent Temozolomide/X-Irradiation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Chemoradiotherapy; Disease Models, Animal; DN | 2019 |
A local combination therapy to inhibit GBM recurrence.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Drug Carriers; Drug Delivery Systems; Glioblastoma; | 2019 |
Temozolomide has anti-tumor effects through the phosphorylation of cPLA
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glioblasto | 2019 |
TMZ regulates GBM stemness via MMP14-DLL4-Notch3 pathway.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Early Grow | 2020 |
Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Cycle; Cell Survival; Com | 2019 |
Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cyclin-D | 2019 |
Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cerebrovascular | 2020 |
Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bevacizumab; Brain N | 2019 |
Validation and optimization of a web-based nomogram for predicting survival of patients with newly diagnosed glioblastoma.
Topics: Aged; Algorithms; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Female; G | 2020 |
MicroRNA-1 suppresses glioblastoma in preclinical models by targeting fibronectin.
Topics: 3' Untranslated Regions; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2019 |
Combining Ellagic Acid with Temozolomide Mediates the Cadherin Switch and Angiogenesis in a Glioblastoma Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cell Line, Tumor; Disease Models | 2019 |
MTBP regulates cell survival and therapeutic sensitivity in TP53 wildtype glioblastomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Carrier Proteins; Cell Lin | 2019 |
The Evaluation of Glioblastoma Cell Dissociation and Its Influence on Its Behavior.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferat | 2019 |
Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; | 2019 |
Simvastatin increases temozolomide-induced cell death by targeting the fusion of autophagosomes and lysosomes.
Topics: Animals; Autophagosomes; Cell Death; Cell Line, Tumor; Female; Glioblastoma; Humans; Lysosomes; Macr | 2020 |
Irradiation or temozolomide chemotherapy enhances anti-CD47 treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; CD47 Antigen; Cell Line, Tumor; Combine | 2020 |
Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Capillary | 2020 |
Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide.
Topics: Animals; Antineoplastic Agents; Aurora Kinase B; Brain Neoplasms; Drug Resistance, Neoplasm; Drug Sy | 2019 |
Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2.
Topics: Adult; Aged; Brain; Brain Neoplasms; Cell Nucleus; Chemoradiotherapy, Adjuvant; Cyclin D2; Female; G | 2020 |
Paradoxical epigenetic regulation of XAF1 mediates plasticity towards adaptive resistance evolution in MGMT-methylated glioblastoma.
Topics: Adaptation, Physiological; Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; | 2019 |
Enhanced Efficacy of Temozolomide Loaded by a Tetrahedral Framework DNA Nanoparticle in the Therapy for Glioblastoma.
Topics: Animals; DNA; Drug Carriers; Female; Glioblastoma; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Na | 2019 |
BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Brain Neo | 2019 |
Role of Sonic hedgehog signaling in cell cycle, oxidative stress, and autophagy of temozolomide resistant glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Beclin-1; Carcinogenesis; Cell Cycle; Cell Li | 2020 |
Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug Res | 2019 |
ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; Brain | 2020 |
A new chance for EGFR inhibition in glioblastoma?
Topics: Brain Neoplasms; ErbB Receptors; Glioblastoma; Humans; Temozolomide | 2019 |
Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expres | 2019 |
Treatment strategies for glioblastoma in older patients: age is just a number.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Stu | 2019 |
Enhanced Copper-Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme.
Topics: Antineoplastic Agents; Apoferritins; Brain Neoplasms; Cell Line, Tumor; Copper; Glioblastoma; Humans | 2019 |
Intracellular Redox-Balance Involvement in Temozolomide Resistance-Related Molecular Mechanisms in Glioblastoma.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Chaperone-Mediated Autophagy; Cytoplasm; Dr | 2019 |
Gossypol Suppresses Growth of Temozolomide-Resistant Glioblastoma Tumor Spheres.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Proliferation; Cell Survival; Combined Modality T | 2019 |
Lovastatin Enhances Cytotoxicity of Temozolomide via Impairing Autophagic Flux in Glioblastoma Cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain N | 2019 |
Multifunctional temozolomide-loaded lipid superparamagnetic nanovectors: dual targeting and disintegration of glioblastoma spheroids by synergic chemotherapy and hyperthermia treatment.
Topics: Cell Line, Tumor; Drug Delivery Systems; Glioblastoma; Humans; Hyperthermia, Induced; Magnetite Nano | 2019 |
Carnosine increases efficiency of temozolomide and irradiation treatment of isocitrate dehydrogenase-wildtype glioblastoma cells in culture.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carnosine; Cell Survival; Female; Glioblas | 2019 |
A man with weak limbs.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Craniotomy; Glioblastoma; Humans; Magnetic Reson | 2019 |
Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherapy; Comb | 2020 |
Influence of wide opening of the lateral ventricle on survival for supratentorial glioblastoma patients with radiotherapy and concomitant temozolomide-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Female; Glioblastoma; | 2020 |
Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.
Topics: Aged; Brain Neoplasms; Brain Stem; Glioblastoma; Humans; Supratentorial Neoplasms; Temozolomide | 2020 |
ANGPTL4 Induces TMZ Resistance of Glioblastoma by Promoting Cancer Stemness Enrichment via the EGFR/AKT/4E-BP1 Cascade.
Topics: Adaptor Proteins, Signal Transducing; Angiopoietin-Like Protein 4; Antineoplastic Agents, Alkylating | 2019 |
Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2019 |
Decreased APE-1 by Nitroxoline Enhances Therapeutic Effect in a Temozolomide-resistant Glioblastoma: Correlation with Diffusion Weighted Imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Diffusion Magnetic Resonance Imaging; | 2019 |
SNAP reverses temozolomide resistance in human glioblastoma multiforme cells through down-regulation of MGMT.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers; DNA Damage; DNA Modification Meth | 2019 |
Efficient delivery of anti-miR-210 using Tachyplesin, a cell penetrating peptide, for glioblastoma treatment.
Topics: Antagomirs; Antimicrobial Cationic Peptides; Antineoplastic Agents; Antineoplastic Agents, Alkylatin | 2019 |
Establishment of a glioblastoma in vitro (in)complete resection dual co-culture model suitable for drug testing.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Astrocyt | 2020 |
Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Gonanes; Humans; Phosphatidyl | 2019 |
Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immu | 2020 |
Molecular Evolution of
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; C | 2020 |
Gamabufotalin induces a negative feedback loop connecting ATP1A3 expression and the AQP4 pathway to promote temozolomide sensitivity in glioblastoma cells by targeting the amino acid Thr794.
Topics: Animals; Aquaporin 4; Bufanolides; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regu | 2020 |
The synergistic effect of DZ‑NEP, panobinostat and temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Prolif | 2020 |
LQB‑118 compound inhibits migration and induces cell death in glioblastoma cells.
Topics: Brain Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell | 2020 |
[RAD51 promotes proliferation and migration of glioblastoma cells and decreases sensitivity of cells to temozolomide].
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Knockdown Tech | 2019 |
BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Brain Neopla | 2019 |
Musashi1 enhances chemotherapy resistance of pediatric glioblastoma cells in vitro.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Case-Contr | 2020 |
Temozolomide induces activation of Wnt/β-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy.
Topics: beta Catenin; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulati | 2020 |
Feasibility study of finalizing the extended adjuvant temozolomide based on methionine positron emission tomography (Met-PET) findings in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisot | 2019 |
Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brai | 2019 |
Persistent HCMV infection of a glioblastoma cell line contributes to the development of resistance to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytomegalovi | 2020 |
Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.
Topics: Brain Neoplasms; Cell Movement; Cell Proliferation; Cell Survival; Cytokines; Dose-Response Relation | 2019 |
Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Di | 2020 |
Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study.
Topics: Adult; Algorithms; Bevacizumab; Chronic Disease; Clinical Decision-Making; Female; Glioblastoma; Hea | 2019 |
Reactive oxygen species metabolism-based prediction model and drug for patients with recurrent glioblastoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antioxidants; Cell Line, Tumor; Cell | 2019 |
Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
Topics: Antineoplastic Agents, Alkylating; Benzene Derivatives; Brain Neoplasms; Cell Line, Tumor; Cell Surv | 2019 |
Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cel | 2019 |
Microarray expression profiles and bioinformatics analysis of mRNAs, lncRNAs, and circRNAs in the secondary temozolomide-resistant glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Computational Biology; Drug Resistance, Neoplasm | 2020 |
Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2020 |
Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Com | 2020 |
Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2019 |
Quantitative Proteomics Analysis Reveals Nuclear Perturbation in Human Glioma U87 Cells treated with Temozolomide.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Computational Biology; DNA Damage; DNA Repair; Glio | 2020 |
Design, synthesis and cytotoxicity of the antitumor agent 1-azabicycles for chemoresistant glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azabicyclo Compounds; Brain Neoplasms; Cell Cycle; Cell M | 2020 |
Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain | 2020 |
Survey of treatment recommendations for elderly patients with glioblastoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasm | 2020 |
IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movem | 2020 |
Effects of temozolomide on U87MG glioblastoma cell expression of CXCR4, MMP2, MMP9, VEGF, anti-proliferatory cytotoxic and apoptotic properties.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers; Cell Line, Tumor; Cell Survival; Dose-Resp | 2020 |
Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; DNA Mismatch Repair; DNA Repair; Drug | 2020 |
Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene E | 2020 |
Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2020 |
A Key Role of DNA Damage-Inducible Transcript 4 (DDIT4) Connects Autophagy and GLUT3-Mediated Stemness To Desensitize Temozolomide Efficacy in Glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, T | 2020 |
Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images.
Topics: Administration, Metronomic; Animals; Antineoplastic Agents, Alkylating; B7-H1 Antigen; Cell Line, Tu | 2020 |
ShRNA-based POLD2 expression knockdown sensitizes glioblastoma to DNA-Damaging therapeutics.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA Polymerase III; D | 2020 |
Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; BRCA1 Protein; DNA Mismatch Repai | 2020 |
Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; G | 2020 |
Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immu | 2020 |
A novel neuronal organoid model mimicking glioblastoma (GBM) features from induced pluripotent stem cells (iPSC).
Topics: Cells, Cultured; Dose-Response Relationship, Drug; Glioblastoma; Humans; Induced Pluripotent Stem Ce | 2020 |
Deleterious impact of a generic temozolomide formulation compared with brand-name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blood Platelets; Brain Neoplasms; Drug Compounding; Drugs, Generi | 2020 |
Identifying Disparities in Care in Treating Glioblastoma: A Retrospective Cohort Study of Patients Treated at a Safety-net Versus Private Hospital Setting.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, | 2020 |
First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combin | 2020 |
Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Child, Preschool; Coh | 2020 |
A Common Rule for Resection of Glioblastoma in the Molecular Era.
Topics: Brain Neoplasms; Glioblastoma; Humans; Temozolomide | 2020 |
Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; Chemoradiothe | 2020 |
DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Cell Proliferation; DNA Me | 2020 |
Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.
Topics: Antineoplastic Agents; Child; Child, Preschool; Female; Glioblastoma; Humans; Neoplasm Recurrence, L | 2020 |
Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; DNA Copy Number Variations; D | 2020 |
EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Cohort Studies; DNA Methylation; DNA | 2020 |
Management of glioblastoma: an Australian perspective.
Topics: Australia; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2021 |
Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT.
Topics: Adult; Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Disulfides; DNA Modification Methylase | 2020 |
Revealing the epigenetic effect of temozolomide on glioblastoma cell lines in therapeutic conditions.
Topics: 5-Methylcytosine; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; DNA Modification Methylases; D | 2020 |
Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelial Cells; Glioblasto | 2020 |
Calpain suppresses cell growth and invasion of glioblastoma multiforme by producing the cleavage of filamin A.
Topics: Biomarkers, Tumor; Brain Neoplasms; Calpain; Cell Line, Tumor; Cell Movement; Cell Proliferation; Ce | 2020 |
Neurological Impairments in Mice Subjected to Irradiation and Chemotherapy.
Topics: Animals; Anxiety; Behavior, Animal; Brain Neoplasms; CA1 Region, Hippocampal; Combined Modality Ther | 2020 |
Major response to temozolomide as first-line treatment for newly-diagnosed DDR2-mutated glioblastoma: A case report.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Discoidin Domain Rece | 2020 |
A troublesome burden, the amplification of EGFR in glioblastoma!
Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; ErbB Receptors; Glioblastoma; Humans; Lomustine; | 2020 |
STAT3 inhibition induced temozolomide-resistant glioblastoma apoptosis via triggering mitochondrial STAT3 translocation and respiratory chain dysfunction.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; | 2020 |
Particle radiation therapy in the management of malignant glioma: Early experience at the Shanghai Proton and Heavy Ion Center.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; DNA Modification Methylases; DNA Repair Enzymes; Dos | 2020 |
Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2020 |
A steroidal saponin form Paris vietnamensis (Takht.) reverses temozolomide resistance in glioblastoma cells via inducing apoptosis through ROS/PI3K/Akt pathway.
Topics: Acetylcysteine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; A | 2020 |
Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Decitabine; Epigenesis, Genetic; Glioblast | 2020 |
Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity.
Topics: Adaptive Immunity; Animals; Antigen Presentation; Apoptosis; CD47 Antigen; Cell Line, Tumor; Cell Pr | 2020 |
Major Contribution of Caspase-9 to Honokiol-Induced Apoptotic Insults to Human Drug-Resistant Glioblastoma Cells.
Topics: Apoptosis; Biphenyl Compounds; Caspase 9; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activa | 2020 |
Interaction Between Near-Infrared Radiation and Temozolomide in a Glioblastoma Multiform Cell Line: A Treatment Strategy?
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell | 2021 |
Control of brain tumor growth by reactivating myeloid cells with niacin.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Mice; Neoplastic | 2020 |
[Dosimetry of tumor treating fields: energy per unit correlates with oncological endpoints in patients with glioblastoma in the EF-14 trial].
Topics: Brain Neoplasms; Glioblastoma; Humans; Radiometry; Temozolomide | 2020 |
Micro-RNA29b enhances the sensitivity of glioblastoma multiforme cells to temozolomide by promoting autophagy.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; | 2021 |
Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway.
Topics: Adult; Aged; Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Resistance, Ne | 2020 |
Reinforcement learning for optimal scheduling of Glioblastoma treatment with Temozolomide.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; | 2020 |
Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
Topics: Animals; Antibodies, Neoplasm; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Brain Neopl | 2020 |
NUSAP1 potentiates chemoresistance in glioblastoma through its SAP domain to stabilize ATR.
Topics: Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Proliferation; DNA Damage; Doxorubi | 2020 |
The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Drug Resista | 2020 |
Entry and exit of chemotherapeutically-promoted cellular dormancy in glioblastoma cells is differentially affected by the chemokines CXCL12, CXCL16, and CX3CL1.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemokine | 2020 |
Chemoradiation in elderly patients with glioblastoma from the multi-institutional GBM-molRPA cohort: is short-course radiotherapy enough or is it a matter of selection?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Coho | 2020 |
The limitations of targeting MEK signalling in Glioblastoma therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Adhesion; Cell Deat | 2020 |
Leucine-rich repeat containing 4 act as an autophagy inhibitor that restores sensitivity of glioblastoma to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2020 |
Feasibility of hippocampus-sparing VMAT for newly diagnosed glioblastoma treated by chemoradiation: pattern of failure analysis.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Hippocampu | 2020 |
Spinal metastasis of glioblastoma multiforme before gliosarcomatous transformation: a case report.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Craniotomy; Fatal Outcome; Female; Gliobl | 2020 |
Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme.
Topics: Animals; Brain Neoplasms; Glioblastoma; Humans; Irinotecan; Mice; Pharmaceutical Preparations; Temoz | 2020 |
Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma.
Topics: Antimalarials; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance | 2020 |
Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2020 |
CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.
Topics: 5'-Nucleotidase; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Prolif | 2020 |
Xanthohumol regulates miR-4749-5p-inhibited RFC2 signaling in enhancing temozolomide cytotoxicity to glioblastoma.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Synergism; Flavonoids; Gene Expres | 2020 |
LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2020 |
Long intergenic noncoding RNA 00021 promotes glioblastoma temozolomide resistance by epigenetically silencing p21 through Notch pathway.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Dru | 2020 |
Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Mice; Oncolytic V | 2020 |
Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modifica | 2020 |
Extreme hypofractionation for newly diagnosed glioblastoma: rationale, dose, techniques, and outcomes.
Topics: Brain Neoplasms; Glioblastoma; Humans; Radiation Dose Hypofractionation; Radiosurgery; Temozolomide | 2020 |
The clinical characteristics and prognostic factors of multiple lesions in glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; DNA Modification | 2020 |
A Prospective Cohort Study of Neural Progenitor Cell-Sparing Radiation Therapy Plus Temozolomide for Newly Diagnosed Patients With Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2020 |
Multidimensional hydrogel models reveal endothelial network angiocrine signals increase glioblastoma cell number, invasion, and temozolomide resistance.
Topics: Biocompatible Materials; Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Movement; Cell Prolifer | 2020 |
Temozolomide, Gemcitabine, and Decitabine Hybrid Nanoconjugates: From Design to Proof-of-Concept (PoC) of Synergies toward the Understanding of Drug Impact on Human Glioblastoma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Decitabine; De | 2020 |
MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm | 2020 |
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
Topics: Adult; Brain Neoplasms; Glioblastoma; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Neoplasm R | 2020 |
The combined effect of neutron irradiation and temozolomide on glioblastoma cell lines with different MGMT and P53 status.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; DNA | 2020 |
PARP inhibition suppresses the emergence of temozolomide resistance in a model system.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Gene Ex | 2020 |
Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Platelets; Brain Neoplasms; Chemoradiotherapy; Com | 2020 |
Granulocyte-macrophage colony-stimulating factor enhances effect of temozolomide on high-grade glioma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Cell Cycle; Central Nervous System Neop | 2020 |
Nuclear Respiratory Factor 1 (NRF1) Transcriptional Activity-Driven Gene Signature Association with Severity of Astrocytoma and Poor Prognosis of Glioblastoma.
Topics: Adult; Apoptosis; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell Differentiation; | 2020 |
Temozolomide in glioblastoma treatment: 15-year clinical experience and analysis of its efficacy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; | 2020 |
Xihuang pill potentiates the anti-tumor effects of temozolomide in glioblastoma xenografts through the Akt/mTOR-dependent pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2020 |
A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Methyl | 2020 |
Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy.
Topics: Adult; Aged; Chemoradiotherapy; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Huma | 2020 |
Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Dendrime | 2020 |
Cyclopamine sensitizes glioblastoma cells to temozolomide treatment through Sonic hedgehog pathway.
Topics: Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glioblastoma; | 2020 |
Conventional Treatment of Glioblastoma Reveals Persistent CD44
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Disease Progression; Glioblastoma; Humans; Hyaluronan Re | 2020 |
Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Survival; Cells, Cul | 2020 |
Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy.
Topics: Antineoplastic Agents; Apoferritins; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Sur | 2020 |
Glioblastoma and bevacizumab in elderly patients: Monocentric study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Female; G | 2021 |
Combination Therapy with Nanomicellar-Curcumin and Temozolomide for In Vitro Therapy of Glioblastoma Multiforme via Wnt Signaling Pathways.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2020 |
Dual MGMT inactivation by promoter hypermethylation and loss of the long arm of chromosome 10 in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Alkylating; | 2020 |
Evaluation of frequency magnetic field, static field, and Temozolomide on viability, free radical production and gene expression (p53) in the human glioblastoma cell line (A172).
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Free Radicals; Gene Expression Regulation; Glio | 2020 |
Suppressing Dazl modulates tumorigenicity and stemness in human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Movement; Ce | 2020 |
HIF1α and p53 Regulated MED30, a Mediator Complex Subunit, is Involved in Regulation of Glioblastoma Pathogenesis and Temozolomide Resistance.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Gliob | 2021 |
Injectable diblock copolypeptide hydrogel provides platform to deliver effective concentrations of paclitaxel to an intracranial xenograft model of glioblastoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Central Nervous System; Drug Carriers; | 2020 |
Fabrication of poly(acrylic acid) grafted-chitosan/polyurethane/magnetic MIL-53 metal organic framework composite core-shell nanofibers for co-delivery of temozolomide and paclitaxel against glioblastoma cancer cells.
Topics: Acrylic Resins; Cell Line, Tumor; Chitosan; Glioblastoma; Humans; Magnetic Phenomena; Metal-Organic | 2020 |
MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.
Topics: Aminopyridines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; A | 2021 |
Vascularized Temporoparietal Fascial Flap: A Novel Surgical Technique to Bypass the Blood-Brain Barrier in Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Chemoradiotherapy, Adjuvant | 2020 |
Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Sur | 2020 |
Phospholipase D1 inhibition sensitizes glioblastoma to temozolomide and suppresses its tumorigenicity.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carcinogenesis; Cell | 2020 |
Influence of glioblastoma contact with the subventricular zone on survival and recurrence patterns.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Confidence Intervals; Female; | 2021 |
Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; B | 2021 |
Activation of dopamine receptor D1 inhibits glioblastoma tumorigenicity by regulating autophagic activity.
Topics: Animals; Autophagy; Calcium; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Hum | 2020 |
NF-κB inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF-κB(p65) and actin cytoskeleton regulatory pathways.
Topics: Actin Cytoskeleton; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; | 2020 |
Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2020 |
Targeting BC200/miR218-5p Signaling Axis for Overcoming Temozolomide Resistance and Suppressing Glioma Stemness.
Topics: Aged; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fem | 2020 |
PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2020 |
TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; DNA Modification Methylases; DNA Repair Enzymes | 2021 |
The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status.
Topics: Adult; Brain Neoplasms; Chitinase-3-Like Protein 1; DNA Methylation; DNA Modification Methylases; DN | 2020 |
Enhancement of glioblastoma multiforme therapy through a novel Quercetin-Losartan hybrid.
Topics: Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Losartan; Quercetin; Temozolomide | 2020 |
Gradient hydrogels for screening stiffness effects on patient-derived glioblastoma xenograft cellfates in 3D.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Pr | 2021 |
Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
Topics: Antineoplastic Agents, Alkylating; Benzamides; Brain Neoplasms; Cell Line, Tumor; DNA Modification M | 2020 |
Anti-PD-1, anti-VEGF, and temozolomide therapy in a patient with recurrent glioblastoma: a case report.
Topics: Adult; Angiogenesis Inhibitors; Bevacizumab; Brain Neoplasms; Female; Glioblastoma; Humans; Neoplasm | 2020 |
Reply to: "Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?"
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2020 |
An interview with Buddy Ratner.
Topics: Brain Neoplasms; Glioblastoma; Humans; Polyesters; Temozolomide | 2020 |
PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; DNA Modification Me | 2020 |
Anti-glioma effects of 2-aminothiophene-3-carboxamide derivatives, ANO1 channel blockers.
Topics: Animals; Anoctamin-1; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dr | 2020 |
A facile and scalable in production non-viral gene engineered mesenchymal stem cells for effective suppression of temozolomide-resistant (TMZR) glioblastoma growth.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Mesenchymal Stem Cells; Mice; Mice | 2020 |
EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1-2 signaling.
Topics: Adaptor Proteins, Signal Transducing; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Prolif | 2021 |
Acute interstitial nephritis and nephrogenic diabetes insipidus following treatment with sulfamethoxazole-trimethoprim and temozolomide.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Diab | 2021 |
Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Brazil; Chemoradiotherapy; Chemotherapy, Adjuvan | 2020 |
Wnt/β-catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Autophagy-Related Proteins; beta Catenin; Cell Line, T | 2020 |
Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Humans; | 2020 |
Sphingosine‑1‑phosphate analogue FTY720 exhibits a potent anti‑proliferative effect on glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Pr | 2020 |
Survival benefit of concomitant chemoradiation in adult supratentorial primary glioblastoma. A propensity score weighted population-based analysis.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Kaplan-Meier Estimate; Propensity Score; Supratentoria | 2022 |
Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cellular Senescence; Cytotoxins; D | 2020 |
Generalized Additive Mixed Modeling of Longitudinal Tumor Growth Reduces Bias and Improves Decision Making in Translational Oncology.
Topics: Anilides; Animals; Antineoplastic Agents, Alkylating; Bias; Decision Making; Disease Models, Animal; | 2020 |
Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2020 |
Central diabetes insipidus induced by temozolomide: A report of two cases.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Deamino Arginine Vasopressin; Diabetes In | 2021 |
MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DN | 2021 |
Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.
Topics: Animals; Brain Neoplasms; Glioblastoma; Glioma; Heterografts; Humans; Mice; Neoplasm Recurrence, Loc | 2020 |
Epigenetic modulator inhibition overcomes temozolomide chemoresistance and antagonizes tumor recurrence of glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; DNA, Neoplasm; Drug Resistance, Neoplas | 2020 |
Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell | 2020 |
The effect of temozolomide in combination with doxorubicin in glioblastoma cells
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubi | 2020 |
LncRNA NEAT1 promotes malignant phenotypes and TMZ resistance in glioblastoma stem cells by regulating let-7g-5p/MAP3K1 axis.
Topics: Brain Neoplasms; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Res | 2020 |
Penetrating the brain tumor space with DNA damage response inhibitors.
Topics: Brain Neoplasms; DNA Damage; Glioblastoma; Humans; Phthalazines; Piperazines; Temozolomide | 2020 |
Spatiotemporal combination of thermosensitive polypeptide fused interferon and temozolomide for post-surgical glioblastoma immunochemotherapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Mice; Neoplasm | 2021 |
The duration of adjuvant temozolomide in patients with glioblastoma and the law of diminishing returns.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2020 |
Clinical characterization of glioblastoma patients living longer than 2 years: A retrospective analysis of two Italian institutions.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblas | 2021 |
Enhanced Caspase-Mediated Abrogation of Autophagy by Temozolomide-Loaded and Panitumumab-Conjugated Poly(lactic-
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Caspase 9; Cell Line, Tumor; Cell Surv | 2020 |
Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Drug Resista | 2020 |
Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma.
Topics: Adult; Anti-Retroviral Agents; Antineoplastic Agents; Autophagy; Cell Line; Drug Repositioning; Drug | 2020 |
Cytotoxic lanthanum oxide nanoparticles sensitize glioblastoma cells to radiation therapy and temozolomide: an in vitro rationale for translational studies.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Drug | 2020 |
Simvastatin Induces Unfolded Protein Response and Enhances Temozolomide-Induced Cell Death in Glioblastoma Cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Caspases; Cell Death; Cell Line, Tumor; Cell Surv | 2020 |
Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplas | 2020 |
Encapsulation of Small Drugs in a Supramolecule Enhances Solubility, Stability, and Therapeutic Efficacy Against Glioblastoma Multiforme.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Glioblasto | 2021 |
Actual body weight dosing of temozolomide and overall survival in patients with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Body Weight; Brain Neoplasms; Combined Modality Therapy; D | 2021 |
Evaluation of hepatic drug-metabolism for glioblastoma using liver-brain chip.
Topics: Astrocytes; Blood-Brain Barrier; Brain; Capecitabine; Coculture Techniques; Endothelial Cells; Gliob | 2021 |
The interruption of atypical PKC signaling and Temozolomide combination therapy against glioblastoma.
Topics: Actin Cytoskeleton; Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Drug Therapy, Combination; | 2021 |
Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell-Free Nucleic Acids; Chemoradiotherapy | 2020 |
[Cathepsin S (CTSS) is highly expressed in temozolomide-resistant glioblastoma T98G cells and associated with poor prognosis].
Topics: Brain Neoplasms; Cathepsins; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation | 2020 |
Methylation associated miR-1246 contributes to poor prognosis in gliomas treated with temozolomide.
Topics: Brain Neoplasms; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; H | 2021 |
Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell S | 2020 |
Molecular Characterization of Temozolomide-Treated and Non Temozolomide-Treated Glioblastoma Cells Released Extracellular Vesicles and Their Role in the Macrophage Response.
Topics: Cell Line, Tumor; Cryoelectron Microscopy; Drug Resistance, Neoplasm; Exosomes; Extracellular Vesicl | 2020 |
Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling.
Topics: Animals; Brain Neoplasms; Female; Glioblastoma; Humans; Mice; Mice, Nude; Protein Serine-Threonine K | 2020 |
Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Machine Learning; Magnetic Resonan | 2020 |
Smarcd1 Inhibits the Malignant Phenotypes of Human Glioblastoma Cells via Crosstalk with Notch1.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell P | 2021 |
Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromatography, High Pressure Liquid; CpG | 2020 |
Comparison of Elemental Anomalies Following Implantation of Different Cell Lines of Glioblastoma Multiforme in the Rat Brain: A Total Reflection X-ray Fluorescence Spectroscopy Study.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Rats; Spectrometry, X-Ray E | 2020 |
Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Disease-Free Su | 2021 |
Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunolog | 2020 |
FDG PET/CT in Recurrent Glioblastoma Multiforme With Leptomeningeal and Diffuse Spinal Cord Metastasis.
Topics: Adult; Brain Neoplasms; Female; Fluorodeoxyglucose F18; Glioblastoma; Humans; Meningeal Neoplasms; P | 2021 |
Determination of the cutoff point of the absolute value of MGMTmRNA for predicting the therapeutic resistance to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; Drug Resistance, N | 2020 |
Flunarizine, a drug approved for treating migraine and vertigo, exhibits cytotoxicity in GBM cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulato | 2021 |
Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Clustered Regularly Interspaced Short Palindromic | 2020 |
The epidermal growth factor receptor variant type III mutation frequently found in gliomas induces astrogenesis in human cerebral organoids.
Topics: Apoptosis; Astrocytes; Brain; Brain Neoplasms; Cell Differentiation; Cell Line; Cell Proliferation; | 2021 |
Inhibition of Intermedin (Adrenomedullin 2) Suppresses the Growth of Glioblastoma and Increases the Antitumor Activity of Temozolomide.
Topics: Adrenomedullin; Animals; Female; Glioblastoma; Humans; Mice; Mice, Nude; Temozolomide | 2021 |
Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma.
Topics: Aged; Anthracyclines; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Class Ia Phosphatidy | 2021 |
Treatment patterns and outcomes for cerebellar glioblastoma in the concomitant chemoradiation era: A National Cancer database study.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality | 2020 |
Regorafenib in glioblastoma recurrence: A case report.
Topics: Brain Neoplasms; Chemoradiotherapy, Adjuvant; Glioblastoma; Humans; Magnetic Resonance Imaging; Male | 2021 |
Final Results of the Prospective Biomarker Trial PETra: [
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2021 |
Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Prol | 2021 |
Guanabenz Sensitizes Glioblastoma Cells to Sunitinib by Inhibiting GADD34-Mediated Autophagic Signaling.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain N | 2021 |
Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Topics: Administration, Intranasal; Animals; Apoptosis; Brain Neoplasms; Cell Line; Cell Line, Tumor; Drug R | 2021 |
Integrated genetic and metabolic landscapes predict vulnerabilities of temozolomide resistant glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; D | 2021 |
Desquamative skin rash associated with temozolomide in a patient with glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Exanthema; Glioblastoma; Humans; Temozolomide | 2021 |
Combinatorial Therapeutic Effect of Inhibitors of Aldehyde Dehydrogenase and Mitochondrial Complex I, and the Chemotherapeutic Drug, Temozolomide against Glioblastoma Tumorspheres.
Topics: Aldehyde Dehydrogenase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Electron Tr | 2021 |
PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Modificat | 2021 |
Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanoparticles Combined with Focused Ultrasound.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Deoxyribonuclease I; Drug Resistanc | 2021 |
The Role of Temozolomide in Patients With Newly Diagnosed Wild-Type IDH, Unmethylated MGMTp Glioblastoma During the COVID-19 Pandemic.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; COVID | 2021 |
Timing of Chemoradiation in Newly Diagnosed Glioblastoma: Comparative Analysis Between County and Managed Care Health Care Models.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modalit | 2021 |
Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tum | 2021 |
Long-Term Near-Infrared Signal Tracking of the Therapeutic Changes of Glioblastoma Cells in Brain Tissue with Ultrasound-Guided Persistent Luminescent Nanocomposites.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; | 2021 |
Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2021 |
Differentiation of recurrent glioblastoma from radiation necrosis using diffusion radiomics with machine learning model development and external validation.
Topics: Adult; Aged; Brain; Chemoradiotherapy, Adjuvant; Diffusion Magnetic Resonance Imaging; Female; Gliob | 2021 |
A neuro evolutionary algorithm for patient calibrated prediction of survival in Glioblastoma patients.
Topics: Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Temozolomide | 2021 |
Bioresorbable, electrospun nonwoven for delayed and prolonged release of temozolomide and nimorazole.
Topics: Absorbable Implants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemistry, Pharmaceutical; | 2021 |
Data-Driven Computational Modeling Identifies Determinants of Glioblastoma Response to SHP2 Inhibition.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Data Science; Dimethyl Sulfoxide; DNA Repair; Drug Resis | 2021 |
Multicentric non-enhancing lesions in glioblastoma: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2021 |
Glioblastoma cell line shows phenotypes of cancer stem cells in hypoxic microenvironment of spheroids.
Topics: AC133 Antigen; Cell Culture Techniques; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cell Survival | 2021 |
Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; ATP Binding Cassette Transporter, Subf | 2021 |
The novel roles of virus infection-associated gene CDKN1A in chemoresistance and immune infiltration of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cyclin-Depende | 2021 |
Cannabinoids in glioblastoma multiforme-hype or hope?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Cell Proliferation; Ce | 2021 |
Predictive value of MGMT promoter methylation on the survival of TMZ treated
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; | 2021 |
APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tu | 2021 |
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylat | 2021 |
The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Sequence; Brain | 2021 |
Survival impact of incidental subventricular zone irradiation in IDH-wildtype glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Humans; Lateral Ventricles; Progno | 2021 |
Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma.
Topics: Animals; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Cycle Proteins; Chemoradiotherapy; Cranioto | 2021 |
CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma.
Topics: B-Cell Lymphoma 3 Protein; Base Sequence; Binding Sites; Brain Neoplasms; CDC2 Protein Kinase; Cell | 2021 |
The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death.
Topics: Administration, Oral; Anaplastic Lymphoma Kinase; Animals; Brain Neoplasms; Carbazoles; Cell Line, T | 2021 |
MPPED2 is downregulated in glioblastoma, and its restoration inhibits proliferation and increases the sensitivity to temozolomide of glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regul | 2021 |
Adjuvant therapeutic potential of moderate hypothermia for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Glioblastoma; Humans; Hy | 2021 |
Patterns of glioblastoma treatment and survival over a 16-years period: pooled data from the German Cancer Registries.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Ne | 2021 |
Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2021 |
Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2021 |
Cancer-specific loss of
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Cell Prol | 2021 |
Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2021 |
Effects of the Anti-Tumorigenic Agent AT101 on Human Glioblastoma Cells in the Microenvironmental Glioma Stem Cell Niche.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carcinogenesis; Cell Line, T | 2021 |
Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Prot | 2021 |
Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Atlases as Topic; Brain Neoplasms; Female; Gene Expr | 2021 |
Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma.
Topics: Animals; Cell Line, Tumor; Dianhydrogalactitol; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mic | 2021 |
PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response.
Topics: Adult; Animals; Brain Neoplasms; Cell Line, Tumor; Class Ib Phosphatidylinositol 3-Kinase; Drug Resi | 2021 |
De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhib | 2021 |
Kinomic profile in patient-derived glioma cells during hypoxia reveals c-MET-PI3K dependency for adaptation.
Topics: Animals; Antioxidants; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; H | 2021 |
Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Models, Animal; Drug Administra | 2021 |
Wnt/β-catenin Antagonists: Exploring New Avenues to Trigger Old Drugs in Alleviating Glioblastoma Multiforme.
Topics: beta Catenin; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Temozolomide; Wnt Signalin | 2022 |
Dual-triggered biomimetic vehicles enable treatment of glioblastoma through a cancer stem cell therapeutic strategy.
Topics: Biomimetics; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Neoplastic Stem Cells; Temozol | 2021 |
Temozolomide Induces the Acquisition of Invasive Phenotype by O6-Methylguanine-DNA Methyltransferase (MGMT)
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Movement; Connexin 43; DNA Modifi | 2021 |
COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell C | 2021 |
Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioblastoma; Humans; Receptors, Do | 2021 |
Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2021 |
Establishment of a Novel Temozolomide Resistant Subline of Glioblastoma Multiforme Cells and Comparative Transcriptome Analysis With Parental Cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; DNA Damage; DNA Repair; Dose-Res | 2021 |
CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cell Plastic | 2021 |
EZH2 regulates the malignancy of human glioblastoma cells via modulation of Twist mRNA stability.
Topics: Brain Neoplasms; Cell Line, Tumor; Enhancer of Zeste Homolog 2 Protein; Gene Knockdown Techniques; G | 2021 |
Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study.
Topics: Biomarkers, Tumor; Glioblastoma; Humans; Mutation; Neoplasm Recurrence, Local; Prospective Studies; | 2022 |
Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Chromones; Drug | 2021 |
NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition.
Topics: beta Catenin; Cell Line, Tumor; Cell Proliferation; DNA Modification Methylases; DNA Repair Enzymes; | 2021 |
Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2021 |
Receptor-Interacting Protein 140 Enhanced Temozolomide-Induced Cellular Apoptosis Through Regulation of E2F1 in Human Glioma Cell Lines.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; E2F1 Transcription Factor; | 2022 |
[Glioblastoma].
Topics: Brain Neoplasms; Glioblastoma; Humans; Japan; Neoplasm Recurrence, Local; Temozolomide | 2021 |
A Nanoantidote Alleviates Glioblastoma Chemotoxicity without Efficacy Compromise.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; | 2021 |
Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells.
Topics: AC133 Antigen; Animals; Brain Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug De | 2021 |
Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Nucl | 2021 |
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Artificial Intell | 2021 |
Experimental design of preclinical experiments: number of PDX lines vs subsampling within PDX lines.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Mice; Research Design; Retrospective Studi | 2021 |
Chemoattractants driven and microglia based biomimetic nanoparticle treating TMZ-resistant glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Biomimetics; Cell Line, Tumor; Chemotactic Factors; Drug Resistan | 2021 |
Clinical Features and Prognostic Factors of Pediatric Glioblastoma: Report of 38 Cases.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Apraxias; Brain Neoplasms; Chemoradiotherapy, Adjuvan | 2021 |
Long non-coding RNA OIP5-AS1 inhibition upregulates microRNA-129-5p to repress resistance to temozolomide in glioblastoma cells via downregulating IGF2BP2.
Topics: Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; | 2022 |
Prediction of Glioma Stemlike Cell Infiltration in the Non-Contrast-Enhancing Area by Quantitative Measurement of Lactate on Magnetic Resonance Spectroscopy in Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2021 |
Synthesis and Characterization of a Series of Temozolomide Esters and Its Anti-glioma Study.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Esters; Glioblastoma; Glioma; | 2021 |
17β-estradiol induces temozolomide resistance through NRF2-mediated redox homeostasis in glioblastoma.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Glioblastoma; Ho | 2021 |
A Deep Dive: SIWV Tetra-Peptide Enhancing the Penetration of Nanotherapeutics into the Glioblastoma.
Topics: Animals; Cell Line, Tumor; Glioblastoma; Humans; Mice; Peptides; Polyethylene Glycols; Silicon; Suga | 2022 |
Glutathione S-Transferase M3 Is Associated with Glycolysis in Intrinsic Temozolomide-Resistant Glioblastoma Multiforme Cells.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Glutathione Transferase; Glycolysis; Huma | 2021 |
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Heterografts; Humans; Mic | 2022 |
Induction Therapy of Retinoic Acid with a Temozolomide-Loaded Gold Nanoparticle-Associated Ultrasound Effect on Glioblastoma Cancer Stem-Like Colonies.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Drug Carriers; Drug Liberation; Drug | 2021 |
Activating transcription factor 4 mediates adaptation of human glioblastoma cells to hypoxia and temozolomide.
Topics: Acetamides; Activating Transcription Factor 4; Adaptation, Physiological; Cell Death; Cell Line, Tum | 2021 |
Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling.
Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Mice; Paracrine Communication; P | 2021 |
Do elderly patients (≥ 75 years old) with glioblastoma benefit from more radical surgeries in the era of temozolomide?
Topics: Aged; Brain Neoplasms; Glioblastoma; Humans; Neurosurgical Procedures; Prognosis; Retrospective Stud | 2022 |
Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2021 |
Reply to: Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
Topics: Glioblastoma; Humans; Temozolomide | 2021 |
Therapeutic Perspective of Temozolomide Resistance in Glioblastoma Treatment.
Topics: Antineoplastic Agents, Alkylating; Drug Resistance, Neoplasm; Glioblastoma; Humans; Temozolomide | 2021 |
Oncological and functional outcomes of supratotal resection of IDH1 wild-type glioblastoma based on
Topics: Adult; Aged; Brain Neoplasms; Carbon Radioisotopes; Contrast Media; Craniotomy; Female; Glioblastoma | 2021 |
Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Exo | 2021 |
Inhibition of metabotropic glutamate receptor III facilitates sensitization to alkylating chemotherapeutics in glioblastoma.
Topics: Amino Acids; Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Cell Survival; Drug Re | 2021 |
Synergistic Effect of Gefitinib and Temozolomide on U87MG Glioblastoma Angiogenesis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Dru | 2022 |
Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling.
Topics: Adolescent; Brain Neoplasms; Glioblastoma; Humans; Methylation; Prognosis; Temozolomide; Valproic Ac | 2022 |
Autophagy inhibition reinforces stemness together with exit from dormancy of polydisperse glioblastoma stem cells.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Autophagy-Related Protein 5; Beclin-1; Cell Line, Tumo | 2021 |
Letter: Is the Stupp Protocol an Expensive and Unsustainable Standard of Care for Glioblastoma in Low- and Middle-Income Country Settings? A Call to Action!
Topics: Dacarbazine; Glioblastoma; Humans; Standard of Care; Temozolomide | 2021 |
Is the Duration of Temozolomide Predictive for Sequential Bevacizumab Treatment Responses in the Glioblastoma Multiforme Cancer Setting?
Topics: Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Female; Glioblastoma; Humans; Male; | 2021 |
Volumetric study reveals the relationship between outcome and early radiographic response during bevacizumab-containing chemoradiotherapy for unresectable glioblastoma.
Topics: Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Gadolinium; Glioblastoma; Humans; Temozolomide; Tre | 2021 |
LINC00511 facilitates Temozolomide resistance of glioblastoma cells via sponging miR-126-5p and activating Wnt/β-catenin signaling.
Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Glioblastoma; Humans; Male; Mice; Mice | 2021 |
Silencing glioblastoma networks to make temozolomide more effective.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2021 |
The protein kinase LKB1 promotes self-renewal and blocks invasiveness in glioblastoma.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation | 2022 |
Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid‑Coated Superparamagnetic Iron Oxide.
Topics: Animals; B7-H1 Antigen; Cell Line, Tumor; Contrast Media; Ferric Compounds; Glioblastoma; Humans; Li | 2021 |
Leukemia associated RUNX1T1 gene reduced proliferation and invasiveness of glioblastoma cells.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Gene | 2021 |
Effects of platinum-coexisting dopamine with X-ray irradiation upon human glioblastoma cell proliferation.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; D | 2021 |
Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic glycolysis and temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multiforme cells.
Topics: Adenosine; Aerobiosis; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Antineoplastic Agents, Alkylat | 2021 |
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothe | 2021 |
Tailoring drug co-delivery nanosystem for mitigating U-87 stem cells drug resistance.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dendrimers; Drug Resistance; Drug Resistance, Neoplasm | 2022 |
Temozolomide Drives Ferroptosis via a DMT1-Dependent Pathway in Glioblastoma Cells.
Topics: Ferroptosis; Glioblastoma; Humans; Lipid Peroxidation; Reactive Oxygen Species; Temozolomide | 2021 |
Combinatorial Effect of Temozolomide and Naringenin in Human Glioblastoma Multiforme Cell Lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tum | 2022 |
Silencing lncRNA LINC01410 suppresses cell viability yet promotes apoptosis and sensitivity to temozolomide in glioblastoma cells by inactivating PTEN/AKT pathway via targeting miR-370-3p.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Surviva | 2021 |
Cytoprotective agent troxipide-cyanine dye conjugate with cytotoxic and antiproliferative activity in patient-derived glioblastoma cell lines.
Topics: Antineoplastic Agents; Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Cell Proliferation; Cell Su | 2021 |
The Combined Treatment with Chemotherapeutic Agents and the Dualsteric Muscarinic Agonist Iper-8-Naphthalimide Affects Drug Resistance in Glioblastoma Stem Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Brain Neoplasms; | 2021 |
Alkylaminophenol and GPR17 Agonist for Glioblastoma Therapy: A Combinational Approach for Enhanced Cell Death Activity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Calcium; Caspase 3; Cell Line, Tumor; Ce | 2021 |
Proton therapy for newly diagnosed glioblastoma: more room for investigation.
Topics: Brain Neoplasms; Glioblastoma; Humans; Proton Therapy; Temozolomide | 2021 |
Answer to the comment of Hai Lu et al. regarding "Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report and review of the literature. Arch Toxicol (2016)".
Topics: Artemisinins; Artesunate; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dacarbazine; Glio | 2017 |
The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Prolif | 2017 |
MiR-223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway.
Topics: Brain Neoplasms; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Female; Glioblastoma; H | 2017 |
Tumortropic adipose-derived stem cells carrying smart nanotherapeutics for targeted delivery and dual-modality therapy of orthotopic glioblastoma.
Topics: Adipocytes; Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain Neoplas | 2017 |
Treatment strategy and IDH status improve nomogram validity in newly diagnosed GBM patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; Ch | 2017 |
Temozolomide-Mediated Apoptotic Death Is Improved by Thymoquinone in U87MG Cell Line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Brain Neoplasms; Cell Line | 2017 |
Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling.
Topics: Aged; Animals; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2017 |
Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2017 |
Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain N | 2017 |
Bax Activation Blocks Self-Renewal and Induces Apoptosis of Human Glioblastoma Stem Cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 7; Cell Cycle; Cell | 2018 |
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2017 |
Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modification Methylase | 2017 |
Primary Spinal Cord Glioblastoma Multiforme: A Retrospective Study of Patients at a Single Institution.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Female | 2017 |
Sex as a biological variable in response to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Glioblastoma; Mice; Sex Factors; Surviv | 2017 |
Influence of incidental radiation dose in the subventricular zone on survival in patients with glioblastoma multiforme treated with surgery, radiotherapy, and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2017 |
Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2017 |
Temozolomide does not influence the transcription or activity of matrix metalloproteinases 9 and 2 in glioma cell lines.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Cell Movement; Dacarbazine; Gliobla | 2017 |
Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Binding Si | 2017 |
SNORD47, a box C/D snoRNA, suppresses tumorigenesis in glioblastoma.
Topics: Adult; Aged; Animals; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transfor | 2017 |
The sustained delivery of temozolomide from electrospun PCL-Diol-b-PU/gold nanocompsite nanofibers to treat glioblastoma tumors.
Topics: Cell Line, Tumor; Dacarbazine; Drug Implants; Glioblastoma; Humans; Nanocomposites; Nanofibers; Temo | 2017 |
MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Astrocytes; Brain Neoplasms; Cell Line, Tum | 2017 |
Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Nucleus; Chemotherapy, Adjuvan | 2018 |
Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
Topics: Aminopyridines; Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
Expression and function of ABCG2 and XIAP in glioblastomas.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Su | 2017 |
Recurrence Pattern Analysis of Primary Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2017 |
EMAP-II sensitize U87MG and glioma stem-like cells to temozolomide via induction of autophagy-mediated cell death and G2/M arrest.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cytokines; Dacarbaz | 2017 |
Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling.
Topics: Animals; beta-Arrestin 1; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Diseas | 2017 |
Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study.
Topics: Adult; Aged; Aged, 80 and over; Bevacizumab; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mod | 2017 |
Cell-intrinsic, Bmal1-dependent Circadian Regulation of Temozolomide Sensitivity in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; ARNTL Transcription Factors; Cell Line, Tumor | 2017 |
Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma.
Topics: Adult; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Male; N | 2017 |
Developing an Algorithm for Optimizing Care of Elderly Patients With Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2018 |
Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Daca | 2017 |
Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chem | 2017 |
Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Su | 2017 |
MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dac | 2017 |
Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Communication; Cell Line, Tumor; Dacarbazine; Drug | 2017 |
Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; CpG Islands; Dacarbazine; DNA | 2017 |
Telodendrimers for Physical Encapsulation and Covalent Linking of Individual or Combined Therapeutics.
Topics: Acetazolamide; Carbonic Anhydrase IX; Cell Line, Tumor; Cell Survival; Dacarbazine; Dendrimers; Drug | 2017 |
A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Craniot | 2017 |
Changes in tumor cell heterogeneity after chemotherapy treatment in a xenograft model of glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Glioblastoma; Heter | 2017 |
Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2017 |
Cytotoxicity of temozolomide on human glioblastoma cells is enhanced by the concomitant exposure to an extremely low-frequency electromagnetic field (100Hz, 100G).
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Cytotoxins; Dacarbazine; Electro | 2017 |
Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Eflornit | 2017 |
Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling.
Topics: Animals; Atorvastatin; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; Disease Mode | 2017 |
Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cohort Studies; Dacarbazine; Drug Resistance, | 2017 |
CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Surviv | 2017 |
Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2017 |
High Expression of Glypican-1 Predicts Dissemination and Poor Prognosis in Glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Disease Progres | 2017 |
Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells.
Topics: Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Dose-Respons | 2018 |
Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-β1-dependent activation of Smad/ERK signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Connective | 2017 |
New strategies for cancer management: how can temozolomide carrier modifications improve its delivery?
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Drug Carriers; | 2017 |
A Novel Theranostic Strategy for
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarba | 2017 |
Liposomal temozolomide drug delivery using convection enhanced delivery.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Convection; Dacarbazine; Drug Delivery | 2017 |
Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resis | 2017 |
Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2017 |
A synthetic BMP-2 mimicking peptide induces glioblastoma stem cell differentiation.
Topics: Antineoplastic Agents; Astrocytes; Bone Morphogenetic Protein 2; Cell Differentiation; Dacarbazine; | 2017 |
[Combination Therapy with Radiation, Temozolomide, and Bevacizumab after Partial Tumor Removal in Glioblastoma Patients with Low Performance Status].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiother | 2017 |
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor | 2017 |
Glioblastoma entities express subtle differences in molecular composition and response to treatment.
Topics: Apoptosis; Astrocytoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle Checkpoi | 2017 |
Genomic profiling of long non-coding RNA and mRNA expression associated with acquired temozolomide resistance in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Resistance, | 2017 |
The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Resistance, Neopl | 2017 |
Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Carcinogenesis; Enzyme Inhibitors; Female; Glioblastoma; | 2017 |
Risk of severe acute liver injury among patients with brain cancer treated with temozolomide: a nested case-control study using the healthcore integrated research database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case | 2017 |
A polymeric temozolomide nanocomposite against orthotopic glioblastoma xenograft: tumor-specific homing directed by nestin.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Ferric Compounds; Glio | 2017 |
Perfusion of surgical cavity wall enhancement in early post-treatment MR imaging may stratify the time-to-progression in glioblastoma.
Topics: Aged; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Contrast Media; Dacarbazine; Di | 2017 |
Blocking LDHA glycolytic pathway sensitizes glioblastoma cells to radiation and temozolomide.
Topics: Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Drug; Glioblastoma; Glycol | 2017 |
FERMT3 contributes to glioblastoma cell proliferation and chemoresistance to temozolomide through integrin mediated Wnt signaling.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazin | 2017 |
Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergis | 2018 |
Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy.
Topics: Animals; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocol | 2017 |
Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Ad | 2017 |
AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma.
Topics: Animals; Brain Neoplasms; Cells, Cultured; CRISPR-Cas Systems; Dacarbazine; Dependovirus; DNA Mutati | 2017 |
Blastomycosis and Histoplasmosis in a Patient with Glioblastoma Receiving Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Blastomycosis; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazi | 2016 |
Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modi | 2017 |
Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Mismatch Repair; Drug Resistan | 2018 |
Induction of Mitochondrial Dysfunction and Oxidative Damage by Antibiotic Drug Doxycycline Enhances the Responsiveness of Glioblastoma to Chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2017 |
A search for the "Goldilocks zone" with regard to the optimal duration of adjuvant temozolomide in patients with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2017 |
Hospitalizations in elderly glioblastoma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Costs and Cost Analys | 2017 |
The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Anim | 2017 |
Phase I/II Trial of Combination of Temozolomide Chemotherapy and Immunotherapy With Fusions of Dendritic and Glioma Cells in Patients With Glioblastoma.
Topics: Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Immunotherapy; Temozolomide | 2017 |
Zika virus has oncolytic activity against glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; C | 2017 |
Wearable medical device improves survival for glioblastoma patients.
Topics: Clinical Trials, Phase III as Topic; Glioblastoma; Humans; Randomized Controlled Trials as Topic; Su | 2017 |
Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; | 2018 |
MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacar | 2017 |
Identification of WISP1 as a novel oncogene in glioblastoma.
Topics: Brain Neoplasms; CCN Intercellular Signaling Proteins; Cell Line, Tumor; Cell Movement; Cell Prolife | 2017 |
Survival improvements with adjuvant therapy in patients with glioblastoma.
Topics: Adult; Aged; Analysis of Variance; Australia; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort S | 2018 |
Stress stimuli induce cancer-stemness gene expression via Sp1 activation leading to therapeutic resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resis | 2017 |
Impact of mesenchymal stem cells' secretome on glioblastoma pathophysiology.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Culture Media, | 2017 |
HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Breaks, Doubl | 2017 |
Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2018 |
Novel nanohydrogel of hyaluronic acid loaded with quercetin alone and in combination with temozolomide as new therapeutic tool, CD44 targeted based, of glioblastoma multiforme.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Carriers; Drug Resistance, Neoplasm; Gene Expression Regu | 2018 |
CUX1 stimulates APE1 enzymatic activity and increases the resistance of glioblastoma cells to the mono-alkylating agent temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Cell Proliferation; DNA Damage; DNA | 2018 |
PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma.
Topics: Animals; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance | 2017 |
miR‑146b‑5p suppresses glioblastoma cell resistance to temozolomide through targeting TRAF6.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease-Free Survival; Drug R | 2017 |
Epidermal Growth Factor Receptor Expression Predicts Time and Patterns of Recurrence in Patients with Glioblastoma After Radiotherapy and Temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2018 |
Probing the Oncolytic and Chemosensitizing Effects of Dihydrotanshinone in an
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Proliferation; | 2017 |
Aberrant glioblastoma neovascularization patterns and their correlation with DCE-MRI-derived parameters following temozolomide and bevacizumab treatment.
Topics: Animals; Bevacizumab; Cell Line, Tumor; Cell Transformation, Neoplastic; Contrast Media; Drug Resist | 2017 |
Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.
Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Femal | 2017 |
Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Che
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Contrast Media; | 2017 |
Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; DNA Repl | 2018 |
Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; | 2017 |
Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2018 |
Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair | 2017 |
Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Cisplatin | 2018 |
Tramadol attenuates the sensitivity of glioblastoma to temozolomide through the suppression of Cx43‑mediated gap junction intercellular communication.
Topics: Analgesics, Opioid; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Communication; Cell Lin | 2018 |
FTY720 inhibits the Nrf2/ARE pathway in human glioblastoma cell lines and sensitizes glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antioxidant Response Elements; Apoptosis; Autophagy; Brain Neopla | 2017 |
Enhancement of invadopodia activity in glioma cells by sublethal doses of irradiation and temozolomide.
Topics: Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dose-Response Relationship, Drug; Glio | 2018 |
Patients Affected by Unmethylated O(6)-Methylguanine-DNA Methyltransferase Glioblastoma Undergoing Radiochemotherapy May Benefit from Moderately Dose-Escalated Radiotherapy.
Topics: Adult; Aged; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA M | 2017 |
Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarb | 2018 |
Intracellular cholesterol level regulates sensitivity of glioblastoma cells against temozolomide-induced cell death by modulation of caspase-8 activation via death receptor 5-accumulation and activation in the plasma membrane lipid raft.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caspase 8; Cell Line, Tumor; Cholesterol; Dacarbazine; | 2018 |
NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Ge | 2018 |
Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biom | 2018 |
Delivery of Exogenous miR-124 to Glioblastoma Multiform Cells by Wharton's Jelly Mesenchymal Stem Cells Decreases Cell Proliferation and Migration, and Confers Chemosensitivity.
Topics: Apoptosis; Cell Differentiation; Cell Line; Cell Movement; Cell Proliferation; Cell Survival; Cells, | 2018 |
Modelling glioblastoma tumour-host cell interactions using adult brain organotypic slice co-culture.
Topics: Aging; Animals; Antigens, CD; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Communication; Cell Pr | 2018 |
Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neop | 2018 |
MRI to MGMT: predicting methylation status in glioblastoma patients using convolutional recurrent neural networks.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Computational Biology; Dacarbazine; Databases, G | 2018 |
Anticancer activity of osmium(VI) nitrido complexes in patient-derived glioblastoma initiating cells and in vivo mouse models.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Coordin | 2018 |
Calvarium mass as the first presentation of glioblastoma multiforme: A very rare manifestation of high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Frontal Lobe; Glioblastoma; Humans; | 2018 |
Integrative analysis of rewired central metabolism in temozolomide resistant cells.
Topics: Amino Acids; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-R | 2018 |
The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Bridged-Ring Compounds; Cell Proliferation | 2017 |
Novel Targeting of Transcription and Metabolism in Glioblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain; Brain Neoplasms; Cell Lin | 2018 |
Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; DNA Da | 2017 |
Formulation and statistical optimization of intravenous temozolomide-loaded PEGylated liposomes to treat glioblastoma multiforme by three-level factorial design.
Topics: Administration, Intravenous; Animals; Brain; Dacarbazine; Drug Liberation; Glioblastoma; Liposomes; | 2018 |
Aldehyde dehydrogenase 1A3 (ALDH1A3) is regulated by autophagy in human glioblastoma cells.
Topics: Aldehyde Oxidoreductases; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, | 2018 |
High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neopla | 2018 |
Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.
Topics: Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell D | 2018 |
Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype.
Topics: AC133 Antigen; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell | 2018 |
Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; DNA-Binding Prote | 2018 |
Photon vs. proton radiochemotherapy: Effects on brain tissue volume and perfusion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cerebrova | 2018 |
Where does O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Methylation; Glioblastoma; Humans; O(6)-Meth | 2018 |
Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dose-Respo | 2018 |
Role of Radiosensitizers in Radiation Treatment of Gliomas.
Topics: Dacarbazine; Glioblastoma; Glioma; Humans; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; | 2018 |
Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Proliferation; Drug | 2018 |
Quantitative Magnetization Transfer in Monitoring Glioblastoma (GBM) Response to Therapy.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Disease Progression; Female; Gamma Rays; | 2018 |
Interference with PSMB4 Expression Exerts an Anti-Tumor Effect by Decreasing the Invasion and Proliferation of Human Glioblastoma Cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Cathepsin B; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Mov | 2018 |
FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells.
Topics: Apoptosis; Aurora Kinase B; Cell Count; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cel | 2018 |
Temozolomide affects Extracellular Vesicles Released by Glioblastoma Cells.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Extracellular Vesicles; Female; Glioblastoma; Huma | 2018 |
Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; B | 2018 |
Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; DNA Modification Methylases; | 2018 |
Transcriptional control of O
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gen | 2018 |
A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.
Topics: AC133 Antigen; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Line, Tumor; Cisp | 2018 |
Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bevacizumab; Carmu | 2018 |
Enhanced antitumor effects of radiotherapy combined local nimustine delivery rendezvousing with oral temozolomide chemotherapy in glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Combined Modality Th | 2018 |
ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Brain Neopl | 2018 |
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme.
Topics: Aged; CpG Islands; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; | 2018 |
Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients.
Topics: Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Gene Expression R | 2018 |
Characterizing the molecular mechanisms of acquired temozolomide resistance in the U251 glioblastoma cell line by protein microarray.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neop | 2018 |
XRCC3 contributes to temozolomide resistance of glioblastoma cells by promoting DNA double-strand break repair.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA Breaks, Double-Stranded; DNA Repair; DNA- | 2018 |
A Chimeric Antibody against ACKR3/CXCR7 in Combination with TMZ Activates Immune Responses and Extends Survival in Mouse GBM Models.
Topics: Animals; Antibodies, Monoclonal; Antibody Affinity; Antineoplastic Agents, Immunological; Cell Line, | 2018 |
Malignancy Index Using Intraoperative Flow Cytometry is a Valuable Prognostic Factor for Glioblastoma Treated With Radiotherapy and Concomitant Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Drug Resistance, Neoplasm; Female | 2019 |
Outlining involvement of stem cell program in regulation of O6-methylguanine DNA methyltransferase and development of temozolomide resistance in glioblastoma: An Editorial Highlight for 'Transcriptional control of O
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA; Drug Resistance, Neoplasm; Glioblastoma; Guanin | 2018 |
Distinct response to GDF15 knockdown in pediatric and adult glioblastoma cell lines.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Proliferation; Child; Ge | 2018 |
A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Comb | 2018 |
Identification of Key Candidate Proteins and Pathways Associated with Temozolomide Resistance in Glioblastoma Based on Subcellular Proteomics and Bioinformatical Analysis.
Topics: Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Computational Biology; Dacarbazine; Down-Regul | 2018 |
Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblas | 2018 |
Regulation of Integrated Stress Response Sensitizes U87MG Glioblastoma Cells to Temozolomide Through the Mitochondrial Apoptosis Pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Glioblastoma; Humans; | 2018 |
Tacrine derivatives stimulate human glioma SF295 cell death and alter important proteins related to disease development: An old drug for new targets.
Topics: Apoptosis; Caspases; Cell Cycle; Cell Line, Tumor; Dacarbazine; Drug Screening Assays, Antitumor; Ge | 2018 |
Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cell Line, Tumor; D | 2018 |
Quality of Life in Patients With Glioblastoma Treated With Tumor-Treating Fields.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Quality of Life; Temozolomide | 2018 |
Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell P | 2018 |
MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Li | 2018 |
Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.
Topics: Actin Cytoskeleton; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Cell | 2018 |
Temozolomide rechallenge in recurrent glioblastoma: when is it useful?
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Magn | 2018 |
Tumour cell dormancy as a contributor to the reduced survival of GBM patients who received standard therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Cell Movement; Cell Proliferation; Combi | 2018 |
Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Databases, Fa | 2018 |
Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 2018 |
Regulation of the oxidative balance with coenzyme Q10 sensitizes human glioblastoma cells to radiation and temozolomide.
Topics: Antioxidants; Apoptosis; Brain Neoplasms; Dacarbazine; DNA Damage; Glioblastoma; Humans; Hydrogen Pe | 2018 |
Role of Molecular Pathology in the Treatment of Anaplastic Gliomas and Glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasms; Chemoradiotherapy, Adj | 2018 |
Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma.
Topics: Angiography, Digital Subtraction; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunolo | 2018 |
Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged > 75 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasm | 2018 |
Memory and attention recovery in patients with High Grade Glioma who completed the Stupp protocol: A before-after study.
Topics: Adult; Aged; Attention; Brain Neoplasms; Cognition; Combined Modality Therapy; Dacarbazine; Female; | 2018 |
Identification of a DNA Repair-Related Multigene Signature as a Novel Prognostic Predictor of Glioblastoma.
Topics: Adenine Phosphoribosyltransferase; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2018 |
miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway.
Topics: Animals; Apoptosis; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mi | 2018 |
Effects of sequentially applied single and combined temozolomide, hydroxychloroquine and AT101 treatment in a long-term stimulation glioblastoma in vitro model.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Dacarbazine | 2018 |
miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; G | 2018 |
Improved survival of Swedish glioblastoma patients treated according to Stupp.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2018 |
A Multi-targeted Natural Flavonoid Myricetin Suppresses Lamellipodia and Focal Adhesions Formation and Impedes Glioblastoma Cell Invasiveness and Abnormal Motility.
Topics: Antineoplastic Agents; Astrocytes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Respons | 2018 |
Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents, Alkylating; | 2018 |
Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain; Central Nervous System Neoplasms; Chemoradiothera | 2018 |
Fabrication and Characterization of Chitosan-Hyaluronic Acid Scaffolds with Varying Stiffness for Glioblastoma Cell Culture.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chitosan; Glioblastoma | 2018 |
The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Move | 2018 |
Autophagy inhibition synergizes with calcium mobilization to achieve efficient therapy of malignant gliomas.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5; Calcium; Cell Line, Tumor; Chloroquine; | 2018 |
Tumor-treating fields: time for demystification.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Electric Stimulation | 2018 |
Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; beta Catenin; Binding Sites; Brain Neopla | 2018 |
High expression of a novel splicing variant of VEGF, L-VEGF144 in glioblastoma multiforme is associated with a poorer prognosis in bevacizumab treatment.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bevacizumab; Brain N | 2018 |
Efficacy of D,L-methadone in the treatment of glioblastoma in vitro.
Topics: Adult; Analgesics, Opioid; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, | 2018 |
Getting to the brain.
Topics: Animals; Antineoplastic Agents; Azepines; Blood-Brain Barrier; Brain; Brain Neoplasms; Drug Carriers | 2018 |
Clinical correlates of severe thrombocytopenia from temozolomide in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2018 |
Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cell Movement; Cell Prolif | 2019 |
Perivascular signals alter global gene expression profile of glioblastoma and response to temozolomide in a gelatin hydrogel.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line; Cell Line, Tumor; Drug Delivery Syste | 2019 |
[
Topics: Animals; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; | 2019 |
C1q/TNF-related peptide 8 (CTRP8) promotes temozolomide resistance in human glioblastoma.
Topics: Adiponectin; Antineoplastic Agents, Alkylating; Apoptosis; bcl-X Protein; Brain Neoplasms; Caspase 3 | 2018 |
Zinc-doped copper oxide nanocomposites reverse temozolomide resistance in glioblastoma by inhibiting AKT and ERK1/2.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Copper; Drug Resistance, Neoplasm; Gene Expression Re | 2018 |
Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Blood Platelets; Brain Neoplasms; Chemoradiotherapy; Female | 2019 |
LIM and SH3 protein 1 regulates cell growth and chemosensitivity of human glioblastoma via the PI3K/AKT pathway.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line, Tumor; Cell Proliferation; Cytoskeletal Pr | 2018 |
Coordinated autophagy modulation overcomes glioblastoma chemoresistance through disruption of mitochondrial bioenergetics.
Topics: Antineoplastic Agents; Autophagy; Autophagy-Related Protein 5; Brain Neoplasms; Cell Line, Tumor; Ce | 2018 |
Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Ce | 2018 |
Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug S | 2018 |
Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Apolipoproteins; Blood-Brain Barrier; Brain; Brain Neoplasms; Cel | 2018 |
Dehydroepiandrosterone Induces Temozolomide Resistance Through Modulating Phosphorylation and Acetylation of Sp1 in Glioblastoma.
Topics: Acetylation; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Dehydroepiandrosterone; DNA Damage; Dr | 2019 |
The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in patients with glioblastoma and anaplastic astrocytoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; | 2020 |
Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.
Topics: Anticoagulants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; B | 2018 |
Impact of human cytomegalovirus on glioblastoma cell viability and chemotherapy treatment.
Topics: Antineoplastic Agents; Carmustine; Cell Line, Tumor; Cell Survival; Cytomegalovirus; Gene Expression | 2018 |
Caffeine Sensitizes U87-MG Human Glioblastoma Cells to Temozolomide through Mitotic Catastrophe by Impeding G2 Arrest.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Caffeine; Cell Line, Tumor; Central Nervous System Sti | 2018 |
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Clustered Regularly Interspaced Short Palin | 2018 |
Brainstem Glioblastoma Multiforme in a Patient with NF1.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Stem; Brain Stem Neoplasms; Chemoradiot | 2018 |
Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasm | 2018 |
Pyr3 Induces Apoptosis and Inhibits Migration in Human Glioblastoma Cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazin | 2018 |
Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Glioblastoma; Hematol | 2018 |
Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Kaplan-Meier | 2018 |
Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tu | 2018 |
Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2019 |
CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth.
Topics: 5'-Nucleotidase; Adenosine; Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Move | 2019 |
MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2018 |
Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Disease-Free Survival | 2018 |
Proapoptotic effects of novel thiazole derivative on human glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Benzofurans; Brain Neoplasms; Cell Line, Tumor; DNA Damage; Doxoru | 2019 |
MIM1, the Mcl-1 - specific BH3 mimetic induces apoptosis in human U87MG glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Su | 2018 |
Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Movement; DNA Modification Methylases; DNA Repair Enzymes; D | 2018 |
Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplas | 2018 |
FoxG1 facilitates proliferation and inhibits differentiation by downregulating FoxO/Smad signaling in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Pro | 2018 |
Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Carr | 2018 |
Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cannabidiol; Cell Line, Tu | 2018 |
Achievable Central Nervous System Concentrations of the Green Tea Catechin EGCG Induce Stress in Glioblastoma Cells in Vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Catechin; Cen | 2018 |
A tension-mediated glycocalyx-integrin feedback loop promotes mesenchymal-like glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Feedback, Physiological; | 2018 |
SOX3 can promote the malignant behavior of glioblastoma cells.
Topics: Adult; Aged; Aged, 80 and over; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Pr | 2019 |
FOXO1 associated with sensitivity to chemotherapy drugs and glial-mesenchymal transition in glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Cell Adh | 2019 |
PDZ-RhoGEF Is a Signaling Effector for TROY-Induced Glioblastoma Cell Invasion and Survival.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Female; Focal Adhesion Kinase 2; Gene Exp | 2018 |
Whole-Genome Multi-omic Study of Survival in Patients with Glioblastoma Multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; DNA Copy Number Variations; DNA Methylatio | 2018 |
IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neo | 2018 |
Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: A multi-institutional collaborative study.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; DNA Methylation; DNA Modification Methylases; DNA R | 2018 |
Thioredoxin Confers Intrinsic Resistance to Cytostatic Drugs in Human Glioma Cells.
Topics: Apoptosis; Blotting, Western; Carrier Proteins; Cell Line, Tumor; Cytostatic Agents; Disulfides; Gli | 2018 |
Diagnostic utility of restriction spectrum imaging (RSI) in glioblastoma patients after concurrent radiation-temozolomide treatment: A pilot study.
Topics: Adult; Aged; Biopsy; Brain Neoplasms; Chemoradiotherapy; Diffusion Magnetic Resonance Imaging; Femal | 2018 |
Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunol | 2018 |
Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Carbonic Anhydras | 2018 |
Polyethylenimine-Spherical Nucleic Acid Nanoparticles against Gli1 Reduce the Chemoresistance and Stemness of Glioblastoma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Drug C | 2018 |
Juniperus Communis Extract Exerts Antitumor Effects in Human Glioblastomas Through Blood-Brain Barrier.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Caspase 3; Cell Cycle Checkpoints; Cell Li | 2018 |
MicroRNA-195 reverses the resistance to temozolomide through targeting cyclin E1 in glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Central Nervous System N | 2019 |
Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagosomes; Autophagy; Brain Neoplasms; | 2019 |
Tunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Cell Line, Tumor; Drug Stability; Glioblastoma; | 2018 |
Aurora kinase B siRNA-loaded lactoferrin nanoparticles potentiate the efficacy of temozolomide in treating glioblastoma.
Topics: Animals; Apoptosis; Aurora Kinase B; Blood-Brain Barrier; Cell Line, Tumor; Cell Proliferation; Cell | 2018 |
Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neopla | 2018 |
Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Compoundin | 2018 |
Loss of programmed cell death 10 activates tumor cells and leads to temozolomide-resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasm | 2019 |
Studies examining the synergy between Dihydrotanshinone and Temozolomide against MGMT+ glioblastoma cells in vitro: Predicting interactions with the blood-brain barrier.
Topics: Abietanes; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor | 2019 |
A Novel Venom-Derived Peptide for Brachytherapy of Glioblastoma: Preclinical Studies in Mice.
Topics: Animals; Brachytherapy; Brain Neoplasms; Cell Proliferation; Cell Survival; Disintegrins; Drug Syner | 2018 |
Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cel | 2019 |
Knockdown of BCL6 Inhibited Malignant Phenotype and Enhanced Sensitivity of Glioblastoma Cells to TMZ through AKT Pathway.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance | 2018 |
Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis.
Topics: Animals; Antagomirs; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; bcl-A | 2018 |
Functional analysis of protein disulfide isomerase P5 in glioblastoma cells as a novel anticancer target.
Topics: Anacardic Acids; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Membrane; Drug Scree | 2019 |
20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Cell | 2019 |
Long noncoding RNA AC003092.1 promotes temozolomide chemosensitivity through miR-195/TFPI-2 signaling modulation in glioblastoma.
Topics: Aged; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expre | 2018 |
Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers; Cerebral Blood Volume; Chemoradiotherapy | 2018 |
CNS inflammatory disorder after concurrent radiotherapy-temozolomide and nivolumab in a glioblastoma patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Chemoradiot | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic | 2019 |
BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; B | 2020 |
Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2019 |
PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma.
Topics: Adolescent; Adult; Aged; Animals; Brain Neoplasms; Cell Line, Tumor; Child; Disease Progression; Dru | 2019 |
Opening the Blood-Brain Barrier and Improving the Efficacy of Temozolomide Treatments of Glioblastoma Using Pulsed, Focused Ultrasound with a Microbubble Contrast Agent.
Topics: Acoustics; Animals; Blood-Brain Barrier; Capillaries; Claudin-5; Contrast Media; Glial Fibrillary Ac | 2018 |
Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations.
Topics: Adult; Aged; Antigens, Neoplasm; Cell Transformation, Neoplastic; Central Nervous System Neoplasms; | 2019 |
Piezoelectric barium titanate nanostimulators for the treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Barium Compounds; Blood-Brain Barrier; Brain Neoplasms | 2019 |
Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma.
Topics: Acetylation; Carrier Proteins; Cell Line, Tumor; DNA Modification Methylases; DNA Repair Enzymes; Dr | 2019 |
Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arginine; Argininosuccinate Synthase; Brain | 2018 |
Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell Movement; Cel | 2019 |
Inhibition of Cyclin D1 Expression in Human Glioblastoma Cells is Associated with Increased Temozolomide Chemosensitivity.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Prolife | 2018 |
Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2018 |
The HIF‑1α/miR‑224‑3p/ATG5 axis affects cell mobility and chemosensitivity by regulating hypoxia‑induced protective autophagy in glioblastoma and astrocytoma.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Autophagy; Autophagy-Related Protein | 2019 |
Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients.
Topics: Age Factors; Chemoradiotherapy; Databases, Genetic; DNA Methylation; DNA Modification Methylases; DN | 2018 |
MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1.
Topics: 3' Untranslated Regions; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regul | 2019 |
Combination of Biochanin A and Temozolomide Impairs Tumor Growth by Modulating Cell Metabolism in Glioblastoma Multiforme.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Prolifera | 2019 |
Combined Applications of Repurposed Drugs and Their Detrimental Effects on Glioblastoma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cel | 2019 |
Isofuranodiene synergizes with temozolomide in inducing glioma cells death.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Su | 2019 |
Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
Conventionally fractionated stereotactic radiotherapy (CFRT) in combination with dose-dense temozolomide (TMZ) in relapsed malignant glioma: A case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Female; Gliobl | 2019 |
Optimal extent of resection for glioblastoma according to site, extension, and size: a population-based study in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Female; Glioblastoma; Human | 2019 |
Medroxyprogesterone effects on colony growth, autophagy and mitochondria of C6 glioma cells are augmented with tibolone and temozolomide: Cell kinetic and electron microscopical studies with a broad review of the literature.
Topics: Autophagy; Brain Neoplasms; Glioblastoma; Glioma; Humans; Medroxyprogesterone; Medroxyprogesterone A | 2019 |
Increased Expression of GRP78 Correlates with Adverse Outcome in Recurrent Glioblastoma Multiforme Patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemoradiotherap | 2020 |
MCCK1 enhances the anticancer effect of temozolomide in attenuating the invasion, migration and epithelial-mesenchymal transition of glioblastoma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neo | 2019 |
Tri-block copolymer nanoparticles modified with folic acid for temozolomide delivery in glioblastoma.
Topics: Animals; Biological Transport; Cell Line, Tumor; Drug Carriers; Folic Acid; Glioblastoma; Nanopartic | 2019 |
Synergistic anticancer effect of acteoside and temozolomide-based glioblastoma chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; | 2019 |
Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; A | 2019 |
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dose-Response R | 2019 |
Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy.
Topics: Antineoplastic Agents, Alkylating; Cholesterol; Dacarbazine; Dimyristoylphosphatidylcholine; Drug In | 2019 |
The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; C | 2019 |
Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2018 |
A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia.
Topics: AC133 Antigen; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Cell Hyp | 2019 |
Targeted and Synergic Glioblastoma Treatment: Multifunctional Nanoparticles Delivering Verteporfin as Adjuvant Therapy for Temozolomide Chemotherapy.
Topics: Animals; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Chemotherapy, Adj | 2019 |
pH as a potential therapeutic target to improve temozolomide antitumor efficacy : A mechanistic modeling study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Computer Simulation; Cytoplasm | 2019 |
Unexpectedly low rates of neuropsychiatric adverse effects associated with mefloquine repurposed for the treatment of glioblastoma.
Topics: Glioblastoma; Humans; Mefloquine; Memantine; Metformin; Temozolomide | 2019 |
Reply to Unexpectedly low rates of neuropsychiatric adverse effects associated with mefloquine repurposed for the treatment of glioblastoma.
Topics: Glioblastoma; Humans; Mefloquine; Memantine; Metformin; Temozolomide | 2019 |
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; B7-H1 Antigen; Brain Neoplasms; Cell Line, Tumor; Gene Expression | 2019 |
Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort Stu | 2019 |
Dissociation Between 11C-Methionine-Positron Emission Tomography and Gadolinium-Enhanced Magnetic Resonance Imaging in Longitudinal Features of Glioblastoma After Postoperative Radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast | 2019 |
The Impact of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2019 |
A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Lin | 2019 |
The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Gli | 2019 |
A Simple Three-dimensional Hydrogel Platform Enables
Topics: Aged; Animals; Carcinoma, Renal Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; | 2019 |
Glioblastoma Recurrence and the Role of O
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; DNA Meth | 2019 |
Effects of solvent used for fabrication on drug loading and release kinetics of electrosprayed temozolomide-loaded PLGA microparticles for the treatment of glioblastoma.
Topics: Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Humans; Polylactic Acid-Polyglycolic Ac | 2019 |
Improving survival in molecularly selected glioblastoma.
Topics: Adult; Brain Neoplasms; Combined Modality Therapy; DNA Modification Methylases; DNA Repair Enzymes; | 2019 |
Lomustine-temozolomide combination efficacious in newly diagnosed glioblastoma.
Topics: Brain Neoplasms; Clinical Trials, Phase III as Topic; DNA Methylation; DNA Modification Methylases; | 2019 |
Aberrant Active cis-Regulatory Elements Associated with Downregulation of RET Finger Protein Overcome Chemoresistance in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Division; Cell Line, Tumor; DNA-Binding | 2019 |
Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF).
Topics: Aged; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; DNA Modifi | 2019 |
What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Electric Stimul | 2019 |
Ex vivo-expanded highly purified natural killer cells in combination with temozolomide induce antitumor effects in human glioblastoma cells in vitro.
Topics: Apoptosis; Coculture Techniques; Glioblastoma; Humans; Immunity, Cellular; K562 Cells; Killer Cells, | 2019 |
High density is a property of slow-cycling and treatment-resistant human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Self Renewal; Drug Resista | 2019 |
HERC3-Mediated SMAD7 Ubiquitination Degradation Promotes Autophagy-Induced EMT and Chemoresistance in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Drug Resis | 2019 |
Tubastatin A, an inhibitor of HDAC6, enhances temozolomide‑induced apoptosis and reverses the malignant phenotype of glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mes | 2019 |
The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells.
Topics: Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplas | 2019 |
Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors.
Topics: Brain Neoplasms; Carbon; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Drug Sy | 2019 |
Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell P | 2019 |
Combined treatment with 2'-hydroxycinnamaldehyde and temozolomide suppresses glioblastoma tumorspheres by decreasing stemness and invasiveness.
Topics: Acrolein; Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzoates; Cell Line, Tumor; Cell | 2019 |
D,L-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro.
Topics: Adult; Aged; Analgesics, Opioid; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Ce | 2019 |
A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasm | 2019 |
Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
Topics: Animals; Apoptosis; Biological Transport; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell | 2019 |
Boswellic acid has anti-inflammatory effects and enhances the anticancer activities of Temozolomide and Afatinib, an irreversible ErbB family blocker, in human glioblastoma cells.
Topics: Afatinib; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Boswellia; Card | 2019 |
Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dose-Response Rela | 2019 |
Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Plasticity; Drug Resistance, Neopla | 2019 |
How to integrate immunotherapy into standard of care in glioblastoma.
Topics: Brain Neoplasms; Glioblastoma; Humans; Immunotherapy; Standard of Care; T-Lymphocytes; Temozolomide | 2019 |
Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Damage; Gene Knoc | 2019 |
Assessment of Early Therapeutic Response to Nitroxoline in Temozolomide-Resistant Glioblastoma by Amide Proton Transfer Imaging: A Preliminary Comparative Study with Diffusion-weighted Imaging.
Topics: Algorithms; Amides; Animals; Brain Neoplasms; Diffusion Magnetic Resonance Imaging; Glioblastoma; Gl | 2019 |
Long-term glioblastoma survival following recovery from cytomegalovirus colitis: A case report.
Topics: Aged; Brain Neoplasms; Chemoradiotherapy; Colitis; Cytomegalovirus Infections; Female; Glioblastoma; | 2019 |
Curcumin Promotes Connexin 43 Degradation and Temozolomide-Induced Apoptosis in Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Connexin 43; Curcumin; Glioblastoma; Humans; Proteolys | 2019 |
Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, | 2019 |
Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2020 |
miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell | 2019 |
Bioengineering fluorescent virus-like particle/RNAi nanocomplexes act synergistically with temozolomide to eradicate brain tumors.
Topics: Animals; Apolipoproteins E; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Cell Movement; C | 2019 |
Modulation of Antioxidant Potential with Coenzyme Q10 Suppressed Invasion of Temozolomide-Resistant Rat Glioma
Topics: Animals; Antioxidants; Brain Neoplasms; Drug Resistance, Neoplasm; Glioblastoma; Humans; Male; Mice; | 2019 |
Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; DNA Breaks, Double-Stranded; DNA-B | 2019 |
Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment.
Topics: Animals; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Cell Line, Tumor; Cell Plastici | 2019 |
Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Brain | 2019 |
Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; CRISPR-Cas Systems; Drug Resistance, | 2019 |
Synergistic effect of arsenic trioxide, vismodegib and temozolomide on glioblastoma.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Casp | 2019 |
Low perfusion compartments in glioblastoma quantified by advanced magnetic resonance imaging and correlated with patient survival.
Topics: Adult; Aged; Chemoradiotherapy; Cohort Studies; Diffusion Magnetic Resonance Imaging; Female; Gliobl | 2019 |
Role of multidimensional assessment of frailty in predicting outcomes in older patients with glioblastoma treated with adjuvant concurrent chemo-radiation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2019 |
Furanodienone overcomes temozolomide resistance in glioblastoma through the downregulation of CSPG4-Akt-ERK signalling by inhibiting EGR1-dependent transcription.
Topics: Adult; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chondroitin Sulfate Proteoglycan | 2019 |
Provocative Question: Should Ketogenic Metabolic Therapy Become the Standard of Care for Glioblastoma?
Topics: Brain Neoplasms; Glioblastoma; Glucose; Glutamine; Humans; Ketone Bodies; Mitochondria; Standard of | 2019 |
The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Auranofin; Brain Neoplasms; Cap | 2019 |
Bioengineered scaffolds for 3D culture demonstrate extracellular matrix-mediated mechanisms of chemotherapy resistance in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Ext | 2020 |
In vitro anti-cancer efficacy of multi-functionalized magnetite nanoparticles combining alternating magnetic hyperthermia in glioblastoma cancer cells.
Topics: Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Folic Acid; Glioblastoma; Humans; Hypertherm | 2019 |
Ovatodiolide inhibits the oncogenicity and cancer stem cell-like phenotype of glioblastoma cells, as well as potentiate the anticancer effect of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Cell Line, Tumor; Diterpene | 2019 |
R406 elicits anti-Warburg effect via Syk-dependent and -independent mechanisms to trigger apoptosis in glioma stem cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Adhesion; Drug Resistance, Neoplasm | 2019 |
Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell | 2019 |
Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2019 |
Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study.
Topics: Antineoplastic Agents, Alkylating; Combined Modality Therapy; Cost-Benefit Analysis; Disease-Free Su | 2019 |
Lnc-TALC promotes O
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; DNA Modificati | 2019 |
Downregulation of miR‑186 promotes the proliferation and drug resistance of glioblastoma cells by targeting Twist1.
Topics: 3' Untranslated Regions; Adult; Aged; Antagomirs; Brain Neoplasms; Case-Control Studies; Cell Line, | 2019 |
Pam
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Sur | 2020 |
Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
Topics: Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, N | 2019 |
Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survi | 2019 |
Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasm | 2019 |
Anticancer effects of a non-narcotic opium alkaloid medicine, papaverine, in human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Heterografts; HM | 2019 |
Application of Electric Cell-Substrate Impedance Sensing to Investigate the Cytotoxic Effects of Andrographolide on U-87 MG Glioblastoma Cell Migration and Apoptosis.
Topics: Apoptosis; Biosensing Techniques; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival | 2019 |
Susceptibility and Tumor Size Changes During the Time Course of Standard Treatment in Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Progression; Female; Gliobl | 2019 |
Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2019 |
Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model.
Topics: Antineoplastic Agents, Alkylating; Bayes Theorem; Cost-Benefit Analysis; Glioblastoma; Health Care C | 2019 |
Survival trends in glioblastoma and association with treating facility volume.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Databases, Fact | 2019 |
A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses to chemoradiotherapy.
Topics: Bioprinting; Brain; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Drug Combinations; Drug Ev | 2019 |
Analysis of peritumoral hyperintensity on pre-operative T2-weighted MR images in glioblastoma: Additive prognostic value of Minkowski functionals.
Topics: Aged; Biomarkers, Tumor; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Re | 2019 |
Cerebral aspergillosis within new tumour site presents as incidental new brain lesion in patient receiving temozolomide for glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Aspergillosis; Brain Abscess; Brain Neoplasms; Combined Modality | 2019 |
Oleuropein modulates glioblastoma miRNA pattern different from
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Cell Line, Tu | 2019 |
Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Follow-Up Studi | 2019 |
Bufothionine Promotes Apoptosis via Triggering ER Stress and Synergizes with Temozolomide in Glioblastoma Multiforme Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Proliferation; Drug | 2019 |
Impact of extremely low-frequency electromagnetic field (100 Hz, 100 G) exposure on human glioblastoma U87 cells during Temozolomide administration.
Topics: Antineoplastic Agents; Apoptosis; Calcium; Carcinogenesis; Cell Differentiation; Cell Line, Tumor; C | 2019 |
Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; En | 2020 |
Aggressive Progression in Glioblastoma Cells through Potentiated Activation of Integrin α5β1 by the Tenascin-C-Derived Peptide TNIIIA2.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cel | 2019 |
Angiopep-2 Modified Cationic Lipid-Poly-Lactic-Co-Glycolic Acid Delivery Temozolomide and DNA Repair Inhibitor Dbait to Achieve Synergetic Chemo-Radiotherapy Against Glioma.
Topics: Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; DNA Repair; Glioblastoma; Glioma; Glycolates; | 2019 |
Topics: Adult; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Humans; Neoplastic Stem Cells; | 2019 |
Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor | 2019 |
microRNA-181d associated with the methylation status of the MGMT gene in Glioblastoma multiforme cancer stem cells submitted to treatments with ionizing radiation and temozolomide.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Brain Neoplasms; Brazil; DNA Methylation; DNA Modificati | 2019 |
MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Drug Resistance, Neoplasm; Fe | 2019 |
Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside.
Topics: Adjuvants, Immunologic; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoc | 2020 |
[Lomustine and temozolomide in combination with radiotherapy : New treatment option for patients with MGMT promoter methylated Glioblastoma].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Gli | 2019 |
Human organotypic brain slice culture: a novel framework for environmental research in neuro-oncology.
Topics: Adult; Aged; Aged, 80 and over; Astrocytes; Brain; Brain Neoplasms; Cell Movement; Cell Proliferatio | 2019 |
Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme.
Topics: Aged, 80 and over; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Fata | 2019 |
The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Combined Modality Therapy; Female; Glio | 2019 |
ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2019 |
Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma.
Topics: Animals; Benzazepines; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Dru | 2019 |
Codelivery of paclitaxel and temozolomide through a photopolymerizable hydrogel prevents glioblastoma recurrence after surgical resection.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Combinations; Drug Delivery | 2019 |
Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calcium-Calmodulin-Dependent Protein Kina | 2020 |
Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide.
Topics: Animals; beta-Cyclodextrins; Cell Line, Tumor; Chitosan; Drug Delivery Systems; Drug Resistance, Neo | 2019 |
Human bone marrow-derived mesenchymal stem cell-secreted exosomes overexpressing microRNA-34a ameliorate glioblastoma development via down-regulating MYCN.
Topics: Animals; Base Sequence; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; D | 2019 |
Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromobox Protein Homolog 5; Cytoplasmi | 2019 |
Ellagic Acid Enhances Antitumor Efficacy of Temozolomide in an in vitro Glioblastoma Model.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Lin | 2020 |
Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell | 2019 |
Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells.
Topics: Amphiregulin; Antibodies, Blocking; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neop | 2019 |
TOPK inhibits autophagy by phosphorylating ULK1 and promotes glioma resistance to TMZ.
Topics: Autophagy; Autophagy-Related Protein-1 Homolog; Cell Line, Tumor; Drug Resistance, Neoplasm; Gliobla | 2019 |
MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells.
Topics: Animals; Brain Neoplasms; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Dacarbazine; For | 2013 |
Reversing the Warburg effect as a treatment for glioblastoma.
Topics: Adenosine Triphosphate; Animals; Annexin A5; Antineoplastic Agents; Antineoplastic Agents, Alkylatin | 2013 |
Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression.
Topics: Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Magnetic Resonance | 2013 |
The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Biomarkers, Tumor; Brain Neoplasms; Che | 2013 |
Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevac | 2013 |
Propolis changes the anticancer activity of temozolomide in U87MG human glioblastoma cell line.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apitherapy; Biological Transport; Cell Lin | 2013 |
Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; | 2013 |
Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2013 |
Steroid management in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Fem | 2013 |
Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptos | 2013 |
Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbaz | 2013 |
Leptomeningeal and intramedullary metastases of glioblastoma multiforme in a patient reoperated during adjuvant radiochemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Combined Modality T | 2013 |
Molecular analysis of a recurrent glioblastoma treated with bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevaci | 2014 |
Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.
Topics: Antineoplastic Agents; Benzimidazoles; Blotting, Western; Cell Line, Tumor; Cell Survival; Chemoradi | 2013 |
Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy.
Topics: Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Dacarbazine; DNA Methylation; Female; Gli | 2013 |
Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotti | 2013 |
Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomide-induced senescence in glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Ataxia Telangiectas | 2013 |
Valproic acid use during radiation therapy for glioblastoma associated with improved survival.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combin | 2013 |
Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, | 2013 |
Pediatric glioblastoma with oligodendroglioma component: aggressive clinical phenotype with distinct molecular characteristics.
Topics: Brain Neoplasms; Chemoradiotherapy; Child; Dacarbazine; Fatal Outcome; Glioblastoma; Humans; Male; M | 2013 |
Increased subventricular zone radiation dose correlates with survival in glioblastoma patients after gross total resection.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neopl | 2013 |
Cerebellar glioblastoma multiforme: a retrospective study of 28 patients at a single institution.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brai | 2013 |
Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carbon; Cell Proliferation; Da | 2013 |
Temozolomide in combination with carbon ion or photon irradiation in glioblastoma multiforme cell lines - does scheduling matter?
Topics: Carbon; Cell Cycle; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; O(6)-Met | 2013 |
Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Brain Neoplasms; Caspase 12; Caspase 3; | 2013 |
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.
Topics: Antibodies; Antibody Specificity; Antineoplastic Agents, Alkylating; B-Cell Activating Factor; Cance | 2013 |
Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Caveolin 1; Cell Line, Tumor; Dacarbazine; D | 2013 |
Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade.
Topics: Amyloid Precursor Protein Secretases; Animals; Cell Proliferation; Cyclic S-Oxides; Dacarbazine; Dru | 2013 |
The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Brain Neopl | 2013 |
Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Case-Control Studies; Chemo | 2013 |
Isotretinoin maintenance therapy for glioblastoma: a retrospective review.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans | 2014 |
Defining pseudoprogression in glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Chemoradi | 2013 |
Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2013 |
Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Apoptotic | 2013 |
Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Lymphom | 2013 |
TROY (TNFRSF19) promotes glioblastoma survival signaling and therapeutic resistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Cell Line, Tumor; Cell Movement; Cell Prolife | 2013 |
Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA (Cytosine-5-)-Methyltransfe | 2013 |
Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2013 |
Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell | 2013 |
Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dif | 2013 |
microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Autophagy; Autophagy-Related Protein 7; Cell Line, Tumor; Dacarba | 2013 |
Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; D | 2014 |
The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA M | 2013 |
Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Separation; Cell Survival; Dacarbazine; Drug Resistance, Neo | 2013 |
MicroRNA-125b inhibitor sensitizes human primary glioblastoma cells to chemotherapeutic drug temozolomide on invasion.
Topics: Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; In Vitr | 2013 |
Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irra | 2013 |
LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; DN | 2013 |
miR-125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3.
Topics: Animals; Cell Line, Tumor; Central Nervous System Neoplasms; Dacarbazine; Gene Expression Regulation | 2014 |
Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Brain Neoplasms; Dacarbazin | 2013 |
Antitumor activity of (2E,5Z)-5-(2-hydroxybenzylidene)-2-((4-phenoxyphenyl)imino) thiazolidin-4-one, a novel microtubule-depolymerizing agent, in U87MG human glioblastoma cells and corresponding mouse xenograft model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Division; Cell Proliferation; Dacar | 2013 |
Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cel | 2013 |
Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model.
Topics: Acridine Orange; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cu | 2013 |
Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; ATP Bindi | 2013 |
Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms | 2013 |
Cytoplasmic TRADD confers a worse prognosis in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor | 2013 |
Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2014 |
The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Transformed; C | 2013 |
The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States.
Topics: Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Dacarbazine; Gliob | 2013 |
Chemoirradiation for glioblastoma multiforme: the national cancer institute experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2013 |
An automated system for detecting nonadherence in laboratory testing and monitoring for myelosuppression in patients receiving self-administered oral chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neopla | 2013 |
Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Brain Neoplasms; Carmustine; Cell | 2013 |
Stupp-treated glioblastoma accompanied by EBV-positive primary CNS lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Dac | 2014 |
Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Checkpo | 2013 |
Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytosine Deaminase; Dacarb | 2013 |
Meningeal seeding from glioblastoma multiforme treated with radiotherapy and temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; | 2017 |
Glioblastoma management in the temozolomide era: have we improved outcome?
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2013 |
Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Che | 2013 |
Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biom | 2013 |
Glioblastoma occurring after the surgical resection of a craniopharyngioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Clinical Protocols; Cra | 2014 |
APO010, a synthetic hexameric CD95 ligand, induces death of human glioblastoma stem-like cells.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarba | 2013 |
Quercetin increases the efficacy of glioblastoma treatment compared to standard chemoradiotherapy by the suppression of PI-3-kinase-Akt pathway.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; Dacarb | 2013 |
Time trends in glioblastoma multiforme survival: the role of temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2013 |
Mitochondrial protein ATPase family, AAA domain containing 3A correlates with radioresistance in glioblastoma.
Topics: Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; ATPases Associated with Diverse Cellul | 2013 |
Temozolomide and irradiation combined treatment-induced Nrf2 activation increases chemoradiation sensitivity in human glioblastoma cells.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regul | 2014 |
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosi | 2013 |
A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regime.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradio | 2014 |
Biliverdin reductase plays a crucial role in hypoxia-induced chemoresistance in human glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Ce | 2013 |
Silencing of Hsp27 and Hsp72 in glioma cells as a tool for programmed cell death induction upon temozolomide and quercetin treatment.
Topics: Apoptosis; Astrocytoma; Autophagy; Caspase 12; Caspase 3; Caspase 9; Cell Line, Tumor; Cytochromes c | 2013 |
High expression of leptin receptor leads to temozolomide resistance with exhibiting stem/progenitor cell features in gliobalastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Lin | 2013 |
Factors associated with a higher rate of distant failure after primary treatment for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Modificati | 2014 |
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dac | 2013 |
Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Treatment results of glioblastoma during the last 30 years in a single institute.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2013 |
Effectiveness of adjuvant temozolomide treatment in patients with glioblastoma.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazine; Female; G | 2013 |
Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Female | 2014 |
Employment following chemoradiotherapy in glioblastoma: a prospective case series.
Topics: Adolescent; Adult; Aged; Brain Damage, Chronic; Brain Neoplasms; Chemoradiotherapy; Combined Modalit | 2014 |
Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine | 2013 |
Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradio | 2014 |
Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Antineoplastic Agents, Alkylating; | 2013 |
Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence.
Topics: Adaptation, Physiological; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Resistance, Neoplasm; Gen | 2013 |
Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results.
Topics: Adolescent; Adult; Aged; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Feasibility Studie | 2013 |
NETRIN-4 protects glioblastoma cells FROM temozolomide induced senescence.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cellular Senescence; Dacarbazine; Dose-Response | 2013 |
Is there pseudoprogression in secondary glioblastomas?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chromo | 2013 |
Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Comb | 2014 |
Temozolomide-related acute lymphoblastic leukemia with translocation (4;11)(q21;q23) in a glioblastoma patient.
Topics: Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Cytogenetic Analysis; Dacarbazine; | 2014 |
Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; Hu | 2014 |
Response of primary glioblastoma cells to therapy is patient specific and independent of cancer stem cell phenotype.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Chem | 2014 |
JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.
Topics: Anthracenes; Antineoplastic Agents, Alkylating; Blotting, Western; Dacarbazine; DNA Modification Met | 2014 |
Lobarstin enhances chemosensitivity in human glioblastoma T98G cells.
Topics: Antineoplastic Agents; Base Sequence; Benzofurans; Brain Neoplasms; Cell Line, Tumor; Comet Assay; D | 2013 |
[Results of postoperative radiochemotherapy of glioblastoma multiforme].
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; Disea | 2013 |
[Our experience with targeted therapy in glioblastoma multiforme].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2013 |
EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Epidermal Growth Factor; ErbB Receptors; Gene Expres | 2015 |
Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Blood-Brain Barrier; Catalytic Domain; Cell Line, T | 2014 |
Concomitant viral and bacterial encephalitis after temozolomide for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Encephalitis, Viral; Glioblastoma; | 2014 |
A fatal case of acute interstitial pneumonia (AIP) in a woman affected by glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Blood Gas Analysis; Brain Neoplasms; Bronchoalveolar Lavage | 2014 |
Improved hippocampal dose with reduced margin radiotherapy for glioblastoma multiforme.
Topics: Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Dac | 2014 |
Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Notificatio | 2014 |
Hyperdiploid tumor cells increase phenotypic heterogeneity within Glioblastoma tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Proliferation; Daca | 2014 |
Cool-1-mediated inhibition of c-Cbl modulates multiple critical properties of glioblastomas, including the ability to generate tumors in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Carmustine; Cell Line, Tumor; Cell Pr | 2014 |
Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2014 |
Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2014 |
Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2014 |
The adherens junction-associated protein 1 is a negative transcriptional regulator of MAGEA2, which potentiates temozolomide-induced apoptosis in GBM.
Topics: Adherens Junctions; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Brain | 2014 |
EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Com | 2014 |
Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; | 2013 |
Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Models, Animal; | 2014 |
Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Asparagine; Aspartate-Ammonia | 2014 |
Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Artemisinins; Artesunate; Cell Line, Tumor; Cell Proliferation; Ce | 2014 |
Marked functional improvement after combined chemoradiotherapy for cervical spine glioblastoma causing quadriparesis in an adolescent.
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkyl | 2014 |
Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Ex | 2014 |
Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Models, Animal; DNA Modification Me | 2014 |
Bevacizumab in glioblastoma--still much to learn.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Dacarbazin | 2014 |
Outcome of conventional treatment and prognostic factor in elderly glioblastoma patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Che | 2014 |
Post-operative management of primary glioblastoma multiforme in patients over 60 years of age.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Che | 2013 |
The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Dacarbazine; Drug | 2014 |
The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Azacitidine; Cell Line, Tumor; CpG Islands; Cytosine; Dacarbazine | 2014 |
miR-181 subunits enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeleton remodeling in glioblastoma cells.
Topics: Actins; Antineoplastic Agents, Alkylating; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Mo | 2014 |
Patterns of care and survival of glioblastoma patients: a comparative study between 2004 and 2008 in Lyon, France.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab | 2014 |
Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; CpG Islands; Dacarbazine; DNA Methylation; Drug | 2014 |
Polish natural bee honeys are anti-proliferative and anti-metastatic agents in human glioblastoma multiforme U87MG cell line.
Topics: Animals; Antineoplastic Agents; Bees; Biological Products; Cell Line, Tumor; Cell Proliferation; Dac | 2014 |
Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Transcription Factors; Brain Neop | 2014 |
Odds of death after glioblastoma diagnosis in the United States by chemotherapeutic era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Ne | 2014 |
Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blotting, Western; Chemoradiother | 2014 |
In vivo chemical exchange saturation transfer imaging allows early detection of a therapeutic response in glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Mice; Mice, SCID | 2014 |
The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation.
Topics: Apoptosis; Azepines; Cell Proliferation; Dacarbazine; Glioblastoma; Humans; Protein Kinase Inhibitor | 2014 |
miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Cell Transformation, Neoplastic; Dacarbazine; | 2014 |
ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.
Topics: Acridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Ca | 2014 |
Relationship between survival and increased radiation dose to subventricular zone in glioblastoma is controversial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2014 |
Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Coloring Agents; Connexin 43; Dacarbazine; Drug Re | 2014 |
Fractionated radiotherapy is the main stimulus for the induction of cell death and of Hsp70 release of p53 mutated glioblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Dacarba | 2014 |
Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevac | 2014 |
First use of (18)F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Dacarbazine; Glioblastoma; Huma | 2014 |
microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Drug Resistan | 2014 |
Combined EGFR and autophagy modulation impairs cell migration and enhances radiosensitivity in human glioblastoma cells.
Topics: Autophagy; Autophagy-Related Protein 7; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Clone Cell | 2014 |
Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioblastoma; Humans; Iron; | 2014 |
Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemorad | 2015 |
Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide.
Topics: Acylation; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chitosan; Dacarbazine; Drug Synergis | 2014 |
Upregulation of NHE1 protein expression enables glioblastoma cells to escape TMZ-mediated toxicity via increased H⁺ extrusion, cell migration and survival.
Topics: Acid-Base Equilibrium; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; Biological | 2014 |
Glioblastoma: If this is the "Temozolomide Era" Where is the Evidence?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Evidence-Based Medicine; Glioblasto | 2014 |
Glioblastoma treatment in the elderly in the temozolomide therapy era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Coho | 2014 |
Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Prolife | 2014 |
Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor | 2014 |
Experimental study of combined therapy for malignant glioma.
Topics: Animals; Animals, Outbred Strains; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2014 |
Progranulin promotes Temozolomide resistance of glioblastoma by orchestrating DNA repair and tumor stemness.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cell Movement; Cell | 2015 |
Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Line, Tumor; Checkpoint Kinase 1; | 2014 |
A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; D | 2014 |
Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2014 |
Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Epithelial | 2014 |
Elderly patients aged 65-75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined M | 2014 |
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Benzimidazoles; Brain Neoplasms; Cell Line, Tumor; Dacar | 2014 |
β-elemene inhibits stemness, promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Blotting, Western; Cell Differentiation | 2014 |
YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
Topics: Adipokines; Animals; Antigens, Neoplasm; Biomarkers, Tumor; Cell Line, Tumor; Chitinase-3-Like Prote | 2014 |
β-Elemene inhibits proliferation through crosstalk between glia maturation factor β and extracellular signal‑regulated kinase 1/2 and impairs drug resistance to temozolomide in glioblastoma cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Curcuma; Dac | 2014 |
The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cranial Irradi | 2014 |
miR-125b controls apoptosis and temozolomide resistance by targeting TNFAIP3 and NKIRAS2 in glioblastomas.
Topics: Apoptosis; Cell Line, Tumor; Dacarbazine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Glioblast | 2014 |
Quercetin sensitizes human glioblastoma cells to temozolomide in vitro via inhibition of Hsp27.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Dacarbazine; | 2014 |
Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Fem | 2014 |
Molecular targeting of TRF2 suppresses the growth and tumorigenesis of glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinogenesis; Cell Differentiation; C | 2014 |
NMR as evaluation strategy for cellular uptake of nanoparticles.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Ferric Compounds; Glioblastoma; Go | 2014 |
Bevacizumab as secondline treatment of glioblastoma - worth the effort?
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasm | 2014 |
Identification of temozolomide resistance factors in glioblastoma via integrative miRNA/mRNA regulatory network analysis.
Topics: Carrier Proteins; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gene Regulatory Networks | 2014 |
Hyperoxia resensitizes chemoresistant glioblastoma cells to temozolomide through unfolded protein response.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation | 2014 |
A topical matter: toxic epidermal necrolysis.
Topics: Acetaminophen; Analgesics, Opioid; Anti-Inflammatory Agents; Anticonvulsants; Antiemetics; Antineopl | 2014 |
3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Biomarkers, Tumor; Brain Neoplasms; C | 2014 |
Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab | 2014 |
miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferat | 2014 |
Analyzing temozolomide medication errors: potentially fatal.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarba | 2014 |
Treatment-related Acute Myeloid Leukaemia After Temozolomide for Glioblastoma Multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Leuke | 2014 |
Survival outcomes of giant cell glioblastoma: institutional experience in the management of 20 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Pr | 2014 |
Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; | 2014 |
Temozolomide induces the production of epidermal growth factor to regulate MDR1 expression in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; Cell Line | 2014 |
Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma.
Topics: Absorbable Implants; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neopla | 2015 |
Radio-chemotherapy with temozolomide in elderly patients with glioblastoma. A mono-institutional experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2014 |
Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain | 2014 |
Effects of single or combined treatments with radiation and chemotherapy on survival and danger signals expression in glioblastoma cell lines.
Topics: Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Dacarbazine; Glioblastoma; HMGB1 Protein | 2014 |
ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents.
Topics: Age Factors; Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Cel | 2014 |
Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Femal | 2014 |
Treatment of poorly differentiated glioma using a combination of monoclonal antibodies to extracellular connexin-43 fragment, temozolomide, and radiotherapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neopl | 2014 |
RIST: a potent new combination therapy for glioblastoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; | 2015 |
RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell | 2014 |
Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: single-center experience with 201 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brachytherapy; Brain | 2014 |
Cilengitide in glioblastoma: when did it fail?
Topics: Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; | 2014 |
Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Chemoradiotherapy; Coho | 2014 |
The butterfly effect on glioblastoma: is volumetric extent of resection more effective than biopsy for these tumors?
Topics: Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain; Brain Neoplasms; Dacarbazine; Female; Glio | 2014 |
Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Dac | 2014 |
SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2014 |
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Artesunate; Auran | 2014 |
Ficus carica latex prevents invasion through induction of let-7d expression in GBM cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Surviv | 2015 |
Glioblastoma recurrence patterns after radiation therapy with regard to the subventricular zone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2014 |
DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Cohort Studies | 2014 |
A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease | 2015 |
Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells.
Topics: Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cadherins; Cell Line, Tum | 2014 |
Asiatic acid induces endoplasmic reticulum stress and apoptotic death in glioblastoma multiforme cells both in vitro and in vivo.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; E | 2015 |
A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Brain Neoplasms; Cell Death; Cell Line, Tumor; Ceramide | 2014 |
Inhibition of Na+/K+-ATPase induces hybrid cell death and enhanced sensitivity to chemotherapy in human glioblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Calcium; Cell Line, Tumor; Dacarbazine; Drug Resi | 2014 |
The interaction of bee products with temozolomide in human diffuse astrocytoma, glioblastoma multiforme and astroglia cell lines.
Topics: Adult; Animals; Astrocytes; Astrocytoma; Bees; Cell Line, Tumor; Dacarbazine; Fatty Acids; Glioblast | 2014 |
Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2014 |
Inhibition of JNK potentiates temozolomide-induced cytotoxicity in U87MG glioblastoma cells via suppression of Akt phosphorylation.
Topics: Antineoplastic Agents, Alkylating; bcl-Associated Death Protein; Cell Line, Tumor; Dacarbazine; Glio | 2014 |
N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Cell Prolifer | 2015 |
A co-culture model with brain tumor-specific bioluminescence demonstrates astrocyte-induced drug resistance in glioblastoma.
Topics: Astrocytes; Brain Neoplasms; Cell Compartmentation; Cell Count; Cell Line, Tumor; Cell Survival; Coc | 2014 |
Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2014 |
Pine (Pinus morrisonicola Hayata) needle extracts sensitize GBM8901 human glioblastoma cells to temozolomide by downregulating autophagy and O(6)-methylguanine-DNA methyltransferase expression.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Sy | 2014 |
KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis.
Topics: Animals; Apoptosis; Arsenites; Dacarbazine; DNA Damage; Drug Synergism; Glioblastoma; Humans; Mice; | 2014 |
Improvement in treatment results of glioblastoma over the last three decades and beneficial factors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Gli | 2015 |
RRAD promotes EGFR-mediated STAT3 activation and induces temozolomide resistance of malignant glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Nucleus; Cell Transformation, Neoplastic; | 2014 |
Hispidulin enhances the anti-tumor effects of temozolomide in glioblastoma by activating AMPK.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, | 2015 |
Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Ce | 2014 |
Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells.
Topics: Apoptosis; Biomarkers, Tumor; Carrier Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Dacarbazine; | 2014 |
Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2015 |
Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain; Brain Neo | 2015 |
Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.
Topics: Aniline Compounds; Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Protein | 2015 |
Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain N | 2015 |
Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Proliferation; Cell | 2015 |
Primary glioblastoma of the trigeminal nerve root entry zone: case report.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Combined Modality Therapy; Cranial Nerve | 2015 |
Synergistic Anti-Cancer Effects of Icariin and Temozolomide in Glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; | 2015 |
Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.
Topics: Antineoplastic Agents, Alkylating; Autoantibodies; Cancer Vaccines; Combined Modality Therapy; Dacar | 2015 |
MGMT methylation in glioblastoma: tale of the tail.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Re | 2015 |
Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member | 2014 |
Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2014 |
Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.
Topics: Adenosine A1 Receptor Agonists; Adenosine A2 Receptor Agonists; Apoptosis; Brain Neoplasms; Cell Dif | 2014 |
Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; D | 2014 |
Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Chemical and Drug Induced Liver | 2014 |
Knockdown of CDC2 expression inhibits proliferation, enhances apoptosis, and increases chemosensitivity to temozolomide in glioblastoma cells.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; CDC2 Protein Kina | 2015 |
Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antirheumatic Agents; Apoptosis Regulatory Proteins; Aut | 2014 |
Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms | 2014 |
Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Br | 2015 |
LRIG1 improves chemosensitivity through inhibition of BCL-2 and MnSOD in glioblastoma.
Topics: Adult; Aged; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Gene Knockdown T | 2015 |
Treatment results and outcome in elderly patients with glioblastoma multiforme--a retrospective single institution analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Modality Therapy; | 2015 |
Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature.
Topics: Aged; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Databases, Genetic; Female; Gene Expression Pr | 2015 |
Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.
Topics: Antineoplastic Agents, Alkylating; Antipsychotic Agents; Apoptosis; Benzodiazepines; Blotting, Weste | 2015 |
Glioblastoma multiforme and hepatitis B: do the right thing(s).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Hepatitis B; Hepatiti | 2014 |
miR-155 Regulates Glioma Cells Invasion and Chemosensitivity by p38 Isforms In Vitro.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Gene K | 2015 |
Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survi | 2015 |
Anticancer potential and mechanism of action of mango ginger (Curcuma amada Roxb.) supercritical CO₂ extract in human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carbon Dioxide; Cell Line, | 2015 |
Histone H3 phosphorylation in GBM: a new rational to guide the use of kinase inhibitors in anti-GBM therapy.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Glioblastoma; Histones; Humans; Indoles; Ma | 2015 |
Tamoxifen in combination with temozolomide induce a synergistic inhibition of PKC-pan in GBM cell lines.
Topics: Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Gliob | 2015 |
Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Gl | 2015 |
Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2015 |
Effects of hnRNP A2/B1 Knockdown on Inhibition of Glioblastoma Cell Invasion, Growth and Survival.
Topics: Brain Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Dr | 2016 |
Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporte | 2015 |
Outcome of salvage treatment for recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2015 |
Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferat | 2015 |
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.
Topics: Animals; Blood-Brain Barrier; Cell Cycle Proteins; Dacarbazine; Disease Models, Animal; DNA Damage; | 2015 |
Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Combined | 2015 |
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkyla | 2015 |
p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regula | 2015 |
Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chitosan; Dacarbazine | 2015 |
The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cel | 2015 |
Elderly patients with glioblastoma multiforme treated with concurrent temozolomide and standard- versus abbreviated-course radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2015 |
The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Growth Processes; Cell Li | 2015 |
Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Epithelial-Mesenc | 2015 |
Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy, Needle; Brain Neoplasms; Chemoth | 2015 |
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Huma | 2015 |
EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.
Topics: Administration, Metronomic; Adult; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Ne | 2015 |
Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
Topics: AC133 Antigen; Antigens, CD; Biomarkers, Tumor; Brain Neoplasms; Cell Proliferation; Dacarbazine; Ge | 2015 |
Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Azacitidine; Biocompa | 2015 |
Temozolomide nanoparticles for targeted glioblastoma therapy.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug | 2015 |
A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gene Expression; Glioblastoma; Homeodomai | 2015 |
Elimination of cancer stem-like cells and potentiation of temozolomide sensitivity by Honokiol in glioblastoma multiforme cells.
Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Biphenyl Compounds; | 2015 |
Post-surgical therapeutic approaches to glioblastoma patients submitted to biopsy (BA) or "partial" resection (PR): the possibilities to treat also them without renunciations. Study from the Brescia Neuro-Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Middl | 2015 |
Dedifferentiation of patient-derived glioblastoma multiforme cell lines results in a cancer stem cell-like state with mitogen-independent growth.
Topics: beta Catenin; Blotting, Western; Cell Dedifferentiation; Cell Line, Tumor; Cell Proliferation; Cell | 2015 |
Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogen | 2015 |
LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member | 2015 |
The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells.
Topics: ADAM Proteins; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Cell Separation; Cell Surv | 2015 |
[Radiation and temozolomide therapy].
Topics: Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease Progression; Glioblastoma | 2015 |
Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazin | 2015 |
Epithelial-to-mesenchymal transition in paired human primary and recurrent glioblastomas.
Topics: Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Epithelial-Mesenchymal Transition | 2015 |
The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2015 |
Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Benzylamines; Brain Neoplasms; Chemokine | 2015 |
Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.
Topics: Adenylate Kinase; Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Division; Cell Line, Tumor; D | 2015 |
MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype.
Topics: Adult; Antineoplastic Agents, Alkylating; Asian People; Biomarkers, Tumor; Brain Neoplasms; China; C | 2015 |
Demethoxycurcumin was prior to temozolomide on inhibiting proliferation and induced apoptosis of glioblastoma stem cells.
Topics: Apoptosis; Caspase 3; Cell Proliferation; Curcumin; Dacarbazine; Diarylheptanoids; Glioblastoma; Hum | 2015 |
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2015 |
miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase.
Topics: Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Gene Express | 2015 |
The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine | 2015 |
Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Topics: Amino Acids; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevaciz | 2015 |
The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neopla | 2015 |
Feasibility of the EORTC/NCIC Trial Protocol in a Neurosurgical Outpatient Unit: The Case for Neurosurgical Neuro-Oncology.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2015 |
Risk factors for glioblastoma therapy associated complications.
Topics: Age Factors; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Cohort Studies; Da | 2015 |
SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Brain Neoplasm | 2015 |
Combination of the multipotent mesenchymal stromal cell transplantation with administration of temozolomide increases survival of rats with experimental glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Models, | 2015 |
Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplas | 2015 |
miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; | 2015 |
The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs-disulfiram and ritonavir.
Topics: Antineoplastic Agents; Dacarbazine; Disulfiram; Glioblastoma; Humans; Interleukin-18; Ritonavir; Tem | 2015 |
Long-term Results of a Survey of Prolonged Adjuvant Treatment with Temozolomide in Patients with Glioblastoma (SV3 Study).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; He | 2015 |
Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2015 |
Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells.
Topics: Adenosine A3 Receptor Antagonists; Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Apopto | 2015 |
Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2015 |
Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, | 2015 |
Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Brain Neoplasms; Dacarbazine; De | 2015 |
A Model to Predict the Feasibility of Concurrent Chemoradiotherapy With Temozolomide in Glioblastoma Multiforme Patients Over Age 65.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2017 |
[Perampanel in the treatment of a patient with glioblastoma multiforme without IDH1 mutation and without MGMT promotor methylation].
Topics: Alkylating Agents; Brain Neoplasms; Dacarbazine; Epilepsies, Partial; Excitatory Amino Acid Antagoni | 2015 |
Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Dacarbazine; DNA Modificat | 2015 |
Down regulation of Akirin-2 increases chemosensitivity in human glioblastomas more efficiently than Twist-1.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Caspase 3; Caspase 7; CD11b Antigen; | 2015 |
Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma?
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Ne | 2015 |
Ca2+-Activated IK K+ Channel Blockade Radiosensitizes Glioblastoma Cells.
Topics: Animals; Calcium; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; F | 2015 |
Resveratrol Inhibits the Invasion of Glioblastoma-Initiating Cells via Down-Regulation of the PI3K/Akt/NF-κB Signaling Pathway.
Topics: Animals; Cell Adhesion; Cell Line, Tumor; Cell Survival; Dacarbazine; Down-Regulation; Glioblastoma; | 2015 |
TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neopla | 2015 |
Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Celecoxib; Chemoradiotherapy; Comor | 2015 |
Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antineoplas | 2015 |
Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle Proteins; | 2015 |
β-elemene enhances both radiosensitivity and chemosensitivity of glioblastoma cells through the inhibition of the ATM signaling pathway.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Repair; Drug Synergis | 2015 |
[A pleural transudate with a 0 g/L protein level].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Catheters, | 2015 |
Brain Stem and Entire Spinal Leptomeningeal Dissemination of Supratentorial Glioblastoma Multiforme in a Patient during Postoperative Radiochemotherapy: Case Report and Review of the Literatures.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Brain Stem Neoplasms; Chemoradiotherapy; Cisplatin; D | 2015 |
Hypercellularity Components of Glioblastoma Identified by High b-Value Diffusion-Weighted Imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Dac | 2015 |
Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice.
Topics: Animals; Cell Division; Cell Line; Cell Line, Tumor; Dacarbazine; Down-Regulation; Endothelial Cells | 2015 |
The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pr | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Colorectal Neoplasms; Dacarbazine; Disease-Free | 2015 |
Management of glioblastoma in Victoria, Australia (2006-2008).
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cohort Studies; Dacarbazine; Female | 2015 |
A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2015 |
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasm | 2015 |
Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Dacarbazine; Gene Expression | 2015 |
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain; Brai | 2015 |
An image guided small animal radiation therapy platform (SmART) to monitor glioblastoma progression and therapy response.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Co | 2015 |
PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/β-catenin signaling pathway.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Cell Movement; Cell Survival; Chromones; | 2015 |
[Exceptional metastasis of glioblastoma].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Gl | 2015 |
In vitro and in vivo effect of human lactoferrin on glioblastoma growth.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Proliferation; Dacarbazine; Drug Therapy, Combinati | 2015 |
Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Carriers; Drug Liberation; Glioblastom | 2016 |
Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B; Binding, | 2015 |
Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma.
Topics: Adult; Aged; Chemoradiotherapy; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repai | 2015 |
Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells.
Topics: Brain Neoplasms; Chondroitin Sulfate Proteoglycans; Dacarbazine; Decorin; Glioblastoma; Humans; Kera | 2015 |
Induction of microRNA-146a is involved in curcumin-mediated enhancement of temozolomide cytotoxicity against human glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Curcumin; D | 2015 |
MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Decanoic Acids | 2015 |
miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosi | 2015 |
Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Alkaloids; Antineoplastic Agents, Alkylating; Brain Neoplasms; Contr | 2015 |
Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbazine | 2015 |
Diagnosis and Management of Spinal Metastasis of Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2015 |
Growth-inhibitory and chemosensitizing effects of microRNA-31 in human glioblastoma multiforme cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; Glioblastom | 2015 |
Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarba | 2015 |
BC3EE2,9B, a synthetic carbazole derivative, upregulates autophagy and synergistically sensitizes human GBM8901 glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents; Autophagy; Brain Neoplasms; Carbazoles; Cell Cycle Checkpoints; Cell Line, Tu | 2015 |
Metformin influences progression in diabetic glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Glucose; Brain; | 2015 |
Spatiotemporal Evolution of the Primary Glioblastoma Genome.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Glioma; Humans; Isoci | 2015 |
Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; D | 2015 |
Smac mimetic-induced upregulation of interferon-β sensitizes glioblastoma to temozolomide-induced cell death.
Topics: Apoptosis; Caspases; Cell Death; Dacarbazine; Glioblastoma; Humans; Interferon-beta; Intracellular S | 2015 |
Dual loading miR-218 mimics and Temozolomide using AuCOOH@FA-CS drug delivery system: promising targeted anti-tumor drug delivery system with sequential release functions.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Lin | 2015 |
Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apopto | 2015 |
Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Topics: Afatinib; Brain Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Co | 2015 |
Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Comb | 2015 |
A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor | 2015 |
Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Differentiation; Cell | 2015 |
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2015 |
Timing of Adjuvant Radiotherapy in Glioblastoma Patients: A Single-Institution Experience With More Than 400 Patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers; Biopsy; Brain Neoplasms; Combined Modali | 2016 |
Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Su | 2015 |
c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA-Binding Proteins; DNA | 2015 |
The radiosensitivity index predicts for overall survival in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Fem | 2015 |
Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic | 2016 |
Low-Dose DMC Significantly Enhances the Effect of TMZ on Glioma Cells by Targeting Multiple Signaling Pathways Both In Vivo and In Vitro.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2015 |
Clinical, Radiographic, and Pathologic Findings in Patients Undergoing Reoperation Following Radiation Therapy and Temozolomide for Newly Diagnosed Glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2017 |
Resveratrol sensitizes glioblastoma-initiating cells to temozolomide by inducing cell apoptosis and promoting differentiation.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Differentiation; Cell Line, | 2016 |
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2015 |
miRNA-182 and the regulation of the glioblastoma phenotype - toward miRNA-based precision therapeutics.
Topics: Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Dacarbazine; Gen | 2015 |
Heterogeneous glioblastoma cell cross-talk promotes phenotype alterations and enhanced drug resistance.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Adhesion; Cell Cycle; Cell Dif | 2015 |
APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Surviva | 2015 |
Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain N | 2015 |
Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth | 2015 |
Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem | 2015 |
Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumo | 2015 |
Connexin 43 Inhibition Sensitizes Chemoresistant Glioblastoma Cells to Temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomimetic Materials; Brain Neoplasms; Cell | 2016 |
Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.
Topics: Antineoplastic Agents, Alkylating; Bone Morphogenetic Protein 7; Cell Proliferation; Cell Survival; | 2015 |
MIR517C inhibits autophagy and the epithelial-to-mesenchymal (-like) transition phenotype in human glioblastoma through KPNA2-dependent disruption of TP53 nuclear translocation.
Topics: Adult; Aged; alpha Karyopherins; Animals; Autophagy; Cadherins; Cell Line, Tumor; Cell Movement; Dac | 2015 |
Nanoparticle-Delivered Antisense MicroRNA-21 Enhances the Effects of Temozolomide on Glioblastoma Cells.
Topics: Antineoplastic Agents, Alkylating; Antisense Elements (Genetics); Brain Neoplasms; Caspase 3; Cell L | 2015 |
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2015 |
Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carm | 2016 |
Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells.
Topics: Antiemetics; Antineoplastic Agents, Alkylating; Apoptosis; Aprepitant; Brain Neoplasms; Cell Prolife | 2016 |
Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Che | 2016 |
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimid | 2016 |
Co-expression of Cytoskeletal Protein Adducin 3 and CD133 in Neurospheres and a Temozolomide-resistant Subclone of Glioblastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Calmodul | 2015 |
SRPX2 Enhances the Epithelial-Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Dacarbazine; Drug Resistance, Neoplasm; Epithelial | 2016 |
Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Modifica | 2016 |
Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplas | 2016 |
Multiple resections and survival of recurrent glioblastoma patients in the temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2016 |
High-grade glioma in children and adolescents: a single-center experience.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astro | 2016 |
Polymer Nanocomposites Based Thermo-Sensitive Gel for Paclitaxel and Temozolomide Co-Delivery to Glioblastoma Cells.
Topics: Animals; Cell Line, Tumor; Dacarbazine; Drug Carriers; Glioblastoma; Humans; Nanocomposites; Paclita | 2015 |
Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Ad | 2016 |
Downregulation of TRAP1 sensitizes glioblastoma cells to temozolomide chemotherapy through regulating metabolic reprogramming.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Down-Regulation; Glioblastoma; HSP | 2016 |
In Vitro Validation of Intratumoral Modulation Therapy for Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chem | 2016 |
Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2016 |
Current trends in the management of glioblastoma in a French University Hospital and associated direct costs.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Cost | 2016 |
Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.
Topics: Antibodies; Antineoplastic Agents, Alkylating; B-Cell Activating Factor; B-Lymphocytes, Regulatory; | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Beva | 2015 |
SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cytokine TWEAK; | 2016 |
Involvement of DDX6 gene in radio- and chemoresistance in glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; DEAD-box RNA Helicases; Dr | 2016 |
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2016 |
Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
Topics: Animals; Astrocytes; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; Drug Resi | 2016 |
Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brai | 2016 |
Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemothera | 2016 |
Temozolomide-induced biliary ductopenia: a case report.
Topics: Antineoplastic Agents, Alkylating; Bile Duct Diseases; Bile Ducts, Intrahepatic; Chemoradiotherapy; | 2016 |
Residual low ADC and high FA at the resection margin correlate with poor chemoradiation response and overall survival in high-grade glioma patients.
Topics: Area Under Curve; Astrocytoma; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Magneti | 2016 |
Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Ant | 2016 |
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; D | 2016 |
Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; Dacarbazin | 2016 |
MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Female; Glioblastom | 2016 |
BIRC3 is a novel driver of therapeutic resistance in Glioblastoma.
Topics: Animals; Baculoviral IAP Repeat-Containing 3 Protein; Brain Neoplasms; Cell Line, Tumor; Dacarbazine | 2016 |
Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carmustine; C | 2016 |
Temozolomide-loaded PLGA nanoparticles to treat glioblastoma cells: a biophysical and cell culture evaluation.
Topics: Biophysical Phenomena; Cell Line, Tumor; Cell Survival; Dacarbazine; Dose-Response Relationship, Dru | 2016 |
SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Dacarbazine; Dr | 2016 |
Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model.
Topics: Animals; Apoptosis; Benzimidazoles; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Disease Models | 2016 |
Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biom | 2016 |
Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methyl | 2016 |
Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarb | 2016 |
Combined inhibition of vascular endothelial growth factor receptor signaling with temozolomide enhances cytotoxicity against human glioblastoma cells via downregulation of Neuropilin-1.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Survival; Cinnamates; Dacarbazine; DNA Met | 2016 |
The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Dacarbazine; | 2016 |
The Error-Prone DNA Polymerase κ Promotes Temozolomide Resistance in Glioblastoma through Rad17-Dependent Activation of ATR-Chk1 Signaling.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; | 2016 |
Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins.
Topics: Acetylation; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Chromatin Immunoprecipi | 2016 |
Adaptive Immune Response to and Survival Effect of Temozolomide- and Valproic Acid-induced Autophagy in Glioblastoma.
Topics: Adaptive Immunity; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplas | 2016 |
Suppressing H19 Modulates Tumorigenicity and Stemness in U251 and U87MG Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; C | 2016 |
Does valproic acid affect tumor growth and improve survival in glioblastomas?
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Prol | 2016 |
Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Shape; Cell Survival; Cell Transformation, | 2016 |
Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; D | 2016 |
Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Copper; Dacarbazine; Disease Mode | 2016 |
Pneumocystis jirovecii pneumonia complicating the progress of a patient with glioblastoma multiforme receiving temozolomide.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothera | 2016 |
Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma.
Topics: Biomarkers, Tumor; Dacarbazine; Disease Progression; DNA Methylation; Gene Expression Regulation, Ne | 2016 |
c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma.
Topics: Animals; Cell Hypoxia; Cell Movement; Cell Proliferation; Dacarbazine; Drug Resistance, Neoplasm; En | 2016 |
A Retrospective Comparative Study of Concomitant Chemoradiotherapy followed by Adjuvant Temozolomide Versus Radiotherapy Alone In Newly Diagnosed Glioblastoma Multiforme - An Experience at Radium Institute, Patna Medical College and Hospital, India.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Da | 2016 |
MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Da | 2016 |
Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience.
Topics: Anisotropy; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Blood Volume; Choline; Crea | 2016 |
Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating Cells.
Topics: 5'-Nucleotidase; Animals; Brain Neoplasms; Carcinogenesis; Cell Cycle Checkpoints; Cell Death; Cell | 2016 |
Pseudo progression identification of glioblastoma with dictionary learning.
Topics: Chemoradiotherapy; Dacarbazine; Diffusion Magnetic Resonance Imaging; Female; Glioblastoma; Humans; | 2016 |
CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Class Ia Phosphatidylinositol 3-Kinase; Dacarbaz | 2016 |
Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzopyrans; Brain Neoplasms; Caspase 3; Cell Line, Tumor | 2016 |
Persistent bone marrow depression following short-term treatment with temozolomide.
Topics: Aged; Anemia, Aplastic; Bone Marrow Diseases; Bone Marrow Failure Disorders; Brain Neoplasms; Dacarb | 2016 |
Protein Markers Predict Survival in Glioma Patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Glioblastom | 2016 |
Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Disease Mode | 2017 |
Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Dacarbazine; Drug Carri | 2016 |
NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Brain Neoplasms; Cell Line, T | 2016 |
Accelerated hyperfractionation plus temozolomide in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chil | 2016 |
Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era: A National Cancer Database Analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combine | 2016 |
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2016 |
Clonal evolution of glioblastoma under therapy.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Proliferation; Clonal Ev | 2016 |
Long noncoding RNA RP11-838N2.4 enhances the cytotoxic effects of temozolomide by inhibiting the functions of miR-10a in glioblastoma cell lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2016 |
ER stress in temozolomide-treated glioblastomas interferes with DNA repair and induces apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumo | 2016 |
Connection between Proliferation Rate and Temozolomide Sensitivity of Primary Glioblastoma Cell Culture and Expression of YB-1 and LRP/MVP.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gene Expression | 2016 |
Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cranial Irradiation; Da | 2017 |
Synergistic increase in efficacy of a combination of 2-deoxy-D-glucose and cisplatin in normoxia and hypoxia: switch from autophagy to apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; bcl-2-Associated X Protein; Blotting, Western; Cell Hyp | 2016 |
Role of irradiation for patients over 80 years old with glioblastoma: a retrospective cohort study.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Cranial Irrad | 2016 |
Sulfasalazine intensifies temozolomide cytotoxicity in human glioblastoma cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytotoxins; Dacarbazine; Drug Screening Assays, | 2016 |
Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Breaks, Double-Stranded; DNA Modificati | 2016 |
Temozolomide induces the expression of the glioma Big Potassium (gBK) ion channel, while inhibiting fascin-1 expression: possible targets for glioma therapy.
Topics: Antineoplastic Agents, Alkylating; Carrier Proteins; Cell Line, Tumor; Cell Movement; Dacarbazine; G | 2016 |
Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Carbazoles; Cell Pr | 2017 |
Expression of dynein, cytoplasmic 2, heavy chain 1 (DHC2) associated with glioblastoma cell resistance to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cytoplasmic Dyneins; Dacarbazine; Dise | 2016 |
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemorad | 2017 |
OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Topics: Acetanilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood- | 2016 |
Combined delivery of temozolomide and the thymidine kinase gene for treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Combined Modality Thera | 2017 |
Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Bevacizumab; Brain Neoplasms; Dacarbazine; Diseas | 2016 |
Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Volume; Brain Neoplasms; Cerebrova | 2017 |
Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy.
Topics: Animals; Antimalarials; Artemisinins; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; | 2016 |
Cyclin D1 Co-localizes with Beclin-1 in Glioblastoma Recurrences: A Clue to a Therapy-induced, Autophagy-mediated Degradative Mechanism?
Topics: Adult; Apoptosis; Autophagy; Beclin-1; Cell Line, Tumor; Cyclin D1; Dacarbazine; Drug Resistance, Ne | 2016 |
miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle Proteins; Cell Pr | 2017 |
The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2016 |
Glioblastoma in the elderly - How do we choose who to treat?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Attitude of Health Personnel; Brain Neop | 2016 |
Antidepressant drugs can modify cytotoxic action of temozolomide.
Topics: Antidepressive Agents; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Division; | 2017 |
Analysis of Treatment Tolerance and Factors Associated with Overall Survival in Elderly Patients with Glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adju | 2016 |
HMGA1 silencing reduces stemness and temozolomide resistance in glioblastoma stem cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2016 |
Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Brain Neoplasm | 2017 |
Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biphenyl Compounds; Brain Neoplasms; Cell Line, Tumor; | 2016 |
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cohort Studies; Combin | 2016 |
Tailored Nanoparticle Codelivery of antimiR-21 and antimiR-10b Augments Glioblastoma Cell Kill by Temozolomide: Toward a "Personalized" Anti-microRNA Therapy.
Topics: Cell Cycle; Cell Line, Tumor; Cell Survival; Dacarbazine; Glioblastoma; Humans; Lactic Acid; MicroRN | 2016 |
Inhibition of STAT3 enhances the radiosensitizing effect of temozolomide in glioblastoma cells in vitro and in vivo.
Topics: Animals; Annexin A5; Apoptosis; Benzoic Acid; Cell Line, Tumor; Cell Movement; Dacarbazine; DNA Modi | 2016 |
Proton beam therapy with concurrent chemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Ka | 2016 |
Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Aspartic Acid; Bevacizumab; Brain Neoplasms; Chol | 2016 |
Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification | 2016 |
Molecular dissection of the valproic acid effects on glioma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatin; Dacarbazine; Decision Support Syst | 2016 |
Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associat | 2016 |
Reversibility of glioma stem cells' phenotypes explains their complex in vitro and in vivo behavior: Discovery of a novel neurosphere-specific enzyme, cGMP-dependent protein kinase 1, using the genomic landscape of human glioma stem cells as a discovery t
Topics: Animals; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prolif | 2016 |
Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dose-Response Relation | 2016 |
Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cho | 2017 |
Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A).
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbaz | 2016 |
Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; C | 2016 |
Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Case-Control Studies; | 2016 |
Survival Trends in Elderly Patients with Glioblastoma in the United States: a Population-based Study.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Kapla | 2016 |
Histone Deacetylase Inhibitor RGFP109 Overcomes Temozolomide Resistance by Blocking NF-κB-Dependent Transcription in Glioblastoma Cell Lines.
Topics: Acetylation; Active Transport, Cell Nucleus; Antineoplastic Agents, Alkylating; Apoptosis; Benzamide | 2016 |
MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Dacarbazi | 2016 |
Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance.
Topics: Amino Acid Transport System y+; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell | 2016 |
The regrowth kinetic of the surviving population is independent of acute and chronic responses to temozolomide in glioblastoma cell lines.
Topics: Animals; Cell Count; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Glioblastoma; | 2016 |
Permeability Surface Area Product Using Perfusion Computed Tomography Is a Valuable Prognostic Factor in Glioblastomas Treated with Radiotherapy Plus Concomitant and Adjuvant Temozolomide.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant | 2017 |
Specific Inhibition of DNMT3A/ISGF3γ Interaction Increases the Temozolomide Efficiency to Reduce Tumor Growth.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Proliferation; Cell Survival; Cells, Cultured; Daca | 2016 |
Inhibition of carbonic anhydrase IX in glioblastoma multiforme.
Topics: Acetazolamide; Antineoplastic Agents; Brain Neoplasms; Carbonic Anhydrase Inhibitors; Carbonic Anhyd | 2016 |
Reciprocal regulation of the cholinic phenotype and epithelial-mesenchymal transition in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Survival; Choline; Choline Kinase; Dacarbazine; Energy Metab | 2016 |
MiRNA203 suppresses the expression of protumorigenic STAT1 in glioblastoma to inhibit tumorigenesis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Pr | 2016 |
A Novel Computer-Assisted Approach to evaluate Multicellular Tumor Spheroid Invasion Assay.
Topics: Algorithms; Animals; Computer Simulation; Dacarbazine; Enzyme Inhibitors; Glioblastoma; Glioma; High | 2016 |
Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Ne | 2017 |
IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; | 2016 |
Comparative effectiveness of radiotherapy with vs. without temozolomide in older patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Combine | 2017 |
[RITA combined with temozolomide inhibits the proliferation of human glioblastoma U87 cells].
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Furans; Glioblastoma; H | 2016 |
Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Mov | 2016 |
MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Meth | 2016 |
DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DN | 2017 |
Pulsed Electromagnetic Field with Temozolomide Can Elicit an Epigenetic Pro-apoptotic Effect on Glioblastoma T98G Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Bioreactors; Cell Proliferation; Dacarbazine; Electrom | 2016 |
Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferat | 2016 |
MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2016 |
The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultu | 2017 |
Cutaneous invasive aspergillosis in a patient with glioblastoma receiving long-term temozolomide and corticosteroid therapy.
Topics: Adrenal Cortex Hormones; Aged; Aspergillosis; Brain Neoplasms; Combined Modality Therapy; Dacarbazin | 2017 |
Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Central Nervo | 2017 |
pH-Sensitive O6-Benzylguanosine Polymer Modified Magnetic Nanoparticles for Treatment of Glioblastomas.
Topics: Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Guanosine; Humans; Hydrogen-Ion Concen | 2017 |
Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Brain Neoplasms; Cell Lin | 2017 |
Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherap | 2017 |
Microtubule actin cross-linking factor 1, a novel target in glioblastoma.
Topics: Animals; Axin Protein; beta Catenin; Dacarbazine; Drug Resistance, Neoplasm; Genetic Heterogeneity; | 2017 |
Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Autoimmunity; Brain Neoplasms; Chemical and Dru | 2016 |
BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53.
Topics: Animals; Basic-Leucine Zipper Transcription Factors; Dacarbazine; DNA Modification Methylases; DNA R | 2016 |
Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cognition Disorders; D | 2016 |
CBX Chromodomain Inhibition Enhances Chemotherapy Response in Glioblastoma Multiforme.
Topics: Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dacarbaz | 2016 |
Prognostic parameters and outcome after re-irradiation for progressive glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Radiosur | 2017 |
Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chitinase-3-Like Protein 1; Da | 2017 |
Comments regarding "Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature".
Topics: Artemisinins; Artesunate; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dacarbazine; Glio | 2017 |
Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.
Topics: 3' Untranslated Regions; Antagomirs; Antineoplastic Agents, Alkylating; Base Sequence; Brain Neoplas | 2017 |
Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA | 2017 |
Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.
Topics: Alleles; Amino Acid Substitution; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, | 2017 |
Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway.
Topics: Acrylamides; Anthracenes; Apoptosis; Caspases; Cell Line, Tumor; Cell Survival; Cytokines; Dacarbazi | 2016 |
Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Aurintricarboxylic Acid; Brain Neoplasms; Cell Line, Tum | 2017 |
The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2017 |
Impact of Including Peritumoral Edema in Radiotherapy Target Volume on Patterns of Failure in Glioblastoma following Temozolomide-based Chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Coh | 2017 |
MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Cell Cycle; Cell P | 2017 |
High-dose Neural Stem Cell Radiation May Not Improve Survival in Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Contra | 2017 |
The Effect of Ascorbic Acid over the Etoposide- and Temozolomide-Mediated Cytotoxicity in Glioblastoma Cell Culture: A Molecular Study.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Br | 2018 |
Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Dose-Respon | 2017 |
The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Fr | 2017 |
Radicol, a Novel Trinorguaiane-Type Sesquiterpene, Induces Temozolomide-Resistant Glioma Cell Apoptosis via ER Stress and Akt/mTOR Pathway Blockade.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; Dictamnus; Drug Resistance | 2017 |
Heat Shock Factor 1 Depletion Sensitizes A172 Glioblastoma Cells to Temozolomide via Suppression of Cancer Stem Cell-Like Properties.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regula | 2017 |
miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA.
Topics: 3' Untranslated Regions; Aged; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azep | 2017 |
FoxO3a induces temozolomide resistance in glioblastoma cells via the regulation of β-catenin nuclear accumulation.
Topics: Apoptosis; beta Catenin; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarb | 2017 |
Role of
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA | 2017 |
Rutin increases the cytotoxicity of temozolomide in glioblastoma via autophagy inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Cell | 2017 |
Transtentorial dissemination of optic nerve glioblastoma: case report.
Topics: Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Glioblastoma; Humans; Male; Neur | 2018 |
Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarb | 2017 |
Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair | 2017 |
Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, | 2009 |
The role of temozolomide in newly-diagnosed glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Temozolomide; Treatment Outcom | 2008 |
Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells.
Topics: Adenoviridae; Animals; Autophagy; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Genetic Therapy; G | 2008 |
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytes; Carb | 2008 |
Temozolomide preferentially depletes cancer stem cells in glioblastoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; C | 2008 |
A novel tool to analyze MRI recurrence patterns in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblas | 2008 |
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplas | 2008 |
A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; ATP Binding Cassette | 2009 |
Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Convection; | 2008 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezo | 2008 |
DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2008 |
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2008 |
TMZ-BioShuttle--a reformulated temozolomide.
Topics: Antineoplastic Agents, Alkylating; Carrier Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferatio | 2008 |
The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Lineage; Combined Modality Therapy; Dacarba | 2008 |
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2009 |
MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dac | 2009 |
[Alveolo-interstitial pneumonia due to Temozolamide].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Bronchoalveolar Lavage; Dacarbazine; Female; Gli | 2008 |
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Dacarbazine; DNA Me | 2009 |
Tuberculosis in a patient on temozolomide: a case report.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antibiotics, Antitubercular; Ant | 2009 |
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; Blotting, Western; Brain Neoplasms; Dacar | 2009 |
Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2009 |
Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens: is the survival really so impressive?: in regard to Combs et al. (Int J Radiat Oncol Biol Phys 2008;71:999-1005).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Follow-U | 2008 |
Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Blotting, Western; Brain Neoplasms; Combined Modal | 2009 |
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Carmustine; Com | 2009 |
Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2008 |
p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzothiazoles; Brain Neoplasms; Dacarbazin | 2008 |
[Diagnostic and treatment delays do not modify the treatment outcome of patients with multiform glioblastoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Chil | 2009 |
Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway.
Topics: Actins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Adhesion; Cell Grow | 2008 |
Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Ataxia; Brain Neoplasms; Chemotherapy, Adjuvant; Con | 2009 |
Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 9; Combined Modality Therapy; C | 2009 |
Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bombesin; Brain Neop | 2009 |
In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Comet Assay; Dacarbazine; DNA Repair; Enzyme | 2009 |
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.
Topics: Animals; Benzimidazoles; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; Drug Resis | 2009 |
Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modificat | 2009 |
Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; | 2009 |
Editorial: on the road to multi-modal and pluri-disciplinary treatment of glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain | 2009 |
Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: treatment-related or dual-pathology?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Squamous Cell; Dacarbazine; Glioblast | 2009 |
Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Di | 2009 |
Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Chemothe | 2008 |
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoquinon | 2009 |
MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Pro | 2008 |
Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Carbon; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Su | 2009 |
Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain; Brain Neoplasms; Dacarbazi | 2009 |
Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide.
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; beta-Galactosidase; Cell Cycle; Cell Line, Tumor; Cell | 2009 |
BNIP3 (Bcl-2 19 kDa interacting protein) acts as transcriptional repressor of apoptosis-inducing factor expression preventing cell death in human malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Apoptosis Inducing Factor; Cell Death; Cell Line; Cell Nucleus; C | 2009 |
Preradiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera | 2009 |
Efficacy of temozolomide treatment in patients with high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemother | 2009 |
EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.
Topics: Animals; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; DNA | 2009 |
Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine; Drug Re | 2009 |
Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Glioblas | 2009 |
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2009 |
Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality | 2009 |
Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Combined Modality Therapy; Cost-Benefit | 2009 |
Non-Hodgkin lymphoma following temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Lymphoma, Non-H | 2009 |
Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemo | 2009 |
Combined modality treatment of newly diagnosed glioblastoma multiforme in a regional neurosurgical centre.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neop | 2009 |
Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Cell Cycle Proteins; Dacarbazine; DNA | 2009 |
Glioblastoma stem cells resistant to temozolomide-induced autophagy.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis Regulatory Proteins; Autop | 2009 |
MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Blotting, Western; Cell Line, Tumor; Cell Survival | 2009 |
Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progre | 2009 |
A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells.
Topics: Aniline Compounds; Antineoplastic Agents, Alkylating; Apoptosis; Caspase 3; Cell Death; Cell Line, T | 2009 |
Comment re: Temozolomide preferentially depletes cancer stem cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Magnetic Reso | 2009 |
Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brachytherapy; Brain Neoplasms; Chemoth | 2009 |
A rare case of aplastic anemia caused by temozolomide.
Topics: Aged; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Dacarbazine; Fema | 2009 |
Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality The | 2009 |
Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy.
Topics: Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Surviv | 2010 |
Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studies; C | 2009 |
Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Attention; Brain Neoplasms; Cognition Di | 2010 |
Glioblastoma masquerading as a hypertensive putaminal hemorrhage: a diagnostic pitfall.
Topics: Antihypertensive Agents; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Dacarbazine; Di | 2009 |
Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2010 |
Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2010 |
Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features.
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anti | 2010 |
The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2009 |
p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor.
Topics: Antineoplastic Agents, Alkylating; Colonic Neoplasms; Consensus Sequence; Dacarbazine; DNA Repair; D | 2009 |
Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.
Topics: Adult; Aged; Biopsy; Bone Marrow Cells; Brain Neoplasms; Dacarbazine; Disease Progression; Female; G | 2009 |
The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Chemothe | 2009 |
Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans | 2009 |
Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Caffeine; Cell Cycle Prot | 2009 |
Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Movement; | 2009 |
Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carotenoids; Cell Line, Tumor; Combined | 2010 |
Therapeutic windows.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; History, 20th Century; Humans; Molecul | 2009 |
Up-front temozolomide in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Modifi | 2010 |
Medical oncology: treatment and management of malignant gliomas.
Topics: Angiogenesis Inhibitors; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glio | 2010 |
Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Dacarbazine; Dideox | 2010 |
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Blotting, West | 2010 |
Commentary on Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase I | 2010 |
Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; DNA Methyl | 2010 |
Pseudoprogression following chemoradiotherapy for glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2010 |
Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Combined Modality Therapy | 2010 |
MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; | 2010 |
Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2010 |
A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Culture | 2009 |
Far-distant metastases along the CSF pathway of glioblastoma multiforme during continuous low-dose chemotherapy with temozolomide and celecoxib.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Celecoxib; Central | 2010 |
Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Huma | 2010 |
MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients.
Topics: Adult; Aged; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methyla | 2010 |
Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Repair; DNA, Neopl | 2010 |
Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Benzodiazepines; Biomedical Research; Brain Neoplasm | 2010 |
Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Cell Line, Tum | 2010 |
Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemota | 2010 |
Sensitivity to temozolomide in brain tumor initiating cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Survival; Dacarbazine; Glioblastoma; Humans | 2010 |
Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Combi | 2011 |
Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Methylation; Fem | 2010 |
Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Cell Adhesion; Cell C | 2010 |
Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2010 |
Tonsillar pseudotumor: complications of chronically-administered temozolomide.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Middle Aged; Palatine | 2010 |
miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Primers; Drug R | 2010 |
Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2010 |
Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Mismatch Repair; DNA Modification Me | 2010 |
STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy?
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Cell Proliferation; Cyclic | 2011 |
Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2010 |
Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; CpG Islands; Dacarbazine; DNA Me | 2010 |
Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Combined Modality The | 2010 |
Initial experience involving treatment and retreatment with carmustine wafers in combination with oral temozolomide: long-term survival in a child with relapsed glioblastoma multiforme.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Combined Modalit | 2010 |
Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modal | 2011 |
Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide.
Topics: Anticonvulsants; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Chromatin Immunopreci | 2010 |
Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Volume; Brain Neoplasms; Da | 2010 |
PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytes; Benzimidazoles; Brain Neoplasms; Cyclin-Depe | 2010 |
Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Dacarbazine; Fema | 2010 |
Temozolomide (Temodar).
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; | 2010 |
MGMT gene promoter methylation in pediatric glioblastomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2010 |
Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Boron Compounds; Boron Neutron Capture Therapy; Clin | 2010 |
Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Benzoates; Brain Neopl | 2010 |
Influence of iMRI-guidance on the extent of resection and survival of patients with glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Magne | 2010 |
Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Dose-Res | 2010 |
MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Caspase 3 | 2010 |
A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
Patterns of care and survival in a retrospective analysis of 1059 patients with glioblastoma multiforme treated between 2002 and 2007: a multicenter study by the Central Nervous System Study Group of Airo (italian Association of Radiation Oncology).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineopla | 2010 |
Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Celecoxi | 2011 |
Long-term outcomes in children with glioblastoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Child | 2010 |
Kitten-transmitted Bordetella bronchiseptica infection in a patient receiving temozolomide for glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Bordetella bronchiseptica; Bordetella Infections; Brain | 2011 |
[Side effects of temozolomide treatment in patient with glioblastoma multiforme--case study].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Gli | 2010 |
Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2011 |
First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2010 |
Hepatic encephalopathy after treatment with temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Fe | 2011 |
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado; | 2011 |
Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Com | 2010 |
Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbazine; Gliobla | 2010 |
Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide.
Topics: Anemia, Aplastic; Antineoplastic Agents, Alkylating; Blood Cell Count; Brain Neoplasms; Cause of Dea | 2010 |
In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; | 2010 |
Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
Topics: Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductases; Animals; Antineoplastic Agents, A | 2010 |
Prolonged survival of a patient with cervical intramedullary glioblastoma multiforme treated with total resection, radiation therapy, and temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Cervical Vertebrae; Chemotherapy, Adjuvant; Combin | 2010 |
Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antin | 2011 |
Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2010 |
Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2010 |
Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2011 |
Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Prot | 2010 |
Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: a case report.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy; Female; Glioblastoma; Humans; Hypericu | 2010 |
MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Sur | 2010 |
Temozolomide for adult brain stem glioblastoma: case report of a long-term survivor.
Topics: Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Dacarbazine; Fatal Outcome; Glioblastoma; H | 2010 |
High-field iMRI in glioblastoma surgery: improvement of resection radicality and survival for the patient?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Magnetic Resonance Imagin | 2011 |
What role should cilengitide have in the treatment of glioblastoma?
Topics: Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblastoma; Humans; Snake Venoms; Temozolo | 2010 |
Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therap | 2011 |
Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
Radiographic patterns of relapse in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Mod | 2011 |
Clinical significance of molecular biomarkers in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neo | 2010 |
Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; D | 2011 |
In vivo imaging of early stage apoptosis by measuring real-time caspase-3/7 activation.
Topics: Animals; Apoptosis; Blotting, Western; Camptothecin; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Pr | 2011 |
Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Cytokine-Induced Killer | 2011 |
Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2011 |
FDA accelerated approval benefits glioblastoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2010 |
Taming glioblastoma by targeting angiogenesis: 3 years later.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chi-Square Distributio | 2011 |
A combined preclinical therapy of cannabinoids and temozolomide against glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cell Growth Pro | 2011 |
Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme.
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dacarbazine; DNA Primers; Flow Cytometry; F | 2011 |
Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Camellia sinensis; Catechin; Cell Line, | 2011 |
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2012 |
Treatment of glioblastoma multiforme with radiotherapy and concomitant and adjuvant temozolomide: translation of randomised controlled trial evidence into routine clinical practice.
Topics: Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; Practi | 2011 |
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Ce | 2011 |
O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2011 |
Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cells; Brain Neoplasms; Combined Modality Ther | 2011 |
Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2012 |
Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Dacarba | 2011 |
Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.
Topics: Acrylamides; Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survi | 2011 |
Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Benzodiazepine | 2011 |
Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphatases; Adult; Aged; Antineoplastic Agents; | 2011 |
[Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2011 |
Computational modeling of tumor response to vascular-targeting therapies--part I: validation.
Topics: Algorithms; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humani | 2011 |
A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase I | 2011 |
Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2011 |
Pseudoprogression following concurrent temozolomide and radiotherapy in a patient with glioblastoma: findings on functional imaging techniques.
Topics: Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Fema | 2010 |
Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combin | 2011 |
Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Cells; Cell Line, | 2011 |
Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Contrast | 2011 |
Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - .
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vacc | 2011 |
How fine a slice: treatment of newly diagnosed glioblastoma with an epidermal growth factor receptor variant III peptide vaccine.
Topics: Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Dacarbazine; DNA Methylation; DNA Modif | 2011 |
Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplasti | 2011 |
FANCD1/BRCA2 plays predominant role in the repair of DNA damage induced by ACNU or TMZ.
Topics: Animals; BRCA2 Protein; Cell Line; Dacarbazine; DNA Damage; DNA Repair; Down-Regulation; Fanconi Ane | 2011 |
[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplas | 2011 |
Another cause of pancytopenia in a patient receiving temozolomide.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Pancytopenia; Risk Fac | 2011 |
Overall survival and extent of surgery in adult versus elderly glioblastoma patients: A population based retrospective study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain; Brain | 2011 |
Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Isotopes; Cell Line, Tumor; Daca | 2011 |
Rare phenomenon: liver metastases from glioblastoma multiforme.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; | 2011 |
Glioblastoma: patterns of recurrence and efficacy of salvage treatments.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; F | 2011 |
Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.
Topics: Angiopoietin-1; Angiopoietin-2; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, | 2011 |
Immunotherapy for glioblastoma: the devil is in the details.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Clinica | 2011 |
Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Chemotherapy, A | 2012 |
MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Disease-Fr | 2011 |
[Significant regression of glioblastoma with low level of Mgmt gene expression following radiotherapy].
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adjuvant | 2011 |
In regard McDonald et al., to Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma (Int J Radiat Oncol Biol Phys 2011;79:130-136).
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2011 |
Method for novel anti-cancer drug development using tumor explants of surgical specimens.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Screening Assays, Antitumor; Flow Cytometr | 2011 |
Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2011 |
MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis.
Topics: Adult; Antineoplastic Agents, Alkylating; Apoptosis; Cytochromes c; Dacarbazine; Drug Resistance, Ne | 2012 |
Early-stage progress on glioma vaccines.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Clinical Trials as | 2011 |
Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fem | 2012 |
Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and β-catenin signaling pathways.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; beta Catenin; Brain Neoplasms; Cell Line | 2011 |
Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2011 |
Communicating hydrocephalus following surgery and adjuvant radiochemotherapy for glioblastoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebrospinal Fluid Shunts; Chemoradiother | 2011 |
Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; DNA Methylation; Glioblastoma; Humans; Isocitrate Dehydro | 2011 |
Noscapine inhibits tumor growth in TMZ-resistant gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Dacarbazine; Drug Resistance, Neopla | 2011 |
MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
Topics: Aminoacetonitrile; Animals; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes | 2011 |
MicroRNA profile of polyunsaturated fatty acid treated glioma cells reveal apoptosis-specific expression changes.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Arachidonic Acid; Cell | 2011 |
Conditional probability of survival in patients with newly diagnosed glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical T | 2011 |
Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Biomarkers, Tumor; Blotting, Western; Brain Neoplasms; | 2012 |
The challenges of managing glioblastoma multiforme in developing countries: a trade-off between cost and quality of care.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Costs and Cost An | 2011 |
Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
American Society of Clinical Oncology 2011 CNS tumors update.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Clinical Trials, Phase II as Topic; Clinica | 2011 |
Toxicity after radiochemotherapy for glioblastoma using temozolomide--a retrospective evaluation.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Pr | 2011 |
Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide--case report.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fatal Outcome; Gliob | 2011 |
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Base Sequence; Biomarkers, Tumor; Brain Neoplasms; D | 2012 |
Avastin: more questions than answers. . .
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2012 |
Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemorad | 2011 |
Glioblastoma survival in the United States before and during the temozolomide era.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dac | 2012 |
Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dos | 2012 |
In vitro and in vivo characterization of a novel Hedgehog signaling antagonist in human glioblastoma cell lines.
Topics: Anilides; Animals; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Gene Expression Profiling; Gli | 2012 |
Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI.
Topics: 3' Untranslated Regions; Aged; Base Sequence; Cell Transformation, Neoplastic; Dacarbazine; Down-Reg | 2012 |
Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Pro | 2012 |
Patterns of imaging failures in glioblastoma patients treated with chemoradiation: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherap | 2012 |
Cell death forms and HSP70 expression in U87 cells after ionizing radiation and/or chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Chemoradiotherapy; Dacarbazine; Dose-Response Relation | 2011 |
Temozolomide: mechanisms of action, repair and resistance.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Central Nervous System Neoplasms; Dacarbazine; | 2012 |
Prognostic impact of hemoglobin level and other factors in patients with high-grade gliomas treated with postoperative radiochemotherapy and sequential chemotherapy based on temozolomide: a 10-year experience at a single institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemoradiotherapy, Adj | 2011 |
Therapeutical doses of temozolomide do not impair the function of dendritic cells and CD8+ T cells.
Topics: Aged; Antigens, Surface; CD8-Positive T-Lymphocytes; Dacarbazine; Dendritic Cells; Female; Glioblast | 2012 |
Temozolomide induced liver injury.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Chemorad | 2011 |
Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Fem | 2011 |
Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Glycosylases; DNA Mod | 2012 |
Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Aurora Kinase B; Aurora Kinases; Benzamides; Blotting, | 2012 |
Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; | 2012 |
Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Blotting, Western; Brain | 2011 |
Dehiscence of corticosteroid-induced abdominal striae in a 14-year-old boy treated with bevacizumab for recurrent glioblastoma.
Topics: Adolescent; Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkyl | 2012 |
Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: changes defined by 18F-fluoromisonidazole positron emission tomography: two case reports.
Topics: Aged; Antineoplastic Agents, Alkylating; Cell Hypoxia; Chemoradiotherapy, Adjuvant; Dacarbazine; Dis | 2012 |
Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2012 |
Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-F | 2012 |
Radiotherapy with and without temozolomide in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2012 |
Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and Paclitaxel.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptos | 2012 |
Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2012 |
Expression of EGFRvIII in glioblastoma: prognostic significance revisited.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; ErbB Receptors; Fema | 2011 |
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Da | 2012 |
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
Prognostic significance of MRP5 immunohistochemical expression in glioblastoma.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Ther | 2012 |
Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2012 |
Invasive Mycoleptodiscus fungal cellulitis and myositis.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Ascomyc | 2012 |
Different involvement of autophagy in human malignant glioma cell lines undergoing irradiation and temozolomide combined treatments.
Topics: Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Brain Neoplasms; Ce | 2012 |
Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis | 2012 |
O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherap
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Chem | 2012 |
Cotard's syndrome with glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Co | 2012 |
Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control.
Topics: Astrocytes; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Surv | 2012 |
Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Alkylating | 2012 |
Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2012 |
The effects of temozolomide delivered by prolonged intracerebral microinfusion against the rat brainstem GBM allograft model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Brain Stem; Cell Line, Tumor; Dacarbazi | 2012 |
Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Admi | 2012 |
Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; | 2012 |
MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease-F | 2012 |
Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Cell Lin | 2012 |
Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma.
Topics: Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Primers; DNA R | 2012 |
Towards personalized medicine with a three-dimensional micro-scale perfusion-based two-chamber tissue model system.
Topics: Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cytochrome P-450 CYP3A; Dacarbazine; Diffu | 2012 |
Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab | 2012 |
Successful pregnancy and delivery after concomitant temozolomide and radiotherapy treatment of glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; | 2012 |
Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemo | 2012 |
Temozolomide-associated bronchiolitis obliterans organizing pneumonia successfully treated with high-dose corticosteroid.
Topics: Antineoplastic Agents, Alkylating; Cryptogenic Organizing Pneumonia; Dacarbazine; Dyspnea; Female; G | 2012 |
In vitro evaluation of combined temozolomide and radiotherapy using X rays and high-linear energy transfer radiation for glioblastoma.
Topics: Alpha Particles; Cell Division; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; DNA Methylation; D | 2012 |
Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-κB-dependent manner.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Biomimetic | 2013 |
SSBP2 variants are associated with survival in glioblastoma patients.
Topics: Brain Neoplasms; Dacarbazine; DNA-Binding Proteins; Female; Genome-Wide Association Study; Glioblast | 2012 |
Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasm | 2012 |
Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Female; | 2012 |
Radiotherapy with concurrent or sequential temozolomide in elderly patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2012 |
Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2012 |
Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme.
Topics: Amino Acid Sequence; Antineoplastic Agents, Alkylating; CD57 Antigens; CD8-Positive T-Lymphocytes; C | 2012 |
Subgroup economic analysis for glioblastoma in a health resource-limited setting.
Topics: Antineoplastic Agents, Alkylating; China; Cohort Studies; Cost-Benefit Analysis; Dacarbazine; Gliobl | 2012 |
MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Glioblastoma; Hum | 2012 |
Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Calcium-Binding Proteins; | 2012 |
STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Central Nervous System Neoplasms; Dacarbazine; | 2012 |
DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line; Chemoradiotherap | 2012 |
Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Base Sequence; Blotting, Western; Brain Neoplasms; | 2012 |
Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; DNA Modification | 2012 |
Drug-induced cholestatic hepatitis: how late can it occur even after the cessation of the culpable drug?
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antineoplastic Agents, Alkylating; Chemical and Drug Induce | 2012 |
Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; | 2012 |
miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification | 2012 |
Comorbidity assessment and adjuvant radiochemotherapy in elderly affected by glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Comorbidity; Dacarbazin | 2012 |
Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Res | 2012 |
In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model.
Topics: Animals; Carmustine; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dogs; Genetic The | 2012 |
Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival.
Topics: Antineoplastic Agents, Alkylating; Blood Platelets; Brain Neoplasms; Chemotherapy, Adjuvant; Combine | 2012 |
Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2012 |
Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Combined M | 2012 |
Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.
Topics: Acetylation; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Dacarbazine; DNA Methyla | 2012 |
Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2012 |
Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
The effects of the NICE Technology Appraisal 121 (gliadel and temozolomide) on survival in high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; Dacarbazine; | 2012 |
Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Daca | 2012 |
Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevac | 2012 |
Olea europaea leaf extract alters microRNA expression in human glioblastoma cells.
Topics: Adult; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells | 2012 |
Quantitative proteomic analysis and functional studies reveal that nucleophosmin is involved in cell death in glioblastoma cell line transfected with siRNA.
Topics: Adult; Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Dacarbazine; Endoplasmic Ret | 2012 |
IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Ther | 2013 |
MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Combined Mo | 2012 |
Inhibition of Na(+)-K(+)-2Cl(-) cotransporter isoform 1 accelerates temozolomide-mediated apoptosis in glioblastoma cancer cells.
Topics: Apoptosis; Bumetanide; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cell Size; Chlori | 2012 |
Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; | 2012 |
Helping patients make the best decision regarding duration of temozolomide chemotherapy treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2012 |
Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide.
Topics: Alkylating Agents; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Sur | 2013 |
A restricted cell population propagates glioblastoma growth after chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Cell Tracking; Daca | 2012 |
Interdisciplinary treatment of glioblastoma: analysis of prognostic factors and treatment results in unselected patients.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Gli | 2012 |
A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; | 2012 |
Glioblastoma therapy in the elderly: one age does not fit all.
Topics: Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Temozolomide | 2012 |
Chemotherapy-associated steatohepatitis with temozolomide and dexamethasone.
Topics: Antineoplastic Agents; Dacarbazine; Dexamethasone; Diabetes Mellitus, Type 2; Fatty Liver; Glioblast | 2012 |
Non-Hodgkin's lymphoma in a patient on treatment with temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Chemoradiotherapy; Dacarbazine; Gliob | 2012 |
Overexpression of WW domain-containing oxidoreductase WOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Shape; C | 2012 |
Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2012 |
Cancer: Resolving the stem-cell debate.
Topics: Animals; Brain Neoplasms; Cell Lineage; Cell Tracking; Dacarbazine; Female; Glioblastoma; Humans; Ma | 2012 |
Prognosis of patients with multifocal glioblastoma: a case-control study.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Case-Control Studies; Cohort Studies; Combined Modalit | 2012 |
Glioblastoma cell line-derived spheres in serum‑containing medium versus serum-free medium: a comparison of cancer stem cell properties.
Topics: Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Culture Media, Serum-Free | 2012 |
Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Cycle | 2012 |
Enhanced stability and activity of temozolomide in primary glioblastoma multiforme cells with cucurbit[n]uril.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Bridged-Ring Compounds; Calorimetry; Cell Survival; Daca | 2012 |
Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force™ in brain tumor cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2012 |
The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; | 2013 |
FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51.
Topics: Antineoplastic Agents, Alkylating; Binding Sites; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Re | 2012 |
Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Fasting enhances the response of glioma to chemo- and radiotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Blood Glucose; Body Weight; Brain Neoplasms | 2012 |
Decision making and management of gliomas: practical considerations.
Topics: Aged; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA | 2012 |
Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Asian People; Biomarkers, Tumor; Central Nervous System Ne | 2013 |
A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2012 |
Alkylation sensitivity screens reveal a conserved cross-species functionome.
Topics: Alkylation; Antineoplastic Agents, Alkylating; Bacterial Proteins; Cell Line, Tumor; Dacarbazine; DN | 2012 |
Prime time for molecular marker diagnostics in neuro-oncology.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; DNA Meth | 2012 |
Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.
Topics: Alcohol Deterrents; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms | 2012 |
ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Blott | 2012 |
Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2013 |
BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Morphogenetic Protein 2; Cell Differentiation; Daca | 2012 |
Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calcium Channel Blockers; Cell Cycle; D | 2013 |
Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amino Acid Transport System y+; Antineoplastic Agents, | 2013 |
High levels of phosphorylated MAP kinase are associated with poor survival among patients with glioblastoma during the temozolomide era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Daca | 2013 |
Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2013 |
Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Resistance, Neoplasm; Glioblas | 2013 |
Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma.
Topics: Aged; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents; Biomarkers, Tu | 2012 |
Effective elimination of cancer stem cells by a novel drug combination strategy.
Topics: Adenosine Triphosphate; Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Dacar | 2013 |
Neuro-oncology: treatment decisions in elderly patients with glioblastoma.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Glioblastoma; Humans; | 2012 |
Equinatoxin II potentiates temozolomide- and etoposide-induced glioblastoma cell death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cni | 2012 |
Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas.
Topics: Amino Acids; Animals; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality T | 2013 |
Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Resistance, | 2013 |
Distance to the neurooncological center: a negative prognostic factor in patients with glioblastoma multiforme. An epidemiological study.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine | 2012 |
Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2013 |
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Biomarkers, Tumor; Brain Neoplasms; Dac | 2012 |
Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplasms; Bystander | 2013 |
DARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome.
Topics: Apoptosis; Brain Neoplasms; Dacarbazine; Dopamine and cAMP-Regulated Phosphoprotein 32; Female; Glio | 2013 |
Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2013 |
The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
Topics: AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Antineoplastic Agents, Alkylating; Blotti | 2013 |
Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Magnet | 2013 |
Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost.
Topics: Brain Neoplasms; Contrast Media; Dacarbazine; Glioblastoma; Humans; Image Processing, Computer-Assis | 2013 |
Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Br | 2013 |
[Mechanism of temozolomide-induced anti-tumor effects on glioblastoma cells in vitro is via ROS-dependent SIRT1 signaling pathway].
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Daca | 2012 |
Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle; Cell | 2013 |
Performance status during and after radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; | 2013 |
Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; DNA Modification Methylas | 2013 |
Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cells, Cultured | 2013 |
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; DNA Methy | 2013 |
Downregulation of Src enhances the cytotoxic effect of temozolomide through AKT in glioma.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Regulation; Gene Expression | 2013 |
In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing.
Topics: 3' Untranslated Regions; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques | 2013 |
Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Cell Proliferation; Dacarbazine; Glioblastoma; Humans; Proto-Onco | 2013 |
The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Ad | 2013 |
Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Daca | 2013 |
The microarray gene profiling analysis of glioblastoma cancer cells reveals genes affected by FAK inhibitor Y15 and combination of Y15 and temozolomide.
Topics: Aniline Compounds; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Drug Interactio | 2014 |
Hypernatremia-associated myelinolysis following the management of sepsis in a patient with glioblastoma treated with radiotherapy and temozolomide.
Topics: Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Carcinoma; Carcinoma, Papillary; Dacarbazine | 2013 |
Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2013 |
Treatment of newly diagnosed glioblastoma multiforme.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Prot | 2002 |
Promising survival and concomitant radiation plus temozolomide followed by adjuvant temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; | 2002 |
The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Apurinic Acid; Brain Neoplasms; Carbon-Oxygen Lyases; Carmustine; | 2002 |
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain | 2002 |
[Treatment of anaplastic astrocytomas and glioblastomas in children by the use of temozolomide (TMZ)].
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Bra | 2002 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2003 |
O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2003 |
Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous Syst | 2003 |
Treatment of glioblastoma multiforme in the elderly in functionally non-critical areas. Clinical remarks on 22 patients.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Neoplasm | 2003 |
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inh | 2003 |
Unusual and severe symptomatic impairment of neutrophil function after one cycle of temozolomide in patients with malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Neu | 2004 |
Irinotecan-induced interstitial pneumonia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; D | 2004 |
[Survival analysis following the addition of temozolomide to surgery and radiotherapy in patients with glioblastoma multiforme].
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Combined Modality Therapy; Daca | 2004 |
Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations.
Topics: Animals; Antineoplastic Agents, Alkylating; Carboplatin; Carmustine; Chromosome Aberrations; Dacarba | 2004 |
Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Protocols; Clinical Trials, Phase III a | 2004 |
Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma.
Topics: Adenoviruses, Human; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Li | 2004 |
Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Cost-Ben | 2004 |
Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; B | 2004 |
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly population.
Topics: Aged; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dacarbazine; Glioblasto | 2004 |
Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Belgium; Brain Neoplasms; Dacarba | 2004 |
The piperidine nitroxide Tempol potentiates the cytotoxic effects of temozolomide in human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Brain Neoplasms; Cell Cycle; Cyclic N-Ox | 2004 |
Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2005 |
Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Apoptosis; bcl-2-Associated X Pr | 2004 |
Low-grade primary meningeal lymphoma: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Gliobl | 2005 |
Dexamethasone decreases temozolomide-induced apoptosis in human gliobastoma T98G cells.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Blotting, Western; Calpain; Cell Line, T | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
MGMT gene silencing and benefit from temozolomide in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease-Fre | 2005 |
Chemotherapy for brain tumors--a new beginning.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2005 |
Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2005 |
Combined cimetidine and temozolomide, compared with temozolomide alone: significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthotopic xenografts.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cimetidine; Dac | 2005 |
Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence.
Topics: Antineoplastic Agents, Alkylating; Astrocytes; Cell Line, Transformed; Cell Line, Tumor; Checkpoint | 2005 |
Treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Gene Silenc | 2005 |
Treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; | 2005 |
Phenytoin may increase the efficacy of temozolomide by methylating DNA-repair enzyme, O6-methylguanine-DNA methyltransferase in patients with glioblastoma.
Topics: Dacarbazine; DNA Repair; Glioblastoma; Humans; Methylation; O(6)-Methylguanine-DNA Methyltransferase | 2005 |
How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Lymphopenia; Neoplasm Recurren | 2005 |
[Temozolomide in patients with a glioblastoma multiforme: new developments].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioblastom | 2005 |
Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2005 |
Current therapies for glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cranial Irradiation; Craniotomy; D | 2004 |
Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Topics: Adult; Aged; alpha-Methyltyrosine; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocyt | 2005 |
Simulating chemotherapeutic schemes in the individualized treatment context: the paradigm of glioblastoma multiforme treated by temozolomide in vivo.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Division; Computer G | 2006 |
Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; C | 2005 |
Avoiding glucocorticoid administration in a neurooncological case.
Topics: Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Celecoxib; Cerebellum; Cyclooxygenase Inhibi | 2005 |
Salvage temozolomide for prior temozolomide responders.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; G | 2005 |
Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Sur | 2005 |
Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Dacarbazine; DNA; DNA-Binding Prote | 2006 |
Evidence, economics, and emotions: the case for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Approval; Female; Glioblastoma; Humans; Male; N | 2005 |
PHARMAC's response on temozolomide and funding costly medicines that prolong life shortly.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Approval; Glioblastoma; Humans; National Health | 2005 |
Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
Topics: Animals; Antigens, Differentiation; Antineoplastic Agents, Alkylating; Cell Cycle Proteins; Cell Lin | 2006 |
Chemotherapy for glioblastoma multiforme (GBM).
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2006 |
Glioblastoma--more questions than answers?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carmustine; Central Nervous System Neoplasms; Combined Mod | 2006 |
More from PHARMAC on temozolomide: feedback needed.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Approval; Glioblastoma; Humans; National Health | 2006 |
[Management of malignant gliomas diagnosed during pregnancy].
Topics: Abortion, Therapeutic; Adrenal Cortex Hormones; Adult; Algorithms; Anesthesia, General; Antineoplast | 2006 |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Complications of a temozolomide overdose: a case report.
Topics: Antineoplastic Agents, Alkylating; Bacterial Infections; Brain Neoplasms; Combined Modality Therapy; | 2006 |
Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide.
Topics: Anemia, Aplastic; Antineoplastic Agents, Alkylating; Dacarbazine; Fatal Outcome; Glioblastoma; Hemat | 2006 |
Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin.
Topics: Animals; Anthracenes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combi | 2006 |
Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide.
Topics: Antineoplastic Agents, Alkylating; Brain Abscess; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans | 2006 |
The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazo | 2006 |
Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms.
Topics: Animals; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Models, Animal | 2006 |
A spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in vivo: the paradigm of glioblastoma multiforme treated by temozolomide.
Topics: Antineoplastic Agents, Alkylating; Cell Proliferation; Cell Survival; Computer Simulation; Dacarbazi | 2006 |
A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Gl | 2007 |
Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2007 |
Ganglioglioma occurring with glioblastoma multiforme: separate lesions or the same lesion?
Topics: Antineoplastic Agents, Alkylating; Astrocytes; Biomarkers, Tumor; Brain Neoplasms; Chemotherapy, Adj | 2007 |
The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity.
Topics: Acid Anhydride Hydrolases; Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; | 2006 |
Interindividual differences in anticancer drug cytotoxicity in primary human glioblastoma cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Culture Techniques; Dacarbazine; Drug | 2007 |
Malignant transformation of conus medullaris ganglioglioma: case report.
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Dacarbazine; Ganglioglioma; Glioblastoma; H | 2007 |
[Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi | 2006 |
[Recent advances in the medical treatment of glioma-temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2006 |
Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modali | 2007 |
[Temozolomide, an oral chemotherapeutic agent with potential severe toxicity].
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Fatal Outcome; Female; Fever; Glioblastoma; Humans; | 2007 |
Fatal outcome related to carmustine implants in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemothera | 2007 |
Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chromosomal Instability; Dacar | 2007 |
Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA, Viral; Glioblastoma; Hepatitis | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Taming a mutinous mutant: an errant receptor becomes a prime cancer target.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Daca | 2007 |
Fatal reactivation of hepatitis B with temozolomide.
Topics: Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Fatal Outcom | 2007 |
A small proportion of glioblastoma patients are probably eligible for concomitant/adjuvant temozolomide.
Topics: Adjuvants, Immunologic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therap | 2007 |
Methylguanine methyltransferase testing in glioblastoma: when and how?
Topics: Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Neoplasm Stagin | 2007 |
Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Drug Int | 2007 |
Adjuvant therapy in glioblastomas: false steps and real advances.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 2007 |
Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide.
Topics: Adult; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Blood Cell Count; Bone Marrow; Brain Neo | 2007 |
In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Improved median survival for glioblastoma multiforme following introduction of adjuvant temozolomide chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Female; Gli | 2007 |
Salvage chemotherapy in progressive high-grade astrocytoma.
Topics: Adult; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; R | 2007 |
Temozolomide-associated organizing pneumonitis.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Glioblastoma; Humans; Male; Pneum | 2007 |
Prophylactic radiotherapy for glioblastoma in the elderly.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Gl | 2007 |
The fallacy of single-agent chemotherapy for cancer.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Glioblastoma; Hu | 2007 |
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Biopsy; Brain Neoplasms; Cell Line, Tumor; Dacarba | 2007 |
Impact of combination therapy with repeat surgery and temozolomide for recurrent or progressive glioblastoma multiforme: a prospective trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Cohort Studies; | 2007 |
Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Gl | 2007 |
The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Caspase 7; Catechin; | 2007 |
[The effect of oxygenation on the biological behaviour of tumours].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 2007 |
Defining the standard of care for high-grade glioma--a NICE deal for patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Temozolomide | 2008 |
Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Dac | 2007 |
Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Fe | 2008 |
Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA M | 2008 |
Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.
Topics: Adult; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; | 2007 |
Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; | 2007 |
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Combined Modality Therapy; Daca | 2008 |
Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2007 |
The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Protocols; Brain Neoplasms; Chemother | 2008 |
In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Dacarba | 2008 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality | 2008 |
Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3.
Topics: Animals; Antibodies; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumo | 2008 |
Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
Topics: Adult; Aged; Aging; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combi | 2008 |
Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, X | 2008 |
[Temozolomide: Temodal].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Dac | 2008 |
Glioblastoma in a patient with a hereditary cancer syndrome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Colorectal Neoplasms; | 2008 |
A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 2008 |
[The sodium pump could constitute a new target to combat glioblastomas].
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; | 2008 |
[Glioblastomas are resistant to apoptosis but less resistant to the autophagic process].
Topics: Algorithms; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Br | 2007 |
Multifocal glioblastoma multiforme with synchronous spontaneous hemorrhage: case report.
Topics: Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Biopsy; Brain Neoplasms; Cerebral Hemorr | 2008 |
Noninvasive imaging of apoptosis and its application in cancer therapeutics.
Topics: Animals; Apoptosis; Caspase 3; Chlorocebus aethiops; Combined Modality Therapy; COS Cells; Dacarbazi | 2008 |
Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Down-Reg | 2008 |
Modulatory effects of acetazolomide and dexamethasone on temozolomide-mediated apoptosis in human glioblastoma T98G and U87MG cells.
Topics: Acetazolamide; Apoptosis; Aquaporin 1; Brain Edema; Brain Neoplasms; Calpain; Carbonic Anhydrases; C | 2008 |
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Brain Neoplasms; Chemotherapy, Adjuv | 2008 |
Adjuvant temozolomide: how long and how much?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Drug Admini | 2008 |
O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Body Weight; Carmustine; Cell Division; Cell Line; Daca | 1996 |
In vitro evaluation of temozolomide combined with X-irradiation.
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Brain Neoplasms; Colonic Neoplasms; Combined Moda | 1997 |
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Repair; DNA, Neopl | 1998 |
Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Dose-Response R | 1999 |
Temozolomide (Temodal) for treatment of primary brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Drug Monitoring; Glioblastoma; Huma | 2000 |
Temozolomide for malignant brain tumours.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioblast | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic | 2000 |
p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.
Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Cell Survival; Cyclin-Dependent Kinase Inhibi | 2001 |
Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2001 |
Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
Topics: Alkaloids; Antineoplastic Agents, Alkylating; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle Pr | 2001 |
NICE verdict on Temozolomide: where next?
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease-Free Survival; | 2002 |
Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; G | 2002 |